{
  "file_name": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
  "total_pages": 117,
  "pdf_type": "normal",
  "font_analysis": {
    "font_sizes_frequency": {
      "9.951866149902344": 2,
      "26.03999900817871": 3,
      "23.03999900817871": 1,
      "18.0": 1,
      "17.03999900817871": 2,
      "11.039999961853027": 203,
      "15.0": 1369,
      "14.039999961853027": 9,
      "12.0": 1155,
      "9.960000038146973": 254,
      "32.040000915527344": 2,
      "20.03999900817871": 12,
      "15.960000038146973": 32,
      "12.960000038146973": 114,
      "8.279999732971191": 1,
      "8.759956359863281": 3,
      "9.0": 19,
      "8.90849494934082": 4,
      "54.553165435791016": 1,
      "53.89981460571289": 1,
      "9.837821960449219": 1,
      "45.79743576049805": 1,
      "6.721034049987793": 4,
      "10.887643814086914": 1,
      "45.460975646972656": 1,
      "7.079999923706055": 7
    },
    "heading_sizes": [
      32.040000915527344,
      26.03999900817871,
      20.03999900817871,
      17.03999900817871,
      15.960000038146973
    ]
  },
  "table_analysis": {
    "total_tables": 16,
    "tables_info": [
      {
        "bbox": [
          68.04000091552734,
          171.1042938232422,
          531.6412353515625,
          754.3483276367188
        ],
        "num_rows": 8,
        "num_cols": 2
      },
      {
        "bbox": [
          62.63999938964844,
          153.59999084472656,
          533.3519897460938,
          329.8799743652344
        ],
        "num_rows": 9,
        "num_cols": 2
      },
      {
        "bbox": [
          76.31999969482422,
          179.51998901367188,
          523.8720092773438,
          251.51998901367188
        ],
        "num_rows": 4,
        "num_cols": 2
      },
      {
        "bbox": [
          74.87999725341797,
          323.7599792480469,
          527.760009765625,
          724.5599975585938
        ],
        "num_rows": 13,
        "num_cols": 4
      },
      {
        "bbox": [
          74.87999725341797,
          153.1199951171875,
          527.760009765625,
          721.7999877929688
        ],
        "num_rows": 10,
        "num_cols": 4
      },
      {
        "bbox": [
          73.19999694824219,
          139.3199920654297,
          522.3599853515625,
          736.5599975585938
        ],
        "num_rows": 18,
        "num_cols": 4
      },
      {
        "bbox": [
          75.0,
          152.39999389648438,
          536.3999633789062,
          697.4400024414062
        ],
        "num_rows": 16,
        "num_cols": 4
      },
      {
        "bbox": [
          75.0,
          139.3199920654297,
          536.3999633789062,
          652.6799926757812
        ],
        "num_rows": 14,
        "num_cols": 3
      },
      {
        "bbox": [
          67.43999481201172,
          151.44000244140625,
          530.5199584960938,
          725.280029296875
        ],
        "num_rows": 12,
        "num_cols": 3
      },
      {
        "bbox": [
          68.04000091552734,
          282.239990234375,
          532.0800170898438,
          743.280029296875
        ],
        "num_rows": 18,
        "num_cols": 5
      },
      {
        "bbox": [
          62.39999771118164,
          269.3999938964844,
          534.0,
          723.6000366210938
        ],
        "num_rows": 17,
        "num_cols": 3
      },
      {
        "bbox": [
          62.39999771118164,
          102.1199951171875,
          534.0,
          768.7200317382812
        ],
        "num_rows": 27,
        "num_cols": 4
      },
      {
        "bbox": [
          62.39999771118164,
          156.83999633789062,
          534.0,
          506.15997314453125
        ],
        "num_rows": 18,
        "num_cols": 4
      },
      {
        "bbox": [
          73.79999542236328,
          296.0325012207031,
          529.0800170898438,
          685.1962280273438
        ],
        "num_rows": 12,
        "num_cols": 3
      },
      {
        "bbox": [
          94.79999542236328,
          397.67999267578125,
          547.7999877929688,
          450.47998046875
        ],
        "num_rows": 3,
        "num_cols": 2
      },
      {
        "bbox": [
          97.43999481201172,
          417.9599914550781,
          530.7601928710938,
          528.6480102539062
        ],
        "num_rows": 5,
        "num_cols": 2
      }
    ]
  },
  "text_blocks": [
    {
      "text": "민원인 안내서 등록번호",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothic",
      "bbox": [
        73.64009094238281,
        89.38206481933594,
        171.5070343017578,
        102.61518096923828
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안내서-1334-01",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothic",
      "bbox": [
        84.31430053710938,
        104.96503448486328,
        160.79945373535156,
        118.19815063476562
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "섭식장애 개선 디지털치료기기",
      "font_size": 26.03999900817871,
      "font_name": "H2hdrM",
      "bbox": [
        122.39999389648438,
        223.64730834960938,
        472.91595458984375,
        249.6873016357422
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성·성능 평가 및 임상시험계획서",
      "font_size": 26.03999900817871,
      "font_name": "H2hdrM",
      "bbox": [
        70.08000183105469,
        265.28729248046875,
        525.1204223632812,
        291.3273010253906
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "작성 가이드라인 (민원인 안내서)",
      "font_size": 26.03999900817871,
      "font_name": "H2hdrM",
      "bbox": [
        101.5199966430664,
        306.92730712890625,
        493.6980285644531,
        332.9673156738281
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2023. 12.",
      "font_size": 23.03999900817871,
      "font_name": "T3",
      "bbox": [
        259.32000732421875,
        462.5999755859375,
        350.8342590332031,
        490.2249450683594
      ],
      "page_num": 1,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의 료 기 기 심 사 부",
      "font_size": 18.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        193.0800018310547,
        656.9691772460938,
        417.1199951171875,
        680.9105834960938
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지침서ᆞ안내서 제ᆞ개정 점검표",
      "font_size": 17.03999900817871,
      "font_name": "H2hdrM",
      "bbox": [
        168.0,
        79.212890625,
        423.0,
        96.25288391113281
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명칭",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        82.55999755859375,
        123.34429931640625,
        103.08004760742188,
        138.0283660888672
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "섭식장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        132.72000122070312,
        114.46429443359375,
        531.6412353515625,
        129.1483612060547
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인(민원인 안내서)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        132.72000122070312,
        132.1042938232422,
        266.5113220214844,
        146.78836059570312
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아래에 해당하는 사항에 체크하여 주시기 바랍니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        165.0,
        151.54429626464844,
        426.3693542480469,
        166.22836303710938
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등록대상",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        70.79999542236328,
        313.4242858886719,
        114.83966064453125,
        328.1083679199219
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "여부",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        81.83999633789062,
        331.06427001953125,
        103.91999816894531,
        345.74835205078125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        171.1042938232422,
        450.76171875,
        185.78836059570312
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서가 있습니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        151.67999267578125,
        186.46429443359375,
        294.8779602050781,
        201.1483612060547
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        171.1042938232422,
        506.6396484375,
        201.1483612060547
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        171.1042938232422,
        506.6396484375,
        201.1483612060547
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        205.904296875,
        527.760009765625,
        220.58836364746094
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "으로 고려하시기 바랍니다. 그럼에도 불구하고 동 지침서ㆍ안내서의 제정이",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.63999938964844,
        221.38429260253906,
        531.6412353515625,
        251.42835998535156
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.63999938964844,
        221.38429260253906,
        531.6412353515625,
        251.42835998535156
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(사유 :                                                                )",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        252.1042938232422,
        525.4837646484375,
        266.7883605957031
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 법령(법ㆍ시행령ㆍ시행규칙) 또는",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        268.7842712402344,
        314.6809997558594,
        283.4683532714844
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.87998962402344,
        285.3442687988281,
        415.72100830078125,
        316.5883483886719
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나열한 것입니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.87998962402344,
        285.3442687988281,
        415.72100830078125,
        316.5883483886719
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        277.6642761230469,
        506.6396484375,
        307.7083435058594
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        277.6642761230469,
        506.6396484375,
        307.7083435058594
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        318.4642639160156,
        506.6396484375,
        348.62835693359375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        318.4642639160156,
        506.6396484375,
        348.62835693359375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        318.4642639160156,
        506.6396484375,
        348.62835693359375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 일회성 지시ㆍ명령에 해당하는 내용입니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        353.38427734375,
        506.6396484375,
        383.4283447265625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        353.38427734375,
        506.6396484375,
        383.4283447265625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        353.38427734375,
        506.6396484375,
        383.4283447265625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 외국 규정을 단순 번역하거나 설명하는 내용입니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        388.30426025390625,
        506.6396484375,
        418.3483581542969
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        388.30426025390625,
        506.6396484375,
        418.3483581542969
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        388.30426025390625,
        506.6396484375,
        418.3483581542969
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        423.1042785644531,
        438.88092041015625,
        437.7883605957031
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정리한 자료입니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.16000366210938,
        438.5842590332031,
        251.56101989746094,
        453.2683410644531
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        423.1042785644531,
        506.6396484375,
        453.2683410644531
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        423.1042785644531,
        506.6396484375,
        453.2683410644531
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        458.0242614746094,
        525.7349853515625,
        488.068359375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        458.0242614746094,
        525.7349853515625,
        488.068359375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.23999786376953,
        516.9442749023438,
        122.52259063720703,
        531.6282958984375
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구분",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        81.83999633789062,
        534.5842895507812,
        103.91999816894531,
        549.268310546875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        492.94427490234375,
        446.8798522949219,
        507.62835693359375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준이나 절차를 제시하는 것입니까? (공무원용)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.27999877929688,
        508.3042907714844,
        375.3637390136719,
        522.9883422851562
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예(☞지침서)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        492.94427490234375,
        527.7637329101562,
        522.9883422851562
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        492.94427490234375,
        527.7637329101562,
        522.9883422851562
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        527.7443237304688,
        450.76129150390625,
        542.4283447265625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        150.72000122070312,
        543.2243041992188,
        450.7612609863281,
        573.268310546875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기술하는 것입니까? (민원인용)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        150.72000122070312,
        543.2243041992188,
        450.7612609863281,
        573.268310546875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 예(☞안내서)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        535.42431640625,
        531.6412353515625,
        565.5883178710938
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        535.42431640625,
        531.6412353515625,
        565.5883178710938
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기타 확인",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        68.04000091552734,
        594.3442993164062,
        117.5999984741211,
        609.0283203125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사항",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        81.83999633789062,
        611.9843139648438,
        103.91999816894531,
        626.6683349609375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        578.0242919921875,
        450.7625427246094,
        592.7083129882812
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민원인을 구속하는 내용이 있습니까?",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        151.67999267578125,
        593.5042724609375,
        338.1979675292969,
        608.1882934570312
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        578.0242919921875,
        506.6396484375,
        608.1882934570312
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        457.1999816894531,
        578.0242919921875,
        506.6396484375,
        608.1882934570312
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        132.72000122070312,
        610.0642700195312,
        527.7615356445312,
        624.748291015625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안내서 제ㆍ개정 절차를 진행하시기 바랍니다.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        149.52000427246094,
        625.5443115234375,
        382.81500244140625,
        640.2283325195312
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상기 사항에 대하여 확인하였음.",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        213.239990234375,
        650.6243286132812,
        379.08935546875,
        665.308349609375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2023년  12월  7일",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        241.79998779296875,
        690.8242797851562,
        339.1199951171875,
        705.50830078125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "담당자",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        276.239990234375,
        725.38427734375,
        350.9913024902344,
        754.3483276367188
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확  인(부서장)",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        276.239990234375,
        725.38427734375,
        350.9913024902344,
        754.3483276367188
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "양 승 하",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        475.1999816894531,
        723.7042846679688,
        519.9599609375,
        738.3883056640625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 원 규",
      "font_size": 11.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        475.1999816894531,
        741.3442993164062,
        519.9599609375,
        756.0283203125
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제·개정 이력",
      "font_size": 17.03999900817871,
      "font_name": "MalgunGothicBold",
      "bbox": [
        249.0,
        78.8940200805664,
        346.20001220703125,
        101.55854797363281
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "섭식장애 개선 디지털치료기기 안전성·성능 작성 및",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        119.75999450683594,
        128.8743133544922,
        480.71343994140625,
        148.8254852294922
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험계획서 작성 가이드라인(민원인 안내서)",
      "font_size": 15.0,
      "font_name": "MalgunGothicBold",
      "bbox": [
        131.75999450683594,
        151.43431091308594,
        464.1286315917969,
        171.38548278808594
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제·개정번호",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        82.91999816894531,
        201.91915893554688,
        440.3994140625,
        220.5934600830078
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "승인일자",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        82.91999816894531,
        201.91915893554688,
        440.3994140625,
        220.5934600830078
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주요 내용",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothicBold",
      "bbox": [
        82.91999816894531,
        201.91915893554688,
        440.3994140625,
        220.5934600830078
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안내서-1334-01",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        248.47914123535156,
        255.91152954101562,
        267.1534423828125
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "’23.12.7.",
      "font_size": 14.039999961853027,
      "font_name": "MalgunGothic",
      "bbox": [
        69.0,
        248.47914123535156,
        255.91152954101562,
        267.1534423828125
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "섭식장애 개선 디지털치료기기 안전성·성능",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        287.1600036621094,
        232.0994415283203,
        533.4187622070312,
        248.0603790283203
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가 및 임상시험계획서 작성 가이드라인",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        287.1600036621094,
        250.09945678710938,
        529.2000122070312,
        284.0603942871094
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(민원인 안내서) 제정",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        287.1600036621094,
        250.09945678710938,
        529.2000122070312,
        284.0603942871094
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 안내서는 섭식장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        69.5999984741211,
        77.89945220947266,
        534.0187377929688,
        93.86038970947266
      ],
      "page_num": 5,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "작성에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        69.5999984741211,
        101.89945220947266,
        526.7849731445312,
        117.86038970947266
      ],
      "page_num": 5,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        69.5999984741211,
        125.89944458007812,
        529.7999877929688,
        141.86038208007812
      ],
      "page_num": 5,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        69.5999984741211,
        149.89944458007812,
        534.0187377929688,
        165.86038208007812
      ],
      "page_num": 5,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아님을 알려드립니다. 또한, 본 안내서는 2023년 12월 현재의 과학적ㆍ기술적 사실",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        69.5999984741211,
        173.89944458007812,
        534.0187377929688,
        189.86038208007812
      ],
      "page_num": 5,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정법규 내용 및 구체적인",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        69.5999984741211,
        197.89944458007812,
        534.0187377929688,
        213.86038208007812
      ],
      "page_num": 5,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.",
      "font_size": 12.0,
      "font_name": "MalgunGothic",
      "bbox": [
        69.5999984741211,
        221.89944458007812,
        390.2250061035156,
        237.86038208007812
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설명하거나",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        74.5199966430664,
        251.47975158691406,
        528.2615966796875,
        264.7273254394531
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품의약품안전처 지침서 등의",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        87.83999633789062,
        267.43975830078125,
        528.2620239257812,
        280.68731689453125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관리에 관한 규정 제2조)",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        87.83999633789062,
        285.19976806640625,
        200.07467651367188,
        298.44732666015625
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 관련 규정",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        343.5675048828125,
        140.87998962402344,
        356.2237548828125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 「의료기기법」 제2조 (정의)",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        367.5675048828125,
        254.6699981689453,
        380.2237548828125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 「의료기기법」 제3조 (등급분류와 지정)",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        391.5675048828125,
        320.66998291015625,
        404.2237548828125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 「의료기기법」 제10조 (임상시험계획의 승인 등)",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        415.5675048828125,
        368.66998291015625,
        428.2237548828125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 「의료기기법 시행규칙」 제9조 (기술문서 등의 심사)",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        439.5675048828125,
        392.66998291015625,
        452.2237548828125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(5) 「의료기기법 시행규칙」 제20조 (임상시험계획의 승인 등)",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        463.5674743652344,
        422.66998291015625,
        476.2237243652344
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 「의료기기법 시행규칙」 제24조 (임상시험 실시기준 등)",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        487.5674743652344,
        410.66998291015625,
        500.2237243652344
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(7) 「의료기기 허가·신고·심사 등에 관한 규정」",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        511.5675048828125,
        361.1999816894531,
        524.2237548828125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(8) 「의료기기 임상시험계획 승인에 관한 규정」",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        535.5675048828125,
        349.1999816894531,
        548.2237548828125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 문의처",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        607.5675048828125,
        122.87999725341797,
        620.2237548828125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식품의약품안전처 식품의약품안전평가원 의료기기심사부 첨단의료기기과",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        631.5675048828125,
        485.6399841308594,
        644.2237548828125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화 : (043) 719-3912",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        655.5675048828125,
        202.44000244140625,
        668.2237548828125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "FAX : (043) 719-3900",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.63999938964844,
        679.5675048828125,
        201.83999633789062,
        692.2237548828125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "목",
      "font_size": 32.040000915527344,
      "font_name": "T6",
      "bbox": [
        242.63999938964844,
        68.87999725341797,
        354.7200012207031,
        107.32799530029297
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "차",
      "font_size": 32.040000915527344,
      "font_name": "T6",
      "bbox": [
        242.63999938964844,
        68.87999725341797,
        354.7200012207031,
        107.32799530029297
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅰ. 개 요 ········································································ 1",
      "font_size": 20.03999900817871,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        158.33811950683594,
        538.5,
        179.47406005859375
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 배경 및 목적 ················································································ 1",
      "font_size": 15.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        198.44436645507812,
        538.4999389648438,
        215.2771759033203
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 적용 범위 ······················································································ 1",
      "font_size": 15.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        230.3643798828125,
        538.4999389648438,
        247.1971893310547
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 용어 설명 ······················································································ 3",
      "font_size": 15.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        262.40435791015625,
        538.4999389648438,
        279.2371826171875
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 현황 ································································································ 4",
      "font_size": 15.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        294.4443664550781,
        538.4999389648438,
        311.2771911621094
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅱ. 안전성·성능 평가 ·············································· 19",
      "font_size": 20.03999900817871,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        342.2981262207031,
        538.4998779296875,
        363.4340515136719
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 국내외 관련 규격 및 가이드라인 ·········································· 19",
      "font_size": 15.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        382.40435791015625,
        538.5006103515625,
        399.2371826171875
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 안전성 평가 항목 ······································································ 22",
      "font_size": 15.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        414.4443664550781,
        538.5006103515625,
        431.2771911621094
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 성능 평가 항목 ·········································································· 34",
      "font_size": 15.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        446.3643493652344,
        538.5006103515625,
        463.1971740722656
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅲ. 임상시험계획서 작성 시 고려사항 및 예시 ·· 36",
      "font_size": 20.03999900817871,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        494.338134765625,
        538.4998779296875,
        515.4740600585938
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅳ. 참고문헌 ······························································ 105",
      "font_size": 20.03999900817871,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        566.338134765625,
        538.499755859375,
        587.4740600585938
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 1 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        789.4503784179688,
        311.7449951171875,
        799.4103393554688
      ],
      "page_num": 8,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅰ",
      "font_size": 20.03999900817871,
      "font_name": "T9",
      "bbox": [
        68.4000015258789,
        77.15999603271484,
        168.3599853515625,
        101.20800018310547
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개 요",
      "font_size": 20.03999900817871,
      "font_name": "H2hdrM",
      "bbox": [
        68.4000015258789,
        77.15999603271484,
        168.3599853515625,
        101.20800018310547
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 배경 및 목적",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        130.8999481201172,
        181.19970703125,
        146.85995483398438
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식품의약품안전처는 정부 지원 과제 중 디지털치료기기에 특화된",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        174.1893768310547,
        546.0599975585938,
        190.0096893310547
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과제의 제품 설계부터 제품화에 필요한 안전성·성능 평가 및 임상시험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        204.1893768310547,
        546.0599975585938,
        220.0096893310547
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "계획서 작성 방법 제공을 통한 신속 제품화 지원을 하고 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        234.1893768310547,
        488.0029602050781,
        250.0096893310547
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 가이드라인은 “섭식장애 개선 디지털치료기기”의 안전성·성능",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        264.1893615722656,
        546.0599975585938,
        280.0096740722656
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가 방법, 임상시험 계획서 작성 시 고려사항 및 예시를 구체적으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        294.1893615722656,
        545.9400024414062,
        310.0096740722656
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시하여 신속 제품화를 위한 맞춤형 기술 지원을 목적으로 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        324.1893615722656,
        500.96295166015625,
        340.0096740722656
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 적용 범위",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        66.0,
        392.7399597167969,
        158.52000427246094,
        408.699951171875
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 가이드라인에서 다루는 섭식장애 개선 디지털치료기기는 「의료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        436.02935791015625,
        538.4400024414062,
        451.84967041015625
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기 품목 및 품목별 등급에 관한 규정(식약처 고시 제2021-83호)」의 품목",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        466.02935791015625,
        546.0599975585938,
        481.84967041015625
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분류에 따라 인지치료소프트웨어(2등급, E06060.02) 의료기기로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        496.02935791015625,
        546.0599975585938,
        511.84967041015625
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분류된다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        526.0293579101562,
        128.82000732421875,
        541.8496704101562
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단, 추후 섭식장애 외 동반된 정신과적 증상에 대한 평가 또는 치료를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        556.0293579101562,
        546.0599975585938,
        571.8496704101562
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동시에 목적으로 한다면 심리평가소프트웨어(2등급, E06050.01) 또는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        586.0293579101562,
        546.0599975585938,
        601.8496704101562
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정서장애치료소프트웨어(2등급, E06070.01)의 의료기기 분류를 추가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        616.0293579101562,
        538.5599975585938,
        631.8496704101562
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여 조합의료기기로 분류할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        646.0293579101562,
        325.7629699707031,
        661.8496704101562
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 2 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        789.4503784179688,
        311.7449951171875,
        799.4103393554688
      ],
      "page_num": 9,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품목명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        79.68000030517578,
        109.68000030517578,
        454.67999267578125,
        124.08000183105469
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영문명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        79.68000030517578,
        109.68000030517578,
        454.67999267578125,
        124.08000183105469
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등급",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        79.68000030517578,
        109.68000030517578,
        454.67999267578125,
        124.08000183105469
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분류번호",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        79.68000030517578,
        109.68000030517578,
        454.67999267578125,
        124.08000183105469
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품목정의",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        79.68000030517578,
        109.68000030517578,
        454.67999267578125,
        124.08000183105469
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인지치료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.63999938964844,
        153.59999084472656,
        122.63999938964844,
        167.99998474121094
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.63999938964844,
        172.8000030517578,
        128.63999938964844,
        187.1999969482422
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Cognitive",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        157.3199920654297,
        144.0,
        204.86399841308594,
        158.39999389648438
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "therapy",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        162.1199951171875,
        163.1999969482422,
        200.1119842529297,
        177.59999084472656
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "software",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        159.47999572753906,
        182.39999389648438,
        202.70399475097656,
        196.79998779296875
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        236.51998901367188,
        163.1999969482422,
        315.8399963378906,
        177.59999084472656
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "E06060.02",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        236.51998901367188,
        163.1999969482422,
        315.8399963378906,
        177.59999084472656
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인지기능을 개선하는 데 사용하는 소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        326.6399841308594,
        153.59999084472656,
        531.239990234375,
        167.99998474121094
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가상·증강(VR·AR) 기반 소프트웨어를 포함",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        326.6399841308594,
        172.8000030517578,
        531.47998046875,
        187.1999969482422
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "심리평가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.63999938964844,
        224.87998962402344,
        122.63999938964844,
        239.2799835205078
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.63999938964844,
        244.07998657226562,
        128.63999938964844,
        258.47998046875
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Psychological",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        146.27999877929688,
        215.27999877929688,
        215.9399871826172,
        229.67999267578125
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "assessment",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        150.36000061035156,
        234.47999572753906,
        211.739990234375,
        248.87998962402344
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "software",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        159.47999572753906,
        253.67999267578125,
        202.70399475097656,
        268.0799865722656
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        236.51998901367188,
        234.47999572753906,
        315.8399963378906,
        248.87998962402344
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "E06050.01",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        236.51998901367188,
        234.47999572753906,
        315.8399963378906,
        248.87998962402344
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료인이 환자의 심리적 상태를 평가,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        326.6399841308594,
        224.87998962402344,
        533.3519897460938,
        239.2799835205078
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결정하는 데 사용하기 위한 소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        326.6399841308594,
        244.07998657226562,
        533.0399780273438,
        258.47998046875
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정서장애치료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        62.63999938964844,
        296.2799987792969,
        134.63999938964844,
        310.67999267578125
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.63999938964844,
        315.47998046875,
        128.63999938964844,
        329.8799743652344
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Affective",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        159.36000061035156,
        277.0799865722656,
        202.82400512695312,
        291.47998046875
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "disorder",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.55999755859375,
        296.2799987792969,
        201.72000122070312,
        310.67999267578125
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "therapy",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        162.1199951171875,
        315.47998046875,
        200.1119842529297,
        329.8799743652344
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "software",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        159.47999572753906,
        334.67999267578125,
        202.70399475097656,
        349.0799865722656
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        236.51998901367188,
        305.8800048828125,
        315.8399963378906,
        320.2799987792969
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "E06070.01",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        236.51998901367188,
        305.8800048828125,
        315.8399963378906,
        320.2799987792969
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정서장애(우울장애",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        326.6399841308594,
        286.67999267578125,
        533.3999633789062,
        301.0799865722656
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등)를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        326.6399841308594,
        286.67999267578125,
        533.3999633789062,
        301.0799865722656
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개선하는데",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        326.6399841308594,
        286.67999267578125,
        533.3999633789062,
        301.0799865722656
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용하는 소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        326.6399841308594,
        305.8800048828125,
        437.8800048828125,
        320.2799987792969
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가상ㆍ증강(VRㆍAR) 기반 소프트웨어를 포함",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        326.6399841308594,
        325.0799865722656,
        532.7999877929688,
        339.47998046875
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표 1. 섭식장애 개선 디지털치료기기 관련 의료기기 품목(식약처 고시 제2021-83호)",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        60.959999084472656,
        81.0,
        533.4417724609375,
        96.552001953125
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 본 가이드라인에서 다루는 섭식장애 개선 디지털치료기기는 소프트웨어 의료",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        56.63999938964844,
        379.20001220703125,
        538.4400024414062,
        394.75201416015625
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기로서, 사용 시 필요한 범용 장비(스마트폰 또는 태블릿 PC 등)는 적용",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        405.239990234375,
        538.4400024414062,
        420.7919921875
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "범위에 포함되지 않으나, 반드시 함께 병용해야 하므로 전기용품 안전 인증과",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        431.1600036621094,
        538.439453125,
        446.7120056152344
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전자파 적합성 인증을 통과한 제품을 사용해야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        457.20001220703125,
        397.8551940917969,
        472.75201416015625
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 실생활 습관을 추적 관찰하기 위해 기타 웨어러블 의료기기를 추가로 사용하는",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        56.63999938964844,
        483.239990234375,
        538.4400024414062,
        498.7919921875
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우는 별도의 안전성과 성능 시험을 통과한 제품의 사용을 권고한다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        509.1600036621094,
        478.7351989746094,
        524.7119750976562
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 3 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        789.4503784179688,
        311.7449951171875,
        799.4103393554688
      ],
      "page_num": 10,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 용어 설명",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        66.0,
        79.29995727539062,
        158.52000427246094,
        95.25996398925781
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 소프트웨어 의료기기(Software as a Medical Device, SaMD)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        120.54937744140625,
        487.6875,
        136.36968994140625
      ],
      "page_num": 10,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하드웨어에 종속되지 않고 의료기기의 사용 목적에 부합하는 기능을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        150.54937744140625,
        546.0599975585938,
        166.36968994140625
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가지며 독립적인 형태의 소프트웨어만으로 이루어진 의료기기이다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        180.54937744140625,
        538.04296875,
        196.36968994140625
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 디지털치료기기(Digital Therapeutics)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        210.54937744140625,
        332.4075012207031,
        226.36968994140625
      ],
      "page_num": 10,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인(민원인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        240.5493621826172,
        538.5599975585938,
        256.36968994140625
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방, 관리, 치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        270.54937744140625,
        538.4400024414062,
        286.36968994140625
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하기 위해 환자에게 근거 기반의 치료적 개입을 제공하는 소프트웨어",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        300.54937744140625,
        546.0599975585938,
        316.36968994140625
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기(SaMD)이다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        330.54937744140625,
        215.60296630859375,
        346.36968994140625
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 정신질환의 진단 및 통계 편람(Diagnostic and Statistical Manual of",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        360.54937744140625,
        545.9400024414062,
        376.36968994140625
      ],
      "page_num": 10,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Mental Disorders, Fifth Edition, DSM-5)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.04000091552734,
        390.54937744140625,
        350.4075012207031,
        406.36968994140625
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미국 정신의학협회(American Psychiatric Association, APA)에서 발행한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        420.54937744140625,
        546.0599975585938,
        436.36968994140625
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정신질환의 신뢰할 만한 진단이 가능하도록 고안된 관련 기준들을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        450.54937744140625,
        546.0599975585938,
        466.36968994140625
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통칭하는 정신질환 분류법이다. DSM-5는 2013년도의 새로운 업데이트",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        480.54937744140625,
        545.9400024414062,
        496.36968994140625
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "버전이다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        510.54937744140625,
        140.00296020507812,
        526.3696899414062
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 4 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        789.4503784179688,
        311.7449951171875,
        799.4103393554688
      ],
      "page_num": 11,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 현황",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        79.29995727539062,
        117.1199951171875,
        95.25996398925781
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 섭식장애 인구학적 특성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        122.58937072753906,
        248.1599884033203,
        138.40968322753906
      ],
      "page_num": 11,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DSM-5에 따르면 섭식장애는 음식 섭취와 관련된 행동에 이상을 보이는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        152.58937072753906,
        545.9400024414062,
        168.40968322753906
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질환으로서, 체중 증가에 대한 극심한 두려움 때문에 식사를 거르는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        182.58937072753906,
        546.0599975585938,
        198.40968322753906
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질병인 신경성 식욕부진증(Anorexia Nervosa), 음식 섭취 후 구토 등의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        212.58937072753906,
        545.9400024414062,
        228.40968322753906
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방식을 사용하여 체중을 줄이려 하는 신경성 폭식증(Bulimia Nervosa),",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        242.58937072753906,
        545.9400024414062,
        258.40966796875
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비정상적으로 많은 양의 음식을 자주 섭취하면서도 먹는 것을 멈출 수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        272.58935546875,
        545.9400024414062,
        288.40966796875
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없다고 느끼는 폭식장애(Binge-Eating Disorder) 등으로 정의된다. 섭식",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        302.58935546875,
        538.5599975585938,
        318.40966796875
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장애는 청소년기 혹은 성인 초기에 발생하며 여성에게 주로 나타난다",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        332.58935546875,
        538.5599975585938,
        348.40966796875
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Park, 2000).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        362.58935546875,
        150.05999755859375,
        378.40966796875
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "섭식장애 유병률은 전 세계 인구의 3%로 추산되며, 미국 섭식장애 유",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        392.58935546875,
        538.4400024414062,
        408.40966796875
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "병률은 신경성 식욕부진증의 경우 약 0.8%, 신경성 폭식증의 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        422.58935546875,
        545.9400024414062,
        438.40966796875
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "0.28%, 폭식장애의 경우 0.85%이다. 성별로 보았을 때는, 소년의 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        452.58935546875,
        546.0599975585938,
        468.40966796875
      ],
      "page_num": 11,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7.1%, 소녀의 경우 13.4% 비율의 유병률을 보인다(Neumark-Sztainer,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        482.58935546875,
        545.9400024414062,
        498.40966796875
      ],
      "page_num": 11,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Hannan, 2000). 건강보험심사평가원 자료에 따르면, 2021년 기준 국내",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        512.58935546875,
        545.9400024414062,
        528.40966796875
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "섭식장애 환자는 약 1만명으로 확인되며, 실제 유병률은 예상보다 높을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        542.58935546875,
        546.0599975585938,
        558.40966796875
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것으로 추정된다. 임상에서 섭식장애가 인지되는 경우는 50%에 미치지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        572.58935546875,
        545.9400024414062,
        588.40966796875
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "못하는 경우가 많은데(Whitehouse et al., 1992), 이는 일반적으로 섭식",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        602.58935546875,
        538.5599975585938,
        618.40966796875
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장애 환자들이 증상을 드러내지 않거나 숨기는 경우가 있기 때문이다",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        632.58935546875,
        538.5599975585938,
        648.40966796875
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Park, 2000). 섭식장애는 신체 합병증을 동반하는 경우가 흔하며, 기능",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        662.58935546875,
        538.5599975585938,
        678.40966796875
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장애를 초래하고 쉽게 만성화된다는 특징을 지닌다(Kim, 2018). 이러한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        692.58935546875,
        546.0599975585938,
        708.40966796875
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과로 치료가 지연되는 경우가 많으며, 모든 원인에 의한 사망률과",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        722.58935546875,
        546.0599975585938,
        738.40966796875
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자살로 인한 사망률의 증가와 관련이 있다(Auger et al. 2021;",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        752.58935546875,
        546.0599975585938,
        768.40966796875
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 5 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        789.4503784179688,
        311.7449951171875,
        799.4103393554688
      ],
      "page_num": 12,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Nielsen and Vilmar 2021; Tith et al. 2020; van Hoeken and Hoek",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        545.9400024414062,
        86.56968688964844
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2020).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        100.74937438964844,
        95.84296417236328,
        116.56968688964844
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한, 섭식장애는 우울, 불안 등의 정신질환을 동반하며, 섭식장애로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        130.74937438964844,
        545.9400024414062,
        146.56968688964844
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인한 영양 부족은 면역력 저하, 수면 장애 등의 증상 발현으로 이어질",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        160.74937438964844,
        546.0599975585938,
        176.56968688964844
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        190.74937438964844,
        119.0999984741211,
        206.56968688964844
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 섭식장애 진단 절차/과정",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        250.74935913085938,
        252.83999633789062,
        266.5696716308594
      ],
      "page_num": 12,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "섭식장애는 크게 1) 신경성 식욕부진증, 2) 신경성 폭식증, 3) 폭식",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        280.7493591308594,
        538.4400024414062,
        296.5696716308594
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장애로 정의된다. 신경성 식욕부진증은 DSM-5 진단 기준에 따라,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        310.7493591308594,
        545.9400024414062,
        326.5696716308594
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연령과 체중에 비해 지나친 음식물 제한으로 현저한 체중의 감소, 체중",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        340.7493591308594,
        545.9400024414062,
        356.5696716308594
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증가 및 비만에 대한 극심한 두려움, 체중 증가를 막기 위한 지속적인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        370.7493591308594,
        545.9400024414062,
        386.5696716308594
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "행동을 보이는 경우 등을 고려해 진단한다. 신경성 폭식증은 폭식 여부",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        400.7493591308594,
        538.4400024414062,
        416.5696716308594
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(통제감 상실 상태로 많은 양의 음식을 2시간 안에 먹는 경우), 자발적인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        430.7493591308594,
        545.9400024414062,
        446.5696716308594
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구토 및 설사제 남용과 같은 행동을 동반할 경우, 체중에 대한 과대",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        460.7493591308594,
        545.9400024414062,
        476.5696716308594
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가 등의 기준으로 진단하게 된다. 여기서 신경성 식욕부진증과 신경성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        490.7493591308594,
        546.0599975585938,
        506.5696716308594
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "폭식증을 포괄하는 범진단적 개념은 체형과 체중에 대한 과대평가이다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        520.7493896484375,
        545.0999755859375,
        536.5697021484375
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "섭식장애 환자는 여러 질환이 동시적으로 발현되기 때문에, 평가 시에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        550.7493896484375,
        546.0599975585938,
        566.5697021484375
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상황을 고려한 진단이 필요하다. 만성적 신경성 식욕부진증은 불안,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        580.7493896484375,
        546.0599975585938,
        596.5697021484375
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자폐, 강박성 스펙트럼, 쾌락에 무반응 등의 특성을 보인다. 반면,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        610.7493896484375,
        546.0599975585938,
        626.5697021484375
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신경성 폭식증에서는 과식 경향과 주의력결핍 과잉행동장애의 특질로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        640.7493896484375,
        546.0599975585938,
        656.5697021484375
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나타나는 집중 및 충동성의 문제가 선행한다(Kim, 2018).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        670.7493896484375,
        440.3629455566406,
        686.5697021484375
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "섭식장애에 대한 치료는 정신건강교육(Psychoeducation)과 영양관리,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        700.7493286132812,
        546.0599975585938,
        716.5696411132812
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "행동치료, 가족치료, 대인관계 정신치료(Interpersonal Psychotherapy:",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        730.7493286132812,
        546.0599975585938,
        746.5696411132812
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 6 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        789.4503784179688,
        311.7449951171875,
        799.4103393554688
      ],
      "page_num": 13,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "IPT), 정신역동적 치료 등 여러 가지 심리적인 치료와 약물치료가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        546.0599975585938,
        86.56968688964844
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시행된다. 그중에서도 인지행동치료(Cognitive Behavioral Therapy, CBT)가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        100.74937438964844,
        546.0599975585938,
        116.56968688964844
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가장 널리 사용되어 왔다(Kong et al., 2000).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        130.74937438964844,
        365.1000061035156,
        146.56968688964844
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 섭식장애 비약물 치료(섭식장애 인지행동치료)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        190.74937438964844,
        399.9674987792969,
        206.56968688964844
      ],
      "page_num": 13,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "섭식장애 환자들의 섭식행동 관련 태도, 경험, 삶 등을 토대로 한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        220.74937438964844,
        545.9400024414062,
        236.56968688964844
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "심리적 개입이나 비약물적 개입이 권장되고 있으며(Reas&Grilo, 2008),",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        250.74935913085938,
        546.0599975585938,
        266.5696716308594
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인지행동치료(Cognitive Behavioral Therapy, CBT)(Kwon&Kwon, 2003;",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        280.7493591308594,
        546.0599975585938,
        296.5696716308594
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Wilfley et al., 1993; Park&Son, 2012), 식단조절(Baer, Fischer, & Huss,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        310.7493591308594,
        545.9400024414062,
        326.5696716308594
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2005; Kristeller&Hallett, 1999; Smith, Shelley, Leahigh, & Vanleit, 20",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        340.7493591308594,
        538.5,
        356.5696716308594
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "06), 명상(Kim, 2004; Lee&Kim, 2015)이나 미술치료(Kim&Jo, 2014)와",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        370.7493591308594,
        545.9400024414062,
        386.5696716308594
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같은 활동치료 등이 사용되고 있다. 그 중에서 인지행동치료는 정신",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        400.7493591308594,
        538.5599975585938,
        416.5696716308594
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질환 및 정서적 문제에 우선적으로 권고되는 치료방법으로서 부정적",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        430.7493591308594,
        538.5599975585938,
        446.5696716308594
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이고 왜곡된 인지구조를 깨닫도록 도와주며 주어진 상황이나 현실에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        460.7493591308594,
        546.0599975585938,
        476.5696716308594
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "더 적절하게 대처할 수 있도록 돕는 것으로 인식된다(Han, 2003).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        490.7493591308594,
        517.260009765625,
        506.5696716308594
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선행연구에 의하면, 섭식장애를 진단받은 환자를 대상으로 비약물적",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        520.7493896484375,
        545.9400024414062,
        536.5697021484375
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중재와 약물적 중재의 효과를 비교한 연구에서 약물적 중재보다",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        550.7493896484375,
        546.0599975585938,
        566.5697021484375
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비약물적 중재를 적용한 군이 오히려 폭식 증상 감소에 효과적인 것",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        580.7493896484375,
        538.5599975585938,
        596.5697021484375
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 보고된 바 있으며(Vocks et al., 2010), 비약물적 중재가 식이에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        610.7493896484375,
        545.9400024414062,
        626.5697021484375
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 태도를 긍정적으로 변화시키는 것으로 나타났다(Yun&Kim,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        640.7493896484375,
        546.0599975585938,
        656.5697021484375
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2018).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        670.7493896484375,
        103.25999450683594,
        686.5697021484375
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영국 국립보건임상평가연구소(National Institute for Health and Care",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        700.7493286132812,
        545.9400024414062,
        716.5696411132812
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Excellence, NICE)가 발간한 섭식장애 가이던스에는 질환 치료법 중 하나로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        730.7493286132812,
        545.9400024414062,
        746.5696411132812
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 7 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        789.4503784179688,
        311.7449951171875,
        799.4103393554688
      ],
      "page_num": 14,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인지행동치료를 포함한다. 성인 신경성 식욕부진증 환자의 경우, 여러 심리",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        538.4400024414062,
        86.56968688964844
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료 중 인지행동치료(Cognitive Behavioral Therapy for Eating Disorder,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        100.74937438964844,
        546.0599975585938,
        116.56968688964844
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CBT-ED) 프로그램을 선택할 수 있다. 일반적으로 40주 동안 최대 40개의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        130.74937438964844,
        545.9400024414062,
        146.56968688964844
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세션으로 구성된 CBT-ED 프로그램을 수행하게 되며, 처음 2~3주 동안은",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        160.74937438964844,
        546.0599975585938,
        176.56968688964844
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주 2회 세션으로 구성된다. 프로그램은 신체적 및 정신적 건강 문제 해결,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        190.74937438964844,
        546.0599975585938,
        206.56968688964844
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "건강한 식습관 장려, 영양, 인지 재구성, 기분 조절, 자존감 관리, 재발 방지를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        220.74937438964844,
        546.0599975585938,
        236.56968688964844
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위한 계획 수립 등의 과정으로 이루어진다. 성인 신경성 폭식증 환자의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        250.74935913085938,
        545.9400024414062,
        266.5696716308594
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우에는 일반적으로 20주 동안 최대 20회 세션으로 구성된 CBT-ED",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        280.7493591308594,
        546.0599975585938,
        296.5696716308594
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로그램을 수행하게 되며, 첫 번째 단계에서는 참여와 교육, 규칙적인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        310.7493591308594,
        545.9400024414062,
        326.5696716308594
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식습관 확립 등을 주 2회 진행한다. 성인 폭식장애 환자의 경우, 일반적",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        340.7493591308594,
        538.5599975585938,
        356.5696716308594
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 4개월에 걸쳐 매주 16개의 90분 그룹 세션을 진행한다. 심리 교육,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        370.7493591308594,
        545.9400024414062,
        386.5696716308594
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식습관 자체 모니터링, 재발 방지를 위한 계획 수립 등의 내용으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        400.7493591308594,
        546.0599975585938,
        416.5696716308594
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성되어 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        430.7493591308594,
        165.66000366210938,
        446.5696716308594
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미국 정신의학회(APA)의 섭식장애 진료지침은 신경성 식욕부진증,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        460.7493591308594,
        546.0599975585938,
        476.5696716308594
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신경성 폭식증, 폭식장애 치료법에 인지행동치료를 권고하고 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        490.7493591308594,
        545.9400024414062,
        506.5696716308594
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다만, 청소년과 나이가 어린 성인 환자의 경우에는, 가족 기반 치료를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        520.7493896484375,
        545.9400024414062,
        536.5697021484375
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "권장한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        550.7493896484375,
        129.89999389648438,
        566.5697021484375
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 8 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        789.4503784179688,
        311.7449951171875,
        799.4103393554688
      ],
      "page_num": 15,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(출처: 섭식장애 환자 치료를 위한 임상 가이드라인, 미국정신의학회(2023))",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        56.63999938964844,
        511.32000732421875,
        466.2120056152344,
        525.7200317382812
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유형",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        94.31999969482422,
        95.63999938964844,
        354.3599853515625,
        110.04000091552734
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        94.31999969482422,
        95.63999938964844,
        354.3599853515625,
        110.04000091552734
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신경성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        88.31999969482422,
        179.51998901367188,
        124.31999969482422,
        193.91998291015625
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식욕부진증",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.31999969482422,
        198.72000122070312,
        136.32000732421875,
        213.1199951171875
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Anorexia",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.68000030517578,
        217.9199981689453,
        129.88800048828125,
        232.3199920654297
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Nervosa)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        83.87999725341797,
        237.1199951171875,
        128.77198791503906,
        251.51998901367188
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 목표 체중 달성을 위한 영양 재활을 진행한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        121.91999816894531,
        428.1000061035156,
        136.3199920654297
      ],
      "page_num": 15,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 영양 재활 중에는 심리적 치료, 신체적 활동 등을 병행할 수 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        141.1199951171875,
        520.5,
        155.51998901367188
      ],
      "page_num": 15,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 심리치료 일환으로 인지행동치료(CBT 또는 CBT-E)를 활용한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        160.3199920654297,
        520.97998046875,
        174.71998596191406
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 인지행동치료(CBT)에 비해 대인관계와 통찰력에 집중하는 초점",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        179.51998901367188,
        523.7999877929688,
        193.91998291015625
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정신역학 심리치료(Focal Psychodynamic Therapy, FPT)를 활용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        198.72000122070312,
        523.7999877929688,
        213.1199951171875
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        217.9199981689453,
        199.6199951171875,
        232.3199920654297
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 전문가 지원 임상관리(Specialist Supportive Clinical Management,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        237.1199951171875,
        523.8720092773438,
        251.51998901367188
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SSCM)를 통한 치료 또한 받을 수 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        256.32000732421875,
        390.29998779296875,
        270.7200012207031
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 성인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        275.5199890136719,
        523.9199829101562,
        289.91998291015625
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "환자",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        275.5199890136719,
        523.9199829101562,
        289.91998291015625
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일부는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        275.5199890136719,
        523.9199829101562,
        289.91998291015625
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가족치료(Family-Based",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        275.5199890136719,
        523.9199829101562,
        289.91998291015625
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Treatment,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        275.5199890136719,
        523.9199829101562,
        289.91998291015625
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "FBT)를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        275.5199890136719,
        523.9199829101562,
        289.91998291015625
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "받기도 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        294.7200012207031,
        241.25999450683594,
        309.1199951171875
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신경성 폭식증",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        67.31999969482422,
        354.0,
        145.3199920654297,
        368.3999938964844
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Bulimia",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        86.5199966430664,
        373.1999816894531,
        126.04800415039062,
        387.5999755859375
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Nervosa)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        83.87999725341797,
        392.3999938964844,
        128.77198791503906,
        406.79998779296875
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 주로 인지행동치료(CBT)를 시행하며, 제한적이긴 하나 대인관계",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        325.1999816894531,
        523.7999877929688,
        339.5999755859375
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 심리역학 치료를 시행하기도 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        175.0800018310547,
        344.3999938964844,
        382.0199890136719,
        358.79998779296875
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 환자의 선호도나 상황에 따라 인지행동치료(CBT)를 기반으로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        363.6000061035156,
        523.9199829101562,
        378.0
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 자료를 사용한 자조 요법(Guided self-help, GSH)이 활용되기도",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        382.79998779296875,
        523.7999877929688,
        397.1999816894531
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        172.9199981689453,
        402.0,
        199.86000061035156,
        416.3999938964844
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 일부는 가족치료(Family-Based Treatment, FBT)를 받기도 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        421.1999816894531,
        514.0199584960938,
        435.5999755859375
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "폭식 장애",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        79.31999969482422,
        451.67999267578125,
        133.32000732421875,
        466.0799865722656
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Binge-Eating",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        71.76000213623047,
        470.8799743652344,
        140.86801147460938,
        485.27996826171875
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Disorder)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        83.75999450683594,
        490.0799865722656,
        128.89199829101562,
        504.47998046875
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 주로 인지행동치료(CBT) 또는 대인관계 치료를 수행하며, 개인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        160.9199981689453,
        461.2799987792969,
        523.9199829101562,
        475.67999267578125
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또는 그룹으로 진행된다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        173.87998962402344,
        480.47998046875,
        307.5,
        494.8799743652344
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 2. 섭식장애 유형별 비약물치료 내용",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        168.72000122070312,
        69.0,
        416.0400390625,
        84.552001953125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 9 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        283.44000244140625,
        789.4503784179688,
        311.7449951171875,
        799.4103393554688
      ],
      "page_num": 16,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라. 섭식장애 약물치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        210.72000122070312,
        86.56968688964844
      ],
      "page_num": 16,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "섭식장애 인지행동치료 등 비약물 치료 효과가 미비한 경우, 필요하다면",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        100.74937438964844,
        545.9400024414062,
        116.56968688964844
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약물치료를 통해 섭식장애를 개선할 수 있다. 약물치료로는 항우울제,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        130.74937438964844,
        545.9400024414062,
        146.56968688964844
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세로토닌·노르에피네프린 재흡수 억제제, 간질 치료제, 비만 치료제",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        160.74937438964844,
        546.0599975585938,
        176.56968688964844
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등의 약제가 사용되나 효과나 부작용 측면에서 사용이 제한적이다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        190.74937438964844,
        545.9400024414062,
        206.56968688964844
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단, 불가피하게 약물치료가 필요할 경우, 환자의 상황에 맞게 임상의가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        220.74937438964844,
        545.9400024414062,
        236.56968688964844
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절하게 판단하여 사용하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        250.74935913085938,
        308.1229553222656,
        266.5696716308594
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 10 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 17,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마. 섭식장애 비약물 치료의 임상 권고 사항",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        360.6000061035156,
        86.56968688964844
      ],
      "page_num": 17,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미국정신의학회(APA), 영국 국립보건임상평가연구소(NICE) 등은 섭식",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        100.74937438964844,
        538.5599975585938,
        116.56968688964844
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장애 치료를 위해 비약물 치료를 우선하여 시행하기를 권고한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        130.74937438964844,
        545.9400024414062,
        146.56968688964844
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한 국제섭식장애학회(Academy for eating disorders, AED)의 ‘섭식",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        160.74937438964844,
        538.5599975585938,
        176.56968688964844
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장애에 대한 증거 기반 심리치료 가이드’에서는 섭식장애에 대한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        190.74937438964844,
        545.9400024414062,
        206.56968688964844
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비약물 치료로 인지행동치료(CBT)를 우선 치료전략으로 제안하였다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        220.74937438964844,
        532.97998046875,
        236.56968688964844
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진료지침*",
      "font_size": 8.279999732971191,
      "font_name": "T10",
      "bbox": [
        107.04000091552734,
        283.9200134277344,
        288.3606262207031,
        306.6719970703125
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신경성",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        107.04000091552734,
        283.9200134277344,
        288.3606262207031,
        306.6719970703125
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식욕부진증",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        234.47999572753906,
        291.1199951171875,
        508.0812072753906,
        313.75201416015625
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신경성 폭식증",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        234.47999572753906,
        291.1199951171875,
        508.0812072753906,
        313.75201416015625
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "폭식장애",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        234.47999572753906,
        291.1199951171875,
        508.0812072753906,
        313.75201416015625
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "APA 진료지침(2023)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.19999694824219,
        316.79998779296875,
        493.44000244140625,
        331.1999816894531
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "권장",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.19999694824219,
        316.79998779296875,
        493.44000244140625,
        331.1999816894531
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "권장",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.19999694824219,
        316.79998779296875,
        493.44000244140625,
        331.1999816894531
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "권장",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.19999694824219,
        316.79998779296875,
        493.44000244140625,
        331.1999816894531
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NICE 진료지침(2017)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        79.91999816894531,
        336.8399963378906,
        493.44000244140625,
        351.239990234375
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "권장",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        79.91999816894531,
        336.8399963378906,
        493.44000244140625,
        351.239990234375
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "권장",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        79.91999816894531,
        336.8399963378906,
        493.44000244140625,
        351.239990234375
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "권장",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        79.91999816894531,
        336.8399963378906,
        493.44000244140625,
        351.239990234375
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AED 가이드라인(2020)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.72000122070312,
        356.8800048828125,
        504.26397705078125,
        371.2799987792969
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "First-line",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.72000122070312,
        356.8800048828125,
        504.26397705078125,
        371.2799987792969
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "First-line",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.72000122070312,
        356.8800048828125,
        504.26397705078125,
        371.2799987792969
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "First-line",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.72000122070312,
        356.8800048828125,
        504.26397705078125,
        371.2799987792969
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* APA: American Psychiatric Association, NICE: National Institute for Health and Care",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        61.79999923706055,
        374.3999938964844,
        529.4639892578125,
        388.79998779296875
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Excellence, AED: Academy for eating disorders",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        72.72000122070312,
        390.0,
        319.32000732421875,
        404.3999938964844
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 3. 진료지침별 섭식장애 인지행동치료의 권고 사항",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        127.43999481201172,
        261.0,
        463.0800476074219,
        276.552001953125
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미국정신의학회(APA) 진료지침(2023)은 섭식장애 치료를 위해 비약물",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        432.0693664550781,
        546.0599975585938,
        447.8896789550781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료 시행을 권장한다. 비약물 치료로는 영양 재활치료를 포함한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        462.0693664550781,
        546.0599975585938,
        477.8896789550781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정상 체중 회복을 위한 심리치료가 진행되며, 인지행동치료(CBT)도",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        492.0693664550781,
        545.9400024414062,
        507.8896789550781
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활용된다. 영국 국립보건임상평가연구소(NICE) 진료지침(2017)도 인지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        522.0693359375,
        538.5599975585938,
        537.8896484375
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "행동치료(CBT)를 포함한 심리치료가 섭식장애 치료법으로 고려되고",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        552.0693359375,
        546.0599975585938,
        567.8896484375
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다. 국제섭식장애학회(AED)가 발간한 섭식장애 가이드라인(2020)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        582.0693359375,
        538.5675048828125,
        597.8896484375
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에서는 섭식장애 치료의 First-line으로 인지행동치료(CBT-ED)가 권고",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        612.0693359375,
        538.5599975585938,
        627.8896484375
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "된다. 다만, 섭식장애 비약물 치료는 섭식장애 유형, 환자의 상태를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        642.0693359375,
        546.0599975585938,
        657.8896484375
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려해 약물치료를 실시할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        672.0693359375,
        300.5629577636719,
        687.8896484375
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 11 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 18,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바. 디지털 기반 섭식장애 치료 관련 선행연구",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        375.6000061035156,
        86.56968688964844
      ],
      "page_num": 18,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디지털 기반 섭식장애 치료는 대게 웹 또는 스마트폰 앱 기반으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        100.74937438964844,
        546.0599975585938,
        116.56968688964844
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인지행동치료(CBT)를 시행한다. 우선, 폭식장애 환자를 대상으로 16주간",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        130.74937438964844,
        546.0599975585938,
        146.56968688964844
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인터넷 기반 중재 프로그램을 시행한 선행연구를 살펴보았다. 해당",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        160.74937438964844,
        545.9400024414062,
        176.56968688964844
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구는 인지행동 대면 치료 및 자조 요법을 포함한 디지털 인지행동",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        190.74937438964844,
        538.5599975585938,
        206.56968688964844
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료 프로그램이 마련되었고, 글쓰기 과제, 임상심리사로부터의 피드백,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        220.74937438964844,
        546.0599975585938,
        236.56968688964844
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활동 일기, 심리 교육 등으로 구성되었다. 위 연구는 폭식 횟수 감소",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        250.74935913085938,
        546.0599975585938,
        266.5696716308594
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등 폭식장애 증상 완화, EDE-Q 척도 감소 또는 유지, 우울 증상 완화",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        280.7493591308594,
        545.9400024414062,
        296.5696716308594
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등의 긍정적 결과를 보였다(Wagner et al., 2016).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        310.7493591308594,
        393.8029479980469,
        326.5696716308594
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한, 디지털 기반 섭식장애 치료는 섭식장애 환자들의 건강 개선에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        340.7493591308594,
        545.9400024414062,
        356.5696716308594
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "효과적인 것으로 입증되었다(terHuurne et al., 2015). 해당 연구에서는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        370.7493591308594,
        546.0599975585938,
        386.5696716308594
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "섭식장애를 겪고 있는 여성 환자 총 214명 대상으로 웹 기반의 인지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        400.7493591308594,
        538.5599975585938,
        416.5696716308594
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "행동치료(CBT) 중재를 수행했다. 웹 기반 애플리케이션은 21개의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        430.7493591308594,
        546.0599975585938,
        446.5696716308594
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세션과 10개의 과제로 구성되었으며, 참가자들은 하루 약 20분 정도의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        460.7493591308594,
        545.9400024414062,
        476.5696716308594
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중재를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        490.7493591308594,
        546.0599975585938,
        506.5696716308594
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "받았다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        490.7493591308594,
        546.0599975585938,
        506.5696716308594
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일차",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        490.7493591308594,
        546.0599975585938,
        506.5696716308594
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        490.7493591308594,
        546.0599975585938,
        506.5696716308594
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변수는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        490.7493591308594,
        546.0599975585938,
        506.5696716308594
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "EDE-Q(Eating",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        490.7493591308594,
        546.0599975585938,
        506.5696716308594
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Disorder",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        490.7493591308594,
        546.0599975585938,
        506.5696716308594
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Examination-Questionnaire), 이차 유효성 변수는 BAT(Body Attitude",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        520.7493896484375,
        546.0599975585938,
        536.5697021484375
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Test)가 사용되었다. 결과적으로 환자들은 신체 및 정신 건강, 자존감",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        550.7493896484375,
        546.0599975585938,
        566.5697021484375
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등이 크게 상승한 것을 알 수 있었다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        580.7493896484375,
        315.5629577636719,
        596.5697021484375
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 12 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 19,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사. 섭식장애 개선 디지털치료기기의 국외 사례",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        383.1600036621094,
        86.56968688964844
      ],
      "page_num": 19,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "현재 국외에서 섭식장애 개선 디지털치료기기로서, 허가된 제품 및",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        100.74937438964844,
        546.0599975585938,
        116.56968688964844
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인지행동치료(CBT)를 이용한 제품은 다음과 같다 <표 6>.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        130.74937438964844,
        450.4429626464844,
        146.56968688964844
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연번",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        66.83999633789062,
        198.0,
        90.83999633789062,
        212.39999389648438
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품명(제조업체)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        138.0,
        187.67999267578125,
        228.85198974609375,
        202.07998657226562
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품설명",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        381.0,
        198.0,
        429.0,
        212.39999389648438
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품외형",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        159.47999572753906,
        208.3199920654297,
        207.47999572753906,
        222.71998596191406
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.83999633789062,
        352.55999755859375,
        81.83999633789062,
        366.9599914550781
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Selfapy",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        164.63999938964844,
        234.47999572753906,
        202.15199279785156,
        248.87998962402344
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Selfapy GmbH)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        141.47999572753906,
        246.95999145507812,
        536.1599731445312,
        268.0799865722656
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 12주 온라인 과정으로 구성되었으며, 오디오와",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        141.47999572753906,
        246.95999145507812,
        536.1599731445312,
        268.0799865722656
      ],
      "page_num": 19,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비디오 클립, 텍스트, 연습 등을 통해 제공된다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.32000732421875,
        266.1600036621094,
        536.0999755859375,
        280.55999755859375
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주제는 심리교육, 부정적인 생각과 감정 다루기,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.32000732421875,
        285.3599853515625,
        536.2319946289062,
        299.7599792480469
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식습관과 자존감, 휴식 기술, 문제 해결 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.32000732421875,
        304.55999755859375,
        536.1599731445312,
        318.9599914550781
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "재발 방지에 관한 내용을 포함하고, 새롭게",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.32000732421875,
        323.7599792480469,
        536.1599731445312,
        338.15997314453125
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "습득한 전략과 기술을 일상생활에 적용하기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.32000732421875,
        342.9599914550781,
        536.1599731445312,
        357.3599853515625
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위한 과제를 제공한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.32000732421875,
        362.1600036621094,
        409.2599792480469,
        376.55999755859375
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 환자는 컴퓨터 또는 노트북, 태블릿 또는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.8399963378906,
        381.3599853515625,
        536.1599731445312,
        395.7599792480469
      ],
      "page_num": 19,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "스마트폰 등 어디에서나 과정을 완료할 수",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.91998291015625,
        400.55999755859375,
        536.1599731445312,
        414.9599914550781
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있고, 일주일에 한 번, 약 60분의 사용을 권장",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.91998291015625,
        419.7599792480469,
        536.1599731445312,
        434.15997314453125
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고 총 90일간 사용 가능하다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        286.91998291015625,
        438.9599914550781,
        457.8599853515625,
        453.3599853515625
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(출처: Selfapy,",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        148.1999969482422,
        450.09033203125,
        222.07803344726562,
        460.0503234863281
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "https://www.selfapy.com/)",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        120.1199951171875,
        466.0503234863281,
        250.03526306152344,
        476.01031494140625
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 4. 국외 섭식장애 개선 디지털치료기기 허가 제품 및 관련 제품의 개발 동향(2023. 8. 기준)",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        62.52000045776367,
        161.87998962402344,
        537.5217895507812,
        177.43199157714844
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 13 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 20,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아. 디지털치료기기의 정의와 국내 가이드라인별 적용 기준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        465.5999755859375,
        86.56968688964844
      ],
      "page_num": 20,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 디지털치료기기 정의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        100.74937438964844,
        233.87998962402344,
        116.56968688964844
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        130.74937438964844,
        546.0599975585938,
        146.56968688964844
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(민원인 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        94.07999420166016,
        160.74937438964844,
        545.9400024414062,
        176.56968688964844
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리, 치료하기 위해 환자에게 근거 기반의 치료적 개입을 제공",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        94.07999420166016,
        190.74937438964844,
        538.4400024414062,
        206.56968688964844
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 소프트웨어 의료기기(SaMD)이다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        94.07999420166016,
        220.74937438964844,
        361.8599853515625,
        236.56968688964844
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ “예방, 관리”의 범위는 치료적 개입이 필요한 “환자”를 대상으로 함",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        90.0,
        248.99998474121094,
        508.91998291015625,
        264.552001953125
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 국내 가이드라인별 적용 기준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        306.78936767578125,
        293.7599792480469,
        322.60968017578125
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 디지털치료기기 허가·심사 가이드라인(민원인 안내서)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        336.78936767578125,
        490.6875,
        352.60968017578125
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "디지털치료기기는 「의료기기법」 제2조에 따른 사용 목적에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        366.78936767578125,
        546.0599975585938,
        382.60968017578125
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당해야 하며, <그림 1>과 같이 소프트웨어 의료기기로써 범용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        396.78936767578125,
        546.0599975585938,
        412.60968017578125
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하드웨어에 설치되고, 질병을 예방, 관리 또는 치료하기 위한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        426.78936767578125,
        546.0599975585938,
        442.60968017578125
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목적으로 환자에게 적용되어야 한다. 또한, 치료 작용기전의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        456.78936767578125,
        546.0599975585938,
        472.60968017578125
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과학적(임상적) 근거에 해당하는 자료가 있어야 한다. 여기서",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        486.78936767578125,
        545.9400024414062,
        502.60968017578125
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질병이란 국제질병분류코드(International Classification of Disease,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        516.7893676757812,
        546.0599975585938,
        532.6096801757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ICD)에 기반한 한국표준질병사인분류에 독립적으로 분류 가능한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        546.7893676757812,
        546.0599975585938,
        562.6096801757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질환으로 정의한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        576.7893676757812,
        240.56295776367188,
        592.6096801757812
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "디지털 섭식장애 인지행동치료(CBT)는 섭식장애 인지행동치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        606.7893676757812,
        546.0599975585938,
        622.6096801757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반의 콘텐츠를 범용 스마트폰이나 태블릿PC에 설치되어 제공",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        636.7893676757812,
        538.5599975585938,
        652.6096801757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하므로 소프트웨어 의료기기에 해당한다. 또한 한국표준질병",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        666.7893676757812,
        538.4400024414062,
        682.6096801757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사인분류에 따라 섭식장애를 의사에게 진단받은 환자들을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        696.7893676757812,
        546.0599975585938,
        712.6096801757812
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대상으로 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        726.7893676757812,
        210.56295776367188,
        742.6096801757812
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 14 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 21,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미국, 영국 등 많은 학회와 연구소에서 개발한 임상진료지침",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        70.74937438964844,
        545.9400024414062,
        86.56968688964844
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등에 따르면, 섭식장애의 비약물 치료를 우선 시행하며, 그중",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        100.74937438964844,
        538.4400024414062,
        116.56968688964844
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에서도 인지행동치료(CBT)를 시행하기를 권고하고 있다. 또한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        130.74937438964844,
        546.0599975585938,
        146.56968688964844
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디지털 기반 섭식장애 관련 선행연구에서 임상시험을 통해",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        160.74937438964844,
        546.0599975585938,
        176.56968688964844
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디지털 섭식장애 인지행동치료의 효과성을 입증된 바 있다",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        190.74937438964844,
        538.5599975585938,
        206.56968688964844
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(terHuurne et al., 2015).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        220.74937438964844,
        274.7629699707031,
        236.56968688964844
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위와 같이 섭식장애 디지털치료기기는 디지털치료기기 대상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        250.74935913085938,
        545.9400024414062,
        266.5696716308594
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여부 판단기준 및 절차를 충족하므로 디지털치료기기 대상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        280.7493591308594,
        538.5599975585938,
        296.5696716308594
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이라고 판단할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        310.7493591308594,
        272.2429504394531,
        326.5696716308594
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "그림 1. 디지털 치료기기 대상여부 판단 기준 및 절차",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        129.72000122070312,
        696.3599853515625,
        464.76055908203125,
        711.9119873046875
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[출처: 식품의약품안전처(2020.08), 디지털치료기기 허가·심사 가이드라인(민원인 안내서)]",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        75.36000061035156,
        716.0399780273438,
        519.8759765625,
        730.4400024414062
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 15 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 22,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나) 의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        70.74937438964844,
        530.16748046875,
        86.56968688964844
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디지털치료기기는 식품의약품안전처‘의료기기의 사이버보안",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        100.74937438964844,
        546.0599975585938,
        116.56968688964844
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허가·심사 가이드라인(민원인 안내서)’에 근거하여 보안성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        130.74937438964844,
        546.0599975585938,
        146.56968688964844
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영역은 가용성(Availability), 기밀성(Confidentiality), 무결성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        160.74937438964844,
        538.5599975585938,
        176.56968688964844
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Integrity)을 고려하여 평가한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        190.74937438964844,
        327.8029479980469,
        206.56968688964844
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가용성은 데이터가 승인된 사용자에게 즉시 제공되어야 하며,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        220.74937438964844,
        545.9400024414062,
        236.56968688964844
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요한 때에 필요한 곳에서 필요한 형태로 존재되어야 함을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        250.74935913085938,
        545.9400024414062,
        266.5696716308594
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의미한다. 기밀성은 데이터가 허가되지 않은 사람에게 공개",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        280.7493591308594,
        538.4400024414062,
        296.5696716308594
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되거나, 허가되지 않은 용도로 사용되지 않아야 함을 의미하며,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        310.7493591308594,
        545.9400024414062,
        326.5696716308594
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무결성은 데이터가 허가되지 않은 방법으로 변환되거나 파괴",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        340.7493591308594,
        538.5599975585938,
        356.5696716308594
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되지 않아야 함을 의미한다. 유·무선 통신이 가능하거나 통신",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        370.7493591308594,
        546.0599975585938,
        386.5696716308594
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경로가 존재하는 의료기기는 정보의 위변조, 오작동 또는 의료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        400.7493591308594,
        538.5599975585938,
        416.5696716308594
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기에 승인되지 않은 접근 등을 방지하기 위한 대책을 마련",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        430.7493591308594,
        538.4400024414062,
        446.5696716308594
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        460.7493591308594,
        195.56295776367188,
        476.5696716308594
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사이버보안 침해로 인한 위해도는 의료기기의 잠재적 결함",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        490.7493591308594,
        538.5599975585938,
        506.5696716308594
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 인해 사용자에게 발생할 수 있는 위해(harm)의 정도, 의료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        520.7493896484375,
        538.4400024414062,
        536.5697021484375
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기의 통신방법 및 사용환경을 종합적으로 고려하여 ‘상’,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        550.7493896484375,
        546.0599975585938,
        566.5697021484375
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘중’, ‘하’로 결정되고, 그에 따른 사이버보안 요구사항을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        580.7493896484375,
        546.0599975585938,
        596.5697021484375
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적용한다. 일반적으로 디지털 치료기기는 ‘치료’를 목적으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        610.7493896484375,
        546.0599975585938,
        626.5697021484375
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 2등급 이상의 의료기기로 품목 분류되므로 사이버보안",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        640.7493896484375,
        546.0599975585938,
        656.5697021484375
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성에서‘하’등급의 분류가 불가능하다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        670.7493896484375,
        404.2429504394531,
        686.5697021484375
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 16 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 23,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그림 2. 데이터 보호 및 보안성 영역 연구의 흐름",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        143.39999389648438,
        281.8800048828125,
        451.08056640625,
        297.4320068359375
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 의료기기의 소프트웨어 허가·심사 가이드라인(민원인 안내서)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        348.54937744140625,
        533.7675170898438,
        364.36968994140625
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어 의료기기도 일반 의료기기와 마찬가지로 제조 및",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        378.54937744140625,
        545.9400024414062,
        394.36968994140625
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품질관리체계의 기준과 위험관리 프로세스가 조화를 이루는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        408.54937744140625,
        545.9400024414062,
        424.36968994140625
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "범위 내에서 개발 및 유지가 되어야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        438.54937744140625,
        398.0029602050781,
        454.36968994140625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식품의약품안전처‘의료기기 소프트웨어 허가·심사 가이드라인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        468.54937744140625,
        546.0599975585938,
        484.36968994140625
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(민원인 안내서)’를 기준으로 디지털치료기기의 위험성 관리",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        498.54937744140625,
        546.0599975585938,
        514.3696899414062
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로세스는 의료기기에서 발생하는 위험분석(risk analysis), 위험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        528.5493774414062,
        538.4400024414062,
        544.3696899414062
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가(risk evaluation), 위험통제(risk control), 잔여 위험 허용평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        558.5493774414062,
        538.5599975585938,
        574.3696899414062
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(evaluation of overall residual risk acceptability), 위험관리 보고서",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        588.5493774414062,
        538.4400024414062,
        604.3696899414062
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(risk management report), 생산 및 생산 후 정보(production",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        618.5493774414062,
        545.9400024414062,
        634.3696899414062
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and post-production information)로 구분한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        648.5493774414062,
        418.7629699707031,
        664.3696899414062
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 소프트웨어 안전성 등급은 고장 또는 잠재적 결함으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        678.5493774414062,
        545.9400024414062,
        694.3696899414062
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인해 환자나 사용자에게 미치는 위해의 영향에 따라 분류한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        708.5493774414062,
        545.9400024414062,
        724.3696899414062
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기 소프트웨어 사용으로 건강상의 상해 또는 손상이 없는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        738.5493774414062,
        545.9400024414062,
        754.3696899414062
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 17 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 24,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우 A등급, 심각하지 않은 상해의 가능성 있으면 B등급, 심각한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        70.74937438964844,
        546.0599975585938,
        86.56968688964844
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상해 또는 사망의 가능성이 있는 경우 C등급으로 구분한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        100.74937438964844,
        506.2429504394531,
        116.56968688964844
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기 소프트웨어는 안전성 등급이 결정될 때까지 초기에는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        130.74937438964844,
        546.0599975585938,
        146.56968688964844
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "C등급 요구사항이 적용되며, 소프트웨어 시스템의 실패가 위험한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        160.74937438964844,
        546.0599975585938,
        176.56968688964844
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상황을 발생하지 않으면 안전성 등급은 A등급에 해당한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        190.74937438964844,
        492.8029479980469,
        206.56968688964844
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "그림 3. 소프트웨어의 안전성 평가 관련 연구의 흐름",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        132.95999145507812,
        461.1600036621094,
        461.52056884765625,
        476.7120056152344
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인(민원인 안내서)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        520.9893798828125,
        534.4874877929688,
        536.8096923828125
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디지털치료기기는 실사용증거(Real World Evidence, RWE)를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        550.9893798828125,
        546.0599975585938,
        566.8096923828125
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용하여 의료기기의 사전 및 사후와 관련된 안전성 및 유효성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        580.9893798828125,
        546.0599975585938,
        596.8096923828125
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "입증 근거로 제시할 수 있으며, 이에 따른 기간 및 비용을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        610.9893798828125,
        545.9400024414062,
        626.8096923828125
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "절약할 수 있다.1)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        640.9462890625,
        237.05999755859375,
        656.8096923828125
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실사용증거 수집은 데이터의 타당성 및 신뢰성 확보를 위해",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        670.9893798828125,
        545.9400024414062,
        686.8096923828125
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품질, 수집 및 분석 방법, 수집한 인력의 역량을 입증할 수 있는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        700.9893798828125,
        546.0599975585938,
        716.8096923828125
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 실사용데이터(RWD)는 기존의 중재적 방법에 의한 임상시험으로부터 수집되지 않은 다양한 유형의 의료데이터에 대한 포괄적인",
      "font_size": 8.759956359863281,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        733.265625,
        542.7031860351562,
        742.7578125
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용어이다. 실사용증거(RWE)는 RWD를 분석하여 파생된 증거로써, RWD 분석을 통해 얻은 의료기기의 사용 결과나 잠재적 이익",
      "font_size": 8.759956359863281,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.91999816894531,
        747.6655883789062,
        542.7031860351562,
        757.1577758789062
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 위험성에 관한 임상적 근거를 말한다. 또한, 임상 문헌을 분석하여 파생된 새로운 증거도 포함한다.",
      "font_size": 8.759956359863281,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.91999816894531,
        762.0656127929688,
        458.298095703125,
        771.5578002929688
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 18 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 25,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "객관적인 사항이 반드시 포함되어야 한다. 또한 실사용증거는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        70.74937438964844,
        545.9400024414062,
        86.56968688964844
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적용 목적, 수집 및 분석 정보, 분석 결과에 대한 사항을 제시",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        100.74937438964844,
        538.5599975585938,
        116.56968688964844
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        130.74937438964844,
        180.56295776367188,
        146.56968688964844
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 19 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 26,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅱ",
      "font_size": 20.03999900817871,
      "font_name": "T9",
      "bbox": [
        68.4000015258789,
        77.15999603271484,
        288.3600158691406,
        101.20800018310547
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성·성능 평가",
      "font_size": 20.03999900817871,
      "font_name": "H2hdrM",
      "bbox": [
        68.4000015258789,
        77.15999603271484,
        288.3600158691406,
        101.20800018310547
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 국내외 관련 규격 및 가이드라인",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        132.93995666503906,
        325.19940185546875,
        148.89996337890625
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 국내외 규격",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        176.2293701171875,
        165.72000122070312,
        192.0496826171875
      ],
      "page_num": 26,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디지털치료기기 관련 국내외 규격은 <표 7>과 같다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        206.2293701171875,
        428.1229553222656,
        222.0496826171875
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "번호",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.27999877929688,
        265.91998291015625,
        527.760009765625,
        280.3199768066406
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표준 번호",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.27999877929688,
        265.91998291015625,
        527.760009765625,
        280.3199768066406
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "규격 명칭",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.27999877929688,
        265.91998291015625,
        527.760009765625,
        280.3199768066406
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주요 내용",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.27999877929688,
        265.91998291015625,
        527.760009765625,
        280.3199768066406
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.27999877929688,
        265.91998291015625,
        527.760009765625,
        280.3199768066406
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.87999725341797,
        323.7599792480469,
        159.95999145507812,
        338.15997314453125
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ISO 13485",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.87999725341797,
        323.7599792480469,
        159.95999145507812,
        338.15997314453125
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Medical devices",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        209.39999389648438,
        294.9599914550781,
        293.5199890136719,
        309.3599853515625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "– Quality management",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        188.27999877929688,
        314.1600036621094,
        314.5799865722656,
        328.55999755859375
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "systems – Requirements for",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        173.16000366210938,
        333.3599853515625,
        329.7599792480469,
        347.7599792480469
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "regulatory purposes",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        199.55999755859375,
        352.55999755859375,
        303.3600158691406,
        366.9599914550781
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 품질관리(Quality",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        344.8800048828125,
        304.55999755859375,
        485.47198486328125,
        318.9599914550781
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Management)에 대한 국제",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        343.91998291015625,
        323.7599792480469,
        486.47998046875,
        338.15997314453125
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "규격",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        403.1999816894531,
        342.9599914550781,
        427.1999816894531,
        357.3599853515625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국외",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        503.7599792480469,
        323.7599792480469,
        527.760009765625,
        338.15997314453125
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.87999725341797,
        413.1600036621094,
        159.95999145507812,
        427.55999755859375
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ISO 14971",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.87999725341797,
        413.1600036621094,
        159.95999145507812,
        427.55999755859375
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Medical devices",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        209.39999389648438,
        393.9599914550781,
        293.5199890136719,
        408.3599853515625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "– Application of risk",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        202.55999755859375,
        413.1600036621094,
        300.2760009765625,
        427.55999755859375
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "management to medical devices",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        176.51998901367188,
        432.3599853515625,
        326.3999938964844,
        446.7599792480469
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 위험관리(Risk",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        351.47998046875,
        393.9599914550781,
        478.95599365234375,
        408.3599853515625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Management)에 대한 국제",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        343.91998291015625,
        413.1600036621094,
        486.47998046875,
        427.55999755859375
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "규격",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        403.1999816894531,
        432.3599853515625,
        427.1999816894531,
        446.7599792480469
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국외",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        503.7599792480469,
        413.1600036621094,
        527.760009765625,
        427.55999755859375
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.87999725341797,
        502.55999755859375,
        159.72000122070312,
        516.9600219726562
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IEC 62304",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        74.87999725341797,
        502.55999755859375,
        159.72000122070312,
        516.9600219726562
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Medical device software –",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        178.55999755859375,
        492.9599914550781,
        324.239990234375,
        507.3599853515625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Software life cycle processes",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        173.51998901367188,
        512.1599731445312,
        329.3999938964844,
        526.5599975585938
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 소프트웨어의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        352.1999816894531,
        473.7599792480469,
        478.1999816894531,
        488.15997314453125
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개발부터 유지보수를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        358.1999816894531,
        492.9599914550781,
        472.1999816894531,
        507.3599853515625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "포함하여 전주기에 대한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        349.1999816894531,
        512.1599731445312,
        481.1999816894531,
        526.5599975585938
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국제 규격",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        388.1999816894531,
        531.3599853515625,
        442.1999816894531,
        545.760009765625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국외",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        503.7599792480469,
        502.55999755859375,
        527.760009765625,
        516.9600219726562
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        74.87999725341797,
        582.3599853515625,
        150.98399353027344,
        606.3599853515625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IEC/TR",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.87999725341797,
        582.3599853515625,
        150.98399353027344,
        606.3599853515625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "80002-1",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        111.0,
        601.5599975585938,
        153.239990234375,
        615.9600219726562
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Medical device software –",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        178.55999755859375,
        563.1599731445312,
        324.239990234375,
        577.5599975585938
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Part 1: Guidance on the",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        185.63999938964844,
        582.3599853515625,
        317.1839904785156,
        596.760009765625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "application of ISO 14971 to",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        177.83999633789062,
        601.5599975585938,
        325.0679931640625,
        615.9600219726562
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "medical device software",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        187.55999755859375,
        620.760009765625,
        315.2640075683594,
        635.1600341796875
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 소프트웨어의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        352.1999816894531,
        572.760009765625,
        478.1999816894531,
        587.1600341796875
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험관리 방법에 대한 국제",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        340.1999816894531,
        591.9599609375,
        490.1999816894531,
        606.3599853515625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "규격",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        403.1999816894531,
        611.1599731445312,
        427.1999816894531,
        625.5599975585938
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국외",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        503.7599792480469,
        591.9599609375,
        527.760009765625,
        606.3599853515625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.87999725341797,
        681.3599853515625,
        141.70799255371094,
        705.3599853515625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IEC",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.87999725341797,
        681.3599853515625,
        141.70799255371094,
        705.3599853515625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "80001-1",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        111.0,
        700.5599975585938,
        153.239990234375,
        714.9600219726562
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Application of risk",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        205.79998779296875,
        652.5599975585938,
        297.1559753417969,
        666.9600219726562
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "management for IT-networks",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        177.1199951171875,
        671.760009765625,
        325.79998779296875,
        686.1600341796875
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "incorporating medical devices",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        176.27999877929688,
        690.9599609375,
        326.6400146484375,
        705.3599853515625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "– Part 1: Roles,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        207.1199951171875,
        710.1599731445312,
        295.7519836425781,
        724.5599975585938
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "responsibilities, and activities",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        178.44000244140625,
        729.3599853515625,
        324.4800109863281,
        743.760009765625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "네트워크로 연결되는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        358.1999816894531,
        671.760009765625,
        472.1999816894531,
        686.1600341796875
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기의 위험관리",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        358.1999816894531,
        690.9599609375,
        472.1999816894531,
        705.3599853515625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방법에 대한 국제 규격",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        352.1999816894531,
        710.1599731445312,
        478.1999816894531,
        724.5599975585938
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국외",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        503.7599792480469,
        690.9599609375,
        527.760009765625,
        705.3599853515625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 5. 디지털치료기기 관련 국내/외 규격",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        171.59999084472656,
        237.239990234375,
        423.1205749511719,
        252.7919921875
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 20 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 27,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 국내외 가이드라인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        458.7093505859375,
        210.72000122070312,
        474.5296630859375
      ],
      "page_num": 27,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디지털치료기기 관련 국내외 가이드라인은 <표 8>과 같다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        488.7093505859375,
        473.1229553222656,
        504.5296630859375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "번호",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.27999877929688,
        79.07999420166016,
        527.760009765625,
        93.47999572753906
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표준 번호",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.27999877929688,
        79.07999420166016,
        527.760009765625,
        93.47999572753906
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규격 명칭",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.27999877929688,
        79.07999420166016,
        527.760009765625,
        93.47999572753906
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요 내용",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.27999877929688,
        79.07999420166016,
        527.760009765625,
        93.47999572753906
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비고",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        65.27999877929688,
        79.07999420166016,
        527.760009765625,
        93.47999572753906
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.87999725341797,
        162.72000122070312,
        150.98399353027344,
        186.71998596191406
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IEC/TR",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.87999725341797,
        162.72000122070312,
        150.98399353027344,
        186.71998596191406
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "80001-2-1",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        104.87999725341797,
        181.9199981689453,
        159.36000061035156,
        196.3199920654297
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Application of risk",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        205.79998779296875,
        114.7199935913086,
        297.1559753417969,
        129.1199951171875
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "management for IT-networks",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        177.1199951171875,
        133.9199981689453,
        325.79998779296875,
        148.3199920654297
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "incorporating medical devices",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        176.27999877929688,
        153.1199951171875,
        326.6400146484375,
        167.51998901367188
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "– Part 2-1: Step by step",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        183.59999084472656,
        172.3199920654297,
        319.3800048828125,
        186.71998596191406
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "risk management of medical",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        178.55999755859375,
        191.51998901367188,
        324.29998779296875,
        205.91998291015625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IT-networks – Practical",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        189.239990234375,
        210.72000122070312,
        313.739990234375,
        225.1199951171875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "applications and examples",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        183.83999633789062,
        229.9199981689453,
        319.08001708984375,
        244.3199920654297
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "네트워크로 연결되는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        358.1999816894531,
        153.1199951171875,
        472.1999816894531,
        167.51998901367188
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기의 위험관리",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        358.1999816894531,
        172.3199920654297,
        472.1999816894531,
        186.71998596191406
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방법에 대한 국제 규격",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        352.1999816894531,
        191.51998901367188,
        478.1999816894531,
        205.91998291015625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국외",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        503.7599792480469,
        172.3199920654297,
        527.760009765625,
        186.71998596191406
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.87999725341797,
        335.3999938964844,
        80.87999725341797,
        349.79998779296875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IEC/TR",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        113.27999877929688,
        325.79998779296875,
        150.98399353027344,
        340.1999816894531
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "80001-2-2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        104.87999725341797,
        345.0,
        159.36000061035156,
        359.3999938964844
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Application of risk management",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        174.1199951171875,
        277.79998779296875,
        328.739990234375,
        292.1999816894531
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "for IT-networks incorporating",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        180.72000122070312,
        297.0,
        322.18798828125,
        311.3999938964844
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "medical devices",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        212.51998901367188,
        316.1999816894531,
        290.3999938964844,
        330.5999755859375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "– Part 2-2: Guidance for the",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        176.63999938964844,
        335.3999938964844,
        326.3039855957031,
        349.79998779296875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "disclosure and communication",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        177.83999633789062,
        354.6000061035156,
        325.0679931640625,
        369.0
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "of medical device security",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        187.3199920654297,
        373.79998779296875,
        315.552001953125,
        388.1999816894531
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "needs, risks and controls",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        189.36000061035156,
        393.0,
        313.55999755859375,
        407.3999938964844
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "네트워크로 연결되는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        358.1999816894531,
        316.1999816894531,
        472.1999816894531,
        330.5999755859375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기의 위험관리",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        358.1999816894531,
        335.3999938964844,
        472.1999816894531,
        349.79998779296875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방법에 대한 국제 규격",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        352.1999816894531,
        354.6000061035156,
        478.1999816894531,
        369.0
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국외",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        503.7599792480469,
        335.3999938964844,
        527.760009765625,
        349.79998779296875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "번호",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        66.5999984741211,
        548.3999633789062,
        522.3599853515625,
        562.7999877929688
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인 명칭",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        66.5999984741211,
        548.3999633789062,
        522.3599853515625,
        562.7999877929688
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요 내용",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        66.5999984741211,
        548.3999633789062,
        522.3599853515625,
        562.7999877929688
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비고",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        66.5999984741211,
        548.3999633789062,
        522.3599853515625,
        562.7999877929688
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        610.2000122070312,
        82.19999694824219,
        624.6000366210938
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "디지털치료기기 허가·심사",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        116.87999725341797,
        600.5999755859375,
        259.44000244140625,
        615.0
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가이드라인(민원인 안내서)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        115.68000030517578,
        619.7999877929688,
        260.5320129394531,
        634.2000122070312
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "「의료기기법」 및 「의료기기법시행",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        571.7999877929688,
        483.7200012207031,
        586.2000122070312
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "규칙」,「의료기기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        591.0,
        483.7200012207031,
        605.4000244140625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가·신고·심사",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        591.0,
        483.7200012207031,
        605.4000244140625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "등에 관한 규정」 기반, 디지털치료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        610.2000122070312,
        483.7200012207031,
        624.6000366210938
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기기에 해당하는 제품의 범위, 판단",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        282.239990234375,
        629.3999633789062,
        483.7200012207031,
        643.7999877929688
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준, 허가·심사 방안 등 제시",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        648.5999755859375,
        445.79998779296875,
        663.0
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국내",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        498.3599853515625,
        610.2000122070312,
        522.3599853515625,
        624.6000366210938
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        688.2000122070312,
        82.19999694824219,
        702.6000366210938
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        131.16000366210938,
        669.0,
        245.1599884033203,
        683.4000244140625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "밸리데이션 가이드라인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        125.15999603271484,
        688.2000122070312,
        251.1599884033203,
        702.6000366210938
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(민원인 안내서)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        145.67999267578125,
        707.3999633789062,
        230.531982421875,
        721.7999877929688
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        669.0,
        483.7200012207031,
        683.4000244140625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        669.0,
        483.7200012207031,
        683.4000244140625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "밸리데이션에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        669.0,
        483.7200012207031,
        683.4000244140625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대하여 알기 쉽게 설명하거나 식품",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        688.2000122070312,
        483.7200012207031,
        702.6000366210938
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의약품안전처의 입장을 기술",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        707.3999633789062,
        438.239990234375,
        721.7999877929688
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국내",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        498.3599853515625,
        688.2000122070312,
        522.3599853515625,
        702.6000366210938
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 6. 디지털치료기기 관련 국내외 가이드라인",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        151.3199920654297,
        519.719970703125,
        439.5617980957031,
        535.27197265625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 21 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 28,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        66.5999984741211,
        79.07999420166016,
        522.3599853515625,
        93.47999572753906
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인 명칭",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        66.5999984741211,
        79.07999420166016,
        522.3599853515625,
        93.47999572753906
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요 내용",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        66.5999984741211,
        79.07999420166016,
        522.3599853515625,
        93.47999572753906
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비고",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        66.5999984741211,
        79.07999420166016,
        522.3599853515625,
        93.47999572753906
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        158.51998901367188,
        82.19999694824219,
        172.91998291015625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        131.16000366210938,
        139.3199920654297,
        245.1599884033203,
        153.71998596191406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가심사 가이드라인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        131.16000366210938,
        158.51998901367188,
        245.1599884033203,
        172.91998291015625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(민원인 안내서)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        145.67999267578125,
        177.72000122070312,
        230.531982421875,
        192.1199951171875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 소프트웨어의 기술문서 작성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        100.91999816894531,
        483.7200012207031,
        115.31999969482422
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        120.1199951171875,
        483.7200012207031,
        134.51998901367188
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대하여",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        282.239990234375,
        120.1199951171875,
        483.7200012207031,
        134.51998901367188
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상세히",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        282.239990234375,
        120.1199951171875,
        483.7200012207031,
        134.51998901367188
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술하고",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        120.1199951171875,
        483.7200012207031,
        134.51998901367188
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘의료기기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        139.3199920654297,
        483.7200012207031,
        153.71998596191406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        139.3199920654297,
        483.7200012207031,
        153.71998596191406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적합성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        139.3199920654297,
        483.7200012207031,
        153.71998596191406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        139.3199920654297,
        483.7200012207031,
        153.71998596191406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보고서’, ‘의료기기 소프트웨어 검증",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        158.51998901367188,
        483.7200012207031,
        172.91998291015625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 유효성 확인’ 자료 등 허가·심사",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        177.72000122070312,
        483.7200012207031,
        192.1199951171875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시 제출해야 할 첨부 자료에 대하여",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        282.239990234375,
        196.9199981689453,
        483.7200012207031,
        211.3199920654297
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제시",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        216.1199951171875,
        306.239990234375,
        230.51998901367188
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국내",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        498.3599853515625,
        158.51998901367188,
        522.3599853515625,
        172.91998291015625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        76.19999694824219,
        262.55999755859375,
        82.19999694824219,
        276.9599914550781
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기의 사이버보안",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        125.15999603271484,
        243.36000061035156,
        251.1599884033203,
        257.760009765625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가·심사 가이드라인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        128.87998962402344,
        262.55999755859375,
        247.4399871826172,
        276.9599914550781
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(민원인 안내서)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        145.67999267578125,
        281.7599792480469,
        230.531982421875,
        296.15997314453125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 허가·심사 시 사용자의 건강에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        233.75999450683594,
        483.7200012207031,
        248.1599884033203
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "직접적인 영향을 미칠 수 있는 사이버",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        282.239990234375,
        252.95999145507812,
        483.7200012207031,
        267.3599853515625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보안 위협에 적용할 수 있는 최소한의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        272.1600036621094,
        483.7200012207031,
        286.55999755859375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "권고 사항 등 제시",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        291.3599853515625,
        384.239990234375,
        305.7599792480469
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국내",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        498.3599853515625,
        262.55999755859375,
        522.3599853515625,
        276.9599914550781
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        328.1999816894531,
        82.19999694824219,
        342.5999755859375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기의 사이버보안",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        125.15999603271484,
        309.0,
        251.1599884033203,
        323.3999938964844
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용방법 및 사례집",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        134.16000366210938,
        328.1999816894531,
        242.1599884033203,
        342.5999755859375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(민원인 안내서)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        145.67999267578125,
        347.3999938964844,
        230.531982421875,
        361.79998779296875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        309.0,
        483.7200012207031,
        323.3999938964844
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사이버보안",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        309.0,
        483.7200012207031,
        323.3999938964844
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        309.0,
        483.7200012207031,
        323.3999938964844
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방법과",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        309.0,
        483.7200012207031,
        323.3999938964844
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가신청 시 제출하는 자료의 작성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        328.1999816894531,
        483.7200012207031,
        342.5999755859375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시를 제시",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        347.3999938964844,
        348.239990234375,
        361.79998779296875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국내",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        498.3599853515625,
        328.1999816894531,
        522.3599853515625,
        342.5999755859375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        374.6399841308594,
        82.19999694824219,
        389.03997802734375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Off-The-Shelf Software Use in",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        105.36000061035156,
        365.03997802734375,
        270.8279724121094,
        379.4399719238281
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Medical Devices",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        145.0800018310547,
        384.239990234375,
        231.1199951171875,
        398.6399841308594
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기에서의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        365.03997802734375,
        483.7200012207031,
        379.4399719238281
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기성품",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        365.03997802734375,
        483.7200012207031,
        379.4399719238281
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        365.03997802734375,
        483.7200012207031,
        379.4399719238281
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용에 대한 가이드",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        384.239990234375,
        390.239990234375,
        398.6399841308594
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미국",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        498.3599853515625,
        374.6399841308594,
        522.3599853515625,
        389.03997802734375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        449.8800048828125,
        82.19999694824219,
        464.2799987792969
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Information for Healthcare",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        119.39999389648438,
        401.8800048828125,
        256.823974609375,
        416.2799987792969
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Organizations about FDA’S",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        115.79999542236328,
        421.0799865722656,
        260.35198974609375,
        435.47998046875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "“Guidance for Industry:",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        127.07999420166016,
        440.2799987792969,
        249.08399963378906,
        454.67999267578125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Cybersecurity for Networked",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        113.27999877929688,
        459.47998046875,
        262.9320068359375,
        473.8799743652344
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Medical Devices Containing",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        478.67999267578125,
        261.4679870605469,
        493.0799865722656
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Off-The-Shelf(OTS) Software”",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        108.47999572753906,
        497.8799743652344,
        267.7799987792969,
        512.2799682617188
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "네트워크를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        440.2799987792969,
        483.7200012207031,
        454.67999267578125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "활용하는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        440.2799987792969,
        483.7200012207031,
        454.67999267578125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        440.2799987792969,
        483.7200012207031,
        454.67999267578125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사이버보안에 대한 정보 가이드라인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        449.8800048828125,
        522.3599853515625,
        473.8799743652344
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미국",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        449.8800048828125,
        522.3599853515625,
        473.8799743652344
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        544.3200073242188,
        82.19999694824219,
        558.7200317382812
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Guidance for the Content of",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        112.19999694824219,
        515.5199584960938,
        264.05999755859375,
        529.9199829101562
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Premarket Submissions for",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        116.63999938964844,
        534.719970703125,
        259.55999755859375,
        549.1199951171875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Software Contained in Medical",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        106.43999481201172,
        553.9199829101562,
        269.8199768066406,
        568.3200073242188
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Devices",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        167.75999450683594,
        573.1199951171875,
        208.55999755859375,
        587.52001953125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        534.719970703125,
        483.7200012207031,
        549.1199951171875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "포함하는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        534.719970703125,
        483.7200012207031,
        549.1199951171875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        534.719970703125,
        483.7200012207031,
        549.1199951171875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 시판 전 제출에 대한 가이드라인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        544.3200073242188,
        522.3599853515625,
        568.3200073242188
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미국",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        544.3200073242188,
        522.3599853515625,
        568.3200073242188
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        609.9599609375,
        82.19999694824219,
        624.3599853515625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Deciding When to Submit a",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        113.27999877929688,
        590.760009765625,
        262.9679870605469,
        605.1600341796875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "510(k) for a Software Change",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        108.36000061035156,
        609.9599609375,
        267.8639831542969,
        624.3599853515625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "to an Existing Device",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        130.55999755859375,
        629.1599731445312,
        245.66400146484375,
        643.5599975585938
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 내 소프트웨어 변경에 따른",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        282.239990234375,
        600.3599853515625,
        483.7200012207031,
        614.760009765625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침 가이드라인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        619.5599975585938,
        372.239990234375,
        633.9600219726562
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미국",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        498.3599853515625,
        609.9599609375,
        522.3599853515625,
        624.3599853515625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        73.19999694824219,
        666.1199951171875,
        85.19999694824219,
        680.52001953125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Postmarket Management of",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        646.9199829101562,
        261.41998291015625,
        661.3200073242188
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Cybersecurity in Medical",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        123.36000061035156,
        666.1199951171875,
        252.89999389648438,
        680.52001953125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Devices",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        167.75999450683594,
        685.3200073242188,
        208.55999755859375,
        699.7200317382812
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 사이버보안의 시판 후 관리에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        656.5199584960938,
        483.7200012207031,
        670.9199829101562
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 가이드라인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        666.1199951171875,
        522.3599853515625,
        690.1199951171875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미국",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        666.1199951171875,
        522.3599853515625,
        690.1199951171875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "11",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        73.19999694824219,
        712.5599975585938,
        85.19999694824219,
        726.9600219726562
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Guidance on Cybersecurity for",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        106.79999542236328,
        702.9599609375,
        269.3999938964844,
        717.3599853515625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "medical devices",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        146.0399932861328,
        722.1599731445312,
        230.2799835205078,
        736.5599975585938
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 사이버보안에 대한 가이드",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        702.9599609375,
        483.7200012207031,
        717.3599853515625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        282.239990234375,
        712.5599975585938,
        522.3599853515625,
        736.5599975585938
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유럽",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        282.239990234375,
        712.5599975585938,
        522.3599853515625,
        736.5599975585938
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 22 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 29,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 안전성 평가 항목",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        79.29995727539062,
        213.1199951171875,
        95.25996398925781
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 소프트웨어 검증 및 유효성 확인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        122.58937072753906,
        308.1600036621094,
        138.40968322753906
      ],
      "page_num": 29,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 개요",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        152.58937072753906,
        121.31999969482422,
        168.40968322753906
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기에 포함되는 소프트웨어 또는 의료기기 자체가 소프트",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        182.58937072753906,
        538.4400024414062,
        198.40968322753906
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "웨어면 ‘의료기기 제조 및 품질관리 기준’ 및 ‘의료기기 위험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        212.58937072753906,
        538.5599975585938,
        228.40968322753906
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리 시스템’과 조화를 이루는 범위에서 개발, 유지되고 사용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        242.58937072753906,
        538.4400024414062,
        258.40966796875
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되어야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        272.58935546875,
        173.1229705810547,
        288.40966796875
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 검증 및 유효성 확인은 의료기기로서의 소프트웨어의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        302.58935546875,
        546.0599975585938,
        318.40966796875
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신뢰도를 높이고 환자 또는 사용자에 대한 위험을 낮추기 위한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        332.58935546875,
        545.9400024414062,
        348.40966796875
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활동으로, 국제 표준 IEC 62304, ISO 14971 및 ‘의료기기 소프트",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        362.58935546875,
        538.5599975585938,
        378.40966796875
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "웨어 밸리데이션 가이드라인(민원인 안내서)’에 따라 수행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        392.58935546875,
        527.3629760742188,
        408.40966796875
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 소프트웨어 개발 및 위험 관리",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        422.58935546875,
        301.32000732421875,
        438.40966796875
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 제조업체는 ‘의료기기 제조 및 품질관리 기준’에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        452.58935546875,
        545.9400024414062,
        468.40966796875
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규정된 바와 같이 수립된 품질시스템에서 관련 절차에 따라 소프트",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        482.58935546875,
        538.4400024414062,
        498.40966796875
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "웨어의 개발 및 유지를 위한 활동을 수행하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        512.58935546875,
        458.0029602050781,
        528.40966796875
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 소프트웨어의 위험관리는 소프트웨어 개발 활동의 일부이며,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        542.58935546875,
        546.0599975585938,
        558.40966796875
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동시에 의료기기의 전체 수명주기의 위험관리 일부로 수행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        572.58935546875,
        495.3229675292969,
        588.40966796875
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 소프트웨어 위험관리를 통해 의료기기에 포함된 소프트",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        602.58935546875,
        538.4400024414062,
        618.40966796875
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "웨어 사용에 따른 허용 불가능한 위험이 발생하지 않고, 의료기기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        632.58935546875,
        538.5599975585938,
        648.40966796875
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로서의 사용 목적을 달성할 수 있음을 증명해야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        662.58935546875,
        458.0029602050781,
        678.40966796875
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 개발 및 위험관리는 <표 9>와 같이 IEC 62304 프로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        692.58935546875,
        538.5599975585938,
        708.40966796875
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세스에 따른다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        722.58935546875,
        188.1229705810547,
        738.40966796875
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 23 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 30,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        66.0,
        94.91999816894531,
        183.72000122070312,
        118.91999816894531
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "IEC 62304",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        66.0,
        94.91999816894531,
        183.72000122070312,
        118.91999816894531
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로세스",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        132.1199951171875,
        104.5199966430664,
        523.4400024414062,
        128.51998901367188
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어 개발",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        132.1199951171875,
        104.5199966430664,
        523.4400024414062,
        128.51998901367188
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어 위험관리",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        132.1199951171875,
        104.5199966430664,
        523.4400024414062,
        128.51998901367188
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.0,
        162.0,
        81.0,
        176.39999389648438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        102.5999984741211,
        402.1199951171875,
        138.60000610351562,
        416.5199890136719
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        108.5999984741211,
        421.3199768066406,
        132.60000610351562,
        435.719970703125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개발",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        108.5999984741211,
        440.5199890136719,
        132.60000610351562,
        454.91998291015625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        108.5999984741211,
        459.7200012207031,
        132.60000610351562,
        474.1199951171875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "세스",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        108.5999984741211,
        478.91998291015625,
        132.60000610351562,
        493.3199768066406
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        150.47999572753906,
        152.39999389648438,
        210.0,
        166.79998779296875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개발 계획",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        153.47999572753906,
        171.59999084472656,
        207.0,
        185.99998474121094
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개발 소프트웨어의 범위, 규모",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        220.79998779296875,
        133.1999969482422,
        386.2799987792969,
        147.59999084472656
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 소프트웨어 안전에 적합한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        152.39999389648438,
        386.2799987792969,
        166.79998779296875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개발 활동을 위하여 소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        171.59999084472656,
        386.2799987792969,
        185.99998474121094
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개발 계획을 수립한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        190.8000030517578,
        336.5400085449219,
        205.1999969482422
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어의 개발 계획을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        142.8000030517578,
        536.3999633789062,
        157.1999969482422
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수립하면서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        162.0,
        536.3999633789062,
        176.39999389648438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "동시에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        162.0,
        536.3999633789062,
        176.39999389648438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        162.0,
        536.3999633789062,
        176.39999389648438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관리 계획을 수립한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        181.1999969482422,
        519.4199829101562,
        195.59999084472656
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.0,
        286.79998779296875,
        81.0,
        301.1999816894531
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        150.239990234375,
        267.6000061035156,
        210.239990234375,
        282.0
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "요구사항",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        156.239990234375,
        286.79998779296875,
        204.239990234375,
        301.1999816894531
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        168.239990234375,
        306.0,
        192.239990234375,
        320.3999938964844
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어가 어떤(what) 기능을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        248.39999389648438,
        386.2799987792969,
        262.79998779296875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "어떻게(how) 수행할 것인지에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        267.6000061035156,
        386.2799987792969,
        282.0
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대하여, 소프트웨어가 수행할 수",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        286.79998779296875,
        386.2799987792969,
        301.1999816894531
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있는 논리적이고 물리적인 표현",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        220.79998779296875,
        306.0,
        386.2799987792969,
        320.3999938964844
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "으로 정의한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        325.1999816894531,
        301.739990234375,
        339.5999755859375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어의 정상 상태 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        219.59999084472656,
        536.3999633789062,
        233.99998474121094
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고장",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        238.79998779296875,
        536.3999633789062,
        253.19998168945312
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상태에서의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        238.79998779296875,
        536.3999633789062,
        253.19998168945312
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재적",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        238.79998779296875,
        536.3999633789062,
        253.19998168945312
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결함을 고려하여 위험을 분석",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        396.47998046875,
        258.0,
        536.3999633789062,
        272.3999938964844
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하고, 해당 위험을 통제하기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        277.1999816894531,
        536.3999633789062,
        291.5999755859375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위한 조치를 결정한다. 이 중",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        296.3999938964844,
        536.3999633789062,
        310.79998779296875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 설계에 해당하는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        315.6000061035156,
        536.3999633789062,
        330.0
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통제 조치를 소프트웨어 요구",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        334.79998779296875,
        536.3999633789062,
        349.1999816894531
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사항에 반영한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        354.0,
        482.2200012207031,
        368.3999938964844
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.0,
        440.8800048828125,
        210.239990234375,
        464.8799743652344
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.0,
        440.8800048828125,
        210.239990234375,
        464.8799743652344
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아키텍처",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        156.239990234375,
        460.0799865722656,
        204.239990234375,
        474.47998046875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 요구사항을 소프트",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        383.2799987792969,
        386.2799987792969,
        397.67999267578125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "웨어 구조로 설명하며 소프트",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        402.47998046875,
        386.2799987792969,
        416.8799743652344
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "웨어 항목(item)을 식별하는 아키",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        220.79998779296875,
        421.67999267578125,
        386.2799987792969,
        436.0799865722656
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "텍처로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        440.8800048828125,
        386.2799987792969,
        455.2799987792969
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "변환한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        440.8800048828125,
        386.2799987792969,
        455.2799987792969
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        440.8800048828125,
        386.2799987792969,
        455.2799987792969
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "항목과 소프트웨어 항목 외부의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        460.0799865722656,
        386.2799987792969,
        474.47998046875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구성요소 간의 연계성과 소프트",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        479.2799987792969,
        386.2799987792969,
        493.67999267578125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "웨어 항목 간 연계성을 위한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        498.47998046875,
        386.2799987792969,
        512.8800048828125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아키텍처를 개발한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        517.6799926757812,
        334.3800048828125,
        532.0800170898438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        421.67999267578125,
        536.3999633789062,
        436.0799865722656
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "요구사항에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        421.67999267578125,
        536.3999633789062,
        436.0799865722656
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반영한 위험 통제 조치가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        440.8800048828125,
        536.3999633789062,
        455.2799987792969
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실현될 수 있도록 안전한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        460.0799865722656,
        536.3999633789062,
        474.47998046875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구조를 갖추어 설계한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        479.2799987792969,
        531.4199829101562,
        493.67999267578125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        75.0,
        644.6400146484375,
        81.0,
        659.0400390625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        150.239990234375,
        635.0399780273438,
        210.239990234375,
        649.4400024414062
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상세 설계",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        153.239990234375,
        654.239990234375,
        207.239990234375,
        668.6400146484375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 아키텍처를 소프트",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        548.6400146484375,
        386.2799987792969,
        563.0400390625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "웨어 유닛으로 표현할 수 있을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        567.8399658203125,
        386.2799987792969,
        582.239990234375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "때까지",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        587.0399780273438,
        386.2799987792969,
        601.4400024414062
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분해하고,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        587.0399780273438,
        386.2799987792969,
        601.4400024414062
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "각",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        587.0399780273438,
        386.2799987792969,
        601.4400024414062
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유닛에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        587.0399780273438,
        386.2799987792969,
        601.4400024414062
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        606.239990234375,
        386.2200012207031,
        620.6400146484375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상세",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        220.79998779296875,
        606.239990234375,
        386.2200012207031,
        620.6400146484375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설계를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        606.239990234375,
        386.2200012207031,
        620.6400146484375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수행한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        606.239990234375,
        386.2200012207031,
        620.6400146484375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또한 소프트웨어 유닛 및 외부",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        625.4400024414062,
        386.2799987792969,
        639.8400268554688
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구성요인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        644.6400146484375,
        386.2799987792969,
        659.0400390625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사이의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        644.6400146484375,
        386.2799987792969,
        659.0400390625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연계성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        644.6400146484375,
        386.2799987792969,
        659.0400390625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        644.6400146484375,
        386.2799987792969,
        659.0400390625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 유닛 사이의 연계성을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        663.8399658203125,
        386.2799987792969,
        678.239990234375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        683.0399780273438,
        386.2200012207031,
        697.4400024414062
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상세",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        220.79998779296875,
        683.0399780273438,
        386.2200012207031,
        697.4400024414062
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설계를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        683.0399780273438,
        386.2200012207031,
        697.4400024414062
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수행한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        683.0399780273438,
        386.2200012207031,
        697.4400024414062
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상세 설계를 바탕으로 코딩을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        702.239990234375,
        386.2799987792969,
        716.6400146484375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하며 코드는 정확하고 요구사항에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        721.4400024414062,
        386.2799987792969,
        735.8400268554688
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부합한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        740.6399536132812,
        265.9800109863281,
        755.0399780273438
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어 위험 통제 조치를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        606.239990234375,
        536.3999633789062,
        620.6400146484375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품에 구현한다. 이때 코드는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        625.4400024414062,
        536.3999633789062,
        639.8400268554688
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험관리 프로세스에서 식별한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        644.6400146484375,
        536.3999633789062,
        659.0400390625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        663.8399658203125,
        536.3999633789062,
        678.239990234375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "요구사항을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        663.8399658203125,
        536.3999633789062,
        678.239990234375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정확하게",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        663.8399658203125,
        536.3999633789062,
        678.239990234375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실현할 수 있어야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        683.0399780273438,
        508.97998046875,
        697.4400024414062
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 7. 소프트웨어 개발 및 위험관리",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        190.1999969482422,
        71.87999725341797,
        410.1612243652344,
        87.43199920654297
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 24 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 31,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        66.0,
        73.31999969482422,
        183.72000122070312,
        97.31999969482422
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "IEC 62304",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        66.0,
        73.31999969482422,
        183.72000122070312,
        97.31999969482422
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로세스",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        132.1199951171875,
        82.91999816894531,
        523.4400024414062,
        106.91999816894531
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어 개발",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        132.1199951171875,
        82.91999816894531,
        523.4400024414062,
        106.91999816894531
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어 위험관리",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        132.1199951171875,
        82.91999816894531,
        523.4400024414062,
        106.91999816894531
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.0,
        148.9199981689453,
        81.0,
        163.3199920654297
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        150.239990234375,
        139.3199920654297,
        210.239990234375,
        153.71998596191406
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유닛 검증",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        153.239990234375,
        158.51998901367188,
        207.239990234375,
        172.91998291015625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "각 유닛에 대한 코드를 검증하는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        120.1199951171875,
        386.2799987792969,
        134.51998901367188
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것으로 코드 실행 전에 오류를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        139.3199920654297,
        386.2799987792969,
        153.71998596191406
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "파악할 수 있는 “static test” 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        158.51998901367188,
        386.2799987792969,
        172.91998291015625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "“white-box” 방법으로 수행한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        177.72000122070312,
        376.8599853515625,
        192.1199951171875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 요구사항에서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        189.239990234375,
        536.3999633789062,
        203.63998413085938
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정의한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        208.44000244140625,
        536.3999633789062,
        222.83999633789062
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험통제",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        208.44000244140625,
        536.3999633789062,
        222.83999633789062
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조치가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        208.44000244140625,
        536.3999633789062,
        222.83999633789062
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실제 제품에 올바르게 반영",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        227.63999938964844,
        536.3999633789062,
        242.0399932861328
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "되었으며, 위험이 효과적",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        246.83999633789062,
        536.3999633789062,
        261.239990234375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "으로 통제되어 잔여 위험이",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        266.0400085449219,
        536.3999633789062,
        280.44000244140625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허용 가능함을 검증한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        285.239990234375,
        531.4199829101562,
        299.6399841308594
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.0,
        246.83999633789062,
        81.0,
        261.239990234375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        150.239990234375,
        237.239990234375,
        210.239990234375,
        251.63998413085938
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통합 검증",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        153.239990234375,
        256.44000244140625,
        207.239990234375,
        270.8399963378906
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통합계획에 따라 소프트웨어를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        218.0399932861328,
        386.2799987792969,
        232.4399871826172
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통합하고",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        237.239990234375,
        386.2799987792969,
        251.63998413085938
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통합한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        237.239990234375,
        386.2799987792969,
        251.63998413085938
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        237.239990234375,
        386.2799987792969,
        251.63998413085938
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "항목이",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        256.44000244140625,
        386.2799987792969,
        270.8399963378906
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의도한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        256.44000244140625,
        386.2799987792969,
        270.8399963378906
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        256.44000244140625,
        386.2799987792969,
        270.8399963378906
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기능을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        256.44000244140625,
        386.2799987792969,
        270.8399963378906
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발휘하는지 확인한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        275.6399841308594,
        337.739990234375,
        290.03997802734375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.0,
        335.03997802734375,
        81.0,
        349.4399719238281
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        150.239990234375,
        315.8399963378906,
        210.239990234375,
        330.239990234375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시스템",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        162.239990234375,
        335.03997802734375,
        198.239990234375,
        349.4399719238281
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        168.239990234375,
        354.239990234375,
        192.239990234375,
        368.6399841308594
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전체 소프트웨어 시스템이 요구",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        325.44000244140625,
        386.2799987792969,
        339.8399963378906
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사항을 충족하는지 확인한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        344.6399841308594,
        373.5,
        359.03997802734375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.0,
        456.1199951171875,
        81.0,
        470.5199890136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        102.5999984741211,
        498.9599914550781,
        138.60000610351562,
        513.3599853515625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        108.5999984741211,
        518.1599731445312,
        132.60000610351562,
        532.5599975585938
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유지",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        108.5999984741211,
        537.3599853515625,
        132.60000610351562,
        551.760009765625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "활동",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        108.5999984741211,
        556.5599975585938,
        132.60000610351562,
        570.9600219726562
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        108.5999984741211,
        575.760009765625,
        132.60000610351562,
        590.1600341796875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "세스",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        108.5999984741211,
        594.9599609375,
        132.60000610351562,
        609.3599853515625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        150.239990234375,
        446.5199890136719,
        210.239990234375,
        460.91998291015625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "형상 관리",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        153.239990234375,
        465.7200012207031,
        207.239990234375,
        480.1199951171875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어의 출시 후에 발생",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        417.7200012207031,
        386.2799987792969,
        432.1199951171875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하는 피드백에 적절히 대응하고",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        436.91998291015625,
        386.2799987792969,
        451.3199768066406
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        456.1199951171875,
        386.2799987792969,
        470.5199890136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "항목의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        456.1199951171875,
        386.2799987792969,
        470.5199890136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일관성을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        456.1199951171875,
        386.2799987792969,
        470.5199890136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유지하면서 설계 변경 및 소프트",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        475.3199768066406,
        386.2799987792969,
        489.719970703125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "웨어 형상을 유지한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        494.5199890136719,
        332.94000244140625,
        508.91998291015625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "새로운 위험의 발생 또는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        398.5199890136719,
        536.3999633789062,
        412.91998291015625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기존에 식별한 위험 평가의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        417.7200012207031,
        536.3999633789062,
        432.1199951171875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "변경이 필요한 경우, 소프트",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        436.91998291015625,
        536.3999633789062,
        451.3199768066406
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "웨어 형상의 변경이 위해",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        456.1199951171875,
        536.3999633789062,
        470.5199890136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "요인이 될 수 있는 경우",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        475.3199768066406,
        536.3999633789062,
        489.719970703125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험관리 프로세스의 입력",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        494.5199890136719,
        536.3999633789062,
        508.91998291015625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "으로 식별한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        513.719970703125,
        477.41998291015625,
        528.1199951171875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.0,
        628.6799926757812,
        81.0,
        643.0800170898438
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        150.239990234375,
        619.0799560546875,
        210.239990234375,
        633.47998046875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "문제해결",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        156.239990234375,
        638.2799682617188,
        204.239990234375,
        652.6799926757812
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시판 후 소프트웨어에 문제가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        590.2799682617188,
        386.2799987792969,
        604.6799926757812
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생하거나 개선의 필요성 때문에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        609.47998046875,
        386.2799987792969,
        623.8800048828125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품 또는 관련 문서가 수정되는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        628.6799926757812,
        386.2799987792969,
        643.0800170898438
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경우 문제점과 그 영향 등을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        647.8800048828125,
        386.2799987792969,
        662.280029296875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분석하여 변경해야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        220.79998779296875,
        667.0799560546875,
        349.1399841308594,
        681.47998046875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시판 후 발견된 문제점을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        561.47998046875,
        536.3999633789062,
        575.8800048828125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분석하고",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        580.6799926757812,
        536.3999633789062,
        595.0800170898438
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전과",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        580.6799926757812,
        536.3999633789062,
        595.0800170898438
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관련된",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        580.6799926757812,
        536.3999633789062,
        595.0800170898438
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "항목은 위험관리 프로세스의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        599.8800048828125,
        536.3999633789062,
        614.280029296875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "입력으로 식별한다. 문제",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        619.0799560546875,
        536.3999633789062,
        633.47998046875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해결 및 설계 변경은 위험",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        638.2799682617188,
        536.3999633789062,
        652.6799926757812
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통제 조치가 될 수 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        657.47998046875,
        536.4599609375,
        671.8800048828125
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요시 규제 당국에 안전성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        676.6799926757812,
        536.3999633789062,
        691.0800170898438
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관련 보고를 시행한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        396.47998046875,
        695.8800048828125,
        519.4199829101562,
        710.280029296875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 25 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 32,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 소프트웨어 안전성 등급",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        70.74937438964844,
        256.32000732421875,
        86.56968688964844
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기 소프트웨어의 고장 또는 잠재적 결함으로 인해 환자나",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        100.74937438964844,
        546.0599975585938,
        116.56968688964844
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용자에게 미치는 위해의 영향에 따라 안전성 등급을 <표 10>과",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        130.74937438964844,
        546.0599975585938,
        146.56968688964844
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같이 분류한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        160.74937438964844,
        195.6599884033203,
        176.56968688964844
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "등급",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        116.04000091552734,
        217.67999267578125,
        369.47998046875,
        232.07998657226562
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설명",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        116.04000091552734,
        217.67999267578125,
        369.47998046875,
        232.07998657226562
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A등급",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        112.31999969482422,
        236.75999450683594,
        446.5799865722656,
        251.1599884033203
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부상이나 신체적 피해가 발생할 가능성이 없다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        112.31999969482422,
        236.75999450683594,
        446.5799865722656,
        251.1599884033203
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "B등급",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        112.31999969482422,
        254.39999389648438,
        465.41998291015625,
        268.79998779296875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "심각하지 않은 부상(경상)이 발생할 가능성이 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        112.31999969482422,
        254.39999389648438,
        465.41998291015625,
        268.79998779296875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "C등급",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        111.83999633789062,
        272.0400085449219,
        452.5799865722656,
        286.44000244140625
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "심각한 부상 또는 사망이 발생할 가능성이 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        111.83999633789062,
        272.0400085449219,
        452.5799865722656,
        286.44000244140625
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 8. 소프트웨어 안전성 등급",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        211.55999755859375,
        191.87998962402344,
        397.9205627441406,
        207.43199157714844
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 안전성 등급은 위험통제 후 잔여 위험의 심각도를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        327.42938232421875,
        546.0599975585938,
        343.24969482421875
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "토대로 분류할 수 있다. 이때, 발생 가능성은 안전성 등급 결정 시",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        357.4293518066406,
        545.9400024414062,
        373.2496643066406
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려하지 않는다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        387.4293518066406,
        203.1229705810547,
        403.2496643066406
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어가 여러 개의 독립적인 모듈이 모여서 구성된 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        417.4293518066406,
        546.0599975585938,
        433.2496643066406
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각 모듈에 대해 별도로 안전성 등급을 부여할 수 있다. 이때 전체",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        447.4293518066406,
        545.9400024414062,
        463.2496643066406
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어의 안전성 등급은 개별 모듈의 안전성 등급 중 가장",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        477.4293518066406,
        545.9400024414062,
        493.2496643066406
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "높은 등급이 된다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        507.42938232421875,
        210.56295776367188,
        523.2496948242188
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 의료기기의 사이버보안",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        567.4293823242188,
        240.72000122070312,
        583.2496948242188
      ],
      "page_num": 32,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 개요",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        597.4293823242188,
        121.31999969482422,
        613.2496948242188
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유·무선 통신이 가능하거나 통신 경로가 존재하는 제품의 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        627.4293823242188,
        546.0599975585938,
        643.2496948242188
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사이버보안에 대한 요구사항을 준수해야 한다. 제조자는 이를 확인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        657.4293823242188,
        538.4400024414062,
        673.2496948242188
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "할 수 있도록 ‘의료기기 사이버보안 요구사항 체크리스트’와",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        687.4293823242188,
        546.0599975585938,
        703.2496948242188
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요구사항을 실제로 검증한 자료를 제출하여야 한다. 다만, 제조사의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        717.4293823242188,
        545.9400024414062,
        733.2496948242188
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위험분석을 통해 요구사항 일부를 제외하거나 수정하여 적용할 때는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        747.4293823242188,
        545.9400024414062,
        763.2496948242188
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 26 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험규격 및 그 설정 근거를 제출하여야 하며 해당 자료로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        70.74937438964844,
        545.9400024414062,
        86.56968688964844
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘사이버보안 위험관리문서’를 제출할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        100.74937438964844,
        430.282958984375,
        116.56968688964844
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사이버보안 요구사항은 ‘의료기기의 사이버보안 허가·심사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        130.74937438964844,
        546.0599975585938,
        146.56968688964844
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인(민원인 안내서)’에 따른다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        160.74937438964844,
        354.9229736328125,
        176.56968688964844
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 사이버보안 요구사항",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        190.74937438964844,
        233.87998962402344,
        206.56968688964844
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‘의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)’",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        220.74937438964844,
        538.5599975585938,
        236.56968688964844
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에는 보안통신, 데이터 보호, 기기 무결성, 사용자 인증, 소프트웨어",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        250.74935913085938,
        546.0599975585938,
        266.5696716308594
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유지보수, 물리적 접근, 신뢰성 및 가용성 등에 대한 요구사항을 제시",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        280.7493591308594,
        538.5599975585938,
        296.5696716308594
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고 있다. 본 요구사항은 제품의 사이버보안 안전성 등급 및",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        310.7493591308594,
        545.9400024414062,
        326.5696716308594
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 적용한다. 해당 가이드라인에 따라 제품에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        340.7493591308594,
        546.0599975585938,
        356.5696716308594
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적합한 통신 개략도와 사이버보안 적용 사항을 기재한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        370.7493591308594,
        480.5629577636719,
        386.5696716308594
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 사이버보안 위험관리",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        400.7493591308594,
        233.87998962402344,
        416.5696716308594
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 위험관리에는 사이버보안에 대한 위험관리 항목이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        430.7493591308594,
        546.0599975585938,
        446.5696716308594
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함되어야 하며, 소프트웨어 위험관리와 동일한 방식으로 위험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        460.7493591308594,
        538.4400024414062,
        476.5696716308594
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리 결과가 검증되어야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        490.7493591308594,
        293.1229553222656,
        506.5696716308594
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 위험분석",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        550.7493896484375,
        173.87998962402344,
        566.5697021484375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‘위해요인 식별’에서는 관련 자료(규격, 가이드라인, 국내외",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        580.7493896484375,
        546.0599975585938,
        596.5697021484375
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상 사례 등)에 근거하여 의료기기의 정상 및 고장상태에서",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        610.7493896484375,
        545.9400024414062,
        626.5697021484375
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이미 알고 있거나 예측 가능한 의료기기 사이버보안 측면의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        640.7493896484375,
        545.9400024414062,
        656.5697021484375
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해요인에 대해 <표 11>과 같이 기록한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        670.7493896484375,
        413.1000061035156,
        686.5697021484375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‘위험산정’에서는 위해상황을 초래할 수 있는 예측 가능한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        700.7493286132812,
        545.9400024414062,
        716.5696411132812
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사건들을 조합하여 각 위해요인에 대한 위험을 산정한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        730.7493286132812,
        503.0029602050781,
        746.5696411132812
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 27 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 34,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해요인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        97.19999694824219,
        96.0,
        423.5999755859375,
        120.0
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구체적인 예시",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        97.19999694824219,
        96.0,
        423.5999755859375,
        120.0
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용자 또는 환자에게",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        97.19999694824219,
        96.0,
        423.5999755859375,
        120.0
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발생 가능한 손상",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        315.6000061035156,
        105.5999984741211,
        513.719970703125,
        129.59999084472656
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        315.6000061035156,
        105.5999984741211,
        513.719970703125,
        129.59999084472656
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비 인가된",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        94.19999694824219,
        151.44000244140625,
        148.1999969482422,
        165.83999633789062
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용자의 접근",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        82.19999694824219,
        170.63999938964844,
        160.1999969482422,
        185.0399932861328
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비 인가된 사용자의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        173.63999938964844,
        141.83999633789062,
        281.6399841308594,
        156.239990234375
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접근으로 인해 환자",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        173.63999938964844,
        161.0399932861328,
        281.6399841308594,
        175.4399871826172
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데이터 손실",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        194.63999938964844,
        180.239990234375,
        260.6400146484375,
        194.63998413085938
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오진, 잘못 된 치료 수행",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        296.1600036621094,
        151.44000244140625,
        431.1600036621094,
        165.83999633789062
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또는 치료기회 박탈",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        309.6000061035156,
        170.63999938964844,
        417.6000061035156,
        185.0399932861328
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국내·외",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        469.44000244140625,
        151.44000244140625,
        510.0,
        165.83999633789062
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이상사례",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        465.7200012207031,
        170.63999938964844,
        513.719970703125,
        185.0399932861328
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 9. 위해요인 식별 예시",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        227.0399932861328,
        71.87999725341797,
        386.16058349609375,
        87.43199920654297
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나) 위험평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        253.86935424804688,
        181.37998962402344,
        269.6896667480469
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식별한 각 위해요인에 대하여 위험관리 계획서에 정의한 위험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        283.8693542480469,
        546.0599975585938,
        299.6896667480469
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허용 기준을 사용하여 위험 감소가 필요한지 결정한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        313.8693542480469,
        495.41998291015625,
        329.6896667480469
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식별한 모든 위험에 대하여 위험의 평가 결과를 ‘위험을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        343.8693542480469,
        546.0599975585938,
        359.6896667480469
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허용할 수 없는 영역(unacceptable)’과‘합리적으로 실현할",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        373.8693542480469,
        546.0599975585938,
        389.6896667480469
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있는 가장 낮은 영역(As Low As Reasonably Practicable,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        403.8693542480469,
        545.9400024414062,
        419.6896667480469
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ALARP)’, ‘허용할 수 있는 영역(acceptable)’의 3단계 또는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        433.8693542480469,
        546.0599975585938,
        449.6896667480469
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘위험을 허용할 수 없는 영역(unacceptable)’과 ‘허용할 수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        463.8693542480469,
        546.0599975585938,
        479.6896667480469
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 영역(Acceptable)’의 2단계로 구분할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        493.8693542480469,
        465.2029724121094,
        509.6896667480469
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험분석",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        236.39999389648438,
        552.1199951171875,
        523.4400024414062,
        566.52001953125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험평가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        236.39999389648438,
        552.1199951171875,
        523.4400024414062,
        566.52001953125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해요인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        67.43999481201172,
        580.7999877929688,
        204.47999572753906,
        604.7999877929688
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생 가능한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        67.43999481201172,
        580.7999877929688,
        204.47999572753906,
        604.7999877929688
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사례",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        159.47999572753906,
        600.0,
        183.47999572753906,
        614.4000244140625
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해상황",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        235.9199981689453,
        590.3999633789062,
        354.3599853515625,
        604.7999877929688
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        235.9199981689453,
        590.3999633789062,
        354.3599853515625,
        604.7999877929688
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        391.3199768066406,
        571.2000122070312,
        415.3199768066406,
        585.6000366210938
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가능",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        391.3199768066406,
        590.3999633789062,
        415.3199768066406,
        604.7999877929688
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        397.3199768066406,
        609.5999755859375,
        409.3199768066406,
        624.0
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "심각",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        429.9599914550781,
        580.7999877929688,
        453.9599914550781,
        595.2000122070312
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        435.9599914550781,
        600.0,
        447.9599914550781,
        614.4000244140625
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        468.47998046875,
        580.7999877929688,
        492.47998046875,
        595.2000122070312
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "도",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.47998046875,
        600.0,
        486.47998046875,
        614.4000244140625
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        506.5199890136719,
        590.3999633789062,
        530.5199584960938,
        604.7999877929688
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        85.43999481201172,
        643.6799926757812,
        97.43999481201172,
        658.0800170898438
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인가된",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        73.43999481201172,
        662.8800048828125,
        109.43999481201172,
        677.280029296875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용자의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        67.43999481201172,
        682.0799560546875,
        115.43999481201172,
        696.47998046875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접근",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        79.43999481201172,
        701.2799682617188,
        103.43999481201172,
        715.6799926757812
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용자 구분을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        132.47999572753906,
        634.0799560546875,
        210.47999572753906,
        648.47998046875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하지 않고",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        144.47999572753906,
        653.2799682617188,
        198.47999572753906,
        667.6799926757812
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "누구나 환자의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        132.47999572753906,
        672.47998046875,
        210.47999572753906,
        686.8800048828125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데이터에 접근",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        132.47999572753906,
        691.6799926757812,
        210.47999572753906,
        706.0800170898438
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하도록 한 경우",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        129.47999572753906,
        710.8800048828125,
        213.47999572753906,
        725.280029296875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조작된 환자",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        226.9199981689453,
        634.0799560546875,
        292.91998291015625,
        648.47998046875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        247.9199981689453,
        653.2799682617188,
        271.91998291015625,
        667.6799926757812
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데이터로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        235.9199981689453,
        672.47998046875,
        283.91998291015625,
        686.8800048828125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전문의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        241.9199981689453,
        691.6799926757812,
        277.91998291015625,
        706.0800170898438
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진료수행",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        235.9199981689453,
        710.8800048828125,
        283.91998291015625,
        725.280029296875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오진, 잘못",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        313.91998291015625,
        634.0799560546875,
        370.79998779296875,
        648.47998046875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "된 치료 수행",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        306.3599853515625,
        653.2799682617188,
        378.3599853515625,
        667.6799926757812
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        330.3599853515625,
        672.47998046875,
        354.3599853515625,
        686.8800048828125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "치료기회",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        318.3599853515625,
        691.6799926757812,
        366.3599853515625,
        706.0800170898438
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "박탈",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        330.3599853515625,
        710.8800048828125,
        354.3599853515625,
        725.280029296875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        400.3199768066406,
        662.8800048828125,
        529.343994140625,
        686.8800048828125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        400.3199768066406,
        662.8800048828125,
        529.343994140625,
        686.8800048828125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        400.3199768066406,
        662.8800048828125,
        529.343994140625,
        686.8800048828125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ALA",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        400.3199768066406,
        662.8800048828125,
        529.343994140625,
        686.8800048828125
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "RP",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        510.47998046875,
        682.0799560546875,
        526.5239868164062,
        696.47998046875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 10. 위험평가 예시",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        231.95999145507812,
        524.8799438476562,
        364.3200378417969,
        540.4319458007812
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 28 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 35,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다) 위험통제",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        70.74937438964844,
        181.37998962402344,
        86.56968688964844
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조자는 위험평가 결과 중 ‘위험을 허용할 수 없는 영역",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        100.74937438964844,
        538.5599975585938,
        116.56968688964844
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(unacceptable)’과‘합리적으로 실현할 수 있는 가장 낮은 영역",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        130.74937438964844,
        538.5599975585938,
        146.56968688964844
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(ALARP)’을 허용 가능한 수준까지 감소시키기 위하여 위험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        160.74937438964844,
        546.0599975585938,
        176.56968688964844
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통제 조치를 식별하고, <표 13>과 같이 위험통제 활동을 수행",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        190.74937438964844,
        538.5599975585938,
        206.56968688964844
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        220.74937438964844,
        195.56295776367188,
        236.56968688964844
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 전체 잔여위험 허용 가능성 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        467.58935546875,
        346.2599792480469,
        483.40966796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모든 위험통제 조치를 하고 검증한 뒤 위험관리 계획에서",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        497.58935546875,
        545.9400024414062,
        513.40966796875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정의한 위험허용 기준을 사용하여 해당 의료기기에서 식별한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        527.58935546875,
        546.0599975585938,
        543.40966796875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전체 잔여위험이 허용 가능한지 아닌지를 결정하고 <표 14>와",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        557.58935546875,
        546.0599975585938,
        573.40966796875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같이 기록한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        587.58935546875,
        210.56295776367188,
        603.40966796875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잔여위험평가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        82.19999694824219,
        641.6400146484375,
        154.1999969482422,
        656.0400390625
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        202.1999969482422,
        658.6799926757812,
        311.2799987792969,
        682.6799926757812
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험/이득",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        202.1999969482422,
        658.6799926757812,
        311.2799987792969,
        682.6799926757812
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분석",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        273.7200012207031,
        677.8800048828125,
        297.7200012207031,
        692.280029296875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        328.91998291015625,
        649.0799560546875,
        352.91998291015625,
        663.47998046875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        328.91998291015625,
        668.2799682617188,
        352.91998291015625,
        682.6799926757812
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        328.91998291015625,
        687.47998046875,
        352.91998291015625,
        701.8800048828125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통제",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        376.3199768066406,
        658.6799926757812,
        400.3199768066406,
        673.0800170898438
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "완료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        376.3199768066406,
        677.8800048828125,
        400.3199768066406,
        692.280029296875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전체 잔여위험 허용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        422.1600036621094,
        649.0799560546875,
        530.1599731445312,
        663.47998046875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가능성 평가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        443.1600036621094,
        668.2799682617188,
        509.1600036621094,
        682.6799926757812
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(허용 가능/불가)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        432.239990234375,
        687.47998046875,
        520.2119750976562,
        701.8800048828125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        67.08000183105469,
        656.5199584960938,
        91.08000183105469,
        670.9199829101562
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        67.08000183105469,
        675.719970703125,
        91.08000183105469,
        690.1199951171875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        73.08000183105469,
        694.9199829101562,
        85.08000183105469,
        709.3200073242188
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "심각",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        106.19999694824219,
        666.1199951171875,
        130.1999969482422,
        680.52001953125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        112.19999694824219,
        685.3200073242188,
        124.19999694824219,
        699.7200317382812
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        145.44000244140625,
        666.1199951171875,
        169.44000244140625,
        680.52001953125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "도",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        151.44000244140625,
        685.3200073242188,
        163.44000244140625,
        699.7200317382812
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.08000183105469,
        728.8800048828125,
        242.5439910888672,
        743.280029296875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.08000183105469,
        728.8800048828125,
        242.5439910888672,
        743.280029296875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.08000183105469,
        728.8800048828125,
        242.5439910888672,
        743.280029296875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Acceptable",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.08000183105469,
        728.8800048828125,
        242.5439910888672,
        743.280029296875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험 <",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        267.239990234375,
        719.2799682617188,
        304.2359924316406,
        733.6799926757812
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이득",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        273.7200012207031,
        738.47998046875,
        297.7200012207031,
        752.8800048828125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        328.91998291015625,
        709.6799926757812,
        352.91998291015625,
        724.0800170898438
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사항",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        328.91998291015625,
        728.8800048828125,
        352.91998291015625,
        743.280029296875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        328.91998291015625,
        748.0799560546875,
        352.91998291015625,
        762.47998046875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "완료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        376.3199768066406,
        728.8800048828125,
        500.1600036621094,
        743.280029296875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허용가능",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        376.3199768066406,
        728.8800048828125,
        500.1600036621094,
        743.280029296875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 12. 전체 잔여위험 허용 가능성 평가 예시",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        157.55999755859375,
        618.719970703125,
        438.7205810546875,
        634.27197265625
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험통제 조치",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.04000091552734,
        301.44000244140625,
        146.0399932861328,
        315.8399963378906
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험통제",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        171.95999145507812,
        291.8399963378906,
        219.95999145507812,
        306.239990234375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조치실행",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        171.95999145507812,
        311.03997802734375,
        219.95999145507812,
        325.4399719238281
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잔여위험평가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        250.9199981689453,
        274.91998291015625,
        322.91998291015625,
        289.3199768066406
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        360.47998046875,
        301.44000244140625,
        384.47998046875,
        315.8399963378906
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험/",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        418.55999755859375,
        282.239990234375,
        445.71600341796875,
        296.6399841308594
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이득",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        420.1199951171875,
        301.44000244140625,
        444.1199951171875,
        315.8399963378906
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분석",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        420.1199951171875,
        320.6399841308594,
        444.1199951171875,
        335.03997802734375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        466.3199768066406,
        282.239990234375,
        490.3199768066406,
        296.6399841308594
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        466.3199768066406,
        301.44000244140625,
        490.3199768066406,
        315.8399963378906
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        466.3199768066406,
        320.6399841308594,
        490.3199768066406,
        335.03997802734375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통제",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        508.0799865722656,
        291.8399963378906,
        532.0800170898438,
        306.239990234375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "완료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        508.0799865722656,
        311.03997802734375,
        532.0800170898438,
        325.4399719238281
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        245.51998901367188,
        289.67999267578125,
        269.5199890136719,
        304.0799865722656
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가능",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        245.51998901367188,
        308.8800048828125,
        269.5199890136719,
        323.2799987792969
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        251.51998901367188,
        328.0799865722656,
        263.5199890136719,
        342.47998046875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "심",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        287.8800048828125,
        289.67999267578125,
        299.8800048828125,
        304.0799865722656
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "각",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        287.8800048828125,
        308.8800048828125,
        299.8800048828125,
        323.2799987792969
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        287.8800048828125,
        328.0799865722656,
        299.8800048828125,
        342.47998046875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        317.2799987792969,
        289.67999267578125,
        329.2799987792969,
        304.0799865722656
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "험",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        317.2799987792969,
        308.8800048828125,
        329.2799987792969,
        323.2799987792969
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "도",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        317.2799987792969,
        328.0799865722656,
        329.2799987792969,
        342.47998046875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설계 변경을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.04000091552734,
        352.55999755859375,
        140.0399932861328,
        366.9599914550781
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통한 사용자별",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.04000091552734,
        371.7599792480469,
        146.0399932861328,
        386.15997314453125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접근통제 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.04000091552734,
        390.9599914550781,
        140.0399932861328,
        405.3599853515625
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인증 기능 구현",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        65.04000091552734,
        410.1600036621094,
        149.0399932861328,
        424.55999755859375
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        165.95999145507812,
        342.9599914550781,
        225.95999145507812,
        357.3599853515625
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 자료로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        162.95999145507812,
        362.1600036621094,
        228.95999145507812,
        376.55999755859375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접근통제 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        162.95999145507812,
        381.3599853515625,
        228.95999145507812,
        395.7599792480469
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인증 기능",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        168.95999145507812,
        400.55999755859375,
        222.95999145507812,
        414.9599914550781
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구현 확인",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        168.95999145507812,
        419.7599792480469,
        222.95999145507812,
        434.15997314453125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        254.51998901367188,
        381.3599853515625,
        400.8240051269531,
        395.7599792480469
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        254.51998901367188,
        381.3599853515625,
        400.8240051269531,
        395.7599792480469
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        254.51998901367188,
        381.3599853515625,
        400.8240051269531,
        395.7599792480469
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Acceptable",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        254.51998901367188,
        381.3599853515625,
        400.8240051269531,
        395.7599792480469
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험 <",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        413.6399841308594,
        371.7599792480469,
        450.635986328125,
        386.15997314453125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이득",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        420.1199951171875,
        390.9599914550781,
        444.1199951171875,
        405.3599853515625
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        466.3199768066406,
        362.1600036621094,
        490.3199768066406,
        376.55999755859375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사항",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        466.3199768066406,
        381.3599853515625,
        490.3199768066406,
        395.7599792480469
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        466.3199768066406,
        400.55999755859375,
        490.3199768066406,
        414.9599914550781
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "완료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        508.0799865722656,
        381.3599853515625,
        532.0800170898438,
        395.7599792480469
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 11. 위험통제 예시",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        232.9199981689453,
        251.87998962402344,
        365.40057373046875,
        267.4320068359375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 29 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 36,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4) 사이버보안 적용 방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        70.74937438964844,
        241.3199920654297,
        86.56968688964844
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "‘의료기기 사이버보안 요구사항 체크리스트’는 의료기기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        100.74937438964844,
        546.0599975585938,
        116.56968688964844
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사이버보안 요구사항에 대한 적합성 여부를 확인할 수 있는 자료로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        130.74937438964844,
        545.9400024414062,
        146.56968688964844
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조자는 체크리스트의 질의 사항을 확인하여 요구사항의 적용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        160.74937438964844,
        538.5599975585938,
        176.56968688964844
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여부 등을 확인할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        190.74937438964844,
        294.9229736328125,
        206.56968688964844
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용되는 통신기술(유·무선 통신 방식 등), 사용환경(병원",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        220.74937438964844,
        545.9400024414062,
        236.56968688964844
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내/외 사용, 공용 네트워크망 사용 등) 등 통신 특성을 확인할",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        250.74935913085938,
        545.9400024414062,
        266.5696716308594
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있는 사항을 기재한다. 이를 기반으로 체크리스트에 따라",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        280.7493591308594,
        545.9400024414062,
        296.5696716308594
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요구사항 적용여부, 적합성 입증방법, 첨부자료 또는 문서번호를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        310.7493591308594,
        545.9400024414062,
        326.5696716308594
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기재한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        340.7493591308594,
        178.13999938964844,
        356.5696716308594
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 30 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 37,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<예시> - 의료기기 사이버보안 요구사항 체크리스트",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        70.89035034179688,
        297.60137939453125,
        80.85034942626953
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "< 의료기기 사이버보안 특성 기재 >",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        75.83999633789062,
        111.62249755859375,
        290.2799987792969,
        125.29124450683594
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 사용되는 통신 기술 : 유선 통신(LAN), 무선통신(Wi-fi, 블루투스)",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        75.83999633789062,
        137.66250610351562,
        480.4499816894531,
        151.3312530517578
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 사용 환경 : 병원 내 사용, 병원 외 사용",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        75.83999633789062,
        163.70249938964844,
        333.84051513671875,
        177.37124633789062
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 공용 네트워크 망 사용여부 : Y",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        75.83999633789062,
        189.62249755859375,
        280.6274719238281,
        203.29124450683594
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사이버보안 요구사항",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        143.27999877929688,
        279.0,
        257.2799987792969,
        293.3999938964844
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당기기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        349.1999816894531,
        269.3999938964844,
        397.1999816894531,
        283.79998779296875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용여부",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        349.1999816894531,
        288.6000061035156,
        397.1999816894531,
        303.0
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적합성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        269.3999938964844,
        453.239990234375,
        283.79998779296875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "입증 방법",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        288.6000061035156,
        462.239990234375,
        303.0
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        492.0,
        250.19998168945312,
        516.0,
        264.5999755859375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "첨부자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        480.0,
        269.3999938964844,
        528.0,
        283.79998779296875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        492.0,
        288.6000061035156,
        516.0,
        303.0
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "문서번호",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        480.0,
        307.79998779296875,
        528.0,
        322.1999816894531
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보안",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.4000015258789,
        466.55999755859375,
        92.4000015258789,
        480.9599914550781
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통신",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.4000015258789,
        485.7599792480469,
        92.4000015258789,
        500.15997314453125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 의료기기가 다른 기기나 네트워크와",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        324.0,
        338.8800048828125,
        338.3999938964844
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "어떻게 접속(유·무선 통신 등)하여야 할지를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        343.1999816894531,
        338.8800048828125,
        357.5999755859375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고려하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        362.3999938964844,
        202.13999938964844,
        376.79998779296875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예: Wi-Fi, 이더넷, 블루투스, USB 등",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        115.19999694824219,
        381.6000061035156,
        335.3999938964844,
        396.0
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        352.79998779296875,
        385.1999816894531,
        367.1999816894531
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        324.0,
        462.8399963378906,
        338.3999938964844
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        414.239990234375,
        343.1999816894531,
        456.239990234375,
        357.5999755859375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        362.3999938964844,
        453.239990234375,
        376.79998779296875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        381.6000061035156,
        462.239990234375,
        396.0
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        343.1999816894531,
        534.0,
        357.5999755859375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        362.3999938964844,
        530.1719970703125,
        376.79998779296875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        399.3599853515625,
        338.8800048828125,
        413.7599792480469
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내·외부의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        399.3599853515625,
        338.8800048828125,
        413.7599792480469
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모든",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        109.19999694824219,
        399.3599853515625,
        338.8800048828125,
        413.7599792480469
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "입력에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        399.3599853515625,
        338.8800048828125,
        413.7599792480469
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        399.3599853515625,
        338.8800048828125,
        413.7599792480469
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성을 확인하는 설계 특성을 고려하여야",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        418.55999755859375,
        338.8800048828125,
        432.9599914550781
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하며, 보안이 취약한 통신(예. 가정용 네트",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        437.7599792480469,
        338.8800048828125,
        452.15997314453125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "워크 혹은 기존 기기)만을 지원하는 기기 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        456.9599914550781,
        338.8800048828125,
        471.3599853515625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "환경에서 이루어지는 통신도 고려한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        476.1600036621094,
        322.1399841308594,
        490.55999755859375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        437.7599792480469,
        385.1999816894531,
        452.15997314453125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        408.9599914550781,
        462.8399963378906,
        423.3599853515625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        414.239990234375,
        428.1600036621094,
        456.239990234375,
        442.55999755859375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        447.3599853515625,
        453.239990234375,
        461.7599792480469
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        466.55999755859375,
        462.239990234375,
        480.9599914550781
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        428.1600036621094,
        534.0,
        442.55999755859375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        447.3599853515625,
        530.1719970703125,
        461.7599792480469
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 비인가 접근/변경/반복을 방지하기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        493.79998779296875,
        338.8800048828125,
        508.1999816894531
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위한 의료기기의 보안이 보장된(secured)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        513.0,
        338.8919982910156,
        527.4000244140625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데이터 송·수신 방법을 고려하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        532.2000122070312,
        332.6999816894531,
        546.6000366210938
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예: 기기/시스템 간 통신 시 상호인증",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        115.19999694824219,
        551.3999633789062,
        338.8800048828125,
        565.7999877929688
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방법, 암호화 필요 여부, 과거에 전송된",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        115.19999694824219,
        570.5999755859375,
        338.8800048828125,
        585.0
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "명령어 및 데이터의 비인가 반복에 대한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        115.19999694824219,
        589.7999877929688,
        338.8800048828125,
        604.2000122070312
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방지, 사전에 정의된 통신 종료 시점의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        115.19999694824219,
        609.0,
        338.8800048828125,
        623.4000244140625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적절성 여부 등",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        115.19999694824219,
        628.2000122070312,
        199.1999969482422,
        642.6000366210938
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        561.0,
        385.1999816894531,
        575.4000244140625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        532.2000122070312,
        462.8399963378906,
        546.6000366210938
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        414.239990234375,
        551.3999633789062,
        456.239990234375,
        565.7999877929688
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        570.5999755859375,
        453.239990234375,
        585.0
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        589.7999877929688,
        462.239990234375,
        604.2000122070312
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        551.3999633789062,
        534.0,
        565.7999877929688
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        570.5999755859375,
        530.1719970703125,
        585.0
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데이터",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        62.39999771118164,
        690.0,
        98.4000015258789,
        704.4000244140625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보호",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.4000015258789,
        709.2000122070312,
        92.4000015258789,
        723.6000366210938
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 안전(safety)과 관련된 데이터가 저장",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        661.2000122070312,
        338.8800048828125,
        675.6000366210938
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "되거나 기기와 송·수신될 때 암호화와 같은",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        109.19999694824219,
        680.3999633789062,
        338.8800048828125,
        694.7999877929688
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일정 수준의 보호가 요구되는지 고려하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        699.5999755859375,
        336.17999267578125,
        714.0
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예: 비밀번호(passwords)는 암호화된 보안",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        718.7999877929688,
        338.8800048828125,
        733.2000122070312
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(secure)이 확보된 해쉬(hash)로 저장되어야 함",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        738.0,
        336.239990234375,
        752.4000244140625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        699.5999755859375,
        385.1999816894531,
        714.0
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        670.7999877929688,
        462.8399963378906,
        685.2000122070312
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        414.239990234375,
        690.0,
        456.239990234375,
        704.4000244140625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        709.2000122070312,
        453.239990234375,
        723.6000366210938
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        728.3999633789062,
        462.239990234375,
        742.7999877929688
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        690.0,
        534.0,
        704.4000244140625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        709.2000122070312,
        530.1719970703125,
        723.6000366210938
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 31 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조자는 기밀성에 대한 위험통제 수단이",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        73.31999969482422,
        338.8800048828125,
        87.72000122070312
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요구될 때, 통신 프로토콜의 컨트롤(control)/",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        109.19999694824219,
        92.5199966430664,
        338.9159851074219,
        106.91999816894531
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시퀀싱(sequencing) 필드의 메시지를 보호",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        111.7199935913086,
        338.8800048828125,
        126.1199951171875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하거나 암호화의 키 관련 자료가 손상되는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        130.9199981689453,
        338.8800048828125,
        145.3199920654297
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "것을 방지하도록 고려하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        150.1199951171875,
        290.6999816894531,
        164.51998901367188
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        111.7199935913086,
        385.1999816894531,
        126.1199951171875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        82.91999816894531,
        462.8399963378906,
        97.31999969482422
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        414.239990234375,
        102.1199951171875,
        456.239990234375,
        116.5199966430664
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        121.31999206542969,
        453.239990234375,
        135.71998596191406
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        140.51998901367188,
        462.239990234375,
        154.91998291015625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        102.1199951171875,
        534.0,
        116.5199966430664
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        121.31999206542969,
        530.1719970703125,
        135.71998596191406
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.4000015258789,
        274.67999267578125,
        92.4000015258789,
        289.0799865722656
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "무결성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        62.39999771118164,
        293.8800048828125,
        98.4000015258789,
        308.2799987792969
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 데이터 부인방지(non-repudiation)를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        170.63999938964844,
        338.8800048828125,
        185.0399932861328
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보장하기 위한 설계 특성이 필요한지를 결정",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        189.83999633789062,
        338.8800048828125,
        204.239990234375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하기 위해 시스템 레벨에서의 아키텍쳐를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        209.0399932861328,
        338.8800048828125,
        223.4399871826172
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        228.239990234375,
        196.74000549316406,
        242.63998413085938
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예: 감사 로그 기록 기능 제공",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        247.44000244140625,
        287.5199890136719,
        261.8399963378906
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        209.0399932861328,
        385.1999816894531,
        223.4399871826172
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        180.239990234375,
        462.8399963378906,
        194.63998413085938
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        414.239990234375,
        199.44000244140625,
        456.239990234375,
        213.83999633789062
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        218.63999938964844,
        453.239990234375,
        233.0399932861328
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        237.83999633789062,
        462.239990234375,
        252.239990234375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        199.44000244140625,
        534.0,
        213.83999633789062
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        218.63999938964844,
        530.1719970703125,
        233.0399932861328
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 기기 소프트웨어의 비인가된 변경과",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        274.67999267578125,
        338.8800048828125,
        289.0799865722656
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "같은 기기의 무결성에 대한 위험을 고려해야",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        293.8800048828125,
        338.8800048828125,
        308.2799987792969
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        313.0799865722656,
        134.6999969482422,
        327.47998046875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        293.8800048828125,
        385.1999816894531,
        308.2799987792969
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        265.0799865722656,
        462.8399963378906,
        279.47998046875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        414.239990234375,
        284.2799987792969,
        456.239990234375,
        298.67999267578125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        303.47998046875,
        453.239990234375,
        317.8799743652344
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        322.67999267578125,
        462.239990234375,
        337.0799865722656
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        284.2799987792969,
        534.0,
        298.67999267578125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        303.47998046875,
        530.1719970703125,
        317.8799743652344
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 바이러스, 스파이웨어, 랜섬웨어 등",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        340.32000732421875,
        338.8800048828125,
        354.7200012207031
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기기에서 실행될 수 있는 악성코드를 막기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        359.5199890136719,
        338.8800048828125,
        373.91998291015625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해 안티 멀웨어 프로그램과 같은 통제",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        378.7200012207031,
        338.8800048828125,
        393.1199951171875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조치를 고려하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        397.91998291015625,
        242.8199920654297,
        412.3199768066406
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        369.1199951171875,
        385.1999816894531,
        383.5199890136719
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        340.32000732421875,
        462.8399963378906,
        354.7200012207031
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        414.239990234375,
        359.5199890136719,
        456.239990234375,
        373.91998291015625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        378.7200012207031,
        453.239990234375,
        393.1199951171875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        397.91998291015625,
        462.239990234375,
        412.3199768066406
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        359.5199890136719,
        534.0,
        373.91998291015625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        378.7200012207031,
        530.1719970703125,
        393.1199951171875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용자",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        62.39999771118164,
        476.03997802734375,
        98.4000015258789,
        490.4399719238281
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인증",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.4000015258789,
        495.239990234375,
        92.4000015258789,
        509.6399841308594
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 기기의 사용이 입증된 사용자이거나,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        418.44000244140625,
        338.8320007324219,
        432.8399963378906
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다른 역할의 사용자에게 사용권한을 부여를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        437.6399841308594,
        338.8800048828125,
        452.03997802734375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허용하거나, 응급상황에서 접근을 허용하는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        456.8399963378906,
        338.8800048828125,
        471.239990234375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용자 접근통제에 대해 고려하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        476.03997802734375,
        338.82000732421875,
        490.4399719238281
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추가로 동일한 자격증명은 기기와 고객들에게",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        495.239990234375,
        338.8800048828125,
        509.6399841308594
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "공유되지 않아야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        514.4400024414062,
        224.94000244140625,
        528.8400268554688
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 접근 통제의 예: 비밀번호, 하드웨어 키,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        533.6400146484375,
        338.8320007324219,
        548.0400390625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생체인증 등",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        552.8399658203125,
        177.59999084472656,
        567.239990234375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        485.6399841308594,
        385.1999816894531,
        500.03997802734375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        456.8399963378906,
        462.8399963378906,
        471.239990234375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        414.239990234375,
        476.03997802734375,
        456.239990234375,
        490.4399719238281
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        495.239990234375,
        453.239990234375,
        509.6399841308594
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        514.4400024414062,
        462.239990234375,
        528.8400268554688
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        476.03997802734375,
        534.0,
        490.4399719238281
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        495.239990234375,
        530.1719970703125,
        509.6399841308594
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        62.39999771118164,
        633.8399658203125,
        98.4000015258789,
        648.239990234375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.4000015258789,
        653.0399780273438,
        92.4000015258789,
        667.4400024414062
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유지",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.4000015258789,
        672.239990234375,
        92.4000015258789,
        686.6400146484375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보수",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        68.4000015258789,
        691.4400024414062,
        92.4000015258789,
        705.8400268554688
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 주기적인 업데이트의 구현과 배포를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        589.6799926757812,
        338.8800048828125,
        604.0800170898438
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위한 수행절차를 수립하고 통보하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        608.8800048828125,
        337.739990234375,
        623.280029296875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        599.2799682617188,
        385.1999816894531,
        613.6799926757812
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        570.47998046875,
        462.8399963378906,
        584.8800048828125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        414.239990234375,
        589.6799926757812,
        456.239990234375,
        604.0800170898438
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        608.8800048828125,
        453.239990234375,
        623.280029296875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        628.0799560546875,
        462.239990234375,
        642.47998046875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        589.6799926757812,
        534.0,
        604.0800170898438
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        608.8800048828125,
        530.1719970703125,
        623.280029296875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 운영 체제(OS) 소프트웨어, 제3자",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        652.4400024414062,
        338.8800048828125,
        666.8400268554688
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어, 오픈 소스 소프트웨어가 업데이트나",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        671.6400146484375,
        338.8800048828125,
        686.0400390625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통제될 경우에 대해 고려하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        690.8399658203125,
        303.8999938964844,
        705.239990234375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        671.6400146484375,
        385.1999816894531,
        686.0400390625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        642.8399658203125,
        462.8399963378906,
        657.239990234375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        414.239990234375,
        662.0399780273438,
        456.239990234375,
        676.4400024414062
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        681.239990234375,
        453.239990234375,
        695.6400146484375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        700.4400024414062,
        462.239990234375,
        714.8400268554688
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        662.0399780273438,
        534.0,
        676.4400024414062
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        681.239990234375,
        530.1719970703125,
        695.6400146484375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또한 제조자는 외부의 통제에 의한 소프트",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        715.9199829101562,
        338.8800048828125,
        730.3200073242188
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "웨어의 업데이트나 운영환경 만료에 대한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        735.1199951171875,
        338.8800048828125,
        749.52001953125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대응 계획을 수립하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        754.3200073242188,
        264.41998291015625,
        768.7200317382812
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        735.1199951171875,
        385.1999816894531,
        749.52001953125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        715.9199829101562,
        462.8399963378906,
        730.3200073242188
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        414.239990234375,
        735.1199951171875,
        456.239990234375,
        749.52001953125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        754.3200073242188,
        453.239990234375,
        768.7200317382812
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        725.5199584960938,
        534.0,
        739.9199829101562
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        744.719970703125,
        530.1719970703125,
        759.1199951171875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 32 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 39,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 예: 보안이 보장되지 않은(unsecure) 운영",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        78.95999908447266,
        338.8800048828125,
        93.36000061035156
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체제 버전에서 운영되는 의료기기 소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        88.55999755859375,
        462.239990234375,
        112.55999755859375
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        88.55999755859375,
        462.239990234375,
        112.55999755859375
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조자는 새로운 사이버보안 취약성에 대응할",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        128.0399932861328,
        338.8800048828125,
        142.4399871826172
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 업데이트 방안을 고려하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        147.239990234375,
        337.739990234375,
        161.63998413085938
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예: 업데이트 시 사용자 개입/ 자동 업",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        166.44000244140625,
        338.7599792480469,
        180.83999633789062
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데이트 여부, 기기의 안전(safety)과 성능에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        185.63999938964844,
        338.8800048828125,
        200.0399932861328
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "영향을 보장할 수 있는 업데이트 유효성 검증",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        204.83999633789062,
        338.03997802734375,
        219.239990234375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        166.44000244140625,
        385.1999816894531,
        180.83999633789062
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        137.63999938964844,
        462.8399963378906,
        152.0399932861328
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        414.239990234375,
        156.83999633789062,
        456.239990234375,
        171.239990234375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        176.0399932861328,
        453.239990234375,
        190.4399871826172
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        195.239990234375,
        462.239990234375,
        209.63998413085938
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        156.83999633789062,
        534.0,
        171.239990234375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        176.0399932861328,
        530.1719970703125,
        190.4399871826172
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 업데이트의 수행하기 위해 어떤",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        109.19999694824219,
        234.47999572753906,
        338.8800048828125,
        248.87998962402344
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연결이 필요한지와 코드 서명 및 기타 비슷한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        253.67999267578125,
        338.8800048828125,
        268.0799865722656
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수단을 통한 연결이나 업데이트의 진본성을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        272.8800048828125,
        338.8800048828125,
        287.2799987792969
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고려하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        292.0799865722656,
        196.74000549316406,
        306.47998046875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        263.2799987792969,
        385.1999816894531,
        277.67999267578125
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        234.47999572753906,
        462.8399963378906,
        248.87998962402344
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        414.239990234375,
        253.67999267578125,
        456.239990234375,
        268.0799865722656
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        272.8800048828125,
        453.239990234375,
        287.2799987792969
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        292.0799865722656,
        462.239990234375,
        306.47998046875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        253.67999267578125,
        534.0,
        268.0799865722656
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        272.8800048828125,
        530.1719970703125,
        287.2799987792969
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "물리적",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        62.39999771118164,
        356.1600036621094,
        98.4000015258789,
        370.55999755859375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접근",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        68.4000015258789,
        375.3599853515625,
        92.4000015258789,
        389.7599792480469
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 비인가 된 개인이 의료기기에 접근",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        109.19999694824219,
        317.7599792480469,
        338.8800048828125,
        332.15997314453125
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하는 것을 방지하기 위한 통제 수단을 고려",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        109.19999694824219,
        336.9599914550781,
        338.8800048828125,
        351.3599853515625
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        356.1600036621094,
        174.17999267578125,
        370.55999755859375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예: 물리적 잠금 혹은 포트(port) 접근의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        375.3599853515625,
        338.8800048828125,
        389.7599792480469
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "물리적 제한, 인증이 필요 없는 물리적",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        394.55999755859375,
        338.8800048828125,
        408.9599914550781
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "케이블의 접근제한 등",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        114.83999633789062,
        413.7599792480469,
        228.36000061035156,
        428.15997314453125
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        365.7599792480469,
        385.1999816894531,
        380.15997314453125
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성능",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        423.239990234375,
        317.7599792480469,
        447.239990234375,
        332.15997314453125
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험소프",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        411.8399963378906,
        336.9599914550781,
        458.6399841308594,
        351.3599853515625
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        418.44000244140625,
        356.1600036621094,
        452.03997802734375,
        370.55999755859375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        414.239990234375,
        375.3599853515625,
        456.239990234375,
        389.7599792480469
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        394.55999755859375,
        453.239990234375,
        408.9599914550781
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        413.7599792480469,
        462.239990234375,
        428.15997314453125
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        356.1600036621094,
        534.0,
        370.55999755859375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        375.3599853515625,
        530.1719970703125,
        389.7599792480469
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신뢰성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        62.39999771118164,
        443.7599792480469,
        98.4000015258789,
        458.15997314453125
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.4000015258789,
        462.9599914550781,
        86.4000015258789,
        477.3599853515625
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가용성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        62.39999771118164,
        482.1600036621094,
        98.4000015258789,
        496.55999755859375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조자는 의료기기가 필수 성능을 유지하기",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        434.1600036621094,
        338.8800048828125,
        448.55999755859375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해 사이버보안 공격을 탐지, 저항, 대응",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        109.19999694824219,
        453.3599853515625,
        338.8800048828125,
        467.7599792480469
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 복구하도록 허용하는 설계 특성을 고려",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        109.19999694824219,
        472.55999755859375,
        338.8800048828125,
        486.9599914550781
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        109.19999694824219,
        491.7599792480469,
        174.17999267578125,
        506.15997314453125
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        361.1999816894531,
        462.9599914550781,
        385.1999816894531,
        477.3599853515625
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        407.6399841308594,
        434.1600036621094,
        462.8399963378906,
        448.55999755859375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검증 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        414.239990234375,
        453.3599853515625,
        456.239990234375,
        467.7599792480469
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        417.239990234375,
        472.55999755859375,
        453.239990234375,
        486.9599914550781
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 자료",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        408.239990234375,
        491.7599792480469,
        462.239990234375,
        506.15997314453125
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험보고서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        474.0,
        453.3599853515625,
        534.0,
        467.7599792480469
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(AB-1234)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        477.9599914550781,
        472.55999755859375,
        530.1719970703125,
        486.9599914550781
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 33 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5) 허가·인증 변경 시 제출자료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        70.74937438964844,
        293.7599792480469,
        86.56968688964844
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사이버 보안에 영향을 미치는 변경(통신방법의 변경/추가,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        100.74937438964844,
        546.0599975585938,
        116.56968688964844
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "운영체제의 변경/추가, 통신 목적 변경/추가 등)이 포함된 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        130.74937438964844,
        538.5599975585938,
        146.56968688964844
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에는 「의료기기 허가·신고·심사 등에 관한 규정」(식약처",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        160.74937438964844,
        546.0599975585938,
        176.56968688964844
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고시) 제19조의2(의료기기 소프트웨어 허가ㆍ인증ㆍ신고의 변경",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        190.74937438964844,
        546.0599975585938,
        206.56968688964844
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "처리)에 따라, 소프트웨어 업그레이드에 해당되므로 변경허가‧",
      "font_size": 15.0,
      "font_name": "Haansoft Batang",
      "bbox": [
        109.07999420166016,
        220.74937438964844,
        538.5274047851562,
        236.56968688964844
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인증‧신고를 하여야한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        250.74935913085938,
        273.2029724121094,
        266.5696716308594
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 경우에는 신규 허가와 마찬가지로 ‘의료기기 소프트웨어",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        280.7493591308594,
        546.0599975585938,
        296.5696716308594
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적합성 확인보고서’, ‘의료기기 사이버보안 요구사항 체크",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        310.7493591308594,
        538.4400024414062,
        326.5696716308594
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "리스트’와 체크리스트의 요구사항을 실제로 검증 또는 검증을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        340.7493591308594,
        546.0599975585938,
        356.5696716308594
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대체한 사유를 확인할 수 있는 자료(소프트웨어 검증 및 유효성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        370.7493591308594,
        545.9400024414062,
        386.5696716308594
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인자료, 성능시험성적서, 위험관리문서 등)를 제출하여야",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        400.7493591308594,
        538.5599975585938,
        416.5696716308594
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        109.07999420166016,
        430.7493591308594,
        143.9629669189453,
        446.5696716308594
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 34 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 41,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 성능 평가 항목",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        63.119998931884766,
        77.85995483398438,
        195.72000122070312,
        93.81996154785156
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "섭식장애 개선 디지털치료기기의 성능 평가 항목은 제품의 주요",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        120.78936767578125,
        546.0599975585938,
        136.60968017578125
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기능을 근거로 설정하며, 시험 기준 및 시험 방법은 제품의 특성을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        150.78936767578125,
        546.0599975585938,
        166.60968017578125
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려하여 가능한 정량적이고 구체적으로 작성한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        180.78936767578125,
        409.282958984375,
        196.60968017578125
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 주요 기능 선정 시 아래 고려사항을 참고하여 선정한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        210.78936767578125,
        517.97998046875,
        226.60968017578125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 제품의 사용목적 상 필요한 기능(능력) 요구사항",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        240.78936767578125,
        445.0799865722656,
        256.60968017578125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 소프트웨어 기반 알람, 경고, 연산 메시지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        270.78936767578125,
        399.239990234375,
        286.60968017578125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 데이터베이스 요구사항",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        300.78936767578125,
        272.6399841308594,
        316.60968017578125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 운영방법 및 유지보수 방법과 관련된 요구사항",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        330.78936767578125,
        435.7200012207031,
        346.60968017578125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 35 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 42,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 예시는 이해를 돕기 위하여 작성된 것으로 실제 신청하려는 제품의 내용과 상이",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.55999755859375,
        90.23999786376953,
        528.0,
        104.63999938964844
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "할 수 있다. 본 예시는 대표적인 예를 작성한 것으로 실제 시험규격에 대해 작성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        114.23999786376953,
        528.1199951171875,
        128.63999938964844
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시에는 해당 제품의 특성 및 주요 기능을 고려하여 작성하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        138.239990234375,
        445.5,
        152.63998413085938
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        218.109375,
        91.32749938964844,
        233.9296875
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.55999755859375,
        253.8074951171875,
        463.55999755859375,
        266.4637451171875
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험 항목",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.55999755859375,
        253.8074951171875,
        463.55999755859375,
        266.4637451171875
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험기준",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.55999755859375,
        253.8074951171875,
        463.55999755859375,
        266.4637451171875
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험 방법",
      "font_size": 12.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.55999755859375,
        253.8074951171875,
        463.55999755859375,
        266.4637451171875
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        296.0325012207031,
        275.5199890136719,
        307.6762390136719
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최소 응답시간",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        296.0325012207031,
        275.5199890136719,
        307.6762390136719
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "OO초 미만일 것",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        296.0325012207031,
        275.5199890136719,
        307.6762390136719
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "OOO 기능이 구현되도록 입력값을",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        278.51251220703125,
        528.9592895507812,
        290.15625
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "입력한 후 그에 대한 응답시간을",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        296.0325012207031,
        529.0796508789062,
        307.6762390136719
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "측정",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        313.6725158691406,
        371.6400146484375,
        325.3162536621094
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        359.2724914550781,
        172.07965087890625,
        370.9162292480469
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "메모리 크기",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        359.2724914550781,
        172.07965087890625,
        370.9162292480469
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "App memory size는 최소",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        350.39251708984375,
        344.8796691894531,
        362.0362548828125
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "OO MB 이상일 것",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        368.0325012207031,
        285.1199951171875,
        379.6762390136719
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설치될 기기의 메모리 공간을",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        341.63250732421875,
        529.0792846679688,
        353.2762451171875
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인한다.",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        359.2724914550781,
        399.3356018066406,
        370.9162292480469
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(ex:설정→애플리케이션→메모리)",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        376.7925109863281,
        513.5700073242188,
        388.4362487792969
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        413.63250732421875,
        172.07965087890625,
        425.2762451171875
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경고 메시지",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        413.63250732421875,
        172.07965087890625,
        425.2762451171875
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‘OOOOO’ 경고푸시 알림이",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        404.75250244140625,
        344.8799743652344,
        416.396240234375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생할 것",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        422.39251708984375,
        243.239990234375,
        434.0362548828125
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 알림이 발생하는 조건을 정하고,",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        404.75250244140625,
        529.07958984375,
        416.396240234375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실제 제품에 구현시킨다.",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        422.39251708984375,
        473.49560546875,
        434.0362548828125
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        467.99249267578125,
        174.8393096923828,
        488.396240234375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데이터베이스",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        467.99249267578125,
        174.8393096923828,
        488.396240234375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "송수신",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        125.27999877929688,
        485.63250732421875,
        158.39999389648438,
        497.2762451171875
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데이터베이스 저장했던 정보와",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        459.2325134277344,
        344.8799743652344,
        470.8762512207031
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다시 호출한 정보가 일치",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        476.75250244140625,
        339.3601379394531,
        488.396240234375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "할 것",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        494.3924865722656,
        221.2799835205078,
        506.0362243652344
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "네트워크 API를 통해 데이터",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        450.3525085449219,
        523.5598754882812,
        461.9962463378906
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "베이스로 미리 정해진 데이터를 송신",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        467.99249267578125,
        529.0800170898438,
        479.63623046875
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 저장한 후, 해당 데이터를 다시",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        485.63250732421875,
        528.9596557617188,
        497.2762451171875
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불러오기 한다.",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        503.15252685546875,
        424.05560302734375,
        514.7962646484375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        566.3925170898438,
        79.31999206542969,
        578.0362548828125
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중복 로그인",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.5999984741211,
        557.5125122070312,
        172.07965087890625,
        569.15625
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방지",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        130.8000030517578,
        575.1525268554688,
        152.87998962402344,
        586.7962646484375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다른 디바이스에서 같은 휴대폰",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        531.1124877929688,
        339.3598937988281,
        542.7562255859375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "번호로 동시에 로그인을 시도",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        548.7525024414062,
        339.3600769042969,
        560.396240234375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "했을 때, 기존 로그인되어",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        566.3925170898438,
        344.87933349609375,
        578.0362548828125
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있던 기기에서는 로그아웃",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        583.9124755859375,
        339.35943603515625,
        595.5562133789062
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "되어야 한다.",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        601.552490234375,
        257.1356201171875,
        613.1962280273438
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한기기에 시험용 정보로 로그인을",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        548.7525024414062,
        529.0796508789062,
        560.396240234375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 후, 다른 기기에서 같은 정보로",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        566.3925170898438,
        528.9596557617188,
        578.0362548828125
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "로그인을 시도한다.",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        583.9124755859375,
        446.0155944824219,
        595.5562133789062
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        647.1525268554688,
        183.1199951171875,
        667.5562133789062
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "섭식장애 증상",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.79999542236328,
        647.1525268554688,
        183.1199951171875,
        667.5562133789062
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정확도",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        125.27999877929688,
        664.6724853515625,
        158.39999389648438,
        676.3162231445312
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "섭식장애 증상 예상값 대비",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        638.2725219726562,
        344.8796691894531,
        649.916259765625
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과값 차이는 ± 1% 이내",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        655.9124755859375,
        339.35968017578125,
        667.5562133789062
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일 것",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.67999267578125,
        673.552490234375,
        221.2799835205078,
        685.1962280273438
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "섭식장애 증상 임의의 시험용 수명",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        638.2725219726562,
        523.5603637695312,
        649.916259765625
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "입력정보를 입력했을 때, 산출되는",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        655.9124755859375,
        528.9592895507812,
        667.5562133789062
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과값과 예상값을 비교한다.",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        349.55999755859375,
        673.552490234375,
        495.5755920410156,
        685.1962280273438
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 36 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅲ",
      "font_size": 20.03999900817871,
      "font_name": "T9",
      "bbox": [
        68.4000015258789,
        82.91999816894531,
        508.32000732421875,
        106.96800231933594
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험계획서 작성 시 고려사항 및 예시",
      "font_size": 20.03999900817871,
      "font_name": "H2hdrM",
      "bbox": [
        68.4000015258789,
        82.91999816894531,
        508.32000732421875,
        106.96800231933594
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "「의료기기법 시행규칙」제20조(임상시험계획의 승인 등) 제2항에 따라",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        148.1493682861328,
        545.9400024414062,
        163.9696807861328
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험계획서에 포함되어야 할 사항은 다음과 같다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        178.1493682861328,
        439.04296875,
        193.9696807861328
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 임상시험의 제목",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        208.1024932861328,
        195.0,
        221.771240234375
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 임상시험기관의 명칭 및 소재지",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        228.9824981689453,
        285.9599914550781,
        242.6512451171875
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 임상시험의 책임자ㆍ담당자 및 공동연구자의 성명 및 직명",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        249.7425079345703,
        448.4399719238281,
        263.4112548828125
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 임상시험용 의료기기를 관리하는 관리자의 성명 및 직명",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        270.5024719238281,
        435.4804992675781,
        284.1712341308594
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5. 임상시험을 하려는 자의 성명 및 주소",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        291.3824768066406,
        324.9599914550781,
        305.0512390136719
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6. 임상시험의 목적 및 배경",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        312.1424865722656,
        246.9600067138672,
        325.8112487792969
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7. 임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다)",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        332.9024658203125,
        503.2499694824219,
        346.57122802734375
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8. 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되어 임상시험에",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        353.782470703125,
        539.9999389648438,
        367.45123291015625
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참여하는 사람(피험자)의 선정기준ㆍ제외기준ㆍ인원 및 그 근거",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.79999542236328,
        374.54248046875,
        467.6399841308594,
        388.21124267578125
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9. 임상시험기간",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        395.302490234375,
        175.56105041503906,
        408.97125244140625
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10. 임상시험방법(사용량ㆍ사용방법ㆍ사용기간ㆍ병용요법 등을 포함한다)",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        416.1824645996094,
        496.16998291015625,
        429.8512268066406
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "11. 관찰항목ㆍ임상검사항목 및 관찰검사방법",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        436.9424743652344,
        344.5205078125,
        450.6112365722656
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "12. 예측되는 부작용 및 사용 시 주의사항",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        457.7024841308594,
        324.96051025390625,
        471.3712463378906
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "13. 중지ㆍ탈락 기준",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        478.5824890136719,
        195.1205291748047,
        492.2512512207031
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "14. 유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 따른다)",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        499.34246826171875,
        480.6899719238281,
        513.01123046875
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "15. 부작용을 포함한 안전성의 평가기준ㆍ평가방법 및 보고방법",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        520.1024780273438,
        455.0404968261719,
        533.771240234375
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "16. 피험자동의서 서식",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        540.9824829101562,
        208.0800018310547,
        554.6512451171875
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "17. 피해자 보상에 대한 규약",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        561.7424926757812,
        247.08053588867188,
        575.4112548828125
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "18. 임상시험 후 피험자의 진료에 관한 사항",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        582.5025024414062,
        338.0404968261719,
        596.1712646484375
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "19. 피험자의 안전보호에 관한 대책",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        603.3824462890625,
        286.08050537109375,
        617.0512084960938
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "20. 그 밖에 임상시험을 안전하고 과학적으로 실시하기 위하여 필요한 사항",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.68000030517578,
        624.1424560546875,
        497.1601867675781,
        637.8112182617188
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 본 장에서 제시한 항목 및 예시는 참고용으로 작성한 것으로 사안에",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        70.08000183105469,
        668.0399780273438,
        531.359619140625,
        683.5919799804688
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "따라 변경될 수 있으며, 제품의 특성에 따라 타당한 근거를 제시할 경우",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        92.15999603271484,
        693.9599609375,
        531.3598022460938,
        709.511962890625
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설정 변경이 가능하다.",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        92.15999603271484,
        719.9999389648438,
        229.73519897460938,
        735.5519409179688
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 37 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 44,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 임상시험의 제목",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        59.52000045776367,
        84.93995666503906,
        200.16000366210938,
        100.89996337890625
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험용 ‘섭식장애 개선 디지털치료기기’의 안전성과 유효성을 증명하고자",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        78.1199951171875,
        145.3199920654297,
        529.9209594726562,
        160.8719940185547
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하는 임상시험의 목적을 구체적으로 알 수 있도록 기입한다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        65.15999603271484,
        171.3599853515625,
        425.0951843261719,
        186.9119873046875
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        379.14935302734375,
        96.24468231201172,
        394.96966552734375
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "섭식장애 진단환자의 섭식장애 증상을 개선하기 위해서 사용되는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        409.14935302734375,
        545.9400024414062,
        424.96966552734375
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "OOO 디지털치료기기의 안전성 및 유효성을 평가하기 위한 전향적",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        79.08000183105469,
        439.14935302734375,
        545.9400024414062,
        454.96966552734375
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무작위 비교 임상시험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        79.08000183105469,
        469.14935302734375,
        229.0800018310547,
        484.96966552734375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 대상 질환 :",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        499.14935302734375,
        177.89999389648438,
        514.9696655273438
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[F50.0] Anorexia nervosa (신경성 식욕부진)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        529.1493530273438,
        370.927490234375,
        544.9696655273438
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        559.1493530273438,
        496.8074951171875,
        574.9696655273438
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[F50.2] Bulimia nervosa (신경성 폭식증)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        589.1493530273438,
        345.48748779296875,
        604.9696655273438
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        619.1493530273438,
        457.6875,
        634.9696655273438
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[F50.4] Overeating associated with other psychological disturbances",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        649.1493530273438,
        546.0599975585938,
        664.9696655273438
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(기타 심리적 장애와 연관된 과식)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        124.91999816894531,
        679.1493530273438,
        359.2875061035156,
        694.9696655273438
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[F50.5] Vomiting associated with other psychological disturbances",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        709.1493530273438,
        546.0599975585938,
        724.9696655273438
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(기타 심리적 장애와 연관된 구토)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        127.43999481201172,
        739.1493530273438,
        361.6875,
        754.9696655273438
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 38 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 45,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[F50.8] Other eating disorders (기타 식사장애)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        70.74937438964844,
        390.48748779296875,
        86.56968688964844
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[F50.9] Eating disorder, unspecified (상세불명의 식사장애)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        100.74937438964844,
        471.36749267578125,
        116.56968688964844
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 의료기기의 사용 목적 : 환자의 섭식장애 증상을 정량적으로 개선",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        130.74937438964844,
        535.6799926757812,
        146.56968688964844
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 임상시험용 의료기기 : 섭식장애 개선 디지털치료기기(OOO)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        160.74937438964844,
        504.36749267578125,
        176.56968688964844
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 임상시험 평가 내용 : 식사장애 검사(EDE-Q)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        190.74937438964844,
        398.8874816894531,
        206.56968688964844
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 임상시험 디자인 : 단일(다)기관, 무작위배정, 전향적 임상시험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        220.74937438964844,
        517.6799926757812,
        236.56968688964844
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 39 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 임상시험기관의 명칭 및 소재지",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        79.29995727539062,
        317.1596984863281,
        95.25996398925781
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식약처장은 [의료법]에 따른 의료기관 중 임상시험에 필요한 시설, 인력 및 기구를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.55999755859375,
        130.0800018310547,
        528.1199951171875,
        144.47999572753906
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "갖춘",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        64.55999755859375,
        154.0800018310547,
        528.1199951171875,
        168.47999572753906
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기관을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        154.0800018310547,
        528.1199951171875,
        168.47999572753906
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험기관으로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        154.0800018310547,
        528.1199951171875,
        168.47999572753906
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지정하여",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        64.55999755859375,
        154.0800018310547,
        528.1199951171875,
        168.47999572753906
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "운영하고",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        154.0800018310547,
        528.1199951171875,
        168.47999572753906
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있으며, 임상시험기관은",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        64.55999755859375,
        154.0800018310547,
        528.1199951171875,
        168.47999572753906
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[의료기기 임상시험기관 지정에 관한 규정(식약처 고시)]에 따라 식약처장으로부터",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        178.0800018310547,
        528.0,
        192.47999572753906
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 임상시험기관으로 지정받은 곳이어야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        202.0800018310547,
        355.5,
        216.47999572753906
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        269.8293762207031,
        110.16468811035156,
        285.6496887207031
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        299.8293762207031,
        124.13999938964844,
        315.6496887207031
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기관명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        100.07999420166016,
        335.2799987792969,
        488.1600036621094,
        349.67999267578125
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소재지",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        100.07999420166016,
        335.2799987792969,
        488.1600036621094,
        349.67999267578125
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        100.07999420166016,
        335.2799987792969,
        488.1600036621094,
        349.67999267578125
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "팩스",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        100.07999420166016,
        335.2799987792969,
        488.1600036621094,
        349.67999267578125
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○병원",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        89.04000091552734,
        355.79998779296875,
        521.280029296875,
        370.1999816894531
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○시 ○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        89.04000091552734,
        355.79998779296875,
        521.280029296875,
        370.1999816894531
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        89.04000091552734,
        355.79998779296875,
        521.280029296875,
        370.1999816894531
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        89.04000091552734,
        355.79998779296875,
        521.280029296875,
        370.1999816894531
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○병원",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        89.04000091552734,
        376.1999816894531,
        521.280029296875,
        390.5999755859375
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○시 ○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        89.04000091552734,
        376.1999816894531,
        521.280029296875,
        390.5999755859375
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        89.04000091552734,
        376.1999816894531,
        521.280029296875,
        390.5999755859375
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        89.04000091552734,
        376.1999816894531,
        521.280029296875,
        390.5999755859375
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 40 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 임상시험 책임자·담당자 및 공동연구자의 성명 및 직명",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        79.29995727539062,
        501.1199951171875,
        95.25996398925781
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 시험자는 시험책임자, 시험담당자, 임상시험 조정자를 포함한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.79999542236328,
        125.16000366210938,
        460.3800048828125,
        139.55999755859375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        70.79999542236328,
        149.16000366210938,
        531.0,
        163.55999755859375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "으로서, 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        83.27999877929688,
        173.1599884033203,
        531.0,
        187.5599822998047
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하기에 충분한 경험이 있는 자가 선정되어야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        83.27999877929688,
        197.1599884033203,
        373.2599792480469,
        211.5599822998047
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 담당",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        70.79999542236328,
        221.1599884033203,
        531.0,
        235.5599822998047
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상시험에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        83.27999877929688,
        245.16000366210938,
        531.0,
        259.55999755859375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관여하는 사람을 말한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        83.27999877929688,
        269.1600036621094,
        222.17999267578125,
        283.55999755859375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 공동연구자는 의학통계 전문가, 의료기기 전문가 등을 말한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.79999542236328,
        293.1600036621094,
        442.1399841308594,
        307.55999755859375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 각 임상시험기관의 적절한 임상시험의 수행을 위하여 임상시험기관 및 시험자의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.79999542236328,
        317.1600036621094,
        531.1199951171875,
        331.55999755859375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의견을 조정하기 위하여 조정위원회를 설치하고 임상시험 조정자를 선정할 수 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        83.27999877929688,
        341.1600036621094,
        528.7799682617188,
        355.55999755859375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        395.109375,
        110.16468811035156,
        410.9296875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 시험책임자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        425.109375,
        158.16000366210938,
        440.9296875
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        457.67999267578125,
        486.8399963378906,
        472.0799865722656
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소속기관명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        457.67999267578125,
        486.8399963378906,
        472.0799865722656
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전공",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        457.67999267578125,
        486.8399963378906,
        472.0799865722656
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "직위",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        457.67999267578125,
        486.8399963378906,
        472.0799865722656
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        457.67999267578125,
        486.8399963378906,
        472.0799865722656
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        475.3199768066406,
        519.9599609375,
        489.719970703125
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○병원",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        86.87999725341797,
        475.3199768066406,
        519.9599609375,
        489.719970703125
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        475.3199768066406,
        519.9599609375,
        489.719970703125
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        475.3199768066406,
        519.9599609375,
        489.719970703125
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        475.3199768066406,
        519.9599609375,
        489.719970703125
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 시험담당자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        508.14935302734375,
        158.16000366210938,
        523.9696655273438
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        540.719970703125,
        486.8399963378906,
        555.1199951171875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소속기관명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        540.719970703125,
        486.8399963378906,
        555.1199951171875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전공",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        540.719970703125,
        486.8399963378906,
        555.1199951171875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "직위",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        540.719970703125,
        486.8399963378906,
        555.1199951171875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        540.719970703125,
        486.8399963378906,
        555.1199951171875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        558.3599853515625,
        519.9599609375,
        572.760009765625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○병원",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        86.87999725341797,
        558.3599853515625,
        519.9599609375,
        572.760009765625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        558.3599853515625,
        519.9599609375,
        572.760009765625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        558.3599853515625,
        519.9599609375,
        572.760009765625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        558.3599853515625,
        519.9599609375,
        572.760009765625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 공동연구자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        591.3093872070312,
        158.16000366210938,
        607.1296997070312
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        623.8800048828125,
        486.8399963378906,
        638.280029296875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소속기관명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        623.8800048828125,
        486.8399963378906,
        638.280029296875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전공",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        623.8800048828125,
        486.8399963378906,
        638.280029296875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "직위",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        623.8800048828125,
        486.8399963378906,
        638.280029296875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        623.8800048828125,
        486.8399963378906,
        638.280029296875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        641.5199584960938,
        519.9599609375,
        655.9199829101562
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○병원",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        86.87999725341797,
        641.5199584960938,
        519.9599609375,
        655.9199829101562
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        641.5199584960938,
        519.9599609375,
        655.9199829101562
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        641.5199584960938,
        519.9599609375,
        655.9199829101562
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        641.5199584960938,
        519.9599609375,
        655.9199829101562
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 임상시험 조정자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        674.4693603515625,
        195.72000122070312,
        690.2896728515625
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        707.0399780273438,
        486.8399963378906,
        721.4400024414062
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소속기관명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        707.0399780273438,
        486.8399963378906,
        721.4400024414062
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전공",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        707.0399780273438,
        486.8399963378906,
        721.4400024414062
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "직위",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        707.0399780273438,
        486.8399963378906,
        721.4400024414062
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        707.0399780273438,
        486.8399963378906,
        721.4400024414062
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        724.6799926757812,
        519.9599609375,
        739.0800170898438
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○병원",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        86.87999725341797,
        724.6799926757812,
        519.9599609375,
        739.0800170898438
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        724.6799926757812,
        519.9599609375,
        739.0800170898438
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        724.6799926757812,
        519.9599609375,
        739.0800170898438
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        724.6799926757812,
        519.9599609375,
        739.0800170898438
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 41 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 임상시험용 의료기기를 관리하는 관리자의 성명 및 직명",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        79.29995727539062,
        501.1199951171875,
        95.25996398925781
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험용 의료기기 관리자는 임상시험기관에서 임상시험용 해당 의료기기를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.55999755859375,
        128.87998962402344,
        528.239990234375,
        143.2799835205078
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보관, 관리하는 임상의, 의료기사 또는 간호사 등으로 임상시험기관의 장이 지정한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        152.87998962402344,
        528.239990234375,
        167.2799835205078
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자를 말하며, 임상시험용 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        176.87998962402344,
        528.239990234375,
        191.2799835205078
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "할 경우 이를 함께 관리한다. 임상시험용 의료기기 관리자의 성명, 소속 기관명 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        200.87998962402344,
        528.239990234375,
        215.2799835205078
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "직명 등 인적 사항을 기재한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        224.87998962402344,
        232.13999938964844,
        239.2799835205078
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        296.58935546875,
        110.16468811035156,
        312.40966796875
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 관리자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        326.58935546875,
        169.0800018310547,
        342.40966796875
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        360.47998046875,
        486.8399963378906,
        374.8799743652344
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소속기관명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        360.47998046875,
        486.8399963378906,
        374.8799743652344
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전공",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        360.47998046875,
        486.8399963378906,
        374.8799743652344
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "직위",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        360.47998046875,
        486.8399963378906,
        374.8799743652344
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        92.27999877929688,
        360.47998046875,
        486.8399963378906,
        374.8799743652344
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        381.0,
        519.9599609375,
        395.3999938964844
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○병원",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        86.87999725341797,
        381.0,
        519.9599609375,
        395.3999938964844
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        381.0,
        519.9599609375,
        395.3999938964844
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        381.0,
        519.9599609375,
        395.3999938964844
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        86.87999725341797,
        381.0,
        519.9599609375,
        395.3999938964844
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 42 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5. 임상시험을 하려는 자의 성명 및 주소",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        84.93995666503906,
        365.15997314453125,
        100.89996337890625
      ],
      "page_num": 49,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 의뢰자는 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.79999542236328,
        140.51998901367188,
        533.760009765625,
        154.91998291015625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 의료기기의 제조업자 또는 수입업자가 해당된다. 의뢰자는 임상시험 모니터",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        64.55999755859375,
        164.51998901367188,
        533.0399780273438,
        178.91998291015625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "요원을 지정하여야 한다. 임상시험 모니터요원의 선정, 자격기준, 수행임무 등에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        188.51998901367188,
        533.6400146484375,
        202.91998291015625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 사항은 「의료기기법 시행규칙」별표3 “의료기기의 임상시험 관리기준” 제8호",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        212.51998901367188,
        533.760009765625,
        226.91998291015625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "머목(모니터링)에서 정하고 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        236.51998901367188,
        247.6199951171875,
        250.91998291015625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        303.1893615722656,
        110.16468811035156,
        319.0096740722656
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 의뢰자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        333.1893615722656,
        128.16000366210938,
        349.0096740722656
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        367.1999816894531,
        461.2799987792969,
        381.5999755859375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대표이사",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        367.1999816894531,
        461.2799987792969,
        381.5999755859375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소재지",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        367.1999816894531,
        461.2799987792969,
        381.5999755859375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        367.1999816894531,
        461.2799987792969,
        381.5999755859375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㈜○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        78.0,
        387.7200012207031,
        506.5199890136719,
        402.1199951171875
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        78.0,
        387.7200012207031,
        506.5199890136719,
        402.1199951171875
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○ ○○시 ○○구",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        78.0,
        387.7200012207031,
        506.5199890136719,
        402.1199951171875
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○- ○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        78.0,
        387.7200012207031,
        506.5199890136719,
        402.1199951171875
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 모니터요원",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        421.9893798828125,
        158.16000366210938,
        437.8096923828125
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        456.0,
        461.2799987792969,
        470.3999938964844
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대표이사",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        456.0,
        461.2799987792969,
        470.3999938964844
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소재지",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        456.0,
        461.2799987792969,
        470.3999938964844
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        456.0,
        461.2799987792969,
        470.3999938964844
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㈜○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        78.0,
        476.5199890136719,
        506.5199890136719,
        490.91998291015625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        78.0,
        476.5199890136719,
        506.5199890136719,
        490.91998291015625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○ ○○시 ○○구",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        78.0,
        476.5199890136719,
        506.5199890136719,
        490.91998291015625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○- ○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        78.0,
        476.5199890136719,
        506.5199890136719,
        490.91998291015625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 임상시험 수탁업체",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        510.78936767578125,
        210.72000122070312,
        526.6096801757812
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        544.7999877929688,
        461.2799987792969,
        559.2000122070312
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대표이사",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        544.7999877929688,
        461.2799987792969,
        559.2000122070312
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소재지",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        544.7999877929688,
        461.2799987792969,
        559.2000122070312
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        83.15999603271484,
        544.7999877929688,
        461.2799987792969,
        559.2000122070312
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㈜○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        78.0,
        565.2000122070312,
        506.5199890136719,
        579.6000366210938
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        78.0,
        565.2000122070312,
        506.5199890136719,
        579.6000366210938
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○ ○○시 ○○구",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        78.0,
        565.2000122070312,
        506.5199890136719,
        579.6000366210938
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○- ○○-○○○○",
      "font_size": 12.0,
      "font_name": "T13",
      "bbox": [
        78.0,
        565.2000122070312,
        506.5199890136719,
        579.6000366210938
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 임상시험 수탁기관(CRO: Contact Research Organization)이 있는 경우 해당",
      "font_size": 12.960000038146973,
      "font_name": "T15",
      "bbox": [
        56.63999938964844,
        597.8399658203125,
        538.4400024414062,
        613.3919677734375
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용을 기재함",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        623.7599487304688,
        160.55999755859375,
        639.3119506835938
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 43 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 50,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6. 임상시험의 목적 및 배경",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        79.29995727539062,
        269.1600036621094,
        95.25996398925781
      ],
      "page_num": 50,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        120.1199951171875,
        530.8800048828125,
        134.51998901367188
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기술하는 것을 말하며, 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        144.1199951171875,
        530.8800048828125,
        158.51998901367188
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적인 사항, 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        168.1199951171875,
        530.8800048828125,
        182.51998901367188
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또는 디자인 특성, 원자재 및 성능, 새로운 제조방법 등에 대한 특이성을 함께",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        192.1199951171875,
        530.8800048828125,
        206.51998901367188
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기재한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        216.1199951171875,
        117.41999816894531,
        230.51998901367188
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 임상시험의 목적",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        277.02935791015625,
        195.72000122070312,
        292.84967041015625
      ],
      "page_num": 50,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        307.02935791015625,
        110.16468811035156,
        322.84967041015625
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 임상시험용 디지털치료기기의 섭식장애 치료에 대한 안전성 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        337.02935791015625,
        539.3399658203125,
        352.84967041015625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 임상시험용 디지털치료기기의 섭식장애 치료에 대한 유효성 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        367.02935791015625,
        539.3399658203125,
        382.84967041015625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최근 섭식장애로 치료받는 환자가 증가하는 추세로 섭식장애를 치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        427.02935791015625,
        538.4400024414062,
        442.84967041015625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 방법 또한 많은 주목을 받고 있다. 임상에서 섭식장애 환자에게",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        457.02935791015625,
        545.9400024414062,
        472.84967041015625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주로 사용되는 치료는 비약물 치료이며, 그중에서도 인지행동치료가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        487.02935791015625,
        546.0599975585938,
        502.84967041015625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가장 널리 사용되고 있다. 선행연구에 의하면, 섭식장애를 진단받은",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        517.0293579101562,
        546.0599975585938,
        532.8496704101562
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자를 대상으로 비약물적 중재와 약물적 중재의 효과를 비교한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        547.0293579101562,
        546.0599975585938,
        562.8496704101562
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구에서 약물적 중재보다 비약물적 중재를 적용한 군이 오히려 폭식",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        577.0293579101562,
        545.9400024414062,
        592.8496704101562
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증상 감소에 효과적인 것으로 보고된 바 있으며(Vocks et al., 2010),",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        607.0293579101562,
        546.0599975585938,
        622.8496704101562
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비약물적 중재가 식이에 대한 태도를 긍정적으로 변화시키는 것으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        637.0293579101562,
        546.0599975585938,
        652.8496704101562
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나타났다(Yun&Kim, 2018).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        667.0293579101562,
        244.37998962402344,
        682.8496704101562
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "섭식장애 인지행동치료 등 비약물 치료 효과가 미비한 경우, 필요",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        697.0293579101562,
        538.4400024414062,
        712.8496704101562
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하다면 약물치료를 통해 섭식장애를 개선할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        727.0293579101562,
        428.0999755859375,
        742.8496704101562
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 44 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 51,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최근 디지털 기반 섭식장애 치료는 웹 또는 스마트폰 앱 기반으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        70.74937438964844,
        546.0599975585938,
        86.56968688964844
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인지행동치료를 시행한다. 이를 통해 환자들이 직접 집에서 컴퓨터,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        100.74937438964844,
        546.0599975585938,
        116.56968688964844
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혹은 스마트폰을 이용하여 치료를 시행 받을 수 있으므로 시·공간의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        130.74937438964844,
        545.9400024414062,
        146.56968688964844
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제약에서 자유롭게 될 것이며, 치료 대부분을 환자가 프로그램을 통해",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        160.74937438964844,
        546.0599975585938,
        176.56968688964844
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수행하고 피드백을 받을 수 있으므로 치료자 관점에서 비용 대비",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        190.74937438964844,
        545.9400024414062,
        206.56968688964844
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "효용성 또한 증가하게 될 것으로 기대된다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        220.74937438964844,
        353.1229553222656,
        236.56968688964844
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "섭식장애 인지행동치료의 효과에 관한 여러 연구 결과가 발표되고",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        250.74935913085938,
        546.0599975585938,
        266.5696716308594
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다. 특히, 최근 연구들은 단순히 섭식장애 인지행동치료를 디지털",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        280.7493591308594,
        545.9400024414062,
        296.5696716308594
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환경으로 옮기는 것에서 발전하여, 애플리케이션을 통하여 환자에게",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        310.7493591308594,
        546.0599975585938,
        326.5696716308594
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바로 피드백을 제공함으로써 의사나 치료자가 직접적인 가이드를 주지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        340.7493591308594,
        546.0599975585938,
        356.5696716308594
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않더라도 치료 효과를 볼 수 있게 하는 “디지털치료기기(Digital",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        370.7493591308594,
        546.0599975585938,
        386.5696716308594
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Therapeutics, DTx)”의 개념을 추구하고 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        400.7493591308594,
        376.6429748535156,
        416.5696716308594
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 임상시험을 통해 섭식장애 환자들을 대상으로 개발된 섭식장애",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        430.7493591308594,
        546.0599975585938,
        446.5696716308594
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개선 디지털치료기기의 작용기전에 대한 안전성(safety)과 유효성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        460.7493591308594,
        538.5599975585938,
        476.5696716308594
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(effectiveness)을 검증하고자 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        490.7493591308594,
        300.29998779296875,
        506.5696716308594
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 45 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 52,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 임상시험의 배경",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        195.72000122070312,
        86.56968688964844
      ],
      "page_num": 52,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디지털치료기기란 질병이나 장애를 예방, 관리, 치료하기 위해 환자에게",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        100.74937438964844,
        546.0599975585938,
        116.56968688964844
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "근거 기반의 치료적 중재(evidence-based therapeutic intervention)를 제공",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        130.74937438964844,
        538.4400024414062,
        146.56968688964844
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 고도화된 소프트웨어 의료기기를 가리킨다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        160.74937438964844,
        380.84295654296875,
        176.56968688964844
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디지털치료기기를 통한 인지행동치료의 제공은 디지털치료기기의 최",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        190.74937438964844,
        538.5599975585938,
        206.56968688964844
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "첨단 접근방식을 통해 환자 개인별로 단계적인 치료를 가능하게 하며,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        220.74937438964844,
        546.0599975585938,
        236.56968688964844
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시간 및 공간 제약 없이 인지행동치료를 가능하게 하여 치료 효과를 높",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        250.74935913085938,
        538.4400024414062,
        266.5696716308594
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이며, 더 많은 환자에게 치료 기회를 줄 수 있다는 장점이 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        280.7493591308594,
        493.97998046875,
        296.5696716308594
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선행연구에 따르면, 폭식장애 환자를 대상으로 16주간 인터넷 기반",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        310.7493591308594,
        545.9400024414062,
        326.5696716308594
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중재 프로그램을 시행하였다. 해당 연구는 인지행동 대면 치료 및",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        340.7493591308594,
        546.0599975585938,
        356.5696716308594
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자조 요법을 포함한 디지털 인지행동치료 프로그램이 마련되었고, 글",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        370.7493591308594,
        538.5599975585938,
        386.5696716308594
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "쓰기 과제, 임상심리사로부터의 피드백, 활동 일기, 심리 교육 등으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        400.7493591308594,
        545.9400024414062,
        416.5696716308594
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성되었다. 위 연구는 폭식 횟수 감소 등 폭식장애 증상 완화,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        430.7493591308594,
        545.9400024414062,
        446.5696716308594
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "EDE-Q 척도 감소 또는 유지, 우울 증상 완화 등의 긍정적 결과를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        460.7493591308594,
        546.0599975585938,
        476.5696716308594
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보였다(Wagner et al., 2016).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        490.7493591308594,
        251.60296630859375,
        506.5696716308594
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한, 디지털 기반 섭식장애 치료는 섭식장애 환자들의 건강 개선에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        520.7493896484375,
        546.0599975585938,
        536.5697021484375
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "효과적인 것으로 입증되었다(terHuurne et al., 2015). 해당 연구에서는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        550.7493896484375,
        546.0599975585938,
        566.5697021484375
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "섭식장애를 겪고 있는 여성 환자 총 214명 대상으로 웹 기반의 인지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        580.7493896484375,
        538.5599975585938,
        596.5697021484375
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "행동치료(CBT) 중재를 수행했다. 웹 기반 애플리케이션은 21개의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        610.7493896484375,
        546.0599975585938,
        626.5697021484375
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세션과 10개의 과제로 구성되었으며, 참가자들은 하루 약 20분 정도의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        640.7493896484375,
        545.9400024414062,
        656.5697021484375
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중재를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        670.7493896484375,
        546.0599975585938,
        686.5697021484375
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "받았다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        670.7493896484375,
        546.0599975585938,
        686.5697021484375
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일차",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        670.7493896484375,
        546.0599975585938,
        686.5697021484375
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        670.7493896484375,
        546.0599975585938,
        686.5697021484375
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변수는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        670.7493896484375,
        546.0599975585938,
        686.5697021484375
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "EDE-Q(Eating",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        670.7493896484375,
        546.0599975585938,
        686.5697021484375
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Disorder",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        670.7493896484375,
        546.0599975585938,
        686.5697021484375
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Examination-Questionnaire), 이차 유효성 변수는 BAT(Body Attitude",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        700.7493286132812,
        546.0599975585938,
        716.5696411132812
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Test)가 사용되었다. 결과적으로 환자들은 신체 및 정신 건강, 자존감",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        730.7493286132812,
        546.0599975585938,
        746.5696411132812
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 46 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 53,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등이 크게 상승한 것을 알 수 있었다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        315.5629577636719,
        86.56968688964844
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한 디지털치료기기는 기존의 섭식장애 개선을 위한 웰니스",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        100.74937438964844,
        546.0599975585938,
        116.56968688964844
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로그램과 다음과 같은 차이점을 가진다. 첫째, 일방적인 콘텐츠",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        130.74937438964844,
        546.0599975585938,
        146.56968688964844
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공을 넘어 쌍방향적인 피드백을 제공한다. 대상자의 섭식장애 증상에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        160.74937438964844,
        545.9400024414062,
        176.56968688964844
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 변수를 지속해서 수집하고, 이에 대해 다음 목표를 제시함으로써",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        190.74937438964844,
        546.0599975585938,
        206.56968688964844
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료 효과를 극대화한다. 이 과정에서 피험자는 단순히 콘텐츠를 소비",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        220.74937438964844,
        538.4400024414062,
        236.56968688964844
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 것을 넘어서, 스스로 콘텐츠에 참여하고 있다는 느낌을 받을 수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        250.74935913085938,
        545.9400024414062,
        266.5696716308594
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다. 둘째, 피험자 맞춤형 콘텐츠 제공이 가능하다. 모든 콘텐츠를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        280.7493591308594,
        546.0599975585938,
        296.5696716308594
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같은 비율로 제공하는 것에 그치지 않고 피험자의 정보를 수집함으로써",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        310.7493591308594,
        546.0599975585938,
        326.5696716308594
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "취약한 부분에 대한 집중적인 맞춤형 콘텐츠 제공을 하는 것이 가능",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        340.7493591308594,
        538.5599975585938,
        356.5696716308594
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하다. 셋째, 일정 시간 동안의 꾸준한 사용을 독려하며 치료 효과에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        370.7493591308594,
        546.0599975585938,
        386.5696716308594
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 모니터링이 가능하다. 일반적으로 디지털치료기기는 모든 콘텐츠를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        400.7493591308594,
        545.9400024414062,
        416.5696716308594
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한 번에 제공하지 않고 일정 기간 순차적으로 콘텐츠 제공하여 사용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        430.7493591308594,
        538.5599975585938,
        446.5696716308594
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기간을 조정한다. 피험자들은 치료 기간 중 섭식장애 증상이 어떻게",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        460.7493591308594,
        545.9400024414062,
        476.5696716308594
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변화하는지 실제 체감하고, 또한 디지털치료기기를 통한 모니터링을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        490.7493591308594,
        546.0599975585938,
        506.5696716308594
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "받을 수 있어 치료 동기 부여에 긍정적으로 작용할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        520.7493896484375,
        480.53997802734375,
        536.5697021484375
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 연구에서는 국내에서 개발된 디지털 섭식장애 인지행동치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        550.7493896484375,
        546.0599975585938,
        566.5697021484375
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "애플리케이션을 무작위배정 임상시험을 통해 효과성과 안전성 검증을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        580.7493896484375,
        546.0599975585938,
        596.5697021484375
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함으로써 해당 애플리케이션을 실제 국내 임상에서 활용할 수 있는지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        610.7493896484375,
        545.9400024414062,
        626.5697021484375
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인을 할 수 있으며 국내 섭식장애 환자들에게 새로운 치료의 선택지를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        640.7493896484375,
        545.9400024414062,
        656.5697021484375
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "열어주고자 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        670.7493896484375,
        173.1229705810547,
        686.5697021484375
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 47 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 54,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7. 임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증 포함)",
      "font_size": 14.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        84.93995666503906,
        524.1658935546875,
        100.89996337890625
      ],
      "page_num": 54,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 임상시험용 의료기기 사용 목적",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        128.46937561035156,
        300.6000061035156,
        144.28968811035156
      ],
      "page_num": 54,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 대상질환 또는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.68000030517578,
        164.63999938964844,
        530.8800048828125,
        179.0399932861328
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적응증을 포함하도록 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        188.63999938964844,
        212.94000244140625,
        203.0399932861328
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        252.42938232421875,
        95.16468811035156,
        268.24969482421875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[사용 목적]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        281.7093811035156,
        133.68467712402344,
        297.5296936035156
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모바일 애플리케이션 형태의 섭식장애 인지행동치료 기반, 혹은 이와",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        310.8693542480469,
        545.9400024414062,
        326.6896667480469
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유사한 과학적 근거를 가진 섭식장애의 비약물적인 치료에 근간한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        340.14935302734375,
        545.9400024414062,
        355.96966552734375
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "콘텐츠를 범용 장비(스마트폰 또는 태블릿 PC)를 통해 제공하는 소프트",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        369.4293518066406,
        538.4400024414062,
        385.2496643066406
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "웨어 의료기기이다. 임상시험용 기기는 섭식장애 인지행동치료(CBT)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        398.58935546875,
        545.9400024414062,
        414.40966796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혹은 이와 유사한 과학적 근거를 가진 섭식장애의 비약물적인 치료를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        427.8693542480469,
        545.9400024414062,
        443.6896667480469
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공하여 대조군 대비 섭식장애 증상을 개선하는 것을 목표로 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        457.14935302734375,
        530.5800170898438,
        472.96966552734375
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 의료기기는 의사에게 섭식장애* 진단을 받은 환자를 대상으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        484.3499755859375,
        546.0599975585938,
        502.1296691894531
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하며, 추후 추가적인 적응증 확대는 가능하나 섭식장애에 대한 의사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        515.58935546875,
        545.9400024414062,
        531.40966796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단을 기반으로 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        544.869384765625,
        210.68296813964844,
        560.689697265625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "* [F50.0] Anorexia nervosa (신경성 식욕부진)",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        68.5199966430664,
        572.2799682617188,
        333.1617431640625,
        587.8319702148438
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진)",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        78.1199951171875,
        597.719970703125,
        438.8817443847656,
        613.27197265625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[F50.2] Bulimia nervosa (신경성 폭식증)",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        78.1199951171875,
        623.0399780273438,
        310.84173583984375,
        638.5919799804688
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증)",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        78.1199951171875,
        648.3599853515625,
        404.3217468261719,
        663.9119873046875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[F50.4] Overeating associated with other psychological disturbances (기타 심리적",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        78.1199951171875,
        673.7999877929688,
        538.439453125,
        689.3519897460938
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장애와 연관된 과식)",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        121.91999816894531,
        699.1199340820312,
        242.44174194335938,
        714.6719360351562
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[F50.5] Vomiting associated with other psychological disturbances (기타 심리적",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        78.1199951171875,
        724.43994140625,
        538.4400024414062,
        739.991943359375
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장애와 연관된 구토)",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        121.79999542236328,
        749.8799438476562,
        242.44174194335938,
        765.4319458007812
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 48 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 55,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[F50.8] Other eating disorders (기타 식사장애)",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        78.1199951171875,
        69.0,
        348.1617431640625,
        84.552001953125
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[F50.9] Eating disorder, unspecified (상세불명의 식사장애)",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        78.1199951171875,
        95.04000091552734,
        417.1617431640625,
        110.59200286865234
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 49 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 56,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 임상시험용 의료기기 정보",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        263.15997314453125,
        86.56968688964844
      ],
      "page_num": 56,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 임상시험용 의료기기 및 대조시험용 의료기기의 품목명, 제조회사, 원재료, 모양,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        78.47999572753906,
        113.27999877929688,
        532.5120239257812,
        127.68000030517578
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구조, 성능 등을 구체적으로 기재하도록 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        66.5999984741211,
        137.27999877929688,
        321.05999755859375,
        151.67999267578125
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        187.0293731689453,
        110.16468811035156,
        202.8496856689453
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 임상시험용 의료기기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        217.0293731689453,
        233.87998962402344,
        232.8496856689453
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 시험기기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        247.02935791015625,
        173.87998962402344,
        262.84967041015625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 품목명(품목분류번호, 등급): 인지치료소프트웨어(E06060.02, 2등급)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        277.02935791015625,
        537.3674926757812,
        292.84967041015625
      ],
      "page_num": 56,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 모델명: ○○○",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        307.02935791015625,
        217.1999969482422,
        322.84967041015625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 제조회사: ㈜○○○",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        337.02935791015625,
        246.95999145507812,
        352.84967041015625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 원재료: (임상시험용 의료기기의 원재료에 대한 특성 기술)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        367.02935791015625,
        515.6474609375,
        382.84967041015625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 독립형 소프트웨어 제품은 소프트웨어 명칭, 버전, 운영환경 기재",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        121.43999481201172,
        395.2799987792969,
        522.4805297851562,
        410.8320007324219
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 모양 및 구조: (임상시험용 의료기기의 모양 및 구조 기술)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        423.0693664550781,
        515.6474609375,
        438.8896789550781
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 성능: (임상시험용 의료기기의 성능 기술)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        453.0693664550781,
        396.9674987792969,
        468.8896789550781
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 대조기기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        483.0693664550781,
        173.87998962402344,
        498.8896789550781
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 대조 시험용 의료기기의 구체적인 정보를 ‘가)’를 참고하여 작성한다. 대조",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        84.95999908447266,
        511.3199768066406,
        538.4402465820312,
        526.8719482421875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험용 의료기기가 설정되지 않았을 경우 생략할 수 있으며, 설정하지",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        104.39999389648438,
        537.3599853515625,
        538.43896484375,
        552.9119873046875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않으면 사유와 이에 대한 근거 등을 제시해야 한다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        104.39999389648438,
        563.2799682617188,
        409.9751892089844,
        578.8319702148438
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 임상시험용 의료기기 사용 방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        621.0693359375,
        300.6000061035156,
        636.8896484375
      ],
      "page_num": 56,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        651.0693359375,
        110.16468811035156,
        666.8896484375
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 사용 전 준비사항",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        681.0693359375,
        211.3199920654297,
        696.8896484375
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 치료에 앞서 범용장비(스마트폰, 태블릿, PC 등)에 OOO",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        711.0693359375,
        546.0599975585938,
        726.8896484375
      ],
      "page_num": 56,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디지털치료기기를 설치한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        741.0693359375,
        317.60296630859375,
        756.8896484375
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 50 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 사용 방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        70.74937438964844,
        158.87998962402344,
        86.56968688964844
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가) OOO 디지털치료기기를 실행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        100.74937438964844,
        344.96295166015625,
        116.56968688964844
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나) 회원가입 및 초기 평가를 시행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        130.74937438964844,
        357.8029479980469,
        146.56968688964844
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 초기 평가에는 최소 다음의 사항이 포함되어야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        160.74937438964844,
        476.72296142578125,
        176.56968688964844
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": 성별, 나이, 섭식장애 치료 약물 복용 여부, 섭식장애 증상에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        190.74937438964844,
        545.9400024414062,
        206.56968688964844
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 기초 평가(섭식장애 증상의 빈도, 섭식장애 증상으로 인한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        220.74937438964844,
        545.9400024414062,
        236.56968688964844
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불편감, 우울을 포함한 기타 정신과적인 정도 등이 포함될 수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        250.74935913085938,
        545.9400024414062,
        266.5696716308594
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.)",
      "font_size": 15.0,
      "font_name": "Haansoft Batang",
      "bbox": [
        116.63999938964844,
        280.7493591308594,
        167.47511291503906,
        296.5696716308594
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 디지털치료기기를 통한 섭식장애와 관련된 인지 및 행동의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        310.7493591308594,
        546.0599975585938,
        326.5696716308594
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "교정은 식사일기(식사 시간, 함께 식사한 대상, 식사를 한 장소,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        113.63999938964844,
        340.7493591308594,
        545.9400024414062,
        356.5696716308594
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식사 전의 배고픔 정도와 식사 후의 배부름 정도, 감정 등),",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        113.63999938964844,
        370.7493591308594,
        546.0599975585938,
        386.5696716308594
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생각연습 등의 컨텐츠가 담긴 인지행동치료로 진행된다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        113.63999938964844,
        400.7493591308594,
        503.5799865722656,
        416.5696716308594
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 상술한 치료의 경우 환자의 순응도를 높이기 위한 전략이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        430.7493591308594,
        545.9400024414062,
        446.5696716308594
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함되어야 하며(콘텐츠 제공 방식의 다양화, 알림 제공, 보상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.23999786376953,
        460.7493591308594,
        546.0599975585938,
        476.5696716308594
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방안 등을 포함) 환자가 입력한 정보에 따른 피드백이 제공",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.23999786376953,
        490.7493591308594,
        538.4400024414062,
        506.5696716308594
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되어야 하고 환자가 스스로 입력한 정보를 모니터링 할 수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.23999786376953,
        520.7493896484375,
        546.0599975585938,
        536.5697021484375
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있도록 하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.23999786376953,
        550.7493896484375,
        257.24298095703125,
        566.5697021484375
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 51 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 58,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8. 피험자의 선정기준·제외기준·인원 및 그 근거",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        84.93995666503906,
        437.15997314453125,
        100.89996337890625
      ],
      "page_num": 58,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 피험자의 선정·제외 기준, 인원 및 근거",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        64.55999755859375,
        156.36000061035156,
        300.1199951171875,
        170.75999450683594
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자(Subject)란 임상시험에 참여하는 임상시험용 또는 대조시험용 의료기기의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.55999755859375,
        180.36000061035156,
        533.6400146484375,
        194.75999450683594
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용 대상이 되는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄격한 피험자의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.23999786376953,
        204.36000061035156,
        533.6400146484375,
        218.75999450683594
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "선정 기준과 제외 기준을 제시하여야 한다. 이 때 임상시험 참여와 연관된 이익을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.23999786376953,
        228.36000061035156,
        533.6400146484375,
        242.75999450683594
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 불이익을 우려하여",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        84.23999786376953,
        252.3599853515625,
        533.6400146484375,
        266.7599792480469
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자발적인 참여 결정에 영향을 받을 소지가 있는 등 취약한 환경에 있는 피험자",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.23999786376953,
        276.3599853515625,
        533.6400146484375,
        290.7599792480469
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Vulnerable Subjects)는 선정대상에서 제외한다. 또한, 시험군과 대조군을 포함한 피험자",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.23999786376953,
        300.3599853515625,
        533.760009765625,
        314.7599792480469
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수는 해당 의료기기의 특성, 임상시험디자인, 근거를 통한 시험에서 기대하는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.23999786376953,
        324.3599853515625,
        533.6400146484375,
        338.7599792480469
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구결과의 사전 예측, 통계적 유의성, 검정 방법, 탈락률 등을 반영하여 통계학",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.23999786376953,
        348.3599853515625,
        533.760009765625,
        362.7599792480469
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적으로 타당하게 제시되어야 하며, 임상시험의 효능 및 안전성 입증에 필요한 충분한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.23999786376953,
        372.3599853515625,
        533.6400146484375,
        386.7599792480469
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수가 확보되어야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.23999786376953,
        396.3599853515625,
        199.97999572753906,
        410.7599792480469
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 피험자 수: 시험대상수 산출시 일반적인 고려사항",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        64.55999755859375,
        444.3599853515625,
        355.55999755859375,
        458.7599792480469
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상연구에서 피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 수가 보장",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.55999755859375,
        468.3599853515625,
        533.6400146484375,
        482.7599792480469
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "되어야 하며, 일반적으로 1차 유효성 평가변수를 기준으로 정해지고, 연구 계획서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        83.4000015258789,
        492.3599853515625,
        533.6400146484375,
        506.7599792480469
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상에 정확한 피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        83.4000015258789,
        516.3599853515625,
        478.97998046875,
        530.760009765625
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 52 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 59,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        70.74937438964844,
        110.16468811035156,
        86.56968688964844
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 피험자 선정기준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        100.74937438964844,
        195.47999572753906,
        116.56968688964844
      ],
      "page_num": 59,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ": 선정기준 모두를 만족하는 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.04000091552734,
        130.74937438964844,
        302.4599914550781,
        146.56968688964844
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 만 19세 이상 65세 이하의 성인에 해당하는 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        160.74937438964844,
        413.7599792480469,
        176.56968688964844
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) DSM-5의 섭식장애 진단기준을 만족하거나 ICD-10에 의거한 섭",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        190.74937438964844,
        538.5599975585938,
        206.56968688964844
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식장애 진단(F50)을 받은 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        220.74937438964844,
        281.8800048828125,
        236.56968688964844
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* [F50.0] Anorexia nervosa (신경성 식욕부진)",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        82.55999755859375,
        248.99998474121094,
        348.1617431640625,
        264.552001953125
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진)",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        91.07999420166016,
        275.0400085449219,
        451.84173583984375,
        290.5920104980469
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[F50.2] Bulimia nervosa (신경성 폭식증)",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        91.07999420166016,
        300.9599914550781,
        323.8017578125,
        316.5119934082031
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증)",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        91.07999420166016,
        327.0,
        417.28173828125,
        342.552001953125
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[F50.4] Overeating associated with other psychological disturbances (기타",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        91.07999420166016,
        353.0400085449219,
        538.4405517578125,
        368.5920104980469
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "심리적 장애와 연관된 과식)",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        137.16000366210938,
        378.9599914550781,
        303.1617431640625,
        394.5119934082031
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[F50.5] Vomiting associated with other psychological disturbances (기타",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        91.07999420166016,
        405.0,
        538.4400634765625,
        420.552001953125
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "심리적 장애와 연관된 구토)",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        137.39999389648438,
        431.0400085449219,
        305.0817565917969,
        446.5920104980469
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[F50.8] Other eating disorders (기타 식사장애)",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        91.07999420166016,
        456.9599914550781,
        361.1217346191406,
        472.5119934082031
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[F50.9] Eating disorder, unspecified (상세불명의 식사장애)",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        91.07999420166016,
        483.0,
        430.1217346191406,
        498.552001953125
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 스마트폰을 이용하여 모바일 애플리케이션 사용에 어려움이 없는 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        536.829345703125,
        535.3200073242188,
        552.649658203125
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4) 본 임상시험에 대해 충분한 설명을 듣고 이해한 후, 자의로 참여를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        566.829345703125,
        545.9400024414062,
        582.649658203125
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결정하고 주의사항을 준수하기로 서면 동의한 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        596.829345703125,
        428.7599792480469,
        612.649658203125
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 피험자 제외기준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        650.829345703125,
        203.8199920654297,
        666.649658203125
      ],
      "page_num": 59,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ": 제외기준 중 어느 하나라도 해당하는 항목이 있는 경우 본",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        680.829345703125,
        546.0599975585938,
        696.649658203125
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험에서 배제",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        83.75999450683594,
        710.829345703125,
        223.25999450683594,
        726.649658203125
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 과거에 섭식장애 치료를 위하여 인지행동치료를 받아본 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        740.829345703125,
        511.1999816894531,
        756.649658203125
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 53 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 비만대사 수술*(Bariatric surgery)의 과거 수술력이 있는 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        68.79000091552734,
        510.0,
        86.56968688964844
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "* 조절형 위밴드술, 위소매 절제술, 담췌 우회술, 루와이 위우회술 등",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        102.0,
        99.0,
        512.6400146484375,
        114.552001953125
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 스크리닝 시점에 BMI 가 17kg/㎡미만, 40kg/㎡이상인 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        126.78936767578125,
        490.44000244140625,
        142.60968017578125
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) MINI(Mini international neuropsychiatric interview)에 의거한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        156.78936767578125,
        546.0599975585938,
        172.60968017578125
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요 정신과적 질환에 해당하는 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        108.72000122070312,
        186.78936767578125,
        348.7200012207031,
        202.60968017578125
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 조현병 및 조울증의 과거 병력이 있거나 현재 진단받은 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        216.78936767578125,
        511.1999816894531,
        232.60968017578125
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) 자살 위험이 있거나 (C-SSRS 4점 이상) 최근 2주 이내에 자살을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        246.78936767578125,
        545.9400024414062,
        262.60968017578125
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시도한 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.79999542236328,
        276.78936767578125,
        174.36000061035156,
        292.60968017578125
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7) 활동적이고 진행중인 신체적 질환 (예:울혈성 심부전, 만성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        306.78936767578125,
        545.9400024414062,
        322.60968017578125
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "폐쇄성 폐질환, 급성 통증), 신경 장애 (예:뇌혈관 질환), 신경",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.15999603271484,
        336.78936767578125,
        546.0599975585938,
        352.60968017578125
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "퇴행성 질환 (예:치매, 다발성 경화증)을 가진 자, 불안정한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.15999603271484,
        366.78936767578125,
        545.9400024414062,
        382.60968017578125
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의학적 상태인　경우　또는 기대 수명이 6개월 이하에 해당하는 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.15999603271484,
        396.78936767578125,
        536.0399780273438,
        412.60968017578125
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8) 임산부 또는 임상시험 기간 동안 임신 계획이 있는 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        426.78936767578125,
        481.1999816894531,
        442.60968017578125
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9) 스크리닝 전 4주 이내에 다른 임상시험에 참여한 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        456.78936767578125,
        466.1999816894531,
        472.60968017578125
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10) 알코올 또는 약물 남용의 과거력이 있는 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        486.78936767578125,
        413.7599792480469,
        502.60968017578125
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "11) 기타 시험자가 본 임상시험 참여에 부적합하다고 판단한 자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        516.7893676757812,
        526.199951171875,
        532.6096801757812
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 피험자 선정기준 및 제외기준은 의료기기의 특성, 내용 구성 등을",
      "font_size": 15.0,
      "font_name": "T11",
      "bbox": [
        60.0,
        574.6799926757812,
        538.4400024414062,
        592.6799926757812
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려하여 적절한 기준을 설정함",
      "font_size": 15.0,
      "font_name": "T11",
      "bbox": [
        82.43999481201172,
        604.6799926757812,
        299.8800048828125,
        622.6799926757812
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 54 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 61,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 목표대상자 수 및 그 근거",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        263.15997314453125,
        86.56968688964844
      ],
      "page_num": 61,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자 수는 임상시험 방법에 따라 식약처의 ‘의료기기 임상시험 관련 통계기법",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.55999755859375,
        103.31999969482422,
        533.6400146484375,
        117.72000122070312
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가이드라인’을 참고하여 임상시험 피험자 수 산출 방식을 적용한다. 피험자 수를 결정",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        122.52000427246094,
        533.760009765625,
        136.9199981689453
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하기 위해서는 사전 정보가 필요한데, 여기에 포함되어야 할 필수 정보로는 다음이 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        141.72000122070312,
        527.0999755859375,
        156.1199951171875
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 연구가설",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.5199966430664,
        160.9199981689453,
        137.8800048828125,
        175.3199920654297
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 유의수준",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        74.5199966430664,
        180.1199951171875,
        137.8800048828125,
        194.51998901367188
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 통계적 검정 방법",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.5199966430664,
        199.3199920654297,
        185.87998962402344,
        213.71998596191406
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 사용될 통계적 분석 방법(즉, 연구디자인과도 관련)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.5199966430664,
        218.51998901367188,
        369.73199462890625,
        232.91998291015625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이(및 표준편차)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        74.5199966430664,
        237.72000122070312,
        456.73199462890625,
        252.1199951171875
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        300.66937255859375,
        110.16468811035156,
        316.48968505859375
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 목표 대상자 수: 총 128명(군당 64명)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        330.66937255859375,
        344.7674865722656,
        346.48968505859375
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 본 가이드라인에 작성된 산출 방법은 공개된 선행연구 결과를 기반으로 작성된",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        98.63999938964844,
        359.03997802734375,
        538.5599975585938,
        373.4399719238281
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시이며, 목표 대상자 수는 개발 제품 특성과 탐색 임상시험 등 제품별 선행",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        116.63999938964844,
        383.03997802734375,
        538.4400024414062,
        397.4399719238281
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구 결과에 따라 다르므로, 개발 제품의 선행연구 결과 및 참고문헌을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        116.63999938964844,
        407.03997802734375,
        538.5599975585938,
        421.4399719238281
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기준으로 산출한다. 이때, 그 근거(가설, 변수, 성공기준)를 함께 제시하여야",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        116.63999938964844,
        431.03997802734375,
        538.4400024414062,
        445.4399719238281
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        116.63999938964844,
        455.03997802734375,
        144.5399932861328,
        469.4399719238281
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 목표 대상자 수 산정의 추정 공식 예시",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        504.66937255859375,
        361.1999816894531,
        520.4896850585938
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 일차목적 및 가설",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        534.6693725585938,
        235.44000244140625,
        550.4896850585938
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 시험의 일차목적: 섭식장애 환자에서 베이스라인 (사용 전)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        564.6693725585938,
        545.9400024414062,
        580.4896850585938
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대비 8 주 시점의 식사장애 검사(EDE-Q)의 변화량이 기존",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        594.6693725585938,
        546.0599975585938,
        610.4896850585938
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료군 대비 의료기기 사용군에서 비열등하게 개선되었는지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        624.6693725585938,
        545.9400024414062,
        640.4896850585938
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확증하는 것이다. 변화량은 치료 시작 전 평가지표 Baseline",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        654.6693725585938,
        546.0599975585938,
        670.4896850585938
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조사에서 수집한 정보와 Post-treatment (의료기기 사용 8주 후",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        684.6693725585938,
        546.0599975585938,
        700.4896850585938
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시점) 조사에서 수집한 정보와의 차이를 의미하며, 이에 대한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        714.6693725585938,
        545.9400024414062,
        730.4896850585938
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가설은 아래와 같다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        744.6693725585938,
        256.5,
        760.4896850585938
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 55 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 62,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "    ≥",
      "font_size": 15.0,
      "font_name": "HyhwpEQ",
      "bbox": [
        176.24488830566406,
        70.90827941894531,
        445.3850402832031,
        90.34828186035156
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "      ",
      "font_size": 15.0,
      "font_name": "HyhwpEQ",
      "bbox": [
        176.24488830566406,
        70.90827941894531,
        445.3850402832031,
        90.34828186035156
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ": 시험군의 치료 전 대비 post-treatment 후 평균 식사장애 검사(EDE-Q) 변화량",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.19999694824219,
        104.86827850341797,
        489.60040283203125,
        122.51202392578125
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": 대조군의 치료 전 대비 post-treatment 후 평균 식사장애 검사(EDE-Q) 변화량",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        97.19999694824219,
        134.0282745361328,
        490.3204040527344,
        151.79202270507812
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ":  비열등성 허용 오차",
      "font_size": 11.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        163.3082733154297,
        211.92018127441406,
        178.3082733154297
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 또한, 비열등성 허용 오차는 임상 근거에 기반하여 수치가 달라질 수 있으나,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        98.63999938964844,
        186.72000122070312,
        538.3920288085938,
        201.1199951171875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이에 대한 명확한 임상적 근거를 제시해야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        116.63999938964844,
        210.72000122070312,
        373.0199890136719,
        225.1199951171875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비열등성 허용오차는 Grilo et al. (2022)에서의 대조군인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        260.4693603515625,
        546.0599975585938,
        276.2896728515625
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "placebo군과 기존 BWL(Behavioral weight loss therapy) 과",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        290.4693603515625,
        545.9400024414062,
        306.2896728515625
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약물(naltrexone, bupropion) 처리군의 변화량 효과 차이를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        320.4693603515625,
        546.0599975585938,
        336.2896728515625
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통해 추정하고자 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        350.4693603515625,
        268.6429748535156,
        366.2896728515625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "섭식장애 환자를 대상으로 한 기존 비교 임상연구를 검토한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        79.91999816894531,
        380.4693603515625,
        546.0599975585938,
        396.2896728515625
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과, 식사장애 검사(EDE-Q) 변화량은 다음 표와 같이 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        410.4693603515625,
        538.4400024414062,
        426.2896728515625
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되었다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        440.4693603515625,
        163.04296875,
        456.2896728515625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "선행연구",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        112.55999755859375,
        501.8399963378906,
        206.2799835205078,
        515.0880126953125
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "군",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        112.55999755859375,
        501.8399963378906,
        206.2799835205078,
        515.0880126953125
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Baseline",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        262.44000244140625,
        492.9599914550781,
        506.760009765625,
        506.2080078125
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "At week 16",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        262.44000244140625,
        492.9599914550781,
        506.760009765625,
        506.2080078125
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전후 차이",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        262.44000244140625,
        492.9599914550781,
        506.760009765625,
        506.2080078125
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "n",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        244.9199981689453,
        510.1199645996094,
        509.49072265625,
        523.3679809570312
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평균",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        244.9199981689453,
        510.1199645996094,
        509.49072265625,
        523.3679809570312
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SD",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        244.9199981689453,
        510.1199645996094,
        509.49072265625,
        523.3679809570312
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "n",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        244.9199981689453,
        510.1199645996094,
        509.49072265625,
        523.3679809570312
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평균",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        244.9199981689453,
        510.1199645996094,
        509.49072265625,
        523.3679809570312
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SD",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        244.9199981689453,
        510.1199645996094,
        509.49072265625,
        523.3679809570312
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평균",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        244.9199981689453,
        510.1199645996094,
        509.49072265625,
        523.3679809570312
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SD",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        244.9199981689453,
        510.1199645996094,
        509.49072265625,
        523.3679809570312
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Grilo et al.",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        108.1199951171875,
        575.8045654296875,
        160.96844482421875,
        596.7752685546875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2022) U.S.A.",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        108.1199951171875,
        575.8045654296875,
        160.96844482421875,
        596.7752685546875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Placebo",
      "font_size": 9.960000038146973,
      "font_name": "T11",
      "bbox": [
        183.47999572753906,
        542.0399780273438,
        218.00831604003906,
        553.9920043945312
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(control)",
      "font_size": 9.960000038146973,
      "font_name": "T11",
      "bbox": [
        183.59999084472656,
        558.1199951171875,
        217.84051513671875,
        570.072021484375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "34",
      "font_size": 9.0,
      "font_name": "T15",
      "bbox": [
        243.36000061035156,
        550.6799926757812,
        512.2193603515625,
        561.47998046875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "13.88",
      "font_size": 9.0,
      "font_name": "T11",
      "bbox": [
        243.36000061035156,
        550.6799926757812,
        512.2193603515625,
        561.47998046875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8.96",
      "font_size": 9.0,
      "font_name": "T11",
      "bbox": [
        243.36000061035156,
        550.6799926757812,
        512.2193603515625,
        561.47998046875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "29",
      "font_size": 9.0,
      "font_name": "T11",
      "bbox": [
        243.36000061035156,
        550.6799926757812,
        512.2193603515625,
        561.47998046875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8.11",
      "font_size": 9.0,
      "font_name": "T11",
      "bbox": [
        243.36000061035156,
        550.6799926757812,
        512.2193603515625,
        561.47998046875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12.39",
      "font_size": 9.0,
      "font_name": "T11",
      "bbox": [
        243.36000061035156,
        550.6799926757812,
        512.2193603515625,
        561.47998046875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-3.74",
      "font_size": 9.0,
      "font_name": "T15",
      "bbox": [
        243.36000061035156,
        550.6799926757812,
        512.2193603515625,
        561.47998046875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "11.32",
      "font_size": 9.0,
      "font_name": "T11",
      "bbox": [
        243.36000061035156,
        550.6799926757812,
        512.2193603515625,
        561.47998046875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "BWL+",
      "font_size": 8.90849494934082,
      "font_name": "T15",
      "bbox": [
        190.9199981689453,
        586.9199829101562,
        210.64675903320312,
        598.8720092773438
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Naltrexone-",
      "font_size": 8.90849494934082,
      "font_name": "T11",
      "bbox": [
        181.3199920654297,
        602.8799438476562,
        220.2468719482422,
        614.8319702148438
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Bupropion",
      "font_size": 8.90849494934082,
      "font_name": "T11",
      "bbox": [
        184.1999969482422,
        618.9599609375,
        217.3333282470703,
        630.9119873046875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(기존대조군)",
      "font_size": 8.90849494934082,
      "font_name": "T11",
      "bbox": [
        179.51998901367188,
        634.9199829101562,
        221.95901489257812,
        646.8720092773438
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "35",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        242.87998962402344,
        610.7245483398438,
        510.51702880859375,
        622.6952514648438
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15.89",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        242.87998962402344,
        610.7245483398438,
        510.51702880859375,
        622.6952514648438
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9.74",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        242.87998962402344,
        610.7245483398438,
        510.51702880859375,
        622.6952514648438
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "29",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        242.87998962402344,
        610.7245483398438,
        510.51702880859375,
        622.6952514648438
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1.96",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        242.87998962402344,
        610.7245483398438,
        510.51702880859375,
        622.6952514648438
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.64",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        242.87998962402344,
        610.7245483398438,
        510.51702880859375,
        622.6952514648438
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-12.79",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        242.87998962402344,
        610.7245483398438,
        510.51702880859375,
        622.6952514648438
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8.24",
      "font_size": 9.0,
      "font_name": "MalgunGothic",
      "bbox": [
        242.87998962402344,
        610.7245483398438,
        510.51702880859375,
        622.6952514648438
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SD: Standard deviation",
      "font_size": 9.0,
      "font_name": "T11",
      "bbox": [
        102.95999908447266,
        650.6400146484375,
        194.83981323242188,
        661.4400024414062
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 1. 식사장애 검사(EDE-Q) 변화량 결과",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        210.83999633789062,
        473.3703308105469,
        406.67950439453125,
        483.330322265625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대조군의 baseline 대비 16주 시점에서의 식사장애 검사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        682.9893798828125,
        538.4400024414062,
        698.8096923828125
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(EDE-Q) 변화량 차이는 –3.74이고 표준편차는 11.32이나",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        712.9893798828125,
        545.9400024414062,
        728.8096923828125
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 임상시험의 치료기간은 8주로 참고문헌에 비해 짧으므로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        742.9893798828125,
        546.0599975585938,
        758.8096923828125
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 56 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 63,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 효과의 50% 정도인 –1.87로 설정하였다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        70.74937438964844,
        432.29998779296875,
        86.56968688964844
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기존 대조군의 baseline 대비 16주 시점에서의 식사장애 검사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        100.74937438964844,
        538.5599975585938,
        116.56968688964844
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(EDE-Q) 변화량 차이는 –12.79이고 표준편차는 8.24이나 위와",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        130.74937438964844,
        546.0599975585938,
        146.56968688964844
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동일하게 해당 효과의 50% 정도인 –6.40로 설정하였다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        160.74937438964844,
        492.3229675292969,
        176.56968688964844
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "각 군의 표준편차도 효과 평균과 동일하게 50% 반영하여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        190.74937438964844,
        545.9400024414062,
        206.56968688964844
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각 4.1, 5.7로 설정하여 차이에 대한 합동표준편차는 5.0로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        220.74937438964844,
        545.9400024414062,
        236.56968688964844
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정하였다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        250.74935913085938,
        178.04296875,
        266.5696716308594
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "합동표준편차  ",
      "font_size": 54.553165435791016,
      "font_name": "HyhwpEQ",
      "bbox": [
        177.0,
        307.7076416015625,
        412.1999816894531,
        337.50421142578125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "",
      "font_size": 53.89981460571289,
      "font_name": "HyhwpEQ",
      "bbox": [
        177.0,
        307.7076416015625,
        412.1999816894531,
        337.50421142578125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "    ",
      "font_size": 9.837821960449219,
      "font_name": "HyhwpEQ",
      "bbox": [
        177.0,
        307.7076416015625,
        412.1999816894531,
        337.50421142578125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "  ×     ×   ",
      "font_size": 9.960000038146973,
      "font_name": "HyhwpEQ",
      "bbox": [
        265.55999755859375,
        310.26422119140625,
        437.82000732421875,
        331.14422607421875
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "두 참고문헌을 통해 8주 시점에서의 기존 대조군 대비",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        381.66937255859375,
        545.9400024414062,
        397.48968505859375
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "placebe 군 효과는 (-6.40)-(-1.87)=-4.53 정도로 추정되며, 비",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        411.66937255859375,
        538.5599975585938,
        427.48968505859375
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "열등성 허용오차 (-기호)는 해당 효과의 절반 정도인 -2.26이다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        441.66937255859375,
        545.9400024414062,
        457.48968505859375
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선행연구인 Mond et al.(2004), Mond et al.(2008)의 연구에서",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        471.66937255859375,
        545.9400024414062,
        487.48968505859375
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "EDE-Q에 대한 cut-off 값을 각각 2.3, 2.8이었던 점을 감안",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        501.66937255859375,
        538.4400024414062,
        517.4896850585938
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여, 본 가이드라인의 비열등성 허용오차는 -2.5로 설정하고자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        531.6693725585938,
        545.9400024414062,
        547.4896850585938
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        561.6693725585938,
        155.5800018310547,
        577.4896850585938
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이에 단측 유의수준 2.5%, 검정력 80%를 만족하는 데",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        591.6693725585938,
        545.9400024414062,
        607.4896850585938
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요한 피험자 수(군당 1:1 배정)를 산출한 결과, 중도 탈락률",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        621.6693725585938,
        546.0599975585938,
        637.4896850585938
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5%를 고려하여 목표 피험자 수는 총 128명(군당 64명)으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        651.6693725585938,
        545.9400024414062,
        667.4896850585938
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "산출되었다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        681.6693725585938,
        191.48297119140625,
        697.4896850585938
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "두 군의 평균 차이 검정에 대한 피험자 수 산출 공식은",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        711.6693725585938,
        545.9400024414062,
        727.4896850585938
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아래와 같다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        114.0,
        741.6693725585938,
        206.2429656982422,
        757.4896850585938
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 57 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 64,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": " ",
      "font_size": 45.79743576049805,
      "font_name": "HyhwpEQ",
      "bbox": [
        164.27999877929688,
        81.18421173095703,
        289.01141357421875,
        99.90422058105469
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "  ",
      "font_size": 6.721034049987793,
      "font_name": "HyhwpEQ",
      "bbox": [
        164.27999877929688,
        81.18421173095703,
        289.01141357421875,
        99.90422058105469
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": " ×  ×      ",
      "font_size": 10.887643814086914,
      "font_name": "HyhwpEQ",
      "bbox": [
        185.1599884033203,
        68.70421600341797,
        285.07781982421875,
        85.62422180175781
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "",
      "font_size": 6.721034049987793,
      "font_name": "HyhwpEQ",
      "bbox": [
        285.0,
        71.2026596069336,
        288.30206298828125,
        78.04265594482422
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "",
      "font_size": 45.460975646972656,
      "font_name": "HyhwpEQ",
      "bbox": [
        291.239990234375,
        81.18421173095703,
        406.2699890136719,
        99.90422058105469
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": " ",
      "font_size": 6.721034049987793,
      "font_name": "HyhwpEQ",
      "bbox": [
        291.239990234375,
        81.18421173095703,
        406.2699890136719,
        99.90422058105469
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": " ×  ×   ",
      "font_size": 6.721034049987793,
      "font_name": "HyhwpEQ",
      "bbox": [
        304.0799865722656,
        70.74421691894531,
        405.54205322265625,
        85.26422119140625
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "≈ ",
      "font_size": 9.960000038146973,
      "font_name": "HyhwpEQ",
      "bbox": [
        408.6000061035156,
        81.78421020507812,
        430.6199951171875,
        91.74421691894531
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ": 한 군당 필요한 피험자 수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        140.52000427246094,
        152.2293701171875,
        341.5199890136719,
        168.0496826171875
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": 제1종 오류 0.025 (유의수준)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        140.52000427246094,
        182.2293701171875,
        355.8074951171875,
        198.0496826171875
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": 제2종 오류 0.2",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        140.52000427246094,
        212.2293701171875,
        262.3800048828125,
        228.0496826171875
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": 예상하는 군간 평균 변화량 차, 0",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        140.52000427246094,
        242.2293701171875,
        396.53997802734375,
        258.0496826171875
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": 비열등성 허용 오차, 0.5×{-12.79-(-3.74)}/2=-2.26",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        139.9199981689453,
        272.109375,
        491.8199768066406,
        287.9296875
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": 예상하는 표준편차, 5.0",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        140.52000427246094,
        302.2293701171875,
        318.8999938964844,
        318.0496826171875
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 58 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        229.98936462402344,
        110.16468811035156,
        245.80967712402344
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자의 모집 기간, 임상 관찰 및 수행 기간, 통계분석 기간, 결과",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        259.9893798828125,
        538.4400024414062,
        275.8096923828125
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보고서 작성 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        289.9893798828125,
        545.9400024414062,
        305.8096923828125
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려하도록 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        319.9893798828125,
        171.92295837402344,
        335.8096923828125
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 식품의약품안전처의 임상 계획 승인일로부터 00개월",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        349.9893798828125,
        451.3199768066406,
        365.8096923828125
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 대상자 모집 기간: 00개월",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        379.9893798828125,
        267.8399963378906,
        395.8096923828125
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 임상시험 수행 기간: 00개월",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        409.9893798828125,
        282.8399963378906,
        425.8096923828125
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 통계처리 및 결과보고서 작성 기간: 00개월",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        439.9893798828125,
        387.8399963378906,
        455.8096923828125
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9. 임상시험기간",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        79.29995727539062,
        181.1994171142578,
        95.25996398925781
      ],
      "page_num": 65,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자의 모집 기간, 임상 관찰 및 시험 수행 기간, 통계 처리 기간, 결과보고서 작성",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        75.83999633789062,
        131.27999877929688,
        530.8800048828125,
        145.67999267578125
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기간, 임상시험심사위원회 심사 기간 등 충분한 기간을 고려하여 “식품의약품안전처의 임상",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        155.27999877929688,
        530.8800048828125,
        169.67999267578125
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획 승인일로부터 OO 개월”로 표시하고 근거자료를 제출한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        179.27999877929688,
        395.94000244140625,
        193.67999267578125
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 59 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        264.1893615722656,
        110.16468811035156,
        280.0096740722656
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 시험방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        294.1893615722656,
        150.66000366210938,
        310.0096740722656
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 시험기기 및 대조기기 정보",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        324.1893615722656,
        278.7599792480469,
        340.0096740722656
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 시험기기: 디지털 섭식장애 인지행동치료 애플리케이션 및",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        354.1893615722656,
        546.0599975585938,
        370.0096740722656
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단축된 표준치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        113.63999938964844,
        384.1893615722656,
        226.1999969482422,
        400.0096740722656
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(예) 섭식장애 인지행동치료 등의 기능이 탑재된 애플리케이션",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        113.63999938964844,
        414.1893615722656,
        538.5599975585938,
        430.0096740722656
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나) 대조기기: 표준치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        444.1893615722656,
        245.39999389648438,
        460.0096740722656
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(예) 상담 및 지지요법, 약물 치료 등",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        113.87999725341797,
        474.1893615722656,
        367.0799865722656,
        490.0096740722656
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 섭식장애 개선 디지털치료기기 허가 제품이 출시된 이후에는 기허가",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        109.91999816894531,
        528.47998046875,
        538.43896484375,
        544.031982421875
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품과 비교시험 하는 동등성 검정 혹은 비열등성 검정 등을 시행",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        129.47999572753906,
        554.3999633789062,
        538.4400024414062,
        569.9519653320312
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여 해당 성능을 증명할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        129.47999572753906,
        580.43994140625,
        334.01519775390625,
        595.991943359375
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 비열등성/동등성 시험(Non-inferiority, equivalence trial): 비교 연구에 있어",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        136.44000244140625,
        606.47998046875,
        538.4396362304688,
        622.031982421875
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대조기기와 비교해 시험기기의 성능이 열등하지 않음을 보이거나,",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        148.3199920654297,
        632.3999633789062,
        538.5081787109375,
        647.9519653320312
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동등함을 보이는 연구시험이다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        148.3199920654297,
        658.43994140625,
        333.4151916503906,
        673.991943359375
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 디지털치료기기 치료 기간: 총 8주",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        716.2293701171875,
        335.3399963378906,
        732.0496826171875
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 최소 3회의 외래 방문을 통한 조사: 방문 1(Screening/Baseline),",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        746.2293701171875,
        545.9400024414062,
        762.0496826171875
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10. 임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)",
      "font_size": 14.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        79.29995727539062,
        490.3258361816406,
        95.25996398925781
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 방법은 해당 의료기기에 대한 모양, 구조 및 사용 전 준비사항, 피험자에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        78.5999984741211,
        142.1999969482422,
        532.9199829101562,
        156.59999084472656
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 준비 등 임상시험을 위한 준비 절차와 사용 단계 절차의 각 단계별 조작 순서,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        66.5999984741211,
        166.1999969482422,
        532.8720092773438,
        180.59999084472656
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "병용 요법 등을 기술한다. 임상시험을 위한 피험자 동의 및 준비, 치료 절차, 관찰 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        66.5999984741211,
        190.1999969482422,
        532.7999877929688,
        204.59999084472656
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가 절차 등을 상세히 시험 방법을 기술한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        66.5999984741211,
        214.1999969482422,
        321.5400085449219,
        228.59999084472656
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 60 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방문 3(Follow-up, 4주 후), 방문 5(Follow-up, 8주 후)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        70.74937438964844,
        456.8475036621094,
        86.56968688964844
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 방문 2(Follow-up, 2주 후), 방문 4(Follow-up, 6주 후)는 전화를 통해",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        98.63999938964844,
        99.0,
        538.4400024414062,
        114.552001953125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시행하나, 필요시 애플리케이션, 이메일, 문자, SNS 등을 통해 수집할",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        118.19999694824219,
        125.04000091552734,
        538.4405517578125,
        140.5919952392578
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있음.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        118.19999694824219,
        150.95999145507812,
        166.85519409179688,
        166.51199340820312
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 층화무작위배정: 성별(남/여), 단일(다)기관, 시험군 및 대조군 1:1 배정",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        178.74937438964844,
        536.8800048828125,
        194.56968688964844
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 단, 층화는 제품 특성 등에 따라 유연하게 적용할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        98.63999938964844,
        206.99998474121094,
        468.89520263671875,
        222.55198669433594
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 시험방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        234.78936767578125,
        151.3199920654297,
        250.60968017578125
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 스크리닝, 선정제외 기준 확인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        264.78936767578125,
        320.2799987792969,
        280.60968017578125
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 기관별로 내원한 환자 중 선정, 제외 기준에 따라 적합한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        294.78936767578125,
        546.0599975585938,
        310.60968017578125
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구 군을 선별한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        324.78936767578125,
        258.5629577636719,
        340.60968017578125
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 피험자 동의 및 준비",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        354.78936767578125,
        256.32000732421875,
        370.60968017578125
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        384.78936767578125,
        546.0599975585938,
        400.60968017578125
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용을 피험자 본인 또는 대리인에게 설명하고, 피험자 또는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        414.78936767578125,
        545.9400024414062,
        430.60968017578125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대리인이 내용을 잘 이해한 것을 확인한 다음, 자유의사에 따른",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        444.78936767578125,
        546.0599975585938,
        460.60968017578125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 참가의 동의를 문서로 받는다. 또한 동의에 서명한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        474.78936767578125,
        545.9400024414062,
        490.60968017578125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연월일을 기록하며, 동의서 사본을 환자에게 제공하여 환자가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        504.78936767578125,
        545.9400024414062,
        520.6096801757812
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지속해서 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        534.7893676757812,
        538.282958984375,
        550.6096801757812
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다) 인구학적 조사, 병력조사 요법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        564.7893676757812,
        320.2799987792969,
        580.6096801757812
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        594.7893676757812,
        545.9400024414062,
        610.6096801757812
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등에 대하여 차트 확인 등을 통하여 점검하고 증례 기록서에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        624.7893676757812,
        545.9400024414062,
        640.6096801757812
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기록한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        654.7893676757812,
        180.0829620361328,
        670.6096801757812
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 인구학적 정보: 성별, 나이, 직업",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        684.7893676757812,
        348.1199951171875,
        700.6096801757812
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 병력 조사: 동반 질환 여부",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        714.7893676757812,
        309.9599914550781,
        730.6096801757812
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 병용약물: 복용 여부 및 종류",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        744.7893676757812,
        324.9599914550781,
        760.6096801757812
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 61 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라) 피험자 식별코드 부여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        70.74937438964844,
        263.760009765625,
        86.56968688964844
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 피험자에게 서명하고 동의를 받은 후 동의 취득 순서에 따라",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        100.74937438964844,
        546.0599975585938,
        116.56968688964844
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "스크리닝 번호를 부여하며 피험자가 참여를 종료할 때까지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        126.0,
        130.74937438964844,
        546.0599975585938,
        146.56968688964844
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자 식별코드를 부여한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        126.0,
        160.74937438964844,
        325.04296875,
        176.56968688964844
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 피험자 적합성 평가: 피험자 선정 및 제외 기준에 적합한지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        190.74937438964844,
        546.0599975585938,
        206.56968688964844
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        126.0,
        220.74937438964844,
        190.04296875,
        236.56968688964844
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 피험자 식별코드는 아래의 방법에 따라 기재한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        250.74935913085938,
        467.48297119140625,
        266.5696716308594
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 피험자 식별코드: 실시기관 코드 - 등록된 순",
      "font_size": 12.960000038146973,
      "font_name": "T15",
      "bbox": [
        134.39999389648438,
        279.0,
        415.4399719238281,
        294.552001953125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마) 외래 방문마다 유효성 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        306.78936767578125,
        301.32000732421875,
        322.60968017578125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 일차와 이차 유효성 평가 관련된 목록을 작성한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        336.78936767578125,
        461.84295654296875,
        352.60968017578125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 일차 유효성 평가지표: 식사장애 검사(EDE-Q)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        366.78936767578125,
        434.7674865722656,
        382.60968017578125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 베이스라인 (사용 전) 대비 8주 시점의 식사장애 검사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        396.78936767578125,
        538.5599975585938,
        412.60968017578125
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(EDE-Q) 변화에 대한 비열등성 확인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        148.67999267578125,
        426.78936767578125,
        392.8800048828125,
        442.60968017578125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 이차 유효성 평가지표",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        456.78936767578125,
        270.1199951171875,
        472.60968017578125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 일차 유효성 평가지표를 통해 유효성을 검증하는 것이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        486.78936767578125,
        546.0599975585938,
        502.60968017578125
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기본적인 원칙이지만, 이외 필요하면 변수를 이차 유효성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        145.55999755859375,
        516.7893676757812,
        545.9400024414062,
        532.6096801757812
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가지표로 사용할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        145.55999755859375,
        546.7893676757812,
        336.4429626464844,
        562.6096801757812
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 과학적인 근거를 가진 변수이되, 기존 섭식장애 증상 개선",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        576.7893676757812,
        546.0599975585938,
        592.6096801757812
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시 함께 개선될 수 있다고 여겨진 영역에 한정한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        142.8000030517578,
        606.7893676757812,
        499.1629638671875,
        622.6096801757812
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 62 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정도구",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        143.0399932861328,
        94.91999816894531,
        402.0,
        109.31999969482422
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        143.0399932861328,
        94.91999816894531,
        402.0,
        109.31999969482422
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "베이스라인 (사용 전)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        95.87999725341797,
        397.67999267578125,
        210.6119842529297,
        412.0799865722656
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대비 4주, 8주 시점의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        94.79999542236328,
        416.8800048828125,
        211.67999267578125,
        431.2799987792969
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하기 지표 변화량",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        105.23999786376953,
        436.0799865722656,
        201.239990234375,
        450.47998046875
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) Eating Disorder Examination Questionnaire (EDE-Q)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        109.68000030517578,
        530.4119873046875,
        124.08000183105469
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EDE-Q는 총 28 개 문항으로 구성되어 있으며, 섭식장애의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        128.87998962402344,
        547.7999877929688,
        143.2799835205078
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        148.0800018310547,
        547.7520141601562,
        162.47999572753906
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "병리를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        148.0800018310547,
        547.7520141601562,
        162.47999572753906
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정하는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        148.0800018310547,
        547.7520141601562,
        162.47999572753906
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식사제한, 식사관심, 체형관심,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        148.0800018310547,
        547.7520141601562,
        162.47999572753906
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체중관심의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        167.27999877929688,
        547.7999877929688,
        181.67999267578125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4개",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        167.27999877929688,
        547.7999877929688,
        181.67999267578125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하위요인으로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        167.27999877929688,
        547.7999877929688,
        181.67999267578125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성되어",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        167.27999877929688,
        547.7999877929688,
        181.67999267578125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다. 점수가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        167.27999877929688,
        547.7999877929688,
        181.67999267578125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "높을수록 섭식 행동 및 태도에 문제가 있는 것을 의미한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        186.47999572753906,
        546.1799926757812,
        200.87998962402344
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) Clinical Impairment Assessment (CIA)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        205.67999267578125,
        450.85198974609375,
        220.07998657226562
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CIA 를 통해 섭식장애와 관련된 세 가지 주요 영역(개인적,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        224.87998962402344,
        547.7520141601562,
        239.2799835205078
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사회적, 인지적)에 대한 이차적인 손상 정도를 평가한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        244.07998657226562,
        547.739990234375,
        258.47998046875
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "점수가 높을수록 섭식장애로 인한 개인적, 사회적, 인지적",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        263.2799987792969,
        547.7999877929688,
        277.67999267578125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "손상이 높은 것을 의미한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        282.47998046875,
        385.1399841308594,
        296.8799743652344
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) Patient Health Questionnaire-9 (PHQ-9)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        301.67999267578125,
        464.4119873046875,
        316.0799865722656
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PHQ-9를 통해 우울 증상을 평가한다. DSM-IV의 주요",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        320.8800048828125,
        547.7999877929688,
        335.2799987792969
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울장애의 진단기준에 의거하여 지난 2주간의 무쾌감,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        340.0799865722656,
        547.7520141601562,
        354.47998046875
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우울감, 수면의 변화, 피로감, 식욕의 변화, 죄책감, 무가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        359.2799987792969,
        547.6799926757812,
        373.67999267578125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치감, 집중력 저하, 좌불안석 또는 쳐진 느낌, 자살사고의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        378.47998046875,
        547.6799926757812,
        392.8799743652344
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "9 가지 문항으로 구성되어 있다. 점수가 높을수록 우울",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        397.67999267578125,
        547.7999877929688,
        412.0799865722656
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증상이 심각하다는 것을 의미한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        416.8800048828125,
        421.1399841308594,
        431.2799987792969
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) Generalized Anxiety Disorder 7-item scale (GAD-7)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        436.0799865722656,
        527.1719970703125,
        450.47998046875
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "GAD-7은 범불안장애 환자를 선별 진단하기 위해 개발된",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        455.2799987792969,
        547.7999877929688,
        469.67999267578125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선별평가도구로 불안 또는 걱정과 관련된 7가지 문항에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        474.47998046875,
        547.7999877929688,
        488.8799743652344
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해 그 정도를 0점 (전혀 없었다)에서 3점(거의 매일",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        493.67999267578125,
        547.6799926757812,
        508.0799865722656
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "괴로웠다.)까지 체크하여 불안 증상을 평가한다. 총점은",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        232.1999969482422,
        512.8800048828125,
        547.7999877929688,
        527.280029296875
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "0-21점 사이가 되며, 점수가 높을수록 불안 증상의 심각도가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        532.0800170898438,
        547.7999877929688,
        546.4800415039062
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "높고 기능저하도 심한 것을 의미한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        551.2799682617188,
        439.1399841308594,
        565.6799926757812
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(5) The EuroQol Visual Analogue Scale (EQ-VAS)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        570.47998046875,
        503.4119873046875,
        584.8800048828125
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EQ-VAS는 일반적으로 사용되는 삶의 질 설문지 중 하나로,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        589.6799926757812,
        547.7520141601562,
        604.0800170898438
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자의 전반적인 건강 상태를 0점에서 100점 척도로",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        608.8800048828125,
        547.7999877929688,
        623.280029296875
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가한다. 점수가 높을수록 전반적인 건강 상태가 좋다는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        628.0799560546875,
        547.7999877929688,
        642.47998046875
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것을 의미한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        647.2799682617188,
        313.1399841308594,
        661.6799926757812
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) Clinical Global Impression of Severity (CGI-S)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        666.47998046875,
        497.7720031738281,
        680.8800048828125
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CGI-S 는 피험자의 전반적인 질병 상태의 심각도를 평가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        685.6799926757812,
        547.6799926757812,
        700.0800170898438
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 설문지로, 점수가 높을수록 질병 심각도가 높다는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        704.8800048828125,
        547.7999877929688,
        719.280029296875
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것을 의미한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        724.0799560546875,
        313.1399841308594,
        738.47998046875
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 13. 섭식장애 이차 유효성 평가 지표 측정도구 예시",
      "font_size": 12.960000038146973,
      "font_name": "T10",
      "bbox": [
        144.72000122070312,
        71.87999725341797,
        486.9605712890625,
        87.43199920654297
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 63 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바) 순응도 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        374.4693603515625,
        196.3199920654297,
        390.2896728515625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 치료 기간 애플리케이션 사용 시간 및 활용 여부를 수집한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        404.4693603515625,
        536.0029296875,
        420.2896728515625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사) 이상 반응 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        434.4693603515625,
        218.75999450683594,
        450.2896728515625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        464.4693603515625,
        545.9400024414062,
        480.2896728515625
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        494.4693603515625,
        538.4400024414062,
        510.2896728515625
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        524.4693603515625,
        538.4400024414062,
        540.2896728515625
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지에 내용을 기록한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        554.4693603515625,
        269.0029602050781,
        570.2896728515625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아) 병용약물 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        584.4693603515625,
        211.3199920654297,
        600.2896728515625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 외래 방문마다 병용약물을 수집하여 기록한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        614.4693603515625,
        432.2029724121094,
        630.2896728515625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자) 관찰 및 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        644.4693603515625,
        203.75999450683594,
        660.2896728515625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 각 관찰 항목에 대한 평가 도구 및 평가 방법에 대한 자세한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        674.4693603515625,
        545.9400024414062,
        690.2896728515625
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용을 기재한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        704.4693603515625,
        233.1229705810547,
        720.2896728515625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "측정도구",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        143.0399932861328,
        73.31999969482422,
        402.0,
        87.72000122070312
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설명",
      "font_size": 12.0,
      "font_name": "T10",
      "bbox": [
        143.0399932861328,
        73.31999969482422,
        402.0,
        87.72000122070312
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4주, 8주 시점의 Clinical",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        88.55999755859375,
        97.79999542236328,
        217.8599853515625,
        112.19999694824219
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Global Impression of",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        98.04000091552734,
        117.0,
        208.5,
        131.39999389648438
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Improvement (CGI-I) 평균",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        84.5999984741211,
        136.1999969482422,
        221.87998962402344,
        150.59999084472656
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "점수",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        141.239990234375,
        155.39999389648438,
        165.239990234375,
        169.79998779296875
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) Clinical Global Impression of Improvement (CGI-I)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        88.19999694824219,
        519.1320190429688,
        102.5999984741211
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CGI-I 는 피험자의 전반적인 건강상태의 개선 정도를 평가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        107.39999389648438,
        547.6799926757812,
        121.79999542236328
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 설문지로, 시험자는 피험자의 건강상태의 개선 또는",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        126.59999084472656,
        547.7999877929688,
        140.99998474121094
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "악화 정도를 7점 척도로 평가하며, 점수가 낮을수록 개선도가",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        145.8000030517578,
        547.7999877929688,
        160.1999969482422
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "높다는 것을 의미한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        165.0,
        355.1399841308594,
        179.39999389648438
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4주, 8주 시점에 폭식",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        97.79999542236328,
        189.36000061035156,
        214.67999267578125,
        203.75999450683594
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "횟수를 0회 달성한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        102.23999786376953,
        208.55999755859375,
        204.239990234375,
        222.95999145507812
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자 비율",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        120.23999786376953,
        227.75999450683594,
        186.239990234375,
        242.1599884033203
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "앱을 통해 수집된 자기 모니터링 식사일기를 통하여 피험자의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        198.95999145507812,
        547.7999877929688,
        213.3599853515625
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "폭식 횟수를 평가한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        218.1599884033203,
        355.1399841308594,
        232.5599822998047
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "베이스라인 (사용 전)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        95.87999725341797,
        261.8399963378906,
        210.6119842529297,
        276.239990234375
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대비 8주 시점의 BMI",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        95.15999603271484,
        281.0400085449219,
        211.27198791503906,
        295.44000244140625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "변화",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        141.239990234375,
        300.239990234375,
        165.239990234375,
        314.6399841308594
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "베이스라인 (사용 전) 대비 임상시험용 의료기기 사용 후 8 주",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        271.44000244140625,
        547.7999877929688,
        285.8399963378906
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(방문 5) 시점에 BMI 변화량을 평가한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        232.1999969482422,
        290.6399841308594,
        454.0199890136719,
        305.03997802734375
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 64 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 설계 방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        150.72000122070312,
        86.56968688964844
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        108.36000061035156,
        529.7999877929688,
        122.76000213623047
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있다. 피험자 배정과 처리",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        63.71999740600586,
        132.36000061035156,
        529.7999877929688,
        146.75999450683594
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "할당에 있어 편향(Bias)을 줄이기 위해 무작위배정(Randomization)과 눈가림(Blinding)",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        63.71999740600586,
        156.36000061035156,
        529.81201171875,
        170.75999450683594
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전략이 잘 포함되어야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        63.71999740600586,
        180.36000061035156,
        216.66000366210938,
        194.75999450683594
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        237.3093719482422,
        96.24468231201172,
        253.1296844482422
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 대상자군",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        267.3093566894531,
        166.3199920654297,
        283.1296691894531
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험군: 디지털 섭식장애 인지행동치료군",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        297.3093566894531,
        395.2799987792969,
        313.1296691894531
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 대조군: 디지털 섭식장애 대조군",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        327.3093566894531,
        335.8800048828125,
        343.1296691894531
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 무작위배정 방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        357.3093566894531,
        217.67999267578125,
        373.1296691894531
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 연구자는 선정제외기준에 합격한 피험자의 순서대로 배정일에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        387.3093566894531,
        545.9400024414062,
        403.1296691894531
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "쌍방향 웹반응시스템(Interactive Web Response System,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        417.3093566894531,
        546.0599975585938,
        433.1296691894531
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IWRS)을 통해서 시험군 혹은 대조군으로 1:1 배정한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        447.3093566894531,
        490.52294921875,
        463.1296691894531
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 본 연구와 독립된 통계학자가 SAS 통계 패키지를 가지고 층화",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        477.3093566894531,
        545.9400024414062,
        493.1296691894531
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "순열화 블록 무작위배정법(stratified permuted block randomization)을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        507.30938720703125,
        546.0599975585938,
        523.1296997070312
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이용하여 발행된 난수표를 적용한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        537.3093872070312,
        365.48297119140625,
        553.1296997070312
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 층: 성별(남/여), 나이(oo세 미만, oo세 이상)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        567.3093872070312,
        441.24749755859375,
        583.1296997070312
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 맹검 방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        597.3093872070312,
        173.87998962402344,
        613.1296997070312
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 연구의 특성상 단일맹검을 지향하되, 필요하면 비맹검 임상시험을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        627.3093872070312,
        546.0599975585938,
        643.1296997070312
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수행할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        657.3093872070312,
        224.48297119140625,
        673.1296997070312
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 단일맹검인 경우, 임상시험 도중 응급상황 발생 등으로 인하여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        687.3093872070312,
        545.9400024414062,
        703.1296997070312
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자의 눈가림을 해제할 수 있다. 이 경우, 사유와 해제일,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        717.3093872070312,
        545.9400024414062,
        733.1296997070312
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "열람자, 해제 후 조치사항 등에 대한 문서를 기록·보관한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        747.3093872070312,
        532.6429443359375,
        763.1296997070312
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 65 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "11. 관찰항목·임상검사항목 및 관찰검사방법",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        84.93995666503906,
        398.5194091796875,
        100.89996337890625
      ],
      "page_num": 72,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 임상시험 전, 중, 후에 관찰해야 할 항목들을 나열한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.55999755859375,
        141.95999145507812,
        385.6199951171875,
        156.3599853515625
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험 전 피험자 선정 과정에서의 확인해야 할 사항, 임상검사, 피험자 동의서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.55999755859375,
        161.16000366210938,
        533.2799682617188,
        175.55999755859375
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유/무, 피험자 기초정보, 병력조사, 선정 및 제외 기준, 식별코드 부여 등에 대해서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        83.5199966430664,
        180.36000061035156,
        533.2799682617188,
        194.75999450683594
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기술한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        83.5199966430664,
        199.55999755859375,
        134.4600067138672,
        213.95999145507812
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자의 방문일에 따른 관찰 시기별 관찰 항목, 임상 검사 항목과 관찰 검사 방법을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.55999755859375,
        218.75999450683594,
        533.2799682617188,
        233.1599884033203
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "명시한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        83.04000091552734,
        237.95999145507812,
        133.97999572753906,
        252.3599853515625
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험 중 관찰 항목을 기술한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.55999755859375,
        257.1600036621094,
        277.739990234375,
        271.55999755859375
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험 후 이상반응 확인에 대해서 기술한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.55999755859375,
        276.3599853515625,
        343.739990234375,
        290.7599792480469
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        347.4693603515625,
        103.73999786376953,
        363.2896728515625
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 임상시험 일정표",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        377.4693603515625,
        195.72000122070312,
        393.2896728515625
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "스크리닝 및",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        191.75999450683594,
        417.9599914550781,
        254.51998901367188,
        431.2080078125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검사일",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        206.0399932861328,
        430.0799865722656,
        240.2397003173828,
        443.3280029296875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Screening)1)",
      "font_size": 7.079999923706055,
      "font_name": "T10",
      "bbox": [
        190.55999755859375,
        441.3600158691406,
        255.78968811035156,
        455.447998046875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "치료 시작일",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        276.7200012207031,
        424.0799865722656,
        339.4797058105469,
        437.3280029296875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Baseline)",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        282.6000061035156,
        436.1999816894531,
        333.7030334472656,
        449.447998046875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "치료 기간 종료",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        356.7599792480469,
        417.9599914550781,
        438.18963623046875,
        455.447998046875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1주 후(8주+1주)",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        356.7599792480469,
        417.9599914550781,
        438.18963623046875,
        455.447998046875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Post-treatment)3)3)3)",
      "font_size": 7.079999923706055,
      "font_name": "T10",
      "bbox": [
        356.7599792480469,
        417.9599914550781,
        438.18963623046875,
        455.447998046875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(선택)",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        475.91998291015625,
        411.9599914550781,
        505.9022216796875,
        425.2080078125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "치료 기간 종료",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        450.9599914550781,
        424.0799865722656,
        530.7601928710938,
        437.3280029296875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3개월 후",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        468.0,
        436.1999816894531,
        513.719970703125,
        449.447998046875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Follow up)4)",
      "font_size": 7.079999923706055,
      "font_name": "T10",
      "bbox": [
        458.3999938964844,
        447.3600158691406,
        523.7496948242188,
        461.5679931640625
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4)",
      "font_size": 7.079999923706055,
      "font_name": "T10",
      "bbox": [
        458.3999938964844,
        447.3600158691406,
        523.7496948242188,
        461.5679931640625
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4)",
      "font_size": 7.079999923706055,
      "font_name": "T10",
      "bbox": [
        458.3999938964844,
        447.3600158691406,
        523.7496948242188,
        461.5679931640625
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방문일",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        103.19999694824219,
        465.3599853515625,
        504.9599914550781,
        478.6080017089844
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방문1",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        103.19999694824219,
        465.3599853515625,
        504.9599914550781,
        478.6080017089844
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방문2",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        103.19999694824219,
        465.3599853515625,
        504.9599914550781,
        478.6080017089844
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방문3",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        103.19999694824219,
        465.3599853515625,
        504.9599914550781,
        478.6080017089844
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방문4",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        103.19999694824219,
        465.3599853515625,
        504.9599914550781,
        478.6080017089844
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경과일수",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        97.43999481201172,
        482.03997802734375,
        493.99871826171875,
        495.2879943847656
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "D-28 이내",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        97.43999481201172,
        482.03997802734375,
        493.99871826171875,
        495.2879943847656
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "DAY1",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        97.43999481201172,
        482.03997802734375,
        493.99871826171875,
        495.2879943847656
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        97.43999481201172,
        482.03997802734375,
        493.99871826171875,
        495.2879943847656
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        97.43999481201172,
        482.03997802734375,
        493.99871826171875,
        495.2879943847656
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관찰형태",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        97.43999481201172,
        503.2799987792969,
        324.9599914550781,
        522.6480102539062
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내원",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        97.43999481201172,
        503.2799987792969,
        324.9599914550781,
        522.6480102539062
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내원과",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        97.43999481201172,
        503.2799987792969,
        324.9599914550781,
        522.6480102539062
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "애플리케이션",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        275.3999938964844,
        515.4000244140625,
        341.3999938964844,
        528.6480102539062
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내원과",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        381.1199951171875,
        503.2799987792969,
        414.11968994140625,
        516.5280151367188
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "애플리케이션",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        364.67999267578125,
        515.4000244140625,
        430.67999267578125,
        528.6480102539062
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내원 또는",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        466.44000244140625,
        497.27996826171875,
        515.879638671875,
        510.5279846191406
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "애플리케이션,",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        456.8399963378906,
        509.3999938964844,
        525.5557861328125,
        522.6480102539062
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이메일, 문자, SNS",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        448.79998779296875,
        521.52001953125,
        533.58154296875,
        534.7680053710938
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구 참여 동의서 취득",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        64.55999755859375,
        538.0800170898438,
        493.99871826171875,
        551.3280029296875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        64.55999755859375,
        538.0800170898438,
        493.99871826171875,
        551.3280029296875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        538.0800170898438,
        493.99871826171875,
        551.3280029296875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        538.0800170898438,
        493.99871826171875,
        551.3280029296875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        538.0800170898438,
        493.99871826171875,
        551.3280029296875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "선정/제외기준 확인",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        69.83999633789062,
        557.4000244140625,
        493.99871826171875,
        570.6480102539062
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        69.83999633789062,
        557.4000244140625,
        493.99871826171875,
        570.6480102539062
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        69.83999633789062,
        557.4000244140625,
        493.99871826171875,
        570.6480102539062
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        69.83999633789062,
        557.4000244140625,
        493.99871826171875,
        570.6480102539062
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        69.83999633789062,
        557.4000244140625,
        493.99871826171875,
        570.6480102539062
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인구학적 정보",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        83.04000091552734,
        576.7200317382812,
        493.99871826171875,
        589.968017578125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        83.04000091552734,
        576.7200317382812,
        493.99871826171875,
        589.968017578125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        83.04000091552734,
        576.7200317382812,
        493.99871826171875,
        589.968017578125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        83.04000091552734,
        576.7200317382812,
        493.99871826171875,
        589.968017578125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        83.04000091552734,
        576.7200317382812,
        493.99871826171875,
        589.968017578125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "과거병력 조사",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        83.04000091552734,
        596.1600341796875,
        493.99871826171875,
        609.4080200195312
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        83.04000091552734,
        596.1600341796875,
        493.99871826171875,
        609.4080200195312
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        83.04000091552734,
        596.1600341796875,
        493.99871826171875,
        609.4080200195312
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        83.04000091552734,
        596.1600341796875,
        493.99871826171875,
        609.4080200195312
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        83.04000091552734,
        596.1600341796875,
        493.99871826171875,
        609.4080200195312
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험 의료기기 적용",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        64.55999755859375,
        615.47998046875,
        495.34893798828125,
        628.7279663085938
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        64.55999755859375,
        615.47998046875,
        495.34893798828125,
        628.7279663085938
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        64.55999755859375,
        615.47998046875,
        495.34893798828125,
        628.7279663085938
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        64.55999755859375,
        615.47998046875,
        495.34893798828125,
        628.7279663085938
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        64.55999755859375,
        615.47998046875,
        495.34893798828125,
        628.7279663085938
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가지표 Baseline 수집",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        64.55999755859375,
        633.47998046875,
        493.99871826171875,
        646.7279663085938
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(O)",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        633.47998046875,
        493.99871826171875,
        646.7279663085938
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        64.55999755859375,
        633.47998046875,
        493.99871826171875,
        646.7279663085938
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        633.47998046875,
        493.99871826171875,
        646.7279663085938
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        633.47998046875,
        493.99871826171875,
        646.7279663085938
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가지표 수집 및 분석2)",
      "font_size": 7.079999923706055,
      "font_name": "T10",
      "bbox": [
        64.55999755859375,
        649.199951171875,
        495.34893798828125,
        663.4080200195312
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2)2)",
      "font_size": 7.079999923706055,
      "font_name": "T10",
      "bbox": [
        64.55999755859375,
        649.199951171875,
        495.34893798828125,
        663.4080200195312
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        64.55999755859375,
        649.199951171875,
        495.34893798828125,
        663.4080200195312
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        64.55999755859375,
        649.199951171875,
        495.34893798828125,
        663.4080200195312
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        64.55999755859375,
        649.199951171875,
        495.34893798828125,
        663.4080200195312
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        64.55999755859375,
        649.199951171875,
        495.34893798828125,
        663.4080200195312
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이상반응 확인",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        83.04000091552734,
        668.1600341796875,
        495.34893798828125,
        681.4080200195312
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        83.04000091552734,
        668.1600341796875,
        495.34893798828125,
        681.4080200195312
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        83.04000091552734,
        668.1600341796875,
        495.34893798828125,
        681.4080200195312
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        83.04000091552734,
        668.1600341796875,
        495.34893798828125,
        681.4080200195312
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        83.04000091552734,
        668.1600341796875,
        495.34893798828125,
        681.4080200195312
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "병용약물 조사",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        83.04000091552734,
        687.47998046875,
        495.34893798828125,
        700.7279663085938
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        83.04000091552734,
        687.47998046875,
        495.34893798828125,
        700.7279663085938
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        83.04000091552734,
        687.47998046875,
        495.34893798828125,
        700.7279663085938
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        83.04000091552734,
        687.47998046875,
        495.34893798828125,
        700.7279663085938
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        83.04000091552734,
        687.47998046875,
        495.34893798828125,
        700.7279663085938
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "순응도 조사",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        88.91999816894531,
        706.7999877929688,
        493.99871826171875,
        720.0479736328125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        88.91999816894531,
        706.7999877929688,
        493.99871826171875,
        720.0479736328125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        88.91999816894531,
        706.7999877929688,
        493.99871826171875,
        720.0479736328125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        88.91999816894531,
        706.7999877929688,
        493.99871826171875,
        720.0479736328125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.039999961853027,
      "font_name": "T11",
      "bbox": [
        88.91999816894531,
        706.7999877929688,
        493.99871826171875,
        720.0479736328125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 스크리닝 및 검사일은 치료 시작일 전 28일 이내에 시작한다.",
      "font_size": 9.960000038146973,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        723.5999755859375,
        499.8401794433594,
        765.552001953125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 수집하는 지표에 따라 수집이 다를 경우 나누어 표현한다.",
      "font_size": 9.960000038146973,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        723.5999755859375,
        499.8401794433594,
        765.552001953125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 섭식장애 개선 디지털치료기기 제품의 치료 기간에 따라 전체 치료 기간은 변경될 수 있다.",
      "font_size": 9.960000038146973,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        723.5999755859375,
        499.8401794433594,
        765.552001953125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 임상시험 설계에 따른 선택사항이므로 치료 기간 종료 후 추적관찰 기간은 변경될 수 있다.",
      "font_size": 9.960000038146973,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        723.5999755859375,
        499.8401794433594,
        765.552001953125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 66 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 임상시험 절차",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        180.72000122070312,
        86.56968688964844
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        100.74937438964844,
        103.73999786376953,
        116.56968688964844
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 방문 1 (스크리닝 및 검사일, Screening)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        130.74937438964844,
        364.2074890136719,
        146.56968688964844
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 임상시험 설명 및 동의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        160.74937438964844,
        271.32000732421875,
        176.56968688964844
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        190.74937438964844,
        545.9400024414062,
        206.56968688964844
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대상자 또는 법정대리인에게 상세히 설명한다. 서명 일자를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        220.74937438964844,
        546.0599975585938,
        236.56968688964844
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정확히 기재하여야 하며, 작성된 동의서 원본은 시험자가 보관",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        250.74935913085938,
        538.5599975585938,
        266.5696716308594
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고 사본은 시험대상자 또는 법정대리인에게 내준다. 대상자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        280.7493591308594,
        538.5599975585938,
        296.5696716308594
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에게 동의를 받은 후 동의 취득 순서에 따라 스크리닝 번호를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        310.7493591308594,
        545.9400024414062,
        326.5696716308594
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부여한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        340.7493591308594,
        180.68296813964844,
        356.5696716308594
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 선정/제외 기준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        370.7493591308594,
        216.0,
        386.5696716308594
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        400.7493591308594,
        545.9400024414062,
        416.5696716308594
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위임자가 모든 선정 및 제외 기준을 검토해야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        430.7493591308594,
        469.282958984375,
        446.5696716308594
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 인구학적 정보",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        460.7493591308594,
        211.3199920654297,
        476.5696716308594
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 인구학적 정보로 대상자 이니셜, 만 나이, 성별, 직업을 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        490.7493591308594,
        538.5599975585938,
        506.5696716308594
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하며 기초 문진에 필요한 환자들의 의학적 특성에 대한 정보",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        520.7493896484375,
        538.4400024414062,
        536.5697021484375
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "들을 수집한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        550.7493896484375,
        217.1629638671875,
        566.5697021484375
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 식사장애 검사(EDE-Q) 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        580.7493896484375,
        304.91998291015625,
        596.5697021484375
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자 선정을 위한 식사장애 검사(EDE-Q) 조사 정보를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        610.7493896484375,
        546.0599975585938,
        626.5697021484375
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수집한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        640.7493896484375,
        182.48297119140625,
        656.5697021484375
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 필요하면 본 단계에서 수집한 정보를 Baseline 지표로 활용할",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        670.7493896484375,
        546.0599975585938,
        686.5697021484375
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        700.7493286132812,
        180.05999755859375,
        716.5696411132812
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 67 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마) 과거 병력 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        70.74937438964844,
        218.75999450683594,
        86.56968688964844
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 병력 등을 문진과 과거 진료 기록을 통해 조사한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        100.74937438964844,
        469.282958984375,
        116.56968688964844
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 병력조사에 포함되어야 하는 내용은 다음과 같다. 치매, 인지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        130.74937438964844,
        546.0599975585938,
        146.56968688964844
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기능 장애, 정신증, 양극성 장애 및 현재 주요 우울 삽화",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        160.74937438964844,
        538.5599975585938,
        176.56968688964844
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(current major depressive episode) 등 스크리닝 확인해야 할",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        190.74937438964844,
        546.0599975585938,
        206.56968688964844
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질병군 등의 과거력 및 현 병력, 발생 시기, 치료와 진행 여부",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        220.74937438964844,
        546.0599975585938,
        236.56968688964844
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 내용 등을 기재한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        250.74935913085938,
        276.4429626464844,
        266.5696716308594
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 동의서 취득일 기준으로 최근 5년 이내 과거 및 현재 병력을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        280.7493591308594,
        545.9400024414062,
        296.5696716308594
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조사한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        310.7493591308594,
        180.0829620361328,
        326.5696716308594
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바) 식사장애 검사(EDE-Q) 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        340.7493591308594,
        304.91998291015625,
        356.5696716308594
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자 선정을 위한 식사장애 검사(EDE-Q) 정보를 수집한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        370.7493591308594,
        524.8429565429688,
        386.5696716308594
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사) 병용약물 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        400.7493591308594,
        211.3199920654297,
        416.5696716308594
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        430.7493591308594,
        513.4429931640625,
        446.5696716308594
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        460.7493591308594,
        538.5599975585938,
        476.5696716308594
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        490.7493591308594,
        545.9400024414062,
        506.5696716308594
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기간, 목적을 확인한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        520.7493896484375,
        273.0829772949219,
        536.5697021484375
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 방문 2 (치료 시작일, Baseline)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        580.7493896484375,
        308.94000244140625,
        596.5697021484375
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 평가지표 Baseline 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        610.7493896484375,
        273.1199951171875,
        626.5697021484375
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 일차 유효성 평가지표, 이차 임상 변수를 평가하기 위해 식사장애",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        640.7493896484375,
        546.0599975585938,
        656.5697021484375
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사(EDE-Q)를 작성하도록 하여 지참하게 하거나, 애플리케이션",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        670.7493896484375,
        546.0599975585938,
        686.5697021484375
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등을 통해 Baseline 정보를 수집한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        700.7493286132812,
        372.05999755859375,
        716.5696411132812
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 필요에 따라 방문 1(스크리닝 단계)에서 측정한 식사장애 검사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        730.7493286132812,
        538.4400024414062,
        746.5696411132812
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 68 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(EDE-Q)를 Baseline 지표로 활용할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        70.74937438964844,
        422.48297119140625,
        86.56968688964844
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나) 무작위배정",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        100.74937438964844,
        196.37998962402344,
        116.56968688964844
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 시험군 혹은 대조군에 무작위배정을 통해 배치한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        130.74937438964844,
        476.8199768066406,
        146.56968688964844
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 임상시험 의료기기 시험방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        160.74937438964844,
        308.7599792480469,
        176.56968688964844
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- OOO 애플리케이션을 실행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        190.74937438964844,
        330.5629577636719,
        206.56968688964844
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 회원가입 및 초기 증상평가를 시행한다(기본 입력 정보: 성별,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        220.74937438964844,
        545.9400024414062,
        236.56968688964844
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나이, 섭식장애 증상의 정도, 섭식장애 증상으로 인한 행동의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        250.74935913085938,
        545.9400024414062,
        266.5696716308594
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제한 혹은 예기 불안, 동반증상 여부, 직업).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        280.7493591308594,
        416.60296630859375,
        296.5696716308594
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 정해진 기간에 상술 된 방식으로 디지털치료기기 콘텐츠를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        310.7493591308594,
        545.9400024414062,
        326.5696716308594
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통한 섭식장애 치료를 수행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        340.7493591308594,
        337.04296875,
        356.5696716308594
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 대조군 검사 시험방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        370.7493591308594,
        263.760009765625,
        386.5696716308594
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 상담 및 지지요법, 약물 치료 등을 실행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        400.7493591308594,
        428.8199768066406,
        416.5696716308594
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 정해진 기간에 환자에게 해가 되지 않는 내용으로 과학적 근거에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        430.7493591308594,
        545.9400024414062,
        446.5696716308594
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기반한 정보를 제공한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        460.7493591308594,
        283.8829650878906,
        476.5696716308594
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마) 이상 반응 확인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        490.7493591308594,
        218.75999450683594,
        506.5696716308594
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        520.7493896484375,
        545.9400024414062,
        536.5697021484375
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상 반응 여부를 방문일에 진찰을 통해 관찰하고, 임상시험용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        550.7493896484375,
        545.9400024414062,
        566.5697021484375
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기와의 인과관계에 대하여 증례 기록지에 기록한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        580.7493896484375,
        513.802978515625,
        596.5697021484375
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        90.0,
        608.9999389648438,
        538.4400024414062,
        624.5519409179688
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대체 수집할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        109.43999481201172,
        635.0399780273438,
        236.09519958496094,
        650.5919799804688
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바) 병용약물 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        662.829345703125,
        211.3199920654297,
        678.649658203125
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        692.829345703125,
        521.2429809570312,
        708.649658203125
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        722.829345703125,
        538.5599975585938,
        738.649658203125
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        752.829345703125,
        545.9400024414062,
        768.649658203125
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 69 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기간, 목적을 확인한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        70.74937438964844,
        273.0829772949219,
        86.56968688964844
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사) 순응도 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        100.74937438964844,
        196.3199920654297,
        116.56968688964844
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        130.74937438964844,
        545.9400024414062,
        146.56968688964844
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "순응도를 조사한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        160.74937438964844,
        241.76296997070312,
        176.56968688964844
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 방문 3 (치료 기간 종료 1주 후, Post-treatment)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        220.74937438964844,
        422.0474853515625,
        236.56968688964844
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 치료 후 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        250.74935913085938,
        203.75999450683594,
        266.5696716308594
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 치료 후 평가 및 일차 유효성 평가지표, 이차 유효성 평가지표의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        280.7493591308594,
        546.0599975585938,
        296.5696716308594
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변화를 검증하기 위해 섭식장애 평가 항목 및 해당하는 자가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        310.7493591308594,
        545.9400024414062,
        326.5696716308594
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보고 척도를 작성하도록 하여 지참하게 하거나, 애플리케이션을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        340.7493591308594,
        546.0599975585938,
        356.5696716308594
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통해 정보를 수집한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        370.7493591308594,
        276.5400085449219,
        386.5696716308594
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 디지털치료기기에 대한 사용자 반응 평가를 함께 수행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        400.7493591308594,
        521.2429809570312,
        416.5696716308594
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 이상 반응 확인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        430.7493591308594,
        218.75999450683594,
        446.5696716308594
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        460.7493591308594,
        545.9400024414062,
        476.5696716308594
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        490.7493591308594,
        538.5599975585938,
        506.5696716308594
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        520.7493896484375,
        545.9400024414062,
        536.5697021484375
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기록한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        550.7493896484375,
        180.0829620361328,
        566.5697021484375
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        99.95999908447266,
        578.9999389648438,
        538.439697265625,
        594.5519409179688
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대체 수집할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        119.39999389648438,
        605.0399780273438,
        242.21519470214844,
        620.5919799804688
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 병용약물 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        658.7493896484375,
        211.3199920654297,
        674.5697021484375
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        688.7493896484375,
        521.2429809570312,
        704.5697021484375
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        718.7493286132812,
        538.5599975585938,
        734.5696411132812
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        748.7493286132812,
        545.9400024414062,
        764.5696411132812
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 70 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 77,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기간, 목적을 확인한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        70.74937438964844,
        273.0829772949219,
        86.56968688964844
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라) 순응도 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        100.74937438964844,
        196.3199920654297,
        116.56968688964844
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        130.74937438964844,
        545.9400024414062,
        146.56968688964844
      ],
      "page_num": 77,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "순응도를 조사한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        160.74937438964844,
        241.76296997070312,
        176.56968688964844
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 방문 4 (치료 기간 종료 3개월 후, Follow up)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        210.78936767578125,
        410.6999816894531,
        226.60968017578125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 장기 효과 검증",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        240.78936767578125,
        218.75999450683594,
        256.60968017578125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 장기 효과 확인을 위한 일차 유효성 평가지표, 이차 유효성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        270.78936767578125,
        546.0599975585938,
        286.60968017578125
      ],
      "page_num": 77,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가지표의 변화를 검증하기 위해 섭식장애 평가 항목 및",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        300.78936767578125,
        546.0599975585938,
        316.60968017578125
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당하는 자가 보고 척도를 작성하도록 하여 지참하게 하거나,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        330.78936767578125,
        546.0599975585938,
        346.60968017578125
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "애플리케이션, 이메일, 문자, SNS 등을 통해 수집한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        360.78936767578125,
        484.04296875,
        376.60968017578125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 내원은 필수가 아니며 앱, 이메일, 문자 등을 통해 수집할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        101.63999938964844,
        389.0400085449219,
        520.4951782226562,
        404.5920104980469
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 디지털치료기기에 대한 장기 사용자 반응 평가를 함께 수행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        416.8293762207031,
        536.0029296875,
        432.6496887207031
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 이상 반응 확인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        446.8293762207031,
        218.75999450683594,
        462.6496887207031
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        476.8293762207031,
        545.9400024414062,
        492.6496887207031
      ],
      "page_num": 77,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        506.829345703125,
        538.4400024414062,
        522.649658203125
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        536.829345703125,
        546.0599975585938,
        552.649658203125
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용을 기록한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        566.829345703125,
        231.92295837402344,
        582.649658203125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        98.63999938964844,
        594.9599609375,
        538.4402465820312,
        610.511962890625
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대체 수집할 수 있다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        118.19999694824219,
        620.9999389648438,
        242.21519470214844,
        636.5519409179688
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 병용약물 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        648.7893676757812,
        211.3199920654297,
        664.6096801757812
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        678.7893676757812,
        521.2429809570312,
        694.6096801757812
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        708.7893676757812,
        538.5599975585938,
        724.6096801757812
      ],
      "page_num": 77,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        738.7893676757812,
        546.0599975585938,
        754.6096801757812
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 71 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 78,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기간, 목적을 확인한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        70.74937438964844,
        270.0829772949219,
        86.56968688964844
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라) 순응도 조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        100.74937438964844,
        196.3199920654297,
        116.56968688964844
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        130.74937438964844,
        545.9400024414062,
        146.56968688964844
      ],
      "page_num": 78,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "순응도를 조사한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        160.74937438964844,
        241.76296997070312,
        176.56968688964844
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 72 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 79,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "12. 예측되는 부작용 및 사용 시 주의사항",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        84.93995666503906,
        374.5196838378906,
        100.89996337890625
      ],
      "page_num": 79,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        77.4000015258789,
        137.75999450683594,
        516.719970703125,
        152.1599884033203
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "등을 제시한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        161.75999450683594,
        148.6199951171875,
        176.1599884033203
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        230.70936584472656,
        103.73999786376953,
        246.52967834472656
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 예측되는 부작용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        260.7093811035156,
        195.72000122070312,
        276.5296936035156
      ],
      "page_num": 79,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 연구에서 적용하는 치료는 디지털 섭식장애 인지행동치료(CBT),",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        290.7093811035156,
        546.0599975585938,
        306.5296936035156
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혹은 이에 상응하는 과학적 근거를 가진 섭식장애의 비약물적인 치료이다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        320.7093811035156,
        546.0599975585938,
        336.5296936035156
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "섭식장애 인지행동치료 및 기타 비약물적인 치료의 경우 행동 요법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        350.7093811035156,
        546.0599975585938,
        366.5296936035156
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 인지 요법을 포함한 교육 이외 침습적이거나 환자에게 유해를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        380.7093811035156,
        546.0599975585938,
        396.5296936035156
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "끼칠 수 있는 내용은 포함되어 있지 않다. 다만, 일반적인 섭식장애",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        410.7093505859375,
        545.9400024414062,
        426.5296630859375
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인지행동치료의 부작용 정도에 대한 부작용 또는 범용장비 사용으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        440.7093505859375,
        546.0599975585938,
        456.5296630859375
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인한 부작용을 예상할 수 있고, 이는 다음과 같다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        470.7093505859375,
        402.08294677734375,
        486.5296630859375
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 섭식장애 인지행동치료의 행동 요법 중 노출 치료의 경우, 섭식",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        500.7093505859375,
        538.4400024414062,
        516.5296630859375
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장애 증상의 발생 및 악화가 나타날 수 있다. 섭식장애 이외 기타",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        530.7093505859375,
        545.9400024414062,
        546.5296630859375
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정신과적인 증상의 악화 위험이 큰 사람, 특히 자살 생각을 하는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        560.7093505859375,
        545.9400024414062,
        576.5296630859375
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사람의 경우 임상시험에서 배제함으로써 위험도를 최소화할 수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        590.7093505859375,
        546.0599975585938,
        606.5296630859375
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다. 이 외에도 치료 시작 시점에서 일시적인 불안감, 악화감이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        620.7093505859375,
        546.0599975585938,
        636.5296630859375
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나타날 수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        650.7093505859375,
        538.4400024414062,
        666.5296630859375
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        680.7093505859375,
        545.219970703125,
        696.5296630859375
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 섭식장애 인지행동치료의 인지 요법 중 왜곡된 인지 교정의 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        710.7093505859375,
        545.9400024414062,
        726.5296630859375
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역기능적인 사고의 탐색 및 교정의 과정에서 일시적인 불안감",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        740.7093505859375,
        546.0599975585938,
        756.5296630859375
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 73 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 80,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "악화를 가져올 수 있다. 상술한 것과 같이 선정 및 제외 기준을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        70.74937438964844,
        545.9400024414062,
        86.56968688964844
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활용하여 위험도를 최소화하며, 실험에 참여한 환자들을 대상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        100.74937438964844,
        538.5599975585938,
        116.56968688964844
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로는 치료 시작 시점에서 일시적인 불안감 악화가 나타날",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        130.74937438964844,
        545.9400024414062,
        146.56968688964844
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통하여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        160.74937438964844,
        545.9400024414062,
        176.56968688964844
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        190.74937438964844,
        500.2429504394531,
        206.56968688964844
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 섭식장애 개선 디지털 치료를 위한 범용 장비(스마트폰 또는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        220.74937438964844,
        546.0599975585938,
        236.56968688964844
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "태블릿 PC 등) 사용으로 두통, 눈의 피로, 눈 또는 근육경련, 눈의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        250.74935913085938,
        546.0599975585938,
        266.5696716308594
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불수의운동, 메스꺼움, 어지럼증, 머리 또는 눈의 불쾌감 또는 통증,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        280.7493591308594,
        545.9400024414062,
        296.5696716308594
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "졸림, 피로감과 같은 부작용이 발생할 수 있다. 해당 경우 24시간",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        310.7493591308594,
        545.9400024414062,
        326.5696716308594
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연락 가능한 연구자 번호를 통하여 즉시 상담과 필요하면 의료진",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        340.7493591308594,
        545.9400024414062,
        356.5696716308594
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연결이 가능하도록 조치한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        370.7493591308594,
        290.36297607421875,
        386.5696716308594
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 연구에서 진행되는 평가는 자가 보고 설문지, 면담 등 모두",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        400.7493591308594,
        545.9400024414062,
        416.5696716308594
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비침습적인 검사로 이루어져 있으므로 예측되는 부작용은 없다.",
      "font_size": 15.0,
      "font_name": "Haansoft Batang",
      "bbox": [
        56.63999938964844,
        430.7493591308594,
        508.03509521484375,
        446.5696716308594
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 사용 시 주의사항",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        520.7493896484375,
        203.1599884033203,
        536.5697021484375
      ],
      "page_num": 80,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 연구에서 적용하는 섭식장애 개선 디지털치료기기의 부작용,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        550.7493896484375,
        545.9400024414062,
        566.5697021484375
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반적 주의, 적용상의 주의는 다음과 같다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        580.7493896484375,
        370.97998046875,
        596.5697021484375
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 부작용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        610.7493896484375,
        136.32000732421875,
        626.5697021484375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 제품을 사용한 후 제품에 대한 부적합 반응이 전부 배제될",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        640.7493896484375,
        545.9400024414062,
        656.5697021484375
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수는 없으며, 이상 반응 문제가 생길 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        670.7493896484375,
        418.5,
        686.5697021484375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) 일반적 주의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        700.7493286132812,
        173.87998962402344,
        716.5696411132812
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사이버 보안과 관련된 사고 발생 시 임상시험 관리자 긴급",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        730.7493286132812,
        545.9400024414062,
        746.5696411132812
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 74 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 81,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호로 연락하고 관리자가 조치할 때까지 대기한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.1199951171875,
        70.74937438964844,
        455.48297119140625,
        86.56968688964844
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7) 적용상의 주의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        100.74937438964844,
        188.87998962402344,
        116.56968688964844
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용 시간, 사용 횟수, 결과 작성 등 임상시험 책임자와 담당자가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        130.74937438964844,
        545.9400024414062,
        146.56968688964844
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요구한 사용 방법을 준수하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        99.1199951171875,
        160.74937438964844,
        342.4429626464844,
        176.56968688964844
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 75 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 82,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "13. 중지·탈락 기준",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        84.93995666503906,
        214.44000244140625,
        100.89996337890625
      ],
      "page_num": 82,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 부작용, 이상반응 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        70.24079895019531,
        148.3199920654297,
        530.8800048828125,
        162.71998596191406
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험의 진행이 피험자의 안전 보호를 위협하여 그 진행을 멈추는 것을 ‘중지’라 하며,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.23999786376953,
        172.3199920654297,
        530.83203125,
        186.71998596191406
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험 개시에서 완료까지 중지될 수 있는 세부 사항을 ‘중지 기준’에 제시한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.23999786376953,
        196.3199920654297,
        530.8200073242188,
        210.71998596191406
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‘중지 처리’에는 각 중지 기준에 대한 유효성 평가 통계 처리 시 그 산입 여부와",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.23999786376953,
        220.3199920654297,
        530.8800048828125,
        234.71998596191406
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자별 중지 사유를 포함한 관련 임상시험 자료의 처리 방법을 제시한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.23999786376953,
        244.32000732421875,
        530.3399658203125,
        258.7200012207031
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- ‘탈락’ 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        71.04000091552734,
        268.32000732421875,
        530.8800048828125,
        282.7200012207031
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험이 완료되지 못한 경우를 말하며, 그 분류기준을 ‘탈락 기준’에, 탈락의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.23999786376953,
        292.32000732421875,
        530.8800048828125,
        306.7200012207031
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사유와 관련 임상자료의 처리 방법을 ‘탈락 처리’에 구체적으로 제시한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.23999786376953,
        316.32000732421875,
        488.5799865722656,
        330.7200012207031
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        388.6293640136719,
        96.24468231201172,
        404.4496765136719
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 중지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        418.6293640136719,
        113.15999603271484,
        434.4496765136719
      ],
      "page_num": 82,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 중지 기준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        448.6293640136719,
        158.87998962402344,
        464.4496765136719
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        478.6293640136719,
        546.0599975585938,
        494.4496765136719
      ],
      "page_num": 82,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 일시 중지시킬 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        508.62933349609375,
        309.8029479980469,
        524.4496459960938
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        538.6293334960938,
        545.9400024414062,
        554.4496459960938
      ],
      "page_num": 82,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것에 무리가 있다고 판단될 때는 임상시험을 중지할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        568.6293334960938,
        536.0029296875,
        584.4496459960938
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 심각한 부작용 발생으로 조기 종료시킬 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        598.6293334960938,
        447.08294677734375,
        614.4496459960938
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 중지 처리",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        628.6293334960938,
        158.87998962402344,
        644.4496459960938
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        658.6293334960938,
        546.0599975585938,
        674.4496459960938
      ],
      "page_num": 82,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 일시 중지시킬 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        688.6293334960938,
        309.8029479980469,
        704.4496459960938
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 중지 시점까지의 검사 결과 관련 자료는 성능과 안전성 평가를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        718.6293334960938,
        546.0599975585938,
        734.4496459960938
      ],
      "page_num": 82,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위한 통계처리 시 삽입할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        748.6293334960938,
        350.60296630859375,
        764.4496459960938
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 76 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 83,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 임상시험을 통해 얻은 자료는 성능 및 안전성 분석을 위한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        70.74937438964844,
        546.0599975585938,
        86.56968688964844
      ],
      "page_num": 83,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "데이터가 정해져야 하며, 만약 자료에 결함이 생기면 적절한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        100.74937438964844,
        545.9400024414062,
        116.56968688964844
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보정 방법을 임상시험계획에서 제시하고 보정 후 분석을 시행",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        130.74937438964844,
        538.4400024414062,
        146.56968688964844
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하도록 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        160.74937438964844,
        202.282958984375,
        176.56968688964844
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 동의를 철회하였으면 해당 시점 이후의 수집된 피험자의 정",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        190.74937438964844,
        538.4400024414062,
        206.56968688964844
      ],
      "page_num": 83,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보는 전면 파기한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        220.74937438964844,
        254.2429656982422,
        236.56968688964844
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 탈락",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        280.7493591308594,
        113.15999603271484,
        296.5696716308594
      ],
      "page_num": 83,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 탈락 기준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        310.7493591308594,
        158.87998962402344,
        326.5696716308594
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": 시험자는 다음과 같은 경우에 연구 참여 대상자를 시험에서",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.43999481201172,
        340.7493591308594,
        546.0599975585938,
        356.5696716308594
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "탈락시킬 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.43999481201172,
        370.7493591308594,
        216.68296813964844,
        386.5696716308594
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자가 임상시험 중 임상시험 참여 중단을 요구하거나 시험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        400.7493591308594,
        538.4400024414062,
        416.5696716308594
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참여 동의를 철회하는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        430.7493591308594,
        300.3599853515625,
        446.5696716308594
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자의 부작용(예: 두통, 눈의 피로, 눈 또는 근육경련, 눈의",
      "font_size": 14.039999961853027,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        460.7493591308594,
        545.4606323242188,
        476.5696716308594
      ],
      "page_num": 83,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불수의운동, 메스꺼움, 어지럼증 등)으로 인하여 임상시험 책임자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        490.7493591308594,
        546.0599975585938,
        506.5696716308594
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 담당자가 임상시험 수행이 불가능한 것으로 판단한 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        520.7493896484375,
        535.2000122070312,
        536.5697021484375
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자가 임상시험 중 임상시험용 의료기기 비교 평가하는 데",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        550.7493896484375,
        545.9400024414062,
        566.5697021484375
      ],
      "page_num": 83,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영향을 줄 것으로 예상하는 약물을 임의로 복용한 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        580.7493896484375,
        495.1199951171875,
        596.5697021484375
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자의 임상시험 중 임상시험용 의료기기 비교 평가하는 데",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        610.7493896484375,
        545.9400024414062,
        626.5697021484375
      ],
      "page_num": 83,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영향을 줄 수 있는 약물의 사용량이 변경된 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        640.7493896484375,
        450.5999755859375,
        656.5697021484375
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험 중 선정/제외 기준 위반 등 중대한 계획서 위반",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        670.7493896484375,
        546.0599975585938,
        686.5697021484375
      ],
      "page_num": 83,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항이 발견되는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        700.7493286132812,
        269.5199890136719,
        716.5696411132812
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자가 제때 방문을 안 하며 연락이 안 되는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        730.7493286132812,
        472.79998779296875,
        746.5696411132812
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 77 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 84,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 기타 사유로 인하여 임상시험 책임자 또는 담당자가 임상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        70.74937438964844,
        538.5599975585938,
        86.56968688964844
      ],
      "page_num": 84,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험을 중지해야 한다고 판단한 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        100.74937438964844,
        378.7200012207031,
        116.56968688964844
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 섭식장애 연관 증상이 지나치게 악화되어 다른 정신과적 건강",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        130.74937438964844,
        545.9400024414062,
        146.56968688964844
      ],
      "page_num": 84,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과 또는 신체 질환 악화가 예상되는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        160.74937438964844,
        413.5199890136719,
        176.56968688964844
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 탈락 처리",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        190.74937438964844,
        158.87998962402344,
        206.56968688964844
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 중도 탈락 시, 시험자는 대상자의 임상시험 조기 탈락의 주요",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        220.74937438964844,
        545.9400024414062,
        236.56968688964844
      ],
      "page_num": 84,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사유를 평가하여 증례 기록서 임상시험 완료 항목에 해당 정보를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        250.74935913085938,
        545.9400024414062,
        266.5696716308594
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기재한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        280.7493591308594,
        178.282958984375,
        296.5696716308594
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 참여 중단 의사를 밝히지 않고 방문에 출석하지 않아 현재",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        310.7493591308594,
        546.0599975585938,
        326.5696716308594
      ],
      "page_num": 84,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상태가 불분명한 대상자의 경우에 시험자는 대상자와 전화",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        340.7493591308594,
        546.0599975585938,
        356.5696716308594
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통화를 하여 탈락의 주요 사유를 파악하도록 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        370.7493591308594,
        469.282958984375,
        386.5696716308594
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 78 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 85,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "14. 유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 의함)",
      "font_size": 14.039999961853027,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        79.29995727539062,
        524.0458374023438,
        95.25996398925781
      ],
      "page_num": 85,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 해당 의료기기의 임상시험에 따른 유효성 평가는 사용된 모든 의료기기를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        71.04000091552734,
        133.9199981689453,
        530.6400146484375,
        148.3199920654297
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능 평가 기준을 제시",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.95999908447266,
        157.9199981689453,
        530.6400146484375,
        172.3199920654297
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한다. 그 밖에 임상시험 결과의 사용 범위에 따른 성능 평가를 위하여 이차",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        84.95999908447266,
        181.9199981689453,
        530.5199584960938,
        196.3199920654297
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성 평가변수를 제시하여 각 임상 검사 항목 및 검사 방법에 대한 기준을",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.95999908447266,
        205.9199981689453,
        530.5199584960938,
        220.3199920654297
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제시한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.95999908447266,
        229.9199981689453,
        140.22000122070312,
        244.3199920654297
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 성능 평가 방법은 임상시험 기간 동안 일차/이차 유효성 평가변수에 대한",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        71.04000091552734,
        253.91998291015625,
        530.6400146484375,
        268.3199768066406
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험군과 대조군간의 비교 분석 방법을 통계적으로 타당하게 제시한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        85.31999969482422,
        277.91998291015625,
        505.8599853515625,
        292.3199768066406
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 통계 분석 방법에 따른 통계적 유의성에 대한 평가 방법과 기준을 제시한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        71.04000091552734,
        301.91998291015625,
        530.4599609375,
        316.3199768066406
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험을 복수의 임상시험 기관에서 실시하는 경우에는 기관에 따라 임상시험",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.47999572753906,
        325.91998291015625,
        530.6400146484375,
        340.3199768066406
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과에 차이가 있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.47999572753906,
        349.91998291015625,
        530.5199584960938,
        364.3199768066406
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보정할 수 있는 경우는 이를 반영하여 분석 결과를 제시해야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        84.47999572753906,
        373.91998291015625,
        453.41998291015625,
        388.3199768066406
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        446.349365234375,
        111.24468231201172,
        462.169677734375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 유효성의 평가 기준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        476.349365234375,
        218.1599884033203,
        492.169677734375
      ],
      "page_num": 85,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[일차 유효성 평가변수]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        506.349365234375,
        222.05999755859375,
        522.169677734375
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Eating Disorder Examination Questionnaire (EDE-Q)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        536.349365234375,
        448.6199951171875,
        552.169677734375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[이차 유효성 평가변수]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        566.349365234375,
        214.56468200683594,
        582.169677734375
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 베이스라인 (사용 전) 대비 4주, 8주 시점의 하기 지표 변화량",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        596.349365234375,
        545.9400024414062,
        612.169677734375
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(설문조사)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.91999816894531,
        626.349365234375,
        168.77999877929688,
        642.169677734375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) Clinical Impairment Assessment (CIA)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        656.349365234375,
        386.5799865722656,
        672.169677734375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) Patient health questionnaire-9 (PHQ-9)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        686.349365234375,
        400.1399841308594,
        702.169677734375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) Generalized anxiety disorder 7-item scale (GAD-7)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        716.349365234375,
        480.53997802734375,
        732.169677734375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) The EuroQol Visual Analogue Scale (EQ-VAS)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        746.349365234375,
        447.41998291015625,
        762.169677734375
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 79 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 86,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(5) Clinical Global Impression of Severity (CGI-S)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        70.74937438964844,
        445.739990234375,
        86.56968688964844
      ],
      "page_num": 86,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 4주, 8주 시점의 Clinical Global Impression of Improvement",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        100.74937438964844,
        546.0599975585938,
        116.56968688964844
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(CGI-I) 평균 점수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        95.04000091552734,
        130.74937438964844,
        214.8000030517578,
        146.56968688964844
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 4주, 8 주 시점에 폭식 횟수를 0회 달성한 피험자 비율",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        160.74937438964844,
        470.2799987792969,
        176.56968688964844
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 베이스라인 (사용 전) 대비 8 주 시점의 BMI 변화",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        190.74937438964844,
        440.2200012207031,
        206.56968688964844
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 80 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 검사방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        143.16000366210938,
        86.56968688964844
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) Eating Disorder Examination Questionnaire (EDE-Q)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        100.74937438964844,
        427.927490234375,
        116.56968688964844
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "EDE-Q는 총 28개 문항으로 구성된 자가 설문지이며, 섭식장애의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        130.74937438964844,
        545.9400024414062,
        146.56968688964844
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요 병리를 측정하는 식사제한, 식사관심, 체형관심, 체중관심의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        160.74937438964844,
        546.0599975585938,
        176.56968688964844
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4개 하위요인으로 구성되어 있다. 빈도를 묻는 문항을 제외하고 지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        190.74937438964844,
        538.5599975585938,
        206.56968688964844
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "난 4주간의 증상을 0점에서 6점까지 7점 척도로 평가한다. 점수가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        220.74937438964844,
        546.0599975585938,
        236.56968688964844
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "높을수록 섭식 행동 및 태도에 문제가 있는 것을 의미한다 (Bang,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        250.74935913085938,
        546.0599975585938,
        266.5696716308594
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Han et al., 2018).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        280.7493591308594,
        203.8199920654297,
        296.5696716308594
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 연구에서는 방문 1, 방문3, 방문 5에 EDE-Q 척도 평가를 수행",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        310.7493591308594,
        538.5599975585938,
        326.5696716308594
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "할 예정이고 일차 유효성 평가는 EDE-Q로 평가할 예정이다. 측정",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        340.7493591308594,
        546.0599975585938,
        356.5696716308594
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법 및 빈도는 이하의 2차 변수에 있어 같이 적용할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        370.7493591308594,
        515.4599609375,
        386.5696716308594
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) Clinical Impairment Assessment (CIA)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        430.7493591308594,
        331.5675048828125,
        446.5696716308594
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CIA를 통해 섭식장애와 관련된 세 가지 주요 영역(개인적, 사회적,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        460.7493591308594,
        545.9400024414062,
        476.5696716308594
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인지적)에 대한 이차적인 손상정도를 평가한다. CIA는 총 16개 문항의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        490.7493591308594,
        545.9400024414062,
        506.5696716308594
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "짧은 자기보고형 평가도구로, 0점에서 3점까지 4점 척도로 평가한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        520.7493896484375,
        546.0599975585938,
        536.5697021484375
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "점수가 높을수록 섭식장애로 인한 개인적, 사회적, 인지적 손상이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        550.7493896484375,
        545.9400024414062,
        566.5697021484375
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "높은 것을 의미한다(Bohn&Fairburn, 2008).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        580.7493896484375,
        368.1229553222656,
        596.5697021484375
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) Patient health questionnaire-9 (PHQ-9)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        640.7493896484375,
        351.41998291015625,
        656.5697021484375
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PHQ-9를 통해 우울 증상을 평가한다. DSM-IV의 주요우울장애의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        670.7493896484375,
        545.9400024414062,
        686.5697021484375
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단기준에 의거하여 지난 2주간의 무쾌감, 우울감, 수면의 변화,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        700.7493286132812,
        545.9400024414062,
        716.5696411132812
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피로감, 식욕의 변화, 죄책감, 무가치감, 집중력 저하, 좌불안석 또는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        730.7493286132812,
        545.9400024414062,
        746.5696411132812
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 81 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 88,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "쳐진 느낌, 자살사고의 9가지 문항으로 구성되어 있다. 각각의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        70.74937438964844,
        546.0599975585938,
        86.56968688964844
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요소는 0점 (전혀없음)에서 3점(거의 매일)으로 구성되어 총점은",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        100.74937438964844,
        546.0599975585938,
        116.56968688964844
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "0-27점 사이가 된다. 점수가 높을수록 우울 증상이 심각하다는 것을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        130.74937438964844,
        545.9400024414062,
        146.56968688964844
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의미한다(Park,Cho et al., 2010).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        160.74937438964844,
        294.6829528808594,
        176.56968688964844
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) Generalized anxiety disorder 7-item scale (GAD-7)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        220.74937438964844,
        450.7799987792969,
        236.56968688964844
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "GAD-7은 범불안장애 환자를 선별 진단하기 위해 개발된 선별평",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        250.74935913085938,
        538.4400024414062,
        266.5696716308594
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가도구로 불안 또는 걱정과 관련된 7가지 문항에 대해 그 정도를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        280.7493591308594,
        545.9400024414062,
        296.5696716308594
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "0점 (전혀 없었다)에서 3점(거의 매일 괴로웠다.)까지 체크하여 불안",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        310.7493591308594,
        545.9400024414062,
        326.5696716308594
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증상을 평가한다. 총점은 0-21점 사이가 되며, 점수가 높을수록 불안",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        340.7493591308594,
        545.9400024414062,
        356.5696716308594
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증상의 심각도가 높고 기능저하도 심한 것을 의미한다(Kim,Park et",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        370.7493591308594,
        545.9400024414062,
        386.5696716308594
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "al., 2017)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        400.7493591308594,
        138.36749267578125,
        416.5696716308594
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) The EuroQol Visual Analogue Scale (EQ-VAS)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        460.7493591308594,
        417.6600036621094,
        476.5696716308594
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EQ-VAS는 일반적으로 사용되는 삶의 질 설문지 중 하나로, 피험자의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        490.7493591308594,
        546.0599975585938,
        506.5696716308594
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전반적인 건강 상태를 0점에서 100점 척도로 평가한다. 점수가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        520.7493896484375,
        545.9400024414062,
        536.5697021484375
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "높을수록",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        550.7493896484375,
        538.5599975585938,
        566.5697021484375
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전반적인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        550.7493896484375,
        538.5599975585938,
        566.5697021484375
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "건강",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        550.7493896484375,
        538.5599975585938,
        566.5697021484375
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상태가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        550.7493896484375,
        538.5599975585938,
        566.5697021484375
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "좋다는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        550.7493896484375,
        538.5599975585938,
        566.5697021484375
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        550.7493896484375,
        538.5599975585938,
        566.5697021484375
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의미한다",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        550.7493896484375,
        538.5599975585938,
        566.5697021484375
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Kim,Won,Kim et al., 2018)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        580.7493896484375,
        259.8074951171875,
        596.5697021484375
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) Clinical Global Impression of Improvement (CGI-I)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        640.7493896484375,
        437.8874816894531,
        656.5697021484375
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CGI-I는 피험자의 전반적인 건강상태의 개선 정도를 평가하는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        670.7493896484375,
        545.9400024414062,
        686.5697021484375
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설문지로, 4주 (방문 3), 8주 (방문 5) 시점에 평가한다. 시험자는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        700.7493286132812,
        546.0599975585938,
        716.5696411132812
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자의 건강상태의 개선 또는 악화 정도를 7점 척도로 평가하며,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        730.7493286132812,
        545.5800170898438,
        746.5696411132812
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 82 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 89,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "점수가 낮을수록 개선도가 높다는 것을 의미한다(Busner&Targum,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        70.74937438964844,
        546.0599975585938,
        86.56968688964844
      ],
      "page_num": 89,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2007).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        100.74937438964844,
        115.40296936035156,
        116.56968688964844
      ],
      "page_num": 89,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7) Clinical Global Impression of Severity (CGI-S)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        160.74937438964844,
        415.97998046875,
        176.56968688964844
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CGI-S는 피험자의 전반적인 질병 상태의 심각도를 평가하는 설문지로,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        190.74937438964844,
        546.0599975585938,
        206.56968688964844
      ],
      "page_num": 89,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "베이스라인, 4주 (방문 3), 8주 (방문 5) 시점에 평가한다. 시험자는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        220.74937438964844,
        545.9400024414062,
        236.56968688964844
      ],
      "page_num": 89,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자의 심각도 정도를 7점 척도로 평가하며, 점수가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        250.74935913085938,
        448.0799865722656,
        266.5696716308594
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "높을수록 질병 심각도가 높다는 것을 의미한다(Busner&Targum,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        280.7493591308594,
        546.0599975585938,
        296.5696716308594
      ],
      "page_num": 89,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2007).",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        310.7493591308594,
        115.40296936035156,
        326.5696716308594
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8) 기타 이차 유효성 평가변수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        370.7493591308594,
        276.6600036621094,
        386.5696716308594
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Follow-up 후 4주, 8주 시점에 폭식 횟수 0회 달성 여부 및 치료 전",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        400.7493591308594,
        545.9400024414062,
        416.5696716308594
      ],
      "page_num": 89,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대비 8주 시점의 BMI 변화를 통해 평가할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        430.7493591308594,
        410.2429504394531,
        446.5696716308594
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 83 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 90,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 통계분석방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        173.16000366210938,
        86.56968688964844
      ],
      "page_num": 90,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 분석대상군",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        100.74937438964844,
        166.3199920654297,
        116.56968688964844
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 계획서 순응 임상시험대상자군(Per-protocol Set, PPS)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        130.74937438964844,
        479.5274963378906,
        146.56968688964844
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모든 분석 대상자군(FAS)에 속한 피험자이면서 임상시험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        160.74937438964844,
        545.9400024414062,
        176.56968688964844
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일정대로 모든 수행을 완료하고, 아래의 주요한 임상시험계획",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        190.74937438964844,
        546.0599975585938,
        206.56968688964844
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위반이 없는 피험자로 정의한다. 1차/2차 유효성 평가는 계획서",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        220.74937438964844,
        545.9400024414062,
        236.56968688964844
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "순응 임상시험대상자군(PPS)를 주요분석군으로 분석한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        250.74935913085938,
        497.0029602050781,
        266.5696716308594
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 앱 불순응*으로 판단되는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        278.7900085449219,
        333.239990234375,
        296.5696716308594
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 섭식장애 관련한 약물을 복용한 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        310.7493591308594,
        381.0,
        326.5696716308594
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 정신과적 전문 치료를 시작한 것으로 판단되는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        340.7493591308594,
        485.8799743652344,
        356.5696716308594
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 임상시험 참여 중 심적/신체적 환경 변화로 있는 것으로 판",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        370.7493591308594,
        538.5599975585938,
        386.5696716308594
      ],
      "page_num": 90,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단되는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        126.0,
        400.7493591308594,
        208.55999755859375,
        416.5696716308594
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 순응도란 치료 기간 내 총 노출된 모듈 횟수를 통해 평가한다. 총",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        121.43999481201172,
        429.0,
        538.4400024414062,
        444.552001953125
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모듈 횟수 중 75% 미만(예, 총 6주의 경우 4주 미만)으로 노출된",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        134.52000427246094,
        455.0400085449219,
        538.4405517578125,
        470.5920104980469
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우 ‘불순응’으로 판단한다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        134.52000427246094,
        480.9599914550781,
        299.4552001953125,
        496.5119934082031
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 모든 분석 대상자군(Full Analysis Set, FAS)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        508.7493896484375,
        408.60748291015625,
        524.5697021484375
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "배정된 대로 분석(Intention-to-treat, ITT) 원칙을 따르며,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        538.7493896484375,
        546.0599975585938,
        554.5697021484375
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무작위배정된 모든 피험자군 중 주요한 선정기준을 위배하거나",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        568.7493896484375,
        546.0599975585938,
        584.5697021484375
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무작위배정된 후 섭식장애 개선 디지털치료기기를 로그인 하여,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        598.7493896484375,
        545.9400024414062,
        614.5697021484375
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한 번이라도 사용한 로그가 존재하지 않거나, 무작위배정 이후",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        628.7493896484375,
        546.0599975585938,
        644.5697021484375
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일차 유효성 평가자료가 전무한 경우는 제외한다. 1차/2차",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        658.7493896484375,
        546.0599975585938,
        674.5697021484375
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효성 평가는 모든 분석 대상자군(Full Analysis Set, FAS)를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        688.7493896484375,
        545.9400024414062,
        704.5697021484375
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보조분석군으로 분석한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        718.7493286132812,
        288.2029724121094,
        734.5696411132812
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 안전성 자료(Safety Set, SS)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        748.7493286132812,
        302.2875061035156,
        764.5696411132812
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 84 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 91,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "섭식장애 개선 디지털치료기기로 한 번이라도 치료를 받은",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        76.68000030517578,
        70.74937438964844,
        546.0599975585938,
        86.56968688964844
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든 피험자로 정의한다. 안전성 평가는 안전성 자료를 대상으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        100.74937438964844,
        546.0599975585938,
        116.56968688964844
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        106.55999755859375,
        130.74937438964844,
        170.60296630859375,
        146.56968688964844
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 일차 유효성 평가변수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        160.74937438964844,
        241.3199920654297,
        176.56968688964844
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 치료 전 대비 Follow-up 후 8주 시점의 식사장애 검사(EDE-Q)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        190.74937438964844,
        538.447509765625,
        206.56968688964844
      ],
      "page_num": 91,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변화에 대한 비열등성 확인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        220.74937438964844,
        302.2799987792969,
        236.56968688964844
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": 해당 시점에서의 Post-treatment 후 치료군별 기술통계량(평",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        250.74935913085938,
        538.4400024414062,
        266.5696716308594
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "균, 표준편차, 중앙값, 최소값, 최대값 등)으로 제시한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        135.95999145507812,
        280.7493591308594,
        516.6829833984375,
        296.5696716308594
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": Post-treatment 후 변화량의 군간 차이 검정은 기저치를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        310.7493591308594,
        545.9400024414062,
        326.5696716308594
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공변량으로 한 공분산분석(ANCOVA)을 적용한다. 다른 변수를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        128.75999450683594,
        340.7493591308594,
        545.9400024414062,
        356.5696716308594
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통제한 후 배정군 간 평균 변화량에 대한 양측 95% 신뢰",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        128.75999450683594,
        370.7493591308594,
        538.4400024414062,
        386.5696716308594
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구간을 제시한다. 95% 신뢰구간 상한이 비열등성 마진(2.5)을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        128.75999450683594,
        400.7493591308594,
        546.0599975585938,
        416.5696716308594
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "포함하지 않으면 통계적으로 비열등하다고 판단한다. 또한,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        128.75999450683594,
        430.7493591308594,
        546.0599975585938,
        446.5696716308594
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과에 대한 임상적 평가를 제시한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        128.75999450683594,
        460.7493591308594,
        386.0029602050781,
        476.5696716308594
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 이차 유효성 평가변수:",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        490.7493591308594,
        252.89999389648438,
        506.5696716308594
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 치료 전 대비 Follow-up 후 4주, 8주 시점의 하기 지표 변화량",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        520.7493896484375,
        538.3200073242188,
        536.5697021484375
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ": CIA, PHQ-9, GAD-7, EQ-VAS, CGI-S 지표를 통해 변화량을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        550.7493896484375,
        545.9400024414062,
        566.5697021484375
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조사한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        122.63999938964844,
        580.7493896484375,
        186.68296813964844,
        596.5697021484375
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 4주, 8주 시점의 Clinical Global Impression of Improvement",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        610.7493896484375,
        546.0599975585938,
        626.5697021484375
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(CGI-I) 평균 점수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        123.1199951171875,
        640.7493896484375,
        241.79998779296875,
        656.5697021484375
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 치료 전 대비 Follow-up 후 4주, 8주 시점의 폭식 횟수를 0회",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        670.7493896484375,
        545.9400024414062,
        686.5697021484375
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "달성한 피험자 비율",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        120.36000061035156,
        700.7493286132812,
        254.0399932861328,
        716.5696411132812
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 치료 전 대비 Follow-up 후 8주 시점의 BMI 변화",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        730.7493286132812,
        447.3599853515625,
        746.5696411132812
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 85 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 92,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4) 결측값 처리",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        70.74937438964844,
        173.87998962402344,
        86.56968688964844
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 모든 분석 대상자군(Full Analysis Set, FAS)에서 중도 탈락 등의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        100.74937438964844,
        545.9400024414062,
        116.56968688964844
      ],
      "page_num": 92,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사유로 치료 후 시점에서 발생하는 결측치는 일차/이차 유효성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        130.74937438964844,
        545.9400024414062,
        146.56968688964844
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가변수에 대해서는 마지막 관측값 선행 대체법(Last Observation",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        160.74937438964844,
        546.0599975585938,
        176.56968688964844
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Carried Forward, LOCF)으로 대치한다. 그 외 자료는 대치 처리",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        190.74937438964844,
        545.9400024414062,
        206.56968688964844
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없이 수집된 자료로 분석한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        220.74937438964844,
        320.96295166015625,
        236.56968688964844
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 이상치 처리",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        250.74935913085938,
        173.87998962402344,
        266.5696716308594
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 각 변수에 대해 이상치는 별도로 고려하지 않는다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        280.7493591308594,
        461.84295654296875,
        296.5696716308594
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) 하위 분석",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        310.7493591308594,
        158.87998962402344,
        326.5696716308594
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 일차 유효성 평가변수는 피험자의 하위집단(성별, 연령별 등)에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        340.7493591308594,
        546.0599975585938,
        356.5696716308594
      ],
      "page_num": 92,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라 차이가 있는지 탐색적으로 확인하기 위해 하위 분석을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        370.7493591308594,
        545.9400024414062,
        386.5696716308594
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        400.7493591308594,
        224.48297119140625,
        416.5696716308594
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7) 민감도분석",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        430.7493591308594,
        166.3199920654297,
        446.5696716308594
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 일차 유효성 평가 결과가 기관에 따라 차이가 있는지를 확인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        460.7493591308594,
        538.4400024414062,
        476.5696716308594
      ],
      "page_num": 92,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하기 위해 기관 및 기관과 그룹 간 상호작용을 공분산 분석",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        490.7493591308594,
        545.9400024414062,
        506.5696716308594
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모형에 포함하여 기관에 따른 군간 차이가 있는지 분석하여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        520.7493896484375,
        545.9400024414062,
        536.5697021484375
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        550.7493896484375,
        180.0829620361328,
        566.5697021484375
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 대치 처리하지 않고 결측치를 고려한 반복측정혼합모형을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        580.7493896484375,
        546.0599975585938,
        596.5697021484375
      ],
      "page_num": 92,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적용하여 주요 결과와 차이가 있는지 탐색적으로 분석하여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        610.7493896484375,
        545.9400024414062,
        626.5697021484375
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        640.7493896484375,
        232.01998901367188,
        656.5697021484375
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8) 중간 분석",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        670.7493896484375,
        158.87998962402344,
        686.5697021484375
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 본 연구는 중간 분석을 수행하지 않는다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        700.7493286132812,
        395.1229553222656,
        716.5696411132812
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 86 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 93,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "15. 부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        84.93995666503906,
        525.96044921875,
        100.89996337890625
      ],
      "page_num": 93,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상사례(의료기기이상반응, 중대한 이상반응/의료기기이상반응 포함)의 발생 시",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.91999816894531,
        136.0800018310547,
        530.6400146484375,
        150.47999572753906
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‘의료기기 임상시험 관리기준’(의료기기법 시행규칙 [별표3])에 의거, 정한 기간",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        160.0800018310547,
        530.5199584960938,
        174.47999572753906
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내에 가능한 신속한 보고가 되어야 하며, 이상반응 등에 대한 의학적 소견·",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        184.0800018310547,
        530.6520385742188,
        198.47999572753906
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정도와",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        208.0800018310547,
        530.6400146484375,
        222.47999572753906
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험용",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        208.0800018310547,
        530.6400146484375,
        222.47999572753906
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기와의",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        208.0800018310547,
        530.6400146484375,
        222.47999572753906
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인과관계를",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        208.0800018310547,
        530.6400146484375,
        222.47999572753906
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가하여",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        64.55999755859375,
        208.0800018310547,
        530.6400146484375,
        222.47999572753906
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증례기록서에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        208.0800018310547,
        530.6400146484375,
        222.47999572753906
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기록",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        64.55999755859375,
        208.0800018310547,
        530.6400146484375,
        222.47999572753906
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하여야",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        232.0800018310547,
        530.5199584960938,
        246.47999572753906
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한다. 따라서 이상반응에 대한 임상시험용 의료기기와의 인과관계에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        232.0800018310547,
        530.5199584960938,
        246.47999572753906
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 평가 기준을 제시하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        256.0799865722656,
        276.8999938964844,
        270.47998046875
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        318.1893615722656,
        111.24468231201172,
        334.0096740722656
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 피험자 안전성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        348.1893615722656,
        180.72000122070312,
        364.0096740722656
      ],
      "page_num": 93,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 임상시험은 저위험(low-risk) 치료용 의료기기의 임상적 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        378.1893615722656,
        538.4400024414062,
        394.0096740722656
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이므로 피험자가 직접적으로 받는 인체의 위해도가 없을 수도 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        408.1893615722656,
        546.0599975585938,
        424.0096740722656
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하지만, 치료 도중 피험자한테 문제(예: 낮 시간 졸음이 과도한 현상 등)가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        438.1893615722656,
        546.0599975585938,
        454.0096740722656
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발생하면 임상시험 담당 연구진에게 연락할 수 있는 긴급 연락망을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        468.1893615722656,
        546.0599975585938,
        484.0096740722656
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공하고, 디지털 기기(애플리케이션) 사용 관련한 문제(예: 버그 문제,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        498.1893615722656,
        546.0599975585938,
        514.0096435546875
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로그인 실패 등)가 발생하면 회사 측 고객센터로 연락할 수 있는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        528.1893920898438,
        545.9400024414062,
        544.0097045898438
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "별도의 연락망을 제공한다. 긴급 연락망과 방문을 통해 이상 반응을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        558.1893920898438,
        546.0599975585938,
        574.0097045898438
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수집한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        588.1893310546875,
        120.68296813964844,
        604.0096435546875
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 시험자 안전성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        648.1893310546875,
        180.72000122070312,
        664.0096435546875
      ],
      "page_num": 93,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 임상시험용 의료기기는 소프트웨어에 속하며 비침습적이며 짧은",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        678.1893310546875,
        545.9400024414062,
        694.0096435546875
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기간 동안 임상시험에 참여하기 때문에 안전에 대한 위험은 없다고",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        708.1893310546875,
        546.0599975585938,
        724.0096435546875
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        738.1893310546875,
        135.68296813964844,
        754.0096435546875
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 87 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 94,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 이상 사례의 정의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        203.1599884033203,
        86.56968688964844
      ],
      "page_num": 94,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 이상 사례(Adverse Event, AE)란 임상시험 중 피험자에게 발생한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        100.74937438964844,
        546.0599975585938,
        116.56968688964844
      ],
      "page_num": 94,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든 의도하지 않은 증후(sign), 증상(symptom) 또는 질병을 말하며,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        130.74937438964844,
        546.0599975585938,
        146.56968688964844
      ],
      "page_num": 94,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 임상시험용 의료기기와 반드시 인과관계를 가져야 하는 것은",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        160.74937438964844,
        546.0599975585938,
        176.56968688964844
      ],
      "page_num": 94,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아니다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        190.74937438964844,
        140.3629608154297,
        206.56968688964844
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 의료기기 이상 반응(Adverse Device Effect, ADE)이란 임상시험용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        220.74937438964844,
        546.0599975585938,
        236.56968688964844
      ],
      "page_num": 94,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기로 인하여 발생한 모든 유해하고 의도하지 않은 반응으로서",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.07999420166016,
        250.74935913085938,
        545.9400024414062,
        266.5696716308594
      ],
      "page_num": 94,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험용 의료기기와의 인과관계를 부정할 수 없는 경우를 말한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.07999420166016,
        280.7493591308594,
        536.2429809570312,
        296.5696716308594
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○ 의료기기의 오류(결함)로 인한 오진률 발생 가능성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        310.7493591308594,
        455.8800048828125,
        326.5696716308594
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 이상 사례의 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        361.02935791015625,
        203.1599884033203,
        376.84967041015625
      ],
      "page_num": 94,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 임상시험용 의료기기와의 인과관계 평가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        391.02935791015625,
        368.7599792480469,
        406.84967041015625
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이상 사례 발현 시 임상시험용 의료기기와의 관련성 여부는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        421.02935791015625,
        545.9400024414062,
        436.84967041015625
      ],
      "page_num": 94,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험자가 다음 기준에 의하여 평가하며, 시험자의 의견을 기술",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        94.07999420166016,
        451.02935791015625,
        538.5599975585938,
        466.84967041015625
      ],
      "page_num": 94,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        94.07999420166016,
        481.02935791015625,
        128.12295532226562,
        496.84967041015625
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○ 관련성이 명백함(Definitely related)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        511.02935791015625,
        348.24749755859375,
        526.8496704101562
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        541.0293579101562,
        546.0599975585938,
        556.8496704101562
      ],
      "page_num": 94,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "순서가 타당한 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        571.0293579101562,
        255.1199951171875,
        586.8496704101562
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 이상 반응이 다른 어떤 이유보다 임상시험용 의료기기의 사용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        601.0293579101562,
        545.9400024414062,
        616.8496704101562
      ],
      "page_num": 94,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "때문에 가장 개연성이 있게 설명되는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        631.0293579101562,
        406.0799865722656,
        646.8496704101562
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 사용 중단으로 이상 반응이 없어지는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        661.0293579101562,
        406.0799865722656,
        676.8496704101562
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 재사용(재사용이 가능한 경우에만 실시) 결과가 양성인 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        691.0293579101562,
        526.6799926757812,
        706.8496704101562
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 이상 반응이 임상시험용 의료기기 또는 동일 계열의 의료기기에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        721.0293579101562,
        545.9400024414062,
        736.8496704101562
      ],
      "page_num": 94,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해 이미 알려진 정보와 일관된 양상을 보이는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        751.0293579101562,
        480.239990234375,
        766.8496704101562
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 88 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 95,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○ 관련성이 많음(Probably related)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        70.74937438964844,
        336.8475036621094,
        86.56968688964844
      ],
      "page_num": 95,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 임상시험용 의료기기를 사용하였다는 증거가 있는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        99.30937194824219,
        495.1199951171875,
        115.12968444824219
      ],
      "page_num": 95,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        129.3093719482422,
        545.9400024414062,
        145.1296844482422
      ],
      "page_num": 95,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "타당한 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        159.3093719482422,
        196.44000244140625,
        175.1296844482422
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 이상 반응이 다른 원인보다 임상시험용 의료기기의 사용으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        189.3093719482422,
        546.0599975585938,
        205.1296844482422
      ],
      "page_num": 95,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "더욱 개연성이 있게 설명되는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        219.3093719482422,
        347.6399841308594,
        235.1296844482422
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험용 의료기기의 사용 중단으로 이상 반응이 사라지는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        249.30935668945312,
        546.0599975585938,
        265.1296691894531
      ],
      "page_num": 95,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        279.3093566894531,
        146.52000427246094,
        295.1296691894531
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○ 관련성이 의심됨(Possibly related)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        309.3093566894531,
        336.12750244140625,
        325.1296691894531
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험용 의료기기를 사용하였다는 증거가 있는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        339.3093566894531,
        495.1199951171875,
        355.1296691894531
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        369.3093566894531,
        545.9400024414062,
        385.1296691894531
      ],
      "page_num": 95,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "타당한 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        399.3093566894531,
        196.44000244140625,
        415.1296691894531
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 이상 반응이 다른 가능성이 있는 원인과 같은 수준으로 임상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        429.3093566894531,
        538.4400024414062,
        445.1296691894531
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험용 의료기기의 사용에 기인한다고 판단되는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        459.3093566894531,
        476.5199890136719,
        475.1296691894531
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험용 의료기기의 사용 중단으로(실시된 경우) 이상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        489.3093566894531,
        546.0599975585938,
        505.1296691894531
      ],
      "page_num": 95,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반응이 사라지는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        519.3093872070312,
        269.5199890136719,
        535.1296997070312
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○ 관련성이 적음(Probably not related)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        549.3093872070312,
        347.8874816894531,
        565.1296997070312
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험용 의료기기를 사용하였다는 증거가 있는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        579.3093872070312,
        495.1199951171875,
        595.1296997070312
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 이상 반응에 대해 보다 가능성 있는 원인이 있는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        609.3093872070312,
        487.67999267578125,
        625.1296997070312
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험용 의료기기의 사용 중단 결과(실시된 경우)가 음성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        639.3093872070312,
        538.5599975585938,
        655.1296997070312
      ],
      "page_num": 95,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이거나 모호한 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        669.3093872070312,
        250.3199920654297,
        685.1296997070312
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험용 의료기기의 재사용(실시된 경우) 결과가 음성이거나",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        699.3093872070312,
        546.0599975585938,
        715.1296997070312
      ],
      "page_num": 95,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모호한 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        729.3093872070312,
        196.44000244140625,
        745.1296997070312
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 89 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 96,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○ 관련성이 없음(Definitely not related)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        70.74937438964844,
        361.6875,
        86.56968688964844
      ],
      "page_num": 96,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 임상시험용 의료기기를 사용하지 않은 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        100.74937438964844,
        413.5199890136719,
        116.56968688964844
      ],
      "page_num": 96,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 임상시험용 의료기기의 사용과 이상 반응 발현과의 시간적",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        130.74937438964844,
        545.9400024414062,
        146.56968688964844
      ],
      "page_num": 96,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "순서가 타당하지 않은 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        160.74937438964844,
        302.2799987792969,
        176.56968688964844
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 이상 반응에 대해 다른 명백한 원인이 있는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        190.74937438964844,
        450.5999755859375,
        206.56968688964844
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○ 평가 불가능(Unknown)",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        81.5999984741211,
        220.74937438964844,
        272.2875061035156,
        236.56968688964844
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 정보가 불충분하거나 상충하여 판단할 수 없고 이를 보완",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        101.63999938964844,
        250.74935913085938,
        538.5599975585938,
        266.5696716308594
      ],
      "page_num": 96,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하거나 확인할 수 없는 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        116.63999938964844,
        280.7493591308594,
        309.6000061035156,
        296.5696716308594
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마. 안전성의 평가 기준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        340.7493591308594,
        218.1599884033203,
        356.5696716308594
      ],
      "page_num": 96,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 임상시험에서 이상 반응은 임상시험 시작 전에 관찰되지 않은",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        370.7493591308594,
        546.0599975585938,
        386.5696716308594
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증상이 발생하는 모든 바람직하지 않은 의학적ㆍ물리적 소견을 이상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        400.7493591308594,
        546.0599975585938,
        416.5696716308594
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반응으로 분류한다. 예측되는 부작용도 이상 반응으로 분류한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        430.7493591308594,
        499.6429443359375,
        446.5696716308594
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바. 이상 사례 보고 방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        490.7493591308594,
        225.59999084472656,
        506.5696716308594
      ],
      "page_num": 96,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 이상 사례 교육",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.5999984741211,
        520.7493896484375,
        191.27999877929688,
        536.5697021484375
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○ 시험책임자는 시험담당자 또는 임상의 등에게 임상시험용 의료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        550.7493896484375,
        538.5599975585938,
        566.5697021484375
      ],
      "page_num": 96,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기 사용 후 나타날 수 있는 모든 이상 사례에 대하여 교육을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.39999389648438,
        580.7493896484375,
        546.0599975585938,
        596.5697021484375
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고 사용 후 나타나는 모든 현상에 대하여 보고하도록 교육을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.39999389648438,
        610.7493896484375,
        545.9400024414062,
        626.5697021484375
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.39999389648438,
        640.7493896484375,
        144.44296264648438,
        656.5697021484375
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 중대한 이상 의료기기 이상 반응 보고",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        66.5999984741211,
        670.7493896484375,
        348.7200012207031,
        686.5697021484375
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※",
      "font_size": 12.960000038146973,
      "font_name": "T13",
      "bbox": [
        56.63999938964844,
        698.9999389648438,
        538.4400024414062,
        714.5519409179688
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 내용은「의료기기법 시행규칙」별표 3“의료기기 임상시험 관리기준” 제8호",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        56.63999938964844,
        698.9999389648438,
        538.4400024414062,
        714.5519409179688
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "러목(의료기기이상 반응의 보고)에 따른다.",
      "font_size": 12.960000038146973,
      "font_name": "T11",
      "bbox": [
        82.68000030517578,
        725.0399780273438,
        333.6551818847656,
        740.5919799804688
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○ 이외에도 시험자가 중대하다고 간주하거나, 임상시험용 의료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        752.829345703125,
        538.4400024414062,
        768.649658203125
      ],
      "page_num": 96,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 90 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 97,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기와의 사용과 연관 지을 수 있는 유의한 위험, 금기, 부작용,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.23999786376953,
        70.74937438964844,
        545.9400024414062,
        86.56968688964844
      ],
      "page_num": 97,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주의사항을 시사하는 사건 등도 중대한 이상 사례/의료기기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.23999786376953,
        100.74937438964844,
        546.0599975585938,
        116.56968688964844
      ],
      "page_num": 97,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상 반응으로 기록하고 사망을 초래하거나 생명을 위협할",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.23999786376953,
        130.74937438964844,
        546.0599975585938,
        146.56968688964844
      ],
      "page_num": 97,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "때는 의뢰자가 이 사실을 보고받거나 알게 된 날로부터 7일",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.23999786376953,
        160.74937438964844,
        545.9400024414062,
        176.56968688964844
      ],
      "page_num": 97,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이내, 이 경우 상세한 정보를 최초 보고일로부터 8일 이내에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.23999786376953,
        190.74937438964844,
        546.0599975585938,
        206.56968688964844
      ],
      "page_num": 97,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가로 보고 하여야 한다. 그 밖의 중대하거나 예상하지 못한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.23999786376953,
        220.74937438964844,
        545.9400024414062,
        236.56968688964844
      ],
      "page_num": 97,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든 이상 반응이 나타났을 때 의뢰자가 이 사실을 보고",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.23999786376953,
        250.74935913085938,
        545.9400024414062,
        266.5696716308594
      ],
      "page_num": 97,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "받거나 알게 된 날로부터 15일 이내 보고한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        111.23999786376953,
        280.7493591308594,
        430.1629638671875,
        296.5696716308594
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 91 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 98,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "16. 피험자 동의서 서식",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        79.29995727539062,
        238.44000244140625,
        95.25996398925781
      ],
      "page_num": 98,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험책임자는 의료기기법 시행규칙 제24조 제1항 제4호의 규정에 따라 임상",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.91999816894531,
        129.0,
        530.5199584960938,
        143.39999389648438
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화할 때, 헬싱키 선언에",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        153.0,
        530.5199584960938,
        167.39999389648438
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 서식,",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        177.0,
        530.592041015625,
        191.39999389648438
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        201.0,
        530.5800170898438,
        215.39999389648438
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행규칙",
      "font_size": 12.0,
      "font_name": "T15",
      "bbox": [
        64.55999755859375,
        225.0,
        530.6400146484375,
        239.39999389648438
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[별표 3])에서 정하고 있다. 이에 따른 피험자 동의서 서식을 제시하여야 하며, 피험자",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        249.0,
        530.6400146484375,
        263.3999938964844
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설명서에는 동 기준의 제7호 아목의 10)을 포함하여야 한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        273.0,
        404.94000244140625,
        287.3999938964844
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        334.7493591308594,
        111.24468231201172,
        350.5696716308594
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 피험자 동의서에 반드시 포함되어야 하는 사항",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        364.7493591308594,
        405.6000061035156,
        380.5696716308594
      ],
      "page_num": 98,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 임상시험의 연구목적으로 수행된다는 사실",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        394.7493591308594,
        383.7599792480469,
        410.5696716308594
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 임상시험의 목적",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        424.7493591308594,
        203.87998962402344,
        440.5696716308594
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 임상시험용 의료기기에 관한 정보 및 시험군 또는 대조군에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        454.7493591308594,
        546.0599975585938,
        470.5696716308594
      ],
      "page_num": 98,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무작위배정 될 확률",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        484.7493591308594,
        226.3199920654297,
        500.5696716308594
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 침습적 시술(invasive procedure)을 포함하여 임상시험에서 피험자가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        514.7493896484375,
        545.9400024414062,
        530.5697021484375
      ],
      "page_num": 98,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "받게 될 각종 검사나 절차",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        544.7493896484375,
        271.32000732421875,
        560.5697021484375
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 피험자가 준수하여야 할 사항",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        574.7493896484375,
        293.7599792480469,
        590.5697021484375
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) 검증되지 않은 임상시험이라는 사실",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        604.7493896484375,
        338.7599792480469,
        620.5697021484375
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7) 피험자에게 미칠 것으로 예상되는 위험이나 불편",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        634.7493896484375,
        428.7599792480469,
        650.5697021484375
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8) 기대되는 이익이 있거나 피험자에게 기대되는 이익이 없을 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        664.7493896484375,
        545.9400024414062,
        680.5697021484375
      ],
      "page_num": 98,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그 사실",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        694.7493896484375,
        143.87998962402344,
        710.5697021484375
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9) 피험자가 선택할 수 있는 다른 치료방법이나 종류 및 그 치료",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        724.7493286132812,
        545.9400024414062,
        740.5696411132812
      ],
      "page_num": 98,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법의 잠재적 위험과 이익",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        754.7493286132812,
        278.7599792480469,
        770.5696411132812
      ],
      "page_num": 98,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 92 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 99,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10) 임상시험과 관련한 손상이 발생하였을 경우 피험자에게 주어질",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        70.74937438964844,
        545.9400024414062,
        86.56968688964844
      ],
      "page_num": 99,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보상이나 치료방법",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        100.74937438964844,
        233.8199920654297,
        116.56968688964844
      ],
      "page_num": 99,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "11) 피험자가 임상시험에 참여함으로써 받게 될 금전적 보상이 있는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        130.74937438964844,
        545.9400024414062,
        146.56968688964844
      ],
      "page_num": 99,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우 예상 금액 및 이 금액이 임상시험 참여의 정도나 기간에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        160.74937438964844,
        546.0599975585938,
        176.56968688964844
      ],
      "page_num": 99,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라 조정될 것이라고 하는 것",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        190.74937438964844,
        308.7599792480469,
        206.56968688964844
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12) 임상시험에 참여함으로써 피험자에게 예상되는 비용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        220.74937438964844,
        454.91998291015625,
        236.56968688964844
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "13) 피험자의 임상시험 참여 여부 결정은 자발적이어야 하며, 피험자가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        250.74935913085938,
        545.9400024414062,
        266.5696716308594
      ],
      "page_num": 99,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원래 받을 수 있는 이익에 대한 손실 없이 임상시험의 참여를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        280.7493591308594,
        546.0599975585938,
        296.5696716308594
      ],
      "page_num": 99,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "거부하거나 임상시험 도중 언제라도 참여를 포기할 수 있다는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        310.7493591308594,
        545.9400024414062,
        326.5696716308594
      ],
      "page_num": 99,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사실",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        340.7493591308594,
        128.8800048828125,
        356.5696716308594
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14) 제8호 항목에 따른 모니터 요원, 제8호 항목에 따른 점검을 실",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        370.7493591308594,
        538.4400024414062,
        386.5696716308594
      ],
      "page_num": 99,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시하는 자, 임상시험심사위원회 및 식품의약품안전처장이 관계",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        400.7493591308594,
        546.0599975585938,
        416.5696716308594
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "법령에 따라 임상시험의 실시 절차와 자료의 품질을 검증하기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        430.7493591308594,
        545.9400024414062,
        446.5696716308594
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위하여 피험자의 신상에 관한 비밀이 보호되는 범위에서 피험자의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        460.7493591308594,
        545.9400024414062,
        476.5696716308594
      ],
      "page_num": 99,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의무기록을 열람할 수 있다는 사실과 피험자 또는 피험자 대리인의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        490.7493591308594,
        545.9400024414062,
        506.5696716308594
      ],
      "page_num": 99,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서명이 이러한 자료의 열람을 허용하게 된다는 사실",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        520.7493896484375,
        458.7599792480469,
        536.5697021484375
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15) 피험자의 신상을 파악할 수 있는 기록은 비밀로 보호될 것이며",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        550.7493896484375,
        546.0599975585938,
        566.5697021484375
      ],
      "page_num": 99,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험의 결과가 출관될 경우 피험자의 신상은 비밀로 보호",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        580.7493896484375,
        538.4400024414062,
        596.5697021484375
      ],
      "page_num": 99,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "될 것이라는 사실",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        610.7493896484375,
        218.87998962402344,
        626.5697021484375
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "16) 피험자의 임상시험 계속 참여 여부에 영향을 줄 수 있는 새로운",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        640.7493896484375,
        546.0599975585938,
        656.5697021484375
      ],
      "page_num": 99,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정보를 취득하면 적시에 피험자 또는 피험자의 대리인에게 알릴",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        670.7493896484375,
        545.9400024414062,
        686.5697021484375
      ],
      "page_num": 99,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이라는 사실",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        700.7493286132812,
        196.3199920654297,
        716.5696411132812
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "17) 임상시험과 피험자의 권익에 관하여 추가적인 정보를 얻고자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        730.7493286132812,
        545.9400024414062,
        746.5696411132812
      ],
      "page_num": 99,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 93 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 100,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하거나 임상시험과 관련이 있는 손상이 발생하면 연락해야 하는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        70.74937438964844,
        545.9400024414062,
        86.56968688964844
      ],
      "page_num": 100,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사람",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        100.74937438964844,
        128.8800048828125,
        116.56968688964844
      ],
      "page_num": 100,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "18) 임상시험 도중 피험자의 임상시험 참여가 중지되는 경우 및 그",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        130.74937438964844,
        546.0599975585938,
        146.56968688964844
      ],
      "page_num": 100,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사유",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        98.87999725341797,
        160.74937438964844,
        128.8800048828125,
        176.56968688964844
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "19) 피험자의 임상시험 예상 참여 기간",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        190.74937438964844,
        338.7599792480469,
        206.56968688964844
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20) 임상시험에 참여하는 대략의 피험자 수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        220.74937438964844,
        368.7599792480469,
        236.56968688964844
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 피험자 동의의 일반적 요건",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        280.7493591308594,
        270.5999755859375,
        296.5696716308594
      ],
      "page_num": 100,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 연구자는 연구를 시작하기 전에 임상시험심사위원회(Institutional",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        310.7493591308594,
        546.0599975585938,
        326.5696716308594
      ],
      "page_num": 100,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Review Board, IRB)로부터 피험자에게 제공될 설명서 및 동의서,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        340.7493591308594,
        546.0599975585938,
        356.5696716308594
      ],
      "page_num": 100,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기타 문서화된 정보의 사전 서면승인을 받아야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        370.7493591308594,
        455.2429504394531,
        386.5696716308594
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 연구자는 임상시험심사위원회 승인 직인이 찍힌 동의서 등을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        400.7493591308594,
        546.0599975585938,
        416.5696716308594
      ],
      "page_num": 100,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자 또는 피험자의 대리인에게 제공해야 하며, 피험자(또는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        430.7493591308594,
        545.9400024414062,
        446.5696716308594
      ],
      "page_num": 100,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대리인)와 동의를 받은 책임연구자(또는 책임연구자의 위임을 받은",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        460.7493591308594,
        546.0599975585938,
        476.5696716308594
      ],
      "page_num": 100,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자)는 동의서 서식에 서명하고, 자필로 해당 날짜를 기재하여야",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        490.7493591308594,
        545.9400024414062,
        506.5696716308594
      ],
      "page_num": 100,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        520.7493896484375,
        125.36296844482422,
        536.5697021484375
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 연구자는 서명된 동의서를 보관해야 하며, 사본을 피험자(또는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        550.7493896484375,
        545.9400024414062,
        566.5697021484375
      ],
      "page_num": 100,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대리인)에게 제공해야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        580.7493896484375,
        280.04296875,
        596.5697021484375
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 동의서를 받는 과정에서 연구자는 피험자 또는 대리인에게 강제나",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        610.7493896484375,
        546.0599975585938,
        626.5697021484375
      ],
      "page_num": 100,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부당한 영향을 미치지 않아야 하며, 피험자 또는 대리인이 연구의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        640.7493896484375,
        546.0599975585938,
        656.5697021484375
      ],
      "page_num": 100,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든 정보를 이해할 수 있는 용어 및 언어로 작성된 동의서 등을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        670.7493896484375,
        546.0599975585938,
        686.5697021484375
      ],
      "page_num": 100,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공하여 설명하고 질문에 대하여 대답한 후 충분히 생각할",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        700.7493286132812,
        546.0599975585938,
        716.5696411132812
      ],
      "page_num": 100,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기회를 제공하여 동의를 얻어야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        730.7493286132812,
        350.36297607421875,
        746.5696411132812
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 94 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 101,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5) 피험자 동의서에는 피험자 또는 대리인의 법적 권리를 포기나",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        70.74937438964844,
        546.0599975585938,
        86.56968688964844
      ],
      "page_num": 101,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제한, 연구자/의뢰자/기관 및 기관장의 과실 책임의 면제를 암시",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        100.74937438964844,
        538.4400024414062,
        116.56968688964844
      ],
      "page_num": 101,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 내용이 포함되어서는 안된다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        130.74937438964844,
        327.8029479980469,
        146.56968688964844
      ],
      "page_num": 101,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) 피험자의 동의에 영향을 줄 수 있는 새로운 연구 관련정보가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        160.74937438964844,
        545.9400024414062,
        176.56968688964844
      ],
      "page_num": 101,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수집되면 동의서 서식, 피험자 설명서 및 기타 문서화된 정보는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        190.74937438964844,
        545.9400024414062,
        206.56968688964844
      ],
      "page_num": 101,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이에 따라 수정되어야 하며, 사용 전에 반드시 위원회의 승인을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        220.74937438964844,
        545.9400024414062,
        236.56968688964844
      ],
      "page_num": 101,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "받아야 한다. 피험자의 지속적인 연구 참여 의지에 영향을 줄 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        250.74935913085938,
        545.9400024414062,
        266.5696716308594
      ],
      "page_num": 101,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구 책임자는 피험자 또는 대리인에게 즉시 알리고, 이러한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        280.7493591308594,
        545.9400024414062,
        296.5696716308594
      ],
      "page_num": 101,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고지와 관련된 모든 사항을 문서화해야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        310.7493591308594,
        402.8029479980469,
        326.5696716308594
      ],
      "page_num": 101,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7) 피험자 또는 대리인이 동의서 등을 읽을 수 없는 경우에는 공정한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        340.7493591308594,
        545.9400024414062,
        356.5696716308594
      ],
      "page_num": 101,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "입회자가 동의를 얻는 전 과정에 참석하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        370.7493591308594,
        436.52294921875,
        386.5696716308594
      ],
      "page_num": 101,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 임상시험 실시 도중 피험자 설명문 등이 변경되었을 때 재동의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        430.7493591308594,
        508.79998779296875,
        446.5696716308594
      ],
      "page_num": 101,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 실시 도중 동의서 서식이 변경되거나, 피험자에게 제공된",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        460.7493591308594,
        546.0599975585938,
        476.5696716308594
      ],
      "page_num": 101,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "문서 정보의 변경이 있는 경우에는 변경일 기준 다음 방문일에 변경",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        490.7493591308594,
        546.0599975585938,
        506.5696716308594
      ],
      "page_num": 101,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용을 피험자에게 충분히 설명하고, 시험책임자(또는 시험담당의사)와",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        520.7493896484375,
        545.9400024414062,
        536.5697021484375
      ],
      "page_num": 101,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자는 변경동의서에 서명하고 해당 날짜를 자필로 적어야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        550.7493896484375,
        518.0029296875,
        566.5697021484375
      ],
      "page_num": 101,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라. 피험자의 대리인이 피험자를 대신하여 임상시험 참여에 동의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        610.7493896484375,
        477.47998046875,
        626.5697021484375
      ],
      "page_num": 101,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자의 이해능력, 의사표현능력의 결여 등의 사유로 동의를 받을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        640.7493896484375,
        546.0599975585938,
        656.5697021484375
      ],
      "page_num": 101,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 없는 경우에는 대리인의 동의를 받을 수 있으며, 이와 같은 경우",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        670.7493896484375,
        538.4400024414062,
        686.5697021484375
      ],
      "page_num": 101,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에도 피험자는 피험자 자신이 이해할 수 있는 정도까지 임상시험에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        700.7493286132812,
        546.0599975585938,
        716.5696411132812
      ],
      "page_num": 101,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관한 정보를 제공 받아야하며, 가능하다면 피험자는 동의서 서식에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        730.7493286132812,
        545.9400024414062,
        746.5696411132812
      ],
      "page_num": 101,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 95 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 102,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서명하고 자필로 날짜를 기재하여야 한다. 또한, 피험자의 대리인임을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        545.9400024414062,
        86.56968688964844
      ],
      "page_num": 102,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인할 수 있는 근거자료 등을 확보하고, 피험자 동의 설명서 등에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        100.74937438964844,
        546.0599975585938,
        116.56968688964844
      ],
      "page_num": 102,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대리인의 동의 사유를 구체적으로 기술할 것을 권장한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        130.74937438964844,
        450.5629577636719,
        146.56968688964844
      ],
      "page_num": 102,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 96 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 103,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "17. 피해자 보상에 대한 규약",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        84.93995666503906,
        278.5196838378906,
        100.89996337890625
      ],
      "page_num": 103,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료 방법 등을 제공",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.43999481201172,
        150.1199951171875,
        530.8800048828125,
        164.51998901367188
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하는 원칙과 절차를 수립하여 제시한다. 피해자 보상에 대한 규약에는 보상원칙과 보상이",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        174.1199951171875,
        530.8800048828125,
        188.51998901367188
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        198.1199951171875,
        425.4599914550781,
        212.51998901367188
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        274.3893737792969,
        111.24468231201172,
        290.2096862792969
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험용 의료기기가 직접적 원인이 되어 피험자에게 손상이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        304.3893737792969,
        546.0599975585938,
        320.2096862792969
      ],
      "page_num": 103,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발생하여 응급조치가 필요한 경우 시험책임자가 가입한 보험에 의해",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        334.3893737792969,
        546.0599975585938,
        350.2096862792969
      ],
      "page_num": 103,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보상한다. 본 임상시험과 관련이 없는 부작용이 발생한 경우에도 해당",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        364.3893737792969,
        545.9400024414062,
        380.2096862792969
      ],
      "page_num": 103,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과와의 긴밀한 협조를 통하여 신속한 검사와 처치를 시행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        394.3893737792969,
        488.0029602050781,
        410.2096862792969
      ],
      "page_num": 103,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예상된 의료기기 이상반응에 대하여 당사자들 간에 미리 합의한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        424.3893737792969,
        546.0599975585938,
        440.2096862792969
      ],
      "page_num": 103,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보상액 또는 조치가 있는 경우, 당해 기준에 따라 이를 보상한다. 그",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        454.3893737792969,
        546.0599975585938,
        470.2096862792969
      ],
      "page_num": 103,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "외의 경우에는 신체손상의 정도, 성격, 지속기간, 유사사례 등을 종합적",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        484.3893737792969,
        538.4400024414062,
        500.2096862792969
      ],
      "page_num": 103,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 고려하여 당사자들 간에 합의한 보상방법에 따라 이를 보상한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        514.3893432617188,
        546.0599975585938,
        530.2096557617188
      ],
      "page_num": 103,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "당사자들 간에 전항의 합의가 이루어지지 아니한 경우에는, 법원의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        544.3893432617188,
        545.9400024414062,
        560.2096557617188
      ],
      "page_num": 103,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "판결 및 이에 준하는 결정의 확정내용에 따라 보상한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        574.3893432617188,
        443.0029602050781,
        590.2096557617188
      ],
      "page_num": 103,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 97 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 104,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "18. 임상시험 후 피험자의 진료에 관한 사항",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        84.93995666503906,
        390.47998046875,
        100.89996337890625
      ],
      "page_num": 104,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상반응 등에 대하여 임상",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.79999542236328,
        137.16000366210938,
        530.8800048828125,
        151.55999755859375
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        161.16000366210938,
        530.8800048828125,
        175.55999755859375
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하는 원칙과 절차를 수립하여 제시한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        185.1599884033203,
        287.82000732421875,
        199.5599822998047
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        248.349365234375,
        111.24468231201172,
        264.169677734375
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 OO병원",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        278.349365234375,
        538.4400024414062,
        294.169677734375
      ],
      "page_num": 104,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에서 진행하던 치료절차가 임상시험 참여 전과 다름없이 진행되며,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        308.349365234375,
        545.9400024414062,
        324.169677734375
      ],
      "page_num": 104,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이후의 치료비는 피험자가 지불하여야 한다. 다만, 부작용 발생 시",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        338.349365234375,
        545.9400024414062,
        354.169677734375
      ],
      "page_num": 104,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험에 사용된 의료기기와의 인과관계 유무를 확인한 후, 본",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        368.349365234375,
        546.0599975585938,
        384.169677734375
      ],
      "page_num": 104,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험에 사용된 의료기기로 인하여 부작용이 발생한 경우 ㈜OOO",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        398.349365234375,
        538.482666015625,
        414.169677734375
      ],
      "page_num": 104,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에서 치료에 관한 부작용이 소실될 때까지 치료비를 지불한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        428.349365234375,
        488.0029602050781,
        444.169677734375
      ],
      "page_num": 104,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 98 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 105,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "19. 피험자의 안전보호에 대한 대책",
      "font_size": 15.960000038146973,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        79.29995727539062,
        326.5196838378906,
        95.25996398925781
      ],
      "page_num": 105,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 및",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.08000183105469,
        133.3199920654297,
        533.760009765625,
        147.71998596191406
      ],
      "page_num": 105,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시한다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        157.3199920654297,
        410.6999816894531,
        171.71998596191406
      ],
      "page_num": 105,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        218.349365234375,
        111.24468231201172,
        234.169677734375
      ],
      "page_num": 105,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 임상시험 실시기관",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        248.349365234375,
        210.72000122070312,
        264.169677734375
      ],
      "page_num": 105,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 실시기관의 장은 해당 임상시험의 실시에 필요한 임상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        278.349365234375,
        538.5599975585938,
        294.169677734375
      ],
      "page_num": 105,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험실, 설비와 전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        308.349365234375,
        546.0599975585938,
        324.169677734375
      ],
      "page_num": 105,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "취할 수 있도록 하는 등 해당 임상시험을 적절하게 실시할 수 있도록",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        338.349365234375,
        545.9400024414062,
        354.169677734375
      ],
      "page_num": 105,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        368.349365234375,
        143.1229705810547,
        384.169677734375
      ],
      "page_num": 105,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 임상시험심사위원회",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        428.349365234375,
        218.1599884033203,
        444.169677734375
      ],
      "page_num": 105,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 임상시험심사위원회는 국내 법규/관례에 따라 구성되어 있어야",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        458.349365234375,
        546.0599975585938,
        474.169677734375
      ],
      "page_num": 105,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다. 임상시험심사위원회는 피험자의 권리, 안전, 복지를 보호해야",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        488.349365234375,
        545.9400024414062,
        504.169677734375
      ],
      "page_num": 105,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        518.349365234375,
        546.0599975585938,
        534.169677734375
      ],
      "page_num": 105,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그 이유의 타당성을 면밀히 검토하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        548.349365234375,
        402.8029479980469,
        564.169677734375
      ],
      "page_num": 105,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        578.349365234375,
        538.4400024414062,
        594.169677734375
      ],
      "page_num": 105,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동의가 적절하게 얻어지지 않았거나 임상시험이 임상시험계획서에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        608.349365234375,
        545.9400024414062,
        624.169677734375
      ],
      "page_num": 105,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라 진행되지 않은 경우 또는 중대한 이상반응/의료기기 이상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        638.349365234375,
        538.4400024414062,
        654.169677734375
      ],
      "page_num": 105,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반응이 나타난 경우에는 임상시험의 일부 또는 전부에 대하여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        668.349365234375,
        546.0599975585938,
        684.169677734375
      ],
      "page_num": 105,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중지 명령 등 필요한 조치를 시험책임자에게 하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        698.349365234375,
        492.8029479980469,
        714.169677734375
      ],
      "page_num": 105,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 99 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        280.55999755859375,
        789.4503784179688,
        314.625,
        799.4103393554688
      ],
      "page_num": 106,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 시험자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        128.16000366210938,
        86.56968688964844
      ],
      "page_num": 106,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 시험자(Investigator)란 시험책임자, 시험담당자, 임상시험조정자를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        100.74937438964844,
        546.0599975585938,
        116.56968688964844
      ],
      "page_num": 106,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "말한다. 시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        130.74937438964844,
        538.4400024414062,
        146.56968688964844
      ],
      "page_num": 106,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품의약품 안전청장의 승인을 득한 임상시험 계획서를 준수하여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        160.74937438964844,
        546.0599975585938,
        176.56968688964844
      ],
      "page_num": 106,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험을 실시하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        190.74937438964844,
        290.36297607421875,
        206.56968688964844
      ],
      "page_num": 106,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        220.74937438964844,
        546.0599975585938,
        236.56968688964844
      ],
      "page_num": 106,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 시험실적 검사치의 이상을 포함하여 임상시험에서 발생한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        250.74935913085938,
        546.0599975585938,
        266.5696716308594
      ],
      "page_num": 106,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모든 이상반응에 대해 피험자가 적절한 의학적 처치를 받을 수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        280.7493591308594,
        546.0599975585938,
        296.5696716308594
      ],
      "page_num": 106,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있도록 조치하여야 하고, 시험자가 알게 된 피험자의 병발질환에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        310.7493591308594,
        546.0599975585938,
        326.5696716308594
      ],
      "page_num": 106,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해 의학적 처치가 필요한 경우 이를 피험자에게 알려주어야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        340.7493591308594,
        536.8429565429688,
        356.5696716308594
      ],
      "page_num": 106,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        370.7493591308594,
        546.0599975585938,
        386.5696716308594
      ],
      "page_num": 106,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "문제점을 적극적으로 대응한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        400.7493591308594,
        305.36297607421875,
        416.5696716308594
      ],
      "page_num": 106,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 의뢰자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        460.7493591308594,
        128.16000366210938,
        476.5696716308594
      ],
      "page_num": 106,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        490.7493591308594,
        545.9400024414062,
        506.5696716308594
      ],
      "page_num": 106,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통상의료기기 임상시험의 경우 의료기기 제조업자(수입자를 포함",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        520.7493896484375,
        538.5599975585938,
        536.5697021484375
      ],
      "page_num": 106,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다)를 말한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        550.7493896484375,
        197.60296630859375,
        566.5697021484375
      ],
      "page_num": 106,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        580.7493896484375,
        538.5599975585938,
        596.5697021484375
      ],
      "page_num": 106,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험계획서의 절차에 따라 이루어지도록 하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        610.7493896484375,
        462.8029479980469,
        626.5697021484375
      ],
      "page_num": 106,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        640.7493896484375,
        545.9400024414062,
        656.5697021484375
      ],
      "page_num": 106,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험의 종류와 복잡성, 피험자에게 미칠 수 있는 잠재적인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        670.7493896484375,
        545.9400024414062,
        686.5697021484375
      ],
      "page_num": 106,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위험의 정도 및 이미 확인된 임상시험 실시상의 문제점 등에 따라",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        700.7493286132812,
        545.9400024414062,
        716.5696411132812
      ],
      "page_num": 106,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결정되어야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        730.7493286132812,
        207.92295837402344,
        746.5696411132812
      ],
      "page_num": 106,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 100 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        789.4503784179688,
        317.5050048828125,
        799.4103393554688
      ],
      "page_num": 107,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마. 모니터링",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        143.16000366210938,
        86.56968688964844
      ],
      "page_num": 107,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 모니터링(Monitoring)이란 임상시험 진행 과정을 감독하고, 해당",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        100.74937438964844,
        545.9400024414062,
        116.56968688964844
      ],
      "page_num": 107,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험이 임상시험계획서, 표준작업지침서, 임상시험 실시 기준",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        130.74937438964844,
        545.9400024414062,
        146.56968688964844
      ],
      "page_num": 107,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 관련 규정에 따라 실시, 기록되는지 여부를 검토, 확인하는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        160.74937438964844,
        545.9400024414062,
        176.56968688964844
      ],
      "page_num": 107,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활동을 말한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        190.74937438964844,
        192.92295837402344,
        206.56968688964844
      ],
      "page_num": 107,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 임상시험에 대한 모니터링은 임상시험모니터요원의 정기적인",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        220.74937438964844,
        546.0599975585938,
        236.56968688964844
      ],
      "page_num": 107,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 실시기관 방문과 전화 등을 통해서 이루어질 것이다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        250.74935913085938,
        545.9400024414062,
        266.5696716308594
      ],
      "page_num": 107,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방문 시 모니터는 환자기록 원본, 임상시험용 의료기기 관리 기록,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        280.7493591308594,
        546.0599975585938,
        296.5696716308594
      ],
      "page_num": 107,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자료보관(연구파일) 등을 확인한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        310.7493591308594,
        329.72296142578125,
        326.5696716308594
      ],
      "page_num": 107,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 또한 임상시험모니터 요원은 임상시험 진행과정을 잘 살피고,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        340.7493591308594,
        546.0599975585938,
        356.5696716308594
      ],
      "page_num": 107,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "문제가 있을 경우 시험자와 상의한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        370.7493591308594,
        350.36297607421875,
        386.5696716308594
      ],
      "page_num": 107,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바. 임상시험계획서의 변경",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        430.7493591308594,
        240.72000122070312,
        446.5696716308594
      ],
      "page_num": 107,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장으로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        460.7493591308594,
        538.5599975585938,
        476.5696716308594
      ],
      "page_num": 107,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부터 승인받은 후, 시험절차가 광범위해지거나 위험도가 높아지",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        490.7493591308594,
        538.4400024414062,
        506.5696716308594
      ],
      "page_num": 107,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "거나 피험자 선정기준에 변화가 있거나 추가적인 안전성 정보로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        520.7493896484375,
        545.9400024414062,
        536.5697021484375
      ],
      "page_num": 107,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인해 임사시험계획서를 변경하는 경우에는 임상시험심사위원회",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        550.7493896484375,
        546.0599975585938,
        566.5697021484375
      ],
      "page_num": 107,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 식품의약품안전처장의 승인을 받아야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        580.7493896484375,
        410.3629455566406,
        596.5697021484375
      ],
      "page_num": 107,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        610.7493896484375,
        546.0599975585938,
        626.5697021484375
      ],
      "page_num": 107,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등을 기록하여 보관하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        640.7493896484375,
        312.8029479980469,
        656.5697021484375
      ],
      "page_num": 107,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        670.7493896484375,
        545.9400024414062,
        686.5697021484375
      ],
      "page_num": 107,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우를 제외하고는, 임상시험심사위원회 및 식품의약품안전처장의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        700.7493286132812,
        546.0599975585938,
        716.5696411132812
      ],
      "page_num": 107,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변경 승인 이전에는 계획서와 다르게 임상시험을 실시하여서는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        730.7493286132812,
        546.0599975585938,
        746.5696411132812
      ],
      "page_num": 107,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 101 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        789.4503784179688,
        317.5050048828125,
        799.4103393554688
      ],
      "page_num": 108,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안 된다. 만일 피험자에게 발생한 즉각적 위험요소를 제거하기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        70.74937438964844,
        545.9400024414062,
        86.56968688964844
      ],
      "page_num": 108,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        100.74937438964844,
        538.5599975585938,
        116.56968688964844
      ],
      "page_num": 108,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        130.74937438964844,
        545.9400024414062,
        146.56968688964844
      ],
      "page_num": 108,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대하여 임상시험심사위원회(사후검토 승인을 위함), 의뢰자, 식품",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        160.74937438964844,
        538.4400024414062,
        176.56968688964844
      ],
      "page_num": 108,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품안전처장에게 제출하여야 한다. 그리고 임상시험심사위원회",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        190.74937438964844,
        546.0599975585938,
        206.56968688964844
      ],
      "page_num": 108,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위원장이나 간사가 승인한 문서를 의뢰자에게 보내야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        220.74937438964844,
        500.2429504394531,
        236.56968688964844
      ],
      "page_num": 108,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        250.74935913085938,
        546.0599975585938,
        266.5696716308594
      ],
      "page_num": 108,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반드시 필요한 것은 아니며 행정상 변경이 필요하다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        280.7493591308594,
        455.2429504394531,
        296.5696716308594
      ],
      "page_num": 108,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사. 피험자 동의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        340.7493591308594,
        165.72000122070312,
        356.5696716308594
      ],
      "page_num": 108,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 피험자 동의(Informed consent)라 함은 피험자가 임상시험 참여",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        370.7493591308594,
        546.0599975585938,
        386.5696716308594
      ],
      "page_num": 108,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유무를 결정하기 전에 피험자를 위한 설명서를 통해 해당 임상",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        400.7493591308594,
        538.5599975585938,
        416.5696716308594
      ],
      "page_num": 108,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험과 관련된 모든 정보를 제공받고, 서명과 서명 날짜가 포함된",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        430.7493591308594,
        546.0599975585938,
        446.5696716308594
      ],
      "page_num": 108,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "문서를 통해 본인이 자발적으로 임상시험에 참여함을 확인하는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        460.7493591308594,
        546.0599975585938,
        476.5696716308594
      ],
      "page_num": 108,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "절차를 말한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        490.7493591308594,
        192.92295837402344,
        506.5696716308594
      ],
      "page_num": 108,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 피험자 본인 또는 대리인이 동의서 서식, 피험자 설명서 및 기타",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        520.7493896484375,
        546.0599975585938,
        536.5697021484375
      ],
      "page_num": 108,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "문서화된 정보를 읽을 수 없는 경우에는 공정한 입회자가 동의를",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        550.7493896484375,
        545.9400024414062,
        566.5697021484375
      ],
      "page_num": 108,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "얻는 전 과정에 참석하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        580.7493896484375,
        320.36297607421875,
        596.5697021484375
      ],
      "page_num": 108,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        610.7493896484375,
        546.0599975585938,
        626.5697021484375
      ],
      "page_num": 108,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세부 사항에 대해 질문하고 해당 임상시험의 참여 여부를 결정",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        640.7493896484375,
        538.5599975585938,
        656.5697021484375
      ],
      "page_num": 108,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "할 수 있도록 충분한 시간과 기회를 주어야 하며, 모든 임상시험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        670.7493896484375,
        546.0599975585938,
        686.5697021484375
      ],
      "page_num": 108,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련 질문에 대해 피험자 또는 대리인이 만족할 수 있도록 대답",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        700.7493286132812,
        538.5599975585938,
        716.5696411132812
      ],
      "page_num": 108,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해주어야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        730.7493286132812,
        192.92295837402344,
        746.5696411132812
      ],
      "page_num": 108,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 102 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        789.4503784179688,
        317.5050048828125,
        799.4103393554688
      ],
      "page_num": 109,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아. 피험자 기록의 비밀보장",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        248.1599884033203,
        86.56968688964844
      ],
      "page_num": 109,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        100.74937438964844,
        545.9400024414062,
        116.56968688964844
      ],
      "page_num": 109,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험의 결과가 출관 될 경우에도 피험자의 신원을 비밀상태로",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        130.74937438964844,
        546.0599975585938,
        146.56968688964844
      ],
      "page_num": 109,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유지한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        160.74937438964844,
        155.3629608154297,
        176.56968688964844
      ],
      "page_num": 109,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        190.74937438964844,
        546.0599975585938,
        206.56968688964844
      ],
      "page_num": 109,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모니터링과 점검 및 진행사항 관리를 위한 목적으로 피험자의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        220.74937438964844,
        546.0599975585938,
        236.56968688964844
      ],
      "page_num": 109,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기록을 열람할 수 있다. 시험자는 본 임상시험 계획서에 서명함",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        250.74935913085938,
        538.4400024414062,
        266.5696716308594
      ],
      "page_num": 109,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로써, 국내의 법규와 윤리적 측면에서 임상시험 의뢰자 또는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        280.7493591308594,
        545.9400024414062,
        296.5696716308594
      ],
      "page_num": 109,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모니터 및 점검자가 피험자의 차트와 증례기록서 기록을 검증하기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        310.7493591308594,
        545.9400024414062,
        326.5696716308594
      ],
      "page_num": 109,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        340.7493591308594,
        545.9400024414062,
        356.5696716308594
      ],
      "page_num": 109,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한 정보들은 기밀로 보관되어야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        370.7493591308594,
        380.3629455566406,
        386.5696716308594
      ],
      "page_num": 109,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 증례기록서 등 임상시험에 관련된 모든 서류에는 피험자 이름이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        400.7493591308594,
        545.9400024414062,
        416.5696716308594
      ],
      "page_num": 109,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아닌 피험자 식별코드(일반적으로 피험자 이니셜)로 기록하고",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        430.7493591308594,
        546.0599975585938,
        446.5696716308594
      ],
      "page_num": 109,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구분한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        460.7493591308594,
        155.3629608154297,
        476.5696716308594
      ],
      "page_num": 109,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자. 기록의 보존",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        520.7493896484375,
        165.72000122070312,
        536.5697021484375
      ],
      "page_num": 109,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        550.7493896484375,
        538.5599975585938,
        566.5697021484375
      ],
      "page_num": 109,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여야 하며 보안을 유지하도록 한다. 제조허가/수입허가 또는 그",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        580.7493896484375,
        545.9400024414062,
        596.5697021484375
      ],
      "page_num": 109,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변경 허가를 위한 임상시험 관련 자료는 허가일로부터 3년간",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        610.7493896484375,
        545.9400024414062,
        626.5697021484375
      ],
      "page_num": 109,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보존하도록 하고, 그 밖의 임상시험 관련 자료는 임상시험이 끝난",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        640.7493896484375,
        546.0599975585938,
        656.5697021484375
      ],
      "page_num": 109,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "날부터 3년간 보존하도록 한다. 다만, 식품의약품안전처장이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        670.7493896484375,
        545.9400024414062,
        686.5697021484375
      ],
      "page_num": 109,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        700.7493286132812,
        545.9400024414062,
        716.5696411132812
      ],
      "page_num": 109,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연장할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        730.7493286132812,
        200.3629608154297,
        746.5696411132812
      ],
      "page_num": 109,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 103 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        789.4503784179688,
        317.5050048828125,
        799.4103393554688
      ],
      "page_num": 110,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "20. 그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항",
      "font_size": 15.0,
      "font_name": "H2hdrM",
      "bbox": [
        64.55999755859375,
        79.29995727539062,
        523.3199462890625,
        95.25996398925781
      ],
      "page_num": 110,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례기록서",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        76.19999694824219,
        130.67999267578125,
        530.8800048828125,
        145.07998657226562
      ],
      "page_num": 110,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험책임자의 이력",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        154.67999267578125,
        530.8800048828125,
        169.07998657226562
      ],
      "page_num": 110,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 의료기기의 공급과",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        178.67999267578125,
        530.8800048828125,
        193.07998657226562
      ],
      "page_num": 110,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "취급에 관한 사항을 추가로 확보할 수 있다.",
      "font_size": 12.0,
      "font_name": "T11",
      "bbox": [
        64.55999755859375,
        202.67999267578125,
        300.17999267578125,
        217.07998657226562
      ],
      "page_num": 110,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[예시]",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        262.02935791015625,
        96.24468231201172,
        277.84967041015625
      ],
      "page_num": 110,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 자료 처리",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        292.02935791015625,
        150.72000122070312,
        307.84967041015625
      ],
      "page_num": 110,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 근거 자료/문서의 직접 열람",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        322.02935791015625,
        283.44000244140625,
        337.84967041015625
      ],
      "page_num": 110,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 임상시험에 관련된 모니터 및 점검자는 본 임상시험의 모니",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        352.02935791015625,
        538.4400024414062,
        367.84967041015625
      ],
      "page_num": 110,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "터링과 점검 및 진행사항 관리를 위한 목적으로 대상자의 기록을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        382.02935791015625,
        546.0599975585938,
        397.84967041015625
      ],
      "page_num": 110,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "열람할 수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        412.02935791015625,
        195.56295776367188,
        427.84967041015625
      ],
      "page_num": 110,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 증례기록서의 작성",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        442.02935791015625,
        218.87998962402344,
        457.84967041015625
      ],
      "page_num": 110,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험용 의료기기와 연관된 유의한 위험, 금기, 부작용, 주의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        472.02935791015625,
        545.9400024414062,
        487.84967041015625
      ],
      "page_num": 110,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항을 시사하는 사건 등을 포함하며, 발생시간, 정도, 처치, 경과,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        502.02935791015625,
        546.0599975585938,
        517.8496704101562
      ],
      "page_num": 110,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험용 의료기기와의 인과관계 등에 대한 정보를 증례기록서에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        532.0293579101562,
        546.0599975585938,
        547.8496704101562
      ],
      "page_num": 110,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기록한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.63999938964844,
        562.0293579101562,
        150.68296813964844,
        577.8496704101562
      ],
      "page_num": 110,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 법규준수",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        622.0293579101562,
        143.16000366210938,
        637.8496704101562
      ],
      "page_num": 110,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험자는 서명록에 서명함으로써, 본 임상시험계획서, 의료기기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        652.0293579101562,
        545.9400024414062,
        667.8496704101562
      ],
      "page_num": 110,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 관리기준, 국내의 모든 관련 법규와 임상시험 수행에 관련",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        682.0293579101562,
        538.4400024414062,
        697.8496704101562
      ],
      "page_num": 110,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "된 규칙 및 규정에 따라서 효과적이고 성실하게 연구를 수행할 것에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        712.0293579101562,
        546.0599975585938,
        727.8496704101562
      ],
      "page_num": 110,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동의하게 된다. 임상시험 담당자 및 참여 연구진은 임상시험계획을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        742.0293579101562,
        545.9400024414062,
        757.8496704101562
      ],
      "page_num": 110,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 104 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        789.4503784179688,
        317.5050048828125,
        799.4103393554688
      ],
      "page_num": 111,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정확히 분석, 숙지하도록 하며 시험책임자는 예기치 않은 이상반응",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        545.9400024414062,
        86.56968688964844
      ],
      "page_num": 111,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등의 출현에 대한 충분한 대처와 필요에 따른 보고, 시험참여 연구진에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        100.74937438964844,
        546.0599975585938,
        116.56968688964844
      ],
      "page_num": 111,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 충분한 교육 등 사전조치를 취한다. 임상시험의 진행은 의료기기",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        130.74937438964844,
        538.4400024414062,
        146.56968688964844
      ],
      "page_num": 111,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 관리 기준에 합당하게 진행한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        160.74937438964844,
        345.5629577636719,
        176.56968688964844
      ],
      "page_num": 111,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 임상시험 자료의 보관 및 열람",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        220.74937438964844,
        293.1600036621094,
        236.56968688964844
      ],
      "page_num": 111,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 자료는 기밀로 보관되고 열람은 본 임상시험의 모니터링",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        250.74935913085938,
        538.5599975585938,
        266.5696716308594
      ],
      "page_num": 111,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과 점검 및 진행 사항 관리를 위한 목적으로 대상자의 기록을 열람할",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        280.7493591308594,
        545.9400024414062,
        296.5696716308594
      ],
      "page_num": 111,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        310.7493591308594,
        113.12296295166016,
        326.5696716308594
      ],
      "page_num": 111,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라. 점검 및 실태조사",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        370.7493591308594,
        203.1599884033203,
        386.5696716308594
      ],
      "page_num": 111,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험의 중요도, 대상자 수, 임상시험의 종류와 복잡성, 대상자",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        400.7493591308594,
        538.5599975585938,
        416.5696716308594
      ],
      "page_num": 111,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        430.7493591308594,
        545.9400024414062,
        446.5696716308594
      ],
      "page_num": 111,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실시상의 문제점 등에 따라 결정된다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        460.7493591308594,
        315.5629577636719,
        476.5696716308594
      ],
      "page_num": 111,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마. 임상시험용 의료기기의 사용 및 관리",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        520.7493896484375,
        338.1600036621094,
        536.5697021484375
      ],
      "page_num": 111,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        550.7493896484375,
        546.0599975585938,
        566.5697021484375
      ],
      "page_num": 111,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리한다. 임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급,",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        580.7493896484375,
        546.0599975585938,
        596.5697021484375
      ],
      "page_num": 111,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "저장하며 “임상시험용”이라는 문구가 있어야 한다. 임상시험용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        610.7493896484375,
        545.9400024414062,
        626.5697021484375
      ],
      "page_num": 111,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기 관리자는 임상시험에 사용되는 의료기기에 대해 인수, 재고",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        640.7493896484375,
        538.5599975585938,
        656.5697021484375
      ],
      "page_num": 111,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리, 반납 등의 업무를 수행하고 관련 기록을 유지하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        670.7493896484375,
        499.52294921875,
        686.5697021484375
      ],
      "page_num": 111,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 105 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        789.4503784179688,
        317.5050048828125,
        799.4103393554688
      ],
      "page_num": 112,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바. 임상시험용 의료기기의 공급과 취급",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.63999938964844,
        70.74937438964844,
        330.6000061035156,
        86.56968688964844
      ],
      "page_num": 112,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 의뢰자는 임상시험계획서에 대한 심사위원회와 청장의 승인을",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        100.74937438964844,
        545.9400024414062,
        116.56968688964844
      ],
      "page_num": 112,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        130.74937438964844,
        545.9400024414062,
        146.56968688964844
      ],
      "page_num": 112,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아니 된다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        160.74937438964844,
        162.92295837402344,
        176.56968688964844
      ],
      "page_num": 112,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 의뢰자는 관리자 등이 임상시험용 의료기기를 취급하고 보관하는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        190.74937438964844,
        546.0599975585938,
        206.56968688964844
      ],
      "page_num": 112,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법에 대해 문서화된 절차를 가지고 있어야 하며, 이 절차에는",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        220.74937438964844,
        545.9400024414062,
        236.56968688964844
      ],
      "page_num": 112,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절하고 안전한 수, 취급, 보관, 미사용 임상시험용 의료기기의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        250.74935913085938,
        546.0599975585938,
        266.5696716308594
      ],
      "page_num": 112,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자로부터의 반납 및 의뢰자에 대한 반납 등에 대한 방법이",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        280.7493591308594,
        546.0599975585938,
        296.5696716308594
      ],
      "page_num": 112,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함된다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        310.7493591308594,
        155.3629608154297,
        326.5696716308594
      ],
      "page_num": 112,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        340.7493591308594,
        546.0599975585938,
        356.5696716308594
      ],
      "page_num": 112,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        370.7493591308594,
        546.0599975585938,
        386.5696716308594
      ],
      "page_num": 112,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관한 기록을 유지하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        400.7493591308594,
        297.8029479980469,
        416.5696716308594
      ],
      "page_num": 112,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        71.63999938964844,
        430.7493591308594,
        546.0599975585938,
        446.5696716308594
      ],
      "page_num": 112,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험의 종료 또는 사용기간의 만료 등에 의한 임상시험용",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        460.7493591308594,
        546.0599975585938,
        476.5696716308594
      ],
      "page_num": 112,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기의 회수체계를 확립하고 이를 문서화하여야 한다.",
      "font_size": 15.0,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        91.31999969482422,
        490.7493591308594,
        492.8029479980469,
        506.5696716308594
      ],
      "page_num": 112,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 106 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        789.4503784179688,
        317.5050048828125,
        799.4103393554688
      ],
      "page_num": 113,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅳ",
      "font_size": 20.03999900817871,
      "font_name": "T9",
      "bbox": [
        68.4000015258789,
        82.91999816894531,
        198.35975646972656,
        106.96800231933594
      ],
      "page_num": 113,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참고문헌",
      "font_size": 20.03999900817871,
      "font_name": "H2hdrM",
      "bbox": [
        68.4000015258789,
        82.91999816894531,
        198.35975646972656,
        106.96800231933594
      ],
      "page_num": 113,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 박용우. (2000). 섭식장애. 가정의학회지, 21(3), 315-324.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        131.13034057617188,
        341.78857421875,
        141.09034729003906
      ],
      "page_num": 113,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. Neumark-Sztainer D., Hannan PJ. (2000). Weight-related behaviors among adolescent girls a",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        147.21034240722656,
        538.438232421875,
        157.17034912109375
      ],
      "page_num": 113,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "nd boys: results from a national survey. Arch Pediatr Adolesc Med, 154(6), 569-77.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        70.79999542236328,
        163.17034912109375,
        493.94866943359375,
        173.13035583496094
      ],
      "page_num": 113,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. Whitehouse, A. M., Cooper, P. J., Vize, C. V., Hill, C., & Vogel, L. (1992). Prevalence of eat",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        179.13034057617188,
        538.5394897460938,
        189.09034729003906
      ],
      "page_num": 113,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ing disorders in three Cambridge general practices: hidden and conspicuous morbidity. The",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        70.68000030517578,
        195.21034240722656,
        541.7566528320312,
        205.17034912109375
      ],
      "page_num": 113,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "British journal of general practice : the journal of the Royal College of General Practitioner",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        70.68000030517578,
        211.17034912109375,
        538.378173828125,
        221.13035583496094
      ],
      "page_num": 113,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "s, 42(355), 57–60.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        70.68000030517578,
        227.13034057617188,
        164.1169891357422,
        237.09034729003906
      ],
      "page_num": 113,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. Youl-Ri Kim. (2018). Medical complications and management of eating disorders. J Korean M",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        243.21034240722656,
        538.4695434570312,
        253.17034912109375
      ],
      "page_num": 113,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ed Assoc 61(3), 191-197.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        70.55999755859375,
        259.17034912109375,
        199.34860229492188,
        269.1303405761719
      ],
      "page_num": 113,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5. Auger, N., Potter, B. J., Ukah, U. V., Low, N., Israël, M., Steiger, H., Healy-Profitós, J., & P",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        275.1303405761719,
        538.4767456054688,
        285.09033203125
      ],
      "page_num": 113,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "aradis, G. (2021). Anorexia nervosa and the long-term risk of mortality in women. World ps",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        70.68000030517578,
        291.2103271484375,
        538.4544067382812,
        301.1703186035156
      ],
      "page_num": 113,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ychiatry : official journal of the World Psychiatric Association (WPA), 20(3), 448–449.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        70.68000030517578,
        307.17034912109375,
        501.0284118652344,
        317.1303405761719
      ],
      "page_num": 113,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6. Nielsen, S., & Vilmar, J. W. (2021). What can we learn about eating disorder mortality from",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        323.1303405761719,
        541.756103515625,
        333.09033203125
      ],
      "page_num": 113,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "eating disorder diagnoses at initial assessment? A Danish nationwide register follow-up stud",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        70.91999816894531,
        339.2103271484375,
        538.4188232421875,
        349.1703186035156
      ],
      "page_num": 113,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "y using record linkage, encompassing 45 years (1970-2014). Psychiatry research, 303, 1140",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        70.91999816894531,
        355.17034912109375,
        538.3733520507812,
        365.1303405761719
      ],
      "page_num": 113,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "91.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        70.91999816894531,
        371.1303405761719,
        85.70853424072266,
        381.09033203125
      ],
      "page_num": 113,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7. Tith RM., Paradis G., Potter BJ., et al. (2020). Association of bulimia nervosa with long-term",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        387.2103271484375,
        541.7571411132812,
        397.1703186035156
      ],
      "page_num": 113,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "risk of cardiovascular disease and mortality among women. JAMA Psychiatry, 77(1), 44–51.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        70.55999755859375,
        403.17034912109375,
        528.6284790039062,
        413.1303405761719
      ],
      "page_num": 113,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8. van Hoeken D., Hoek HW. (2020). Review of the burden of eating disorders: mortality, disab",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        419.1303405761719,
        538.4194946289062,
        429.09033203125
      ],
      "page_num": 113,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ility, costs, quality of life, and family burden. Curr Opin Psychiatry, 33(6), 521–527.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        70.68000030517578,
        435.2103271484375,
        490.7088928222656,
        445.1703186035156
      ],
      "page_num": 113,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9. Kong, S., Kim, J., & Bae, J. (2000). Effects of cognitive-behavioral group therapy for binge",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        451.17034912109375,
        541.7567138671875,
        461.1303405761719
      ],
      "page_num": 113,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "eating. Journal of Korean Neuropsychiatric Association, 1072-1082.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        71.04000091552734,
        467.1303405761719,
        408.5098571777344,
        477.09033203125
      ],
      "page_num": 113,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10. Reas, D. L., & Grilo, C. M. (2008). Review and meta-analysis of pharmacotherapy for binge",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        483.2103271484375,
        538.4192504882812,
        493.1703186035156
      ],
      "page_num": 113,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "-eating disorder. Obesity (Silver Spring, Md.), 16(9), 2024–2038.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.55999755859375,
        499.17034912109375,
        399.98834228515625,
        509.1303405761719
      ],
      "page_num": 113,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "11. Kwon, H. I. & Kwon, J. H. (2003). The effects of cognitive-behavioral treatment of college",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        515.13037109375,
        541.7574462890625,
        525.09033203125
      ],
      "page_num": 113,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "women with binge eating. Cognitive Behavior Therapy in Korea, 3(1), 27-42.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.68000030517578,
        531.2103881835938,
        463.3492736816406,
        541.1703491210938
      ],
      "page_num": 113,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12. Wilfley, D. E., Agras, W. S., Telch, C. F., Rossiter, E. M., Schneider, J. A., Cole, … Raebur",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        547.1703491210938,
        538.3773803710938,
        557.1303100585938
      ],
      "page_num": 113,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "n, S. D. (1993). Group cognitive-behavioral therapy and group interpersonal psychotherapy",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.68000030517578,
        563.13037109375,
        541.7579345703125,
        573.09033203125
      ],
      "page_num": 113,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for the nonpurging bulimic individual: A controlled comparison. Journal of Consulting and Cl",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.68000030517578,
        579.2103881835938,
        538.4678344726562,
        589.1703491210938
      ],
      "page_num": 113,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "inical Psychology, 61(2), 296-605.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.68000030517578,
        595.1703491210938,
        248.07003784179688,
        605.1303100585938
      ],
      "page_num": 113,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "13. Park, N. R., & Son, C. N. (2012). Characteristics of binge eating disorder and the effective",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        611.13037109375,
        538.4180908203125,
        621.09033203125
      ],
      "page_num": 113,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ness of cognitive behavioral therapy with college students prone to BED. The Korean Jour",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.68000030517578,
        627.2103881835938,
        538.497802734375,
        637.1703491210938
      ],
      "page_num": 113,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "nal of Health Psychology, 17(3), 609-642.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.68000030517578,
        643.1703491210938,
        287.548583984375,
        653.1303100585938
      ],
      "page_num": 113,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14. Baer, R. A., Fischer, S., & Huss, D. B. (2005). Mindfulness-based cognitive therapy applied",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        659.13037109375,
        541.7573852539062,
        669.09033203125
      ],
      "page_num": 113,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "to binge eating: A case study. Cognitive and Behavioral Practice, 12(3), 351-358.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.68000030517578,
        675.2103881835938,
        486.6285705566406,
        685.1703491210938
      ],
      "page_num": 113,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15. Kristeller, J. L., & Hallett, C. B. (1999). An Exploratory Study of a Meditation-based Interv",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        691.1703491210938,
        538.4992065429688,
        701.1303100585938
      ],
      "page_num": 113,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ention for Binge Eating Disorder. Journal of health psychology, 4(3), 357–363.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.68000030517578,
        707.13037109375,
        468.1484375,
        717.09033203125
      ],
      "page_num": 113,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "16. Smith, B.W., Shelley, B.M., Leahigh, L., & Vanleit, B.J. (2006). A Preliminary Study of the",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        723.2103881835938,
        541.7560424804688,
        733.1703491210938
      ],
      "page_num": 113,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Effects of a Modified Mindfulness Intervention on Binge Eating. Complementary Health Prac",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        77.15999603271484,
        739.1703491210938,
        538.5587158203125,
        749.1303100585938
      ],
      "page_num": 113,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "tice Review, 11, 133 - 143.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        77.15999603271484,
        755.13037109375,
        217.34844970703125,
        765.09033203125
      ],
      "page_num": 113,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 107 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        789.4503784179688,
        317.5050048828125,
        799.4103393554688
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "17. Kim, J. H. (2004). Types of mindfulness meditation and their implications for cognitive beha",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        70.89035034179688,
        538.4378662109375,
        80.85034942626953
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "vioral therapy. Cognitive Behavior Therapy in Korea, 4(2), 27-44.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.55999755859375,
        86.85035705566406,
        407.5492858886719,
        96.81035614013672
      ],
      "page_num": 114,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "18. Lee, S. J., & Kim, M. (2015). The effects of mindfulness meditation on binge eating, body",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        102.93034362792969,
        541.75732421875,
        112.89035034179688
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "dissatisfaction, depression and anger in patients with eating disorders: A preliminary study.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        77.04000091552734,
        118.89035034179688,
        541.7581787109375,
        128.850341796875
      ],
      "page_num": 114,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Mental Health & Social Work, 43(3), 58-81.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        77.04000091552734,
        134.850341796875,
        297.1492919921875,
        144.8103485107422
      ],
      "page_num": 114,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "19. Kim, S. H. & Jo, M. J. (2014). Effect of clinical art therapy on self-esteem and depression",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        150.9303436279297,
        541.7567749023438,
        160.89035034179688
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of eating disorder patients. Journal of The Korean Academy of Clinical Art Therapy, 9(2),",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.79999542236328,
        166.89035034179688,
        541.757080078125,
        176.85035705566406
      ],
      "page_num": 114,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "27-38.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.79999542236328,
        182.850341796875,
        109.7087631225586,
        192.8103485107422
      ],
      "page_num": 114,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20. Han, J. H. (2003). Effect of cognitive-behavioral group therapy of bulimia nervosa. Unpublis",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        198.9303436279297,
        538.3360595703125,
        208.89035034179688
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "hed master’ thesis, Duksung Women’s University, Seoul, Korea.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.43999481201172,
        214.89035034179688,
        394.2281188964844,
        224.85035705566406
      ],
      "page_num": 114,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "21. Vocks, S., Tuschen Caffier, B., Pietrowsky, R., Rustenbach, S. J., Kersting, A., & Herpertz,",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        230.850341796875,
        541.756103515625,
        240.8103485107422
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "S. (2010). Meta-analysis of the effectiveness of psychological and pharmacological treatme",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.91999816894531,
        246.9303436279297,
        538.4182739257812,
        256.8903503417969
      ],
      "page_num": 114,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "nts for binge eating disorder. International Journal of Eating Disorders, 43(3), 205-217",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.91999816894531,
        262.8903503417969,
        512.45458984375,
        272.850341796875
      ],
      "page_num": 114,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "22. So Hyeon Yun, & Gaeun Kim (2018). The effects of non-pharmacological interventions for",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        278.850341796875,
        541.8768920898438,
        288.8103332519531
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "adults with eating disorders : A systematic review and meta-analysis. Korean Journal of H",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        77.04000091552734,
        294.9303283691406,
        538.3856201171875,
        304.89031982421875
      ],
      "page_num": 114,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ealth Education and Promotion, 35(5), 35-45.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        77.04000091552734,
        310.8903503417969,
        302.66876220703125,
        320.850341796875
      ],
      "page_num": 114,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "23. National Institute for Health and Care Excellence 홈페이지, https://www.nice.org.uk/guidance",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        326.850341796875,
        538.420654296875,
        336.8103332519531
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "/ng69",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.68000030517578,
        342.9303283691406,
        103.97242736816406,
        352.89031982421875
      ],
      "page_num": 114,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "24. Eating disorders: recognition and treatment NICE guideline, National Institute for Health an",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        358.8903503417969,
        538.4805908203125,
        368.850341796875
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "d Care Excellence, NICE, 2017.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.91999816894531,
        374.850341796875,
        235.10882568359375,
        384.8103332519531
      ],
      "page_num": 114,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "25. The American Psychiatric Association Practice Guideline for the Treatment of Patients With",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        390.9303283691406,
        541.8775024414062,
        400.89031982421875
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Eating Disorders FOURTH EDITION, American Psychiatric Association, APA, 2023.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.55999755859375,
        406.8903503417969,
        491.0683288574219,
        416.850341796875
      ],
      "page_num": 114,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "26. A Guide to Selecting Evidence-based Psychological Therapies for Eating Disorders Academ",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        422.850341796875,
        538.463134765625,
        432.8103332519531
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "y for Eating Disorders First edition, Academy for eating disorders, AED, 2020.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.68000030517578,
        438.9303283691406,
        472.58880615234375,
        448.89031982421875
      ],
      "page_num": 114,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "27. Birgit Wagner., Michaela Nagl., Ruth Dölemeyer., Grit Klinitzke., Jana Steinig., Anja Hilbert.,",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        454.8903503417969,
        541.8765869140625,
        464.850341796875
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Anette Kersting. (2016). Randomized Controlled Trial of an Internet-Based Cognitive-Behav",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.68000030517578,
        470.850341796875,
        538.500244140625,
        480.8103332519531
      ],
      "page_num": 114,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ioral Treatment Program for Binge-Eating Disorder. Behavior Therapy, 47(4).",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.68000030517578,
        486.9303283691406,
        465.8680725097656,
        496.89031982421875
      ],
      "page_num": 114,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "28. Elke D. ter Huurne, Marloes G. Postel, Hein A. de Haan, Job van der Palen, Cor A.J. DeJon",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        502.8903503417969,
        538.4808349609375,
        512.850341796875
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "g. (2017). Treatment dropout in web-based cognitive behavioral therapy for patients with e",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.43999481201172,
        518.850341796875,
        538.5386352539062,
        528.810302734375
      ],
      "page_num": 114,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ating disorders. Psychiatry Research, 247, 182-193.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.43999481201172,
        534.9303588867188,
        336.98858642578125,
        544.8903198242188
      ],
      "page_num": 114,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "29. Selfapy 홈페이지, https://www.selfapy.com/",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        550.890380859375,
        287.8944396972656,
        560.850341796875
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "30. 디지털치료기기 허가·심사 가이드라인 민원인 안내서, 식품의약품안전처 2020.08",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        566.850341796875,
        451.3736572265625,
        576.810302734375
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "31. 의료기기의 사이버보안 허가·심사 가이드라인 민원인안내서, 식품의약품안전처 2023.07.13",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        582.9303588867188,
        496.25390625,
        592.8903198242188
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "32. 의료기기 소프트웨어 허가·심사 가이드라인, 식품의약품안전처, 2023.07.05",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        598.890380859375,
        424.1343994140625,
        608.850341796875
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "33. 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인 민원인 안내서 2023.07",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        614.850341796875,
        440.57366943359375,
        624.810302734375
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "34. 의료기기 소프트웨어 밸리데이션 가이드라인, 식품의약품안전처, 2007.03",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        630.9303588867188,
        415.9736633300781,
        640.8903198242188
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "35. Grilo, C. M., Lydecker, J. A., Fineberg, S. K., Moreno, J. O., Ivezaj, V., & Gueorguieva, R.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        646.890380859375,
        541.6371459960938,
        656.850341796875
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2022). Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eatin",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        77.04000091552734,
        662.850341796875,
        538.4806518554688,
        672.810302734375
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "g Disorder: Randomized Double-Blind Placebo-Controlled Trial. The American journal of ps",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        77.04000091552734,
        678.9303588867188,
        538.4544067382812,
        688.8903198242188
      ],
      "page_num": 114,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ychiatry, 179(12), 927–937.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        77.04000091552734,
        694.890380859375,
        213.0284423828125,
        704.850341796875
      ],
      "page_num": 114,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "36. Mond JM, Hay PJ, Rodgers B, Owen C, Beumont P. Validity of the eating disorder examinat",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        710.850341796875,
        538.4202270507812,
        720.810302734375
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ion questionnaire (EDE-Q) in screening for eating disorders in community samples. Behav",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        77.04000091552734,
        726.9303588867188,
        541.7567749023438,
        736.8903198242188
      ],
      "page_num": 114,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Res Ther. 2004;42:551–67.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        77.04000091552734,
        742.890380859375,
        211.10853576660156,
        752.850341796875
      ],
      "page_num": 114,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "37. Mond JM, Myers TC, Crosby RD, Hay PJ, Rodgers B, Morgan JF, Lacey JH, Mitchell JE. Sc",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        758.850341796875,
        538.4381713867188,
        768.810302734375
      ],
      "page_num": 114,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 108 -",
      "font_size": 9.960000038146973,
      "font_name": "Gulim",
      "bbox": [
        277.67999267578125,
        789.4503784179688,
        317.5050048828125,
        799.4103393554688
      ],
      "page_num": 115,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "reening for eating disorders in primary care: EDE-Q versus SCOFF. Behav Res Ther. 200",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        77.04000091552734,
        70.89035034179688,
        538.4929809570312,
        80.85034942626953
      ],
      "page_num": 115,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8;46(5):612–22.Return to ref 6 in article",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        77.04000091552734,
        86.85035705566406,
        277.7789306640625,
        96.81035614013672
      ],
      "page_num": 115,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "38. Althunian, T. A., de Boer, A., Groenwold, R. H. H., & Klungel, O. H. (2017). Defining the n",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        102.93034362792969,
        538.4802856445312,
        112.89035034179688
      ],
      "page_num": 115,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "oninferiority margin and analysing noninferiority: An overview. British journal of clinical ph",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.68000030517578,
        118.89035034179688,
        538.5191040039062,
        128.850341796875
      ],
      "page_num": 115,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "armacology, 83(8), 1636–1642.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.68000030517578,
        134.850341796875,
        228.8683624267578,
        144.8103485107422
      ],
      "page_num": 115,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "39. 방은별, 한초롱, 전예림, 김율리. (2018). 한국판 DSM-5 섭식장애진단척도(Korean version of the",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        150.9303436279297,
        541.7560424804688,
        160.89035034179688
      ],
      "page_num": 115,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Eating Disorder Diagnostic Scale DSM-5, K-EDDS DSM-5) : 신뢰도와 타당도 연구. 대한불안",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.68000030517578,
        166.89035034179688,
        538.4395141601562,
        176.85035705566406
      ],
      "page_num": 115,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의학회지, 14(2), 127-134.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.68000030517578,
        182.850341796875,
        202.82859802246094,
        192.8103485107422
      ],
      "page_num": 115,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "40. K. Bohn,. C. Fairburn. (2008). The Clinical Impairment Assessment questionnaire (CIA), Cog",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        198.9303436279297,
        538.4867553710938,
        208.89035034179688
      ],
      "page_num": 115,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "nitive Behavior Therapy and Eating Disorders. 315-317.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.55999755859375,
        214.89035034179688,
        358.10858154296875,
        224.85035705566406
      ],
      "page_num": 115,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "41. Kristin Bohn, Helen A. Doll, Zafra Cooper, Marianne O'Connor, Robert L. Palmer, Christoph",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        230.850341796875,
        538.3994140625,
        240.8103485107422
      ],
      "page_num": 115,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "er G. Fairburn. (2008). The measurement of impairment due to eating disorder psychopatho",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.79999542236328,
        246.9303436279297,
        538.4874267578125,
        256.8903503417969
      ],
      "page_num": 115,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "logy. Behaviour Research and Therapy, 46(10), 1105-1110.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.79999542236328,
        262.8903503417969,
        374.4288635253906,
        272.850341796875
      ],
      "page_num": 115,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "42. 박승진, 최혜라, 최지혜, 김건우, 홍진표. (2010). 한글판 우울증 선별도구(Patient Health Question",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        278.850341796875,
        538.3602905273438,
        288.8103332519531
      ],
      "page_num": 115,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "naire-9, PHQ-9)의 신뢰도와 타당도. 대한불안의학회지, 6(2), 119-124.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.68000030517578,
        294.9303283691406,
        416.6685791015625,
        304.89031982421875
      ],
      "page_num": 115,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "43. 김용, 박종일, 박태원, 정상근, 양종철. (2017). 범불안장애 환자의 스트레스 대처방식과 신체증상",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        310.8903503417969,
        541.7562866210938,
        320.850341796875
      ],
      "page_num": 115,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지각에 대한 인지적 특성. 대한불안의학회지, 13(2), 100-107.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        77.63999938964844,
        326.850341796875,
        366.7485656738281,
        336.8103332519531
      ],
      "page_num": 115,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "44. Kim et al., (2018). EuroQol Visual Analogue Scale (EQ-VAS) as a Predicting Tool for Frailt",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        342.9303283691406,
        538.4196166992188,
        352.89031982421875
      ],
      "page_num": 115,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "y in Older Korean Adults: The Korean Frailty an Aging Cohort Study (KFACS). The journal",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.55999755859375,
        358.8903503417969,
        541.7576904296875,
        368.850341796875
      ],
      "page_num": 115,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of nutrition, health & aging, 22(10), 1275–1280.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        76.55999755859375,
        374.850341796875,
        315.2683410644531,
        384.8103332519531
      ],
      "page_num": 115,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "45. Busner, Joan & Targum, Steven. (2007). The Clinical Global Impressions Scale: applying a",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        56.63999938964844,
        390.9303283691406,
        541.757080078125,
        400.89031982421875
      ],
      "page_num": 115,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "research tool in clinical practice. Psychiatry, 4(7), 28-37.",
      "font_size": 9.960000038146973,
      "font_name": "Batang",
      "bbox": [
        77.15999603271484,
        406.8903503417969,
        365.30926513671875,
        416.850341796875
      ],
      "page_num": 115,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "섭식장애 개선 디지털치료기기 안전성·성능 평가 및",
      "font_size": 15.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        107.87999725341797,
        383.4294738769531,
        492.930908203125,
        404.6575012207031
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험계획서 작성 가이드라인(민원인 안내서)",
      "font_size": 15.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        120.7199935913086,
        408.9894714355469,
        475.2722473144531,
        430.2174987792969
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        437.7197570800781,
        354.59857177734375,
        450.9673156738281
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        437.7197570800781,
        354.59857177734375,
        450.9673156738281
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "처 식품의약품안전처 식품의약품안전평가원",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        64.91999816894531,
        437.7197570800781,
        354.59857177734375,
        450.9673156738281
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        464.7197570800781,
        248.27999877929688,
        477.9673156738281
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        464.7197570800781,
        248.27999877929688,
        477.9673156738281
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일 2023년 12월 7일",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        64.91999816894531,
        464.7197570800781,
        248.27999877929688,
        477.9673156738281
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        491.7197570800781,
        199.6795196533203,
        504.9673156738281
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        491.7197570800781,
        199.6795196533203,
        504.9673156738281
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        491.7197570800781,
        199.6795196533203,
        504.9673156738281
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "박윤주",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        64.91999816894531,
        491.7197570800781,
        199.6795196533203,
        504.9673156738281
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "편 집 위 원 장 이정림",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        64.91999816894531,
        518.5997314453125,
        199.6795196533203,
        531.8473510742188
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "편",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        547.9996948242188,
        381.4809265136719,
        561.247314453125
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "집",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        547.9996948242188,
        381.4809265136719,
        561.247314453125
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        547.9996948242188,
        381.4809265136719,
        561.247314453125
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "원",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        547.9996948242188,
        381.4809265136719,
        561.247314453125
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이원규, 박해대, 양승하, 한영민, 김건소, 채형래",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        64.91999816894531,
        547.9996948242188,
        381.4809265136719,
        561.247314453125
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "문",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        628.0397338867188,
        159.36000061035156,
        641.287353515625
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        628.0397338867188,
        159.36000061035156,
        641.287353515625
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "처",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.91999816894531,
        628.0397338867188,
        159.36000061035156,
        641.287353515625
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "28159 충북 청주시 흥덕구 오송읍 오송생명2로 187",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        169.67999267578125,
        580.0397338867188,
        409.2854309082031,
        593.287353515625
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오송보건의료행정타운",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        169.67999267578125,
        596.1196899414062,
        269.6385498046875,
        609.3673095703125
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식품의약품안전처 식품의약품안전평가원",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        169.67999267578125,
        612.0797119140625,
        354.59857177734375,
        625.3273315429688
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기심사부 첨단의료기기과",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        169.67999267578125,
        628.0397338867188,
        314.6390380859375,
        641.287353515625
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화: 043-719-3912",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        169.67999267578125,
        660.0797119140625,
        260.2435607910156,
        673.3273315429688
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "팩스: 043-719-3900",
      "font_size": 9.960000038146973,
      "font_name": "MalgunGothic",
      "bbox": [
        169.67999267578125,
        676.0397338867188,
        260.2435607910156,
        689.287353515625
      ],
      "page_num": 116,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "28159 충북 청주시 흥덕구 오송읍 오송생명2로 187",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        144.83999633789062,
        385.7024841308594,
        450.36053466796875,
        399.3712463378906
      ],
      "page_num": 117,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오송보건의료행정타운",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        232.55999755859375,
        406.46246337890625,
        362.5215759277344,
        420.1312255859375
      ],
      "page_num": 117,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식품의약품안전처 식품의약품안전평가원",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        177.36000061035156,
        427.22247314453125,
        417.841552734375,
        440.8912353515625
      ],
      "page_num": 117,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기심사부 첨단의료기기과",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        203.39999389648438,
        448.10247802734375,
        391.801025390625,
        461.771240234375
      ],
      "page_num": 117,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TEL : 043) 719-3912   FAX : 043) 719-3900",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.51998901367188,
        468.86248779296875,
        430.5610656738281,
        482.53125
      ],
      "page_num": 117,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "https://www.nifds.go.kr",
      "font_size": 12.960000038146973,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        231.83999633789062,
        489.6224670410156,
        363.4131164550781,
        503.2912292480469
      ],
      "page_num": 117,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[부패·공익신고 안내] ※ 신고자 및 신고내용은 보호됩니다.",
      "font_size": 11.039999961853027,
      "font_name": "T10",
      "bbox": [
        156.95999145507812,
        678.8400268554688,
        469.7447814941406,
        692.0880126953125
      ],
      "page_num": 117,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‣ 식약처 홈페이지 “국민소통 > 신고센터 > 부패·공익신고 상담”코너",
      "font_size": 11.039999961853027,
      "font_name": "T15",
      "bbox": [
        156.95999145507812,
        696.47998046875,
        512.0399780273438,
        709.7279663085938
      ],
      "page_num": 117,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    }
  ],
  "markdown_content": "민원인 안내서 등록번호\n\n안내서-1334-01\n\n<!-- PAGE_1 -->\n## 섭식장애 개선 디지털치료기기\n\n<!-- PAGE_1 -->\n## 안전성·성능 평가 및 임상시험계획서\n\n<!-- PAGE_1 -->\n## 작성 가이드라인 (민원인 안내서)\n\n- 2023. 12.\n의 료 기 기 심 사 부\n\n<!-- PAGE_3 -->\n#### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n섭식장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n**[표 시작]**\n\n| 시험의 진행이 피험자의 안전 보호를 위협하여 그 진행을 멈추는 것을 ‘중지’라 하며, | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 개발 계획 | – Part 2-1: Step by step | 개발 활동을 위하여 소프트웨어 | 의료기기의 위험관리 | □ 예 | ■ 아니오 | 국외 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 소프트웨어 | 으로서, 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시 | 가상·증강(VR·AR) 기반 소프트웨어를 포함 | 유효성 | (AB-1234) |\n| 2) 유의수준 | 한다. 그 밖에 임상시험 결과의 사용 범위에 따른 성능 평가를 위하여 이차 | 신경성 | 80001-2-1 | : 제1종 오류 0.025 (유의수준) | (민원인 안내서) | software | - 인지행동치료(CBT)에 비해 대인관계와 통찰력에 집중하는 초점 | 데이터 손실 | “white-box” 방법으로 수행한다. | 및 유효성 확인’ 자료 등 허가·심사 | 관리 계획을 수립한다. | 소프트웨어 |\n| [예시] | 의학회지, 14(2), 127-134. | 27-38. | 주요 정신과적 질환에 해당하는 자 | 데이트 여부, 기기의 안전(safety)과 성능에 | 지침서ㆍ안내서가 있습니까? |\n| 2) 사이버보안 요구사항 | 4) 임상시험 평가 내용 : 식사장애 검사(EDE-Q) | 2) 탈락 처리 | 4) 베이스라인 (사용 전) 대비 8 주 시점의 BMI 변화 | 19) 피험자의 임상시험 예상 참여 기간 | 3) 공용 네트워크 망 사용여부 : Y | 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다. | 아니다. | 임상시험을 실시하여야 한다. | 활동을 말한다. | 4주, 8주 시점에 폭식 | 따라 조정될 것이라고 하는 것 | - OOO 애플리케이션을 실행한다. | - 이상 반응에 대해 다른 명백한 원인이 있는 경우 | (Integrity)을 고려하여 평가한다. | 상황을 발생하지 않으면 안전성 등급은 A등급에 해당한다. | 여부 등을 확인할 수 있다. | 보장하기 위한 설계 특성이 필요한지를 결정 | 제품명(제조업체) | risk management of medical | 표 8. 소프트웨어 안전성 등급 | 개발 계획을 수립한다. | 방법에 대한 국제 규격 |\n| 하기에 충분한 경험이 있는 자가 선정되어야 한다. | 임상시험 개시에서 완료까지 중지될 수 있는 세부 사항을 ‘중지 기준’에 제시한다. | 시 제출해야 할 첨부 자료에 대하여 | 확인 자료 |\n| 3) 통계적 검정 방법 | 식욕부진증 | 제·개정번호 | 승인일자 | 주요 내용 | 기술한다. | 정신역학 심리치료(Focal Psychodynamic Therapy, FPT)를 활용 | 제품설명 | 검증 및 |\n| 디지털치료기기 관련 국내외 규격은 <표 7>과 같다. | 유효성 평가변수를 제시하여 각 임상 검사 항목 및 검사 방법에 대한 기준을 | ※ 단, 층화는 제품 특성 등에 따라 유연하게 적용할 수 있다. | 영향을 보장할 수 있는 업데이트 유효성 검증 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | (2) Clinical Impairment Assessment (CIA) |\n| 제품의 주요 기능 선정 시 아래 고려사항을 참고하여 선정한다. | 4) 방문 4 (치료 기간 종료 3개월 후, Follow up) | 횟수를 0회 달성한 | 하기 위해 시스템 레벨에서의 아키텍쳐를 | 이에 대한 명확한 임상적 근거를 제시해야 한다. | : 제2종 오류 0.2 | 제품외형 | IT-networks – Practical | 적용 |\n| 1) 임상시험용 의료기기 | hed master’ thesis, Duksung Women’s University, Seoul, Korea. | nitive Behavior Therapy and Eating Disorders. 315-317. | 5) 조현병 및 조울증의 과거 병력이 있거나 현재 진단받은 자 | Psychological | 제시 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다. | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 담당 | 5) 임상시험 디자인 : 단일(다)기관, 무작위배정, 전향적 임상시험 | 3) 방문 3 (치료 기간 종료 1주 후, Post-treatment) | 12) 임상시험에 참여함으로써 피험자에게 예상되는 비용 | 20) 임상시험에 참여하는 대략의 피험자 수 | [예시] | 4) 사용될 통계적 분석 방법(즉, 연구디자인과도 관련) | 4) Generalized anxiety disorder 7-item scale (GAD-7) | ○ 평가 불가능(Unknown) | (Anorexia | ‘중지 처리’에는 각 중지 기준에 대한 유효성 평가 통계 처리 시 그 산입 여부와 | 식장애 진단(F50)을 받은 자 | 위원장이나 간사가 승인한 문서를 의뢰자에게 보내야 한다. | 하는 소프트웨어 의료기기(SaMD)이다. | (terHuurne et al., 2015). | 하여야 한다. | 등급 | 설명 | 보는 전면 파기한다. | 변화에 대한 비열등성 확인 | 없이 수집된 자료로 분석한다. | 더욱 개연성이 있게 설명되는 경우 | 평가한다. | 으로 고려하시기 바랍니다. 그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 | 필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다. | 한다. | 통합계획에 따라 소프트웨어를 | 폭식 횟수를 평가한다. | 유효성 | (AB-1234) |\n| s, 42(355), 57–60. | 심리평가 |\n| [예시] | 제시한다. | 평가하여야 한다. | 피험자 비율 | applications and examples |\n| 5) 시험방법 | Nervosa) | 제조자는 업데이트의 수행하기 위해 어떤 | A등급 | 부상이나 신체적 피해가 발생할 가능성이 없다. | 소프트웨어 | assessment | - 전문가 지원 임상관리(Specialist Supportive Clinical Management, | Selfapy | 표 5. 디지털치료기기 관련 국내/외 규격 | 통합하고 | 통합한 | 소프트웨어 | 2 | E06050.01 | 의료기기 허가·심사 시 사용자의 건강에 | 소프트웨어 |\n| 5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이(및 표준편차) | 명시한다. | 가) 장기 효과 검증 | - 제품의 사용목적 상 필요한 기능(능력) 요구사항 | : 예상하는 군간 평균 변화량 차, 0 | 확인 자료 |\n| 소프트웨어 | 6 | 하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상시험에 | 피험자별 중지 사유를 포함한 관련 임상시험 자료의 처리 방법을 제시한다. | 가) 시험기기 | ※ 예: 감사 로그 기록 기능 제공 | 의료기기의 사이버보안 |\n| 안내서-1334-01 | ’23.12.7. | 5) 이상치 처리 | [예시] | ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설명하거나 | 피험자의 심각도 정도를 7점 척도로 평가하며, 점수가 | * [F50.0] Anorexia nervosa (신경성 식욕부진) | 가) 치료 후 평가 | ※ “예방, 관리”의 범위는 치료적 개입이 필요한 “환자”를 대상으로 함 | (3) 피험자 식별코드는 아래의 방법에 따라 기재한다. | 순응 임상시험대상자군(PPS)를 주요분석군으로 분석한다. | 인증‧신고를 하여야한다. | 정하였다. | 및 내용 등을 기재한다. | (사유 :                                                                ) | 소프트웨어가 어떤(what) 기능을 | 표 11. 위험통제 예시 | 평가 및 임상시험계획서 작성 가이드라인 | (민원인 안내서) 제정 | 해당 |\n| - 임상시험 중 관찰 항목을 기술한다. | - 성능 평가 방법은 임상시험 기간 동안 일차/이차 유효성 평가변수에 대한 | 나) 위험평가 | 연결이 필요한지와 코드 서명 및 기타 비슷한 | B등급 | 심각하지 않은 부상(경상)이 발생할 가능성이 있다. | 통합 검증 | software | SSCM)를 통한 치료 또한 받을 수 있다. | 항목이 | 의도한 | 대로 | 기능을 | 직접적인 영향을 미칠 수 있는 사이버 | 검증 및 |\n| ed Assoc 61(3), 191-197. | 베이스라인 (사용 전) | 표 3. 진료지침별 섭식장애 인지행동치료의 권고 사항 |\n| [예시] | 4 | logy. Behaviour Research and Therapy, 46(10), 1105-1110. | nts for binge eating disorder. International Journal of Eating Disorders, 43(3), 205-217 | 가) 스크리닝, 선정제외 기준 확인 | 1) 대상자군 | 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품의약품안전처 지침서 등의 | 허가·심사 가이드라인 | 적용 | 소프트웨어 | 국내 |\n| - ‘탈락’ 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상 | [예시] | 관여하는 사람을 말한다. | - 소프트웨어 기반 알람, 경고, 연산 메시지 | C등급 | 심각한 부상 또는 사망이 발생할 가능성이 있다. | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | : 비열등성 허용 오차, 0.5×{-12.79-(-3.74)}/2=-2.26 | 소프트웨어 | 어떻게(how) 수행할 것인지에 | 보안 위협에 적용할 수 있는 최소한의 | 해당기기 | 적합성 | 첨부자료 |\n| 기기 | - 임상시험 후 이상반응 확인에 대해서 기술한다. | [예시] | 되어야 한다. | [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | 시도한 자 | 제조자는 기기 소프트웨어의 비인가된 변경과 | 수단을 통한 연결이나 업데이트의 진본성을 | Affective | - 성인 | 환자 | 일부는 | 가족치료(Family-Based | Treatment, | FBT)를 | 발휘하는지 확인한다. | 잔여위험평가 | 유효성 | (AB-1234) |\n| Han et al., 2018). | 시험군과 대조군간의 비교 분석 방법을 통계적으로 타당하게 제시한다. | 반드시 필요한 것은 아니며 행정상 변경이 필요하다. | 대비 8주 시점의 BMI | (1) 앱 불순응*으로 판단되는 경우 | - 각 변수에 대해 이상치는 별도로 고려하지 않는다. | 받거나 알게 된 날로부터 15일 이내 보고한다. | 있다.) | 제한 혹은 예기 불안, 동반증상 여부, 직업). | 기재한다. | 경우 | 하거나 확인할 수 없는 경우 | * 피험자 식별코드: 실시기관 코드 - 등록된 순 | 균, 표준편차, 중앙값, 최소값, 최대값 등)으로 제시한다. | 사이버보안 요구사항 | 그림 2. 데이터 보호 및 보안성 영역 연구의 흐름 | (민원인 안내서) | Application of risk management | 손상이 높은 것을 의미한다. | OOO 기능이 구현되도록 입력값을 | 위험/ | □ 예 | ■ 아니오 | 추가 |\n| 2 | 관리에 관한 규정 제2조) | 진료지침* | 신경성 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? | 요구사항 | 대하여, 소프트웨어가 수행할 수 | 허용 가능함을 검증한다. | 검증 및 |\n| 시험이 완료되지 못한 경우를 말하며, 그 분류기준을 ‘탈락 기준’에, 탈락의 | 고려하여야 한다. | 위험통제 | (방문 5) 시점에 BMI 변화량을 평가한다. | 식욕부진증 | 신경성 폭식증 | 폭식장애 | 발생 | 권고 사항 등 제시 | 심 | 위 | 적용여부 | 입증 방법 | 확인 자료 | 또는 |\n| - 공동연구자는 의학통계 전문가, 의료기기 전문가 등을 말한다. | [예시] | 1 | 최소 응답시간 | OO초 미만일 것 | naire-9, PHQ-9)의 신뢰도와 타당도. 대한불안의학회지, 6(2), 119-124. | - 시험군: 디지털 섭식장애 인지행동치료군 | 같은 기기의 무결성에 대한 위험을 고려해야 | disorder | 받기도 한다. | for IT-networks incorporating | Medical devices | 입력한 후 그에 대한 응답시간을 | 적용 |\n| 위험통제 조치 | - 통계 분석 방법에 따른 통계적 유의성에 대한 평가 방법과 기준을 제시한다. | [예시] | [F50.2] Bulimia nervosa (신경성 폭식증) | - 데이터베이스 요구사항 | : 예상하는 표준편차, 5.0 | 변화 | (3) Patient Health Questionnaire-9 (PHQ-9) | 결과 | 이득 | 발생 |\n| ychiatry : official journal of the World Psychiatric Association (WPA), 20(3), 448–449. | 2) 국내 가이드라인별 적용 기준 | [예시] | [예시] | 마) 외래 방문마다 유효성 평가 | - 모델명: ○○○ | 정의 | 있는 논리적이고 물리적인 표현 | 2 | E06070.01 | 사용하는 소프트웨어 | 의료기기 품질관리(Quality | 유효성 | (AB-1234) |\n| 1) 탈락 기준 | 6) 하위 분석 | ○ 의료기기의 오류(결함)로 인한 오진률 발생 가능성 | ○ 관련성이 의심됨(Possibly related) | 2007). | ealth Education and Promotion, 35(5), 35-45. | 고지와 관련된 모든 사항을 문서화해야 한다. | 자료보관(연구파일) 등을 확인한다. | 포함된다. | (2) 섭식장애 관련한 약물을 복용한 경우 | 이라고 판단할 수 있다. | 조사한다. | 의료기기의 사이버보안 | 조치실행 | 합동표준편차   |  |      | 가능 |   ×     ×    | 의료기기 | 사이버보안 | 적용 | 방법과 | 각 | 험 | 문서번호 |\n| 소프트웨어 | 등록대상 | - 각 임상시험기관의 적절한 임상시험의 수행을 위하여 임상시험기관 및 시험자의 | APA 진료지침(2023) | 권장 | 권장 | 권장 | 사유와 관련 임상자료의 처리 방법을 ‘탈락 처리’에 구체적으로 제시한다. | 허용 기준을 사용하여 위험 감소가 필요한지 결정한다. | 한다. | 소프트웨어 | therapy | – Quality management | medical devices | 측정 | 네트워크로 연결되는 |\n| [예시] | 1) 근거 자료/문서의 직접 열람 | 제조자는 비인가 된 개인이 의료기기에 접근 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? | □ 예 | ■ 아니오 | 분석 | 성능 | 위험 |\n| 1) 시험기기 및 대조기기 정보 | 1 | ISO 13485 | 지각에 대한 인지적 특성. 대한불안의학회지, 13(2), 100-107. | 임상시험을 복수의 임상시험 기관에서 실시하는 경우에는 기관에 따라 임상시험 | [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | - 대조군: 디지털 섭식장애 대조군 | 제조자는 의료기기가 다른 기기나 네트워크와 | IEC/TR | 연구 군을 선별한다. | - 주로 인지행동치료(CBT)를 시행하며, 제한적이긴 하나 대인관계 | 으로 정의한다. | 전체 소프트웨어 시스템이 요구 | Management)에 대한 국제 | 소프트웨어 | 확인 자료 | 국외 |\n| 1) 목표 대상자 수: 총 128명(군당 64명) | 5 | 의료기기(SaMD)이다. | 여부 | - 운영방법 및 유지보수 방법과 관련된 요구사항 | 적용방법 및 사례집 | 성 | 허가신청 시 제출하는 자료의 작성 | 성 | 도 | 국내 |\n| [예시] | 7 | 7 | NICE 진료지침(2017) | 권장 | 권장 | 권장 | 가) 디지털치료기기 허가·심사 가이드라인(민원인 안내서) | 기관명 | 소재지 | 전화 | 팩스 | - 제조회사: ㈜○○○ | - 일차와 이차 유효성 평가 관련된 목록을 작성한다. | 하는 것을 방지하기 위한 통제 수단을 고려 | software | 시스템 | systems – Requirements for | – Part 2-2: Guidance for the | 의료기기의 위험관리 | 시험소프 | 국외 |\n| 의견을 조정하기 위하여 조정위원회를 설치하고 임상시험 조정자를 선정할 수 있다. | 바) 식사장애 검사(EDE-Q) 조사 | 사실 | (3) 정신과적 전문 치료를 시작한 것으로 판단되는 경우 | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 기재한다. | 제조자는 바이러스, 스파이웨어, 랜섬웨어 등 | 부여한다. | 통한 섭식장애 치료를 수행한다. | 설치될 기기의 메모리 공간을 | 소프트웨어 |\n| 1. 관련 규정 | /ng69 | 80001-2-2 | 어떻게 접속(유·무선 통신 등)하여야 할지를 | (민원인 안내서) | 소프트웨어 | 및 심리역학 치료를 시행하기도 한다. | 사항을 충족하는지 확인한다. | 예시를 제시 | 규격 | 검증 및 |\n| 1) 식품의약품안전처의 임상 계획 승인일로부터 00개월 | 결과에 차이가 있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 | 통해 추정하고자 한다. | App memory size는 최소 |\n| 설계 변경을 | AED 가이드라인(2020) | First-line | First-line | First-line | 1 | 나) 피험자 동의 및 준비 | 2) 무작위배정 방법 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 하여야 한다. | □ 일회성 지시ㆍ명령에 해당하는 내용입니까? | □ 예 | ■ 아니오 | 검증 | disclosure and communication | regulatory purposes | 방법에 대한 국제 규격 | 적용 | 사항에 반영한다. | 트웨어 |\n| 2 | 메모리 크기 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 고려하여야 한다. | 기기에서 실행될 수 있는 악성코드를 막기 | 애플리케이션, 이메일, 문자, SNS 등을 통해 수집한다. | 검증 자료로 | 위한 과제를 제공한다. | 확인한다. | 검증 및 | 유효성 | 해당 | (AB-1234) |\n| 회사명 | 대표이사 | 소재지 | 전화 | - 원재료: (임상시험용 의료기기의 원재료에 대한 특성 기술) | (1) 일차 유효성 평가지표: 식사장애 검사(EDE-Q) | Off-The-Shelf Software Use in | - 환자의 선호도나 상황에 따라 인지행동치료(CBT)를 기반으로 | 의료기기에서의 | 기성품 | 소프트웨어 | 적용 |\n| 통한 사용자별 | 91. | (1) 「의료기기법」 제2조 (정의) | 8) 기타 이차 유효성 평가변수 | 방법 및 빈도는 이하의 2차 변수에 있어 같이 적용할 수 있다. | 적합한 통신 개략도와 사이버보안 적용 사항을 기재한다. | 나) 선정/제외 기준 | 라) 대조군 검사 시험방법 | 연결이 가능하도록 조치한다. | 기타 문서화된 정보의 사전 서면승인을 받아야 한다. | 입회자가 동의를 얻는 전 과정에 참석하여야 한다. | 문제가 있을 경우 시험자와 상의한다. | 이러한 정보들은 기밀로 보관되어야 한다. | 탈락시킬 수 있다. | - 피험자 선정을 위한 식사장애 검사(EDE-Q) 정보를 수집한다. | 통해 정보를 수집한다. | 통화를 하여 탈락의 주요 사유를 파악하도록 한다. | OO MB 이상일 것 | 적용 | 위험 < |\n| 접근 | 6 | of nutrition, health & aging, 22(10), 1275–1280. | d Care Excellence, NICE, 2017. | 보정할 수 있는 경우는 이를 반영하여 분석 결과를 제시해야 한다. | (Bulimia | 바) 순응도 조사 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 참여하는 사람(피험자)의 선정기준ㆍ제외기준ㆍ인원 및 그 근거 | ※ 예: 물리적 잠금 혹은 포트(port) 접근의 | of medical device security | (ex:설정→애플리케이션→메모리) | 검증 및 | (AB-1234) | 미국 |\n| 2) 대상자 모집 기간: 00개월 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 위해 안티 멀웨어 프로그램과 같은 통제 | ※ 예: Wi-Fi, 이더넷, 블루투스, USB 등 | 심리적 장애와 연관된 과식) | 접근통제 및 | 1 | 2 | 2 | Acceptable | 확인 자료 | 유효성 | 사항 | (AB-1234) |\n| 고려하지 않는다. | 섭식장애 개선 디지털치료기기 안전성·성능 평가 및 | 단축된 표준치료 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | Medical Devices | 한 자료를 사용한 자조 요법(Guided self-help, GSH)이 활용되기도 | 소프트웨어 요구사항을 소프트 | 사용에 대한 가이드 |\n| (2) 「의료기기법」 제3조 (등급분류와 지정) | 1) 임상시험용 의료기기와의 인과관계 평가 | Excellence, AED: Academy for eating disorders | 접근통제 및 | ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | Mental Disorders, Fifth Edition, DSM-5) | Nervosa) | ※ 내원은 필수가 아니며 앱, 이메일, 문자 등을 통해 수집할 수 있다. | □ 외국 규정을 단순 번역하거나 설명하는 내용입니까? | □ 예 | ■ 아니오 | 이득 |\n| [예시] | 1) 임상시험의 연구목적으로 수행된다는 사실 | 수가 확보되어야 한다. | 웨어 밸리데이션 가이드라인(민원인 안내서)’에 따라 수행한다. | 물리적 제한, 인증이 필요 없는 물리적 | * 독립형 소프트웨어 제품은 소프트웨어 명칭, 버전, 운영환경 기재 | needs, risks and controls | Medical devices | 의료기기 위험관리(Risk | 유효성 |\n| 3) 사이버보안 위험관리 | al., 2017) | 사) 병용약물 조사 | 문제점을 적극적으로 대응한다. | 관한 기록을 유지하여야 한다. | 베이스라인 (사용 전) | - 상담 및 지지요법, 약물 치료 등을 실행한다. | - 디지털치료기기에 대한 사용자 반응 평가를 함께 수행한다. | 소프트 | 제조자는 | 내·외부의 | 모든 | 입력에 | 대한 | 조치를 고려하여야 한다. | 생각연습 등의 컨텐츠가 담긴 인지행동치료로 진행된다. | 제시할 수 있다. | 타당한 경우 | Information for Healthcare | 단되는 경우 | 인증 기능 | 한다. | 웨어 구조로 설명하며 소프트 | 확인 자료 | 없음 |\n| risk of cardiovascular disease and mortality among women. JAMA Psychiatry, 77(1), 44–51. | Eating Disorders FOURTH EDITION, American Psychiatric Association, APA, 2023. | research tool in clinical practice. Psychiatry, 4(7), 28-37. | ‘OOOOO’ 경고푸시 알림이 | 오송보건의료행정타운 | 해당 알림이 발생하는 조건을 정하고, |\n| 3) 임상시험 수행 기간: 00개월 | 열람할 수 있다. | 임상시험계획서 작성 가이드라인(민원인 안내서) | 소프트웨어 | (선택) |\n| (3) 「의료기기법」 제10조 (임상시험계획의 승인 등) | 3 | 경고 메시지 | 2 | ISO 14971 | 대비 4주, 8주 시점의 | 케이블의 접근제한 등 | – Application of risk | 증상이 심각하다는 것을 의미한다. | Management)에 대한 국제 | 확인 자료 | 국외 |\n| 웨어 | 유효성을 확인하는 설계 특성을 고려하여야 | 제조자는 기기의 사용이 입증된 사용자이거나, | Organizations about FDA’S | - 일부는 가족치료(Family-Based Treatment, FBT)를 받기도 한다. | 구현 확인 | 스크리닝 및 | 발생할 것 | 웨어 항목(item)을 식별하는 아키 | 소프트웨어의 출시 후에 발생 | 실제 제품에 구현시킨다. | 치료 기간 종료 | 1주 후(8주+1주) | (Post-treatment)3)3)3) |\n| 2) 소프트웨어 개발 및 위험 관리 | 2) 임상시험의 목적 | 8) 임산부 또는 임상시험 기간 동안 임신 계획이 있는 자 | - 모양 및 구조: (임상시험용 의료기기의 모양 및 구조 기술) | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | (EDE-Q) 변화에 대한 비열등성 확인 | 식품의약품안전처 식품의약품안전평가원 | 치료 시작일 | 치료 기간 종료 | □ 예 | ■ 아니오 |\n| 2) Clinical Impairment Assessment (CIA) | 7) 민감도분석 | 대비 8주 시점의 BMI 변화를 통해 평가할 수 있다. | 나) 이상 반응 확인 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. | 한다. | 위임자가 모든 선정 및 제외 기준을 검토해야 한다. | 참여 동의를 철회하는 경우 | 심리적 장애와 연관된 구토) | management to medical devices | 검사일 | 규격 | 검증 및 |\n| ility, costs, quality of life, and family burden. Curr Opin Psychiatry, 33(6), 521–527. | 사) 이상 반응 조사 | 하기 지표 변화량 | 제조자는 의료기기가 필수 성능을 유지하기 | 하는 피드백에 적절히 대응하고 | (4) Generalized Anxiety Disorder 7-item scale (GAD-7) | (Baseline) | 소프트웨어 | 3개월 후 |\n| (4) 「의료기기법 시행규칙」 제9조 (기술문서 등의 심사) | 4) 통계처리 및 결과보고서 작성 기간: 00개월 | 2) 증례기록서의 작성 | 3 | 소프트웨어 | y for Eating Disorders First edition, Academy for eating disorders, AED, 2020. | 개발 | 범위 내에서 개발 및 유지가 되어야 한다. | 하며, 보안이 취약한 통신(예. 가정용 네트 | 다른 역할의 사용자에게 사용권한을 부여를 | 되었다. | “Guidance for Industry: | 정리한 자료입니까? | (Screening)1) | 텍처로 | 변환한다. | 소프트웨어 | 네트워크를 | 활용하는 | 의료기기의 | 하고 총 90일간 사용 가능하다. | 적용 |\n| [예시] | 나) 대조기기: 표준치료 | 나) 이상 반응 확인 | IWRS)을 통해서 시험군 혹은 대조군으로 1:1 배정한다. | 소프트웨어 | 유효성 | (Follow up)4) | 4) | 4) | (AB-1234) |\n| 1) 중지 기준 | 7 | 폭식 장애 | (출처: Selfapy, | 의료기기심사부 첨단의료기기과 | 사이버보안에 대한 정보 가이드라인 | 미국 | 네트워크 API를 통해 데이터 |\n| 8 | 전자파 적합성 인증을 통과한 제품을 사용해야 한다. | 회사명 | 대표이사 | 소재지 | 전화 | 9) 스크리닝 전 4주 이내에 다른 임상시험에 참여한 자 | [F50.8] Other eating disorders (기타 식사장애) | - 성능: (임상시험용 의료기기의 성능 기술) | (2) 이차 유효성 평가지표 | 워크 혹은 기존 기기)만을 지원하는 기기 및 | 허용하거나, 응급상황에서 접근을 허용하는 | 위해 사이버보안 공격을 탐지, 저항, 대응 | 한다. | 소프트웨어 | 항목의 | 일관성을 | 소프트웨어 | 검증 및 |\n| 5) The EuroQol Visual Analogue Scale (EQ-VAS) | 다) 인구학적 정보 | 구분한다. | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 프로 | 하여야 한다. | Cybersecurity for Networked | 기반한 정보를 제공한다. | 시험용 의료기기의 사용에 기인한다고 판단되는 경우 | 결과에 대한 임상적 평가를 제시한다. | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. | 그림 3. 소프트웨어의 안전성 평가 관련 연구의 흐름 | 아키텍처 | - 주로 인지행동치료(CBT) 또는 대인관계 치료를 수행하며, 개인 | 데이터베이스 저장했던 정보와 | 항목과 소프트웨어 항목 외부의 |\n| 보안 | eating. Journal of Korean Neuropsychiatric Association, 1072-1082. | (5) 「의료기기법 시행규칙」 제20조 (임상시험계획의 승인 등) | 및 | 방문일 | 방문1 | 방문2 | 방문3 | 방문4 | https://www.selfapy.com/) | 형상 관리 | 적용 | 확인 자료 |\n| (Binge-Eating | 4 | 데이터베이스 | 무작위 비교 임상시험 | 라) 전체 잔여위험 허용 가능성 평가 | TEL : 043) 719-3912   FAX : 043) 719-3900 | 베이스로 미리 정해진 데이터를 송신 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 환경에서 이루어지는 통신도 고려한다. | 사용자 접근통제에 대해 고려하여야 한다. | 및 복구하도록 허용하는 설계 특성을 고려 | (예) 상담 및 지지요법, 약물 치료 등 | 다시 호출한 정보가 일치 | 표 1. 식사장애 검사(EDE-Q) 변화량 결과 | 유지하면서 설계 변경 및 소프트 | 의료기기 소프트웨어의 | 검증 및 | 유효성 | (AB-1234) |\n| 한다. | 경과일수 | D-28 이내 | DAY1 | - | - | 세스 | Medical Devices Containing | 경우 ‘불순응’으로 판단한다. | 또는 그룹으로 진행된다. | 구성요소 간의 연계성과 소프트 | 구조를 갖추어 설계한다. |\n| 통신 | ioral Treatment Program for Binge-Eating Disorder. Behavior Therapy, 47(4). | 나) 대조기기 | 10) 알코올 또는 약물 남용의 과거력이 있는 자 | [F50.9] Eating disorder, unspecified (상세불명의 식사장애) | 무작위배정 될 확률 | 송수신 | 및 저장한 후, 해당 데이터를 다시 | 적용 |\n| (6) 「의료기기법 시행규칙」 제24조 (임상시험 실시기준 등) | 디지털치료기기 관련 국내외 가이드라인은 <표 8>과 같다. | 3) 이차 유효성 평가변수: | Disorder) | 관리 결과가 검증되어야 한다. | 마) 이상 반응 확인 | 절차를 말한다. | 의료기기의 회수체계를 확립하고 이를 문서화하여야 한다. | 하여야 한다. | https://www.nifds.go.kr | 확인 자료 |\n| 인증 | 있는 영역(Acceptable)’의 2단계로 구분할 수 있다. | 제조자는 비인가 접근/변경/반복을 방지하기 | 추가로 동일한 자격증명은 기기와 고객들에게 | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | Medical device software – | 할 것 | 웨어 형상을 유지한다. | Baseline | At week 16 | 전후 차이 | 개발부터 유지보수를 | 유효성 | □ 예(☞지침서) | ■ 아니오 | 내원 또는 | (AB-1234) |\n| 1) 대상 질환 : | -eating disorder. Obesity (Silver Spring, Md.), 16(9), 2024–2038. | 소프트 | Off-The-Shelf(OTS) Software” | 선행연구 | 군 | 웨어 항목 간 연계성을 위한 |\n| 2) 목표 대상자 수 산정의 추정 공식 예시 | 3 | IEC 62304 | 높은 등급이 된다. | 관찰형태 | 내원 | 내원과 | 불러오기 한다. | 내원과 | 국외 |\n| (7) 「의료기기 허가·신고·심사 등에 관한 규정」 | ○ 관련성이 명백함(Definitely related) | 경우는 별도의 안전성과 성능 시험을 통과한 제품의 사용을 권고한다. | 버전이다. | - 모든 분석 대상자군(Full Analysis Set, FAS) | 또는 일시 중지시킬 수 있다. | 기준이나 절차를 제시하는 것입니까? (공무원용) | Software life cycle processes | n | 평균 | SD | n | 평균 | SD | 평균 | SD | 포함하여 전주기에 대한 | 애플리케이션, |\n| 상에 정확한 피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 한다. | 웨어의 개발 및 유지를 위한 활동을 수행하여야 한다. | 11) 기타 시험자가 본 임상시험 참여에 부적합하다고 판단한 자 | 위한 의료기기의 보안이 보장된(secured) | 공유되지 않아야 한다. | Guidance for the Content of | 애플리케이션 | 애플리케이션 | 으로 식별한다. | 확인 자료 |\n| 한다. | 서명이 이러한 자료의 열람을 허용하게 된다는 사실 | 웨어 | 기간, 목적을 확인한다. | 반응이 사라지는 경우 | 표 6. 디지털치료기기 관련 국내외 가이드라인 | 아키텍처를 개발한다. |\n**표 10. 위험평가 예시**\n| [F50.0] Anorexia nervosa (신경성 식욕부진) | women with binge eating. Cognitive Behavior Therapy in Korea, 3(1), 27-42. | 데이터 송·수신 방법을 고려하여야 한다. | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 다른 디바이스에서 같은 휴대폰 | 국제 규격 | 소프트웨어 |\n| (8) 「의료기기 임상시험계획 승인에 관한 규정」 | Eating Disorder Examination Questionnaire (EDE-Q) | ating disorders. Psychiatry Research, 247, 182-193. | 구분 | - 일차목적 및 가설 | 유지 | ※ 접근 통제의 예: 비밀번호, 하드웨어 키, | Premarket Submissions for | 이용하여 발행된 난수표를 적용한다. | 소프트웨어를 | 포함하는 | 의료기기에 | ■ 예(☞안내서) | □ 아니오 |\n| 성명 | 소속기관명 | 전공 | 직위 | 전화 | Placebo |\n| 8 | 회사명 | 대표이사 | 소재지 | 전화 | 받게 될 각종 검사나 절차 | 평가지표로 사용할 수 있다. | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까? (민원인용) | 대한 시판 전 제출에 대한 가이드라인 | 미국 |\n| ○ 관련성이 적음(Probably not related) | 가) 위험분석 | 그 이유의 타당성을 면밀히 검토하여야 한다. | 한다)를 말한다. | 있도록 하여야 한다. | ※ 예: 기기/시스템 간 통신 시 상호인증 | 들을 수집한다. | 기록한다. | 제시한다. | 번호로 동시에 로그인을 시도 | 소프트웨어 아키텍처를 소프트 | 높고 기능저하도 심한 것을 의미한다. | 위험분석 | 위험평가 | 34 | 13.88 | 8.96 | 29 | 8.11 | 12.39 | -3.74 | 11.32 | 한기기에 시험용 정보로 로그인을 | 검증 및 |\n| 선정/제외기준 확인 | O | O | - | - | Software Contained in Medical | 활동 | 생체인증 등 | 지에 내용을 기록한다. |\n| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | 기록한다. | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 중복 로그인 | 한다. | (control) | 적용 |\n| 5 | · 층: 성별(남/여), 나이(oo세 미만, oo세 이상) | ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 다) 인구학적 조사, 병력조사 요법 | 않으면 사유와 이에 대한 근거 등을 제시해야 한다. | 내용을 기록한다. | Medical device software – | 했을 때, 기존 로그인되어 | 한 후, 다른 기기에서 같은 정보로 |\n| * [F50.0] Anorexia nervosa (신경성 식욕부진) | 방법, 암호화 필요 여부, 과거에 전송된 | 순서가 타당한 경우 | 웨어 유닛으로 표현할 수 있을 | (5) The EuroQol Visual Analogue Scale (EQ-VAS) | 「의료기기법」 및 「의료기기법시행 | 발생 | 소프트웨어 | 유효성 | (AB-1234) |\n| 5) 피험자가 준수하여야 할 사항 | 인구학적 정보 | O | - | - | - | 동시에 의료기기의 전체 수명주기의 위험관리 일부로 수행한다. | Grilo et al. | (2022) U.S.A. | 프로 | 질환으로 정의한다. | 방지 | Devices | 의료기기 소프트웨어의 |\n| 2) 방문 2 (치료 시작일, Baseline) | 4 | IEC/TR | 높은 것을 의미한다(Bohn&Fairburn, 2008). | (Kim,Won,Kim et al., 2018) | 라) 식사장애 검사(EDE-Q) 조사 | 대리인)에게 제공해야 한다. | 및 식품의약품안전처장의 승인을 받아야 한다. | 얻는 전 과정에 참석하여야 한다. | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 의료기기와의 인과관계에 대하여 증례 기록지에 기록한다. | 영향을 줄 것으로 예상하는 약물을 임의로 복용한 경우 | 조사한다. | 하여 해당 성능을 증명할 수 있다. | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | Part 1: Guidance on the | 심각 | □ 예 | ■ 아니오 | 위험 |\n| 아) 병용약물 조사 | BWL+ | 있던 기기에서는 로그아웃 | 때까지 | 분해하고, | 각 | 유닛에 | 로그인을 시도한다. |\n| [F50.2] Bulimia nervosa (신경성 폭식증) | 같이 기록한다. | 제조자는 주기적인 업데이트의 구현과 배포를 | Deciding When to Submit a | 명령어 및 데이터의 비인가 반복에 대한 | 시판 후 소프트웨어에 문제가 | 위해상황 | 위해 | 규칙」,「의료기기 | 허가·신고·심사 | 위험관리 방법에 대한 국제 | 가능 | 확인 자료 | 검증 및 | 국외 | 결과 |\n| 기타 확인 | 1) 개요 | inical Psychology, 61(2), 296-605. | 과거병력 조사 | O | - | - | - | 3) 맹검 방법 | 결정하고 주의사항을 준수하기로 서면 동의한 자 | 세스 | 민원인을 구속하는 내용이 있습니까? | 오송보건의료행정타운 |\n| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | - 심각한 부작용 발생으로 조기 종료시킬 수 있다. | 80002-1 | 디지털치료기기 허가·심사 | 사례 | application of ISO 14971 to | 되어야 한다. | 의료기기 내 소프트웨어 변경에 따른 | 적용 | 성 | 도 |\n| 6) 검증되지 않은 임상시험이라는 사실 | 고려하여 적절한 기준을 설정함 | 대체 수집할 수 있다. | 시 함께 개선될 수 있다고 여겨진 영역에 한정한다. | Naltrexone- | 대한 | 상세 | 설계를 | 수행한다. |\n| 2. 문의처 | 1) 부작용 | 1 | 9 | 사항 | 가) 평가지표 Baseline 조사 | 시험계획서의 절차에 따라 이루어지도록 하여야 한다. | 될 것이라는 사실 | - 이상 반응에 대해 보다 가능성 있는 원인이 있는 경우 | 510(k) for a Software Change | 위한 수행절차를 수립하고 통보하여야 한다. | 방지, 사전에 정의된 통신 종료 시점의 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 식품의약품안전처 식품의약품안전평가원 | 발생하거나 개선의 필요성 때문에 | 35 | 15.89 | 9.74 | 29 | 1.96 | 3.64 | -12.79 | 8.24 | 등에 관한 규정」 기반, 디지털치료 | 성 | 규격 | 유효성 | (AB-1234) | 국내 | 미국 |\n**- 외래 방문마다 병용약물을 수집하여 기록한다.**\n| [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | 가이드라인(민원인 안내서) | 대체 수집할 수 있다. | 소프트웨어 | 표 12. 전체 잔여위험 허용 가능성 평가 예시 | Bupropion | medical device software | 지침 가이드라인 |\n| 내용을 기재함 | [F50.2] Bulimia nervosa (신경성 폭식증) | (설문조사) | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다. | 또한 소프트웨어 유닛 및 외부 |\n| 식품의약품안전처 식품의약품안전평가원 의료기기심사부 첨단의료기기과 | 2) 중지 처리 | 9 | 적절성 여부 등 | 때문에 가장 개연성이 있게 설명되는 경우 | to an Existing Device | 의료기기심사부 첨단의료기기과 | 제품 또는 관련 문서가 수정되는 | 기기에 해당하는 제품의 범위, 판단 | 확인 자료 |\n| 7) 피험자에게 미칠 것으로 예상되는 위험이나 불편 | 대체 수집할 수 있다. | 사용자 구분을 | 소프트웨어 | (기존대조군) | 조작된 환자 | 오진, 잘못 |\n| 3) Patient health questionnaire-9 (PHQ-9) | 6) Clinical Global Impression of Improvement (CGI-I) | 잔여위험평가 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 등을 기록하여 보관하여야 한다. | 절약할 수 있다.1) | 한다. | 수집한다. | 영향을 줄 수 있는 약물의 사용량이 변경된 경우 | 제시할 수 있다. | (CGI-I) 평균 점수 | 문제해결 | 섭식장애 증상 예상값 대비 | 섭식장애 증상 임의의 시험용 수명 |\n| 6 | 섭식장애 증상 | 4 | nal of Health Psychology, 17(3), 609-642. | 비 | 자) 관찰 및 평가 | Postmarket Management of | 구성요인 | 사이의 | 연계성 | 및 | 것을 의미한다. | 소프트웨어 |\n| [예시] | [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | 다) 병용약물 조사 | SD: Standard deviation | and post-production information)로 구분한다. | 제조자는 운영 체제(OS) 소프트웨어, 제3자 | 상기 사항에 대하여 확인하였음. | 경우 문제점과 그 영향 등을 | 기준, 허가·심사 방안 등 제시 | 추가 | 전체 잔여위험 허용 |\n| 웨어 | 전화 : (043) 719-3912 | (1) Clinical Impairment Assessment (CIA) | 기록한다. | 수행할 수 있다. | 하지 않고 | 상세 설계 | 결과값 차이는 ± 1% 이내 | Application of risk | 결과 | 의료기기 사이버보안의 시판 후 관리에 | 된 치료 수행 | 입력정보를 입력했을 때, 산출되는 |\n| 다) 병용약물 조사 | - 사용 중단으로 이상 반응이 없어지는 경우 | 제조자는 안전(safety)과 관련된 데이터가 저장 | 동등함을 보이는 연구시험이다. | 전화: 043-719-3912 | 결과 | 위험/이득 | 통제 | 검증 및 |\n| 10 | 인가된 | 로서의 사용 목적을 달성할 수 있음을 증명해야 한다. | 바) 병용약물 조사 | 심각 | Cybersecurity in Medical | 정확도 | 위험 | 소프트웨어 유닛 사이의 연계성을 | 분석하여 변경해야 한다. | (6) Clinical Global Impression of Severity (CGI-S) | 대한 가이드라인 | 미국 | 3 | 2 | 6 | ALA |\n| 유지 | ※ 본 장에서 제시한 항목 및 예시는 참고용으로 작성한 것으로 사안에 | 8) 중간 분석 | 이상반응 확인 | - | O | O | O | 수는 없으며, 이상 반응 문제가 생길 수 있다. | 안전성에서‘하’등급의 분류가 불가능하다. | 위해요인에 대해 <표 11>과 같이 기록한다. | 소프트웨어, 오픈 소스 소프트웨어가 업데이트나 | 이거나 모호한 경우 | 의료기기 소프트웨어 | 누구나 환자의 | management for IT-networks | 데이터로 | 의료기기 | 소프트웨어 | 밸리데이션에 | 발생 | 또는 | 네트워크로 연결되는 | 적용 | 소프트웨어 | 가능성 평가 |\n| to binge eating: A case study. Cognitive and Behavioral Practice, 12(3), 351-358. | 팩스: 043-719-3900 | 일 것 | 결과값과 예상값을 비교한다. |\n| 1) 사용 전 준비사항 | 5 | IEC | FAX : (043) 719-3900 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. | 되거나 기기와 송·수신될 때 암호화와 같은 | 산출되었다. | (기타 심리적 장애와 연관된 과식) | [부패·공익신고 안내] ※ 신고자 및 신고내용은 보호됩니다. | 분석 | 완료 | 유효성 | (AB-1234) | RP |\n| 병용약물 조사 | O | O | O | O | (1) 인구학적 정보: 성별, 나이, 직업 | (2) Patient health questionnaire-9 (PHQ-9) | 성 | 도 | Devices | 위한 | 상세 | 설계를 | 수행한다. | 위험 | 실현할 수 있어야 한다. | (허용 가능/불가) |\n| 보수 | 2 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. | - 재사용(재사용이 가능한 경우에만 실시) 결과가 양성인 경우 | 통제될 경우에 대해 고려하여야 한다. | 또는 일시 중지시킬 수 있다. | 밸리데이션 가이드라인 | 데이터에 접근 | incorporating medical devices | 2023년  12월  7일 | 전문의 | 대하여 알기 쉽게 설명하거나 식품 | 치료기회 | 의료기기의 위험관리 | 검증 및 | 국내 | 국외 |\n| 성 | ychiatry, 179(12), 927–937. | 그 사실 | 따라 변경될 수 있으며, 제품의 특성에 따라 타당한 근거를 제시할 경우 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. | 그림 1. 디지털 치료기기 대상여부 판단 기준 및 절차 | ‣ 식약처 홈페이지 “국민소통 > 신고센터 > 부패·공익신고 상담”코너 | 관련 보고를 시행한다. |\n| 6) 일반적 주의 | 접근 | 중지 명령 등 필요한 조치를 시험책임자에게 하여야 한다. | 것이라는 사실 | - 본 연구는 중간 분석을 수행하지 않는다. | 일정 수준의 보호가 요구되는지 고려하여야 한다. | 80001-1 | 수 있다. | 등을 통해 Baseline 정보를 수집한다. | 사항이 발견되는 경우 | 달성한 피험자 비율 | 장애와 연관된 과식) | 상세 설계를 바탕으로 코딩을 | 적용 | 확인 자료 |\n| ention for Binge Eating Disorder. Journal of health psychology, 4(3), 357–363. | 순응도 조사 | - | O | O | - | 성명 | 소속기관명 | 전공 | 직위 | 전화 | Guidance on Cybersecurity for | 내용을 기재한다. | (민원인 안내서) | 의약품안전처의 입장을 기술 | 의료기기 사이버보안에 대한 가이드 |\n| 보호 | 임상시험에서 배제 | 하도록 한 경우 | – Part 1: Roles, | 진료수행 | 해당 | 박탈 | 방법에 대한 국제 규격 | 유효성 | (AB-1234) |\n| 2) 디지털치료기기 치료 기간: 총 8주 | 11 | [출처: 식품의약품안전처(2020.08), 디지털치료기기 허가·심사 가이드라인(민원인 안내서)] | (2) 병력 조사: 동반 질환 여부 | (3) Generalized anxiety disorder 7-item scale (GAD-7) | 또한 제조자는 외부의 통제에 의한 소프트 | 라인 | 유럽 | 소프트웨어 |\n| 설정 변경이 가능하다. | 보조분석군으로 분석한다. | ※ 예: 비밀번호(passwords)는 암호화된 보안 | medical devices | 하며 코드는 정확하고 요구사항에 | 위험 < |\n| 러목(의료기기이상 반응의 보고)에 따른다. | 세스에 따른다. | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 대상으로 한다. | 것을 의미한다. | 담당자 | 확  인(부서장) | 양 승 하 |\n| 1 | 2 | 2 | Acceptable | 기회를 제공하여 동의를 얻어야 한다. | 결정되어야 한다. | 해주어야 한다. | 연장할 수 있다. | - 피험자가 제때 방문을 안 하며 연락이 안 되는 경우 | 4) 치료 전 대비 Follow-up 후 8주 시점의 BMI 변화 | 사건들을 조합하여 각 위해요인에 대한 위험을 산정한다. | 모호한 경우 | responsibilities, and activities | 사항 | 완료 | 허용가능 | 확인 자료 |\n| 웨어의 업데이트나 운영환경 만료에 대한 | 적용 | 검증 및 |\n| (secure)이 확보된 해쉬(hash)로 저장되어야 함 | 이득 |\n**Res Ther. 2004;42:551–67.**\n\n**[표 끝]**\n\n지침서ㆍ안내서\n\n이 원 규\n\n<!-- PAGE_4 -->\n#### 제·개정 이력\n\n섭식장애 개선 디지털치료기기 안전성·성능 작성 및\n\n임상시험계획서 작성 가이드라인(민원인 안내서)\n\n섭식장애 개선 디지털치료기기 안전성·성능\n\n이 안내서는 섭식장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서\n\n작성에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이\n\n아님을 알려드립니다. 또한, 본 안내서는 2023년 12월 현재의 과학적ㆍ기술적 사실\n\n및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정법규 내용 및 구체적인\n\n<!-- PAGE_7 -->\n# 목\n\n<!-- PAGE_7 -->\n# 차\n\n<!-- PAGE_7 -->\n### Ⅰ. 개 요 ········································································ 1\n\n<!-- PAGE_7 -->\n##### 1. 배경 및 목적 ················································································ 1\n\n<!-- PAGE_7 -->\n##### 2. 적용 범위 ······················································································ 1\n\n<!-- PAGE_7 -->\n##### 3. 용어 설명 ······················································································ 3\n\n<!-- PAGE_7 -->\n##### 4. 현황 ································································································ 4\n\n<!-- PAGE_7 -->\n### Ⅱ. 안전성·성능 평가 ·············································· 19\n\n<!-- PAGE_7 -->\n##### 1. 국내외 관련 규격 및 가이드라인 ·········································· 19\n\n<!-- PAGE_7 -->\n##### 2. 안전성 평가 항목 ······································································ 22\n\n<!-- PAGE_7 -->\n##### 3. 성능 평가 항목 ·········································································· 34\n\n<!-- PAGE_7 -->\n### Ⅲ. 임상시험계획서 작성 시 고려사항 및 예시 ·· 36\n\n<!-- PAGE_7 -->\n### Ⅳ. 참고문헌 ······························································ 105\n\n- - 1 -\n<!-- PAGE_8 -->\n### Ⅰ\n\n<!-- PAGE_8 -->\n### 개 요\n\n<!-- PAGE_8 -->\n##### 1. 배경 및 목적\n\n식품의약품안전처는 정부 지원 과제 중 디지털치료기기에 특화된\n\n과제의 제품 설계부터 제품화에 필요한 안전성·성능 평가 및 임상시험\n\n계획서 작성 방법 제공을 통한 신속 제품화 지원을 하고 있다.\n\n본 가이드라인은 “섭식장애 개선 디지털치료기기”의 안전성·성능\n\n평가 방법, 임상시험 계획서 작성 시 고려사항 및 예시를 구체적으로\n\n제시하여 신속 제품화를 위한 맞춤형 기술 지원을 목적으로 한다.\n\n<!-- PAGE_8 -->\n##### 2. 적용 범위\n\n본 가이드라인에서 다루는 섭식장애 개선 디지털치료기기는 「의료\n\n기기 품목 및 품목별 등급에 관한 규정(식약처 고시 제2021-83호)」의 품목\n\n분류에 따라 인지치료소프트웨어(2등급, E06060.02) 의료기기로\n\n분류된다.\n\n단, 추후 섭식장애 외 동반된 정신과적 증상에 대한 평가 또는 치료를\n\n동시에 목적으로 한다면 심리평가소프트웨어(2등급, E06050.01) 또는\n\n정서장애치료소프트웨어(2등급, E06070.01)의 의료기기 분류를 추가\n\n하여 조합의료기기로 분류할 수 있다.\n\n- - 2 -\n품목명\n\n영문명\n\n등급\n\n분류번호\n\n품목정의\n\n**[표 시작]**\n\n| 할당에 있어 편향(Bias)을 줄이기 위해 무작위배정(Randomization)과 눈가림(Blinding) | 갖춘 | 의료기관을 | 임상시험기관으로 | 지정하여 | 운영하고 | 있으며, 임상시험기관은 | ※ 피험자의 선정·제외 기준, 인원 및 근거 | 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을 고려하여 “식품의약품안전처의 임상 | 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시한다. | (Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험책임자의 이력 | 인지치료 | 점수 | 인지기능을 개선하는 데 사용하는 소프트웨어 | 검증 및 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 등을 제시한다. | ‘의료기기 임상시험 관리기준’(의료기기법 시행규칙 [별표3])에 의거, 정한 기간 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | - 임상시험 전 피험자 선정 과정에서의 확인해야 할 사항, 임상검사, 피험자 동의서 | 3) 임상시험용 의료기기 : 섭식장애 개선 디지털치료기기(OOO) | 1) 만 19세 이상 65세 이하의 성인에 해당하는 자 | 3) 4주, 8 주 시점에 폭식 횟수를 0회 달성한 피험자 비율 | 2) 일차 유효성 평가변수 | 1) 연구가설 | 1 | 3 | 의미한다(Park,Cho et al., 2010). | 7) Clinical Global Impression of Severity (CGI-S) | 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능 평가 기준을 제시 | 같이 분류한다. | 가이드라인(민원인 안내서)’에 따른다. | 가) 임상시험 설명 및 동의 | 다) 임상시험 의료기기 시험방법 | 유지한다. | 아니 된다. | 사유 | 요구한 사용 방법을 준수하여야 한다. | - 초기 평가에는 최소 다음의 사항이 포함되어야 한다. | 동일하게 해당 효과의 50% 정도인 –6.40로 설정하였다. | 순응도를 조사한다. | 순응도를 조사한다. | 순응도를 조사한다. | 하도록 한다. | 결과 또는 신체 질환 악화가 예상되는 경우 | 타당한 경우 | 순서가 타당하지 않은 경우 | 피험자 식별코드를 부여한다. | 허가심사 가이드라인 | 유닛 검증 | - 심리치료 일환으로 인지행동치료(CBT 또는 CBT-E)를 활용한다. | 접근으로 인해 환자 | 파악할 수 있는 “static test” 및 | 보고서’, ‘의료기기 소프트웨어 검증 | 국내 |\n| 해당 의료기기의 제조업자 또는 수입업자가 해당된다. 의뢰자는 임상시험 모니터 | 대한 준비 등 임상시험을 위한 준비 절차와 사용 단계 절차의 각 단계별 조작 순서, | nd boys: results from a national survey. Arch Pediatr Adolesc Med, 154(6), 569-77. | 6 | IEC/TR | 2) 사용 환경 : 병원 내 사용, 병원 외 사용 | 해당 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 대상질환 또는 | :  비열등성 허용 오차 | ※ 예: 업데이트 시 사용자 개입/ 자동 업 | therapy | 높다는 것을 의미한다. | 2 | E06060.02 | 적용 |\n| 일반적인 사항, 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 | 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입한다. | 사용자의 접근 | 제조자는 데이터 부인방지(non-repudiation)를 | 또는 치료기회 박탈 | 이상사례 |\n| 자를 말하며, 임상시험용 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용 | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 서식, | 하는 원칙과 절차를 수립하여 제시한다. 피해자 보상에 대한 규약에는 보상원칙과 보상이 |\n| 전략이 잘 포함되어야 한다. | [의료기기 임상시험기관 지정에 관한 규정(식약처 고시)]에 따라 식약처장으로부터 | 계획 승인일로부터 OO 개월”로 표시하고 근거자료를 제출한다. | 사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 의료기기의 공급과 | 유/무, 피험자 기초정보, 병력조사, 선정 및 제외 기준, 식별코드 부여 등에 대해서 |\n| 내에 가능한 신속한 보고가 되어야 하며, 이상반응 등에 대한 의학적 소견· | 하는 원칙과 절차를 수립하여 제시한다. |\n| 또는 디자인 특성, 원자재 및 성능, 새로운 제조방법 등에 대한 특이성을 함께 | 적응증을 포함하도록 한다. | 병용 요법 등을 기술한다. 임상시험을 위한 피험자 동의 및 준비, 치료 절차, 관찰 및 |\n| 의료기기 임상시험기관으로 지정받은 곳이어야 한다. | 할 경우 이를 함께 관리한다. 임상시험용 의료기기 관리자의 성명, 소속 기관명 및 | 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 한다. | 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함한다. | 연번 |\n**취급에 관한 사항을 추가로 확보할 수 있다.**\n| 정도와 | 임상시험용 | 의료기기와의 | 인과관계를 | 평가하여 | 증례기록서에 | 기록 |\n| 기재한다. | 평가 절차 등을 상세히 시험 방법을 기술한다. |\n**- 피험자의 방문일에 따른 관찰 시기별 관찰 항목, 임상 검사 항목과 관찰 검사 방법을**\n| 직명 등 인적 사항을 기재한다. | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행규칙 | 의료인이 환자의 심리적 상태를 평가, |\n| 하여야 | 한다. 따라서 이상반응에 대한 임상시험용 의료기기와의 인과관계에 |\n**머목(모니터링)에서 정하고 있다.**\n**결정하는 데 사용하기 위한 소프트웨어**\n**[별표 3])에서 정하고 있다. 이에 따른 피험자 동의서 서식을 제시하여야 하며, 피험자**\n| 번호 | 시험 항목 | 시험기준 | 시험 방법 | 대한 평가 기준을 제시하여야 한다. |\n| 번호 | 표준 번호 | 규격 명칭 | 주요 내용 | 비고 |\n**설명서에는 동 기준의 제7호 아목의 10)을 포함하여야 한다.**\n**통제**\n**정서장애치료**\n**완료**\n\n**[표 끝]**\n\nCognitive\n\n정서장애(우울장애\n\n등)를\n\n개선하는데\n\n가상ㆍ증강(VRㆍAR) 기반 소프트웨어를 포함\n\n표 1. 섭식장애 개선 디지털치료기기 관련 의료기기 품목(식약처 고시 제2021-83호)\n\n※ 본 가이드라인에서 다루는 섭식장애 개선 디지털치료기기는 소프트웨어 의료\n\n기기로서, 사용 시 필요한 범용 장비(스마트폰 또는 태블릿 PC 등)는 적용\n\n범위에 포함되지 않으나, 반드시 함께 병용해야 하므로 전기용품 안전 인증과\n\n※ 실생활 습관을 추적 관찰하기 위해 기타 웨어러블 의료기기를 추가로 사용하는\n\n- - 3 -\n<!-- PAGE_10 -->\n##### 3. 용어 설명\n\n- 가. 소프트웨어 의료기기(Software as a Medical Device, SaMD)\n하드웨어에 종속되지 않고 의료기기의 사용 목적에 부합하는 기능을\n\n가지며 독립적인 형태의 소프트웨어만으로 이루어진 의료기기이다.\n\n- 나. 디지털치료기기(Digital Therapeutics)\n식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인(민원인\n\n안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방, 관리, 치료\n\n하기 위해 환자에게 근거 기반의 치료적 개입을 제공하는 소프트웨어\n\n- 다. 정신질환의 진단 및 통계 편람(Diagnostic and Statistical Manual of\n미국 정신의학협회(American Psychiatric Association, APA)에서 발행한\n\n정신질환의 신뢰할 만한 진단이 가능하도록 고안된 관련 기준들을\n\n통칭하는 정신질환 분류법이다. DSM-5는 2013년도의 새로운 업데이트\n\n- - 4 -\n<!-- PAGE_11 -->\n##### 4. 현황\n\n- 가. 섭식장애 인구학적 특성\nDSM-5에 따르면 섭식장애는 음식 섭취와 관련된 행동에 이상을 보이는\n\n질환으로서, 체중 증가에 대한 극심한 두려움 때문에 식사를 거르는\n\n질병인 신경성 식욕부진증(Anorexia Nervosa), 음식 섭취 후 구토 등의\n\n방식을 사용하여 체중을 줄이려 하는 신경성 폭식증(Bulimia Nervosa),\n\n비정상적으로 많은 양의 음식을 자주 섭취하면서도 먹는 것을 멈출 수\n\n없다고 느끼는 폭식장애(Binge-Eating Disorder) 등으로 정의된다. 섭식\n\n장애는 청소년기 혹은 성인 초기에 발생하며 여성에게 주로 나타난다\n\n(Park, 2000).\n\n섭식장애 유병률은 전 세계 인구의 3%로 추산되며, 미국 섭식장애 유\n\n병률은 신경성 식욕부진증의 경우 약 0.8%, 신경성 폭식증의 경우\n\n- 0.28%, 폭식장애의 경우 0.85%이다. 성별로 보았을 때는, 소년의 경우\n- 7.1%, 소녀의 경우 13.4% 비율의 유병률을 보인다(Neumark-Sztainer,\nHannan, 2000). 건강보험심사평가원 자료에 따르면, 2021년 기준 국내\n\n섭식장애 환자는 약 1만명으로 확인되며, 실제 유병률은 예상보다 높을\n\n것으로 추정된다. 임상에서 섭식장애가 인지되는 경우는 50%에 미치지\n\n못하는 경우가 많은데(Whitehouse et al., 1992), 이는 일반적으로 섭식\n\n장애 환자들이 증상을 드러내지 않거나 숨기는 경우가 있기 때문이다\n\n(Park, 2000). 섭식장애는 신체 합병증을 동반하는 경우가 흔하며, 기능\n\n장애를 초래하고 쉽게 만성화된다는 특징을 지닌다(Kim, 2018). 이러한\n\n결과로 치료가 지연되는 경우가 많으며, 모든 원인에 의한 사망률과\n\n자살로 인한 사망률의 증가와 관련이 있다(Auger et al. 2021;\n\n- - 5 -\nNielsen and Vilmar 2021; Tith et al. 2020; van Hoeken and Hoek\n\n2020).\n\n또한, 섭식장애는 우울, 불안 등의 정신질환을 동반하며, 섭식장애로\n\n인한 영양 부족은 면역력 저하, 수면 장애 등의 증상 발현으로 이어질\n\n수 있다.\n\n- 나. 섭식장애 진단 절차/과정\n섭식장애는 크게 1) 신경성 식욕부진증, 2) 신경성 폭식증, 3) 폭식\n\n장애로 정의된다. 신경성 식욕부진증은 DSM-5 진단 기준에 따라,\n\n연령과 체중에 비해 지나친 음식물 제한으로 현저한 체중의 감소, 체중\n\n증가 및 비만에 대한 극심한 두려움, 체중 증가를 막기 위한 지속적인\n\n행동을 보이는 경우 등을 고려해 진단한다. 신경성 폭식증은 폭식 여부\n\n(통제감 상실 상태로 많은 양의 음식을 2시간 안에 먹는 경우), 자발적인\n\n구토 및 설사제 남용과 같은 행동을 동반할 경우, 체중에 대한 과대\n\n평가 등의 기준으로 진단하게 된다. 여기서 신경성 식욕부진증과 신경성\n\n폭식증을 포괄하는 범진단적 개념은 체형과 체중에 대한 과대평가이다.\n\n섭식장애 환자는 여러 질환이 동시적으로 발현되기 때문에, 평가 시에\n\n상황을 고려한 진단이 필요하다. 만성적 신경성 식욕부진증은 불안,\n\n자폐, 강박성 스펙트럼, 쾌락에 무반응 등의 특성을 보인다. 반면,\n\n신경성 폭식증에서는 과식 경향과 주의력결핍 과잉행동장애의 특질로\n\n나타나는 집중 및 충동성의 문제가 선행한다(Kim, 2018).\n\n섭식장애에 대한 치료는 정신건강교육(Psychoeducation)과 영양관리,\n\n행동치료, 가족치료, 대인관계 정신치료(Interpersonal Psychotherapy:\n\n- - 6 -\nIPT), 정신역동적 치료 등 여러 가지 심리적인 치료와 약물치료가\n\n시행된다. 그중에서도 인지행동치료(Cognitive Behavioral Therapy, CBT)가\n\n가장 널리 사용되어 왔다(Kong et al., 2000).\n\n- 다. 섭식장애 비약물 치료(섭식장애 인지행동치료)\n섭식장애 환자들의 섭식행동 관련 태도, 경험, 삶 등을 토대로 한\n\n심리적 개입이나 비약물적 개입이 권장되고 있으며(Reas&Grilo, 2008),\n\n인지행동치료(Cognitive Behavioral Therapy, CBT)(Kwon&Kwon, 2003;\n\nWilfley et al., 1993; Park&Son, 2012), 식단조절(Baer, Fischer, & Huss,\n\n2005; Kristeller&Hallett, 1999; Smith, Shelley, Leahigh, & Vanleit, 20\n\n06), 명상(Kim, 2004; Lee&Kim, 2015)이나 미술치료(Kim&Jo, 2014)와\n\n같은 활동치료 등이 사용되고 있다. 그 중에서 인지행동치료는 정신\n\n질환 및 정서적 문제에 우선적으로 권고되는 치료방법으로서 부정적\n\n이고 왜곡된 인지구조를 깨닫도록 도와주며 주어진 상황이나 현실에\n\n더 적절하게 대처할 수 있도록 돕는 것으로 인식된다(Han, 2003).\n\n선행연구에 의하면, 섭식장애를 진단받은 환자를 대상으로 비약물적\n\n중재와 약물적 중재의 효과를 비교한 연구에서 약물적 중재보다\n\n비약물적 중재를 적용한 군이 오히려 폭식 증상 감소에 효과적인 것\n\n으로 보고된 바 있으며(Vocks et al., 2010), 비약물적 중재가 식이에\n\n대한 태도를 긍정적으로 변화시키는 것으로 나타났다(Yun&Kim,\n\n2018).\n\n영국 국립보건임상평가연구소(National Institute for Health and Care\n\nExcellence, NICE)가 발간한 섭식장애 가이던스에는 질환 치료법 중 하나로\n\n- - 7 -\n인지행동치료를 포함한다. 성인 신경성 식욕부진증 환자의 경우, 여러 심리\n\n치료 중 인지행동치료(Cognitive Behavioral Therapy for Eating Disorder,\n\nCBT-ED) 프로그램을 선택할 수 있다. 일반적으로 40주 동안 최대 40개의\n\n세션으로 구성된 CBT-ED 프로그램을 수행하게 되며, 처음 2~3주 동안은\n\n주 2회 세션으로 구성된다. 프로그램은 신체적 및 정신적 건강 문제 해결,\n\n건강한 식습관 장려, 영양, 인지 재구성, 기분 조절, 자존감 관리, 재발 방지를\n\n위한 계획 수립 등의 과정으로 이루어진다. 성인 신경성 폭식증 환자의\n\n경우에는 일반적으로 20주 동안 최대 20회 세션으로 구성된 CBT-ED\n\n프로그램을 수행하게 되며, 첫 번째 단계에서는 참여와 교육, 규칙적인\n\n식습관 확립 등을 주 2회 진행한다. 성인 폭식장애 환자의 경우, 일반적\n\n으로 4개월에 걸쳐 매주 16개의 90분 그룹 세션을 진행한다. 심리 교육,\n\n식습관 자체 모니터링, 재발 방지를 위한 계획 수립 등의 내용으로\n\n구성되어 있다.\n\n미국 정신의학회(APA)의 섭식장애 진료지침은 신경성 식욕부진증,\n\n신경성 폭식증, 폭식장애 치료법에 인지행동치료를 권고하고 있다.\n\n다만, 청소년과 나이가 어린 성인 환자의 경우에는, 가족 기반 치료를\n\n권장한다.\n\n- - 8 -\n(출처: 섭식장애 환자 치료를 위한 임상 가이드라인, 미국정신의학회(2023))\n\n유형\n\n내용\n\n- - 목표 체중 달성을 위한 영양 재활을 진행한다.\n- - 영양 재활 중에는 심리적 치료, 신체적 활동 등을 병행할 수 있다.\n신경성 폭식증\n\n표 2. 섭식장애 유형별 비약물치료 내용\n\n- - 9 -\n- 라. 섭식장애 약물치료\n섭식장애 인지행동치료 등 비약물 치료 효과가 미비한 경우, 필요하다면\n\n약물치료를 통해 섭식장애를 개선할 수 있다. 약물치료로는 항우울제,\n\n세로토닌·노르에피네프린 재흡수 억제제, 간질 치료제, 비만 치료제\n\n등의 약제가 사용되나 효과나 부작용 측면에서 사용이 제한적이다.\n\n단, 불가피하게 약물치료가 필요할 경우, 환자의 상황에 맞게 임상의가\n\n적절하게 판단하여 사용하여야 한다.\n\n- - 10 -\n- 마. 섭식장애 비약물 치료의 임상 권고 사항\n미국정신의학회(APA), 영국 국립보건임상평가연구소(NICE) 등은 섭식\n\n장애 치료를 위해 비약물 치료를 우선하여 시행하기를 권고한다.\n\n또한 국제섭식장애학회(Academy for eating disorders, AED)의 ‘섭식\n\n장애에 대한 증거 기반 심리치료 가이드’에서는 섭식장애에 대한\n\n비약물 치료로 인지행동치료(CBT)를 우선 치료전략으로 제안하였다.\n\n* APA: American Psychiatric Association, NICE: National Institute for Health and Care\n\n미국정신의학회(APA) 진료지침(2023)은 섭식장애 치료를 위해 비약물\n\n치료 시행을 권장한다. 비약물 치료로는 영양 재활치료를 포함한\n\n정상 체중 회복을 위한 심리치료가 진행되며, 인지행동치료(CBT)도\n\n활용된다. 영국 국립보건임상평가연구소(NICE) 진료지침(2017)도 인지\n\n행동치료(CBT)를 포함한 심리치료가 섭식장애 치료법으로 고려되고\n\n있다. 국제섭식장애학회(AED)가 발간한 섭식장애 가이드라인(2020)\n\n에서는 섭식장애 치료의 First-line으로 인지행동치료(CBT-ED)가 권고\n\n된다. 다만, 섭식장애 비약물 치료는 섭식장애 유형, 환자의 상태를\n\n고려해 약물치료를 실시할 수 있다.\n\n- - 11 -\n- 바. 디지털 기반 섭식장애 치료 관련 선행연구\n디지털 기반 섭식장애 치료는 대게 웹 또는 스마트폰 앱 기반으로\n\n인지행동치료(CBT)를 시행한다. 우선, 폭식장애 환자를 대상으로 16주간\n\n인터넷 기반 중재 프로그램을 시행한 선행연구를 살펴보았다. 해당\n\n연구는 인지행동 대면 치료 및 자조 요법을 포함한 디지털 인지행동\n\n치료 프로그램이 마련되었고, 글쓰기 과제, 임상심리사로부터의 피드백,\n\n활동 일기, 심리 교육 등으로 구성되었다. 위 연구는 폭식 횟수 감소\n\n등 폭식장애 증상 완화, EDE-Q 척도 감소 또는 유지, 우울 증상 완화\n\n등의 긍정적 결과를 보였다(Wagner et al., 2016).\n\n또한, 디지털 기반 섭식장애 치료는 섭식장애 환자들의 건강 개선에\n\n효과적인 것으로 입증되었다(terHuurne et al., 2015). 해당 연구에서는\n\n섭식장애를 겪고 있는 여성 환자 총 214명 대상으로 웹 기반의 인지\n\n행동치료(CBT) 중재를 수행했다. 웹 기반 애플리케이션은 21개의\n\n세션과 10개의 과제로 구성되었으며, 참가자들은 하루 약 20분 정도의\n\n중재를\n\n받았다.\n\n일차\n\n유효성\n\n변수는\n\nEDE-Q(Eating\n\nDisorder\n\nExamination-Questionnaire), 이차 유효성 변수는 BAT(Body Attitude\n\nTest)가 사용되었다. 결과적으로 환자들은 신체 및 정신 건강, 자존감\n\n등이 크게 상승한 것을 알 수 있었다.\n\n- - 12 -\n- 사. 섭식장애 개선 디지털치료기기의 국외 사례\n현재 국외에서 섭식장애 개선 디지털치료기기로서, 허가된 제품 및\n\n인지행동치료(CBT)를 이용한 제품은 다음과 같다 <표 6>.\n\n(Selfapy GmbH)\n\n- - 12주 온라인 과정으로 구성되었으며, 오디오와\n비디오 클립, 텍스트, 연습 등을 통해 제공된다.\n\n주제는 심리교육, 부정적인 생각과 감정 다루기,\n\n식습관과 자존감, 휴식 기술, 문제 해결 및\n\n재발 방지에 관한 내용을 포함하고, 새롭게\n\n습득한 전략과 기술을 일상생활에 적용하기\n\n- - 환자는 컴퓨터 또는 노트북, 태블릿 또는\n스마트폰 등 어디에서나 과정을 완료할 수\n\n있고, 일주일에 한 번, 약 60분의 사용을 권장\n\n표 4. 국외 섭식장애 개선 디지털치료기기 허가 제품 및 관련 제품의 개발 동향(2023. 8. 기준)\n\n- - 13 -\n- 아. 디지털치료기기의 정의와 국내 가이드라인별 적용 기준\n1) 디지털치료기기 정의\n\n식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인\n\n(민원인 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방,\n\n관리, 치료하기 위해 환자에게 근거 기반의 치료적 개입을 제공\n\n디지털치료기기는 「의료기기법」 제2조에 따른 사용 목적에\n\n해당해야 하며, <그림 1>과 같이 소프트웨어 의료기기로써 범용\n\n하드웨어에 설치되고, 질병을 예방, 관리 또는 치료하기 위한\n\n목적으로 환자에게 적용되어야 한다. 또한, 치료 작용기전의\n\n과학적(임상적) 근거에 해당하는 자료가 있어야 한다. 여기서\n\n질병이란 국제질병분류코드(International Classification of Disease,\n\nICD)에 기반한 한국표준질병사인분류에 독립적으로 분류 가능한\n\n디지털 섭식장애 인지행동치료(CBT)는 섭식장애 인지행동치료\n\n기반의 콘텐츠를 범용 스마트폰이나 태블릿PC에 설치되어 제공\n\n하므로 소프트웨어 의료기기에 해당한다. 또한 한국표준질병\n\n사인분류에 따라 섭식장애를 의사에게 진단받은 환자들을\n\n- - 14 -\n미국, 영국 등 많은 학회와 연구소에서 개발한 임상진료지침\n\n등에 따르면, 섭식장애의 비약물 치료를 우선 시행하며, 그중\n\n에서도 인지행동치료(CBT)를 시행하기를 권고하고 있다. 또한\n\n디지털 기반 섭식장애 관련 선행연구에서 임상시험을 통해\n\n디지털 섭식장애 인지행동치료의 효과성을 입증된 바 있다\n\n위와 같이 섭식장애 디지털치료기기는 디지털치료기기 대상\n\n여부 판단기준 및 절차를 충족하므로 디지털치료기기 대상\n\n- - 15 -\n나) 의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)\n\n디지털치료기기는 식품의약품안전처‘의료기기의 사이버보안\n\n허가·심사 가이드라인(민원인 안내서)’에 근거하여 보안성\n\n영역은 가용성(Availability), 기밀성(Confidentiality), 무결성\n\n가용성은 데이터가 승인된 사용자에게 즉시 제공되어야 하며,\n\n필요한 때에 필요한 곳에서 필요한 형태로 존재되어야 함을\n\n의미한다. 기밀성은 데이터가 허가되지 않은 사람에게 공개\n\n되거나, 허가되지 않은 용도로 사용되지 않아야 함을 의미하며,\n\n무결성은 데이터가 허가되지 않은 방법으로 변환되거나 파괴\n\n되지 않아야 함을 의미한다. 유·무선 통신이 가능하거나 통신\n\n경로가 존재하는 의료기기는 정보의 위변조, 오작동 또는 의료\n\n기기에 승인되지 않은 접근 등을 방지하기 위한 대책을 마련\n\n사이버보안 침해로 인한 위해도는 의료기기의 잠재적 결함\n\n으로 인해 사용자에게 발생할 수 있는 위해(harm)의 정도, 의료\n\n기기의 통신방법 및 사용환경을 종합적으로 고려하여 ‘상’,\n\n‘중’, ‘하’로 결정되고, 그에 따른 사이버보안 요구사항을\n\n적용한다. 일반적으로 디지털 치료기기는 ‘치료’를 목적으로\n\n하는 2등급 이상의 의료기기로 품목 분류되므로 사이버보안\n\n- - 16 -\n다) 의료기기의 소프트웨어 허가·심사 가이드라인(민원인 안내서)\n\n소프트웨어 의료기기도 일반 의료기기와 마찬가지로 제조 및\n\n품질관리체계의 기준과 위험관리 프로세스가 조화를 이루는\n\n식품의약품안전처‘의료기기 소프트웨어 허가·심사 가이드라인\n\n(민원인 안내서)’를 기준으로 디지털치료기기의 위험성 관리\n\n프로세스는 의료기기에서 발생하는 위험분석(risk analysis), 위험\n\n평가(risk evaluation), 위험통제(risk control), 잔여 위험 허용평가\n\n(evaluation of overall residual risk acceptability), 위험관리 보고서\n\n(risk management report), 생산 및 생산 후 정보(production\n\n의료기기 소프트웨어 안전성 등급은 고장 또는 잠재적 결함으로\n\n인해 환자나 사용자에게 미치는 위해의 영향에 따라 분류한다.\n\n의료기기 소프트웨어 사용으로 건강상의 상해 또는 손상이 없는\n\n- - 17 -\n경우 A등급, 심각하지 않은 상해의 가능성 있으면 B등급, 심각한\n\n상해 또는 사망의 가능성이 있는 경우 C등급으로 구분한다.\n\n의료기기 소프트웨어는 안전성 등급이 결정될 때까지 초기에는\n\nC등급 요구사항이 적용되며, 소프트웨어 시스템의 실패가 위험한\n\n라) 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인(민원인 안내서)\n\n디지털치료기기는 실사용증거(Real World Evidence, RWE)를\n\n사용하여 의료기기의 사전 및 사후와 관련된 안전성 및 유효성\n\n입증 근거로 제시할 수 있으며, 이에 따른 기간 및 비용을\n\n실사용증거 수집은 데이터의 타당성 및 신뢰성 확보를 위해\n\n품질, 수집 및 분석 방법, 수집한 인력의 역량을 입증할 수 있는\n\n1) 실사용데이터(RWD)는 기존의 중재적 방법에 의한 임상시험으로부터 수집되지 않은 다양한 유형의 의료데이터에 대한 포괄적인\n\n용어이다. 실사용증거(RWE)는 RWD를 분석하여 파생된 증거로써, RWD 분석을 통해 얻은 의료기기의 사용 결과나 잠재적 이익\n\n또는 위험성에 관한 임상적 근거를 말한다. 또한, 임상 문헌을 분석하여 파생된 새로운 증거도 포함한다.\n\n- - 18 -\n객관적인 사항이 반드시 포함되어야 한다. 또한 실사용증거는\n\n적용 목적, 수집 및 분석 정보, 분석 결과에 대한 사항을 제시\n\n해야 한다.\n\n- - 19 -\n<!-- PAGE_26 -->\n### Ⅱ\n\n<!-- PAGE_26 -->\n### 안전성·성능 평가\n\n<!-- PAGE_26 -->\n##### 1. 국내외 관련 규격 및 가이드라인\n\n- 가. 국내외 규격\n- - 20 -\n- 나. 국내외 가이드라인\n번호\n\n표준 번호\n\n규격 명칭\n\n주요 내용\n\n비고\n\nApplication of risk\n\nmanagement for IT-networks\n\n**[표 시작]**\n\n| incorporating medical devices | 네트워크로 연결되는 |\n| --- | --- |\n\n**[표 끝]**\n\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n- - 21 -\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n**[표 시작]**\n\n| 의료기기 소프트웨어 | 소프트웨어 | 비 인가된 사용자의 | 것으로 코드 실행 전에 오류를 | ‘의료기기 | 소프트웨어 | 적합성 | 확인 | 확인 자료 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n**의료기기 업데이트 방안을 고려하여야 한다.**\n| 5 | 비 인가된 | 것을 방지하도록 고려하여야 한다. | 수 있음. | : 한 군당 필요한 피험자 수 | 소프트웨어 | 및 소프트웨어 안전에 적합한 | 오진, 잘못 된 치료 수행 | 국내·외 |\n\n**[표 끝]**\n\n의료기기 소프트웨어의 기술문서 작성\n\n방법에\n\n대하여\n\n상세히\n\n기술하고\n\n- - 22 -\n<!-- PAGE_29 -->\n##### 2. 안전성 평가 항목\n\n- 가. 소프트웨어 검증 및 유효성 확인\n1) 개요\n\n의료기기에 포함되는 소프트웨어 또는 의료기기 자체가 소프트\n\n웨어면 ‘의료기기 제조 및 품질관리 기준’ 및 ‘의료기기 위험\n\n관리 시스템’과 조화를 이루는 범위에서 개발, 유지되고 사용\n\n소프트웨어 검증 및 유효성 확인은 의료기기로서의 소프트웨어의\n\n신뢰도를 높이고 환자 또는 사용자에 대한 위험을 낮추기 위한\n\n활동으로, 국제 표준 IEC 62304, ISO 14971 및 ‘의료기기 소프트\n\n의료기기 제조업체는 ‘의료기기 제조 및 품질관리 기준’에\n\n규정된 바와 같이 수립된 품질시스템에서 관련 절차에 따라 소프트\n\n의료기기 소프트웨어의 위험관리는 소프트웨어 개발 활동의 일부이며,\n\n제조자는 소프트웨어 위험관리를 통해 의료기기에 포함된 소프트\n\n웨어 사용에 따른 허용 불가능한 위험이 발생하지 않고, 의료기기\n\n소프트웨어 개발 및 위험관리는 <표 9>와 같이 IEC 62304 프로\n\n- - 23 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n개발 소프트웨어의 범위, 규모\n\n소프트웨어의 개발 계획을\n\n**[표 시작]**\n\n**시험보고서**\n| 수립하면서 | 동시에 | 위험 |\n**소프트웨어 요구사항에서**\n**시험보고서**\n**적용 대상이 되는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄격한 피험자의**\n| 정의한 | 위험통제 | 조치가 |\n**소프트웨어의 정상 상태 및**\n| 선정 기준과 제외 기준을 제시하여야 한다. 이 때 임상시험 참여와 연관된 이익을 | 실제 제품에 올바르게 반영 |\n| 고장 | 상태에서의 | 잠재적 |\n**되었으며, 위험이 효과적**\n**기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 불이익을 우려하여**\n**시험보고서**\n**결함을 고려하여 위험을 분석**\n**으로 통제되어 잔여 위험이**\n| 자발적인 참여 결정에 영향을 받을 소지가 있는 등 취약한 환경에 있는 피험자 | 하고, 해당 위험을 통제하기 |\n**임상시험용 의료기기와의 인과관계를 부정할 수 없는 경우를 말한다.**\n**시험보고서**\n**위한 조치를 결정한다. 이 중**\n**(Vulnerable Subjects)는 선정대상에서 제외한다. 또한, 시험군과 대조군을 포함한 피험자**\n**소프트웨어 설계에 해당하는**\n**수는 해당 의료기기의 특성, 임상시험디자인, 근거를 통한 시험에서 기대하는**\n**통제 조치를 소프트웨어 요구**\n**시험보고서**\n**연구결과의 사전 예측, 통계적 유의성, 검정 방법, 탈락률 등을 반영하여 통계학**\n**시험보고서**\n**시험보고서**\n**적으로 타당하게 제시되어야 하며, 임상시험의 효능 및 안전성 입증에 필요한 충분한**\n**완료**\n**의학적 상태인　경우　또는 기대 수명이 6개월 이하에 해당하는 자**\n**새로운 위험의 발생 또는**\n**- 치료 기간 애플리케이션 사용 시간 및 활용 여부를 수집한다.**\n**- 디지털치료기기에 대한 장기 사용자 반응 평가를 함께 수행한다.**\n| 소프트웨어 | 요구사항에 | 기존에 식별한 위험 평가의 |\n**시험보고서**\n**변경이 필요한 경우, 소프트**\n**반영한 위험 통제 조치가**\n| 웨어 형상의 변경이 위해 | 시험보고서 |\n**실현될 수 있도록 안전한**\n| 요인이 될 수 있는 경우 | 시험보고서 |\n**되어야 하며, 일반적으로 1차 유효성 평가변수를 기준으로 정해지고, 연구 계획서**\n**위험관리 프로세스의 입력**\n| 또는 담당자가 임상시험 수행이 불가능한 것으로 판단한 경우 | 이메일, 문자, SNS |\n**시험보고서**\n**시판 후 발견된 문제점을**\n**것에 무리가 있다고 판단될 때는 임상시험을 중지할 수 있다.**\n| 분석하고 | 안전과 | 관련된 |\n**시험보고서**\n**항목은 위험관리 프로세스의**\n**소프트웨어 위험 통제 조치를**\n**입력으로 식별한다. 문제**\n**제품에 구현한다. 이때 코드는**\n**해결 및 설계 변경은 위험**\n**위험관리 프로세스에서 식별한**\n**시험보고서**\n| 안전 | 요구사항을 | 정확하게 |\n**필요시 규제 당국에 안전성**\n\n**[표 끝]**\n\n부합한다.\n\n표 7. 소프트웨어 개발 및 위험관리\n\n- - 24 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n각 유닛에 대한 코드를 검증하는\n\n통제 조치가 될 수 있다.\n\n- - 25 -\n3) 소프트웨어 안전성 등급\n\n의료기기 소프트웨어의 고장 또는 잠재적 결함으로 인해 환자나\n\n사용자에게 미치는 위해의 영향에 따라 안전성 등급을 <표 10>과\n\n소프트웨어 안전성 등급은 위험통제 후 잔여 위험의 심각도를\n\n토대로 분류할 수 있다. 이때, 발생 가능성은 안전성 등급 결정 시\n\n소프트웨어가 여러 개의 독립적인 모듈이 모여서 구성된 경우\n\n각 모듈에 대해 별도로 안전성 등급을 부여할 수 있다. 이때 전체\n\n소프트웨어의 안전성 등급은 개별 모듈의 안전성 등급 중 가장\n\n- 나. 의료기기의 사이버보안\n유·무선 통신이 가능하거나 통신 경로가 존재하는 제품의 경우\n\n사이버보안에 대한 요구사항을 준수해야 한다. 제조자는 이를 확인\n\n할 수 있도록 ‘의료기기 사이버보안 요구사항 체크리스트’와\n\n요구사항을 실제로 검증한 자료를 제출하여야 한다. 다만, 제조사의\n\n위험분석을 통해 요구사항 일부를 제외하거나 수정하여 적용할 때는\n\n- - 26 -\n시험규격 및 그 설정 근거를 제출하여야 하며 해당 자료로\n\n‘사이버보안 위험관리문서’를 제출할 수 있다.\n\n사이버보안 요구사항은 ‘의료기기의 사이버보안 허가·심사\n\n‘의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)’\n\n에는 보안통신, 데이터 보호, 기기 무결성, 사용자 인증, 소프트웨어\n\n유지보수, 물리적 접근, 신뢰성 및 가용성 등에 대한 요구사항을 제시\n\n하고 있다. 본 요구사항은 제품의 사이버보안 안전성 등급 및\n\n제품의 특성에 따라 적용한다. 해당 가이드라인에 따라 제품에\n\n소프트웨어 위험관리에는 사이버보안에 대한 위험관리 항목이\n\n포함되어야 하며, 소프트웨어 위험관리와 동일한 방식으로 위험\n\n‘위해요인 식별’에서는 관련 자료(규격, 가이드라인, 국내외\n\n이상 사례 등)에 근거하여 의료기기의 정상 및 고장상태에서\n\n이미 알고 있거나 예측 가능한 의료기기 사이버보안 측면의\n\n‘위험산정’에서는 위해상황을 초래할 수 있는 예측 가능한\n\n- - 27 -\n위해요인\n\n구체적인 예시\n\n사용자 또는 환자에게\n\n발생 가능한 손상\n\n관련자료\n\n표 9. 위해요인 식별 예시\n\n식별한 각 위해요인에 대하여 위험관리 계획서에 정의한 위험\n\n식별한 모든 위험에 대하여 위험의 평가 결과를 ‘위험을\n\n허용할 수 없는 영역(unacceptable)’과‘합리적으로 실현할\n\n수 있는 가장 낮은 영역(As Low As Reasonably Practicable,\n\nALARP)’, ‘허용할 수 있는 영역(acceptable)’의 3단계 또는\n\n‘위험을 허용할 수 없는 영역(unacceptable)’과 ‘허용할 수\n\n**[표 시작]**\n\n| 위해요인 | 발생 가능한 |\n| --- | --- |\n**사용자의**\n\n**[표 끝]**\n\n- - 28 -\n다) 위험통제\n\n제조자는 위험평가 결과 중 ‘위험을 허용할 수 없는 영역\n\n(unacceptable)’과‘합리적으로 실현할 수 있는 가장 낮은 영역\n\n(ALARP)’을 허용 가능한 수준까지 감소시키기 위하여 위험\n\n통제 조치를 식별하고, <표 13>과 같이 위험통제 활동을 수행\n\n모든 위험통제 조치를 하고 검증한 뒤 위험관리 계획에서\n\n정의한 위험허용 기준을 사용하여 해당 의료기기에서 식별한\n\n전체 잔여위험이 허용 가능한지 아닌지를 결정하고 <표 14>와\n\n발생\n\n가능\n\n없음\n\n인증 기능 구현\n\n- - 29 -\n4) 사이버보안 적용 방법\n\n‘의료기기 사이버보안 요구사항 체크리스트’는 의료기기\n\n사이버보안 요구사항에 대한 적합성 여부를 확인할 수 있는 자료로\n\n제조자는 체크리스트의 질의 사항을 확인하여 요구사항의 적용\n\n사용되는 통신기술(유·무선 통신 방식 등), 사용환경(병원\n\n내/외 사용, 공용 네트워크망 사용 등) 등 통신 특성을 확인할\n\n수 있는 사항을 기재한다. 이를 기반으로 체크리스트에 따라\n\n요구사항 적용여부, 적합성 입증방법, 첨부자료 또는 문서번호를\n\n- - 30 -\n<예시> - 의료기기 사이버보안 요구사항 체크리스트\n\n< 의료기기 사이버보안 특성 기재 >\n\n1) 사용되는 통신 기술 : 유선 통신(LAN), 무선통신(Wi-fi, 블루투스)\n\n**[표 시작]**\n\n**무결성**\n**물리적**\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 |\n| 신뢰성 | ※ 피험자 수: 시험대상수 산출시 일반적인 고려사항 |\n| 발 | 행 | 일 2023년 12월 7일 |\n**- 임상연구에서 피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 수가 보장**\n**사용자**\n**가용성**\n| 발 | 행 | 인 | 박윤주 |\n| 편 집 위 원 장 이정림 | 1) 이상 사례 교육 |\n| 연구 참여 동의서 취득 | O | - | - | - |\n| 편 | 집 | 위 | 원 | 이원규, 박해대, 양승하, 한영민, 김건소, 채형래 |\n| 임상시험 의료기기 적용 | O | O | O | O |\n| 문 | 의 | 처 |\n| 소프트 | 평가지표 Baseline 수집 | (O) | O | - | - |\n| 평가지표 수집 및 분석2) | 2)2) | O | O | O | O |\n**2) 중대한 이상 의료기기 이상 반응 보고**\n| 데이터 | 시험보고서 |\n\n**[표 끝]**\n\n- - 31 -\n제조자는 기밀성에 대한 위험통제 수단이\n\n요구될 때, 통신 프로토콜의 컨트롤(control)/\n\n**[표 시작]**\n\n| 검증 및 | 시험보고서 |\n| --- | --- |\n| 피험자 수는 임상시험 방법에 따라 식약처의 ‘의료기기 임상시험 관련 통계기법 | : 시험군의 치료 전 대비 post-treatment 후 평균 식사장애 검사(EDE-Q) 변화량 |\n| 임상시험 디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고 | 시퀀싱(sequencing) 필드의 메시지를 보호 | (1) Eating Disorder Examination Questionnaire (EDE-Q) | 적용 |\n| 할 수 있다. 본 예시는 대표적인 예를 작성한 것으로 실제 시험규격에 대해 작성 | 해당 임상시험용 의료기기 및 대조시험용 의료기기의 품목명, 제조회사, 원재료, 모양, | Global Impression of |\n| 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | 유효성 | (AB-1234) |\n| 가이드라인’을 참고하여 임상시험 피험자 수 산출 방식을 적용한다. 피험자 수를 결정 | - 시험자는 시험책임자, 시험담당자, 임상시험 조정자를 포함한다. | 3) 스크리닝 시점에 BMI 가 17kg/㎡미만, 40kg/㎡이상인 자 |\n| 그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있다. 피험자 배정과 처리 | 1) 방문 1 (스크리닝 및 검사일, Screening) | 피험자의 모집 기간, 임상 관찰 및 시험 수행 기간, 통계 처리 기간, 결과보고서 작성 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례기록서 | 식약처장은 [의료법]에 따른 의료기관 중 임상시험에 필요한 시설, 인력 및 기구를 | 임상시험용 의료기기 관리자는 임상시험기관에서 임상시험용 해당 의료기기를 | 시험책임자는 의료기기법 시행규칙 제24조 제1항 제4호의 규정에 따라 임상 | : 선정기준 모두를 만족하는 자 | 나) 회원가입 및 초기 평가를 시행한다. | 하는 내용이 포함되어서는 안된다. | (CGI-I) 평균 점수 | - 시험군 혹은 대조군에 무작위배정을 통해 배치한다. | - 계획서 순응 임상시험대상자군(Per-protocol Set, PPS) | 분석한다. | 하거나 암호화의 키 관련 자료가 손상되는 | 제조자는 새로운 사이버보안 취약성에 대응할 |\n| 구조, 성능 등을 구체적으로 기재하도록 한다. | - 해당 의료기기의 임상시험에 따른 유효성 평가는 사용된 모든 의료기기를 | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 및 | armacology, 83(8), 1636–1642. | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상반응 등에 대하여 임상 | 이상사례(의료기기이상반응, 중대한 이상반응/의료기기이상반응 포함)의 발생 시 | Mental Health & Social Work, 43(3), 58-81. | Improvement (CGI-I) 평균 | : 대조군의 치료 전 대비 post-treatment 후 평균 식사장애 검사(EDE-Q) 변화량 |\n| 시에는 해당 제품의 특성 및 주요 기능을 고려하여 작성하여야 한다. | 하기 위해서는 사전 정보가 필요한데, 여기에 포함되어야 할 필수 정보로는 다음이 있다. | - 임상시험 전, 중, 후에 관찰해야 할 항목들을 나열한다. | 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 | 소프트웨어 |\n**기술하는 것을 말하며, 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의**\n| - 부작용, 이상반응 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람 |\n| 보관, 관리하는 임상의, 의료기사 또는 간호사 등으로 임상시험기관의 장이 지정한 | 시험을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화할 때, 헬싱키 선언에 |\n**- 피험자(Subject)란 임상시험에 참여하는 임상시험용 또는 대조시험용 의료기기의**\n**요원을 지정하여야 한다. 임상시험 모니터요원의 선정, 자격기준, 수행임무 등에**\n**대한 사항은 「의료기기법 시행규칙」별표3 “의료기기의 임상시험 관리기준” 제8호**\n| 1) 스크리닝 및 검사일은 치료 시작일 전 28일 이내에 시작한다. | 2) 수집하는 지표에 따라 수집이 다를 경우 나누어 표현한다. | 3) 섭식장애 개선 디지털치료기기 제품의 치료 기간에 따라 전체 치료 기간은 변경될 수 있다. | 4) 임상시험 설계에 따른 선택사항이므로 치료 기간 종료 후 추적관찰 기간은 변경될 수 있다. | 시험보고서 |\n| 1) 과거에 섭식장애 치료를 위하여 인지행동치료를 받아본 자 | 아래와 같다. | 디지털치료기기를 설치한다. | (기타 심리적 장애와 연관된 구토) |\n| (3) 병용약물: 복용 여부 및 종류 | (4) The EuroQol Visual Analogue Scale (EQ-VAS) | 가설은 아래와 같다. | 열람자, 해제 후 조치사항 등에 대한 문서를 기록·보관한다. | (AB-1234) |\n| - 안전성 자료(Safety Set, SS) | 위한 통계처리 시 삽입할 수 있다. | 대해 이미 알려진 정보와 일관된 양상을 보이는 경우 | 장애와 연관된 구토) |\n| tice Review, 11, 133 - 143. | 대응 계획을 수립하여야 한다. | 유효성 |\n\n**[표 끝]**\n\n소프트웨어\n\n- - 32 -\n※ 예: 보안이 보장되지 않은(unsecure) 운영\n\n체제 버전에서 운영되는 의료기기 소프트웨어\n\n확인 자료\n\n- - 33 -\n5) 허가·인증 변경 시 제출자료\n\n사이버 보안에 영향을 미치는 변경(통신방법의 변경/추가,\n\n운영체제의 변경/추가, 통신 목적 변경/추가 등)이 포함된 경우\n\n에는 「의료기기 허가·신고·심사 등에 관한 규정」(식약처\n\n고시) 제19조의2(의료기기 소프트웨어 허가ㆍ인증ㆍ신고의 변경\n\n처리)에 따라, 소프트웨어 업그레이드에 해당되므로 변경허가‧\n\n이 경우에는 신규 허가와 마찬가지로 ‘의료기기 소프트웨어\n\n적합성 확인보고서’, ‘의료기기 사이버보안 요구사항 체크\n\n리스트’와 체크리스트의 요구사항을 실제로 검증 또는 검증을\n\n대체한 사유를 확인할 수 있는 자료(소프트웨어 검증 및 유효성\n\n확인자료, 성능시험성적서, 위험관리문서 등)를 제출하여야\n\n- - 34 -\n<!-- PAGE_41 -->\n##### 3. 성능 평가 항목\n\n섭식장애 개선 디지털치료기기의 성능 평가 항목은 제품의 주요\n\n기능을 근거로 설정하며, 시험 기준 및 시험 방법은 제품의 특성을\n\n고려하여 가능한 정량적이고 구체적으로 작성한다.\n\n- - 35 -\n본 예시는 이해를 돕기 위하여 작성된 것으로 실제 신청하려는 제품의 내용과 상이\n\n예시)\n\n- - 36 -\n<!-- PAGE_43 -->\n### Ⅲ\n\n<!-- PAGE_43 -->\n### 임상시험계획서 작성 시 고려사항 및 예시\n\n「의료기기법 시행규칙」제20조(임상시험계획의 승인 등) 제2항에 따라\n\n임상시험계획서에 포함되어야 할 사항은 다음과 같다.\n\n- 1. 임상시험의 제목\n- 2. 임상시험기관의 명칭 및 소재지\n- 3. 임상시험의 책임자ㆍ담당자 및 공동연구자의 성명 및 직명\n- 4. 임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n- 5. 임상시험을 하려는 자의 성명 및 주소\n- 6. 임상시험의 목적 및 배경\n- 7. 임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다)\n- 8. 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되어 임상시험에\n- 9. 임상시험기간\n- 10. 임상시험방법(사용량ㆍ사용방법ㆍ사용기간ㆍ병용요법 등을 포함한다)\n- 11. 관찰항목ㆍ임상검사항목 및 관찰검사방법\n- 12. 예측되는 부작용 및 사용 시 주의사항\n- 13. 중지ㆍ탈락 기준\n- 14. 유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 따른다)\n- 15. 부작용을 포함한 안전성의 평가기준ㆍ평가방법 및 보고방법\n- 16. 피험자동의서 서식\n- 17. 피해자 보상에 대한 규약\n- 18. 임상시험 후 피험자의 진료에 관한 사항\n- 19. 피험자의 안전보호에 관한 대책\n- 20. 그 밖에 임상시험을 안전하고 과학적으로 실시하기 위하여 필요한 사항\n- - 37 -\n<!-- PAGE_44 -->\n##### 1. 임상시험의 제목\n\n**[표 시작]**\n\n| 임상시험 의뢰자는 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 | 임상시험 방법은 해당 의료기기에 대한 모양, 구조 및 사용 전 준비사항, 피험자에 |\n| --- | --- |\n**임상시험용 ‘섭식장애 개선 디지털치료기기’의 안전성과 유효성을 증명하고자**\n**임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료 방법 등을 제공**\n\n**[표 끝]**\n\n[예시]\n\n섭식장애 진단환자의 섭식장애 증상을 개선하기 위해서 사용되는\n\nOOO 디지털치료기기의 안전성 및 유효성을 평가하기 위한 전향적\n\n[F50.4] Overeating associated with other psychological disturbances\n\n[F50.5] Vomiting associated with other psychological disturbances\n\n- - 38 -\n[F50.8] Other eating disorders (기타 식사장애)\n\n[F50.9] Eating disorder, unspecified (상세불명의 식사장애)\n\n2) 의료기기의 사용 목적 : 환자의 섭식장애 증상을 정량적으로 개선\n\n- - 39 -\n<!-- PAGE_46 -->\n##### 2. 임상시험기관의 명칭 및 소재지\n\n임상시험\n\n- - 40 -\n<!-- PAGE_47 -->\n##### 3. 임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n- 가. 시험책임자\n- 나. 시험담당자\n- 다. 공동연구자\n- 라. 임상시험 조정자\n- - 41 -\n<!-- PAGE_48 -->\n##### 4. 임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n의료기기 관리자\n\n- - 42 -\n<!-- PAGE_49 -->\n##### 5. 임상시험을 하려는 자의 성명 및 주소\n\n- 가. 의뢰자\n- 나. 모니터요원\n- 다. 임상시험 수탁업체\n※ 임상시험 수탁기관(CRO: Contact Research Organization)이 있는 경우 해당\n\n- - 43 -\n<!-- PAGE_50 -->\n##### 6. 임상시험의 목적 및 배경\n\n- 가. 임상시험의 목적\n1) 임상시험용 디지털치료기기의 섭식장애 치료에 대한 안전성 평가\n\n2) 임상시험용 디지털치료기기의 섭식장애 치료에 대한 유효성 평가\n\n최근 섭식장애로 치료받는 환자가 증가하는 추세로 섭식장애를 치료\n\n하는 방법 또한 많은 주목을 받고 있다. 임상에서 섭식장애 환자에게\n\n주로 사용되는 치료는 비약물 치료이며, 그중에서도 인지행동치료가\n\n가장 널리 사용되고 있다. 선행연구에 의하면, 섭식장애를 진단받은\n\n환자를 대상으로 비약물적 중재와 약물적 중재의 효과를 비교한\n\n연구에서 약물적 중재보다 비약물적 중재를 적용한 군이 오히려 폭식\n\n증상 감소에 효과적인 것으로 보고된 바 있으며(Vocks et al., 2010),\n\n비약물적 중재가 식이에 대한 태도를 긍정적으로 변화시키는 것으로\n\n나타났다(Yun&Kim, 2018).\n\n섭식장애 인지행동치료 등 비약물 치료 효과가 미비한 경우, 필요\n\n하다면 약물치료를 통해 섭식장애를 개선할 수 있다.\n\n- - 44 -\n최근 디지털 기반 섭식장애 치료는 웹 또는 스마트폰 앱 기반으로\n\n인지행동치료를 시행한다. 이를 통해 환자들이 직접 집에서 컴퓨터,\n\n혹은 스마트폰을 이용하여 치료를 시행 받을 수 있으므로 시·공간의\n\n제약에서 자유롭게 될 것이며, 치료 대부분을 환자가 프로그램을 통해\n\n수행하고 피드백을 받을 수 있으므로 치료자 관점에서 비용 대비\n\n효용성 또한 증가하게 될 것으로 기대된다.\n\n섭식장애 인지행동치료의 효과에 관한 여러 연구 결과가 발표되고\n\n있다. 특히, 최근 연구들은 단순히 섭식장애 인지행동치료를 디지털\n\n환경으로 옮기는 것에서 발전하여, 애플리케이션을 통하여 환자에게\n\n바로 피드백을 제공함으로써 의사나 치료자가 직접적인 가이드를 주지\n\n않더라도 치료 효과를 볼 수 있게 하는 “디지털치료기기(Digital\n\nTherapeutics, DTx)”의 개념을 추구하고 있다.\n\n본 임상시험을 통해 섭식장애 환자들을 대상으로 개발된 섭식장애\n\n개선 디지털치료기기의 작용기전에 대한 안전성(safety)과 유효성\n\n(effectiveness)을 검증하고자 한다.\n\n- - 45 -\n- 나. 임상시험의 배경\n디지털치료기기란 질병이나 장애를 예방, 관리, 치료하기 위해 환자에게\n\n근거 기반의 치료적 중재(evidence-based therapeutic intervention)를 제공\n\n하는 고도화된 소프트웨어 의료기기를 가리킨다.\n\n디지털치료기기를 통한 인지행동치료의 제공은 디지털치료기기의 최\n\n첨단 접근방식을 통해 환자 개인별로 단계적인 치료를 가능하게 하며,\n\n시간 및 공간 제약 없이 인지행동치료를 가능하게 하여 치료 효과를 높\n\n이며, 더 많은 환자에게 치료 기회를 줄 수 있다는 장점이 있다.\n\n선행연구에 따르면, 폭식장애 환자를 대상으로 16주간 인터넷 기반\n\n중재 프로그램을 시행하였다. 해당 연구는 인지행동 대면 치료 및\n\n자조 요법을 포함한 디지털 인지행동치료 프로그램이 마련되었고, 글\n\n쓰기 과제, 임상심리사로부터의 피드백, 활동 일기, 심리 교육 등으로\n\n구성되었다. 위 연구는 폭식 횟수 감소 등 폭식장애 증상 완화,\n\nEDE-Q 척도 감소 또는 유지, 우울 증상 완화 등의 긍정적 결과를\n\n보였다(Wagner et al., 2016).\n\n또한, 디지털 기반 섭식장애 치료는 섭식장애 환자들의 건강 개선에\n\n효과적인 것으로 입증되었다(terHuurne et al., 2015). 해당 연구에서는\n\n섭식장애를 겪고 있는 여성 환자 총 214명 대상으로 웹 기반의 인지\n\n행동치료(CBT) 중재를 수행했다. 웹 기반 애플리케이션은 21개의\n\n세션과 10개의 과제로 구성되었으며, 참가자들은 하루 약 20분 정도의\n\n중재를\n\n받았다.\n\n일차\n\n유효성\n\n변수는\n\nEDE-Q(Eating\n\nDisorder\n\nExamination-Questionnaire), 이차 유효성 변수는 BAT(Body Attitude\n\nTest)가 사용되었다. 결과적으로 환자들은 신체 및 정신 건강, 자존감\n\n- - 46 -\n등이 크게 상승한 것을 알 수 있었다.\n\n이러한 디지털치료기기는 기존의 섭식장애 개선을 위한 웰니스\n\n프로그램과 다음과 같은 차이점을 가진다. 첫째, 일방적인 콘텐츠\n\n제공을 넘어 쌍방향적인 피드백을 제공한다. 대상자의 섭식장애 증상에\n\n대한 변수를 지속해서 수집하고, 이에 대해 다음 목표를 제시함으로써\n\n치료 효과를 극대화한다. 이 과정에서 피험자는 단순히 콘텐츠를 소비\n\n하는 것을 넘어서, 스스로 콘텐츠에 참여하고 있다는 느낌을 받을 수\n\n있다. 둘째, 피험자 맞춤형 콘텐츠 제공이 가능하다. 모든 콘텐츠를\n\n같은 비율로 제공하는 것에 그치지 않고 피험자의 정보를 수집함으로써\n\n취약한 부분에 대한 집중적인 맞춤형 콘텐츠 제공을 하는 것이 가능\n\n하다. 셋째, 일정 시간 동안의 꾸준한 사용을 독려하며 치료 효과에\n\n대한 모니터링이 가능하다. 일반적으로 디지털치료기기는 모든 콘텐츠를\n\n한 번에 제공하지 않고 일정 기간 순차적으로 콘텐츠 제공하여 사용\n\n기간을 조정한다. 피험자들은 치료 기간 중 섭식장애 증상이 어떻게\n\n변화하는지 실제 체감하고, 또한 디지털치료기기를 통한 모니터링을\n\n받을 수 있어 치료 동기 부여에 긍정적으로 작용할 수 있다.\n\n본 연구에서는 국내에서 개발된 디지털 섭식장애 인지행동치료\n\n애플리케이션을 무작위배정 임상시험을 통해 효과성과 안전성 검증을\n\n함으로써 해당 애플리케이션을 실제 국내 임상에서 활용할 수 있는지\n\n확인을 할 수 있으며 국내 섭식장애 환자들에게 새로운 치료의 선택지를\n\n열어주고자 한다.\n\n- - 47 -\n- 7. 임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증 포함)\n- 가. 임상시험용 의료기기 사용 목적\n[예시]\n\n[사용 목적]\n\n모바일 애플리케이션 형태의 섭식장애 인지행동치료 기반, 혹은 이와\n\n유사한 과학적 근거를 가진 섭식장애의 비약물적인 치료에 근간한\n\n콘텐츠를 범용 장비(스마트폰 또는 태블릿 PC)를 통해 제공하는 소프트\n\n웨어 의료기기이다. 임상시험용 기기는 섭식장애 인지행동치료(CBT)\n\n혹은 이와 유사한 과학적 근거를 가진 섭식장애의 비약물적인 치료를\n\n제공하여 대조군 대비 섭식장애 증상을 개선하는 것을 목표로 한다.\n\n본 의료기기는 의사에게 섭식장애* 진단을 받은 환자를 대상으로\n\n하며, 추후 추가적인 적응증 확대는 가능하나 섭식장애에 대한 의사\n\n진단을 기반으로 한다.\n\n[F50.4] Overeating associated with other psychological disturbances (기타 심리적\n\n[F50.5] Vomiting associated with other psychological disturbances (기타 심리적\n\n- - 48 -\n[F50.8] Other eating disorders (기타 식사장애)\n\n[F50.9] Eating disorder, unspecified (상세불명의 식사장애)\n\n- - 49 -\n- 나. 임상시험용 의료기기 정보\n- - 품목명(품목분류번호, 등급): 인지치료소프트웨어(E06060.02, 2등급)\n※ 대조 시험용 의료기기의 구체적인 정보를 ‘가)’를 참고하여 작성한다. 대조\n\n시험용 의료기기가 설정되지 않았을 경우 생략할 수 있으며, 설정하지\n\n- 다. 임상시험용 의료기기 사용 방법\n- - 치료에 앞서 범용장비(스마트폰, 태블릿, PC 등)에 OOO\n- - 50 -\n2) 사용 방법\n\n가) OOO 디지털치료기기를 실행한다.\n\n: 성별, 나이, 섭식장애 치료 약물 복용 여부, 섭식장애 증상에\n\n대한 기초 평가(섭식장애 증상의 빈도, 섭식장애 증상으로 인한\n\n불편감, 우울을 포함한 기타 정신과적인 정도 등이 포함될 수\n\n다) 디지털치료기기를 통한 섭식장애와 관련된 인지 및 행동의\n\n교정은 식사일기(식사 시간, 함께 식사한 대상, 식사를 한 장소,\n\n식사 전의 배고픔 정도와 식사 후의 배부름 정도, 감정 등),\n\n라) 상술한 치료의 경우 환자의 순응도를 높이기 위한 전략이\n\n포함되어야 하며(콘텐츠 제공 방식의 다양화, 알림 제공, 보상\n\n방안 등을 포함) 환자가 입력한 정보에 따른 피드백이 제공\n\n되어야 하고 환자가 스스로 입력한 정보를 모니터링 할 수\n\n- - 51 -\n<!-- PAGE_58 -->\n##### 8. 피험자의 선정기준·제외기준·인원 및 그 근거\n\n- - 52 -\n[예시]\n\n- 가. 피험자 선정기준\n2) DSM-5의 섭식장애 진단기준을 만족하거나 ICD-10에 의거한 섭\n\n[F50.4] Overeating associated with other psychological disturbances (기타\n\n[F50.5] Vomiting associated with other psychological disturbances (기타\n\n3) 스마트폰을 이용하여 모바일 애플리케이션 사용에 어려움이 없는 자\n\n4) 본 임상시험에 대해 충분한 설명을 듣고 이해한 후, 자의로 참여를\n\n- 나. 피험자 제외기준\n: 제외기준 중 어느 하나라도 해당하는 항목이 있는 경우 본\n\n- - 53 -\n2) 비만대사 수술*(Bariatric surgery)의 과거 수술력이 있는 자\n\n* 조절형 위밴드술, 위소매 절제술, 담췌 우회술, 루와이 위우회술 등\n\n4) MINI(Mini international neuropsychiatric interview)에 의거한\n\n6) 자살 위험이 있거나 (C-SSRS 4점 이상) 최근 2주 이내에 자살을\n\n7) 활동적이고 진행중인 신체적 질환 (예:울혈성 심부전, 만성\n\n폐쇄성 폐질환, 급성 통증), 신경 장애 (예:뇌혈관 질환), 신경\n\n퇴행성 질환 (예:치매, 다발성 경화증)을 가진 자, 불안정한\n\n※ 피험자 선정기준 및 제외기준은 의료기기의 특성, 내용 구성 등을\n\n- - 54 -\n- 다. 목표대상자 수 및 그 근거\n※ 본 가이드라인에 작성된 산출 방법은 공개된 선행연구 결과를 기반으로 작성된\n\n예시이며, 목표 대상자 수는 개발 제품 특성과 탐색 임상시험 등 제품별 선행\n\n연구 결과에 따라 다르므로, 개발 제품의 선행연구 결과 및 참고문헌을\n\n기준으로 산출한다. 이때, 그 근거(가설, 변수, 성공기준)를 함께 제시하여야\n\n본 시험의 일차목적: 섭식장애 환자에서 베이스라인 (사용 전)\n\n대비 8 주 시점의 식사장애 검사(EDE-Q)의 변화량이 기존\n\n치료군 대비 의료기기 사용군에서 비열등하게 개선되었는지\n\n확증하는 것이다. 변화량은 치료 시작 전 평가지표 Baseline\n\n조사에서 수집한 정보와 Post-treatment (의료기기 사용 8주 후\n\n시점) 조사에서 수집한 정보와의 차이를 의미하며, 이에 대한\n\n- - 55 -\n    ≥\n\n      \n\n※ 또한, 비열등성 허용 오차는 임상 근거에 기반하여 수치가 달라질 수 있으나,\n\n비열등성 허용오차는 Grilo et al. (2022)에서의 대조군인\n\nplacebo군과 기존 BWL(Behavioral weight loss therapy) 과\n\n약물(naltrexone, bupropion) 처리군의 변화량 효과 차이를\n\n섭식장애 환자를 대상으로 한 기존 비교 임상연구를 검토한\n\n결과, 식사장애 검사(EDE-Q) 변화량은 다음 표와 같이 조사\n\n대조군의 baseline 대비 16주 시점에서의 식사장애 검사\n\n(EDE-Q) 변화량 차이는 –3.74이고 표준편차는 11.32이나\n\n본 임상시험의 치료기간은 8주로 참고문헌에 비해 짧으므로\n\n- - 56 -\n해당 효과의 50% 정도인 –1.87로 설정하였다.\n\n기존 대조군의 baseline 대비 16주 시점에서의 식사장애 검사\n\n(EDE-Q) 변화량 차이는 –12.79이고 표준편차는 8.24이나 위와\n\n각 군의 표준편차도 효과 평균과 동일하게 50% 반영하여\n\n각 4.1, 5.7로 설정하여 차이에 대한 합동표준편차는 5.0로\n\n두 참고문헌을 통해 8주 시점에서의 기존 대조군 대비\n\nplacebe 군 효과는 (-6.40)-(-1.87)=-4.53 정도로 추정되며, 비\n\n열등성 허용오차 (-기호)는 해당 효과의 절반 정도인 -2.26이다.\n\n선행연구인 Mond et al.(2004), Mond et al.(2008)의 연구에서\n\nEDE-Q에 대한 cut-off 값을 각각 2.3, 2.8이었던 점을 감안\n\n하여, 본 가이드라인의 비열등성 허용오차는 -2.5로 설정하고자\n\n이에 단측 유의수준 2.5%, 검정력 80%를 만족하는 데\n\n필요한 피험자 수(군당 1:1 배정)를 산출한 결과, 중도 탈락률\n\n5%를 고려하여 목표 피험자 수는 총 128명(군당 64명)으로\n\n두 군의 평균 차이 검정에 대한 피험자 수 산출 공식은\n\n- - 57 -\n \n\n  \n\n ×  ×      \n\n\n\n\n\n \n\n ×  ×   \n\n≈ \n\n- - 58 -\n피험자의 모집 기간, 임상 관찰 및 수행 기간, 통계분석 기간, 결과\n\n보고서 작성 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을\n\n고려하도록 한다.\n\n<!-- PAGE_65 -->\n##### 9. 임상시험기간\n\n- - 59 -\n- 가. 시험방법\n가) 시험기기: 디지털 섭식장애 인지행동치료 애플리케이션 및\n\n- (예) 섭식장애 인지행동치료 등의 기능이 탑재된 애플리케이션\n※ 섭식장애 개선 디지털치료기기 허가 제품이 출시된 이후에는 기허가\n\n제품과 비교시험 하는 동등성 검정 혹은 비열등성 검정 등을 시행\n\n* 비열등성/동등성 시험(Non-inferiority, equivalence trial): 비교 연구에 있어\n\n대조기기와 비교해 시험기기의 성능이 열등하지 않음을 보이거나,\n\n3) 최소 3회의 외래 방문을 통한 조사: 방문 1(Screening/Baseline),\n\n- 10. 임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n- - 60 -\n방문 3(Follow-up, 4주 후), 방문 5(Follow-up, 8주 후)\n\n※ 방문 2(Follow-up, 2주 후), 방문 4(Follow-up, 6주 후)는 전화를 통해\n\n시행하나, 필요시 애플리케이션, 이메일, 문자, SNS 등을 통해 수집할\n\n4) 층화무작위배정: 성별(남/여), 단일(다)기관, 시험군 및 대조군 1:1 배정\n\n- - 기관별로 내원한 환자 중 선정, 제외 기준에 따라 적합한\n- - 본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한\n내용을 피험자 본인 또는 대리인에게 설명하고, 피험자 또는\n\n대리인이 내용을 잘 이해한 것을 확인한 다음, 자유의사에 따른\n\n임상시험 참가의 동의를 문서로 받는다. 또한 동의에 서명한\n\n연월일을 기록하며, 동의서 사본을 환자에게 제공하여 환자가\n\n지속해서 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n- - 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력\n등에 대하여 차트 확인 등을 통하여 점검하고 증례 기록서에\n\n- - 61 -\n라) 피험자 식별코드 부여\n\n- (1) 피험자에게 서명하고 동의를 받은 후 동의 취득 순서에 따라\n스크리닝 번호를 부여하며 피험자가 참여를 종료할 때까지\n\n- (2) 피험자 적합성 평가: 피험자 선정 및 제외 기준에 적합한지\n· 베이스라인 (사용 전) 대비 8주 시점의 식사장애 검사\n\n· 일차 유효성 평가지표를 통해 유효성을 검증하는 것이\n\n기본적인 원칙이지만, 이외 필요하면 변수를 이차 유효성\n\n· 과학적인 근거를 가진 변수이되, 기존 섭식장애 증상 개선\n\n- - 62 -\n측정도구\n\n설명\n\nEDE-Q는 총 28 개 문항으로 구성되어 있으며, 섭식장애의\n\n주요\n\n병리를\n\n측정하는\n\n식사제한, 식사관심, 체형관심,\n\n체중관심의\n\n4개\n\n하위요인으로\n\n구성되어\n\n있다. 점수가\n\n높을수록 섭식 행동 및 태도에 문제가 있는 것을 의미한다.\n\nCIA 를 통해 섭식장애와 관련된 세 가지 주요 영역(개인적,\n\n사회적, 인지적)에 대한 이차적인 손상 정도를 평가한다.\n\n점수가 높을수록 섭식장애로 인한 개인적, 사회적, 인지적\n\nPHQ-9를 통해 우울 증상을 평가한다. DSM-IV의 주요\n\n우울장애의 진단기준에 의거하여 지난 2주간의 무쾌감,\n\n우울감, 수면의 변화, 피로감, 식욕의 변화, 죄책감, 무가\n\n치감, 집중력 저하, 좌불안석 또는 쳐진 느낌, 자살사고의\n\n**[표 시작]**\n\n| 시하는 자, 임상시험심사위원회 및 식품의약품안전처장이 관계 | - 대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 | - 피험자가 임상시험 중 임상시험 참여 중단을 요구하거나 시험 | 구간을 제시한다. 95% 신뢰구간 상한이 비열등성 마진(2.5)을 | 9 가지 문항으로 구성되어 있다. 점수가 높을수록 우울 |\n| --- | --- | --- | --- | --- |\n**쌍방향 웹반응시스템(Interactive Web Response System,**\n| 법령에 따라 임상시험의 실시 절차와 자료의 품질을 검증하기 | - 정해진 기간에 환자에게 해가 되지 않는 내용으로 과학적 근거에 | - 이상 반응이 다른 가능성이 있는 원인과 같은 수준으로 임상 | * 순응도란 치료 기간 내 총 노출된 모듈 횟수를 통해 평가한다. 총 | 포함하지 않으면 통계적으로 비열등하다고 판단한다. 또한, |\n\n**[표 끝]**\n\nGAD-7은 범불안장애 환자를 선별 진단하기 위해 개발된\n\n선별평가도구로 불안 또는 걱정과 관련된 7가지 문항에\n\n대해 그 정도를 0점 (전혀 없었다)에서 3점(거의 매일\n\n괴로웠다.)까지 체크하여 불안 증상을 평가한다. 총점은\n\n0-21점 사이가 되며, 점수가 높을수록 불안 증상의 심각도가\n\nEQ-VAS는 일반적으로 사용되는 삶의 질 설문지 중 하나로,\n\n피험자의 전반적인 건강 상태를 0점에서 100점 척도로\n\n평가한다. 점수가 높을수록 전반적인 건강 상태가 좋다는\n\nCGI-S 는 피험자의 전반적인 질병 상태의 심각도를 평가\n\n하는 설문지로, 점수가 높을수록 질병 심각도가 높다는\n\n표 13. 섭식장애 이차 유효성 평가 지표 측정도구 예시\n\n- - 63 -\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록\n\n- - 각 관찰 항목에 대한 평가 도구 및 평가 방법에 대한 자세한\n측정도구\n\n설명\n\n4주, 8주 시점의 Clinical\n\n- (1) Clinical Global Impression of Improvement (CGI-I)\nCGI-I 는 피험자의 전반적인 건강상태의 개선 정도를 평가\n\n하는 설문지로, 시험자는 피험자의 건강상태의 개선 또는\n\n악화 정도를 7점 척도로 평가하며, 점수가 낮을수록 개선도가\n\n앱을 통해 수집된 자기 모니터링 식사일기를 통하여 피험자의\n\n베이스라인 (사용 전) 대비 임상시험용 의료기기 사용 후 8 주\n\n- - 64 -\n- 나. 설계 방법\n[예시]\n\n- - 연구자는 선정제외기준에 합격한 피험자의 순서대로 배정일에\n- - 본 연구와 독립된 통계학자가 SAS 통계 패키지를 가지고 층화\n순열화 블록 무작위배정법(stratified permuted block randomization)을\n\n- - 연구의 특성상 단일맹검을 지향하되, 필요하면 비맹검 임상시험을\n- - 단일맹검인 경우, 임상시험 도중 응급상황 발생 등으로 인하여\n피험자의 눈가림을 해제할 수 있다. 이 경우, 사유와 해제일,\n\n- - 65 -\n<!-- PAGE_72 -->\n##### 11. 관찰항목·임상검사항목 및 관찰검사방법\n\n[예시]\n\n- 가. 임상시험 일정표\n- - 66 -\n- 나. 임상시험 절차\n[예시]\n\n- - 임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여\n대상자 또는 법정대리인에게 상세히 설명한다. 서명 일자를\n\n정확히 기재하여야 하며, 작성된 동의서 원본은 시험자가 보관\n\n하고 사본은 시험대상자 또는 법정대리인에게 내준다. 대상자\n\n에게 동의를 받은 후 동의 취득 순서에 따라 스크리닝 번호를\n\n- - 인구학적 정보로 대상자 이니셜, 만 나이, 성별, 직업을 조사\n하며 기초 문진에 필요한 환자들의 의학적 특성에 대한 정보\n\n- - 피험자 선정을 위한 식사장애 검사(EDE-Q) 조사 정보를\n- - 필요하면 본 단계에서 수집한 정보를 Baseline 지표로 활용할\n- - 67 -\n마) 과거 병력 조사\n\n- - 병력 등을 문진과 과거 진료 기록을 통해 조사한다.\n- - 병력조사에 포함되어야 하는 내용은 다음과 같다. 치매, 인지\n기능 장애, 정신증, 양극성 장애 및 현재 주요 우울 삽화\n\n(current major depressive episode) 등 스크리닝 확인해야 할\n\n질병군 등의 과거력 및 현 병력, 발생 시기, 치료와 진행 여부\n\n- - 동의서 취득일 기준으로 최근 5년 이내 과거 및 현재 병력을\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 일차 유효성 평가지표, 이차 임상 변수를 평가하기 위해 식사장애\n검사(EDE-Q)를 작성하도록 하여 지참하게 하거나, 애플리케이션\n\n- - 필요에 따라 방문 1(스크리닝 단계)에서 측정한 식사장애 검사\n- - 68 -\n(EDE-Q)를 Baseline 지표로 활용할 수 있다.\n\n나) 무작위배정\n\n- - 회원가입 및 초기 증상평가를 시행한다(기본 입력 정보: 성별,\n나이, 섭식장애 증상의 정도, 섭식장애 증상으로 인한 행동의\n\n- - 정해진 기간에 상술 된 방식으로 디지털치료기기 콘텐츠를\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 진찰을 통해 관찰하고, 임상시험용\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 69 -\n기간, 목적을 확인한다.\n\n사) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 치료 후 평가 및 일차 유효성 평가지표, 이차 유효성 평가지표의\n변화를 검증하기 위해 섭식장애 평가 항목 및 해당하는 자가\n\n보고 척도를 작성하도록 하여 지참하게 하거나, 애플리케이션을\n\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 70 -\n기간, 목적을 확인한다.\n\n라) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 장기 효과 확인을 위한 일차 유효성 평가지표, 이차 유효성\n평가지표의 변화를 검증하기 위해 섭식장애 평가 항목 및\n\n해당하는 자가 보고 척도를 작성하도록 하여 지참하게 하거나,\n\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 71 -\n기간, 목적을 확인한다.\n\n라) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 72 -\n<!-- PAGE_79 -->\n##### 12. 예측되는 부작용 및 사용 시 주의사항\n\n[예시]\n\n- 가. 예측되는 부작용\n본 연구에서 적용하는 치료는 디지털 섭식장애 인지행동치료(CBT),\n\n혹은 이에 상응하는 과학적 근거를 가진 섭식장애의 비약물적인 치료이다.\n\n섭식장애 인지행동치료 및 기타 비약물적인 치료의 경우 행동 요법\n\n또는 인지 요법을 포함한 교육 이외 침습적이거나 환자에게 유해를\n\n끼칠 수 있는 내용은 포함되어 있지 않다. 다만, 일반적인 섭식장애\n\n인지행동치료의 부작용 정도에 대한 부작용 또는 범용장비 사용으로\n\n인한 부작용을 예상할 수 있고, 이는 다음과 같다.\n\n1) 섭식장애 인지행동치료의 행동 요법 중 노출 치료의 경우, 섭식\n\n장애 증상의 발생 및 악화가 나타날 수 있다. 섭식장애 이외 기타\n\n정신과적인 증상의 악화 위험이 큰 사람, 특히 자살 생각을 하는\n\n사람의 경우 임상시험에서 배제함으로써 위험도를 최소화할 수\n\n있다. 이 외에도 치료 시작 시점에서 일시적인 불안감, 악화감이\n\n나타날 수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통\n\n하여 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.\n\n2) 섭식장애 인지행동치료의 인지 요법 중 왜곡된 인지 교정의 경우\n\n역기능적인 사고의 탐색 및 교정의 과정에서 일시적인 불안감\n\n- - 73 -\n악화를 가져올 수 있다. 상술한 것과 같이 선정 및 제외 기준을\n\n활용하여 위험도를 최소화하며, 실험에 참여한 환자들을 대상\n\n으로는 치료 시작 시점에서 일시적인 불안감 악화가 나타날\n\n수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통하여\n\n3) 섭식장애 개선 디지털 치료를 위한 범용 장비(스마트폰 또는\n\n태블릿 PC 등) 사용으로 두통, 눈의 피로, 눈 또는 근육경련, 눈의\n\n불수의운동, 메스꺼움, 어지럼증, 머리 또는 눈의 불쾌감 또는 통증,\n\n졸림, 피로감과 같은 부작용이 발생할 수 있다. 해당 경우 24시간\n\n연락 가능한 연구자 번호를 통하여 즉시 상담과 필요하면 의료진\n\n본 연구에서 진행되는 평가는 자가 보고 설문지, 면담 등 모두\n\n비침습적인 검사로 이루어져 있으므로 예측되는 부작용은 없다.\n\n- 나. 사용 시 주의사항\n본 연구에서 적용하는 섭식장애 개선 디지털치료기기의 부작용,\n\n일반적 주의, 적용상의 주의는 다음과 같다.\n\n본 제품을 사용한 후 제품에 대한 부적합 반응이 전부 배제될\n\n사이버 보안과 관련된 사고 발생 시 임상시험 관리자 긴급\n\n- - 74 -\n번호로 연락하고 관리자가 조치할 때까지 대기한다.\n\n7) 적용상의 주의\n\n사용 시간, 사용 횟수, 결과 작성 등 임상시험 책임자와 담당자가\n\n- - 75 -\n<!-- PAGE_82 -->\n##### 13. 중지·탈락 기준\n\n[예시]\n\n- 가. 중지\n- - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n- - 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는\n- - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n- - 중지 시점까지의 검사 결과 관련 자료는 성능과 안전성 평가를\n- - 76 -\n- - 임상시험을 통해 얻은 자료는 성능 및 안전성 분석을 위한\n데이터가 정해져야 하며, 만약 자료에 결함이 생기면 적절한\n\n보정 방법을 임상시험계획에서 제시하고 보정 후 분석을 시행\n\n- - 동의를 철회하였으면 해당 시점 이후의 수집된 피험자의 정\n- 나. 탈락\n: 시험자는 다음과 같은 경우에 연구 참여 대상자를 시험에서\n\n- - 피험자의 부작용(예: 두통, 눈의 피로, 눈 또는 근육경련, 눈의\n불수의운동, 메스꺼움, 어지럼증 등)으로 인하여 임상시험 책임자\n\n- - 피험자가 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n- - 피험자의 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n- - 임상시험 중 선정/제외 기준 위반 등 중대한 계획서 위반\n- - 77 -\n- - 기타 사유로 인하여 임상시험 책임자 또는 담당자가 임상\n시험을 중지해야 한다고 판단한 경우\n\n- - 섭식장애 연관 증상이 지나치게 악화되어 다른 정신과적 건강\n- - 중도 탈락 시, 시험자는 대상자의 임상시험 조기 탈락의 주요\n사유를 평가하여 증례 기록서 임상시험 완료 항목에 해당 정보를\n\n- - 참여 중단 의사를 밝히지 않고 방문에 출석하지 않아 현재\n상태가 불분명한 대상자의 경우에 시험자는 대상자와 전화\n\n- - 78 -\n- 14. 유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 의함)\n- 가. 유효성의 평가 기준\n[일차 유효성 평가변수]\n\n[이차 유효성 평가변수]\n\n1) 베이스라인 (사용 전) 대비 4주, 8주 시점의 하기 지표 변화량\n\n- - 79 -\n- (5) Clinical Global Impression of Severity (CGI-S)\n2) 4주, 8주 시점의 Clinical Global Impression of Improvement\n\n- - 80 -\n- 나. 검사방법\n1) Eating Disorder Examination Questionnaire (EDE-Q)\n\nEDE-Q는 총 28개 문항으로 구성된 자가 설문지이며, 섭식장애의\n\n주요 병리를 측정하는 식사제한, 식사관심, 체형관심, 체중관심의\n\n4개 하위요인으로 구성되어 있다. 빈도를 묻는 문항을 제외하고 지\n\n난 4주간의 증상을 0점에서 6점까지 7점 척도로 평가한다. 점수가\n\n높을수록 섭식 행동 및 태도에 문제가 있는 것을 의미한다 (Bang,\n\n본 연구에서는 방문 1, 방문3, 방문 5에 EDE-Q 척도 평가를 수행\n\n할 예정이고 일차 유효성 평가는 EDE-Q로 평가할 예정이다. 측정\n\nCIA를 통해 섭식장애와 관련된 세 가지 주요 영역(개인적, 사회적,\n\n인지적)에 대한 이차적인 손상정도를 평가한다. CIA는 총 16개 문항의\n\n짧은 자기보고형 평가도구로, 0점에서 3점까지 4점 척도로 평가한다.\n\n점수가 높을수록 섭식장애로 인한 개인적, 사회적, 인지적 손상이\n\nPHQ-9를 통해 우울 증상을 평가한다. DSM-IV의 주요우울장애의\n\n진단기준에 의거하여 지난 2주간의 무쾌감, 우울감, 수면의 변화,\n\n피로감, 식욕의 변화, 죄책감, 무가치감, 집중력 저하, 좌불안석 또는\n\n- - 81 -\n쳐진 느낌, 자살사고의 9가지 문항으로 구성되어 있다. 각각의\n\n요소는 0점 (전혀없음)에서 3점(거의 매일)으로 구성되어 총점은\n\n0-27점 사이가 된다. 점수가 높을수록 우울 증상이 심각하다는 것을\n\nGAD-7은 범불안장애 환자를 선별 진단하기 위해 개발된 선별평\n\n가도구로 불안 또는 걱정과 관련된 7가지 문항에 대해 그 정도를\n\n0점 (전혀 없었다)에서 3점(거의 매일 괴로웠다.)까지 체크하여 불안\n\n증상을 평가한다. 총점은 0-21점 사이가 되며, 점수가 높을수록 불안\n\n증상의 심각도가 높고 기능저하도 심한 것을 의미한다(Kim,Park et\n\nEQ-VAS는 일반적으로 사용되는 삶의 질 설문지 중 하나로, 피험자의\n\n전반적인 건강 상태를 0점에서 100점 척도로 평가한다. 점수가\n\n높을수록\n\n전반적인\n\n건강\n\n상태가\n\n좋다는\n\n것을\n\n의미한다\n\nCGI-I는 피험자의 전반적인 건강상태의 개선 정도를 평가하는\n\n설문지로, 4주 (방문 3), 8주 (방문 5) 시점에 평가한다. 시험자는\n\n피험자의 건강상태의 개선 또는 악화 정도를 7점 척도로 평가하며,\n\n- - 82 -\n점수가 낮을수록 개선도가 높다는 것을 의미한다(Busner&Targum,\n\n2007).\n\nCGI-S는 피험자의 전반적인 질병 상태의 심각도를 평가하는 설문지로,\n\n베이스라인, 4주 (방문 3), 8주 (방문 5) 시점에 평가한다. 시험자는\n\n높을수록 질병 심각도가 높다는 것을 의미한다(Busner&Targum,\n\nFollow-up 후 4주, 8주 시점에 폭식 횟수 0회 달성 여부 및 치료 전\n\n- - 83 -\n- 다. 통계분석방법\n1) 분석대상군\n\n모든 분석 대상자군(FAS)에 속한 피험자이면서 임상시험\n\n일정대로 모든 수행을 완료하고, 아래의 주요한 임상시험계획\n\n위반이 없는 피험자로 정의한다. 1차/2차 유효성 평가는 계획서\n\n- (4) 임상시험 참여 중 심적/신체적 환경 변화로 있는 것으로 판\n모듈 횟수 중 75% 미만(예, 총 6주의 경우 4주 미만)으로 노출된\n\n배정된 대로 분석(Intention-to-treat, ITT) 원칙을 따르며,\n\n무작위배정된 모든 피험자군 중 주요한 선정기준을 위배하거나\n\n무작위배정된 후 섭식장애 개선 디지털치료기기를 로그인 하여,\n\n한 번이라도 사용한 로그가 존재하지 않거나, 무작위배정 이후\n\n일차 유효성 평가자료가 전무한 경우는 제외한다. 1차/2차\n\n유효성 평가는 모든 분석 대상자군(Full Analysis Set, FAS)를\n\n- - 84 -\n섭식장애 개선 디지털치료기기로 한 번이라도 치료를 받은\n\n모든 피험자로 정의한다. 안전성 평가는 안전성 자료를 대상으로\n\n- - 치료 전 대비 Follow-up 후 8주 시점의 식사장애 검사(EDE-Q)\n: 해당 시점에서의 Post-treatment 후 치료군별 기술통계량(평\n\n: Post-treatment 후 변화량의 군간 차이 검정은 기저치를\n\n공변량으로 한 공분산분석(ANCOVA)을 적용한다. 다른 변수를\n\n통제한 후 배정군 간 평균 변화량에 대한 양측 95% 신뢰\n\n1) 치료 전 대비 Follow-up 후 4주, 8주 시점의 하기 지표 변화량\n\n: CIA, PHQ-9, GAD-7, EQ-VAS, CGI-S 지표를 통해 변화량을\n\n2) 4주, 8주 시점의 Clinical Global Impression of Improvement\n\n3) 치료 전 대비 Follow-up 후 4주, 8주 시점의 폭식 횟수를 0회\n\n- - 85 -\n4) 결측값 처리\n\n- - 모든 분석 대상자군(Full Analysis Set, FAS)에서 중도 탈락 등의\n사유로 치료 후 시점에서 발생하는 결측치는 일차/이차 유효성\n\n평가변수에 대해서는 마지막 관측값 선행 대체법(Last Observation\n\nCarried Forward, LOCF)으로 대치한다. 그 외 자료는 대치 처리\n\n- - 일차 유효성 평가변수는 피험자의 하위집단(성별, 연령별 등)에\n따라 차이가 있는지 탐색적으로 확인하기 위해 하위 분석을\n\n- - 일차 유효성 평가 결과가 기관에 따라 차이가 있는지를 확인\n하기 위해 기관 및 기관과 그룹 간 상호작용을 공분산 분석\n\n모형에 포함하여 기관에 따른 군간 차이가 있는지 분석하여\n\n- - 대치 처리하지 않고 결측치를 고려한 반복측정혼합모형을\n적용하여 주요 결과와 차이가 있는지 탐색적으로 분석하여\n\n- - 86 -\n<!-- PAGE_93 -->\n##### 15. 부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n- 가. 피험자 안전성\n본 임상시험은 저위험(low-risk) 치료용 의료기기의 임상적 평가\n\n이므로 피험자가 직접적으로 받는 인체의 위해도가 없을 수도 있다.\n\n하지만, 치료 도중 피험자한테 문제(예: 낮 시간 졸음이 과도한 현상 등)가\n\n발생하면 임상시험 담당 연구진에게 연락할 수 있는 긴급 연락망을\n\n제공하고, 디지털 기기(애플리케이션) 사용 관련한 문제(예: 버그 문제,\n\n로그인 실패 등)가 발생하면 회사 측 고객센터로 연락할 수 있는\n\n별도의 연락망을 제공한다. 긴급 연락망과 방문을 통해 이상 반응을\n\n수집한다.\n\n- 나. 시험자 안전성\n해당 임상시험용 의료기기는 소프트웨어에 속하며 비침습적이며 짧은\n\n기간 동안 임상시험에 참여하기 때문에 안전에 대한 위험은 없다고\n\n할 수 있다.\n\n- - 87 -\n- 다. 이상 사례의 정의\n1) 이상 사례(Adverse Event, AE)란 임상시험 중 피험자에게 발생한\n\n모든 의도하지 않은 증후(sign), 증상(symptom) 또는 질병을 말하며,\n\n해당 임상시험용 의료기기와 반드시 인과관계를 가져야 하는 것은\n\n2) 의료기기 이상 반응(Adverse Device Effect, ADE)이란 임상시험용\n\n의료기기로 인하여 발생한 모든 유해하고 의도하지 않은 반응으로서\n\n- 라. 이상 사례의 평가\n이상 사례 발현 시 임상시험용 의료기기와의 관련성 여부는\n\n시험자가 다음 기준에 의하여 평가하며, 시험자의 의견을 기술\n\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적\n- - 이상 반응이 다른 어떤 이유보다 임상시험용 의료기기의 사용\n- - 이상 반응이 임상시험용 의료기기 또는 동일 계열의 의료기기에\n- - 88 -\n- ○ 관련성이 많음(Probably related)\n- - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n- - 이상 반응이 다른 원인보다 임상시험용 의료기기의 사용으로\n- - 임상시험용 의료기기의 사용 중단으로 이상 반응이 사라지는\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n- - 임상시험용 의료기기의 사용 중단으로(실시된 경우) 이상\n- - 임상시험용 의료기기의 사용 중단 결과(실시된 경우)가 음성\n- - 임상시험용 의료기기의 재사용(실시된 경우) 결과가 음성이거나\n- - 89 -\n- ○ 관련성이 없음(Definitely not related)\n- - 임상시험용 의료기기를 사용하지 않은 경우\n- - 임상시험용 의료기기의 사용과 이상 반응 발현과의 시간적\n- - 정보가 불충분하거나 상충하여 판단할 수 없고 이를 보완\n- 마. 안전성의 평가 기준\n본 임상시험에서 이상 반응은 임상시험 시작 전에 관찰되지 않은\n\n증상이 발생하는 모든 바람직하지 않은 의학적ㆍ물리적 소견을 이상\n\n반응으로 분류한다. 예측되는 부작용도 이상 반응으로 분류한다.\n\n- 바. 이상 사례 보고 방법\n- ○ 시험책임자는 시험담당자 또는 임상의 등에게 임상시험용 의료\n기기 사용 후 나타날 수 있는 모든 이상 사례에 대하여 교육을\n\n하고 사용 후 나타나는 모든 현상에 대하여 보고하도록 교육을\n\n※\n\n본 내용은「의료기기법 시행규칙」별표 3“의료기기 임상시험 관리기준” 제8호\n\n- ○ 이외에도 시험자가 중대하다고 간주하거나, 임상시험용 의료\n- - 90 -\n기기와의 사용과 연관 지을 수 있는 유의한 위험, 금기, 부작용,\n\n주의사항을 시사하는 사건 등도 중대한 이상 사례/의료기기\n\n이상 반응으로 기록하고 사망을 초래하거나 생명을 위협할\n\n때는 의뢰자가 이 사실을 보고받거나 알게 된 날로부터 7일\n\n이내, 이 경우 상세한 정보를 최초 보고일로부터 8일 이내에\n\n추가로 보고 하여야 한다. 그 밖의 중대하거나 예상하지 못한\n\n모든 이상 반응이 나타났을 때 의뢰자가 이 사실을 보고\n\n- - 91 -\n<!-- PAGE_98 -->\n##### 16. 피험자 동의서 서식\n\n- 가. 피험자 동의서에 반드시 포함되어야 하는 사항\n3) 임상시험용 의료기기에 관한 정보 및 시험군 또는 대조군에\n\n4) 침습적 시술(invasive procedure)을 포함하여 임상시험에서 피험자가\n\n8) 기대되는 이익이 있거나 피험자에게 기대되는 이익이 없을 경우\n\n9) 피험자가 선택할 수 있는 다른 치료방법이나 종류 및 그 치료\n\n방법의 잠재적 위험과 이익\n\n- - 92 -\n10) 임상시험과 관련한 손상이 발생하였을 경우 피험자에게 주어질\n\n보상이나 치료방법\n\n11) 피험자가 임상시험에 참여함으로써 받게 될 금전적 보상이 있는\n\n경우 예상 금액 및 이 금액이 임상시험 참여의 정도나 기간에\n\n13) 피험자의 임상시험 참여 여부 결정은 자발적이어야 하며, 피험자가\n\n원래 받을 수 있는 이익에 대한 손실 없이 임상시험의 참여를\n\n거부하거나 임상시험 도중 언제라도 참여를 포기할 수 있다는\n\n14) 제8호 항목에 따른 모니터 요원, 제8호 항목에 따른 점검을 실\n\n위하여 피험자의 신상에 관한 비밀이 보호되는 범위에서 피험자의\n\n의무기록을 열람할 수 있다는 사실과 피험자 또는 피험자 대리인의\n\n15) 피험자의 신상을 파악할 수 있는 기록은 비밀로 보호될 것이며\n\n임상시험의 결과가 출관될 경우 피험자의 신상은 비밀로 보호\n\n16) 피험자의 임상시험 계속 참여 여부에 영향을 줄 수 있는 새로운\n\n정보를 취득하면 적시에 피험자 또는 피험자의 대리인에게 알릴\n\n17) 임상시험과 피험자의 권익에 관하여 추가적인 정보를 얻고자\n\n- - 93 -\n하거나 임상시험과 관련이 있는 손상이 발생하면 연락해야 하는\n\n사람\n\n18) 임상시험 도중 피험자의 임상시험 참여가 중지되는 경우 및 그\n\n- 나. 피험자 동의의 일반적 요건\n1) 연구자는 연구를 시작하기 전에 임상시험심사위원회(Institutional\n\nReview Board, IRB)로부터 피험자에게 제공될 설명서 및 동의서,\n\n2) 연구자는 임상시험심사위원회 승인 직인이 찍힌 동의서 등을\n\n피험자 또는 피험자의 대리인에게 제공해야 하며, 피험자(또는\n\n대리인)와 동의를 받은 책임연구자(또는 책임연구자의 위임을 받은\n\n자)는 동의서 서식에 서명하고, 자필로 해당 날짜를 기재하여야\n\n3) 연구자는 서명된 동의서를 보관해야 하며, 사본을 피험자(또는\n\n4) 동의서를 받는 과정에서 연구자는 피험자 또는 대리인에게 강제나\n\n부당한 영향을 미치지 않아야 하며, 피험자 또는 대리인이 연구의\n\n모든 정보를 이해할 수 있는 용어 및 언어로 작성된 동의서 등을\n\n제공하여 설명하고 질문에 대하여 대답한 후 충분히 생각할\n\n- - 94 -\n5) 피험자 동의서에는 피험자 또는 대리인의 법적 권리를 포기나\n\n제한, 연구자/의뢰자/기관 및 기관장의 과실 책임의 면제를 암시\n\n6) 피험자의 동의에 영향을 줄 수 있는 새로운 연구 관련정보가\n\n수집되면 동의서 서식, 피험자 설명서 및 기타 문서화된 정보는\n\n이에 따라 수정되어야 하며, 사용 전에 반드시 위원회의 승인을\n\n받아야 한다. 피험자의 지속적인 연구 참여 의지에 영향을 줄 경우\n\n연구 책임자는 피험자 또는 대리인에게 즉시 알리고, 이러한\n\n7) 피험자 또는 대리인이 동의서 등을 읽을 수 없는 경우에는 공정한\n\n- 다. 임상시험 실시 도중 피험자 설명문 등이 변경되었을 때 재동의\n임상시험 실시 도중 동의서 서식이 변경되거나, 피험자에게 제공된\n\n문서 정보의 변경이 있는 경우에는 변경일 기준 다음 방문일에 변경\n\n내용을 피험자에게 충분히 설명하고, 시험책임자(또는 시험담당의사)와\n\n피험자는 변경동의서에 서명하고 해당 날짜를 자필로 적어야 한다.\n\n- 라. 피험자의 대리인이 피험자를 대신하여 임상시험 참여에 동의\n피험자의 이해능력, 의사표현능력의 결여 등의 사유로 동의를 받을\n\n수 없는 경우에는 대리인의 동의를 받을 수 있으며, 이와 같은 경우\n\n에도 피험자는 피험자 자신이 이해할 수 있는 정도까지 임상시험에\n\n관한 정보를 제공 받아야하며, 가능하다면 피험자는 동의서 서식에\n\n- - 95 -\n서명하고 자필로 날짜를 기재하여야 한다. 또한, 피험자의 대리인임을\n\n확인할 수 있는 근거자료 등을 확보하고, 피험자 동의 설명서 등에\n\n대리인의 동의 사유를 구체적으로 기술할 것을 권장한다.\n\n- - 96 -\n<!-- PAGE_103 -->\n##### 17. 피해자 보상에 대한 규약\n\n임상시험용 의료기기가 직접적 원인이 되어 피험자에게 손상이\n\n발생하여 응급조치가 필요한 경우 시험책임자가 가입한 보험에 의해\n\n보상한다. 본 임상시험과 관련이 없는 부작용이 발생한 경우에도 해당\n\n과와의 긴밀한 협조를 통하여 신속한 검사와 처치를 시행한다.\n\n예상된 의료기기 이상반응에 대하여 당사자들 간에 미리 합의한\n\n보상액 또는 조치가 있는 경우, 당해 기준에 따라 이를 보상한다. 그\n\n외의 경우에는 신체손상의 정도, 성격, 지속기간, 유사사례 등을 종합적\n\n으로 고려하여 당사자들 간에 합의한 보상방법에 따라 이를 보상한다.\n\n당사자들 간에 전항의 합의가 이루어지지 아니한 경우에는, 법원의\n\n판결 및 이에 준하는 결정의 확정내용에 따라 보상한다.\n\n- - 97 -\n<!-- PAGE_104 -->\n##### 18. 임상시험 후 피험자의 진료에 관한 사항\n\n본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 OO병원\n\n에서 진행하던 치료절차가 임상시험 참여 전과 다름없이 진행되며,\n\n이후의 치료비는 피험자가 지불하여야 한다. 다만, 부작용 발생 시\n\n임상시험에 사용된 의료기기와의 인과관계 유무를 확인한 후, 본\n\n임상시험에 사용된 의료기기로 인하여 부작용이 발생한 경우 ㈜OOO\n\n에서 치료에 관한 부작용이 소실될 때까지 치료비를 지불한다.\n\n- - 98 -\n<!-- PAGE_105 -->\n##### 19. 피험자의 안전보호에 대한 대책\n\n- 가. 임상시험 실시기관\n임상시험 실시기관의 장은 해당 임상시험의 실시에 필요한 임상\n\n시험실, 설비와 전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를\n\n취할 수 있도록 하는 등 해당 임상시험을 적절하게 실시할 수 있도록\n\n하여야 한다.\n\n- 나. 임상시험심사위원회\n1) 임상시험심사위원회는 국내 법규/관례에 따라 구성되어 있어야\n\n한다. 임상시험심사위원회는 피험자의 권리, 안전, 복지를 보호해야\n\n하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에는\n\n2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가\n\n동의가 적절하게 얻어지지 않았거나 임상시험이 임상시험계획서에\n\n따라 진행되지 않은 경우 또는 중대한 이상반응/의료기기 이상\n\n반응이 나타난 경우에는 임상시험의 일부 또는 전부에 대하여\n\n- - 99 -\n- 다. 시험자\n1) 시험자(Investigator)란 시험책임자, 시험담당자, 임상시험조정자를\n\n말한다. 시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식\n\n품의약품 안전청장의 승인을 득한 임상시험 계획서를 준수하여\n\n2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미\n\n있는 시험실적 검사치의 이상을 포함하여 임상시험에서 발생한\n\n모든 이상반응에 대해 피험자가 적절한 의학적 처치를 받을 수\n\n있도록 조치하여야 하고, 시험자가 알게 된 피험자의 병발질환에\n\n대해 의학적 처치가 필요한 경우 이를 피험자에게 알려주어야 한다.\n\n3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의\n\n- 라. 의뢰자\n1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로\n\n통상의료기기 임상시험의 경우 의료기기 제조업자(수입자를 포함\n\n2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상\n\n3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수,\n\n임상시험의 종류와 복잡성, 피험자에게 미칠 수 있는 잠재적인\n\n위험의 정도 및 이미 확인된 임상시험 실시상의 문제점 등에 따라\n\n- - 100 -\n- 마. 모니터링\n1) 모니터링(Monitoring)이란 임상시험 진행 과정을 감독하고, 해당\n\n임상시험이 임상시험계획서, 표준작업지침서, 임상시험 실시 기준\n\n및 관련 규정에 따라 실시, 기록되는지 여부를 검토, 확인하는\n\n2) 임상시험에 대한 모니터링은 임상시험모니터요원의 정기적인\n\n임상시험 실시기관 방문과 전화 등을 통해서 이루어질 것이다.\n\n방문 시 모니터는 환자기록 원본, 임상시험용 의료기기 관리 기록,\n\n3) 또한 임상시험모니터 요원은 임상시험 진행과정을 잘 살피고,\n\n- 바. 임상시험계획서의 변경\n1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장으로\n\n부터 승인받은 후, 시험절차가 광범위해지거나 위험도가 높아지\n\n거나 피험자 선정기준에 변화가 있거나 추가적인 안전성 정보로\n\n인해 임사시험계획서를 변경하는 경우에는 임상시험심사위원회\n\n2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용\n\n3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한\n\n경우를 제외하고는, 임상시험심사위원회 및 식품의약품안전처장의\n\n변경 승인 이전에는 계획서와 다르게 임상시험을 실시하여서는\n\n- - 101 -\n안 된다. 만일 피험자에게 발생한 즉각적 위험요소를 제거하기\n\n위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험\n\n계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에\n\n대하여 임상시험심사위원회(사후검토 승인을 위함), 의뢰자, 식품\n\n의약품안전처장에게 제출하여야 한다. 그리고 임상시험심사위원회\n\n4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이\n\n- 사. 피험자 동의\n1) 피험자 동의(Informed consent)라 함은 피험자가 임상시험 참여\n\n유무를 결정하기 전에 피험자를 위한 설명서를 통해 해당 임상\n\n시험과 관련된 모든 정보를 제공받고, 서명과 서명 날짜가 포함된\n\n문서를 통해 본인이 자발적으로 임상시험에 참여함을 확인하는\n\n2) 피험자 본인 또는 대리인이 동의서 서식, 피험자 설명서 및 기타\n\n문서화된 정보를 읽을 수 없는 경우에는 공정한 입회자가 동의를\n\n3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의\n\n세부 사항에 대해 질문하고 해당 임상시험의 참여 여부를 결정\n\n할 수 있도록 충분한 시간과 기회를 주어야 하며, 모든 임상시험\n\n관련 질문에 대해 피험자 또는 대리인이 만족할 수 있도록 대답\n\n- - 102 -\n- 아. 피험자 기록의 비밀보장\n1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며,\n\n임상시험의 결과가 출관 될 경우에도 피험자의 신원을 비밀상태로\n\n2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의\n\n모니터링과 점검 및 진행사항 관리를 위한 목적으로 피험자의\n\n기록을 열람할 수 있다. 시험자는 본 임상시험 계획서에 서명함\n\n으로써, 국내의 법규와 윤리적 측면에서 임상시험 의뢰자 또는\n\n모니터 및 점검자가 피험자의 차트와 증례기록서 기록을 검증하기\n\n위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.\n\n3) 증례기록서 등 임상시험에 관련된 모든 서류에는 피험자 이름이\n\n아닌 피험자 식별코드(일반적으로 피험자 이니셜)로 기록하고\n\n- 자. 기록의 보존\n1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하\n\n여야 하며 보안을 유지하도록 한다. 제조허가/수입허가 또는 그\n\n변경 허가를 위한 임상시험 관련 자료는 허가일로부터 3년간\n\n보존하도록 하고, 그 밖의 임상시험 관련 자료는 임상시험이 끝난\n\n날부터 3년간 보존하도록 한다. 다만, 식품의약품안전처장이\n\n지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을\n\n- - 103 -\n- 20. 그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n[예시]\n\n- 가. 자료 처리\n본 임상시험에 관련된 모니터 및 점검자는 본 임상시험의 모니\n\n터링과 점검 및 진행사항 관리를 위한 목적으로 대상자의 기록을\n\n임상시험용 의료기기와 연관된 유의한 위험, 금기, 부작용, 주의\n\n사항을 시사하는 사건 등을 포함하며, 발생시간, 정도, 처치, 경과,\n\n임상시험용 의료기기와의 인과관계 등에 대한 정보를 증례기록서에\n\n- 나. 법규준수\n시험자는 서명록에 서명함으로써, 본 임상시험계획서, 의료기기\n\n임상시험 관리기준, 국내의 모든 관련 법규와 임상시험 수행에 관련\n\n된 규칙 및 규정에 따라서 효과적이고 성실하게 연구를 수행할 것에\n\n동의하게 된다. 임상시험 담당자 및 참여 연구진은 임상시험계획을\n\n- - 104 -\n정확히 분석, 숙지하도록 하며 시험책임자는 예기치 않은 이상반응\n\n등의 출현에 대한 충분한 대처와 필요에 따른 보고, 시험참여 연구진에\n\n대한 충분한 교육 등 사전조치를 취한다. 임상시험의 진행은 의료기기\n\n임상시험 관리 기준에 합당하게 진행한다.\n\n- 다. 임상시험 자료의 보관 및 열람\n임상시험 자료는 기밀로 보관되고 열람은 본 임상시험의 모니터링\n\n과 점검 및 진행 사항 관리를 위한 목적으로 대상자의 기록을 열람할\n\n수 있다.\n\n- 라. 점검 및 실태조사\n임상시험의 중요도, 대상자 수, 임상시험의 종류와 복잡성, 대상자\n\n에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n실시상의 문제점 등에 따라 결정된다.\n\n- 마. 임상시험용 의료기기의 사용 및 관리\n임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가\n\n관리한다. 임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급,\n\n저장하며 “임상시험용”이라는 문구가 있어야 한다. 임상시험용\n\n의료기기 관리자는 임상시험에 사용되는 의료기기에 대해 인수, 재고\n\n관리, 반납 등의 업무를 수행하고 관련 기록을 유지하여야 한다.\n\n- - 105 -\n- 바. 임상시험용 의료기기의 공급과 취급\n1) 의뢰자는 임상시험계획서에 대한 심사위원회와 청장의 승인을\n\n얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는\n\n2) 의뢰자는 관리자 등이 임상시험용 의료기기를 취급하고 보관하는\n\n방법에 대해 문서화된 절차를 가지고 있어야 하며, 이 절차에는\n\n적절하고 안전한 수, 취급, 보관, 미사용 임상시험용 의료기기의\n\n피험자로부터의 반납 및 의뢰자에 대한 반납 등에 대한 방법이\n\n3) 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에\n\n4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나\n\n임상시험의 종료 또는 사용기간의 만료 등에 의한 임상시험용\n\n- - 106 -\n<!-- PAGE_113 -->\n### Ⅳ\n\n<!-- PAGE_113 -->\n### 참고문헌\n\n- 1. 박용우. (2000). 섭식장애. 가정의학회지, 21(3), 315-324.\n- 2. Neumark-Sztainer D., Hannan PJ. (2000). Weight-related behaviors among adolescent girls a\n- 3. Whitehouse, A. M., Cooper, P. J., Vize, C. V., Hill, C., & Vogel, L. (1992). Prevalence of eat\ning disorders in three Cambridge general practices: hidden and conspicuous morbidity. The\n\nBritish journal of general practice : the journal of the Royal College of General Practitioner\n\n- 4. Youl-Ri Kim. (2018). Medical complications and management of eating disorders. J Korean M\n- 5. Auger, N., Potter, B. J., Ukah, U. V., Low, N., Israël, M., Steiger, H., Healy-Profitós, J., & P\naradis, G. (2021). Anorexia nervosa and the long-term risk of mortality in women. World ps\n\n- 6. Nielsen, S., & Vilmar, J. W. (2021). What can we learn about eating disorder mortality from\neating disorder diagnoses at initial assessment? A Danish nationwide register follow-up stud\n\ny using record linkage, encompassing 45 years (1970-2014). Psychiatry research, 303, 1140\n\n- 7. Tith RM., Paradis G., Potter BJ., et al. (2020). Association of bulimia nervosa with long-term\n- 8. van Hoeken D., Hoek HW. (2020). Review of the burden of eating disorders: mortality, disab\n- 9. Kong, S., Kim, J., & Bae, J. (2000). Effects of cognitive-behavioral group therapy for binge\n- 10. Reas, D. L., & Grilo, C. M. (2008). Review and meta-analysis of pharmacotherapy for binge\n- 11. Kwon, H. I. & Kwon, J. H. (2003). The effects of cognitive-behavioral treatment of college\n- 12. Wilfley, D. E., Agras, W. S., Telch, C. F., Rossiter, E. M., Schneider, J. A., Cole, … Raebur\nn, S. D. (1993). Group cognitive-behavioral therapy and group interpersonal psychotherapy\n\nfor the nonpurging bulimic individual: A controlled comparison. Journal of Consulting and Cl\n\n- 13. Park, N. R., & Son, C. N. (2012). Characteristics of binge eating disorder and the effective\nness of cognitive behavioral therapy with college students prone to BED. The Korean Jour\n\n- 14. Baer, R. A., Fischer, S., & Huss, D. B. (2005). Mindfulness-based cognitive therapy applied\n- 15. Kristeller, J. L., & Hallett, C. B. (1999). An Exploratory Study of a Meditation-based Interv\n- 16. Smith, B.W., Shelley, B.M., Leahigh, L., & Vanleit, B.J. (2006). A Preliminary Study of the\nEffects of a Modified Mindfulness Intervention on Binge Eating. Complementary Health Prac\n\n- - 107 -\n- 17. Kim, J. H. (2004). Types of mindfulness meditation and their implications for cognitive beha\nvioral therapy. Cognitive Behavior Therapy in Korea, 4(2), 27-44.\n\n- 18. Lee, S. J., & Kim, M. (2015). The effects of mindfulness meditation on binge eating, body\ndissatisfaction, depression and anger in patients with eating disorders: A preliminary study.\n\n- 19. Kim, S. H. & Jo, M. J. (2014). Effect of clinical art therapy on self-esteem and depression\nof eating disorder patients. Journal of The Korean Academy of Clinical Art Therapy, 9(2),\n\n- 20. Han, J. H. (2003). Effect of cognitive-behavioral group therapy of bulimia nervosa. Unpublis\n- 21. Vocks, S., Tuschen Caffier, B., Pietrowsky, R., Rustenbach, S. J., Kersting, A., & Herpertz,\nS. (2010). Meta-analysis of the effectiveness of psychological and pharmacological treatme\n\n- 22. So Hyeon Yun, & Gaeun Kim (2018). The effects of non-pharmacological interventions for\nadults with eating disorders : A systematic review and meta-analysis. Korean Journal of H\n\n- 23. National Institute for Health and Care Excellence 홈페이지, https://www.nice.org.uk/guidance\n- 24. Eating disorders: recognition and treatment NICE guideline, National Institute for Health an\n- 25. The American Psychiatric Association Practice Guideline for the Treatment of Patients With\n- 26. A Guide to Selecting Evidence-based Psychological Therapies for Eating Disorders Academ\n- 27. Birgit Wagner., Michaela Nagl., Ruth Dölemeyer., Grit Klinitzke., Jana Steinig., Anja Hilbert.,\nAnette Kersting. (2016). Randomized Controlled Trial of an Internet-Based Cognitive-Behav\n\n- 28. Elke D. ter Huurne, Marloes G. Postel, Hein A. de Haan, Job van der Palen, Cor A.J. DeJon\ng. (2017). Treatment dropout in web-based cognitive behavioral therapy for patients with e\n\n- 29. Selfapy 홈페이지, https://www.selfapy.com/\n- 30. 디지털치료기기 허가·심사 가이드라인 민원인 안내서, 식품의약품안전처 2020.08\n- 31. 의료기기의 사이버보안 허가·심사 가이드라인 민원인안내서, 식품의약품안전처 2023.07.13\n- 32. 의료기기 소프트웨어 허가·심사 가이드라인, 식품의약품안전처, 2023.07.05\n- 33. 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인 민원인 안내서 2023.07\n- 34. 의료기기 소프트웨어 밸리데이션 가이드라인, 식품의약품안전처, 2007.03\n- 35. Grilo, C. M., Lydecker, J. A., Fineberg, S. K., Moreno, J. O., Ivezaj, V., & Gueorguieva, R.\n- (2022). Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eatin\ng Disorder: Randomized Double-Blind Placebo-Controlled Trial. The American journal of ps\n\n- 36. Mond JM, Hay PJ, Rodgers B, Owen C, Beumont P. Validity of the eating disorder examinat\nion questionnaire (EDE-Q) in screening for eating disorders in community samples. Behav\n\n- 37. Mond JM, Myers TC, Crosby RD, Hay PJ, Rodgers B, Morgan JF, Lacey JH, Mitchell JE. Sc\n- - 108 -\nreening for eating disorders in primary care: EDE-Q versus SCOFF. Behav Res Ther. 200\n\n8;46(5):612–22.Return to ref 6 in article\n\n- 38. Althunian, T. A., de Boer, A., Groenwold, R. H. H., & Klungel, O. H. (2017). Defining the n\noninferiority margin and analysing noninferiority: An overview. British journal of clinical ph\n\n- 39. 방은별, 한초롱, 전예림, 김율리. (2018). 한국판 DSM-5 섭식장애진단척도(Korean version of the\nEating Disorder Diagnostic Scale DSM-5, K-EDDS DSM-5) : 신뢰도와 타당도 연구. 대한불안\n\n- 40. K. Bohn,. C. Fairburn. (2008). The Clinical Impairment Assessment questionnaire (CIA), Cog\n- 41. Kristin Bohn, Helen A. Doll, Zafra Cooper, Marianne O'Connor, Robert L. Palmer, Christoph\ner G. Fairburn. (2008). The measurement of impairment due to eating disorder psychopatho\n\n- 42. 박승진, 최혜라, 최지혜, 김건우, 홍진표. (2010). 한글판 우울증 선별도구(Patient Health Question\n- 43. 김용, 박종일, 박태원, 정상근, 양종철. (2017). 범불안장애 환자의 스트레스 대처방식과 신체증상\n- 44. Kim et al., (2018). EuroQol Visual Analogue Scale (EQ-VAS) as a Predicting Tool for Frailt\ny in Older Korean Adults: The Korean Frailty an Aging Cohort Study (KFACS). The journal\n\n- 45. Busner, Joan & Targum, Steven. (2007). The Clinical Global Impressions Scale: applying a",
  "chunks": [
    {
      "chunk_id": "chunk_001",
      "text": "민원인 안내서 등록번호\n\n안내서-1334-01\n\n<!-- PAGE_1 -->\n## 섭식장애 개선 디지털치료기기\n\n<!-- PAGE_1 -->\n## 안전성·성능 평가 및 임상시험계획서\n\n<!-- PAGE_1 -->\n## 작성 가이드라인 (민원인 안내서)\n\n- 2023. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 0,
        "window_size": 3,
        "char_count": 150,
        "word_count": 29,
        "page_number": 1,
        "window_text": "민원인 안내서 등록번호\n\n안내서-1334-01\n\n<!-- PAGE_1 -->\n## 섭식장애 개선 디지털치료기기\n\n<!-- PAGE_1 -->\n## 안전성·성능 평가 및 임상시험계획서\n\n<!-- PAGE_1 -->\n## 작성 가이드라인 (민원인 안내서)\n\n- 2023.  12.\n 의 료 기 기 심 사 부\n\n<!-- PAGE_3 -->\n#### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n섭식장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 시험의 진행이 피험자의 안전 보호를 위협하여 그 진행을 멈추는 것을 ‘중지’라 하며, | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 개발 계획 | – Part 2-1: Step by step | 개발 활동을 위하여 소프트웨어 | 의료기기의 위험관리 | □ 예 | ■ 아니오 | 국외 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 소프트웨어 | 으로서, 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시 | 가상·증강(VR·AR) 기반 소프트웨어를 포함 | 유효성 | (AB-1234) |\n| 2) 유의수준 | 한다. ",
        "original_sentence": "민원인 안내서 등록번호\n\n안내서-1334-01\n\n<!-- PAGE_1 -->\n## 섭식장애 개선 디지털치료기기\n\n<!-- PAGE_1 -->\n## 안전성·성능 평가 및 임상시험계획서\n\n<!-- PAGE_1 -->\n## 작성 가이드라인 (민원인 안내서)\n\n- 2023. "
      }
    },
    {
      "chunk_id": "chunk_002",
      "text": "12.\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 1,
        "window_size": 3,
        "char_count": 4,
        "word_count": 1,
        "page_number": 1,
        "window_text": "민원인 안내서 등록번호\n\n안내서-1334-01\n\n<!-- PAGE_1 -->\n## 섭식장애 개선 디지털치료기기\n\n<!-- PAGE_1 -->\n## 안전성·성능 평가 및 임상시험계획서\n\n<!-- PAGE_1 -->\n## 작성 가이드라인 (민원인 안내서)\n\n- 2023.  12.\n 의 료 기 기 심 사 부\n\n<!-- PAGE_3 -->\n#### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n섭식장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 시험의 진행이 피험자의 안전 보호를 위협하여 그 진행을 멈추는 것을 ‘중지’라 하며, | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 개발 계획 | – Part 2-1: Step by step | 개발 활동을 위하여 소프트웨어 | 의료기기의 위험관리 | □ 예 | ■ 아니오 | 국외 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 소프트웨어 | 으로서, 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시 | 가상·증강(VR·AR) 기반 소프트웨어를 포함 | 유효성 | (AB-1234) |\n| 2) 유의수준 | 한다.  그 밖에 임상시험 결과의 사용 범위에 따른 성능 평가를 위하여 이차 | 신경성 | 80001-2-1 | : 제1종 오류 0.025 (유의수준) | (민원인 안내서) | software | - 인지행동치료(CBT)에 비해 대인관계와 통찰력에 집중하는 초점 | 데이터 손실 | “white-box” 방법으로 수행한다. ",
        "original_sentence": "12.\n"
      }
    },
    {
      "chunk_id": "chunk_003",
      "text": "의 료 기 기 심 사 부\n\n<!-- PAGE_3 -->\n#### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n섭식장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 2,
        "window_size": 3,
        "char_count": 143,
        "word_count": 31,
        "page_number": 3,
        "window_text": "민원인 안내서 등록번호\n\n안내서-1334-01\n\n<!-- PAGE_1 -->\n## 섭식장애 개선 디지털치료기기\n\n<!-- PAGE_1 -->\n## 안전성·성능 평가 및 임상시험계획서\n\n<!-- PAGE_1 -->\n## 작성 가이드라인 (민원인 안내서)\n\n- 2023.  12.\n 의 료 기 기 심 사 부\n\n<!-- PAGE_3 -->\n#### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n섭식장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 시험의 진행이 피험자의 안전 보호를 위협하여 그 진행을 멈추는 것을 ‘중지’라 하며, | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 개발 계획 | – Part 2-1: Step by step | 개발 활동을 위하여 소프트웨어 | 의료기기의 위험관리 | □ 예 | ■ 아니오 | 국외 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 소프트웨어 | 으로서, 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시 | 가상·증강(VR·AR) 기반 소프트웨어를 포함 | 유효성 | (AB-1234) |\n| 2) 유의수준 | 한다.  그 밖에 임상시험 결과의 사용 범위에 따른 성능 평가를 위하여 이차 | 신경성 | 80001-2-1 | : 제1종 오류 0.025 (유의수준) | (민원인 안내서) | software | - 인지행동치료(CBT)에 비해 대인관계와 통찰력에 집중하는 초점 | 데이터 손실 | “white-box” 방법으로 수행한다.  | 및 유효성 확인’ 자료 등 허가·심사 | 관리 계획을 수립한다. ",
        "original_sentence": "의 료 기 기 심 사 부\n\n<!-- PAGE_3 -->\n#### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n섭식장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_004",
      "text": "**[표 시작]**\n\n| 시험의 진행이 피험자의 안전 보호를 위협하여 그 진행을 멈추는 것을 ‘중지’라 하며, | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 개발 계획 | – Part 2-1: Step by step | 개발 활동을 위하여 소프트웨어 | 의료기기의 위험관리 | □ 예 | ■ 아니오 | 국외 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 소프트웨어 | 으로서, 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시 | 가상·증강(VR·AR) 기반 소프트웨어를 포함 | 유효성 | (AB-1234) |\n| 2) 유의수준 | 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 3,
        "window_size": 3,
        "char_count": 353,
        "word_count": 96,
        "page_number": 30,
        "window_text": "민원인 안내서 등록번호\n\n안내서-1334-01\n\n<!-- PAGE_1 -->\n## 섭식장애 개선 디지털치료기기\n\n<!-- PAGE_1 -->\n## 안전성·성능 평가 및 임상시험계획서\n\n<!-- PAGE_1 -->\n## 작성 가이드라인 (민원인 안내서)\n\n- 2023.  12.\n 의 료 기 기 심 사 부\n\n<!-- PAGE_3 -->\n#### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n섭식장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 시험의 진행이 피험자의 안전 보호를 위협하여 그 진행을 멈추는 것을 ‘중지’라 하며, | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 개발 계획 | – Part 2-1: Step by step | 개발 활동을 위하여 소프트웨어 | 의료기기의 위험관리 | □ 예 | ■ 아니오 | 국외 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 소프트웨어 | 으로서, 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시 | 가상·증강(VR·AR) 기반 소프트웨어를 포함 | 유효성 | (AB-1234) |\n| 2) 유의수준 | 한다.  그 밖에 임상시험 결과의 사용 범위에 따른 성능 평가를 위하여 이차 | 신경성 | 80001-2-1 | : 제1종 오류 0.025 (유의수준) | (민원인 안내서) | software | - 인지행동치료(CBT)에 비해 대인관계와 통찰력에 집중하는 초점 | 데이터 손실 | “white-box” 방법으로 수행한다.  | 및 유효성 확인’ 자료 등 허가·심사 | 관리 계획을 수립한다.  | 소프트웨어 |\n| [예시] | 의학회지, 14(2), 127-134. ",
        "original_sentence": "**[표 시작]**\n\n| 시험의 진행이 피험자의 안전 보호를 위협하여 그 진행을 멈추는 것을 ‘중지’라 하며, | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 개발 계획 | – Part 2-1: Step by step | 개발 활동을 위하여 소프트웨어 | 의료기기의 위험관리 | □ 예 | ■ 아니오 | 국외 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 소프트웨어 | 으로서, 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시 | 가상·증강(VR·AR) 기반 소프트웨어를 포함 | 유효성 | (AB-1234) |\n| 2) 유의수준 | 한다. "
      }
    },
    {
      "chunk_id": "chunk_005",
      "text": "그 밖에 임상시험 결과의 사용 범위에 따른 성능 평가를 위하여 이차 | 신경성 | 80001-2-1 | : 제1종 오류 0.025 (유의수준) | (민원인 안내서) | software | - 인지행동치료(CBT)에 비해 대인관계와 통찰력에 집중하는 초점 | 데이터 손실 | “white-box” 방법으로 수행한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 4,
        "window_size": 3,
        "char_count": 177,
        "word_count": 41,
        "page_number": 7,
        "window_text": "12.\n 의 료 기 기 심 사 부\n\n<!-- PAGE_3 -->\n#### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n섭식장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 시험의 진행이 피험자의 안전 보호를 위협하여 그 진행을 멈추는 것을 ‘중지’라 하며, | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 개발 계획 | – Part 2-1: Step by step | 개발 활동을 위하여 소프트웨어 | 의료기기의 위험관리 | □ 예 | ■ 아니오 | 국외 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 소프트웨어 | 으로서, 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시 | 가상·증강(VR·AR) 기반 소프트웨어를 포함 | 유효성 | (AB-1234) |\n| 2) 유의수준 | 한다.  그 밖에 임상시험 결과의 사용 범위에 따른 성능 평가를 위하여 이차 | 신경성 | 80001-2-1 | : 제1종 오류 0.025 (유의수준) | (민원인 안내서) | software | - 인지행동치료(CBT)에 비해 대인관계와 통찰력에 집중하는 초점 | 데이터 손실 | “white-box” 방법으로 수행한다.  | 및 유효성 확인’ 자료 등 허가·심사 | 관리 계획을 수립한다.  | 소프트웨어 |\n| [예시] | 의학회지, 14(2), 127-134.  | 27-38. ",
        "original_sentence": "그 밖에 임상시험 결과의 사용 범위에 따른 성능 평가를 위하여 이차 | 신경성 | 80001-2-1 | : 제1종 오류 0.025 (유의수준) | (민원인 안내서) | software | - 인지행동치료(CBT)에 비해 대인관계와 통찰력에 집중하는 초점 | 데이터 손실 | “white-box” 방법으로 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_006",
      "text": "| 및 유효성 확인’ 자료 등 허가·심사 | 관리 계획을 수립한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 5,
        "window_size": 3,
        "char_count": 38,
        "word_count": 11,
        "page_number": 15,
        "window_text": "의 료 기 기 심 사 부\n\n<!-- PAGE_3 -->\n#### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n섭식장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서 작성\n\n가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| 시험의 진행이 피험자의 안전 보호를 위협하여 그 진행을 멈추는 것을 ‘중지’라 하며, | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 개발 계획 | – Part 2-1: Step by step | 개발 활동을 위하여 소프트웨어 | 의료기기의 위험관리 | □ 예 | ■ 아니오 | 국외 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 소프트웨어 | 으로서, 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시 | 가상·증강(VR·AR) 기반 소프트웨어를 포함 | 유효성 | (AB-1234) |\n| 2) 유의수준 | 한다.  그 밖에 임상시험 결과의 사용 범위에 따른 성능 평가를 위하여 이차 | 신경성 | 80001-2-1 | : 제1종 오류 0.025 (유의수준) | (민원인 안내서) | software | - 인지행동치료(CBT)에 비해 대인관계와 통찰력에 집중하는 초점 | 데이터 손실 | “white-box” 방법으로 수행한다.  | 및 유효성 확인’ 자료 등 허가·심사 | 관리 계획을 수립한다.  | 소프트웨어 |\n| [예시] | 의학회지, 14(2), 127-134.  | 27-38.  | 주요 정신과적 질환에 해당하는 자 | 데이트 여부, 기기의 안전(safety)과 성능에 | 지침서ㆍ안내서가 있습니까? ",
        "original_sentence": "| 및 유효성 확인’ 자료 등 허가·심사 | 관리 계획을 수립한다. "
      }
    },
    {
      "chunk_id": "chunk_007",
      "text": "| 소프트웨어 |\n| [예시] | 의학회지, 14(2), 127-134. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 6,
        "window_size": 3,
        "char_count": 41,
        "word_count": 9,
        "page_number": 9,
        "window_text": "**[표 시작]**\n\n| 시험의 진행이 피험자의 안전 보호를 위협하여 그 진행을 멈추는 것을 ‘중지’라 하며, | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | 개발 계획 | – Part 2-1: Step by step | 개발 활동을 위하여 소프트웨어 | 의료기기의 위험관리 | □ 예 | ■ 아니오 | 국외 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 소프트웨어 | 으로서, 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시 | 가상·증강(VR·AR) 기반 소프트웨어를 포함 | 유효성 | (AB-1234) |\n| 2) 유의수준 | 한다.  그 밖에 임상시험 결과의 사용 범위에 따른 성능 평가를 위하여 이차 | 신경성 | 80001-2-1 | : 제1종 오류 0.025 (유의수준) | (민원인 안내서) | software | - 인지행동치료(CBT)에 비해 대인관계와 통찰력에 집중하는 초점 | 데이터 손실 | “white-box” 방법으로 수행한다.  | 및 유효성 확인’ 자료 등 허가·심사 | 관리 계획을 수립한다.  | 소프트웨어 |\n| [예시] | 의학회지, 14(2), 127-134.  | 27-38.  | 주요 정신과적 질환에 해당하는 자 | 데이트 여부, 기기의 안전(safety)과 성능에 | 지침서ㆍ안내서가 있습니까?  |\n| 2) 사이버보안 요구사항 | 4) 임상시험 평가 내용 : 식사장애 검사(EDE-Q) | 2) 탈락 처리 | 4) 베이스라인 (사용 전) 대비 8 주 시점의 BMI 변화 | 19) 피험자의 임상시험 예상 참여 기간 | 3) 공용 네트워크 망 사용여부 : Y | 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다. ",
        "original_sentence": "| 소프트웨어 |\n| [예시] | 의학회지, 14(2), 127-134. "
      }
    },
    {
      "chunk_id": "chunk_008",
      "text": "| 27-38. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 7,
        "window_size": 3,
        "char_count": 9,
        "word_count": 2,
        "page_number": 9,
        "window_text": "그 밖에 임상시험 결과의 사용 범위에 따른 성능 평가를 위하여 이차 | 신경성 | 80001-2-1 | : 제1종 오류 0.025 (유의수준) | (민원인 안내서) | software | - 인지행동치료(CBT)에 비해 대인관계와 통찰력에 집중하는 초점 | 데이터 손실 | “white-box” 방법으로 수행한다.  | 및 유효성 확인’ 자료 등 허가·심사 | 관리 계획을 수립한다.  | 소프트웨어 |\n| [예시] | 의학회지, 14(2), 127-134.  | 27-38.  | 주요 정신과적 질환에 해당하는 자 | 데이트 여부, 기기의 안전(safety)과 성능에 | 지침서ㆍ안내서가 있습니까?  |\n| 2) 사이버보안 요구사항 | 4) 임상시험 평가 내용 : 식사장애 검사(EDE-Q) | 2) 탈락 처리 | 4) 베이스라인 (사용 전) 대비 8 주 시점의 BMI 변화 | 19) 피험자의 임상시험 예상 참여 기간 | 3) 공용 네트워크 망 사용여부 : Y | 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.  | 아니다. ",
        "original_sentence": "| 27-38. "
      }
    },
    {
      "chunk_id": "chunk_009",
      "text": "| 주요 정신과적 질환에 해당하는 자 | 데이트 여부, 기기의 안전(safety)과 성능에 | 지침서ㆍ안내서가 있습니까? ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 8,
        "window_size": 3,
        "char_count": 68,
        "word_count": 15,
        "page_number": 3,
        "window_text": "| 및 유효성 확인’ 자료 등 허가·심사 | 관리 계획을 수립한다.  | 소프트웨어 |\n| [예시] | 의학회지, 14(2), 127-134.  | 27-38.  | 주요 정신과적 질환에 해당하는 자 | 데이트 여부, 기기의 안전(safety)과 성능에 | 지침서ㆍ안내서가 있습니까?  |\n| 2) 사이버보안 요구사항 | 4) 임상시험 평가 내용 : 식사장애 검사(EDE-Q) | 2) 탈락 처리 | 4) 베이스라인 (사용 전) 대비 8 주 시점의 BMI 변화 | 19) 피험자의 임상시험 예상 참여 기간 | 3) 공용 네트워크 망 사용여부 : Y | 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.  | 아니다.  | 임상시험을 실시하여야 한다. ",
        "original_sentence": "| 주요 정신과적 질환에 해당하는 자 | 데이트 여부, 기기의 안전(safety)과 성능에 | 지침서ㆍ안내서가 있습니까? "
      }
    },
    {
      "chunk_id": "chunk_010",
      "text": "|\n| 2) 사이버보안 요구사항 | 4) 임상시험 평가 내용 : 식사장애 검사(EDE-Q) | 2) 탈락 처리 | 4) 베이스라인 (사용 전) 대비 8 주 시점의 BMI 변화 | 19) 피험자의 임상시험 예상 참여 기간 | 3) 공용 네트워크 망 사용여부 : Y | 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 9,
        "window_size": 3,
        "char_count": 181,
        "word_count": 51,
        "page_number": 3,
        "window_text": "| 소프트웨어 |\n| [예시] | 의학회지, 14(2), 127-134.  | 27-38.  | 주요 정신과적 질환에 해당하는 자 | 데이트 여부, 기기의 안전(safety)과 성능에 | 지침서ㆍ안내서가 있습니까?  |\n| 2) 사이버보안 요구사항 | 4) 임상시험 평가 내용 : 식사장애 검사(EDE-Q) | 2) 탈락 처리 | 4) 베이스라인 (사용 전) 대비 8 주 시점의 BMI 변화 | 19) 피험자의 임상시험 예상 참여 기간 | 3) 공용 네트워크 망 사용여부 : Y | 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.  | 아니다.  | 임상시험을 실시하여야 한다.  | 활동을 말한다. ",
        "original_sentence": "|\n| 2) 사이버보안 요구사항 | 4) 임상시험 평가 내용 : 식사장애 검사(EDE-Q) | 2) 탈락 처리 | 4) 베이스라인 (사용 전) 대비 8 주 시점의 BMI 변화 | 19) 피험자의 임상시험 예상 참여 기간 | 3) 공용 네트워크 망 사용여부 : Y | 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다. "
      }
    },
    {
      "chunk_id": "chunk_011",
      "text": "| 아니다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 10,
        "window_size": 3,
        "char_count": 7,
        "word_count": 2,
        "page_number": 94,
        "window_text": "| 27-38.  | 주요 정신과적 질환에 해당하는 자 | 데이트 여부, 기기의 안전(safety)과 성능에 | 지침서ㆍ안내서가 있습니까?  |\n| 2) 사이버보안 요구사항 | 4) 임상시험 평가 내용 : 식사장애 검사(EDE-Q) | 2) 탈락 처리 | 4) 베이스라인 (사용 전) 대비 8 주 시점의 BMI 변화 | 19) 피험자의 임상시험 예상 참여 기간 | 3) 공용 네트워크 망 사용여부 : Y | 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.  | 아니다.  | 임상시험을 실시하여야 한다.  | 활동을 말한다.  | 4주, 8주 시점에 폭식 | 따라 조정될 것이라고 하는 것 | - OOO 애플리케이션을 실행한다. ",
        "original_sentence": "| 아니다. "
      }
    },
    {
      "chunk_id": "chunk_012",
      "text": "| 임상시험을 실시하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 11,
        "window_size": 3,
        "char_count": 18,
        "word_count": 4,
        "page_number": 15,
        "window_text": "| 주요 정신과적 질환에 해당하는 자 | 데이트 여부, 기기의 안전(safety)과 성능에 | 지침서ㆍ안내서가 있습니까?  |\n| 2) 사이버보안 요구사항 | 4) 임상시험 평가 내용 : 식사장애 검사(EDE-Q) | 2) 탈락 처리 | 4) 베이스라인 (사용 전) 대비 8 주 시점의 BMI 변화 | 19) 피험자의 임상시험 예상 참여 기간 | 3) 공용 네트워크 망 사용여부 : Y | 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.  | 아니다.  | 임상시험을 실시하여야 한다.  | 활동을 말한다.  | 4주, 8주 시점에 폭식 | 따라 조정될 것이라고 하는 것 | - OOO 애플리케이션을 실행한다.  | - 이상 반응에 대해 다른 명백한 원인이 있는 경우 | (Integrity)을 고려하여 평가한다. ",
        "original_sentence": "| 임상시험을 실시하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_013",
      "text": "| 활동을 말한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 12,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 15,
        "window_text": "|\n| 2) 사이버보안 요구사항 | 4) 임상시험 평가 내용 : 식사장애 검사(EDE-Q) | 2) 탈락 처리 | 4) 베이스라인 (사용 전) 대비 8 주 시점의 BMI 변화 | 19) 피험자의 임상시험 예상 참여 기간 | 3) 공용 네트워크 망 사용여부 : Y | 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.  | 아니다.  | 임상시험을 실시하여야 한다.  | 활동을 말한다.  | 4주, 8주 시점에 폭식 | 따라 조정될 것이라고 하는 것 | - OOO 애플리케이션을 실행한다.  | - 이상 반응에 대해 다른 명백한 원인이 있는 경우 | (Integrity)을 고려하여 평가한다.  | 상황을 발생하지 않으면 안전성 등급은 A등급에 해당한다. ",
        "original_sentence": "| 활동을 말한다. "
      }
    },
    {
      "chunk_id": "chunk_014",
      "text": "| 4주, 8주 시점에 폭식 | 따라 조정될 것이라고 하는 것 | - OOO 애플리케이션을 실행한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 13,
        "window_size": 3,
        "char_count": 57,
        "word_count": 16,
        "page_number": 26,
        "window_text": "| 아니다.  | 임상시험을 실시하여야 한다.  | 활동을 말한다.  | 4주, 8주 시점에 폭식 | 따라 조정될 것이라고 하는 것 | - OOO 애플리케이션을 실행한다.  | - 이상 반응에 대해 다른 명백한 원인이 있는 경우 | (Integrity)을 고려하여 평가한다.  | 상황을 발생하지 않으면 안전성 등급은 A등급에 해당한다.  | 여부 등을 확인할 수 있다. ",
        "original_sentence": "| 4주, 8주 시점에 폭식 | 따라 조정될 것이라고 하는 것 | - OOO 애플리케이션을 실행한다. "
      }
    },
    {
      "chunk_id": "chunk_015",
      "text": "| - 이상 반응에 대해 다른 명백한 원인이 있는 경우 | (Integrity)을 고려하여 평가한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 14,
        "window_size": 3,
        "char_count": 57,
        "word_count": 14,
        "page_number": 62,
        "window_text": "| 임상시험을 실시하여야 한다.  | 활동을 말한다.  | 4주, 8주 시점에 폭식 | 따라 조정될 것이라고 하는 것 | - OOO 애플리케이션을 실행한다.  | - 이상 반응에 대해 다른 명백한 원인이 있는 경우 | (Integrity)을 고려하여 평가한다.  | 상황을 발생하지 않으면 안전성 등급은 A등급에 해당한다.  | 여부 등을 확인할 수 있다.  | 보장하기 위한 설계 특성이 필요한지를 결정 | 제품명(제조업체) | risk management of medical | 표 8. ",
        "original_sentence": "| - 이상 반응에 대해 다른 명백한 원인이 있는 경우 | (Integrity)을 고려하여 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_016",
      "text": "| 상황을 발생하지 않으면 안전성 등급은 A등급에 해당한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 15,
        "window_size": 3,
        "char_count": 34,
        "word_count": 8,
        "page_number": 9,
        "window_text": "| 활동을 말한다.  | 4주, 8주 시점에 폭식 | 따라 조정될 것이라고 하는 것 | - OOO 애플리케이션을 실행한다.  | - 이상 반응에 대해 다른 명백한 원인이 있는 경우 | (Integrity)을 고려하여 평가한다.  | 상황을 발생하지 않으면 안전성 등급은 A등급에 해당한다.  | 여부 등을 확인할 수 있다.  | 보장하기 위한 설계 특성이 필요한지를 결정 | 제품명(제조업체) | risk management of medical | 표 8.  소프트웨어 안전성 등급 | 개발 계획을 수립한다. ",
        "original_sentence": "| 상황을 발생하지 않으면 안전성 등급은 A등급에 해당한다. "
      }
    },
    {
      "chunk_id": "chunk_017",
      "text": "| 여부 등을 확인할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 16,
        "window_size": 3,
        "char_count": 18,
        "word_count": 6,
        "page_number": 3,
        "window_text": "| 4주, 8주 시점에 폭식 | 따라 조정될 것이라고 하는 것 | - OOO 애플리케이션을 실행한다.  | - 이상 반응에 대해 다른 명백한 원인이 있는 경우 | (Integrity)을 고려하여 평가한다.  | 상황을 발생하지 않으면 안전성 등급은 A등급에 해당한다.  | 여부 등을 확인할 수 있다.  | 보장하기 위한 설계 특성이 필요한지를 결정 | 제품명(제조업체) | risk management of medical | 표 8.  소프트웨어 안전성 등급 | 개발 계획을 수립한다.  | 방법에 대한 국제 규격 |\n| 하기에 충분한 경험이 있는 자가 선정되어야 한다. ",
        "original_sentence": "| 여부 등을 확인할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_018",
      "text": "| 보장하기 위한 설계 특성이 필요한지를 결정 | 제품명(제조업체) | risk management of medical | 표 8. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 17,
        "window_size": 3,
        "char_count": 74,
        "word_count": 17,
        "page_number": 19,
        "window_text": "| - 이상 반응에 대해 다른 명백한 원인이 있는 경우 | (Integrity)을 고려하여 평가한다.  | 상황을 발생하지 않으면 안전성 등급은 A등급에 해당한다.  | 여부 등을 확인할 수 있다.  | 보장하기 위한 설계 특성이 필요한지를 결정 | 제품명(제조업체) | risk management of medical | 표 8.  소프트웨어 안전성 등급 | 개발 계획을 수립한다.  | 방법에 대한 국제 규격 |\n| 하기에 충분한 경험이 있는 자가 선정되어야 한다.  | 임상시험 개시에서 완료까지 중지될 수 있는 세부 사항을 ‘중지 기준’에 제시한다. ",
        "original_sentence": "| 보장하기 위한 설계 특성이 필요한지를 결정 | 제품명(제조업체) | risk management of medical | 표 8. "
      }
    },
    {
      "chunk_id": "chunk_019",
      "text": "소프트웨어 안전성 등급 | 개발 계획을 수립한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 18,
        "window_size": 3,
        "char_count": 28,
        "word_count": 7,
        "page_number": 9,
        "window_text": "| 상황을 발생하지 않으면 안전성 등급은 A등급에 해당한다.  | 여부 등을 확인할 수 있다.  | 보장하기 위한 설계 특성이 필요한지를 결정 | 제품명(제조업체) | risk management of medical | 표 8.  소프트웨어 안전성 등급 | 개발 계획을 수립한다.  | 방법에 대한 국제 규격 |\n| 하기에 충분한 경험이 있는 자가 선정되어야 한다.  | 임상시험 개시에서 완료까지 중지될 수 있는 세부 사항을 ‘중지 기준’에 제시한다.  | 시 제출해야 할 첨부 자료에 대하여 | 확인 자료 |\n| 3) 통계적 검정 방법 | 식욕부진증 | 제·개정번호 | 승인일자 | 주요 내용 | 기술한다. ",
        "original_sentence": "소프트웨어 안전성 등급 | 개발 계획을 수립한다. "
      }
    },
    {
      "chunk_id": "chunk_020",
      "text": "| 방법에 대한 국제 규격 |\n| 하기에 충분한 경험이 있는 자가 선정되어야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 19,
        "window_size": 3,
        "char_count": 47,
        "word_count": 14,
        "page_number": 15,
        "window_text": "| 여부 등을 확인할 수 있다.  | 보장하기 위한 설계 특성이 필요한지를 결정 | 제품명(제조업체) | risk management of medical | 표 8.  소프트웨어 안전성 등급 | 개발 계획을 수립한다.  | 방법에 대한 국제 규격 |\n| 하기에 충분한 경험이 있는 자가 선정되어야 한다.  | 임상시험 개시에서 완료까지 중지될 수 있는 세부 사항을 ‘중지 기준’에 제시한다.  | 시 제출해야 할 첨부 자료에 대하여 | 확인 자료 |\n| 3) 통계적 검정 방법 | 식욕부진증 | 제·개정번호 | 승인일자 | 주요 내용 | 기술한다.  | 정신역학 심리치료(Focal Psychodynamic Therapy, FPT)를 활용 | 제품설명 | 검증 및 |\n| 디지털치료기기 관련 국내외 규격은 <표 7>과 같다. ",
        "original_sentence": "| 방법에 대한 국제 규격 |\n| 하기에 충분한 경험이 있는 자가 선정되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_021",
      "text": "| 임상시험 개시에서 완료까지 중지될 수 있는 세부 사항을 ‘중지 기준’에 제시한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 20,
        "window_size": 3,
        "char_count": 48,
        "word_count": 12,
        "page_number": 3,
        "window_text": "| 보장하기 위한 설계 특성이 필요한지를 결정 | 제품명(제조업체) | risk management of medical | 표 8.  소프트웨어 안전성 등급 | 개발 계획을 수립한다.  | 방법에 대한 국제 규격 |\n| 하기에 충분한 경험이 있는 자가 선정되어야 한다.  | 임상시험 개시에서 완료까지 중지될 수 있는 세부 사항을 ‘중지 기준’에 제시한다.  | 시 제출해야 할 첨부 자료에 대하여 | 확인 자료 |\n| 3) 통계적 검정 방법 | 식욕부진증 | 제·개정번호 | 승인일자 | 주요 내용 | 기술한다.  | 정신역학 심리치료(Focal Psychodynamic Therapy, FPT)를 활용 | 제품설명 | 검증 및 |\n| 디지털치료기기 관련 국내외 규격은 <표 7>과 같다.  | 유효성 평가변수를 제시하여 각 임상 검사 항목 및 검사 방법에 대한 기준을 | ※ 단, 층화는 제품 특성 등에 따라 유연하게 적용할 수 있다. ",
        "original_sentence": "| 임상시험 개시에서 완료까지 중지될 수 있는 세부 사항을 ‘중지 기준’에 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_022",
      "text": "| 시 제출해야 할 첨부 자료에 대하여 | 확인 자료 |\n| 3) 통계적 검정 방법 | 식욕부진증 | 제·개정번호 | 승인일자 | 주요 내용 | 기술한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 21,
        "window_size": 3,
        "char_count": 87,
        "word_count": 27,
        "page_number": 26,
        "window_text": "소프트웨어 안전성 등급 | 개발 계획을 수립한다.  | 방법에 대한 국제 규격 |\n| 하기에 충분한 경험이 있는 자가 선정되어야 한다.  | 임상시험 개시에서 완료까지 중지될 수 있는 세부 사항을 ‘중지 기준’에 제시한다.  | 시 제출해야 할 첨부 자료에 대하여 | 확인 자료 |\n| 3) 통계적 검정 방법 | 식욕부진증 | 제·개정번호 | 승인일자 | 주요 내용 | 기술한다.  | 정신역학 심리치료(Focal Psychodynamic Therapy, FPT)를 활용 | 제품설명 | 검증 및 |\n| 디지털치료기기 관련 국내외 규격은 <표 7>과 같다.  | 유효성 평가변수를 제시하여 각 임상 검사 항목 및 검사 방법에 대한 기준을 | ※ 단, 층화는 제품 특성 등에 따라 유연하게 적용할 수 있다.  | 영향을 보장할 수 있는 업데이트 유효성 검증 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | (2) Clinical Impairment Assessment (CIA) |\n| 제품의 주요 기능 선정 시 아래 고려사항을 참고하여 선정한다. ",
        "original_sentence": "| 시 제출해야 할 첨부 자료에 대하여 | 확인 자료 |\n| 3) 통계적 검정 방법 | 식욕부진증 | 제·개정번호 | 승인일자 | 주요 내용 | 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_023",
      "text": "| 정신역학 심리치료(Focal Psychodynamic Therapy, FPT)를 활용 | 제품설명 | 검증 및 |\n| 디지털치료기기 관련 국내외 규격은 <표 7>과 같다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 22,
        "window_size": 3,
        "char_count": 98,
        "word_count": 21,
        "page_number": 15,
        "window_text": "| 방법에 대한 국제 규격 |\n| 하기에 충분한 경험이 있는 자가 선정되어야 한다.  | 임상시험 개시에서 완료까지 중지될 수 있는 세부 사항을 ‘중지 기준’에 제시한다.  | 시 제출해야 할 첨부 자료에 대하여 | 확인 자료 |\n| 3) 통계적 검정 방법 | 식욕부진증 | 제·개정번호 | 승인일자 | 주요 내용 | 기술한다.  | 정신역학 심리치료(Focal Psychodynamic Therapy, FPT)를 활용 | 제품설명 | 검증 및 |\n| 디지털치료기기 관련 국내외 규격은 <표 7>과 같다.  | 유효성 평가변수를 제시하여 각 임상 검사 항목 및 검사 방법에 대한 기준을 | ※ 단, 층화는 제품 특성 등에 따라 유연하게 적용할 수 있다.  | 영향을 보장할 수 있는 업데이트 유효성 검증 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | (2) Clinical Impairment Assessment (CIA) |\n| 제품의 주요 기능 선정 시 아래 고려사항을 참고하여 선정한다.  | 4) 방문 4 (치료 기간 종료 3개월 후, Follow up) | 횟수를 0회 달성한 | 하기 위해 시스템 레벨에서의 아키텍쳐를 | 이에 대한 명확한 임상적 근거를 제시해야 한다. ",
        "original_sentence": "| 정신역학 심리치료(Focal Psychodynamic Therapy, FPT)를 활용 | 제품설명 | 검증 및 |\n| 디지털치료기기 관련 국내외 규격은 <표 7>과 같다. "
      }
    },
    {
      "chunk_id": "chunk_024",
      "text": "| 유효성 평가변수를 제시하여 각 임상 검사 항목 및 검사 방법에 대한 기준을 | ※ 단, 층화는 제품 특성 등에 따라 유연하게 적용할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 23,
        "window_size": 3,
        "char_count": 82,
        "word_count": 25,
        "page_number": 7,
        "window_text": "| 임상시험 개시에서 완료까지 중지될 수 있는 세부 사항을 ‘중지 기준’에 제시한다.  | 시 제출해야 할 첨부 자료에 대하여 | 확인 자료 |\n| 3) 통계적 검정 방법 | 식욕부진증 | 제·개정번호 | 승인일자 | 주요 내용 | 기술한다.  | 정신역학 심리치료(Focal Psychodynamic Therapy, FPT)를 활용 | 제품설명 | 검증 및 |\n| 디지털치료기기 관련 국내외 규격은 <표 7>과 같다.  | 유효성 평가변수를 제시하여 각 임상 검사 항목 및 검사 방법에 대한 기준을 | ※ 단, 층화는 제품 특성 등에 따라 유연하게 적용할 수 있다.  | 영향을 보장할 수 있는 업데이트 유효성 검증 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | (2) Clinical Impairment Assessment (CIA) |\n| 제품의 주요 기능 선정 시 아래 고려사항을 참고하여 선정한다.  | 4) 방문 4 (치료 기간 종료 3개월 후, Follow up) | 횟수를 0회 달성한 | 하기 위해 시스템 레벨에서의 아키텍쳐를 | 이에 대한 명확한 임상적 근거를 제시해야 한다.  | : 제2종 오류 0.2 | 제품외형 | IT-networks – Practical | 적용 |\n| 1) 임상시험용 의료기기 | hed master’ thesis, Duksung Women’s University, Seoul, Korea. ",
        "original_sentence": "| 유효성 평가변수를 제시하여 각 임상 검사 항목 및 검사 방법에 대한 기준을 | ※ 단, 층화는 제품 특성 등에 따라 유연하게 적용할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_025",
      "text": "| 영향을 보장할 수 있는 업데이트 유효성 검증 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | (2) Clinical Impairment Assessment (CIA) |\n| 제품의 주요 기능 선정 시 아래 고려사항을 참고하여 선정한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 24,
        "window_size": 3,
        "char_count": 154,
        "word_count": 36,
        "page_number": 18,
        "window_text": "| 시 제출해야 할 첨부 자료에 대하여 | 확인 자료 |\n| 3) 통계적 검정 방법 | 식욕부진증 | 제·개정번호 | 승인일자 | 주요 내용 | 기술한다.  | 정신역학 심리치료(Focal Psychodynamic Therapy, FPT)를 활용 | 제품설명 | 검증 및 |\n| 디지털치료기기 관련 국내외 규격은 <표 7>과 같다.  | 유효성 평가변수를 제시하여 각 임상 검사 항목 및 검사 방법에 대한 기준을 | ※ 단, 층화는 제품 특성 등에 따라 유연하게 적용할 수 있다.  | 영향을 보장할 수 있는 업데이트 유효성 검증 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | (2) Clinical Impairment Assessment (CIA) |\n| 제품의 주요 기능 선정 시 아래 고려사항을 참고하여 선정한다.  | 4) 방문 4 (치료 기간 종료 3개월 후, Follow up) | 횟수를 0회 달성한 | 하기 위해 시스템 레벨에서의 아키텍쳐를 | 이에 대한 명확한 임상적 근거를 제시해야 한다.  | : 제2종 오류 0.2 | 제품외형 | IT-networks – Practical | 적용 |\n| 1) 임상시험용 의료기기 | hed master’ thesis, Duksung Women’s University, Seoul, Korea.  | nitive Behavior Therapy and Eating Disorders. ",
        "original_sentence": "| 영향을 보장할 수 있는 업데이트 유효성 검증 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | (2) Clinical Impairment Assessment (CIA) |\n| 제품의 주요 기능 선정 시 아래 고려사항을 참고하여 선정한다. "
      }
    },
    {
      "chunk_id": "chunk_026",
      "text": "| 4) 방문 4 (치료 기간 종료 3개월 후, Follow up) | 횟수를 0회 달성한 | 하기 위해 시스템 레벨에서의 아키텍쳐를 | 이에 대한 명확한 임상적 근거를 제시해야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 25,
        "window_size": 3,
        "char_count": 104,
        "word_count": 29,
        "page_number": 26,
        "window_text": "| 정신역학 심리치료(Focal Psychodynamic Therapy, FPT)를 활용 | 제품설명 | 검증 및 |\n| 디지털치료기기 관련 국내외 규격은 <표 7>과 같다.  | 유효성 평가변수를 제시하여 각 임상 검사 항목 및 검사 방법에 대한 기준을 | ※ 단, 층화는 제품 특성 등에 따라 유연하게 적용할 수 있다.  | 영향을 보장할 수 있는 업데이트 유효성 검증 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | (2) Clinical Impairment Assessment (CIA) |\n| 제품의 주요 기능 선정 시 아래 고려사항을 참고하여 선정한다.  | 4) 방문 4 (치료 기간 종료 3개월 후, Follow up) | 횟수를 0회 달성한 | 하기 위해 시스템 레벨에서의 아키텍쳐를 | 이에 대한 명확한 임상적 근거를 제시해야 한다.  | : 제2종 오류 0.2 | 제품외형 | IT-networks – Practical | 적용 |\n| 1) 임상시험용 의료기기 | hed master’ thesis, Duksung Women’s University, Seoul, Korea.  | nitive Behavior Therapy and Eating Disorders.  315-317. ",
        "original_sentence": "| 4) 방문 4 (치료 기간 종료 3개월 후, Follow up) | 횟수를 0회 달성한 | 하기 위해 시스템 레벨에서의 아키텍쳐를 | 이에 대한 명확한 임상적 근거를 제시해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_027",
      "text": "| : 제2종 오류 0.2 | 제품외형 | IT-networks – Practical | 적용 |\n| 1) 임상시험용 의료기기 | hed master’ thesis, Duksung Women’s University, Seoul, Korea. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 26,
        "window_size": 3,
        "char_count": 136,
        "word_count": 27,
        "page_number": 9,
        "window_text": "| 유효성 평가변수를 제시하여 각 임상 검사 항목 및 검사 방법에 대한 기준을 | ※ 단, 층화는 제품 특성 등에 따라 유연하게 적용할 수 있다.  | 영향을 보장할 수 있는 업데이트 유효성 검증 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | (2) Clinical Impairment Assessment (CIA) |\n| 제품의 주요 기능 선정 시 아래 고려사항을 참고하여 선정한다.  | 4) 방문 4 (치료 기간 종료 3개월 후, Follow up) | 횟수를 0회 달성한 | 하기 위해 시스템 레벨에서의 아키텍쳐를 | 이에 대한 명확한 임상적 근거를 제시해야 한다.  | : 제2종 오류 0.2 | 제품외형 | IT-networks – Practical | 적용 |\n| 1) 임상시험용 의료기기 | hed master’ thesis, Duksung Women’s University, Seoul, Korea.  | nitive Behavior Therapy and Eating Disorders.  315-317.  | 5) 조현병 및 조울증의 과거 병력이 있거나 현재 진단받은 자 | Psychological | 제시 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다. ",
        "original_sentence": "| : 제2종 오류 0.2 | 제품외형 | IT-networks – Practical | 적용 |\n| 1) 임상시험용 의료기기 | hed master’ thesis, Duksung Women’s University, Seoul, Korea. "
      }
    },
    {
      "chunk_id": "chunk_028",
      "text": "| nitive Behavior Therapy and Eating Disorders. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 27,
        "window_size": 3,
        "char_count": 48,
        "word_count": 7,
        "page_number": 18,
        "window_text": "| 영향을 보장할 수 있는 업데이트 유효성 검증 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | (2) Clinical Impairment Assessment (CIA) |\n| 제품의 주요 기능 선정 시 아래 고려사항을 참고하여 선정한다.  | 4) 방문 4 (치료 기간 종료 3개월 후, Follow up) | 횟수를 0회 달성한 | 하기 위해 시스템 레벨에서의 아키텍쳐를 | 이에 대한 명확한 임상적 근거를 제시해야 한다.  | : 제2종 오류 0.2 | 제품외형 | IT-networks – Practical | 적용 |\n| 1) 임상시험용 의료기기 | hed master’ thesis, Duksung Women’s University, Seoul, Korea.  | nitive Behavior Therapy and Eating Disorders.  315-317.  | 5) 조현병 및 조울증의 과거 병력이 있거나 현재 진단받은 자 | Psychological | 제시 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.  | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 담당 | 5) 임상시험 디자인 : 단일(다)기관, 무작위배정, 전향적 임상시험 | 3) 방문 3 (치료 기간 종료 1주 후, Post-treatment) | 12) 임상시험에 참여함으로써 피험자에게 예상되는 비용 | 20) 임상시험에 참여하는 대략의 피험자 수 | [예시] | 4) 사용될 통계적 분석 방법(즉, 연구디자인과도 관련) | 4) Generalized anxiety disorder 7-item scale (GAD-7) | ○ 평가 불가능(Unknown) | (Anorexia | ‘중지 처리’에는 각 중지 기준에 대한 유효성 평가 통계 처리 시 그 산입 여부와 | 식장애 진단(F50)을 받은 자 | 위원장이나 간사가 승인한 문서를 의뢰자에게 보내야 한다. ",
        "original_sentence": "| nitive Behavior Therapy and Eating Disorders. "
      }
    },
    {
      "chunk_id": "chunk_029",
      "text": "315-317. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 28,
        "window_size": 3,
        "char_count": 9,
        "word_count": 1,
        "page_number": 19,
        "window_text": "| 4) 방문 4 (치료 기간 종료 3개월 후, Follow up) | 횟수를 0회 달성한 | 하기 위해 시스템 레벨에서의 아키텍쳐를 | 이에 대한 명확한 임상적 근거를 제시해야 한다.  | : 제2종 오류 0.2 | 제품외형 | IT-networks – Practical | 적용 |\n| 1) 임상시험용 의료기기 | hed master’ thesis, Duksung Women’s University, Seoul, Korea.  | nitive Behavior Therapy and Eating Disorders.  315-317.  | 5) 조현병 및 조울증의 과거 병력이 있거나 현재 진단받은 자 | Psychological | 제시 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.  | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 담당 | 5) 임상시험 디자인 : 단일(다)기관, 무작위배정, 전향적 임상시험 | 3) 방문 3 (치료 기간 종료 1주 후, Post-treatment) | 12) 임상시험에 참여함으로써 피험자에게 예상되는 비용 | 20) 임상시험에 참여하는 대략의 피험자 수 | [예시] | 4) 사용될 통계적 분석 방법(즉, 연구디자인과도 관련) | 4) Generalized anxiety disorder 7-item scale (GAD-7) | ○ 평가 불가능(Unknown) | (Anorexia | ‘중지 처리’에는 각 중지 기준에 대한 유효성 평가 통계 처리 시 그 산입 여부와 | 식장애 진단(F50)을 받은 자 | 위원장이나 간사가 승인한 문서를 의뢰자에게 보내야 한다.  | 하는 소프트웨어 의료기기(SaMD)이다. ",
        "original_sentence": "315-317. "
      }
    },
    {
      "chunk_id": "chunk_030",
      "text": "| 5) 조현병 및 조울증의 과거 병력이 있거나 현재 진단받은 자 | Psychological | 제시 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 29,
        "window_size": 3,
        "char_count": 94,
        "word_count": 25,
        "page_number": 26,
        "window_text": "| : 제2종 오류 0.2 | 제품외형 | IT-networks – Practical | 적용 |\n| 1) 임상시험용 의료기기 | hed master’ thesis, Duksung Women’s University, Seoul, Korea.  | nitive Behavior Therapy and Eating Disorders.  315-317.  | 5) 조현병 및 조울증의 과거 병력이 있거나 현재 진단받은 자 | Psychological | 제시 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.  | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 담당 | 5) 임상시험 디자인 : 단일(다)기관, 무작위배정, 전향적 임상시험 | 3) 방문 3 (치료 기간 종료 1주 후, Post-treatment) | 12) 임상시험에 참여함으로써 피험자에게 예상되는 비용 | 20) 임상시험에 참여하는 대략의 피험자 수 | [예시] | 4) 사용될 통계적 분석 방법(즉, 연구디자인과도 관련) | 4) Generalized anxiety disorder 7-item scale (GAD-7) | ○ 평가 불가능(Unknown) | (Anorexia | ‘중지 처리’에는 각 중지 기준에 대한 유효성 평가 통계 처리 시 그 산입 여부와 | 식장애 진단(F50)을 받은 자 | 위원장이나 간사가 승인한 문서를 의뢰자에게 보내야 한다.  | 하는 소프트웨어 의료기기(SaMD)이다.  | (terHuurne et al., 2015). ",
        "original_sentence": "| 5) 조현병 및 조울증의 과거 병력이 있거나 현재 진단받은 자 | Psychological | 제시 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다. "
      }
    },
    {
      "chunk_id": "chunk_031",
      "text": "| - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 담당 | 5) 임상시험 디자인 : 단일(다)기관, 무작위배정, 전향적 임상시험 | 3) 방문 3 (치료 기간 종료 1주 후, Post-treatment) | 12) 임상시험에 참여함으로써 피험자에게 예상되는 비용 | 20) 임상시험에 참여하는 대략의 피험자 수 | [예시] | 4) 사용될 통계적 분석 방법(즉, 연구디자인과도 관련) | 4) Generalized anxiety disorder 7-item scale (GAD-7) | ○ 평가 불가능(Unknown) | (Anorexia | ‘중지 처리’에는 각 중지 기준에 대한 유효성 평가 통계 처리 시 그 산입 여부와 | 식장애 진단(F50)을 받은 자 | 위원장이나 간사가 승인한 문서를 의뢰자에게 보내야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 30,
        "window_size": 3,
        "char_count": 419,
        "word_count": 97,
        "page_number": 3,
        "window_text": "| nitive Behavior Therapy and Eating Disorders.  315-317.  | 5) 조현병 및 조울증의 과거 병력이 있거나 현재 진단받은 자 | Psychological | 제시 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.  | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 담당 | 5) 임상시험 디자인 : 단일(다)기관, 무작위배정, 전향적 임상시험 | 3) 방문 3 (치료 기간 종료 1주 후, Post-treatment) | 12) 임상시험에 참여함으로써 피험자에게 예상되는 비용 | 20) 임상시험에 참여하는 대략의 피험자 수 | [예시] | 4) 사용될 통계적 분석 방법(즉, 연구디자인과도 관련) | 4) Generalized anxiety disorder 7-item scale (GAD-7) | ○ 평가 불가능(Unknown) | (Anorexia | ‘중지 처리’에는 각 중지 기준에 대한 유효성 평가 통계 처리 시 그 산입 여부와 | 식장애 진단(F50)을 받은 자 | 위원장이나 간사가 승인한 문서를 의뢰자에게 보내야 한다.  | 하는 소프트웨어 의료기기(SaMD)이다.  | (terHuurne et al., 2015).  | 하여야 한다. ",
        "original_sentence": "| - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 담당 | 5) 임상시험 디자인 : 단일(다)기관, 무작위배정, 전향적 임상시험 | 3) 방문 3 (치료 기간 종료 1주 후, Post-treatment) | 12) 임상시험에 참여함으로써 피험자에게 예상되는 비용 | 20) 임상시험에 참여하는 대략의 피험자 수 | [예시] | 4) 사용될 통계적 분석 방법(즉, 연구디자인과도 관련) | 4) Generalized anxiety disorder 7-item scale (GAD-7) | ○ 평가 불가능(Unknown) | (Anorexia | ‘중지 처리’에는 각 중지 기준에 대한 유효성 평가 통계 처리 시 그 산입 여부와 | 식장애 진단(F50)을 받은 자 | 위원장이나 간사가 승인한 문서를 의뢰자에게 보내야 한다. "
      }
    },
    {
      "chunk_id": "chunk_032",
      "text": "| 하는 소프트웨어 의료기기(SaMD)이다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 31,
        "window_size": 3,
        "char_count": 25,
        "word_count": 4,
        "page_number": 9,
        "window_text": "315-317.  | 5) 조현병 및 조울증의 과거 병력이 있거나 현재 진단받은 자 | Psychological | 제시 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.  | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 담당 | 5) 임상시험 디자인 : 단일(다)기관, 무작위배정, 전향적 임상시험 | 3) 방문 3 (치료 기간 종료 1주 후, Post-treatment) | 12) 임상시험에 참여함으로써 피험자에게 예상되는 비용 | 20) 임상시험에 참여하는 대략의 피험자 수 | [예시] | 4) 사용될 통계적 분석 방법(즉, 연구디자인과도 관련) | 4) Generalized anxiety disorder 7-item scale (GAD-7) | ○ 평가 불가능(Unknown) | (Anorexia | ‘중지 처리’에는 각 중지 기준에 대한 유효성 평가 통계 처리 시 그 산입 여부와 | 식장애 진단(F50)을 받은 자 | 위원장이나 간사가 승인한 문서를 의뢰자에게 보내야 한다.  | 하는 소프트웨어 의료기기(SaMD)이다.  | (terHuurne et al., 2015).  | 하여야 한다.  | 등급 | 설명 | 보는 전면 파기한다. ",
        "original_sentence": "| 하는 소프트웨어 의료기기(SaMD)이다. "
      }
    },
    {
      "chunk_id": "chunk_033",
      "text": "| (terHuurne et al., 2015). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 32,
        "window_size": 3,
        "char_count": 28,
        "word_count": 5,
        "page_number": 9,
        "window_text": "| 5) 조현병 및 조울증의 과거 병력이 있거나 현재 진단받은 자 | Psychological | 제시 |\n| 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.  | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 담당 | 5) 임상시험 디자인 : 단일(다)기관, 무작위배정, 전향적 임상시험 | 3) 방문 3 (치료 기간 종료 1주 후, Post-treatment) | 12) 임상시험에 참여함으로써 피험자에게 예상되는 비용 | 20) 임상시험에 참여하는 대략의 피험자 수 | [예시] | 4) 사용될 통계적 분석 방법(즉, 연구디자인과도 관련) | 4) Generalized anxiety disorder 7-item scale (GAD-7) | ○ 평가 불가능(Unknown) | (Anorexia | ‘중지 처리’에는 각 중지 기준에 대한 유효성 평가 통계 처리 시 그 산입 여부와 | 식장애 진단(F50)을 받은 자 | 위원장이나 간사가 승인한 문서를 의뢰자에게 보내야 한다.  | 하는 소프트웨어 의료기기(SaMD)이다.  | (terHuurne et al., 2015).  | 하여야 한다.  | 등급 | 설명 | 보는 전면 파기한다.  | 변화에 대한 비열등성 확인 | 없이 수집된 자료로 분석한다. ",
        "original_sentence": "| (terHuurne et al., 2015). "
      }
    },
    {
      "chunk_id": "chunk_034",
      "text": "| 하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 33,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 15,
        "window_text": "| - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 담당 | 5) 임상시험 디자인 : 단일(다)기관, 무작위배정, 전향적 임상시험 | 3) 방문 3 (치료 기간 종료 1주 후, Post-treatment) | 12) 임상시험에 참여함으로써 피험자에게 예상되는 비용 | 20) 임상시험에 참여하는 대략의 피험자 수 | [예시] | 4) 사용될 통계적 분석 방법(즉, 연구디자인과도 관련) | 4) Generalized anxiety disorder 7-item scale (GAD-7) | ○ 평가 불가능(Unknown) | (Anorexia | ‘중지 처리’에는 각 중지 기준에 대한 유효성 평가 통계 처리 시 그 산입 여부와 | 식장애 진단(F50)을 받은 자 | 위원장이나 간사가 승인한 문서를 의뢰자에게 보내야 한다.  | 하는 소프트웨어 의료기기(SaMD)이다.  | (terHuurne et al., 2015).  | 하여야 한다.  | 등급 | 설명 | 보는 전면 파기한다.  | 변화에 대한 비열등성 확인 | 없이 수집된 자료로 분석한다.  | 더욱 개연성이 있게 설명되는 경우 | 평가한다. ",
        "original_sentence": "| 하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_035",
      "text": "| 등급 | 설명 | 보는 전면 파기한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 34,
        "window_size": 3,
        "char_count": 24,
        "word_count": 8,
        "page_number": 9,
        "window_text": "| 하는 소프트웨어 의료기기(SaMD)이다.  | (terHuurne et al., 2015).  | 하여야 한다.  | 등급 | 설명 | 보는 전면 파기한다.  | 변화에 대한 비열등성 확인 | 없이 수집된 자료로 분석한다.  | 더욱 개연성이 있게 설명되는 경우 | 평가한다.  | 으로 고려하시기 바랍니다. ",
        "original_sentence": "| 등급 | 설명 | 보는 전면 파기한다. "
      }
    },
    {
      "chunk_id": "chunk_036",
      "text": "| 변화에 대한 비열등성 확인 | 없이 수집된 자료로 분석한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 35,
        "window_size": 3,
        "char_count": 36,
        "word_count": 10,
        "page_number": 15,
        "window_text": "| (terHuurne et al., 2015).  | 하여야 한다.  | 등급 | 설명 | 보는 전면 파기한다.  | 변화에 대한 비열등성 확인 | 없이 수집된 자료로 분석한다.  | 더욱 개연성이 있게 설명되는 경우 | 평가한다.  | 으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 | 필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다. ",
        "original_sentence": "| 변화에 대한 비열등성 확인 | 없이 수집된 자료로 분석한다. "
      }
    },
    {
      "chunk_id": "chunk_037",
      "text": "| 더욱 개연성이 있게 설명되는 경우 | 평가한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 36,
        "window_size": 3,
        "char_count": 29,
        "word_count": 8,
        "page_number": 15,
        "window_text": "| 하여야 한다.  | 등급 | 설명 | 보는 전면 파기한다.  | 변화에 대한 비열등성 확인 | 없이 수집된 자료로 분석한다.  | 더욱 개연성이 있게 설명되는 경우 | 평가한다.  | 으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 | 필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.  | 한다. ",
        "original_sentence": "| 더욱 개연성이 있게 설명되는 경우 | 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_038",
      "text": "| 으로 고려하시기 바랍니다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 37,
        "window_size": 3,
        "char_count": 17,
        "word_count": 4,
        "page_number": 1,
        "window_text": "| 등급 | 설명 | 보는 전면 파기한다.  | 변화에 대한 비열등성 확인 | 없이 수집된 자료로 분석한다.  | 더욱 개연성이 있게 설명되는 경우 | 평가한다.  | 으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 | 필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.  | 한다.  | 통합계획에 따라 소프트웨어를 | 폭식 횟수를 평가한다. ",
        "original_sentence": "| 으로 고려하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_039",
      "text": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 | 필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 38,
        "window_size": 3,
        "char_count": 58,
        "word_count": 14,
        "page_number": 3,
        "window_text": "| 변화에 대한 비열등성 확인 | 없이 수집된 자료로 분석한다.  | 더욱 개연성이 있게 설명되는 경우 | 평가한다.  | 으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 | 필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.  | 한다.  | 통합계획에 따라 소프트웨어를 | 폭식 횟수를 평가한다.  | 유효성 | (AB-1234) |\n| s, 42(355), 57–60. ",
        "original_sentence": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 | 필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_040",
      "text": "| 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 39,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 15,
        "window_text": "| 더욱 개연성이 있게 설명되는 경우 | 평가한다.  | 으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 | 필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.  | 한다.  | 통합계획에 따라 소프트웨어를 | 폭식 횟수를 평가한다.  | 유효성 | (AB-1234) |\n| s, 42(355), 57–60.  | 심리평가 |\n| [예시] | 제시한다. ",
        "original_sentence": "| 한다. "
      }
    },
    {
      "chunk_id": "chunk_041",
      "text": "| 통합계획에 따라 소프트웨어를 | 폭식 횟수를 평가한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 40,
        "window_size": 3,
        "char_count": 33,
        "word_count": 8,
        "page_number": 9,
        "window_text": "| 으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 | 필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.  | 한다.  | 통합계획에 따라 소프트웨어를 | 폭식 횟수를 평가한다.  | 유효성 | (AB-1234) |\n| s, 42(355), 57–60.  | 심리평가 |\n| [예시] | 제시한다.  | 평가하여야 한다. ",
        "original_sentence": "| 통합계획에 따라 소프트웨어를 | 폭식 횟수를 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_042",
      "text": "| 유효성 | (AB-1234) |\n| s, 42(355), 57–60. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 41,
        "window_size": 3,
        "char_count": 41,
        "word_count": 9,
        "page_number": 9,
        "window_text": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이 | 필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.  | 한다.  | 통합계획에 따라 소프트웨어를 | 폭식 횟수를 평가한다.  | 유효성 | (AB-1234) |\n| s, 42(355), 57–60.  | 심리평가 |\n| [예시] | 제시한다.  | 평가하여야 한다.  | 피험자 비율 | applications and examples |\n| 5) 시험방법 | Nervosa) | 제조자는 업데이트의 수행하기 위해 어떤 | A등급 | 부상이나 신체적 피해가 발생할 가능성이 없다. ",
        "original_sentence": "| 유효성 | (AB-1234) |\n| s, 42(355), 57–60. "
      }
    },
    {
      "chunk_id": "chunk_043",
      "text": "| 심리평가 |\n| [예시] | 제시한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 42,
        "window_size": 3,
        "char_count": 24,
        "word_count": 7,
        "page_number": 9,
        "window_text": "| 한다.  | 통합계획에 따라 소프트웨어를 | 폭식 횟수를 평가한다.  | 유효성 | (AB-1234) |\n| s, 42(355), 57–60.  | 심리평가 |\n| [예시] | 제시한다.  | 평가하여야 한다.  | 피험자 비율 | applications and examples |\n| 5) 시험방법 | Nervosa) | 제조자는 업데이트의 수행하기 위해 어떤 | A등급 | 부상이나 신체적 피해가 발생할 가능성이 없다.  | 소프트웨어 | assessment | - 전문가 지원 임상관리(Specialist Supportive Clinical Management, | Selfapy | 표 5. ",
        "original_sentence": "| 심리평가 |\n| [예시] | 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_044",
      "text": "| 평가하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 43,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 15,
        "window_text": "| 통합계획에 따라 소프트웨어를 | 폭식 횟수를 평가한다.  | 유효성 | (AB-1234) |\n| s, 42(355), 57–60.  | 심리평가 |\n| [예시] | 제시한다.  | 평가하여야 한다.  | 피험자 비율 | applications and examples |\n| 5) 시험방법 | Nervosa) | 제조자는 업데이트의 수행하기 위해 어떤 | A등급 | 부상이나 신체적 피해가 발생할 가능성이 없다.  | 소프트웨어 | assessment | - 전문가 지원 임상관리(Specialist Supportive Clinical Management, | Selfapy | 표 5.  디지털치료기기 관련 국내/외 규격 | 통합하고 | 통합한 | 소프트웨어 | 2 | E06050.01 | 의료기기 허가·심사 시 사용자의 건강에 | 소프트웨어 |\n| 5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이(및 표준편차) | 명시한다. ",
        "original_sentence": "| 평가하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_045",
      "text": "| 피험자 비율 | applications and examples |\n| 5) 시험방법 | Nervosa) | 제조자는 업데이트의 수행하기 위해 어떤 | A등급 | 부상이나 신체적 피해가 발생할 가능성이 없다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 44,
        "window_size": 3,
        "char_count": 118,
        "word_count": 28,
        "page_number": 26,
        "window_text": "| 유효성 | (AB-1234) |\n| s, 42(355), 57–60.  | 심리평가 |\n| [예시] | 제시한다.  | 평가하여야 한다.  | 피험자 비율 | applications and examples |\n| 5) 시험방법 | Nervosa) | 제조자는 업데이트의 수행하기 위해 어떤 | A등급 | 부상이나 신체적 피해가 발생할 가능성이 없다.  | 소프트웨어 | assessment | - 전문가 지원 임상관리(Specialist Supportive Clinical Management, | Selfapy | 표 5.  디지털치료기기 관련 국내/외 규격 | 통합하고 | 통합한 | 소프트웨어 | 2 | E06050.01 | 의료기기 허가·심사 시 사용자의 건강에 | 소프트웨어 |\n| 5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이(및 표준편차) | 명시한다.  | 가) 장기 효과 검증 | - 제품의 사용목적 상 필요한 기능(능력) 요구사항 | : 예상하는 군간 평균 변화량 차, 0 | 확인 자료 |\n| 소프트웨어 | 6 | 하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상시험에 | 피험자별 중지 사유를 포함한 관련 임상시험 자료의 처리 방법을 제시한다. ",
        "original_sentence": "| 피험자 비율 | applications and examples |\n| 5) 시험방법 | Nervosa) | 제조자는 업데이트의 수행하기 위해 어떤 | A등급 | 부상이나 신체적 피해가 발생할 가능성이 없다. "
      }
    },
    {
      "chunk_id": "chunk_046",
      "text": "| 소프트웨어 | assessment | - 전문가 지원 임상관리(Specialist Supportive Clinical Management, | Selfapy | 표 5. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 45,
        "window_size": 3,
        "char_count": 97,
        "word_count": 17,
        "page_number": 9,
        "window_text": "| 심리평가 |\n| [예시] | 제시한다.  | 평가하여야 한다.  | 피험자 비율 | applications and examples |\n| 5) 시험방법 | Nervosa) | 제조자는 업데이트의 수행하기 위해 어떤 | A등급 | 부상이나 신체적 피해가 발생할 가능성이 없다.  | 소프트웨어 | assessment | - 전문가 지원 임상관리(Specialist Supportive Clinical Management, | Selfapy | 표 5.  디지털치료기기 관련 국내/외 규격 | 통합하고 | 통합한 | 소프트웨어 | 2 | E06050.01 | 의료기기 허가·심사 시 사용자의 건강에 | 소프트웨어 |\n| 5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이(및 표준편차) | 명시한다.  | 가) 장기 효과 검증 | - 제품의 사용목적 상 필요한 기능(능력) 요구사항 | : 예상하는 군간 평균 변화량 차, 0 | 확인 자료 |\n| 소프트웨어 | 6 | 하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상시험에 | 피험자별 중지 사유를 포함한 관련 임상시험 자료의 처리 방법을 제시한다.  | 가) 시험기기 | ※ 예: 감사 로그 기록 기능 제공 | 의료기기의 사이버보안 |\n| 안내서-1334-01 | ’23.12.7. ",
        "original_sentence": "| 소프트웨어 | assessment | - 전문가 지원 임상관리(Specialist Supportive Clinical Management, | Selfapy | 표 5. "
      }
    },
    {
      "chunk_id": "chunk_047",
      "text": "디지털치료기기 관련 국내/외 규격 | 통합하고 | 통합한 | 소프트웨어 | 2 | E06050.01 | 의료기기 허가·심사 시 사용자의 건강에 | 소프트웨어 |\n| 5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이(및 표준편차) | 명시한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 46,
        "window_size": 3,
        "char_count": 140,
        "word_count": 36,
        "page_number": 9,
        "window_text": "| 평가하여야 한다.  | 피험자 비율 | applications and examples |\n| 5) 시험방법 | Nervosa) | 제조자는 업데이트의 수행하기 위해 어떤 | A등급 | 부상이나 신체적 피해가 발생할 가능성이 없다.  | 소프트웨어 | assessment | - 전문가 지원 임상관리(Specialist Supportive Clinical Management, | Selfapy | 표 5.  디지털치료기기 관련 국내/외 규격 | 통합하고 | 통합한 | 소프트웨어 | 2 | E06050.01 | 의료기기 허가·심사 시 사용자의 건강에 | 소프트웨어 |\n| 5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이(및 표준편차) | 명시한다.  | 가) 장기 효과 검증 | - 제품의 사용목적 상 필요한 기능(능력) 요구사항 | : 예상하는 군간 평균 변화량 차, 0 | 확인 자료 |\n| 소프트웨어 | 6 | 하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상시험에 | 피험자별 중지 사유를 포함한 관련 임상시험 자료의 처리 방법을 제시한다.  | 가) 시험기기 | ※ 예: 감사 로그 기록 기능 제공 | 의료기기의 사이버보안 |\n| 안내서-1334-01 | ’23.12.7.  | 5) 이상치 처리 | [예시] | ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설명하거나 | 피험자의 심각도 정도를 7점 척도로 평가하며, 점수가 | * [F50.0] Anorexia nervosa (신경성 식욕부진) | 가) 치료 후 평가 | ※ “예방, 관리”의 범위는 치료적 개입이 필요한 “환자”를 대상으로 함 | (3) 피험자 식별코드는 아래의 방법에 따라 기재한다. ",
        "original_sentence": "디지털치료기기 관련 국내/외 규격 | 통합하고 | 통합한 | 소프트웨어 | 2 | E06050.01 | 의료기기 허가·심사 시 사용자의 건강에 | 소프트웨어 |\n| 5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이(및 표준편차) | 명시한다. "
      }
    },
    {
      "chunk_id": "chunk_048",
      "text": "| 가) 장기 효과 검증 | - 제품의 사용목적 상 필요한 기능(능력) 요구사항 | : 예상하는 군간 평균 변화량 차, 0 | 확인 자료 |\n| 소프트웨어 | 6 | 하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상시험에 | 피험자별 중지 사유를 포함한 관련 임상시험 자료의 처리 방법을 제시한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 47,
        "window_size": 3,
        "char_count": 181,
        "word_count": 52,
        "page_number": 3,
        "window_text": "| 피험자 비율 | applications and examples |\n| 5) 시험방법 | Nervosa) | 제조자는 업데이트의 수행하기 위해 어떤 | A등급 | 부상이나 신체적 피해가 발생할 가능성이 없다.  | 소프트웨어 | assessment | - 전문가 지원 임상관리(Specialist Supportive Clinical Management, | Selfapy | 표 5.  디지털치료기기 관련 국내/외 규격 | 통합하고 | 통합한 | 소프트웨어 | 2 | E06050.01 | 의료기기 허가·심사 시 사용자의 건강에 | 소프트웨어 |\n| 5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이(및 표준편차) | 명시한다.  | 가) 장기 효과 검증 | - 제품의 사용목적 상 필요한 기능(능력) 요구사항 | : 예상하는 군간 평균 변화량 차, 0 | 확인 자료 |\n| 소프트웨어 | 6 | 하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상시험에 | 피험자별 중지 사유를 포함한 관련 임상시험 자료의 처리 방법을 제시한다.  | 가) 시험기기 | ※ 예: 감사 로그 기록 기능 제공 | 의료기기의 사이버보안 |\n| 안내서-1334-01 | ’23.12.7.  | 5) 이상치 처리 | [예시] | ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설명하거나 | 피험자의 심각도 정도를 7점 척도로 평가하며, 점수가 | * [F50.0] Anorexia nervosa (신경성 식욕부진) | 가) 치료 후 평가 | ※ “예방, 관리”의 범위는 치료적 개입이 필요한 “환자”를 대상으로 함 | (3) 피험자 식별코드는 아래의 방법에 따라 기재한다.  | 순응 임상시험대상자군(PPS)를 주요분석군으로 분석한다. ",
        "original_sentence": "| 가) 장기 효과 검증 | - 제품의 사용목적 상 필요한 기능(능력) 요구사항 | : 예상하는 군간 평균 변화량 차, 0 | 확인 자료 |\n| 소프트웨어 | 6 | 하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상시험에 | 피험자별 중지 사유를 포함한 관련 임상시험 자료의 처리 방법을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_049",
      "text": "| 가) 시험기기 | ※ 예: 감사 로그 기록 기능 제공 | 의료기기의 사이버보안 |\n| 안내서-1334-01 | ’23.12.7. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 48,
        "window_size": 3,
        "char_count": 74,
        "word_count": 19,
        "page_number": 27,
        "window_text": "| 소프트웨어 | assessment | - 전문가 지원 임상관리(Specialist Supportive Clinical Management, | Selfapy | 표 5.  디지털치료기기 관련 국내/외 규격 | 통합하고 | 통합한 | 소프트웨어 | 2 | E06050.01 | 의료기기 허가·심사 시 사용자의 건강에 | 소프트웨어 |\n| 5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이(및 표준편차) | 명시한다.  | 가) 장기 효과 검증 | - 제품의 사용목적 상 필요한 기능(능력) 요구사항 | : 예상하는 군간 평균 변화량 차, 0 | 확인 자료 |\n| 소프트웨어 | 6 | 하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상시험에 | 피험자별 중지 사유를 포함한 관련 임상시험 자료의 처리 방법을 제시한다.  | 가) 시험기기 | ※ 예: 감사 로그 기록 기능 제공 | 의료기기의 사이버보안 |\n| 안내서-1334-01 | ’23.12.7.  | 5) 이상치 처리 | [예시] | ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설명하거나 | 피험자의 심각도 정도를 7점 척도로 평가하며, 점수가 | * [F50.0] Anorexia nervosa (신경성 식욕부진) | 가) 치료 후 평가 | ※ “예방, 관리”의 범위는 치료적 개입이 필요한 “환자”를 대상으로 함 | (3) 피험자 식별코드는 아래의 방법에 따라 기재한다.  | 순응 임상시험대상자군(PPS)를 주요분석군으로 분석한다.  | 인증‧신고를 하여야한다. ",
        "original_sentence": "| 가) 시험기기 | ※ 예: 감사 로그 기록 기능 제공 | 의료기기의 사이버보안 |\n| 안내서-1334-01 | ’23.12.7. "
      }
    },
    {
      "chunk_id": "chunk_050",
      "text": "| 5) 이상치 처리 | [예시] | ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설명하거나 | 피험자의 심각도 정도를 7점 척도로 평가하며, 점수가 | * [F50.0] Anorexia nervosa (신경성 식욕부진) | 가) 치료 후 평가 | ※ “예방, 관리”의 범위는 치료적 개입이 필요한 “환자”를 대상으로 함 | (3) 피험자 식별코드는 아래의 방법에 따라 기재한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 49,
        "window_size": 3,
        "char_count": 236,
        "word_count": 58,
        "page_number": 26,
        "window_text": "디지털치료기기 관련 국내/외 규격 | 통합하고 | 통합한 | 소프트웨어 | 2 | E06050.01 | 의료기기 허가·심사 시 사용자의 건강에 | 소프트웨어 |\n| 5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이(및 표준편차) | 명시한다.  | 가) 장기 효과 검증 | - 제품의 사용목적 상 필요한 기능(능력) 요구사항 | : 예상하는 군간 평균 변화량 차, 0 | 확인 자료 |\n| 소프트웨어 | 6 | 하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상시험에 | 피험자별 중지 사유를 포함한 관련 임상시험 자료의 처리 방법을 제시한다.  | 가) 시험기기 | ※ 예: 감사 로그 기록 기능 제공 | 의료기기의 사이버보안 |\n| 안내서-1334-01 | ’23.12.7.  | 5) 이상치 처리 | [예시] | ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설명하거나 | 피험자의 심각도 정도를 7점 척도로 평가하며, 점수가 | * [F50.0] Anorexia nervosa (신경성 식욕부진) | 가) 치료 후 평가 | ※ “예방, 관리”의 범위는 치료적 개입이 필요한 “환자”를 대상으로 함 | (3) 피험자 식별코드는 아래의 방법에 따라 기재한다.  | 순응 임상시험대상자군(PPS)를 주요분석군으로 분석한다.  | 인증‧신고를 하여야한다.  | 정하였다. ",
        "original_sentence": "| 5) 이상치 처리 | [예시] | ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설명하거나 | 피험자의 심각도 정도를 7점 척도로 평가하며, 점수가 | * [F50.0] Anorexia nervosa (신경성 식욕부진) | 가) 치료 후 평가 | ※ “예방, 관리”의 범위는 치료적 개입이 필요한 “환자”를 대상으로 함 | (3) 피험자 식별코드는 아래의 방법에 따라 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_051",
      "text": "| 순응 임상시험대상자군(PPS)를 주요분석군으로 분석한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 50,
        "window_size": 3,
        "char_count": 34,
        "word_count": 5,
        "page_number": 15,
        "window_text": "| 가) 장기 효과 검증 | - 제품의 사용목적 상 필요한 기능(능력) 요구사항 | : 예상하는 군간 평균 변화량 차, 0 | 확인 자료 |\n| 소프트웨어 | 6 | 하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상시험에 | 피험자별 중지 사유를 포함한 관련 임상시험 자료의 처리 방법을 제시한다.  | 가) 시험기기 | ※ 예: 감사 로그 기록 기능 제공 | 의료기기의 사이버보안 |\n| 안내서-1334-01 | ’23.12.7.  | 5) 이상치 처리 | [예시] | ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설명하거나 | 피험자의 심각도 정도를 7점 척도로 평가하며, 점수가 | * [F50.0] Anorexia nervosa (신경성 식욕부진) | 가) 치료 후 평가 | ※ “예방, 관리”의 범위는 치료적 개입이 필요한 “환자”를 대상으로 함 | (3) 피험자 식별코드는 아래의 방법에 따라 기재한다.  | 순응 임상시험대상자군(PPS)를 주요분석군으로 분석한다.  | 인증‧신고를 하여야한다.  | 정하였다.  | 및 내용 등을 기재한다. ",
        "original_sentence": "| 순응 임상시험대상자군(PPS)를 주요분석군으로 분석한다. "
      }
    },
    {
      "chunk_id": "chunk_052",
      "text": "| 인증‧신고를 하여야한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 51,
        "window_size": 3,
        "char_count": 16,
        "word_count": 3,
        "page_number": 15,
        "window_text": "| 가) 시험기기 | ※ 예: 감사 로그 기록 기능 제공 | 의료기기의 사이버보안 |\n| 안내서-1334-01 | ’23.12.7.  | 5) 이상치 처리 | [예시] | ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설명하거나 | 피험자의 심각도 정도를 7점 척도로 평가하며, 점수가 | * [F50.0] Anorexia nervosa (신경성 식욕부진) | 가) 치료 후 평가 | ※ “예방, 관리”의 범위는 치료적 개입이 필요한 “환자”를 대상으로 함 | (3) 피험자 식별코드는 아래의 방법에 따라 기재한다.  | 순응 임상시험대상자군(PPS)를 주요분석군으로 분석한다.  | 인증‧신고를 하여야한다.  | 정하였다.  | 및 내용 등을 기재한다.  | (사유 :                                                                ) | 소프트웨어가 어떤(what) 기능을 | 표 11. ",
        "original_sentence": "| 인증‧신고를 하여야한다. "
      }
    },
    {
      "chunk_id": "chunk_053",
      "text": "| 정하였다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 52,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 63,
        "window_text": "| 5) 이상치 처리 | [예시] | ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 설명하거나 | 피험자의 심각도 정도를 7점 척도로 평가하며, 점수가 | * [F50.0] Anorexia nervosa (신경성 식욕부진) | 가) 치료 후 평가 | ※ “예방, 관리”의 범위는 치료적 개입이 필요한 “환자”를 대상으로 함 | (3) 피험자 식별코드는 아래의 방법에 따라 기재한다.  | 순응 임상시험대상자군(PPS)를 주요분석군으로 분석한다.  | 인증‧신고를 하여야한다.  | 정하였다.  | 및 내용 등을 기재한다.  | (사유 :                                                                ) | 소프트웨어가 어떤(what) 기능을 | 표 11.  위험통제 예시 | 평가 및 임상시험계획서 작성 가이드라인 | (민원인 안내서) 제정 | 해당 |\n| - 임상시험 중 관찰 항목을 기술한다. ",
        "original_sentence": "| 정하였다. "
      }
    },
    {
      "chunk_id": "chunk_054",
      "text": "| 및 내용 등을 기재한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 53,
        "window_size": 3,
        "char_count": 16,
        "word_count": 5,
        "page_number": 15,
        "window_text": "| 순응 임상시험대상자군(PPS)를 주요분석군으로 분석한다.  | 인증‧신고를 하여야한다.  | 정하였다.  | 및 내용 등을 기재한다.  | (사유 :                                                                ) | 소프트웨어가 어떤(what) 기능을 | 표 11.  위험통제 예시 | 평가 및 임상시험계획서 작성 가이드라인 | (민원인 안내서) 제정 | 해당 |\n| - 임상시험 중 관찰 항목을 기술한다.  | - 성능 평가 방법은 임상시험 기간 동안 일차/이차 유효성 평가변수에 대한 | 나) 위험평가 | 연결이 필요한지와 코드 서명 및 기타 비슷한 | B등급 | 심각하지 않은 부상(경상)이 발생할 가능성이 있다. ",
        "original_sentence": "| 및 내용 등을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_055",
      "text": "| (사유 :                                                                ) | 소프트웨어가 어떤(what) 기능을 | 표 11. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 54,
        "window_size": 3,
        "char_count": 103,
        "word_count": 11,
        "page_number": 100,
        "window_text": "| 인증‧신고를 하여야한다.  | 정하였다.  | 및 내용 등을 기재한다.  | (사유 :                                                                ) | 소프트웨어가 어떤(what) 기능을 | 표 11.  위험통제 예시 | 평가 및 임상시험계획서 작성 가이드라인 | (민원인 안내서) 제정 | 해당 |\n| - 임상시험 중 관찰 항목을 기술한다.  | - 성능 평가 방법은 임상시험 기간 동안 일차/이차 유효성 평가변수에 대한 | 나) 위험평가 | 연결이 필요한지와 코드 서명 및 기타 비슷한 | B등급 | 심각하지 않은 부상(경상)이 발생할 가능성이 있다.  | 통합 검증 | software | SSCM)를 통한 치료 또한 받을 수 있다. ",
        "original_sentence": "| (사유 :                                                                ) | 소프트웨어가 어떤(what) 기능을 | 표 11. "
      }
    },
    {
      "chunk_id": "chunk_056",
      "text": "위험통제 예시 | 평가 및 임상시험계획서 작성 가이드라인 | (민원인 안내서) 제정 | 해당 |\n| - 임상시험 중 관찰 항목을 기술한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 55,
        "window_size": 3,
        "char_count": 78,
        "word_count": 22,
        "page_number": 4,
        "window_text": "| 정하였다.  | 및 내용 등을 기재한다.  | (사유 :                                                                ) | 소프트웨어가 어떤(what) 기능을 | 표 11.  위험통제 예시 | 평가 및 임상시험계획서 작성 가이드라인 | (민원인 안내서) 제정 | 해당 |\n| - 임상시험 중 관찰 항목을 기술한다.  | - 성능 평가 방법은 임상시험 기간 동안 일차/이차 유효성 평가변수에 대한 | 나) 위험평가 | 연결이 필요한지와 코드 서명 및 기타 비슷한 | B등급 | 심각하지 않은 부상(경상)이 발생할 가능성이 있다.  | 통합 검증 | software | SSCM)를 통한 치료 또한 받을 수 있다.  | 항목이 | 의도한 | 대로 | 기능을 | 직접적인 영향을 미칠 수 있는 사이버 | 검증 및 |\n| ed Assoc 61(3), 191-197. ",
        "original_sentence": "위험통제 예시 | 평가 및 임상시험계획서 작성 가이드라인 | (민원인 안내서) 제정 | 해당 |\n| - 임상시험 중 관찰 항목을 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_057",
      "text": "| - 성능 평가 방법은 임상시험 기간 동안 일차/이차 유효성 평가변수에 대한 | 나) 위험평가 | 연결이 필요한지와 코드 서명 및 기타 비슷한 | B등급 | 심각하지 않은 부상(경상)이 발생할 가능성이 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 56,
        "window_size": 3,
        "char_count": 118,
        "word_count": 32,
        "page_number": 7,
        "window_text": "| 및 내용 등을 기재한다.  | (사유 :                                                                ) | 소프트웨어가 어떤(what) 기능을 | 표 11.  위험통제 예시 | 평가 및 임상시험계획서 작성 가이드라인 | (민원인 안내서) 제정 | 해당 |\n| - 임상시험 중 관찰 항목을 기술한다.  | - 성능 평가 방법은 임상시험 기간 동안 일차/이차 유효성 평가변수에 대한 | 나) 위험평가 | 연결이 필요한지와 코드 서명 및 기타 비슷한 | B등급 | 심각하지 않은 부상(경상)이 발생할 가능성이 있다.  | 통합 검증 | software | SSCM)를 통한 치료 또한 받을 수 있다.  | 항목이 | 의도한 | 대로 | 기능을 | 직접적인 영향을 미칠 수 있는 사이버 | 검증 및 |\n| ed Assoc 61(3), 191-197.  | 베이스라인 (사용 전) | 표 3. ",
        "original_sentence": "| - 성능 평가 방법은 임상시험 기간 동안 일차/이차 유효성 평가변수에 대한 | 나) 위험평가 | 연결이 필요한지와 코드 서명 및 기타 비슷한 | B등급 | 심각하지 않은 부상(경상)이 발생할 가능성이 있다. "
      }
    },
    {
      "chunk_id": "chunk_058",
      "text": "| 통합 검증 | software | SSCM)를 통한 치료 또한 받을 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 57,
        "window_size": 3,
        "char_count": 46,
        "word_count": 13,
        "page_number": 9,
        "window_text": "| (사유 :                                                                ) | 소프트웨어가 어떤(what) 기능을 | 표 11.  위험통제 예시 | 평가 및 임상시험계획서 작성 가이드라인 | (민원인 안내서) 제정 | 해당 |\n| - 임상시험 중 관찰 항목을 기술한다.  | - 성능 평가 방법은 임상시험 기간 동안 일차/이차 유효성 평가변수에 대한 | 나) 위험평가 | 연결이 필요한지와 코드 서명 및 기타 비슷한 | B등급 | 심각하지 않은 부상(경상)이 발생할 가능성이 있다.  | 통합 검증 | software | SSCM)를 통한 치료 또한 받을 수 있다.  | 항목이 | 의도한 | 대로 | 기능을 | 직접적인 영향을 미칠 수 있는 사이버 | 검증 및 |\n| ed Assoc 61(3), 191-197.  | 베이스라인 (사용 전) | 표 3.  진료지침별 섭식장애 인지행동치료의 권고 사항 |\n| [예시] | 4 | logy. ",
        "original_sentence": "| 통합 검증 | software | SSCM)를 통한 치료 또한 받을 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_059",
      "text": "| 항목이 | 의도한 | 대로 | 기능을 | 직접적인 영향을 미칠 수 있는 사이버 | 검증 및 |\n| ed Assoc 61(3), 191-197. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 58,
        "window_size": 3,
        "char_count": 82,
        "word_count": 24,
        "page_number": 7,
        "window_text": "위험통제 예시 | 평가 및 임상시험계획서 작성 가이드라인 | (민원인 안내서) 제정 | 해당 |\n| - 임상시험 중 관찰 항목을 기술한다.  | - 성능 평가 방법은 임상시험 기간 동안 일차/이차 유효성 평가변수에 대한 | 나) 위험평가 | 연결이 필요한지와 코드 서명 및 기타 비슷한 | B등급 | 심각하지 않은 부상(경상)이 발생할 가능성이 있다.  | 통합 검증 | software | SSCM)를 통한 치료 또한 받을 수 있다.  | 항목이 | 의도한 | 대로 | 기능을 | 직접적인 영향을 미칠 수 있는 사이버 | 검증 및 |\n| ed Assoc 61(3), 191-197.  | 베이스라인 (사용 전) | 표 3.  진료지침별 섭식장애 인지행동치료의 권고 사항 |\n| [예시] | 4 | logy.  Behaviour Research and Therapy, 46(10), 1105-1110. ",
        "original_sentence": "| 항목이 | 의도한 | 대로 | 기능을 | 직접적인 영향을 미칠 수 있는 사이버 | 검증 및 |\n| ed Assoc 61(3), 191-197. "
      }
    },
    {
      "chunk_id": "chunk_060",
      "text": "| 베이스라인 (사용 전) | 표 3. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 59,
        "window_size": 3,
        "char_count": 22,
        "word_count": 7,
        "page_number": 26,
        "window_text": "| - 성능 평가 방법은 임상시험 기간 동안 일차/이차 유효성 평가변수에 대한 | 나) 위험평가 | 연결이 필요한지와 코드 서명 및 기타 비슷한 | B등급 | 심각하지 않은 부상(경상)이 발생할 가능성이 있다.  | 통합 검증 | software | SSCM)를 통한 치료 또한 받을 수 있다.  | 항목이 | 의도한 | 대로 | 기능을 | 직접적인 영향을 미칠 수 있는 사이버 | 검증 및 |\n| ed Assoc 61(3), 191-197.  | 베이스라인 (사용 전) | 표 3.  진료지침별 섭식장애 인지행동치료의 권고 사항 |\n| [예시] | 4 | logy.  Behaviour Research and Therapy, 46(10), 1105-1110.  | nts for binge eating disorder. ",
        "original_sentence": "| 베이스라인 (사용 전) | 표 3. "
      }
    },
    {
      "chunk_id": "chunk_061",
      "text": "진료지침별 섭식장애 인지행동치료의 권고 사항 |\n| [예시] | 4 | logy. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 60,
        "window_size": 3,
        "char_count": 46,
        "word_count": 12,
        "page_number": 3,
        "window_text": "| 통합 검증 | software | SSCM)를 통한 치료 또한 받을 수 있다.  | 항목이 | 의도한 | 대로 | 기능을 | 직접적인 영향을 미칠 수 있는 사이버 | 검증 및 |\n| ed Assoc 61(3), 191-197.  | 베이스라인 (사용 전) | 표 3.  진료지침별 섭식장애 인지행동치료의 권고 사항 |\n| [예시] | 4 | logy.  Behaviour Research and Therapy, 46(10), 1105-1110.  | nts for binge eating disorder.  International Journal of Eating Disorders, 43(3), 205-217 | 가) 스크리닝, 선정제외 기준 확인 | 1) 대상자군 | 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품의약품안전처 지침서 등의 | 허가·심사 가이드라인 | 적용 | 소프트웨어 | 국내 |\n| - ‘탈락’ 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상 | [예시] | 관여하는 사람을 말한다. ",
        "original_sentence": "진료지침별 섭식장애 인지행동치료의 권고 사항 |\n| [예시] | 4 | logy. "
      }
    },
    {
      "chunk_id": "chunk_062",
      "text": "Behaviour Research and Therapy, 46(10), 1105-1110. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 61,
        "window_size": 3,
        "char_count": 51,
        "word_count": 6,
        "page_number": 19,
        "window_text": "| 항목이 | 의도한 | 대로 | 기능을 | 직접적인 영향을 미칠 수 있는 사이버 | 검증 및 |\n| ed Assoc 61(3), 191-197.  | 베이스라인 (사용 전) | 표 3.  진료지침별 섭식장애 인지행동치료의 권고 사항 |\n| [예시] | 4 | logy.  Behaviour Research and Therapy, 46(10), 1105-1110.  | nts for binge eating disorder.  International Journal of Eating Disorders, 43(3), 205-217 | 가) 스크리닝, 선정제외 기준 확인 | 1) 대상자군 | 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품의약품안전처 지침서 등의 | 허가·심사 가이드라인 | 적용 | 소프트웨어 | 국내 |\n| - ‘탈락’ 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상 | [예시] | 관여하는 사람을 말한다.  | - 소프트웨어 기반 알람, 경고, 연산 메시지 | C등급 | 심각한 부상 또는 사망이 발생할 가능성이 있다. ",
        "original_sentence": "Behaviour Research and Therapy, 46(10), 1105-1110. "
      }
    },
    {
      "chunk_id": "chunk_063",
      "text": "| nts for binge eating disorder. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 62,
        "window_size": 3,
        "char_count": 33,
        "word_count": 6,
        "page_number": 9,
        "window_text": "| 베이스라인 (사용 전) | 표 3.  진료지침별 섭식장애 인지행동치료의 권고 사항 |\n| [예시] | 4 | logy.  Behaviour Research and Therapy, 46(10), 1105-1110.  | nts for binge eating disorder.  International Journal of Eating Disorders, 43(3), 205-217 | 가) 스크리닝, 선정제외 기준 확인 | 1) 대상자군 | 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품의약품안전처 지침서 등의 | 허가·심사 가이드라인 | 적용 | 소프트웨어 | 국내 |\n| - ‘탈락’ 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상 | [예시] | 관여하는 사람을 말한다.  | - 소프트웨어 기반 알람, 경고, 연산 메시지 | C등급 | 심각한 부상 또는 사망이 발생할 가능성이 있다.  | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | : 비열등성 허용 오차, 0.5×{-12.79-(-3.74)}/2=-2.26 | 소프트웨어 | 어떻게(how) 수행할 것인지에 | 보안 위협에 적용할 수 있는 최소한의 | 해당기기 | 적합성 | 첨부자료 |\n| 기기 | - 임상시험 후 이상반응 확인에 대해서 기술한다. ",
        "original_sentence": "| nts for binge eating disorder. "
      }
    },
    {
      "chunk_id": "chunk_064",
      "text": "International Journal of Eating Disorders, 43(3), 205-217 | 가) 스크리닝, 선정제외 기준 확인 | 1) 대상자군 | 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품의약품안전처 지침서 등의 | 허가·심사 가이드라인 | 적용 | 소프트웨어 | 국내 |\n| - ‘탈락’ 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상 | [예시] | 관여하는 사람을 말한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 63,
        "window_size": 3,
        "char_count": 247,
        "word_count": 56,
        "page_number": 18,
        "window_text": "진료지침별 섭식장애 인지행동치료의 권고 사항 |\n| [예시] | 4 | logy.  Behaviour Research and Therapy, 46(10), 1105-1110.  | nts for binge eating disorder.  International Journal of Eating Disorders, 43(3), 205-217 | 가) 스크리닝, 선정제외 기준 확인 | 1) 대상자군 | 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품의약품안전처 지침서 등의 | 허가·심사 가이드라인 | 적용 | 소프트웨어 | 국내 |\n| - ‘탈락’ 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상 | [예시] | 관여하는 사람을 말한다.  | - 소프트웨어 기반 알람, 경고, 연산 메시지 | C등급 | 심각한 부상 또는 사망이 발생할 가능성이 있다.  | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | : 비열등성 허용 오차, 0.5×{-12.79-(-3.74)}/2=-2.26 | 소프트웨어 | 어떻게(how) 수행할 것인지에 | 보안 위협에 적용할 수 있는 최소한의 | 해당기기 | 적합성 | 첨부자료 |\n| 기기 | - 임상시험 후 이상반응 확인에 대해서 기술한다.  | [예시] | 되어야 한다. ",
        "original_sentence": "International Journal of Eating Disorders, 43(3), 205-217 | 가) 스크리닝, 선정제외 기준 확인 | 1) 대상자군 | 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품의약품안전처 지침서 등의 | 허가·심사 가이드라인 | 적용 | 소프트웨어 | 국내 |\n| - ‘탈락’ 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상 | [예시] | 관여하는 사람을 말한다. "
      }
    },
    {
      "chunk_id": "chunk_065",
      "text": "| - 소프트웨어 기반 알람, 경고, 연산 메시지 | C등급 | 심각한 부상 또는 사망이 발생할 가능성이 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 64,
        "window_size": 3,
        "char_count": 63,
        "word_count": 18,
        "page_number": 9,
        "window_text": "Behaviour Research and Therapy, 46(10), 1105-1110.  | nts for binge eating disorder.  International Journal of Eating Disorders, 43(3), 205-217 | 가) 스크리닝, 선정제외 기준 확인 | 1) 대상자군 | 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품의약품안전처 지침서 등의 | 허가·심사 가이드라인 | 적용 | 소프트웨어 | 국내 |\n| - ‘탈락’ 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상 | [예시] | 관여하는 사람을 말한다.  | - 소프트웨어 기반 알람, 경고, 연산 메시지 | C등급 | 심각한 부상 또는 사망이 발생할 가능성이 있다.  | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | : 비열등성 허용 오차, 0.5×{-12.79-(-3.74)}/2=-2.26 | 소프트웨어 | 어떻게(how) 수행할 것인지에 | 보안 위협에 적용할 수 있는 최소한의 | 해당기기 | 적합성 | 첨부자료 |\n| 기기 | - 임상시험 후 이상반응 확인에 대해서 기술한다.  | [예시] | 되어야 한다.  | [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | 시도한 자 | 제조자는 기기 소프트웨어의 비인가된 변경과 | 수단을 통한 연결이나 업데이트의 진본성을 | Affective | - 성인 | 환자 | 일부는 | 가족치료(Family-Based | Treatment, | FBT)를 | 발휘하는지 확인한다. ",
        "original_sentence": "| - 소프트웨어 기반 알람, 경고, 연산 메시지 | C등급 | 심각한 부상 또는 사망이 발생할 가능성이 있다. "
      }
    },
    {
      "chunk_id": "chunk_066",
      "text": "| □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | : 비열등성 허용 오차, 0.5×{-12.79-(-3.74)}/2=-2.26 | 소프트웨어 | 어떻게(how) 수행할 것인지에 | 보안 위협에 적용할 수 있는 최소한의 | 해당기기 | 적합성 | 첨부자료 |\n| 기기 | - 임상시험 후 이상반응 확인에 대해서 기술한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 65,
        "window_size": 3,
        "char_count": 176,
        "word_count": 40,
        "page_number": 3,
        "window_text": "| nts for binge eating disorder.  International Journal of Eating Disorders, 43(3), 205-217 | 가) 스크리닝, 선정제외 기준 확인 | 1) 대상자군 | 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품의약품안전처 지침서 등의 | 허가·심사 가이드라인 | 적용 | 소프트웨어 | 국내 |\n| - ‘탈락’ 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상 | [예시] | 관여하는 사람을 말한다.  | - 소프트웨어 기반 알람, 경고, 연산 메시지 | C등급 | 심각한 부상 또는 사망이 발생할 가능성이 있다.  | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | : 비열등성 허용 오차, 0.5×{-12.79-(-3.74)}/2=-2.26 | 소프트웨어 | 어떻게(how) 수행할 것인지에 | 보안 위협에 적용할 수 있는 최소한의 | 해당기기 | 적합성 | 첨부자료 |\n| 기기 | - 임상시험 후 이상반응 확인에 대해서 기술한다.  | [예시] | 되어야 한다.  | [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | 시도한 자 | 제조자는 기기 소프트웨어의 비인가된 변경과 | 수단을 통한 연결이나 업데이트의 진본성을 | Affective | - 성인 | 환자 | 일부는 | 가족치료(Family-Based | Treatment, | FBT)를 | 발휘하는지 확인한다.  | 잔여위험평가 | 유효성 | (AB-1234) |\n| Han et al., 2018). ",
        "original_sentence": "| □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | : 비열등성 허용 오차, 0.5×{-12.79-(-3.74)}/2=-2.26 | 소프트웨어 | 어떻게(how) 수행할 것인지에 | 보안 위협에 적용할 수 있는 최소한의 | 해당기기 | 적합성 | 첨부자료 |\n| 기기 | - 임상시험 후 이상반응 확인에 대해서 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_067",
      "text": "| [예시] | 되어야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 66,
        "window_size": 3,
        "char_count": 17,
        "word_count": 5,
        "page_number": 15,
        "window_text": "International Journal of Eating Disorders, 43(3), 205-217 | 가) 스크리닝, 선정제외 기준 확인 | 1) 대상자군 | 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품의약품안전처 지침서 등의 | 허가·심사 가이드라인 | 적용 | 소프트웨어 | 국내 |\n| - ‘탈락’ 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상 | [예시] | 관여하는 사람을 말한다.  | - 소프트웨어 기반 알람, 경고, 연산 메시지 | C등급 | 심각한 부상 또는 사망이 발생할 가능성이 있다.  | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | : 비열등성 허용 오차, 0.5×{-12.79-(-3.74)}/2=-2.26 | 소프트웨어 | 어떻게(how) 수행할 것인지에 | 보안 위협에 적용할 수 있는 최소한의 | 해당기기 | 적합성 | 첨부자료 |\n| 기기 | - 임상시험 후 이상반응 확인에 대해서 기술한다.  | [예시] | 되어야 한다.  | [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | 시도한 자 | 제조자는 기기 소프트웨어의 비인가된 변경과 | 수단을 통한 연결이나 업데이트의 진본성을 | Affective | - 성인 | 환자 | 일부는 | 가족치료(Family-Based | Treatment, | FBT)를 | 발휘하는지 확인한다.  | 잔여위험평가 | 유효성 | (AB-1234) |\n| Han et al., 2018).  | 시험군과 대조군간의 비교 분석 방법을 통계적으로 타당하게 제시한다. ",
        "original_sentence": "| [예시] | 되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_068",
      "text": "| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | 시도한 자 | 제조자는 기기 소프트웨어의 비인가된 변경과 | 수단을 통한 연결이나 업데이트의 진본성을 | Affective | - 성인 | 환자 | 일부는 | 가족치료(Family-Based | Treatment, | FBT)를 | 발휘하는지 확인한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 67,
        "window_size": 3,
        "char_count": 196,
        "word_count": 41,
        "page_number": 15,
        "window_text": "| - 소프트웨어 기반 알람, 경고, 연산 메시지 | C등급 | 심각한 부상 또는 사망이 발생할 가능성이 있다.  | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | : 비열등성 허용 오차, 0.5×{-12.79-(-3.74)}/2=-2.26 | 소프트웨어 | 어떻게(how) 수행할 것인지에 | 보안 위협에 적용할 수 있는 최소한의 | 해당기기 | 적합성 | 첨부자료 |\n| 기기 | - 임상시험 후 이상반응 확인에 대해서 기술한다.  | [예시] | 되어야 한다.  | [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | 시도한 자 | 제조자는 기기 소프트웨어의 비인가된 변경과 | 수단을 통한 연결이나 업데이트의 진본성을 | Affective | - 성인 | 환자 | 일부는 | 가족치료(Family-Based | Treatment, | FBT)를 | 발휘하는지 확인한다.  | 잔여위험평가 | 유효성 | (AB-1234) |\n| Han et al., 2018).  | 시험군과 대조군간의 비교 분석 방법을 통계적으로 타당하게 제시한다.  | 반드시 필요한 것은 아니며 행정상 변경이 필요하다. ",
        "original_sentence": "| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | 시도한 자 | 제조자는 기기 소프트웨어의 비인가된 변경과 | 수단을 통한 연결이나 업데이트의 진본성을 | Affective | - 성인 | 환자 | 일부는 | 가족치료(Family-Based | Treatment, | FBT)를 | 발휘하는지 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_069",
      "text": "| 잔여위험평가 | 유효성 | (AB-1234) |\n| Han et al., 2018). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 68,
        "window_size": 3,
        "char_count": 50,
        "word_count": 12,
        "page_number": 9,
        "window_text": "| □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | : 비열등성 허용 오차, 0.5×{-12.79-(-3.74)}/2=-2.26 | 소프트웨어 | 어떻게(how) 수행할 것인지에 | 보안 위협에 적용할 수 있는 최소한의 | 해당기기 | 적합성 | 첨부자료 |\n| 기기 | - 임상시험 후 이상반응 확인에 대해서 기술한다.  | [예시] | 되어야 한다.  | [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | 시도한 자 | 제조자는 기기 소프트웨어의 비인가된 변경과 | 수단을 통한 연결이나 업데이트의 진본성을 | Affective | - 성인 | 환자 | 일부는 | 가족치료(Family-Based | Treatment, | FBT)를 | 발휘하는지 확인한다.  | 잔여위험평가 | 유효성 | (AB-1234) |\n| Han et al., 2018).  | 시험군과 대조군간의 비교 분석 방법을 통계적으로 타당하게 제시한다.  | 반드시 필요한 것은 아니며 행정상 변경이 필요하다.  | 대비 8주 시점의 BMI | (1) 앱 불순응*으로 판단되는 경우 | - 각 변수에 대해 이상치는 별도로 고려하지 않는다. ",
        "original_sentence": "| 잔여위험평가 | 유효성 | (AB-1234) |\n| Han et al., 2018). "
      }
    },
    {
      "chunk_id": "chunk_070",
      "text": "| 시험군과 대조군간의 비교 분석 방법을 통계적으로 타당하게 제시한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 69,
        "window_size": 3,
        "char_count": 40,
        "word_count": 9,
        "page_number": 15,
        "window_text": "| [예시] | 되어야 한다.  | [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | 시도한 자 | 제조자는 기기 소프트웨어의 비인가된 변경과 | 수단을 통한 연결이나 업데이트의 진본성을 | Affective | - 성인 | 환자 | 일부는 | 가족치료(Family-Based | Treatment, | FBT)를 | 발휘하는지 확인한다.  | 잔여위험평가 | 유효성 | (AB-1234) |\n| Han et al., 2018).  | 시험군과 대조군간의 비교 분석 방법을 통계적으로 타당하게 제시한다.  | 반드시 필요한 것은 아니며 행정상 변경이 필요하다.  | 대비 8주 시점의 BMI | (1) 앱 불순응*으로 판단되는 경우 | - 각 변수에 대해 이상치는 별도로 고려하지 않는다.  | 받거나 알게 된 날로부터 15일 이내 보고한다. ",
        "original_sentence": "| 시험군과 대조군간의 비교 분석 방법을 통계적으로 타당하게 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_071",
      "text": "| 반드시 필요한 것은 아니며 행정상 변경이 필요하다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 70,
        "window_size": 3,
        "char_count": 31,
        "word_count": 8,
        "page_number": 108,
        "window_text": "| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | 시도한 자 | 제조자는 기기 소프트웨어의 비인가된 변경과 | 수단을 통한 연결이나 업데이트의 진본성을 | Affective | - 성인 | 환자 | 일부는 | 가족치료(Family-Based | Treatment, | FBT)를 | 발휘하는지 확인한다.  | 잔여위험평가 | 유효성 | (AB-1234) |\n| Han et al., 2018).  | 시험군과 대조군간의 비교 분석 방법을 통계적으로 타당하게 제시한다.  | 반드시 필요한 것은 아니며 행정상 변경이 필요하다.  | 대비 8주 시점의 BMI | (1) 앱 불순응*으로 판단되는 경우 | - 각 변수에 대해 이상치는 별도로 고려하지 않는다.  | 받거나 알게 된 날로부터 15일 이내 보고한다.  | 있다.) ",
        "original_sentence": "| 반드시 필요한 것은 아니며 행정상 변경이 필요하다. "
      }
    },
    {
      "chunk_id": "chunk_072",
      "text": "| 대비 8주 시점의 BMI | (1) 앱 불순응*으로 판단되는 경우 | - 각 변수에 대해 이상치는 별도로 고려하지 않는다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 71,
        "window_size": 3,
        "char_count": 71,
        "word_count": 20,
        "page_number": 19,
        "window_text": "| 잔여위험평가 | 유효성 | (AB-1234) |\n| Han et al., 2018).  | 시험군과 대조군간의 비교 분석 방법을 통계적으로 타당하게 제시한다.  | 반드시 필요한 것은 아니며 행정상 변경이 필요하다.  | 대비 8주 시점의 BMI | (1) 앱 불순응*으로 판단되는 경우 | - 각 변수에 대해 이상치는 별도로 고려하지 않는다.  | 받거나 알게 된 날로부터 15일 이내 보고한다.  | 있다.)  | 제한 혹은 예기 불안, 동반증상 여부, 직업). ",
        "original_sentence": "| 대비 8주 시점의 BMI | (1) 앱 불순응*으로 판단되는 경우 | - 각 변수에 대해 이상치는 별도로 고려하지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_073",
      "text": "| 받거나 알게 된 날로부터 15일 이내 보고한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 72,
        "window_size": 3,
        "char_count": 29,
        "word_count": 8,
        "page_number": 15,
        "window_text": "| 시험군과 대조군간의 비교 분석 방법을 통계적으로 타당하게 제시한다.  | 반드시 필요한 것은 아니며 행정상 변경이 필요하다.  | 대비 8주 시점의 BMI | (1) 앱 불순응*으로 판단되는 경우 | - 각 변수에 대해 이상치는 별도로 고려하지 않는다.  | 받거나 알게 된 날로부터 15일 이내 보고한다.  | 있다.)  | 제한 혹은 예기 불안, 동반증상 여부, 직업).  | 기재한다. ",
        "original_sentence": "| 받거나 알게 된 날로부터 15일 이내 보고한다. "
      }
    },
    {
      "chunk_id": "chunk_074",
      "text": "| 있다.) ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 73,
        "window_size": 3,
        "char_count": 7,
        "word_count": 2,
        "page_number": 57,
        "window_text": "| 반드시 필요한 것은 아니며 행정상 변경이 필요하다.  | 대비 8주 시점의 BMI | (1) 앱 불순응*으로 판단되는 경우 | - 각 변수에 대해 이상치는 별도로 고려하지 않는다.  | 받거나 알게 된 날로부터 15일 이내 보고한다.  | 있다.)  | 제한 혹은 예기 불안, 동반증상 여부, 직업).  | 기재한다.  | 경우 | 하거나 확인할 수 없는 경우 | * 피험자 식별코드: 실시기관 코드 - 등록된 순 | 균, 표준편차, 중앙값, 최소값, 최대값 등)으로 제시한다. ",
        "original_sentence": "| 있다.) "
      }
    },
    {
      "chunk_id": "chunk_075",
      "text": "| 제한 혹은 예기 불안, 동반증상 여부, 직업). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 74,
        "window_size": 3,
        "char_count": 29,
        "word_count": 8,
        "page_number": 3,
        "window_text": "| 대비 8주 시점의 BMI | (1) 앱 불순응*으로 판단되는 경우 | - 각 변수에 대해 이상치는 별도로 고려하지 않는다.  | 받거나 알게 된 날로부터 15일 이내 보고한다.  | 있다.)  | 제한 혹은 예기 불안, 동반증상 여부, 직업).  | 기재한다.  | 경우 | 하거나 확인할 수 없는 경우 | * 피험자 식별코드: 실시기관 코드 - 등록된 순 | 균, 표준편차, 중앙값, 최소값, 최대값 등)으로 제시한다.  | 사이버보안 요구사항 | 그림 2. ",
        "original_sentence": "| 제한 혹은 예기 불안, 동반증상 여부, 직업). "
      }
    },
    {
      "chunk_id": "chunk_076",
      "text": "| 기재한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 75,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 15,
        "window_text": "| 받거나 알게 된 날로부터 15일 이내 보고한다.  | 있다.)  | 제한 혹은 예기 불안, 동반증상 여부, 직업).  | 기재한다.  | 경우 | 하거나 확인할 수 없는 경우 | * 피험자 식별코드: 실시기관 코드 - 등록된 순 | 균, 표준편차, 중앙값, 최소값, 최대값 등)으로 제시한다.  | 사이버보안 요구사항 | 그림 2.  데이터 보호 및 보안성 영역 연구의 흐름 | (민원인 안내서) | Application of risk management | 손상이 높은 것을 의미한다. ",
        "original_sentence": "| 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_077",
      "text": "| 경우 | 하거나 확인할 수 없는 경우 | * 피험자 식별코드: 실시기관 코드 - 등록된 순 | 균, 표준편차, 중앙값, 최소값, 최대값 등)으로 제시한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 76,
        "window_size": 3,
        "char_count": 89,
        "word_count": 25,
        "page_number": 28,
        "window_text": "| 있다.)  | 제한 혹은 예기 불안, 동반증상 여부, 직업).  | 기재한다.  | 경우 | 하거나 확인할 수 없는 경우 | * 피험자 식별코드: 실시기관 코드 - 등록된 순 | 균, 표준편차, 중앙값, 최소값, 최대값 등)으로 제시한다.  | 사이버보안 요구사항 | 그림 2.  데이터 보호 및 보안성 영역 연구의 흐름 | (민원인 안내서) | Application of risk management | 손상이 높은 것을 의미한다.  | OOO 기능이 구현되도록 입력값을 | 위험/ | □ 예 | ■ 아니오 | 추가 |\n| 2 | 관리에 관한 규정 제2조) | 진료지침* | 신경성 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? ",
        "original_sentence": "| 경우 | 하거나 확인할 수 없는 경우 | * 피험자 식별코드: 실시기관 코드 - 등록된 순 | 균, 표준편차, 중앙값, 최소값, 최대값 등)으로 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_078",
      "text": "| 사이버보안 요구사항 | 그림 2. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 77,
        "window_size": 3,
        "char_count": 21,
        "word_count": 6,
        "page_number": 3,
        "window_text": "| 제한 혹은 예기 불안, 동반증상 여부, 직업).  | 기재한다.  | 경우 | 하거나 확인할 수 없는 경우 | * 피험자 식별코드: 실시기관 코드 - 등록된 순 | 균, 표준편차, 중앙값, 최소값, 최대값 등)으로 제시한다.  | 사이버보안 요구사항 | 그림 2.  데이터 보호 및 보안성 영역 연구의 흐름 | (민원인 안내서) | Application of risk management | 손상이 높은 것을 의미한다.  | OOO 기능이 구현되도록 입력값을 | 위험/ | □ 예 | ■ 아니오 | 추가 |\n| 2 | 관리에 관한 규정 제2조) | 진료지침* | 신경성 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 요구사항 | 대하여, 소프트웨어가 수행할 수 | 허용 가능함을 검증한다. ",
        "original_sentence": "| 사이버보안 요구사항 | 그림 2. "
      }
    },
    {
      "chunk_id": "chunk_079",
      "text": "데이터 보호 및 보안성 영역 연구의 흐름 | (민원인 안내서) | Application of risk management | 손상이 높은 것을 의미한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 78,
        "window_size": 3,
        "char_count": 86,
        "word_count": 20,
        "page_number": 27,
        "window_text": "| 기재한다.  | 경우 | 하거나 확인할 수 없는 경우 | * 피험자 식별코드: 실시기관 코드 - 등록된 순 | 균, 표준편차, 중앙값, 최소값, 최대값 등)으로 제시한다.  | 사이버보안 요구사항 | 그림 2.  데이터 보호 및 보안성 영역 연구의 흐름 | (민원인 안내서) | Application of risk management | 손상이 높은 것을 의미한다.  | OOO 기능이 구현되도록 입력값을 | 위험/ | □ 예 | ■ 아니오 | 추가 |\n| 2 | 관리에 관한 규정 제2조) | 진료지침* | 신경성 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 요구사항 | 대하여, 소프트웨어가 수행할 수 | 허용 가능함을 검증한다.  | 검증 및 |\n| 시험이 완료되지 못한 경우를 말하며, 그 분류기준을 ‘탈락 기준’에, 탈락의 | 고려하여야 한다. ",
        "original_sentence": "데이터 보호 및 보안성 영역 연구의 흐름 | (민원인 안내서) | Application of risk management | 손상이 높은 것을 의미한다. "
      }
    },
    {
      "chunk_id": "chunk_080",
      "text": "| OOO 기능이 구현되도록 입력값을 | 위험/ | □ 예 | ■ 아니오 | 추가 |\n| 2 | 관리에 관한 규정 제2조) | 진료지침* | 신경성 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 79,
        "window_size": 3,
        "char_count": 126,
        "word_count": 36,
        "page_number": 3,
        "window_text": "| 경우 | 하거나 확인할 수 없는 경우 | * 피험자 식별코드: 실시기관 코드 - 등록된 순 | 균, 표준편차, 중앙값, 최소값, 최대값 등)으로 제시한다.  | 사이버보안 요구사항 | 그림 2.  데이터 보호 및 보안성 영역 연구의 흐름 | (민원인 안내서) | Application of risk management | 손상이 높은 것을 의미한다.  | OOO 기능이 구현되도록 입력값을 | 위험/ | □ 예 | ■ 아니오 | 추가 |\n| 2 | 관리에 관한 규정 제2조) | 진료지침* | 신경성 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 요구사항 | 대하여, 소프트웨어가 수행할 수 | 허용 가능함을 검증한다.  | 검증 및 |\n| 시험이 완료되지 못한 경우를 말하며, 그 분류기준을 ‘탈락 기준’에, 탈락의 | 고려하여야 한다.  | 위험통제 | (방문 5) 시점에 BMI 변화량을 평가한다. ",
        "original_sentence": "| OOO 기능이 구현되도록 입력값을 | 위험/ | □ 예 | ■ 아니오 | 추가 |\n| 2 | 관리에 관한 규정 제2조) | 진료지침* | 신경성 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_081",
      "text": "| 요구사항 | 대하여, 소프트웨어가 수행할 수 | 허용 가능함을 검증한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 80,
        "window_size": 3,
        "char_count": 43,
        "word_count": 11,
        "page_number": 3,
        "window_text": "| 사이버보안 요구사항 | 그림 2.  데이터 보호 및 보안성 영역 연구의 흐름 | (민원인 안내서) | Application of risk management | 손상이 높은 것을 의미한다.  | OOO 기능이 구현되도록 입력값을 | 위험/ | □ 예 | ■ 아니오 | 추가 |\n| 2 | 관리에 관한 규정 제2조) | 진료지침* | 신경성 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 요구사항 | 대하여, 소프트웨어가 수행할 수 | 허용 가능함을 검증한다.  | 검증 및 |\n| 시험이 완료되지 못한 경우를 말하며, 그 분류기준을 ‘탈락 기준’에, 탈락의 | 고려하여야 한다.  | 위험통제 | (방문 5) 시점에 BMI 변화량을 평가한다.  | 식욕부진증 | 신경성 폭식증 | 폭식장애 | 발생 | 권고 사항 등 제시 | 심 | 위 | 적용여부 | 입증 방법 | 확인 자료 | 또는 |\n| - 공동연구자는 의학통계 전문가, 의료기기 전문가 등을 말한다. ",
        "original_sentence": "| 요구사항 | 대하여, 소프트웨어가 수행할 수 | 허용 가능함을 검증한다. "
      }
    },
    {
      "chunk_id": "chunk_082",
      "text": "| 검증 및 |\n| 시험이 완료되지 못한 경우를 말하며, 그 분류기준을 ‘탈락 기준’에, 탈락의 | 고려하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 81,
        "window_size": 3,
        "char_count": 66,
        "word_count": 18,
        "page_number": 30,
        "window_text": "데이터 보호 및 보안성 영역 연구의 흐름 | (민원인 안내서) | Application of risk management | 손상이 높은 것을 의미한다.  | OOO 기능이 구현되도록 입력값을 | 위험/ | □ 예 | ■ 아니오 | 추가 |\n| 2 | 관리에 관한 규정 제2조) | 진료지침* | 신경성 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 요구사항 | 대하여, 소프트웨어가 수행할 수 | 허용 가능함을 검증한다.  | 검증 및 |\n| 시험이 완료되지 못한 경우를 말하며, 그 분류기준을 ‘탈락 기준’에, 탈락의 | 고려하여야 한다.  | 위험통제 | (방문 5) 시점에 BMI 변화량을 평가한다.  | 식욕부진증 | 신경성 폭식증 | 폭식장애 | 발생 | 권고 사항 등 제시 | 심 | 위 | 적용여부 | 입증 방법 | 확인 자료 | 또는 |\n| - 공동연구자는 의학통계 전문가, 의료기기 전문가 등을 말한다.  | [예시] | 1 | 최소 응답시간 | OO초 미만일 것 | naire-9, PHQ-9)의 신뢰도와 타당도. ",
        "original_sentence": "| 검증 및 |\n| 시험이 완료되지 못한 경우를 말하며, 그 분류기준을 ‘탈락 기준’에, 탈락의 | 고려하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_083",
      "text": "| 위험통제 | (방문 5) 시점에 BMI 변화량을 평가한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 82,
        "window_size": 3,
        "char_count": 35,
        "word_count": 9,
        "page_number": 15,
        "window_text": "| OOO 기능이 구현되도록 입력값을 | 위험/ | □ 예 | ■ 아니오 | 추가 |\n| 2 | 관리에 관한 규정 제2조) | 진료지침* | 신경성 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 요구사항 | 대하여, 소프트웨어가 수행할 수 | 허용 가능함을 검증한다.  | 검증 및 |\n| 시험이 완료되지 못한 경우를 말하며, 그 분류기준을 ‘탈락 기준’에, 탈락의 | 고려하여야 한다.  | 위험통제 | (방문 5) 시점에 BMI 변화량을 평가한다.  | 식욕부진증 | 신경성 폭식증 | 폭식장애 | 발생 | 권고 사항 등 제시 | 심 | 위 | 적용여부 | 입증 방법 | 확인 자료 | 또는 |\n| - 공동연구자는 의학통계 전문가, 의료기기 전문가 등을 말한다.  | [예시] | 1 | 최소 응답시간 | OO초 미만일 것 | naire-9, PHQ-9)의 신뢰도와 타당도.  대한불안의학회지, 6(2), 119-124. ",
        "original_sentence": "| 위험통제 | (방문 5) 시점에 BMI 변화량을 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_084",
      "text": "| 식욕부진증 | 신경성 폭식증 | 폭식장애 | 발생 | 권고 사항 등 제시 | 심 | 위 | 적용여부 | 입증 방법 | 확인 자료 | 또는 |\n| - 공동연구자는 의학통계 전문가, 의료기기 전문가 등을 말한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 83,
        "window_size": 3,
        "char_count": 119,
        "word_count": 38,
        "page_number": 3,
        "window_text": "| 요구사항 | 대하여, 소프트웨어가 수행할 수 | 허용 가능함을 검증한다.  | 검증 및 |\n| 시험이 완료되지 못한 경우를 말하며, 그 분류기준을 ‘탈락 기준’에, 탈락의 | 고려하여야 한다.  | 위험통제 | (방문 5) 시점에 BMI 변화량을 평가한다.  | 식욕부진증 | 신경성 폭식증 | 폭식장애 | 발생 | 권고 사항 등 제시 | 심 | 위 | 적용여부 | 입증 방법 | 확인 자료 | 또는 |\n| - 공동연구자는 의학통계 전문가, 의료기기 전문가 등을 말한다.  | [예시] | 1 | 최소 응답시간 | OO초 미만일 것 | naire-9, PHQ-9)의 신뢰도와 타당도.  대한불안의학회지, 6(2), 119-124.  | - 시험군: 디지털 섭식장애 인지행동치료군 | 같은 기기의 무결성에 대한 위험을 고려해야 | disorder | 받기도 한다. ",
        "original_sentence": "| 식욕부진증 | 신경성 폭식증 | 폭식장애 | 발생 | 권고 사항 등 제시 | 심 | 위 | 적용여부 | 입증 방법 | 확인 자료 | 또는 |\n| - 공동연구자는 의학통계 전문가, 의료기기 전문가 등을 말한다. "
      }
    },
    {
      "chunk_id": "chunk_085",
      "text": "| [예시] | 1 | 최소 응답시간 | OO초 미만일 것 | naire-9, PHQ-9)의 신뢰도와 타당도. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 84,
        "window_size": 3,
        "char_count": 62,
        "word_count": 16,
        "page_number": 19,
        "window_text": "| 검증 및 |\n| 시험이 완료되지 못한 경우를 말하며, 그 분류기준을 ‘탈락 기준’에, 탈락의 | 고려하여야 한다.  | 위험통제 | (방문 5) 시점에 BMI 변화량을 평가한다.  | 식욕부진증 | 신경성 폭식증 | 폭식장애 | 발생 | 권고 사항 등 제시 | 심 | 위 | 적용여부 | 입증 방법 | 확인 자료 | 또는 |\n| - 공동연구자는 의학통계 전문가, 의료기기 전문가 등을 말한다.  | [예시] | 1 | 최소 응답시간 | OO초 미만일 것 | naire-9, PHQ-9)의 신뢰도와 타당도.  대한불안의학회지, 6(2), 119-124.  | - 시험군: 디지털 섭식장애 인지행동치료군 | 같은 기기의 무결성에 대한 위험을 고려해야 | disorder | 받기도 한다.  | for IT-networks incorporating | Medical devices | 입력한 후 그에 대한 응답시간을 | 적용 |\n| 위험통제 조치 | - 통계 분석 방법에 따른 통계적 유의성에 대한 평가 방법과 기준을 제시한다. ",
        "original_sentence": "| [예시] | 1 | 최소 응답시간 | OO초 미만일 것 | naire-9, PHQ-9)의 신뢰도와 타당도. "
      }
    },
    {
      "chunk_id": "chunk_086",
      "text": "대한불안의학회지, 6(2), 119-124. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 85,
        "window_size": 3,
        "char_count": 25,
        "word_count": 3,
        "page_number": 9,
        "window_text": "| 위험통제 | (방문 5) 시점에 BMI 변화량을 평가한다.  | 식욕부진증 | 신경성 폭식증 | 폭식장애 | 발생 | 권고 사항 등 제시 | 심 | 위 | 적용여부 | 입증 방법 | 확인 자료 | 또는 |\n| - 공동연구자는 의학통계 전문가, 의료기기 전문가 등을 말한다.  | [예시] | 1 | 최소 응답시간 | OO초 미만일 것 | naire-9, PHQ-9)의 신뢰도와 타당도.  대한불안의학회지, 6(2), 119-124.  | - 시험군: 디지털 섭식장애 인지행동치료군 | 같은 기기의 무결성에 대한 위험을 고려해야 | disorder | 받기도 한다.  | for IT-networks incorporating | Medical devices | 입력한 후 그에 대한 응답시간을 | 적용 |\n| 위험통제 조치 | - 통계 분석 방법에 따른 통계적 유의성에 대한 평가 방법과 기준을 제시한다.  | [예시] | [F50.2] Bulimia nervosa (신경성 폭식증) | - 데이터베이스 요구사항 | : 예상하는 표준편차, 5.0 | 변화 | (3) Patient Health Questionnaire-9 (PHQ-9) | 결과 | 이득 | 발생 |\n| ychiatry : official journal of the World Psychiatric Association (WPA), 20(3), 448–449. ",
        "original_sentence": "대한불안의학회지, 6(2), 119-124. "
      }
    },
    {
      "chunk_id": "chunk_087",
      "text": "| - 시험군: 디지털 섭식장애 인지행동치료군 | 같은 기기의 무결성에 대한 위험을 고려해야 | disorder | 받기도 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 86,
        "window_size": 3,
        "char_count": 73,
        "word_count": 18,
        "page_number": 30,
        "window_text": "| 식욕부진증 | 신경성 폭식증 | 폭식장애 | 발생 | 권고 사항 등 제시 | 심 | 위 | 적용여부 | 입증 방법 | 확인 자료 | 또는 |\n| - 공동연구자는 의학통계 전문가, 의료기기 전문가 등을 말한다.  | [예시] | 1 | 최소 응답시간 | OO초 미만일 것 | naire-9, PHQ-9)의 신뢰도와 타당도.  대한불안의학회지, 6(2), 119-124.  | - 시험군: 디지털 섭식장애 인지행동치료군 | 같은 기기의 무결성에 대한 위험을 고려해야 | disorder | 받기도 한다.  | for IT-networks incorporating | Medical devices | 입력한 후 그에 대한 응답시간을 | 적용 |\n| 위험통제 조치 | - 통계 분석 방법에 따른 통계적 유의성에 대한 평가 방법과 기준을 제시한다.  | [예시] | [F50.2] Bulimia nervosa (신경성 폭식증) | - 데이터베이스 요구사항 | : 예상하는 표준편차, 5.0 | 변화 | (3) Patient Health Questionnaire-9 (PHQ-9) | 결과 | 이득 | 발생 |\n| ychiatry : official journal of the World Psychiatric Association (WPA), 20(3), 448–449.  | 2) 국내 가이드라인별 적용 기준 | [예시] | [예시] | 마) 외래 방문마다 유효성 평가 | - 모델명: ○○○ | 정의 | 있는 논리적이고 물리적인 표현 | 2 | E06070.01 | 사용하는 소프트웨어 | 의료기기 품질관리(Quality | 유효성 | (AB-1234) |\n| 1) 탈락 기준 | 6) 하위 분석 | ○ 의료기기의 오류(결함)로 인한 오진률 발생 가능성 | ○ 관련성이 의심됨(Possibly related) | 2007). ",
        "original_sentence": "| - 시험군: 디지털 섭식장애 인지행동치료군 | 같은 기기의 무결성에 대한 위험을 고려해야 | disorder | 받기도 한다. "
      }
    },
    {
      "chunk_id": "chunk_088",
      "text": "| for IT-networks incorporating | Medical devices | 입력한 후 그에 대한 응답시간을 | 적용 |\n| 위험통제 조치 | - 통계 분석 방법에 따른 통계적 유의성에 대한 평가 방법과 기준을 제시한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 87,
        "window_size": 3,
        "char_count": 133,
        "word_count": 32,
        "page_number": 26,
        "window_text": "| [예시] | 1 | 최소 응답시간 | OO초 미만일 것 | naire-9, PHQ-9)의 신뢰도와 타당도.  대한불안의학회지, 6(2), 119-124.  | - 시험군: 디지털 섭식장애 인지행동치료군 | 같은 기기의 무결성에 대한 위험을 고려해야 | disorder | 받기도 한다.  | for IT-networks incorporating | Medical devices | 입력한 후 그에 대한 응답시간을 | 적용 |\n| 위험통제 조치 | - 통계 분석 방법에 따른 통계적 유의성에 대한 평가 방법과 기준을 제시한다.  | [예시] | [F50.2] Bulimia nervosa (신경성 폭식증) | - 데이터베이스 요구사항 | : 예상하는 표준편차, 5.0 | 변화 | (3) Patient Health Questionnaire-9 (PHQ-9) | 결과 | 이득 | 발생 |\n| ychiatry : official journal of the World Psychiatric Association (WPA), 20(3), 448–449.  | 2) 국내 가이드라인별 적용 기준 | [예시] | [예시] | 마) 외래 방문마다 유효성 평가 | - 모델명: ○○○ | 정의 | 있는 논리적이고 물리적인 표현 | 2 | E06070.01 | 사용하는 소프트웨어 | 의료기기 품질관리(Quality | 유효성 | (AB-1234) |\n| 1) 탈락 기준 | 6) 하위 분석 | ○ 의료기기의 오류(결함)로 인한 오진률 발생 가능성 | ○ 관련성이 의심됨(Possibly related) | 2007).  | ealth Education and Promotion, 35(5), 35-45. ",
        "original_sentence": "| for IT-networks incorporating | Medical devices | 입력한 후 그에 대한 응답시간을 | 적용 |\n| 위험통제 조치 | - 통계 분석 방법에 따른 통계적 유의성에 대한 평가 방법과 기준을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_089",
      "text": "| [예시] | [F50.2] Bulimia nervosa (신경성 폭식증) | - 데이터베이스 요구사항 | : 예상하는 표준편차, 5.0 | 변화 | (3) Patient Health Questionnaire-9 (PHQ-9) | 결과 | 이득 | 발생 |\n| ychiatry : official journal of the World Psychiatric Association (WPA), 20(3), 448–449. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 88,
        "window_size": 3,
        "char_count": 236,
        "word_count": 45,
        "page_number": 9,
        "window_text": "대한불안의학회지, 6(2), 119-124.  | - 시험군: 디지털 섭식장애 인지행동치료군 | 같은 기기의 무결성에 대한 위험을 고려해야 | disorder | 받기도 한다.  | for IT-networks incorporating | Medical devices | 입력한 후 그에 대한 응답시간을 | 적용 |\n| 위험통제 조치 | - 통계 분석 방법에 따른 통계적 유의성에 대한 평가 방법과 기준을 제시한다.  | [예시] | [F50.2] Bulimia nervosa (신경성 폭식증) | - 데이터베이스 요구사항 | : 예상하는 표준편차, 5.0 | 변화 | (3) Patient Health Questionnaire-9 (PHQ-9) | 결과 | 이득 | 발생 |\n| ychiatry : official journal of the World Psychiatric Association (WPA), 20(3), 448–449.  | 2) 국내 가이드라인별 적용 기준 | [예시] | [예시] | 마) 외래 방문마다 유효성 평가 | - 모델명: ○○○ | 정의 | 있는 논리적이고 물리적인 표현 | 2 | E06070.01 | 사용하는 소프트웨어 | 의료기기 품질관리(Quality | 유효성 | (AB-1234) |\n| 1) 탈락 기준 | 6) 하위 분석 | ○ 의료기기의 오류(결함)로 인한 오진률 발생 가능성 | ○ 관련성이 의심됨(Possibly related) | 2007).  | ealth Education and Promotion, 35(5), 35-45.  | 고지와 관련된 모든 사항을 문서화해야 한다. ",
        "original_sentence": "| [예시] | [F50.2] Bulimia nervosa (신경성 폭식증) | - 데이터베이스 요구사항 | : 예상하는 표준편차, 5.0 | 변화 | (3) Patient Health Questionnaire-9 (PHQ-9) | 결과 | 이득 | 발생 |\n| ychiatry : official journal of the World Psychiatric Association (WPA), 20(3), 448–449. "
      }
    },
    {
      "chunk_id": "chunk_090",
      "text": "| 2) 국내 가이드라인별 적용 기준 | [예시] | [예시] | 마) 외래 방문마다 유효성 평가 | - 모델명: ○○○ | 정의 | 있는 논리적이고 물리적인 표현 | 2 | E06070.01 | 사용하는 소프트웨어 | 의료기기 품질관리(Quality | 유효성 | (AB-1234) |\n| 1) 탈락 기준 | 6) 하위 분석 | ○ 의료기기의 오류(결함)로 인한 오진률 발생 가능성 | ○ 관련성이 의심됨(Possibly related) | 2007). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 89,
        "window_size": 3,
        "char_count": 255,
        "word_count": 65,
        "page_number": 9,
        "window_text": "| - 시험군: 디지털 섭식장애 인지행동치료군 | 같은 기기의 무결성에 대한 위험을 고려해야 | disorder | 받기도 한다.  | for IT-networks incorporating | Medical devices | 입력한 후 그에 대한 응답시간을 | 적용 |\n| 위험통제 조치 | - 통계 분석 방법에 따른 통계적 유의성에 대한 평가 방법과 기준을 제시한다.  | [예시] | [F50.2] Bulimia nervosa (신경성 폭식증) | - 데이터베이스 요구사항 | : 예상하는 표준편차, 5.0 | 변화 | (3) Patient Health Questionnaire-9 (PHQ-9) | 결과 | 이득 | 발생 |\n| ychiatry : official journal of the World Psychiatric Association (WPA), 20(3), 448–449.  | 2) 국내 가이드라인별 적용 기준 | [예시] | [예시] | 마) 외래 방문마다 유효성 평가 | - 모델명: ○○○ | 정의 | 있는 논리적이고 물리적인 표현 | 2 | E06070.01 | 사용하는 소프트웨어 | 의료기기 품질관리(Quality | 유효성 | (AB-1234) |\n| 1) 탈락 기준 | 6) 하위 분석 | ○ 의료기기의 오류(결함)로 인한 오진률 발생 가능성 | ○ 관련성이 의심됨(Possibly related) | 2007).  | ealth Education and Promotion, 35(5), 35-45.  | 고지와 관련된 모든 사항을 문서화해야 한다.  | 자료보관(연구파일) 등을 확인한다. ",
        "original_sentence": "| 2) 국내 가이드라인별 적용 기준 | [예시] | [예시] | 마) 외래 방문마다 유효성 평가 | - 모델명: ○○○ | 정의 | 있는 논리적이고 물리적인 표현 | 2 | E06070.01 | 사용하는 소프트웨어 | 의료기기 품질관리(Quality | 유효성 | (AB-1234) |\n| 1) 탈락 기준 | 6) 하위 분석 | ○ 의료기기의 오류(결함)로 인한 오진률 발생 가능성 | ○ 관련성이 의심됨(Possibly related) | 2007). "
      }
    },
    {
      "chunk_id": "chunk_091",
      "text": "| ealth Education and Promotion, 35(5), 35-45. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 90,
        "window_size": 3,
        "char_count": 47,
        "word_count": 7,
        "page_number": 26,
        "window_text": "| for IT-networks incorporating | Medical devices | 입력한 후 그에 대한 응답시간을 | 적용 |\n| 위험통제 조치 | - 통계 분석 방법에 따른 통계적 유의성에 대한 평가 방법과 기준을 제시한다.  | [예시] | [F50.2] Bulimia nervosa (신경성 폭식증) | - 데이터베이스 요구사항 | : 예상하는 표준편차, 5.0 | 변화 | (3) Patient Health Questionnaire-9 (PHQ-9) | 결과 | 이득 | 발생 |\n| ychiatry : official journal of the World Psychiatric Association (WPA), 20(3), 448–449.  | 2) 국내 가이드라인별 적용 기준 | [예시] | [예시] | 마) 외래 방문마다 유효성 평가 | - 모델명: ○○○ | 정의 | 있는 논리적이고 물리적인 표현 | 2 | E06070.01 | 사용하는 소프트웨어 | 의료기기 품질관리(Quality | 유효성 | (AB-1234) |\n| 1) 탈락 기준 | 6) 하위 분석 | ○ 의료기기의 오류(결함)로 인한 오진률 발생 가능성 | ○ 관련성이 의심됨(Possibly related) | 2007).  | ealth Education and Promotion, 35(5), 35-45.  | 고지와 관련된 모든 사항을 문서화해야 한다.  | 자료보관(연구파일) 등을 확인한다.  | 포함된다. ",
        "original_sentence": "| ealth Education and Promotion, 35(5), 35-45. "
      }
    },
    {
      "chunk_id": "chunk_092",
      "text": "| 고지와 관련된 모든 사항을 문서화해야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 91,
        "window_size": 3,
        "char_count": 27,
        "word_count": 7,
        "page_number": 3,
        "window_text": "| [예시] | [F50.2] Bulimia nervosa (신경성 폭식증) | - 데이터베이스 요구사항 | : 예상하는 표준편차, 5.0 | 변화 | (3) Patient Health Questionnaire-9 (PHQ-9) | 결과 | 이득 | 발생 |\n| ychiatry : official journal of the World Psychiatric Association (WPA), 20(3), 448–449.  | 2) 국내 가이드라인별 적용 기준 | [예시] | [예시] | 마) 외래 방문마다 유효성 평가 | - 모델명: ○○○ | 정의 | 있는 논리적이고 물리적인 표현 | 2 | E06070.01 | 사용하는 소프트웨어 | 의료기기 품질관리(Quality | 유효성 | (AB-1234) |\n| 1) 탈락 기준 | 6) 하위 분석 | ○ 의료기기의 오류(결함)로 인한 오진률 발생 가능성 | ○ 관련성이 의심됨(Possibly related) | 2007).  | ealth Education and Promotion, 35(5), 35-45.  | 고지와 관련된 모든 사항을 문서화해야 한다.  | 자료보관(연구파일) 등을 확인한다.  | 포함된다.  | (2) 섭식장애 관련한 약물을 복용한 경우 | 이라고 판단할 수 있다. ",
        "original_sentence": "| 고지와 관련된 모든 사항을 문서화해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_093",
      "text": "| 자료보관(연구파일) 등을 확인한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 92,
        "window_size": 3,
        "char_count": 22,
        "word_count": 4,
        "page_number": 15,
        "window_text": "| 2) 국내 가이드라인별 적용 기준 | [예시] | [예시] | 마) 외래 방문마다 유효성 평가 | - 모델명: ○○○ | 정의 | 있는 논리적이고 물리적인 표현 | 2 | E06070.01 | 사용하는 소프트웨어 | 의료기기 품질관리(Quality | 유효성 | (AB-1234) |\n| 1) 탈락 기준 | 6) 하위 분석 | ○ 의료기기의 오류(결함)로 인한 오진률 발생 가능성 | ○ 관련성이 의심됨(Possibly related) | 2007).  | ealth Education and Promotion, 35(5), 35-45.  | 고지와 관련된 모든 사항을 문서화해야 한다.  | 자료보관(연구파일) 등을 확인한다.  | 포함된다.  | (2) 섭식장애 관련한 약물을 복용한 경우 | 이라고 판단할 수 있다.  | 조사한다. ",
        "original_sentence": "| 자료보관(연구파일) 등을 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_094",
      "text": "| 포함된다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 93,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 112,
        "window_text": "| ealth Education and Promotion, 35(5), 35-45.  | 고지와 관련된 모든 사항을 문서화해야 한다.  | 자료보관(연구파일) 등을 확인한다.  | 포함된다.  | (2) 섭식장애 관련한 약물을 복용한 경우 | 이라고 판단할 수 있다.  | 조사한다.  | 의료기기의 사이버보안 | 조치실행 | 합동표준편차   |  |      | 가능 |   ×     ×    | 의료기기 | 사이버보안 | 적용 | 방법과 | 각 | 험 | 문서번호 |\n| 소프트웨어 | 등록대상 | - 각 임상시험기관의 적절한 임상시험의 수행을 위하여 임상시험기관 및 시험자의 | APA 진료지침(2023) | 권장 | 권장 | 권장 | 사유와 관련 임상자료의 처리 방법을 ‘탈락 처리’에 구체적으로 제시한다. ",
        "original_sentence": "| 포함된다. "
      }
    },
    {
      "chunk_id": "chunk_095",
      "text": "| (2) 섭식장애 관련한 약물을 복용한 경우 | 이라고 판단할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 94,
        "window_size": 3,
        "char_count": 42,
        "word_count": 12,
        "page_number": 9,
        "window_text": "| 고지와 관련된 모든 사항을 문서화해야 한다.  | 자료보관(연구파일) 등을 확인한다.  | 포함된다.  | (2) 섭식장애 관련한 약물을 복용한 경우 | 이라고 판단할 수 있다.  | 조사한다.  | 의료기기의 사이버보안 | 조치실행 | 합동표준편차   |  |      | 가능 |   ×     ×    | 의료기기 | 사이버보안 | 적용 | 방법과 | 각 | 험 | 문서번호 |\n| 소프트웨어 | 등록대상 | - 각 임상시험기관의 적절한 임상시험의 수행을 위하여 임상시험기관 및 시험자의 | APA 진료지침(2023) | 권장 | 권장 | 권장 | 사유와 관련 임상자료의 처리 방법을 ‘탈락 처리’에 구체적으로 제시한다.  | 허용 기준을 사용하여 위험 감소가 필요한지 결정한다. ",
        "original_sentence": "| (2) 섭식장애 관련한 약물을 복용한 경우 | 이라고 판단할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_096",
      "text": "| 조사한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 95,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 15,
        "window_text": "| 자료보관(연구파일) 등을 확인한다.  | 포함된다.  | (2) 섭식장애 관련한 약물을 복용한 경우 | 이라고 판단할 수 있다.  | 조사한다.  | 의료기기의 사이버보안 | 조치실행 | 합동표준편차   |  |      | 가능 |   ×     ×    | 의료기기 | 사이버보안 | 적용 | 방법과 | 각 | 험 | 문서번호 |\n| 소프트웨어 | 등록대상 | - 각 임상시험기관의 적절한 임상시험의 수행을 위하여 임상시험기관 및 시험자의 | APA 진료지침(2023) | 권장 | 권장 | 권장 | 사유와 관련 임상자료의 처리 방법을 ‘탈락 처리’에 구체적으로 제시한다.  | 허용 기준을 사용하여 위험 감소가 필요한지 결정한다.  | 한다. ",
        "original_sentence": "| 조사한다. "
      }
    },
    {
      "chunk_id": "chunk_097",
      "text": "| 의료기기의 사이버보안 | 조치실행 | 합동표준편차   |  |      | 가능 |   ×     ×    | 의료기기 | 사이버보안 | 적용 | 방법과 | 각 | 험 | 문서번호 |\n| 소프트웨어 | 등록대상 | - 각 임상시험기관의 적절한 임상시험의 수행을 위하여 임상시험기관 및 시험자의 | APA 진료지침(2023) | 권장 | 권장 | 권장 | 사유와 관련 임상자료의 처리 방법을 ‘탈락 처리’에 구체적으로 제시한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 96,
        "window_size": 3,
        "char_count": 281,
        "word_count": 80,
        "page_number": 7,
        "window_text": "| 포함된다.  | (2) 섭식장애 관련한 약물을 복용한 경우 | 이라고 판단할 수 있다.  | 조사한다.  | 의료기기의 사이버보안 | 조치실행 | 합동표준편차   |  |      | 가능 |   ×     ×    | 의료기기 | 사이버보안 | 적용 | 방법과 | 각 | 험 | 문서번호 |\n| 소프트웨어 | 등록대상 | - 각 임상시험기관의 적절한 임상시험의 수행을 위하여 임상시험기관 및 시험자의 | APA 진료지침(2023) | 권장 | 권장 | 권장 | 사유와 관련 임상자료의 처리 방법을 ‘탈락 처리’에 구체적으로 제시한다.  | 허용 기준을 사용하여 위험 감소가 필요한지 결정한다.  | 한다.  | 소프트웨어 | therapy | – Quality management | medical devices | 측정 | 네트워크로 연결되는 |\n| [예시] | 1) 근거 자료/문서의 직접 열람 | 제조자는 비인가 된 개인이 의료기기에 접근 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? ",
        "original_sentence": "| 의료기기의 사이버보안 | 조치실행 | 합동표준편차   |  |      | 가능 |   ×     ×    | 의료기기 | 사이버보안 | 적용 | 방법과 | 각 | 험 | 문서번호 |\n| 소프트웨어 | 등록대상 | - 각 임상시험기관의 적절한 임상시험의 수행을 위하여 임상시험기관 및 시험자의 | APA 진료지침(2023) | 권장 | 권장 | 권장 | 사유와 관련 임상자료의 처리 방법을 ‘탈락 처리’에 구체적으로 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_098",
      "text": "| 허용 기준을 사용하여 위험 감소가 필요한지 결정한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 97,
        "window_size": 3,
        "char_count": 32,
        "word_count": 8,
        "page_number": 15,
        "window_text": "| (2) 섭식장애 관련한 약물을 복용한 경우 | 이라고 판단할 수 있다.  | 조사한다.  | 의료기기의 사이버보안 | 조치실행 | 합동표준편차   |  |      | 가능 |   ×     ×    | 의료기기 | 사이버보안 | 적용 | 방법과 | 각 | 험 | 문서번호 |\n| 소프트웨어 | 등록대상 | - 각 임상시험기관의 적절한 임상시험의 수행을 위하여 임상시험기관 및 시험자의 | APA 진료지침(2023) | 권장 | 권장 | 권장 | 사유와 관련 임상자료의 처리 방법을 ‘탈락 처리’에 구체적으로 제시한다.  | 허용 기준을 사용하여 위험 감소가 필요한지 결정한다.  | 한다.  | 소프트웨어 | therapy | – Quality management | medical devices | 측정 | 네트워크로 연결되는 |\n| [예시] | 1) 근거 자료/문서의 직접 열람 | 제조자는 비인가 된 개인이 의료기기에 접근 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | 분석 | 성능 | 위험 |\n| 1) 시험기기 및 대조기기 정보 | 1 | ISO 13485 | 지각에 대한 인지적 특성. ",
        "original_sentence": "| 허용 기준을 사용하여 위험 감소가 필요한지 결정한다. "
      }
    },
    {
      "chunk_id": "chunk_099",
      "text": "| 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 98,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 15,
        "window_text": "| 조사한다.  | 의료기기의 사이버보안 | 조치실행 | 합동표준편차   |  |      | 가능 |   ×     ×    | 의료기기 | 사이버보안 | 적용 | 방법과 | 각 | 험 | 문서번호 |\n| 소프트웨어 | 등록대상 | - 각 임상시험기관의 적절한 임상시험의 수행을 위하여 임상시험기관 및 시험자의 | APA 진료지침(2023) | 권장 | 권장 | 권장 | 사유와 관련 임상자료의 처리 방법을 ‘탈락 처리’에 구체적으로 제시한다.  | 허용 기준을 사용하여 위험 감소가 필요한지 결정한다.  | 한다.  | 소프트웨어 | therapy | – Quality management | medical devices | 측정 | 네트워크로 연결되는 |\n| [예시] | 1) 근거 자료/문서의 직접 열람 | 제조자는 비인가 된 개인이 의료기기에 접근 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | 분석 | 성능 | 위험 |\n| 1) 시험기기 및 대조기기 정보 | 1 | ISO 13485 | 지각에 대한 인지적 특성.  대한불안의학회지, 13(2), 100-107. ",
        "original_sentence": "| 한다. "
      }
    },
    {
      "chunk_id": "chunk_100",
      "text": "| 소프트웨어 | therapy | – Quality management | medical devices | 측정 | 네트워크로 연결되는 |\n| [예시] | 1) 근거 자료/문서의 직접 열람 | 제조자는 비인가 된 개인이 의료기기에 접근 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 99,
        "window_size": 3,
        "char_count": 166,
        "word_count": 40,
        "page_number": 9,
        "window_text": "| 의료기기의 사이버보안 | 조치실행 | 합동표준편차   |  |      | 가능 |   ×     ×    | 의료기기 | 사이버보안 | 적용 | 방법과 | 각 | 험 | 문서번호 |\n| 소프트웨어 | 등록대상 | - 각 임상시험기관의 적절한 임상시험의 수행을 위하여 임상시험기관 및 시험자의 | APA 진료지침(2023) | 권장 | 권장 | 권장 | 사유와 관련 임상자료의 처리 방법을 ‘탈락 처리’에 구체적으로 제시한다.  | 허용 기준을 사용하여 위험 감소가 필요한지 결정한다.  | 한다.  | 소프트웨어 | therapy | – Quality management | medical devices | 측정 | 네트워크로 연결되는 |\n| [예시] | 1) 근거 자료/문서의 직접 열람 | 제조자는 비인가 된 개인이 의료기기에 접근 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | 분석 | 성능 | 위험 |\n| 1) 시험기기 및 대조기기 정보 | 1 | ISO 13485 | 지각에 대한 인지적 특성.  대한불안의학회지, 13(2), 100-107.  | 임상시험을 복수의 임상시험 기관에서 실시하는 경우에는 기관에 따라 임상시험 | [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | - 대조군: 디지털 섭식장애 대조군 | 제조자는 의료기기가 다른 기기나 네트워크와 | IEC/TR | 연구 군을 선별한다. ",
        "original_sentence": "| 소프트웨어 | therapy | – Quality management | medical devices | 측정 | 네트워크로 연결되는 |\n| [예시] | 1) 근거 자료/문서의 직접 열람 | 제조자는 비인가 된 개인이 의료기기에 접근 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_101",
      "text": "| □ 예 | ■ 아니오 | 분석 | 성능 | 위험 |\n| 1) 시험기기 및 대조기기 정보 | 1 | ISO 13485 | 지각에 대한 인지적 특성. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 100,
        "window_size": 3,
        "char_count": 84,
        "word_count": 29,
        "page_number": 3,
        "window_text": "| 허용 기준을 사용하여 위험 감소가 필요한지 결정한다.  | 한다.  | 소프트웨어 | therapy | – Quality management | medical devices | 측정 | 네트워크로 연결되는 |\n| [예시] | 1) 근거 자료/문서의 직접 열람 | 제조자는 비인가 된 개인이 의료기기에 접근 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | 분석 | 성능 | 위험 |\n| 1) 시험기기 및 대조기기 정보 | 1 | ISO 13485 | 지각에 대한 인지적 특성.  대한불안의학회지, 13(2), 100-107.  | 임상시험을 복수의 임상시험 기관에서 실시하는 경우에는 기관에 따라 임상시험 | [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | - 대조군: 디지털 섭식장애 대조군 | 제조자는 의료기기가 다른 기기나 네트워크와 | IEC/TR | 연구 군을 선별한다.  | - 주로 인지행동치료(CBT)를 시행하며, 제한적이긴 하나 대인관계 | 으로 정의한다. ",
        "original_sentence": "| □ 예 | ■ 아니오 | 분석 | 성능 | 위험 |\n| 1) 시험기기 및 대조기기 정보 | 1 | ISO 13485 | 지각에 대한 인지적 특성. "
      }
    },
    {
      "chunk_id": "chunk_102",
      "text": "대한불안의학회지, 13(2), 100-107. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 101,
        "window_size": 3,
        "char_count": 26,
        "word_count": 3,
        "page_number": 9,
        "window_text": "| 한다.  | 소프트웨어 | therapy | – Quality management | medical devices | 측정 | 네트워크로 연결되는 |\n| [예시] | 1) 근거 자료/문서의 직접 열람 | 제조자는 비인가 된 개인이 의료기기에 접근 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | 분석 | 성능 | 위험 |\n| 1) 시험기기 및 대조기기 정보 | 1 | ISO 13485 | 지각에 대한 인지적 특성.  대한불안의학회지, 13(2), 100-107.  | 임상시험을 복수의 임상시험 기관에서 실시하는 경우에는 기관에 따라 임상시험 | [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | - 대조군: 디지털 섭식장애 대조군 | 제조자는 의료기기가 다른 기기나 네트워크와 | IEC/TR | 연구 군을 선별한다.  | - 주로 인지행동치료(CBT)를 시행하며, 제한적이긴 하나 대인관계 | 으로 정의한다.  | 전체 소프트웨어 시스템이 요구 | Management)에 대한 국제 | 소프트웨어 | 확인 자료 | 국외 |\n| 1) 목표 대상자 수: 총 128명(군당 64명) | 5 | 의료기기(SaMD)이다. ",
        "original_sentence": "대한불안의학회지, 13(2), 100-107. "
      }
    },
    {
      "chunk_id": "chunk_103",
      "text": "| 임상시험을 복수의 임상시험 기관에서 실시하는 경우에는 기관에 따라 임상시험 | [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | - 대조군: 디지털 섭식장애 대조군 | 제조자는 의료기기가 다른 기기나 네트워크와 | IEC/TR | 연구 군을 선별한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 102,
        "window_size": 3,
        "char_count": 164,
        "word_count": 36,
        "page_number": 26,
        "window_text": "| 소프트웨어 | therapy | – Quality management | medical devices | 측정 | 네트워크로 연결되는 |\n| [예시] | 1) 근거 자료/문서의 직접 열람 | 제조자는 비인가 된 개인이 의료기기에 접근 | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | 분석 | 성능 | 위험 |\n| 1) 시험기기 및 대조기기 정보 | 1 | ISO 13485 | 지각에 대한 인지적 특성.  대한불안의학회지, 13(2), 100-107.  | 임상시험을 복수의 임상시험 기관에서 실시하는 경우에는 기관에 따라 임상시험 | [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | - 대조군: 디지털 섭식장애 대조군 | 제조자는 의료기기가 다른 기기나 네트워크와 | IEC/TR | 연구 군을 선별한다.  | - 주로 인지행동치료(CBT)를 시행하며, 제한적이긴 하나 대인관계 | 으로 정의한다.  | 전체 소프트웨어 시스템이 요구 | Management)에 대한 국제 | 소프트웨어 | 확인 자료 | 국외 |\n| 1) 목표 대상자 수: 총 128명(군당 64명) | 5 | 의료기기(SaMD)이다.  | 여부 | - 운영방법 및 유지보수 방법과 관련된 요구사항 | 적용방법 및 사례집 | 성 | 허가신청 시 제출하는 자료의 작성 | 성 | 도 | 국내 |\n| [예시] | 7 | 7 | NICE 진료지침(2017) | 권장 | 권장 | 권장 | 가) 디지털치료기기 허가·심사 가이드라인(민원인 안내서) | 기관명 | 소재지 | 전화 | 팩스 | - 제조회사: ㈜○○○ | - 일차와 이차 유효성 평가 관련된 목록을 작성한다. ",
        "original_sentence": "| 임상시험을 복수의 임상시험 기관에서 실시하는 경우에는 기관에 따라 임상시험 | [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | - 대조군: 디지털 섭식장애 대조군 | 제조자는 의료기기가 다른 기기나 네트워크와 | IEC/TR | 연구 군을 선별한다. "
      }
    },
    {
      "chunk_id": "chunk_104",
      "text": "| - 주로 인지행동치료(CBT)를 시행하며, 제한적이긴 하나 대인관계 | 으로 정의한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 103,
        "window_size": 3,
        "char_count": 51,
        "word_count": 11,
        "page_number": 15,
        "window_text": "| □ 예 | ■ 아니오 | 분석 | 성능 | 위험 |\n| 1) 시험기기 및 대조기기 정보 | 1 | ISO 13485 | 지각에 대한 인지적 특성.  대한불안의학회지, 13(2), 100-107.  | 임상시험을 복수의 임상시험 기관에서 실시하는 경우에는 기관에 따라 임상시험 | [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | - 대조군: 디지털 섭식장애 대조군 | 제조자는 의료기기가 다른 기기나 네트워크와 | IEC/TR | 연구 군을 선별한다.  | - 주로 인지행동치료(CBT)를 시행하며, 제한적이긴 하나 대인관계 | 으로 정의한다.  | 전체 소프트웨어 시스템이 요구 | Management)에 대한 국제 | 소프트웨어 | 확인 자료 | 국외 |\n| 1) 목표 대상자 수: 총 128명(군당 64명) | 5 | 의료기기(SaMD)이다.  | 여부 | - 운영방법 및 유지보수 방법과 관련된 요구사항 | 적용방법 및 사례집 | 성 | 허가신청 시 제출하는 자료의 작성 | 성 | 도 | 국내 |\n| [예시] | 7 | 7 | NICE 진료지침(2017) | 권장 | 권장 | 권장 | 가) 디지털치료기기 허가·심사 가이드라인(민원인 안내서) | 기관명 | 소재지 | 전화 | 팩스 | - 제조회사: ㈜○○○ | - 일차와 이차 유효성 평가 관련된 목록을 작성한다.  | 하는 것을 방지하기 위한 통제 수단을 고려 | software | 시스템 | systems – Requirements for | – Part 2-2: Guidance for the | 의료기기의 위험관리 | 시험소프 | 국외 |\n| 의견을 조정하기 위하여 조정위원회를 설치하고 임상시험 조정자를 선정할 수 있다. ",
        "original_sentence": "| - 주로 인지행동치료(CBT)를 시행하며, 제한적이긴 하나 대인관계 | 으로 정의한다. "
      }
    },
    {
      "chunk_id": "chunk_105",
      "text": "| 전체 소프트웨어 시스템이 요구 | Management)에 대한 국제 | 소프트웨어 | 확인 자료 | 국외 |\n| 1) 목표 대상자 수: 총 128명(군당 64명) | 5 | 의료기기(SaMD)이다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 104,
        "window_size": 3,
        "char_count": 113,
        "word_count": 29,
        "page_number": 9,
        "window_text": "대한불안의학회지, 13(2), 100-107.  | 임상시험을 복수의 임상시험 기관에서 실시하는 경우에는 기관에 따라 임상시험 | [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | - 대조군: 디지털 섭식장애 대조군 | 제조자는 의료기기가 다른 기기나 네트워크와 | IEC/TR | 연구 군을 선별한다.  | - 주로 인지행동치료(CBT)를 시행하며, 제한적이긴 하나 대인관계 | 으로 정의한다.  | 전체 소프트웨어 시스템이 요구 | Management)에 대한 국제 | 소프트웨어 | 확인 자료 | 국외 |\n| 1) 목표 대상자 수: 총 128명(군당 64명) | 5 | 의료기기(SaMD)이다.  | 여부 | - 운영방법 및 유지보수 방법과 관련된 요구사항 | 적용방법 및 사례집 | 성 | 허가신청 시 제출하는 자료의 작성 | 성 | 도 | 국내 |\n| [예시] | 7 | 7 | NICE 진료지침(2017) | 권장 | 권장 | 권장 | 가) 디지털치료기기 허가·심사 가이드라인(민원인 안내서) | 기관명 | 소재지 | 전화 | 팩스 | - 제조회사: ㈜○○○ | - 일차와 이차 유효성 평가 관련된 목록을 작성한다.  | 하는 것을 방지하기 위한 통제 수단을 고려 | software | 시스템 | systems – Requirements for | – Part 2-2: Guidance for the | 의료기기의 위험관리 | 시험소프 | 국외 |\n| 의견을 조정하기 위하여 조정위원회를 설치하고 임상시험 조정자를 선정할 수 있다.  | 바) 식사장애 검사(EDE-Q) 조사 | 사실 | (3) 정신과적 전문 치료를 시작한 것으로 판단되는 경우 | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 기재한다. ",
        "original_sentence": "| 전체 소프트웨어 시스템이 요구 | Management)에 대한 국제 | 소프트웨어 | 확인 자료 | 국외 |\n| 1) 목표 대상자 수: 총 128명(군당 64명) | 5 | 의료기기(SaMD)이다. "
      }
    },
    {
      "chunk_id": "chunk_106",
      "text": "| 여부 | - 운영방법 및 유지보수 방법과 관련된 요구사항 | 적용방법 및 사례집 | 성 | 허가신청 시 제출하는 자료의 작성 | 성 | 도 | 국내 |\n| [예시] | 7 | 7 | NICE 진료지침(2017) | 권장 | 권장 | 권장 | 가) 디지털치료기기 허가·심사 가이드라인(민원인 안내서) | 기관명 | 소재지 | 전화 | 팩스 | - 제조회사: ㈜○○○ | - 일차와 이차 유효성 평가 관련된 목록을 작성한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 105,
        "window_size": 3,
        "char_count": 238,
        "word_count": 71,
        "page_number": 3,
        "window_text": "| 임상시험을 복수의 임상시험 기관에서 실시하는 경우에는 기관에 따라 임상시험 | [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | - 대조군: 디지털 섭식장애 대조군 | 제조자는 의료기기가 다른 기기나 네트워크와 | IEC/TR | 연구 군을 선별한다.  | - 주로 인지행동치료(CBT)를 시행하며, 제한적이긴 하나 대인관계 | 으로 정의한다.  | 전체 소프트웨어 시스템이 요구 | Management)에 대한 국제 | 소프트웨어 | 확인 자료 | 국외 |\n| 1) 목표 대상자 수: 총 128명(군당 64명) | 5 | 의료기기(SaMD)이다.  | 여부 | - 운영방법 및 유지보수 방법과 관련된 요구사항 | 적용방법 및 사례집 | 성 | 허가신청 시 제출하는 자료의 작성 | 성 | 도 | 국내 |\n| [예시] | 7 | 7 | NICE 진료지침(2017) | 권장 | 권장 | 권장 | 가) 디지털치료기기 허가·심사 가이드라인(민원인 안내서) | 기관명 | 소재지 | 전화 | 팩스 | - 제조회사: ㈜○○○ | - 일차와 이차 유효성 평가 관련된 목록을 작성한다.  | 하는 것을 방지하기 위한 통제 수단을 고려 | software | 시스템 | systems – Requirements for | – Part 2-2: Guidance for the | 의료기기의 위험관리 | 시험소프 | 국외 |\n| 의견을 조정하기 위하여 조정위원회를 설치하고 임상시험 조정자를 선정할 수 있다.  | 바) 식사장애 검사(EDE-Q) 조사 | 사실 | (3) 정신과적 전문 치료를 시작한 것으로 판단되는 경우 | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 기재한다.  | 제조자는 바이러스, 스파이웨어, 랜섬웨어 등 | 부여한다. ",
        "original_sentence": "| 여부 | - 운영방법 및 유지보수 방법과 관련된 요구사항 | 적용방법 및 사례집 | 성 | 허가신청 시 제출하는 자료의 작성 | 성 | 도 | 국내 |\n| [예시] | 7 | 7 | NICE 진료지침(2017) | 권장 | 권장 | 권장 | 가) 디지털치료기기 허가·심사 가이드라인(민원인 안내서) | 기관명 | 소재지 | 전화 | 팩스 | - 제조회사: ㈜○○○ | - 일차와 이차 유효성 평가 관련된 목록을 작성한다. "
      }
    },
    {
      "chunk_id": "chunk_107",
      "text": "| 하는 것을 방지하기 위한 통제 수단을 고려 | software | 시스템 | systems – Requirements for | – Part 2-2: Guidance for the | 의료기기의 위험관리 | 시험소프 | 국외 |\n| 의견을 조정하기 위하여 조정위원회를 설치하고 임상시험 조정자를 선정할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 106,
        "window_size": 3,
        "char_count": 177,
        "word_count": 43,
        "page_number": 9,
        "window_text": "| - 주로 인지행동치료(CBT)를 시행하며, 제한적이긴 하나 대인관계 | 으로 정의한다.  | 전체 소프트웨어 시스템이 요구 | Management)에 대한 국제 | 소프트웨어 | 확인 자료 | 국외 |\n| 1) 목표 대상자 수: 총 128명(군당 64명) | 5 | 의료기기(SaMD)이다.  | 여부 | - 운영방법 및 유지보수 방법과 관련된 요구사항 | 적용방법 및 사례집 | 성 | 허가신청 시 제출하는 자료의 작성 | 성 | 도 | 국내 |\n| [예시] | 7 | 7 | NICE 진료지침(2017) | 권장 | 권장 | 권장 | 가) 디지털치료기기 허가·심사 가이드라인(민원인 안내서) | 기관명 | 소재지 | 전화 | 팩스 | - 제조회사: ㈜○○○ | - 일차와 이차 유효성 평가 관련된 목록을 작성한다.  | 하는 것을 방지하기 위한 통제 수단을 고려 | software | 시스템 | systems – Requirements for | – Part 2-2: Guidance for the | 의료기기의 위험관리 | 시험소프 | 국외 |\n| 의견을 조정하기 위하여 조정위원회를 설치하고 임상시험 조정자를 선정할 수 있다.  | 바) 식사장애 검사(EDE-Q) 조사 | 사실 | (3) 정신과적 전문 치료를 시작한 것으로 판단되는 경우 | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 기재한다.  | 제조자는 바이러스, 스파이웨어, 랜섬웨어 등 | 부여한다.  | 통한 섭식장애 치료를 수행한다. ",
        "original_sentence": "| 하는 것을 방지하기 위한 통제 수단을 고려 | software | 시스템 | systems – Requirements for | – Part 2-2: Guidance for the | 의료기기의 위험관리 | 시험소프 | 국외 |\n| 의견을 조정하기 위하여 조정위원회를 설치하고 임상시험 조정자를 선정할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_108",
      "text": "| 바) 식사장애 검사(EDE-Q) 조사 | 사실 | (3) 정신과적 전문 치료를 시작한 것으로 판단되는 경우 | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 기재한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 107,
        "window_size": 3,
        "char_count": 103,
        "word_count": 26,
        "page_number": 26,
        "window_text": "| 전체 소프트웨어 시스템이 요구 | Management)에 대한 국제 | 소프트웨어 | 확인 자료 | 국외 |\n| 1) 목표 대상자 수: 총 128명(군당 64명) | 5 | 의료기기(SaMD)이다.  | 여부 | - 운영방법 및 유지보수 방법과 관련된 요구사항 | 적용방법 및 사례집 | 성 | 허가신청 시 제출하는 자료의 작성 | 성 | 도 | 국내 |\n| [예시] | 7 | 7 | NICE 진료지침(2017) | 권장 | 권장 | 권장 | 가) 디지털치료기기 허가·심사 가이드라인(민원인 안내서) | 기관명 | 소재지 | 전화 | 팩스 | - 제조회사: ㈜○○○ | - 일차와 이차 유효성 평가 관련된 목록을 작성한다.  | 하는 것을 방지하기 위한 통제 수단을 고려 | software | 시스템 | systems – Requirements for | – Part 2-2: Guidance for the | 의료기기의 위험관리 | 시험소프 | 국외 |\n| 의견을 조정하기 위하여 조정위원회를 설치하고 임상시험 조정자를 선정할 수 있다.  | 바) 식사장애 검사(EDE-Q) 조사 | 사실 | (3) 정신과적 전문 치료를 시작한 것으로 판단되는 경우 | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 기재한다.  | 제조자는 바이러스, 스파이웨어, 랜섬웨어 등 | 부여한다.  | 통한 섭식장애 치료를 수행한다.  | 설치될 기기의 메모리 공간을 | 소프트웨어 |\n| 1. ",
        "original_sentence": "| 바) 식사장애 검사(EDE-Q) 조사 | 사실 | (3) 정신과적 전문 치료를 시작한 것으로 판단되는 경우 | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_109",
      "text": "| 제조자는 바이러스, 스파이웨어, 랜섬웨어 등 | 부여한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 108,
        "window_size": 3,
        "char_count": 35,
        "word_count": 8,
        "page_number": 15,
        "window_text": "| 여부 | - 운영방법 및 유지보수 방법과 관련된 요구사항 | 적용방법 및 사례집 | 성 | 허가신청 시 제출하는 자료의 작성 | 성 | 도 | 국내 |\n| [예시] | 7 | 7 | NICE 진료지침(2017) | 권장 | 권장 | 권장 | 가) 디지털치료기기 허가·심사 가이드라인(민원인 안내서) | 기관명 | 소재지 | 전화 | 팩스 | - 제조회사: ㈜○○○ | - 일차와 이차 유효성 평가 관련된 목록을 작성한다.  | 하는 것을 방지하기 위한 통제 수단을 고려 | software | 시스템 | systems – Requirements for | – Part 2-2: Guidance for the | 의료기기의 위험관리 | 시험소프 | 국외 |\n| 의견을 조정하기 위하여 조정위원회를 설치하고 임상시험 조정자를 선정할 수 있다.  | 바) 식사장애 검사(EDE-Q) 조사 | 사실 | (3) 정신과적 전문 치료를 시작한 것으로 판단되는 경우 | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 기재한다.  | 제조자는 바이러스, 스파이웨어, 랜섬웨어 등 | 부여한다.  | 통한 섭식장애 치료를 수행한다.  | 설치될 기기의 메모리 공간을 | 소프트웨어 |\n| 1.  관련 규정 | /ng69 | 80001-2-2 | 어떻게 접속(유·무선 통신 등)하여야 할지를 | (민원인 안내서) | 소프트웨어 | 및 심리역학 치료를 시행하기도 한다. ",
        "original_sentence": "| 제조자는 바이러스, 스파이웨어, 랜섬웨어 등 | 부여한다. "
      }
    },
    {
      "chunk_id": "chunk_110",
      "text": "| 통한 섭식장애 치료를 수행한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 109,
        "window_size": 3,
        "char_count": 20,
        "word_count": 5,
        "page_number": 15,
        "window_text": "| 하는 것을 방지하기 위한 통제 수단을 고려 | software | 시스템 | systems – Requirements for | – Part 2-2: Guidance for the | 의료기기의 위험관리 | 시험소프 | 국외 |\n| 의견을 조정하기 위하여 조정위원회를 설치하고 임상시험 조정자를 선정할 수 있다.  | 바) 식사장애 검사(EDE-Q) 조사 | 사실 | (3) 정신과적 전문 치료를 시작한 것으로 판단되는 경우 | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 기재한다.  | 제조자는 바이러스, 스파이웨어, 랜섬웨어 등 | 부여한다.  | 통한 섭식장애 치료를 수행한다.  | 설치될 기기의 메모리 공간을 | 소프트웨어 |\n| 1.  관련 규정 | /ng69 | 80001-2-2 | 어떻게 접속(유·무선 통신 등)하여야 할지를 | (민원인 안내서) | 소프트웨어 | 및 심리역학 치료를 시행하기도 한다.  | 사항을 충족하는지 확인한다. ",
        "original_sentence": "| 통한 섭식장애 치료를 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_111",
      "text": "| 설치될 기기의 메모리 공간을 | 소프트웨어 |\n| 1. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 110,
        "window_size": 3,
        "char_count": 33,
        "word_count": 10,
        "page_number": 9,
        "window_text": "| 바) 식사장애 검사(EDE-Q) 조사 | 사실 | (3) 정신과적 전문 치료를 시작한 것으로 판단되는 경우 | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 기재한다.  | 제조자는 바이러스, 스파이웨어, 랜섬웨어 등 | 부여한다.  | 통한 섭식장애 치료를 수행한다.  | 설치될 기기의 메모리 공간을 | 소프트웨어 |\n| 1.  관련 규정 | /ng69 | 80001-2-2 | 어떻게 접속(유·무선 통신 등)하여야 할지를 | (민원인 안내서) | 소프트웨어 | 및 심리역학 치료를 시행하기도 한다.  | 사항을 충족하는지 확인한다.  | 예시를 제시 | 규격 | 검증 및 |\n| 1) 식품의약품안전처의 임상 계획 승인일로부터 00개월 | 결과에 차이가 있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 | 통해 추정하고자 한다. ",
        "original_sentence": "| 설치될 기기의 메모리 공간을 | 소프트웨어 |\n| 1. "
      }
    },
    {
      "chunk_id": "chunk_112",
      "text": "관련 규정 | /ng69 | 80001-2-2 | 어떻게 접속(유·무선 통신 등)하여야 할지를 | (민원인 안내서) | 소프트웨어 | 및 심리역학 치료를 시행하기도 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 111,
        "window_size": 3,
        "char_count": 96,
        "word_count": 23,
        "page_number": 9,
        "window_text": "| 제조자는 바이러스, 스파이웨어, 랜섬웨어 등 | 부여한다.  | 통한 섭식장애 치료를 수행한다.  | 설치될 기기의 메모리 공간을 | 소프트웨어 |\n| 1.  관련 규정 | /ng69 | 80001-2-2 | 어떻게 접속(유·무선 통신 등)하여야 할지를 | (민원인 안내서) | 소프트웨어 | 및 심리역학 치료를 시행하기도 한다.  | 사항을 충족하는지 확인한다.  | 예시를 제시 | 규격 | 검증 및 |\n| 1) 식품의약품안전처의 임상 계획 승인일로부터 00개월 | 결과에 차이가 있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 | 통해 추정하고자 한다.  | App memory size는 최소 |\n| 설계 변경을 | AED 가이드라인(2020) | First-line | First-line | First-line | 1 | 나) 피험자 동의 및 준비 | 2) 무작위배정 방법 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 하여야 한다. ",
        "original_sentence": "관련 규정 | /ng69 | 80001-2-2 | 어떻게 접속(유·무선 통신 등)하여야 할지를 | (민원인 안내서) | 소프트웨어 | 및 심리역학 치료를 시행하기도 한다. "
      }
    },
    {
      "chunk_id": "chunk_113",
      "text": "| 사항을 충족하는지 확인한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 112,
        "window_size": 3,
        "char_count": 18,
        "word_count": 4,
        "page_number": 3,
        "window_text": "| 통한 섭식장애 치료를 수행한다.  | 설치될 기기의 메모리 공간을 | 소프트웨어 |\n| 1.  관련 규정 | /ng69 | 80001-2-2 | 어떻게 접속(유·무선 통신 등)하여야 할지를 | (민원인 안내서) | 소프트웨어 | 및 심리역학 치료를 시행하기도 한다.  | 사항을 충족하는지 확인한다.  | 예시를 제시 | 규격 | 검증 및 |\n| 1) 식품의약품안전처의 임상 계획 승인일로부터 00개월 | 결과에 차이가 있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 | 통해 추정하고자 한다.  | App memory size는 최소 |\n| 설계 변경을 | AED 가이드라인(2020) | First-line | First-line | First-line | 1 | 나) 피험자 동의 및 준비 | 2) 무작위배정 방법 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 하여야 한다.  | □ 일회성 지시ㆍ명령에 해당하는 내용입니까? ",
        "original_sentence": "| 사항을 충족하는지 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_114",
      "text": "| 예시를 제시 | 규격 | 검증 및 |\n| 1) 식품의약품안전처의 임상 계획 승인일로부터 00개월 | 결과에 차이가 있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 | 통해 추정하고자 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 113,
        "window_size": 3,
        "char_count": 117,
        "word_count": 32,
        "page_number": 19,
        "window_text": "| 설치될 기기의 메모리 공간을 | 소프트웨어 |\n| 1.  관련 규정 | /ng69 | 80001-2-2 | 어떻게 접속(유·무선 통신 등)하여야 할지를 | (민원인 안내서) | 소프트웨어 | 및 심리역학 치료를 시행하기도 한다.  | 사항을 충족하는지 확인한다.  | 예시를 제시 | 규격 | 검증 및 |\n| 1) 식품의약품안전처의 임상 계획 승인일로부터 00개월 | 결과에 차이가 있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 | 통해 추정하고자 한다.  | App memory size는 최소 |\n| 설계 변경을 | AED 가이드라인(2020) | First-line | First-line | First-line | 1 | 나) 피험자 동의 및 준비 | 2) 무작위배정 방법 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 하여야 한다.  | □ 일회성 지시ㆍ명령에 해당하는 내용입니까?  | □ 예 | ■ 아니오 | 검증 | disclosure and communication | regulatory purposes | 방법에 대한 국제 규격 | 적용 | 사항에 반영한다. ",
        "original_sentence": "| 예시를 제시 | 규격 | 검증 및 |\n| 1) 식품의약품안전처의 임상 계획 승인일로부터 00개월 | 결과에 차이가 있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 | 통해 추정하고자 한다. "
      }
    },
    {
      "chunk_id": "chunk_115",
      "text": "| App memory size는 최소 |\n| 설계 변경을 | AED 가이드라인(2020) | First-line | First-line | First-line | 1 | 나) 피험자 동의 및 준비 | 2) 무작위배정 방법 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 114,
        "window_size": 3,
        "char_count": 174,
        "word_count": 42,
        "page_number": 9,
        "window_text": "관련 규정 | /ng69 | 80001-2-2 | 어떻게 접속(유·무선 통신 등)하여야 할지를 | (민원인 안내서) | 소프트웨어 | 및 심리역학 치료를 시행하기도 한다.  | 사항을 충족하는지 확인한다.  | 예시를 제시 | 규격 | 검증 및 |\n| 1) 식품의약품안전처의 임상 계획 승인일로부터 00개월 | 결과에 차이가 있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 | 통해 추정하고자 한다.  | App memory size는 최소 |\n| 설계 변경을 | AED 가이드라인(2020) | First-line | First-line | First-line | 1 | 나) 피험자 동의 및 준비 | 2) 무작위배정 방법 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 하여야 한다.  | □ 일회성 지시ㆍ명령에 해당하는 내용입니까?  | □ 예 | ■ 아니오 | 검증 | disclosure and communication | regulatory purposes | 방법에 대한 국제 규격 | 적용 | 사항에 반영한다.  | 트웨어 |\n| 2 | 메모리 크기 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 고려하여야 한다. ",
        "original_sentence": "| App memory size는 최소 |\n| 설계 변경을 | AED 가이드라인(2020) | First-line | First-line | First-line | 1 | 나) 피험자 동의 및 준비 | 2) 무작위배정 방법 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_116",
      "text": "| □ 일회성 지시ㆍ명령에 해당하는 내용입니까? ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 115,
        "window_size": 3,
        "char_count": 27,
        "word_count": 6,
        "page_number": 3,
        "window_text": "| 사항을 충족하는지 확인한다.  | 예시를 제시 | 규격 | 검증 및 |\n| 1) 식품의약품안전처의 임상 계획 승인일로부터 00개월 | 결과에 차이가 있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 | 통해 추정하고자 한다.  | App memory size는 최소 |\n| 설계 변경을 | AED 가이드라인(2020) | First-line | First-line | First-line | 1 | 나) 피험자 동의 및 준비 | 2) 무작위배정 방법 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 하여야 한다.  | □ 일회성 지시ㆍ명령에 해당하는 내용입니까?  | □ 예 | ■ 아니오 | 검증 | disclosure and communication | regulatory purposes | 방법에 대한 국제 규격 | 적용 | 사항에 반영한다.  | 트웨어 |\n| 2 | 메모리 크기 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 고려하여야 한다.  | 기기에서 실행될 수 있는 악성코드를 막기 | 애플리케이션, 이메일, 문자, SNS 등을 통해 수집한다. ",
        "original_sentence": "| □ 일회성 지시ㆍ명령에 해당하는 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_117",
      "text": "| □ 예 | ■ 아니오 | 검증 | disclosure and communication | regulatory purposes | 방법에 대한 국제 규격 | 적용 | 사항에 반영한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 116,
        "window_size": 3,
        "char_count": 104,
        "word_count": 25,
        "page_number": 3,
        "window_text": "| 예시를 제시 | 규격 | 검증 및 |\n| 1) 식품의약품안전처의 임상 계획 승인일로부터 00개월 | 결과에 차이가 있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 | 통해 추정하고자 한다.  | App memory size는 최소 |\n| 설계 변경을 | AED 가이드라인(2020) | First-line | First-line | First-line | 1 | 나) 피험자 동의 및 준비 | 2) 무작위배정 방법 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 하여야 한다.  | □ 일회성 지시ㆍ명령에 해당하는 내용입니까?  | □ 예 | ■ 아니오 | 검증 | disclosure and communication | regulatory purposes | 방법에 대한 국제 규격 | 적용 | 사항에 반영한다.  | 트웨어 |\n| 2 | 메모리 크기 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 고려하여야 한다.  | 기기에서 실행될 수 있는 악성코드를 막기 | 애플리케이션, 이메일, 문자, SNS 등을 통해 수집한다.  | 검증 자료로 | 위한 과제를 제공한다. ",
        "original_sentence": "| □ 예 | ■ 아니오 | 검증 | disclosure and communication | regulatory purposes | 방법에 대한 국제 규격 | 적용 | 사항에 반영한다. "
      }
    },
    {
      "chunk_id": "chunk_118",
      "text": "| 트웨어 |\n| 2 | 메모리 크기 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 고려하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 117,
        "window_size": 3,
        "char_count": 61,
        "word_count": 21,
        "page_number": 9,
        "window_text": "| App memory size는 최소 |\n| 설계 변경을 | AED 가이드라인(2020) | First-line | First-line | First-line | 1 | 나) 피험자 동의 및 준비 | 2) 무작위배정 방법 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 하여야 한다.  | □ 일회성 지시ㆍ명령에 해당하는 내용입니까?  | □ 예 | ■ 아니오 | 검증 | disclosure and communication | regulatory purposes | 방법에 대한 국제 규격 | 적용 | 사항에 반영한다.  | 트웨어 |\n| 2 | 메모리 크기 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 고려하여야 한다.  | 기기에서 실행될 수 있는 악성코드를 막기 | 애플리케이션, 이메일, 문자, SNS 등을 통해 수집한다.  | 검증 자료로 | 위한 과제를 제공한다.  | 확인한다. ",
        "original_sentence": "| 트웨어 |\n| 2 | 메모리 크기 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 고려하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_119",
      "text": "| 기기에서 실행될 수 있는 악성코드를 막기 | 애플리케이션, 이메일, 문자, SNS 등을 통해 수집한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 118,
        "window_size": 3,
        "char_count": 60,
        "word_count": 15,
        "page_number": 34,
        "window_text": "| □ 일회성 지시ㆍ명령에 해당하는 내용입니까?  | □ 예 | ■ 아니오 | 검증 | disclosure and communication | regulatory purposes | 방법에 대한 국제 규격 | 적용 | 사항에 반영한다.  | 트웨어 |\n| 2 | 메모리 크기 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 고려하여야 한다.  | 기기에서 실행될 수 있는 악성코드를 막기 | 애플리케이션, 이메일, 문자, SNS 등을 통해 수집한다.  | 검증 자료로 | 위한 과제를 제공한다.  | 확인한다.  | 검증 및 | 유효성 | 해당 | (AB-1234) |\n| 회사명 | 대표이사 | 소재지 | 전화 | - 원재료: (임상시험용 의료기기의 원재료에 대한 특성 기술) | (1) 일차 유효성 평가지표: 식사장애 검사(EDE-Q) | Off-The-Shelf Software Use in | - 환자의 선호도나 상황에 따라 인지행동치료(CBT)를 기반으로 | 의료기기에서의 | 기성품 | 소프트웨어 | 적용 |\n| 통한 사용자별 | 91. ",
        "original_sentence": "| 기기에서 실행될 수 있는 악성코드를 막기 | 애플리케이션, 이메일, 문자, SNS 등을 통해 수집한다. "
      }
    },
    {
      "chunk_id": "chunk_120",
      "text": "| 검증 자료로 | 위한 과제를 제공한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 119,
        "window_size": 3,
        "char_count": 24,
        "word_count": 7,
        "page_number": 15,
        "window_text": "| □ 예 | ■ 아니오 | 검증 | disclosure and communication | regulatory purposes | 방법에 대한 국제 규격 | 적용 | 사항에 반영한다.  | 트웨어 |\n| 2 | 메모리 크기 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 고려하여야 한다.  | 기기에서 실행될 수 있는 악성코드를 막기 | 애플리케이션, 이메일, 문자, SNS 등을 통해 수집한다.  | 검증 자료로 | 위한 과제를 제공한다.  | 확인한다.  | 검증 및 | 유효성 | 해당 | (AB-1234) |\n| 회사명 | 대표이사 | 소재지 | 전화 | - 원재료: (임상시험용 의료기기의 원재료에 대한 특성 기술) | (1) 일차 유효성 평가지표: 식사장애 검사(EDE-Q) | Off-The-Shelf Software Use in | - 환자의 선호도나 상황에 따라 인지행동치료(CBT)를 기반으로 | 의료기기에서의 | 기성품 | 소프트웨어 | 적용 |\n| 통한 사용자별 | 91.  | (1) 「의료기기법」 제2조 (정의) | 8) 기타 이차 유효성 평가변수 | 방법 및 빈도는 이하의 2차 변수에 있어 같이 적용할 수 있다. ",
        "original_sentence": "| 검증 자료로 | 위한 과제를 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_121",
      "text": "| 확인한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 120,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 15,
        "window_text": "| 트웨어 |\n| 2 | 메모리 크기 | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 고려하여야 한다.  | 기기에서 실행될 수 있는 악성코드를 막기 | 애플리케이션, 이메일, 문자, SNS 등을 통해 수집한다.  | 검증 자료로 | 위한 과제를 제공한다.  | 확인한다.  | 검증 및 | 유효성 | 해당 | (AB-1234) |\n| 회사명 | 대표이사 | 소재지 | 전화 | - 원재료: (임상시험용 의료기기의 원재료에 대한 특성 기술) | (1) 일차 유효성 평가지표: 식사장애 검사(EDE-Q) | Off-The-Shelf Software Use in | - 환자의 선호도나 상황에 따라 인지행동치료(CBT)를 기반으로 | 의료기기에서의 | 기성품 | 소프트웨어 | 적용 |\n| 통한 사용자별 | 91.  | (1) 「의료기기법」 제2조 (정의) | 8) 기타 이차 유효성 평가변수 | 방법 및 빈도는 이하의 2차 변수에 있어 같이 적용할 수 있다.  | 적합한 통신 개략도와 사이버보안 적용 사항을 기재한다. ",
        "original_sentence": "| 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_122",
      "text": "| 검증 및 | 유효성 | 해당 | (AB-1234) |\n| 회사명 | 대표이사 | 소재지 | 전화 | - 원재료: (임상시험용 의료기기의 원재료에 대한 특성 기술) | (1) 일차 유효성 평가지표: 식사장애 검사(EDE-Q) | Off-The-Shelf Software Use in | - 환자의 선호도나 상황에 따라 인지행동치료(CBT)를 기반으로 | 의료기기에서의 | 기성품 | 소프트웨어 | 적용 |\n| 통한 사용자별 | 91. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 121,
        "window_size": 3,
        "char_count": 244,
        "word_count": 61,
        "page_number": 9,
        "window_text": "| 기기에서 실행될 수 있는 악성코드를 막기 | 애플리케이션, 이메일, 문자, SNS 등을 통해 수집한다.  | 검증 자료로 | 위한 과제를 제공한다.  | 확인한다.  | 검증 및 | 유효성 | 해당 | (AB-1234) |\n| 회사명 | 대표이사 | 소재지 | 전화 | - 원재료: (임상시험용 의료기기의 원재료에 대한 특성 기술) | (1) 일차 유효성 평가지표: 식사장애 검사(EDE-Q) | Off-The-Shelf Software Use in | - 환자의 선호도나 상황에 따라 인지행동치료(CBT)를 기반으로 | 의료기기에서의 | 기성품 | 소프트웨어 | 적용 |\n| 통한 사용자별 | 91.  | (1) 「의료기기법」 제2조 (정의) | 8) 기타 이차 유효성 평가변수 | 방법 및 빈도는 이하의 2차 변수에 있어 같이 적용할 수 있다.  | 적합한 통신 개략도와 사이버보안 적용 사항을 기재한다.  | 나) 선정/제외 기준 | 라) 대조군 검사 시험방법 | 연결이 가능하도록 조치한다. ",
        "original_sentence": "| 검증 및 | 유효성 | 해당 | (AB-1234) |\n| 회사명 | 대표이사 | 소재지 | 전화 | - 원재료: (임상시험용 의료기기의 원재료에 대한 특성 기술) | (1) 일차 유효성 평가지표: 식사장애 검사(EDE-Q) | Off-The-Shelf Software Use in | - 환자의 선호도나 상황에 따라 인지행동치료(CBT)를 기반으로 | 의료기기에서의 | 기성품 | 소프트웨어 | 적용 |\n| 통한 사용자별 | 91. "
      }
    },
    {
      "chunk_id": "chunk_123",
      "text": "| (1) 「의료기기법」 제2조 (정의) | 8) 기타 이차 유효성 평가변수 | 방법 및 빈도는 이하의 2차 변수에 있어 같이 적용할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 122,
        "window_size": 3,
        "char_count": 81,
        "word_count": 23,
        "page_number": 5,
        "window_text": "| 검증 자료로 | 위한 과제를 제공한다.  | 확인한다.  | 검증 및 | 유효성 | 해당 | (AB-1234) |\n| 회사명 | 대표이사 | 소재지 | 전화 | - 원재료: (임상시험용 의료기기의 원재료에 대한 특성 기술) | (1) 일차 유효성 평가지표: 식사장애 검사(EDE-Q) | Off-The-Shelf Software Use in | - 환자의 선호도나 상황에 따라 인지행동치료(CBT)를 기반으로 | 의료기기에서의 | 기성품 | 소프트웨어 | 적용 |\n| 통한 사용자별 | 91.  | (1) 「의료기기법」 제2조 (정의) | 8) 기타 이차 유효성 평가변수 | 방법 및 빈도는 이하의 2차 변수에 있어 같이 적용할 수 있다.  | 적합한 통신 개략도와 사이버보안 적용 사항을 기재한다.  | 나) 선정/제외 기준 | 라) 대조군 검사 시험방법 | 연결이 가능하도록 조치한다.  | 기타 문서화된 정보의 사전 서면승인을 받아야 한다. ",
        "original_sentence": "| (1) 「의료기기법」 제2조 (정의) | 8) 기타 이차 유효성 평가변수 | 방법 및 빈도는 이하의 2차 변수에 있어 같이 적용할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_124",
      "text": "| 적합한 통신 개략도와 사이버보안 적용 사항을 기재한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 123,
        "window_size": 3,
        "char_count": 33,
        "word_count": 8,
        "page_number": 3,
        "window_text": "| 확인한다.  | 검증 및 | 유효성 | 해당 | (AB-1234) |\n| 회사명 | 대표이사 | 소재지 | 전화 | - 원재료: (임상시험용 의료기기의 원재료에 대한 특성 기술) | (1) 일차 유효성 평가지표: 식사장애 검사(EDE-Q) | Off-The-Shelf Software Use in | - 환자의 선호도나 상황에 따라 인지행동치료(CBT)를 기반으로 | 의료기기에서의 | 기성품 | 소프트웨어 | 적용 |\n| 통한 사용자별 | 91.  | (1) 「의료기기법」 제2조 (정의) | 8) 기타 이차 유효성 평가변수 | 방법 및 빈도는 이하의 2차 변수에 있어 같이 적용할 수 있다.  | 적합한 통신 개략도와 사이버보안 적용 사항을 기재한다.  | 나) 선정/제외 기준 | 라) 대조군 검사 시험방법 | 연결이 가능하도록 조치한다.  | 기타 문서화된 정보의 사전 서면승인을 받아야 한다.  | 입회자가 동의를 얻는 전 과정에 참석하여야 한다. ",
        "original_sentence": "| 적합한 통신 개략도와 사이버보안 적용 사항을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_125",
      "text": "| 나) 선정/제외 기준 | 라) 대조군 검사 시험방법 | 연결이 가능하도록 조치한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 124,
        "window_size": 3,
        "char_count": 49,
        "word_count": 13,
        "page_number": 15,
        "window_text": "| 검증 및 | 유효성 | 해당 | (AB-1234) |\n| 회사명 | 대표이사 | 소재지 | 전화 | - 원재료: (임상시험용 의료기기의 원재료에 대한 특성 기술) | (1) 일차 유효성 평가지표: 식사장애 검사(EDE-Q) | Off-The-Shelf Software Use in | - 환자의 선호도나 상황에 따라 인지행동치료(CBT)를 기반으로 | 의료기기에서의 | 기성품 | 소프트웨어 | 적용 |\n| 통한 사용자별 | 91.  | (1) 「의료기기법」 제2조 (정의) | 8) 기타 이차 유효성 평가변수 | 방법 및 빈도는 이하의 2차 변수에 있어 같이 적용할 수 있다.  | 적합한 통신 개략도와 사이버보안 적용 사항을 기재한다.  | 나) 선정/제외 기준 | 라) 대조군 검사 시험방법 | 연결이 가능하도록 조치한다.  | 기타 문서화된 정보의 사전 서면승인을 받아야 한다.  | 입회자가 동의를 얻는 전 과정에 참석하여야 한다.  | 문제가 있을 경우 시험자와 상의한다. ",
        "original_sentence": "| 나) 선정/제외 기준 | 라) 대조군 검사 시험방법 | 연결이 가능하도록 조치한다. "
      }
    },
    {
      "chunk_id": "chunk_126",
      "text": "| 기타 문서화된 정보의 사전 서면승인을 받아야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 125,
        "window_size": 3,
        "char_count": 31,
        "word_count": 8,
        "page_number": 15,
        "window_text": "| (1) 「의료기기법」 제2조 (정의) | 8) 기타 이차 유효성 평가변수 | 방법 및 빈도는 이하의 2차 변수에 있어 같이 적용할 수 있다.  | 적합한 통신 개략도와 사이버보안 적용 사항을 기재한다.  | 나) 선정/제외 기준 | 라) 대조군 검사 시험방법 | 연결이 가능하도록 조치한다.  | 기타 문서화된 정보의 사전 서면승인을 받아야 한다.  | 입회자가 동의를 얻는 전 과정에 참석하여야 한다.  | 문제가 있을 경우 시험자와 상의한다.  | 이러한 정보들은 기밀로 보관되어야 한다. ",
        "original_sentence": "| 기타 문서화된 정보의 사전 서면승인을 받아야 한다. "
      }
    },
    {
      "chunk_id": "chunk_127",
      "text": "| 입회자가 동의를 얻는 전 과정에 참석하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 126,
        "window_size": 3,
        "char_count": 30,
        "word_count": 8,
        "page_number": 15,
        "window_text": "| 적합한 통신 개략도와 사이버보안 적용 사항을 기재한다.  | 나) 선정/제외 기준 | 라) 대조군 검사 시험방법 | 연결이 가능하도록 조치한다.  | 기타 문서화된 정보의 사전 서면승인을 받아야 한다.  | 입회자가 동의를 얻는 전 과정에 참석하여야 한다.  | 문제가 있을 경우 시험자와 상의한다.  | 이러한 정보들은 기밀로 보관되어야 한다.  | 탈락시킬 수 있다. ",
        "original_sentence": "| 입회자가 동의를 얻는 전 과정에 참석하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_128",
      "text": "| 문제가 있을 경우 시험자와 상의한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 127,
        "window_size": 3,
        "char_count": 23,
        "word_count": 6,
        "page_number": 15,
        "window_text": "| 나) 선정/제외 기준 | 라) 대조군 검사 시험방법 | 연결이 가능하도록 조치한다.  | 기타 문서화된 정보의 사전 서면승인을 받아야 한다.  | 입회자가 동의를 얻는 전 과정에 참석하여야 한다.  | 문제가 있을 경우 시험자와 상의한다.  | 이러한 정보들은 기밀로 보관되어야 한다.  | 탈락시킬 수 있다.  | - 피험자 선정을 위한 식사장애 검사(EDE-Q) 정보를 수집한다. ",
        "original_sentence": "| 문제가 있을 경우 시험자와 상의한다. "
      }
    },
    {
      "chunk_id": "chunk_129",
      "text": "| 이러한 정보들은 기밀로 보관되어야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 128,
        "window_size": 3,
        "char_count": 25,
        "word_count": 6,
        "page_number": 15,
        "window_text": "| 기타 문서화된 정보의 사전 서면승인을 받아야 한다.  | 입회자가 동의를 얻는 전 과정에 참석하여야 한다.  | 문제가 있을 경우 시험자와 상의한다.  | 이러한 정보들은 기밀로 보관되어야 한다.  | 탈락시킬 수 있다.  | - 피험자 선정을 위한 식사장애 검사(EDE-Q) 정보를 수집한다.  | 통해 정보를 수집한다. ",
        "original_sentence": "| 이러한 정보들은 기밀로 보관되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_130",
      "text": "| 탈락시킬 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 129,
        "window_size": 3,
        "char_count": 13,
        "word_count": 4,
        "page_number": 12,
        "window_text": "| 입회자가 동의를 얻는 전 과정에 참석하여야 한다.  | 문제가 있을 경우 시험자와 상의한다.  | 이러한 정보들은 기밀로 보관되어야 한다.  | 탈락시킬 수 있다.  | - 피험자 선정을 위한 식사장애 검사(EDE-Q) 정보를 수집한다.  | 통해 정보를 수집한다.  | 통화를 하여 탈락의 주요 사유를 파악하도록 한다. ",
        "original_sentence": "| 탈락시킬 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_131",
      "text": "| - 피험자 선정을 위한 식사장애 검사(EDE-Q) 정보를 수집한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 130,
        "window_size": 3,
        "char_count": 40,
        "word_count": 9,
        "page_number": 15,
        "window_text": "| 문제가 있을 경우 시험자와 상의한다.  | 이러한 정보들은 기밀로 보관되어야 한다.  | 탈락시킬 수 있다.  | - 피험자 선정을 위한 식사장애 검사(EDE-Q) 정보를 수집한다.  | 통해 정보를 수집한다.  | 통화를 하여 탈락의 주요 사유를 파악하도록 한다.  | OO MB 이상일 것 | 적용 | 위험 < |\n| 접근 | 6 | of nutrition, health & aging, 22(10), 1275–1280. ",
        "original_sentence": "| - 피험자 선정을 위한 식사장애 검사(EDE-Q) 정보를 수집한다. "
      }
    },
    {
      "chunk_id": "chunk_132",
      "text": "| 통해 정보를 수집한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 131,
        "window_size": 3,
        "char_count": 15,
        "word_count": 4,
        "page_number": 15,
        "window_text": "| 이러한 정보들은 기밀로 보관되어야 한다.  | 탈락시킬 수 있다.  | - 피험자 선정을 위한 식사장애 검사(EDE-Q) 정보를 수집한다.  | 통해 정보를 수집한다.  | 통화를 하여 탈락의 주요 사유를 파악하도록 한다.  | OO MB 이상일 것 | 적용 | 위험 < |\n| 접근 | 6 | of nutrition, health & aging, 22(10), 1275–1280.  | d Care Excellence, NICE, 2017. ",
        "original_sentence": "| 통해 정보를 수집한다. "
      }
    },
    {
      "chunk_id": "chunk_133",
      "text": "| 통화를 하여 탈락의 주요 사유를 파악하도록 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 132,
        "window_size": 3,
        "char_count": 30,
        "word_count": 8,
        "page_number": 15,
        "window_text": "| 탈락시킬 수 있다.  | - 피험자 선정을 위한 식사장애 검사(EDE-Q) 정보를 수집한다.  | 통해 정보를 수집한다.  | 통화를 하여 탈락의 주요 사유를 파악하도록 한다.  | OO MB 이상일 것 | 적용 | 위험 < |\n| 접근 | 6 | of nutrition, health & aging, 22(10), 1275–1280.  | d Care Excellence, NICE, 2017.  | 보정할 수 있는 경우는 이를 반영하여 분석 결과를 제시해야 한다. ",
        "original_sentence": "| 통화를 하여 탈락의 주요 사유를 파악하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_134",
      "text": "| OO MB 이상일 것 | 적용 | 위험 < |\n| 접근 | 6 | of nutrition, health & aging, 22(10), 1275–1280. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 133,
        "window_size": 3,
        "char_count": 88,
        "word_count": 23,
        "page_number": 27,
        "window_text": "| - 피험자 선정을 위한 식사장애 검사(EDE-Q) 정보를 수집한다.  | 통해 정보를 수집한다.  | 통화를 하여 탈락의 주요 사유를 파악하도록 한다.  | OO MB 이상일 것 | 적용 | 위험 < |\n| 접근 | 6 | of nutrition, health & aging, 22(10), 1275–1280.  | d Care Excellence, NICE, 2017.  | 보정할 수 있는 경우는 이를 반영하여 분석 결과를 제시해야 한다.  | (Bulimia | 바) 순응도 조사 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 참여하는 사람(피험자)의 선정기준ㆍ제외기준ㆍ인원 및 그 근거 | ※ 예: 물리적 잠금 혹은 포트(port) 접근의 | of medical device security | (ex:설정→애플리케이션→메모리) | 검증 및 | (AB-1234) | 미국 |\n| 2) 대상자 모집 기간: 00개월 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 위해 안티 멀웨어 프로그램과 같은 통제 | ※ 예: Wi-Fi, 이더넷, 블루투스, USB 등 | 심리적 장애와 연관된 과식) | 접근통제 및 | 1 | 2 | 2 | Acceptable | 확인 자료 | 유효성 | 사항 | (AB-1234) |\n| 고려하지 않는다. ",
        "original_sentence": "| OO MB 이상일 것 | 적용 | 위험 < |\n| 접근 | 6 | of nutrition, health & aging, 22(10), 1275–1280. "
      }
    },
    {
      "chunk_id": "chunk_135",
      "text": "| d Care Excellence, NICE, 2017. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 134,
        "window_size": 3,
        "char_count": 33,
        "word_count": 6,
        "page_number": 9,
        "window_text": "| 통해 정보를 수집한다.  | 통화를 하여 탈락의 주요 사유를 파악하도록 한다.  | OO MB 이상일 것 | 적용 | 위험 < |\n| 접근 | 6 | of nutrition, health & aging, 22(10), 1275–1280.  | d Care Excellence, NICE, 2017.  | 보정할 수 있는 경우는 이를 반영하여 분석 결과를 제시해야 한다.  | (Bulimia | 바) 순응도 조사 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 참여하는 사람(피험자)의 선정기준ㆍ제외기준ㆍ인원 및 그 근거 | ※ 예: 물리적 잠금 혹은 포트(port) 접근의 | of medical device security | (ex:설정→애플리케이션→메모리) | 검증 및 | (AB-1234) | 미국 |\n| 2) 대상자 모집 기간: 00개월 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 위해 안티 멀웨어 프로그램과 같은 통제 | ※ 예: Wi-Fi, 이더넷, 블루투스, USB 등 | 심리적 장애와 연관된 과식) | 접근통제 및 | 1 | 2 | 2 | Acceptable | 확인 자료 | 유효성 | 사항 | (AB-1234) |\n| 고려하지 않는다.  | 섭식장애 개선 디지털치료기기 안전성·성능 평가 및 | 단축된 표준치료 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | Medical Devices | 한 자료를 사용한 자조 요법(Guided self-help, GSH)이 활용되기도 | 소프트웨어 요구사항을 소프트 | 사용에 대한 가이드 |\n| (2) 「의료기기법」 제3조 (등급분류와 지정) | 1) 임상시험용 의료기기와의 인과관계 평가 | Excellence, AED: Academy for eating disorders | 접근통제 및 | ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | Mental Disorders, Fifth Edition, DSM-5) | Nervosa) | ※ 내원은 필수가 아니며 앱, 이메일, 문자 등을 통해 수집할 수 있다. ",
        "original_sentence": "| d Care Excellence, NICE, 2017. "
      }
    },
    {
      "chunk_id": "chunk_136",
      "text": "| 보정할 수 있는 경우는 이를 반영하여 분석 결과를 제시해야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 135,
        "window_size": 3,
        "char_count": 39,
        "word_count": 11,
        "page_number": 15,
        "window_text": "| 통화를 하여 탈락의 주요 사유를 파악하도록 한다.  | OO MB 이상일 것 | 적용 | 위험 < |\n| 접근 | 6 | of nutrition, health & aging, 22(10), 1275–1280.  | d Care Excellence, NICE, 2017.  | 보정할 수 있는 경우는 이를 반영하여 분석 결과를 제시해야 한다.  | (Bulimia | 바) 순응도 조사 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 참여하는 사람(피험자)의 선정기준ㆍ제외기준ㆍ인원 및 그 근거 | ※ 예: 물리적 잠금 혹은 포트(port) 접근의 | of medical device security | (ex:설정→애플리케이션→메모리) | 검증 및 | (AB-1234) | 미국 |\n| 2) 대상자 모집 기간: 00개월 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 위해 안티 멀웨어 프로그램과 같은 통제 | ※ 예: Wi-Fi, 이더넷, 블루투스, USB 등 | 심리적 장애와 연관된 과식) | 접근통제 및 | 1 | 2 | 2 | Acceptable | 확인 자료 | 유효성 | 사항 | (AB-1234) |\n| 고려하지 않는다.  | 섭식장애 개선 디지털치료기기 안전성·성능 평가 및 | 단축된 표준치료 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | Medical Devices | 한 자료를 사용한 자조 요법(Guided self-help, GSH)이 활용되기도 | 소프트웨어 요구사항을 소프트 | 사용에 대한 가이드 |\n| (2) 「의료기기법」 제3조 (등급분류와 지정) | 1) 임상시험용 의료기기와의 인과관계 평가 | Excellence, AED: Academy for eating disorders | 접근통제 및 | ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | Mental Disorders, Fifth Edition, DSM-5) | Nervosa) | ※ 내원은 필수가 아니며 앱, 이메일, 문자 등을 통해 수집할 수 있다.  | □ 외국 규정을 단순 번역하거나 설명하는 내용입니까? ",
        "original_sentence": "| 보정할 수 있는 경우는 이를 반영하여 분석 결과를 제시해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_137",
      "text": "| (Bulimia | 바) 순응도 조사 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 참여하는 사람(피험자)의 선정기준ㆍ제외기준ㆍ인원 및 그 근거 | ※ 예: 물리적 잠금 혹은 포트(port) 접근의 | of medical device security | (ex:설정→애플리케이션→메모리) | 검증 및 | (AB-1234) | 미국 |\n| 2) 대상자 모집 기간: 00개월 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 위해 안티 멀웨어 프로그램과 같은 통제 | ※ 예: Wi-Fi, 이더넷, 블루투스, USB 등 | 심리적 장애와 연관된 과식) | 접근통제 및 | 1 | 2 | 2 | Acceptable | 확인 자료 | 유효성 | 사항 | (AB-1234) |\n| 고려하지 않는다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 136,
        "window_size": 3,
        "char_count": 413,
        "word_count": 105,
        "page_number": 15,
        "window_text": "| OO MB 이상일 것 | 적용 | 위험 < |\n| 접근 | 6 | of nutrition, health & aging, 22(10), 1275–1280.  | d Care Excellence, NICE, 2017.  | 보정할 수 있는 경우는 이를 반영하여 분석 결과를 제시해야 한다.  | (Bulimia | 바) 순응도 조사 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 참여하는 사람(피험자)의 선정기준ㆍ제외기준ㆍ인원 및 그 근거 | ※ 예: 물리적 잠금 혹은 포트(port) 접근의 | of medical device security | (ex:설정→애플리케이션→메모리) | 검증 및 | (AB-1234) | 미국 |\n| 2) 대상자 모집 기간: 00개월 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 위해 안티 멀웨어 프로그램과 같은 통제 | ※ 예: Wi-Fi, 이더넷, 블루투스, USB 등 | 심리적 장애와 연관된 과식) | 접근통제 및 | 1 | 2 | 2 | Acceptable | 확인 자료 | 유효성 | 사항 | (AB-1234) |\n| 고려하지 않는다.  | 섭식장애 개선 디지털치료기기 안전성·성능 평가 및 | 단축된 표준치료 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | Medical Devices | 한 자료를 사용한 자조 요법(Guided self-help, GSH)이 활용되기도 | 소프트웨어 요구사항을 소프트 | 사용에 대한 가이드 |\n| (2) 「의료기기법」 제3조 (등급분류와 지정) | 1) 임상시험용 의료기기와의 인과관계 평가 | Excellence, AED: Academy for eating disorders | 접근통제 및 | ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | Mental Disorders, Fifth Edition, DSM-5) | Nervosa) | ※ 내원은 필수가 아니며 앱, 이메일, 문자 등을 통해 수집할 수 있다.  | □ 외국 규정을 단순 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 이득 |\n| [예시] | 1) 임상시험의 연구목적으로 수행된다는 사실 | 수가 확보되어야 한다. ",
        "original_sentence": "| (Bulimia | 바) 순응도 조사 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 참여하는 사람(피험자)의 선정기준ㆍ제외기준ㆍ인원 및 그 근거 | ※ 예: 물리적 잠금 혹은 포트(port) 접근의 | of medical device security | (ex:설정→애플리케이션→메모리) | 검증 및 | (AB-1234) | 미국 |\n| 2) 대상자 모집 기간: 00개월 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 위해 안티 멀웨어 프로그램과 같은 통제 | ※ 예: Wi-Fi, 이더넷, 블루투스, USB 등 | 심리적 장애와 연관된 과식) | 접근통제 및 | 1 | 2 | 2 | Acceptable | 확인 자료 | 유효성 | 사항 | (AB-1234) |\n| 고려하지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_138",
      "text": "| 섭식장애 개선 디지털치료기기 안전성·성능 평가 및 | 단축된 표준치료 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | Medical Devices | 한 자료를 사용한 자조 요법(Guided self-help, GSH)이 활용되기도 | 소프트웨어 요구사항을 소프트 | 사용에 대한 가이드 |\n| (2) 「의료기기법」 제3조 (등급분류와 지정) | 1) 임상시험용 의료기기와의 인과관계 평가 | Excellence, AED: Academy for eating disorders | 접근통제 및 | ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | Mental Disorders, Fifth Edition, DSM-5) | Nervosa) | ※ 내원은 필수가 아니며 앱, 이메일, 문자 등을 통해 수집할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 137,
        "window_size": 3,
        "char_count": 423,
        "word_count": 93,
        "page_number": 1,
        "window_text": "| d Care Excellence, NICE, 2017.  | 보정할 수 있는 경우는 이를 반영하여 분석 결과를 제시해야 한다.  | (Bulimia | 바) 순응도 조사 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 참여하는 사람(피험자)의 선정기준ㆍ제외기준ㆍ인원 및 그 근거 | ※ 예: 물리적 잠금 혹은 포트(port) 접근의 | of medical device security | (ex:설정→애플리케이션→메모리) | 검증 및 | (AB-1234) | 미국 |\n| 2) 대상자 모집 기간: 00개월 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 위해 안티 멀웨어 프로그램과 같은 통제 | ※ 예: Wi-Fi, 이더넷, 블루투스, USB 등 | 심리적 장애와 연관된 과식) | 접근통제 및 | 1 | 2 | 2 | Acceptable | 확인 자료 | 유효성 | 사항 | (AB-1234) |\n| 고려하지 않는다.  | 섭식장애 개선 디지털치료기기 안전성·성능 평가 및 | 단축된 표준치료 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | Medical Devices | 한 자료를 사용한 자조 요법(Guided self-help, GSH)이 활용되기도 | 소프트웨어 요구사항을 소프트 | 사용에 대한 가이드 |\n| (2) 「의료기기법」 제3조 (등급분류와 지정) | 1) 임상시험용 의료기기와의 인과관계 평가 | Excellence, AED: Academy for eating disorders | 접근통제 및 | ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | Mental Disorders, Fifth Edition, DSM-5) | Nervosa) | ※ 내원은 필수가 아니며 앱, 이메일, 문자 등을 통해 수집할 수 있다.  | □ 외국 규정을 단순 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 이득 |\n| [예시] | 1) 임상시험의 연구목적으로 수행된다는 사실 | 수가 확보되어야 한다.  | 웨어 밸리데이션 가이드라인(민원인 안내서)’에 따라 수행한다. ",
        "original_sentence": "| 섭식장애 개선 디지털치료기기 안전성·성능 평가 및 | 단축된 표준치료 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | Medical Devices | 한 자료를 사용한 자조 요법(Guided self-help, GSH)이 활용되기도 | 소프트웨어 요구사항을 소프트 | 사용에 대한 가이드 |\n| (2) 「의료기기법」 제3조 (등급분류와 지정) | 1) 임상시험용 의료기기와의 인과관계 평가 | Excellence, AED: Academy for eating disorders | 접근통제 및 | ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | Mental Disorders, Fifth Edition, DSM-5) | Nervosa) | ※ 내원은 필수가 아니며 앱, 이메일, 문자 등을 통해 수집할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_139",
      "text": "| □ 외국 규정을 단순 번역하거나 설명하는 내용입니까? ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 138,
        "window_size": 3,
        "char_count": 32,
        "word_count": 8,
        "page_number": 3,
        "window_text": "| 보정할 수 있는 경우는 이를 반영하여 분석 결과를 제시해야 한다.  | (Bulimia | 바) 순응도 조사 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 참여하는 사람(피험자)의 선정기준ㆍ제외기준ㆍ인원 및 그 근거 | ※ 예: 물리적 잠금 혹은 포트(port) 접근의 | of medical device security | (ex:설정→애플리케이션→메모리) | 검증 및 | (AB-1234) | 미국 |\n| 2) 대상자 모집 기간: 00개월 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 위해 안티 멀웨어 프로그램과 같은 통제 | ※ 예: Wi-Fi, 이더넷, 블루투스, USB 등 | 심리적 장애와 연관된 과식) | 접근통제 및 | 1 | 2 | 2 | Acceptable | 확인 자료 | 유효성 | 사항 | (AB-1234) |\n| 고려하지 않는다.  | 섭식장애 개선 디지털치료기기 안전성·성능 평가 및 | 단축된 표준치료 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | Medical Devices | 한 자료를 사용한 자조 요법(Guided self-help, GSH)이 활용되기도 | 소프트웨어 요구사항을 소프트 | 사용에 대한 가이드 |\n| (2) 「의료기기법」 제3조 (등급분류와 지정) | 1) 임상시험용 의료기기와의 인과관계 평가 | Excellence, AED: Academy for eating disorders | 접근통제 및 | ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | Mental Disorders, Fifth Edition, DSM-5) | Nervosa) | ※ 내원은 필수가 아니며 앱, 이메일, 문자 등을 통해 수집할 수 있다.  | □ 외국 규정을 단순 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 이득 |\n| [예시] | 1) 임상시험의 연구목적으로 수행된다는 사실 | 수가 확보되어야 한다.  | 웨어 밸리데이션 가이드라인(민원인 안내서)’에 따라 수행한다.  | 물리적 제한, 인증이 필요 없는 물리적 | * 독립형 소프트웨어 제품은 소프트웨어 명칭, 버전, 운영환경 기재 | needs, risks and controls | Medical devices | 의료기기 위험관리(Risk | 유효성 |\n| 3) 사이버보안 위험관리 | al., 2017) | 사) 병용약물 조사 | 문제점을 적극적으로 대응한다. ",
        "original_sentence": "| □ 외국 규정을 단순 번역하거나 설명하는 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_140",
      "text": "| □ 예 | ■ 아니오 | 이득 |\n| [예시] | 1) 임상시험의 연구목적으로 수행된다는 사실 | 수가 확보되어야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 139,
        "window_size": 3,
        "char_count": 70,
        "word_count": 21,
        "page_number": 3,
        "window_text": "| (Bulimia | 바) 순응도 조사 | ○○○병원 | ○○시 ○○ | ○○○-○○○○ | ○○○-○○○○ | 참여하는 사람(피험자)의 선정기준ㆍ제외기준ㆍ인원 및 그 근거 | ※ 예: 물리적 잠금 혹은 포트(port) 접근의 | of medical device security | (ex:설정→애플리케이션→메모리) | 검증 및 | (AB-1234) | 미국 |\n| 2) 대상자 모집 기간: 00개월 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 위해 안티 멀웨어 프로그램과 같은 통제 | ※ 예: Wi-Fi, 이더넷, 블루투스, USB 등 | 심리적 장애와 연관된 과식) | 접근통제 및 | 1 | 2 | 2 | Acceptable | 확인 자료 | 유효성 | 사항 | (AB-1234) |\n| 고려하지 않는다.  | 섭식장애 개선 디지털치료기기 안전성·성능 평가 및 | 단축된 표준치료 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | Medical Devices | 한 자료를 사용한 자조 요법(Guided self-help, GSH)이 활용되기도 | 소프트웨어 요구사항을 소프트 | 사용에 대한 가이드 |\n| (2) 「의료기기법」 제3조 (등급분류와 지정) | 1) 임상시험용 의료기기와의 인과관계 평가 | Excellence, AED: Academy for eating disorders | 접근통제 및 | ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | Mental Disorders, Fifth Edition, DSM-5) | Nervosa) | ※ 내원은 필수가 아니며 앱, 이메일, 문자 등을 통해 수집할 수 있다.  | □ 외국 규정을 단순 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 이득 |\n| [예시] | 1) 임상시험의 연구목적으로 수행된다는 사실 | 수가 확보되어야 한다.  | 웨어 밸리데이션 가이드라인(민원인 안내서)’에 따라 수행한다.  | 물리적 제한, 인증이 필요 없는 물리적 | * 독립형 소프트웨어 제품은 소프트웨어 명칭, 버전, 운영환경 기재 | needs, risks and controls | Medical devices | 의료기기 위험관리(Risk | 유효성 |\n| 3) 사이버보안 위험관리 | al., 2017) | 사) 병용약물 조사 | 문제점을 적극적으로 대응한다.  | 관한 기록을 유지하여야 한다. ",
        "original_sentence": "| □ 예 | ■ 아니오 | 이득 |\n| [예시] | 1) 임상시험의 연구목적으로 수행된다는 사실 | 수가 확보되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_141",
      "text": "| 웨어 밸리데이션 가이드라인(민원인 안내서)’에 따라 수행한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 140,
        "window_size": 3,
        "char_count": 37,
        "word_count": 7,
        "page_number": 3,
        "window_text": "| 섭식장애 개선 디지털치료기기 안전성·성능 평가 및 | 단축된 표준치료 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | Medical Devices | 한 자료를 사용한 자조 요법(Guided self-help, GSH)이 활용되기도 | 소프트웨어 요구사항을 소프트 | 사용에 대한 가이드 |\n| (2) 「의료기기법」 제3조 (등급분류와 지정) | 1) 임상시험용 의료기기와의 인과관계 평가 | Excellence, AED: Academy for eating disorders | 접근통제 및 | ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | Mental Disorders, Fifth Edition, DSM-5) | Nervosa) | ※ 내원은 필수가 아니며 앱, 이메일, 문자 등을 통해 수집할 수 있다.  | □ 외국 규정을 단순 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 이득 |\n| [예시] | 1) 임상시험의 연구목적으로 수행된다는 사실 | 수가 확보되어야 한다.  | 웨어 밸리데이션 가이드라인(민원인 안내서)’에 따라 수행한다.  | 물리적 제한, 인증이 필요 없는 물리적 | * 독립형 소프트웨어 제품은 소프트웨어 명칭, 버전, 운영환경 기재 | needs, risks and controls | Medical devices | 의료기기 위험관리(Risk | 유효성 |\n| 3) 사이버보안 위험관리 | al., 2017) | 사) 병용약물 조사 | 문제점을 적극적으로 대응한다.  | 관한 기록을 유지하여야 한다.  | 베이스라인 (사용 전) | - 상담 및 지지요법, 약물 치료 등을 실행한다. ",
        "original_sentence": "| 웨어 밸리데이션 가이드라인(민원인 안내서)’에 따라 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_142",
      "text": "| 물리적 제한, 인증이 필요 없는 물리적 | * 독립형 소프트웨어 제품은 소프트웨어 명칭, 버전, 운영환경 기재 | needs, risks and controls | Medical devices | 의료기기 위험관리(Risk | 유효성 |\n| 3) 사이버보안 위험관리 | al., 2017) | 사) 병용약물 조사 | 문제점을 적극적으로 대응한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 141,
        "window_size": 3,
        "char_count": 196,
        "word_count": 46,
        "page_number": 3,
        "window_text": "| □ 외국 규정을 단순 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 이득 |\n| [예시] | 1) 임상시험의 연구목적으로 수행된다는 사실 | 수가 확보되어야 한다.  | 웨어 밸리데이션 가이드라인(민원인 안내서)’에 따라 수행한다.  | 물리적 제한, 인증이 필요 없는 물리적 | * 독립형 소프트웨어 제품은 소프트웨어 명칭, 버전, 운영환경 기재 | needs, risks and controls | Medical devices | 의료기기 위험관리(Risk | 유효성 |\n| 3) 사이버보안 위험관리 | al., 2017) | 사) 병용약물 조사 | 문제점을 적극적으로 대응한다.  | 관한 기록을 유지하여야 한다.  | 베이스라인 (사용 전) | - 상담 및 지지요법, 약물 치료 등을 실행한다.  | - 디지털치료기기에 대한 사용자 반응 평가를 함께 수행한다. ",
        "original_sentence": "| 물리적 제한, 인증이 필요 없는 물리적 | * 독립형 소프트웨어 제품은 소프트웨어 명칭, 버전, 운영환경 기재 | needs, risks and controls | Medical devices | 의료기기 위험관리(Risk | 유효성 |\n| 3) 사이버보안 위험관리 | al., 2017) | 사) 병용약물 조사 | 문제점을 적극적으로 대응한다. "
      }
    },
    {
      "chunk_id": "chunk_143",
      "text": "| 관한 기록을 유지하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 142,
        "window_size": 3,
        "char_count": 19,
        "word_count": 5,
        "page_number": 15,
        "window_text": "| □ 예 | ■ 아니오 | 이득 |\n| [예시] | 1) 임상시험의 연구목적으로 수행된다는 사실 | 수가 확보되어야 한다.  | 웨어 밸리데이션 가이드라인(민원인 안내서)’에 따라 수행한다.  | 물리적 제한, 인증이 필요 없는 물리적 | * 독립형 소프트웨어 제품은 소프트웨어 명칭, 버전, 운영환경 기재 | needs, risks and controls | Medical devices | 의료기기 위험관리(Risk | 유효성 |\n| 3) 사이버보안 위험관리 | al., 2017) | 사) 병용약물 조사 | 문제점을 적극적으로 대응한다.  | 관한 기록을 유지하여야 한다.  | 베이스라인 (사용 전) | - 상담 및 지지요법, 약물 치료 등을 실행한다.  | - 디지털치료기기에 대한 사용자 반응 평가를 함께 수행한다.  | 소프트 | 제조자는 | 내·외부의 | 모든 | 입력에 | 대한 | 조치를 고려하여야 한다. ",
        "original_sentence": "| 관한 기록을 유지하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_144",
      "text": "| 베이스라인 (사용 전) | - 상담 및 지지요법, 약물 치료 등을 실행한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 143,
        "window_size": 3,
        "char_count": 45,
        "word_count": 13,
        "page_number": 15,
        "window_text": "| 웨어 밸리데이션 가이드라인(민원인 안내서)’에 따라 수행한다.  | 물리적 제한, 인증이 필요 없는 물리적 | * 독립형 소프트웨어 제품은 소프트웨어 명칭, 버전, 운영환경 기재 | needs, risks and controls | Medical devices | 의료기기 위험관리(Risk | 유효성 |\n| 3) 사이버보안 위험관리 | al., 2017) | 사) 병용약물 조사 | 문제점을 적극적으로 대응한다.  | 관한 기록을 유지하여야 한다.  | 베이스라인 (사용 전) | - 상담 및 지지요법, 약물 치료 등을 실행한다.  | - 디지털치료기기에 대한 사용자 반응 평가를 함께 수행한다.  | 소프트 | 제조자는 | 내·외부의 | 모든 | 입력에 | 대한 | 조치를 고려하여야 한다.  | 생각연습 등의 컨텐츠가 담긴 인지행동치료로 진행된다. ",
        "original_sentence": "| 베이스라인 (사용 전) | - 상담 및 지지요법, 약물 치료 등을 실행한다. "
      }
    },
    {
      "chunk_id": "chunk_145",
      "text": "| - 디지털치료기기에 대한 사용자 반응 평가를 함께 수행한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 144,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 15,
        "window_text": "| 물리적 제한, 인증이 필요 없는 물리적 | * 독립형 소프트웨어 제품은 소프트웨어 명칭, 버전, 운영환경 기재 | needs, risks and controls | Medical devices | 의료기기 위험관리(Risk | 유효성 |\n| 3) 사이버보안 위험관리 | al., 2017) | 사) 병용약물 조사 | 문제점을 적극적으로 대응한다.  | 관한 기록을 유지하여야 한다.  | 베이스라인 (사용 전) | - 상담 및 지지요법, 약물 치료 등을 실행한다.  | - 디지털치료기기에 대한 사용자 반응 평가를 함께 수행한다.  | 소프트 | 제조자는 | 내·외부의 | 모든 | 입력에 | 대한 | 조치를 고려하여야 한다.  | 생각연습 등의 컨텐츠가 담긴 인지행동치료로 진행된다.  | 제시할 수 있다. ",
        "original_sentence": "| - 디지털치료기기에 대한 사용자 반응 평가를 함께 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_146",
      "text": "| 소프트 | 제조자는 | 내·외부의 | 모든 | 입력에 | 대한 | 조치를 고려하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 145,
        "window_size": 3,
        "char_count": 53,
        "word_count": 16,
        "page_number": 30,
        "window_text": "| 관한 기록을 유지하여야 한다.  | 베이스라인 (사용 전) | - 상담 및 지지요법, 약물 치료 등을 실행한다.  | - 디지털치료기기에 대한 사용자 반응 평가를 함께 수행한다.  | 소프트 | 제조자는 | 내·외부의 | 모든 | 입력에 | 대한 | 조치를 고려하여야 한다.  | 생각연습 등의 컨텐츠가 담긴 인지행동치료로 진행된다.  | 제시할 수 있다.  | 타당한 경우 | Information for Healthcare | 단되는 경우 | 인증 기능 | 한다. ",
        "original_sentence": "| 소프트 | 제조자는 | 내·외부의 | 모든 | 입력에 | 대한 | 조치를 고려하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_147",
      "text": "| 생각연습 등의 컨텐츠가 담긴 인지행동치료로 진행된다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 146,
        "window_size": 3,
        "char_count": 32,
        "word_count": 7,
        "page_number": 30,
        "window_text": "| 베이스라인 (사용 전) | - 상담 및 지지요법, 약물 치료 등을 실행한다.  | - 디지털치료기기에 대한 사용자 반응 평가를 함께 수행한다.  | 소프트 | 제조자는 | 내·외부의 | 모든 | 입력에 | 대한 | 조치를 고려하여야 한다.  | 생각연습 등의 컨텐츠가 담긴 인지행동치료로 진행된다.  | 제시할 수 있다.  | 타당한 경우 | Information for Healthcare | 단되는 경우 | 인증 기능 | 한다.  | 웨어 구조로 설명하며 소프트 | 확인 자료 | 없음 |\n| risk of cardiovascular disease and mortality among women. ",
        "original_sentence": "| 생각연습 등의 컨텐츠가 담긴 인지행동치료로 진행된다. "
      }
    },
    {
      "chunk_id": "chunk_148",
      "text": "| 제시할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 147,
        "window_size": 3,
        "char_count": 12,
        "word_count": 4,
        "page_number": 12,
        "window_text": "| - 디지털치료기기에 대한 사용자 반응 평가를 함께 수행한다.  | 소프트 | 제조자는 | 내·외부의 | 모든 | 입력에 | 대한 | 조치를 고려하여야 한다.  | 생각연습 등의 컨텐츠가 담긴 인지행동치료로 진행된다.  | 제시할 수 있다.  | 타당한 경우 | Information for Healthcare | 단되는 경우 | 인증 기능 | 한다.  | 웨어 구조로 설명하며 소프트 | 확인 자료 | 없음 |\n| risk of cardiovascular disease and mortality among women.  JAMA Psychiatry, 77(1), 44–51. ",
        "original_sentence": "| 제시할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_149",
      "text": "| 타당한 경우 | Information for Healthcare | 단되는 경우 | 인증 기능 | 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 148,
        "window_size": 3,
        "char_count": 61,
        "word_count": 15,
        "page_number": 28,
        "window_text": "| 소프트 | 제조자는 | 내·외부의 | 모든 | 입력에 | 대한 | 조치를 고려하여야 한다.  | 생각연습 등의 컨텐츠가 담긴 인지행동치료로 진행된다.  | 제시할 수 있다.  | 타당한 경우 | Information for Healthcare | 단되는 경우 | 인증 기능 | 한다.  | 웨어 구조로 설명하며 소프트 | 확인 자료 | 없음 |\n| risk of cardiovascular disease and mortality among women.  JAMA Psychiatry, 77(1), 44–51.  | Eating Disorders FOURTH EDITION, American Psychiatric Association, APA, 2023. ",
        "original_sentence": "| 타당한 경우 | Information for Healthcare | 단되는 경우 | 인증 기능 | 한다. "
      }
    },
    {
      "chunk_id": "chunk_150",
      "text": "| 웨어 구조로 설명하며 소프트 | 확인 자료 | 없음 |\n| risk of cardiovascular disease and mortality among women. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 149,
        "window_size": 3,
        "char_count": 93,
        "word_count": 20,
        "page_number": 28,
        "window_text": "| 생각연습 등의 컨텐츠가 담긴 인지행동치료로 진행된다.  | 제시할 수 있다.  | 타당한 경우 | Information for Healthcare | 단되는 경우 | 인증 기능 | 한다.  | 웨어 구조로 설명하며 소프트 | 확인 자료 | 없음 |\n| risk of cardiovascular disease and mortality among women.  JAMA Psychiatry, 77(1), 44–51.  | Eating Disorders FOURTH EDITION, American Psychiatric Association, APA, 2023.  | research tool in clinical practice. ",
        "original_sentence": "| 웨어 구조로 설명하며 소프트 | 확인 자료 | 없음 |\n| risk of cardiovascular disease and mortality among women. "
      }
    },
    {
      "chunk_id": "chunk_151",
      "text": "JAMA Psychiatry, 77(1), 44–51. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 150,
        "window_size": 3,
        "char_count": 31,
        "word_count": 4,
        "page_number": 19,
        "window_text": "| 제시할 수 있다.  | 타당한 경우 | Information for Healthcare | 단되는 경우 | 인증 기능 | 한다.  | 웨어 구조로 설명하며 소프트 | 확인 자료 | 없음 |\n| risk of cardiovascular disease and mortality among women.  JAMA Psychiatry, 77(1), 44–51.  | Eating Disorders FOURTH EDITION, American Psychiatric Association, APA, 2023.  | research tool in clinical practice.  Psychiatry, 4(7), 28-37. ",
        "original_sentence": "JAMA Psychiatry, 77(1), 44–51. "
      }
    },
    {
      "chunk_id": "chunk_152",
      "text": "| Eating Disorders FOURTH EDITION, American Psychiatric Association, APA, 2023. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 151,
        "window_size": 3,
        "char_count": 80,
        "word_count": 10,
        "page_number": 18,
        "window_text": "| 타당한 경우 | Information for Healthcare | 단되는 경우 | 인증 기능 | 한다.  | 웨어 구조로 설명하며 소프트 | 확인 자료 | 없음 |\n| risk of cardiovascular disease and mortality among women.  JAMA Psychiatry, 77(1), 44–51.  | Eating Disorders FOURTH EDITION, American Psychiatric Association, APA, 2023.  | research tool in clinical practice.  Psychiatry, 4(7), 28-37.  | ‘OOOOO’ 경고푸시 알림이 | 오송보건의료행정타운 | 해당 알림이 발생하는 조건을 정하고, |\n| 3) 임상시험 수행 기간: 00개월 | 열람할 수 있다. ",
        "original_sentence": "| Eating Disorders FOURTH EDITION, American Psychiatric Association, APA, 2023. "
      }
    },
    {
      "chunk_id": "chunk_153",
      "text": "| research tool in clinical practice. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 152,
        "window_size": 3,
        "char_count": 38,
        "word_count": 6,
        "page_number": 62,
        "window_text": "| 웨어 구조로 설명하며 소프트 | 확인 자료 | 없음 |\n| risk of cardiovascular disease and mortality among women.  JAMA Psychiatry, 77(1), 44–51.  | Eating Disorders FOURTH EDITION, American Psychiatric Association, APA, 2023.  | research tool in clinical practice.  Psychiatry, 4(7), 28-37.  | ‘OOOOO’ 경고푸시 알림이 | 오송보건의료행정타운 | 해당 알림이 발생하는 조건을 정하고, |\n| 3) 임상시험 수행 기간: 00개월 | 열람할 수 있다.  | 임상시험계획서 작성 가이드라인(민원인 안내서) | 소프트웨어 | (선택) |\n| (3) 「의료기기법」 제10조 (임상시험계획의 승인 등) | 3 | 경고 메시지 | 2 | ISO 14971 | 대비 4주, 8주 시점의 | 케이블의 접근제한 등 | – Application of risk | 증상이 심각하다는 것을 의미한다. ",
        "original_sentence": "| research tool in clinical practice. "
      }
    },
    {
      "chunk_id": "chunk_154",
      "text": "Psychiatry, 4(7), 28-37. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 153,
        "window_size": 3,
        "char_count": 25,
        "word_count": 3,
        "page_number": 9,
        "window_text": "JAMA Psychiatry, 77(1), 44–51.  | Eating Disorders FOURTH EDITION, American Psychiatric Association, APA, 2023.  | research tool in clinical practice.  Psychiatry, 4(7), 28-37.  | ‘OOOOO’ 경고푸시 알림이 | 오송보건의료행정타운 | 해당 알림이 발생하는 조건을 정하고, |\n| 3) 임상시험 수행 기간: 00개월 | 열람할 수 있다.  | 임상시험계획서 작성 가이드라인(민원인 안내서) | 소프트웨어 | (선택) |\n| (3) 「의료기기법」 제10조 (임상시험계획의 승인 등) | 3 | 경고 메시지 | 2 | ISO 14971 | 대비 4주, 8주 시점의 | 케이블의 접근제한 등 | – Application of risk | 증상이 심각하다는 것을 의미한다.  | Management)에 대한 국제 | 확인 자료 | 국외 |\n| 웨어 | 유효성을 확인하는 설계 특성을 고려하여야 | 제조자는 기기의 사용이 입증된 사용자이거나, | Organizations about FDA’S | - 일부는 가족치료(Family-Based Treatment, FBT)를 받기도 한다. ",
        "original_sentence": "Psychiatry, 4(7), 28-37. "
      }
    },
    {
      "chunk_id": "chunk_155",
      "text": "| ‘OOOOO’ 경고푸시 알림이 | 오송보건의료행정타운 | 해당 알림이 발생하는 조건을 정하고, |\n| 3) 임상시험 수행 기간: 00개월 | 열람할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 154,
        "window_size": 3,
        "char_count": 91,
        "word_count": 23,
        "page_number": 34,
        "window_text": "| Eating Disorders FOURTH EDITION, American Psychiatric Association, APA, 2023.  | research tool in clinical practice.  Psychiatry, 4(7), 28-37.  | ‘OOOOO’ 경고푸시 알림이 | 오송보건의료행정타운 | 해당 알림이 발생하는 조건을 정하고, |\n| 3) 임상시험 수행 기간: 00개월 | 열람할 수 있다.  | 임상시험계획서 작성 가이드라인(민원인 안내서) | 소프트웨어 | (선택) |\n| (3) 「의료기기법」 제10조 (임상시험계획의 승인 등) | 3 | 경고 메시지 | 2 | ISO 14971 | 대비 4주, 8주 시점의 | 케이블의 접근제한 등 | – Application of risk | 증상이 심각하다는 것을 의미한다.  | Management)에 대한 국제 | 확인 자료 | 국외 |\n| 웨어 | 유효성을 확인하는 설계 특성을 고려하여야 | 제조자는 기기의 사용이 입증된 사용자이거나, | Organizations about FDA’S | - 일부는 가족치료(Family-Based Treatment, FBT)를 받기도 한다.  | 구현 확인 | 스크리닝 및 | 발생할 것 | 웨어 항목(item)을 식별하는 아키 | 소프트웨어의 출시 후에 발생 | 실제 제품에 구현시킨다. ",
        "original_sentence": "| ‘OOOOO’ 경고푸시 알림이 | 오송보건의료행정타운 | 해당 알림이 발생하는 조건을 정하고, |\n| 3) 임상시험 수행 기간: 00개월 | 열람할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_156",
      "text": "| 임상시험계획서 작성 가이드라인(민원인 안내서) | 소프트웨어 | (선택) |\n| (3) 「의료기기법」 제10조 (임상시험계획의 승인 등) | 3 | 경고 메시지 | 2 | ISO 14971 | 대비 4주, 8주 시점의 | 케이블의 접근제한 등 | – Application of risk | 증상이 심각하다는 것을 의미한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 155,
        "window_size": 3,
        "char_count": 183,
        "word_count": 46,
        "page_number": 3,
        "window_text": "| research tool in clinical practice.  Psychiatry, 4(7), 28-37.  | ‘OOOOO’ 경고푸시 알림이 | 오송보건의료행정타운 | 해당 알림이 발생하는 조건을 정하고, |\n| 3) 임상시험 수행 기간: 00개월 | 열람할 수 있다.  | 임상시험계획서 작성 가이드라인(민원인 안내서) | 소프트웨어 | (선택) |\n| (3) 「의료기기법」 제10조 (임상시험계획의 승인 등) | 3 | 경고 메시지 | 2 | ISO 14971 | 대비 4주, 8주 시점의 | 케이블의 접근제한 등 | – Application of risk | 증상이 심각하다는 것을 의미한다.  | Management)에 대한 국제 | 확인 자료 | 국외 |\n| 웨어 | 유효성을 확인하는 설계 특성을 고려하여야 | 제조자는 기기의 사용이 입증된 사용자이거나, | Organizations about FDA’S | - 일부는 가족치료(Family-Based Treatment, FBT)를 받기도 한다.  | 구현 확인 | 스크리닝 및 | 발생할 것 | 웨어 항목(item)을 식별하는 아키 | 소프트웨어의 출시 후에 발생 | 실제 제품에 구현시킨다.  | 치료 기간 종료 | 1주 후(8주+1주) | (Post-treatment)3)3)3) |\n| 2) 소프트웨어 개발 및 위험 관리 | 2) 임상시험의 목적 | 8) 임산부 또는 임상시험 기간 동안 임신 계획이 있는 자 | - 모양 및 구조: (임상시험용 의료기기의 모양 및 구조 기술) | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | (EDE-Q) 변화에 대한 비열등성 확인 | 식품의약품안전처 식품의약품안전평가원 | 치료 시작일 | 치료 기간 종료 | □ 예 | ■ 아니오 |\n| 2) Clinical Impairment Assessment (CIA) | 7) 민감도분석 | 대비 8주 시점의 BMI 변화를 통해 평가할 수 있다. ",
        "original_sentence": "| 임상시험계획서 작성 가이드라인(민원인 안내서) | 소프트웨어 | (선택) |\n| (3) 「의료기기법」 제10조 (임상시험계획의 승인 등) | 3 | 경고 메시지 | 2 | ISO 14971 | 대비 4주, 8주 시점의 | 케이블의 접근제한 등 | – Application of risk | 증상이 심각하다는 것을 의미한다. "
      }
    },
    {
      "chunk_id": "chunk_157",
      "text": "| Management)에 대한 국제 | 확인 자료 | 국외 |\n| 웨어 | 유효성을 확인하는 설계 특성을 고려하여야 | 제조자는 기기의 사용이 입증된 사용자이거나, | Organizations about FDA’S | - 일부는 가족치료(Family-Based Treatment, FBT)를 받기도 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 156,
        "window_size": 3,
        "char_count": 172,
        "word_count": 36,
        "page_number": 18,
        "window_text": "Psychiatry, 4(7), 28-37.  | ‘OOOOO’ 경고푸시 알림이 | 오송보건의료행정타운 | 해당 알림이 발생하는 조건을 정하고, |\n| 3) 임상시험 수행 기간: 00개월 | 열람할 수 있다.  | 임상시험계획서 작성 가이드라인(민원인 안내서) | 소프트웨어 | (선택) |\n| (3) 「의료기기법」 제10조 (임상시험계획의 승인 등) | 3 | 경고 메시지 | 2 | ISO 14971 | 대비 4주, 8주 시점의 | 케이블의 접근제한 등 | – Application of risk | 증상이 심각하다는 것을 의미한다.  | Management)에 대한 국제 | 확인 자료 | 국외 |\n| 웨어 | 유효성을 확인하는 설계 특성을 고려하여야 | 제조자는 기기의 사용이 입증된 사용자이거나, | Organizations about FDA’S | - 일부는 가족치료(Family-Based Treatment, FBT)를 받기도 한다.  | 구현 확인 | 스크리닝 및 | 발생할 것 | 웨어 항목(item)을 식별하는 아키 | 소프트웨어의 출시 후에 발생 | 실제 제품에 구현시킨다.  | 치료 기간 종료 | 1주 후(8주+1주) | (Post-treatment)3)3)3) |\n| 2) 소프트웨어 개발 및 위험 관리 | 2) 임상시험의 목적 | 8) 임산부 또는 임상시험 기간 동안 임신 계획이 있는 자 | - 모양 및 구조: (임상시험용 의료기기의 모양 및 구조 기술) | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | (EDE-Q) 변화에 대한 비열등성 확인 | 식품의약품안전처 식품의약품안전평가원 | 치료 시작일 | 치료 기간 종료 | □ 예 | ■ 아니오 |\n| 2) Clinical Impairment Assessment (CIA) | 7) 민감도분석 | 대비 8주 시점의 BMI 변화를 통해 평가할 수 있다.  | 나) 이상 반응 확인 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. ",
        "original_sentence": "| Management)에 대한 국제 | 확인 자료 | 국외 |\n| 웨어 | 유효성을 확인하는 설계 특성을 고려하여야 | 제조자는 기기의 사용이 입증된 사용자이거나, | Organizations about FDA’S | - 일부는 가족치료(Family-Based Treatment, FBT)를 받기도 한다. "
      }
    },
    {
      "chunk_id": "chunk_158",
      "text": "| 구현 확인 | 스크리닝 및 | 발생할 것 | 웨어 항목(item)을 식별하는 아키 | 소프트웨어의 출시 후에 발생 | 실제 제품에 구현시킨다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 157,
        "window_size": 3,
        "char_count": 82,
        "word_count": 23,
        "page_number": 7,
        "window_text": "| ‘OOOOO’ 경고푸시 알림이 | 오송보건의료행정타운 | 해당 알림이 발생하는 조건을 정하고, |\n| 3) 임상시험 수행 기간: 00개월 | 열람할 수 있다.  | 임상시험계획서 작성 가이드라인(민원인 안내서) | 소프트웨어 | (선택) |\n| (3) 「의료기기법」 제10조 (임상시험계획의 승인 등) | 3 | 경고 메시지 | 2 | ISO 14971 | 대비 4주, 8주 시점의 | 케이블의 접근제한 등 | – Application of risk | 증상이 심각하다는 것을 의미한다.  | Management)에 대한 국제 | 확인 자료 | 국외 |\n| 웨어 | 유효성을 확인하는 설계 특성을 고려하여야 | 제조자는 기기의 사용이 입증된 사용자이거나, | Organizations about FDA’S | - 일부는 가족치료(Family-Based Treatment, FBT)를 받기도 한다.  | 구현 확인 | 스크리닝 및 | 발생할 것 | 웨어 항목(item)을 식별하는 아키 | 소프트웨어의 출시 후에 발생 | 실제 제품에 구현시킨다.  | 치료 기간 종료 | 1주 후(8주+1주) | (Post-treatment)3)3)3) |\n| 2) 소프트웨어 개발 및 위험 관리 | 2) 임상시험의 목적 | 8) 임산부 또는 임상시험 기간 동안 임신 계획이 있는 자 | - 모양 및 구조: (임상시험용 의료기기의 모양 및 구조 기술) | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | (EDE-Q) 변화에 대한 비열등성 확인 | 식품의약품안전처 식품의약품안전평가원 | 치료 시작일 | 치료 기간 종료 | □ 예 | ■ 아니오 |\n| 2) Clinical Impairment Assessment (CIA) | 7) 민감도분석 | 대비 8주 시점의 BMI 변화를 통해 평가할 수 있다.  | 나) 이상 반응 확인 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 한다. ",
        "original_sentence": "| 구현 확인 | 스크리닝 및 | 발생할 것 | 웨어 항목(item)을 식별하는 아키 | 소프트웨어의 출시 후에 발생 | 실제 제품에 구현시킨다. "
      }
    },
    {
      "chunk_id": "chunk_159",
      "text": "| 치료 기간 종료 | 1주 후(8주+1주) | (Post-treatment)3)3)3) |\n| 2) 소프트웨어 개발 및 위험 관리 | 2) 임상시험의 목적 | 8) 임산부 또는 임상시험 기간 동안 임신 계획이 있는 자 | - 모양 및 구조: (임상시험용 의료기기의 모양 및 구조 기술) | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | (EDE-Q) 변화에 대한 비열등성 확인 | 식품의약품안전처 식품의약품안전평가원 | 치료 시작일 | 치료 기간 종료 | □ 예 | ■ 아니오 |\n| 2) Clinical Impairment Assessment (CIA) | 7) 민감도분석 | 대비 8주 시점의 BMI 변화를 통해 평가할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 158,
        "window_size": 3,
        "char_count": 365,
        "word_count": 96,
        "page_number": 19,
        "window_text": "| 임상시험계획서 작성 가이드라인(민원인 안내서) | 소프트웨어 | (선택) |\n| (3) 「의료기기법」 제10조 (임상시험계획의 승인 등) | 3 | 경고 메시지 | 2 | ISO 14971 | 대비 4주, 8주 시점의 | 케이블의 접근제한 등 | – Application of risk | 증상이 심각하다는 것을 의미한다.  | Management)에 대한 국제 | 확인 자료 | 국외 |\n| 웨어 | 유효성을 확인하는 설계 특성을 고려하여야 | 제조자는 기기의 사용이 입증된 사용자이거나, | Organizations about FDA’S | - 일부는 가족치료(Family-Based Treatment, FBT)를 받기도 한다.  | 구현 확인 | 스크리닝 및 | 발생할 것 | 웨어 항목(item)을 식별하는 아키 | 소프트웨어의 출시 후에 발생 | 실제 제품에 구현시킨다.  | 치료 기간 종료 | 1주 후(8주+1주) | (Post-treatment)3)3)3) |\n| 2) 소프트웨어 개발 및 위험 관리 | 2) 임상시험의 목적 | 8) 임산부 또는 임상시험 기간 동안 임신 계획이 있는 자 | - 모양 및 구조: (임상시험용 의료기기의 모양 및 구조 기술) | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | (EDE-Q) 변화에 대한 비열등성 확인 | 식품의약품안전처 식품의약품안전평가원 | 치료 시작일 | 치료 기간 종료 | □ 예 | ■ 아니오 |\n| 2) Clinical Impairment Assessment (CIA) | 7) 민감도분석 | 대비 8주 시점의 BMI 변화를 통해 평가할 수 있다.  | 나) 이상 반응 확인 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 한다.  | 위임자가 모든 선정 및 제외 기준을 검토해야 한다. ",
        "original_sentence": "| 치료 기간 종료 | 1주 후(8주+1주) | (Post-treatment)3)3)3) |\n| 2) 소프트웨어 개발 및 위험 관리 | 2) 임상시험의 목적 | 8) 임산부 또는 임상시험 기간 동안 임신 계획이 있는 자 | - 모양 및 구조: (임상시험용 의료기기의 모양 및 구조 기술) | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | (EDE-Q) 변화에 대한 비열등성 확인 | 식품의약품안전처 식품의약품안전평가원 | 치료 시작일 | 치료 기간 종료 | □ 예 | ■ 아니오 |\n| 2) Clinical Impairment Assessment (CIA) | 7) 민감도분석 | 대비 8주 시점의 BMI 변화를 통해 평가할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_160",
      "text": "| 나) 이상 반응 확인 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 159,
        "window_size": 3,
        "char_count": 51,
        "word_count": 16,
        "page_number": 15,
        "window_text": "| Management)에 대한 국제 | 확인 자료 | 국외 |\n| 웨어 | 유효성을 확인하는 설계 특성을 고려하여야 | 제조자는 기기의 사용이 입증된 사용자이거나, | Organizations about FDA’S | - 일부는 가족치료(Family-Based Treatment, FBT)를 받기도 한다.  | 구현 확인 | 스크리닝 및 | 발생할 것 | 웨어 항목(item)을 식별하는 아키 | 소프트웨어의 출시 후에 발생 | 실제 제품에 구현시킨다.  | 치료 기간 종료 | 1주 후(8주+1주) | (Post-treatment)3)3)3) |\n| 2) 소프트웨어 개발 및 위험 관리 | 2) 임상시험의 목적 | 8) 임산부 또는 임상시험 기간 동안 임신 계획이 있는 자 | - 모양 및 구조: (임상시험용 의료기기의 모양 및 구조 기술) | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | (EDE-Q) 변화에 대한 비열등성 확인 | 식품의약품안전처 식품의약품안전평가원 | 치료 시작일 | 치료 기간 종료 | □ 예 | ■ 아니오 |\n| 2) Clinical Impairment Assessment (CIA) | 7) 민감도분석 | 대비 8주 시점의 BMI 변화를 통해 평가할 수 있다.  | 나) 이상 반응 확인 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 한다.  | 위임자가 모든 선정 및 제외 기준을 검토해야 한다.  | 참여 동의를 철회하는 경우 | 심리적 장애와 연관된 구토) | management to medical devices | 검사일 | 규격 | 검증 및 |\n| ility, costs, quality of life, and family burden. ",
        "original_sentence": "| 나) 이상 반응 확인 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. "
      }
    },
    {
      "chunk_id": "chunk_161",
      "text": "| 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 160,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 15,
        "window_text": "| 구현 확인 | 스크리닝 및 | 발생할 것 | 웨어 항목(item)을 식별하는 아키 | 소프트웨어의 출시 후에 발생 | 실제 제품에 구현시킨다.  | 치료 기간 종료 | 1주 후(8주+1주) | (Post-treatment)3)3)3) |\n| 2) 소프트웨어 개발 및 위험 관리 | 2) 임상시험의 목적 | 8) 임산부 또는 임상시험 기간 동안 임신 계획이 있는 자 | - 모양 및 구조: (임상시험용 의료기기의 모양 및 구조 기술) | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | (EDE-Q) 변화에 대한 비열등성 확인 | 식품의약품안전처 식품의약품안전평가원 | 치료 시작일 | 치료 기간 종료 | □ 예 | ■ 아니오 |\n| 2) Clinical Impairment Assessment (CIA) | 7) 민감도분석 | 대비 8주 시점의 BMI 변화를 통해 평가할 수 있다.  | 나) 이상 반응 확인 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 한다.  | 위임자가 모든 선정 및 제외 기준을 검토해야 한다.  | 참여 동의를 철회하는 경우 | 심리적 장애와 연관된 구토) | management to medical devices | 검사일 | 규격 | 검증 및 |\n| ility, costs, quality of life, and family burden.  Curr Opin Psychiatry, 33(6), 521–527. ",
        "original_sentence": "| 한다. "
      }
    },
    {
      "chunk_id": "chunk_162",
      "text": "| 위임자가 모든 선정 및 제외 기준을 검토해야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 161,
        "window_size": 3,
        "char_count": 31,
        "word_count": 9,
        "page_number": 15,
        "window_text": "| 치료 기간 종료 | 1주 후(8주+1주) | (Post-treatment)3)3)3) |\n| 2) 소프트웨어 개발 및 위험 관리 | 2) 임상시험의 목적 | 8) 임산부 또는 임상시험 기간 동안 임신 계획이 있는 자 | - 모양 및 구조: (임상시험용 의료기기의 모양 및 구조 기술) | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | (EDE-Q) 변화에 대한 비열등성 확인 | 식품의약품안전처 식품의약품안전평가원 | 치료 시작일 | 치료 기간 종료 | □ 예 | ■ 아니오 |\n| 2) Clinical Impairment Assessment (CIA) | 7) 민감도분석 | 대비 8주 시점의 BMI 변화를 통해 평가할 수 있다.  | 나) 이상 반응 확인 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 한다.  | 위임자가 모든 선정 및 제외 기준을 검토해야 한다.  | 참여 동의를 철회하는 경우 | 심리적 장애와 연관된 구토) | management to medical devices | 검사일 | 규격 | 검증 및 |\n| ility, costs, quality of life, and family burden.  Curr Opin Psychiatry, 33(6), 521–527.  | 사) 이상 반응 조사 | 하기 지표 변화량 | 제조자는 의료기기가 필수 성능을 유지하기 | 하는 피드백에 적절히 대응하고 | (4) Generalized Anxiety Disorder 7-item scale (GAD-7) | (Baseline) | 소프트웨어 | 3개월 후 |\n| (4) 「의료기기법 시행규칙」 제9조 (기술문서 등의 심사) | 4) 통계처리 및 결과보고서 작성 기간: 00개월 | 2) 증례기록서의 작성 | 3 | 소프트웨어 | y for Eating Disorders First edition, Academy for eating disorders, AED, 2020. ",
        "original_sentence": "| 위임자가 모든 선정 및 제외 기준을 검토해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_163",
      "text": "| 참여 동의를 철회하는 경우 | 심리적 장애와 연관된 구토) | management to medical devices | 검사일 | 규격 | 검증 및 |\n| ility, costs, quality of life, and family burden. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 162,
        "window_size": 3,
        "char_count": 139,
        "word_count": 32,
        "page_number": 35,
        "window_text": "| 나) 이상 반응 확인 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 한다.  | 위임자가 모든 선정 및 제외 기준을 검토해야 한다.  | 참여 동의를 철회하는 경우 | 심리적 장애와 연관된 구토) | management to medical devices | 검사일 | 규격 | 검증 및 |\n| ility, costs, quality of life, and family burden.  Curr Opin Psychiatry, 33(6), 521–527.  | 사) 이상 반응 조사 | 하기 지표 변화량 | 제조자는 의료기기가 필수 성능을 유지하기 | 하는 피드백에 적절히 대응하고 | (4) Generalized Anxiety Disorder 7-item scale (GAD-7) | (Baseline) | 소프트웨어 | 3개월 후 |\n| (4) 「의료기기법 시행규칙」 제9조 (기술문서 등의 심사) | 4) 통계처리 및 결과보고서 작성 기간: 00개월 | 2) 증례기록서의 작성 | 3 | 소프트웨어 | y for Eating Disorders First edition, Academy for eating disorders, AED, 2020.  | 개발 | 범위 내에서 개발 및 유지가 되어야 한다. ",
        "original_sentence": "| 참여 동의를 철회하는 경우 | 심리적 장애와 연관된 구토) | management to medical devices | 검사일 | 규격 | 검증 및 |\n| ility, costs, quality of life, and family burden. "
      }
    },
    {
      "chunk_id": "chunk_164",
      "text": "Curr Opin Psychiatry, 33(6), 521–527. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 163,
        "window_size": 3,
        "char_count": 38,
        "word_count": 5,
        "page_number": 9,
        "window_text": "| 한다.  | 위임자가 모든 선정 및 제외 기준을 검토해야 한다.  | 참여 동의를 철회하는 경우 | 심리적 장애와 연관된 구토) | management to medical devices | 검사일 | 규격 | 검증 및 |\n| ility, costs, quality of life, and family burden.  Curr Opin Psychiatry, 33(6), 521–527.  | 사) 이상 반응 조사 | 하기 지표 변화량 | 제조자는 의료기기가 필수 성능을 유지하기 | 하는 피드백에 적절히 대응하고 | (4) Generalized Anxiety Disorder 7-item scale (GAD-7) | (Baseline) | 소프트웨어 | 3개월 후 |\n| (4) 「의료기기법 시행규칙」 제9조 (기술문서 등의 심사) | 4) 통계처리 및 결과보고서 작성 기간: 00개월 | 2) 증례기록서의 작성 | 3 | 소프트웨어 | y for Eating Disorders First edition, Academy for eating disorders, AED, 2020.  | 개발 | 범위 내에서 개발 및 유지가 되어야 한다.  | 하며, 보안이 취약한 통신(예. ",
        "original_sentence": "Curr Opin Psychiatry, 33(6), 521–527. "
      }
    },
    {
      "chunk_id": "chunk_165",
      "text": "| 사) 이상 반응 조사 | 하기 지표 변화량 | 제조자는 의료기기가 필수 성능을 유지하기 | 하는 피드백에 적절히 대응하고 | (4) Generalized Anxiety Disorder 7-item scale (GAD-7) | (Baseline) | 소프트웨어 | 3개월 후 |\n| (4) 「의료기기법 시행규칙」 제9조 (기술문서 등의 심사) | 4) 통계처리 및 결과보고서 작성 기간: 00개월 | 2) 증례기록서의 작성 | 3 | 소프트웨어 | y for Eating Disorders First edition, Academy for eating disorders, AED, 2020. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 164,
        "window_size": 3,
        "char_count": 331,
        "word_count": 73,
        "page_number": 27,
        "window_text": "| 위임자가 모든 선정 및 제외 기준을 검토해야 한다.  | 참여 동의를 철회하는 경우 | 심리적 장애와 연관된 구토) | management to medical devices | 검사일 | 규격 | 검증 및 |\n| ility, costs, quality of life, and family burden.  Curr Opin Psychiatry, 33(6), 521–527.  | 사) 이상 반응 조사 | 하기 지표 변화량 | 제조자는 의료기기가 필수 성능을 유지하기 | 하는 피드백에 적절히 대응하고 | (4) Generalized Anxiety Disorder 7-item scale (GAD-7) | (Baseline) | 소프트웨어 | 3개월 후 |\n| (4) 「의료기기법 시행규칙」 제9조 (기술문서 등의 심사) | 4) 통계처리 및 결과보고서 작성 기간: 00개월 | 2) 증례기록서의 작성 | 3 | 소프트웨어 | y for Eating Disorders First edition, Academy for eating disorders, AED, 2020.  | 개발 | 범위 내에서 개발 및 유지가 되어야 한다.  | 하며, 보안이 취약한 통신(예.  가정용 네트 | 다른 역할의 사용자에게 사용권한을 부여를 | 되었다. ",
        "original_sentence": "| 사) 이상 반응 조사 | 하기 지표 변화량 | 제조자는 의료기기가 필수 성능을 유지하기 | 하는 피드백에 적절히 대응하고 | (4) Generalized Anxiety Disorder 7-item scale (GAD-7) | (Baseline) | 소프트웨어 | 3개월 후 |\n| (4) 「의료기기법 시행규칙」 제9조 (기술문서 등의 심사) | 4) 통계처리 및 결과보고서 작성 기간: 00개월 | 2) 증례기록서의 작성 | 3 | 소프트웨어 | y for Eating Disorders First edition, Academy for eating disorders, AED, 2020. "
      }
    },
    {
      "chunk_id": "chunk_166",
      "text": "| 개발 | 범위 내에서 개발 및 유지가 되어야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 165,
        "window_size": 3,
        "char_count": 31,
        "word_count": 10,
        "page_number": 15,
        "window_text": "| 참여 동의를 철회하는 경우 | 심리적 장애와 연관된 구토) | management to medical devices | 검사일 | 규격 | 검증 및 |\n| ility, costs, quality of life, and family burden.  Curr Opin Psychiatry, 33(6), 521–527.  | 사) 이상 반응 조사 | 하기 지표 변화량 | 제조자는 의료기기가 필수 성능을 유지하기 | 하는 피드백에 적절히 대응하고 | (4) Generalized Anxiety Disorder 7-item scale (GAD-7) | (Baseline) | 소프트웨어 | 3개월 후 |\n| (4) 「의료기기법 시행규칙」 제9조 (기술문서 등의 심사) | 4) 통계처리 및 결과보고서 작성 기간: 00개월 | 2) 증례기록서의 작성 | 3 | 소프트웨어 | y for Eating Disorders First edition, Academy for eating disorders, AED, 2020.  | 개발 | 범위 내에서 개발 및 유지가 되어야 한다.  | 하며, 보안이 취약한 통신(예.  가정용 네트 | 다른 역할의 사용자에게 사용권한을 부여를 | 되었다.  | “Guidance for Industry: | 정리한 자료입니까? ",
        "original_sentence": "| 개발 | 범위 내에서 개발 및 유지가 되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_167",
      "text": "| 하며, 보안이 취약한 통신(예. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 166,
        "window_size": 3,
        "char_count": 20,
        "word_count": 5,
        "page_number": 37,
        "window_text": "Curr Opin Psychiatry, 33(6), 521–527.  | 사) 이상 반응 조사 | 하기 지표 변화량 | 제조자는 의료기기가 필수 성능을 유지하기 | 하는 피드백에 적절히 대응하고 | (4) Generalized Anxiety Disorder 7-item scale (GAD-7) | (Baseline) | 소프트웨어 | 3개월 후 |\n| (4) 「의료기기법 시행규칙」 제9조 (기술문서 등의 심사) | 4) 통계처리 및 결과보고서 작성 기간: 00개월 | 2) 증례기록서의 작성 | 3 | 소프트웨어 | y for Eating Disorders First edition, Academy for eating disorders, AED, 2020.  | 개발 | 범위 내에서 개발 및 유지가 되어야 한다.  | 하며, 보안이 취약한 통신(예.  가정용 네트 | 다른 역할의 사용자에게 사용권한을 부여를 | 되었다.  | “Guidance for Industry: | 정리한 자료입니까?  | (Screening)1) | 텍처로 | 변환한다. ",
        "original_sentence": "| 하며, 보안이 취약한 통신(예. "
      }
    },
    {
      "chunk_id": "chunk_168",
      "text": "가정용 네트 | 다른 역할의 사용자에게 사용권한을 부여를 | 되었다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 167,
        "window_size": 3,
        "char_count": 39,
        "word_count": 10,
        "page_number": 38,
        "window_text": "| 사) 이상 반응 조사 | 하기 지표 변화량 | 제조자는 의료기기가 필수 성능을 유지하기 | 하는 피드백에 적절히 대응하고 | (4) Generalized Anxiety Disorder 7-item scale (GAD-7) | (Baseline) | 소프트웨어 | 3개월 후 |\n| (4) 「의료기기법 시행규칙」 제9조 (기술문서 등의 심사) | 4) 통계처리 및 결과보고서 작성 기간: 00개월 | 2) 증례기록서의 작성 | 3 | 소프트웨어 | y for Eating Disorders First edition, Academy for eating disorders, AED, 2020.  | 개발 | 범위 내에서 개발 및 유지가 되어야 한다.  | 하며, 보안이 취약한 통신(예.  가정용 네트 | 다른 역할의 사용자에게 사용권한을 부여를 | 되었다.  | “Guidance for Industry: | 정리한 자료입니까?  | (Screening)1) | 텍처로 | 변환한다.  | 소프트웨어 | 네트워크를 | 활용하는 | 의료기기의 | 하고 총 90일간 사용 가능하다. ",
        "original_sentence": "가정용 네트 | 다른 역할의 사용자에게 사용권한을 부여를 | 되었다. "
      }
    },
    {
      "chunk_id": "chunk_169",
      "text": "| “Guidance for Industry: | 정리한 자료입니까? ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 168,
        "window_size": 3,
        "char_count": 39,
        "word_count": 7,
        "page_number": 3,
        "window_text": "| 개발 | 범위 내에서 개발 및 유지가 되어야 한다.  | 하며, 보안이 취약한 통신(예.  가정용 네트 | 다른 역할의 사용자에게 사용권한을 부여를 | 되었다.  | “Guidance for Industry: | 정리한 자료입니까?  | (Screening)1) | 텍처로 | 변환한다.  | 소프트웨어 | 네트워크를 | 활용하는 | 의료기기의 | 하고 총 90일간 사용 가능하다.  | 적용 |\n| [예시] | 나) 대조기기: 표준치료 | 나) 이상 반응 확인 | IWRS)을 통해서 시험군 혹은 대조군으로 1:1 배정한다. ",
        "original_sentence": "| “Guidance for Industry: | 정리한 자료입니까? "
      }
    },
    {
      "chunk_id": "chunk_170",
      "text": "| (Screening)1) | 텍처로 | 변환한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 169,
        "window_size": 3,
        "char_count": 30,
        "word_count": 6,
        "page_number": 15,
        "window_text": "| 하며, 보안이 취약한 통신(예.  가정용 네트 | 다른 역할의 사용자에게 사용권한을 부여를 | 되었다.  | “Guidance for Industry: | 정리한 자료입니까?  | (Screening)1) | 텍처로 | 변환한다.  | 소프트웨어 | 네트워크를 | 활용하는 | 의료기기의 | 하고 총 90일간 사용 가능하다.  | 적용 |\n| [예시] | 나) 대조기기: 표준치료 | 나) 이상 반응 확인 | IWRS)을 통해서 시험군 혹은 대조군으로 1:1 배정한다.  | 소프트웨어 | 유효성 | (Follow up)4) | 4) | 4) | (AB-1234) |\n| 1) 중지 기준 | 7 | 폭식 장애 | (출처: Selfapy, | 의료기기심사부 첨단의료기기과 | 사이버보안에 대한 정보 가이드라인 | 미국 | 네트워크 API를 통해 데이터 |\n| 8 | 전자파 적합성 인증을 통과한 제품을 사용해야 한다. ",
        "original_sentence": "| (Screening)1) | 텍처로 | 변환한다. "
      }
    },
    {
      "chunk_id": "chunk_171",
      "text": "| 소프트웨어 | 네트워크를 | 활용하는 | 의료기기의 | 하고 총 90일간 사용 가능하다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 170,
        "window_size": 3,
        "char_count": 52,
        "word_count": 14,
        "page_number": 9,
        "window_text": "가정용 네트 | 다른 역할의 사용자에게 사용권한을 부여를 | 되었다.  | “Guidance for Industry: | 정리한 자료입니까?  | (Screening)1) | 텍처로 | 변환한다.  | 소프트웨어 | 네트워크를 | 활용하는 | 의료기기의 | 하고 총 90일간 사용 가능하다.  | 적용 |\n| [예시] | 나) 대조기기: 표준치료 | 나) 이상 반응 확인 | IWRS)을 통해서 시험군 혹은 대조군으로 1:1 배정한다.  | 소프트웨어 | 유효성 | (Follow up)4) | 4) | 4) | (AB-1234) |\n| 1) 중지 기준 | 7 | 폭식 장애 | (출처: Selfapy, | 의료기기심사부 첨단의료기기과 | 사이버보안에 대한 정보 가이드라인 | 미국 | 네트워크 API를 통해 데이터 |\n| 8 | 전자파 적합성 인증을 통과한 제품을 사용해야 한다.  | 회사명 | 대표이사 | 소재지 | 전화 | 9) 스크리닝 전 4주 이내에 다른 임상시험에 참여한 자 | [F50.8] Other eating disorders (기타 식사장애) | - 성능: (임상시험용 의료기기의 성능 기술) | (2) 이차 유효성 평가지표 | 워크 혹은 기존 기기)만을 지원하는 기기 및 | 허용하거나, 응급상황에서 접근을 허용하는 | 위해 사이버보안 공격을 탐지, 저항, 대응 | 한다. ",
        "original_sentence": "| 소프트웨어 | 네트워크를 | 활용하는 | 의료기기의 | 하고 총 90일간 사용 가능하다. "
      }
    },
    {
      "chunk_id": "chunk_172",
      "text": "| 적용 |\n| [예시] | 나) 대조기기: 표준치료 | 나) 이상 반응 확인 | IWRS)을 통해서 시험군 혹은 대조군으로 1:1 배정한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 171,
        "window_size": 3,
        "char_count": 80,
        "word_count": 22,
        "page_number": 28,
        "window_text": "| “Guidance for Industry: | 정리한 자료입니까?  | (Screening)1) | 텍처로 | 변환한다.  | 소프트웨어 | 네트워크를 | 활용하는 | 의료기기의 | 하고 총 90일간 사용 가능하다.  | 적용 |\n| [예시] | 나) 대조기기: 표준치료 | 나) 이상 반응 확인 | IWRS)을 통해서 시험군 혹은 대조군으로 1:1 배정한다.  | 소프트웨어 | 유효성 | (Follow up)4) | 4) | 4) | (AB-1234) |\n| 1) 중지 기준 | 7 | 폭식 장애 | (출처: Selfapy, | 의료기기심사부 첨단의료기기과 | 사이버보안에 대한 정보 가이드라인 | 미국 | 네트워크 API를 통해 데이터 |\n| 8 | 전자파 적합성 인증을 통과한 제품을 사용해야 한다.  | 회사명 | 대표이사 | 소재지 | 전화 | 9) 스크리닝 전 4주 이내에 다른 임상시험에 참여한 자 | [F50.8] Other eating disorders (기타 식사장애) | - 성능: (임상시험용 의료기기의 성능 기술) | (2) 이차 유효성 평가지표 | 워크 혹은 기존 기기)만을 지원하는 기기 및 | 허용하거나, 응급상황에서 접근을 허용하는 | 위해 사이버보안 공격을 탐지, 저항, 대응 | 한다.  | 소프트웨어 | 항목의 | 일관성을 | 소프트웨어 | 검증 및 |\n| 5) The EuroQol Visual Analogue Scale (EQ-VAS) | 다) 인구학적 정보 | 구분한다. ",
        "original_sentence": "| 적용 |\n| [예시] | 나) 대조기기: 표준치료 | 나) 이상 반응 확인 | IWRS)을 통해서 시험군 혹은 대조군으로 1:1 배정한다. "
      }
    },
    {
      "chunk_id": "chunk_173",
      "text": "| 소프트웨어 | 유효성 | (Follow up)4) | 4) | 4) | (AB-1234) |\n| 1) 중지 기준 | 7 | 폭식 장애 | (출처: Selfapy, | 의료기기심사부 첨단의료기기과 | 사이버보안에 대한 정보 가이드라인 | 미국 | 네트워크 API를 통해 데이터 |\n| 8 | 전자파 적합성 인증을 통과한 제품을 사용해야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 172,
        "window_size": 3,
        "char_count": 193,
        "word_count": 52,
        "page_number": 9,
        "window_text": "| (Screening)1) | 텍처로 | 변환한다.  | 소프트웨어 | 네트워크를 | 활용하는 | 의료기기의 | 하고 총 90일간 사용 가능하다.  | 적용 |\n| [예시] | 나) 대조기기: 표준치료 | 나) 이상 반응 확인 | IWRS)을 통해서 시험군 혹은 대조군으로 1:1 배정한다.  | 소프트웨어 | 유효성 | (Follow up)4) | 4) | 4) | (AB-1234) |\n| 1) 중지 기준 | 7 | 폭식 장애 | (출처: Selfapy, | 의료기기심사부 첨단의료기기과 | 사이버보안에 대한 정보 가이드라인 | 미국 | 네트워크 API를 통해 데이터 |\n| 8 | 전자파 적합성 인증을 통과한 제품을 사용해야 한다.  | 회사명 | 대표이사 | 소재지 | 전화 | 9) 스크리닝 전 4주 이내에 다른 임상시험에 참여한 자 | [F50.8] Other eating disorders (기타 식사장애) | - 성능: (임상시험용 의료기기의 성능 기술) | (2) 이차 유효성 평가지표 | 워크 혹은 기존 기기)만을 지원하는 기기 및 | 허용하거나, 응급상황에서 접근을 허용하는 | 위해 사이버보안 공격을 탐지, 저항, 대응 | 한다.  | 소프트웨어 | 항목의 | 일관성을 | 소프트웨어 | 검증 및 |\n| 5) The EuroQol Visual Analogue Scale (EQ-VAS) | 다) 인구학적 정보 | 구분한다.  | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 프로 | 하여야 한다. ",
        "original_sentence": "| 소프트웨어 | 유효성 | (Follow up)4) | 4) | 4) | (AB-1234) |\n| 1) 중지 기준 | 7 | 폭식 장애 | (출처: Selfapy, | 의료기기심사부 첨단의료기기과 | 사이버보안에 대한 정보 가이드라인 | 미국 | 네트워크 API를 통해 데이터 |\n| 8 | 전자파 적합성 인증을 통과한 제품을 사용해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_174",
      "text": "| 회사명 | 대표이사 | 소재지 | 전화 | 9) 스크리닝 전 4주 이내에 다른 임상시험에 참여한 자 | [F50.8] Other eating disorders (기타 식사장애) | - 성능: (임상시험용 의료기기의 성능 기술) | (2) 이차 유효성 평가지표 | 워크 혹은 기존 기기)만을 지원하는 기기 및 | 허용하거나, 응급상황에서 접근을 허용하는 | 위해 사이버보안 공격을 탐지, 저항, 대응 | 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 173,
        "window_size": 3,
        "char_count": 231,
        "word_count": 59,
        "page_number": 26,
        "window_text": "| 소프트웨어 | 네트워크를 | 활용하는 | 의료기기의 | 하고 총 90일간 사용 가능하다.  | 적용 |\n| [예시] | 나) 대조기기: 표준치료 | 나) 이상 반응 확인 | IWRS)을 통해서 시험군 혹은 대조군으로 1:1 배정한다.  | 소프트웨어 | 유효성 | (Follow up)4) | 4) | 4) | (AB-1234) |\n| 1) 중지 기준 | 7 | 폭식 장애 | (출처: Selfapy, | 의료기기심사부 첨단의료기기과 | 사이버보안에 대한 정보 가이드라인 | 미국 | 네트워크 API를 통해 데이터 |\n| 8 | 전자파 적합성 인증을 통과한 제품을 사용해야 한다.  | 회사명 | 대표이사 | 소재지 | 전화 | 9) 스크리닝 전 4주 이내에 다른 임상시험에 참여한 자 | [F50.8] Other eating disorders (기타 식사장애) | - 성능: (임상시험용 의료기기의 성능 기술) | (2) 이차 유효성 평가지표 | 워크 혹은 기존 기기)만을 지원하는 기기 및 | 허용하거나, 응급상황에서 접근을 허용하는 | 위해 사이버보안 공격을 탐지, 저항, 대응 | 한다.  | 소프트웨어 | 항목의 | 일관성을 | 소프트웨어 | 검증 및 |\n| 5) The EuroQol Visual Analogue Scale (EQ-VAS) | 다) 인구학적 정보 | 구분한다.  | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 프로 | 하여야 한다.  | Cybersecurity for Networked | 기반한 정보를 제공한다. ",
        "original_sentence": "| 회사명 | 대표이사 | 소재지 | 전화 | 9) 스크리닝 전 4주 이내에 다른 임상시험에 참여한 자 | [F50.8] Other eating disorders (기타 식사장애) | - 성능: (임상시험용 의료기기의 성능 기술) | (2) 이차 유효성 평가지표 | 워크 혹은 기존 기기)만을 지원하는 기기 및 | 허용하거나, 응급상황에서 접근을 허용하는 | 위해 사이버보안 공격을 탐지, 저항, 대응 | 한다. "
      }
    },
    {
      "chunk_id": "chunk_175",
      "text": "| 소프트웨어 | 항목의 | 일관성을 | 소프트웨어 | 검증 및 |\n| 5) The EuroQol Visual Analogue Scale (EQ-VAS) | 다) 인구학적 정보 | 구분한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 174,
        "window_size": 3,
        "char_count": 107,
        "word_count": 26,
        "page_number": 7,
        "window_text": "| 적용 |\n| [예시] | 나) 대조기기: 표준치료 | 나) 이상 반응 확인 | IWRS)을 통해서 시험군 혹은 대조군으로 1:1 배정한다.  | 소프트웨어 | 유효성 | (Follow up)4) | 4) | 4) | (AB-1234) |\n| 1) 중지 기준 | 7 | 폭식 장애 | (출처: Selfapy, | 의료기기심사부 첨단의료기기과 | 사이버보안에 대한 정보 가이드라인 | 미국 | 네트워크 API를 통해 데이터 |\n| 8 | 전자파 적합성 인증을 통과한 제품을 사용해야 한다.  | 회사명 | 대표이사 | 소재지 | 전화 | 9) 스크리닝 전 4주 이내에 다른 임상시험에 참여한 자 | [F50.8] Other eating disorders (기타 식사장애) | - 성능: (임상시험용 의료기기의 성능 기술) | (2) 이차 유효성 평가지표 | 워크 혹은 기존 기기)만을 지원하는 기기 및 | 허용하거나, 응급상황에서 접근을 허용하는 | 위해 사이버보안 공격을 탐지, 저항, 대응 | 한다.  | 소프트웨어 | 항목의 | 일관성을 | 소프트웨어 | 검증 및 |\n| 5) The EuroQol Visual Analogue Scale (EQ-VAS) | 다) 인구학적 정보 | 구분한다.  | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 프로 | 하여야 한다.  | Cybersecurity for Networked | 기반한 정보를 제공한다.  | 시험용 의료기기의 사용에 기인한다고 판단되는 경우 | 결과에 대한 임상적 평가를 제시한다. ",
        "original_sentence": "| 소프트웨어 | 항목의 | 일관성을 | 소프트웨어 | 검증 및 |\n| 5) The EuroQol Visual Analogue Scale (EQ-VAS) | 다) 인구학적 정보 | 구분한다. "
      }
    },
    {
      "chunk_id": "chunk_176",
      "text": "| 성명 | 소속기관명 | 전공 | 직위 | 전화 | 프로 | 하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 175,
        "window_size": 3,
        "char_count": 43,
        "word_count": 15,
        "page_number": 15,
        "window_text": "| 소프트웨어 | 유효성 | (Follow up)4) | 4) | 4) | (AB-1234) |\n| 1) 중지 기준 | 7 | 폭식 장애 | (출처: Selfapy, | 의료기기심사부 첨단의료기기과 | 사이버보안에 대한 정보 가이드라인 | 미국 | 네트워크 API를 통해 데이터 |\n| 8 | 전자파 적합성 인증을 통과한 제품을 사용해야 한다.  | 회사명 | 대표이사 | 소재지 | 전화 | 9) 스크리닝 전 4주 이내에 다른 임상시험에 참여한 자 | [F50.8] Other eating disorders (기타 식사장애) | - 성능: (임상시험용 의료기기의 성능 기술) | (2) 이차 유효성 평가지표 | 워크 혹은 기존 기기)만을 지원하는 기기 및 | 허용하거나, 응급상황에서 접근을 허용하는 | 위해 사이버보안 공격을 탐지, 저항, 대응 | 한다.  | 소프트웨어 | 항목의 | 일관성을 | 소프트웨어 | 검증 및 |\n| 5) The EuroQol Visual Analogue Scale (EQ-VAS) | 다) 인구학적 정보 | 구분한다.  | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 프로 | 하여야 한다.  | Cybersecurity for Networked | 기반한 정보를 제공한다.  | 시험용 의료기기의 사용에 기인한다고 판단되는 경우 | 결과에 대한 임상적 평가를 제시한다.  | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. ",
        "original_sentence": "| 성명 | 소속기관명 | 전공 | 직위 | 전화 | 프로 | 하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_177",
      "text": "| Cybersecurity for Networked | 기반한 정보를 제공한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 176,
        "window_size": 3,
        "char_count": 46,
        "word_count": 8,
        "page_number": 15,
        "window_text": "| 회사명 | 대표이사 | 소재지 | 전화 | 9) 스크리닝 전 4주 이내에 다른 임상시험에 참여한 자 | [F50.8] Other eating disorders (기타 식사장애) | - 성능: (임상시험용 의료기기의 성능 기술) | (2) 이차 유효성 평가지표 | 워크 혹은 기존 기기)만을 지원하는 기기 및 | 허용하거나, 응급상황에서 접근을 허용하는 | 위해 사이버보안 공격을 탐지, 저항, 대응 | 한다.  | 소프트웨어 | 항목의 | 일관성을 | 소프트웨어 | 검증 및 |\n| 5) The EuroQol Visual Analogue Scale (EQ-VAS) | 다) 인구학적 정보 | 구분한다.  | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 프로 | 하여야 한다.  | Cybersecurity for Networked | 기반한 정보를 제공한다.  | 시험용 의료기기의 사용에 기인한다고 판단되는 경우 | 결과에 대한 임상적 평가를 제시한다.  | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. ",
        "original_sentence": "| Cybersecurity for Networked | 기반한 정보를 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_178",
      "text": "| 시험용 의료기기의 사용에 기인한다고 판단되는 경우 | 결과에 대한 임상적 평가를 제시한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 177,
        "window_size": 3,
        "char_count": 53,
        "word_count": 13,
        "page_number": 27,
        "window_text": "| 소프트웨어 | 항목의 | 일관성을 | 소프트웨어 | 검증 및 |\n| 5) The EuroQol Visual Analogue Scale (EQ-VAS) | 다) 인구학적 정보 | 구분한다.  | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 프로 | 하여야 한다.  | Cybersecurity for Networked | 기반한 정보를 제공한다.  | 시험용 의료기기의 사용에 기인한다고 판단되는 경우 | 결과에 대한 임상적 평가를 제시한다.  | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 그림 3. ",
        "original_sentence": "| 시험용 의료기기의 사용에 기인한다고 판단되는 경우 | 결과에 대한 임상적 평가를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_179",
      "text": "| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 178,
        "window_size": 3,
        "char_count": 55,
        "word_count": 14,
        "page_number": 3,
        "window_text": "| 성명 | 소속기관명 | 전공 | 직위 | 전화 | 프로 | 하여야 한다.  | Cybersecurity for Networked | 기반한 정보를 제공한다.  | 시험용 의료기기의 사용에 기인한다고 판단되는 경우 | 결과에 대한 임상적 평가를 제시한다.  | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 그림 3.  소프트웨어의 안전성 평가 관련 연구의 흐름 | 아키텍처 | - 주로 인지행동치료(CBT) 또는 대인관계 치료를 수행하며, 개인 | 데이터베이스 저장했던 정보와 | 항목과 소프트웨어 항목 외부의 |\n| 보안 | eating. ",
        "original_sentence": "| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. "
      }
    },
    {
      "chunk_id": "chunk_180",
      "text": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 179,
        "window_size": 3,
        "char_count": 34,
        "word_count": 7,
        "page_number": 3,
        "window_text": "| Cybersecurity for Networked | 기반한 정보를 제공한다.  | 시험용 의료기기의 사용에 기인한다고 판단되는 경우 | 결과에 대한 임상적 평가를 제시한다.  | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 그림 3.  소프트웨어의 안전성 평가 관련 연구의 흐름 | 아키텍처 | - 주로 인지행동치료(CBT) 또는 대인관계 치료를 수행하며, 개인 | 데이터베이스 저장했던 정보와 | 항목과 소프트웨어 항목 외부의 |\n| 보안 | eating.  Journal of Korean Neuropsychiatric Association, 1072-1082. ",
        "original_sentence": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. "
      }
    },
    {
      "chunk_id": "chunk_181",
      "text": "| 그림 3. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 180,
        "window_size": 3,
        "char_count": 8,
        "word_count": 3,
        "page_number": 26,
        "window_text": "| 시험용 의료기기의 사용에 기인한다고 판단되는 경우 | 결과에 대한 임상적 평가를 제시한다.  | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 그림 3.  소프트웨어의 안전성 평가 관련 연구의 흐름 | 아키텍처 | - 주로 인지행동치료(CBT) 또는 대인관계 치료를 수행하며, 개인 | 데이터베이스 저장했던 정보와 | 항목과 소프트웨어 항목 외부의 |\n| 보안 | eating.  Journal of Korean Neuropsychiatric Association, 1072-1082.  | (5) 「의료기기법 시행규칙」 제20조 (임상시험계획의 승인 등) | 및 | 방문일 | 방문1 | 방문2 | 방문3 | 방문4 | https://www.selfapy.com/) | 형상 관리 | 적용 | 확인 자료 |\n| (Binge-Eating | 4 | 데이터베이스 | 무작위 비교 임상시험 | 라) 전체 잔여위험 허용 가능성 평가 | TEL : 043) 719-3912   FAX : 043) 719-3900 | 베이스로 미리 정해진 데이터를 송신 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 환경에서 이루어지는 통신도 고려한다. ",
        "original_sentence": "| 그림 3. "
      }
    },
    {
      "chunk_id": "chunk_182",
      "text": "소프트웨어의 안전성 평가 관련 연구의 흐름 | 아키텍처 | - 주로 인지행동치료(CBT) 또는 대인관계 치료를 수행하며, 개인 | 데이터베이스 저장했던 정보와 | 항목과 소프트웨어 항목 외부의 |\n| 보안 | eating. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 181,
        "window_size": 3,
        "char_count": 125,
        "word_count": 31,
        "page_number": 9,
        "window_text": "| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 그림 3.  소프트웨어의 안전성 평가 관련 연구의 흐름 | 아키텍처 | - 주로 인지행동치료(CBT) 또는 대인관계 치료를 수행하며, 개인 | 데이터베이스 저장했던 정보와 | 항목과 소프트웨어 항목 외부의 |\n| 보안 | eating.  Journal of Korean Neuropsychiatric Association, 1072-1082.  | (5) 「의료기기법 시행규칙」 제20조 (임상시험계획의 승인 등) | 및 | 방문일 | 방문1 | 방문2 | 방문3 | 방문4 | https://www.selfapy.com/) | 형상 관리 | 적용 | 확인 자료 |\n| (Binge-Eating | 4 | 데이터베이스 | 무작위 비교 임상시험 | 라) 전체 잔여위험 허용 가능성 평가 | TEL : 043) 719-3912   FAX : 043) 719-3900 | 베이스로 미리 정해진 데이터를 송신 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 환경에서 이루어지는 통신도 고려한다.  | 사용자 접근통제에 대해 고려하여야 한다. ",
        "original_sentence": "소프트웨어의 안전성 평가 관련 연구의 흐름 | 아키텍처 | - 주로 인지행동치료(CBT) 또는 대인관계 치료를 수행하며, 개인 | 데이터베이스 저장했던 정보와 | 항목과 소프트웨어 항목 외부의 |\n| 보안 | eating. "
      }
    },
    {
      "chunk_id": "chunk_183",
      "text": "Journal of Korean Neuropsychiatric Association, 1072-1082. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 182,
        "window_size": 3,
        "char_count": 59,
        "word_count": 6,
        "page_number": 19,
        "window_text": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 그림 3.  소프트웨어의 안전성 평가 관련 연구의 흐름 | 아키텍처 | - 주로 인지행동치료(CBT) 또는 대인관계 치료를 수행하며, 개인 | 데이터베이스 저장했던 정보와 | 항목과 소프트웨어 항목 외부의 |\n| 보안 | eating.  Journal of Korean Neuropsychiatric Association, 1072-1082.  | (5) 「의료기기법 시행규칙」 제20조 (임상시험계획의 승인 등) | 및 | 방문일 | 방문1 | 방문2 | 방문3 | 방문4 | https://www.selfapy.com/) | 형상 관리 | 적용 | 확인 자료 |\n| (Binge-Eating | 4 | 데이터베이스 | 무작위 비교 임상시험 | 라) 전체 잔여위험 허용 가능성 평가 | TEL : 043) 719-3912   FAX : 043) 719-3900 | 베이스로 미리 정해진 데이터를 송신 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 환경에서 이루어지는 통신도 고려한다.  | 사용자 접근통제에 대해 고려하여야 한다.  | 및 복구하도록 허용하는 설계 특성을 고려 | (예) 상담 및 지지요법, 약물 치료 등 | 다시 호출한 정보가 일치 | 표 1. ",
        "original_sentence": "Journal of Korean Neuropsychiatric Association, 1072-1082. "
      }
    },
    {
      "chunk_id": "chunk_184",
      "text": "| (5) 「의료기기법 시행규칙」 제20조 (임상시험계획의 승인 등) | 및 | 방문일 | 방문1 | 방문2 | 방문3 | 방문4 | https://www.selfapy.com/) | 형상 관리 | 적용 | 확인 자료 |\n| (Binge-Eating | 4 | 데이터베이스 | 무작위 비교 임상시험 | 라) 전체 잔여위험 허용 가능성 평가 | TEL : 043) 719-3912   FAX : 043) 719-3900 | 베이스로 미리 정해진 데이터를 송신 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 환경에서 이루어지는 통신도 고려한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 183,
        "window_size": 3,
        "char_count": 358,
        "word_count": 90,
        "page_number": 5,
        "window_text": "| 그림 3.  소프트웨어의 안전성 평가 관련 연구의 흐름 | 아키텍처 | - 주로 인지행동치료(CBT) 또는 대인관계 치료를 수행하며, 개인 | 데이터베이스 저장했던 정보와 | 항목과 소프트웨어 항목 외부의 |\n| 보안 | eating.  Journal of Korean Neuropsychiatric Association, 1072-1082.  | (5) 「의료기기법 시행규칙」 제20조 (임상시험계획의 승인 등) | 및 | 방문일 | 방문1 | 방문2 | 방문3 | 방문4 | https://www.selfapy.com/) | 형상 관리 | 적용 | 확인 자료 |\n| (Binge-Eating | 4 | 데이터베이스 | 무작위 비교 임상시험 | 라) 전체 잔여위험 허용 가능성 평가 | TEL : 043) 719-3912   FAX : 043) 719-3900 | 베이스로 미리 정해진 데이터를 송신 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 환경에서 이루어지는 통신도 고려한다.  | 사용자 접근통제에 대해 고려하여야 한다.  | 및 복구하도록 허용하는 설계 특성을 고려 | (예) 상담 및 지지요법, 약물 치료 등 | 다시 호출한 정보가 일치 | 표 1.  식사장애 검사(EDE-Q) 변화량 결과 | 유지하면서 설계 변경 및 소프트 | 의료기기 소프트웨어의 | 검증 및 | 유효성 | (AB-1234) |\n| 한다. ",
        "original_sentence": "| (5) 「의료기기법 시행규칙」 제20조 (임상시험계획의 승인 등) | 및 | 방문일 | 방문1 | 방문2 | 방문3 | 방문4 | https://www.selfapy.com/) | 형상 관리 | 적용 | 확인 자료 |\n| (Binge-Eating | 4 | 데이터베이스 | 무작위 비교 임상시험 | 라) 전체 잔여위험 허용 가능성 평가 | TEL : 043) 719-3912   FAX : 043) 719-3900 | 베이스로 미리 정해진 데이터를 송신 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 환경에서 이루어지는 통신도 고려한다. "
      }
    },
    {
      "chunk_id": "chunk_185",
      "text": "| 사용자 접근통제에 대해 고려하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 184,
        "window_size": 3,
        "char_count": 25,
        "word_count": 6,
        "page_number": 15,
        "window_text": "소프트웨어의 안전성 평가 관련 연구의 흐름 | 아키텍처 | - 주로 인지행동치료(CBT) 또는 대인관계 치료를 수행하며, 개인 | 데이터베이스 저장했던 정보와 | 항목과 소프트웨어 항목 외부의 |\n| 보안 | eating.  Journal of Korean Neuropsychiatric Association, 1072-1082.  | (5) 「의료기기법 시행규칙」 제20조 (임상시험계획의 승인 등) | 및 | 방문일 | 방문1 | 방문2 | 방문3 | 방문4 | https://www.selfapy.com/) | 형상 관리 | 적용 | 확인 자료 |\n| (Binge-Eating | 4 | 데이터베이스 | 무작위 비교 임상시험 | 라) 전체 잔여위험 허용 가능성 평가 | TEL : 043) 719-3912   FAX : 043) 719-3900 | 베이스로 미리 정해진 데이터를 송신 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 환경에서 이루어지는 통신도 고려한다.  | 사용자 접근통제에 대해 고려하여야 한다.  | 및 복구하도록 허용하는 설계 특성을 고려 | (예) 상담 및 지지요법, 약물 치료 등 | 다시 호출한 정보가 일치 | 표 1.  식사장애 검사(EDE-Q) 변화량 결과 | 유지하면서 설계 변경 및 소프트 | 의료기기 소프트웨어의 | 검증 및 | 유효성 | (AB-1234) |\n| 한다.  | 경과일수 | D-28 이내 | DAY1 | - | - | 세스 | Medical Devices Containing | 경우 ‘불순응’으로 판단한다. ",
        "original_sentence": "| 사용자 접근통제에 대해 고려하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_186",
      "text": "| 및 복구하도록 허용하는 설계 특성을 고려 | (예) 상담 및 지지요법, 약물 치료 등 | 다시 호출한 정보가 일치 | 표 1. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 185,
        "window_size": 3,
        "char_count": 73,
        "word_count": 23,
        "page_number": 30,
        "window_text": "Journal of Korean Neuropsychiatric Association, 1072-1082.  | (5) 「의료기기법 시행규칙」 제20조 (임상시험계획의 승인 등) | 및 | 방문일 | 방문1 | 방문2 | 방문3 | 방문4 | https://www.selfapy.com/) | 형상 관리 | 적용 | 확인 자료 |\n| (Binge-Eating | 4 | 데이터베이스 | 무작위 비교 임상시험 | 라) 전체 잔여위험 허용 가능성 평가 | TEL : 043) 719-3912   FAX : 043) 719-3900 | 베이스로 미리 정해진 데이터를 송신 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 환경에서 이루어지는 통신도 고려한다.  | 사용자 접근통제에 대해 고려하여야 한다.  | 및 복구하도록 허용하는 설계 특성을 고려 | (예) 상담 및 지지요법, 약물 치료 등 | 다시 호출한 정보가 일치 | 표 1.  식사장애 검사(EDE-Q) 변화량 결과 | 유지하면서 설계 변경 및 소프트 | 의료기기 소프트웨어의 | 검증 및 | 유효성 | (AB-1234) |\n| 한다.  | 경과일수 | D-28 이내 | DAY1 | - | - | 세스 | Medical Devices Containing | 경우 ‘불순응’으로 판단한다.  | 또는 그룹으로 진행된다. ",
        "original_sentence": "| 및 복구하도록 허용하는 설계 특성을 고려 | (예) 상담 및 지지요법, 약물 치료 등 | 다시 호출한 정보가 일치 | 표 1. "
      }
    },
    {
      "chunk_id": "chunk_187",
      "text": "식사장애 검사(EDE-Q) 변화량 결과 | 유지하면서 설계 변경 및 소프트 | 의료기기 소프트웨어의 | 검증 및 | 유효성 | (AB-1234) |\n| 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 186,
        "window_size": 3,
        "char_count": 89,
        "word_count": 23,
        "page_number": 27,
        "window_text": "| (5) 「의료기기법 시행규칙」 제20조 (임상시험계획의 승인 등) | 및 | 방문일 | 방문1 | 방문2 | 방문3 | 방문4 | https://www.selfapy.com/) | 형상 관리 | 적용 | 확인 자료 |\n| (Binge-Eating | 4 | 데이터베이스 | 무작위 비교 임상시험 | 라) 전체 잔여위험 허용 가능성 평가 | TEL : 043) 719-3912   FAX : 043) 719-3900 | 베이스로 미리 정해진 데이터를 송신 |\n| ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 환경에서 이루어지는 통신도 고려한다.  | 사용자 접근통제에 대해 고려하여야 한다.  | 및 복구하도록 허용하는 설계 특성을 고려 | (예) 상담 및 지지요법, 약물 치료 등 | 다시 호출한 정보가 일치 | 표 1.  식사장애 검사(EDE-Q) 변화량 결과 | 유지하면서 설계 변경 및 소프트 | 의료기기 소프트웨어의 | 검증 및 | 유효성 | (AB-1234) |\n| 한다.  | 경과일수 | D-28 이내 | DAY1 | - | - | 세스 | Medical Devices Containing | 경우 ‘불순응’으로 판단한다.  | 또는 그룹으로 진행된다.  | 구성요소 간의 연계성과 소프트 | 구조를 갖추어 설계한다. ",
        "original_sentence": "식사장애 검사(EDE-Q) 변화량 결과 | 유지하면서 설계 변경 및 소프트 | 의료기기 소프트웨어의 | 검증 및 | 유효성 | (AB-1234) |\n| 한다. "
      }
    },
    {
      "chunk_id": "chunk_188",
      "text": "| 경과일수 | D-28 이내 | DAY1 | - | - | 세스 | Medical Devices Containing | 경우 ‘불순응’으로 판단한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 187,
        "window_size": 3,
        "char_count": 85,
        "word_count": 21,
        "page_number": 9,
        "window_text": "| 사용자 접근통제에 대해 고려하여야 한다.  | 및 복구하도록 허용하는 설계 특성을 고려 | (예) 상담 및 지지요법, 약물 치료 등 | 다시 호출한 정보가 일치 | 표 1.  식사장애 검사(EDE-Q) 변화량 결과 | 유지하면서 설계 변경 및 소프트 | 의료기기 소프트웨어의 | 검증 및 | 유효성 | (AB-1234) |\n| 한다.  | 경과일수 | D-28 이내 | DAY1 | - | - | 세스 | Medical Devices Containing | 경우 ‘불순응’으로 판단한다.  | 또는 그룹으로 진행된다.  | 구성요소 간의 연계성과 소프트 | 구조를 갖추어 설계한다.  |\n| 통신 | ioral Treatment Program for Binge-Eating Disorder. ",
        "original_sentence": "| 경과일수 | D-28 이내 | DAY1 | - | - | 세스 | Medical Devices Containing | 경우 ‘불순응’으로 판단한다. "
      }
    },
    {
      "chunk_id": "chunk_189",
      "text": "| 또는 그룹으로 진행된다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 188,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 15,
        "window_text": "| 및 복구하도록 허용하는 설계 특성을 고려 | (예) 상담 및 지지요법, 약물 치료 등 | 다시 호출한 정보가 일치 | 표 1.  식사장애 검사(EDE-Q) 변화량 결과 | 유지하면서 설계 변경 및 소프트 | 의료기기 소프트웨어의 | 검증 및 | 유효성 | (AB-1234) |\n| 한다.  | 경과일수 | D-28 이내 | DAY1 | - | - | 세스 | Medical Devices Containing | 경우 ‘불순응’으로 판단한다.  | 또는 그룹으로 진행된다.  | 구성요소 간의 연계성과 소프트 | 구조를 갖추어 설계한다.  |\n| 통신 | ioral Treatment Program for Binge-Eating Disorder.  Behavior Therapy, 47(4). ",
        "original_sentence": "| 또는 그룹으로 진행된다. "
      }
    },
    {
      "chunk_id": "chunk_190",
      "text": "| 구성요소 간의 연계성과 소프트 | 구조를 갖추어 설계한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 189,
        "window_size": 3,
        "char_count": 35,
        "word_count": 9,
        "page_number": 15,
        "window_text": "식사장애 검사(EDE-Q) 변화량 결과 | 유지하면서 설계 변경 및 소프트 | 의료기기 소프트웨어의 | 검증 및 | 유효성 | (AB-1234) |\n| 한다.  | 경과일수 | D-28 이내 | DAY1 | - | - | 세스 | Medical Devices Containing | 경우 ‘불순응’으로 판단한다.  | 또는 그룹으로 진행된다.  | 구성요소 간의 연계성과 소프트 | 구조를 갖추어 설계한다.  |\n| 통신 | ioral Treatment Program for Binge-Eating Disorder.  Behavior Therapy, 47(4).  | 나) 대조기기 | 10) 알코올 또는 약물 남용의 과거력이 있는 자 | [F50.9] Eating disorder, unspecified (상세불명의 식사장애) | 무작위배정 될 확률 | 송수신 | 및 저장한 후, 해당 데이터를 다시 | 적용 |\n| (6) 「의료기기법 시행규칙」 제24조 (임상시험 실시기준 등) | 디지털치료기기 관련 국내외 가이드라인은 <표 8>과 같다. ",
        "original_sentence": "| 구성요소 간의 연계성과 소프트 | 구조를 갖추어 설계한다. "
      }
    },
    {
      "chunk_id": "chunk_191",
      "text": "|\n| 통신 | ioral Treatment Program for Binge-Eating Disorder. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 190,
        "window_size": 3,
        "char_count": 60,
        "word_count": 10,
        "page_number": 37,
        "window_text": "| 경과일수 | D-28 이내 | DAY1 | - | - | 세스 | Medical Devices Containing | 경우 ‘불순응’으로 판단한다.  | 또는 그룹으로 진행된다.  | 구성요소 간의 연계성과 소프트 | 구조를 갖추어 설계한다.  |\n| 통신 | ioral Treatment Program for Binge-Eating Disorder.  Behavior Therapy, 47(4).  | 나) 대조기기 | 10) 알코올 또는 약물 남용의 과거력이 있는 자 | [F50.9] Eating disorder, unspecified (상세불명의 식사장애) | 무작위배정 될 확률 | 송수신 | 및 저장한 후, 해당 데이터를 다시 | 적용 |\n| (6) 「의료기기법 시행규칙」 제24조 (임상시험 실시기준 등) | 디지털치료기기 관련 국내외 가이드라인은 <표 8>과 같다.  | 3) 이차 유효성 평가변수: | Disorder) | 관리 결과가 검증되어야 한다. ",
        "original_sentence": "|\n| 통신 | ioral Treatment Program for Binge-Eating Disorder. "
      }
    },
    {
      "chunk_id": "chunk_192",
      "text": "Behavior Therapy, 47(4). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 191,
        "window_size": 3,
        "char_count": 25,
        "word_count": 3,
        "page_number": 26,
        "window_text": "| 또는 그룹으로 진행된다.  | 구성요소 간의 연계성과 소프트 | 구조를 갖추어 설계한다.  |\n| 통신 | ioral Treatment Program for Binge-Eating Disorder.  Behavior Therapy, 47(4).  | 나) 대조기기 | 10) 알코올 또는 약물 남용의 과거력이 있는 자 | [F50.9] Eating disorder, unspecified (상세불명의 식사장애) | 무작위배정 될 확률 | 송수신 | 및 저장한 후, 해당 데이터를 다시 | 적용 |\n| (6) 「의료기기법 시행규칙」 제24조 (임상시험 실시기준 등) | 디지털치료기기 관련 국내외 가이드라인은 <표 8>과 같다.  | 3) 이차 유효성 평가변수: | Disorder) | 관리 결과가 검증되어야 한다.  | 마) 이상 반응 확인 | 절차를 말한다. ",
        "original_sentence": "Behavior Therapy, 47(4). "
      }
    },
    {
      "chunk_id": "chunk_193",
      "text": "| 나) 대조기기 | 10) 알코올 또는 약물 남용의 과거력이 있는 자 | [F50.9] Eating disorder, unspecified (상세불명의 식사장애) | 무작위배정 될 확률 | 송수신 | 및 저장한 후, 해당 데이터를 다시 | 적용 |\n| (6) 「의료기기법 시행규칙」 제24조 (임상시험 실시기준 등) | 디지털치료기기 관련 국내외 가이드라인은 <표 8>과 같다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 192,
        "window_size": 3,
        "char_count": 213,
        "word_count": 51,
        "page_number": 19,
        "window_text": "| 구성요소 간의 연계성과 소프트 | 구조를 갖추어 설계한다.  |\n| 통신 | ioral Treatment Program for Binge-Eating Disorder.  Behavior Therapy, 47(4).  | 나) 대조기기 | 10) 알코올 또는 약물 남용의 과거력이 있는 자 | [F50.9] Eating disorder, unspecified (상세불명의 식사장애) | 무작위배정 될 확률 | 송수신 | 및 저장한 후, 해당 데이터를 다시 | 적용 |\n| (6) 「의료기기법 시행규칙」 제24조 (임상시험 실시기준 등) | 디지털치료기기 관련 국내외 가이드라인은 <표 8>과 같다.  | 3) 이차 유효성 평가변수: | Disorder) | 관리 결과가 검증되어야 한다.  | 마) 이상 반응 확인 | 절차를 말한다.  | 의료기기의 회수체계를 확립하고 이를 문서화하여야 한다. ",
        "original_sentence": "| 나) 대조기기 | 10) 알코올 또는 약물 남용의 과거력이 있는 자 | [F50.9] Eating disorder, unspecified (상세불명의 식사장애) | 무작위배정 될 확률 | 송수신 | 및 저장한 후, 해당 데이터를 다시 | 적용 |\n| (6) 「의료기기법 시행규칙」 제24조 (임상시험 실시기준 등) | 디지털치료기기 관련 국내외 가이드라인은 <표 8>과 같다. "
      }
    },
    {
      "chunk_id": "chunk_194",
      "text": "| 3) 이차 유효성 평가변수: | Disorder) | 관리 결과가 검증되어야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 193,
        "window_size": 3,
        "char_count": 49,
        "word_count": 12,
        "page_number": 7,
        "window_text": "|\n| 통신 | ioral Treatment Program for Binge-Eating Disorder.  Behavior Therapy, 47(4).  | 나) 대조기기 | 10) 알코올 또는 약물 남용의 과거력이 있는 자 | [F50.9] Eating disorder, unspecified (상세불명의 식사장애) | 무작위배정 될 확률 | 송수신 | 및 저장한 후, 해당 데이터를 다시 | 적용 |\n| (6) 「의료기기법 시행규칙」 제24조 (임상시험 실시기준 등) | 디지털치료기기 관련 국내외 가이드라인은 <표 8>과 같다.  | 3) 이차 유효성 평가변수: | Disorder) | 관리 결과가 검증되어야 한다.  | 마) 이상 반응 확인 | 절차를 말한다.  | 의료기기의 회수체계를 확립하고 이를 문서화하여야 한다.  | 하여야 한다. ",
        "original_sentence": "| 3) 이차 유효성 평가변수: | Disorder) | 관리 결과가 검증되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_195",
      "text": "| 마) 이상 반응 확인 | 절차를 말한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 194,
        "window_size": 3,
        "char_count": 25,
        "word_count": 8,
        "page_number": 7,
        "window_text": "Behavior Therapy, 47(4).  | 나) 대조기기 | 10) 알코올 또는 약물 남용의 과거력이 있는 자 | [F50.9] Eating disorder, unspecified (상세불명의 식사장애) | 무작위배정 될 확률 | 송수신 | 및 저장한 후, 해당 데이터를 다시 | 적용 |\n| (6) 「의료기기법 시행규칙」 제24조 (임상시험 실시기준 등) | 디지털치료기기 관련 국내외 가이드라인은 <표 8>과 같다.  | 3) 이차 유효성 평가변수: | Disorder) | 관리 결과가 검증되어야 한다.  | 마) 이상 반응 확인 | 절차를 말한다.  | 의료기기의 회수체계를 확립하고 이를 문서화하여야 한다.  | 하여야 한다.  | https://www.nifds.go.kr | 확인 자료 |\n| 인증 | 있는 영역(Acceptable)’의 2단계로 구분할 수 있다. ",
        "original_sentence": "| 마) 이상 반응 확인 | 절차를 말한다. "
      }
    },
    {
      "chunk_id": "chunk_196",
      "text": "| 의료기기의 회수체계를 확립하고 이를 문서화하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 195,
        "window_size": 3,
        "char_count": 33,
        "word_count": 7,
        "page_number": 15,
        "window_text": "| 나) 대조기기 | 10) 알코올 또는 약물 남용의 과거력이 있는 자 | [F50.9] Eating disorder, unspecified (상세불명의 식사장애) | 무작위배정 될 확률 | 송수신 | 및 저장한 후, 해당 데이터를 다시 | 적용 |\n| (6) 「의료기기법 시행규칙」 제24조 (임상시험 실시기준 등) | 디지털치료기기 관련 국내외 가이드라인은 <표 8>과 같다.  | 3) 이차 유효성 평가변수: | Disorder) | 관리 결과가 검증되어야 한다.  | 마) 이상 반응 확인 | 절차를 말한다.  | 의료기기의 회수체계를 확립하고 이를 문서화하여야 한다.  | 하여야 한다.  | https://www.nifds.go.kr | 확인 자료 |\n| 인증 | 있는 영역(Acceptable)’의 2단계로 구분할 수 있다.  | 제조자는 비인가 접근/변경/반복을 방지하기 | 추가로 동일한 자격증명은 기기와 고객들에게 | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | Medical device software – | 할 것 | 웨어 형상을 유지한다. ",
        "original_sentence": "| 의료기기의 회수체계를 확립하고 이를 문서화하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_197",
      "text": "| 하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 196,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 15,
        "window_text": "| 3) 이차 유효성 평가변수: | Disorder) | 관리 결과가 검증되어야 한다.  | 마) 이상 반응 확인 | 절차를 말한다.  | 의료기기의 회수체계를 확립하고 이를 문서화하여야 한다.  | 하여야 한다.  | https://www.nifds.go.kr | 확인 자료 |\n| 인증 | 있는 영역(Acceptable)’의 2단계로 구분할 수 있다.  | 제조자는 비인가 접근/변경/반복을 방지하기 | 추가로 동일한 자격증명은 기기와 고객들에게 | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | Medical device software – | 할 것 | 웨어 형상을 유지한다.  | Baseline | At week 16 | 전후 차이 | 개발부터 유지보수를 | 유효성 | □ 예(☞지침서) | ■ 아니오 | 내원 또는 | (AB-1234) |\n| 1) 대상 질환 : | -eating disorder. ",
        "original_sentence": "| 하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_198",
      "text": "| https://www.nifds.go.kr | 확인 자료 |\n| 인증 | 있는 영역(Acceptable)’의 2단계로 구분할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 197,
        "window_size": 3,
        "char_count": 78,
        "word_count": 15,
        "page_number": 28,
        "window_text": "| 마) 이상 반응 확인 | 절차를 말한다.  | 의료기기의 회수체계를 확립하고 이를 문서화하여야 한다.  | 하여야 한다.  | https://www.nifds.go.kr | 확인 자료 |\n| 인증 | 있는 영역(Acceptable)’의 2단계로 구분할 수 있다.  | 제조자는 비인가 접근/변경/반복을 방지하기 | 추가로 동일한 자격증명은 기기와 고객들에게 | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | Medical device software – | 할 것 | 웨어 형상을 유지한다.  | Baseline | At week 16 | 전후 차이 | 개발부터 유지보수를 | 유효성 | □ 예(☞지침서) | ■ 아니오 | 내원 또는 | (AB-1234) |\n| 1) 대상 질환 : | -eating disorder.  Obesity (Silver Spring, Md.",
        "original_sentence": "| https://www.nifds.go.kr | 확인 자료 |\n| 인증 | 있는 영역(Acceptable)’의 2단계로 구분할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_199",
      "text": "| 제조자는 비인가 접근/변경/반복을 방지하기 | 추가로 동일한 자격증명은 기기와 고객들에게 | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | Medical device software – | 할 것 | 웨어 형상을 유지한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 198,
        "window_size": 3,
        "char_count": 138,
        "word_count": 32,
        "page_number": 34,
        "window_text": "| 의료기기의 회수체계를 확립하고 이를 문서화하여야 한다.  | 하여야 한다.  | https://www.nifds.go.kr | 확인 자료 |\n| 인증 | 있는 영역(Acceptable)’의 2단계로 구분할 수 있다.  | 제조자는 비인가 접근/변경/반복을 방지하기 | 추가로 동일한 자격증명은 기기와 고객들에게 | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | Medical device software – | 할 것 | 웨어 형상을 유지한다.  | Baseline | At week 16 | 전후 차이 | 개발부터 유지보수를 | 유효성 | □ 예(☞지침서) | ■ 아니오 | 내원 또는 | (AB-1234) |\n| 1) 대상 질환 : | -eating disorder.  Obesity (Silver Spring, Md. ), 16(9), 2024–2038. ",
        "original_sentence": "| 제조자는 비인가 접근/변경/반복을 방지하기 | 추가로 동일한 자격증명은 기기와 고객들에게 | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | Medical device software – | 할 것 | 웨어 형상을 유지한다. "
      }
    },
    {
      "chunk_id": "chunk_200",
      "text": "| Baseline | At week 16 | 전후 차이 | 개발부터 유지보수를 | 유효성 | □ 예(☞지침서) | ■ 아니오 | 내원 또는 | (AB-1234) |\n| 1) 대상 질환 : | -eating disorder. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 199,
        "window_size": 3,
        "char_count": 126,
        "word_count": 34,
        "page_number": 7,
        "window_text": "| 하여야 한다.  | https://www.nifds.go.kr | 확인 자료 |\n| 인증 | 있는 영역(Acceptable)’의 2단계로 구분할 수 있다.  | 제조자는 비인가 접근/변경/반복을 방지하기 | 추가로 동일한 자격증명은 기기와 고객들에게 | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | Medical device software – | 할 것 | 웨어 형상을 유지한다.  | Baseline | At week 16 | 전후 차이 | 개발부터 유지보수를 | 유효성 | □ 예(☞지침서) | ■ 아니오 | 내원 또는 | (AB-1234) |\n| 1) 대상 질환 : | -eating disorder.  Obesity (Silver Spring, Md. ), 16(9), 2024–2038.  | 소프트 | Off-The-Shelf(OTS) Software” | 선행연구 | 군 | 웨어 항목 간 연계성을 위한 |\n| 2) 목표 대상자 수 산정의 추정 공식 예시 | 3 | IEC 62304 | 높은 등급이 된다. ",
        "original_sentence": "| Baseline | At week 16 | 전후 차이 | 개발부터 유지보수를 | 유효성 | □ 예(☞지침서) | ■ 아니오 | 내원 또는 | (AB-1234) |\n| 1) 대상 질환 : | -eating disorder. "
      }
    },
    {
      "chunk_id": "chunk_201",
      "text": "Obesity (Silver Spring, Md.",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 200,
        "window_size": 3,
        "char_count": 27,
        "word_count": 4,
        "page_number": 62,
        "window_text": "| https://www.nifds.go.kr | 확인 자료 |\n| 인증 | 있는 영역(Acceptable)’의 2단계로 구분할 수 있다.  | 제조자는 비인가 접근/변경/반복을 방지하기 | 추가로 동일한 자격증명은 기기와 고객들에게 | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | Medical device software – | 할 것 | 웨어 형상을 유지한다.  | Baseline | At week 16 | 전후 차이 | 개발부터 유지보수를 | 유효성 | □ 예(☞지침서) | ■ 아니오 | 내원 또는 | (AB-1234) |\n| 1) 대상 질환 : | -eating disorder.  Obesity (Silver Spring, Md. ), 16(9), 2024–2038.  | 소프트 | Off-The-Shelf(OTS) Software” | 선행연구 | 군 | 웨어 항목 간 연계성을 위한 |\n| 2) 목표 대상자 수 산정의 추정 공식 예시 | 3 | IEC 62304 | 높은 등급이 된다.  | 관찰형태 | 내원 | 내원과 | 불러오기 한다. ",
        "original_sentence": "Obesity (Silver Spring, Md."
      }
    },
    {
      "chunk_id": "chunk_202",
      "text": "), 16(9), 2024–2038. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 201,
        "window_size": 3,
        "char_count": 21,
        "word_count": 3,
        "page_number": 9,
        "window_text": "| 제조자는 비인가 접근/변경/반복을 방지하기 | 추가로 동일한 자격증명은 기기와 고객들에게 | □ 행정사무의 통일을 기하기 위하여 내부적으로 행정사무의 세부 | Medical device software – | 할 것 | 웨어 형상을 유지한다.  | Baseline | At week 16 | 전후 차이 | 개발부터 유지보수를 | 유효성 | □ 예(☞지침서) | ■ 아니오 | 내원 또는 | (AB-1234) |\n| 1) 대상 질환 : | -eating disorder.  Obesity (Silver Spring, Md. ), 16(9), 2024–2038.  | 소프트 | Off-The-Shelf(OTS) Software” | 선행연구 | 군 | 웨어 항목 간 연계성을 위한 |\n| 2) 목표 대상자 수 산정의 추정 공식 예시 | 3 | IEC 62304 | 높은 등급이 된다.  | 관찰형태 | 내원 | 내원과 | 불러오기 한다.  | 내원과 | 국외 |\n| (7) 「의료기기 허가·신고·심사 등에 관한 규정」 | ○ 관련성이 명백함(Definitely related) | 경우는 별도의 안전성과 성능 시험을 통과한 제품의 사용을 권고한다. ",
        "original_sentence": "), 16(9), 2024–2038. "
      }
    },
    {
      "chunk_id": "chunk_203",
      "text": "| 소프트 | Off-The-Shelf(OTS) Software” | 선행연구 | 군 | 웨어 항목 간 연계성을 위한 |\n| 2) 목표 대상자 수 산정의 추정 공식 예시 | 3 | IEC 62304 | 높은 등급이 된다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 202,
        "window_size": 3,
        "char_count": 124,
        "word_count": 34,
        "page_number": 28,
        "window_text": "| Baseline | At week 16 | 전후 차이 | 개발부터 유지보수를 | 유효성 | □ 예(☞지침서) | ■ 아니오 | 내원 또는 | (AB-1234) |\n| 1) 대상 질환 : | -eating disorder.  Obesity (Silver Spring, Md. ), 16(9), 2024–2038.  | 소프트 | Off-The-Shelf(OTS) Software” | 선행연구 | 군 | 웨어 항목 간 연계성을 위한 |\n| 2) 목표 대상자 수 산정의 추정 공식 예시 | 3 | IEC 62304 | 높은 등급이 된다.  | 관찰형태 | 내원 | 내원과 | 불러오기 한다.  | 내원과 | 국외 |\n| (7) 「의료기기 허가·신고·심사 등에 관한 규정」 | ○ 관련성이 명백함(Definitely related) | 경우는 별도의 안전성과 성능 시험을 통과한 제품의 사용을 권고한다.  | 버전이다. ",
        "original_sentence": "| 소프트 | Off-The-Shelf(OTS) Software” | 선행연구 | 군 | 웨어 항목 간 연계성을 위한 |\n| 2) 목표 대상자 수 산정의 추정 공식 예시 | 3 | IEC 62304 | 높은 등급이 된다. "
      }
    },
    {
      "chunk_id": "chunk_204",
      "text": "| 관찰형태 | 내원 | 내원과 | 불러오기 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 203,
        "window_size": 3,
        "char_count": 29,
        "word_count": 9,
        "page_number": 15,
        "window_text": "Obesity (Silver Spring, Md. ), 16(9), 2024–2038.  | 소프트 | Off-The-Shelf(OTS) Software” | 선행연구 | 군 | 웨어 항목 간 연계성을 위한 |\n| 2) 목표 대상자 수 산정의 추정 공식 예시 | 3 | IEC 62304 | 높은 등급이 된다.  | 관찰형태 | 내원 | 내원과 | 불러오기 한다.  | 내원과 | 국외 |\n| (7) 「의료기기 허가·신고·심사 등에 관한 규정」 | ○ 관련성이 명백함(Definitely related) | 경우는 별도의 안전성과 성능 시험을 통과한 제품의 사용을 권고한다.  | 버전이다.  | - 모든 분석 대상자군(Full Analysis Set, FAS) | 또는 일시 중지시킬 수 있다. ",
        "original_sentence": "| 관찰형태 | 내원 | 내원과 | 불러오기 한다. "
      }
    },
    {
      "chunk_id": "chunk_205",
      "text": "| 내원과 | 국외 |\n| (7) 「의료기기 허가·신고·심사 등에 관한 규정」 | ○ 관련성이 명백함(Definitely related) | 경우는 별도의 안전성과 성능 시험을 통과한 제품의 사용을 권고한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 204,
        "window_size": 3,
        "char_count": 117,
        "word_count": 27,
        "page_number": 5,
        "window_text": "), 16(9), 2024–2038.  | 소프트 | Off-The-Shelf(OTS) Software” | 선행연구 | 군 | 웨어 항목 간 연계성을 위한 |\n| 2) 목표 대상자 수 산정의 추정 공식 예시 | 3 | IEC 62304 | 높은 등급이 된다.  | 관찰형태 | 내원 | 내원과 | 불러오기 한다.  | 내원과 | 국외 |\n| (7) 「의료기기 허가·신고·심사 등에 관한 규정」 | ○ 관련성이 명백함(Definitely related) | 경우는 별도의 안전성과 성능 시험을 통과한 제품의 사용을 권고한다.  | 버전이다.  | - 모든 분석 대상자군(Full Analysis Set, FAS) | 또는 일시 중지시킬 수 있다.  | 기준이나 절차를 제시하는 것입니까? ",
        "original_sentence": "| 내원과 | 국외 |\n| (7) 「의료기기 허가·신고·심사 등에 관한 규정」 | ○ 관련성이 명백함(Definitely related) | 경우는 별도의 안전성과 성능 시험을 통과한 제품의 사용을 권고한다. "
      }
    },
    {
      "chunk_id": "chunk_206",
      "text": "| 버전이다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 205,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 10,
        "window_text": "| 소프트 | Off-The-Shelf(OTS) Software” | 선행연구 | 군 | 웨어 항목 간 연계성을 위한 |\n| 2) 목표 대상자 수 산정의 추정 공식 예시 | 3 | IEC 62304 | 높은 등급이 된다.  | 관찰형태 | 내원 | 내원과 | 불러오기 한다.  | 내원과 | 국외 |\n| (7) 「의료기기 허가·신고·심사 등에 관한 규정」 | ○ 관련성이 명백함(Definitely related) | 경우는 별도의 안전성과 성능 시험을 통과한 제품의 사용을 권고한다.  | 버전이다.  | - 모든 분석 대상자군(Full Analysis Set, FAS) | 또는 일시 중지시킬 수 있다.  | 기준이나 절차를 제시하는 것입니까?  (공무원용) | Software life cycle processes | n | 평균 | SD | n | 평균 | SD | 평균 | SD | 포함하여 전주기에 대한 | 애플리케이션, |\n| 상에 정확한 피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 한다. ",
        "original_sentence": "| 버전이다. "
      }
    },
    {
      "chunk_id": "chunk_207",
      "text": "| - 모든 분석 대상자군(Full Analysis Set, FAS) | 또는 일시 중지시킬 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 206,
        "window_size": 3,
        "char_count": 58,
        "word_count": 14,
        "page_number": 34,
        "window_text": "| 관찰형태 | 내원 | 내원과 | 불러오기 한다.  | 내원과 | 국외 |\n| (7) 「의료기기 허가·신고·심사 등에 관한 규정」 | ○ 관련성이 명백함(Definitely related) | 경우는 별도의 안전성과 성능 시험을 통과한 제품의 사용을 권고한다.  | 버전이다.  | - 모든 분석 대상자군(Full Analysis Set, FAS) | 또는 일시 중지시킬 수 있다.  | 기준이나 절차를 제시하는 것입니까?  (공무원용) | Software life cycle processes | n | 평균 | SD | n | 평균 | SD | 평균 | SD | 포함하여 전주기에 대한 | 애플리케이션, |\n| 상에 정확한 피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 한다.  | 웨어의 개발 및 유지를 위한 활동을 수행하여야 한다. ",
        "original_sentence": "| - 모든 분석 대상자군(Full Analysis Set, FAS) | 또는 일시 중지시킬 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_208",
      "text": "| 기준이나 절차를 제시하는 것입니까? ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 207,
        "window_size": 3,
        "char_count": 22,
        "word_count": 5,
        "page_number": 7,
        "window_text": "| 내원과 | 국외 |\n| (7) 「의료기기 허가·신고·심사 등에 관한 규정」 | ○ 관련성이 명백함(Definitely related) | 경우는 별도의 안전성과 성능 시험을 통과한 제품의 사용을 권고한다.  | 버전이다.  | - 모든 분석 대상자군(Full Analysis Set, FAS) | 또는 일시 중지시킬 수 있다.  | 기준이나 절차를 제시하는 것입니까?  (공무원용) | Software life cycle processes | n | 평균 | SD | n | 평균 | SD | 평균 | SD | 포함하여 전주기에 대한 | 애플리케이션, |\n| 상에 정확한 피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 한다.  | 웨어의 개발 및 유지를 위한 활동을 수행하여야 한다.  | 11) 기타 시험자가 본 임상시험 참여에 부적합하다고 판단한 자 | 위한 의료기기의 보안이 보장된(secured) | 공유되지 않아야 한다. ",
        "original_sentence": "| 기준이나 절차를 제시하는 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_209",
      "text": "(공무원용) | Software life cycle processes | n | 평균 | SD | n | 평균 | SD | 평균 | SD | 포함하여 전주기에 대한 | 애플리케이션, |\n| 상에 정확한 피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 208,
        "window_size": 3,
        "char_count": 147,
        "word_count": 40,
        "page_number": 26,
        "window_text": "| 버전이다.  | - 모든 분석 대상자군(Full Analysis Set, FAS) | 또는 일시 중지시킬 수 있다.  | 기준이나 절차를 제시하는 것입니까?  (공무원용) | Software life cycle processes | n | 평균 | SD | n | 평균 | SD | 평균 | SD | 포함하여 전주기에 대한 | 애플리케이션, |\n| 상에 정확한 피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 한다.  | 웨어의 개발 및 유지를 위한 활동을 수행하여야 한다.  | 11) 기타 시험자가 본 임상시험 참여에 부적합하다고 판단한 자 | 위한 의료기기의 보안이 보장된(secured) | 공유되지 않아야 한다.  | Guidance for the Content of | 애플리케이션 | 애플리케이션 | 으로 식별한다. ",
        "original_sentence": "(공무원용) | Software life cycle processes | n | 평균 | SD | n | 평균 | SD | 평균 | SD | 포함하여 전주기에 대한 | 애플리케이션, |\n| 상에 정확한 피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_210",
      "text": "| 웨어의 개발 및 유지를 위한 활동을 수행하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 209,
        "window_size": 3,
        "char_count": 32,
        "word_count": 9,
        "page_number": 15,
        "window_text": "| - 모든 분석 대상자군(Full Analysis Set, FAS) | 또는 일시 중지시킬 수 있다.  | 기준이나 절차를 제시하는 것입니까?  (공무원용) | Software life cycle processes | n | 평균 | SD | n | 평균 | SD | 평균 | SD | 포함하여 전주기에 대한 | 애플리케이션, |\n| 상에 정확한 피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 한다.  | 웨어의 개발 및 유지를 위한 활동을 수행하여야 한다.  | 11) 기타 시험자가 본 임상시험 참여에 부적합하다고 판단한 자 | 위한 의료기기의 보안이 보장된(secured) | 공유되지 않아야 한다.  | Guidance for the Content of | 애플리케이션 | 애플리케이션 | 으로 식별한다.  | 확인 자료 |\n| 한다. ",
        "original_sentence": "| 웨어의 개발 및 유지를 위한 활동을 수행하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_211",
      "text": "| 11) 기타 시험자가 본 임상시험 참여에 부적합하다고 판단한 자 | 위한 의료기기의 보안이 보장된(secured) | 공유되지 않아야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 210,
        "window_size": 3,
        "char_count": 81,
        "word_count": 19,
        "page_number": 19,
        "window_text": "| 기준이나 절차를 제시하는 것입니까?  (공무원용) | Software life cycle processes | n | 평균 | SD | n | 평균 | SD | 평균 | SD | 포함하여 전주기에 대한 | 애플리케이션, |\n| 상에 정확한 피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 한다.  | 웨어의 개발 및 유지를 위한 활동을 수행하여야 한다.  | 11) 기타 시험자가 본 임상시험 참여에 부적합하다고 판단한 자 | 위한 의료기기의 보안이 보장된(secured) | 공유되지 않아야 한다.  | Guidance for the Content of | 애플리케이션 | 애플리케이션 | 으로 식별한다.  | 확인 자료 |\n| 한다.  | 서명이 이러한 자료의 열람을 허용하게 된다는 사실 | 웨어 | 기간, 목적을 확인한다. ",
        "original_sentence": "| 11) 기타 시험자가 본 임상시험 참여에 부적합하다고 판단한 자 | 위한 의료기기의 보안이 보장된(secured) | 공유되지 않아야 한다. "
      }
    },
    {
      "chunk_id": "chunk_212",
      "text": "| Guidance for the Content of | 애플리케이션 | 애플리케이션 | 으로 식별한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 211,
        "window_size": 3,
        "char_count": 59,
        "word_count": 13,
        "page_number": 28,
        "window_text": "(공무원용) | Software life cycle processes | n | 평균 | SD | n | 평균 | SD | 평균 | SD | 포함하여 전주기에 대한 | 애플리케이션, |\n| 상에 정확한 피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 한다.  | 웨어의 개발 및 유지를 위한 활동을 수행하여야 한다.  | 11) 기타 시험자가 본 임상시험 참여에 부적합하다고 판단한 자 | 위한 의료기기의 보안이 보장된(secured) | 공유되지 않아야 한다.  | Guidance for the Content of | 애플리케이션 | 애플리케이션 | 으로 식별한다.  | 확인 자료 |\n| 한다.  | 서명이 이러한 자료의 열람을 허용하게 된다는 사실 | 웨어 | 기간, 목적을 확인한다.  | 반응이 사라지는 경우 | 표 6. ",
        "original_sentence": "| Guidance for the Content of | 애플리케이션 | 애플리케이션 | 으로 식별한다. "
      }
    },
    {
      "chunk_id": "chunk_213",
      "text": "| 확인 자료 |\n| 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 212,
        "window_size": 3,
        "char_count": 16,
        "word_count": 6,
        "page_number": 15,
        "window_text": "| 웨어의 개발 및 유지를 위한 활동을 수행하여야 한다.  | 11) 기타 시험자가 본 임상시험 참여에 부적합하다고 판단한 자 | 위한 의료기기의 보안이 보장된(secured) | 공유되지 않아야 한다.  | Guidance for the Content of | 애플리케이션 | 애플리케이션 | 으로 식별한다.  | 확인 자료 |\n| 한다.  | 서명이 이러한 자료의 열람을 허용하게 된다는 사실 | 웨어 | 기간, 목적을 확인한다.  | 반응이 사라지는 경우 | 표 6.  디지털치료기기 관련 국내외 가이드라인 | 아키텍처를 개발한다. ",
        "original_sentence": "| 확인 자료 |\n| 한다. "
      }
    },
    {
      "chunk_id": "chunk_214",
      "text": "| 서명이 이러한 자료의 열람을 허용하게 된다는 사실 | 웨어 | 기간, 목적을 확인한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 213,
        "window_size": 3,
        "char_count": 51,
        "word_count": 14,
        "page_number": 7,
        "window_text": "| 11) 기타 시험자가 본 임상시험 참여에 부적합하다고 판단한 자 | 위한 의료기기의 보안이 보장된(secured) | 공유되지 않아야 한다.  | Guidance for the Content of | 애플리케이션 | 애플리케이션 | 으로 식별한다.  | 확인 자료 |\n| 한다.  | 서명이 이러한 자료의 열람을 허용하게 된다는 사실 | 웨어 | 기간, 목적을 확인한다.  | 반응이 사라지는 경우 | 표 6.  디지털치료기기 관련 국내외 가이드라인 | 아키텍처를 개발한다.  |\n**표 10. ",
        "original_sentence": "| 서명이 이러한 자료의 열람을 허용하게 된다는 사실 | 웨어 | 기간, 목적을 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_215",
      "text": "| 반응이 사라지는 경우 | 표 6. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 214,
        "window_size": 3,
        "char_count": 21,
        "word_count": 7,
        "page_number": 27,
        "window_text": "| Guidance for the Content of | 애플리케이션 | 애플리케이션 | 으로 식별한다.  | 확인 자료 |\n| 한다.  | 서명이 이러한 자료의 열람을 허용하게 된다는 사실 | 웨어 | 기간, 목적을 확인한다.  | 반응이 사라지는 경우 | 표 6.  디지털치료기기 관련 국내외 가이드라인 | 아키텍처를 개발한다.  |\n**표 10.  위험평가 예시**\n| [F50.0] Anorexia nervosa (신경성 식욕부진) | women with binge eating. ",
        "original_sentence": "| 반응이 사라지는 경우 | 표 6. "
      }
    },
    {
      "chunk_id": "chunk_216",
      "text": "디지털치료기기 관련 국내외 가이드라인 | 아키텍처를 개발한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 215,
        "window_size": 3,
        "char_count": 35,
        "word_count": 7,
        "page_number": 15,
        "window_text": "| 확인 자료 |\n| 한다.  | 서명이 이러한 자료의 열람을 허용하게 된다는 사실 | 웨어 | 기간, 목적을 확인한다.  | 반응이 사라지는 경우 | 표 6.  디지털치료기기 관련 국내외 가이드라인 | 아키텍처를 개발한다.  |\n**표 10.  위험평가 예시**\n| [F50.0] Anorexia nervosa (신경성 식욕부진) | women with binge eating.  Cognitive Behavior Therapy in Korea, 3(1), 27-42. ",
        "original_sentence": "디지털치료기기 관련 국내외 가이드라인 | 아키텍처를 개발한다. "
      }
    },
    {
      "chunk_id": "chunk_217",
      "text": "|\n**표 10. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 216,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 19,
        "window_text": "| 서명이 이러한 자료의 열람을 허용하게 된다는 사실 | 웨어 | 기간, 목적을 확인한다.  | 반응이 사라지는 경우 | 표 6.  디지털치료기기 관련 국내외 가이드라인 | 아키텍처를 개발한다.  |\n**표 10.  위험평가 예시**\n| [F50.0] Anorexia nervosa (신경성 식욕부진) | women with binge eating.  Cognitive Behavior Therapy in Korea, 3(1), 27-42.  | 데이터 송·수신 방법을 고려하여야 한다. ",
        "original_sentence": "|\n**표 10. "
      }
    },
    {
      "chunk_id": "chunk_218",
      "text": "위험평가 예시**\n| [F50.0] Anorexia nervosa (신경성 식욕부진) | women with binge eating. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 217,
        "window_size": 3,
        "char_count": 75,
        "word_count": 13,
        "page_number": 15,
        "window_text": "| 반응이 사라지는 경우 | 표 6.  디지털치료기기 관련 국내외 가이드라인 | 아키텍처를 개발한다.  |\n**표 10.  위험평가 예시**\n| [F50.0] Anorexia nervosa (신경성 식욕부진) | women with binge eating.  Cognitive Behavior Therapy in Korea, 3(1), 27-42.  | 데이터 송·수신 방법을 고려하여야 한다.  | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 다른 디바이스에서 같은 휴대폰 | 국제 규격 | 소프트웨어 |\n| (8) 「의료기기 임상시험계획 승인에 관한 규정」 | Eating Disorder Examination Questionnaire (EDE-Q) | ating disorders. ",
        "original_sentence": "위험평가 예시**\n| [F50.0] Anorexia nervosa (신경성 식욕부진) | women with binge eating. "
      }
    },
    {
      "chunk_id": "chunk_219",
      "text": "Cognitive Behavior Therapy in Korea, 3(1), 27-42. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 218,
        "window_size": 3,
        "char_count": 50,
        "word_count": 7,
        "page_number": 9,
        "window_text": "디지털치료기기 관련 국내외 가이드라인 | 아키텍처를 개발한다.  |\n**표 10.  위험평가 예시**\n| [F50.0] Anorexia nervosa (신경성 식욕부진) | women with binge eating.  Cognitive Behavior Therapy in Korea, 3(1), 27-42.  | 데이터 송·수신 방법을 고려하여야 한다.  | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 다른 디바이스에서 같은 휴대폰 | 국제 규격 | 소프트웨어 |\n| (8) 「의료기기 임상시험계획 승인에 관한 규정」 | Eating Disorder Examination Questionnaire (EDE-Q) | ating disorders.  Psychiatry Research, 247, 182-193. ",
        "original_sentence": "Cognitive Behavior Therapy in Korea, 3(1), 27-42. "
      }
    },
    {
      "chunk_id": "chunk_220",
      "text": "| 데이터 송·수신 방법을 고려하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 219,
        "window_size": 3,
        "char_count": 25,
        "word_count": 6,
        "page_number": 15,
        "window_text": "|\n**표 10.  위험평가 예시**\n| [F50.0] Anorexia nervosa (신경성 식욕부진) | women with binge eating.  Cognitive Behavior Therapy in Korea, 3(1), 27-42.  | 데이터 송·수신 방법을 고려하여야 한다.  | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 다른 디바이스에서 같은 휴대폰 | 국제 규격 | 소프트웨어 |\n| (8) 「의료기기 임상시험계획 승인에 관한 규정」 | Eating Disorder Examination Questionnaire (EDE-Q) | ating disorders.  Psychiatry Research, 247, 182-193.  | 구분 | - 일차목적 및 가설 | 유지 | ※ 접근 통제의 예: 비밀번호, 하드웨어 키, | Premarket Submissions for | 이용하여 발행된 난수표를 적용한다. ",
        "original_sentence": "| 데이터 송·수신 방법을 고려하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_221",
      "text": "| □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 다른 디바이스에서 같은 휴대폰 | 국제 규격 | 소프트웨어 |\n| (8) 「의료기기 임상시험계획 승인에 관한 규정」 | Eating Disorder Examination Questionnaire (EDE-Q) | ating disorders. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 220,
        "window_size": 3,
        "char_count": 174,
        "word_count": 37,
        "page_number": 3,
        "window_text": "위험평가 예시**\n| [F50.0] Anorexia nervosa (신경성 식욕부진) | women with binge eating.  Cognitive Behavior Therapy in Korea, 3(1), 27-42.  | 데이터 송·수신 방법을 고려하여야 한다.  | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 다른 디바이스에서 같은 휴대폰 | 국제 규격 | 소프트웨어 |\n| (8) 「의료기기 임상시험계획 승인에 관한 규정」 | Eating Disorder Examination Questionnaire (EDE-Q) | ating disorders.  Psychiatry Research, 247, 182-193.  | 구분 | - 일차목적 및 가설 | 유지 | ※ 접근 통제의 예: 비밀번호, 하드웨어 키, | Premarket Submissions for | 이용하여 발행된 난수표를 적용한다.  | 소프트웨어를 | 포함하는 | 의료기기에 | ■ 예(☞안내서) | □ 아니오 |\n| 성명 | 소속기관명 | 전공 | 직위 | 전화 | Placebo |\n| 8 | 회사명 | 대표이사 | 소재지 | 전화 | 받게 될 각종 검사나 절차 | 평가지표로 사용할 수 있다. ",
        "original_sentence": "| □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 다른 디바이스에서 같은 휴대폰 | 국제 규격 | 소프트웨어 |\n| (8) 「의료기기 임상시험계획 승인에 관한 규정」 | Eating Disorder Examination Questionnaire (EDE-Q) | ating disorders. "
      }
    },
    {
      "chunk_id": "chunk_222",
      "text": "Psychiatry Research, 247, 182-193. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 221,
        "window_size": 3,
        "char_count": 35,
        "word_count": 4,
        "page_number": 9,
        "window_text": "Cognitive Behavior Therapy in Korea, 3(1), 27-42.  | 데이터 송·수신 방법을 고려하여야 한다.  | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 다른 디바이스에서 같은 휴대폰 | 국제 규격 | 소프트웨어 |\n| (8) 「의료기기 임상시험계획 승인에 관한 규정」 | Eating Disorder Examination Questionnaire (EDE-Q) | ating disorders.  Psychiatry Research, 247, 182-193.  | 구분 | - 일차목적 및 가설 | 유지 | ※ 접근 통제의 예: 비밀번호, 하드웨어 키, | Premarket Submissions for | 이용하여 발행된 난수표를 적용한다.  | 소프트웨어를 | 포함하는 | 의료기기에 | ■ 예(☞안내서) | □ 아니오 |\n| 성명 | 소속기관명 | 전공 | 직위 | 전화 | Placebo |\n| 8 | 회사명 | 대표이사 | 소재지 | 전화 | 받게 될 각종 검사나 절차 | 평가지표로 사용할 수 있다.  | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까? ",
        "original_sentence": "Psychiatry Research, 247, 182-193. "
      }
    },
    {
      "chunk_id": "chunk_223",
      "text": "| 구분 | - 일차목적 및 가설 | 유지 | ※ 접근 통제의 예: 비밀번호, 하드웨어 키, | Premarket Submissions for | 이용하여 발행된 난수표를 적용한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 222,
        "window_size": 3,
        "char_count": 102,
        "word_count": 26,
        "page_number": 3,
        "window_text": "| 데이터 송·수신 방법을 고려하여야 한다.  | □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 다른 디바이스에서 같은 휴대폰 | 국제 규격 | 소프트웨어 |\n| (8) 「의료기기 임상시험계획 승인에 관한 규정」 | Eating Disorder Examination Questionnaire (EDE-Q) | ating disorders.  Psychiatry Research, 247, 182-193.  | 구분 | - 일차목적 및 가설 | 유지 | ※ 접근 통제의 예: 비밀번호, 하드웨어 키, | Premarket Submissions for | 이용하여 발행된 난수표를 적용한다.  | 소프트웨어를 | 포함하는 | 의료기기에 | ■ 예(☞안내서) | □ 아니오 |\n| 성명 | 소속기관명 | 전공 | 직위 | 전화 | Placebo |\n| 8 | 회사명 | 대표이사 | 소재지 | 전화 | 받게 될 각종 검사나 절차 | 평가지표로 사용할 수 있다.  | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까?  (민원인용) | 대한 시판 전 제출에 대한 가이드라인 | 미국 |\n| ○ 관련성이 적음(Probably not related) | 가) 위험분석 | 그 이유의 타당성을 면밀히 검토하여야 한다. ",
        "original_sentence": "| 구분 | - 일차목적 및 가설 | 유지 | ※ 접근 통제의 예: 비밀번호, 하드웨어 키, | Premarket Submissions for | 이용하여 발행된 난수표를 적용한다. "
      }
    },
    {
      "chunk_id": "chunk_224",
      "text": "| 소프트웨어를 | 포함하는 | 의료기기에 | ■ 예(☞안내서) | □ 아니오 |\n| 성명 | 소속기관명 | 전공 | 직위 | 전화 | Placebo |\n| 8 | 회사명 | 대표이사 | 소재지 | 전화 | 받게 될 각종 검사나 절차 | 평가지표로 사용할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 223,
        "window_size": 3,
        "char_count": 149,
        "word_count": 47,
        "page_number": 3,
        "window_text": "| □ 민원인들의 이해를 돕기 위하여 법령 또는 행정규칙을 알기 | 다른 디바이스에서 같은 휴대폰 | 국제 규격 | 소프트웨어 |\n| (8) 「의료기기 임상시험계획 승인에 관한 규정」 | Eating Disorder Examination Questionnaire (EDE-Q) | ating disorders.  Psychiatry Research, 247, 182-193.  | 구분 | - 일차목적 및 가설 | 유지 | ※ 접근 통제의 예: 비밀번호, 하드웨어 키, | Premarket Submissions for | 이용하여 발행된 난수표를 적용한다.  | 소프트웨어를 | 포함하는 | 의료기기에 | ■ 예(☞안내서) | □ 아니오 |\n| 성명 | 소속기관명 | 전공 | 직위 | 전화 | Placebo |\n| 8 | 회사명 | 대표이사 | 소재지 | 전화 | 받게 될 각종 검사나 절차 | 평가지표로 사용할 수 있다.  | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까?  (민원인용) | 대한 시판 전 제출에 대한 가이드라인 | 미국 |\n| ○ 관련성이 적음(Probably not related) | 가) 위험분석 | 그 이유의 타당성을 면밀히 검토하여야 한다.  | 한다)를 말한다. ",
        "original_sentence": "| 소프트웨어를 | 포함하는 | 의료기기에 | ■ 예(☞안내서) | □ 아니오 |\n| 성명 | 소속기관명 | 전공 | 직위 | 전화 | Placebo |\n| 8 | 회사명 | 대표이사 | 소재지 | 전화 | 받게 될 각종 검사나 절차 | 평가지표로 사용할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_225",
      "text": "| 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까? ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 224,
        "window_size": 3,
        "char_count": 51,
        "word_count": 12,
        "page_number": 3,
        "window_text": "Psychiatry Research, 247, 182-193.  | 구분 | - 일차목적 및 가설 | 유지 | ※ 접근 통제의 예: 비밀번호, 하드웨어 키, | Premarket Submissions for | 이용하여 발행된 난수표를 적용한다.  | 소프트웨어를 | 포함하는 | 의료기기에 | ■ 예(☞안내서) | □ 아니오 |\n| 성명 | 소속기관명 | 전공 | 직위 | 전화 | Placebo |\n| 8 | 회사명 | 대표이사 | 소재지 | 전화 | 받게 될 각종 검사나 절차 | 평가지표로 사용할 수 있다.  | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까?  (민원인용) | 대한 시판 전 제출에 대한 가이드라인 | 미국 |\n| ○ 관련성이 적음(Probably not related) | 가) 위험분석 | 그 이유의 타당성을 면밀히 검토하여야 한다.  | 한다)를 말한다.  | 있도록 하여야 한다. ",
        "original_sentence": "| 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_226",
      "text": "(민원인용) | 대한 시판 전 제출에 대한 가이드라인 | 미국 |\n| ○ 관련성이 적음(Probably not related) | 가) 위험분석 | 그 이유의 타당성을 면밀히 검토하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 225,
        "window_size": 3,
        "char_count": 108,
        "word_count": 27,
        "page_number": 28,
        "window_text": "| 구분 | - 일차목적 및 가설 | 유지 | ※ 접근 통제의 예: 비밀번호, 하드웨어 키, | Premarket Submissions for | 이용하여 발행된 난수표를 적용한다.  | 소프트웨어를 | 포함하는 | 의료기기에 | ■ 예(☞안내서) | □ 아니오 |\n| 성명 | 소속기관명 | 전공 | 직위 | 전화 | Placebo |\n| 8 | 회사명 | 대표이사 | 소재지 | 전화 | 받게 될 각종 검사나 절차 | 평가지표로 사용할 수 있다.  | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까?  (민원인용) | 대한 시판 전 제출에 대한 가이드라인 | 미국 |\n| ○ 관련성이 적음(Probably not related) | 가) 위험분석 | 그 이유의 타당성을 면밀히 검토하여야 한다.  | 한다)를 말한다.  | 있도록 하여야 한다.  | ※ 예: 기기/시스템 간 통신 시 상호인증 | 들을 수집한다. ",
        "original_sentence": "(민원인용) | 대한 시판 전 제출에 대한 가이드라인 | 미국 |\n| ○ 관련성이 적음(Probably not related) | 가) 위험분석 | 그 이유의 타당성을 면밀히 검토하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_227",
      "text": "| 한다)를 말한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 226,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 15,
        "window_text": "| 소프트웨어를 | 포함하는 | 의료기기에 | ■ 예(☞안내서) | □ 아니오 |\n| 성명 | 소속기관명 | 전공 | 직위 | 전화 | Placebo |\n| 8 | 회사명 | 대표이사 | 소재지 | 전화 | 받게 될 각종 검사나 절차 | 평가지표로 사용할 수 있다.  | 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까?  (민원인용) | 대한 시판 전 제출에 대한 가이드라인 | 미국 |\n| ○ 관련성이 적음(Probably not related) | 가) 위험분석 | 그 이유의 타당성을 면밀히 검토하여야 한다.  | 한다)를 말한다.  | 있도록 하여야 한다.  | ※ 예: 기기/시스템 간 통신 시 상호인증 | 들을 수집한다.  | 기록한다. ",
        "original_sentence": "| 한다)를 말한다. "
      }
    },
    {
      "chunk_id": "chunk_228",
      "text": "| 있도록 하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 227,
        "window_size": 3,
        "char_count": 14,
        "word_count": 4,
        "page_number": 15,
        "window_text": "| 쉽게 설명하거나 특정 민원업무에 대한 행정기관의 대외적인 입장을 | 기술하는 것입니까?  (민원인용) | 대한 시판 전 제출에 대한 가이드라인 | 미국 |\n| ○ 관련성이 적음(Probably not related) | 가) 위험분석 | 그 이유의 타당성을 면밀히 검토하여야 한다.  | 한다)를 말한다.  | 있도록 하여야 한다.  | ※ 예: 기기/시스템 간 통신 시 상호인증 | 들을 수집한다.  | 기록한다.  | 제시한다. ",
        "original_sentence": "| 있도록 하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_229",
      "text": "| ※ 예: 기기/시스템 간 통신 시 상호인증 | 들을 수집한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 228,
        "window_size": 3,
        "char_count": 37,
        "word_count": 11,
        "page_number": 15,
        "window_text": "(민원인용) | 대한 시판 전 제출에 대한 가이드라인 | 미국 |\n| ○ 관련성이 적음(Probably not related) | 가) 위험분석 | 그 이유의 타당성을 면밀히 검토하여야 한다.  | 한다)를 말한다.  | 있도록 하여야 한다.  | ※ 예: 기기/시스템 간 통신 시 상호인증 | 들을 수집한다.  | 기록한다.  | 제시한다.  | 번호로 동시에 로그인을 시도 | 소프트웨어 아키텍처를 소프트 | 높고 기능저하도 심한 것을 의미한다. ",
        "original_sentence": "| ※ 예: 기기/시스템 간 통신 시 상호인증 | 들을 수집한다. "
      }
    },
    {
      "chunk_id": "chunk_230",
      "text": "| 기록한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 229,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 15,
        "window_text": "| 한다)를 말한다.  | 있도록 하여야 한다.  | ※ 예: 기기/시스템 간 통신 시 상호인증 | 들을 수집한다.  | 기록한다.  | 제시한다.  | 번호로 동시에 로그인을 시도 | 소프트웨어 아키텍처를 소프트 | 높고 기능저하도 심한 것을 의미한다.  | 위험분석 | 위험평가 | 34 | 13.88 | 8.96 | 29 | 8.11 | 12.39 | -3.74 | 11.32 | 한기기에 시험용 정보로 로그인을 | 검증 및 |\n| 선정/제외기준 확인 | O | O | - | - | Software Contained in Medical | 활동 | 생체인증 등 | 지에 내용을 기록한다. ",
        "original_sentence": "| 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_231",
      "text": "| 제시한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 230,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 15,
        "window_text": "| 있도록 하여야 한다.  | ※ 예: 기기/시스템 간 통신 시 상호인증 | 들을 수집한다.  | 기록한다.  | 제시한다.  | 번호로 동시에 로그인을 시도 | 소프트웨어 아키텍처를 소프트 | 높고 기능저하도 심한 것을 의미한다.  | 위험분석 | 위험평가 | 34 | 13.88 | 8.96 | 29 | 8.11 | 12.39 | -3.74 | 11.32 | 한기기에 시험용 정보로 로그인을 | 검증 및 |\n| 선정/제외기준 확인 | O | O | - | - | Software Contained in Medical | 활동 | 생체인증 등 | 지에 내용을 기록한다.  |\n| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | 기록한다. ",
        "original_sentence": "| 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_232",
      "text": "| 번호로 동시에 로그인을 시도 | 소프트웨어 아키텍처를 소프트 | 높고 기능저하도 심한 것을 의미한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 231,
        "window_size": 3,
        "char_count": 59,
        "word_count": 15,
        "page_number": 9,
        "window_text": "| ※ 예: 기기/시스템 간 통신 시 상호인증 | 들을 수집한다.  | 기록한다.  | 제시한다.  | 번호로 동시에 로그인을 시도 | 소프트웨어 아키텍처를 소프트 | 높고 기능저하도 심한 것을 의미한다.  | 위험분석 | 위험평가 | 34 | 13.88 | 8.96 | 29 | 8.11 | 12.39 | -3.74 | 11.32 | 한기기에 시험용 정보로 로그인을 | 검증 및 |\n| 선정/제외기준 확인 | O | O | - | - | Software Contained in Medical | 활동 | 생체인증 등 | 지에 내용을 기록한다.  |\n| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | 기록한다.  | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 중복 로그인 | 한다. ",
        "original_sentence": "| 번호로 동시에 로그인을 시도 | 소프트웨어 아키텍처를 소프트 | 높고 기능저하도 심한 것을 의미한다. "
      }
    },
    {
      "chunk_id": "chunk_233",
      "text": "| 위험분석 | 위험평가 | 34 | 13.88 | 8.96 | 29 | 8.11 | 12.39 | -3.74 | 11.32 | 한기기에 시험용 정보로 로그인을 | 검증 및 |\n| 선정/제외기준 확인 | O | O | - | - | Software Contained in Medical | 활동 | 생체인증 등 | 지에 내용을 기록한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 232,
        "window_size": 3,
        "char_count": 189,
        "word_count": 54,
        "page_number": 9,
        "window_text": "| 기록한다.  | 제시한다.  | 번호로 동시에 로그인을 시도 | 소프트웨어 아키텍처를 소프트 | 높고 기능저하도 심한 것을 의미한다.  | 위험분석 | 위험평가 | 34 | 13.88 | 8.96 | 29 | 8.11 | 12.39 | -3.74 | 11.32 | 한기기에 시험용 정보로 로그인을 | 검증 및 |\n| 선정/제외기준 확인 | O | O | - | - | Software Contained in Medical | 활동 | 생체인증 등 | 지에 내용을 기록한다.  |\n| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | 기록한다.  | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 중복 로그인 | 한다.  | (control) | 적용 |\n| 5 | · 층: 성별(남/여), 나이(oo세 미만, oo세 이상) | ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 다) 인구학적 조사, 병력조사 요법 | 않으면 사유와 이에 대한 근거 등을 제시해야 한다. ",
        "original_sentence": "| 위험분석 | 위험평가 | 34 | 13.88 | 8.96 | 29 | 8.11 | 12.39 | -3.74 | 11.32 | 한기기에 시험용 정보로 로그인을 | 검증 및 |\n| 선정/제외기준 확인 | O | O | - | - | Software Contained in Medical | 활동 | 생체인증 등 | 지에 내용을 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_234",
      "text": "|\n| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | 기록한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 233,
        "window_size": 3,
        "char_count": 62,
        "word_count": 11,
        "page_number": 15,
        "window_text": "| 제시한다.  | 번호로 동시에 로그인을 시도 | 소프트웨어 아키텍처를 소프트 | 높고 기능저하도 심한 것을 의미한다.  | 위험분석 | 위험평가 | 34 | 13.88 | 8.96 | 29 | 8.11 | 12.39 | -3.74 | 11.32 | 한기기에 시험용 정보로 로그인을 | 검증 및 |\n| 선정/제외기준 확인 | O | O | - | - | Software Contained in Medical | 활동 | 생체인증 등 | 지에 내용을 기록한다.  |\n| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | 기록한다.  | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 중복 로그인 | 한다.  | (control) | 적용 |\n| 5 | · 층: 성별(남/여), 나이(oo세 미만, oo세 이상) | ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 다) 인구학적 조사, 병력조사 요법 | 않으면 사유와 이에 대한 근거 등을 제시해야 한다.  | 내용을 기록한다. ",
        "original_sentence": "|\n| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_235",
      "text": "| ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 중복 로그인 | 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 234,
        "window_size": 3,
        "char_count": 51,
        "word_count": 15,
        "page_number": 15,
        "window_text": "| 번호로 동시에 로그인을 시도 | 소프트웨어 아키텍처를 소프트 | 높고 기능저하도 심한 것을 의미한다.  | 위험분석 | 위험평가 | 34 | 13.88 | 8.96 | 29 | 8.11 | 12.39 | -3.74 | 11.32 | 한기기에 시험용 정보로 로그인을 | 검증 및 |\n| 선정/제외기준 확인 | O | O | - | - | Software Contained in Medical | 활동 | 생체인증 등 | 지에 내용을 기록한다.  |\n| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | 기록한다.  | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 중복 로그인 | 한다.  | (control) | 적용 |\n| 5 | · 층: 성별(남/여), 나이(oo세 미만, oo세 이상) | ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 다) 인구학적 조사, 병력조사 요법 | 않으면 사유와 이에 대한 근거 등을 제시해야 한다.  | 내용을 기록한다.  | Medical device software – | 했을 때, 기존 로그인되어 | 한 후, 다른 기기에서 같은 정보로 |\n| * [F50.0] Anorexia nervosa (신경성 식욕부진) | 방법, 암호화 필요 여부, 과거에 전송된 | 순서가 타당한 경우 | 웨어 유닛으로 표현할 수 있을 | (5) The EuroQol Visual Analogue Scale (EQ-VAS) | 「의료기기법」 및 「의료기기법시행 | 발생 | 소프트웨어 | 유효성 | (AB-1234) |\n| 5) 피험자가 준수하여야 할 사항 | 인구학적 정보 | O | - | - | - | 동시에 의료기기의 전체 수명주기의 위험관리 일부로 수행한다. ",
        "original_sentence": "| ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 중복 로그인 | 한다. "
      }
    },
    {
      "chunk_id": "chunk_236",
      "text": "| (control) | 적용 |\n| 5 | · 층: 성별(남/여), 나이(oo세 미만, oo세 이상) | ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 다) 인구학적 조사, 병력조사 요법 | 않으면 사유와 이에 대한 근거 등을 제시해야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 235,
        "window_size": 3,
        "char_count": 152,
        "word_count": 41,
        "page_number": 26,
        "window_text": "| 위험분석 | 위험평가 | 34 | 13.88 | 8.96 | 29 | 8.11 | 12.39 | -3.74 | 11.32 | 한기기에 시험용 정보로 로그인을 | 검증 및 |\n| 선정/제외기준 확인 | O | O | - | - | Software Contained in Medical | 활동 | 생체인증 등 | 지에 내용을 기록한다.  |\n| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | 기록한다.  | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 중복 로그인 | 한다.  | (control) | 적용 |\n| 5 | · 층: 성별(남/여), 나이(oo세 미만, oo세 이상) | ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 다) 인구학적 조사, 병력조사 요법 | 않으면 사유와 이에 대한 근거 등을 제시해야 한다.  | 내용을 기록한다.  | Medical device software – | 했을 때, 기존 로그인되어 | 한 후, 다른 기기에서 같은 정보로 |\n| * [F50.0] Anorexia nervosa (신경성 식욕부진) | 방법, 암호화 필요 여부, 과거에 전송된 | 순서가 타당한 경우 | 웨어 유닛으로 표현할 수 있을 | (5) The EuroQol Visual Analogue Scale (EQ-VAS) | 「의료기기법」 및 「의료기기법시행 | 발생 | 소프트웨어 | 유효성 | (AB-1234) |\n| 5) 피험자가 준수하여야 할 사항 | 인구학적 정보 | O | - | - | - | 동시에 의료기기의 전체 수명주기의 위험관리 일부로 수행한다.  | Grilo et al. ",
        "original_sentence": "| (control) | 적용 |\n| 5 | · 층: 성별(남/여), 나이(oo세 미만, oo세 이상) | ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 다) 인구학적 조사, 병력조사 요법 | 않으면 사유와 이에 대한 근거 등을 제시해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_237",
      "text": "| 내용을 기록한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 236,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 15,
        "window_text": "|\n| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | 기록한다.  | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 중복 로그인 | 한다.  | (control) | 적용 |\n| 5 | · 층: 성별(남/여), 나이(oo세 미만, oo세 이상) | ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 다) 인구학적 조사, 병력조사 요법 | 않으면 사유와 이에 대한 근거 등을 제시해야 한다.  | 내용을 기록한다.  | Medical device software – | 했을 때, 기존 로그인되어 | 한 후, 다른 기기에서 같은 정보로 |\n| * [F50.0] Anorexia nervosa (신경성 식욕부진) | 방법, 암호화 필요 여부, 과거에 전송된 | 순서가 타당한 경우 | 웨어 유닛으로 표현할 수 있을 | (5) The EuroQol Visual Analogue Scale (EQ-VAS) | 「의료기기법」 및 「의료기기법시행 | 발생 | 소프트웨어 | 유효성 | (AB-1234) |\n| 5) 피험자가 준수하여야 할 사항 | 인구학적 정보 | O | - | - | - | 동시에 의료기기의 전체 수명주기의 위험관리 일부로 수행한다.  | Grilo et al.  | (2022) U.S.A. ",
        "original_sentence": "| 내용을 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_238",
      "text": "| Medical device software – | 했을 때, 기존 로그인되어 | 한 후, 다른 기기에서 같은 정보로 |\n| * [F50.0] Anorexia nervosa (신경성 식욕부진) | 방법, 암호화 필요 여부, 과거에 전송된 | 순서가 타당한 경우 | 웨어 유닛으로 표현할 수 있을 | (5) The EuroQol Visual Analogue Scale (EQ-VAS) | 「의료기기법」 및 「의료기기법시행 | 발생 | 소프트웨어 | 유효성 | (AB-1234) |\n| 5) 피험자가 준수하여야 할 사항 | 인구학적 정보 | O | - | - | - | 동시에 의료기기의 전체 수명주기의 위험관리 일부로 수행한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 237,
        "window_size": 3,
        "char_count": 352,
        "word_count": 88,
        "page_number": 9,
        "window_text": "| ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 중복 로그인 | 한다.  | (control) | 적용 |\n| 5 | · 층: 성별(남/여), 나이(oo세 미만, oo세 이상) | ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 다) 인구학적 조사, 병력조사 요법 | 않으면 사유와 이에 대한 근거 등을 제시해야 한다.  | 내용을 기록한다.  | Medical device software – | 했을 때, 기존 로그인되어 | 한 후, 다른 기기에서 같은 정보로 |\n| * [F50.0] Anorexia nervosa (신경성 식욕부진) | 방법, 암호화 필요 여부, 과거에 전송된 | 순서가 타당한 경우 | 웨어 유닛으로 표현할 수 있을 | (5) The EuroQol Visual Analogue Scale (EQ-VAS) | 「의료기기법」 및 「의료기기법시행 | 발생 | 소프트웨어 | 유효성 | (AB-1234) |\n| 5) 피험자가 준수하여야 할 사항 | 인구학적 정보 | O | - | - | - | 동시에 의료기기의 전체 수명주기의 위험관리 일부로 수행한다.  | Grilo et al.  | (2022) U.S.A.  | 프로 | 질환으로 정의한다. ",
        "original_sentence": "| Medical device software – | 했을 때, 기존 로그인되어 | 한 후, 다른 기기에서 같은 정보로 |\n| * [F50.0] Anorexia nervosa (신경성 식욕부진) | 방법, 암호화 필요 여부, 과거에 전송된 | 순서가 타당한 경우 | 웨어 유닛으로 표현할 수 있을 | (5) The EuroQol Visual Analogue Scale (EQ-VAS) | 「의료기기법」 및 「의료기기법시행 | 발생 | 소프트웨어 | 유효성 | (AB-1234) |\n| 5) 피험자가 준수하여야 할 사항 | 인구학적 정보 | O | - | - | - | 동시에 의료기기의 전체 수명주기의 위험관리 일부로 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_239",
      "text": "| Grilo et al. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 238,
        "window_size": 3,
        "char_count": 15,
        "word_count": 4,
        "page_number": 62,
        "window_text": "| (control) | 적용 |\n| 5 | · 층: 성별(남/여), 나이(oo세 미만, oo세 이상) | ㈜○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○- ○○-○○○○ | 다) 인구학적 조사, 병력조사 요법 | 않으면 사유와 이에 대한 근거 등을 제시해야 한다.  | 내용을 기록한다.  | Medical device software – | 했을 때, 기존 로그인되어 | 한 후, 다른 기기에서 같은 정보로 |\n| * [F50.0] Anorexia nervosa (신경성 식욕부진) | 방법, 암호화 필요 여부, 과거에 전송된 | 순서가 타당한 경우 | 웨어 유닛으로 표현할 수 있을 | (5) The EuroQol Visual Analogue Scale (EQ-VAS) | 「의료기기법」 및 「의료기기법시행 | 발생 | 소프트웨어 | 유효성 | (AB-1234) |\n| 5) 피험자가 준수하여야 할 사항 | 인구학적 정보 | O | - | - | - | 동시에 의료기기의 전체 수명주기의 위험관리 일부로 수행한다.  | Grilo et al.  | (2022) U.S.A.  | 프로 | 질환으로 정의한다.  | 방지 | Devices | 의료기기 소프트웨어의 |\n| 2) 방문 2 (치료 시작일, Baseline) | 4 | IEC/TR | 높은 것을 의미한다(Bohn&Fairburn, 2008). ",
        "original_sentence": "| Grilo et al. "
      }
    },
    {
      "chunk_id": "chunk_240",
      "text": "| (2022) U.S.A. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 239,
        "window_size": 3,
        "char_count": 16,
        "word_count": 3,
        "page_number": 9,
        "window_text": "| 내용을 기록한다.  | Medical device software – | 했을 때, 기존 로그인되어 | 한 후, 다른 기기에서 같은 정보로 |\n| * [F50.0] Anorexia nervosa (신경성 식욕부진) | 방법, 암호화 필요 여부, 과거에 전송된 | 순서가 타당한 경우 | 웨어 유닛으로 표현할 수 있을 | (5) The EuroQol Visual Analogue Scale (EQ-VAS) | 「의료기기법」 및 「의료기기법시행 | 발생 | 소프트웨어 | 유효성 | (AB-1234) |\n| 5) 피험자가 준수하여야 할 사항 | 인구학적 정보 | O | - | - | - | 동시에 의료기기의 전체 수명주기의 위험관리 일부로 수행한다.  | Grilo et al.  | (2022) U.S.A.  | 프로 | 질환으로 정의한다.  | 방지 | Devices | 의료기기 소프트웨어의 |\n| 2) 방문 2 (치료 시작일, Baseline) | 4 | IEC/TR | 높은 것을 의미한다(Bohn&Fairburn, 2008).  | (Kim,Won,Kim et al., 2018) | 라) 식사장애 검사(EDE-Q) 조사 | 대리인)에게 제공해야 한다. ",
        "original_sentence": "| (2022) U.S.A. "
      }
    },
    {
      "chunk_id": "chunk_241",
      "text": "| 프로 | 질환으로 정의한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 240,
        "window_size": 3,
        "char_count": 18,
        "word_count": 5,
        "page_number": 15,
        "window_text": "| Medical device software – | 했을 때, 기존 로그인되어 | 한 후, 다른 기기에서 같은 정보로 |\n| * [F50.0] Anorexia nervosa (신경성 식욕부진) | 방법, 암호화 필요 여부, 과거에 전송된 | 순서가 타당한 경우 | 웨어 유닛으로 표현할 수 있을 | (5) The EuroQol Visual Analogue Scale (EQ-VAS) | 「의료기기법」 및 「의료기기법시행 | 발생 | 소프트웨어 | 유효성 | (AB-1234) |\n| 5) 피험자가 준수하여야 할 사항 | 인구학적 정보 | O | - | - | - | 동시에 의료기기의 전체 수명주기의 위험관리 일부로 수행한다.  | Grilo et al.  | (2022) U.S.A.  | 프로 | 질환으로 정의한다.  | 방지 | Devices | 의료기기 소프트웨어의 |\n| 2) 방문 2 (치료 시작일, Baseline) | 4 | IEC/TR | 높은 것을 의미한다(Bohn&Fairburn, 2008).  | (Kim,Won,Kim et al., 2018) | 라) 식사장애 검사(EDE-Q) 조사 | 대리인)에게 제공해야 한다.  | 및 식품의약품안전처장의 승인을 받아야 한다. ",
        "original_sentence": "| 프로 | 질환으로 정의한다. "
      }
    },
    {
      "chunk_id": "chunk_242",
      "text": "| 방지 | Devices | 의료기기 소프트웨어의 |\n| 2) 방문 2 (치료 시작일, Baseline) | 4 | IEC/TR | 높은 것을 의미한다(Bohn&Fairburn, 2008). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 241,
        "window_size": 3,
        "char_count": 108,
        "word_count": 24,
        "page_number": 9,
        "window_text": "| Grilo et al.  | (2022) U.S.A.  | 프로 | 질환으로 정의한다.  | 방지 | Devices | 의료기기 소프트웨어의 |\n| 2) 방문 2 (치료 시작일, Baseline) | 4 | IEC/TR | 높은 것을 의미한다(Bohn&Fairburn, 2008).  | (Kim,Won,Kim et al., 2018) | 라) 식사장애 검사(EDE-Q) 조사 | 대리인)에게 제공해야 한다.  | 및 식품의약품안전처장의 승인을 받아야 한다.  | 얻는 전 과정에 참석하여야 한다. ",
        "original_sentence": "| 방지 | Devices | 의료기기 소프트웨어의 |\n| 2) 방문 2 (치료 시작일, Baseline) | 4 | IEC/TR | 높은 것을 의미한다(Bohn&Fairburn, 2008). "
      }
    },
    {
      "chunk_id": "chunk_243",
      "text": "| (Kim,Won,Kim et al., 2018) | 라) 식사장애 검사(EDE-Q) 조사 | 대리인)에게 제공해야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 242,
        "window_size": 3,
        "char_count": 70,
        "word_count": 14,
        "page_number": 9,
        "window_text": "| (2022) U.S.A.  | 프로 | 질환으로 정의한다.  | 방지 | Devices | 의료기기 소프트웨어의 |\n| 2) 방문 2 (치료 시작일, Baseline) | 4 | IEC/TR | 높은 것을 의미한다(Bohn&Fairburn, 2008).  | (Kim,Won,Kim et al., 2018) | 라) 식사장애 검사(EDE-Q) 조사 | 대리인)에게 제공해야 한다.  | 및 식품의약품안전처장의 승인을 받아야 한다.  | 얻는 전 과정에 참석하여야 한다.  | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 의료기기와의 인과관계에 대하여 증례 기록지에 기록한다. ",
        "original_sentence": "| (Kim,Won,Kim et al., 2018) | 라) 식사장애 검사(EDE-Q) 조사 | 대리인)에게 제공해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_244",
      "text": "| 및 식품의약품안전처장의 승인을 받아야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 243,
        "window_size": 3,
        "char_count": 27,
        "word_count": 6,
        "page_number": 15,
        "window_text": "| 프로 | 질환으로 정의한다.  | 방지 | Devices | 의료기기 소프트웨어의 |\n| 2) 방문 2 (치료 시작일, Baseline) | 4 | IEC/TR | 높은 것을 의미한다(Bohn&Fairburn, 2008).  | (Kim,Won,Kim et al., 2018) | 라) 식사장애 검사(EDE-Q) 조사 | 대리인)에게 제공해야 한다.  | 및 식품의약품안전처장의 승인을 받아야 한다.  | 얻는 전 과정에 참석하여야 한다.  | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 의료기기와의 인과관계에 대하여 증례 기록지에 기록한다.  | 영향을 줄 것으로 예상하는 약물을 임의로 복용한 경우 | 조사한다. ",
        "original_sentence": "| 및 식품의약품안전처장의 승인을 받아야 한다. "
      }
    },
    {
      "chunk_id": "chunk_245",
      "text": "| 얻는 전 과정에 참석하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 244,
        "window_size": 3,
        "char_count": 21,
        "word_count": 6,
        "page_number": 15,
        "window_text": "| 방지 | Devices | 의료기기 소프트웨어의 |\n| 2) 방문 2 (치료 시작일, Baseline) | 4 | IEC/TR | 높은 것을 의미한다(Bohn&Fairburn, 2008).  | (Kim,Won,Kim et al., 2018) | 라) 식사장애 검사(EDE-Q) 조사 | 대리인)에게 제공해야 한다.  | 및 식품의약품안전처장의 승인을 받아야 한다.  | 얻는 전 과정에 참석하여야 한다.  | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 의료기기와의 인과관계에 대하여 증례 기록지에 기록한다.  | 영향을 줄 것으로 예상하는 약물을 임의로 복용한 경우 | 조사한다.  | 하여 해당 성능을 증명할 수 있다. ",
        "original_sentence": "| 얻는 전 과정에 참석하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_246",
      "text": "| - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 의료기기와의 인과관계에 대하여 증례 기록지에 기록한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 245,
        "window_size": 3,
        "char_count": 66,
        "word_count": 15,
        "page_number": 27,
        "window_text": "| (Kim,Won,Kim et al., 2018) | 라) 식사장애 검사(EDE-Q) 조사 | 대리인)에게 제공해야 한다.  | 및 식품의약품안전처장의 승인을 받아야 한다.  | 얻는 전 과정에 참석하여야 한다.  | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 의료기기와의 인과관계에 대하여 증례 기록지에 기록한다.  | 영향을 줄 것으로 예상하는 약물을 임의로 복용한 경우 | 조사한다.  | 하여 해당 성능을 증명할 수 있다.  | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | Part 1: Guidance on the | 심각 | □ 예 | ■ 아니오 | 위험 |\n| 아) 병용약물 조사 | BWL+ | 있던 기기에서는 로그아웃 | 때까지 | 분해하고, | 각 | 유닛에 | 로그인을 시도한다. ",
        "original_sentence": "| - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 의료기기와의 인과관계에 대하여 증례 기록지에 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_247",
      "text": "| 영향을 줄 것으로 예상하는 약물을 임의로 복용한 경우 | 조사한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 246,
        "window_size": 3,
        "char_count": 40,
        "word_count": 11,
        "page_number": 15,
        "window_text": "| 및 식품의약품안전처장의 승인을 받아야 한다.  | 얻는 전 과정에 참석하여야 한다.  | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 의료기기와의 인과관계에 대하여 증례 기록지에 기록한다.  | 영향을 줄 것으로 예상하는 약물을 임의로 복용한 경우 | 조사한다.  | 하여 해당 성능을 증명할 수 있다.  | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | Part 1: Guidance on the | 심각 | □ 예 | ■ 아니오 | 위험 |\n| 아) 병용약물 조사 | BWL+ | 있던 기기에서는 로그아웃 | 때까지 | 분해하고, | 각 | 유닛에 | 로그인을 시도한다.  |\n| [F50.2] Bulimia nervosa (신경성 폭식증) | 같이 기록한다. ",
        "original_sentence": "| 영향을 줄 것으로 예상하는 약물을 임의로 복용한 경우 | 조사한다. "
      }
    },
    {
      "chunk_id": "chunk_248",
      "text": "| 하여 해당 성능을 증명할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 247,
        "window_size": 3,
        "char_count": 22,
        "word_count": 7,
        "page_number": 12,
        "window_text": "| 얻는 전 과정에 참석하여야 한다.  | - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 의료기기와의 인과관계에 대하여 증례 기록지에 기록한다.  | 영향을 줄 것으로 예상하는 약물을 임의로 복용한 경우 | 조사한다.  | 하여 해당 성능을 증명할 수 있다.  | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | Part 1: Guidance on the | 심각 | □ 예 | ■ 아니오 | 위험 |\n| 아) 병용약물 조사 | BWL+ | 있던 기기에서는 로그아웃 | 때까지 | 분해하고, | 각 | 유닛에 | 로그인을 시도한다.  |\n| [F50.2] Bulimia nervosa (신경성 폭식증) | 같이 기록한다.  | 제조자는 주기적인 업데이트의 구현과 배포를 | Deciding When to Submit a | 명령어 및 데이터의 비인가 반복에 대한 | 시판 후 소프트웨어에 문제가 | 위해상황 | 위해 | 규칙」,「의료기기 | 허가·신고·심사 | 위험관리 방법에 대한 국제 | 가능 | 확인 자료 | 검증 및 | 국외 | 결과 |\n| 기타 확인 | 1) 개요 | inical Psychology, 61(2), 296-605. ",
        "original_sentence": "| 하여 해당 성능을 증명할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_249",
      "text": "| □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | Part 1: Guidance on the | 심각 | □ 예 | ■ 아니오 | 위험 |\n| 아) 병용약물 조사 | BWL+ | 있던 기기에서는 로그아웃 | 때까지 | 분해하고, | 각 | 유닛에 | 로그인을 시도한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 248,
        "window_size": 3,
        "char_count": 192,
        "word_count": 54,
        "page_number": 3,
        "window_text": "| - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우 | 의료기기와의 인과관계에 대하여 증례 기록지에 기록한다.  | 영향을 줄 것으로 예상하는 약물을 임의로 복용한 경우 | 조사한다.  | 하여 해당 성능을 증명할 수 있다.  | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | Part 1: Guidance on the | 심각 | □ 예 | ■ 아니오 | 위험 |\n| 아) 병용약물 조사 | BWL+ | 있던 기기에서는 로그아웃 | 때까지 | 분해하고, | 각 | 유닛에 | 로그인을 시도한다.  |\n| [F50.2] Bulimia nervosa (신경성 폭식증) | 같이 기록한다.  | 제조자는 주기적인 업데이트의 구현과 배포를 | Deciding When to Submit a | 명령어 및 데이터의 비인가 반복에 대한 | 시판 후 소프트웨어에 문제가 | 위해상황 | 위해 | 규칙」,「의료기기 | 허가·신고·심사 | 위험관리 방법에 대한 국제 | 가능 | 확인 자료 | 검증 및 | 국외 | 결과 |\n| 기타 확인 | 1) 개요 | inical Psychology, 61(2), 296-605.  | 과거병력 조사 | O | - | - | - | 3) 맹검 방법 | 결정하고 주의사항을 준수하기로 서면 동의한 자 | 세스 | 민원인을 구속하는 내용이 있습니까? ",
        "original_sentence": "| □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | Part 1: Guidance on the | 심각 | □ 예 | ■ 아니오 | 위험 |\n| 아) 병용약물 조사 | BWL+ | 있던 기기에서는 로그아웃 | 때까지 | 분해하고, | 각 | 유닛에 | 로그인을 시도한다. "
      }
    },
    {
      "chunk_id": "chunk_250",
      "text": "|\n| [F50.2] Bulimia nervosa (신경성 폭식증) | 같이 기록한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 249,
        "window_size": 3,
        "char_count": 49,
        "word_count": 10,
        "page_number": 9,
        "window_text": "| 영향을 줄 것으로 예상하는 약물을 임의로 복용한 경우 | 조사한다.  | 하여 해당 성능을 증명할 수 있다.  | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | Part 1: Guidance on the | 심각 | □ 예 | ■ 아니오 | 위험 |\n| 아) 병용약물 조사 | BWL+ | 있던 기기에서는 로그아웃 | 때까지 | 분해하고, | 각 | 유닛에 | 로그인을 시도한다.  |\n| [F50.2] Bulimia nervosa (신경성 폭식증) | 같이 기록한다.  | 제조자는 주기적인 업데이트의 구현과 배포를 | Deciding When to Submit a | 명령어 및 데이터의 비인가 반복에 대한 | 시판 후 소프트웨어에 문제가 | 위해상황 | 위해 | 규칙」,「의료기기 | 허가·신고·심사 | 위험관리 방법에 대한 국제 | 가능 | 확인 자료 | 검증 및 | 국외 | 결과 |\n| 기타 확인 | 1) 개요 | inical Psychology, 61(2), 296-605.  | 과거병력 조사 | O | - | - | - | 3) 맹검 방법 | 결정하고 주의사항을 준수하기로 서면 동의한 자 | 세스 | 민원인을 구속하는 내용이 있습니까?  | 오송보건의료행정타운 |\n| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | - 심각한 부작용 발생으로 조기 종료시킬 수 있다. ",
        "original_sentence": "|\n| [F50.2] Bulimia nervosa (신경성 폭식증) | 같이 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_251",
      "text": "| 제조자는 주기적인 업데이트의 구현과 배포를 | Deciding When to Submit a | 명령어 및 데이터의 비인가 반복에 대한 | 시판 후 소프트웨어에 문제가 | 위해상황 | 위해 | 규칙」,「의료기기 | 허가·신고·심사 | 위험관리 방법에 대한 국제 | 가능 | 확인 자료 | 검증 및 | 국외 | 결과 |\n| 기타 확인 | 1) 개요 | inical Psychology, 61(2), 296-605. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 250,
        "window_size": 3,
        "char_count": 233,
        "word_count": 61,
        "page_number": 37,
        "window_text": "| 하여 해당 성능을 증명할 수 있다.  | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | Part 1: Guidance on the | 심각 | □ 예 | ■ 아니오 | 위험 |\n| 아) 병용약물 조사 | BWL+ | 있던 기기에서는 로그아웃 | 때까지 | 분해하고, | 각 | 유닛에 | 로그인을 시도한다.  |\n| [F50.2] Bulimia nervosa (신경성 폭식증) | 같이 기록한다.  | 제조자는 주기적인 업데이트의 구현과 배포를 | Deciding When to Submit a | 명령어 및 데이터의 비인가 반복에 대한 | 시판 후 소프트웨어에 문제가 | 위해상황 | 위해 | 규칙」,「의료기기 | 허가·신고·심사 | 위험관리 방법에 대한 국제 | 가능 | 확인 자료 | 검증 및 | 국외 | 결과 |\n| 기타 확인 | 1) 개요 | inical Psychology, 61(2), 296-605.  | 과거병력 조사 | O | - | - | - | 3) 맹검 방법 | 결정하고 주의사항을 준수하기로 서면 동의한 자 | 세스 | 민원인을 구속하는 내용이 있습니까?  | 오송보건의료행정타운 |\n| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | - 심각한 부작용 발생으로 조기 종료시킬 수 있다.  | 80002-1 | 디지털치료기기 허가·심사 | 사례 | application of ISO 14971 to | 되어야 한다. ",
        "original_sentence": "| 제조자는 주기적인 업데이트의 구현과 배포를 | Deciding When to Submit a | 명령어 및 데이터의 비인가 반복에 대한 | 시판 후 소프트웨어에 문제가 | 위해상황 | 위해 | 규칙」,「의료기기 | 허가·신고·심사 | 위험관리 방법에 대한 국제 | 가능 | 확인 자료 | 검증 및 | 국외 | 결과 |\n| 기타 확인 | 1) 개요 | inical Psychology, 61(2), 296-605. "
      }
    },
    {
      "chunk_id": "chunk_252",
      "text": "| 과거병력 조사 | O | - | - | - | 3) 맹검 방법 | 결정하고 주의사항을 준수하기로 서면 동의한 자 | 세스 | 민원인을 구속하는 내용이 있습니까? ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 251,
        "window_size": 3,
        "char_count": 92,
        "word_count": 29,
        "page_number": 3,
        "window_text": "| □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 28159 충북 청주시 흥덕구 오송읍 오송생명2로 187 | Part 1: Guidance on the | 심각 | □ 예 | ■ 아니오 | 위험 |\n| 아) 병용약물 조사 | BWL+ | 있던 기기에서는 로그아웃 | 때까지 | 분해하고, | 각 | 유닛에 | 로그인을 시도한다.  |\n| [F50.2] Bulimia nervosa (신경성 폭식증) | 같이 기록한다.  | 제조자는 주기적인 업데이트의 구현과 배포를 | Deciding When to Submit a | 명령어 및 데이터의 비인가 반복에 대한 | 시판 후 소프트웨어에 문제가 | 위해상황 | 위해 | 규칙」,「의료기기 | 허가·신고·심사 | 위험관리 방법에 대한 국제 | 가능 | 확인 자료 | 검증 및 | 국외 | 결과 |\n| 기타 확인 | 1) 개요 | inical Psychology, 61(2), 296-605.  | 과거병력 조사 | O | - | - | - | 3) 맹검 방법 | 결정하고 주의사항을 준수하기로 서면 동의한 자 | 세스 | 민원인을 구속하는 내용이 있습니까?  | 오송보건의료행정타운 |\n| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | - 심각한 부작용 발생으로 조기 종료시킬 수 있다.  | 80002-1 | 디지털치료기기 허가·심사 | 사례 | application of ISO 14971 to | 되어야 한다.  | 의료기기 내 소프트웨어 변경에 따른 | 적용 | 성 | 도 |\n| 6) 검증되지 않은 임상시험이라는 사실 | 고려하여 적절한 기준을 설정함 | 대체 수집할 수 있다. ",
        "original_sentence": "| 과거병력 조사 | O | - | - | - | 3) 맹검 방법 | 결정하고 주의사항을 준수하기로 서면 동의한 자 | 세스 | 민원인을 구속하는 내용이 있습니까? "
      }
    },
    {
      "chunk_id": "chunk_253",
      "text": "| 오송보건의료행정타운 |\n| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | - 심각한 부작용 발생으로 조기 종료시킬 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 252,
        "window_size": 3,
        "char_count": 98,
        "word_count": 20,
        "page_number": 19,
        "window_text": "|\n| [F50.2] Bulimia nervosa (신경성 폭식증) | 같이 기록한다.  | 제조자는 주기적인 업데이트의 구현과 배포를 | Deciding When to Submit a | 명령어 및 데이터의 비인가 반복에 대한 | 시판 후 소프트웨어에 문제가 | 위해상황 | 위해 | 규칙」,「의료기기 | 허가·신고·심사 | 위험관리 방법에 대한 국제 | 가능 | 확인 자료 | 검증 및 | 국외 | 결과 |\n| 기타 확인 | 1) 개요 | inical Psychology, 61(2), 296-605.  | 과거병력 조사 | O | - | - | - | 3) 맹검 방법 | 결정하고 주의사항을 준수하기로 서면 동의한 자 | 세스 | 민원인을 구속하는 내용이 있습니까?  | 오송보건의료행정타운 |\n| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | - 심각한 부작용 발생으로 조기 종료시킬 수 있다.  | 80002-1 | 디지털치료기기 허가·심사 | 사례 | application of ISO 14971 to | 되어야 한다.  | 의료기기 내 소프트웨어 변경에 따른 | 적용 | 성 | 도 |\n| 6) 검증되지 않은 임상시험이라는 사실 | 고려하여 적절한 기준을 설정함 | 대체 수집할 수 있다.  | 시 함께 개선될 수 있다고 여겨진 영역에 한정한다. ",
        "original_sentence": "| 오송보건의료행정타운 |\n| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | - 심각한 부작용 발생으로 조기 종료시킬 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_254",
      "text": "| 80002-1 | 디지털치료기기 허가·심사 | 사례 | application of ISO 14971 to | 되어야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 253,
        "window_size": 3,
        "char_count": 71,
        "word_count": 16,
        "page_number": 9,
        "window_text": "| 제조자는 주기적인 업데이트의 구현과 배포를 | Deciding When to Submit a | 명령어 및 데이터의 비인가 반복에 대한 | 시판 후 소프트웨어에 문제가 | 위해상황 | 위해 | 규칙」,「의료기기 | 허가·신고·심사 | 위험관리 방법에 대한 국제 | 가능 | 확인 자료 | 검증 및 | 국외 | 결과 |\n| 기타 확인 | 1) 개요 | inical Psychology, 61(2), 296-605.  | 과거병력 조사 | O | - | - | - | 3) 맹검 방법 | 결정하고 주의사항을 준수하기로 서면 동의한 자 | 세스 | 민원인을 구속하는 내용이 있습니까?  | 오송보건의료행정타운 |\n| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | - 심각한 부작용 발생으로 조기 종료시킬 수 있다.  | 80002-1 | 디지털치료기기 허가·심사 | 사례 | application of ISO 14971 to | 되어야 한다.  | 의료기기 내 소프트웨어 변경에 따른 | 적용 | 성 | 도 |\n| 6) 검증되지 않은 임상시험이라는 사실 | 고려하여 적절한 기준을 설정함 | 대체 수집할 수 있다.  | 시 함께 개선될 수 있다고 여겨진 영역에 한정한다.  | Naltrexone- | 대한 | 상세 | 설계를 | 수행한다. ",
        "original_sentence": "| 80002-1 | 디지털치료기기 허가·심사 | 사례 | application of ISO 14971 to | 되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_255",
      "text": "| 의료기기 내 소프트웨어 변경에 따른 | 적용 | 성 | 도 |\n| 6) 검증되지 않은 임상시험이라는 사실 | 고려하여 적절한 기준을 설정함 | 대체 수집할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 254,
        "window_size": 3,
        "char_count": 95,
        "word_count": 29,
        "page_number": 9,
        "window_text": "| 과거병력 조사 | O | - | - | - | 3) 맹검 방법 | 결정하고 주의사항을 준수하기로 서면 동의한 자 | 세스 | 민원인을 구속하는 내용이 있습니까?  | 오송보건의료행정타운 |\n| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | - 심각한 부작용 발생으로 조기 종료시킬 수 있다.  | 80002-1 | 디지털치료기기 허가·심사 | 사례 | application of ISO 14971 to | 되어야 한다.  | 의료기기 내 소프트웨어 변경에 따른 | 적용 | 성 | 도 |\n| 6) 검증되지 않은 임상시험이라는 사실 | 고려하여 적절한 기준을 설정함 | 대체 수집할 수 있다.  | 시 함께 개선될 수 있다고 여겨진 영역에 한정한다.  | Naltrexone- | 대한 | 상세 | 설계를 | 수행한다.  |\n| 2. ",
        "original_sentence": "| 의료기기 내 소프트웨어 변경에 따른 | 적용 | 성 | 도 |\n| 6) 검증되지 않은 임상시험이라는 사실 | 고려하여 적절한 기준을 설정함 | 대체 수집할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_256",
      "text": "| 시 함께 개선될 수 있다고 여겨진 영역에 한정한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 255,
        "window_size": 3,
        "char_count": 31,
        "word_count": 9,
        "page_number": 15,
        "window_text": "| 오송보건의료행정타운 |\n| [F50.1] Atypical anorexia nervosa (비전형적 신경성 식욕부진) | - 심각한 부작용 발생으로 조기 종료시킬 수 있다.  | 80002-1 | 디지털치료기기 허가·심사 | 사례 | application of ISO 14971 to | 되어야 한다.  | 의료기기 내 소프트웨어 변경에 따른 | 적용 | 성 | 도 |\n| 6) 검증되지 않은 임상시험이라는 사실 | 고려하여 적절한 기준을 설정함 | 대체 수집할 수 있다.  | 시 함께 개선될 수 있다고 여겨진 영역에 한정한다.  | Naltrexone- | 대한 | 상세 | 설계를 | 수행한다.  |\n| 2.  문의처 | 1) 부작용 | 1 | 9 | 사항 | 가) 평가지표 Baseline 조사 | 시험계획서의 절차에 따라 이루어지도록 하여야 한다. ",
        "original_sentence": "| 시 함께 개선될 수 있다고 여겨진 영역에 한정한다. "
      }
    },
    {
      "chunk_id": "chunk_257",
      "text": "| Naltrexone- | 대한 | 상세 | 설계를 | 수행한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 256,
        "window_size": 3,
        "char_count": 38,
        "word_count": 10,
        "page_number": 15,
        "window_text": "| 80002-1 | 디지털치료기기 허가·심사 | 사례 | application of ISO 14971 to | 되어야 한다.  | 의료기기 내 소프트웨어 변경에 따른 | 적용 | 성 | 도 |\n| 6) 검증되지 않은 임상시험이라는 사실 | 고려하여 적절한 기준을 설정함 | 대체 수집할 수 있다.  | 시 함께 개선될 수 있다고 여겨진 영역에 한정한다.  | Naltrexone- | 대한 | 상세 | 설계를 | 수행한다.  |\n| 2.  문의처 | 1) 부작용 | 1 | 9 | 사항 | 가) 평가지표 Baseline 조사 | 시험계획서의 절차에 따라 이루어지도록 하여야 한다.  | 될 것이라는 사실 | - 이상 반응에 대해 보다 가능성 있는 원인이 있는 경우 | 510(k) for a Software Change | 위한 수행절차를 수립하고 통보하여야 한다. ",
        "original_sentence": "| Naltrexone- | 대한 | 상세 | 설계를 | 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_258",
      "text": "|\n| 2. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 257,
        "window_size": 3,
        "char_count": 7,
        "word_count": 3,
        "page_number": 9,
        "window_text": "| 의료기기 내 소프트웨어 변경에 따른 | 적용 | 성 | 도 |\n| 6) 검증되지 않은 임상시험이라는 사실 | 고려하여 적절한 기준을 설정함 | 대체 수집할 수 있다.  | 시 함께 개선될 수 있다고 여겨진 영역에 한정한다.  | Naltrexone- | 대한 | 상세 | 설계를 | 수행한다.  |\n| 2.  문의처 | 1) 부작용 | 1 | 9 | 사항 | 가) 평가지표 Baseline 조사 | 시험계획서의 절차에 따라 이루어지도록 하여야 한다.  | 될 것이라는 사실 | - 이상 반응에 대해 보다 가능성 있는 원인이 있는 경우 | 510(k) for a Software Change | 위한 수행절차를 수립하고 통보하여야 한다.  | 방지, 사전에 정의된 통신 종료 시점의 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 식품의약품안전처 식품의약품안전평가원 | 발생하거나 개선의 필요성 때문에 | 35 | 15.89 | 9.74 | 29 | 1.96 | 3.64 | -12.79 | 8.24 | 등에 관한 규정」 기반, 디지털치료 | 성 | 규격 | 유효성 | (AB-1234) | 국내 | 미국 |\n**- 외래 방문마다 병용약물을 수집하여 기록한다.",
        "original_sentence": "|\n| 2. "
      }
    },
    {
      "chunk_id": "chunk_259",
      "text": "문의처 | 1) 부작용 | 1 | 9 | 사항 | 가) 평가지표 Baseline 조사 | 시험계획서의 절차에 따라 이루어지도록 하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 258,
        "window_size": 3,
        "char_count": 79,
        "word_count": 22,
        "page_number": 3,
        "window_text": "| 시 함께 개선될 수 있다고 여겨진 영역에 한정한다.  | Naltrexone- | 대한 | 상세 | 설계를 | 수행한다.  |\n| 2.  문의처 | 1) 부작용 | 1 | 9 | 사항 | 가) 평가지표 Baseline 조사 | 시험계획서의 절차에 따라 이루어지도록 하여야 한다.  | 될 것이라는 사실 | - 이상 반응에 대해 보다 가능성 있는 원인이 있는 경우 | 510(k) for a Software Change | 위한 수행절차를 수립하고 통보하여야 한다.  | 방지, 사전에 정의된 통신 종료 시점의 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 식품의약품안전처 식품의약품안전평가원 | 발생하거나 개선의 필요성 때문에 | 35 | 15.89 | 9.74 | 29 | 1.96 | 3.64 | -12.79 | 8.24 | 등에 관한 규정」 기반, 디지털치료 | 성 | 규격 | 유효성 | (AB-1234) | 국내 | 미국 |\n**- 외래 방문마다 병용약물을 수집하여 기록한다. **\n| [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | 가이드라인(민원인 안내서) | 대체 수집할 수 있다. ",
        "original_sentence": "문의처 | 1) 부작용 | 1 | 9 | 사항 | 가) 평가지표 Baseline 조사 | 시험계획서의 절차에 따라 이루어지도록 하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_260",
      "text": "| 될 것이라는 사실 | - 이상 반응에 대해 보다 가능성 있는 원인이 있는 경우 | 510(k) for a Software Change | 위한 수행절차를 수립하고 통보하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 259,
        "window_size": 3,
        "char_count": 103,
        "word_count": 27,
        "page_number": 19,
        "window_text": "| Naltrexone- | 대한 | 상세 | 설계를 | 수행한다.  |\n| 2.  문의처 | 1) 부작용 | 1 | 9 | 사항 | 가) 평가지표 Baseline 조사 | 시험계획서의 절차에 따라 이루어지도록 하여야 한다.  | 될 것이라는 사실 | - 이상 반응에 대해 보다 가능성 있는 원인이 있는 경우 | 510(k) for a Software Change | 위한 수행절차를 수립하고 통보하여야 한다.  | 방지, 사전에 정의된 통신 종료 시점의 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 식품의약품안전처 식품의약품안전평가원 | 발생하거나 개선의 필요성 때문에 | 35 | 15.89 | 9.74 | 29 | 1.96 | 3.64 | -12.79 | 8.24 | 등에 관한 규정」 기반, 디지털치료 | 성 | 규격 | 유효성 | (AB-1234) | 국내 | 미국 |\n**- 외래 방문마다 병용약물을 수집하여 기록한다. **\n| [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | 가이드라인(민원인 안내서) | 대체 수집할 수 있다.  | 소프트웨어 | 표 12. ",
        "original_sentence": "| 될 것이라는 사실 | - 이상 반응에 대해 보다 가능성 있는 원인이 있는 경우 | 510(k) for a Software Change | 위한 수행절차를 수립하고 통보하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_261",
      "text": "| 방지, 사전에 정의된 통신 종료 시점의 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 식품의약품안전처 식품의약품안전평가원 | 발생하거나 개선의 필요성 때문에 | 35 | 15.89 | 9.74 | 29 | 1.96 | 3.64 | -12.79 | 8.24 | 등에 관한 규정」 기반, 디지털치료 | 성 | 규격 | 유효성 | (AB-1234) | 국내 | 미국 |\n**- 외래 방문마다 병용약물을 수집하여 기록한다.",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 260,
        "window_size": 3,
        "char_count": 257,
        "word_count": 68,
        "page_number": 30,
        "window_text": "|\n| 2.  문의처 | 1) 부작용 | 1 | 9 | 사항 | 가) 평가지표 Baseline 조사 | 시험계획서의 절차에 따라 이루어지도록 하여야 한다.  | 될 것이라는 사실 | - 이상 반응에 대해 보다 가능성 있는 원인이 있는 경우 | 510(k) for a Software Change | 위한 수행절차를 수립하고 통보하여야 한다.  | 방지, 사전에 정의된 통신 종료 시점의 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 식품의약품안전처 식품의약품안전평가원 | 발생하거나 개선의 필요성 때문에 | 35 | 15.89 | 9.74 | 29 | 1.96 | 3.64 | -12.79 | 8.24 | 등에 관한 규정」 기반, 디지털치료 | 성 | 규격 | 유효성 | (AB-1234) | 국내 | 미국 |\n**- 외래 방문마다 병용약물을 수집하여 기록한다. **\n| [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | 가이드라인(민원인 안내서) | 대체 수집할 수 있다.  | 소프트웨어 | 표 12.  전체 잔여위험 허용 가능성 평가 예시 | Bupropion | medical device software | 지침 가이드라인 |\n| 내용을 기재함 | [F50.2] Bulimia nervosa (신경성 폭식증) | (설문조사) | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다. ",
        "original_sentence": "| 방지, 사전에 정의된 통신 종료 시점의 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 식품의약품안전처 식품의약품안전평가원 | 발생하거나 개선의 필요성 때문에 | 35 | 15.89 | 9.74 | 29 | 1.96 | 3.64 | -12.79 | 8.24 | 등에 관한 규정」 기반, 디지털치료 | 성 | 규격 | 유효성 | (AB-1234) | 국내 | 미국 |\n**- 외래 방문마다 병용약물을 수집하여 기록한다."
      }
    },
    {
      "chunk_id": "chunk_262",
      "text": "**\n| [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | 가이드라인(민원인 안내서) | 대체 수집할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 261,
        "window_size": 3,
        "char_count": 84,
        "word_count": 17,
        "page_number": 15,
        "window_text": "문의처 | 1) 부작용 | 1 | 9 | 사항 | 가) 평가지표 Baseline 조사 | 시험계획서의 절차에 따라 이루어지도록 하여야 한다.  | 될 것이라는 사실 | - 이상 반응에 대해 보다 가능성 있는 원인이 있는 경우 | 510(k) for a Software Change | 위한 수행절차를 수립하고 통보하여야 한다.  | 방지, 사전에 정의된 통신 종료 시점의 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 식품의약품안전처 식품의약품안전평가원 | 발생하거나 개선의 필요성 때문에 | 35 | 15.89 | 9.74 | 29 | 1.96 | 3.64 | -12.79 | 8.24 | 등에 관한 규정」 기반, 디지털치료 | 성 | 규격 | 유효성 | (AB-1234) | 국내 | 미국 |\n**- 외래 방문마다 병용약물을 수집하여 기록한다. **\n| [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | 가이드라인(민원인 안내서) | 대체 수집할 수 있다.  | 소프트웨어 | 표 12.  전체 잔여위험 허용 가능성 평가 예시 | Bupropion | medical device software | 지침 가이드라인 |\n| 내용을 기재함 | [F50.2] Bulimia nervosa (신경성 폭식증) | (설문조사) | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | 또한 소프트웨어 유닛 및 외부 |\n| 식품의약품안전처 식품의약품안전평가원 의료기기심사부 첨단의료기기과 | 2) 중지 처리 | 9 | 적절성 여부 등 | 때문에 가장 개연성이 있게 설명되는 경우 | to an Existing Device | 의료기기심사부 첨단의료기기과 | 제품 또는 관련 문서가 수정되는 | 기기에 해당하는 제품의 범위, 판단 | 확인 자료 |\n| 7) 피험자에게 미칠 것으로 예상되는 위험이나 불편 | 대체 수집할 수 있다. ",
        "original_sentence": "**\n| [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | 가이드라인(민원인 안내서) | 대체 수집할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_263",
      "text": "| 소프트웨어 | 표 12. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 262,
        "window_size": 3,
        "char_count": 16,
        "word_count": 5,
        "page_number": 9,
        "window_text": "| 될 것이라는 사실 | - 이상 반응에 대해 보다 가능성 있는 원인이 있는 경우 | 510(k) for a Software Change | 위한 수행절차를 수립하고 통보하여야 한다.  | 방지, 사전에 정의된 통신 종료 시점의 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 식품의약품안전처 식품의약품안전평가원 | 발생하거나 개선의 필요성 때문에 | 35 | 15.89 | 9.74 | 29 | 1.96 | 3.64 | -12.79 | 8.24 | 등에 관한 규정」 기반, 디지털치료 | 성 | 규격 | 유효성 | (AB-1234) | 국내 | 미국 |\n**- 외래 방문마다 병용약물을 수집하여 기록한다. **\n| [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | 가이드라인(민원인 안내서) | 대체 수집할 수 있다.  | 소프트웨어 | 표 12.  전체 잔여위험 허용 가능성 평가 예시 | Bupropion | medical device software | 지침 가이드라인 |\n| 내용을 기재함 | [F50.2] Bulimia nervosa (신경성 폭식증) | (설문조사) | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | 또한 소프트웨어 유닛 및 외부 |\n| 식품의약품안전처 식품의약품안전평가원 의료기기심사부 첨단의료기기과 | 2) 중지 처리 | 9 | 적절성 여부 등 | 때문에 가장 개연성이 있게 설명되는 경우 | to an Existing Device | 의료기기심사부 첨단의료기기과 | 제품 또는 관련 문서가 수정되는 | 기기에 해당하는 제품의 범위, 판단 | 확인 자료 |\n| 7) 피험자에게 미칠 것으로 예상되는 위험이나 불편 | 대체 수집할 수 있다.  | 사용자 구분을 | 소프트웨어 | (기존대조군) | 조작된 환자 | 오진, 잘못 |\n| 3) Patient health questionnaire-9 (PHQ-9) | 6) Clinical Global Impression of Improvement (CGI-I) | 잔여위험평가 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 등을 기록하여 보관하여야 한다. ",
        "original_sentence": "| 소프트웨어 | 표 12. "
      }
    },
    {
      "chunk_id": "chunk_264",
      "text": "전체 잔여위험 허용 가능성 평가 예시 | Bupropion | medical device software | 지침 가이드라인 |\n| 내용을 기재함 | [F50.2] Bulimia nervosa (신경성 폭식증) | (설문조사) | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 263,
        "window_size": 3,
        "char_count": 182,
        "word_count": 43,
        "page_number": 30,
        "window_text": "| 방지, 사전에 정의된 통신 종료 시점의 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | 식품의약품안전처 식품의약품안전평가원 | 발생하거나 개선의 필요성 때문에 | 35 | 15.89 | 9.74 | 29 | 1.96 | 3.64 | -12.79 | 8.24 | 등에 관한 규정」 기반, 디지털치료 | 성 | 규격 | 유효성 | (AB-1234) | 국내 | 미국 |\n**- 외래 방문마다 병용약물을 수집하여 기록한다. **\n| [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | 가이드라인(민원인 안내서) | 대체 수집할 수 있다.  | 소프트웨어 | 표 12.  전체 잔여위험 허용 가능성 평가 예시 | Bupropion | medical device software | 지침 가이드라인 |\n| 내용을 기재함 | [F50.2] Bulimia nervosa (신경성 폭식증) | (설문조사) | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | 또한 소프트웨어 유닛 및 외부 |\n| 식품의약품안전처 식품의약품안전평가원 의료기기심사부 첨단의료기기과 | 2) 중지 처리 | 9 | 적절성 여부 등 | 때문에 가장 개연성이 있게 설명되는 경우 | to an Existing Device | 의료기기심사부 첨단의료기기과 | 제품 또는 관련 문서가 수정되는 | 기기에 해당하는 제품의 범위, 판단 | 확인 자료 |\n| 7) 피험자에게 미칠 것으로 예상되는 위험이나 불편 | 대체 수집할 수 있다.  | 사용자 구분을 | 소프트웨어 | (기존대조군) | 조작된 환자 | 오진, 잘못 |\n| 3) Patient health questionnaire-9 (PHQ-9) | 6) Clinical Global Impression of Improvement (CGI-I) | 잔여위험평가 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 등을 기록하여 보관하여야 한다.  | 절약할 수 있다.1) | 한다. ",
        "original_sentence": "전체 잔여위험 허용 가능성 평가 예시 | Bupropion | medical device software | 지침 가이드라인 |\n| 내용을 기재함 | [F50.2] Bulimia nervosa (신경성 폭식증) | (설문조사) | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_265",
      "text": "| 또한 소프트웨어 유닛 및 외부 |\n| 식품의약품안전처 식품의약품안전평가원 의료기기심사부 첨단의료기기과 | 2) 중지 처리 | 9 | 적절성 여부 등 | 때문에 가장 개연성이 있게 설명되는 경우 | to an Existing Device | 의료기기심사부 첨단의료기기과 | 제품 또는 관련 문서가 수정되는 | 기기에 해당하는 제품의 범위, 판단 | 확인 자료 |\n| 7) 피험자에게 미칠 것으로 예상되는 위험이나 불편 | 대체 수집할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 264,
        "window_size": 3,
        "char_count": 250,
        "word_count": 66,
        "page_number": 9,
        "window_text": "**\n| [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | 가이드라인(민원인 안내서) | 대체 수집할 수 있다.  | 소프트웨어 | 표 12.  전체 잔여위험 허용 가능성 평가 예시 | Bupropion | medical device software | 지침 가이드라인 |\n| 내용을 기재함 | [F50.2] Bulimia nervosa (신경성 폭식증) | (설문조사) | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | 또한 소프트웨어 유닛 및 외부 |\n| 식품의약품안전처 식품의약품안전평가원 의료기기심사부 첨단의료기기과 | 2) 중지 처리 | 9 | 적절성 여부 등 | 때문에 가장 개연성이 있게 설명되는 경우 | to an Existing Device | 의료기기심사부 첨단의료기기과 | 제품 또는 관련 문서가 수정되는 | 기기에 해당하는 제품의 범위, 판단 | 확인 자료 |\n| 7) 피험자에게 미칠 것으로 예상되는 위험이나 불편 | 대체 수집할 수 있다.  | 사용자 구분을 | 소프트웨어 | (기존대조군) | 조작된 환자 | 오진, 잘못 |\n| 3) Patient health questionnaire-9 (PHQ-9) | 6) Clinical Global Impression of Improvement (CGI-I) | 잔여위험평가 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 등을 기록하여 보관하여야 한다.  | 절약할 수 있다.1) | 한다.  | 수집한다. ",
        "original_sentence": "| 또한 소프트웨어 유닛 및 외부 |\n| 식품의약품안전처 식품의약품안전평가원 의료기기심사부 첨단의료기기과 | 2) 중지 처리 | 9 | 적절성 여부 등 | 때문에 가장 개연성이 있게 설명되는 경우 | to an Existing Device | 의료기기심사부 첨단의료기기과 | 제품 또는 관련 문서가 수정되는 | 기기에 해당하는 제품의 범위, 판단 | 확인 자료 |\n| 7) 피험자에게 미칠 것으로 예상되는 위험이나 불편 | 대체 수집할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_266",
      "text": "| 사용자 구분을 | 소프트웨어 | (기존대조군) | 조작된 환자 | 오진, 잘못 |\n| 3) Patient health questionnaire-9 (PHQ-9) | 6) Clinical Global Impression of Improvement (CGI-I) | 잔여위험평가 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 등을 기록하여 보관하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 265,
        "window_size": 3,
        "char_count": 212,
        "word_count": 45,
        "page_number": 3,
        "window_text": "| 소프트웨어 | 표 12.  전체 잔여위험 허용 가능성 평가 예시 | Bupropion | medical device software | 지침 가이드라인 |\n| 내용을 기재함 | [F50.2] Bulimia nervosa (신경성 폭식증) | (설문조사) | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | 또한 소프트웨어 유닛 및 외부 |\n| 식품의약품안전처 식품의약품안전평가원 의료기기심사부 첨단의료기기과 | 2) 중지 처리 | 9 | 적절성 여부 등 | 때문에 가장 개연성이 있게 설명되는 경우 | to an Existing Device | 의료기기심사부 첨단의료기기과 | 제품 또는 관련 문서가 수정되는 | 기기에 해당하는 제품의 범위, 판단 | 확인 자료 |\n| 7) 피험자에게 미칠 것으로 예상되는 위험이나 불편 | 대체 수집할 수 있다.  | 사용자 구분을 | 소프트웨어 | (기존대조군) | 조작된 환자 | 오진, 잘못 |\n| 3) Patient health questionnaire-9 (PHQ-9) | 6) Clinical Global Impression of Improvement (CGI-I) | 잔여위험평가 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 등을 기록하여 보관하여야 한다.  | 절약할 수 있다.1) | 한다.  | 수집한다.  | 영향을 줄 수 있는 약물의 사용량이 변경된 경우 | 제시할 수 있다. ",
        "original_sentence": "| 사용자 구분을 | 소프트웨어 | (기존대조군) | 조작된 환자 | 오진, 잘못 |\n| 3) Patient health questionnaire-9 (PHQ-9) | 6) Clinical Global Impression of Improvement (CGI-I) | 잔여위험평가 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 등을 기록하여 보관하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_267",
      "text": "| 절약할 수 있다.1) | 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 266,
        "window_size": 3,
        "char_count": 20,
        "word_count": 6,
        "page_number": 12,
        "window_text": "전체 잔여위험 허용 가능성 평가 예시 | Bupropion | medical device software | 지침 가이드라인 |\n| 내용을 기재함 | [F50.2] Bulimia nervosa (신경성 폭식증) | (설문조사) | 성명 | 소속기관명 | 전공 | 직위 | 전화 | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | 또한 소프트웨어 유닛 및 외부 |\n| 식품의약품안전처 식품의약품안전평가원 의료기기심사부 첨단의료기기과 | 2) 중지 처리 | 9 | 적절성 여부 등 | 때문에 가장 개연성이 있게 설명되는 경우 | to an Existing Device | 의료기기심사부 첨단의료기기과 | 제품 또는 관련 문서가 수정되는 | 기기에 해당하는 제품의 범위, 판단 | 확인 자료 |\n| 7) 피험자에게 미칠 것으로 예상되는 위험이나 불편 | 대체 수집할 수 있다.  | 사용자 구분을 | 소프트웨어 | (기존대조군) | 조작된 환자 | 오진, 잘못 |\n| 3) Patient health questionnaire-9 (PHQ-9) | 6) Clinical Global Impression of Improvement (CGI-I) | 잔여위험평가 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 등을 기록하여 보관하여야 한다.  | 절약할 수 있다.1) | 한다.  | 수집한다.  | 영향을 줄 수 있는 약물의 사용량이 변경된 경우 | 제시할 수 있다.  | (CGI-I) 평균 점수 | 문제해결 | 섭식장애 증상 예상값 대비 | 섭식장애 증상 임의의 시험용 수명 |\n| 6 | 섭식장애 증상 | 4 | nal of Health Psychology, 17(3), 609-642. ",
        "original_sentence": "| 절약할 수 있다.1) | 한다. "
      }
    },
    {
      "chunk_id": "chunk_268",
      "text": "| 수집한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 267,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 15,
        "window_text": "| 또한 소프트웨어 유닛 및 외부 |\n| 식품의약품안전처 식품의약품안전평가원 의료기기심사부 첨단의료기기과 | 2) 중지 처리 | 9 | 적절성 여부 등 | 때문에 가장 개연성이 있게 설명되는 경우 | to an Existing Device | 의료기기심사부 첨단의료기기과 | 제품 또는 관련 문서가 수정되는 | 기기에 해당하는 제품의 범위, 판단 | 확인 자료 |\n| 7) 피험자에게 미칠 것으로 예상되는 위험이나 불편 | 대체 수집할 수 있다.  | 사용자 구분을 | 소프트웨어 | (기존대조군) | 조작된 환자 | 오진, 잘못 |\n| 3) Patient health questionnaire-9 (PHQ-9) | 6) Clinical Global Impression of Improvement (CGI-I) | 잔여위험평가 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 등을 기록하여 보관하여야 한다.  | 절약할 수 있다.1) | 한다.  | 수집한다.  | 영향을 줄 수 있는 약물의 사용량이 변경된 경우 | 제시할 수 있다.  | (CGI-I) 평균 점수 | 문제해결 | 섭식장애 증상 예상값 대비 | 섭식장애 증상 임의의 시험용 수명 |\n| 6 | 섭식장애 증상 | 4 | nal of Health Psychology, 17(3), 609-642.  | 비 | 자) 관찰 및 평가 | Postmarket Management of | 구성요인 | 사이의 | 연계성 | 및 | 것을 의미한다. ",
        "original_sentence": "| 수집한다. "
      }
    },
    {
      "chunk_id": "chunk_269",
      "text": "| 영향을 줄 수 있는 약물의 사용량이 변경된 경우 | 제시할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 268,
        "window_size": 3,
        "char_count": 41,
        "word_count": 13,
        "page_number": 12,
        "window_text": "| 사용자 구분을 | 소프트웨어 | (기존대조군) | 조작된 환자 | 오진, 잘못 |\n| 3) Patient health questionnaire-9 (PHQ-9) | 6) Clinical Global Impression of Improvement (CGI-I) | 잔여위험평가 | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 등을 기록하여 보관하여야 한다.  | 절약할 수 있다.1) | 한다.  | 수집한다.  | 영향을 줄 수 있는 약물의 사용량이 변경된 경우 | 제시할 수 있다.  | (CGI-I) 평균 점수 | 문제해결 | 섭식장애 증상 예상값 대비 | 섭식장애 증상 임의의 시험용 수명 |\n| 6 | 섭식장애 증상 | 4 | nal of Health Psychology, 17(3), 609-642.  | 비 | 자) 관찰 및 평가 | Postmarket Management of | 구성요인 | 사이의 | 연계성 | 및 | 것을 의미한다.  | 소프트웨어 |\n| [예시] | [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | 다) 병용약물 조사 | SD: Standard deviation | and post-production information)로 구분한다. ",
        "original_sentence": "| 영향을 줄 수 있는 약물의 사용량이 변경된 경우 | 제시할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_270",
      "text": "| (CGI-I) 평균 점수 | 문제해결 | 섭식장애 증상 예상값 대비 | 섭식장애 증상 임의의 시험용 수명 |\n| 6 | 섭식장애 증상 | 4 | nal of Health Psychology, 17(3), 609-642. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 269,
        "window_size": 3,
        "char_count": 125,
        "word_count": 32,
        "page_number": 31,
        "window_text": "| 절약할 수 있다.1) | 한다.  | 수집한다.  | 영향을 줄 수 있는 약물의 사용량이 변경된 경우 | 제시할 수 있다.  | (CGI-I) 평균 점수 | 문제해결 | 섭식장애 증상 예상값 대비 | 섭식장애 증상 임의의 시험용 수명 |\n| 6 | 섭식장애 증상 | 4 | nal of Health Psychology, 17(3), 609-642.  | 비 | 자) 관찰 및 평가 | Postmarket Management of | 구성요인 | 사이의 | 연계성 | 및 | 것을 의미한다.  | 소프트웨어 |\n| [예시] | [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | 다) 병용약물 조사 | SD: Standard deviation | and post-production information)로 구분한다.  | 제조자는 운영 체제(OS) 소프트웨어, 제3자 | 상기 사항에 대하여 확인하였음. ",
        "original_sentence": "| (CGI-I) 평균 점수 | 문제해결 | 섭식장애 증상 예상값 대비 | 섭식장애 증상 임의의 시험용 수명 |\n| 6 | 섭식장애 증상 | 4 | nal of Health Psychology, 17(3), 609-642. "
      }
    },
    {
      "chunk_id": "chunk_271",
      "text": "| 비 | 자) 관찰 및 평가 | Postmarket Management of | 구성요인 | 사이의 | 연계성 | 및 | 것을 의미한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 270,
        "window_size": 3,
        "char_count": 78,
        "word_count": 22,
        "page_number": 28,
        "window_text": "| 수집한다.  | 영향을 줄 수 있는 약물의 사용량이 변경된 경우 | 제시할 수 있다.  | (CGI-I) 평균 점수 | 문제해결 | 섭식장애 증상 예상값 대비 | 섭식장애 증상 임의의 시험용 수명 |\n| 6 | 섭식장애 증상 | 4 | nal of Health Psychology, 17(3), 609-642.  | 비 | 자) 관찰 및 평가 | Postmarket Management of | 구성요인 | 사이의 | 연계성 | 및 | 것을 의미한다.  | 소프트웨어 |\n| [예시] | [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | 다) 병용약물 조사 | SD: Standard deviation | and post-production information)로 구분한다.  | 제조자는 운영 체제(OS) 소프트웨어, 제3자 | 상기 사항에 대하여 확인하였음.  | 경우 문제점과 그 영향 등을 | 기준, 허가·심사 방안 등 제시 | 추가 | 전체 잔여위험 허용 |\n| 웨어 | 전화 : (043) 719-3912 | (1) Clinical Impairment Assessment (CIA) | 기록한다. ",
        "original_sentence": "| 비 | 자) 관찰 및 평가 | Postmarket Management of | 구성요인 | 사이의 | 연계성 | 및 | 것을 의미한다. "
      }
    },
    {
      "chunk_id": "chunk_272",
      "text": "| 소프트웨어 |\n| [예시] | [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | 다) 병용약물 조사 | SD: Standard deviation | and post-production information)로 구분한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 271,
        "window_size": 3,
        "char_count": 146,
        "word_count": 26,
        "page_number": 9,
        "window_text": "| 영향을 줄 수 있는 약물의 사용량이 변경된 경우 | 제시할 수 있다.  | (CGI-I) 평균 점수 | 문제해결 | 섭식장애 증상 예상값 대비 | 섭식장애 증상 임의의 시험용 수명 |\n| 6 | 섭식장애 증상 | 4 | nal of Health Psychology, 17(3), 609-642.  | 비 | 자) 관찰 및 평가 | Postmarket Management of | 구성요인 | 사이의 | 연계성 | 및 | 것을 의미한다.  | 소프트웨어 |\n| [예시] | [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | 다) 병용약물 조사 | SD: Standard deviation | and post-production information)로 구분한다.  | 제조자는 운영 체제(OS) 소프트웨어, 제3자 | 상기 사항에 대하여 확인하였음.  | 경우 문제점과 그 영향 등을 | 기준, 허가·심사 방안 등 제시 | 추가 | 전체 잔여위험 허용 |\n| 웨어 | 전화 : (043) 719-3912 | (1) Clinical Impairment Assessment (CIA) | 기록한다.  | 수행할 수 있다. ",
        "original_sentence": "| 소프트웨어 |\n| [예시] | [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | 다) 병용약물 조사 | SD: Standard deviation | and post-production information)로 구분한다. "
      }
    },
    {
      "chunk_id": "chunk_273",
      "text": "| 제조자는 운영 체제(OS) 소프트웨어, 제3자 | 상기 사항에 대하여 확인하였음. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 272,
        "window_size": 3,
        "char_count": 48,
        "word_count": 11,
        "page_number": 3,
        "window_text": "| (CGI-I) 평균 점수 | 문제해결 | 섭식장애 증상 예상값 대비 | 섭식장애 증상 임의의 시험용 수명 |\n| 6 | 섭식장애 증상 | 4 | nal of Health Psychology, 17(3), 609-642.  | 비 | 자) 관찰 및 평가 | Postmarket Management of | 구성요인 | 사이의 | 연계성 | 및 | 것을 의미한다.  | 소프트웨어 |\n| [예시] | [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | 다) 병용약물 조사 | SD: Standard deviation | and post-production information)로 구분한다.  | 제조자는 운영 체제(OS) 소프트웨어, 제3자 | 상기 사항에 대하여 확인하였음.  | 경우 문제점과 그 영향 등을 | 기준, 허가·심사 방안 등 제시 | 추가 | 전체 잔여위험 허용 |\n| 웨어 | 전화 : (043) 719-3912 | (1) Clinical Impairment Assessment (CIA) | 기록한다.  | 수행할 수 있다.  | 하지 않고 | 상세 설계 | 결과값 차이는 ± 1% 이내 | Application of risk | 결과 | 의료기기 사이버보안의 시판 후 관리에 | 된 치료 수행 | 입력정보를 입력했을 때, 산출되는 |\n| 다) 병용약물 조사 | - 사용 중단으로 이상 반응이 없어지는 경우 | 제조자는 안전(safety)과 관련된 데이터가 저장 | 동등함을 보이는 연구시험이다. ",
        "original_sentence": "| 제조자는 운영 체제(OS) 소프트웨어, 제3자 | 상기 사항에 대하여 확인하였음. "
      }
    },
    {
      "chunk_id": "chunk_274",
      "text": "| 경우 문제점과 그 영향 등을 | 기준, 허가·심사 방안 등 제시 | 추가 | 전체 잔여위험 허용 |\n| 웨어 | 전화 : (043) 719-3912 | (1) Clinical Impairment Assessment (CIA) | 기록한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 273,
        "window_size": 3,
        "char_count": 136,
        "word_count": 34,
        "page_number": 27,
        "window_text": "| 비 | 자) 관찰 및 평가 | Postmarket Management of | 구성요인 | 사이의 | 연계성 | 및 | 것을 의미한다.  | 소프트웨어 |\n| [예시] | [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | 다) 병용약물 조사 | SD: Standard deviation | and post-production information)로 구분한다.  | 제조자는 운영 체제(OS) 소프트웨어, 제3자 | 상기 사항에 대하여 확인하였음.  | 경우 문제점과 그 영향 등을 | 기준, 허가·심사 방안 등 제시 | 추가 | 전체 잔여위험 허용 |\n| 웨어 | 전화 : (043) 719-3912 | (1) Clinical Impairment Assessment (CIA) | 기록한다.  | 수행할 수 있다.  | 하지 않고 | 상세 설계 | 결과값 차이는 ± 1% 이내 | Application of risk | 결과 | 의료기기 사이버보안의 시판 후 관리에 | 된 치료 수행 | 입력정보를 입력했을 때, 산출되는 |\n| 다) 병용약물 조사 | - 사용 중단으로 이상 반응이 없어지는 경우 | 제조자는 안전(safety)과 관련된 데이터가 저장 | 동등함을 보이는 연구시험이다.  | 전화: 043-719-3912 | 결과 | 위험/이득 | 통제 | 검증 및 |\n| 10 | 인가된 | 로서의 사용 목적을 달성할 수 있음을 증명해야 한다. ",
        "original_sentence": "| 경우 문제점과 그 영향 등을 | 기준, 허가·심사 방안 등 제시 | 추가 | 전체 잔여위험 허용 |\n| 웨어 | 전화 : (043) 719-3912 | (1) Clinical Impairment Assessment (CIA) | 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_275",
      "text": "| 수행할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 274,
        "window_size": 3,
        "char_count": 12,
        "word_count": 4,
        "page_number": 12,
        "window_text": "| 소프트웨어 |\n| [예시] | [F50.3] Atypical bulimia nervosa (비전형 신경성 폭식증) | 다) 병용약물 조사 | SD: Standard deviation | and post-production information)로 구분한다.  | 제조자는 운영 체제(OS) 소프트웨어, 제3자 | 상기 사항에 대하여 확인하였음.  | 경우 문제점과 그 영향 등을 | 기준, 허가·심사 방안 등 제시 | 추가 | 전체 잔여위험 허용 |\n| 웨어 | 전화 : (043) 719-3912 | (1) Clinical Impairment Assessment (CIA) | 기록한다.  | 수행할 수 있다.  | 하지 않고 | 상세 설계 | 결과값 차이는 ± 1% 이내 | Application of risk | 결과 | 의료기기 사이버보안의 시판 후 관리에 | 된 치료 수행 | 입력정보를 입력했을 때, 산출되는 |\n| 다) 병용약물 조사 | - 사용 중단으로 이상 반응이 없어지는 경우 | 제조자는 안전(safety)과 관련된 데이터가 저장 | 동등함을 보이는 연구시험이다.  | 전화: 043-719-3912 | 결과 | 위험/이득 | 통제 | 검증 및 |\n| 10 | 인가된 | 로서의 사용 목적을 달성할 수 있음을 증명해야 한다.  | 바) 병용약물 조사 | 심각 | Cybersecurity in Medical | 정확도 | 위험 | 소프트웨어 유닛 사이의 연계성을 | 분석하여 변경해야 한다. ",
        "original_sentence": "| 수행할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_276",
      "text": "| 하지 않고 | 상세 설계 | 결과값 차이는 ± 1% 이내 | Application of risk | 결과 | 의료기기 사이버보안의 시판 후 관리에 | 된 치료 수행 | 입력정보를 입력했을 때, 산출되는 |\n| 다) 병용약물 조사 | - 사용 중단으로 이상 반응이 없어지는 경우 | 제조자는 안전(safety)과 관련된 데이터가 저장 | 동등함을 보이는 연구시험이다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 275,
        "window_size": 3,
        "char_count": 207,
        "word_count": 56,
        "page_number": 7,
        "window_text": "| 제조자는 운영 체제(OS) 소프트웨어, 제3자 | 상기 사항에 대하여 확인하였음.  | 경우 문제점과 그 영향 등을 | 기준, 허가·심사 방안 등 제시 | 추가 | 전체 잔여위험 허용 |\n| 웨어 | 전화 : (043) 719-3912 | (1) Clinical Impairment Assessment (CIA) | 기록한다.  | 수행할 수 있다.  | 하지 않고 | 상세 설계 | 결과값 차이는 ± 1% 이내 | Application of risk | 결과 | 의료기기 사이버보안의 시판 후 관리에 | 된 치료 수행 | 입력정보를 입력했을 때, 산출되는 |\n| 다) 병용약물 조사 | - 사용 중단으로 이상 반응이 없어지는 경우 | 제조자는 안전(safety)과 관련된 데이터가 저장 | 동등함을 보이는 연구시험이다.  | 전화: 043-719-3912 | 결과 | 위험/이득 | 통제 | 검증 및 |\n| 10 | 인가된 | 로서의 사용 목적을 달성할 수 있음을 증명해야 한다.  | 바) 병용약물 조사 | 심각 | Cybersecurity in Medical | 정확도 | 위험 | 소프트웨어 유닛 사이의 연계성을 | 분석하여 변경해야 한다.  | (6) Clinical Global Impression of Severity (CGI-S) | 대한 가이드라인 | 미국 | 3 | 2 | 6 | ALA |\n| 유지 | ※ 본 장에서 제시한 항목 및 예시는 참고용으로 작성한 것으로 사안에 | 8) 중간 분석 | 이상반응 확인 | - | O | O | O | 수는 없으며, 이상 반응 문제가 생길 수 있다. ",
        "original_sentence": "| 하지 않고 | 상세 설계 | 결과값 차이는 ± 1% 이내 | Application of risk | 결과 | 의료기기 사이버보안의 시판 후 관리에 | 된 치료 수행 | 입력정보를 입력했을 때, 산출되는 |\n| 다) 병용약물 조사 | - 사용 중단으로 이상 반응이 없어지는 경우 | 제조자는 안전(safety)과 관련된 데이터가 저장 | 동등함을 보이는 연구시험이다. "
      }
    },
    {
      "chunk_id": "chunk_277",
      "text": "| 전화: 043-719-3912 | 결과 | 위험/이득 | 통제 | 검증 및 |\n| 10 | 인가된 | 로서의 사용 목적을 달성할 수 있음을 증명해야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 276,
        "window_size": 3,
        "char_count": 89,
        "word_count": 26,
        "page_number": 9,
        "window_text": "| 경우 문제점과 그 영향 등을 | 기준, 허가·심사 방안 등 제시 | 추가 | 전체 잔여위험 허용 |\n| 웨어 | 전화 : (043) 719-3912 | (1) Clinical Impairment Assessment (CIA) | 기록한다.  | 수행할 수 있다.  | 하지 않고 | 상세 설계 | 결과값 차이는 ± 1% 이내 | Application of risk | 결과 | 의료기기 사이버보안의 시판 후 관리에 | 된 치료 수행 | 입력정보를 입력했을 때, 산출되는 |\n| 다) 병용약물 조사 | - 사용 중단으로 이상 반응이 없어지는 경우 | 제조자는 안전(safety)과 관련된 데이터가 저장 | 동등함을 보이는 연구시험이다.  | 전화: 043-719-3912 | 결과 | 위험/이득 | 통제 | 검증 및 |\n| 10 | 인가된 | 로서의 사용 목적을 달성할 수 있음을 증명해야 한다.  | 바) 병용약물 조사 | 심각 | Cybersecurity in Medical | 정확도 | 위험 | 소프트웨어 유닛 사이의 연계성을 | 분석하여 변경해야 한다.  | (6) Clinical Global Impression of Severity (CGI-S) | 대한 가이드라인 | 미국 | 3 | 2 | 6 | ALA |\n| 유지 | ※ 본 장에서 제시한 항목 및 예시는 참고용으로 작성한 것으로 사안에 | 8) 중간 분석 | 이상반응 확인 | - | O | O | O | 수는 없으며, 이상 반응 문제가 생길 수 있다.  | 안전성에서‘하’등급의 분류가 불가능하다. ",
        "original_sentence": "| 전화: 043-719-3912 | 결과 | 위험/이득 | 통제 | 검증 및 |\n| 10 | 인가된 | 로서의 사용 목적을 달성할 수 있음을 증명해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_278",
      "text": "| 바) 병용약물 조사 | 심각 | Cybersecurity in Medical | 정확도 | 위험 | 소프트웨어 유닛 사이의 연계성을 | 분석하여 변경해야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 277,
        "window_size": 3,
        "char_count": 92,
        "word_count": 23,
        "page_number": 28,
        "window_text": "| 수행할 수 있다.  | 하지 않고 | 상세 설계 | 결과값 차이는 ± 1% 이내 | Application of risk | 결과 | 의료기기 사이버보안의 시판 후 관리에 | 된 치료 수행 | 입력정보를 입력했을 때, 산출되는 |\n| 다) 병용약물 조사 | - 사용 중단으로 이상 반응이 없어지는 경우 | 제조자는 안전(safety)과 관련된 데이터가 저장 | 동등함을 보이는 연구시험이다.  | 전화: 043-719-3912 | 결과 | 위험/이득 | 통제 | 검증 및 |\n| 10 | 인가된 | 로서의 사용 목적을 달성할 수 있음을 증명해야 한다.  | 바) 병용약물 조사 | 심각 | Cybersecurity in Medical | 정확도 | 위험 | 소프트웨어 유닛 사이의 연계성을 | 분석하여 변경해야 한다.  | (6) Clinical Global Impression of Severity (CGI-S) | 대한 가이드라인 | 미국 | 3 | 2 | 6 | ALA |\n| 유지 | ※ 본 장에서 제시한 항목 및 예시는 참고용으로 작성한 것으로 사안에 | 8) 중간 분석 | 이상반응 확인 | - | O | O | O | 수는 없으며, 이상 반응 문제가 생길 수 있다.  | 안전성에서‘하’등급의 분류가 불가능하다.  | 위해요인에 대해 <표 11>과 같이 기록한다. ",
        "original_sentence": "| 바) 병용약물 조사 | 심각 | Cybersecurity in Medical | 정확도 | 위험 | 소프트웨어 유닛 사이의 연계성을 | 분석하여 변경해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_279",
      "text": "| (6) Clinical Global Impression of Severity (CGI-S) | 대한 가이드라인 | 미국 | 3 | 2 | 6 | ALA |\n| 유지 | ※ 본 장에서 제시한 항목 및 예시는 참고용으로 작성한 것으로 사안에 | 8) 중간 분석 | 이상반응 확인 | - | O | O | O | 수는 없으며, 이상 반응 문제가 생길 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 278,
        "window_size": 3,
        "char_count": 201,
        "word_count": 60,
        "page_number": 27,
        "window_text": "| 하지 않고 | 상세 설계 | 결과값 차이는 ± 1% 이내 | Application of risk | 결과 | 의료기기 사이버보안의 시판 후 관리에 | 된 치료 수행 | 입력정보를 입력했을 때, 산출되는 |\n| 다) 병용약물 조사 | - 사용 중단으로 이상 반응이 없어지는 경우 | 제조자는 안전(safety)과 관련된 데이터가 저장 | 동등함을 보이는 연구시험이다.  | 전화: 043-719-3912 | 결과 | 위험/이득 | 통제 | 검증 및 |\n| 10 | 인가된 | 로서의 사용 목적을 달성할 수 있음을 증명해야 한다.  | 바) 병용약물 조사 | 심각 | Cybersecurity in Medical | 정확도 | 위험 | 소프트웨어 유닛 사이의 연계성을 | 분석하여 변경해야 한다.  | (6) Clinical Global Impression of Severity (CGI-S) | 대한 가이드라인 | 미국 | 3 | 2 | 6 | ALA |\n| 유지 | ※ 본 장에서 제시한 항목 및 예시는 참고용으로 작성한 것으로 사안에 | 8) 중간 분석 | 이상반응 확인 | - | O | O | O | 수는 없으며, 이상 반응 문제가 생길 수 있다.  | 안전성에서‘하’등급의 분류가 불가능하다.  | 위해요인에 대해 <표 11>과 같이 기록한다.  | 소프트웨어, 오픈 소스 소프트웨어가 업데이트나 | 이거나 모호한 경우 | 의료기기 소프트웨어 | 누구나 환자의 | management for IT-networks | 데이터로 | 의료기기 | 소프트웨어 | 밸리데이션에 | 발생 | 또는 | 네트워크로 연결되는 | 적용 | 소프트웨어 | 가능성 평가 |\n| to binge eating: A case study. ",
        "original_sentence": "| (6) Clinical Global Impression of Severity (CGI-S) | 대한 가이드라인 | 미국 | 3 | 2 | 6 | ALA |\n| 유지 | ※ 본 장에서 제시한 항목 및 예시는 참고용으로 작성한 것으로 사안에 | 8) 중간 분석 | 이상반응 확인 | - | O | O | O | 수는 없으며, 이상 반응 문제가 생길 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_280",
      "text": "| 안전성에서‘하’등급의 분류가 불가능하다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 279,
        "window_size": 3,
        "char_count": 25,
        "word_count": 4,
        "page_number": 9,
        "window_text": "| 전화: 043-719-3912 | 결과 | 위험/이득 | 통제 | 검증 및 |\n| 10 | 인가된 | 로서의 사용 목적을 달성할 수 있음을 증명해야 한다.  | 바) 병용약물 조사 | 심각 | Cybersecurity in Medical | 정확도 | 위험 | 소프트웨어 유닛 사이의 연계성을 | 분석하여 변경해야 한다.  | (6) Clinical Global Impression of Severity (CGI-S) | 대한 가이드라인 | 미국 | 3 | 2 | 6 | ALA |\n| 유지 | ※ 본 장에서 제시한 항목 및 예시는 참고용으로 작성한 것으로 사안에 | 8) 중간 분석 | 이상반응 확인 | - | O | O | O | 수는 없으며, 이상 반응 문제가 생길 수 있다.  | 안전성에서‘하’등급의 분류가 불가능하다.  | 위해요인에 대해 <표 11>과 같이 기록한다.  | 소프트웨어, 오픈 소스 소프트웨어가 업데이트나 | 이거나 모호한 경우 | 의료기기 소프트웨어 | 누구나 환자의 | management for IT-networks | 데이터로 | 의료기기 | 소프트웨어 | 밸리데이션에 | 발생 | 또는 | 네트워크로 연결되는 | 적용 | 소프트웨어 | 가능성 평가 |\n| to binge eating: A case study.  Cognitive and Behavioral Practice, 12(3), 351-358. ",
        "original_sentence": "| 안전성에서‘하’등급의 분류가 불가능하다. "
      }
    },
    {
      "chunk_id": "chunk_281",
      "text": "| 위해요인에 대해 <표 11>과 같이 기록한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 280,
        "window_size": 3,
        "char_count": 28,
        "word_count": 7,
        "page_number": 15,
        "window_text": "| 바) 병용약물 조사 | 심각 | Cybersecurity in Medical | 정확도 | 위험 | 소프트웨어 유닛 사이의 연계성을 | 분석하여 변경해야 한다.  | (6) Clinical Global Impression of Severity (CGI-S) | 대한 가이드라인 | 미국 | 3 | 2 | 6 | ALA |\n| 유지 | ※ 본 장에서 제시한 항목 및 예시는 참고용으로 작성한 것으로 사안에 | 8) 중간 분석 | 이상반응 확인 | - | O | O | O | 수는 없으며, 이상 반응 문제가 생길 수 있다.  | 안전성에서‘하’등급의 분류가 불가능하다.  | 위해요인에 대해 <표 11>과 같이 기록한다.  | 소프트웨어, 오픈 소스 소프트웨어가 업데이트나 | 이거나 모호한 경우 | 의료기기 소프트웨어 | 누구나 환자의 | management for IT-networks | 데이터로 | 의료기기 | 소프트웨어 | 밸리데이션에 | 발생 | 또는 | 네트워크로 연결되는 | 적용 | 소프트웨어 | 가능성 평가 |\n| to binge eating: A case study.  Cognitive and Behavioral Practice, 12(3), 351-358.  | 팩스: 043-719-3900 | 일 것 | 결과값과 예상값을 비교한다. ",
        "original_sentence": "| 위해요인에 대해 <표 11>과 같이 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_282",
      "text": "| 소프트웨어, 오픈 소스 소프트웨어가 업데이트나 | 이거나 모호한 경우 | 의료기기 소프트웨어 | 누구나 환자의 | management for IT-networks | 데이터로 | 의료기기 | 소프트웨어 | 밸리데이션에 | 발생 | 또는 | 네트워크로 연결되는 | 적용 | 소프트웨어 | 가능성 평가 |\n| to binge eating: A case study. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 281,
        "window_size": 3,
        "char_count": 204,
        "word_count": 50,
        "page_number": 9,
        "window_text": "| (6) Clinical Global Impression of Severity (CGI-S) | 대한 가이드라인 | 미국 | 3 | 2 | 6 | ALA |\n| 유지 | ※ 본 장에서 제시한 항목 및 예시는 참고용으로 작성한 것으로 사안에 | 8) 중간 분석 | 이상반응 확인 | - | O | O | O | 수는 없으며, 이상 반응 문제가 생길 수 있다.  | 안전성에서‘하’등급의 분류가 불가능하다.  | 위해요인에 대해 <표 11>과 같이 기록한다.  | 소프트웨어, 오픈 소스 소프트웨어가 업데이트나 | 이거나 모호한 경우 | 의료기기 소프트웨어 | 누구나 환자의 | management for IT-networks | 데이터로 | 의료기기 | 소프트웨어 | 밸리데이션에 | 발생 | 또는 | 네트워크로 연결되는 | 적용 | 소프트웨어 | 가능성 평가 |\n| to binge eating: A case study.  Cognitive and Behavioral Practice, 12(3), 351-358.  | 팩스: 043-719-3900 | 일 것 | 결과값과 예상값을 비교한다.  |\n| 1) 사용 전 준비사항 | 5 | IEC | FAX : (043) 719-3900 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. ",
        "original_sentence": "| 소프트웨어, 오픈 소스 소프트웨어가 업데이트나 | 이거나 모호한 경우 | 의료기기 소프트웨어 | 누구나 환자의 | management for IT-networks | 데이터로 | 의료기기 | 소프트웨어 | 밸리데이션에 | 발생 | 또는 | 네트워크로 연결되는 | 적용 | 소프트웨어 | 가능성 평가 |\n| to binge eating: A case study. "
      }
    },
    {
      "chunk_id": "chunk_283",
      "text": "Cognitive and Behavioral Practice, 12(3), 351-358. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 282,
        "window_size": 3,
        "char_count": 51,
        "word_count": 6,
        "page_number": 9,
        "window_text": "| 안전성에서‘하’등급의 분류가 불가능하다.  | 위해요인에 대해 <표 11>과 같이 기록한다.  | 소프트웨어, 오픈 소스 소프트웨어가 업데이트나 | 이거나 모호한 경우 | 의료기기 소프트웨어 | 누구나 환자의 | management for IT-networks | 데이터로 | 의료기기 | 소프트웨어 | 밸리데이션에 | 발생 | 또는 | 네트워크로 연결되는 | 적용 | 소프트웨어 | 가능성 평가 |\n| to binge eating: A case study.  Cognitive and Behavioral Practice, 12(3), 351-358.  | 팩스: 043-719-3900 | 일 것 | 결과값과 예상값을 비교한다.  |\n| 1) 사용 전 준비사항 | 5 | IEC | FAX : (043) 719-3900 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 되거나 기기와 송·수신될 때 암호화와 같은 | 산출되었다. ",
        "original_sentence": "Cognitive and Behavioral Practice, 12(3), 351-358. "
      }
    },
    {
      "chunk_id": "chunk_284",
      "text": "| 팩스: 043-719-3900 | 일 것 | 결과값과 예상값을 비교한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 283,
        "window_size": 3,
        "char_count": 43,
        "word_count": 10,
        "page_number": 15,
        "window_text": "| 위해요인에 대해 <표 11>과 같이 기록한다.  | 소프트웨어, 오픈 소스 소프트웨어가 업데이트나 | 이거나 모호한 경우 | 의료기기 소프트웨어 | 누구나 환자의 | management for IT-networks | 데이터로 | 의료기기 | 소프트웨어 | 밸리데이션에 | 발생 | 또는 | 네트워크로 연결되는 | 적용 | 소프트웨어 | 가능성 평가 |\n| to binge eating: A case study.  Cognitive and Behavioral Practice, 12(3), 351-358.  | 팩스: 043-719-3900 | 일 것 | 결과값과 예상값을 비교한다.  |\n| 1) 사용 전 준비사항 | 5 | IEC | FAX : (043) 719-3900 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 되거나 기기와 송·수신될 때 암호화와 같은 | 산출되었다.  | (기타 심리적 장애와 연관된 과식) | [부패·공익신고 안내] ※ 신고자 및 신고내용은 보호됩니다. ",
        "original_sentence": "| 팩스: 043-719-3900 | 일 것 | 결과값과 예상값을 비교한다. "
      }
    },
    {
      "chunk_id": "chunk_285",
      "text": "|\n| 1) 사용 전 준비사항 | 5 | IEC | FAX : (043) 719-3900 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 284,
        "window_size": 3,
        "char_count": 87,
        "word_count": 26,
        "page_number": 3,
        "window_text": "| 소프트웨어, 오픈 소스 소프트웨어가 업데이트나 | 이거나 모호한 경우 | 의료기기 소프트웨어 | 누구나 환자의 | management for IT-networks | 데이터로 | 의료기기 | 소프트웨어 | 밸리데이션에 | 발생 | 또는 | 네트워크로 연결되는 | 적용 | 소프트웨어 | 가능성 평가 |\n| to binge eating: A case study.  Cognitive and Behavioral Practice, 12(3), 351-358.  | 팩스: 043-719-3900 | 일 것 | 결과값과 예상값을 비교한다.  |\n| 1) 사용 전 준비사항 | 5 | IEC | FAX : (043) 719-3900 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 되거나 기기와 송·수신될 때 암호화와 같은 | 산출되었다.  | (기타 심리적 장애와 연관된 과식) | [부패·공익신고 안내] ※ 신고자 및 신고내용은 보호됩니다.  | 분석 | 완료 | 유효성 | (AB-1234) | RP |\n| 병용약물 조사 | O | O | O | O | (1) 인구학적 정보: 성별, 나이, 직업 | (2) Patient health questionnaire-9 (PHQ-9) | 성 | 도 | Devices | 위한 | 상세 | 설계를 | 수행한다. ",
        "original_sentence": "|\n| 1) 사용 전 준비사항 | 5 | IEC | FAX : (043) 719-3900 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. "
      }
    },
    {
      "chunk_id": "chunk_286",
      "text": "| 되거나 기기와 송·수신될 때 암호화와 같은 | 산출되었다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 285,
        "window_size": 3,
        "char_count": 35,
        "word_count": 9,
        "page_number": 37,
        "window_text": "Cognitive and Behavioral Practice, 12(3), 351-358.  | 팩스: 043-719-3900 | 일 것 | 결과값과 예상값을 비교한다.  |\n| 1) 사용 전 준비사항 | 5 | IEC | FAX : (043) 719-3900 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 되거나 기기와 송·수신될 때 암호화와 같은 | 산출되었다.  | (기타 심리적 장애와 연관된 과식) | [부패·공익신고 안내] ※ 신고자 및 신고내용은 보호됩니다.  | 분석 | 완료 | 유효성 | (AB-1234) | RP |\n| 병용약물 조사 | O | O | O | O | (1) 인구학적 정보: 성별, 나이, 직업 | (2) Patient health questionnaire-9 (PHQ-9) | 성 | 도 | Devices | 위한 | 상세 | 설계를 | 수행한다.  | 위험 | 실현할 수 있어야 한다. ",
        "original_sentence": "| 되거나 기기와 송·수신될 때 암호화와 같은 | 산출되었다. "
      }
    },
    {
      "chunk_id": "chunk_287",
      "text": "| (기타 심리적 장애와 연관된 과식) | [부패·공익신고 안내] ※ 신고자 및 신고내용은 보호됩니다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 286,
        "window_size": 3,
        "char_count": 58,
        "word_count": 14,
        "page_number": 15,
        "window_text": "| 팩스: 043-719-3900 | 일 것 | 결과값과 예상값을 비교한다.  |\n| 1) 사용 전 준비사항 | 5 | IEC | FAX : (043) 719-3900 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 되거나 기기와 송·수신될 때 암호화와 같은 | 산출되었다.  | (기타 심리적 장애와 연관된 과식) | [부패·공익신고 안내] ※ 신고자 및 신고내용은 보호됩니다.  | 분석 | 완료 | 유효성 | (AB-1234) | RP |\n| 병용약물 조사 | O | O | O | O | (1) 인구학적 정보: 성별, 나이, 직업 | (2) Patient health questionnaire-9 (PHQ-9) | 성 | 도 | Devices | 위한 | 상세 | 설계를 | 수행한다.  | 위험 | 실현할 수 있어야 한다.  | (허용 가능/불가) |\n| 보수 | 2 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. ",
        "original_sentence": "| (기타 심리적 장애와 연관된 과식) | [부패·공익신고 안내] ※ 신고자 및 신고내용은 보호됩니다. "
      }
    },
    {
      "chunk_id": "chunk_288",
      "text": "| 분석 | 완료 | 유효성 | (AB-1234) | RP |\n| 병용약물 조사 | O | O | O | O | (1) 인구학적 정보: 성별, 나이, 직업 | (2) Patient health questionnaire-9 (PHQ-9) | 성 | 도 | Devices | 위한 | 상세 | 설계를 | 수행한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 287,
        "window_size": 3,
        "char_count": 174,
        "word_count": 49,
        "page_number": 9,
        "window_text": "|\n| 1) 사용 전 준비사항 | 5 | IEC | FAX : (043) 719-3900 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 되거나 기기와 송·수신될 때 암호화와 같은 | 산출되었다.  | (기타 심리적 장애와 연관된 과식) | [부패·공익신고 안내] ※ 신고자 및 신고내용은 보호됩니다.  | 분석 | 완료 | 유효성 | (AB-1234) | RP |\n| 병용약물 조사 | O | O | O | O | (1) 인구학적 정보: 성별, 나이, 직업 | (2) Patient health questionnaire-9 (PHQ-9) | 성 | 도 | Devices | 위한 | 상세 | 설계를 | 수행한다.  | 위험 | 실현할 수 있어야 한다.  | (허용 가능/불가) |\n| 보수 | 2 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | - 재사용(재사용이 가능한 경우에만 실시) 결과가 양성인 경우 | 통제될 경우에 대해 고려하여야 한다. ",
        "original_sentence": "| 분석 | 완료 | 유효성 | (AB-1234) | RP |\n| 병용약물 조사 | O | O | O | O | (1) 인구학적 정보: 성별, 나이, 직업 | (2) Patient health questionnaire-9 (PHQ-9) | 성 | 도 | Devices | 위한 | 상세 | 설계를 | 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_289",
      "text": "| 위험 | 실현할 수 있어야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 288,
        "window_size": 3,
        "char_count": 21,
        "word_count": 7,
        "page_number": 15,
        "window_text": "| 되거나 기기와 송·수신될 때 암호화와 같은 | 산출되었다.  | (기타 심리적 장애와 연관된 과식) | [부패·공익신고 안내] ※ 신고자 및 신고내용은 보호됩니다.  | 분석 | 완료 | 유효성 | (AB-1234) | RP |\n| 병용약물 조사 | O | O | O | O | (1) 인구학적 정보: 성별, 나이, 직업 | (2) Patient health questionnaire-9 (PHQ-9) | 성 | 도 | Devices | 위한 | 상세 | 설계를 | 수행한다.  | 위험 | 실현할 수 있어야 한다.  | (허용 가능/불가) |\n| 보수 | 2 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | - 재사용(재사용이 가능한 경우에만 실시) 결과가 양성인 경우 | 통제될 경우에 대해 고려하여야 한다.  | 또는 일시 중지시킬 수 있다. ",
        "original_sentence": "| 위험 | 실현할 수 있어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_290",
      "text": "| (허용 가능/불가) |\n| 보수 | 2 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 289,
        "window_size": 3,
        "char_count": 61,
        "word_count": 19,
        "page_number": 9,
        "window_text": "| (기타 심리적 장애와 연관된 과식) | [부패·공익신고 안내] ※ 신고자 및 신고내용은 보호됩니다.  | 분석 | 완료 | 유효성 | (AB-1234) | RP |\n| 병용약물 조사 | O | O | O | O | (1) 인구학적 정보: 성별, 나이, 직업 | (2) Patient health questionnaire-9 (PHQ-9) | 성 | 도 | Devices | 위한 | 상세 | 설계를 | 수행한다.  | 위험 | 실현할 수 있어야 한다.  | (허용 가능/불가) |\n| 보수 | 2 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | - 재사용(재사용이 가능한 경우에만 실시) 결과가 양성인 경우 | 통제될 경우에 대해 고려하여야 한다.  | 또는 일시 중지시킬 수 있다.  | 밸리데이션 가이드라인 | 데이터에 접근 | incorporating medical devices | 2023년  12월  7일 | 전문의 | 대하여 알기 쉽게 설명하거나 식품 | 치료기회 | 의료기기의 위험관리 | 검증 및 | 국내 | 국외 |\n| 성 | ychiatry, 179(12), 927–937. ",
        "original_sentence": "| (허용 가능/불가) |\n| 보수 | 2 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. "
      }
    },
    {
      "chunk_id": "chunk_291",
      "text": "| - 재사용(재사용이 가능한 경우에만 실시) 결과가 양성인 경우 | 통제될 경우에 대해 고려하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 290,
        "window_size": 3,
        "char_count": 60,
        "word_count": 15,
        "page_number": 34,
        "window_text": "| 분석 | 완료 | 유효성 | (AB-1234) | RP |\n| 병용약물 조사 | O | O | O | O | (1) 인구학적 정보: 성별, 나이, 직업 | (2) Patient health questionnaire-9 (PHQ-9) | 성 | 도 | Devices | 위한 | 상세 | 설계를 | 수행한다.  | 위험 | 실현할 수 있어야 한다.  | (허용 가능/불가) |\n| 보수 | 2 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | - 재사용(재사용이 가능한 경우에만 실시) 결과가 양성인 경우 | 통제될 경우에 대해 고려하여야 한다.  | 또는 일시 중지시킬 수 있다.  | 밸리데이션 가이드라인 | 데이터에 접근 | incorporating medical devices | 2023년  12월  7일 | 전문의 | 대하여 알기 쉽게 설명하거나 식품 | 치료기회 | 의료기기의 위험관리 | 검증 및 | 국내 | 국외 |\n| 성 | ychiatry, 179(12), 927–937.  | 그 사실 | 따라 변경될 수 있으며, 제품의 특성에 따라 타당한 근거를 제시할 경우 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. ",
        "original_sentence": "| - 재사용(재사용이 가능한 경우에만 실시) 결과가 양성인 경우 | 통제될 경우에 대해 고려하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_292",
      "text": "| 또는 일시 중지시킬 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 291,
        "window_size": 3,
        "char_count": 19,
        "word_count": 6,
        "page_number": 12,
        "window_text": "| 위험 | 실현할 수 있어야 한다.  | (허용 가능/불가) |\n| 보수 | 2 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | - 재사용(재사용이 가능한 경우에만 실시) 결과가 양성인 경우 | 통제될 경우에 대해 고려하여야 한다.  | 또는 일시 중지시킬 수 있다.  | 밸리데이션 가이드라인 | 데이터에 접근 | incorporating medical devices | 2023년  12월  7일 | 전문의 | 대하여 알기 쉽게 설명하거나 식품 | 치료기회 | 의료기기의 위험관리 | 검증 및 | 국내 | 국외 |\n| 성 | ychiatry, 179(12), 927–937.  | 그 사실 | 따라 변경될 수 있으며, 제품의 특성에 따라 타당한 근거를 제시할 경우 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 그림 1. ",
        "original_sentence": "| 또는 일시 중지시킬 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_293",
      "text": "| 밸리데이션 가이드라인 | 데이터에 접근 | incorporating medical devices | 2023년  12월  7일 | 전문의 | 대하여 알기 쉽게 설명하거나 식품 | 치료기회 | 의료기기의 위험관리 | 검증 및 | 국내 | 국외 |\n| 성 | ychiatry, 179(12), 927–937. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 292,
        "window_size": 3,
        "char_count": 173,
        "word_count": 41,
        "page_number": 27,
        "window_text": "| (허용 가능/불가) |\n| 보수 | 2 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | - 재사용(재사용이 가능한 경우에만 실시) 결과가 양성인 경우 | 통제될 경우에 대해 고려하여야 한다.  | 또는 일시 중지시킬 수 있다.  | 밸리데이션 가이드라인 | 데이터에 접근 | incorporating medical devices | 2023년  12월  7일 | 전문의 | 대하여 알기 쉽게 설명하거나 식품 | 치료기회 | 의료기기의 위험관리 | 검증 및 | 국내 | 국외 |\n| 성 | ychiatry, 179(12), 927–937.  | 그 사실 | 따라 변경될 수 있으며, 제품의 특성에 따라 타당한 근거를 제시할 경우 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 그림 1.  디지털 치료기기 대상여부 판단 기준 및 절차 | ‣ 식약처 홈페이지 “국민소통 > 신고센터 > 부패·공익신고 상담”코너 | 관련 보고를 시행한다. ",
        "original_sentence": "| 밸리데이션 가이드라인 | 데이터에 접근 | incorporating medical devices | 2023년  12월  7일 | 전문의 | 대하여 알기 쉽게 설명하거나 식품 | 치료기회 | 의료기기의 위험관리 | 검증 및 | 국내 | 국외 |\n| 성 | ychiatry, 179(12), 927–937. "
      }
    },
    {
      "chunk_id": "chunk_294",
      "text": "| 그 사실 | 따라 변경될 수 있으며, 제품의 특성에 따라 타당한 근거를 제시할 경우 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 293,
        "window_size": 3,
        "char_count": 86,
        "word_count": 26,
        "page_number": 28,
        "window_text": "| - 재사용(재사용이 가능한 경우에만 실시) 결과가 양성인 경우 | 통제될 경우에 대해 고려하여야 한다.  | 또는 일시 중지시킬 수 있다.  | 밸리데이션 가이드라인 | 데이터에 접근 | incorporating medical devices | 2023년  12월  7일 | 전문의 | 대하여 알기 쉽게 설명하거나 식품 | 치료기회 | 의료기기의 위험관리 | 검증 및 | 국내 | 국외 |\n| 성 | ychiatry, 179(12), 927–937.  | 그 사실 | 따라 변경될 수 있으며, 제품의 특성에 따라 타당한 근거를 제시할 경우 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 그림 1.  디지털 치료기기 대상여부 판단 기준 및 절차 | ‣ 식약처 홈페이지 “국민소통 > 신고센터 > 부패·공익신고 상담”코너 | 관련 보고를 시행한다.  |\n| 6) 일반적 주의 | 접근 | 중지 명령 등 필요한 조치를 시험책임자에게 하여야 한다. ",
        "original_sentence": "| 그 사실 | 따라 변경될 수 있으며, 제품의 특성에 따라 타당한 근거를 제시할 경우 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다. "
      }
    },
    {
      "chunk_id": "chunk_295",
      "text": "| 그림 1. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 294,
        "window_size": 3,
        "char_count": 8,
        "word_count": 3,
        "page_number": 19,
        "window_text": "| 또는 일시 중지시킬 수 있다.  | 밸리데이션 가이드라인 | 데이터에 접근 | incorporating medical devices | 2023년  12월  7일 | 전문의 | 대하여 알기 쉽게 설명하거나 식품 | 치료기회 | 의료기기의 위험관리 | 검증 및 | 국내 | 국외 |\n| 성 | ychiatry, 179(12), 927–937.  | 그 사실 | 따라 변경될 수 있으며, 제품의 특성에 따라 타당한 근거를 제시할 경우 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 그림 1.  디지털 치료기기 대상여부 판단 기준 및 절차 | ‣ 식약처 홈페이지 “국민소통 > 신고센터 > 부패·공익신고 상담”코너 | 관련 보고를 시행한다.  |\n| 6) 일반적 주의 | 접근 | 중지 명령 등 필요한 조치를 시험책임자에게 하여야 한다.  | 것이라는 사실 | - 본 연구는 중간 분석을 수행하지 않는다. ",
        "original_sentence": "| 그림 1. "
      }
    },
    {
      "chunk_id": "chunk_296",
      "text": "디지털 치료기기 대상여부 판단 기준 및 절차 | ‣ 식약처 홈페이지 “국민소통 > 신고센터 > 부패·공익신고 상담”코너 | 관련 보고를 시행한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 295,
        "window_size": 3,
        "char_count": 82,
        "word_count": 21,
        "page_number": 3,
        "window_text": "| 밸리데이션 가이드라인 | 데이터에 접근 | incorporating medical devices | 2023년  12월  7일 | 전문의 | 대하여 알기 쉽게 설명하거나 식품 | 치료기회 | 의료기기의 위험관리 | 검증 및 | 국내 | 국외 |\n| 성 | ychiatry, 179(12), 927–937.  | 그 사실 | 따라 변경될 수 있으며, 제품의 특성에 따라 타당한 근거를 제시할 경우 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 그림 1.  디지털 치료기기 대상여부 판단 기준 및 절차 | ‣ 식약처 홈페이지 “국민소통 > 신고센터 > 부패·공익신고 상담”코너 | 관련 보고를 시행한다.  |\n| 6) 일반적 주의 | 접근 | 중지 명령 등 필요한 조치를 시험책임자에게 하여야 한다.  | 것이라는 사실 | - 본 연구는 중간 분석을 수행하지 않는다.  | 일정 수준의 보호가 요구되는지 고려하여야 한다. ",
        "original_sentence": "디지털 치료기기 대상여부 판단 기준 및 절차 | ‣ 식약처 홈페이지 “국민소통 > 신고센터 > 부패·공익신고 상담”코너 | 관련 보고를 시행한다. "
      }
    },
    {
      "chunk_id": "chunk_297",
      "text": "|\n| 6) 일반적 주의 | 접근 | 중지 명령 등 필요한 조치를 시험책임자에게 하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 296,
        "window_size": 3,
        "char_count": 53,
        "word_count": 16,
        "page_number": 27,
        "window_text": "| 그 사실 | 따라 변경될 수 있으며, 제품의 특성에 따라 타당한 근거를 제시할 경우 | - 약물 복용력 등을 문진과 과거 진료 기록을 통해 조사한다.  | 그림 1.  디지털 치료기기 대상여부 판단 기준 및 절차 | ‣ 식약처 홈페이지 “국민소통 > 신고센터 > 부패·공익신고 상담”코너 | 관련 보고를 시행한다.  |\n| 6) 일반적 주의 | 접근 | 중지 명령 등 필요한 조치를 시험책임자에게 하여야 한다.  | 것이라는 사실 | - 본 연구는 중간 분석을 수행하지 않는다.  | 일정 수준의 보호가 요구되는지 고려하여야 한다.  | 80001-1 | 수 있다. ",
        "original_sentence": "|\n| 6) 일반적 주의 | 접근 | 중지 명령 등 필요한 조치를 시험책임자에게 하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_298",
      "text": "| 것이라는 사실 | - 본 연구는 중간 분석을 수행하지 않는다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 297,
        "window_size": 3,
        "char_count": 37,
        "word_count": 11,
        "page_number": 35,
        "window_text": "| 그림 1.  디지털 치료기기 대상여부 판단 기준 및 절차 | ‣ 식약처 홈페이지 “국민소통 > 신고센터 > 부패·공익신고 상담”코너 | 관련 보고를 시행한다.  |\n| 6) 일반적 주의 | 접근 | 중지 명령 등 필요한 조치를 시험책임자에게 하여야 한다.  | 것이라는 사실 | - 본 연구는 중간 분석을 수행하지 않는다.  | 일정 수준의 보호가 요구되는지 고려하여야 한다.  | 80001-1 | 수 있다.  | 등을 통해 Baseline 정보를 수집한다. ",
        "original_sentence": "| 것이라는 사실 | - 본 연구는 중간 분석을 수행하지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_299",
      "text": "| 일정 수준의 보호가 요구되는지 고려하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 298,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 15,
        "window_text": "디지털 치료기기 대상여부 판단 기준 및 절차 | ‣ 식약처 홈페이지 “국민소통 > 신고센터 > 부패·공익신고 상담”코너 | 관련 보고를 시행한다.  |\n| 6) 일반적 주의 | 접근 | 중지 명령 등 필요한 조치를 시험책임자에게 하여야 한다.  | 것이라는 사실 | - 본 연구는 중간 분석을 수행하지 않는다.  | 일정 수준의 보호가 요구되는지 고려하여야 한다.  | 80001-1 | 수 있다.  | 등을 통해 Baseline 정보를 수집한다.  | 사항이 발견되는 경우 | 달성한 피험자 비율 | 장애와 연관된 과식) | 상세 설계를 바탕으로 코딩을 | 적용 | 확인 자료 |\n| ention for Binge Eating Disorder. ",
        "original_sentence": "| 일정 수준의 보호가 요구되는지 고려하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_300",
      "text": "| 80001-1 | 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 299,
        "window_size": 3,
        "char_count": 18,
        "word_count": 5,
        "page_number": 12,
        "window_text": "|\n| 6) 일반적 주의 | 접근 | 중지 명령 등 필요한 조치를 시험책임자에게 하여야 한다.  | 것이라는 사실 | - 본 연구는 중간 분석을 수행하지 않는다.  | 일정 수준의 보호가 요구되는지 고려하여야 한다.  | 80001-1 | 수 있다.  | 등을 통해 Baseline 정보를 수집한다.  | 사항이 발견되는 경우 | 달성한 피험자 비율 | 장애와 연관된 과식) | 상세 설계를 바탕으로 코딩을 | 적용 | 확인 자료 |\n| ention for Binge Eating Disorder.  Journal of health psychology, 4(3), 357–363. ",
        "original_sentence": "| 80001-1 | 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_301",
      "text": "| 등을 통해 Baseline 정보를 수집한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 300,
        "window_size": 3,
        "char_count": 27,
        "word_count": 6,
        "page_number": 15,
        "window_text": "| 것이라는 사실 | - 본 연구는 중간 분석을 수행하지 않는다.  | 일정 수준의 보호가 요구되는지 고려하여야 한다.  | 80001-1 | 수 있다.  | 등을 통해 Baseline 정보를 수집한다.  | 사항이 발견되는 경우 | 달성한 피험자 비율 | 장애와 연관된 과식) | 상세 설계를 바탕으로 코딩을 | 적용 | 확인 자료 |\n| ention for Binge Eating Disorder.  Journal of health psychology, 4(3), 357–363.  | 순응도 조사 | - | O | O | - | 성명 | 소속기관명 | 전공 | 직위 | 전화 | Guidance on Cybersecurity for | 내용을 기재한다. ",
        "original_sentence": "| 등을 통해 Baseline 정보를 수집한다. "
      }
    },
    {
      "chunk_id": "chunk_302",
      "text": "| 사항이 발견되는 경우 | 달성한 피험자 비율 | 장애와 연관된 과식) | 상세 설계를 바탕으로 코딩을 | 적용 | 확인 자료 |\n| ention for Binge Eating Disorder. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 301,
        "window_size": 3,
        "char_count": 110,
        "word_count": 29,
        "page_number": 3,
        "window_text": "| 일정 수준의 보호가 요구되는지 고려하여야 한다.  | 80001-1 | 수 있다.  | 등을 통해 Baseline 정보를 수집한다.  | 사항이 발견되는 경우 | 달성한 피험자 비율 | 장애와 연관된 과식) | 상세 설계를 바탕으로 코딩을 | 적용 | 확인 자료 |\n| ention for Binge Eating Disorder.  Journal of health psychology, 4(3), 357–363.  | 순응도 조사 | - | O | O | - | 성명 | 소속기관명 | 전공 | 직위 | 전화 | Guidance on Cybersecurity for | 내용을 기재한다.  | (민원인 안내서) | 의약품안전처의 입장을 기술 | 의료기기 사이버보안에 대한 가이드 |\n| 보호 | 임상시험에서 배제 | 하도록 한 경우 | – Part 1: Roles, | 진료수행 | 해당 | 박탈 | 방법에 대한 국제 규격 | 유효성 | (AB-1234) |\n| 2) 디지털치료기기 치료 기간: 총 8주 | 11 | [출처: 식품의약품안전처(2020.08), 디지털치료기기 허가·심사 가이드라인(민원인 안내서)] | (2) 병력 조사: 동반 질환 여부 | (3) Generalized anxiety disorder 7-item scale (GAD-7) | 또한 제조자는 외부의 통제에 의한 소프트 | 라인 | 유럽 | 소프트웨어 |\n| 설정 변경이 가능하다. ",
        "original_sentence": "| 사항이 발견되는 경우 | 달성한 피험자 비율 | 장애와 연관된 과식) | 상세 설계를 바탕으로 코딩을 | 적용 | 확인 자료 |\n| ention for Binge Eating Disorder. "
      }
    },
    {
      "chunk_id": "chunk_303",
      "text": "Journal of health psychology, 4(3), 357–363. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 302,
        "window_size": 3,
        "char_count": 45,
        "word_count": 6,
        "page_number": 26,
        "window_text": "| 80001-1 | 수 있다.  | 등을 통해 Baseline 정보를 수집한다.  | 사항이 발견되는 경우 | 달성한 피험자 비율 | 장애와 연관된 과식) | 상세 설계를 바탕으로 코딩을 | 적용 | 확인 자료 |\n| ention for Binge Eating Disorder.  Journal of health psychology, 4(3), 357–363.  | 순응도 조사 | - | O | O | - | 성명 | 소속기관명 | 전공 | 직위 | 전화 | Guidance on Cybersecurity for | 내용을 기재한다.  | (민원인 안내서) | 의약품안전처의 입장을 기술 | 의료기기 사이버보안에 대한 가이드 |\n| 보호 | 임상시험에서 배제 | 하도록 한 경우 | – Part 1: Roles, | 진료수행 | 해당 | 박탈 | 방법에 대한 국제 규격 | 유효성 | (AB-1234) |\n| 2) 디지털치료기기 치료 기간: 총 8주 | 11 | [출처: 식품의약품안전처(2020.08), 디지털치료기기 허가·심사 가이드라인(민원인 안내서)] | (2) 병력 조사: 동반 질환 여부 | (3) Generalized anxiety disorder 7-item scale (GAD-7) | 또한 제조자는 외부의 통제에 의한 소프트 | 라인 | 유럽 | 소프트웨어 |\n| 설정 변경이 가능하다.  | 보조분석군으로 분석한다. ",
        "original_sentence": "Journal of health psychology, 4(3), 357–363. "
      }
    },
    {
      "chunk_id": "chunk_304",
      "text": "| 순응도 조사 | - | O | O | - | 성명 | 소속기관명 | 전공 | 직위 | 전화 | Guidance on Cybersecurity for | 내용을 기재한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 303,
        "window_size": 3,
        "char_count": 97,
        "word_count": 29,
        "page_number": 34,
        "window_text": "| 등을 통해 Baseline 정보를 수집한다.  | 사항이 발견되는 경우 | 달성한 피험자 비율 | 장애와 연관된 과식) | 상세 설계를 바탕으로 코딩을 | 적용 | 확인 자료 |\n| ention for Binge Eating Disorder.  Journal of health psychology, 4(3), 357–363.  | 순응도 조사 | - | O | O | - | 성명 | 소속기관명 | 전공 | 직위 | 전화 | Guidance on Cybersecurity for | 내용을 기재한다.  | (민원인 안내서) | 의약품안전처의 입장을 기술 | 의료기기 사이버보안에 대한 가이드 |\n| 보호 | 임상시험에서 배제 | 하도록 한 경우 | – Part 1: Roles, | 진료수행 | 해당 | 박탈 | 방법에 대한 국제 규격 | 유효성 | (AB-1234) |\n| 2) 디지털치료기기 치료 기간: 총 8주 | 11 | [출처: 식품의약품안전처(2020.08), 디지털치료기기 허가·심사 가이드라인(민원인 안내서)] | (2) 병력 조사: 동반 질환 여부 | (3) Generalized anxiety disorder 7-item scale (GAD-7) | 또한 제조자는 외부의 통제에 의한 소프트 | 라인 | 유럽 | 소프트웨어 |\n| 설정 변경이 가능하다.  | 보조분석군으로 분석한다.  | ※ 예: 비밀번호(passwords)는 암호화된 보안 | medical devices | 하며 코드는 정확하고 요구사항에 | 위험 < |\n| 러목(의료기기이상 반응의 보고)에 따른다. ",
        "original_sentence": "| 순응도 조사 | - | O | O | - | 성명 | 소속기관명 | 전공 | 직위 | 전화 | Guidance on Cybersecurity for | 내용을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_305",
      "text": "| (민원인 안내서) | 의약품안전처의 입장을 기술 | 의료기기 사이버보안에 대한 가이드 |\n| 보호 | 임상시험에서 배제 | 하도록 한 경우 | – Part 1: Roles, | 진료수행 | 해당 | 박탈 | 방법에 대한 국제 규격 | 유효성 | (AB-1234) |\n| 2) 디지털치료기기 치료 기간: 총 8주 | 11 | [출처: 식품의약품안전처(2020.08), 디지털치료기기 허가·심사 가이드라인(민원인 안내서)] | (2) 병력 조사: 동반 질환 여부 | (3) Generalized anxiety disorder 7-item scale (GAD-7) | 또한 제조자는 외부의 통제에 의한 소프트 | 라인 | 유럽 | 소프트웨어 |\n| 설정 변경이 가능하다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 304,
        "window_size": 3,
        "char_count": 375,
        "word_count": 92,
        "page_number": 27,
        "window_text": "| 사항이 발견되는 경우 | 달성한 피험자 비율 | 장애와 연관된 과식) | 상세 설계를 바탕으로 코딩을 | 적용 | 확인 자료 |\n| ention for Binge Eating Disorder.  Journal of health psychology, 4(3), 357–363.  | 순응도 조사 | - | O | O | - | 성명 | 소속기관명 | 전공 | 직위 | 전화 | Guidance on Cybersecurity for | 내용을 기재한다.  | (민원인 안내서) | 의약품안전처의 입장을 기술 | 의료기기 사이버보안에 대한 가이드 |\n| 보호 | 임상시험에서 배제 | 하도록 한 경우 | – Part 1: Roles, | 진료수행 | 해당 | 박탈 | 방법에 대한 국제 규격 | 유효성 | (AB-1234) |\n| 2) 디지털치료기기 치료 기간: 총 8주 | 11 | [출처: 식품의약품안전처(2020.08), 디지털치료기기 허가·심사 가이드라인(민원인 안내서)] | (2) 병력 조사: 동반 질환 여부 | (3) Generalized anxiety disorder 7-item scale (GAD-7) | 또한 제조자는 외부의 통제에 의한 소프트 | 라인 | 유럽 | 소프트웨어 |\n| 설정 변경이 가능하다.  | 보조분석군으로 분석한다.  | ※ 예: 비밀번호(passwords)는 암호화된 보안 | medical devices | 하며 코드는 정확하고 요구사항에 | 위험 < |\n| 러목(의료기기이상 반응의 보고)에 따른다.  | 세스에 따른다. ",
        "original_sentence": "| (민원인 안내서) | 의약품안전처의 입장을 기술 | 의료기기 사이버보안에 대한 가이드 |\n| 보호 | 임상시험에서 배제 | 하도록 한 경우 | – Part 1: Roles, | 진료수행 | 해당 | 박탈 | 방법에 대한 국제 규격 | 유효성 | (AB-1234) |\n| 2) 디지털치료기기 치료 기간: 총 8주 | 11 | [출처: 식품의약품안전처(2020.08), 디지털치료기기 허가·심사 가이드라인(민원인 안내서)] | (2) 병력 조사: 동반 질환 여부 | (3) Generalized anxiety disorder 7-item scale (GAD-7) | 또한 제조자는 외부의 통제에 의한 소프트 | 라인 | 유럽 | 소프트웨어 |\n| 설정 변경이 가능하다. "
      }
    },
    {
      "chunk_id": "chunk_306",
      "text": "| 보조분석군으로 분석한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 305,
        "window_size": 3,
        "char_count": 16,
        "word_count": 3,
        "page_number": 15,
        "window_text": "Journal of health psychology, 4(3), 357–363.  | 순응도 조사 | - | O | O | - | 성명 | 소속기관명 | 전공 | 직위 | 전화 | Guidance on Cybersecurity for | 내용을 기재한다.  | (민원인 안내서) | 의약품안전처의 입장을 기술 | 의료기기 사이버보안에 대한 가이드 |\n| 보호 | 임상시험에서 배제 | 하도록 한 경우 | – Part 1: Roles, | 진료수행 | 해당 | 박탈 | 방법에 대한 국제 규격 | 유효성 | (AB-1234) |\n| 2) 디지털치료기기 치료 기간: 총 8주 | 11 | [출처: 식품의약품안전처(2020.08), 디지털치료기기 허가·심사 가이드라인(민원인 안내서)] | (2) 병력 조사: 동반 질환 여부 | (3) Generalized anxiety disorder 7-item scale (GAD-7) | 또한 제조자는 외부의 통제에 의한 소프트 | 라인 | 유럽 | 소프트웨어 |\n| 설정 변경이 가능하다.  | 보조분석군으로 분석한다.  | ※ 예: 비밀번호(passwords)는 암호화된 보안 | medical devices | 하며 코드는 정확하고 요구사항에 | 위험 < |\n| 러목(의료기기이상 반응의 보고)에 따른다.  | 세스에 따른다.  | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 대상으로 한다. ",
        "original_sentence": "| 보조분석군으로 분석한다. "
      }
    },
    {
      "chunk_id": "chunk_307",
      "text": "| ※ 예: 비밀번호(passwords)는 암호화된 보안 | medical devices | 하며 코드는 정확하고 요구사항에 | 위험 < |\n| 러목(의료기기이상 반응의 보고)에 따른다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 306,
        "window_size": 3,
        "char_count": 105,
        "word_count": 23,
        "page_number": 26,
        "window_text": "| 순응도 조사 | - | O | O | - | 성명 | 소속기관명 | 전공 | 직위 | 전화 | Guidance on Cybersecurity for | 내용을 기재한다.  | (민원인 안내서) | 의약품안전처의 입장을 기술 | 의료기기 사이버보안에 대한 가이드 |\n| 보호 | 임상시험에서 배제 | 하도록 한 경우 | – Part 1: Roles, | 진료수행 | 해당 | 박탈 | 방법에 대한 국제 규격 | 유효성 | (AB-1234) |\n| 2) 디지털치료기기 치료 기간: 총 8주 | 11 | [출처: 식품의약품안전처(2020.08), 디지털치료기기 허가·심사 가이드라인(민원인 안내서)] | (2) 병력 조사: 동반 질환 여부 | (3) Generalized anxiety disorder 7-item scale (GAD-7) | 또한 제조자는 외부의 통제에 의한 소프트 | 라인 | 유럽 | 소프트웨어 |\n| 설정 변경이 가능하다.  | 보조분석군으로 분석한다.  | ※ 예: 비밀번호(passwords)는 암호화된 보안 | medical devices | 하며 코드는 정확하고 요구사항에 | 위험 < |\n| 러목(의료기기이상 반응의 보고)에 따른다.  | 세스에 따른다.  | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 대상으로 한다.  | 것을 의미한다. ",
        "original_sentence": "| ※ 예: 비밀번호(passwords)는 암호화된 보안 | medical devices | 하며 코드는 정확하고 요구사항에 | 위험 < |\n| 러목(의료기기이상 반응의 보고)에 따른다. "
      }
    },
    {
      "chunk_id": "chunk_308",
      "text": "| 세스에 따른다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 307,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 29,
        "window_text": "| (민원인 안내서) | 의약품안전처의 입장을 기술 | 의료기기 사이버보안에 대한 가이드 |\n| 보호 | 임상시험에서 배제 | 하도록 한 경우 | – Part 1: Roles, | 진료수행 | 해당 | 박탈 | 방법에 대한 국제 규격 | 유효성 | (AB-1234) |\n| 2) 디지털치료기기 치료 기간: 총 8주 | 11 | [출처: 식품의약품안전처(2020.08), 디지털치료기기 허가·심사 가이드라인(민원인 안내서)] | (2) 병력 조사: 동반 질환 여부 | (3) Generalized anxiety disorder 7-item scale (GAD-7) | 또한 제조자는 외부의 통제에 의한 소프트 | 라인 | 유럽 | 소프트웨어 |\n| 설정 변경이 가능하다.  | 보조분석군으로 분석한다.  | ※ 예: 비밀번호(passwords)는 암호화된 보안 | medical devices | 하며 코드는 정확하고 요구사항에 | 위험 < |\n| 러목(의료기기이상 반응의 보고)에 따른다.  | 세스에 따른다.  | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 대상으로 한다.  | 것을 의미한다.  | 담당자 | 확  인(부서장) | 양 승 하 |\n| 1 | 2 | 2 | Acceptable | 기회를 제공하여 동의를 얻어야 한다. ",
        "original_sentence": "| 세스에 따른다. "
      }
    },
    {
      "chunk_id": "chunk_309",
      "text": "| ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 대상으로 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 308,
        "window_size": 3,
        "char_count": 47,
        "word_count": 13,
        "page_number": 15,
        "window_text": "| 보조분석군으로 분석한다.  | ※ 예: 비밀번호(passwords)는 암호화된 보안 | medical devices | 하며 코드는 정확하고 요구사항에 | 위험 < |\n| 러목(의료기기이상 반응의 보고)에 따른다.  | 세스에 따른다.  | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 대상으로 한다.  | 것을 의미한다.  | 담당자 | 확  인(부서장) | 양 승 하 |\n| 1 | 2 | 2 | Acceptable | 기회를 제공하여 동의를 얻어야 한다.  | 결정되어야 한다. ",
        "original_sentence": "| ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 대상으로 한다. "
      }
    },
    {
      "chunk_id": "chunk_310",
      "text": "| 것을 의미한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 309,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 15,
        "window_text": "| ※ 예: 비밀번호(passwords)는 암호화된 보안 | medical devices | 하며 코드는 정확하고 요구사항에 | 위험 < |\n| 러목(의료기기이상 반응의 보고)에 따른다.  | 세스에 따른다.  | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 대상으로 한다.  | 것을 의미한다.  | 담당자 | 확  인(부서장) | 양 승 하 |\n| 1 | 2 | 2 | Acceptable | 기회를 제공하여 동의를 얻어야 한다.  | 결정되어야 한다.  | 해주어야 한다. ",
        "original_sentence": "| 것을 의미한다. "
      }
    },
    {
      "chunk_id": "chunk_311",
      "text": "| 담당자 | 확  인(부서장) | 양 승 하 |\n| 1 | 2 | 2 | Acceptable | 기회를 제공하여 동의를 얻어야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 310,
        "window_size": 3,
        "char_count": 76,
        "word_count": 24,
        "page_number": 3,
        "window_text": "| 세스에 따른다.  | ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 대상으로 한다.  | 것을 의미한다.  | 담당자 | 확  인(부서장) | 양 승 하 |\n| 1 | 2 | 2 | Acceptable | 기회를 제공하여 동의를 얻어야 한다.  | 결정되어야 한다.  | 해주어야 한다.  | 연장할 수 있다. ",
        "original_sentence": "| 담당자 | 확  인(부서장) | 양 승 하 |\n| 1 | 2 | 2 | Acceptable | 기회를 제공하여 동의를 얻어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_312",
      "text": "| 결정되어야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 311,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 15,
        "window_text": "| ○○○ | ○○병원 | ○○○ | ○○○ | ○○○-○○○○ | 대상으로 한다.  | 것을 의미한다.  | 담당자 | 확  인(부서장) | 양 승 하 |\n| 1 | 2 | 2 | Acceptable | 기회를 제공하여 동의를 얻어야 한다.  | 결정되어야 한다.  | 해주어야 한다.  | 연장할 수 있다.  | - 피험자가 제때 방문을 안 하며 연락이 안 되는 경우 | 4) 치료 전 대비 Follow-up 후 8주 시점의 BMI 변화 | 사건들을 조합하여 각 위해요인에 대한 위험을 산정한다. ",
        "original_sentence": "| 결정되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_313",
      "text": "| 해주어야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 312,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 15,
        "window_text": "| 것을 의미한다.  | 담당자 | 확  인(부서장) | 양 승 하 |\n| 1 | 2 | 2 | Acceptable | 기회를 제공하여 동의를 얻어야 한다.  | 결정되어야 한다.  | 해주어야 한다.  | 연장할 수 있다.  | - 피험자가 제때 방문을 안 하며 연락이 안 되는 경우 | 4) 치료 전 대비 Follow-up 후 8주 시점의 BMI 변화 | 사건들을 조합하여 각 위해요인에 대한 위험을 산정한다.  | 모호한 경우 | responsibilities, and activities | 사항 | 완료 | 허용가능 | 확인 자료 |\n| 웨어의 업데이트나 운영환경 만료에 대한 | 적용 | 검증 및 |\n| (secure)이 확보된 해쉬(hash)로 저장되어야 함 | 이득 |\n**Res Ther. ",
        "original_sentence": "| 해주어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_314",
      "text": "| 연장할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 313,
        "window_size": 3,
        "char_count": 12,
        "word_count": 4,
        "page_number": 12,
        "window_text": "| 담당자 | 확  인(부서장) | 양 승 하 |\n| 1 | 2 | 2 | Acceptable | 기회를 제공하여 동의를 얻어야 한다.  | 결정되어야 한다.  | 해주어야 한다.  | 연장할 수 있다.  | - 피험자가 제때 방문을 안 하며 연락이 안 되는 경우 | 4) 치료 전 대비 Follow-up 후 8주 시점의 BMI 변화 | 사건들을 조합하여 각 위해요인에 대한 위험을 산정한다.  | 모호한 경우 | responsibilities, and activities | 사항 | 완료 | 허용가능 | 확인 자료 |\n| 웨어의 업데이트나 운영환경 만료에 대한 | 적용 | 검증 및 |\n| (secure)이 확보된 해쉬(hash)로 저장되어야 함 | 이득 |\n**Res Ther.  2004;42:551–67.",
        "original_sentence": "| 연장할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_315",
      "text": "| - 피험자가 제때 방문을 안 하며 연락이 안 되는 경우 | 4) 치료 전 대비 Follow-up 후 8주 시점의 BMI 변화 | 사건들을 조합하여 각 위해요인에 대한 위험을 산정한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 314,
        "window_size": 3,
        "char_count": 105,
        "word_count": 30,
        "page_number": 26,
        "window_text": "| 결정되어야 한다.  | 해주어야 한다.  | 연장할 수 있다.  | - 피험자가 제때 방문을 안 하며 연락이 안 되는 경우 | 4) 치료 전 대비 Follow-up 후 8주 시점의 BMI 변화 | 사건들을 조합하여 각 위해요인에 대한 위험을 산정한다.  | 모호한 경우 | responsibilities, and activities | 사항 | 완료 | 허용가능 | 확인 자료 |\n| 웨어의 업데이트나 운영환경 만료에 대한 | 적용 | 검증 및 |\n| (secure)이 확보된 해쉬(hash)로 저장되어야 함 | 이득 |\n**Res Ther.  2004;42:551–67. **\n\n**[표 끝]**\n\n지침서ㆍ안내서\n\n이 원 규\n\n<!-- PAGE_4 -->\n#### 제·개정 이력\n\n섭식장애 개선 디지털치료기기 안전성·성능 작성 및\n\n임상시험계획서 작성 가이드라인(민원인 안내서)\n\n섭식장애 개선 디지털치료기기 안전성·성능\n\n이 안내서는 섭식장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서\n\n작성에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n",
        "original_sentence": "| - 피험자가 제때 방문을 안 하며 연락이 안 되는 경우 | 4) 치료 전 대비 Follow-up 후 8주 시점의 BMI 변화 | 사건들을 조합하여 각 위해요인에 대한 위험을 산정한다. "
      }
    },
    {
      "chunk_id": "chunk_316",
      "text": "| 모호한 경우 | responsibilities, and activities | 사항 | 완료 | 허용가능 | 확인 자료 |\n| 웨어의 업데이트나 운영환경 만료에 대한 | 적용 | 검증 및 |\n| (secure)이 확보된 해쉬(hash)로 저장되어야 함 | 이득 |\n**Res Ther. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 315,
        "window_size": 3,
        "char_count": 162,
        "word_count": 40,
        "page_number": 3,
        "window_text": "| 해주어야 한다.  | 연장할 수 있다.  | - 피험자가 제때 방문을 안 하며 연락이 안 되는 경우 | 4) 치료 전 대비 Follow-up 후 8주 시점의 BMI 변화 | 사건들을 조합하여 각 위해요인에 대한 위험을 산정한다.  | 모호한 경우 | responsibilities, and activities | 사항 | 완료 | 허용가능 | 확인 자료 |\n| 웨어의 업데이트나 운영환경 만료에 대한 | 적용 | 검증 및 |\n| (secure)이 확보된 해쉬(hash)로 저장되어야 함 | 이득 |\n**Res Ther.  2004;42:551–67. **\n\n**[표 끝]**\n\n지침서ㆍ안내서\n\n이 원 규\n\n<!-- PAGE_4 -->\n#### 제·개정 이력\n\n섭식장애 개선 디지털치료기기 안전성·성능 작성 및\n\n임상시험계획서 작성 가이드라인(민원인 안내서)\n\n섭식장애 개선 디지털치료기기 안전성·성능\n\n이 안내서는 섭식장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서\n\n작성에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이\n\n아님을 알려드립니다. ",
        "original_sentence": "| 모호한 경우 | responsibilities, and activities | 사항 | 완료 | 허용가능 | 확인 자료 |\n| 웨어의 업데이트나 운영환경 만료에 대한 | 적용 | 검증 및 |\n| (secure)이 확보된 해쉬(hash)로 저장되어야 함 | 이득 |\n**Res Ther. "
      }
    },
    {
      "chunk_id": "chunk_317",
      "text": "2004;42:551–67.",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 316,
        "window_size": 3,
        "char_count": 15,
        "word_count": 1,
        "page_number": 9,
        "window_text": "| 연장할 수 있다.  | - 피험자가 제때 방문을 안 하며 연락이 안 되는 경우 | 4) 치료 전 대비 Follow-up 후 8주 시점의 BMI 변화 | 사건들을 조합하여 각 위해요인에 대한 위험을 산정한다.  | 모호한 경우 | responsibilities, and activities | 사항 | 완료 | 허용가능 | 확인 자료 |\n| 웨어의 업데이트나 운영환경 만료에 대한 | 적용 | 검증 및 |\n| (secure)이 확보된 해쉬(hash)로 저장되어야 함 | 이득 |\n**Res Ther.  2004;42:551–67. **\n\n**[표 끝]**\n\n지침서ㆍ안내서\n\n이 원 규\n\n<!-- PAGE_4 -->\n#### 제·개정 이력\n\n섭식장애 개선 디지털치료기기 안전성·성능 작성 및\n\n임상시험계획서 작성 가이드라인(민원인 안내서)\n\n섭식장애 개선 디지털치료기기 안전성·성능\n\n이 안내서는 섭식장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서\n\n작성에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이\n\n아님을 알려드립니다.  또한, 본 안내서는 2023년 12월 현재의 과학적ㆍ기술적 사실\n\n및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정법규 내용 및 구체적인\n\n<!-- PAGE_7 -->\n# 목\n\n<!-- PAGE_7 -->\n# 차\n\n<!-- PAGE_7 -->\n### Ⅰ. ",
        "original_sentence": "2004;42:551–67."
      }
    },
    {
      "chunk_id": "chunk_318",
      "text": "**\n\n**[표 끝]**\n\n지침서ㆍ안내서\n\n이 원 규\n\n<!-- PAGE_4 -->\n#### 제·개정 이력\n\n섭식장애 개선 디지털치료기기 안전성·성능 작성 및\n\n임상시험계획서 작성 가이드라인(민원인 안내서)\n\n섭식장애 개선 디지털치료기기 안전성·성능\n\n이 안내서는 섭식장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서\n\n작성에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 317,
        "window_size": 3,
        "char_count": 230,
        "word_count": 45,
        "page_number": 4,
        "window_text": "| - 피험자가 제때 방문을 안 하며 연락이 안 되는 경우 | 4) 치료 전 대비 Follow-up 후 8주 시점의 BMI 변화 | 사건들을 조합하여 각 위해요인에 대한 위험을 산정한다.  | 모호한 경우 | responsibilities, and activities | 사항 | 완료 | 허용가능 | 확인 자료 |\n| 웨어의 업데이트나 운영환경 만료에 대한 | 적용 | 검증 및 |\n| (secure)이 확보된 해쉬(hash)로 저장되어야 함 | 이득 |\n**Res Ther.  2004;42:551–67. **\n\n**[표 끝]**\n\n지침서ㆍ안내서\n\n이 원 규\n\n<!-- PAGE_4 -->\n#### 제·개정 이력\n\n섭식장애 개선 디지털치료기기 안전성·성능 작성 및\n\n임상시험계획서 작성 가이드라인(민원인 안내서)\n\n섭식장애 개선 디지털치료기기 안전성·성능\n\n이 안내서는 섭식장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서\n\n작성에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이\n\n아님을 알려드립니다.  또한, 본 안내서는 2023년 12월 현재의 과학적ㆍ기술적 사실\n\n및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정법규 내용 및 구체적인\n\n<!-- PAGE_7 -->\n# 목\n\n<!-- PAGE_7 -->\n# 차\n\n<!-- PAGE_7 -->\n### Ⅰ.  개 요 ········································································ 1\n\n<!-- PAGE_7 -->\n##### 1. ",
        "original_sentence": "**\n\n**[표 끝]**\n\n지침서ㆍ안내서\n\n이 원 규\n\n<!-- PAGE_4 -->\n#### 제·개정 이력\n\n섭식장애 개선 디지털치료기기 안전성·성능 작성 및\n\n임상시험계획서 작성 가이드라인(민원인 안내서)\n\n섭식장애 개선 디지털치료기기 안전성·성능\n\n이 안내서는 섭식장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서\n\n작성에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_319",
      "text": "본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이\n\n아님을 알려드립니다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 318,
        "window_size": 3,
        "char_count": 103,
        "word_count": 22,
        "page_number": 5,
        "window_text": "| 모호한 경우 | responsibilities, and activities | 사항 | 완료 | 허용가능 | 확인 자료 |\n| 웨어의 업데이트나 운영환경 만료에 대한 | 적용 | 검증 및 |\n| (secure)이 확보된 해쉬(hash)로 저장되어야 함 | 이득 |\n**Res Ther.  2004;42:551–67. **\n\n**[표 끝]**\n\n지침서ㆍ안내서\n\n이 원 규\n\n<!-- PAGE_4 -->\n#### 제·개정 이력\n\n섭식장애 개선 디지털치료기기 안전성·성능 작성 및\n\n임상시험계획서 작성 가이드라인(민원인 안내서)\n\n섭식장애 개선 디지털치료기기 안전성·성능\n\n이 안내서는 섭식장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서\n\n작성에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이\n\n아님을 알려드립니다.  또한, 본 안내서는 2023년 12월 현재의 과학적ㆍ기술적 사실\n\n및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정법규 내용 및 구체적인\n\n<!-- PAGE_7 -->\n# 목\n\n<!-- PAGE_7 -->\n# 차\n\n<!-- PAGE_7 -->\n### Ⅰ.  개 요 ········································································ 1\n\n<!-- PAGE_7 -->\n##### 1.  배경 및 목적 ················································································ 1\n\n<!-- PAGE_7 -->\n##### 2. ",
        "original_sentence": "본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이\n\n아님을 알려드립니다. "
      }
    },
    {
      "chunk_id": "chunk_320",
      "text": "또한, 본 안내서는 2023년 12월 현재의 과학적ㆍ기술적 사실\n\n및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정법규 내용 및 구체적인\n\n<!-- PAGE_7 -->\n# 목\n\n<!-- PAGE_7 -->\n# 차\n\n<!-- PAGE_7 -->\n### Ⅰ. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 319,
        "window_size": 3,
        "char_count": 146,
        "word_count": 34,
        "page_number": 7,
        "window_text": "2004;42:551–67. **\n\n**[표 끝]**\n\n지침서ㆍ안내서\n\n이 원 규\n\n<!-- PAGE_4 -->\n#### 제·개정 이력\n\n섭식장애 개선 디지털치료기기 안전성·성능 작성 및\n\n임상시험계획서 작성 가이드라인(민원인 안내서)\n\n섭식장애 개선 디지털치료기기 안전성·성능\n\n이 안내서는 섭식장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서\n\n작성에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이\n\n아님을 알려드립니다.  또한, 본 안내서는 2023년 12월 현재의 과학적ㆍ기술적 사실\n\n및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정법규 내용 및 구체적인\n\n<!-- PAGE_7 -->\n# 목\n\n<!-- PAGE_7 -->\n# 차\n\n<!-- PAGE_7 -->\n### Ⅰ.  개 요 ········································································ 1\n\n<!-- PAGE_7 -->\n##### 1.  배경 및 목적 ················································································ 1\n\n<!-- PAGE_7 -->\n##### 2.  적용 범위 ······················································································ 1\n\n<!-- PAGE_7 -->\n##### 3. ",
        "original_sentence": "또한, 본 안내서는 2023년 12월 현재의 과학적ㆍ기술적 사실\n\n및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정법규 내용 및 구체적인\n\n<!-- PAGE_7 -->\n# 목\n\n<!-- PAGE_7 -->\n# 차\n\n<!-- PAGE_7 -->\n### Ⅰ. "
      }
    },
    {
      "chunk_id": "chunk_321",
      "text": "개 요 ········································································ 1\n\n<!-- PAGE_7 -->\n##### 1. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 320,
        "window_size": 3,
        "char_count": 105,
        "word_count": 9,
        "page_number": 7,
        "window_text": "**\n\n**[표 끝]**\n\n지침서ㆍ안내서\n\n이 원 규\n\n<!-- PAGE_4 -->\n#### 제·개정 이력\n\n섭식장애 개선 디지털치료기기 안전성·성능 작성 및\n\n임상시험계획서 작성 가이드라인(민원인 안내서)\n\n섭식장애 개선 디지털치료기기 안전성·성능\n\n이 안내서는 섭식장애 개선 디지털치료기기 안전성·성능 평가 및 임상시험계획서\n\n작성에 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이\n\n아님을 알려드립니다.  또한, 본 안내서는 2023년 12월 현재의 과학적ㆍ기술적 사실\n\n및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정법규 내용 및 구체적인\n\n<!-- PAGE_7 -->\n# 목\n\n<!-- PAGE_7 -->\n# 차\n\n<!-- PAGE_7 -->\n### Ⅰ.  개 요 ········································································ 1\n\n<!-- PAGE_7 -->\n##### 1.  배경 및 목적 ················································································ 1\n\n<!-- PAGE_7 -->\n##### 2.  적용 범위 ······················································································ 1\n\n<!-- PAGE_7 -->\n##### 3.  용어 설명 ······················································································ 3\n\n<!-- PAGE_7 -->\n##### 4. ",
        "original_sentence": "개 요 ········································································ 1\n\n<!-- PAGE_7 -->\n##### 1. "
      }
    },
    {
      "chunk_id": "chunk_322",
      "text": "배경 및 목적 ················································································ 1\n\n<!-- PAGE_7 -->\n##### 2. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 321,
        "window_size": 3,
        "char_count": 117,
        "word_count": 10,
        "page_number": 7,
        "window_text": "본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이\n\n아님을 알려드립니다.  또한, 본 안내서는 2023년 12월 현재의 과학적ㆍ기술적 사실\n\n및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정법규 내용 및 구체적인\n\n<!-- PAGE_7 -->\n# 목\n\n<!-- PAGE_7 -->\n# 차\n\n<!-- PAGE_7 -->\n### Ⅰ.  개 요 ········································································ 1\n\n<!-- PAGE_7 -->\n##### 1.  배경 및 목적 ················································································ 1\n\n<!-- PAGE_7 -->\n##### 2.  적용 범위 ······················································································ 1\n\n<!-- PAGE_7 -->\n##### 3.  용어 설명 ······················································································ 3\n\n<!-- PAGE_7 -->\n##### 4.  현황 ································································································ 4\n\n<!-- PAGE_7 -->\n### Ⅱ. ",
        "original_sentence": "배경 및 목적 ················································································ 1\n\n<!-- PAGE_7 -->\n##### 2. "
      }
    },
    {
      "chunk_id": "chunk_323",
      "text": "적용 범위 ······················································································ 1\n\n<!-- PAGE_7 -->\n##### 3. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 322,
        "window_size": 3,
        "char_count": 121,
        "word_count": 9,
        "page_number": 7,
        "window_text": "또한, 본 안내서는 2023년 12월 현재의 과학적ㆍ기술적 사실\n\n및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정법규 내용 및 구체적인\n\n<!-- PAGE_7 -->\n# 목\n\n<!-- PAGE_7 -->\n# 차\n\n<!-- PAGE_7 -->\n### Ⅰ.  개 요 ········································································ 1\n\n<!-- PAGE_7 -->\n##### 1.  배경 및 목적 ················································································ 1\n\n<!-- PAGE_7 -->\n##### 2.  적용 범위 ······················································································ 1\n\n<!-- PAGE_7 -->\n##### 3.  용어 설명 ······················································································ 3\n\n<!-- PAGE_7 -->\n##### 4.  현황 ································································································ 4\n\n<!-- PAGE_7 -->\n### Ⅱ.  안전성·성능 평가 ·············································· 19\n\n<!-- PAGE_7 -->\n##### 1. ",
        "original_sentence": "적용 범위 ······················································································ 1\n\n<!-- PAGE_7 -->\n##### 3. "
      }
    },
    {
      "chunk_id": "chunk_324",
      "text": "용어 설명 ······················································································ 3\n\n<!-- PAGE_7 -->\n##### 4. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 323,
        "window_size": 3,
        "char_count": 121,
        "word_count": 9,
        "page_number": 7,
        "window_text": "개 요 ········································································ 1\n\n<!-- PAGE_7 -->\n##### 1.  배경 및 목적 ················································································ 1\n\n<!-- PAGE_7 -->\n##### 2.  적용 범위 ······················································································ 1\n\n<!-- PAGE_7 -->\n##### 3.  용어 설명 ······················································································ 3\n\n<!-- PAGE_7 -->\n##### 4.  현황 ································································································ 4\n\n<!-- PAGE_7 -->\n### Ⅱ.  안전성·성능 평가 ·············································· 19\n\n<!-- PAGE_7 -->\n##### 1.  국내외 관련 규격 및 가이드라인 ·········································· 19\n\n<!-- PAGE_7 -->\n##### 2. ",
        "original_sentence": "용어 설명 ······················································································ 3\n\n<!-- PAGE_7 -->\n##### 4. "
      }
    },
    {
      "chunk_id": "chunk_325",
      "text": "현황 ································································································ 4\n\n<!-- PAGE_7 -->\n### Ⅱ. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 324,
        "window_size": 3,
        "char_count": 126,
        "word_count": 8,
        "page_number": 7,
        "window_text": "배경 및 목적 ················································································ 1\n\n<!-- PAGE_7 -->\n##### 2.  적용 범위 ······················································································ 1\n\n<!-- PAGE_7 -->\n##### 3.  용어 설명 ······················································································ 3\n\n<!-- PAGE_7 -->\n##### 4.  현황 ································································································ 4\n\n<!-- PAGE_7 -->\n### Ⅱ.  안전성·성능 평가 ·············································· 19\n\n<!-- PAGE_7 -->\n##### 1.  국내외 관련 규격 및 가이드라인 ·········································· 19\n\n<!-- PAGE_7 -->\n##### 2.  안전성 평가 항목 ······································································ 22\n\n<!-- PAGE_7 -->\n##### 3. ",
        "original_sentence": "현황 ································································································ 4\n\n<!-- PAGE_7 -->\n### Ⅱ. "
      }
    },
    {
      "chunk_id": "chunk_326",
      "text": "안전성·성능 평가 ·············································· 19\n\n<!-- PAGE_7 -->\n##### 1. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 325,
        "window_size": 3,
        "char_count": 86,
        "word_count": 9,
        "page_number": 7,
        "window_text": "적용 범위 ······················································································ 1\n\n<!-- PAGE_7 -->\n##### 3.  용어 설명 ······················································································ 3\n\n<!-- PAGE_7 -->\n##### 4.  현황 ································································································ 4\n\n<!-- PAGE_7 -->\n### Ⅱ.  안전성·성능 평가 ·············································· 19\n\n<!-- PAGE_7 -->\n##### 1.  국내외 관련 규격 및 가이드라인 ·········································· 19\n\n<!-- PAGE_7 -->\n##### 2.  안전성 평가 항목 ······································································ 22\n\n<!-- PAGE_7 -->\n##### 3.  성능 평가 항목 ·········································································· 34\n\n<!-- PAGE_7 -->\n### Ⅲ. ",
        "original_sentence": "안전성·성능 평가 ·············································· 19\n\n<!-- PAGE_7 -->\n##### 1. "
      }
    },
    {
      "chunk_id": "chunk_327",
      "text": "국내외 관련 규격 및 가이드라인 ·········································· 19\n\n<!-- PAGE_7 -->\n##### 2. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 326,
        "window_size": 3,
        "char_count": 90,
        "word_count": 12,
        "page_number": 7,
        "window_text": "용어 설명 ······················································································ 3\n\n<!-- PAGE_7 -->\n##### 4.  현황 ································································································ 4\n\n<!-- PAGE_7 -->\n### Ⅱ.  안전성·성능 평가 ·············································· 19\n\n<!-- PAGE_7 -->\n##### 1.  국내외 관련 규격 및 가이드라인 ·········································· 19\n\n<!-- PAGE_7 -->\n##### 2.  안전성 평가 항목 ······································································ 22\n\n<!-- PAGE_7 -->\n##### 3.  성능 평가 항목 ·········································································· 34\n\n<!-- PAGE_7 -->\n### Ⅲ.  임상시험계획서 작성 시 고려사항 및 예시 ·· 36\n\n<!-- PAGE_7 -->\n### Ⅳ. ",
        "original_sentence": "국내외 관련 규격 및 가이드라인 ·········································· 19\n\n<!-- PAGE_7 -->\n##### 2. "
      }
    },
    {
      "chunk_id": "chunk_328",
      "text": "안전성 평가 항목 ······································································ 22\n\n<!-- PAGE_7 -->\n##### 3. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 327,
        "window_size": 3,
        "char_count": 110,
        "word_count": 10,
        "page_number": 7,
        "window_text": "현황 ································································································ 4\n\n<!-- PAGE_7 -->\n### Ⅱ.  안전성·성능 평가 ·············································· 19\n\n<!-- PAGE_7 -->\n##### 1.  국내외 관련 규격 및 가이드라인 ·········································· 19\n\n<!-- PAGE_7 -->\n##### 2.  안전성 평가 항목 ······································································ 22\n\n<!-- PAGE_7 -->\n##### 3.  성능 평가 항목 ·········································································· 34\n\n<!-- PAGE_7 -->\n### Ⅲ.  임상시험계획서 작성 시 고려사항 및 예시 ·· 36\n\n<!-- PAGE_7 -->\n### Ⅳ.  참고문헌 ······························································ 105\n\n- - 1 -\n<!-- PAGE_8 -->\n### Ⅰ\n\n<!-- PAGE_8 -->\n### 개 요\n\n<!-- PAGE_8 -->\n##### 1. ",
        "original_sentence": "안전성 평가 항목 ······································································ 22\n\n<!-- PAGE_7 -->\n##### 3. "
      }
    },
    {
      "chunk_id": "chunk_329",
      "text": "성능 평가 항목 ·········································································· 34\n\n<!-- PAGE_7 -->\n### Ⅲ. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 328,
        "window_size": 3,
        "char_count": 111,
        "word_count": 10,
        "page_number": 7,
        "window_text": "안전성·성능 평가 ·············································· 19\n\n<!-- PAGE_7 -->\n##### 1.  국내외 관련 규격 및 가이드라인 ·········································· 19\n\n<!-- PAGE_7 -->\n##### 2.  안전성 평가 항목 ······································································ 22\n\n<!-- PAGE_7 -->\n##### 3.  성능 평가 항목 ·········································································· 34\n\n<!-- PAGE_7 -->\n### Ⅲ.  임상시험계획서 작성 시 고려사항 및 예시 ·· 36\n\n<!-- PAGE_7 -->\n### Ⅳ.  참고문헌 ······························································ 105\n\n- - 1 -\n<!-- PAGE_8 -->\n### Ⅰ\n\n<!-- PAGE_8 -->\n### 개 요\n\n<!-- PAGE_8 -->\n##### 1.  배경 및 목적\n\n식품의약품안전처는 정부 지원 과제 중 디지털치료기기에 특화된\n\n과제의 제품 설계부터 제품화에 필요한 안전성·성능 평가 및 임상시험\n\n계획서 작성 방법 제공을 통한 신속 제품화 지원을 하고 있다.\n\n",
        "original_sentence": "성능 평가 항목 ·········································································· 34\n\n<!-- PAGE_7 -->\n### Ⅲ. "
      }
    },
    {
      "chunk_id": "chunk_330",
      "text": "임상시험계획서 작성 시 고려사항 및 예시 ·· 36\n\n<!-- PAGE_7 -->\n### Ⅳ. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 329,
        "window_size": 3,
        "char_count": 53,
        "word_count": 13,
        "page_number": 7,
        "window_text": "국내외 관련 규격 및 가이드라인 ·········································· 19\n\n<!-- PAGE_7 -->\n##### 2.  안전성 평가 항목 ······································································ 22\n\n<!-- PAGE_7 -->\n##### 3.  성능 평가 항목 ·········································································· 34\n\n<!-- PAGE_7 -->\n### Ⅲ.  임상시험계획서 작성 시 고려사항 및 예시 ·· 36\n\n<!-- PAGE_7 -->\n### Ⅳ.  참고문헌 ······························································ 105\n\n- - 1 -\n<!-- PAGE_8 -->\n### Ⅰ\n\n<!-- PAGE_8 -->\n### 개 요\n\n<!-- PAGE_8 -->\n##### 1.  배경 및 목적\n\n식품의약품안전처는 정부 지원 과제 중 디지털치료기기에 특화된\n\n과제의 제품 설계부터 제품화에 필요한 안전성·성능 평가 및 임상시험\n\n계획서 작성 방법 제공을 통한 신속 제품화 지원을 하고 있다.\n\n 본 가이드라인은 “섭식장애 개선 디지털치료기기”의 안전성·성능\n\n평가 방법, 임상시험 계획서 작성 시 고려사항 및 예시를 구체적으로\n\n제시하여 신속 제품화를 위한 맞춤형 기술 지원을 목적으로 한다.\n\n",
        "original_sentence": "임상시험계획서 작성 시 고려사항 및 예시 ·· 36\n\n<!-- PAGE_7 -->\n### Ⅳ. "
      }
    },
    {
      "chunk_id": "chunk_331",
      "text": "참고문헌 ······························································ 105\n\n- - 1 -\n<!-- PAGE_8 -->\n### Ⅰ\n\n<!-- PAGE_8 -->\n### 개 요\n\n<!-- PAGE_8 -->\n##### 1. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 330,
        "window_size": 3,
        "char_count": 154,
        "word_count": 23,
        "page_number": 8,
        "window_text": "안전성 평가 항목 ······································································ 22\n\n<!-- PAGE_7 -->\n##### 3.  성능 평가 항목 ·········································································· 34\n\n<!-- PAGE_7 -->\n### Ⅲ.  임상시험계획서 작성 시 고려사항 및 예시 ·· 36\n\n<!-- PAGE_7 -->\n### Ⅳ.  참고문헌 ······························································ 105\n\n- - 1 -\n<!-- PAGE_8 -->\n### Ⅰ\n\n<!-- PAGE_8 -->\n### 개 요\n\n<!-- PAGE_8 -->\n##### 1.  배경 및 목적\n\n식품의약품안전처는 정부 지원 과제 중 디지털치료기기에 특화된\n\n과제의 제품 설계부터 제품화에 필요한 안전성·성능 평가 및 임상시험\n\n계획서 작성 방법 제공을 통한 신속 제품화 지원을 하고 있다.\n\n 본 가이드라인은 “섭식장애 개선 디지털치료기기”의 안전성·성능\n\n평가 방법, 임상시험 계획서 작성 시 고려사항 및 예시를 구체적으로\n\n제시하여 신속 제품화를 위한 맞춤형 기술 지원을 목적으로 한다.\n\n <!-- PAGE_8 -->\n##### 2. ",
        "original_sentence": "참고문헌 ······························································ 105\n\n- - 1 -\n<!-- PAGE_8 -->\n### Ⅰ\n\n<!-- PAGE_8 -->\n### 개 요\n\n<!-- PAGE_8 -->\n##### 1. "
      }
    },
    {
      "chunk_id": "chunk_332",
      "text": "배경 및 목적\n\n식품의약품안전처는 정부 지원 과제 중 디지털치료기기에 특화된\n\n과제의 제품 설계부터 제품화에 필요한 안전성·성능 평가 및 임상시험\n\n계획서 작성 방법 제공을 통한 신속 제품화 지원을 하고 있다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 331,
        "window_size": 3,
        "char_count": 119,
        "word_count": 29,
        "page_number": 7,
        "window_text": "성능 평가 항목 ·········································································· 34\n\n<!-- PAGE_7 -->\n### Ⅲ.  임상시험계획서 작성 시 고려사항 및 예시 ·· 36\n\n<!-- PAGE_7 -->\n### Ⅳ.  참고문헌 ······························································ 105\n\n- - 1 -\n<!-- PAGE_8 -->\n### Ⅰ\n\n<!-- PAGE_8 -->\n### 개 요\n\n<!-- PAGE_8 -->\n##### 1.  배경 및 목적\n\n식품의약품안전처는 정부 지원 과제 중 디지털치료기기에 특화된\n\n과제의 제품 설계부터 제품화에 필요한 안전성·성능 평가 및 임상시험\n\n계획서 작성 방법 제공을 통한 신속 제품화 지원을 하고 있다.\n\n 본 가이드라인은 “섭식장애 개선 디지털치료기기”의 안전성·성능\n\n평가 방법, 임상시험 계획서 작성 시 고려사항 및 예시를 구체적으로\n\n제시하여 신속 제품화를 위한 맞춤형 기술 지원을 목적으로 한다.\n\n <!-- PAGE_8 -->\n##### 2.  적용 범위\n\n본 가이드라인에서 다루는 섭식장애 개선 디지털치료기기는 「의료\n\n기기 품목 및 품목별 등급에 관한 규정(식약처 고시 제2021-83호)」의 품목\n\n분류에 따라 인지치료소프트웨어(2등급, E06060.02) 의료기기로\n\n분류된다.\n\n",
        "original_sentence": "배경 및 목적\n\n식품의약품안전처는 정부 지원 과제 중 디지털치료기기에 특화된\n\n과제의 제품 설계부터 제품화에 필요한 안전성·성능 평가 및 임상시험\n\n계획서 작성 방법 제공을 통한 신속 제품화 지원을 하고 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_333",
      "text": "본 가이드라인은 “섭식장애 개선 디지털치료기기”의 안전성·성능\n\n평가 방법, 임상시험 계획서 작성 시 고려사항 및 예시를 구체적으로\n\n제시하여 신속 제품화를 위한 맞춤형 기술 지원을 목적으로 한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 332,
        "window_size": 3,
        "char_count": 112,
        "word_count": 25,
        "page_number": 1,
        "window_text": "임상시험계획서 작성 시 고려사항 및 예시 ·· 36\n\n<!-- PAGE_7 -->\n### Ⅳ.  참고문헌 ······························································ 105\n\n- - 1 -\n<!-- PAGE_8 -->\n### Ⅰ\n\n<!-- PAGE_8 -->\n### 개 요\n\n<!-- PAGE_8 -->\n##### 1.  배경 및 목적\n\n식품의약품안전처는 정부 지원 과제 중 디지털치료기기에 특화된\n\n과제의 제품 설계부터 제품화에 필요한 안전성·성능 평가 및 임상시험\n\n계획서 작성 방법 제공을 통한 신속 제품화 지원을 하고 있다.\n\n 본 가이드라인은 “섭식장애 개선 디지털치료기기”의 안전성·성능\n\n평가 방법, 임상시험 계획서 작성 시 고려사항 및 예시를 구체적으로\n\n제시하여 신속 제품화를 위한 맞춤형 기술 지원을 목적으로 한다.\n\n <!-- PAGE_8 -->\n##### 2.  적용 범위\n\n본 가이드라인에서 다루는 섭식장애 개선 디지털치료기기는 「의료\n\n기기 품목 및 품목별 등급에 관한 규정(식약처 고시 제2021-83호)」의 품목\n\n분류에 따라 인지치료소프트웨어(2등급, E06060.02) 의료기기로\n\n분류된다.\n\n 단, 추후 섭식장애 외 동반된 정신과적 증상에 대한 평가 또는 치료를\n\n동시에 목적으로 한다면 심리평가소프트웨어(2등급, E06050.01) 또는\n\n정서장애치료소프트웨어(2등급, E06070.01)의 의료기기 분류를 추가\n\n하여 조합의료기기로 분류할 수 있다.\n\n",
        "original_sentence": "본 가이드라인은 “섭식장애 개선 디지털치료기기”의 안전성·성능\n\n평가 방법, 임상시험 계획서 작성 시 고려사항 및 예시를 구체적으로\n\n제시하여 신속 제품화를 위한 맞춤형 기술 지원을 목적으로 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_334",
      "text": "<!-- PAGE_8 -->\n##### 2. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 333,
        "window_size": 3,
        "char_count": 25,
        "word_count": 5,
        "page_number": 8,
        "window_text": "참고문헌 ······························································ 105\n\n- - 1 -\n<!-- PAGE_8 -->\n### Ⅰ\n\n<!-- PAGE_8 -->\n### 개 요\n\n<!-- PAGE_8 -->\n##### 1.  배경 및 목적\n\n식품의약품안전처는 정부 지원 과제 중 디지털치료기기에 특화된\n\n과제의 제품 설계부터 제품화에 필요한 안전성·성능 평가 및 임상시험\n\n계획서 작성 방법 제공을 통한 신속 제품화 지원을 하고 있다.\n\n 본 가이드라인은 “섭식장애 개선 디지털치료기기”의 안전성·성능\n\n평가 방법, 임상시험 계획서 작성 시 고려사항 및 예시를 구체적으로\n\n제시하여 신속 제품화를 위한 맞춤형 기술 지원을 목적으로 한다.\n\n <!-- PAGE_8 -->\n##### 2.  적용 범위\n\n본 가이드라인에서 다루는 섭식장애 개선 디지털치료기기는 「의료\n\n기기 품목 및 품목별 등급에 관한 규정(식약처 고시 제2021-83호)」의 품목\n\n분류에 따라 인지치료소프트웨어(2등급, E06060.02) 의료기기로\n\n분류된다.\n\n 단, 추후 섭식장애 외 동반된 정신과적 증상에 대한 평가 또는 치료를\n\n동시에 목적으로 한다면 심리평가소프트웨어(2등급, E06050.01) 또는\n\n정서장애치료소프트웨어(2등급, E06070.01)의 의료기기 분류를 추가\n\n하여 조합의료기기로 분류할 수 있다.\n\n - - 2 -\n품목명\n\n영문명\n\n등급\n\n분류번호\n\n품목정의\n\n**[표 시작]**\n\n| 할당에 있어 편향(Bias)을 줄이기 위해 무작위배정(Randomization)과 눈가림(Blinding) | 갖춘 | 의료기관을 | 임상시험기관으로 | 지정하여 | 운영하고 | 있으며, 임상시험기관은 | ※ 피험자의 선정·제외 기준, 인원 및 근거 | 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을 고려하여 “식품의약품안전처의 임상 | 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시한다. ",
        "original_sentence": "<!-- PAGE_8 -->\n##### 2. "
      }
    },
    {
      "chunk_id": "chunk_335",
      "text": "적용 범위\n\n본 가이드라인에서 다루는 섭식장애 개선 디지털치료기기는 「의료\n\n기기 품목 및 품목별 등급에 관한 규정(식약처 고시 제2021-83호)」의 품목\n\n분류에 따라 인지치료소프트웨어(2등급, E06060.02) 의료기기로\n\n분류된다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 334,
        "window_size": 3,
        "char_count": 136,
        "word_count": 25,
        "page_number": 1,
        "window_text": "배경 및 목적\n\n식품의약품안전처는 정부 지원 과제 중 디지털치료기기에 특화된\n\n과제의 제품 설계부터 제품화에 필요한 안전성·성능 평가 및 임상시험\n\n계획서 작성 방법 제공을 통한 신속 제품화 지원을 하고 있다.\n\n 본 가이드라인은 “섭식장애 개선 디지털치료기기”의 안전성·성능\n\n평가 방법, 임상시험 계획서 작성 시 고려사항 및 예시를 구체적으로\n\n제시하여 신속 제품화를 위한 맞춤형 기술 지원을 목적으로 한다.\n\n <!-- PAGE_8 -->\n##### 2.  적용 범위\n\n본 가이드라인에서 다루는 섭식장애 개선 디지털치료기기는 「의료\n\n기기 품목 및 품목별 등급에 관한 규정(식약처 고시 제2021-83호)」의 품목\n\n분류에 따라 인지치료소프트웨어(2등급, E06060.02) 의료기기로\n\n분류된다.\n\n 단, 추후 섭식장애 외 동반된 정신과적 증상에 대한 평가 또는 치료를\n\n동시에 목적으로 한다면 심리평가소프트웨어(2등급, E06050.01) 또는\n\n정서장애치료소프트웨어(2등급, E06070.01)의 의료기기 분류를 추가\n\n하여 조합의료기기로 분류할 수 있다.\n\n - - 2 -\n품목명\n\n영문명\n\n등급\n\n분류번호\n\n품목정의\n\n**[표 시작]**\n\n| 할당에 있어 편향(Bias)을 줄이기 위해 무작위배정(Randomization)과 눈가림(Blinding) | 갖춘 | 의료기관을 | 임상시험기관으로 | 지정하여 | 운영하고 | 있으며, 임상시험기관은 | ※ 피험자의 선정·제외 기준, 인원 및 근거 | 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을 고려하여 “식품의약품안전처의 임상 | 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시한다.  | (Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험책임자의 이력 | 인지치료 | 점수 | 인지기능을 개선하는 데 사용하는 소프트웨어 | 검증 및 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 등을 제시한다. ",
        "original_sentence": "적용 범위\n\n본 가이드라인에서 다루는 섭식장애 개선 디지털치료기기는 「의료\n\n기기 품목 및 품목별 등급에 관한 규정(식약처 고시 제2021-83호)」의 품목\n\n분류에 따라 인지치료소프트웨어(2등급, E06060.02) 의료기기로\n\n분류된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_336",
      "text": "단, 추후 섭식장애 외 동반된 정신과적 증상에 대한 평가 또는 치료를\n\n동시에 목적으로 한다면 심리평가소프트웨어(2등급, E06050.01) 또는\n\n정서장애치료소프트웨어(2등급, E06070.01)의 의료기기 분류를 추가\n\n하여 조합의료기기로 분류할 수 있다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 335,
        "window_size": 3,
        "char_count": 147,
        "word_count": 27,
        "page_number": 7,
        "window_text": "본 가이드라인은 “섭식장애 개선 디지털치료기기”의 안전성·성능\n\n평가 방법, 임상시험 계획서 작성 시 고려사항 및 예시를 구체적으로\n\n제시하여 신속 제품화를 위한 맞춤형 기술 지원을 목적으로 한다.\n\n <!-- PAGE_8 -->\n##### 2.  적용 범위\n\n본 가이드라인에서 다루는 섭식장애 개선 디지털치료기기는 「의료\n\n기기 품목 및 품목별 등급에 관한 규정(식약처 고시 제2021-83호)」의 품목\n\n분류에 따라 인지치료소프트웨어(2등급, E06060.02) 의료기기로\n\n분류된다.\n\n 단, 추후 섭식장애 외 동반된 정신과적 증상에 대한 평가 또는 치료를\n\n동시에 목적으로 한다면 심리평가소프트웨어(2등급, E06050.01) 또는\n\n정서장애치료소프트웨어(2등급, E06070.01)의 의료기기 분류를 추가\n\n하여 조합의료기기로 분류할 수 있다.\n\n - - 2 -\n품목명\n\n영문명\n\n등급\n\n분류번호\n\n품목정의\n\n**[표 시작]**\n\n| 할당에 있어 편향(Bias)을 줄이기 위해 무작위배정(Randomization)과 눈가림(Blinding) | 갖춘 | 의료기관을 | 임상시험기관으로 | 지정하여 | 운영하고 | 있으며, 임상시험기관은 | ※ 피험자의 선정·제외 기준, 인원 및 근거 | 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을 고려하여 “식품의약품안전처의 임상 | 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시한다.  | (Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험책임자의 이력 | 인지치료 | 점수 | 인지기능을 개선하는 데 사용하는 소프트웨어 | 검증 및 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 등을 제시한다.  | ‘의료기기 임상시험 관리기준’(의료기기법 시행규칙 [별표3])에 의거, 정한 기간 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | - 임상시험 전 피험자 선정 과정에서의 확인해야 할 사항, 임상검사, 피험자 동의서 | 3) 임상시험용 의료기기 : 섭식장애 개선 디지털치료기기(OOO) | 1) 만 19세 이상 65세 이하의 성인에 해당하는 자 | 3) 4주, 8 주 시점에 폭식 횟수를 0회 달성한 피험자 비율 | 2) 일차 유효성 평가변수 | 1) 연구가설 | 1 | 3 | 의미한다(Park,Cho et al., 2010). ",
        "original_sentence": "단, 추후 섭식장애 외 동반된 정신과적 증상에 대한 평가 또는 치료를\n\n동시에 목적으로 한다면 심리평가소프트웨어(2등급, E06050.01) 또는\n\n정서장애치료소프트웨어(2등급, E06070.01)의 의료기기 분류를 추가\n\n하여 조합의료기기로 분류할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_337",
      "text": "- - 2 -\n품목명\n\n영문명\n\n등급\n\n분류번호\n\n품목정의\n\n**[표 시작]**\n\n| 할당에 있어 편향(Bias)을 줄이기 위해 무작위배정(Randomization)과 눈가림(Blinding) | 갖춘 | 의료기관을 | 임상시험기관으로 | 지정하여 | 운영하고 | 있으며, 임상시험기관은 | ※ 피험자의 선정·제외 기준, 인원 및 근거 | 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을 고려하여 “식품의약품안전처의 임상 | 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 336,
        "window_size": 3,
        "char_count": 277,
        "word_count": 59,
        "page_number": 7,
        "window_text": "<!-- PAGE_8 -->\n##### 2.  적용 범위\n\n본 가이드라인에서 다루는 섭식장애 개선 디지털치료기기는 「의료\n\n기기 품목 및 품목별 등급에 관한 규정(식약처 고시 제2021-83호)」의 품목\n\n분류에 따라 인지치료소프트웨어(2등급, E06060.02) 의료기기로\n\n분류된다.\n\n 단, 추후 섭식장애 외 동반된 정신과적 증상에 대한 평가 또는 치료를\n\n동시에 목적으로 한다면 심리평가소프트웨어(2등급, E06050.01) 또는\n\n정서장애치료소프트웨어(2등급, E06070.01)의 의료기기 분류를 추가\n\n하여 조합의료기기로 분류할 수 있다.\n\n - - 2 -\n품목명\n\n영문명\n\n등급\n\n분류번호\n\n품목정의\n\n**[표 시작]**\n\n| 할당에 있어 편향(Bias)을 줄이기 위해 무작위배정(Randomization)과 눈가림(Blinding) | 갖춘 | 의료기관을 | 임상시험기관으로 | 지정하여 | 운영하고 | 있으며, 임상시험기관은 | ※ 피험자의 선정·제외 기준, 인원 및 근거 | 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을 고려하여 “식품의약품안전처의 임상 | 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시한다.  | (Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험책임자의 이력 | 인지치료 | 점수 | 인지기능을 개선하는 데 사용하는 소프트웨어 | 검증 및 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 등을 제시한다.  | ‘의료기기 임상시험 관리기준’(의료기기법 시행규칙 [별표3])에 의거, 정한 기간 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | - 임상시험 전 피험자 선정 과정에서의 확인해야 할 사항, 임상검사, 피험자 동의서 | 3) 임상시험용 의료기기 : 섭식장애 개선 디지털치료기기(OOO) | 1) 만 19세 이상 65세 이하의 성인에 해당하는 자 | 3) 4주, 8 주 시점에 폭식 횟수를 0회 달성한 피험자 비율 | 2) 일차 유효성 평가변수 | 1) 연구가설 | 1 | 3 | 의미한다(Park,Cho et al., 2010).  | 7) Clinical Global Impression of Severity (CGI-S) | 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능 평가 기준을 제시 | 같이 분류한다. ",
        "original_sentence": "- - 2 -\n품목명\n\n영문명\n\n등급\n\n분류번호\n\n품목정의\n\n**[표 시작]**\n\n| 할당에 있어 편향(Bias)을 줄이기 위해 무작위배정(Randomization)과 눈가림(Blinding) | 갖춘 | 의료기관을 | 임상시험기관으로 | 지정하여 | 운영하고 | 있으며, 임상시험기관은 | ※ 피험자의 선정·제외 기준, 인원 및 근거 | 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을 고려하여 “식품의약품안전처의 임상 | 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_338",
      "text": "| (Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험책임자의 이력 | 인지치료 | 점수 | 인지기능을 개선하는 데 사용하는 소프트웨어 | 검증 및 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 등을 제시한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 337,
        "window_size": 3,
        "char_count": 208,
        "word_count": 59,
        "page_number": 35,
        "window_text": "적용 범위\n\n본 가이드라인에서 다루는 섭식장애 개선 디지털치료기기는 「의료\n\n기기 품목 및 품목별 등급에 관한 규정(식약처 고시 제2021-83호)」의 품목\n\n분류에 따라 인지치료소프트웨어(2등급, E06060.02) 의료기기로\n\n분류된다.\n\n 단, 추후 섭식장애 외 동반된 정신과적 증상에 대한 평가 또는 치료를\n\n동시에 목적으로 한다면 심리평가소프트웨어(2등급, E06050.01) 또는\n\n정서장애치료소프트웨어(2등급, E06070.01)의 의료기기 분류를 추가\n\n하여 조합의료기기로 분류할 수 있다.\n\n - - 2 -\n품목명\n\n영문명\n\n등급\n\n분류번호\n\n품목정의\n\n**[표 시작]**\n\n| 할당에 있어 편향(Bias)을 줄이기 위해 무작위배정(Randomization)과 눈가림(Blinding) | 갖춘 | 의료기관을 | 임상시험기관으로 | 지정하여 | 운영하고 | 있으며, 임상시험기관은 | ※ 피험자의 선정·제외 기준, 인원 및 근거 | 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을 고려하여 “식품의약품안전처의 임상 | 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시한다.  | (Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험책임자의 이력 | 인지치료 | 점수 | 인지기능을 개선하는 데 사용하는 소프트웨어 | 검증 및 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 등을 제시한다.  | ‘의료기기 임상시험 관리기준’(의료기기법 시행규칙 [별표3])에 의거, 정한 기간 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | - 임상시험 전 피험자 선정 과정에서의 확인해야 할 사항, 임상검사, 피험자 동의서 | 3) 임상시험용 의료기기 : 섭식장애 개선 디지털치료기기(OOO) | 1) 만 19세 이상 65세 이하의 성인에 해당하는 자 | 3) 4주, 8 주 시점에 폭식 횟수를 0회 달성한 피험자 비율 | 2) 일차 유효성 평가변수 | 1) 연구가설 | 1 | 3 | 의미한다(Park,Cho et al., 2010).  | 7) Clinical Global Impression of Severity (CGI-S) | 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능 평가 기준을 제시 | 같이 분류한다.  | 가이드라인(민원인 안내서)’에 따른다. ",
        "original_sentence": "| (Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험책임자의 이력 | 인지치료 | 점수 | 인지기능을 개선하는 데 사용하는 소프트웨어 | 검증 및 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 등을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_339",
      "text": "| ‘의료기기 임상시험 관리기준’(의료기기법 시행규칙 [별표3])에 의거, 정한 기간 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | - 임상시험 전 피험자 선정 과정에서의 확인해야 할 사항, 임상검사, 피험자 동의서 | 3) 임상시험용 의료기기 : 섭식장애 개선 디지털치료기기(OOO) | 1) 만 19세 이상 65세 이하의 성인에 해당하는 자 | 3) 4주, 8 주 시점에 폭식 횟수를 0회 달성한 피험자 비율 | 2) 일차 유효성 평가변수 | 1) 연구가설 | 1 | 3 | 의미한다(Park,Cho et al., 2010). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 338,
        "window_size": 3,
        "char_count": 319,
        "word_count": 81,
        "page_number": 26,
        "window_text": "단, 추후 섭식장애 외 동반된 정신과적 증상에 대한 평가 또는 치료를\n\n동시에 목적으로 한다면 심리평가소프트웨어(2등급, E06050.01) 또는\n\n정서장애치료소프트웨어(2등급, E06070.01)의 의료기기 분류를 추가\n\n하여 조합의료기기로 분류할 수 있다.\n\n - - 2 -\n품목명\n\n영문명\n\n등급\n\n분류번호\n\n품목정의\n\n**[표 시작]**\n\n| 할당에 있어 편향(Bias)을 줄이기 위해 무작위배정(Randomization)과 눈가림(Blinding) | 갖춘 | 의료기관을 | 임상시험기관으로 | 지정하여 | 운영하고 | 있으며, 임상시험기관은 | ※ 피험자의 선정·제외 기준, 인원 및 근거 | 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을 고려하여 “식품의약품안전처의 임상 | 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시한다.  | (Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험책임자의 이력 | 인지치료 | 점수 | 인지기능을 개선하는 데 사용하는 소프트웨어 | 검증 및 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 등을 제시한다.  | ‘의료기기 임상시험 관리기준’(의료기기법 시행규칙 [별표3])에 의거, 정한 기간 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | - 임상시험 전 피험자 선정 과정에서의 확인해야 할 사항, 임상검사, 피험자 동의서 | 3) 임상시험용 의료기기 : 섭식장애 개선 디지털치료기기(OOO) | 1) 만 19세 이상 65세 이하의 성인에 해당하는 자 | 3) 4주, 8 주 시점에 폭식 횟수를 0회 달성한 피험자 비율 | 2) 일차 유효성 평가변수 | 1) 연구가설 | 1 | 3 | 의미한다(Park,Cho et al., 2010).  | 7) Clinical Global Impression of Severity (CGI-S) | 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능 평가 기준을 제시 | 같이 분류한다.  | 가이드라인(민원인 안내서)’에 따른다.  | 가) 임상시험 설명 및 동의 | 다) 임상시험 의료기기 시험방법 | 유지한다. ",
        "original_sentence": "| ‘의료기기 임상시험 관리기준’(의료기기법 시행규칙 [별표3])에 의거, 정한 기간 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | - 임상시험 전 피험자 선정 과정에서의 확인해야 할 사항, 임상검사, 피험자 동의서 | 3) 임상시험용 의료기기 : 섭식장애 개선 디지털치료기기(OOO) | 1) 만 19세 이상 65세 이하의 성인에 해당하는 자 | 3) 4주, 8 주 시점에 폭식 횟수를 0회 달성한 피험자 비율 | 2) 일차 유효성 평가변수 | 1) 연구가설 | 1 | 3 | 의미한다(Park,Cho et al., 2010). "
      }
    },
    {
      "chunk_id": "chunk_340",
      "text": "| 7) Clinical Global Impression of Severity (CGI-S) | 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능 평가 기준을 제시 | 같이 분류한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 339,
        "window_size": 3,
        "char_count": 107,
        "word_count": 22,
        "page_number": 27,
        "window_text": "- - 2 -\n품목명\n\n영문명\n\n등급\n\n분류번호\n\n품목정의\n\n**[표 시작]**\n\n| 할당에 있어 편향(Bias)을 줄이기 위해 무작위배정(Randomization)과 눈가림(Blinding) | 갖춘 | 의료기관을 | 임상시험기관으로 | 지정하여 | 운영하고 | 있으며, 임상시험기관은 | ※ 피험자의 선정·제외 기준, 인원 및 근거 | 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을 고려하여 “식품의약품안전처의 임상 | 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시한다.  | (Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험책임자의 이력 | 인지치료 | 점수 | 인지기능을 개선하는 데 사용하는 소프트웨어 | 검증 및 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 등을 제시한다.  | ‘의료기기 임상시험 관리기준’(의료기기법 시행규칙 [별표3])에 의거, 정한 기간 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | - 임상시험 전 피험자 선정 과정에서의 확인해야 할 사항, 임상검사, 피험자 동의서 | 3) 임상시험용 의료기기 : 섭식장애 개선 디지털치료기기(OOO) | 1) 만 19세 이상 65세 이하의 성인에 해당하는 자 | 3) 4주, 8 주 시점에 폭식 횟수를 0회 달성한 피험자 비율 | 2) 일차 유효성 평가변수 | 1) 연구가설 | 1 | 3 | 의미한다(Park,Cho et al., 2010).  | 7) Clinical Global Impression of Severity (CGI-S) | 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능 평가 기준을 제시 | 같이 분류한다.  | 가이드라인(민원인 안내서)’에 따른다.  | 가) 임상시험 설명 및 동의 | 다) 임상시험 의료기기 시험방법 | 유지한다.  | 아니 된다. ",
        "original_sentence": "| 7) Clinical Global Impression of Severity (CGI-S) | 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능 평가 기준을 제시 | 같이 분류한다. "
      }
    },
    {
      "chunk_id": "chunk_341",
      "text": "| 가이드라인(민원인 안내서)’에 따른다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 340,
        "window_size": 3,
        "char_count": 24,
        "word_count": 4,
        "page_number": 3,
        "window_text": "| (Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험책임자의 이력 | 인지치료 | 점수 | 인지기능을 개선하는 데 사용하는 소프트웨어 | 검증 및 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 등을 제시한다.  | ‘의료기기 임상시험 관리기준’(의료기기법 시행규칙 [별표3])에 의거, 정한 기간 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | - 임상시험 전 피험자 선정 과정에서의 확인해야 할 사항, 임상검사, 피험자 동의서 | 3) 임상시험용 의료기기 : 섭식장애 개선 디지털치료기기(OOO) | 1) 만 19세 이상 65세 이하의 성인에 해당하는 자 | 3) 4주, 8 주 시점에 폭식 횟수를 0회 달성한 피험자 비율 | 2) 일차 유효성 평가변수 | 1) 연구가설 | 1 | 3 | 의미한다(Park,Cho et al., 2010).  | 7) Clinical Global Impression of Severity (CGI-S) | 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능 평가 기준을 제시 | 같이 분류한다.  | 가이드라인(민원인 안내서)’에 따른다.  | 가) 임상시험 설명 및 동의 | 다) 임상시험 의료기기 시험방법 | 유지한다.  | 아니 된다.  | 사유 | 요구한 사용 방법을 준수하여야 한다. ",
        "original_sentence": "| 가이드라인(민원인 안내서)’에 따른다. "
      }
    },
    {
      "chunk_id": "chunk_342",
      "text": "| 가) 임상시험 설명 및 동의 | 다) 임상시험 의료기기 시험방법 | 유지한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 341,
        "window_size": 3,
        "char_count": 46,
        "word_count": 13,
        "page_number": 15,
        "window_text": "| ‘의료기기 임상시험 관리기준’(의료기기법 시행규칙 [별표3])에 의거, 정한 기간 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | - 임상시험 전 피험자 선정 과정에서의 확인해야 할 사항, 임상검사, 피험자 동의서 | 3) 임상시험용 의료기기 : 섭식장애 개선 디지털치료기기(OOO) | 1) 만 19세 이상 65세 이하의 성인에 해당하는 자 | 3) 4주, 8 주 시점에 폭식 횟수를 0회 달성한 피험자 비율 | 2) 일차 유효성 평가변수 | 1) 연구가설 | 1 | 3 | 의미한다(Park,Cho et al., 2010).  | 7) Clinical Global Impression of Severity (CGI-S) | 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능 평가 기준을 제시 | 같이 분류한다.  | 가이드라인(민원인 안내서)’에 따른다.  | 가) 임상시험 설명 및 동의 | 다) 임상시험 의료기기 시험방법 | 유지한다.  | 아니 된다.  | 사유 | 요구한 사용 방법을 준수하여야 한다.  | - 초기 평가에는 최소 다음의 사항이 포함되어야 한다. ",
        "original_sentence": "| 가) 임상시험 설명 및 동의 | 다) 임상시험 의료기기 시험방법 | 유지한다. "
      }
    },
    {
      "chunk_id": "chunk_343",
      "text": "| 아니 된다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 342,
        "window_size": 3,
        "char_count": 9,
        "word_count": 3,
        "page_number": 112,
        "window_text": "| 7) Clinical Global Impression of Severity (CGI-S) | 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능 평가 기준을 제시 | 같이 분류한다.  | 가이드라인(민원인 안내서)’에 따른다.  | 가) 임상시험 설명 및 동의 | 다) 임상시험 의료기기 시험방법 | 유지한다.  | 아니 된다.  | 사유 | 요구한 사용 방법을 준수하여야 한다.  | - 초기 평가에는 최소 다음의 사항이 포함되어야 한다.  | 동일하게 해당 효과의 50% 정도인 –6.40로 설정하였다. ",
        "original_sentence": "| 아니 된다. "
      }
    },
    {
      "chunk_id": "chunk_344",
      "text": "| 사유 | 요구한 사용 방법을 준수하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 343,
        "window_size": 3,
        "char_count": 28,
        "word_count": 8,
        "page_number": 15,
        "window_text": "| 가이드라인(민원인 안내서)’에 따른다.  | 가) 임상시험 설명 및 동의 | 다) 임상시험 의료기기 시험방법 | 유지한다.  | 아니 된다.  | 사유 | 요구한 사용 방법을 준수하여야 한다.  | - 초기 평가에는 최소 다음의 사항이 포함되어야 한다.  | 동일하게 해당 효과의 50% 정도인 –6.40로 설정하였다.  | 순응도를 조사한다. ",
        "original_sentence": "| 사유 | 요구한 사용 방법을 준수하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_345",
      "text": "| - 초기 평가에는 최소 다음의 사항이 포함되어야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 344,
        "window_size": 3,
        "char_count": 33,
        "word_count": 9,
        "page_number": 3,
        "window_text": "| 가) 임상시험 설명 및 동의 | 다) 임상시험 의료기기 시험방법 | 유지한다.  | 아니 된다.  | 사유 | 요구한 사용 방법을 준수하여야 한다.  | - 초기 평가에는 최소 다음의 사항이 포함되어야 한다.  | 동일하게 해당 효과의 50% 정도인 –6.40로 설정하였다.  | 순응도를 조사한다.  | 순응도를 조사한다. ",
        "original_sentence": "| - 초기 평가에는 최소 다음의 사항이 포함되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_346",
      "text": "| 동일하게 해당 효과의 50% 정도인 –6.40로 설정하였다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 345,
        "window_size": 3,
        "char_count": 36,
        "word_count": 8,
        "page_number": 26,
        "window_text": "| 아니 된다.  | 사유 | 요구한 사용 방법을 준수하여야 한다.  | - 초기 평가에는 최소 다음의 사항이 포함되어야 한다.  | 동일하게 해당 효과의 50% 정도인 –6.40로 설정하였다.  | 순응도를 조사한다.  | 순응도를 조사한다.  | 순응도를 조사한다. ",
        "original_sentence": "| 동일하게 해당 효과의 50% 정도인 –6.40로 설정하였다. "
      }
    },
    {
      "chunk_id": "chunk_347",
      "text": "| 순응도를 조사한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 346,
        "window_size": 3,
        "char_count": 13,
        "word_count": 3,
        "page_number": 15,
        "window_text": "| 사유 | 요구한 사용 방법을 준수하여야 한다.  | - 초기 평가에는 최소 다음의 사항이 포함되어야 한다.  | 동일하게 해당 효과의 50% 정도인 –6.40로 설정하였다.  | 순응도를 조사한다.  | 순응도를 조사한다.  | 순응도를 조사한다.  | 하도록 한다. ",
        "original_sentence": "| 순응도를 조사한다. "
      }
    },
    {
      "chunk_id": "chunk_348",
      "text": "| 순응도를 조사한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 347,
        "window_size": 3,
        "char_count": 13,
        "word_count": 3,
        "page_number": 15,
        "window_text": "| - 초기 평가에는 최소 다음의 사항이 포함되어야 한다.  | 동일하게 해당 효과의 50% 정도인 –6.40로 설정하였다.  | 순응도를 조사한다.  | 순응도를 조사한다.  | 순응도를 조사한다.  | 하도록 한다.  | 결과 또는 신체 질환 악화가 예상되는 경우 | 타당한 경우 | 순서가 타당하지 않은 경우 | 피험자 식별코드를 부여한다. ",
        "original_sentence": "| 순응도를 조사한다. "
      }
    },
    {
      "chunk_id": "chunk_349",
      "text": "| 순응도를 조사한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 348,
        "window_size": 3,
        "char_count": 13,
        "word_count": 3,
        "page_number": 15,
        "window_text": "| 동일하게 해당 효과의 50% 정도인 –6.40로 설정하였다.  | 순응도를 조사한다.  | 순응도를 조사한다.  | 순응도를 조사한다.  | 하도록 한다.  | 결과 또는 신체 질환 악화가 예상되는 경우 | 타당한 경우 | 순서가 타당하지 않은 경우 | 피험자 식별코드를 부여한다.  | 허가심사 가이드라인 | 유닛 검증 | - 심리치료 일환으로 인지행동치료(CBT 또는 CBT-E)를 활용한다. ",
        "original_sentence": "| 순응도를 조사한다. "
      }
    },
    {
      "chunk_id": "chunk_350",
      "text": "| 하도록 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 349,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 15,
        "window_text": "| 순응도를 조사한다.  | 순응도를 조사한다.  | 순응도를 조사한다.  | 하도록 한다.  | 결과 또는 신체 질환 악화가 예상되는 경우 | 타당한 경우 | 순서가 타당하지 않은 경우 | 피험자 식별코드를 부여한다.  | 허가심사 가이드라인 | 유닛 검증 | - 심리치료 일환으로 인지행동치료(CBT 또는 CBT-E)를 활용한다.  | 접근으로 인해 환자 | 파악할 수 있는 “static test” 및 | 보고서’, ‘의료기기 소프트웨어 검증 | 국내 |\n| 해당 의료기기의 제조업자 또는 수입업자가 해당된다. ",
        "original_sentence": "| 하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_351",
      "text": "| 결과 또는 신체 질환 악화가 예상되는 경우 | 타당한 경우 | 순서가 타당하지 않은 경우 | 피험자 식별코드를 부여한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 350,
        "window_size": 3,
        "char_count": 70,
        "word_count": 20,
        "page_number": 34,
        "window_text": "| 순응도를 조사한다.  | 순응도를 조사한다.  | 하도록 한다.  | 결과 또는 신체 질환 악화가 예상되는 경우 | 타당한 경우 | 순서가 타당하지 않은 경우 | 피험자 식별코드를 부여한다.  | 허가심사 가이드라인 | 유닛 검증 | - 심리치료 일환으로 인지행동치료(CBT 또는 CBT-E)를 활용한다.  | 접근으로 인해 환자 | 파악할 수 있는 “static test” 및 | 보고서’, ‘의료기기 소프트웨어 검증 | 국내 |\n| 해당 의료기기의 제조업자 또는 수입업자가 해당된다.  의뢰자는 임상시험 모니터 | 대한 준비 등 임상시험을 위한 준비 절차와 사용 단계 절차의 각 단계별 조작 순서, | nd boys: results from a national survey. ",
        "original_sentence": "| 결과 또는 신체 질환 악화가 예상되는 경우 | 타당한 경우 | 순서가 타당하지 않은 경우 | 피험자 식별코드를 부여한다. "
      }
    },
    {
      "chunk_id": "chunk_352",
      "text": "| 허가심사 가이드라인 | 유닛 검증 | - 심리치료 일환으로 인지행동치료(CBT 또는 CBT-E)를 활용한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 351,
        "window_size": 3,
        "char_count": 63,
        "word_count": 14,
        "page_number": 28,
        "window_text": "| 순응도를 조사한다.  | 하도록 한다.  | 결과 또는 신체 질환 악화가 예상되는 경우 | 타당한 경우 | 순서가 타당하지 않은 경우 | 피험자 식별코드를 부여한다.  | 허가심사 가이드라인 | 유닛 검증 | - 심리치료 일환으로 인지행동치료(CBT 또는 CBT-E)를 활용한다.  | 접근으로 인해 환자 | 파악할 수 있는 “static test” 및 | 보고서’, ‘의료기기 소프트웨어 검증 | 국내 |\n| 해당 의료기기의 제조업자 또는 수입업자가 해당된다.  의뢰자는 임상시험 모니터 | 대한 준비 등 임상시험을 위한 준비 절차와 사용 단계 절차의 각 단계별 조작 순서, | nd boys: results from a national survey.  Arch Pediatr Adolesc Med, 154(6), 569-77. ",
        "original_sentence": "| 허가심사 가이드라인 | 유닛 검증 | - 심리치료 일환으로 인지행동치료(CBT 또는 CBT-E)를 활용한다. "
      }
    },
    {
      "chunk_id": "chunk_353",
      "text": "| 접근으로 인해 환자 | 파악할 수 있는 “static test” 및 | 보고서’, ‘의료기기 소프트웨어 검증 | 국내 |\n| 해당 의료기기의 제조업자 또는 수입업자가 해당된다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 352,
        "window_size": 3,
        "char_count": 101,
        "word_count": 26,
        "page_number": 15,
        "window_text": "| 하도록 한다.  | 결과 또는 신체 질환 악화가 예상되는 경우 | 타당한 경우 | 순서가 타당하지 않은 경우 | 피험자 식별코드를 부여한다.  | 허가심사 가이드라인 | 유닛 검증 | - 심리치료 일환으로 인지행동치료(CBT 또는 CBT-E)를 활용한다.  | 접근으로 인해 환자 | 파악할 수 있는 “static test” 및 | 보고서’, ‘의료기기 소프트웨어 검증 | 국내 |\n| 해당 의료기기의 제조업자 또는 수입업자가 해당된다.  의뢰자는 임상시험 모니터 | 대한 준비 등 임상시험을 위한 준비 절차와 사용 단계 절차의 각 단계별 조작 순서, | nd boys: results from a national survey.  Arch Pediatr Adolesc Med, 154(6), 569-77.  | 6 | IEC/TR | 2) 사용 환경 : 병원 내 사용, 병원 외 사용 | 해당 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 대상질환 또는 | :  비열등성 허용 오차 | ※ 예: 업데이트 시 사용자 개입/ 자동 업 | therapy | 높다는 것을 의미한다. ",
        "original_sentence": "| 접근으로 인해 환자 | 파악할 수 있는 “static test” 및 | 보고서’, ‘의료기기 소프트웨어 검증 | 국내 |\n| 해당 의료기기의 제조업자 또는 수입업자가 해당된다. "
      }
    },
    {
      "chunk_id": "chunk_354",
      "text": "의뢰자는 임상시험 모니터 | 대한 준비 등 임상시험을 위한 준비 절차와 사용 단계 절차의 각 단계별 조작 순서, | nd boys: results from a national survey. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 353,
        "window_size": 3,
        "char_count": 106,
        "word_count": 26,
        "page_number": 7,
        "window_text": "| 결과 또는 신체 질환 악화가 예상되는 경우 | 타당한 경우 | 순서가 타당하지 않은 경우 | 피험자 식별코드를 부여한다.  | 허가심사 가이드라인 | 유닛 검증 | - 심리치료 일환으로 인지행동치료(CBT 또는 CBT-E)를 활용한다.  | 접근으로 인해 환자 | 파악할 수 있는 “static test” 및 | 보고서’, ‘의료기기 소프트웨어 검증 | 국내 |\n| 해당 의료기기의 제조업자 또는 수입업자가 해당된다.  의뢰자는 임상시험 모니터 | 대한 준비 등 임상시험을 위한 준비 절차와 사용 단계 절차의 각 단계별 조작 순서, | nd boys: results from a national survey.  Arch Pediatr Adolesc Med, 154(6), 569-77.  | 6 | IEC/TR | 2) 사용 환경 : 병원 내 사용, 병원 외 사용 | 해당 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 대상질환 또는 | :  비열등성 허용 오차 | ※ 예: 업데이트 시 사용자 개입/ 자동 업 | therapy | 높다는 것을 의미한다.  | 2 | E06060.02 | 적용 |\n| 일반적인 사항, 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 | 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입한다. ",
        "original_sentence": "의뢰자는 임상시험 모니터 | 대한 준비 등 임상시험을 위한 준비 절차와 사용 단계 절차의 각 단계별 조작 순서, | nd boys: results from a national survey. "
      }
    },
    {
      "chunk_id": "chunk_355",
      "text": "Arch Pediatr Adolesc Med, 154(6), 569-77. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 354,
        "window_size": 3,
        "char_count": 42,
        "word_count": 6,
        "page_number": 19,
        "window_text": "| 허가심사 가이드라인 | 유닛 검증 | - 심리치료 일환으로 인지행동치료(CBT 또는 CBT-E)를 활용한다.  | 접근으로 인해 환자 | 파악할 수 있는 “static test” 및 | 보고서’, ‘의료기기 소프트웨어 검증 | 국내 |\n| 해당 의료기기의 제조업자 또는 수입업자가 해당된다.  의뢰자는 임상시험 모니터 | 대한 준비 등 임상시험을 위한 준비 절차와 사용 단계 절차의 각 단계별 조작 순서, | nd boys: results from a national survey.  Arch Pediatr Adolesc Med, 154(6), 569-77.  | 6 | IEC/TR | 2) 사용 환경 : 병원 내 사용, 병원 외 사용 | 해당 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 대상질환 또는 | :  비열등성 허용 오차 | ※ 예: 업데이트 시 사용자 개입/ 자동 업 | therapy | 높다는 것을 의미한다.  | 2 | E06060.02 | 적용 |\n| 일반적인 사항, 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 | 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입한다.  | 사용자의 접근 | 제조자는 데이터 부인방지(non-repudiation)를 | 또는 치료기회 박탈 | 이상사례 |\n| 자를 말하며, 임상시험용 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용 | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 서식, | 하는 원칙과 절차를 수립하여 제시한다. ",
        "original_sentence": "Arch Pediatr Adolesc Med, 154(6), 569-77. "
      }
    },
    {
      "chunk_id": "chunk_356",
      "text": "| 6 | IEC/TR | 2) 사용 환경 : 병원 내 사용, 병원 외 사용 | 해당 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 대상질환 또는 | :  비열등성 허용 오차 | ※ 예: 업데이트 시 사용자 개입/ 자동 업 | therapy | 높다는 것을 의미한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 355,
        "window_size": 3,
        "char_count": 156,
        "word_count": 45,
        "page_number": 9,
        "window_text": "| 접근으로 인해 환자 | 파악할 수 있는 “static test” 및 | 보고서’, ‘의료기기 소프트웨어 검증 | 국내 |\n| 해당 의료기기의 제조업자 또는 수입업자가 해당된다.  의뢰자는 임상시험 모니터 | 대한 준비 등 임상시험을 위한 준비 절차와 사용 단계 절차의 각 단계별 조작 순서, | nd boys: results from a national survey.  Arch Pediatr Adolesc Med, 154(6), 569-77.  | 6 | IEC/TR | 2) 사용 환경 : 병원 내 사용, 병원 외 사용 | 해당 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 대상질환 또는 | :  비열등성 허용 오차 | ※ 예: 업데이트 시 사용자 개입/ 자동 업 | therapy | 높다는 것을 의미한다.  | 2 | E06060.02 | 적용 |\n| 일반적인 사항, 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 | 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입한다.  | 사용자의 접근 | 제조자는 데이터 부인방지(non-repudiation)를 | 또는 치료기회 박탈 | 이상사례 |\n| 자를 말하며, 임상시험용 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용 | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 서식, | 하는 원칙과 절차를 수립하여 제시한다.  피해자 보상에 대한 규약에는 보상원칙과 보상이 |\n| 전략이 잘 포함되어야 한다. ",
        "original_sentence": "| 6 | IEC/TR | 2) 사용 환경 : 병원 내 사용, 병원 외 사용 | 해당 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 대상질환 또는 | :  비열등성 허용 오차 | ※ 예: 업데이트 시 사용자 개입/ 자동 업 | therapy | 높다는 것을 의미한다. "
      }
    },
    {
      "chunk_id": "chunk_357",
      "text": "| 2 | E06060.02 | 적용 |\n| 일반적인 사항, 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 | 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 356,
        "window_size": 3,
        "char_count": 104,
        "word_count": 27,
        "page_number": 3,
        "window_text": "의뢰자는 임상시험 모니터 | 대한 준비 등 임상시험을 위한 준비 절차와 사용 단계 절차의 각 단계별 조작 순서, | nd boys: results from a national survey.  Arch Pediatr Adolesc Med, 154(6), 569-77.  | 6 | IEC/TR | 2) 사용 환경 : 병원 내 사용, 병원 외 사용 | 해당 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 대상질환 또는 | :  비열등성 허용 오차 | ※ 예: 업데이트 시 사용자 개입/ 자동 업 | therapy | 높다는 것을 의미한다.  | 2 | E06060.02 | 적용 |\n| 일반적인 사항, 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 | 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입한다.  | 사용자의 접근 | 제조자는 데이터 부인방지(non-repudiation)를 | 또는 치료기회 박탈 | 이상사례 |\n| 자를 말하며, 임상시험용 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용 | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 서식, | 하는 원칙과 절차를 수립하여 제시한다.  피해자 보상에 대한 규약에는 보상원칙과 보상이 |\n| 전략이 잘 포함되어야 한다.  | [의료기기 임상시험기관 지정에 관한 규정(식약처 고시)]에 따라 식약처장으로부터 | 계획 승인일로부터 OO 개월”로 표시하고 근거자료를 제출한다. ",
        "original_sentence": "| 2 | E06060.02 | 적용 |\n| 일반적인 사항, 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 | 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입한다. "
      }
    },
    {
      "chunk_id": "chunk_358",
      "text": "| 사용자의 접근 | 제조자는 데이터 부인방지(non-repudiation)를 | 또는 치료기회 박탈 | 이상사례 |\n| 자를 말하며, 임상시험용 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용 | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 서식, | 하는 원칙과 절차를 수립하여 제시한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 357,
        "window_size": 3,
        "char_count": 184,
        "word_count": 42,
        "page_number": 34,
        "window_text": "Arch Pediatr Adolesc Med, 154(6), 569-77.  | 6 | IEC/TR | 2) 사용 환경 : 병원 내 사용, 병원 외 사용 | 해당 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 대상질환 또는 | :  비열등성 허용 오차 | ※ 예: 업데이트 시 사용자 개입/ 자동 업 | therapy | 높다는 것을 의미한다.  | 2 | E06060.02 | 적용 |\n| 일반적인 사항, 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 | 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입한다.  | 사용자의 접근 | 제조자는 데이터 부인방지(non-repudiation)를 | 또는 치료기회 박탈 | 이상사례 |\n| 자를 말하며, 임상시험용 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용 | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 서식, | 하는 원칙과 절차를 수립하여 제시한다.  피해자 보상에 대한 규약에는 보상원칙과 보상이 |\n| 전략이 잘 포함되어야 한다.  | [의료기기 임상시험기관 지정에 관한 규정(식약처 고시)]에 따라 식약처장으로부터 | 계획 승인일로부터 OO 개월”로 표시하고 근거자료를 제출한다.  | 사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 의료기기의 공급과 | 유/무, 피험자 기초정보, 병력조사, 선정 및 제외 기준, 식별코드 부여 등에 대해서 |\n| 내에 가능한 신속한 보고가 되어야 하며, 이상반응 등에 대한 의학적 소견· | 하는 원칙과 절차를 수립하여 제시한다. ",
        "original_sentence": "| 사용자의 접근 | 제조자는 데이터 부인방지(non-repudiation)를 | 또는 치료기회 박탈 | 이상사례 |\n| 자를 말하며, 임상시험용 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용 | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 서식, | 하는 원칙과 절차를 수립하여 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_359",
      "text": "피해자 보상에 대한 규약에는 보상원칙과 보상이 |\n| 전략이 잘 포함되어야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 358,
        "window_size": 3,
        "char_count": 46,
        "word_count": 12,
        "page_number": 15,
        "window_text": "| 6 | IEC/TR | 2) 사용 환경 : 병원 내 사용, 병원 외 사용 | 해당 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 대상질환 또는 | :  비열등성 허용 오차 | ※ 예: 업데이트 시 사용자 개입/ 자동 업 | therapy | 높다는 것을 의미한다.  | 2 | E06060.02 | 적용 |\n| 일반적인 사항, 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 | 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입한다.  | 사용자의 접근 | 제조자는 데이터 부인방지(non-repudiation)를 | 또는 치료기회 박탈 | 이상사례 |\n| 자를 말하며, 임상시험용 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용 | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 서식, | 하는 원칙과 절차를 수립하여 제시한다.  피해자 보상에 대한 규약에는 보상원칙과 보상이 |\n| 전략이 잘 포함되어야 한다.  | [의료기기 임상시험기관 지정에 관한 규정(식약처 고시)]에 따라 식약처장으로부터 | 계획 승인일로부터 OO 개월”로 표시하고 근거자료를 제출한다.  | 사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 의료기기의 공급과 | 유/무, 피험자 기초정보, 병력조사, 선정 및 제외 기준, 식별코드 부여 등에 대해서 |\n| 내에 가능한 신속한 보고가 되어야 하며, 이상반응 등에 대한 의학적 소견· | 하는 원칙과 절차를 수립하여 제시한다.  |\n| 또는 디자인 특성, 원자재 및 성능, 새로운 제조방법 등에 대한 특이성을 함께 | 적응증을 포함하도록 한다. ",
        "original_sentence": "피해자 보상에 대한 규약에는 보상원칙과 보상이 |\n| 전략이 잘 포함되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_360",
      "text": "| [의료기기 임상시험기관 지정에 관한 규정(식약처 고시)]에 따라 식약처장으로부터 | 계획 승인일로부터 OO 개월”로 표시하고 근거자료를 제출한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 359,
        "window_size": 3,
        "char_count": 84,
        "word_count": 17,
        "page_number": 27,
        "window_text": "| 2 | E06060.02 | 적용 |\n| 일반적인 사항, 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 | 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입한다.  | 사용자의 접근 | 제조자는 데이터 부인방지(non-repudiation)를 | 또는 치료기회 박탈 | 이상사례 |\n| 자를 말하며, 임상시험용 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용 | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 서식, | 하는 원칙과 절차를 수립하여 제시한다.  피해자 보상에 대한 규약에는 보상원칙과 보상이 |\n| 전략이 잘 포함되어야 한다.  | [의료기기 임상시험기관 지정에 관한 규정(식약처 고시)]에 따라 식약처장으로부터 | 계획 승인일로부터 OO 개월”로 표시하고 근거자료를 제출한다.  | 사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 의료기기의 공급과 | 유/무, 피험자 기초정보, 병력조사, 선정 및 제외 기준, 식별코드 부여 등에 대해서 |\n| 내에 가능한 신속한 보고가 되어야 하며, 이상반응 등에 대한 의학적 소견· | 하는 원칙과 절차를 수립하여 제시한다.  |\n| 또는 디자인 특성, 원자재 및 성능, 새로운 제조방법 등에 대한 특이성을 함께 | 적응증을 포함하도록 한다.  | 병용 요법 등을 기술한다. ",
        "original_sentence": "| [의료기기 임상시험기관 지정에 관한 규정(식약처 고시)]에 따라 식약처장으로부터 | 계획 승인일로부터 OO 개월”로 표시하고 근거자료를 제출한다. "
      }
    },
    {
      "chunk_id": "chunk_361",
      "text": "| 사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 의료기기의 공급과 | 유/무, 피험자 기초정보, 병력조사, 선정 및 제외 기준, 식별코드 부여 등에 대해서 |\n| 내에 가능한 신속한 보고가 되어야 하며, 이상반응 등에 대한 의학적 소견· | 하는 원칙과 절차를 수립하여 제시한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 360,
        "window_size": 3,
        "char_count": 169,
        "word_count": 44,
        "page_number": 3,
        "window_text": "| 사용자의 접근 | 제조자는 데이터 부인방지(non-repudiation)를 | 또는 치료기회 박탈 | 이상사례 |\n| 자를 말하며, 임상시험용 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용 | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 서식, | 하는 원칙과 절차를 수립하여 제시한다.  피해자 보상에 대한 규약에는 보상원칙과 보상이 |\n| 전략이 잘 포함되어야 한다.  | [의료기기 임상시험기관 지정에 관한 규정(식약처 고시)]에 따라 식약처장으로부터 | 계획 승인일로부터 OO 개월”로 표시하고 근거자료를 제출한다.  | 사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 의료기기의 공급과 | 유/무, 피험자 기초정보, 병력조사, 선정 및 제외 기준, 식별코드 부여 등에 대해서 |\n| 내에 가능한 신속한 보고가 되어야 하며, 이상반응 등에 대한 의학적 소견· | 하는 원칙과 절차를 수립하여 제시한다.  |\n| 또는 디자인 특성, 원자재 및 성능, 새로운 제조방법 등에 대한 특이성을 함께 | 적응증을 포함하도록 한다.  | 병용 요법 등을 기술한다.  임상시험을 위한 피험자 동의 및 준비, 치료 절차, 관찰 및 |\n| 의료기기 임상시험기관으로 지정받은 곳이어야 한다. ",
        "original_sentence": "| 사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 의료기기의 공급과 | 유/무, 피험자 기초정보, 병력조사, 선정 및 제외 기준, 식별코드 부여 등에 대해서 |\n| 내에 가능한 신속한 보고가 되어야 하며, 이상반응 등에 대한 의학적 소견· | 하는 원칙과 절차를 수립하여 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_362",
      "text": "|\n| 또는 디자인 특성, 원자재 및 성능, 새로운 제조방법 등에 대한 특이성을 함께 | 적응증을 포함하도록 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 361,
        "window_size": 3,
        "char_count": 65,
        "word_count": 18,
        "page_number": 30,
        "window_text": "피해자 보상에 대한 규약에는 보상원칙과 보상이 |\n| 전략이 잘 포함되어야 한다.  | [의료기기 임상시험기관 지정에 관한 규정(식약처 고시)]에 따라 식약처장으로부터 | 계획 승인일로부터 OO 개월”로 표시하고 근거자료를 제출한다.  | 사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 의료기기의 공급과 | 유/무, 피험자 기초정보, 병력조사, 선정 및 제외 기준, 식별코드 부여 등에 대해서 |\n| 내에 가능한 신속한 보고가 되어야 하며, 이상반응 등에 대한 의학적 소견· | 하는 원칙과 절차를 수립하여 제시한다.  |\n| 또는 디자인 특성, 원자재 및 성능, 새로운 제조방법 등에 대한 특이성을 함께 | 적응증을 포함하도록 한다.  | 병용 요법 등을 기술한다.  임상시험을 위한 피험자 동의 및 준비, 치료 절차, 관찰 및 |\n| 의료기기 임상시험기관으로 지정받은 곳이어야 한다.  | 할 경우 이를 함께 관리한다. ",
        "original_sentence": "|\n| 또는 디자인 특성, 원자재 및 성능, 새로운 제조방법 등에 대한 특이성을 함께 | 적응증을 포함하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_363",
      "text": "| 병용 요법 등을 기술한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 362,
        "window_size": 3,
        "char_count": 17,
        "word_count": 5,
        "page_number": 15,
        "window_text": "| [의료기기 임상시험기관 지정에 관한 규정(식약처 고시)]에 따라 식약처장으로부터 | 계획 승인일로부터 OO 개월”로 표시하고 근거자료를 제출한다.  | 사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 의료기기의 공급과 | 유/무, 피험자 기초정보, 병력조사, 선정 및 제외 기준, 식별코드 부여 등에 대해서 |\n| 내에 가능한 신속한 보고가 되어야 하며, 이상반응 등에 대한 의학적 소견· | 하는 원칙과 절차를 수립하여 제시한다.  |\n| 또는 디자인 특성, 원자재 및 성능, 새로운 제조방법 등에 대한 특이성을 함께 | 적응증을 포함하도록 한다.  | 병용 요법 등을 기술한다.  임상시험을 위한 피험자 동의 및 준비, 치료 절차, 관찰 및 |\n| 의료기기 임상시험기관으로 지정받은 곳이어야 한다.  | 할 경우 이를 함께 관리한다.  임상시험용 의료기기 관리자의 성명, 소속 기관명 및 | 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 한다. ",
        "original_sentence": "| 병용 요법 등을 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_364",
      "text": "임상시험을 위한 피험자 동의 및 준비, 치료 절차, 관찰 및 |\n| 의료기기 임상시험기관으로 지정받은 곳이어야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 363,
        "window_size": 3,
        "char_count": 66,
        "word_count": 17,
        "page_number": 7,
        "window_text": "| 사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 의료기기의 공급과 | 유/무, 피험자 기초정보, 병력조사, 선정 및 제외 기준, 식별코드 부여 등에 대해서 |\n| 내에 가능한 신속한 보고가 되어야 하며, 이상반응 등에 대한 의학적 소견· | 하는 원칙과 절차를 수립하여 제시한다.  |\n| 또는 디자인 특성, 원자재 및 성능, 새로운 제조방법 등에 대한 특이성을 함께 | 적응증을 포함하도록 한다.  | 병용 요법 등을 기술한다.  임상시험을 위한 피험자 동의 및 준비, 치료 절차, 관찰 및 |\n| 의료기기 임상시험기관으로 지정받은 곳이어야 한다.  | 할 경우 이를 함께 관리한다.  임상시험용 의료기기 관리자의 성명, 소속 기관명 및 | 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 한다.  | 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함한다. ",
        "original_sentence": "임상시험을 위한 피험자 동의 및 준비, 치료 절차, 관찰 및 |\n| 의료기기 임상시험기관으로 지정받은 곳이어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_365",
      "text": "| 할 경우 이를 함께 관리한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 364,
        "window_size": 3,
        "char_count": 19,
        "word_count": 6,
        "page_number": 15,
        "window_text": "|\n| 또는 디자인 특성, 원자재 및 성능, 새로운 제조방법 등에 대한 특이성을 함께 | 적응증을 포함하도록 한다.  | 병용 요법 등을 기술한다.  임상시험을 위한 피험자 동의 및 준비, 치료 절차, 관찰 및 |\n| 의료기기 임상시험기관으로 지정받은 곳이어야 한다.  | 할 경우 이를 함께 관리한다.  임상시험용 의료기기 관리자의 성명, 소속 기관명 및 | 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 한다.  | 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함한다.  | 연번 |\n**취급에 관한 사항을 추가로 확보할 수 있다.",
        "original_sentence": "| 할 경우 이를 함께 관리한다. "
      }
    },
    {
      "chunk_id": "chunk_366",
      "text": "임상시험용 의료기기 관리자의 성명, 소속 기관명 및 | 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 365,
        "window_size": 3,
        "char_count": 74,
        "word_count": 19,
        "page_number": 27,
        "window_text": "| 병용 요법 등을 기술한다.  임상시험을 위한 피험자 동의 및 준비, 치료 절차, 관찰 및 |\n| 의료기기 임상시험기관으로 지정받은 곳이어야 한다.  | 할 경우 이를 함께 관리한다.  임상시험용 의료기기 관리자의 성명, 소속 기관명 및 | 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 한다.  | 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함한다.  | 연번 |\n**취급에 관한 사항을 추가로 확보할 수 있다. **\n| 정도와 | 임상시험용 | 의료기기와의 | 인과관계를 | 평가하여 | 증례기록서에 | 기록 |\n| 기재한다. ",
        "original_sentence": "임상시험용 의료기기 관리자의 성명, 소속 기관명 및 | 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 한다. "
      }
    },
    {
      "chunk_id": "chunk_367",
      "text": "| 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 366,
        "window_size": 3,
        "char_count": 38,
        "word_count": 10,
        "page_number": 15,
        "window_text": "임상시험을 위한 피험자 동의 및 준비, 치료 절차, 관찰 및 |\n| 의료기기 임상시험기관으로 지정받은 곳이어야 한다.  | 할 경우 이를 함께 관리한다.  임상시험용 의료기기 관리자의 성명, 소속 기관명 및 | 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 한다.  | 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함한다.  | 연번 |\n**취급에 관한 사항을 추가로 확보할 수 있다. **\n| 정도와 | 임상시험용 | 의료기기와의 | 인과관계를 | 평가하여 | 증례기록서에 | 기록 |\n| 기재한다.  | 평가 절차 등을 상세히 시험 방법을 기술한다. ",
        "original_sentence": "| 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함한다. "
      }
    },
    {
      "chunk_id": "chunk_368",
      "text": "| 연번 |\n**취급에 관한 사항을 추가로 확보할 수 있다.",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 367,
        "window_size": 3,
        "char_count": 33,
        "word_count": 10,
        "page_number": 3,
        "window_text": "| 할 경우 이를 함께 관리한다.  임상시험용 의료기기 관리자의 성명, 소속 기관명 및 | 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 한다.  | 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함한다.  | 연번 |\n**취급에 관한 사항을 추가로 확보할 수 있다. **\n| 정도와 | 임상시험용 | 의료기기와의 | 인과관계를 | 평가하여 | 증례기록서에 | 기록 |\n| 기재한다.  | 평가 절차 등을 상세히 시험 방법을 기술한다.  |\n**- 피험자의 방문일에 따른 관찰 시기별 관찰 항목, 임상 검사 항목과 관찰 검사 방법을**\n| 직명 등 인적 사항을 기재한다. ",
        "original_sentence": "| 연번 |\n**취급에 관한 사항을 추가로 확보할 수 있다."
      }
    },
    {
      "chunk_id": "chunk_369",
      "text": "**\n| 정도와 | 임상시험용 | 의료기기와의 | 인과관계를 | 평가하여 | 증례기록서에 | 기록 |\n| 기재한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 368,
        "window_size": 3,
        "char_count": 65,
        "word_count": 18,
        "page_number": 27,
        "window_text": "임상시험용 의료기기 관리자의 성명, 소속 기관명 및 | 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 한다.  | 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함한다.  | 연번 |\n**취급에 관한 사항을 추가로 확보할 수 있다. **\n| 정도와 | 임상시험용 | 의료기기와의 | 인과관계를 | 평가하여 | 증례기록서에 | 기록 |\n| 기재한다.  | 평가 절차 등을 상세히 시험 방법을 기술한다.  |\n**- 피험자의 방문일에 따른 관찰 시기별 관찰 항목, 임상 검사 항목과 관찰 검사 방법을**\n| 직명 등 인적 사항을 기재한다.  | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행규칙 | 의료인이 환자의 심리적 상태를 평가, |\n| 하여야 | 한다. ",
        "original_sentence": "**\n| 정도와 | 임상시험용 | 의료기기와의 | 인과관계를 | 평가하여 | 증례기록서에 | 기록 |\n| 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_370",
      "text": "| 평가 절차 등을 상세히 시험 방법을 기술한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 369,
        "window_size": 3,
        "char_count": 28,
        "word_count": 8,
        "page_number": 7,
        "window_text": "| 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함한다.  | 연번 |\n**취급에 관한 사항을 추가로 확보할 수 있다. **\n| 정도와 | 임상시험용 | 의료기기와의 | 인과관계를 | 평가하여 | 증례기록서에 | 기록 |\n| 기재한다.  | 평가 절차 등을 상세히 시험 방법을 기술한다.  |\n**- 피험자의 방문일에 따른 관찰 시기별 관찰 항목, 임상 검사 항목과 관찰 검사 방법을**\n| 직명 등 인적 사항을 기재한다.  | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행규칙 | 의료인이 환자의 심리적 상태를 평가, |\n| 하여야 | 한다.  따라서 이상반응에 대한 임상시험용 의료기기와의 인과관계에 |\n**머목(모니터링)에서 정하고 있다.",
        "original_sentence": "| 평가 절차 등을 상세히 시험 방법을 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_371",
      "text": "|\n**- 피험자의 방문일에 따른 관찰 시기별 관찰 항목, 임상 검사 항목과 관찰 검사 방법을**\n| 직명 등 인적 사항을 기재한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 370,
        "window_size": 3,
        "char_count": 75,
        "word_count": 21,
        "page_number": 7,
        "window_text": "| 연번 |\n**취급에 관한 사항을 추가로 확보할 수 있다. **\n| 정도와 | 임상시험용 | 의료기기와의 | 인과관계를 | 평가하여 | 증례기록서에 | 기록 |\n| 기재한다.  | 평가 절차 등을 상세히 시험 방법을 기술한다.  |\n**- 피험자의 방문일에 따른 관찰 시기별 관찰 항목, 임상 검사 항목과 관찰 검사 방법을**\n| 직명 등 인적 사항을 기재한다.  | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행규칙 | 의료인이 환자의 심리적 상태를 평가, |\n| 하여야 | 한다.  따라서 이상반응에 대한 임상시험용 의료기기와의 인과관계에 |\n**머목(모니터링)에서 정하고 있다. **\n**결정하는 데 사용하기 위한 소프트웨어**\n**[별표 3])에서 정하고 있다. ",
        "original_sentence": "|\n**- 피험자의 방문일에 따른 관찰 시기별 관찰 항목, 임상 검사 항목과 관찰 검사 방법을**\n| 직명 등 인적 사항을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_372",
      "text": "| 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행규칙 | 의료인이 환자의 심리적 상태를 평가, |\n| 하여야 | 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 371,
        "window_size": 3,
        "char_count": 83,
        "word_count": 20,
        "page_number": 3,
        "window_text": "**\n| 정도와 | 임상시험용 | 의료기기와의 | 인과관계를 | 평가하여 | 증례기록서에 | 기록 |\n| 기재한다.  | 평가 절차 등을 상세히 시험 방법을 기술한다.  |\n**- 피험자의 방문일에 따른 관찰 시기별 관찰 항목, 임상 검사 항목과 관찰 검사 방법을**\n| 직명 등 인적 사항을 기재한다.  | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행규칙 | 의료인이 환자의 심리적 상태를 평가, |\n| 하여야 | 한다.  따라서 이상반응에 대한 임상시험용 의료기기와의 인과관계에 |\n**머목(모니터링)에서 정하고 있다. **\n**결정하는 데 사용하기 위한 소프트웨어**\n**[별표 3])에서 정하고 있다.  이에 따른 피험자 동의서 서식을 제시하여야 하며, 피험자**\n| 번호 | 시험 항목 | 시험기준 | 시험 방법 | 대한 평가 기준을 제시하여야 한다. ",
        "original_sentence": "| 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행규칙 | 의료인이 환자의 심리적 상태를 평가, |\n| 하여야 | 한다. "
      }
    },
    {
      "chunk_id": "chunk_373",
      "text": "따라서 이상반응에 대한 임상시험용 의료기기와의 인과관계에 |\n**머목(모니터링)에서 정하고 있다.",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 372,
        "window_size": 3,
        "char_count": 54,
        "word_count": 10,
        "page_number": 7,
        "window_text": "| 평가 절차 등을 상세히 시험 방법을 기술한다.  |\n**- 피험자의 방문일에 따른 관찰 시기별 관찰 항목, 임상 검사 항목과 관찰 검사 방법을**\n| 직명 등 인적 사항을 기재한다.  | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행규칙 | 의료인이 환자의 심리적 상태를 평가, |\n| 하여야 | 한다.  따라서 이상반응에 대한 임상시험용 의료기기와의 인과관계에 |\n**머목(모니터링)에서 정하고 있다. **\n**결정하는 데 사용하기 위한 소프트웨어**\n**[별표 3])에서 정하고 있다.  이에 따른 피험자 동의서 서식을 제시하여야 하며, 피험자**\n| 번호 | 시험 항목 | 시험기준 | 시험 방법 | 대한 평가 기준을 제시하여야 한다.  |\n| 번호 | 표준 번호 | 규격 명칭 | 주요 내용 | 비고 |\n**설명서에는 동 기준의 제7호 아목의 10)을 포함하여야 한다.",
        "original_sentence": "따라서 이상반응에 대한 임상시험용 의료기기와의 인과관계에 |\n**머목(모니터링)에서 정하고 있다."
      }
    },
    {
      "chunk_id": "chunk_374",
      "text": "**\n**결정하는 데 사용하기 위한 소프트웨어**\n**[별표 3])에서 정하고 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 373,
        "window_size": 3,
        "char_count": 48,
        "word_count": 10,
        "page_number": 9,
        "window_text": "|\n**- 피험자의 방문일에 따른 관찰 시기별 관찰 항목, 임상 검사 항목과 관찰 검사 방법을**\n| 직명 등 인적 사항을 기재한다.  | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행규칙 | 의료인이 환자의 심리적 상태를 평가, |\n| 하여야 | 한다.  따라서 이상반응에 대한 임상시험용 의료기기와의 인과관계에 |\n**머목(모니터링)에서 정하고 있다. **\n**결정하는 데 사용하기 위한 소프트웨어**\n**[별표 3])에서 정하고 있다.  이에 따른 피험자 동의서 서식을 제시하여야 하며, 피험자**\n| 번호 | 시험 항목 | 시험기준 | 시험 방법 | 대한 평가 기준을 제시하여야 한다.  |\n| 번호 | 표준 번호 | 규격 명칭 | 주요 내용 | 비고 |\n**설명서에는 동 기준의 제7호 아목의 10)을 포함하여야 한다. **\n**통제**\n**정서장애치료**\n**완료**\n\n**[표 끝]**\n\nCognitive\n\n정서장애(우울장애\n\n등)를\n\n개선하는데\n\n가상ㆍ증강(VRㆍAR) 기반 소프트웨어를 포함\n\n표 1. ",
        "original_sentence": "**\n**결정하는 데 사용하기 위한 소프트웨어**\n**[별표 3])에서 정하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_375",
      "text": "이에 따른 피험자 동의서 서식을 제시하여야 하며, 피험자**\n| 번호 | 시험 항목 | 시험기준 | 시험 방법 | 대한 평가 기준을 제시하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 374,
        "window_size": 3,
        "char_count": 84,
        "word_count": 24,
        "page_number": 7,
        "window_text": "| 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행규칙 | 의료인이 환자의 심리적 상태를 평가, |\n| 하여야 | 한다.  따라서 이상반응에 대한 임상시험용 의료기기와의 인과관계에 |\n**머목(모니터링)에서 정하고 있다. **\n**결정하는 데 사용하기 위한 소프트웨어**\n**[별표 3])에서 정하고 있다.  이에 따른 피험자 동의서 서식을 제시하여야 하며, 피험자**\n| 번호 | 시험 항목 | 시험기준 | 시험 방법 | 대한 평가 기준을 제시하여야 한다.  |\n| 번호 | 표준 번호 | 규격 명칭 | 주요 내용 | 비고 |\n**설명서에는 동 기준의 제7호 아목의 10)을 포함하여야 한다. **\n**통제**\n**정서장애치료**\n**완료**\n\n**[표 끝]**\n\nCognitive\n\n정서장애(우울장애\n\n등)를\n\n개선하는데\n\n가상ㆍ증강(VRㆍAR) 기반 소프트웨어를 포함\n\n표 1.  섭식장애 개선 디지털치료기기 관련 의료기기 품목(식약처 고시 제2021-83호)\n\n※ 본 가이드라인에서 다루는 섭식장애 개선 디지털치료기기는 소프트웨어 의료\n\n기기로서, 사용 시 필요한 범용 장비(스마트폰 또는 태블릿 PC 등)는 적용\n\n범위에 포함되지 않으나, 반드시 함께 병용해야 하므로 전기용품 안전 인증과\n\n※ 실생활 습관을 추적 관찰하기 위해 기타 웨어러블 의료기기를 추가로 사용하는\n\n- - 3 -\n<!-- PAGE_10 -->\n##### 3. ",
        "original_sentence": "이에 따른 피험자 동의서 서식을 제시하여야 하며, 피험자**\n| 번호 | 시험 항목 | 시험기준 | 시험 방법 | 대한 평가 기준을 제시하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_376",
      "text": "|\n| 번호 | 표준 번호 | 규격 명칭 | 주요 내용 | 비고 |\n**설명서에는 동 기준의 제7호 아목의 10)을 포함하여야 한다.",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 375,
        "window_size": 3,
        "char_count": 74,
        "word_count": 23,
        "page_number": 3,
        "window_text": "따라서 이상반응에 대한 임상시험용 의료기기와의 인과관계에 |\n**머목(모니터링)에서 정하고 있다. **\n**결정하는 데 사용하기 위한 소프트웨어**\n**[별표 3])에서 정하고 있다.  이에 따른 피험자 동의서 서식을 제시하여야 하며, 피험자**\n| 번호 | 시험 항목 | 시험기준 | 시험 방법 | 대한 평가 기준을 제시하여야 한다.  |\n| 번호 | 표준 번호 | 규격 명칭 | 주요 내용 | 비고 |\n**설명서에는 동 기준의 제7호 아목의 10)을 포함하여야 한다. **\n**통제**\n**정서장애치료**\n**완료**\n\n**[표 끝]**\n\nCognitive\n\n정서장애(우울장애\n\n등)를\n\n개선하는데\n\n가상ㆍ증강(VRㆍAR) 기반 소프트웨어를 포함\n\n표 1.  섭식장애 개선 디지털치료기기 관련 의료기기 품목(식약처 고시 제2021-83호)\n\n※ 본 가이드라인에서 다루는 섭식장애 개선 디지털치료기기는 소프트웨어 의료\n\n기기로서, 사용 시 필요한 범용 장비(스마트폰 또는 태블릿 PC 등)는 적용\n\n범위에 포함되지 않으나, 반드시 함께 병용해야 하므로 전기용품 안전 인증과\n\n※ 실생활 습관을 추적 관찰하기 위해 기타 웨어러블 의료기기를 추가로 사용하는\n\n- - 3 -\n<!-- PAGE_10 -->\n##### 3.  용어 설명\n\n- 가. ",
        "original_sentence": "|\n| 번호 | 표준 번호 | 규격 명칭 | 주요 내용 | 비고 |\n**설명서에는 동 기준의 제7호 아목의 10)을 포함하여야 한다."
      }
    },
    {
      "chunk_id": "chunk_377",
      "text": "**\n**통제**\n**정서장애치료**\n**완료**\n\n**[표 끝]**\n\nCognitive\n\n정서장애(우울장애\n\n등)를\n\n개선하는데\n\n가상ㆍ증강(VRㆍAR) 기반 소프트웨어를 포함\n\n표 1. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 376,
        "window_size": 3,
        "char_count": 106,
        "word_count": 16,
        "page_number": 9,
        "window_text": "**\n**결정하는 데 사용하기 위한 소프트웨어**\n**[별표 3])에서 정하고 있다.  이에 따른 피험자 동의서 서식을 제시하여야 하며, 피험자**\n| 번호 | 시험 항목 | 시험기준 | 시험 방법 | 대한 평가 기준을 제시하여야 한다.  |\n| 번호 | 표준 번호 | 규격 명칭 | 주요 내용 | 비고 |\n**설명서에는 동 기준의 제7호 아목의 10)을 포함하여야 한다. **\n**통제**\n**정서장애치료**\n**완료**\n\n**[표 끝]**\n\nCognitive\n\n정서장애(우울장애\n\n등)를\n\n개선하는데\n\n가상ㆍ증강(VRㆍAR) 기반 소프트웨어를 포함\n\n표 1.  섭식장애 개선 디지털치료기기 관련 의료기기 품목(식약처 고시 제2021-83호)\n\n※ 본 가이드라인에서 다루는 섭식장애 개선 디지털치료기기는 소프트웨어 의료\n\n기기로서, 사용 시 필요한 범용 장비(스마트폰 또는 태블릿 PC 등)는 적용\n\n범위에 포함되지 않으나, 반드시 함께 병용해야 하므로 전기용품 안전 인증과\n\n※ 실생활 습관을 추적 관찰하기 위해 기타 웨어러블 의료기기를 추가로 사용하는\n\n- - 3 -\n<!-- PAGE_10 -->\n##### 3.  용어 설명\n\n- 가.  소프트웨어 의료기기(Software as a Medical Device, SaMD)\n하드웨어에 종속되지 않고 의료기기의 사용 목적에 부합하는 기능을\n\n가지며 독립적인 형태의 소프트웨어만으로 이루어진 의료기기이다.\n\n",
        "original_sentence": "**\n**통제**\n**정서장애치료**\n**완료**\n\n**[표 끝]**\n\nCognitive\n\n정서장애(우울장애\n\n등)를\n\n개선하는데\n\n가상ㆍ증강(VRㆍAR) 기반 소프트웨어를 포함\n\n표 1. "
      }
    },
    {
      "chunk_id": "chunk_378",
      "text": "섭식장애 개선 디지털치료기기 관련 의료기기 품목(식약처 고시 제2021-83호)\n\n※ 본 가이드라인에서 다루는 섭식장애 개선 디지털치료기기는 소프트웨어 의료\n\n기기로서, 사용 시 필요한 범용 장비(스마트폰 또는 태블릿 PC 등)는 적용\n\n범위에 포함되지 않으나, 반드시 함께 병용해야 하므로 전기용품 안전 인증과\n\n※ 실생활 습관을 추적 관찰하기 위해 기타 웨어러블 의료기기를 추가로 사용하는\n\n- - 3 -\n<!-- PAGE_10 -->\n##### 3. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 377,
        "window_size": 3,
        "char_count": 255,
        "word_count": 58,
        "page_number": 10,
        "window_text": "이에 따른 피험자 동의서 서식을 제시하여야 하며, 피험자**\n| 번호 | 시험 항목 | 시험기준 | 시험 방법 | 대한 평가 기준을 제시하여야 한다.  |\n| 번호 | 표준 번호 | 규격 명칭 | 주요 내용 | 비고 |\n**설명서에는 동 기준의 제7호 아목의 10)을 포함하여야 한다. **\n**통제**\n**정서장애치료**\n**완료**\n\n**[표 끝]**\n\nCognitive\n\n정서장애(우울장애\n\n등)를\n\n개선하는데\n\n가상ㆍ증강(VRㆍAR) 기반 소프트웨어를 포함\n\n표 1.  섭식장애 개선 디지털치료기기 관련 의료기기 품목(식약처 고시 제2021-83호)\n\n※ 본 가이드라인에서 다루는 섭식장애 개선 디지털치료기기는 소프트웨어 의료\n\n기기로서, 사용 시 필요한 범용 장비(스마트폰 또는 태블릿 PC 등)는 적용\n\n범위에 포함되지 않으나, 반드시 함께 병용해야 하므로 전기용품 안전 인증과\n\n※ 실생활 습관을 추적 관찰하기 위해 기타 웨어러블 의료기기를 추가로 사용하는\n\n- - 3 -\n<!-- PAGE_10 -->\n##### 3.  용어 설명\n\n- 가.  소프트웨어 의료기기(Software as a Medical Device, SaMD)\n하드웨어에 종속되지 않고 의료기기의 사용 목적에 부합하는 기능을\n\n가지며 독립적인 형태의 소프트웨어만으로 이루어진 의료기기이다.\n\n - 나. ",
        "original_sentence": "섭식장애 개선 디지털치료기기 관련 의료기기 품목(식약처 고시 제2021-83호)\n\n※ 본 가이드라인에서 다루는 섭식장애 개선 디지털치료기기는 소프트웨어 의료\n\n기기로서, 사용 시 필요한 범용 장비(스마트폰 또는 태블릿 PC 등)는 적용\n\n범위에 포함되지 않으나, 반드시 함께 병용해야 하므로 전기용품 안전 인증과\n\n※ 실생활 습관을 추적 관찰하기 위해 기타 웨어러블 의료기기를 추가로 사용하는\n\n- - 3 -\n<!-- PAGE_10 -->\n##### 3. "
      }
    },
    {
      "chunk_id": "chunk_379",
      "text": "용어 설명\n\n- 가. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 378,
        "window_size": 3,
        "char_count": 12,
        "word_count": 4,
        "page_number": 32,
        "window_text": "|\n| 번호 | 표준 번호 | 규격 명칭 | 주요 내용 | 비고 |\n**설명서에는 동 기준의 제7호 아목의 10)을 포함하여야 한다. **\n**통제**\n**정서장애치료**\n**완료**\n\n**[표 끝]**\n\nCognitive\n\n정서장애(우울장애\n\n등)를\n\n개선하는데\n\n가상ㆍ증강(VRㆍAR) 기반 소프트웨어를 포함\n\n표 1.  섭식장애 개선 디지털치료기기 관련 의료기기 품목(식약처 고시 제2021-83호)\n\n※ 본 가이드라인에서 다루는 섭식장애 개선 디지털치료기기는 소프트웨어 의료\n\n기기로서, 사용 시 필요한 범용 장비(스마트폰 또는 태블릿 PC 등)는 적용\n\n범위에 포함되지 않으나, 반드시 함께 병용해야 하므로 전기용품 안전 인증과\n\n※ 실생활 습관을 추적 관찰하기 위해 기타 웨어러블 의료기기를 추가로 사용하는\n\n- - 3 -\n<!-- PAGE_10 -->\n##### 3.  용어 설명\n\n- 가.  소프트웨어 의료기기(Software as a Medical Device, SaMD)\n하드웨어에 종속되지 않고 의료기기의 사용 목적에 부합하는 기능을\n\n가지며 독립적인 형태의 소프트웨어만으로 이루어진 의료기기이다.\n\n - 나.  디지털치료기기(Digital Therapeutics)\n식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인(민원인\n\n안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방, 관리, 치료\n\n하기 위해 환자에게 근거 기반의 치료적 개입을 제공하는 소프트웨어\n\n- 다. ",
        "original_sentence": "용어 설명\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_380",
      "text": "소프트웨어 의료기기(Software as a Medical Device, SaMD)\n하드웨어에 종속되지 않고 의료기기의 사용 목적에 부합하는 기능을\n\n가지며 독립적인 형태의 소프트웨어만으로 이루어진 의료기기이다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 379,
        "window_size": 3,
        "char_count": 120,
        "word_count": 21,
        "page_number": 9,
        "window_text": "**\n**통제**\n**정서장애치료**\n**완료**\n\n**[표 끝]**\n\nCognitive\n\n정서장애(우울장애\n\n등)를\n\n개선하는데\n\n가상ㆍ증강(VRㆍAR) 기반 소프트웨어를 포함\n\n표 1.  섭식장애 개선 디지털치료기기 관련 의료기기 품목(식약처 고시 제2021-83호)\n\n※ 본 가이드라인에서 다루는 섭식장애 개선 디지털치료기기는 소프트웨어 의료\n\n기기로서, 사용 시 필요한 범용 장비(스마트폰 또는 태블릿 PC 등)는 적용\n\n범위에 포함되지 않으나, 반드시 함께 병용해야 하므로 전기용품 안전 인증과\n\n※ 실생활 습관을 추적 관찰하기 위해 기타 웨어러블 의료기기를 추가로 사용하는\n\n- - 3 -\n<!-- PAGE_10 -->\n##### 3.  용어 설명\n\n- 가.  소프트웨어 의료기기(Software as a Medical Device, SaMD)\n하드웨어에 종속되지 않고 의료기기의 사용 목적에 부합하는 기능을\n\n가지며 독립적인 형태의 소프트웨어만으로 이루어진 의료기기이다.\n\n - 나.  디지털치료기기(Digital Therapeutics)\n식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인(민원인\n\n안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방, 관리, 치료\n\n하기 위해 환자에게 근거 기반의 치료적 개입을 제공하는 소프트웨어\n\n- 다.  정신질환의 진단 및 통계 편람(Diagnostic and Statistical Manual of\n미국 정신의학협회(American Psychiatric Association, APA)에서 발행한\n\n정신질환의 신뢰할 만한 진단이 가능하도록 고안된 관련 기준들을\n\n통칭하는 정신질환 분류법이다. ",
        "original_sentence": "소프트웨어 의료기기(Software as a Medical Device, SaMD)\n하드웨어에 종속되지 않고 의료기기의 사용 목적에 부합하는 기능을\n\n가지며 독립적인 형태의 소프트웨어만으로 이루어진 의료기기이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_381",
      "text": "- 나. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 380,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 72,
        "window_text": "섭식장애 개선 디지털치료기기 관련 의료기기 품목(식약처 고시 제2021-83호)\n\n※ 본 가이드라인에서 다루는 섭식장애 개선 디지털치료기기는 소프트웨어 의료\n\n기기로서, 사용 시 필요한 범용 장비(스마트폰 또는 태블릿 PC 등)는 적용\n\n범위에 포함되지 않으나, 반드시 함께 병용해야 하므로 전기용품 안전 인증과\n\n※ 실생활 습관을 추적 관찰하기 위해 기타 웨어러블 의료기기를 추가로 사용하는\n\n- - 3 -\n<!-- PAGE_10 -->\n##### 3.  용어 설명\n\n- 가.  소프트웨어 의료기기(Software as a Medical Device, SaMD)\n하드웨어에 종속되지 않고 의료기기의 사용 목적에 부합하는 기능을\n\n가지며 독립적인 형태의 소프트웨어만으로 이루어진 의료기기이다.\n\n - 나.  디지털치료기기(Digital Therapeutics)\n식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인(민원인\n\n안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방, 관리, 치료\n\n하기 위해 환자에게 근거 기반의 치료적 개입을 제공하는 소프트웨어\n\n- 다.  정신질환의 진단 및 통계 편람(Diagnostic and Statistical Manual of\n미국 정신의학협회(American Psychiatric Association, APA)에서 발행한\n\n정신질환의 신뢰할 만한 진단이 가능하도록 고안된 관련 기준들을\n\n통칭하는 정신질환 분류법이다.  DSM-5는 2013년도의 새로운 업데이트\n\n- - 4 -\n<!-- PAGE_11 -->\n##### 4. ",
        "original_sentence": "- 나. "
      }
    },
    {
      "chunk_id": "chunk_382",
      "text": "디지털치료기기(Digital Therapeutics)\n식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인(민원인\n\n안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방, 관리, 치료\n\n하기 위해 환자에게 근거 기반의 치료적 개입을 제공하는 소프트웨어\n\n- 다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 381,
        "window_size": 3,
        "char_count": 147,
        "word_count": 26,
        "page_number": 30,
        "window_text": "용어 설명\n\n- 가.  소프트웨어 의료기기(Software as a Medical Device, SaMD)\n하드웨어에 종속되지 않고 의료기기의 사용 목적에 부합하는 기능을\n\n가지며 독립적인 형태의 소프트웨어만으로 이루어진 의료기기이다.\n\n - 나.  디지털치료기기(Digital Therapeutics)\n식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인(민원인\n\n안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방, 관리, 치료\n\n하기 위해 환자에게 근거 기반의 치료적 개입을 제공하는 소프트웨어\n\n- 다.  정신질환의 진단 및 통계 편람(Diagnostic and Statistical Manual of\n미국 정신의학협회(American Psychiatric Association, APA)에서 발행한\n\n정신질환의 신뢰할 만한 진단이 가능하도록 고안된 관련 기준들을\n\n통칭하는 정신질환 분류법이다.  DSM-5는 2013년도의 새로운 업데이트\n\n- - 4 -\n<!-- PAGE_11 -->\n##### 4.  현황\n\n- 가. ",
        "original_sentence": "디지털치료기기(Digital Therapeutics)\n식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인(민원인\n\n안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방, 관리, 치료\n\n하기 위해 환자에게 근거 기반의 치료적 개입을 제공하는 소프트웨어\n\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_383",
      "text": "정신질환의 진단 및 통계 편람(Diagnostic and Statistical Manual of\n미국 정신의학협회(American Psychiatric Association, APA)에서 발행한\n\n정신질환의 신뢰할 만한 진단이 가능하도록 고안된 관련 기준들을\n\n통칭하는 정신질환 분류법이다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 382,
        "window_size": 3,
        "char_count": 163,
        "word_count": 26,
        "page_number": 10,
        "window_text": "소프트웨어 의료기기(Software as a Medical Device, SaMD)\n하드웨어에 종속되지 않고 의료기기의 사용 목적에 부합하는 기능을\n\n가지며 독립적인 형태의 소프트웨어만으로 이루어진 의료기기이다.\n\n - 나.  디지털치료기기(Digital Therapeutics)\n식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인(민원인\n\n안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방, 관리, 치료\n\n하기 위해 환자에게 근거 기반의 치료적 개입을 제공하는 소프트웨어\n\n- 다.  정신질환의 진단 및 통계 편람(Diagnostic and Statistical Manual of\n미국 정신의학협회(American Psychiatric Association, APA)에서 발행한\n\n정신질환의 신뢰할 만한 진단이 가능하도록 고안된 관련 기준들을\n\n통칭하는 정신질환 분류법이다.  DSM-5는 2013년도의 새로운 업데이트\n\n- - 4 -\n<!-- PAGE_11 -->\n##### 4.  현황\n\n- 가.  섭식장애 인구학적 특성\nDSM-5에 따르면 섭식장애는 음식 섭취와 관련된 행동에 이상을 보이는\n\n질환으로서, 체중 증가에 대한 극심한 두려움 때문에 식사를 거르는\n\n질병인 신경성 식욕부진증(Anorexia Nervosa), 음식 섭취 후 구토 등의\n\n방식을 사용하여 체중을 줄이려 하는 신경성 폭식증(Bulimia Nervosa),\n\n비정상적으로 많은 양의 음식을 자주 섭취하면서도 먹는 것을 멈출 수\n\n없다고 느끼는 폭식장애(Binge-Eating Disorder) 등으로 정의된다. ",
        "original_sentence": "정신질환의 진단 및 통계 편람(Diagnostic and Statistical Manual of\n미국 정신의학협회(American Psychiatric Association, APA)에서 발행한\n\n정신질환의 신뢰할 만한 진단이 가능하도록 고안된 관련 기준들을\n\n통칭하는 정신질환 분류법이다. "
      }
    },
    {
      "chunk_id": "chunk_384",
      "text": "DSM-5는 2013년도의 새로운 업데이트\n\n- - 4 -\n<!-- PAGE_11 -->\n##### 4. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 383,
        "window_size": 3,
        "char_count": 59,
        "word_count": 13,
        "page_number": 11,
        "window_text": "- 나.  디지털치료기기(Digital Therapeutics)\n식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인(민원인\n\n안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방, 관리, 치료\n\n하기 위해 환자에게 근거 기반의 치료적 개입을 제공하는 소프트웨어\n\n- 다.  정신질환의 진단 및 통계 편람(Diagnostic and Statistical Manual of\n미국 정신의학협회(American Psychiatric Association, APA)에서 발행한\n\n정신질환의 신뢰할 만한 진단이 가능하도록 고안된 관련 기준들을\n\n통칭하는 정신질환 분류법이다.  DSM-5는 2013년도의 새로운 업데이트\n\n- - 4 -\n<!-- PAGE_11 -->\n##### 4.  현황\n\n- 가.  섭식장애 인구학적 특성\nDSM-5에 따르면 섭식장애는 음식 섭취와 관련된 행동에 이상을 보이는\n\n질환으로서, 체중 증가에 대한 극심한 두려움 때문에 식사를 거르는\n\n질병인 신경성 식욕부진증(Anorexia Nervosa), 음식 섭취 후 구토 등의\n\n방식을 사용하여 체중을 줄이려 하는 신경성 폭식증(Bulimia Nervosa),\n\n비정상적으로 많은 양의 음식을 자주 섭취하면서도 먹는 것을 멈출 수\n\n없다고 느끼는 폭식장애(Binge-Eating Disorder) 등으로 정의된다.  섭식\n\n장애는 청소년기 혹은 성인 초기에 발생하며 여성에게 주로 나타난다\n\n(Park, 2000).\n\n",
        "original_sentence": "DSM-5는 2013년도의 새로운 업데이트\n\n- - 4 -\n<!-- PAGE_11 -->\n##### 4. "
      }
    },
    {
      "chunk_id": "chunk_385",
      "text": "현황\n\n- 가. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 384,
        "window_size": 3,
        "char_count": 9,
        "word_count": 3,
        "page_number": 72,
        "window_text": "디지털치료기기(Digital Therapeutics)\n식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인(민원인\n\n안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방, 관리, 치료\n\n하기 위해 환자에게 근거 기반의 치료적 개입을 제공하는 소프트웨어\n\n- 다.  정신질환의 진단 및 통계 편람(Diagnostic and Statistical Manual of\n미국 정신의학협회(American Psychiatric Association, APA)에서 발행한\n\n정신질환의 신뢰할 만한 진단이 가능하도록 고안된 관련 기준들을\n\n통칭하는 정신질환 분류법이다.  DSM-5는 2013년도의 새로운 업데이트\n\n- - 4 -\n<!-- PAGE_11 -->\n##### 4.  현황\n\n- 가.  섭식장애 인구학적 특성\nDSM-5에 따르면 섭식장애는 음식 섭취와 관련된 행동에 이상을 보이는\n\n질환으로서, 체중 증가에 대한 극심한 두려움 때문에 식사를 거르는\n\n질병인 신경성 식욕부진증(Anorexia Nervosa), 음식 섭취 후 구토 등의\n\n방식을 사용하여 체중을 줄이려 하는 신경성 폭식증(Bulimia Nervosa),\n\n비정상적으로 많은 양의 음식을 자주 섭취하면서도 먹는 것을 멈출 수\n\n없다고 느끼는 폭식장애(Binge-Eating Disorder) 등으로 정의된다.  섭식\n\n장애는 청소년기 혹은 성인 초기에 발생하며 여성에게 주로 나타난다\n\n(Park, 2000).\n\n 섭식장애 유병률은 전 세계 인구의 3%로 추산되며, 미국 섭식장애 유\n\n병률은 신경성 식욕부진증의 경우 약 0.8%, 신경성 폭식증의 경우\n\n- 0.28%, 폭식장애의 경우 0.85%이다. ",
        "original_sentence": "현황\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_386",
      "text": "섭식장애 인구학적 특성\nDSM-5에 따르면 섭식장애는 음식 섭취와 관련된 행동에 이상을 보이는\n\n질환으로서, 체중 증가에 대한 극심한 두려움 때문에 식사를 거르는\n\n질병인 신경성 식욕부진증(Anorexia Nervosa), 음식 섭취 후 구토 등의\n\n방식을 사용하여 체중을 줄이려 하는 신경성 폭식증(Bulimia Nervosa),\n\n비정상적으로 많은 양의 음식을 자주 섭취하면서도 먹는 것을 멈출 수\n\n없다고 느끼는 폭식장애(Binge-Eating Disorder) 등으로 정의된다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 385,
        "window_size": 3,
        "char_count": 272,
        "word_count": 54,
        "page_number": 26,
        "window_text": "정신질환의 진단 및 통계 편람(Diagnostic and Statistical Manual of\n미국 정신의학협회(American Psychiatric Association, APA)에서 발행한\n\n정신질환의 신뢰할 만한 진단이 가능하도록 고안된 관련 기준들을\n\n통칭하는 정신질환 분류법이다.  DSM-5는 2013년도의 새로운 업데이트\n\n- - 4 -\n<!-- PAGE_11 -->\n##### 4.  현황\n\n- 가.  섭식장애 인구학적 특성\nDSM-5에 따르면 섭식장애는 음식 섭취와 관련된 행동에 이상을 보이는\n\n질환으로서, 체중 증가에 대한 극심한 두려움 때문에 식사를 거르는\n\n질병인 신경성 식욕부진증(Anorexia Nervosa), 음식 섭취 후 구토 등의\n\n방식을 사용하여 체중을 줄이려 하는 신경성 폭식증(Bulimia Nervosa),\n\n비정상적으로 많은 양의 음식을 자주 섭취하면서도 먹는 것을 멈출 수\n\n없다고 느끼는 폭식장애(Binge-Eating Disorder) 등으로 정의된다.  섭식\n\n장애는 청소년기 혹은 성인 초기에 발생하며 여성에게 주로 나타난다\n\n(Park, 2000).\n\n 섭식장애 유병률은 전 세계 인구의 3%로 추산되며, 미국 섭식장애 유\n\n병률은 신경성 식욕부진증의 경우 약 0.8%, 신경성 폭식증의 경우\n\n- 0.28%, 폭식장애의 경우 0.85%이다.  성별로 보았을 때는, 소년의 경우\n- 7.1%, 소녀의 경우 13.4% 비율의 유병률을 보인다(Neumark-Sztainer,\nHannan, 2000). ",
        "original_sentence": "섭식장애 인구학적 특성\nDSM-5에 따르면 섭식장애는 음식 섭취와 관련된 행동에 이상을 보이는\n\n질환으로서, 체중 증가에 대한 극심한 두려움 때문에 식사를 거르는\n\n질병인 신경성 식욕부진증(Anorexia Nervosa), 음식 섭취 후 구토 등의\n\n방식을 사용하여 체중을 줄이려 하는 신경성 폭식증(Bulimia Nervosa),\n\n비정상적으로 많은 양의 음식을 자주 섭취하면서도 먹는 것을 멈출 수\n\n없다고 느끼는 폭식장애(Binge-Eating Disorder) 등으로 정의된다. "
      }
    },
    {
      "chunk_id": "chunk_387",
      "text": "섭식\n\n장애는 청소년기 혹은 성인 초기에 발생하며 여성에게 주로 나타난다\n\n(Park, 2000).\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 386,
        "window_size": 3,
        "char_count": 57,
        "word_count": 12,
        "page_number": 9,
        "window_text": "DSM-5는 2013년도의 새로운 업데이트\n\n- - 4 -\n<!-- PAGE_11 -->\n##### 4.  현황\n\n- 가.  섭식장애 인구학적 특성\nDSM-5에 따르면 섭식장애는 음식 섭취와 관련된 행동에 이상을 보이는\n\n질환으로서, 체중 증가에 대한 극심한 두려움 때문에 식사를 거르는\n\n질병인 신경성 식욕부진증(Anorexia Nervosa), 음식 섭취 후 구토 등의\n\n방식을 사용하여 체중을 줄이려 하는 신경성 폭식증(Bulimia Nervosa),\n\n비정상적으로 많은 양의 음식을 자주 섭취하면서도 먹는 것을 멈출 수\n\n없다고 느끼는 폭식장애(Binge-Eating Disorder) 등으로 정의된다.  섭식\n\n장애는 청소년기 혹은 성인 초기에 발생하며 여성에게 주로 나타난다\n\n(Park, 2000).\n\n 섭식장애 유병률은 전 세계 인구의 3%로 추산되며, 미국 섭식장애 유\n\n병률은 신경성 식욕부진증의 경우 약 0.8%, 신경성 폭식증의 경우\n\n- 0.28%, 폭식장애의 경우 0.85%이다.  성별로 보았을 때는, 소년의 경우\n- 7.1%, 소녀의 경우 13.4% 비율의 유병률을 보인다(Neumark-Sztainer,\nHannan, 2000).  건강보험심사평가원 자료에 따르면, 2021년 기준 국내\n\n섭식장애 환자는 약 1만명으로 확인되며, 실제 유병률은 예상보다 높을\n\n것으로 추정된다. ",
        "original_sentence": "섭식\n\n장애는 청소년기 혹은 성인 초기에 발생하며 여성에게 주로 나타난다\n\n(Park, 2000).\n\n"
      }
    },
    {
      "chunk_id": "chunk_388",
      "text": "섭식장애 유병률은 전 세계 인구의 3%로 추산되며, 미국 섭식장애 유\n\n병률은 신경성 식욕부진증의 경우 약 0.8%, 신경성 폭식증의 경우\n\n- 0.28%, 폭식장애의 경우 0.85%이다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 387,
        "window_size": 3,
        "char_count": 106,
        "word_count": 24,
        "page_number": 11,
        "window_text": "현황\n\n- 가.  섭식장애 인구학적 특성\nDSM-5에 따르면 섭식장애는 음식 섭취와 관련된 행동에 이상을 보이는\n\n질환으로서, 체중 증가에 대한 극심한 두려움 때문에 식사를 거르는\n\n질병인 신경성 식욕부진증(Anorexia Nervosa), 음식 섭취 후 구토 등의\n\n방식을 사용하여 체중을 줄이려 하는 신경성 폭식증(Bulimia Nervosa),\n\n비정상적으로 많은 양의 음식을 자주 섭취하면서도 먹는 것을 멈출 수\n\n없다고 느끼는 폭식장애(Binge-Eating Disorder) 등으로 정의된다.  섭식\n\n장애는 청소년기 혹은 성인 초기에 발생하며 여성에게 주로 나타난다\n\n(Park, 2000).\n\n 섭식장애 유병률은 전 세계 인구의 3%로 추산되며, 미국 섭식장애 유\n\n병률은 신경성 식욕부진증의 경우 약 0.8%, 신경성 폭식증의 경우\n\n- 0.28%, 폭식장애의 경우 0.85%이다.  성별로 보았을 때는, 소년의 경우\n- 7.1%, 소녀의 경우 13.4% 비율의 유병률을 보인다(Neumark-Sztainer,\nHannan, 2000).  건강보험심사평가원 자료에 따르면, 2021년 기준 국내\n\n섭식장애 환자는 약 1만명으로 확인되며, 실제 유병률은 예상보다 높을\n\n것으로 추정된다.  임상에서 섭식장애가 인지되는 경우는 50%에 미치지\n\n못하는 경우가 많은데(Whitehouse et al., 1992), 이는 일반적으로 섭식\n\n장애 환자들이 증상을 드러내지 않거나 숨기는 경우가 있기 때문이다\n\n(Park, 2000). ",
        "original_sentence": "섭식장애 유병률은 전 세계 인구의 3%로 추산되며, 미국 섭식장애 유\n\n병률은 신경성 식욕부진증의 경우 약 0.8%, 신경성 폭식증의 경우\n\n- 0.28%, 폭식장애의 경우 0.85%이다. "
      }
    },
    {
      "chunk_id": "chunk_389",
      "text": "성별로 보았을 때는, 소년의 경우\n- 7.1%, 소녀의 경우 13.4% 비율의 유병률을 보인다(Neumark-Sztainer,\nHannan, 2000). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 388,
        "window_size": 3,
        "char_count": 86,
        "word_count": 15,
        "page_number": 19,
        "window_text": "섭식장애 인구학적 특성\nDSM-5에 따르면 섭식장애는 음식 섭취와 관련된 행동에 이상을 보이는\n\n질환으로서, 체중 증가에 대한 극심한 두려움 때문에 식사를 거르는\n\n질병인 신경성 식욕부진증(Anorexia Nervosa), 음식 섭취 후 구토 등의\n\n방식을 사용하여 체중을 줄이려 하는 신경성 폭식증(Bulimia Nervosa),\n\n비정상적으로 많은 양의 음식을 자주 섭취하면서도 먹는 것을 멈출 수\n\n없다고 느끼는 폭식장애(Binge-Eating Disorder) 등으로 정의된다.  섭식\n\n장애는 청소년기 혹은 성인 초기에 발생하며 여성에게 주로 나타난다\n\n(Park, 2000).\n\n 섭식장애 유병률은 전 세계 인구의 3%로 추산되며, 미국 섭식장애 유\n\n병률은 신경성 식욕부진증의 경우 약 0.8%, 신경성 폭식증의 경우\n\n- 0.28%, 폭식장애의 경우 0.85%이다.  성별로 보았을 때는, 소년의 경우\n- 7.1%, 소녀의 경우 13.4% 비율의 유병률을 보인다(Neumark-Sztainer,\nHannan, 2000).  건강보험심사평가원 자료에 따르면, 2021년 기준 국내\n\n섭식장애 환자는 약 1만명으로 확인되며, 실제 유병률은 예상보다 높을\n\n것으로 추정된다.  임상에서 섭식장애가 인지되는 경우는 50%에 미치지\n\n못하는 경우가 많은데(Whitehouse et al., 1992), 이는 일반적으로 섭식\n\n장애 환자들이 증상을 드러내지 않거나 숨기는 경우가 있기 때문이다\n\n(Park, 2000).  섭식장애는 신체 합병증을 동반하는 경우가 흔하며, 기능\n\n장애를 초래하고 쉽게 만성화된다는 특징을 지닌다(Kim, 2018). ",
        "original_sentence": "성별로 보았을 때는, 소년의 경우\n- 7.1%, 소녀의 경우 13.4% 비율의 유병률을 보인다(Neumark-Sztainer,\nHannan, 2000). "
      }
    },
    {
      "chunk_id": "chunk_390",
      "text": "건강보험심사평가원 자료에 따르면, 2021년 기준 국내\n\n섭식장애 환자는 약 1만명으로 확인되며, 실제 유병률은 예상보다 높을\n\n것으로 추정된다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 389,
        "window_size": 3,
        "char_count": 82,
        "word_count": 17,
        "page_number": 9,
        "window_text": "섭식\n\n장애는 청소년기 혹은 성인 초기에 발생하며 여성에게 주로 나타난다\n\n(Park, 2000).\n\n 섭식장애 유병률은 전 세계 인구의 3%로 추산되며, 미국 섭식장애 유\n\n병률은 신경성 식욕부진증의 경우 약 0.8%, 신경성 폭식증의 경우\n\n- 0.28%, 폭식장애의 경우 0.85%이다.  성별로 보았을 때는, 소년의 경우\n- 7.1%, 소녀의 경우 13.4% 비율의 유병률을 보인다(Neumark-Sztainer,\nHannan, 2000).  건강보험심사평가원 자료에 따르면, 2021년 기준 국내\n\n섭식장애 환자는 약 1만명으로 확인되며, 실제 유병률은 예상보다 높을\n\n것으로 추정된다.  임상에서 섭식장애가 인지되는 경우는 50%에 미치지\n\n못하는 경우가 많은데(Whitehouse et al., 1992), 이는 일반적으로 섭식\n\n장애 환자들이 증상을 드러내지 않거나 숨기는 경우가 있기 때문이다\n\n(Park, 2000).  섭식장애는 신체 합병증을 동반하는 경우가 흔하며, 기능\n\n장애를 초래하고 쉽게 만성화된다는 특징을 지닌다(Kim, 2018).  이러한\n\n결과로 치료가 지연되는 경우가 많으며, 모든 원인에 의한 사망률과\n\n자살로 인한 사망률의 증가와 관련이 있다(Auger et al. ",
        "original_sentence": "건강보험심사평가원 자료에 따르면, 2021년 기준 국내\n\n섭식장애 환자는 약 1만명으로 확인되며, 실제 유병률은 예상보다 높을\n\n것으로 추정된다. "
      }
    },
    {
      "chunk_id": "chunk_391",
      "text": "임상에서 섭식장애가 인지되는 경우는 50%에 미치지\n\n못하는 경우가 많은데(Whitehouse et al., 1992), 이는 일반적으로 섭식\n\n장애 환자들이 증상을 드러내지 않거나 숨기는 경우가 있기 때문이다\n\n(Park, 2000). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 390,
        "window_size": 3,
        "char_count": 133,
        "word_count": 26,
        "page_number": 26,
        "window_text": "섭식장애 유병률은 전 세계 인구의 3%로 추산되며, 미국 섭식장애 유\n\n병률은 신경성 식욕부진증의 경우 약 0.8%, 신경성 폭식증의 경우\n\n- 0.28%, 폭식장애의 경우 0.85%이다.  성별로 보았을 때는, 소년의 경우\n- 7.1%, 소녀의 경우 13.4% 비율의 유병률을 보인다(Neumark-Sztainer,\nHannan, 2000).  건강보험심사평가원 자료에 따르면, 2021년 기준 국내\n\n섭식장애 환자는 약 1만명으로 확인되며, 실제 유병률은 예상보다 높을\n\n것으로 추정된다.  임상에서 섭식장애가 인지되는 경우는 50%에 미치지\n\n못하는 경우가 많은데(Whitehouse et al., 1992), 이는 일반적으로 섭식\n\n장애 환자들이 증상을 드러내지 않거나 숨기는 경우가 있기 때문이다\n\n(Park, 2000).  섭식장애는 신체 합병증을 동반하는 경우가 흔하며, 기능\n\n장애를 초래하고 쉽게 만성화된다는 특징을 지닌다(Kim, 2018).  이러한\n\n결과로 치료가 지연되는 경우가 많으며, 모든 원인에 의한 사망률과\n\n자살로 인한 사망률의 증가와 관련이 있다(Auger et al.  2021;\n\n- - 5 -\nNielsen and Vilmar 2021; Tith et al. ",
        "original_sentence": "임상에서 섭식장애가 인지되는 경우는 50%에 미치지\n\n못하는 경우가 많은데(Whitehouse et al., 1992), 이는 일반적으로 섭식\n\n장애 환자들이 증상을 드러내지 않거나 숨기는 경우가 있기 때문이다\n\n(Park, 2000). "
      }
    },
    {
      "chunk_id": "chunk_392",
      "text": "섭식장애는 신체 합병증을 동반하는 경우가 흔하며, 기능\n\n장애를 초래하고 쉽게 만성화된다는 특징을 지닌다(Kim, 2018). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 391,
        "window_size": 3,
        "char_count": 71,
        "word_count": 14,
        "page_number": 34,
        "window_text": "성별로 보았을 때는, 소년의 경우\n- 7.1%, 소녀의 경우 13.4% 비율의 유병률을 보인다(Neumark-Sztainer,\nHannan, 2000).  건강보험심사평가원 자료에 따르면, 2021년 기준 국내\n\n섭식장애 환자는 약 1만명으로 확인되며, 실제 유병률은 예상보다 높을\n\n것으로 추정된다.  임상에서 섭식장애가 인지되는 경우는 50%에 미치지\n\n못하는 경우가 많은데(Whitehouse et al., 1992), 이는 일반적으로 섭식\n\n장애 환자들이 증상을 드러내지 않거나 숨기는 경우가 있기 때문이다\n\n(Park, 2000).  섭식장애는 신체 합병증을 동반하는 경우가 흔하며, 기능\n\n장애를 초래하고 쉽게 만성화된다는 특징을 지닌다(Kim, 2018).  이러한\n\n결과로 치료가 지연되는 경우가 많으며, 모든 원인에 의한 사망률과\n\n자살로 인한 사망률의 증가와 관련이 있다(Auger et al.  2021;\n\n- - 5 -\nNielsen and Vilmar 2021; Tith et al.  2020; van Hoeken and Hoek\n\n2020).\n\n",
        "original_sentence": "섭식장애는 신체 합병증을 동반하는 경우가 흔하며, 기능\n\n장애를 초래하고 쉽게 만성화된다는 특징을 지닌다(Kim, 2018). "
      }
    },
    {
      "chunk_id": "chunk_393",
      "text": "이러한\n\n결과로 치료가 지연되는 경우가 많으며, 모든 원인에 의한 사망률과\n\n자살로 인한 사망률의 증가와 관련이 있다(Auger et al. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 392,
        "window_size": 3,
        "char_count": 79,
        "word_count": 18,
        "page_number": 11,
        "window_text": "건강보험심사평가원 자료에 따르면, 2021년 기준 국내\n\n섭식장애 환자는 약 1만명으로 확인되며, 실제 유병률은 예상보다 높을\n\n것으로 추정된다.  임상에서 섭식장애가 인지되는 경우는 50%에 미치지\n\n못하는 경우가 많은데(Whitehouse et al., 1992), 이는 일반적으로 섭식\n\n장애 환자들이 증상을 드러내지 않거나 숨기는 경우가 있기 때문이다\n\n(Park, 2000).  섭식장애는 신체 합병증을 동반하는 경우가 흔하며, 기능\n\n장애를 초래하고 쉽게 만성화된다는 특징을 지닌다(Kim, 2018).  이러한\n\n결과로 치료가 지연되는 경우가 많으며, 모든 원인에 의한 사망률과\n\n자살로 인한 사망률의 증가와 관련이 있다(Auger et al.  2021;\n\n- - 5 -\nNielsen and Vilmar 2021; Tith et al.  2020; van Hoeken and Hoek\n\n2020).\n\n 또한, 섭식장애는 우울, 불안 등의 정신질환을 동반하며, 섭식장애로\n\n인한 영양 부족은 면역력 저하, 수면 장애 등의 증상 발현으로 이어질\n\n수 있다.\n\n",
        "original_sentence": "이러한\n\n결과로 치료가 지연되는 경우가 많으며, 모든 원인에 의한 사망률과\n\n자살로 인한 사망률의 증가와 관련이 있다(Auger et al. "
      }
    },
    {
      "chunk_id": "chunk_394",
      "text": "2021;\n\n- - 5 -\nNielsen and Vilmar 2021; Tith et al. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 393,
        "window_size": 3,
        "char_count": 52,
        "word_count": 12,
        "page_number": 9,
        "window_text": "임상에서 섭식장애가 인지되는 경우는 50%에 미치지\n\n못하는 경우가 많은데(Whitehouse et al., 1992), 이는 일반적으로 섭식\n\n장애 환자들이 증상을 드러내지 않거나 숨기는 경우가 있기 때문이다\n\n(Park, 2000).  섭식장애는 신체 합병증을 동반하는 경우가 흔하며, 기능\n\n장애를 초래하고 쉽게 만성화된다는 특징을 지닌다(Kim, 2018).  이러한\n\n결과로 치료가 지연되는 경우가 많으며, 모든 원인에 의한 사망률과\n\n자살로 인한 사망률의 증가와 관련이 있다(Auger et al.  2021;\n\n- - 5 -\nNielsen and Vilmar 2021; Tith et al.  2020; van Hoeken and Hoek\n\n2020).\n\n 또한, 섭식장애는 우울, 불안 등의 정신질환을 동반하며, 섭식장애로\n\n인한 영양 부족은 면역력 저하, 수면 장애 등의 증상 발현으로 이어질\n\n수 있다.\n\n - 나. ",
        "original_sentence": "2021;\n\n- - 5 -\nNielsen and Vilmar 2021; Tith et al. "
      }
    },
    {
      "chunk_id": "chunk_395",
      "text": "2020; van Hoeken and Hoek\n\n2020).\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 394,
        "window_size": 3,
        "char_count": 35,
        "word_count": 6,
        "page_number": 9,
        "window_text": "섭식장애는 신체 합병증을 동반하는 경우가 흔하며, 기능\n\n장애를 초래하고 쉽게 만성화된다는 특징을 지닌다(Kim, 2018).  이러한\n\n결과로 치료가 지연되는 경우가 많으며, 모든 원인에 의한 사망률과\n\n자살로 인한 사망률의 증가와 관련이 있다(Auger et al.  2021;\n\n- - 5 -\nNielsen and Vilmar 2021; Tith et al.  2020; van Hoeken and Hoek\n\n2020).\n\n 또한, 섭식장애는 우울, 불안 등의 정신질환을 동반하며, 섭식장애로\n\n인한 영양 부족은 면역력 저하, 수면 장애 등의 증상 발현으로 이어질\n\n수 있다.\n\n - 나.  섭식장애 진단 절차/과정\n섭식장애는 크게 1) 신경성 식욕부진증, 2) 신경성 폭식증, 3) 폭식\n\n장애로 정의된다. ",
        "original_sentence": "2020; van Hoeken and Hoek\n\n2020).\n\n"
      }
    },
    {
      "chunk_id": "chunk_396",
      "text": "또한, 섭식장애는 우울, 불안 등의 정신질환을 동반하며, 섭식장애로\n\n인한 영양 부족은 면역력 저하, 수면 장애 등의 증상 발현으로 이어질\n\n수 있다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 395,
        "window_size": 3,
        "char_count": 86,
        "word_count": 21,
        "page_number": 12,
        "window_text": "이러한\n\n결과로 치료가 지연되는 경우가 많으며, 모든 원인에 의한 사망률과\n\n자살로 인한 사망률의 증가와 관련이 있다(Auger et al.  2021;\n\n- - 5 -\nNielsen and Vilmar 2021; Tith et al.  2020; van Hoeken and Hoek\n\n2020).\n\n 또한, 섭식장애는 우울, 불안 등의 정신질환을 동반하며, 섭식장애로\n\n인한 영양 부족은 면역력 저하, 수면 장애 등의 증상 발현으로 이어질\n\n수 있다.\n\n - 나.  섭식장애 진단 절차/과정\n섭식장애는 크게 1) 신경성 식욕부진증, 2) 신경성 폭식증, 3) 폭식\n\n장애로 정의된다.  신경성 식욕부진증은 DSM-5 진단 기준에 따라,\n\n연령과 체중에 비해 지나친 음식물 제한으로 현저한 체중의 감소, 체중\n\n증가 및 비만에 대한 극심한 두려움, 체중 증가를 막기 위한 지속적인\n\n행동을 보이는 경우 등을 고려해 진단한다. ",
        "original_sentence": "또한, 섭식장애는 우울, 불안 등의 정신질환을 동반하며, 섭식장애로\n\n인한 영양 부족은 면역력 저하, 수면 장애 등의 증상 발현으로 이어질\n\n수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_397",
      "text": "- 나. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 396,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 72,
        "window_text": "2021;\n\n- - 5 -\nNielsen and Vilmar 2021; Tith et al.  2020; van Hoeken and Hoek\n\n2020).\n\n 또한, 섭식장애는 우울, 불안 등의 정신질환을 동반하며, 섭식장애로\n\n인한 영양 부족은 면역력 저하, 수면 장애 등의 증상 발현으로 이어질\n\n수 있다.\n\n - 나.  섭식장애 진단 절차/과정\n섭식장애는 크게 1) 신경성 식욕부진증, 2) 신경성 폭식증, 3) 폭식\n\n장애로 정의된다.  신경성 식욕부진증은 DSM-5 진단 기준에 따라,\n\n연령과 체중에 비해 지나친 음식물 제한으로 현저한 체중의 감소, 체중\n\n증가 및 비만에 대한 극심한 두려움, 체중 증가를 막기 위한 지속적인\n\n행동을 보이는 경우 등을 고려해 진단한다.  신경성 폭식증은 폭식 여부\n\n(통제감 상실 상태로 많은 양의 음식을 2시간 안에 먹는 경우), 자발적인\n\n구토 및 설사제 남용과 같은 행동을 동반할 경우, 체중에 대한 과대\n\n평가 등의 기준으로 진단하게 된다. ",
        "original_sentence": "- 나. "
      }
    },
    {
      "chunk_id": "chunk_398",
      "text": "섭식장애 진단 절차/과정\n섭식장애는 크게 1) 신경성 식욕부진증, 2) 신경성 폭식증, 3) 폭식\n\n장애로 정의된다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 397,
        "window_size": 3,
        "char_count": 66,
        "word_count": 15,
        "page_number": 7,
        "window_text": "2020; van Hoeken and Hoek\n\n2020).\n\n 또한, 섭식장애는 우울, 불안 등의 정신질환을 동반하며, 섭식장애로\n\n인한 영양 부족은 면역력 저하, 수면 장애 등의 증상 발현으로 이어질\n\n수 있다.\n\n - 나.  섭식장애 진단 절차/과정\n섭식장애는 크게 1) 신경성 식욕부진증, 2) 신경성 폭식증, 3) 폭식\n\n장애로 정의된다.  신경성 식욕부진증은 DSM-5 진단 기준에 따라,\n\n연령과 체중에 비해 지나친 음식물 제한으로 현저한 체중의 감소, 체중\n\n증가 및 비만에 대한 극심한 두려움, 체중 증가를 막기 위한 지속적인\n\n행동을 보이는 경우 등을 고려해 진단한다.  신경성 폭식증은 폭식 여부\n\n(통제감 상실 상태로 많은 양의 음식을 2시간 안에 먹는 경우), 자발적인\n\n구토 및 설사제 남용과 같은 행동을 동반할 경우, 체중에 대한 과대\n\n평가 등의 기준으로 진단하게 된다.  여기서 신경성 식욕부진증과 신경성\n\n폭식증을 포괄하는 범진단적 개념은 체형과 체중에 대한 과대평가이다.\n\n",
        "original_sentence": "섭식장애 진단 절차/과정\n섭식장애는 크게 1) 신경성 식욕부진증, 2) 신경성 폭식증, 3) 폭식\n\n장애로 정의된다. "
      }
    },
    {
      "chunk_id": "chunk_399",
      "text": "신경성 식욕부진증은 DSM-5 진단 기준에 따라,\n\n연령과 체중에 비해 지나친 음식물 제한으로 현저한 체중의 감소, 체중\n\n증가 및 비만에 대한 극심한 두려움, 체중 증가를 막기 위한 지속적인\n\n행동을 보이는 경우 등을 고려해 진단한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 398,
        "window_size": 3,
        "char_count": 133,
        "word_count": 33,
        "page_number": 15,
        "window_text": "또한, 섭식장애는 우울, 불안 등의 정신질환을 동반하며, 섭식장애로\n\n인한 영양 부족은 면역력 저하, 수면 장애 등의 증상 발현으로 이어질\n\n수 있다.\n\n - 나.  섭식장애 진단 절차/과정\n섭식장애는 크게 1) 신경성 식욕부진증, 2) 신경성 폭식증, 3) 폭식\n\n장애로 정의된다.  신경성 식욕부진증은 DSM-5 진단 기준에 따라,\n\n연령과 체중에 비해 지나친 음식물 제한으로 현저한 체중의 감소, 체중\n\n증가 및 비만에 대한 극심한 두려움, 체중 증가를 막기 위한 지속적인\n\n행동을 보이는 경우 등을 고려해 진단한다.  신경성 폭식증은 폭식 여부\n\n(통제감 상실 상태로 많은 양의 음식을 2시간 안에 먹는 경우), 자발적인\n\n구토 및 설사제 남용과 같은 행동을 동반할 경우, 체중에 대한 과대\n\n평가 등의 기준으로 진단하게 된다.  여기서 신경성 식욕부진증과 신경성\n\n폭식증을 포괄하는 범진단적 개념은 체형과 체중에 대한 과대평가이다.\n\n 섭식장애 환자는 여러 질환이 동시적으로 발현되기 때문에, 평가 시에\n\n상황을 고려한 진단이 필요하다. ",
        "original_sentence": "신경성 식욕부진증은 DSM-5 진단 기준에 따라,\n\n연령과 체중에 비해 지나친 음식물 제한으로 현저한 체중의 감소, 체중\n\n증가 및 비만에 대한 극심한 두려움, 체중 증가를 막기 위한 지속적인\n\n행동을 보이는 경우 등을 고려해 진단한다. "
      }
    },
    {
      "chunk_id": "chunk_400",
      "text": "신경성 폭식증은 폭식 여부\n\n(통제감 상실 상태로 많은 양의 음식을 2시간 안에 먹는 경우), 자발적인\n\n구토 및 설사제 남용과 같은 행동을 동반할 경우, 체중에 대한 과대\n\n평가 등의 기준으로 진단하게 된다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 399,
        "window_size": 3,
        "char_count": 118,
        "word_count": 31,
        "page_number": 3,
        "window_text": "- 나.  섭식장애 진단 절차/과정\n섭식장애는 크게 1) 신경성 식욕부진증, 2) 신경성 폭식증, 3) 폭식\n\n장애로 정의된다.  신경성 식욕부진증은 DSM-5 진단 기준에 따라,\n\n연령과 체중에 비해 지나친 음식물 제한으로 현저한 체중의 감소, 체중\n\n증가 및 비만에 대한 극심한 두려움, 체중 증가를 막기 위한 지속적인\n\n행동을 보이는 경우 등을 고려해 진단한다.  신경성 폭식증은 폭식 여부\n\n(통제감 상실 상태로 많은 양의 음식을 2시간 안에 먹는 경우), 자발적인\n\n구토 및 설사제 남용과 같은 행동을 동반할 경우, 체중에 대한 과대\n\n평가 등의 기준으로 진단하게 된다.  여기서 신경성 식욕부진증과 신경성\n\n폭식증을 포괄하는 범진단적 개념은 체형과 체중에 대한 과대평가이다.\n\n 섭식장애 환자는 여러 질환이 동시적으로 발현되기 때문에, 평가 시에\n\n상황을 고려한 진단이 필요하다.  만성적 신경성 식욕부진증은 불안,\n\n자폐, 강박성 스펙트럼, 쾌락에 무반응 등의 특성을 보인다. ",
        "original_sentence": "신경성 폭식증은 폭식 여부\n\n(통제감 상실 상태로 많은 양의 음식을 2시간 안에 먹는 경우), 자발적인\n\n구토 및 설사제 남용과 같은 행동을 동반할 경우, 체중에 대한 과대\n\n평가 등의 기준으로 진단하게 된다. "
      }
    },
    {
      "chunk_id": "chunk_401",
      "text": "여기서 신경성 식욕부진증과 신경성\n\n폭식증을 포괄하는 범진단적 개념은 체형과 체중에 대한 과대평가이다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 400,
        "window_size": 3,
        "char_count": 59,
        "word_count": 12,
        "page_number": 15,
        "window_text": "섭식장애 진단 절차/과정\n섭식장애는 크게 1) 신경성 식욕부진증, 2) 신경성 폭식증, 3) 폭식\n\n장애로 정의된다.  신경성 식욕부진증은 DSM-5 진단 기준에 따라,\n\n연령과 체중에 비해 지나친 음식물 제한으로 현저한 체중의 감소, 체중\n\n증가 및 비만에 대한 극심한 두려움, 체중 증가를 막기 위한 지속적인\n\n행동을 보이는 경우 등을 고려해 진단한다.  신경성 폭식증은 폭식 여부\n\n(통제감 상실 상태로 많은 양의 음식을 2시간 안에 먹는 경우), 자발적인\n\n구토 및 설사제 남용과 같은 행동을 동반할 경우, 체중에 대한 과대\n\n평가 등의 기준으로 진단하게 된다.  여기서 신경성 식욕부진증과 신경성\n\n폭식증을 포괄하는 범진단적 개념은 체형과 체중에 대한 과대평가이다.\n\n 섭식장애 환자는 여러 질환이 동시적으로 발현되기 때문에, 평가 시에\n\n상황을 고려한 진단이 필요하다.  만성적 신경성 식욕부진증은 불안,\n\n자폐, 강박성 스펙트럼, 쾌락에 무반응 등의 특성을 보인다.  반면,\n\n신경성 폭식증에서는 과식 경향과 주의력결핍 과잉행동장애의 특질로\n\n나타나는 집중 및 충동성의 문제가 선행한다(Kim, 2018).\n\n",
        "original_sentence": "여기서 신경성 식욕부진증과 신경성\n\n폭식증을 포괄하는 범진단적 개념은 체형과 체중에 대한 과대평가이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_402",
      "text": "섭식장애 환자는 여러 질환이 동시적으로 발현되기 때문에, 평가 시에\n\n상황을 고려한 진단이 필요하다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 401,
        "window_size": 3,
        "char_count": 57,
        "word_count": 13,
        "page_number": 12,
        "window_text": "신경성 식욕부진증은 DSM-5 진단 기준에 따라,\n\n연령과 체중에 비해 지나친 음식물 제한으로 현저한 체중의 감소, 체중\n\n증가 및 비만에 대한 극심한 두려움, 체중 증가를 막기 위한 지속적인\n\n행동을 보이는 경우 등을 고려해 진단한다.  신경성 폭식증은 폭식 여부\n\n(통제감 상실 상태로 많은 양의 음식을 2시간 안에 먹는 경우), 자발적인\n\n구토 및 설사제 남용과 같은 행동을 동반할 경우, 체중에 대한 과대\n\n평가 등의 기준으로 진단하게 된다.  여기서 신경성 식욕부진증과 신경성\n\n폭식증을 포괄하는 범진단적 개념은 체형과 체중에 대한 과대평가이다.\n\n 섭식장애 환자는 여러 질환이 동시적으로 발현되기 때문에, 평가 시에\n\n상황을 고려한 진단이 필요하다.  만성적 신경성 식욕부진증은 불안,\n\n자폐, 강박성 스펙트럼, 쾌락에 무반응 등의 특성을 보인다.  반면,\n\n신경성 폭식증에서는 과식 경향과 주의력결핍 과잉행동장애의 특질로\n\n나타나는 집중 및 충동성의 문제가 선행한다(Kim, 2018).\n\n 섭식장애에 대한 치료는 정신건강교육(Psychoeducation)과 영양관리,\n\n행동치료, 가족치료, 대인관계 정신치료(Interpersonal Psychotherapy:\n\n- - 6 -\nIPT), 정신역동적 치료 등 여러 가지 심리적인 치료와 약물치료가\n\n시행된다. ",
        "original_sentence": "섭식장애 환자는 여러 질환이 동시적으로 발현되기 때문에, 평가 시에\n\n상황을 고려한 진단이 필요하다. "
      }
    },
    {
      "chunk_id": "chunk_403",
      "text": "만성적 신경성 식욕부진증은 불안,\n\n자폐, 강박성 스펙트럼, 쾌락에 무반응 등의 특성을 보인다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 402,
        "window_size": 3,
        "char_count": 54,
        "word_count": 12,
        "page_number": 15,
        "window_text": "신경성 폭식증은 폭식 여부\n\n(통제감 상실 상태로 많은 양의 음식을 2시간 안에 먹는 경우), 자발적인\n\n구토 및 설사제 남용과 같은 행동을 동반할 경우, 체중에 대한 과대\n\n평가 등의 기준으로 진단하게 된다.  여기서 신경성 식욕부진증과 신경성\n\n폭식증을 포괄하는 범진단적 개념은 체형과 체중에 대한 과대평가이다.\n\n 섭식장애 환자는 여러 질환이 동시적으로 발현되기 때문에, 평가 시에\n\n상황을 고려한 진단이 필요하다.  만성적 신경성 식욕부진증은 불안,\n\n자폐, 강박성 스펙트럼, 쾌락에 무반응 등의 특성을 보인다.  반면,\n\n신경성 폭식증에서는 과식 경향과 주의력결핍 과잉행동장애의 특질로\n\n나타나는 집중 및 충동성의 문제가 선행한다(Kim, 2018).\n\n 섭식장애에 대한 치료는 정신건강교육(Psychoeducation)과 영양관리,\n\n행동치료, 가족치료, 대인관계 정신치료(Interpersonal Psychotherapy:\n\n- - 6 -\nIPT), 정신역동적 치료 등 여러 가지 심리적인 치료와 약물치료가\n\n시행된다.  그중에서도 인지행동치료(Cognitive Behavioral Therapy, CBT)가\n\n가장 널리 사용되어 왔다(Kong et al., 2000).\n\n",
        "original_sentence": "만성적 신경성 식욕부진증은 불안,\n\n자폐, 강박성 스펙트럼, 쾌락에 무반응 등의 특성을 보인다. "
      }
    },
    {
      "chunk_id": "chunk_404",
      "text": "반면,\n\n신경성 폭식증에서는 과식 경향과 주의력결핍 과잉행동장애의 특질로\n\n나타나는 집중 및 충동성의 문제가 선행한다(Kim, 2018).\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 403,
        "window_size": 3,
        "char_count": 79,
        "word_count": 15,
        "page_number": 12,
        "window_text": "여기서 신경성 식욕부진증과 신경성\n\n폭식증을 포괄하는 범진단적 개념은 체형과 체중에 대한 과대평가이다.\n\n 섭식장애 환자는 여러 질환이 동시적으로 발현되기 때문에, 평가 시에\n\n상황을 고려한 진단이 필요하다.  만성적 신경성 식욕부진증은 불안,\n\n자폐, 강박성 스펙트럼, 쾌락에 무반응 등의 특성을 보인다.  반면,\n\n신경성 폭식증에서는 과식 경향과 주의력결핍 과잉행동장애의 특질로\n\n나타나는 집중 및 충동성의 문제가 선행한다(Kim, 2018).\n\n 섭식장애에 대한 치료는 정신건강교육(Psychoeducation)과 영양관리,\n\n행동치료, 가족치료, 대인관계 정신치료(Interpersonal Psychotherapy:\n\n- - 6 -\nIPT), 정신역동적 치료 등 여러 가지 심리적인 치료와 약물치료가\n\n시행된다.  그중에서도 인지행동치료(Cognitive Behavioral Therapy, CBT)가\n\n가장 널리 사용되어 왔다(Kong et al., 2000).\n\n - 다. ",
        "original_sentence": "반면,\n\n신경성 폭식증에서는 과식 경향과 주의력결핍 과잉행동장애의 특질로\n\n나타나는 집중 및 충동성의 문제가 선행한다(Kim, 2018).\n\n"
      }
    },
    {
      "chunk_id": "chunk_405",
      "text": "섭식장애에 대한 치료는 정신건강교육(Psychoeducation)과 영양관리,\n\n행동치료, 가족치료, 대인관계 정신치료(Interpersonal Psychotherapy:\n\n- - 6 -\nIPT), 정신역동적 치료 등 여러 가지 심리적인 치료와 약물치료가\n\n시행된다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 404,
        "window_size": 3,
        "char_count": 150,
        "word_count": 24,
        "page_number": 12,
        "window_text": "섭식장애 환자는 여러 질환이 동시적으로 발현되기 때문에, 평가 시에\n\n상황을 고려한 진단이 필요하다.  만성적 신경성 식욕부진증은 불안,\n\n자폐, 강박성 스펙트럼, 쾌락에 무반응 등의 특성을 보인다.  반면,\n\n신경성 폭식증에서는 과식 경향과 주의력결핍 과잉행동장애의 특질로\n\n나타나는 집중 및 충동성의 문제가 선행한다(Kim, 2018).\n\n 섭식장애에 대한 치료는 정신건강교육(Psychoeducation)과 영양관리,\n\n행동치료, 가족치료, 대인관계 정신치료(Interpersonal Psychotherapy:\n\n- - 6 -\nIPT), 정신역동적 치료 등 여러 가지 심리적인 치료와 약물치료가\n\n시행된다.  그중에서도 인지행동치료(Cognitive Behavioral Therapy, CBT)가\n\n가장 널리 사용되어 왔다(Kong et al., 2000).\n\n - 다.  섭식장애 비약물 치료(섭식장애 인지행동치료)\n섭식장애 환자들의 섭식행동 관련 태도, 경험, 삶 등을 토대로 한\n\n심리적 개입이나 비약물적 개입이 권장되고 있으며(Reas&Grilo, 2008),\n\n인지행동치료(Cognitive Behavioral Therapy, CBT)(Kwon&Kwon, 2003;\n\nWilfley et al., 1993; Park&Son, 2012), 식단조절(Baer, Fischer, & Huss,\n\n2005; Kristeller&Hallett, 1999; Smith, Shelley, Leahigh, & Vanleit, 20\n\n06), 명상(Kim, 2004; Lee&Kim, 2015)이나 미술치료(Kim&Jo, 2014)와\n\n같은 활동치료 등이 사용되고 있다. ",
        "original_sentence": "섭식장애에 대한 치료는 정신건강교육(Psychoeducation)과 영양관리,\n\n행동치료, 가족치료, 대인관계 정신치료(Interpersonal Psychotherapy:\n\n- - 6 -\nIPT), 정신역동적 치료 등 여러 가지 심리적인 치료와 약물치료가\n\n시행된다. "
      }
    },
    {
      "chunk_id": "chunk_406",
      "text": "그중에서도 인지행동치료(Cognitive Behavioral Therapy, CBT)가\n\n가장 널리 사용되어 왔다(Kong et al., 2000).\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 405,
        "window_size": 3,
        "char_count": 85,
        "word_count": 12,
        "page_number": 9,
        "window_text": "만성적 신경성 식욕부진증은 불안,\n\n자폐, 강박성 스펙트럼, 쾌락에 무반응 등의 특성을 보인다.  반면,\n\n신경성 폭식증에서는 과식 경향과 주의력결핍 과잉행동장애의 특질로\n\n나타나는 집중 및 충동성의 문제가 선행한다(Kim, 2018).\n\n 섭식장애에 대한 치료는 정신건강교육(Psychoeducation)과 영양관리,\n\n행동치료, 가족치료, 대인관계 정신치료(Interpersonal Psychotherapy:\n\n- - 6 -\nIPT), 정신역동적 치료 등 여러 가지 심리적인 치료와 약물치료가\n\n시행된다.  그중에서도 인지행동치료(Cognitive Behavioral Therapy, CBT)가\n\n가장 널리 사용되어 왔다(Kong et al., 2000).\n\n - 다.  섭식장애 비약물 치료(섭식장애 인지행동치료)\n섭식장애 환자들의 섭식행동 관련 태도, 경험, 삶 등을 토대로 한\n\n심리적 개입이나 비약물적 개입이 권장되고 있으며(Reas&Grilo, 2008),\n\n인지행동치료(Cognitive Behavioral Therapy, CBT)(Kwon&Kwon, 2003;\n\nWilfley et al., 1993; Park&Son, 2012), 식단조절(Baer, Fischer, & Huss,\n\n2005; Kristeller&Hallett, 1999; Smith, Shelley, Leahigh, & Vanleit, 20\n\n06), 명상(Kim, 2004; Lee&Kim, 2015)이나 미술치료(Kim&Jo, 2014)와\n\n같은 활동치료 등이 사용되고 있다.  그 중에서 인지행동치료는 정신\n\n질환 및 정서적 문제에 우선적으로 권고되는 치료방법으로서 부정적\n\n이고 왜곡된 인지구조를 깨닫도록 도와주며 주어진 상황이나 현실에\n\n더 적절하게 대처할 수 있도록 돕는 것으로 인식된다(Han, 2003).\n\n",
        "original_sentence": "그중에서도 인지행동치료(Cognitive Behavioral Therapy, CBT)가\n\n가장 널리 사용되어 왔다(Kong et al., 2000).\n\n"
      }
    },
    {
      "chunk_id": "chunk_407",
      "text": "- 다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 406,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 72,
        "window_text": "반면,\n\n신경성 폭식증에서는 과식 경향과 주의력결핍 과잉행동장애의 특질로\n\n나타나는 집중 및 충동성의 문제가 선행한다(Kim, 2018).\n\n 섭식장애에 대한 치료는 정신건강교육(Psychoeducation)과 영양관리,\n\n행동치료, 가족치료, 대인관계 정신치료(Interpersonal Psychotherapy:\n\n- - 6 -\nIPT), 정신역동적 치료 등 여러 가지 심리적인 치료와 약물치료가\n\n시행된다.  그중에서도 인지행동치료(Cognitive Behavioral Therapy, CBT)가\n\n가장 널리 사용되어 왔다(Kong et al., 2000).\n\n - 다.  섭식장애 비약물 치료(섭식장애 인지행동치료)\n섭식장애 환자들의 섭식행동 관련 태도, 경험, 삶 등을 토대로 한\n\n심리적 개입이나 비약물적 개입이 권장되고 있으며(Reas&Grilo, 2008),\n\n인지행동치료(Cognitive Behavioral Therapy, CBT)(Kwon&Kwon, 2003;\n\nWilfley et al., 1993; Park&Son, 2012), 식단조절(Baer, Fischer, & Huss,\n\n2005; Kristeller&Hallett, 1999; Smith, Shelley, Leahigh, & Vanleit, 20\n\n06), 명상(Kim, 2004; Lee&Kim, 2015)이나 미술치료(Kim&Jo, 2014)와\n\n같은 활동치료 등이 사용되고 있다.  그 중에서 인지행동치료는 정신\n\n질환 및 정서적 문제에 우선적으로 권고되는 치료방법으로서 부정적\n\n이고 왜곡된 인지구조를 깨닫도록 도와주며 주어진 상황이나 현실에\n\n더 적절하게 대처할 수 있도록 돕는 것으로 인식된다(Han, 2003).\n\n 선행연구에 의하면, 섭식장애를 진단받은 환자를 대상으로 비약물적\n\n중재와 약물적 중재의 효과를 비교한 연구에서 약물적 중재보다\n\n비약물적 중재를 적용한 군이 오히려 폭식 증상 감소에 효과적인 것\n\n으로 보고된 바 있으며(Vocks et al., 2010), 비약물적 중재가 식이에\n\n대한 태도를 긍정적으로 변화시키는 것으로 나타났다(Yun&Kim,\n\n2018).\n\n",
        "original_sentence": "- 다. "
      }
    },
    {
      "chunk_id": "chunk_408",
      "text": "섭식장애 비약물 치료(섭식장애 인지행동치료)\n섭식장애 환자들의 섭식행동 관련 태도, 경험, 삶 등을 토대로 한\n\n심리적 개입이나 비약물적 개입이 권장되고 있으며(Reas&Grilo, 2008),\n\n인지행동치료(Cognitive Behavioral Therapy, CBT)(Kwon&Kwon, 2003;\n\nWilfley et al., 1993; Park&Son, 2012), 식단조절(Baer, Fischer, & Huss,\n\n2005; Kristeller&Hallett, 1999; Smith, Shelley, Leahigh, & Vanleit, 20\n\n06), 명상(Kim, 2004; Lee&Kim, 2015)이나 미술치료(Kim&Jo, 2014)와\n\n같은 활동치료 등이 사용되고 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 407,
        "window_size": 3,
        "char_count": 387,
        "word_count": 57,
        "page_number": 15,
        "window_text": "섭식장애에 대한 치료는 정신건강교육(Psychoeducation)과 영양관리,\n\n행동치료, 가족치료, 대인관계 정신치료(Interpersonal Psychotherapy:\n\n- - 6 -\nIPT), 정신역동적 치료 등 여러 가지 심리적인 치료와 약물치료가\n\n시행된다.  그중에서도 인지행동치료(Cognitive Behavioral Therapy, CBT)가\n\n가장 널리 사용되어 왔다(Kong et al., 2000).\n\n - 다.  섭식장애 비약물 치료(섭식장애 인지행동치료)\n섭식장애 환자들의 섭식행동 관련 태도, 경험, 삶 등을 토대로 한\n\n심리적 개입이나 비약물적 개입이 권장되고 있으며(Reas&Grilo, 2008),\n\n인지행동치료(Cognitive Behavioral Therapy, CBT)(Kwon&Kwon, 2003;\n\nWilfley et al., 1993; Park&Son, 2012), 식단조절(Baer, Fischer, & Huss,\n\n2005; Kristeller&Hallett, 1999; Smith, Shelley, Leahigh, & Vanleit, 20\n\n06), 명상(Kim, 2004; Lee&Kim, 2015)이나 미술치료(Kim&Jo, 2014)와\n\n같은 활동치료 등이 사용되고 있다.  그 중에서 인지행동치료는 정신\n\n질환 및 정서적 문제에 우선적으로 권고되는 치료방법으로서 부정적\n\n이고 왜곡된 인지구조를 깨닫도록 도와주며 주어진 상황이나 현실에\n\n더 적절하게 대처할 수 있도록 돕는 것으로 인식된다(Han, 2003).\n\n 선행연구에 의하면, 섭식장애를 진단받은 환자를 대상으로 비약물적\n\n중재와 약물적 중재의 효과를 비교한 연구에서 약물적 중재보다\n\n비약물적 중재를 적용한 군이 오히려 폭식 증상 감소에 효과적인 것\n\n으로 보고된 바 있으며(Vocks et al., 2010), 비약물적 중재가 식이에\n\n대한 태도를 긍정적으로 변화시키는 것으로 나타났다(Yun&Kim,\n\n2018).\n\n 영국 국립보건임상평가연구소(National Institute for Health and Care\n\nExcellence, NICE)가 발간한 섭식장애 가이던스에는 질환 치료법 중 하나로\n\n- - 7 -\n인지행동치료를 포함한다. ",
        "original_sentence": "섭식장애 비약물 치료(섭식장애 인지행동치료)\n섭식장애 환자들의 섭식행동 관련 태도, 경험, 삶 등을 토대로 한\n\n심리적 개입이나 비약물적 개입이 권장되고 있으며(Reas&Grilo, 2008),\n\n인지행동치료(Cognitive Behavioral Therapy, CBT)(Kwon&Kwon, 2003;\n\nWilfley et al., 1993; Park&Son, 2012), 식단조절(Baer, Fischer, & Huss,\n\n2005; Kristeller&Hallett, 1999; Smith, Shelley, Leahigh, & Vanleit, 20\n\n06), 명상(Kim, 2004; Lee&Kim, 2015)이나 미술치료(Kim&Jo, 2014)와\n\n같은 활동치료 등이 사용되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_409",
      "text": "그 중에서 인지행동치료는 정신\n\n질환 및 정서적 문제에 우선적으로 권고되는 치료방법으로서 부정적\n\n이고 왜곡된 인지구조를 깨닫도록 도와주며 주어진 상황이나 현실에\n\n더 적절하게 대처할 수 있도록 돕는 것으로 인식된다(Han, 2003).\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 408,
        "window_size": 3,
        "char_count": 134,
        "word_count": 29,
        "page_number": 30,
        "window_text": "그중에서도 인지행동치료(Cognitive Behavioral Therapy, CBT)가\n\n가장 널리 사용되어 왔다(Kong et al., 2000).\n\n - 다.  섭식장애 비약물 치료(섭식장애 인지행동치료)\n섭식장애 환자들의 섭식행동 관련 태도, 경험, 삶 등을 토대로 한\n\n심리적 개입이나 비약물적 개입이 권장되고 있으며(Reas&Grilo, 2008),\n\n인지행동치료(Cognitive Behavioral Therapy, CBT)(Kwon&Kwon, 2003;\n\nWilfley et al., 1993; Park&Son, 2012), 식단조절(Baer, Fischer, & Huss,\n\n2005; Kristeller&Hallett, 1999; Smith, Shelley, Leahigh, & Vanleit, 20\n\n06), 명상(Kim, 2004; Lee&Kim, 2015)이나 미술치료(Kim&Jo, 2014)와\n\n같은 활동치료 등이 사용되고 있다.  그 중에서 인지행동치료는 정신\n\n질환 및 정서적 문제에 우선적으로 권고되는 치료방법으로서 부정적\n\n이고 왜곡된 인지구조를 깨닫도록 도와주며 주어진 상황이나 현실에\n\n더 적절하게 대처할 수 있도록 돕는 것으로 인식된다(Han, 2003).\n\n 선행연구에 의하면, 섭식장애를 진단받은 환자를 대상으로 비약물적\n\n중재와 약물적 중재의 효과를 비교한 연구에서 약물적 중재보다\n\n비약물적 중재를 적용한 군이 오히려 폭식 증상 감소에 효과적인 것\n\n으로 보고된 바 있으며(Vocks et al., 2010), 비약물적 중재가 식이에\n\n대한 태도를 긍정적으로 변화시키는 것으로 나타났다(Yun&Kim,\n\n2018).\n\n 영국 국립보건임상평가연구소(National Institute for Health and Care\n\nExcellence, NICE)가 발간한 섭식장애 가이던스에는 질환 치료법 중 하나로\n\n- - 7 -\n인지행동치료를 포함한다.  성인 신경성 식욕부진증 환자의 경우, 여러 심리\n\n치료 중 인지행동치료(Cognitive Behavioral Therapy for Eating Disorder,\n\nCBT-ED) 프로그램을 선택할 수 있다. ",
        "original_sentence": "그 중에서 인지행동치료는 정신\n\n질환 및 정서적 문제에 우선적으로 권고되는 치료방법으로서 부정적\n\n이고 왜곡된 인지구조를 깨닫도록 도와주며 주어진 상황이나 현실에\n\n더 적절하게 대처할 수 있도록 돕는 것으로 인식된다(Han, 2003).\n\n"
      }
    },
    {
      "chunk_id": "chunk_410",
      "text": "선행연구에 의하면, 섭식장애를 진단받은 환자를 대상으로 비약물적\n\n중재와 약물적 중재의 효과를 비교한 연구에서 약물적 중재보다\n\n비약물적 중재를 적용한 군이 오히려 폭식 증상 감소에 효과적인 것\n\n으로 보고된 바 있으며(Vocks et al., 2010), 비약물적 중재가 식이에\n\n대한 태도를 긍정적으로 변화시키는 것으로 나타났다(Yun&Kim,\n\n2018).\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 409,
        "window_size": 3,
        "char_count": 204,
        "word_count": 42,
        "page_number": 13,
        "window_text": "- 다.  섭식장애 비약물 치료(섭식장애 인지행동치료)\n섭식장애 환자들의 섭식행동 관련 태도, 경험, 삶 등을 토대로 한\n\n심리적 개입이나 비약물적 개입이 권장되고 있으며(Reas&Grilo, 2008),\n\n인지행동치료(Cognitive Behavioral Therapy, CBT)(Kwon&Kwon, 2003;\n\nWilfley et al., 1993; Park&Son, 2012), 식단조절(Baer, Fischer, & Huss,\n\n2005; Kristeller&Hallett, 1999; Smith, Shelley, Leahigh, & Vanleit, 20\n\n06), 명상(Kim, 2004; Lee&Kim, 2015)이나 미술치료(Kim&Jo, 2014)와\n\n같은 활동치료 등이 사용되고 있다.  그 중에서 인지행동치료는 정신\n\n질환 및 정서적 문제에 우선적으로 권고되는 치료방법으로서 부정적\n\n이고 왜곡된 인지구조를 깨닫도록 도와주며 주어진 상황이나 현실에\n\n더 적절하게 대처할 수 있도록 돕는 것으로 인식된다(Han, 2003).\n\n 선행연구에 의하면, 섭식장애를 진단받은 환자를 대상으로 비약물적\n\n중재와 약물적 중재의 효과를 비교한 연구에서 약물적 중재보다\n\n비약물적 중재를 적용한 군이 오히려 폭식 증상 감소에 효과적인 것\n\n으로 보고된 바 있으며(Vocks et al., 2010), 비약물적 중재가 식이에\n\n대한 태도를 긍정적으로 변화시키는 것으로 나타났다(Yun&Kim,\n\n2018).\n\n 영국 국립보건임상평가연구소(National Institute for Health and Care\n\nExcellence, NICE)가 발간한 섭식장애 가이던스에는 질환 치료법 중 하나로\n\n- - 7 -\n인지행동치료를 포함한다.  성인 신경성 식욕부진증 환자의 경우, 여러 심리\n\n치료 중 인지행동치료(Cognitive Behavioral Therapy for Eating Disorder,\n\nCBT-ED) 프로그램을 선택할 수 있다.  일반적으로 40주 동안 최대 40개의\n\n세션으로 구성된 CBT-ED 프로그램을 수행하게 되며, 처음 2~3주 동안은\n\n주 2회 세션으로 구성된다. ",
        "original_sentence": "선행연구에 의하면, 섭식장애를 진단받은 환자를 대상으로 비약물적\n\n중재와 약물적 중재의 효과를 비교한 연구에서 약물적 중재보다\n\n비약물적 중재를 적용한 군이 오히려 폭식 증상 감소에 효과적인 것\n\n으로 보고된 바 있으며(Vocks et al., 2010), 비약물적 중재가 식이에\n\n대한 태도를 긍정적으로 변화시키는 것으로 나타났다(Yun&Kim,\n\n2018).\n\n"
      }
    },
    {
      "chunk_id": "chunk_411",
      "text": "영국 국립보건임상평가연구소(National Institute for Health and Care\n\nExcellence, NICE)가 발간한 섭식장애 가이던스에는 질환 치료법 중 하나로\n\n- - 7 -\n인지행동치료를 포함한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 410,
        "window_size": 3,
        "char_count": 126,
        "word_count": 22,
        "page_number": 13,
        "window_text": "섭식장애 비약물 치료(섭식장애 인지행동치료)\n섭식장애 환자들의 섭식행동 관련 태도, 경험, 삶 등을 토대로 한\n\n심리적 개입이나 비약물적 개입이 권장되고 있으며(Reas&Grilo, 2008),\n\n인지행동치료(Cognitive Behavioral Therapy, CBT)(Kwon&Kwon, 2003;\n\nWilfley et al., 1993; Park&Son, 2012), 식단조절(Baer, Fischer, & Huss,\n\n2005; Kristeller&Hallett, 1999; Smith, Shelley, Leahigh, & Vanleit, 20\n\n06), 명상(Kim, 2004; Lee&Kim, 2015)이나 미술치료(Kim&Jo, 2014)와\n\n같은 활동치료 등이 사용되고 있다.  그 중에서 인지행동치료는 정신\n\n질환 및 정서적 문제에 우선적으로 권고되는 치료방법으로서 부정적\n\n이고 왜곡된 인지구조를 깨닫도록 도와주며 주어진 상황이나 현실에\n\n더 적절하게 대처할 수 있도록 돕는 것으로 인식된다(Han, 2003).\n\n 선행연구에 의하면, 섭식장애를 진단받은 환자를 대상으로 비약물적\n\n중재와 약물적 중재의 효과를 비교한 연구에서 약물적 중재보다\n\n비약물적 중재를 적용한 군이 오히려 폭식 증상 감소에 효과적인 것\n\n으로 보고된 바 있으며(Vocks et al., 2010), 비약물적 중재가 식이에\n\n대한 태도를 긍정적으로 변화시키는 것으로 나타났다(Yun&Kim,\n\n2018).\n\n 영국 국립보건임상평가연구소(National Institute for Health and Care\n\nExcellence, NICE)가 발간한 섭식장애 가이던스에는 질환 치료법 중 하나로\n\n- - 7 -\n인지행동치료를 포함한다.  성인 신경성 식욕부진증 환자의 경우, 여러 심리\n\n치료 중 인지행동치료(Cognitive Behavioral Therapy for Eating Disorder,\n\nCBT-ED) 프로그램을 선택할 수 있다.  일반적으로 40주 동안 최대 40개의\n\n세션으로 구성된 CBT-ED 프로그램을 수행하게 되며, 처음 2~3주 동안은\n\n주 2회 세션으로 구성된다.  프로그램은 신체적 및 정신적 건강 문제 해결,\n\n건강한 식습관 장려, 영양, 인지 재구성, 기분 조절, 자존감 관리, 재발 방지를\n\n위한 계획 수립 등의 과정으로 이루어진다. ",
        "original_sentence": "영국 국립보건임상평가연구소(National Institute for Health and Care\n\nExcellence, NICE)가 발간한 섭식장애 가이던스에는 질환 치료법 중 하나로\n\n- - 7 -\n인지행동치료를 포함한다. "
      }
    },
    {
      "chunk_id": "chunk_412",
      "text": "성인 신경성 식욕부진증 환자의 경우, 여러 심리\n\n치료 중 인지행동치료(Cognitive Behavioral Therapy for Eating Disorder,\n\nCBT-ED) 프로그램을 선택할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 411,
        "window_size": 3,
        "char_count": 115,
        "word_count": 20,
        "page_number": 9,
        "window_text": "그 중에서 인지행동치료는 정신\n\n질환 및 정서적 문제에 우선적으로 권고되는 치료방법으로서 부정적\n\n이고 왜곡된 인지구조를 깨닫도록 도와주며 주어진 상황이나 현실에\n\n더 적절하게 대처할 수 있도록 돕는 것으로 인식된다(Han, 2003).\n\n 선행연구에 의하면, 섭식장애를 진단받은 환자를 대상으로 비약물적\n\n중재와 약물적 중재의 효과를 비교한 연구에서 약물적 중재보다\n\n비약물적 중재를 적용한 군이 오히려 폭식 증상 감소에 효과적인 것\n\n으로 보고된 바 있으며(Vocks et al., 2010), 비약물적 중재가 식이에\n\n대한 태도를 긍정적으로 변화시키는 것으로 나타났다(Yun&Kim,\n\n2018).\n\n 영국 국립보건임상평가연구소(National Institute for Health and Care\n\nExcellence, NICE)가 발간한 섭식장애 가이던스에는 질환 치료법 중 하나로\n\n- - 7 -\n인지행동치료를 포함한다.  성인 신경성 식욕부진증 환자의 경우, 여러 심리\n\n치료 중 인지행동치료(Cognitive Behavioral Therapy for Eating Disorder,\n\nCBT-ED) 프로그램을 선택할 수 있다.  일반적으로 40주 동안 최대 40개의\n\n세션으로 구성된 CBT-ED 프로그램을 수행하게 되며, 처음 2~3주 동안은\n\n주 2회 세션으로 구성된다.  프로그램은 신체적 및 정신적 건강 문제 해결,\n\n건강한 식습관 장려, 영양, 인지 재구성, 기분 조절, 자존감 관리, 재발 방지를\n\n위한 계획 수립 등의 과정으로 이루어진다.  성인 신경성 폭식증 환자의\n\n경우에는 일반적으로 20주 동안 최대 20회 세션으로 구성된 CBT-ED\n\n프로그램을 수행하게 되며, 첫 번째 단계에서는 참여와 교육, 규칙적인\n\n식습관 확립 등을 주 2회 진행한다. ",
        "original_sentence": "성인 신경성 식욕부진증 환자의 경우, 여러 심리\n\n치료 중 인지행동치료(Cognitive Behavioral Therapy for Eating Disorder,\n\nCBT-ED) 프로그램을 선택할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_413",
      "text": "일반적으로 40주 동안 최대 40개의\n\n세션으로 구성된 CBT-ED 프로그램을 수행하게 되며, 처음 2~3주 동안은\n\n주 2회 세션으로 구성된다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 412,
        "window_size": 3,
        "char_count": 82,
        "word_count": 18,
        "page_number": 26,
        "window_text": "선행연구에 의하면, 섭식장애를 진단받은 환자를 대상으로 비약물적\n\n중재와 약물적 중재의 효과를 비교한 연구에서 약물적 중재보다\n\n비약물적 중재를 적용한 군이 오히려 폭식 증상 감소에 효과적인 것\n\n으로 보고된 바 있으며(Vocks et al., 2010), 비약물적 중재가 식이에\n\n대한 태도를 긍정적으로 변화시키는 것으로 나타났다(Yun&Kim,\n\n2018).\n\n 영국 국립보건임상평가연구소(National Institute for Health and Care\n\nExcellence, NICE)가 발간한 섭식장애 가이던스에는 질환 치료법 중 하나로\n\n- - 7 -\n인지행동치료를 포함한다.  성인 신경성 식욕부진증 환자의 경우, 여러 심리\n\n치료 중 인지행동치료(Cognitive Behavioral Therapy for Eating Disorder,\n\nCBT-ED) 프로그램을 선택할 수 있다.  일반적으로 40주 동안 최대 40개의\n\n세션으로 구성된 CBT-ED 프로그램을 수행하게 되며, 처음 2~3주 동안은\n\n주 2회 세션으로 구성된다.  프로그램은 신체적 및 정신적 건강 문제 해결,\n\n건강한 식습관 장려, 영양, 인지 재구성, 기분 조절, 자존감 관리, 재발 방지를\n\n위한 계획 수립 등의 과정으로 이루어진다.  성인 신경성 폭식증 환자의\n\n경우에는 일반적으로 20주 동안 최대 20회 세션으로 구성된 CBT-ED\n\n프로그램을 수행하게 되며, 첫 번째 단계에서는 참여와 교육, 규칙적인\n\n식습관 확립 등을 주 2회 진행한다.  성인 폭식장애 환자의 경우, 일반적\n\n으로 4개월에 걸쳐 매주 16개의 90분 그룹 세션을 진행한다. ",
        "original_sentence": "일반적으로 40주 동안 최대 40개의\n\n세션으로 구성된 CBT-ED 프로그램을 수행하게 되며, 처음 2~3주 동안은\n\n주 2회 세션으로 구성된다. "
      }
    },
    {
      "chunk_id": "chunk_414",
      "text": "프로그램은 신체적 및 정신적 건강 문제 해결,\n\n건강한 식습관 장려, 영양, 인지 재구성, 기분 조절, 자존감 관리, 재발 방지를\n\n위한 계획 수립 등의 과정으로 이루어진다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 413,
        "window_size": 3,
        "char_count": 98,
        "word_count": 25,
        "page_number": 30,
        "window_text": "영국 국립보건임상평가연구소(National Institute for Health and Care\n\nExcellence, NICE)가 발간한 섭식장애 가이던스에는 질환 치료법 중 하나로\n\n- - 7 -\n인지행동치료를 포함한다.  성인 신경성 식욕부진증 환자의 경우, 여러 심리\n\n치료 중 인지행동치료(Cognitive Behavioral Therapy for Eating Disorder,\n\nCBT-ED) 프로그램을 선택할 수 있다.  일반적으로 40주 동안 최대 40개의\n\n세션으로 구성된 CBT-ED 프로그램을 수행하게 되며, 처음 2~3주 동안은\n\n주 2회 세션으로 구성된다.  프로그램은 신체적 및 정신적 건강 문제 해결,\n\n건강한 식습관 장려, 영양, 인지 재구성, 기분 조절, 자존감 관리, 재발 방지를\n\n위한 계획 수립 등의 과정으로 이루어진다.  성인 신경성 폭식증 환자의\n\n경우에는 일반적으로 20주 동안 최대 20회 세션으로 구성된 CBT-ED\n\n프로그램을 수행하게 되며, 첫 번째 단계에서는 참여와 교육, 규칙적인\n\n식습관 확립 등을 주 2회 진행한다.  성인 폭식장애 환자의 경우, 일반적\n\n으로 4개월에 걸쳐 매주 16개의 90분 그룹 세션을 진행한다.  심리 교육,\n\n식습관 자체 모니터링, 재발 방지를 위한 계획 수립 등의 내용으로\n\n구성되어 있다.\n\n",
        "original_sentence": "프로그램은 신체적 및 정신적 건강 문제 해결,\n\n건강한 식습관 장려, 영양, 인지 재구성, 기분 조절, 자존감 관리, 재발 방지를\n\n위한 계획 수립 등의 과정으로 이루어진다. "
      }
    },
    {
      "chunk_id": "chunk_415",
      "text": "성인 신경성 폭식증 환자의\n\n경우에는 일반적으로 20주 동안 최대 20회 세션으로 구성된 CBT-ED\n\n프로그램을 수행하게 되며, 첫 번째 단계에서는 참여와 교육, 규칙적인\n\n식습관 확립 등을 주 2회 진행한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 414,
        "window_size": 3,
        "char_count": 119,
        "word_count": 28,
        "page_number": 9,
        "window_text": "성인 신경성 식욕부진증 환자의 경우, 여러 심리\n\n치료 중 인지행동치료(Cognitive Behavioral Therapy for Eating Disorder,\n\nCBT-ED) 프로그램을 선택할 수 있다.  일반적으로 40주 동안 최대 40개의\n\n세션으로 구성된 CBT-ED 프로그램을 수행하게 되며, 처음 2~3주 동안은\n\n주 2회 세션으로 구성된다.  프로그램은 신체적 및 정신적 건강 문제 해결,\n\n건강한 식습관 장려, 영양, 인지 재구성, 기분 조절, 자존감 관리, 재발 방지를\n\n위한 계획 수립 등의 과정으로 이루어진다.  성인 신경성 폭식증 환자의\n\n경우에는 일반적으로 20주 동안 최대 20회 세션으로 구성된 CBT-ED\n\n프로그램을 수행하게 되며, 첫 번째 단계에서는 참여와 교육, 규칙적인\n\n식습관 확립 등을 주 2회 진행한다.  성인 폭식장애 환자의 경우, 일반적\n\n으로 4개월에 걸쳐 매주 16개의 90분 그룹 세션을 진행한다.  심리 교육,\n\n식습관 자체 모니터링, 재발 방지를 위한 계획 수립 등의 내용으로\n\n구성되어 있다.\n\n 미국 정신의학회(APA)의 섭식장애 진료지침은 신경성 식욕부진증,\n\n신경성 폭식증, 폭식장애 치료법에 인지행동치료를 권고하고 있다.\n\n",
        "original_sentence": "성인 신경성 폭식증 환자의\n\n경우에는 일반적으로 20주 동안 최대 20회 세션으로 구성된 CBT-ED\n\n프로그램을 수행하게 되며, 첫 번째 단계에서는 참여와 교육, 규칙적인\n\n식습관 확립 등을 주 2회 진행한다. "
      }
    },
    {
      "chunk_id": "chunk_416",
      "text": "성인 폭식장애 환자의 경우, 일반적\n\n으로 4개월에 걸쳐 매주 16개의 90분 그룹 세션을 진행한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 415,
        "window_size": 3,
        "char_count": 57,
        "word_count": 14,
        "page_number": 15,
        "window_text": "일반적으로 40주 동안 최대 40개의\n\n세션으로 구성된 CBT-ED 프로그램을 수행하게 되며, 처음 2~3주 동안은\n\n주 2회 세션으로 구성된다.  프로그램은 신체적 및 정신적 건강 문제 해결,\n\n건강한 식습관 장려, 영양, 인지 재구성, 기분 조절, 자존감 관리, 재발 방지를\n\n위한 계획 수립 등의 과정으로 이루어진다.  성인 신경성 폭식증 환자의\n\n경우에는 일반적으로 20주 동안 최대 20회 세션으로 구성된 CBT-ED\n\n프로그램을 수행하게 되며, 첫 번째 단계에서는 참여와 교육, 규칙적인\n\n식습관 확립 등을 주 2회 진행한다.  성인 폭식장애 환자의 경우, 일반적\n\n으로 4개월에 걸쳐 매주 16개의 90분 그룹 세션을 진행한다.  심리 교육,\n\n식습관 자체 모니터링, 재발 방지를 위한 계획 수립 등의 내용으로\n\n구성되어 있다.\n\n 미국 정신의학회(APA)의 섭식장애 진료지침은 신경성 식욕부진증,\n\n신경성 폭식증, 폭식장애 치료법에 인지행동치료를 권고하고 있다.\n\n 다만, 청소년과 나이가 어린 성인 환자의 경우에는, 가족 기반 치료를\n\n권장한다.\n\n",
        "original_sentence": "성인 폭식장애 환자의 경우, 일반적\n\n으로 4개월에 걸쳐 매주 16개의 90분 그룹 세션을 진행한다. "
      }
    },
    {
      "chunk_id": "chunk_417",
      "text": "심리 교육,\n\n식습관 자체 모니터링, 재발 방지를 위한 계획 수립 등의 내용으로\n\n구성되어 있다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 416,
        "window_size": 3,
        "char_count": 56,
        "word_count": 14,
        "page_number": 14,
        "window_text": "프로그램은 신체적 및 정신적 건강 문제 해결,\n\n건강한 식습관 장려, 영양, 인지 재구성, 기분 조절, 자존감 관리, 재발 방지를\n\n위한 계획 수립 등의 과정으로 이루어진다.  성인 신경성 폭식증 환자의\n\n경우에는 일반적으로 20주 동안 최대 20회 세션으로 구성된 CBT-ED\n\n프로그램을 수행하게 되며, 첫 번째 단계에서는 참여와 교육, 규칙적인\n\n식습관 확립 등을 주 2회 진행한다.  성인 폭식장애 환자의 경우, 일반적\n\n으로 4개월에 걸쳐 매주 16개의 90분 그룹 세션을 진행한다.  심리 교육,\n\n식습관 자체 모니터링, 재발 방지를 위한 계획 수립 등의 내용으로\n\n구성되어 있다.\n\n 미국 정신의학회(APA)의 섭식장애 진료지침은 신경성 식욕부진증,\n\n신경성 폭식증, 폭식장애 치료법에 인지행동치료를 권고하고 있다.\n\n 다만, 청소년과 나이가 어린 성인 환자의 경우에는, 가족 기반 치료를\n\n권장한다.\n\n - - 8 -\n(출처: 섭식장애 환자 치료를 위한 임상 가이드라인, 미국정신의학회(2023))\n\n유형\n\n내용\n\n- - 목표 체중 달성을 위한 영양 재활을 진행한다.\n",
        "original_sentence": "심리 교육,\n\n식습관 자체 모니터링, 재발 방지를 위한 계획 수립 등의 내용으로\n\n구성되어 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_418",
      "text": "미국 정신의학회(APA)의 섭식장애 진료지침은 신경성 식욕부진증,\n\n신경성 폭식증, 폭식장애 치료법에 인지행동치료를 권고하고 있다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 417,
        "window_size": 3,
        "char_count": 75,
        "word_count": 13,
        "page_number": 14,
        "window_text": "성인 신경성 폭식증 환자의\n\n경우에는 일반적으로 20주 동안 최대 20회 세션으로 구성된 CBT-ED\n\n프로그램을 수행하게 되며, 첫 번째 단계에서는 참여와 교육, 규칙적인\n\n식습관 확립 등을 주 2회 진행한다.  성인 폭식장애 환자의 경우, 일반적\n\n으로 4개월에 걸쳐 매주 16개의 90분 그룹 세션을 진행한다.  심리 교육,\n\n식습관 자체 모니터링, 재발 방지를 위한 계획 수립 등의 내용으로\n\n구성되어 있다.\n\n 미국 정신의학회(APA)의 섭식장애 진료지침은 신경성 식욕부진증,\n\n신경성 폭식증, 폭식장애 치료법에 인지행동치료를 권고하고 있다.\n\n 다만, 청소년과 나이가 어린 성인 환자의 경우에는, 가족 기반 치료를\n\n권장한다.\n\n - - 8 -\n(출처: 섭식장애 환자 치료를 위한 임상 가이드라인, 미국정신의학회(2023))\n\n유형\n\n내용\n\n- - 목표 체중 달성을 위한 영양 재활을 진행한다.\n - - 영양 재활 중에는 심리적 치료, 신체적 활동 등을 병행할 수 있다.\n",
        "original_sentence": "미국 정신의학회(APA)의 섭식장애 진료지침은 신경성 식욕부진증,\n\n신경성 폭식증, 폭식장애 치료법에 인지행동치료를 권고하고 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_419",
      "text": "다만, 청소년과 나이가 어린 성인 환자의 경우에는, 가족 기반 치료를\n\n권장한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 418,
        "window_size": 3,
        "char_count": 47,
        "word_count": 11,
        "page_number": 14,
        "window_text": "성인 폭식장애 환자의 경우, 일반적\n\n으로 4개월에 걸쳐 매주 16개의 90분 그룹 세션을 진행한다.  심리 교육,\n\n식습관 자체 모니터링, 재발 방지를 위한 계획 수립 등의 내용으로\n\n구성되어 있다.\n\n 미국 정신의학회(APA)의 섭식장애 진료지침은 신경성 식욕부진증,\n\n신경성 폭식증, 폭식장애 치료법에 인지행동치료를 권고하고 있다.\n\n 다만, 청소년과 나이가 어린 성인 환자의 경우에는, 가족 기반 치료를\n\n권장한다.\n\n - - 8 -\n(출처: 섭식장애 환자 치료를 위한 임상 가이드라인, 미국정신의학회(2023))\n\n유형\n\n내용\n\n- - 목표 체중 달성을 위한 영양 재활을 진행한다.\n - - 영양 재활 중에는 심리적 치료, 신체적 활동 등을 병행할 수 있다.\n 신경성 폭식증\n\n표 2. ",
        "original_sentence": "다만, 청소년과 나이가 어린 성인 환자의 경우에는, 가족 기반 치료를\n\n권장한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_420",
      "text": "- - 8 -\n(출처: 섭식장애 환자 치료를 위한 임상 가이드라인, 미국정신의학회(2023))\n\n유형\n\n내용\n\n- - 목표 체중 달성을 위한 영양 재활을 진행한다.\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 419,
        "window_size": 3,
        "char_count": 92,
        "word_count": 23,
        "page_number": 9,
        "window_text": "심리 교육,\n\n식습관 자체 모니터링, 재발 방지를 위한 계획 수립 등의 내용으로\n\n구성되어 있다.\n\n 미국 정신의학회(APA)의 섭식장애 진료지침은 신경성 식욕부진증,\n\n신경성 폭식증, 폭식장애 치료법에 인지행동치료를 권고하고 있다.\n\n 다만, 청소년과 나이가 어린 성인 환자의 경우에는, 가족 기반 치료를\n\n권장한다.\n\n - - 8 -\n(출처: 섭식장애 환자 치료를 위한 임상 가이드라인, 미국정신의학회(2023))\n\n유형\n\n내용\n\n- - 목표 체중 달성을 위한 영양 재활을 진행한다.\n - - 영양 재활 중에는 심리적 치료, 신체적 활동 등을 병행할 수 있다.\n 신경성 폭식증\n\n표 2.  섭식장애 유형별 비약물치료 내용\n\n- - 9 -\n- 라. ",
        "original_sentence": "- - 8 -\n(출처: 섭식장애 환자 치료를 위한 임상 가이드라인, 미국정신의학회(2023))\n\n유형\n\n내용\n\n- - 목표 체중 달성을 위한 영양 재활을 진행한다.\n"
      }
    },
    {
      "chunk_id": "chunk_421",
      "text": "- - 영양 재활 중에는 심리적 치료, 신체적 활동 등을 병행할 수 있다.\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 420,
        "window_size": 3,
        "char_count": 42,
        "word_count": 13,
        "page_number": 12,
        "window_text": "미국 정신의학회(APA)의 섭식장애 진료지침은 신경성 식욕부진증,\n\n신경성 폭식증, 폭식장애 치료법에 인지행동치료를 권고하고 있다.\n\n 다만, 청소년과 나이가 어린 성인 환자의 경우에는, 가족 기반 치료를\n\n권장한다.\n\n - - 8 -\n(출처: 섭식장애 환자 치료를 위한 임상 가이드라인, 미국정신의학회(2023))\n\n유형\n\n내용\n\n- - 목표 체중 달성을 위한 영양 재활을 진행한다.\n - - 영양 재활 중에는 심리적 치료, 신체적 활동 등을 병행할 수 있다.\n 신경성 폭식증\n\n표 2.  섭식장애 유형별 비약물치료 내용\n\n- - 9 -\n- 라.  섭식장애 약물치료\n섭식장애 인지행동치료 등 비약물 치료 효과가 미비한 경우, 필요하다면\n\n약물치료를 통해 섭식장애를 개선할 수 있다. ",
        "original_sentence": "- - 영양 재활 중에는 심리적 치료, 신체적 활동 등을 병행할 수 있다.\n"
      }
    },
    {
      "chunk_id": "chunk_422",
      "text": "신경성 폭식증\n\n표 2. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 421,
        "window_size": 3,
        "char_count": 14,
        "word_count": 4,
        "page_number": 9,
        "window_text": "다만, 청소년과 나이가 어린 성인 환자의 경우에는, 가족 기반 치료를\n\n권장한다.\n\n - - 8 -\n(출처: 섭식장애 환자 치료를 위한 임상 가이드라인, 미국정신의학회(2023))\n\n유형\n\n내용\n\n- - 목표 체중 달성을 위한 영양 재활을 진행한다.\n - - 영양 재활 중에는 심리적 치료, 신체적 활동 등을 병행할 수 있다.\n 신경성 폭식증\n\n표 2.  섭식장애 유형별 비약물치료 내용\n\n- - 9 -\n- 라.  섭식장애 약물치료\n섭식장애 인지행동치료 등 비약물 치료 효과가 미비한 경우, 필요하다면\n\n약물치료를 통해 섭식장애를 개선할 수 있다.  약물치료로는 항우울제,\n\n세로토닌·노르에피네프린 재흡수 억제제, 간질 치료제, 비만 치료제\n\n등의 약제가 사용되나 효과나 부작용 측면에서 사용이 제한적이다.\n\n",
        "original_sentence": "신경성 폭식증\n\n표 2. "
      }
    },
    {
      "chunk_id": "chunk_423",
      "text": "섭식장애 유형별 비약물치료 내용\n\n- - 9 -\n- 라. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 422,
        "window_size": 3,
        "char_count": 32,
        "word_count": 10,
        "page_number": 15,
        "window_text": "- - 8 -\n(출처: 섭식장애 환자 치료를 위한 임상 가이드라인, 미국정신의학회(2023))\n\n유형\n\n내용\n\n- - 목표 체중 달성을 위한 영양 재활을 진행한다.\n - - 영양 재활 중에는 심리적 치료, 신체적 활동 등을 병행할 수 있다.\n 신경성 폭식증\n\n표 2.  섭식장애 유형별 비약물치료 내용\n\n- - 9 -\n- 라.  섭식장애 약물치료\n섭식장애 인지행동치료 등 비약물 치료 효과가 미비한 경우, 필요하다면\n\n약물치료를 통해 섭식장애를 개선할 수 있다.  약물치료로는 항우울제,\n\n세로토닌·노르에피네프린 재흡수 억제제, 간질 치료제, 비만 치료제\n\n등의 약제가 사용되나 효과나 부작용 측면에서 사용이 제한적이다.\n\n 단, 불가피하게 약물치료가 필요할 경우, 환자의 상황에 맞게 임상의가\n\n적절하게 판단하여 사용하여야 한다.\n\n",
        "original_sentence": "섭식장애 유형별 비약물치료 내용\n\n- - 9 -\n- 라. "
      }
    },
    {
      "chunk_id": "chunk_424",
      "text": "섭식장애 약물치료\n섭식장애 인지행동치료 등 비약물 치료 효과가 미비한 경우, 필요하다면\n\n약물치료를 통해 섭식장애를 개선할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 423,
        "window_size": 3,
        "char_count": 75,
        "word_count": 17,
        "page_number": 16,
        "window_text": "- - 영양 재활 중에는 심리적 치료, 신체적 활동 등을 병행할 수 있다.\n 신경성 폭식증\n\n표 2.  섭식장애 유형별 비약물치료 내용\n\n- - 9 -\n- 라.  섭식장애 약물치료\n섭식장애 인지행동치료 등 비약물 치료 효과가 미비한 경우, 필요하다면\n\n약물치료를 통해 섭식장애를 개선할 수 있다.  약물치료로는 항우울제,\n\n세로토닌·노르에피네프린 재흡수 억제제, 간질 치료제, 비만 치료제\n\n등의 약제가 사용되나 효과나 부작용 측면에서 사용이 제한적이다.\n\n 단, 불가피하게 약물치료가 필요할 경우, 환자의 상황에 맞게 임상의가\n\n적절하게 판단하여 사용하여야 한다.\n\n - - 10 -\n- 마. ",
        "original_sentence": "섭식장애 약물치료\n섭식장애 인지행동치료 등 비약물 치료 효과가 미비한 경우, 필요하다면\n\n약물치료를 통해 섭식장애를 개선할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_425",
      "text": "약물치료로는 항우울제,\n\n세로토닌·노르에피네프린 재흡수 억제제, 간질 치료제, 비만 치료제\n\n등의 약제가 사용되나 효과나 부작용 측면에서 사용이 제한적이다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 424,
        "window_size": 3,
        "char_count": 89,
        "word_count": 17,
        "page_number": 16,
        "window_text": "신경성 폭식증\n\n표 2.  섭식장애 유형별 비약물치료 내용\n\n- - 9 -\n- 라.  섭식장애 약물치료\n섭식장애 인지행동치료 등 비약물 치료 효과가 미비한 경우, 필요하다면\n\n약물치료를 통해 섭식장애를 개선할 수 있다.  약물치료로는 항우울제,\n\n세로토닌·노르에피네프린 재흡수 억제제, 간질 치료제, 비만 치료제\n\n등의 약제가 사용되나 효과나 부작용 측면에서 사용이 제한적이다.\n\n 단, 불가피하게 약물치료가 필요할 경우, 환자의 상황에 맞게 임상의가\n\n적절하게 판단하여 사용하여야 한다.\n\n - - 10 -\n- 마.  섭식장애 비약물 치료의 임상 권고 사항\n미국정신의학회(APA), 영국 국립보건임상평가연구소(NICE) 등은 섭식\n\n장애 치료를 위해 비약물 치료를 우선하여 시행하기를 권고한다.\n\n",
        "original_sentence": "약물치료로는 항우울제,\n\n세로토닌·노르에피네프린 재흡수 억제제, 간질 치료제, 비만 치료제\n\n등의 약제가 사용되나 효과나 부작용 측면에서 사용이 제한적이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_426",
      "text": "단, 불가피하게 약물치료가 필요할 경우, 환자의 상황에 맞게 임상의가\n\n적절하게 판단하여 사용하여야 한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 425,
        "window_size": 3,
        "char_count": 61,
        "word_count": 13,
        "page_number": 15,
        "window_text": "섭식장애 유형별 비약물치료 내용\n\n- - 9 -\n- 라.  섭식장애 약물치료\n섭식장애 인지행동치료 등 비약물 치료 효과가 미비한 경우, 필요하다면\n\n약물치료를 통해 섭식장애를 개선할 수 있다.  약물치료로는 항우울제,\n\n세로토닌·노르에피네프린 재흡수 억제제, 간질 치료제, 비만 치료제\n\n등의 약제가 사용되나 효과나 부작용 측면에서 사용이 제한적이다.\n\n 단, 불가피하게 약물치료가 필요할 경우, 환자의 상황에 맞게 임상의가\n\n적절하게 판단하여 사용하여야 한다.\n\n - - 10 -\n- 마.  섭식장애 비약물 치료의 임상 권고 사항\n미국정신의학회(APA), 영국 국립보건임상평가연구소(NICE) 등은 섭식\n\n장애 치료를 위해 비약물 치료를 우선하여 시행하기를 권고한다.\n\n 또한 국제섭식장애학회(Academy for eating disorders, AED)의 ‘섭식\n\n장애에 대한 증거 기반 심리치료 가이드’에서는 섭식장애에 대한\n\n비약물 치료로 인지행동치료(CBT)를 우선 치료전략으로 제안하였다.\n\n",
        "original_sentence": "단, 불가피하게 약물치료가 필요할 경우, 환자의 상황에 맞게 임상의가\n\n적절하게 판단하여 사용하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_427",
      "text": "- - 10 -\n- 마. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 426,
        "window_size": 3,
        "char_count": 14,
        "word_count": 6,
        "page_number": 17,
        "window_text": "섭식장애 약물치료\n섭식장애 인지행동치료 등 비약물 치료 효과가 미비한 경우, 필요하다면\n\n약물치료를 통해 섭식장애를 개선할 수 있다.  약물치료로는 항우울제,\n\n세로토닌·노르에피네프린 재흡수 억제제, 간질 치료제, 비만 치료제\n\n등의 약제가 사용되나 효과나 부작용 측면에서 사용이 제한적이다.\n\n 단, 불가피하게 약물치료가 필요할 경우, 환자의 상황에 맞게 임상의가\n\n적절하게 판단하여 사용하여야 한다.\n\n - - 10 -\n- 마.  섭식장애 비약물 치료의 임상 권고 사항\n미국정신의학회(APA), 영국 국립보건임상평가연구소(NICE) 등은 섭식\n\n장애 치료를 위해 비약물 치료를 우선하여 시행하기를 권고한다.\n\n 또한 국제섭식장애학회(Academy for eating disorders, AED)의 ‘섭식\n\n장애에 대한 증거 기반 심리치료 가이드’에서는 섭식장애에 대한\n\n비약물 치료로 인지행동치료(CBT)를 우선 치료전략으로 제안하였다.\n\n * APA: American Psychiatric Association, NICE: National Institute for Health and Care\n\n미국정신의학회(APA) 진료지침(2023)은 섭식장애 치료를 위해 비약물\n\n치료 시행을 권장한다. ",
        "original_sentence": "- - 10 -\n- 마. "
      }
    },
    {
      "chunk_id": "chunk_428",
      "text": "섭식장애 비약물 치료의 임상 권고 사항\n미국정신의학회(APA), 영국 국립보건임상평가연구소(NICE) 등은 섭식\n\n장애 치료를 위해 비약물 치료를 우선하여 시행하기를 권고한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 427,
        "window_size": 3,
        "char_count": 100,
        "word_count": 19,
        "page_number": 3,
        "window_text": "약물치료로는 항우울제,\n\n세로토닌·노르에피네프린 재흡수 억제제, 간질 치료제, 비만 치료제\n\n등의 약제가 사용되나 효과나 부작용 측면에서 사용이 제한적이다.\n\n 단, 불가피하게 약물치료가 필요할 경우, 환자의 상황에 맞게 임상의가\n\n적절하게 판단하여 사용하여야 한다.\n\n - - 10 -\n- 마.  섭식장애 비약물 치료의 임상 권고 사항\n미국정신의학회(APA), 영국 국립보건임상평가연구소(NICE) 등은 섭식\n\n장애 치료를 위해 비약물 치료를 우선하여 시행하기를 권고한다.\n\n 또한 국제섭식장애학회(Academy for eating disorders, AED)의 ‘섭식\n\n장애에 대한 증거 기반 심리치료 가이드’에서는 섭식장애에 대한\n\n비약물 치료로 인지행동치료(CBT)를 우선 치료전략으로 제안하였다.\n\n * APA: American Psychiatric Association, NICE: National Institute for Health and Care\n\n미국정신의학회(APA) 진료지침(2023)은 섭식장애 치료를 위해 비약물\n\n치료 시행을 권장한다.  비약물 치료로는 영양 재활치료를 포함한\n\n정상 체중 회복을 위한 심리치료가 진행되며, 인지행동치료(CBT)도\n\n활용된다. ",
        "original_sentence": "섭식장애 비약물 치료의 임상 권고 사항\n미국정신의학회(APA), 영국 국립보건임상평가연구소(NICE) 등은 섭식\n\n장애 치료를 위해 비약물 치료를 우선하여 시행하기를 권고한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_429",
      "text": "또한 국제섭식장애학회(Academy for eating disorders, AED)의 ‘섭식\n\n장애에 대한 증거 기반 심리치료 가이드’에서는 섭식장애에 대한\n\n비약물 치료로 인지행동치료(CBT)를 우선 치료전략으로 제안하였다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 428,
        "window_size": 3,
        "char_count": 128,
        "word_count": 21,
        "page_number": 9,
        "window_text": "단, 불가피하게 약물치료가 필요할 경우, 환자의 상황에 맞게 임상의가\n\n적절하게 판단하여 사용하여야 한다.\n\n - - 10 -\n- 마.  섭식장애 비약물 치료의 임상 권고 사항\n미국정신의학회(APA), 영국 국립보건임상평가연구소(NICE) 등은 섭식\n\n장애 치료를 위해 비약물 치료를 우선하여 시행하기를 권고한다.\n\n 또한 국제섭식장애학회(Academy for eating disorders, AED)의 ‘섭식\n\n장애에 대한 증거 기반 심리치료 가이드’에서는 섭식장애에 대한\n\n비약물 치료로 인지행동치료(CBT)를 우선 치료전략으로 제안하였다.\n\n * APA: American Psychiatric Association, NICE: National Institute for Health and Care\n\n미국정신의학회(APA) 진료지침(2023)은 섭식장애 치료를 위해 비약물\n\n치료 시행을 권장한다.  비약물 치료로는 영양 재활치료를 포함한\n\n정상 체중 회복을 위한 심리치료가 진행되며, 인지행동치료(CBT)도\n\n활용된다.  영국 국립보건임상평가연구소(NICE) 진료지침(2017)도 인지\n\n행동치료(CBT)를 포함한 심리치료가 섭식장애 치료법으로 고려되고\n\n있다. ",
        "original_sentence": "또한 국제섭식장애학회(Academy for eating disorders, AED)의 ‘섭식\n\n장애에 대한 증거 기반 심리치료 가이드’에서는 섭식장애에 대한\n\n비약물 치료로 인지행동치료(CBT)를 우선 치료전략으로 제안하였다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_430",
      "text": "* APA: American Psychiatric Association, NICE: National Institute for Health and Care\n\n미국정신의학회(APA) 진료지침(2023)은 섭식장애 치료를 위해 비약물\n\n치료 시행을 권장한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 429,
        "window_size": 3,
        "char_count": 142,
        "word_count": 21,
        "page_number": 17,
        "window_text": "- - 10 -\n- 마.  섭식장애 비약물 치료의 임상 권고 사항\n미국정신의학회(APA), 영국 국립보건임상평가연구소(NICE) 등은 섭식\n\n장애 치료를 위해 비약물 치료를 우선하여 시행하기를 권고한다.\n\n 또한 국제섭식장애학회(Academy for eating disorders, AED)의 ‘섭식\n\n장애에 대한 증거 기반 심리치료 가이드’에서는 섭식장애에 대한\n\n비약물 치료로 인지행동치료(CBT)를 우선 치료전략으로 제안하였다.\n\n * APA: American Psychiatric Association, NICE: National Institute for Health and Care\n\n미국정신의학회(APA) 진료지침(2023)은 섭식장애 치료를 위해 비약물\n\n치료 시행을 권장한다.  비약물 치료로는 영양 재활치료를 포함한\n\n정상 체중 회복을 위한 심리치료가 진행되며, 인지행동치료(CBT)도\n\n활용된다.  영국 국립보건임상평가연구소(NICE) 진료지침(2017)도 인지\n\n행동치료(CBT)를 포함한 심리치료가 섭식장애 치료법으로 고려되고\n\n있다.  국제섭식장애학회(AED)가 발간한 섭식장애 가이드라인(2020)\n\n에서는 섭식장애 치료의 First-line으로 인지행동치료(CBT-ED)가 권고\n\n된다. ",
        "original_sentence": "* APA: American Psychiatric Association, NICE: National Institute for Health and Care\n\n미국정신의학회(APA) 진료지침(2023)은 섭식장애 치료를 위해 비약물\n\n치료 시행을 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_431",
      "text": "비약물 치료로는 영양 재활치료를 포함한\n\n정상 체중 회복을 위한 심리치료가 진행되며, 인지행동치료(CBT)도\n\n활용된다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 430,
        "window_size": 3,
        "char_count": 68,
        "word_count": 13,
        "page_number": 30,
        "window_text": "섭식장애 비약물 치료의 임상 권고 사항\n미국정신의학회(APA), 영국 국립보건임상평가연구소(NICE) 등은 섭식\n\n장애 치료를 위해 비약물 치료를 우선하여 시행하기를 권고한다.\n\n 또한 국제섭식장애학회(Academy for eating disorders, AED)의 ‘섭식\n\n장애에 대한 증거 기반 심리치료 가이드’에서는 섭식장애에 대한\n\n비약물 치료로 인지행동치료(CBT)를 우선 치료전략으로 제안하였다.\n\n * APA: American Psychiatric Association, NICE: National Institute for Health and Care\n\n미국정신의학회(APA) 진료지침(2023)은 섭식장애 치료를 위해 비약물\n\n치료 시행을 권장한다.  비약물 치료로는 영양 재활치료를 포함한\n\n정상 체중 회복을 위한 심리치료가 진행되며, 인지행동치료(CBT)도\n\n활용된다.  영국 국립보건임상평가연구소(NICE) 진료지침(2017)도 인지\n\n행동치료(CBT)를 포함한 심리치료가 섭식장애 치료법으로 고려되고\n\n있다.  국제섭식장애학회(AED)가 발간한 섭식장애 가이드라인(2020)\n\n에서는 섭식장애 치료의 First-line으로 인지행동치료(CBT-ED)가 권고\n\n된다.  다만, 섭식장애 비약물 치료는 섭식장애 유형, 환자의 상태를\n\n고려해 약물치료를 실시할 수 있다.\n\n",
        "original_sentence": "비약물 치료로는 영양 재활치료를 포함한\n\n정상 체중 회복을 위한 심리치료가 진행되며, 인지행동치료(CBT)도\n\n활용된다. "
      }
    },
    {
      "chunk_id": "chunk_432",
      "text": "영국 국립보건임상평가연구소(NICE) 진료지침(2017)도 인지\n\n행동치료(CBT)를 포함한 심리치료가 섭식장애 치료법으로 고려되고\n\n있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 431,
        "window_size": 3,
        "char_count": 79,
        "word_count": 11,
        "page_number": 9,
        "window_text": "또한 국제섭식장애학회(Academy for eating disorders, AED)의 ‘섭식\n\n장애에 대한 증거 기반 심리치료 가이드’에서는 섭식장애에 대한\n\n비약물 치료로 인지행동치료(CBT)를 우선 치료전략으로 제안하였다.\n\n * APA: American Psychiatric Association, NICE: National Institute for Health and Care\n\n미국정신의학회(APA) 진료지침(2023)은 섭식장애 치료를 위해 비약물\n\n치료 시행을 권장한다.  비약물 치료로는 영양 재활치료를 포함한\n\n정상 체중 회복을 위한 심리치료가 진행되며, 인지행동치료(CBT)도\n\n활용된다.  영국 국립보건임상평가연구소(NICE) 진료지침(2017)도 인지\n\n행동치료(CBT)를 포함한 심리치료가 섭식장애 치료법으로 고려되고\n\n있다.  국제섭식장애학회(AED)가 발간한 섭식장애 가이드라인(2020)\n\n에서는 섭식장애 치료의 First-line으로 인지행동치료(CBT-ED)가 권고\n\n된다.  다만, 섭식장애 비약물 치료는 섭식장애 유형, 환자의 상태를\n\n고려해 약물치료를 실시할 수 있다.\n\n - - 11 -\n- 바. ",
        "original_sentence": "영국 국립보건임상평가연구소(NICE) 진료지침(2017)도 인지\n\n행동치료(CBT)를 포함한 심리치료가 섭식장애 치료법으로 고려되고\n\n있다. "
      }
    },
    {
      "chunk_id": "chunk_433",
      "text": "국제섭식장애학회(AED)가 발간한 섭식장애 가이드라인(2020)\n\n에서는 섭식장애 치료의 First-line으로 인지행동치료(CBT-ED)가 권고\n\n된다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 432,
        "window_size": 3,
        "char_count": 87,
        "word_count": 11,
        "page_number": 9,
        "window_text": "* APA: American Psychiatric Association, NICE: National Institute for Health and Care\n\n미국정신의학회(APA) 진료지침(2023)은 섭식장애 치료를 위해 비약물\n\n치료 시행을 권장한다.  비약물 치료로는 영양 재활치료를 포함한\n\n정상 체중 회복을 위한 심리치료가 진행되며, 인지행동치료(CBT)도\n\n활용된다.  영국 국립보건임상평가연구소(NICE) 진료지침(2017)도 인지\n\n행동치료(CBT)를 포함한 심리치료가 섭식장애 치료법으로 고려되고\n\n있다.  국제섭식장애학회(AED)가 발간한 섭식장애 가이드라인(2020)\n\n에서는 섭식장애 치료의 First-line으로 인지행동치료(CBT-ED)가 권고\n\n된다.  다만, 섭식장애 비약물 치료는 섭식장애 유형, 환자의 상태를\n\n고려해 약물치료를 실시할 수 있다.\n\n - - 11 -\n- 바.  디지털 기반 섭식장애 치료 관련 선행연구\n디지털 기반 섭식장애 치료는 대게 웹 또는 스마트폰 앱 기반으로\n\n인지행동치료(CBT)를 시행한다. ",
        "original_sentence": "국제섭식장애학회(AED)가 발간한 섭식장애 가이드라인(2020)\n\n에서는 섭식장애 치료의 First-line으로 인지행동치료(CBT-ED)가 권고\n\n된다. "
      }
    },
    {
      "chunk_id": "chunk_434",
      "text": "다만, 섭식장애 비약물 치료는 섭식장애 유형, 환자의 상태를\n\n고려해 약물치료를 실시할 수 있다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 433,
        "window_size": 3,
        "char_count": 56,
        "word_count": 13,
        "page_number": 15,
        "window_text": "비약물 치료로는 영양 재활치료를 포함한\n\n정상 체중 회복을 위한 심리치료가 진행되며, 인지행동치료(CBT)도\n\n활용된다.  영국 국립보건임상평가연구소(NICE) 진료지침(2017)도 인지\n\n행동치료(CBT)를 포함한 심리치료가 섭식장애 치료법으로 고려되고\n\n있다.  국제섭식장애학회(AED)가 발간한 섭식장애 가이드라인(2020)\n\n에서는 섭식장애 치료의 First-line으로 인지행동치료(CBT-ED)가 권고\n\n된다.  다만, 섭식장애 비약물 치료는 섭식장애 유형, 환자의 상태를\n\n고려해 약물치료를 실시할 수 있다.\n\n - - 11 -\n- 바.  디지털 기반 섭식장애 치료 관련 선행연구\n디지털 기반 섭식장애 치료는 대게 웹 또는 스마트폰 앱 기반으로\n\n인지행동치료(CBT)를 시행한다.  우선, 폭식장애 환자를 대상으로 16주간\n\n인터넷 기반 중재 프로그램을 시행한 선행연구를 살펴보았다. ",
        "original_sentence": "다만, 섭식장애 비약물 치료는 섭식장애 유형, 환자의 상태를\n\n고려해 약물치료를 실시할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_435",
      "text": "- - 11 -\n- 바. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 434,
        "window_size": 3,
        "char_count": 14,
        "word_count": 6,
        "page_number": 18,
        "window_text": "영국 국립보건임상평가연구소(NICE) 진료지침(2017)도 인지\n\n행동치료(CBT)를 포함한 심리치료가 섭식장애 치료법으로 고려되고\n\n있다.  국제섭식장애학회(AED)가 발간한 섭식장애 가이드라인(2020)\n\n에서는 섭식장애 치료의 First-line으로 인지행동치료(CBT-ED)가 권고\n\n된다.  다만, 섭식장애 비약물 치료는 섭식장애 유형, 환자의 상태를\n\n고려해 약물치료를 실시할 수 있다.\n\n - - 11 -\n- 바.  디지털 기반 섭식장애 치료 관련 선행연구\n디지털 기반 섭식장애 치료는 대게 웹 또는 스마트폰 앱 기반으로\n\n인지행동치료(CBT)를 시행한다.  우선, 폭식장애 환자를 대상으로 16주간\n\n인터넷 기반 중재 프로그램을 시행한 선행연구를 살펴보았다.  해당\n\n연구는 인지행동 대면 치료 및 자조 요법을 포함한 디지털 인지행동\n\n치료 프로그램이 마련되었고, 글쓰기 과제, 임상심리사로부터의 피드백,\n\n활동 일기, 심리 교육 등으로 구성되었다. ",
        "original_sentence": "- - 11 -\n- 바. "
      }
    },
    {
      "chunk_id": "chunk_436",
      "text": "디지털 기반 섭식장애 치료 관련 선행연구\n디지털 기반 섭식장애 치료는 대게 웹 또는 스마트폰 앱 기반으로\n\n인지행동치료(CBT)를 시행한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 435,
        "window_size": 3,
        "char_count": 79,
        "word_count": 18,
        "page_number": 34,
        "window_text": "국제섭식장애학회(AED)가 발간한 섭식장애 가이드라인(2020)\n\n에서는 섭식장애 치료의 First-line으로 인지행동치료(CBT-ED)가 권고\n\n된다.  다만, 섭식장애 비약물 치료는 섭식장애 유형, 환자의 상태를\n\n고려해 약물치료를 실시할 수 있다.\n\n - - 11 -\n- 바.  디지털 기반 섭식장애 치료 관련 선행연구\n디지털 기반 섭식장애 치료는 대게 웹 또는 스마트폰 앱 기반으로\n\n인지행동치료(CBT)를 시행한다.  우선, 폭식장애 환자를 대상으로 16주간\n\n인터넷 기반 중재 프로그램을 시행한 선행연구를 살펴보았다.  해당\n\n연구는 인지행동 대면 치료 및 자조 요법을 포함한 디지털 인지행동\n\n치료 프로그램이 마련되었고, 글쓰기 과제, 임상심리사로부터의 피드백,\n\n활동 일기, 심리 교육 등으로 구성되었다.  위 연구는 폭식 횟수 감소\n\n등 폭식장애 증상 완화, EDE-Q 척도 감소 또는 유지, 우울 증상 완화\n\n등의 긍정적 결과를 보였다(Wagner et al., 2016).\n\n",
        "original_sentence": "디지털 기반 섭식장애 치료 관련 선행연구\n디지털 기반 섭식장애 치료는 대게 웹 또는 스마트폰 앱 기반으로\n\n인지행동치료(CBT)를 시행한다. "
      }
    },
    {
      "chunk_id": "chunk_437",
      "text": "우선, 폭식장애 환자를 대상으로 16주간\n\n인터넷 기반 중재 프로그램을 시행한 선행연구를 살펴보았다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 436,
        "window_size": 3,
        "char_count": 57,
        "word_count": 12,
        "page_number": 15,
        "window_text": "다만, 섭식장애 비약물 치료는 섭식장애 유형, 환자의 상태를\n\n고려해 약물치료를 실시할 수 있다.\n\n - - 11 -\n- 바.  디지털 기반 섭식장애 치료 관련 선행연구\n디지털 기반 섭식장애 치료는 대게 웹 또는 스마트폰 앱 기반으로\n\n인지행동치료(CBT)를 시행한다.  우선, 폭식장애 환자를 대상으로 16주간\n\n인터넷 기반 중재 프로그램을 시행한 선행연구를 살펴보았다.  해당\n\n연구는 인지행동 대면 치료 및 자조 요법을 포함한 디지털 인지행동\n\n치료 프로그램이 마련되었고, 글쓰기 과제, 임상심리사로부터의 피드백,\n\n활동 일기, 심리 교육 등으로 구성되었다.  위 연구는 폭식 횟수 감소\n\n등 폭식장애 증상 완화, EDE-Q 척도 감소 또는 유지, 우울 증상 완화\n\n등의 긍정적 결과를 보였다(Wagner et al., 2016).\n\n 또한, 디지털 기반 섭식장애 치료는 섭식장애 환자들의 건강 개선에\n\n효과적인 것으로 입증되었다(terHuurne et al., 2015). ",
        "original_sentence": "우선, 폭식장애 환자를 대상으로 16주간\n\n인터넷 기반 중재 프로그램을 시행한 선행연구를 살펴보았다. "
      }
    },
    {
      "chunk_id": "chunk_438",
      "text": "해당\n\n연구는 인지행동 대면 치료 및 자조 요법을 포함한 디지털 인지행동\n\n치료 프로그램이 마련되었고, 글쓰기 과제, 임상심리사로부터의 피드백,\n\n활동 일기, 심리 교육 등으로 구성되었다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 437,
        "window_size": 3,
        "char_count": 106,
        "word_count": 24,
        "page_number": 18,
        "window_text": "- - 11 -\n- 바.  디지털 기반 섭식장애 치료 관련 선행연구\n디지털 기반 섭식장애 치료는 대게 웹 또는 스마트폰 앱 기반으로\n\n인지행동치료(CBT)를 시행한다.  우선, 폭식장애 환자를 대상으로 16주간\n\n인터넷 기반 중재 프로그램을 시행한 선행연구를 살펴보았다.  해당\n\n연구는 인지행동 대면 치료 및 자조 요법을 포함한 디지털 인지행동\n\n치료 프로그램이 마련되었고, 글쓰기 과제, 임상심리사로부터의 피드백,\n\n활동 일기, 심리 교육 등으로 구성되었다.  위 연구는 폭식 횟수 감소\n\n등 폭식장애 증상 완화, EDE-Q 척도 감소 또는 유지, 우울 증상 완화\n\n등의 긍정적 결과를 보였다(Wagner et al., 2016).\n\n 또한, 디지털 기반 섭식장애 치료는 섭식장애 환자들의 건강 개선에\n\n효과적인 것으로 입증되었다(terHuurne et al., 2015).  해당 연구에서는\n\n섭식장애를 겪고 있는 여성 환자 총 214명 대상으로 웹 기반의 인지\n\n행동치료(CBT) 중재를 수행했다. ",
        "original_sentence": "해당\n\n연구는 인지행동 대면 치료 및 자조 요법을 포함한 디지털 인지행동\n\n치료 프로그램이 마련되었고, 글쓰기 과제, 임상심리사로부터의 피드백,\n\n활동 일기, 심리 교육 등으로 구성되었다. "
      }
    },
    {
      "chunk_id": "chunk_439",
      "text": "위 연구는 폭식 횟수 감소\n\n등 폭식장애 증상 완화, EDE-Q 척도 감소 또는 유지, 우울 증상 완화\n\n등의 긍정적 결과를 보였다(Wagner et al., 2016).\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 438,
        "window_size": 3,
        "char_count": 97,
        "word_count": 24,
        "page_number": 17,
        "window_text": "디지털 기반 섭식장애 치료 관련 선행연구\n디지털 기반 섭식장애 치료는 대게 웹 또는 스마트폰 앱 기반으로\n\n인지행동치료(CBT)를 시행한다.  우선, 폭식장애 환자를 대상으로 16주간\n\n인터넷 기반 중재 프로그램을 시행한 선행연구를 살펴보았다.  해당\n\n연구는 인지행동 대면 치료 및 자조 요법을 포함한 디지털 인지행동\n\n치료 프로그램이 마련되었고, 글쓰기 과제, 임상심리사로부터의 피드백,\n\n활동 일기, 심리 교육 등으로 구성되었다.  위 연구는 폭식 횟수 감소\n\n등 폭식장애 증상 완화, EDE-Q 척도 감소 또는 유지, 우울 증상 완화\n\n등의 긍정적 결과를 보였다(Wagner et al., 2016).\n\n 또한, 디지털 기반 섭식장애 치료는 섭식장애 환자들의 건강 개선에\n\n효과적인 것으로 입증되었다(terHuurne et al., 2015).  해당 연구에서는\n\n섭식장애를 겪고 있는 여성 환자 총 214명 대상으로 웹 기반의 인지\n\n행동치료(CBT) 중재를 수행했다.  웹 기반 애플리케이션은 21개의\n\n세션과 10개의 과제로 구성되었으며, 참가자들은 하루 약 20분 정도의\n\n중재를\n\n받았다.\n\n",
        "original_sentence": "위 연구는 폭식 횟수 감소\n\n등 폭식장애 증상 완화, EDE-Q 척도 감소 또는 유지, 우울 증상 완화\n\n등의 긍정적 결과를 보였다(Wagner et al., 2016).\n\n"
      }
    },
    {
      "chunk_id": "chunk_440",
      "text": "또한, 디지털 기반 섭식장애 치료는 섭식장애 환자들의 건강 개선에\n\n효과적인 것으로 입증되었다(terHuurne et al., 2015). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 439,
        "window_size": 3,
        "char_count": 78,
        "word_count": 15,
        "page_number": 15,
        "window_text": "우선, 폭식장애 환자를 대상으로 16주간\n\n인터넷 기반 중재 프로그램을 시행한 선행연구를 살펴보았다.  해당\n\n연구는 인지행동 대면 치료 및 자조 요법을 포함한 디지털 인지행동\n\n치료 프로그램이 마련되었고, 글쓰기 과제, 임상심리사로부터의 피드백,\n\n활동 일기, 심리 교육 등으로 구성되었다.  위 연구는 폭식 횟수 감소\n\n등 폭식장애 증상 완화, EDE-Q 척도 감소 또는 유지, 우울 증상 완화\n\n등의 긍정적 결과를 보였다(Wagner et al., 2016).\n\n 또한, 디지털 기반 섭식장애 치료는 섭식장애 환자들의 건강 개선에\n\n효과적인 것으로 입증되었다(terHuurne et al., 2015).  해당 연구에서는\n\n섭식장애를 겪고 있는 여성 환자 총 214명 대상으로 웹 기반의 인지\n\n행동치료(CBT) 중재를 수행했다.  웹 기반 애플리케이션은 21개의\n\n세션과 10개의 과제로 구성되었으며, 참가자들은 하루 약 20분 정도의\n\n중재를\n\n받았다.\n\n 일차\n\n유효성\n\n변수는\n\nEDE-Q(Eating\n\nDisorder\n\nExamination-Questionnaire), 이차 유효성 변수는 BAT(Body Attitude\n\nTest)가 사용되었다. ",
        "original_sentence": "또한, 디지털 기반 섭식장애 치료는 섭식장애 환자들의 건강 개선에\n\n효과적인 것으로 입증되었다(terHuurne et al., 2015). "
      }
    },
    {
      "chunk_id": "chunk_441",
      "text": "해당 연구에서는\n\n섭식장애를 겪고 있는 여성 환자 총 214명 대상으로 웹 기반의 인지\n\n행동치료(CBT) 중재를 수행했다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 440,
        "window_size": 3,
        "char_count": 70,
        "word_count": 16,
        "page_number": 9,
        "window_text": "해당\n\n연구는 인지행동 대면 치료 및 자조 요법을 포함한 디지털 인지행동\n\n치료 프로그램이 마련되었고, 글쓰기 과제, 임상심리사로부터의 피드백,\n\n활동 일기, 심리 교육 등으로 구성되었다.  위 연구는 폭식 횟수 감소\n\n등 폭식장애 증상 완화, EDE-Q 척도 감소 또는 유지, 우울 증상 완화\n\n등의 긍정적 결과를 보였다(Wagner et al., 2016).\n\n 또한, 디지털 기반 섭식장애 치료는 섭식장애 환자들의 건강 개선에\n\n효과적인 것으로 입증되었다(terHuurne et al., 2015).  해당 연구에서는\n\n섭식장애를 겪고 있는 여성 환자 총 214명 대상으로 웹 기반의 인지\n\n행동치료(CBT) 중재를 수행했다.  웹 기반 애플리케이션은 21개의\n\n세션과 10개의 과제로 구성되었으며, 참가자들은 하루 약 20분 정도의\n\n중재를\n\n받았다.\n\n 일차\n\n유효성\n\n변수는\n\nEDE-Q(Eating\n\nDisorder\n\nExamination-Questionnaire), 이차 유효성 변수는 BAT(Body Attitude\n\nTest)가 사용되었다.  결과적으로 환자들은 신체 및 정신 건강, 자존감\n\n등이 크게 상승한 것을 알 수 있었다.\n\n",
        "original_sentence": "해당 연구에서는\n\n섭식장애를 겪고 있는 여성 환자 총 214명 대상으로 웹 기반의 인지\n\n행동치료(CBT) 중재를 수행했다. "
      }
    },
    {
      "chunk_id": "chunk_442",
      "text": "웹 기반 애플리케이션은 21개의\n\n세션과 10개의 과제로 구성되었으며, 참가자들은 하루 약 20분 정도의\n\n중재를\n\n받았다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 441,
        "window_size": 3,
        "char_count": 71,
        "word_count": 15,
        "page_number": 9,
        "window_text": "위 연구는 폭식 횟수 감소\n\n등 폭식장애 증상 완화, EDE-Q 척도 감소 또는 유지, 우울 증상 완화\n\n등의 긍정적 결과를 보였다(Wagner et al., 2016).\n\n 또한, 디지털 기반 섭식장애 치료는 섭식장애 환자들의 건강 개선에\n\n효과적인 것으로 입증되었다(terHuurne et al., 2015).  해당 연구에서는\n\n섭식장애를 겪고 있는 여성 환자 총 214명 대상으로 웹 기반의 인지\n\n행동치료(CBT) 중재를 수행했다.  웹 기반 애플리케이션은 21개의\n\n세션과 10개의 과제로 구성되었으며, 참가자들은 하루 약 20분 정도의\n\n중재를\n\n받았다.\n\n 일차\n\n유효성\n\n변수는\n\nEDE-Q(Eating\n\nDisorder\n\nExamination-Questionnaire), 이차 유효성 변수는 BAT(Body Attitude\n\nTest)가 사용되었다.  결과적으로 환자들은 신체 및 정신 건강, 자존감\n\n등이 크게 상승한 것을 알 수 있었다.\n\n - - 12 -\n- 사. ",
        "original_sentence": "웹 기반 애플리케이션은 21개의\n\n세션과 10개의 과제로 구성되었으며, 참가자들은 하루 약 20분 정도의\n\n중재를\n\n받았다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_443",
      "text": "일차\n\n유효성\n\n변수는\n\nEDE-Q(Eating\n\nDisorder\n\nExamination-Questionnaire), 이차 유효성 변수는 BAT(Body Attitude\n\nTest)가 사용되었다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 442,
        "window_size": 3,
        "char_count": 110,
        "word_count": 13,
        "page_number": 7,
        "window_text": "또한, 디지털 기반 섭식장애 치료는 섭식장애 환자들의 건강 개선에\n\n효과적인 것으로 입증되었다(terHuurne et al., 2015).  해당 연구에서는\n\n섭식장애를 겪고 있는 여성 환자 총 214명 대상으로 웹 기반의 인지\n\n행동치료(CBT) 중재를 수행했다.  웹 기반 애플리케이션은 21개의\n\n세션과 10개의 과제로 구성되었으며, 참가자들은 하루 약 20분 정도의\n\n중재를\n\n받았다.\n\n 일차\n\n유효성\n\n변수는\n\nEDE-Q(Eating\n\nDisorder\n\nExamination-Questionnaire), 이차 유효성 변수는 BAT(Body Attitude\n\nTest)가 사용되었다.  결과적으로 환자들은 신체 및 정신 건강, 자존감\n\n등이 크게 상승한 것을 알 수 있었다.\n\n - - 12 -\n- 사.  섭식장애 개선 디지털치료기기의 국외 사례\n현재 국외에서 섭식장애 개선 디지털치료기기로서, 허가된 제품 및\n\n인지행동치료(CBT)를 이용한 제품은 다음과 같다 <표 6>.\n\n",
        "original_sentence": "일차\n\n유효성\n\n변수는\n\nEDE-Q(Eating\n\nDisorder\n\nExamination-Questionnaire), 이차 유효성 변수는 BAT(Body Attitude\n\nTest)가 사용되었다. "
      }
    },
    {
      "chunk_id": "chunk_444",
      "text": "결과적으로 환자들은 신체 및 정신 건강, 자존감\n\n등이 크게 상승한 것을 알 수 있었다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 443,
        "window_size": 3,
        "char_count": 51,
        "word_count": 14,
        "page_number": 15,
        "window_text": "해당 연구에서는\n\n섭식장애를 겪고 있는 여성 환자 총 214명 대상으로 웹 기반의 인지\n\n행동치료(CBT) 중재를 수행했다.  웹 기반 애플리케이션은 21개의\n\n세션과 10개의 과제로 구성되었으며, 참가자들은 하루 약 20분 정도의\n\n중재를\n\n받았다.\n\n 일차\n\n유효성\n\n변수는\n\nEDE-Q(Eating\n\nDisorder\n\nExamination-Questionnaire), 이차 유효성 변수는 BAT(Body Attitude\n\nTest)가 사용되었다.  결과적으로 환자들은 신체 및 정신 건강, 자존감\n\n등이 크게 상승한 것을 알 수 있었다.\n\n - - 12 -\n- 사.  섭식장애 개선 디지털치료기기의 국외 사례\n현재 국외에서 섭식장애 개선 디지털치료기기로서, 허가된 제품 및\n\n인지행동치료(CBT)를 이용한 제품은 다음과 같다 <표 6>.\n\n (Selfapy GmbH)\n\n- - 12주 온라인 과정으로 구성되었으며, 오디오와\n비디오 클립, 텍스트, 연습 등을 통해 제공된다.\n\n",
        "original_sentence": "결과적으로 환자들은 신체 및 정신 건강, 자존감\n\n등이 크게 상승한 것을 알 수 있었다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_445",
      "text": "- - 12 -\n- 사. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 444,
        "window_size": 3,
        "char_count": 14,
        "word_count": 6,
        "page_number": 9,
        "window_text": "웹 기반 애플리케이션은 21개의\n\n세션과 10개의 과제로 구성되었으며, 참가자들은 하루 약 20분 정도의\n\n중재를\n\n받았다.\n\n 일차\n\n유효성\n\n변수는\n\nEDE-Q(Eating\n\nDisorder\n\nExamination-Questionnaire), 이차 유효성 변수는 BAT(Body Attitude\n\nTest)가 사용되었다.  결과적으로 환자들은 신체 및 정신 건강, 자존감\n\n등이 크게 상승한 것을 알 수 있었다.\n\n - - 12 -\n- 사.  섭식장애 개선 디지털치료기기의 국외 사례\n현재 국외에서 섭식장애 개선 디지털치료기기로서, 허가된 제품 및\n\n인지행동치료(CBT)를 이용한 제품은 다음과 같다 <표 6>.\n\n (Selfapy GmbH)\n\n- - 12주 온라인 과정으로 구성되었으며, 오디오와\n비디오 클립, 텍스트, 연습 등을 통해 제공된다.\n\n 주제는 심리교육, 부정적인 생각과 감정 다루기,\n\n식습관과 자존감, 휴식 기술, 문제 해결 및\n\n재발 방지에 관한 내용을 포함하고, 새롭게\n\n습득한 전략과 기술을 일상생활에 적용하기\n\n- - 환자는 컴퓨터 또는 노트북, 태블릿 또는\n스마트폰 등 어디에서나 과정을 완료할 수\n\n있고, 일주일에 한 번, 약 60분의 사용을 권장\n\n표 4. ",
        "original_sentence": "- - 12 -\n- 사. "
      }
    },
    {
      "chunk_id": "chunk_446",
      "text": "섭식장애 개선 디지털치료기기의 국외 사례\n현재 국외에서 섭식장애 개선 디지털치료기기로서, 허가된 제품 및\n\n인지행동치료(CBT)를 이용한 제품은 다음과 같다 <표 6>.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 445,
        "window_size": 3,
        "char_count": 96,
        "word_count": 20,
        "page_number": 1,
        "window_text": "일차\n\n유효성\n\n변수는\n\nEDE-Q(Eating\n\nDisorder\n\nExamination-Questionnaire), 이차 유효성 변수는 BAT(Body Attitude\n\nTest)가 사용되었다.  결과적으로 환자들은 신체 및 정신 건강, 자존감\n\n등이 크게 상승한 것을 알 수 있었다.\n\n - - 12 -\n- 사.  섭식장애 개선 디지털치료기기의 국외 사례\n현재 국외에서 섭식장애 개선 디지털치료기기로서, 허가된 제품 및\n\n인지행동치료(CBT)를 이용한 제품은 다음과 같다 <표 6>.\n\n (Selfapy GmbH)\n\n- - 12주 온라인 과정으로 구성되었으며, 오디오와\n비디오 클립, 텍스트, 연습 등을 통해 제공된다.\n\n 주제는 심리교육, 부정적인 생각과 감정 다루기,\n\n식습관과 자존감, 휴식 기술, 문제 해결 및\n\n재발 방지에 관한 내용을 포함하고, 새롭게\n\n습득한 전략과 기술을 일상생활에 적용하기\n\n- - 환자는 컴퓨터 또는 노트북, 태블릿 또는\n스마트폰 등 어디에서나 과정을 완료할 수\n\n있고, 일주일에 한 번, 약 60분의 사용을 권장\n\n표 4.  국외 섭식장애 개선 디지털치료기기 허가 제품 및 관련 제품의 개발 동향(2023. ",
        "original_sentence": "섭식장애 개선 디지털치료기기의 국외 사례\n현재 국외에서 섭식장애 개선 디지털치료기기로서, 허가된 제품 및\n\n인지행동치료(CBT)를 이용한 제품은 다음과 같다 <표 6>.\n\n"
      }
    },
    {
      "chunk_id": "chunk_447",
      "text": "(Selfapy GmbH)\n\n- - 12주 온라인 과정으로 구성되었으며, 오디오와\n비디오 클립, 텍스트, 연습 등을 통해 제공된다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 446,
        "window_size": 3,
        "char_count": 75,
        "word_count": 16,
        "page_number": 9,
        "window_text": "결과적으로 환자들은 신체 및 정신 건강, 자존감\n\n등이 크게 상승한 것을 알 수 있었다.\n\n - - 12 -\n- 사.  섭식장애 개선 디지털치료기기의 국외 사례\n현재 국외에서 섭식장애 개선 디지털치료기기로서, 허가된 제품 및\n\n인지행동치료(CBT)를 이용한 제품은 다음과 같다 <표 6>.\n\n (Selfapy GmbH)\n\n- - 12주 온라인 과정으로 구성되었으며, 오디오와\n비디오 클립, 텍스트, 연습 등을 통해 제공된다.\n\n 주제는 심리교육, 부정적인 생각과 감정 다루기,\n\n식습관과 자존감, 휴식 기술, 문제 해결 및\n\n재발 방지에 관한 내용을 포함하고, 새롭게\n\n습득한 전략과 기술을 일상생활에 적용하기\n\n- - 환자는 컴퓨터 또는 노트북, 태블릿 또는\n스마트폰 등 어디에서나 과정을 완료할 수\n\n있고, 일주일에 한 번, 약 60분의 사용을 권장\n\n표 4.  국외 섭식장애 개선 디지털치료기기 허가 제품 및 관련 제품의 개발 동향(2023.  8. ",
        "original_sentence": "(Selfapy GmbH)\n\n- - 12주 온라인 과정으로 구성되었으며, 오디오와\n비디오 클립, 텍스트, 연습 등을 통해 제공된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_448",
      "text": "주제는 심리교육, 부정적인 생각과 감정 다루기,\n\n식습관과 자존감, 휴식 기술, 문제 해결 및\n\n재발 방지에 관한 내용을 포함하고, 새롭게\n\n습득한 전략과 기술을 일상생활에 적용하기\n\n- - 환자는 컴퓨터 또는 노트북, 태블릿 또는\n스마트폰 등 어디에서나 과정을 완료할 수\n\n있고, 일주일에 한 번, 약 60분의 사용을 권장\n\n표 4. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 447,
        "window_size": 3,
        "char_count": 188,
        "word_count": 48,
        "page_number": 19,
        "window_text": "- - 12 -\n- 사.  섭식장애 개선 디지털치료기기의 국외 사례\n현재 국외에서 섭식장애 개선 디지털치료기기로서, 허가된 제품 및\n\n인지행동치료(CBT)를 이용한 제품은 다음과 같다 <표 6>.\n\n (Selfapy GmbH)\n\n- - 12주 온라인 과정으로 구성되었으며, 오디오와\n비디오 클립, 텍스트, 연습 등을 통해 제공된다.\n\n 주제는 심리교육, 부정적인 생각과 감정 다루기,\n\n식습관과 자존감, 휴식 기술, 문제 해결 및\n\n재발 방지에 관한 내용을 포함하고, 새롭게\n\n습득한 전략과 기술을 일상생활에 적용하기\n\n- - 환자는 컴퓨터 또는 노트북, 태블릿 또는\n스마트폰 등 어디에서나 과정을 완료할 수\n\n있고, 일주일에 한 번, 약 60분의 사용을 권장\n\n표 4.  국외 섭식장애 개선 디지털치료기기 허가 제품 및 관련 제품의 개발 동향(2023.  8.  기준)\n\n- - 13 -\n- 아. ",
        "original_sentence": "주제는 심리교육, 부정적인 생각과 감정 다루기,\n\n식습관과 자존감, 휴식 기술, 문제 해결 및\n\n재발 방지에 관한 내용을 포함하고, 새롭게\n\n습득한 전략과 기술을 일상생활에 적용하기\n\n- - 환자는 컴퓨터 또는 노트북, 태블릿 또는\n스마트폰 등 어디에서나 과정을 완료할 수\n\n있고, 일주일에 한 번, 약 60분의 사용을 권장\n\n표 4. "
      }
    },
    {
      "chunk_id": "chunk_449",
      "text": "국외 섭식장애 개선 디지털치료기기 허가 제품 및 관련 제품의 개발 동향(2023. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 448,
        "window_size": 3,
        "char_count": 46,
        "word_count": 11,
        "page_number": 1,
        "window_text": "섭식장애 개선 디지털치료기기의 국외 사례\n현재 국외에서 섭식장애 개선 디지털치료기기로서, 허가된 제품 및\n\n인지행동치료(CBT)를 이용한 제품은 다음과 같다 <표 6>.\n\n (Selfapy GmbH)\n\n- - 12주 온라인 과정으로 구성되었으며, 오디오와\n비디오 클립, 텍스트, 연습 등을 통해 제공된다.\n\n 주제는 심리교육, 부정적인 생각과 감정 다루기,\n\n식습관과 자존감, 휴식 기술, 문제 해결 및\n\n재발 방지에 관한 내용을 포함하고, 새롭게\n\n습득한 전략과 기술을 일상생활에 적용하기\n\n- - 환자는 컴퓨터 또는 노트북, 태블릿 또는\n스마트폰 등 어디에서나 과정을 완료할 수\n\n있고, 일주일에 한 번, 약 60분의 사용을 권장\n\n표 4.  국외 섭식장애 개선 디지털치료기기 허가 제품 및 관련 제품의 개발 동향(2023.  8.  기준)\n\n- - 13 -\n- 아.  디지털치료기기의 정의와 국내 가이드라인별 적용 기준\n1) 디지털치료기기 정의\n\n식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인\n\n(민원인 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방,\n\n관리, 치료하기 위해 환자에게 근거 기반의 치료적 개입을 제공\n\n디지털치료기기는 「의료기기법」 제2조에 따른 사용 목적에\n\n해당해야 하며, <그림 1>과 같이 소프트웨어 의료기기로써 범용\n\n하드웨어에 설치되고, 질병을 예방, 관리 또는 치료하기 위한\n\n목적으로 환자에게 적용되어야 한다. ",
        "original_sentence": "국외 섭식장애 개선 디지털치료기기 허가 제품 및 관련 제품의 개발 동향(2023. "
      }
    },
    {
      "chunk_id": "chunk_450",
      "text": "8. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 449,
        "window_size": 3,
        "char_count": 3,
        "word_count": 1,
        "page_number": 19,
        "window_text": "(Selfapy GmbH)\n\n- - 12주 온라인 과정으로 구성되었으며, 오디오와\n비디오 클립, 텍스트, 연습 등을 통해 제공된다.\n\n 주제는 심리교육, 부정적인 생각과 감정 다루기,\n\n식습관과 자존감, 휴식 기술, 문제 해결 및\n\n재발 방지에 관한 내용을 포함하고, 새롭게\n\n습득한 전략과 기술을 일상생활에 적용하기\n\n- - 환자는 컴퓨터 또는 노트북, 태블릿 또는\n스마트폰 등 어디에서나 과정을 완료할 수\n\n있고, 일주일에 한 번, 약 60분의 사용을 권장\n\n표 4.  국외 섭식장애 개선 디지털치료기기 허가 제품 및 관련 제품의 개발 동향(2023.  8.  기준)\n\n- - 13 -\n- 아.  디지털치료기기의 정의와 국내 가이드라인별 적용 기준\n1) 디지털치료기기 정의\n\n식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인\n\n(민원인 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방,\n\n관리, 치료하기 위해 환자에게 근거 기반의 치료적 개입을 제공\n\n디지털치료기기는 「의료기기법」 제2조에 따른 사용 목적에\n\n해당해야 하며, <그림 1>과 같이 소프트웨어 의료기기로써 범용\n\n하드웨어에 설치되고, 질병을 예방, 관리 또는 치료하기 위한\n\n목적으로 환자에게 적용되어야 한다.  또한, 치료 작용기전의\n\n과학적(임상적) 근거에 해당하는 자료가 있어야 한다. ",
        "original_sentence": "8. "
      }
    },
    {
      "chunk_id": "chunk_451",
      "text": "기준)\n\n- - 13 -\n- 아. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 450,
        "window_size": 3,
        "char_count": 19,
        "word_count": 7,
        "page_number": 19,
        "window_text": "주제는 심리교육, 부정적인 생각과 감정 다루기,\n\n식습관과 자존감, 휴식 기술, 문제 해결 및\n\n재발 방지에 관한 내용을 포함하고, 새롭게\n\n습득한 전략과 기술을 일상생활에 적용하기\n\n- - 환자는 컴퓨터 또는 노트북, 태블릿 또는\n스마트폰 등 어디에서나 과정을 완료할 수\n\n있고, 일주일에 한 번, 약 60분의 사용을 권장\n\n표 4.  국외 섭식장애 개선 디지털치료기기 허가 제품 및 관련 제품의 개발 동향(2023.  8.  기준)\n\n- - 13 -\n- 아.  디지털치료기기의 정의와 국내 가이드라인별 적용 기준\n1) 디지털치료기기 정의\n\n식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인\n\n(민원인 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방,\n\n관리, 치료하기 위해 환자에게 근거 기반의 치료적 개입을 제공\n\n디지털치료기기는 「의료기기법」 제2조에 따른 사용 목적에\n\n해당해야 하며, <그림 1>과 같이 소프트웨어 의료기기로써 범용\n\n하드웨어에 설치되고, 질병을 예방, 관리 또는 치료하기 위한\n\n목적으로 환자에게 적용되어야 한다.  또한, 치료 작용기전의\n\n과학적(임상적) 근거에 해당하는 자료가 있어야 한다.  여기서\n\n질병이란 국제질병분류코드(International Classification of Disease,\n\nICD)에 기반한 한국표준질병사인분류에 독립적으로 분류 가능한\n\n디지털 섭식장애 인지행동치료(CBT)는 섭식장애 인지행동치료\n\n기반의 콘텐츠를 범용 스마트폰이나 태블릿PC에 설치되어 제공\n\n하므로 소프트웨어 의료기기에 해당한다. ",
        "original_sentence": "기준)\n\n- - 13 -\n- 아. "
      }
    },
    {
      "chunk_id": "chunk_452",
      "text": "디지털치료기기의 정의와 국내 가이드라인별 적용 기준\n1) 디지털치료기기 정의\n\n식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인\n\n(민원인 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방,\n\n관리, 치료하기 위해 환자에게 근거 기반의 치료적 개입을 제공\n\n디지털치료기기는 「의료기기법」 제2조에 따른 사용 목적에\n\n해당해야 하며, <그림 1>과 같이 소프트웨어 의료기기로써 범용\n\n하드웨어에 설치되고, 질병을 예방, 관리 또는 치료하기 위한\n\n목적으로 환자에게 적용되어야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 451,
        "window_size": 3,
        "char_count": 273,
        "word_count": 56,
        "page_number": 19,
        "window_text": "국외 섭식장애 개선 디지털치료기기 허가 제품 및 관련 제품의 개발 동향(2023.  8.  기준)\n\n- - 13 -\n- 아.  디지털치료기기의 정의와 국내 가이드라인별 적용 기준\n1) 디지털치료기기 정의\n\n식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인\n\n(민원인 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방,\n\n관리, 치료하기 위해 환자에게 근거 기반의 치료적 개입을 제공\n\n디지털치료기기는 「의료기기법」 제2조에 따른 사용 목적에\n\n해당해야 하며, <그림 1>과 같이 소프트웨어 의료기기로써 범용\n\n하드웨어에 설치되고, 질병을 예방, 관리 또는 치료하기 위한\n\n목적으로 환자에게 적용되어야 한다.  또한, 치료 작용기전의\n\n과학적(임상적) 근거에 해당하는 자료가 있어야 한다.  여기서\n\n질병이란 국제질병분류코드(International Classification of Disease,\n\nICD)에 기반한 한국표준질병사인분류에 독립적으로 분류 가능한\n\n디지털 섭식장애 인지행동치료(CBT)는 섭식장애 인지행동치료\n\n기반의 콘텐츠를 범용 스마트폰이나 태블릿PC에 설치되어 제공\n\n하므로 소프트웨어 의료기기에 해당한다.  또한 한국표준질병\n\n사인분류에 따라 섭식장애를 의사에게 진단받은 환자들을\n\n- - 14 -\n미국, 영국 등 많은 학회와 연구소에서 개발한 임상진료지침\n\n등에 따르면, 섭식장애의 비약물 치료를 우선 시행하며, 그중\n\n에서도 인지행동치료(CBT)를 시행하기를 권고하고 있다. ",
        "original_sentence": "디지털치료기기의 정의와 국내 가이드라인별 적용 기준\n1) 디지털치료기기 정의\n\n식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인\n\n(민원인 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방,\n\n관리, 치료하기 위해 환자에게 근거 기반의 치료적 개입을 제공\n\n디지털치료기기는 「의료기기법」 제2조에 따른 사용 목적에\n\n해당해야 하며, <그림 1>과 같이 소프트웨어 의료기기로써 범용\n\n하드웨어에 설치되고, 질병을 예방, 관리 또는 치료하기 위한\n\n목적으로 환자에게 적용되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_453",
      "text": "또한, 치료 작용기전의\n\n과학적(임상적) 근거에 해당하는 자료가 있어야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 452,
        "window_size": 3,
        "char_count": 44,
        "word_count": 9,
        "page_number": 15,
        "window_text": "8.  기준)\n\n- - 13 -\n- 아.  디지털치료기기의 정의와 국내 가이드라인별 적용 기준\n1) 디지털치료기기 정의\n\n식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인\n\n(민원인 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방,\n\n관리, 치료하기 위해 환자에게 근거 기반의 치료적 개입을 제공\n\n디지털치료기기는 「의료기기법」 제2조에 따른 사용 목적에\n\n해당해야 하며, <그림 1>과 같이 소프트웨어 의료기기로써 범용\n\n하드웨어에 설치되고, 질병을 예방, 관리 또는 치료하기 위한\n\n목적으로 환자에게 적용되어야 한다.  또한, 치료 작용기전의\n\n과학적(임상적) 근거에 해당하는 자료가 있어야 한다.  여기서\n\n질병이란 국제질병분류코드(International Classification of Disease,\n\nICD)에 기반한 한국표준질병사인분류에 독립적으로 분류 가능한\n\n디지털 섭식장애 인지행동치료(CBT)는 섭식장애 인지행동치료\n\n기반의 콘텐츠를 범용 스마트폰이나 태블릿PC에 설치되어 제공\n\n하므로 소프트웨어 의료기기에 해당한다.  또한 한국표준질병\n\n사인분류에 따라 섭식장애를 의사에게 진단받은 환자들을\n\n- - 14 -\n미국, 영국 등 많은 학회와 연구소에서 개발한 임상진료지침\n\n등에 따르면, 섭식장애의 비약물 치료를 우선 시행하며, 그중\n\n에서도 인지행동치료(CBT)를 시행하기를 권고하고 있다.  또한\n\n디지털 기반 섭식장애 관련 선행연구에서 임상시험을 통해\n\n디지털 섭식장애 인지행동치료의 효과성을 입증된 바 있다\n\n위와 같이 섭식장애 디지털치료기기는 디지털치료기기 대상\n\n여부 판단기준 및 절차를 충족하므로 디지털치료기기 대상\n\n- - 15 -\n나) 의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)\n\n디지털치료기기는 식품의약품안전처‘의료기기의 사이버보안\n\n허가·심사 가이드라인(민원인 안내서)’에 근거하여 보안성\n\n영역은 가용성(Availability), 기밀성(Confidentiality), 무결성\n\n가용성은 데이터가 승인된 사용자에게 즉시 제공되어야 하며,\n\n필요한 때에 필요한 곳에서 필요한 형태로 존재되어야 함을\n\n의미한다. ",
        "original_sentence": "또한, 치료 작용기전의\n\n과학적(임상적) 근거에 해당하는 자료가 있어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_454",
      "text": "여기서\n\n질병이란 국제질병분류코드(International Classification of Disease,\n\nICD)에 기반한 한국표준질병사인분류에 독립적으로 분류 가능한\n\n디지털 섭식장애 인지행동치료(CBT)는 섭식장애 인지행동치료\n\n기반의 콘텐츠를 범용 스마트폰이나 태블릿PC에 설치되어 제공\n\n하므로 소프트웨어 의료기기에 해당한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 453,
        "window_size": 3,
        "char_count": 189,
        "word_count": 28,
        "page_number": 62,
        "window_text": "기준)\n\n- - 13 -\n- 아.  디지털치료기기의 정의와 국내 가이드라인별 적용 기준\n1) 디지털치료기기 정의\n\n식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인\n\n(민원인 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방,\n\n관리, 치료하기 위해 환자에게 근거 기반의 치료적 개입을 제공\n\n디지털치료기기는 「의료기기법」 제2조에 따른 사용 목적에\n\n해당해야 하며, <그림 1>과 같이 소프트웨어 의료기기로써 범용\n\n하드웨어에 설치되고, 질병을 예방, 관리 또는 치료하기 위한\n\n목적으로 환자에게 적용되어야 한다.  또한, 치료 작용기전의\n\n과학적(임상적) 근거에 해당하는 자료가 있어야 한다.  여기서\n\n질병이란 국제질병분류코드(International Classification of Disease,\n\nICD)에 기반한 한국표준질병사인분류에 독립적으로 분류 가능한\n\n디지털 섭식장애 인지행동치료(CBT)는 섭식장애 인지행동치료\n\n기반의 콘텐츠를 범용 스마트폰이나 태블릿PC에 설치되어 제공\n\n하므로 소프트웨어 의료기기에 해당한다.  또한 한국표준질병\n\n사인분류에 따라 섭식장애를 의사에게 진단받은 환자들을\n\n- - 14 -\n미국, 영국 등 많은 학회와 연구소에서 개발한 임상진료지침\n\n등에 따르면, 섭식장애의 비약물 치료를 우선 시행하며, 그중\n\n에서도 인지행동치료(CBT)를 시행하기를 권고하고 있다.  또한\n\n디지털 기반 섭식장애 관련 선행연구에서 임상시험을 통해\n\n디지털 섭식장애 인지행동치료의 효과성을 입증된 바 있다\n\n위와 같이 섭식장애 디지털치료기기는 디지털치료기기 대상\n\n여부 판단기준 및 절차를 충족하므로 디지털치료기기 대상\n\n- - 15 -\n나) 의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)\n\n디지털치료기기는 식품의약품안전처‘의료기기의 사이버보안\n\n허가·심사 가이드라인(민원인 안내서)’에 근거하여 보안성\n\n영역은 가용성(Availability), 기밀성(Confidentiality), 무결성\n\n가용성은 데이터가 승인된 사용자에게 즉시 제공되어야 하며,\n\n필요한 때에 필요한 곳에서 필요한 형태로 존재되어야 함을\n\n의미한다.  기밀성은 데이터가 허가되지 않은 사람에게 공개\n\n되거나, 허가되지 않은 용도로 사용되지 않아야 함을 의미하며,\n\n무결성은 데이터가 허가되지 않은 방법으로 변환되거나 파괴\n\n되지 않아야 함을 의미한다. ",
        "original_sentence": "여기서\n\n질병이란 국제질병분류코드(International Classification of Disease,\n\nICD)에 기반한 한국표준질병사인분류에 독립적으로 분류 가능한\n\n디지털 섭식장애 인지행동치료(CBT)는 섭식장애 인지행동치료\n\n기반의 콘텐츠를 범용 스마트폰이나 태블릿PC에 설치되어 제공\n\n하므로 소프트웨어 의료기기에 해당한다. "
      }
    },
    {
      "chunk_id": "chunk_455",
      "text": "또한 한국표준질병\n\n사인분류에 따라 섭식장애를 의사에게 진단받은 환자들을\n\n- - 14 -\n미국, 영국 등 많은 학회와 연구소에서 개발한 임상진료지침\n\n등에 따르면, 섭식장애의 비약물 치료를 우선 시행하며, 그중\n\n에서도 인지행동치료(CBT)를 시행하기를 권고하고 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 454,
        "window_size": 3,
        "char_count": 152,
        "word_count": 33,
        "page_number": 15,
        "window_text": "디지털치료기기의 정의와 국내 가이드라인별 적용 기준\n1) 디지털치료기기 정의\n\n식품의약품안전처 ‘디지털치료기기 허가·심사 가이드라인\n\n(민원인 안내서)’ 기준을 준용하여 의학적 장애나 질병을 예방,\n\n관리, 치료하기 위해 환자에게 근거 기반의 치료적 개입을 제공\n\n디지털치료기기는 「의료기기법」 제2조에 따른 사용 목적에\n\n해당해야 하며, <그림 1>과 같이 소프트웨어 의료기기로써 범용\n\n하드웨어에 설치되고, 질병을 예방, 관리 또는 치료하기 위한\n\n목적으로 환자에게 적용되어야 한다.  또한, 치료 작용기전의\n\n과학적(임상적) 근거에 해당하는 자료가 있어야 한다.  여기서\n\n질병이란 국제질병분류코드(International Classification of Disease,\n\nICD)에 기반한 한국표준질병사인분류에 독립적으로 분류 가능한\n\n디지털 섭식장애 인지행동치료(CBT)는 섭식장애 인지행동치료\n\n기반의 콘텐츠를 범용 스마트폰이나 태블릿PC에 설치되어 제공\n\n하므로 소프트웨어 의료기기에 해당한다.  또한 한국표준질병\n\n사인분류에 따라 섭식장애를 의사에게 진단받은 환자들을\n\n- - 14 -\n미국, 영국 등 많은 학회와 연구소에서 개발한 임상진료지침\n\n등에 따르면, 섭식장애의 비약물 치료를 우선 시행하며, 그중\n\n에서도 인지행동치료(CBT)를 시행하기를 권고하고 있다.  또한\n\n디지털 기반 섭식장애 관련 선행연구에서 임상시험을 통해\n\n디지털 섭식장애 인지행동치료의 효과성을 입증된 바 있다\n\n위와 같이 섭식장애 디지털치료기기는 디지털치료기기 대상\n\n여부 판단기준 및 절차를 충족하므로 디지털치료기기 대상\n\n- - 15 -\n나) 의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)\n\n디지털치료기기는 식품의약품안전처‘의료기기의 사이버보안\n\n허가·심사 가이드라인(민원인 안내서)’에 근거하여 보안성\n\n영역은 가용성(Availability), 기밀성(Confidentiality), 무결성\n\n가용성은 데이터가 승인된 사용자에게 즉시 제공되어야 하며,\n\n필요한 때에 필요한 곳에서 필요한 형태로 존재되어야 함을\n\n의미한다.  기밀성은 데이터가 허가되지 않은 사람에게 공개\n\n되거나, 허가되지 않은 용도로 사용되지 않아야 함을 의미하며,\n\n무결성은 데이터가 허가되지 않은 방법으로 변환되거나 파괴\n\n되지 않아야 함을 의미한다.  유·무선 통신이 가능하거나 통신\n\n경로가 존재하는 의료기기는 정보의 위변조, 오작동 또는 의료\n\n기기에 승인되지 않은 접근 등을 방지하기 위한 대책을 마련\n\n사이버보안 침해로 인한 위해도는 의료기기의 잠재적 결함\n\n으로 인해 사용자에게 발생할 수 있는 위해(harm)의 정도, 의료\n\n기기의 통신방법 및 사용환경을 종합적으로 고려하여 ‘상’,\n\n‘중’, ‘하’로 결정되고, 그에 따른 사이버보안 요구사항을\n\n적용한다. ",
        "original_sentence": "또한 한국표준질병\n\n사인분류에 따라 섭식장애를 의사에게 진단받은 환자들을\n\n- - 14 -\n미국, 영국 등 많은 학회와 연구소에서 개발한 임상진료지침\n\n등에 따르면, 섭식장애의 비약물 치료를 우선 시행하며, 그중\n\n에서도 인지행동치료(CBT)를 시행하기를 권고하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_456",
      "text": "또한\n\n디지털 기반 섭식장애 관련 선행연구에서 임상시험을 통해\n\n디지털 섭식장애 인지행동치료의 효과성을 입증된 바 있다\n\n위와 같이 섭식장애 디지털치료기기는 디지털치료기기 대상\n\n여부 판단기준 및 절차를 충족하므로 디지털치료기기 대상\n\n- - 15 -\n나) 의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)\n\n디지털치료기기는 식품의약품안전처‘의료기기의 사이버보안\n\n허가·심사 가이드라인(민원인 안내서)’에 근거하여 보안성\n\n영역은 가용성(Availability), 기밀성(Confidentiality), 무결성\n\n가용성은 데이터가 승인된 사용자에게 즉시 제공되어야 하며,\n\n필요한 때에 필요한 곳에서 필요한 형태로 존재되어야 함을\n\n의미한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 455,
        "window_size": 3,
        "char_count": 365,
        "word_count": 66,
        "page_number": 21,
        "window_text": "또한, 치료 작용기전의\n\n과학적(임상적) 근거에 해당하는 자료가 있어야 한다.  여기서\n\n질병이란 국제질병분류코드(International Classification of Disease,\n\nICD)에 기반한 한국표준질병사인분류에 독립적으로 분류 가능한\n\n디지털 섭식장애 인지행동치료(CBT)는 섭식장애 인지행동치료\n\n기반의 콘텐츠를 범용 스마트폰이나 태블릿PC에 설치되어 제공\n\n하므로 소프트웨어 의료기기에 해당한다.  또한 한국표준질병\n\n사인분류에 따라 섭식장애를 의사에게 진단받은 환자들을\n\n- - 14 -\n미국, 영국 등 많은 학회와 연구소에서 개발한 임상진료지침\n\n등에 따르면, 섭식장애의 비약물 치료를 우선 시행하며, 그중\n\n에서도 인지행동치료(CBT)를 시행하기를 권고하고 있다.  또한\n\n디지털 기반 섭식장애 관련 선행연구에서 임상시험을 통해\n\n디지털 섭식장애 인지행동치료의 효과성을 입증된 바 있다\n\n위와 같이 섭식장애 디지털치료기기는 디지털치료기기 대상\n\n여부 판단기준 및 절차를 충족하므로 디지털치료기기 대상\n\n- - 15 -\n나) 의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)\n\n디지털치료기기는 식품의약품안전처‘의료기기의 사이버보안\n\n허가·심사 가이드라인(민원인 안내서)’에 근거하여 보안성\n\n영역은 가용성(Availability), 기밀성(Confidentiality), 무결성\n\n가용성은 데이터가 승인된 사용자에게 즉시 제공되어야 하며,\n\n필요한 때에 필요한 곳에서 필요한 형태로 존재되어야 함을\n\n의미한다.  기밀성은 데이터가 허가되지 않은 사람에게 공개\n\n되거나, 허가되지 않은 용도로 사용되지 않아야 함을 의미하며,\n\n무결성은 데이터가 허가되지 않은 방법으로 변환되거나 파괴\n\n되지 않아야 함을 의미한다.  유·무선 통신이 가능하거나 통신\n\n경로가 존재하는 의료기기는 정보의 위변조, 오작동 또는 의료\n\n기기에 승인되지 않은 접근 등을 방지하기 위한 대책을 마련\n\n사이버보안 침해로 인한 위해도는 의료기기의 잠재적 결함\n\n으로 인해 사용자에게 발생할 수 있는 위해(harm)의 정도, 의료\n\n기기의 통신방법 및 사용환경을 종합적으로 고려하여 ‘상’,\n\n‘중’, ‘하’로 결정되고, 그에 따른 사이버보안 요구사항을\n\n적용한다.  일반적으로 디지털 치료기기는 ‘치료’를 목적으로\n\n하는 2등급 이상의 의료기기로 품목 분류되므로 사이버보안\n\n- - 16 -\n다) 의료기기의 소프트웨어 허가·심사 가이드라인(민원인 안내서)\n\n소프트웨어 의료기기도 일반 의료기기와 마찬가지로 제조 및\n\n품질관리체계의 기준과 위험관리 프로세스가 조화를 이루는\n\n식품의약품안전처‘의료기기 소프트웨어 허가·심사 가이드라인\n\n(민원인 안내서)’를 기준으로 디지털치료기기의 위험성 관리\n\n프로세스는 의료기기에서 발생하는 위험분석(risk analysis), 위험\n\n평가(risk evaluation), 위험통제(risk control), 잔여 위험 허용평가\n\n(evaluation of overall residual risk acceptability), 위험관리 보고서\n\n(risk management report), 생산 및 생산 후 정보(production\n\n의료기기 소프트웨어 안전성 등급은 고장 또는 잠재적 결함으로\n\n인해 환자나 사용자에게 미치는 위해의 영향에 따라 분류한다.\n\n",
        "original_sentence": "또한\n\n디지털 기반 섭식장애 관련 선행연구에서 임상시험을 통해\n\n디지털 섭식장애 인지행동치료의 효과성을 입증된 바 있다\n\n위와 같이 섭식장애 디지털치료기기는 디지털치료기기 대상\n\n여부 판단기준 및 절차를 충족하므로 디지털치료기기 대상\n\n- - 15 -\n나) 의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)\n\n디지털치료기기는 식품의약품안전처‘의료기기의 사이버보안\n\n허가·심사 가이드라인(민원인 안내서)’에 근거하여 보안성\n\n영역은 가용성(Availability), 기밀성(Confidentiality), 무결성\n\n가용성은 데이터가 승인된 사용자에게 즉시 제공되어야 하며,\n\n필요한 때에 필요한 곳에서 필요한 형태로 존재되어야 함을\n\n의미한다. "
      }
    },
    {
      "chunk_id": "chunk_457",
      "text": "기밀성은 데이터가 허가되지 않은 사람에게 공개\n\n되거나, 허가되지 않은 용도로 사용되지 않아야 함을 의미하며,\n\n무결성은 데이터가 허가되지 않은 방법으로 변환되거나 파괴\n\n되지 않아야 함을 의미한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 456,
        "window_size": 3,
        "char_count": 112,
        "word_count": 25,
        "page_number": 34,
        "window_text": "여기서\n\n질병이란 국제질병분류코드(International Classification of Disease,\n\nICD)에 기반한 한국표준질병사인분류에 독립적으로 분류 가능한\n\n디지털 섭식장애 인지행동치료(CBT)는 섭식장애 인지행동치료\n\n기반의 콘텐츠를 범용 스마트폰이나 태블릿PC에 설치되어 제공\n\n하므로 소프트웨어 의료기기에 해당한다.  또한 한국표준질병\n\n사인분류에 따라 섭식장애를 의사에게 진단받은 환자들을\n\n- - 14 -\n미국, 영국 등 많은 학회와 연구소에서 개발한 임상진료지침\n\n등에 따르면, 섭식장애의 비약물 치료를 우선 시행하며, 그중\n\n에서도 인지행동치료(CBT)를 시행하기를 권고하고 있다.  또한\n\n디지털 기반 섭식장애 관련 선행연구에서 임상시험을 통해\n\n디지털 섭식장애 인지행동치료의 효과성을 입증된 바 있다\n\n위와 같이 섭식장애 디지털치료기기는 디지털치료기기 대상\n\n여부 판단기준 및 절차를 충족하므로 디지털치료기기 대상\n\n- - 15 -\n나) 의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)\n\n디지털치료기기는 식품의약품안전처‘의료기기의 사이버보안\n\n허가·심사 가이드라인(민원인 안내서)’에 근거하여 보안성\n\n영역은 가용성(Availability), 기밀성(Confidentiality), 무결성\n\n가용성은 데이터가 승인된 사용자에게 즉시 제공되어야 하며,\n\n필요한 때에 필요한 곳에서 필요한 형태로 존재되어야 함을\n\n의미한다.  기밀성은 데이터가 허가되지 않은 사람에게 공개\n\n되거나, 허가되지 않은 용도로 사용되지 않아야 함을 의미하며,\n\n무결성은 데이터가 허가되지 않은 방법으로 변환되거나 파괴\n\n되지 않아야 함을 의미한다.  유·무선 통신이 가능하거나 통신\n\n경로가 존재하는 의료기기는 정보의 위변조, 오작동 또는 의료\n\n기기에 승인되지 않은 접근 등을 방지하기 위한 대책을 마련\n\n사이버보안 침해로 인한 위해도는 의료기기의 잠재적 결함\n\n으로 인해 사용자에게 발생할 수 있는 위해(harm)의 정도, 의료\n\n기기의 통신방법 및 사용환경을 종합적으로 고려하여 ‘상’,\n\n‘중’, ‘하’로 결정되고, 그에 따른 사이버보안 요구사항을\n\n적용한다.  일반적으로 디지털 치료기기는 ‘치료’를 목적으로\n\n하는 2등급 이상의 의료기기로 품목 분류되므로 사이버보안\n\n- - 16 -\n다) 의료기기의 소프트웨어 허가·심사 가이드라인(민원인 안내서)\n\n소프트웨어 의료기기도 일반 의료기기와 마찬가지로 제조 및\n\n품질관리체계의 기준과 위험관리 프로세스가 조화를 이루는\n\n식품의약품안전처‘의료기기 소프트웨어 허가·심사 가이드라인\n\n(민원인 안내서)’를 기준으로 디지털치료기기의 위험성 관리\n\n프로세스는 의료기기에서 발생하는 위험분석(risk analysis), 위험\n\n평가(risk evaluation), 위험통제(risk control), 잔여 위험 허용평가\n\n(evaluation of overall residual risk acceptability), 위험관리 보고서\n\n(risk management report), 생산 및 생산 후 정보(production\n\n의료기기 소프트웨어 안전성 등급은 고장 또는 잠재적 결함으로\n\n인해 환자나 사용자에게 미치는 위해의 영향에 따라 분류한다.\n\n 의료기기 소프트웨어 사용으로 건강상의 상해 또는 손상이 없는\n\n- - 17 -\n경우 A등급, 심각하지 않은 상해의 가능성 있으면 B등급, 심각한\n\n상해 또는 사망의 가능성이 있는 경우 C등급으로 구분한다.\n\n",
        "original_sentence": "기밀성은 데이터가 허가되지 않은 사람에게 공개\n\n되거나, 허가되지 않은 용도로 사용되지 않아야 함을 의미하며,\n\n무결성은 데이터가 허가되지 않은 방법으로 변환되거나 파괴\n\n되지 않아야 함을 의미한다. "
      }
    },
    {
      "chunk_id": "chunk_458",
      "text": "유·무선 통신이 가능하거나 통신\n\n경로가 존재하는 의료기기는 정보의 위변조, 오작동 또는 의료\n\n기기에 승인되지 않은 접근 등을 방지하기 위한 대책을 마련\n\n사이버보안 침해로 인한 위해도는 의료기기의 잠재적 결함\n\n으로 인해 사용자에게 발생할 수 있는 위해(harm)의 정도, 의료\n\n기기의 통신방법 및 사용환경을 종합적으로 고려하여 ‘상’,\n\n‘중’, ‘하’로 결정되고, 그에 따른 사이버보안 요구사항을\n\n적용한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 457,
        "window_size": 3,
        "char_count": 234,
        "word_count": 52,
        "page_number": 27,
        "window_text": "또한 한국표준질병\n\n사인분류에 따라 섭식장애를 의사에게 진단받은 환자들을\n\n- - 14 -\n미국, 영국 등 많은 학회와 연구소에서 개발한 임상진료지침\n\n등에 따르면, 섭식장애의 비약물 치료를 우선 시행하며, 그중\n\n에서도 인지행동치료(CBT)를 시행하기를 권고하고 있다.  또한\n\n디지털 기반 섭식장애 관련 선행연구에서 임상시험을 통해\n\n디지털 섭식장애 인지행동치료의 효과성을 입증된 바 있다\n\n위와 같이 섭식장애 디지털치료기기는 디지털치료기기 대상\n\n여부 판단기준 및 절차를 충족하므로 디지털치료기기 대상\n\n- - 15 -\n나) 의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)\n\n디지털치료기기는 식품의약품안전처‘의료기기의 사이버보안\n\n허가·심사 가이드라인(민원인 안내서)’에 근거하여 보안성\n\n영역은 가용성(Availability), 기밀성(Confidentiality), 무결성\n\n가용성은 데이터가 승인된 사용자에게 즉시 제공되어야 하며,\n\n필요한 때에 필요한 곳에서 필요한 형태로 존재되어야 함을\n\n의미한다.  기밀성은 데이터가 허가되지 않은 사람에게 공개\n\n되거나, 허가되지 않은 용도로 사용되지 않아야 함을 의미하며,\n\n무결성은 데이터가 허가되지 않은 방법으로 변환되거나 파괴\n\n되지 않아야 함을 의미한다.  유·무선 통신이 가능하거나 통신\n\n경로가 존재하는 의료기기는 정보의 위변조, 오작동 또는 의료\n\n기기에 승인되지 않은 접근 등을 방지하기 위한 대책을 마련\n\n사이버보안 침해로 인한 위해도는 의료기기의 잠재적 결함\n\n으로 인해 사용자에게 발생할 수 있는 위해(harm)의 정도, 의료\n\n기기의 통신방법 및 사용환경을 종합적으로 고려하여 ‘상’,\n\n‘중’, ‘하’로 결정되고, 그에 따른 사이버보안 요구사항을\n\n적용한다.  일반적으로 디지털 치료기기는 ‘치료’를 목적으로\n\n하는 2등급 이상의 의료기기로 품목 분류되므로 사이버보안\n\n- - 16 -\n다) 의료기기의 소프트웨어 허가·심사 가이드라인(민원인 안내서)\n\n소프트웨어 의료기기도 일반 의료기기와 마찬가지로 제조 및\n\n품질관리체계의 기준과 위험관리 프로세스가 조화를 이루는\n\n식품의약품안전처‘의료기기 소프트웨어 허가·심사 가이드라인\n\n(민원인 안내서)’를 기준으로 디지털치료기기의 위험성 관리\n\n프로세스는 의료기기에서 발생하는 위험분석(risk analysis), 위험\n\n평가(risk evaluation), 위험통제(risk control), 잔여 위험 허용평가\n\n(evaluation of overall residual risk acceptability), 위험관리 보고서\n\n(risk management report), 생산 및 생산 후 정보(production\n\n의료기기 소프트웨어 안전성 등급은 고장 또는 잠재적 결함으로\n\n인해 환자나 사용자에게 미치는 위해의 영향에 따라 분류한다.\n\n 의료기기 소프트웨어 사용으로 건강상의 상해 또는 손상이 없는\n\n- - 17 -\n경우 A등급, 심각하지 않은 상해의 가능성 있으면 B등급, 심각한\n\n상해 또는 사망의 가능성이 있는 경우 C등급으로 구분한다.\n\n 의료기기 소프트웨어는 안전성 등급이 결정될 때까지 초기에는\n\nC등급 요구사항이 적용되며, 소프트웨어 시스템의 실패가 위험한\n\n라) 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인(민원인 안내서)\n\n디지털치료기기는 실사용증거(Real World Evidence, RWE)를\n\n사용하여 의료기기의 사전 및 사후와 관련된 안전성 및 유효성\n\n입증 근거로 제시할 수 있으며, 이에 따른 기간 및 비용을\n\n실사용증거 수집은 데이터의 타당성 및 신뢰성 확보를 위해\n\n품질, 수집 및 분석 방법, 수집한 인력의 역량을 입증할 수 있는\n\n1) 실사용데이터(RWD)는 기존의 중재적 방법에 의한 임상시험으로부터 수집되지 않은 다양한 유형의 의료데이터에 대한 포괄적인\n\n용어이다. ",
        "original_sentence": "유·무선 통신이 가능하거나 통신\n\n경로가 존재하는 의료기기는 정보의 위변조, 오작동 또는 의료\n\n기기에 승인되지 않은 접근 등을 방지하기 위한 대책을 마련\n\n사이버보안 침해로 인한 위해도는 의료기기의 잠재적 결함\n\n으로 인해 사용자에게 발생할 수 있는 위해(harm)의 정도, 의료\n\n기기의 통신방법 및 사용환경을 종합적으로 고려하여 ‘상’,\n\n‘중’, ‘하’로 결정되고, 그에 따른 사이버보안 요구사항을\n\n적용한다. "
      }
    },
    {
      "chunk_id": "chunk_459",
      "text": "일반적으로 디지털 치료기기는 ‘치료’를 목적으로\n\n하는 2등급 이상의 의료기기로 품목 분류되므로 사이버보안\n\n- - 16 -\n다) 의료기기의 소프트웨어 허가·심사 가이드라인(민원인 안내서)\n\n소프트웨어 의료기기도 일반 의료기기와 마찬가지로 제조 및\n\n품질관리체계의 기준과 위험관리 프로세스가 조화를 이루는\n\n식품의약품안전처‘의료기기 소프트웨어 허가·심사 가이드라인\n\n(민원인 안내서)’를 기준으로 디지털치료기기의 위험성 관리\n\n프로세스는 의료기기에서 발생하는 위험분석(risk analysis), 위험\n\n평가(risk evaluation), 위험통제(risk control), 잔여 위험 허용평가\n\n(evaluation of overall residual risk acceptability), 위험관리 보고서\n\n(risk management report), 생산 및 생산 후 정보(production\n\n의료기기 소프트웨어 안전성 등급은 고장 또는 잠재적 결함으로\n\n인해 환자나 사용자에게 미치는 위해의 영향에 따라 분류한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 458,
        "window_size": 3,
        "char_count": 519,
        "word_count": 90,
        "page_number": 7,
        "window_text": "또한\n\n디지털 기반 섭식장애 관련 선행연구에서 임상시험을 통해\n\n디지털 섭식장애 인지행동치료의 효과성을 입증된 바 있다\n\n위와 같이 섭식장애 디지털치료기기는 디지털치료기기 대상\n\n여부 판단기준 및 절차를 충족하므로 디지털치료기기 대상\n\n- - 15 -\n나) 의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)\n\n디지털치료기기는 식품의약품안전처‘의료기기의 사이버보안\n\n허가·심사 가이드라인(민원인 안내서)’에 근거하여 보안성\n\n영역은 가용성(Availability), 기밀성(Confidentiality), 무결성\n\n가용성은 데이터가 승인된 사용자에게 즉시 제공되어야 하며,\n\n필요한 때에 필요한 곳에서 필요한 형태로 존재되어야 함을\n\n의미한다.  기밀성은 데이터가 허가되지 않은 사람에게 공개\n\n되거나, 허가되지 않은 용도로 사용되지 않아야 함을 의미하며,\n\n무결성은 데이터가 허가되지 않은 방법으로 변환되거나 파괴\n\n되지 않아야 함을 의미한다.  유·무선 통신이 가능하거나 통신\n\n경로가 존재하는 의료기기는 정보의 위변조, 오작동 또는 의료\n\n기기에 승인되지 않은 접근 등을 방지하기 위한 대책을 마련\n\n사이버보안 침해로 인한 위해도는 의료기기의 잠재적 결함\n\n으로 인해 사용자에게 발생할 수 있는 위해(harm)의 정도, 의료\n\n기기의 통신방법 및 사용환경을 종합적으로 고려하여 ‘상’,\n\n‘중’, ‘하’로 결정되고, 그에 따른 사이버보안 요구사항을\n\n적용한다.  일반적으로 디지털 치료기기는 ‘치료’를 목적으로\n\n하는 2등급 이상의 의료기기로 품목 분류되므로 사이버보안\n\n- - 16 -\n다) 의료기기의 소프트웨어 허가·심사 가이드라인(민원인 안내서)\n\n소프트웨어 의료기기도 일반 의료기기와 마찬가지로 제조 및\n\n품질관리체계의 기준과 위험관리 프로세스가 조화를 이루는\n\n식품의약품안전처‘의료기기 소프트웨어 허가·심사 가이드라인\n\n(민원인 안내서)’를 기준으로 디지털치료기기의 위험성 관리\n\n프로세스는 의료기기에서 발생하는 위험분석(risk analysis), 위험\n\n평가(risk evaluation), 위험통제(risk control), 잔여 위험 허용평가\n\n(evaluation of overall residual risk acceptability), 위험관리 보고서\n\n(risk management report), 생산 및 생산 후 정보(production\n\n의료기기 소프트웨어 안전성 등급은 고장 또는 잠재적 결함으로\n\n인해 환자나 사용자에게 미치는 위해의 영향에 따라 분류한다.\n\n 의료기기 소프트웨어 사용으로 건강상의 상해 또는 손상이 없는\n\n- - 17 -\n경우 A등급, 심각하지 않은 상해의 가능성 있으면 B등급, 심각한\n\n상해 또는 사망의 가능성이 있는 경우 C등급으로 구분한다.\n\n 의료기기 소프트웨어는 안전성 등급이 결정될 때까지 초기에는\n\nC등급 요구사항이 적용되며, 소프트웨어 시스템의 실패가 위험한\n\n라) 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인(민원인 안내서)\n\n디지털치료기기는 실사용증거(Real World Evidence, RWE)를\n\n사용하여 의료기기의 사전 및 사후와 관련된 안전성 및 유효성\n\n입증 근거로 제시할 수 있으며, 이에 따른 기간 및 비용을\n\n실사용증거 수집은 데이터의 타당성 및 신뢰성 확보를 위해\n\n품질, 수집 및 분석 방법, 수집한 인력의 역량을 입증할 수 있는\n\n1) 실사용데이터(RWD)는 기존의 중재적 방법에 의한 임상시험으로부터 수집되지 않은 다양한 유형의 의료데이터에 대한 포괄적인\n\n용어이다.  실사용증거(RWE)는 RWD를 분석하여 파생된 증거로써, RWD 분석을 통해 얻은 의료기기의 사용 결과나 잠재적 이익\n\n또는 위험성에 관한 임상적 근거를 말한다. ",
        "original_sentence": "일반적으로 디지털 치료기기는 ‘치료’를 목적으로\n\n하는 2등급 이상의 의료기기로 품목 분류되므로 사이버보안\n\n- - 16 -\n다) 의료기기의 소프트웨어 허가·심사 가이드라인(민원인 안내서)\n\n소프트웨어 의료기기도 일반 의료기기와 마찬가지로 제조 및\n\n품질관리체계의 기준과 위험관리 프로세스가 조화를 이루는\n\n식품의약품안전처‘의료기기 소프트웨어 허가·심사 가이드라인\n\n(민원인 안내서)’를 기준으로 디지털치료기기의 위험성 관리\n\n프로세스는 의료기기에서 발생하는 위험분석(risk analysis), 위험\n\n평가(risk evaluation), 위험통제(risk control), 잔여 위험 허용평가\n\n(evaluation of overall residual risk acceptability), 위험관리 보고서\n\n(risk management report), 생산 및 생산 후 정보(production\n\n의료기기 소프트웨어 안전성 등급은 고장 또는 잠재적 결함으로\n\n인해 환자나 사용자에게 미치는 위해의 영향에 따라 분류한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_460",
      "text": "의료기기 소프트웨어 사용으로 건강상의 상해 또는 손상이 없는\n\n- - 17 -\n경우 A등급, 심각하지 않은 상해의 가능성 있으면 B등급, 심각한\n\n상해 또는 사망의 가능성이 있는 경우 C등급으로 구분한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 459,
        "window_size": 3,
        "char_count": 116,
        "word_count": 29,
        "page_number": 9,
        "window_text": "기밀성은 데이터가 허가되지 않은 사람에게 공개\n\n되거나, 허가되지 않은 용도로 사용되지 않아야 함을 의미하며,\n\n무결성은 데이터가 허가되지 않은 방법으로 변환되거나 파괴\n\n되지 않아야 함을 의미한다.  유·무선 통신이 가능하거나 통신\n\n경로가 존재하는 의료기기는 정보의 위변조, 오작동 또는 의료\n\n기기에 승인되지 않은 접근 등을 방지하기 위한 대책을 마련\n\n사이버보안 침해로 인한 위해도는 의료기기의 잠재적 결함\n\n으로 인해 사용자에게 발생할 수 있는 위해(harm)의 정도, 의료\n\n기기의 통신방법 및 사용환경을 종합적으로 고려하여 ‘상’,\n\n‘중’, ‘하’로 결정되고, 그에 따른 사이버보안 요구사항을\n\n적용한다.  일반적으로 디지털 치료기기는 ‘치료’를 목적으로\n\n하는 2등급 이상의 의료기기로 품목 분류되므로 사이버보안\n\n- - 16 -\n다) 의료기기의 소프트웨어 허가·심사 가이드라인(민원인 안내서)\n\n소프트웨어 의료기기도 일반 의료기기와 마찬가지로 제조 및\n\n품질관리체계의 기준과 위험관리 프로세스가 조화를 이루는\n\n식품의약품안전처‘의료기기 소프트웨어 허가·심사 가이드라인\n\n(민원인 안내서)’를 기준으로 디지털치료기기의 위험성 관리\n\n프로세스는 의료기기에서 발생하는 위험분석(risk analysis), 위험\n\n평가(risk evaluation), 위험통제(risk control), 잔여 위험 허용평가\n\n(evaluation of overall residual risk acceptability), 위험관리 보고서\n\n(risk management report), 생산 및 생산 후 정보(production\n\n의료기기 소프트웨어 안전성 등급은 고장 또는 잠재적 결함으로\n\n인해 환자나 사용자에게 미치는 위해의 영향에 따라 분류한다.\n\n 의료기기 소프트웨어 사용으로 건강상의 상해 또는 손상이 없는\n\n- - 17 -\n경우 A등급, 심각하지 않은 상해의 가능성 있으면 B등급, 심각한\n\n상해 또는 사망의 가능성이 있는 경우 C등급으로 구분한다.\n\n 의료기기 소프트웨어는 안전성 등급이 결정될 때까지 초기에는\n\nC등급 요구사항이 적용되며, 소프트웨어 시스템의 실패가 위험한\n\n라) 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인(민원인 안내서)\n\n디지털치료기기는 실사용증거(Real World Evidence, RWE)를\n\n사용하여 의료기기의 사전 및 사후와 관련된 안전성 및 유효성\n\n입증 근거로 제시할 수 있으며, 이에 따른 기간 및 비용을\n\n실사용증거 수집은 데이터의 타당성 및 신뢰성 확보를 위해\n\n품질, 수집 및 분석 방법, 수집한 인력의 역량을 입증할 수 있는\n\n1) 실사용데이터(RWD)는 기존의 중재적 방법에 의한 임상시험으로부터 수집되지 않은 다양한 유형의 의료데이터에 대한 포괄적인\n\n용어이다.  실사용증거(RWE)는 RWD를 분석하여 파생된 증거로써, RWD 분석을 통해 얻은 의료기기의 사용 결과나 잠재적 이익\n\n또는 위험성에 관한 임상적 근거를 말한다.  또한, 임상 문헌을 분석하여 파생된 새로운 증거도 포함한다.\n\n",
        "original_sentence": "의료기기 소프트웨어 사용으로 건강상의 상해 또는 손상이 없는\n\n- - 17 -\n경우 A등급, 심각하지 않은 상해의 가능성 있으면 B등급, 심각한\n\n상해 또는 사망의 가능성이 있는 경우 C등급으로 구분한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_461",
      "text": "의료기기 소프트웨어는 안전성 등급이 결정될 때까지 초기에는\n\nC등급 요구사항이 적용되며, 소프트웨어 시스템의 실패가 위험한\n\n라) 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인(민원인 안내서)\n\n디지털치료기기는 실사용증거(Real World Evidence, RWE)를\n\n사용하여 의료기기의 사전 및 사후와 관련된 안전성 및 유효성\n\n입증 근거로 제시할 수 있으며, 이에 따른 기간 및 비용을\n\n실사용증거 수집은 데이터의 타당성 및 신뢰성 확보를 위해\n\n품질, 수집 및 분석 방법, 수집한 인력의 역량을 입증할 수 있는\n\n1) 실사용데이터(RWD)는 기존의 중재적 방법에 의한 임상시험으로부터 수집되지 않은 다양한 유형의 의료데이터에 대한 포괄적인\n\n용어이다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 460,
        "window_size": 3,
        "char_count": 374,
        "word_count": 79,
        "page_number": 3,
        "window_text": "유·무선 통신이 가능하거나 통신\n\n경로가 존재하는 의료기기는 정보의 위변조, 오작동 또는 의료\n\n기기에 승인되지 않은 접근 등을 방지하기 위한 대책을 마련\n\n사이버보안 침해로 인한 위해도는 의료기기의 잠재적 결함\n\n으로 인해 사용자에게 발생할 수 있는 위해(harm)의 정도, 의료\n\n기기의 통신방법 및 사용환경을 종합적으로 고려하여 ‘상’,\n\n‘중’, ‘하’로 결정되고, 그에 따른 사이버보안 요구사항을\n\n적용한다.  일반적으로 디지털 치료기기는 ‘치료’를 목적으로\n\n하는 2등급 이상의 의료기기로 품목 분류되므로 사이버보안\n\n- - 16 -\n다) 의료기기의 소프트웨어 허가·심사 가이드라인(민원인 안내서)\n\n소프트웨어 의료기기도 일반 의료기기와 마찬가지로 제조 및\n\n품질관리체계의 기준과 위험관리 프로세스가 조화를 이루는\n\n식품의약품안전처‘의료기기 소프트웨어 허가·심사 가이드라인\n\n(민원인 안내서)’를 기준으로 디지털치료기기의 위험성 관리\n\n프로세스는 의료기기에서 발생하는 위험분석(risk analysis), 위험\n\n평가(risk evaluation), 위험통제(risk control), 잔여 위험 허용평가\n\n(evaluation of overall residual risk acceptability), 위험관리 보고서\n\n(risk management report), 생산 및 생산 후 정보(production\n\n의료기기 소프트웨어 안전성 등급은 고장 또는 잠재적 결함으로\n\n인해 환자나 사용자에게 미치는 위해의 영향에 따라 분류한다.\n\n 의료기기 소프트웨어 사용으로 건강상의 상해 또는 손상이 없는\n\n- - 17 -\n경우 A등급, 심각하지 않은 상해의 가능성 있으면 B등급, 심각한\n\n상해 또는 사망의 가능성이 있는 경우 C등급으로 구분한다.\n\n 의료기기 소프트웨어는 안전성 등급이 결정될 때까지 초기에는\n\nC등급 요구사항이 적용되며, 소프트웨어 시스템의 실패가 위험한\n\n라) 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인(민원인 안내서)\n\n디지털치료기기는 실사용증거(Real World Evidence, RWE)를\n\n사용하여 의료기기의 사전 및 사후와 관련된 안전성 및 유효성\n\n입증 근거로 제시할 수 있으며, 이에 따른 기간 및 비용을\n\n실사용증거 수집은 데이터의 타당성 및 신뢰성 확보를 위해\n\n품질, 수집 및 분석 방법, 수집한 인력의 역량을 입증할 수 있는\n\n1) 실사용데이터(RWD)는 기존의 중재적 방법에 의한 임상시험으로부터 수집되지 않은 다양한 유형의 의료데이터에 대한 포괄적인\n\n용어이다.  실사용증거(RWE)는 RWD를 분석하여 파생된 증거로써, RWD 분석을 통해 얻은 의료기기의 사용 결과나 잠재적 이익\n\n또는 위험성에 관한 임상적 근거를 말한다.  또한, 임상 문헌을 분석하여 파생된 새로운 증거도 포함한다.\n\n - - 18 -\n객관적인 사항이 반드시 포함되어야 한다. ",
        "original_sentence": "의료기기 소프트웨어는 안전성 등급이 결정될 때까지 초기에는\n\nC등급 요구사항이 적용되며, 소프트웨어 시스템의 실패가 위험한\n\n라) 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인(민원인 안내서)\n\n디지털치료기기는 실사용증거(Real World Evidence, RWE)를\n\n사용하여 의료기기의 사전 및 사후와 관련된 안전성 및 유효성\n\n입증 근거로 제시할 수 있으며, 이에 따른 기간 및 비용을\n\n실사용증거 수집은 데이터의 타당성 및 신뢰성 확보를 위해\n\n품질, 수집 및 분석 방법, 수집한 인력의 역량을 입증할 수 있는\n\n1) 실사용데이터(RWD)는 기존의 중재적 방법에 의한 임상시험으로부터 수집되지 않은 다양한 유형의 의료데이터에 대한 포괄적인\n\n용어이다. "
      }
    },
    {
      "chunk_id": "chunk_462",
      "text": "실사용증거(RWE)는 RWD를 분석하여 파생된 증거로써, RWD 분석을 통해 얻은 의료기기의 사용 결과나 잠재적 이익\n\n또는 위험성에 관한 임상적 근거를 말한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 461,
        "window_size": 3,
        "char_count": 91,
        "word_count": 20,
        "page_number": 24,
        "window_text": "일반적으로 디지털 치료기기는 ‘치료’를 목적으로\n\n하는 2등급 이상의 의료기기로 품목 분류되므로 사이버보안\n\n- - 16 -\n다) 의료기기의 소프트웨어 허가·심사 가이드라인(민원인 안내서)\n\n소프트웨어 의료기기도 일반 의료기기와 마찬가지로 제조 및\n\n품질관리체계의 기준과 위험관리 프로세스가 조화를 이루는\n\n식품의약품안전처‘의료기기 소프트웨어 허가·심사 가이드라인\n\n(민원인 안내서)’를 기준으로 디지털치료기기의 위험성 관리\n\n프로세스는 의료기기에서 발생하는 위험분석(risk analysis), 위험\n\n평가(risk evaluation), 위험통제(risk control), 잔여 위험 허용평가\n\n(evaluation of overall residual risk acceptability), 위험관리 보고서\n\n(risk management report), 생산 및 생산 후 정보(production\n\n의료기기 소프트웨어 안전성 등급은 고장 또는 잠재적 결함으로\n\n인해 환자나 사용자에게 미치는 위해의 영향에 따라 분류한다.\n\n 의료기기 소프트웨어 사용으로 건강상의 상해 또는 손상이 없는\n\n- - 17 -\n경우 A등급, 심각하지 않은 상해의 가능성 있으면 B등급, 심각한\n\n상해 또는 사망의 가능성이 있는 경우 C등급으로 구분한다.\n\n 의료기기 소프트웨어는 안전성 등급이 결정될 때까지 초기에는\n\nC등급 요구사항이 적용되며, 소프트웨어 시스템의 실패가 위험한\n\n라) 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인(민원인 안내서)\n\n디지털치료기기는 실사용증거(Real World Evidence, RWE)를\n\n사용하여 의료기기의 사전 및 사후와 관련된 안전성 및 유효성\n\n입증 근거로 제시할 수 있으며, 이에 따른 기간 및 비용을\n\n실사용증거 수집은 데이터의 타당성 및 신뢰성 확보를 위해\n\n품질, 수집 및 분석 방법, 수집한 인력의 역량을 입증할 수 있는\n\n1) 실사용데이터(RWD)는 기존의 중재적 방법에 의한 임상시험으로부터 수집되지 않은 다양한 유형의 의료데이터에 대한 포괄적인\n\n용어이다.  실사용증거(RWE)는 RWD를 분석하여 파생된 증거로써, RWD 분석을 통해 얻은 의료기기의 사용 결과나 잠재적 이익\n\n또는 위험성에 관한 임상적 근거를 말한다.  또한, 임상 문헌을 분석하여 파생된 새로운 증거도 포함한다.\n\n - - 18 -\n객관적인 사항이 반드시 포함되어야 한다.  또한 실사용증거는\n\n적용 목적, 수집 및 분석 정보, 분석 결과에 대한 사항을 제시\n\n해야 한다.\n\n",
        "original_sentence": "실사용증거(RWE)는 RWD를 분석하여 파생된 증거로써, RWD 분석을 통해 얻은 의료기기의 사용 결과나 잠재적 이익\n\n또는 위험성에 관한 임상적 근거를 말한다. "
      }
    },
    {
      "chunk_id": "chunk_463",
      "text": "또한, 임상 문헌을 분석하여 파생된 새로운 증거도 포함한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 462,
        "window_size": 3,
        "char_count": 35,
        "word_count": 8,
        "page_number": 15,
        "window_text": "의료기기 소프트웨어 사용으로 건강상의 상해 또는 손상이 없는\n\n- - 17 -\n경우 A등급, 심각하지 않은 상해의 가능성 있으면 B등급, 심각한\n\n상해 또는 사망의 가능성이 있는 경우 C등급으로 구분한다.\n\n 의료기기 소프트웨어는 안전성 등급이 결정될 때까지 초기에는\n\nC등급 요구사항이 적용되며, 소프트웨어 시스템의 실패가 위험한\n\n라) 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인(민원인 안내서)\n\n디지털치료기기는 실사용증거(Real World Evidence, RWE)를\n\n사용하여 의료기기의 사전 및 사후와 관련된 안전성 및 유효성\n\n입증 근거로 제시할 수 있으며, 이에 따른 기간 및 비용을\n\n실사용증거 수집은 데이터의 타당성 및 신뢰성 확보를 위해\n\n품질, 수집 및 분석 방법, 수집한 인력의 역량을 입증할 수 있는\n\n1) 실사용데이터(RWD)는 기존의 중재적 방법에 의한 임상시험으로부터 수집되지 않은 다양한 유형의 의료데이터에 대한 포괄적인\n\n용어이다.  실사용증거(RWE)는 RWD를 분석하여 파생된 증거로써, RWD 분석을 통해 얻은 의료기기의 사용 결과나 잠재적 이익\n\n또는 위험성에 관한 임상적 근거를 말한다.  또한, 임상 문헌을 분석하여 파생된 새로운 증거도 포함한다.\n\n - - 18 -\n객관적인 사항이 반드시 포함되어야 한다.  또한 실사용증거는\n\n적용 목적, 수집 및 분석 정보, 분석 결과에 대한 사항을 제시\n\n해야 한다.\n\n - - 19 -\n<!-- PAGE_26 -->\n### Ⅱ\n\n<!-- PAGE_26 -->\n### 안전성·성능 평가\n\n<!-- PAGE_26 -->\n##### 1. ",
        "original_sentence": "또한, 임상 문헌을 분석하여 파생된 새로운 증거도 포함한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_464",
      "text": "- - 18 -\n객관적인 사항이 반드시 포함되어야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 463,
        "window_size": 3,
        "char_count": 32,
        "word_count": 9,
        "page_number": 3,
        "window_text": "의료기기 소프트웨어는 안전성 등급이 결정될 때까지 초기에는\n\nC등급 요구사항이 적용되며, 소프트웨어 시스템의 실패가 위험한\n\n라) 의료기기의 실사용증거(RWE) 적용에 대한 가이드라인(민원인 안내서)\n\n디지털치료기기는 실사용증거(Real World Evidence, RWE)를\n\n사용하여 의료기기의 사전 및 사후와 관련된 안전성 및 유효성\n\n입증 근거로 제시할 수 있으며, 이에 따른 기간 및 비용을\n\n실사용증거 수집은 데이터의 타당성 및 신뢰성 확보를 위해\n\n품질, 수집 및 분석 방법, 수집한 인력의 역량을 입증할 수 있는\n\n1) 실사용데이터(RWD)는 기존의 중재적 방법에 의한 임상시험으로부터 수집되지 않은 다양한 유형의 의료데이터에 대한 포괄적인\n\n용어이다.  실사용증거(RWE)는 RWD를 분석하여 파생된 증거로써, RWD 분석을 통해 얻은 의료기기의 사용 결과나 잠재적 이익\n\n또는 위험성에 관한 임상적 근거를 말한다.  또한, 임상 문헌을 분석하여 파생된 새로운 증거도 포함한다.\n\n - - 18 -\n객관적인 사항이 반드시 포함되어야 한다.  또한 실사용증거는\n\n적용 목적, 수집 및 분석 정보, 분석 결과에 대한 사항을 제시\n\n해야 한다.\n\n - - 19 -\n<!-- PAGE_26 -->\n### Ⅱ\n\n<!-- PAGE_26 -->\n### 안전성·성능 평가\n\n<!-- PAGE_26 -->\n##### 1.  국내외 관련 규격 및 가이드라인\n\n- 가. ",
        "original_sentence": "- - 18 -\n객관적인 사항이 반드시 포함되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_465",
      "text": "또한 실사용증거는\n\n적용 목적, 수집 및 분석 정보, 분석 결과에 대한 사항을 제시\n\n해야 한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 464,
        "window_size": 3,
        "char_count": 56,
        "word_count": 15,
        "page_number": 3,
        "window_text": "실사용증거(RWE)는 RWD를 분석하여 파생된 증거로써, RWD 분석을 통해 얻은 의료기기의 사용 결과나 잠재적 이익\n\n또는 위험성에 관한 임상적 근거를 말한다.  또한, 임상 문헌을 분석하여 파생된 새로운 증거도 포함한다.\n\n - - 18 -\n객관적인 사항이 반드시 포함되어야 한다.  또한 실사용증거는\n\n적용 목적, 수집 및 분석 정보, 분석 결과에 대한 사항을 제시\n\n해야 한다.\n\n - - 19 -\n<!-- PAGE_26 -->\n### Ⅱ\n\n<!-- PAGE_26 -->\n### 안전성·성능 평가\n\n<!-- PAGE_26 -->\n##### 1.  국내외 관련 규격 및 가이드라인\n\n- 가.  국내외 규격\n- - 20 -\n- 나. ",
        "original_sentence": "또한 실사용증거는\n\n적용 목적, 수집 및 분석 정보, 분석 결과에 대한 사항을 제시\n\n해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_466",
      "text": "- - 19 -\n<!-- PAGE_26 -->\n### Ⅱ\n\n<!-- PAGE_26 -->\n### 안전성·성능 평가\n\n<!-- PAGE_26 -->\n##### 1. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 465,
        "window_size": 3,
        "char_count": 91,
        "word_count": 20,
        "page_number": 26,
        "window_text": "또한, 임상 문헌을 분석하여 파생된 새로운 증거도 포함한다.\n\n - - 18 -\n객관적인 사항이 반드시 포함되어야 한다.  또한 실사용증거는\n\n적용 목적, 수집 및 분석 정보, 분석 결과에 대한 사항을 제시\n\n해야 한다.\n\n - - 19 -\n<!-- PAGE_26 -->\n### Ⅱ\n\n<!-- PAGE_26 -->\n### 안전성·성능 평가\n\n<!-- PAGE_26 -->\n##### 1.  국내외 관련 규격 및 가이드라인\n\n- 가.  국내외 규격\n- - 20 -\n- 나.  국내외 가이드라인\n번호\n\n표준 번호\n\n규격 명칭\n\n주요 내용\n\n비고\n\nApplication of risk\n\nmanagement for IT-networks\n\n**[표 시작]**\n\n| incorporating medical devices | 네트워크로 연결되는 |\n| --- | --- |\n\n**[표 끝]**\n\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n- - 21 -\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n**[표 시작]**\n\n| 의료기기 소프트웨어 | 소프트웨어 | 비 인가된 사용자의 | 것으로 코드 실행 전에 오류를 | ‘의료기기 | 소프트웨어 | 적합성 | 확인 | 확인 자료 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n**의료기기 업데이트 방안을 고려하여야 한다.",
        "original_sentence": "- - 19 -\n<!-- PAGE_26 -->\n### Ⅱ\n\n<!-- PAGE_26 -->\n### 안전성·성능 평가\n\n<!-- PAGE_26 -->\n##### 1. "
      }
    },
    {
      "chunk_id": "chunk_467",
      "text": "국내외 관련 규격 및 가이드라인\n\n- 가. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 466,
        "window_size": 3,
        "char_count": 24,
        "word_count": 7,
        "page_number": 26,
        "window_text": "- - 18 -\n객관적인 사항이 반드시 포함되어야 한다.  또한 실사용증거는\n\n적용 목적, 수집 및 분석 정보, 분석 결과에 대한 사항을 제시\n\n해야 한다.\n\n - - 19 -\n<!-- PAGE_26 -->\n### Ⅱ\n\n<!-- PAGE_26 -->\n### 안전성·성능 평가\n\n<!-- PAGE_26 -->\n##### 1.  국내외 관련 규격 및 가이드라인\n\n- 가.  국내외 규격\n- - 20 -\n- 나.  국내외 가이드라인\n번호\n\n표준 번호\n\n규격 명칭\n\n주요 내용\n\n비고\n\nApplication of risk\n\nmanagement for IT-networks\n\n**[표 시작]**\n\n| incorporating medical devices | 네트워크로 연결되는 |\n| --- | --- |\n\n**[표 끝]**\n\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n- - 21 -\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n**[표 시작]**\n\n| 의료기기 소프트웨어 | 소프트웨어 | 비 인가된 사용자의 | 것으로 코드 실행 전에 오류를 | ‘의료기기 | 소프트웨어 | 적합성 | 확인 | 확인 자료 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n**의료기기 업데이트 방안을 고려하여야 한다. **\n| 5 | 비 인가된 | 것을 방지하도록 고려하여야 한다. ",
        "original_sentence": "국내외 관련 규격 및 가이드라인\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_468",
      "text": "국내외 규격\n- - 20 -\n- 나. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 467,
        "window_size": 3,
        "char_count": 21,
        "word_count": 8,
        "page_number": 9,
        "window_text": "또한 실사용증거는\n\n적용 목적, 수집 및 분석 정보, 분석 결과에 대한 사항을 제시\n\n해야 한다.\n\n - - 19 -\n<!-- PAGE_26 -->\n### Ⅱ\n\n<!-- PAGE_26 -->\n### 안전성·성능 평가\n\n<!-- PAGE_26 -->\n##### 1.  국내외 관련 규격 및 가이드라인\n\n- 가.  국내외 규격\n- - 20 -\n- 나.  국내외 가이드라인\n번호\n\n표준 번호\n\n규격 명칭\n\n주요 내용\n\n비고\n\nApplication of risk\n\nmanagement for IT-networks\n\n**[표 시작]**\n\n| incorporating medical devices | 네트워크로 연결되는 |\n| --- | --- |\n\n**[표 끝]**\n\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n- - 21 -\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n**[표 시작]**\n\n| 의료기기 소프트웨어 | 소프트웨어 | 비 인가된 사용자의 | 것으로 코드 실행 전에 오류를 | ‘의료기기 | 소프트웨어 | 적합성 | 확인 | 확인 자료 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n**의료기기 업데이트 방안을 고려하여야 한다. **\n| 5 | 비 인가된 | 것을 방지하도록 고려하여야 한다.  | 수 있음. ",
        "original_sentence": "국내외 규격\n- - 20 -\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_469",
      "text": "국내외 가이드라인\n번호\n\n표준 번호\n\n규격 명칭\n\n주요 내용\n\n비고\n\nApplication of risk\n\nmanagement for IT-networks\n\n**[표 시작]**\n\n| incorporating medical devices | 네트워크로 연결되는 |\n| --- | --- |\n\n**[표 끝]**\n\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n- - 21 -\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n**[표 시작]**\n\n| 의료기기 소프트웨어 | 소프트웨어 | 비 인가된 사용자의 | 것으로 코드 실행 전에 오류를 | ‘의료기기 | 소프트웨어 | 적합성 | 확인 | 확인 자료 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n**의료기기 업데이트 방안을 고려하여야 한다.",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 468,
        "window_size": 3,
        "char_count": 415,
        "word_count": 102,
        "page_number": 3,
        "window_text": "- - 19 -\n<!-- PAGE_26 -->\n### Ⅱ\n\n<!-- PAGE_26 -->\n### 안전성·성능 평가\n\n<!-- PAGE_26 -->\n##### 1.  국내외 관련 규격 및 가이드라인\n\n- 가.  국내외 규격\n- - 20 -\n- 나.  국내외 가이드라인\n번호\n\n표준 번호\n\n규격 명칭\n\n주요 내용\n\n비고\n\nApplication of risk\n\nmanagement for IT-networks\n\n**[표 시작]**\n\n| incorporating medical devices | 네트워크로 연결되는 |\n| --- | --- |\n\n**[표 끝]**\n\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n- - 21 -\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n**[표 시작]**\n\n| 의료기기 소프트웨어 | 소프트웨어 | 비 인가된 사용자의 | 것으로 코드 실행 전에 오류를 | ‘의료기기 | 소프트웨어 | 적합성 | 확인 | 확인 자료 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n**의료기기 업데이트 방안을 고려하여야 한다. **\n| 5 | 비 인가된 | 것을 방지하도록 고려하여야 한다.  | 수 있음.  | : 한 군당 필요한 피험자 수 | 소프트웨어 | 및 소프트웨어 안전에 적합한 | 오진, 잘못 된 치료 수행 | 국내·외 |\n\n**[표 끝]**\n\n의료기기 소프트웨어의 기술문서 작성\n\n방법에\n\n대하여\n\n상세히\n\n기술하고\n\n- - 22 -\n<!-- PAGE_29 -->\n##### 2. ",
        "original_sentence": "국내외 가이드라인\n번호\n\n표준 번호\n\n규격 명칭\n\n주요 내용\n\n비고\n\nApplication of risk\n\nmanagement for IT-networks\n\n**[표 시작]**\n\n| incorporating medical devices | 네트워크로 연결되는 |\n| --- | --- |\n\n**[표 끝]**\n\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n- - 21 -\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n**[표 시작]**\n\n| 의료기기 소프트웨어 | 소프트웨어 | 비 인가된 사용자의 | 것으로 코드 실행 전에 오류를 | ‘의료기기 | 소프트웨어 | 적합성 | 확인 | 확인 자료 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n**의료기기 업데이트 방안을 고려하여야 한다."
      }
    },
    {
      "chunk_id": "chunk_470",
      "text": "**\n| 5 | 비 인가된 | 것을 방지하도록 고려하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 469,
        "window_size": 3,
        "char_count": 36,
        "word_count": 11,
        "page_number": 15,
        "window_text": "국내외 관련 규격 및 가이드라인\n\n- 가.  국내외 규격\n- - 20 -\n- 나.  국내외 가이드라인\n번호\n\n표준 번호\n\n규격 명칭\n\n주요 내용\n\n비고\n\nApplication of risk\n\nmanagement for IT-networks\n\n**[표 시작]**\n\n| incorporating medical devices | 네트워크로 연결되는 |\n| --- | --- |\n\n**[표 끝]**\n\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n- - 21 -\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n**[표 시작]**\n\n| 의료기기 소프트웨어 | 소프트웨어 | 비 인가된 사용자의 | 것으로 코드 실행 전에 오류를 | ‘의료기기 | 소프트웨어 | 적합성 | 확인 | 확인 자료 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n**의료기기 업데이트 방안을 고려하여야 한다. **\n| 5 | 비 인가된 | 것을 방지하도록 고려하여야 한다.  | 수 있음.  | : 한 군당 필요한 피험자 수 | 소프트웨어 | 및 소프트웨어 안전에 적합한 | 오진, 잘못 된 치료 수행 | 국내·외 |\n\n**[표 끝]**\n\n의료기기 소프트웨어의 기술문서 작성\n\n방법에\n\n대하여\n\n상세히\n\n기술하고\n\n- - 22 -\n<!-- PAGE_29 -->\n##### 2.  안전성 평가 항목\n\n- 가. ",
        "original_sentence": "**\n| 5 | 비 인가된 | 것을 방지하도록 고려하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_471",
      "text": "| 수 있음. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 470,
        "window_size": 3,
        "char_count": 8,
        "word_count": 3,
        "page_number": 67,
        "window_text": "국내외 규격\n- - 20 -\n- 나.  국내외 가이드라인\n번호\n\n표준 번호\n\n규격 명칭\n\n주요 내용\n\n비고\n\nApplication of risk\n\nmanagement for IT-networks\n\n**[표 시작]**\n\n| incorporating medical devices | 네트워크로 연결되는 |\n| --- | --- |\n\n**[표 끝]**\n\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n- - 21 -\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n**[표 시작]**\n\n| 의료기기 소프트웨어 | 소프트웨어 | 비 인가된 사용자의 | 것으로 코드 실행 전에 오류를 | ‘의료기기 | 소프트웨어 | 적합성 | 확인 | 확인 자료 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n**의료기기 업데이트 방안을 고려하여야 한다. **\n| 5 | 비 인가된 | 것을 방지하도록 고려하여야 한다.  | 수 있음.  | : 한 군당 필요한 피험자 수 | 소프트웨어 | 및 소프트웨어 안전에 적합한 | 오진, 잘못 된 치료 수행 | 국내·외 |\n\n**[표 끝]**\n\n의료기기 소프트웨어의 기술문서 작성\n\n방법에\n\n대하여\n\n상세히\n\n기술하고\n\n- - 22 -\n<!-- PAGE_29 -->\n##### 2.  안전성 평가 항목\n\n- 가.  소프트웨어 검증 및 유효성 확인\n1) 개요\n\n의료기기에 포함되는 소프트웨어 또는 의료기기 자체가 소프트\n\n웨어면 ‘의료기기 제조 및 품질관리 기준’ 및 ‘의료기기 위험\n\n관리 시스템’과 조화를 이루는 범위에서 개발, 유지되고 사용\n\n소프트웨어 검증 및 유효성 확인은 의료기기로서의 소프트웨어의\n\n신뢰도를 높이고 환자 또는 사용자에 대한 위험을 낮추기 위한\n\n활동으로, 국제 표준 IEC 62304, ISO 14971 및 ‘의료기기 소프트\n\n의료기기 제조업체는 ‘의료기기 제조 및 품질관리 기준’에\n\n규정된 바와 같이 수립된 품질시스템에서 관련 절차에 따라 소프트\n\n의료기기 소프트웨어의 위험관리는 소프트웨어 개발 활동의 일부이며,\n\n제조자는 소프트웨어 위험관리를 통해 의료기기에 포함된 소프트\n\n웨어 사용에 따른 허용 불가능한 위험이 발생하지 않고, 의료기기\n\n소프트웨어 개발 및 위험관리는 <표 9>와 같이 IEC 62304 프로\n\n- - 23 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n개발 소프트웨어의 범위, 규모\n\n소프트웨어의 개발 계획을\n\n**[표 시작]**\n\n**시험보고서**\n| 수립하면서 | 동시에 | 위험 |\n**소프트웨어 요구사항에서**\n**시험보고서**\n**적용 대상이 되는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄격한 피험자의**\n| 정의한 | 위험통제 | 조치가 |\n**소프트웨어의 정상 상태 및**\n| 선정 기준과 제외 기준을 제시하여야 한다. ",
        "original_sentence": "| 수 있음. "
      }
    },
    {
      "chunk_id": "chunk_472",
      "text": "| : 한 군당 필요한 피험자 수 | 소프트웨어 | 및 소프트웨어 안전에 적합한 | 오진, 잘못 된 치료 수행 | 국내·외 |\n\n**[표 끝]**\n\n의료기기 소프트웨어의 기술문서 작성\n\n방법에\n\n대하여\n\n상세히\n\n기술하고\n\n- - 22 -\n<!-- PAGE_29 -->\n##### 2. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 471,
        "window_size": 3,
        "char_count": 161,
        "word_count": 42,
        "page_number": 29,
        "window_text": "국내외 가이드라인\n번호\n\n표준 번호\n\n규격 명칭\n\n주요 내용\n\n비고\n\nApplication of risk\n\nmanagement for IT-networks\n\n**[표 시작]**\n\n| incorporating medical devices | 네트워크로 연결되는 |\n| --- | --- |\n\n**[표 끝]**\n\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n- - 21 -\n번호\n\n가이드라인 명칭\n\n주요 내용\n\n비고\n\n**[표 시작]**\n\n| 의료기기 소프트웨어 | 소프트웨어 | 비 인가된 사용자의 | 것으로 코드 실행 전에 오류를 | ‘의료기기 | 소프트웨어 | 적합성 | 확인 | 확인 자료 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n**의료기기 업데이트 방안을 고려하여야 한다. **\n| 5 | 비 인가된 | 것을 방지하도록 고려하여야 한다.  | 수 있음.  | : 한 군당 필요한 피험자 수 | 소프트웨어 | 및 소프트웨어 안전에 적합한 | 오진, 잘못 된 치료 수행 | 국내·외 |\n\n**[표 끝]**\n\n의료기기 소프트웨어의 기술문서 작성\n\n방법에\n\n대하여\n\n상세히\n\n기술하고\n\n- - 22 -\n<!-- PAGE_29 -->\n##### 2.  안전성 평가 항목\n\n- 가.  소프트웨어 검증 및 유효성 확인\n1) 개요\n\n의료기기에 포함되는 소프트웨어 또는 의료기기 자체가 소프트\n\n웨어면 ‘의료기기 제조 및 품질관리 기준’ 및 ‘의료기기 위험\n\n관리 시스템’과 조화를 이루는 범위에서 개발, 유지되고 사용\n\n소프트웨어 검증 및 유효성 확인은 의료기기로서의 소프트웨어의\n\n신뢰도를 높이고 환자 또는 사용자에 대한 위험을 낮추기 위한\n\n활동으로, 국제 표준 IEC 62304, ISO 14971 및 ‘의료기기 소프트\n\n의료기기 제조업체는 ‘의료기기 제조 및 품질관리 기준’에\n\n규정된 바와 같이 수립된 품질시스템에서 관련 절차에 따라 소프트\n\n의료기기 소프트웨어의 위험관리는 소프트웨어 개발 활동의 일부이며,\n\n제조자는 소프트웨어 위험관리를 통해 의료기기에 포함된 소프트\n\n웨어 사용에 따른 허용 불가능한 위험이 발생하지 않고, 의료기기\n\n소프트웨어 개발 및 위험관리는 <표 9>와 같이 IEC 62304 프로\n\n- - 23 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n개발 소프트웨어의 범위, 규모\n\n소프트웨어의 개발 계획을\n\n**[표 시작]**\n\n**시험보고서**\n| 수립하면서 | 동시에 | 위험 |\n**소프트웨어 요구사항에서**\n**시험보고서**\n**적용 대상이 되는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄격한 피험자의**\n| 정의한 | 위험통제 | 조치가 |\n**소프트웨어의 정상 상태 및**\n| 선정 기준과 제외 기준을 제시하여야 한다.  이 때 임상시험 참여와 연관된 이익을 | 실제 제품에 올바르게 반영 |\n| 고장 | 상태에서의 | 잠재적 |\n**되었으며, 위험이 효과적**\n**기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 불이익을 우려하여**\n**시험보고서**\n**결함을 고려하여 위험을 분석**\n**으로 통제되어 잔여 위험이**\n| 자발적인 참여 결정에 영향을 받을 소지가 있는 등 취약한 환경에 있는 피험자 | 하고, 해당 위험을 통제하기 |\n**임상시험용 의료기기와의 인과관계를 부정할 수 없는 경우를 말한다.",
        "original_sentence": "| : 한 군당 필요한 피험자 수 | 소프트웨어 | 및 소프트웨어 안전에 적합한 | 오진, 잘못 된 치료 수행 | 국내·외 |\n\n**[표 끝]**\n\n의료기기 소프트웨어의 기술문서 작성\n\n방법에\n\n대하여\n\n상세히\n\n기술하고\n\n- - 22 -\n<!-- PAGE_29 -->\n##### 2. "
      }
    },
    {
      "chunk_id": "chunk_473",
      "text": "안전성 평가 항목\n\n- 가. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 472,
        "window_size": 3,
        "char_count": 16,
        "word_count": 5,
        "page_number": 7,
        "window_text": "**\n| 5 | 비 인가된 | 것을 방지하도록 고려하여야 한다.  | 수 있음.  | : 한 군당 필요한 피험자 수 | 소프트웨어 | 및 소프트웨어 안전에 적합한 | 오진, 잘못 된 치료 수행 | 국내·외 |\n\n**[표 끝]**\n\n의료기기 소프트웨어의 기술문서 작성\n\n방법에\n\n대하여\n\n상세히\n\n기술하고\n\n- - 22 -\n<!-- PAGE_29 -->\n##### 2.  안전성 평가 항목\n\n- 가.  소프트웨어 검증 및 유효성 확인\n1) 개요\n\n의료기기에 포함되는 소프트웨어 또는 의료기기 자체가 소프트\n\n웨어면 ‘의료기기 제조 및 품질관리 기준’ 및 ‘의료기기 위험\n\n관리 시스템’과 조화를 이루는 범위에서 개발, 유지되고 사용\n\n소프트웨어 검증 및 유효성 확인은 의료기기로서의 소프트웨어의\n\n신뢰도를 높이고 환자 또는 사용자에 대한 위험을 낮추기 위한\n\n활동으로, 국제 표준 IEC 62304, ISO 14971 및 ‘의료기기 소프트\n\n의료기기 제조업체는 ‘의료기기 제조 및 품질관리 기준’에\n\n규정된 바와 같이 수립된 품질시스템에서 관련 절차에 따라 소프트\n\n의료기기 소프트웨어의 위험관리는 소프트웨어 개발 활동의 일부이며,\n\n제조자는 소프트웨어 위험관리를 통해 의료기기에 포함된 소프트\n\n웨어 사용에 따른 허용 불가능한 위험이 발생하지 않고, 의료기기\n\n소프트웨어 개발 및 위험관리는 <표 9>와 같이 IEC 62304 프로\n\n- - 23 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n개발 소프트웨어의 범위, 규모\n\n소프트웨어의 개발 계획을\n\n**[표 시작]**\n\n**시험보고서**\n| 수립하면서 | 동시에 | 위험 |\n**소프트웨어 요구사항에서**\n**시험보고서**\n**적용 대상이 되는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄격한 피험자의**\n| 정의한 | 위험통제 | 조치가 |\n**소프트웨어의 정상 상태 및**\n| 선정 기준과 제외 기준을 제시하여야 한다.  이 때 임상시험 참여와 연관된 이익을 | 실제 제품에 올바르게 반영 |\n| 고장 | 상태에서의 | 잠재적 |\n**되었으며, 위험이 효과적**\n**기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 불이익을 우려하여**\n**시험보고서**\n**결함을 고려하여 위험을 분석**\n**으로 통제되어 잔여 위험이**\n| 자발적인 참여 결정에 영향을 받을 소지가 있는 등 취약한 환경에 있는 피험자 | 하고, 해당 위험을 통제하기 |\n**임상시험용 의료기기와의 인과관계를 부정할 수 없는 경우를 말한다. **\n**시험보고서**\n**위한 조치를 결정한다. ",
        "original_sentence": "안전성 평가 항목\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_474",
      "text": "소프트웨어 검증 및 유효성 확인\n1) 개요\n\n의료기기에 포함되는 소프트웨어 또는 의료기기 자체가 소프트\n\n웨어면 ‘의료기기 제조 및 품질관리 기준’ 및 ‘의료기기 위험\n\n관리 시스템’과 조화를 이루는 범위에서 개발, 유지되고 사용\n\n소프트웨어 검증 및 유효성 확인은 의료기기로서의 소프트웨어의\n\n신뢰도를 높이고 환자 또는 사용자에 대한 위험을 낮추기 위한\n\n활동으로, 국제 표준 IEC 62304, ISO 14971 및 ‘의료기기 소프트\n\n의료기기 제조업체는 ‘의료기기 제조 및 품질관리 기준’에\n\n규정된 바와 같이 수립된 품질시스템에서 관련 절차에 따라 소프트\n\n의료기기 소프트웨어의 위험관리는 소프트웨어 개발 활동의 일부이며,\n\n제조자는 소프트웨어 위험관리를 통해 의료기기에 포함된 소프트\n\n웨어 사용에 따른 허용 불가능한 위험이 발생하지 않고, 의료기기\n\n소프트웨어 개발 및 위험관리는 <표 9>와 같이 IEC 62304 프로\n\n- - 23 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n개발 소프트웨어의 범위, 규모\n\n소프트웨어의 개발 계획을\n\n**[표 시작]**\n\n**시험보고서**\n| 수립하면서 | 동시에 | 위험 |\n**소프트웨어 요구사항에서**\n**시험보고서**\n**적용 대상이 되는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄격한 피험자의**\n| 정의한 | 위험통제 | 조치가 |\n**소프트웨어의 정상 상태 및**\n| 선정 기준과 제외 기준을 제시하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 473,
        "window_size": 3,
        "char_count": 737,
        "word_count": 166,
        "page_number": 9,
        "window_text": "| 수 있음.  | : 한 군당 필요한 피험자 수 | 소프트웨어 | 및 소프트웨어 안전에 적합한 | 오진, 잘못 된 치료 수행 | 국내·외 |\n\n**[표 끝]**\n\n의료기기 소프트웨어의 기술문서 작성\n\n방법에\n\n대하여\n\n상세히\n\n기술하고\n\n- - 22 -\n<!-- PAGE_29 -->\n##### 2.  안전성 평가 항목\n\n- 가.  소프트웨어 검증 및 유효성 확인\n1) 개요\n\n의료기기에 포함되는 소프트웨어 또는 의료기기 자체가 소프트\n\n웨어면 ‘의료기기 제조 및 품질관리 기준’ 및 ‘의료기기 위험\n\n관리 시스템’과 조화를 이루는 범위에서 개발, 유지되고 사용\n\n소프트웨어 검증 및 유효성 확인은 의료기기로서의 소프트웨어의\n\n신뢰도를 높이고 환자 또는 사용자에 대한 위험을 낮추기 위한\n\n활동으로, 국제 표준 IEC 62304, ISO 14971 및 ‘의료기기 소프트\n\n의료기기 제조업체는 ‘의료기기 제조 및 품질관리 기준’에\n\n규정된 바와 같이 수립된 품질시스템에서 관련 절차에 따라 소프트\n\n의료기기 소프트웨어의 위험관리는 소프트웨어 개발 활동의 일부이며,\n\n제조자는 소프트웨어 위험관리를 통해 의료기기에 포함된 소프트\n\n웨어 사용에 따른 허용 불가능한 위험이 발생하지 않고, 의료기기\n\n소프트웨어 개발 및 위험관리는 <표 9>와 같이 IEC 62304 프로\n\n- - 23 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n개발 소프트웨어의 범위, 규모\n\n소프트웨어의 개발 계획을\n\n**[표 시작]**\n\n**시험보고서**\n| 수립하면서 | 동시에 | 위험 |\n**소프트웨어 요구사항에서**\n**시험보고서**\n**적용 대상이 되는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄격한 피험자의**\n| 정의한 | 위험통제 | 조치가 |\n**소프트웨어의 정상 상태 및**\n| 선정 기준과 제외 기준을 제시하여야 한다.  이 때 임상시험 참여와 연관된 이익을 | 실제 제품에 올바르게 반영 |\n| 고장 | 상태에서의 | 잠재적 |\n**되었으며, 위험이 효과적**\n**기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 불이익을 우려하여**\n**시험보고서**\n**결함을 고려하여 위험을 분석**\n**으로 통제되어 잔여 위험이**\n| 자발적인 참여 결정에 영향을 받을 소지가 있는 등 취약한 환경에 있는 피험자 | 하고, 해당 위험을 통제하기 |\n**임상시험용 의료기기와의 인과관계를 부정할 수 없는 경우를 말한다. **\n**시험보고서**\n**위한 조치를 결정한다.  이 중**\n**(Vulnerable Subjects)는 선정대상에서 제외한다. ",
        "original_sentence": "소프트웨어 검증 및 유효성 확인\n1) 개요\n\n의료기기에 포함되는 소프트웨어 또는 의료기기 자체가 소프트\n\n웨어면 ‘의료기기 제조 및 품질관리 기준’ 및 ‘의료기기 위험\n\n관리 시스템’과 조화를 이루는 범위에서 개발, 유지되고 사용\n\n소프트웨어 검증 및 유효성 확인은 의료기기로서의 소프트웨어의\n\n신뢰도를 높이고 환자 또는 사용자에 대한 위험을 낮추기 위한\n\n활동으로, 국제 표준 IEC 62304, ISO 14971 및 ‘의료기기 소프트\n\n의료기기 제조업체는 ‘의료기기 제조 및 품질관리 기준’에\n\n규정된 바와 같이 수립된 품질시스템에서 관련 절차에 따라 소프트\n\n의료기기 소프트웨어의 위험관리는 소프트웨어 개발 활동의 일부이며,\n\n제조자는 소프트웨어 위험관리를 통해 의료기기에 포함된 소프트\n\n웨어 사용에 따른 허용 불가능한 위험이 발생하지 않고, 의료기기\n\n소프트웨어 개발 및 위험관리는 <표 9>와 같이 IEC 62304 프로\n\n- - 23 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n개발 소프트웨어의 범위, 규모\n\n소프트웨어의 개발 계획을\n\n**[표 시작]**\n\n**시험보고서**\n| 수립하면서 | 동시에 | 위험 |\n**소프트웨어 요구사항에서**\n**시험보고서**\n**적용 대상이 되는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄격한 피험자의**\n| 정의한 | 위험통제 | 조치가 |\n**소프트웨어의 정상 상태 및**\n| 선정 기준과 제외 기준을 제시하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_475",
      "text": "이 때 임상시험 참여와 연관된 이익을 | 실제 제품에 올바르게 반영 |\n| 고장 | 상태에서의 | 잠재적 |\n**되었으며, 위험이 효과적**\n**기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 불이익을 우려하여**\n**시험보고서**\n**결함을 고려하여 위험을 분석**\n**으로 통제되어 잔여 위험이**\n| 자발적인 참여 결정에 영향을 받을 소지가 있는 등 취약한 환경에 있는 피험자 | 하고, 해당 위험을 통제하기 |\n**임상시험용 의료기기와의 인과관계를 부정할 수 없는 경우를 말한다.",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 474,
        "window_size": 3,
        "char_count": 279,
        "word_count": 68,
        "page_number": 30,
        "window_text": "| : 한 군당 필요한 피험자 수 | 소프트웨어 | 및 소프트웨어 안전에 적합한 | 오진, 잘못 된 치료 수행 | 국내·외 |\n\n**[표 끝]**\n\n의료기기 소프트웨어의 기술문서 작성\n\n방법에\n\n대하여\n\n상세히\n\n기술하고\n\n- - 22 -\n<!-- PAGE_29 -->\n##### 2.  안전성 평가 항목\n\n- 가.  소프트웨어 검증 및 유효성 확인\n1) 개요\n\n의료기기에 포함되는 소프트웨어 또는 의료기기 자체가 소프트\n\n웨어면 ‘의료기기 제조 및 품질관리 기준’ 및 ‘의료기기 위험\n\n관리 시스템’과 조화를 이루는 범위에서 개발, 유지되고 사용\n\n소프트웨어 검증 및 유효성 확인은 의료기기로서의 소프트웨어의\n\n신뢰도를 높이고 환자 또는 사용자에 대한 위험을 낮추기 위한\n\n활동으로, 국제 표준 IEC 62304, ISO 14971 및 ‘의료기기 소프트\n\n의료기기 제조업체는 ‘의료기기 제조 및 품질관리 기준’에\n\n규정된 바와 같이 수립된 품질시스템에서 관련 절차에 따라 소프트\n\n의료기기 소프트웨어의 위험관리는 소프트웨어 개발 활동의 일부이며,\n\n제조자는 소프트웨어 위험관리를 통해 의료기기에 포함된 소프트\n\n웨어 사용에 따른 허용 불가능한 위험이 발생하지 않고, 의료기기\n\n소프트웨어 개발 및 위험관리는 <표 9>와 같이 IEC 62304 프로\n\n- - 23 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n개발 소프트웨어의 범위, 규모\n\n소프트웨어의 개발 계획을\n\n**[표 시작]**\n\n**시험보고서**\n| 수립하면서 | 동시에 | 위험 |\n**소프트웨어 요구사항에서**\n**시험보고서**\n**적용 대상이 되는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄격한 피험자의**\n| 정의한 | 위험통제 | 조치가 |\n**소프트웨어의 정상 상태 및**\n| 선정 기준과 제외 기준을 제시하여야 한다.  이 때 임상시험 참여와 연관된 이익을 | 실제 제품에 올바르게 반영 |\n| 고장 | 상태에서의 | 잠재적 |\n**되었으며, 위험이 효과적**\n**기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 불이익을 우려하여**\n**시험보고서**\n**결함을 고려하여 위험을 분석**\n**으로 통제되어 잔여 위험이**\n| 자발적인 참여 결정에 영향을 받을 소지가 있는 등 취약한 환경에 있는 피험자 | 하고, 해당 위험을 통제하기 |\n**임상시험용 의료기기와의 인과관계를 부정할 수 없는 경우를 말한다. **\n**시험보고서**\n**위한 조치를 결정한다.  이 중**\n**(Vulnerable Subjects)는 선정대상에서 제외한다.  또한, 시험군과 대조군을 포함한 피험자**\n**소프트웨어 설계에 해당하는**\n**수는 해당 의료기기의 특성, 임상시험디자인, 근거를 통한 시험에서 기대하는**\n**통제 조치를 소프트웨어 요구**\n**시험보고서**\n**연구결과의 사전 예측, 통계적 유의성, 검정 방법, 탈락률 등을 반영하여 통계학**\n**시험보고서**\n**시험보고서**\n**적으로 타당하게 제시되어야 하며, 임상시험의 효능 및 안전성 입증에 필요한 충분한**\n**완료**\n**의학적 상태인　경우　또는 기대 수명이 6개월 이하에 해당하는 자**\n**새로운 위험의 발생 또는**\n**- 치료 기간 애플리케이션 사용 시간 및 활용 여부를 수집한다.",
        "original_sentence": "이 때 임상시험 참여와 연관된 이익을 | 실제 제품에 올바르게 반영 |\n| 고장 | 상태에서의 | 잠재적 |\n**되었으며, 위험이 효과적**\n**기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 불이익을 우려하여**\n**시험보고서**\n**결함을 고려하여 위험을 분석**\n**으로 통제되어 잔여 위험이**\n| 자발적인 참여 결정에 영향을 받을 소지가 있는 등 취약한 환경에 있는 피험자 | 하고, 해당 위험을 통제하기 |\n**임상시험용 의료기기와의 인과관계를 부정할 수 없는 경우를 말한다."
      }
    },
    {
      "chunk_id": "chunk_476",
      "text": "**\n**시험보고서**\n**위한 조치를 결정한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 475,
        "window_size": 3,
        "char_count": 28,
        "word_count": 5,
        "page_number": 15,
        "window_text": "안전성 평가 항목\n\n- 가.  소프트웨어 검증 및 유효성 확인\n1) 개요\n\n의료기기에 포함되는 소프트웨어 또는 의료기기 자체가 소프트\n\n웨어면 ‘의료기기 제조 및 품질관리 기준’ 및 ‘의료기기 위험\n\n관리 시스템’과 조화를 이루는 범위에서 개발, 유지되고 사용\n\n소프트웨어 검증 및 유효성 확인은 의료기기로서의 소프트웨어의\n\n신뢰도를 높이고 환자 또는 사용자에 대한 위험을 낮추기 위한\n\n활동으로, 국제 표준 IEC 62304, ISO 14971 및 ‘의료기기 소프트\n\n의료기기 제조업체는 ‘의료기기 제조 및 품질관리 기준’에\n\n규정된 바와 같이 수립된 품질시스템에서 관련 절차에 따라 소프트\n\n의료기기 소프트웨어의 위험관리는 소프트웨어 개발 활동의 일부이며,\n\n제조자는 소프트웨어 위험관리를 통해 의료기기에 포함된 소프트\n\n웨어 사용에 따른 허용 불가능한 위험이 발생하지 않고, 의료기기\n\n소프트웨어 개발 및 위험관리는 <표 9>와 같이 IEC 62304 프로\n\n- - 23 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n개발 소프트웨어의 범위, 규모\n\n소프트웨어의 개발 계획을\n\n**[표 시작]**\n\n**시험보고서**\n| 수립하면서 | 동시에 | 위험 |\n**소프트웨어 요구사항에서**\n**시험보고서**\n**적용 대상이 되는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄격한 피험자의**\n| 정의한 | 위험통제 | 조치가 |\n**소프트웨어의 정상 상태 및**\n| 선정 기준과 제외 기준을 제시하여야 한다.  이 때 임상시험 참여와 연관된 이익을 | 실제 제품에 올바르게 반영 |\n| 고장 | 상태에서의 | 잠재적 |\n**되었으며, 위험이 효과적**\n**기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 불이익을 우려하여**\n**시험보고서**\n**결함을 고려하여 위험을 분석**\n**으로 통제되어 잔여 위험이**\n| 자발적인 참여 결정에 영향을 받을 소지가 있는 등 취약한 환경에 있는 피험자 | 하고, 해당 위험을 통제하기 |\n**임상시험용 의료기기와의 인과관계를 부정할 수 없는 경우를 말한다. **\n**시험보고서**\n**위한 조치를 결정한다.  이 중**\n**(Vulnerable Subjects)는 선정대상에서 제외한다.  또한, 시험군과 대조군을 포함한 피험자**\n**소프트웨어 설계에 해당하는**\n**수는 해당 의료기기의 특성, 임상시험디자인, 근거를 통한 시험에서 기대하는**\n**통제 조치를 소프트웨어 요구**\n**시험보고서**\n**연구결과의 사전 예측, 통계적 유의성, 검정 방법, 탈락률 등을 반영하여 통계학**\n**시험보고서**\n**시험보고서**\n**적으로 타당하게 제시되어야 하며, 임상시험의 효능 및 안전성 입증에 필요한 충분한**\n**완료**\n**의학적 상태인　경우　또는 기대 수명이 6개월 이하에 해당하는 자**\n**새로운 위험의 발생 또는**\n**- 치료 기간 애플리케이션 사용 시간 및 활용 여부를 수집한다. **\n**- 디지털치료기기에 대한 장기 사용자 반응 평가를 함께 수행한다.",
        "original_sentence": "**\n**시험보고서**\n**위한 조치를 결정한다. "
      }
    },
    {
      "chunk_id": "chunk_477",
      "text": "이 중**\n**(Vulnerable Subjects)는 선정대상에서 제외한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 476,
        "window_size": 3,
        "char_count": 44,
        "word_count": 6,
        "page_number": 15,
        "window_text": "소프트웨어 검증 및 유효성 확인\n1) 개요\n\n의료기기에 포함되는 소프트웨어 또는 의료기기 자체가 소프트\n\n웨어면 ‘의료기기 제조 및 품질관리 기준’ 및 ‘의료기기 위험\n\n관리 시스템’과 조화를 이루는 범위에서 개발, 유지되고 사용\n\n소프트웨어 검증 및 유효성 확인은 의료기기로서의 소프트웨어의\n\n신뢰도를 높이고 환자 또는 사용자에 대한 위험을 낮추기 위한\n\n활동으로, 국제 표준 IEC 62304, ISO 14971 및 ‘의료기기 소프트\n\n의료기기 제조업체는 ‘의료기기 제조 및 품질관리 기준’에\n\n규정된 바와 같이 수립된 품질시스템에서 관련 절차에 따라 소프트\n\n의료기기 소프트웨어의 위험관리는 소프트웨어 개발 활동의 일부이며,\n\n제조자는 소프트웨어 위험관리를 통해 의료기기에 포함된 소프트\n\n웨어 사용에 따른 허용 불가능한 위험이 발생하지 않고, 의료기기\n\n소프트웨어 개발 및 위험관리는 <표 9>와 같이 IEC 62304 프로\n\n- - 23 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n개발 소프트웨어의 범위, 규모\n\n소프트웨어의 개발 계획을\n\n**[표 시작]**\n\n**시험보고서**\n| 수립하면서 | 동시에 | 위험 |\n**소프트웨어 요구사항에서**\n**시험보고서**\n**적용 대상이 되는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄격한 피험자의**\n| 정의한 | 위험통제 | 조치가 |\n**소프트웨어의 정상 상태 및**\n| 선정 기준과 제외 기준을 제시하여야 한다.  이 때 임상시험 참여와 연관된 이익을 | 실제 제품에 올바르게 반영 |\n| 고장 | 상태에서의 | 잠재적 |\n**되었으며, 위험이 효과적**\n**기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 불이익을 우려하여**\n**시험보고서**\n**결함을 고려하여 위험을 분석**\n**으로 통제되어 잔여 위험이**\n| 자발적인 참여 결정에 영향을 받을 소지가 있는 등 취약한 환경에 있는 피험자 | 하고, 해당 위험을 통제하기 |\n**임상시험용 의료기기와의 인과관계를 부정할 수 없는 경우를 말한다. **\n**시험보고서**\n**위한 조치를 결정한다.  이 중**\n**(Vulnerable Subjects)는 선정대상에서 제외한다.  또한, 시험군과 대조군을 포함한 피험자**\n**소프트웨어 설계에 해당하는**\n**수는 해당 의료기기의 특성, 임상시험디자인, 근거를 통한 시험에서 기대하는**\n**통제 조치를 소프트웨어 요구**\n**시험보고서**\n**연구결과의 사전 예측, 통계적 유의성, 검정 방법, 탈락률 등을 반영하여 통계학**\n**시험보고서**\n**시험보고서**\n**적으로 타당하게 제시되어야 하며, 임상시험의 효능 및 안전성 입증에 필요한 충분한**\n**완료**\n**의학적 상태인　경우　또는 기대 수명이 6개월 이하에 해당하는 자**\n**새로운 위험의 발생 또는**\n**- 치료 기간 애플리케이션 사용 시간 및 활용 여부를 수집한다. **\n**- 디지털치료기기에 대한 장기 사용자 반응 평가를 함께 수행한다. **\n| 소프트웨어 | 요구사항에 | 기존에 식별한 위험 평가의 |\n**시험보고서**\n**변경이 필요한 경우, 소프트**\n**반영한 위험 통제 조치가**\n| 웨어 형상의 변경이 위해 | 시험보고서 |\n**실현될 수 있도록 안전한**\n| 요인이 될 수 있는 경우 | 시험보고서 |\n**되어야 하며, 일반적으로 1차 유효성 평가변수를 기준으로 정해지고, 연구 계획서**\n**위험관리 프로세스의 입력**\n| 또는 담당자가 임상시험 수행이 불가능한 것으로 판단한 경우 | 이메일, 문자, SNS |\n**시험보고서**\n**시판 후 발견된 문제점을**\n**것에 무리가 있다고 판단될 때는 임상시험을 중지할 수 있다.",
        "original_sentence": "이 중**\n**(Vulnerable Subjects)는 선정대상에서 제외한다. "
      }
    },
    {
      "chunk_id": "chunk_478",
      "text": "또한, 시험군과 대조군을 포함한 피험자**\n**소프트웨어 설계에 해당하는**\n**수는 해당 의료기기의 특성, 임상시험디자인, 근거를 통한 시험에서 기대하는**\n**통제 조치를 소프트웨어 요구**\n**시험보고서**\n**연구결과의 사전 예측, 통계적 유의성, 검정 방법, 탈락률 등을 반영하여 통계학**\n**시험보고서**\n**시험보고서**\n**적으로 타당하게 제시되어야 하며, 임상시험의 효능 및 안전성 입증에 필요한 충분한**\n**완료**\n**의학적 상태인　경우　또는 기대 수명이 6개월 이하에 해당하는 자**\n**새로운 위험의 발생 또는**\n**- 치료 기간 애플리케이션 사용 시간 및 활용 여부를 수집한다.",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 477,
        "window_size": 3,
        "char_count": 340,
        "word_count": 71,
        "page_number": 9,
        "window_text": "이 때 임상시험 참여와 연관된 이익을 | 실제 제품에 올바르게 반영 |\n| 고장 | 상태에서의 | 잠재적 |\n**되었으며, 위험이 효과적**\n**기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 불이익을 우려하여**\n**시험보고서**\n**결함을 고려하여 위험을 분석**\n**으로 통제되어 잔여 위험이**\n| 자발적인 참여 결정에 영향을 받을 소지가 있는 등 취약한 환경에 있는 피험자 | 하고, 해당 위험을 통제하기 |\n**임상시험용 의료기기와의 인과관계를 부정할 수 없는 경우를 말한다. **\n**시험보고서**\n**위한 조치를 결정한다.  이 중**\n**(Vulnerable Subjects)는 선정대상에서 제외한다.  또한, 시험군과 대조군을 포함한 피험자**\n**소프트웨어 설계에 해당하는**\n**수는 해당 의료기기의 특성, 임상시험디자인, 근거를 통한 시험에서 기대하는**\n**통제 조치를 소프트웨어 요구**\n**시험보고서**\n**연구결과의 사전 예측, 통계적 유의성, 검정 방법, 탈락률 등을 반영하여 통계학**\n**시험보고서**\n**시험보고서**\n**적으로 타당하게 제시되어야 하며, 임상시험의 효능 및 안전성 입증에 필요한 충분한**\n**완료**\n**의학적 상태인　경우　또는 기대 수명이 6개월 이하에 해당하는 자**\n**새로운 위험의 발생 또는**\n**- 치료 기간 애플리케이션 사용 시간 및 활용 여부를 수집한다. **\n**- 디지털치료기기에 대한 장기 사용자 반응 평가를 함께 수행한다. **\n| 소프트웨어 | 요구사항에 | 기존에 식별한 위험 평가의 |\n**시험보고서**\n**변경이 필요한 경우, 소프트**\n**반영한 위험 통제 조치가**\n| 웨어 형상의 변경이 위해 | 시험보고서 |\n**실현될 수 있도록 안전한**\n| 요인이 될 수 있는 경우 | 시험보고서 |\n**되어야 하며, 일반적으로 1차 유효성 평가변수를 기준으로 정해지고, 연구 계획서**\n**위험관리 프로세스의 입력**\n| 또는 담당자가 임상시험 수행이 불가능한 것으로 판단한 경우 | 이메일, 문자, SNS |\n**시험보고서**\n**시판 후 발견된 문제점을**\n**것에 무리가 있다고 판단될 때는 임상시험을 중지할 수 있다. **\n| 분석하고 | 안전과 | 관련된 |\n**시험보고서**\n**항목은 위험관리 프로세스의**\n**소프트웨어 위험 통제 조치를**\n**입력으로 식별한다. ",
        "original_sentence": "또한, 시험군과 대조군을 포함한 피험자**\n**소프트웨어 설계에 해당하는**\n**수는 해당 의료기기의 특성, 임상시험디자인, 근거를 통한 시험에서 기대하는**\n**통제 조치를 소프트웨어 요구**\n**시험보고서**\n**연구결과의 사전 예측, 통계적 유의성, 검정 방법, 탈락률 등을 반영하여 통계학**\n**시험보고서**\n**시험보고서**\n**적으로 타당하게 제시되어야 하며, 임상시험의 효능 및 안전성 입증에 필요한 충분한**\n**완료**\n**의학적 상태인　경우　또는 기대 수명이 6개월 이하에 해당하는 자**\n**새로운 위험의 발생 또는**\n**- 치료 기간 애플리케이션 사용 시간 및 활용 여부를 수집한다."
      }
    },
    {
      "chunk_id": "chunk_479",
      "text": "**\n**- 디지털치료기기에 대한 장기 사용자 반응 평가를 함께 수행한다.",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 478,
        "window_size": 3,
        "char_count": 41,
        "word_count": 10,
        "page_number": 15,
        "window_text": "**\n**시험보고서**\n**위한 조치를 결정한다.  이 중**\n**(Vulnerable Subjects)는 선정대상에서 제외한다.  또한, 시험군과 대조군을 포함한 피험자**\n**소프트웨어 설계에 해당하는**\n**수는 해당 의료기기의 특성, 임상시험디자인, 근거를 통한 시험에서 기대하는**\n**통제 조치를 소프트웨어 요구**\n**시험보고서**\n**연구결과의 사전 예측, 통계적 유의성, 검정 방법, 탈락률 등을 반영하여 통계학**\n**시험보고서**\n**시험보고서**\n**적으로 타당하게 제시되어야 하며, 임상시험의 효능 및 안전성 입증에 필요한 충분한**\n**완료**\n**의학적 상태인　경우　또는 기대 수명이 6개월 이하에 해당하는 자**\n**새로운 위험의 발생 또는**\n**- 치료 기간 애플리케이션 사용 시간 및 활용 여부를 수집한다. **\n**- 디지털치료기기에 대한 장기 사용자 반응 평가를 함께 수행한다. **\n| 소프트웨어 | 요구사항에 | 기존에 식별한 위험 평가의 |\n**시험보고서**\n**변경이 필요한 경우, 소프트**\n**반영한 위험 통제 조치가**\n| 웨어 형상의 변경이 위해 | 시험보고서 |\n**실현될 수 있도록 안전한**\n| 요인이 될 수 있는 경우 | 시험보고서 |\n**되어야 하며, 일반적으로 1차 유효성 평가변수를 기준으로 정해지고, 연구 계획서**\n**위험관리 프로세스의 입력**\n| 또는 담당자가 임상시험 수행이 불가능한 것으로 판단한 경우 | 이메일, 문자, SNS |\n**시험보고서**\n**시판 후 발견된 문제점을**\n**것에 무리가 있다고 판단될 때는 임상시험을 중지할 수 있다. **\n| 분석하고 | 안전과 | 관련된 |\n**시험보고서**\n**항목은 위험관리 프로세스의**\n**소프트웨어 위험 통제 조치를**\n**입력으로 식별한다.  문제**\n**제품에 구현한다. ",
        "original_sentence": "**\n**- 디지털치료기기에 대한 장기 사용자 반응 평가를 함께 수행한다."
      }
    },
    {
      "chunk_id": "chunk_480",
      "text": "**\n| 소프트웨어 | 요구사항에 | 기존에 식별한 위험 평가의 |\n**시험보고서**\n**변경이 필요한 경우, 소프트**\n**반영한 위험 통제 조치가**\n| 웨어 형상의 변경이 위해 | 시험보고서 |\n**실현될 수 있도록 안전한**\n| 요인이 될 수 있는 경우 | 시험보고서 |\n**되어야 하며, 일반적으로 1차 유효성 평가변수를 기준으로 정해지고, 연구 계획서**\n**위험관리 프로세스의 입력**\n| 또는 담당자가 임상시험 수행이 불가능한 것으로 판단한 경우 | 이메일, 문자, SNS |\n**시험보고서**\n**시판 후 발견된 문제점을**\n**것에 무리가 있다고 판단될 때는 임상시험을 중지할 수 있다.",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 479,
        "window_size": 3,
        "char_count": 338,
        "word_count": 82,
        "page_number": 3,
        "window_text": "이 중**\n**(Vulnerable Subjects)는 선정대상에서 제외한다.  또한, 시험군과 대조군을 포함한 피험자**\n**소프트웨어 설계에 해당하는**\n**수는 해당 의료기기의 특성, 임상시험디자인, 근거를 통한 시험에서 기대하는**\n**통제 조치를 소프트웨어 요구**\n**시험보고서**\n**연구결과의 사전 예측, 통계적 유의성, 검정 방법, 탈락률 등을 반영하여 통계학**\n**시험보고서**\n**시험보고서**\n**적으로 타당하게 제시되어야 하며, 임상시험의 효능 및 안전성 입증에 필요한 충분한**\n**완료**\n**의학적 상태인　경우　또는 기대 수명이 6개월 이하에 해당하는 자**\n**새로운 위험의 발생 또는**\n**- 치료 기간 애플리케이션 사용 시간 및 활용 여부를 수집한다. **\n**- 디지털치료기기에 대한 장기 사용자 반응 평가를 함께 수행한다. **\n| 소프트웨어 | 요구사항에 | 기존에 식별한 위험 평가의 |\n**시험보고서**\n**변경이 필요한 경우, 소프트**\n**반영한 위험 통제 조치가**\n| 웨어 형상의 변경이 위해 | 시험보고서 |\n**실현될 수 있도록 안전한**\n| 요인이 될 수 있는 경우 | 시험보고서 |\n**되어야 하며, 일반적으로 1차 유효성 평가변수를 기준으로 정해지고, 연구 계획서**\n**위험관리 프로세스의 입력**\n| 또는 담당자가 임상시험 수행이 불가능한 것으로 판단한 경우 | 이메일, 문자, SNS |\n**시험보고서**\n**시판 후 발견된 문제점을**\n**것에 무리가 있다고 판단될 때는 임상시험을 중지할 수 있다. **\n| 분석하고 | 안전과 | 관련된 |\n**시험보고서**\n**항목은 위험관리 프로세스의**\n**소프트웨어 위험 통제 조치를**\n**입력으로 식별한다.  문제**\n**제품에 구현한다.  이때 코드는**\n**해결 및 설계 변경은 위험**\n**위험관리 프로세스에서 식별한**\n**시험보고서**\n| 안전 | 요구사항을 | 정확하게 |\n**필요시 규제 당국에 안전성**\n\n**[표 끝]**\n\n부합한다.\n\n",
        "original_sentence": "**\n| 소프트웨어 | 요구사항에 | 기존에 식별한 위험 평가의 |\n**시험보고서**\n**변경이 필요한 경우, 소프트**\n**반영한 위험 통제 조치가**\n| 웨어 형상의 변경이 위해 | 시험보고서 |\n**실현될 수 있도록 안전한**\n| 요인이 될 수 있는 경우 | 시험보고서 |\n**되어야 하며, 일반적으로 1차 유효성 평가변수를 기준으로 정해지고, 연구 계획서**\n**위험관리 프로세스의 입력**\n| 또는 담당자가 임상시험 수행이 불가능한 것으로 판단한 경우 | 이메일, 문자, SNS |\n**시험보고서**\n**시판 후 발견된 문제점을**\n**것에 무리가 있다고 판단될 때는 임상시험을 중지할 수 있다."
      }
    },
    {
      "chunk_id": "chunk_481",
      "text": "**\n| 분석하고 | 안전과 | 관련된 |\n**시험보고서**\n**항목은 위험관리 프로세스의**\n**소프트웨어 위험 통제 조치를**\n**입력으로 식별한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 480,
        "window_size": 3,
        "char_count": 86,
        "word_count": 18,
        "page_number": 7,
        "window_text": "또한, 시험군과 대조군을 포함한 피험자**\n**소프트웨어 설계에 해당하는**\n**수는 해당 의료기기의 특성, 임상시험디자인, 근거를 통한 시험에서 기대하는**\n**통제 조치를 소프트웨어 요구**\n**시험보고서**\n**연구결과의 사전 예측, 통계적 유의성, 검정 방법, 탈락률 등을 반영하여 통계학**\n**시험보고서**\n**시험보고서**\n**적으로 타당하게 제시되어야 하며, 임상시험의 효능 및 안전성 입증에 필요한 충분한**\n**완료**\n**의학적 상태인　경우　또는 기대 수명이 6개월 이하에 해당하는 자**\n**새로운 위험의 발생 또는**\n**- 치료 기간 애플리케이션 사용 시간 및 활용 여부를 수집한다. **\n**- 디지털치료기기에 대한 장기 사용자 반응 평가를 함께 수행한다. **\n| 소프트웨어 | 요구사항에 | 기존에 식별한 위험 평가의 |\n**시험보고서**\n**변경이 필요한 경우, 소프트**\n**반영한 위험 통제 조치가**\n| 웨어 형상의 변경이 위해 | 시험보고서 |\n**실현될 수 있도록 안전한**\n| 요인이 될 수 있는 경우 | 시험보고서 |\n**되어야 하며, 일반적으로 1차 유효성 평가변수를 기준으로 정해지고, 연구 계획서**\n**위험관리 프로세스의 입력**\n| 또는 담당자가 임상시험 수행이 불가능한 것으로 판단한 경우 | 이메일, 문자, SNS |\n**시험보고서**\n**시판 후 발견된 문제점을**\n**것에 무리가 있다고 판단될 때는 임상시험을 중지할 수 있다. **\n| 분석하고 | 안전과 | 관련된 |\n**시험보고서**\n**항목은 위험관리 프로세스의**\n**소프트웨어 위험 통제 조치를**\n**입력으로 식별한다.  문제**\n**제품에 구현한다.  이때 코드는**\n**해결 및 설계 변경은 위험**\n**위험관리 프로세스에서 식별한**\n**시험보고서**\n| 안전 | 요구사항을 | 정확하게 |\n**필요시 규제 당국에 안전성**\n\n**[표 끝]**\n\n부합한다.\n\n 표 7. ",
        "original_sentence": "**\n| 분석하고 | 안전과 | 관련된 |\n**시험보고서**\n**항목은 위험관리 프로세스의**\n**소프트웨어 위험 통제 조치를**\n**입력으로 식별한다. "
      }
    },
    {
      "chunk_id": "chunk_482",
      "text": "문제**\n**제품에 구현한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 481,
        "window_size": 3,
        "char_count": 17,
        "word_count": 3,
        "page_number": 15,
        "window_text": "**\n**- 디지털치료기기에 대한 장기 사용자 반응 평가를 함께 수행한다. **\n| 소프트웨어 | 요구사항에 | 기존에 식별한 위험 평가의 |\n**시험보고서**\n**변경이 필요한 경우, 소프트**\n**반영한 위험 통제 조치가**\n| 웨어 형상의 변경이 위해 | 시험보고서 |\n**실현될 수 있도록 안전한**\n| 요인이 될 수 있는 경우 | 시험보고서 |\n**되어야 하며, 일반적으로 1차 유효성 평가변수를 기준으로 정해지고, 연구 계획서**\n**위험관리 프로세스의 입력**\n| 또는 담당자가 임상시험 수행이 불가능한 것으로 판단한 경우 | 이메일, 문자, SNS |\n**시험보고서**\n**시판 후 발견된 문제점을**\n**것에 무리가 있다고 판단될 때는 임상시험을 중지할 수 있다. **\n| 분석하고 | 안전과 | 관련된 |\n**시험보고서**\n**항목은 위험관리 프로세스의**\n**소프트웨어 위험 통제 조치를**\n**입력으로 식별한다.  문제**\n**제품에 구현한다.  이때 코드는**\n**해결 및 설계 변경은 위험**\n**위험관리 프로세스에서 식별한**\n**시험보고서**\n| 안전 | 요구사항을 | 정확하게 |\n**필요시 규제 당국에 안전성**\n\n**[표 끝]**\n\n부합한다.\n\n 표 7.  소프트웨어 개발 및 위험관리\n\n- - 24 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n각 유닛에 대한 코드를 검증하는\n\n통제 조치가 될 수 있다.\n\n",
        "original_sentence": "문제**\n**제품에 구현한다. "
      }
    },
    {
      "chunk_id": "chunk_483",
      "text": "이때 코드는**\n**해결 및 설계 변경은 위험**\n**위험관리 프로세스에서 식별한**\n**시험보고서**\n| 안전 | 요구사항을 | 정확하게 |\n**필요시 규제 당국에 안전성**\n\n**[표 끝]**\n\n부합한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 482,
        "window_size": 3,
        "char_count": 118,
        "word_count": 25,
        "page_number": 30,
        "window_text": "**\n| 소프트웨어 | 요구사항에 | 기존에 식별한 위험 평가의 |\n**시험보고서**\n**변경이 필요한 경우, 소프트**\n**반영한 위험 통제 조치가**\n| 웨어 형상의 변경이 위해 | 시험보고서 |\n**실현될 수 있도록 안전한**\n| 요인이 될 수 있는 경우 | 시험보고서 |\n**되어야 하며, 일반적으로 1차 유효성 평가변수를 기준으로 정해지고, 연구 계획서**\n**위험관리 프로세스의 입력**\n| 또는 담당자가 임상시험 수행이 불가능한 것으로 판단한 경우 | 이메일, 문자, SNS |\n**시험보고서**\n**시판 후 발견된 문제점을**\n**것에 무리가 있다고 판단될 때는 임상시험을 중지할 수 있다. **\n| 분석하고 | 안전과 | 관련된 |\n**시험보고서**\n**항목은 위험관리 프로세스의**\n**소프트웨어 위험 통제 조치를**\n**입력으로 식별한다.  문제**\n**제품에 구현한다.  이때 코드는**\n**해결 및 설계 변경은 위험**\n**위험관리 프로세스에서 식별한**\n**시험보고서**\n| 안전 | 요구사항을 | 정확하게 |\n**필요시 규제 당국에 안전성**\n\n**[표 끝]**\n\n부합한다.\n\n 표 7.  소프트웨어 개발 및 위험관리\n\n- - 24 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n각 유닛에 대한 코드를 검증하는\n\n통제 조치가 될 수 있다.\n\n - - 25 -\n3) 소프트웨어 안전성 등급\n\n의료기기 소프트웨어의 고장 또는 잠재적 결함으로 인해 환자나\n\n사용자에게 미치는 위해의 영향에 따라 안전성 등급을 <표 10>과\n\n소프트웨어 안전성 등급은 위험통제 후 잔여 위험의 심각도를\n\n토대로 분류할 수 있다. ",
        "original_sentence": "이때 코드는**\n**해결 및 설계 변경은 위험**\n**위험관리 프로세스에서 식별한**\n**시험보고서**\n| 안전 | 요구사항을 | 정확하게 |\n**필요시 규제 당국에 안전성**\n\n**[표 끝]**\n\n부합한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_484",
      "text": "표 7. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 483,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 27,
        "window_text": "**\n| 분석하고 | 안전과 | 관련된 |\n**시험보고서**\n**항목은 위험관리 프로세스의**\n**소프트웨어 위험 통제 조치를**\n**입력으로 식별한다.  문제**\n**제품에 구현한다.  이때 코드는**\n**해결 및 설계 변경은 위험**\n**위험관리 프로세스에서 식별한**\n**시험보고서**\n| 안전 | 요구사항을 | 정확하게 |\n**필요시 규제 당국에 안전성**\n\n**[표 끝]**\n\n부합한다.\n\n 표 7.  소프트웨어 개발 및 위험관리\n\n- - 24 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n각 유닛에 대한 코드를 검증하는\n\n통제 조치가 될 수 있다.\n\n - - 25 -\n3) 소프트웨어 안전성 등급\n\n의료기기 소프트웨어의 고장 또는 잠재적 결함으로 인해 환자나\n\n사용자에게 미치는 위해의 영향에 따라 안전성 등급을 <표 10>과\n\n소프트웨어 안전성 등급은 위험통제 후 잔여 위험의 심각도를\n\n토대로 분류할 수 있다.  이때, 발생 가능성은 안전성 등급 결정 시\n\n소프트웨어가 여러 개의 독립적인 모듈이 모여서 구성된 경우\n\n각 모듈에 대해 별도로 안전성 등급을 부여할 수 있다. ",
        "original_sentence": "표 7. "
      }
    },
    {
      "chunk_id": "chunk_485",
      "text": "소프트웨어 개발 및 위험관리\n\n- - 24 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n각 유닛에 대한 코드를 검증하는\n\n통제 조치가 될 수 있다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 484,
        "window_size": 3,
        "char_count": 104,
        "word_count": 26,
        "page_number": 9,
        "window_text": "문제**\n**제품에 구현한다.  이때 코드는**\n**해결 및 설계 변경은 위험**\n**위험관리 프로세스에서 식별한**\n**시험보고서**\n| 안전 | 요구사항을 | 정확하게 |\n**필요시 규제 당국에 안전성**\n\n**[표 끝]**\n\n부합한다.\n\n 표 7.  소프트웨어 개발 및 위험관리\n\n- - 24 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n각 유닛에 대한 코드를 검증하는\n\n통제 조치가 될 수 있다.\n\n - - 25 -\n3) 소프트웨어 안전성 등급\n\n의료기기 소프트웨어의 고장 또는 잠재적 결함으로 인해 환자나\n\n사용자에게 미치는 위해의 영향에 따라 안전성 등급을 <표 10>과\n\n소프트웨어 안전성 등급은 위험통제 후 잔여 위험의 심각도를\n\n토대로 분류할 수 있다.  이때, 발생 가능성은 안전성 등급 결정 시\n\n소프트웨어가 여러 개의 독립적인 모듈이 모여서 구성된 경우\n\n각 모듈에 대해 별도로 안전성 등급을 부여할 수 있다.  이때 전체\n\n소프트웨어의 안전성 등급은 개별 모듈의 안전성 등급 중 가장\n\n- 나. ",
        "original_sentence": "소프트웨어 개발 및 위험관리\n\n- - 24 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n각 유닛에 대한 코드를 검증하는\n\n통제 조치가 될 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_486",
      "text": "- - 25 -\n3) 소프트웨어 안전성 등급\n\n의료기기 소프트웨어의 고장 또는 잠재적 결함으로 인해 환자나\n\n사용자에게 미치는 위해의 영향에 따라 안전성 등급을 <표 10>과\n\n소프트웨어 안전성 등급은 위험통제 후 잔여 위험의 심각도를\n\n토대로 분류할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 485,
        "window_size": 3,
        "char_count": 147,
        "word_count": 37,
        "page_number": 9,
        "window_text": "이때 코드는**\n**해결 및 설계 변경은 위험**\n**위험관리 프로세스에서 식별한**\n**시험보고서**\n| 안전 | 요구사항을 | 정확하게 |\n**필요시 규제 당국에 안전성**\n\n**[표 끝]**\n\n부합한다.\n\n 표 7.  소프트웨어 개발 및 위험관리\n\n- - 24 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n각 유닛에 대한 코드를 검증하는\n\n통제 조치가 될 수 있다.\n\n - - 25 -\n3) 소프트웨어 안전성 등급\n\n의료기기 소프트웨어의 고장 또는 잠재적 결함으로 인해 환자나\n\n사용자에게 미치는 위해의 영향에 따라 안전성 등급을 <표 10>과\n\n소프트웨어 안전성 등급은 위험통제 후 잔여 위험의 심각도를\n\n토대로 분류할 수 있다.  이때, 발생 가능성은 안전성 등급 결정 시\n\n소프트웨어가 여러 개의 독립적인 모듈이 모여서 구성된 경우\n\n각 모듈에 대해 별도로 안전성 등급을 부여할 수 있다.  이때 전체\n\n소프트웨어의 안전성 등급은 개별 모듈의 안전성 등급 중 가장\n\n- 나.  의료기기의 사이버보안\n유·무선 통신이 가능하거나 통신 경로가 존재하는 제품의 경우\n\n사이버보안에 대한 요구사항을 준수해야 한다. ",
        "original_sentence": "- - 25 -\n3) 소프트웨어 안전성 등급\n\n의료기기 소프트웨어의 고장 또는 잠재적 결함으로 인해 환자나\n\n사용자에게 미치는 위해의 영향에 따라 안전성 등급을 <표 10>과\n\n소프트웨어 안전성 등급은 위험통제 후 잔여 위험의 심각도를\n\n토대로 분류할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_487",
      "text": "이때, 발생 가능성은 안전성 등급 결정 시\n\n소프트웨어가 여러 개의 독립적인 모듈이 모여서 구성된 경우\n\n각 모듈에 대해 별도로 안전성 등급을 부여할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 486,
        "window_size": 3,
        "char_count": 90,
        "word_count": 24,
        "page_number": 9,
        "window_text": "표 7.  소프트웨어 개발 및 위험관리\n\n- - 24 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n각 유닛에 대한 코드를 검증하는\n\n통제 조치가 될 수 있다.\n\n - - 25 -\n3) 소프트웨어 안전성 등급\n\n의료기기 소프트웨어의 고장 또는 잠재적 결함으로 인해 환자나\n\n사용자에게 미치는 위해의 영향에 따라 안전성 등급을 <표 10>과\n\n소프트웨어 안전성 등급은 위험통제 후 잔여 위험의 심각도를\n\n토대로 분류할 수 있다.  이때, 발생 가능성은 안전성 등급 결정 시\n\n소프트웨어가 여러 개의 독립적인 모듈이 모여서 구성된 경우\n\n각 모듈에 대해 별도로 안전성 등급을 부여할 수 있다.  이때 전체\n\n소프트웨어의 안전성 등급은 개별 모듈의 안전성 등급 중 가장\n\n- 나.  의료기기의 사이버보안\n유·무선 통신이 가능하거나 통신 경로가 존재하는 제품의 경우\n\n사이버보안에 대한 요구사항을 준수해야 한다.  제조자는 이를 확인\n\n할 수 있도록 ‘의료기기 사이버보안 요구사항 체크리스트’와\n\n요구사항을 실제로 검증한 자료를 제출하여야 한다. ",
        "original_sentence": "이때, 발생 가능성은 안전성 등급 결정 시\n\n소프트웨어가 여러 개의 독립적인 모듈이 모여서 구성된 경우\n\n각 모듈에 대해 별도로 안전성 등급을 부여할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_488",
      "text": "이때 전체\n\n소프트웨어의 안전성 등급은 개별 모듈의 안전성 등급 중 가장\n\n- 나. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 487,
        "window_size": 3,
        "char_count": 47,
        "word_count": 13,
        "page_number": 9,
        "window_text": "소프트웨어 개발 및 위험관리\n\n- - 24 -\n번호\n\nIEC 62304\n\n프로세스\n\n소프트웨어 개발\n\n소프트웨어 위험관리\n\n각 유닛에 대한 코드를 검증하는\n\n통제 조치가 될 수 있다.\n\n - - 25 -\n3) 소프트웨어 안전성 등급\n\n의료기기 소프트웨어의 고장 또는 잠재적 결함으로 인해 환자나\n\n사용자에게 미치는 위해의 영향에 따라 안전성 등급을 <표 10>과\n\n소프트웨어 안전성 등급은 위험통제 후 잔여 위험의 심각도를\n\n토대로 분류할 수 있다.  이때, 발생 가능성은 안전성 등급 결정 시\n\n소프트웨어가 여러 개의 독립적인 모듈이 모여서 구성된 경우\n\n각 모듈에 대해 별도로 안전성 등급을 부여할 수 있다.  이때 전체\n\n소프트웨어의 안전성 등급은 개별 모듈의 안전성 등급 중 가장\n\n- 나.  의료기기의 사이버보안\n유·무선 통신이 가능하거나 통신 경로가 존재하는 제품의 경우\n\n사이버보안에 대한 요구사항을 준수해야 한다.  제조자는 이를 확인\n\n할 수 있도록 ‘의료기기 사이버보안 요구사항 체크리스트’와\n\n요구사항을 실제로 검증한 자료를 제출하여야 한다.  다만, 제조사의\n\n위험분석을 통해 요구사항 일부를 제외하거나 수정하여 적용할 때는\n\n- - 26 -\n시험규격 및 그 설정 근거를 제출하여야 하며 해당 자료로\n\n‘사이버보안 위험관리문서’를 제출할 수 있다.\n\n",
        "original_sentence": "이때 전체\n\n소프트웨어의 안전성 등급은 개별 모듈의 안전성 등급 중 가장\n\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_489",
      "text": "의료기기의 사이버보안\n유·무선 통신이 가능하거나 통신 경로가 존재하는 제품의 경우\n\n사이버보안에 대한 요구사항을 준수해야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 488,
        "window_size": 3,
        "char_count": 72,
        "word_count": 15,
        "page_number": 27,
        "window_text": "- - 25 -\n3) 소프트웨어 안전성 등급\n\n의료기기 소프트웨어의 고장 또는 잠재적 결함으로 인해 환자나\n\n사용자에게 미치는 위해의 영향에 따라 안전성 등급을 <표 10>과\n\n소프트웨어 안전성 등급은 위험통제 후 잔여 위험의 심각도를\n\n토대로 분류할 수 있다.  이때, 발생 가능성은 안전성 등급 결정 시\n\n소프트웨어가 여러 개의 독립적인 모듈이 모여서 구성된 경우\n\n각 모듈에 대해 별도로 안전성 등급을 부여할 수 있다.  이때 전체\n\n소프트웨어의 안전성 등급은 개별 모듈의 안전성 등급 중 가장\n\n- 나.  의료기기의 사이버보안\n유·무선 통신이 가능하거나 통신 경로가 존재하는 제품의 경우\n\n사이버보안에 대한 요구사항을 준수해야 한다.  제조자는 이를 확인\n\n할 수 있도록 ‘의료기기 사이버보안 요구사항 체크리스트’와\n\n요구사항을 실제로 검증한 자료를 제출하여야 한다.  다만, 제조사의\n\n위험분석을 통해 요구사항 일부를 제외하거나 수정하여 적용할 때는\n\n- - 26 -\n시험규격 및 그 설정 근거를 제출하여야 하며 해당 자료로\n\n‘사이버보안 위험관리문서’를 제출할 수 있다.\n\n 사이버보안 요구사항은 ‘의료기기의 사이버보안 허가·심사\n\n‘의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)’\n\n에는 보안통신, 데이터 보호, 기기 무결성, 사용자 인증, 소프트웨어\n\n유지보수, 물리적 접근, 신뢰성 및 가용성 등에 대한 요구사항을 제시\n\n하고 있다. ",
        "original_sentence": "의료기기의 사이버보안\n유·무선 통신이 가능하거나 통신 경로가 존재하는 제품의 경우\n\n사이버보안에 대한 요구사항을 준수해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_490",
      "text": "제조자는 이를 확인\n\n할 수 있도록 ‘의료기기 사이버보안 요구사항 체크리스트’와\n\n요구사항을 실제로 검증한 자료를 제출하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 489,
        "window_size": 3,
        "char_count": 74,
        "word_count": 16,
        "page_number": 3,
        "window_text": "이때, 발생 가능성은 안전성 등급 결정 시\n\n소프트웨어가 여러 개의 독립적인 모듈이 모여서 구성된 경우\n\n각 모듈에 대해 별도로 안전성 등급을 부여할 수 있다.  이때 전체\n\n소프트웨어의 안전성 등급은 개별 모듈의 안전성 등급 중 가장\n\n- 나.  의료기기의 사이버보안\n유·무선 통신이 가능하거나 통신 경로가 존재하는 제품의 경우\n\n사이버보안에 대한 요구사항을 준수해야 한다.  제조자는 이를 확인\n\n할 수 있도록 ‘의료기기 사이버보안 요구사항 체크리스트’와\n\n요구사항을 실제로 검증한 자료를 제출하여야 한다.  다만, 제조사의\n\n위험분석을 통해 요구사항 일부를 제외하거나 수정하여 적용할 때는\n\n- - 26 -\n시험규격 및 그 설정 근거를 제출하여야 하며 해당 자료로\n\n‘사이버보안 위험관리문서’를 제출할 수 있다.\n\n 사이버보안 요구사항은 ‘의료기기의 사이버보안 허가·심사\n\n‘의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)’\n\n에는 보안통신, 데이터 보호, 기기 무결성, 사용자 인증, 소프트웨어\n\n유지보수, 물리적 접근, 신뢰성 및 가용성 등에 대한 요구사항을 제시\n\n하고 있다.  본 요구사항은 제품의 사이버보안 안전성 등급 및\n\n제품의 특성에 따라 적용한다. ",
        "original_sentence": "제조자는 이를 확인\n\n할 수 있도록 ‘의료기기 사이버보안 요구사항 체크리스트’와\n\n요구사항을 실제로 검증한 자료를 제출하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_491",
      "text": "다만, 제조사의\n\n위험분석을 통해 요구사항 일부를 제외하거나 수정하여 적용할 때는\n\n- - 26 -\n시험규격 및 그 설정 근거를 제출하여야 하며 해당 자료로\n\n‘사이버보안 위험관리문서’를 제출할 수 있다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 490,
        "window_size": 3,
        "char_count": 116,
        "word_count": 28,
        "page_number": 3,
        "window_text": "이때 전체\n\n소프트웨어의 안전성 등급은 개별 모듈의 안전성 등급 중 가장\n\n- 나.  의료기기의 사이버보안\n유·무선 통신이 가능하거나 통신 경로가 존재하는 제품의 경우\n\n사이버보안에 대한 요구사항을 준수해야 한다.  제조자는 이를 확인\n\n할 수 있도록 ‘의료기기 사이버보안 요구사항 체크리스트’와\n\n요구사항을 실제로 검증한 자료를 제출하여야 한다.  다만, 제조사의\n\n위험분석을 통해 요구사항 일부를 제외하거나 수정하여 적용할 때는\n\n- - 26 -\n시험규격 및 그 설정 근거를 제출하여야 하며 해당 자료로\n\n‘사이버보안 위험관리문서’를 제출할 수 있다.\n\n 사이버보안 요구사항은 ‘의료기기의 사이버보안 허가·심사\n\n‘의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)’\n\n에는 보안통신, 데이터 보호, 기기 무결성, 사용자 인증, 소프트웨어\n\n유지보수, 물리적 접근, 신뢰성 및 가용성 등에 대한 요구사항을 제시\n\n하고 있다.  본 요구사항은 제품의 사이버보안 안전성 등급 및\n\n제품의 특성에 따라 적용한다.  해당 가이드라인에 따라 제품에\n\n소프트웨어 위험관리에는 사이버보안에 대한 위험관리 항목이\n\n포함되어야 하며, 소프트웨어 위험관리와 동일한 방식으로 위험\n\n‘위해요인 식별’에서는 관련 자료(규격, 가이드라인, 국내외\n\n이상 사례 등)에 근거하여 의료기기의 정상 및 고장상태에서\n\n이미 알고 있거나 예측 가능한 의료기기 사이버보안 측면의\n\n‘위험산정’에서는 위해상황을 초래할 수 있는 예측 가능한\n\n- - 27 -\n위해요인\n\n구체적인 예시\n\n사용자 또는 환자에게\n\n발생 가능한 손상\n\n관련자료\n\n표 9. ",
        "original_sentence": "다만, 제조사의\n\n위험분석을 통해 요구사항 일부를 제외하거나 수정하여 적용할 때는\n\n- - 26 -\n시험규격 및 그 설정 근거를 제출하여야 하며 해당 자료로\n\n‘사이버보안 위험관리문서’를 제출할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_492",
      "text": "사이버보안 요구사항은 ‘의료기기의 사이버보안 허가·심사\n\n‘의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)’\n\n에는 보안통신, 데이터 보호, 기기 무결성, 사용자 인증, 소프트웨어\n\n유지보수, 물리적 접근, 신뢰성 및 가용성 등에 대한 요구사항을 제시\n\n하고 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 491,
        "window_size": 3,
        "char_count": 155,
        "word_count": 31,
        "page_number": 3,
        "window_text": "의료기기의 사이버보안\n유·무선 통신이 가능하거나 통신 경로가 존재하는 제품의 경우\n\n사이버보안에 대한 요구사항을 준수해야 한다.  제조자는 이를 확인\n\n할 수 있도록 ‘의료기기 사이버보안 요구사항 체크리스트’와\n\n요구사항을 실제로 검증한 자료를 제출하여야 한다.  다만, 제조사의\n\n위험분석을 통해 요구사항 일부를 제외하거나 수정하여 적용할 때는\n\n- - 26 -\n시험규격 및 그 설정 근거를 제출하여야 하며 해당 자료로\n\n‘사이버보안 위험관리문서’를 제출할 수 있다.\n\n 사이버보안 요구사항은 ‘의료기기의 사이버보안 허가·심사\n\n‘의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)’\n\n에는 보안통신, 데이터 보호, 기기 무결성, 사용자 인증, 소프트웨어\n\n유지보수, 물리적 접근, 신뢰성 및 가용성 등에 대한 요구사항을 제시\n\n하고 있다.  본 요구사항은 제품의 사이버보안 안전성 등급 및\n\n제품의 특성에 따라 적용한다.  해당 가이드라인에 따라 제품에\n\n소프트웨어 위험관리에는 사이버보안에 대한 위험관리 항목이\n\n포함되어야 하며, 소프트웨어 위험관리와 동일한 방식으로 위험\n\n‘위해요인 식별’에서는 관련 자료(규격, 가이드라인, 국내외\n\n이상 사례 등)에 근거하여 의료기기의 정상 및 고장상태에서\n\n이미 알고 있거나 예측 가능한 의료기기 사이버보안 측면의\n\n‘위험산정’에서는 위해상황을 초래할 수 있는 예측 가능한\n\n- - 27 -\n위해요인\n\n구체적인 예시\n\n사용자 또는 환자에게\n\n발생 가능한 손상\n\n관련자료\n\n표 9.  위해요인 식별 예시\n\n식별한 각 위해요인에 대하여 위험관리 계획서에 정의한 위험\n\n식별한 모든 위험에 대하여 위험의 평가 결과를 ‘위험을\n\n허용할 수 없는 영역(unacceptable)’과‘합리적으로 실현할\n\n수 있는 가장 낮은 영역(As Low As Reasonably Practicable,\n\nALARP)’, ‘허용할 수 있는 영역(acceptable)’의 3단계 또는\n\n‘위험을 허용할 수 없는 영역(unacceptable)’과 ‘허용할 수\n\n**[표 시작]**\n\n| 위해요인 | 발생 가능한 |\n| --- | --- |\n**사용자의**\n\n**[표 끝]**\n\n- - 28 -\n다) 위험통제\n\n제조자는 위험평가 결과 중 ‘위험을 허용할 수 없는 영역\n\n(unacceptable)’과‘합리적으로 실현할 수 있는 가장 낮은 영역\n\n(ALARP)’을 허용 가능한 수준까지 감소시키기 위하여 위험\n\n통제 조치를 식별하고, <표 13>과 같이 위험통제 활동을 수행\n\n모든 위험통제 조치를 하고 검증한 뒤 위험관리 계획에서\n\n정의한 위험허용 기준을 사용하여 해당 의료기기에서 식별한\n\n전체 잔여위험이 허용 가능한지 아닌지를 결정하고 <표 14>와\n\n발생\n\n가능\n\n없음\n\n인증 기능 구현\n\n- - 29 -\n4) 사이버보안 적용 방법\n\n‘의료기기 사이버보안 요구사항 체크리스트’는 의료기기\n\n사이버보안 요구사항에 대한 적합성 여부를 확인할 수 있는 자료로\n\n제조자는 체크리스트의 질의 사항을 확인하여 요구사항의 적용\n\n사용되는 통신기술(유·무선 통신 방식 등), 사용환경(병원\n\n내/외 사용, 공용 네트워크망 사용 등) 등 통신 특성을 확인할\n\n수 있는 사항을 기재한다. ",
        "original_sentence": "사이버보안 요구사항은 ‘의료기기의 사이버보안 허가·심사\n\n‘의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)’\n\n에는 보안통신, 데이터 보호, 기기 무결성, 사용자 인증, 소프트웨어\n\n유지보수, 물리적 접근, 신뢰성 및 가용성 등에 대한 요구사항을 제시\n\n하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_493",
      "text": "본 요구사항은 제품의 사이버보안 안전성 등급 및\n\n제품의 특성에 따라 적용한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 492,
        "window_size": 3,
        "char_count": 45,
        "word_count": 11,
        "page_number": 3,
        "window_text": "제조자는 이를 확인\n\n할 수 있도록 ‘의료기기 사이버보안 요구사항 체크리스트’와\n\n요구사항을 실제로 검증한 자료를 제출하여야 한다.  다만, 제조사의\n\n위험분석을 통해 요구사항 일부를 제외하거나 수정하여 적용할 때는\n\n- - 26 -\n시험규격 및 그 설정 근거를 제출하여야 하며 해당 자료로\n\n‘사이버보안 위험관리문서’를 제출할 수 있다.\n\n 사이버보안 요구사항은 ‘의료기기의 사이버보안 허가·심사\n\n‘의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)’\n\n에는 보안통신, 데이터 보호, 기기 무결성, 사용자 인증, 소프트웨어\n\n유지보수, 물리적 접근, 신뢰성 및 가용성 등에 대한 요구사항을 제시\n\n하고 있다.  본 요구사항은 제품의 사이버보안 안전성 등급 및\n\n제품의 특성에 따라 적용한다.  해당 가이드라인에 따라 제품에\n\n소프트웨어 위험관리에는 사이버보안에 대한 위험관리 항목이\n\n포함되어야 하며, 소프트웨어 위험관리와 동일한 방식으로 위험\n\n‘위해요인 식별’에서는 관련 자료(규격, 가이드라인, 국내외\n\n이상 사례 등)에 근거하여 의료기기의 정상 및 고장상태에서\n\n이미 알고 있거나 예측 가능한 의료기기 사이버보안 측면의\n\n‘위험산정’에서는 위해상황을 초래할 수 있는 예측 가능한\n\n- - 27 -\n위해요인\n\n구체적인 예시\n\n사용자 또는 환자에게\n\n발생 가능한 손상\n\n관련자료\n\n표 9.  위해요인 식별 예시\n\n식별한 각 위해요인에 대하여 위험관리 계획서에 정의한 위험\n\n식별한 모든 위험에 대하여 위험의 평가 결과를 ‘위험을\n\n허용할 수 없는 영역(unacceptable)’과‘합리적으로 실현할\n\n수 있는 가장 낮은 영역(As Low As Reasonably Practicable,\n\nALARP)’, ‘허용할 수 있는 영역(acceptable)’의 3단계 또는\n\n‘위험을 허용할 수 없는 영역(unacceptable)’과 ‘허용할 수\n\n**[표 시작]**\n\n| 위해요인 | 발생 가능한 |\n| --- | --- |\n**사용자의**\n\n**[표 끝]**\n\n- - 28 -\n다) 위험통제\n\n제조자는 위험평가 결과 중 ‘위험을 허용할 수 없는 영역\n\n(unacceptable)’과‘합리적으로 실현할 수 있는 가장 낮은 영역\n\n(ALARP)’을 허용 가능한 수준까지 감소시키기 위하여 위험\n\n통제 조치를 식별하고, <표 13>과 같이 위험통제 활동을 수행\n\n모든 위험통제 조치를 하고 검증한 뒤 위험관리 계획에서\n\n정의한 위험허용 기준을 사용하여 해당 의료기기에서 식별한\n\n전체 잔여위험이 허용 가능한지 아닌지를 결정하고 <표 14>와\n\n발생\n\n가능\n\n없음\n\n인증 기능 구현\n\n- - 29 -\n4) 사이버보안 적용 방법\n\n‘의료기기 사이버보안 요구사항 체크리스트’는 의료기기\n\n사이버보안 요구사항에 대한 적합성 여부를 확인할 수 있는 자료로\n\n제조자는 체크리스트의 질의 사항을 확인하여 요구사항의 적용\n\n사용되는 통신기술(유·무선 통신 방식 등), 사용환경(병원\n\n내/외 사용, 공용 네트워크망 사용 등) 등 통신 특성을 확인할\n\n수 있는 사항을 기재한다.  이를 기반으로 체크리스트에 따라\n\n요구사항 적용여부, 적합성 입증방법, 첨부자료 또는 문서번호를\n\n- - 30 -\n<예시> - 의료기기 사이버보안 요구사항 체크리스트\n\n< 의료기기 사이버보안 특성 기재 >\n\n1) 사용되는 통신 기술 : 유선 통신(LAN), 무선통신(Wi-fi, 블루투스)\n\n**[표 시작]**\n\n**무결성**\n**물리적**\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 |\n| 신뢰성 | ※ 피험자 수: 시험대상수 산출시 일반적인 고려사항 |\n| 발 | 행 | 일 2023년 12월 7일 |\n**- 임상연구에서 피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 수가 보장**\n**사용자**\n**가용성**\n| 발 | 행 | 인 | 박윤주 |\n| 편 집 위 원 장 이정림 | 1) 이상 사례 교육 |\n| 연구 참여 동의서 취득 | O | - | - | - |\n| 편 | 집 | 위 | 원 | 이원규, 박해대, 양승하, 한영민, 김건소, 채형래 |\n| 임상시험 의료기기 적용 | O | O | O | O |\n| 문 | 의 | 처 |\n| 소프트 | 평가지표 Baseline 수집 | (O) | O | - | - |\n| 평가지표 수집 및 분석2) | 2)2) | O | O | O | O |\n**2) 중대한 이상 의료기기 이상 반응 보고**\n| 데이터 | 시험보고서 |\n\n**[표 끝]**\n\n- - 31 -\n제조자는 기밀성에 대한 위험통제 수단이\n\n요구될 때, 통신 프로토콜의 컨트롤(control)/\n\n**[표 시작]**\n\n| 검증 및 | 시험보고서 |\n| --- | --- |\n| 피험자 수는 임상시험 방법에 따라 식약처의 ‘의료기기 임상시험 관련 통계기법 | : 시험군의 치료 전 대비 post-treatment 후 평균 식사장애 검사(EDE-Q) 변화량 |\n| 임상시험 디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고 | 시퀀싱(sequencing) 필드의 메시지를 보호 | (1) Eating Disorder Examination Questionnaire (EDE-Q) | 적용 |\n| 할 수 있다. ",
        "original_sentence": "본 요구사항은 제품의 사이버보안 안전성 등급 및\n\n제품의 특성에 따라 적용한다. "
      }
    },
    {
      "chunk_id": "chunk_494",
      "text": "해당 가이드라인에 따라 제품에\n\n소프트웨어 위험관리에는 사이버보안에 대한 위험관리 항목이\n\n포함되어야 하며, 소프트웨어 위험관리와 동일한 방식으로 위험\n\n‘위해요인 식별’에서는 관련 자료(규격, 가이드라인, 국내외\n\n이상 사례 등)에 근거하여 의료기기의 정상 및 고장상태에서\n\n이미 알고 있거나 예측 가능한 의료기기 사이버보안 측면의\n\n‘위험산정’에서는 위해상황을 초래할 수 있는 예측 가능한\n\n- - 27 -\n위해요인\n\n구체적인 예시\n\n사용자 또는 환자에게\n\n발생 가능한 손상\n\n관련자료\n\n표 9. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 493,
        "window_size": 3,
        "char_count": 280,
        "word_count": 62,
        "page_number": 7,
        "window_text": "다만, 제조사의\n\n위험분석을 통해 요구사항 일부를 제외하거나 수정하여 적용할 때는\n\n- - 26 -\n시험규격 및 그 설정 근거를 제출하여야 하며 해당 자료로\n\n‘사이버보안 위험관리문서’를 제출할 수 있다.\n\n 사이버보안 요구사항은 ‘의료기기의 사이버보안 허가·심사\n\n‘의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)’\n\n에는 보안통신, 데이터 보호, 기기 무결성, 사용자 인증, 소프트웨어\n\n유지보수, 물리적 접근, 신뢰성 및 가용성 등에 대한 요구사항을 제시\n\n하고 있다.  본 요구사항은 제품의 사이버보안 안전성 등급 및\n\n제품의 특성에 따라 적용한다.  해당 가이드라인에 따라 제품에\n\n소프트웨어 위험관리에는 사이버보안에 대한 위험관리 항목이\n\n포함되어야 하며, 소프트웨어 위험관리와 동일한 방식으로 위험\n\n‘위해요인 식별’에서는 관련 자료(규격, 가이드라인, 국내외\n\n이상 사례 등)에 근거하여 의료기기의 정상 및 고장상태에서\n\n이미 알고 있거나 예측 가능한 의료기기 사이버보안 측면의\n\n‘위험산정’에서는 위해상황을 초래할 수 있는 예측 가능한\n\n- - 27 -\n위해요인\n\n구체적인 예시\n\n사용자 또는 환자에게\n\n발생 가능한 손상\n\n관련자료\n\n표 9.  위해요인 식별 예시\n\n식별한 각 위해요인에 대하여 위험관리 계획서에 정의한 위험\n\n식별한 모든 위험에 대하여 위험의 평가 결과를 ‘위험을\n\n허용할 수 없는 영역(unacceptable)’과‘합리적으로 실현할\n\n수 있는 가장 낮은 영역(As Low As Reasonably Practicable,\n\nALARP)’, ‘허용할 수 있는 영역(acceptable)’의 3단계 또는\n\n‘위험을 허용할 수 없는 영역(unacceptable)’과 ‘허용할 수\n\n**[표 시작]**\n\n| 위해요인 | 발생 가능한 |\n| --- | --- |\n**사용자의**\n\n**[표 끝]**\n\n- - 28 -\n다) 위험통제\n\n제조자는 위험평가 결과 중 ‘위험을 허용할 수 없는 영역\n\n(unacceptable)’과‘합리적으로 실현할 수 있는 가장 낮은 영역\n\n(ALARP)’을 허용 가능한 수준까지 감소시키기 위하여 위험\n\n통제 조치를 식별하고, <표 13>과 같이 위험통제 활동을 수행\n\n모든 위험통제 조치를 하고 검증한 뒤 위험관리 계획에서\n\n정의한 위험허용 기준을 사용하여 해당 의료기기에서 식별한\n\n전체 잔여위험이 허용 가능한지 아닌지를 결정하고 <표 14>와\n\n발생\n\n가능\n\n없음\n\n인증 기능 구현\n\n- - 29 -\n4) 사이버보안 적용 방법\n\n‘의료기기 사이버보안 요구사항 체크리스트’는 의료기기\n\n사이버보안 요구사항에 대한 적합성 여부를 확인할 수 있는 자료로\n\n제조자는 체크리스트의 질의 사항을 확인하여 요구사항의 적용\n\n사용되는 통신기술(유·무선 통신 방식 등), 사용환경(병원\n\n내/외 사용, 공용 네트워크망 사용 등) 등 통신 특성을 확인할\n\n수 있는 사항을 기재한다.  이를 기반으로 체크리스트에 따라\n\n요구사항 적용여부, 적합성 입증방법, 첨부자료 또는 문서번호를\n\n- - 30 -\n<예시> - 의료기기 사이버보안 요구사항 체크리스트\n\n< 의료기기 사이버보안 특성 기재 >\n\n1) 사용되는 통신 기술 : 유선 통신(LAN), 무선통신(Wi-fi, 블루투스)\n\n**[표 시작]**\n\n**무결성**\n**물리적**\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 |\n| 신뢰성 | ※ 피험자 수: 시험대상수 산출시 일반적인 고려사항 |\n| 발 | 행 | 일 2023년 12월 7일 |\n**- 임상연구에서 피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 수가 보장**\n**사용자**\n**가용성**\n| 발 | 행 | 인 | 박윤주 |\n| 편 집 위 원 장 이정림 | 1) 이상 사례 교육 |\n| 연구 참여 동의서 취득 | O | - | - | - |\n| 편 | 집 | 위 | 원 | 이원규, 박해대, 양승하, 한영민, 김건소, 채형래 |\n| 임상시험 의료기기 적용 | O | O | O | O |\n| 문 | 의 | 처 |\n| 소프트 | 평가지표 Baseline 수집 | (O) | O | - | - |\n| 평가지표 수집 및 분석2) | 2)2) | O | O | O | O |\n**2) 중대한 이상 의료기기 이상 반응 보고**\n| 데이터 | 시험보고서 |\n\n**[표 끝]**\n\n- - 31 -\n제조자는 기밀성에 대한 위험통제 수단이\n\n요구될 때, 통신 프로토콜의 컨트롤(control)/\n\n**[표 시작]**\n\n| 검증 및 | 시험보고서 |\n| --- | --- |\n| 피험자 수는 임상시험 방법에 따라 식약처의 ‘의료기기 임상시험 관련 통계기법 | : 시험군의 치료 전 대비 post-treatment 후 평균 식사장애 검사(EDE-Q) 변화량 |\n| 임상시험 디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고 | 시퀀싱(sequencing) 필드의 메시지를 보호 | (1) Eating Disorder Examination Questionnaire (EDE-Q) | 적용 |\n| 할 수 있다.  본 예시는 대표적인 예를 작성한 것으로 실제 시험규격에 대해 작성 | 해당 임상시험용 의료기기 및 대조시험용 의료기기의 품목명, 제조회사, 원재료, 모양, | Global Impression of |\n| 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | 유효성 | (AB-1234) |\n| 가이드라인’을 참고하여 임상시험 피험자 수 산출 방식을 적용한다. ",
        "original_sentence": "해당 가이드라인에 따라 제품에\n\n소프트웨어 위험관리에는 사이버보안에 대한 위험관리 항목이\n\n포함되어야 하며, 소프트웨어 위험관리와 동일한 방식으로 위험\n\n‘위해요인 식별’에서는 관련 자료(규격, 가이드라인, 국내외\n\n이상 사례 등)에 근거하여 의료기기의 정상 및 고장상태에서\n\n이미 알고 있거나 예측 가능한 의료기기 사이버보안 측면의\n\n‘위험산정’에서는 위해상황을 초래할 수 있는 예측 가능한\n\n- - 27 -\n위해요인\n\n구체적인 예시\n\n사용자 또는 환자에게\n\n발생 가능한 손상\n\n관련자료\n\n표 9. "
      }
    },
    {
      "chunk_id": "chunk_495",
      "text": "위해요인 식별 예시\n\n식별한 각 위해요인에 대하여 위험관리 계획서에 정의한 위험\n\n식별한 모든 위험에 대하여 위험의 평가 결과를 ‘위험을\n\n허용할 수 없는 영역(unacceptable)’과‘합리적으로 실현할\n\n수 있는 가장 낮은 영역(As Low As Reasonably Practicable,\n\nALARP)’, ‘허용할 수 있는 영역(acceptable)’의 3단계 또는\n\n‘위험을 허용할 수 없는 영역(unacceptable)’과 ‘허용할 수\n\n**[표 시작]**\n\n| 위해요인 | 발생 가능한 |\n| --- | --- |\n**사용자의**\n\n**[표 끝]**\n\n- - 28 -\n다) 위험통제\n\n제조자는 위험평가 결과 중 ‘위험을 허용할 수 없는 영역\n\n(unacceptable)’과‘합리적으로 실현할 수 있는 가장 낮은 영역\n\n(ALARP)’을 허용 가능한 수준까지 감소시키기 위하여 위험\n\n통제 조치를 식별하고, <표 13>과 같이 위험통제 활동을 수행\n\n모든 위험통제 조치를 하고 검증한 뒤 위험관리 계획에서\n\n정의한 위험허용 기준을 사용하여 해당 의료기기에서 식별한\n\n전체 잔여위험이 허용 가능한지 아닌지를 결정하고 <표 14>와\n\n발생\n\n가능\n\n없음\n\n인증 기능 구현\n\n- - 29 -\n4) 사이버보안 적용 방법\n\n‘의료기기 사이버보안 요구사항 체크리스트’는 의료기기\n\n사이버보안 요구사항에 대한 적합성 여부를 확인할 수 있는 자료로\n\n제조자는 체크리스트의 질의 사항을 확인하여 요구사항의 적용\n\n사용되는 통신기술(유·무선 통신 방식 등), 사용환경(병원\n\n내/외 사용, 공용 네트워크망 사용 등) 등 통신 특성을 확인할\n\n수 있는 사항을 기재한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 494,
        "window_size": 3,
        "char_count": 818,
        "word_count": 179,
        "page_number": 28,
        "window_text": "사이버보안 요구사항은 ‘의료기기의 사이버보안 허가·심사\n\n‘의료기기의 사이버보안 허가·심사 가이드라인(민원인 안내서)’\n\n에는 보안통신, 데이터 보호, 기기 무결성, 사용자 인증, 소프트웨어\n\n유지보수, 물리적 접근, 신뢰성 및 가용성 등에 대한 요구사항을 제시\n\n하고 있다.  본 요구사항은 제품의 사이버보안 안전성 등급 및\n\n제품의 특성에 따라 적용한다.  해당 가이드라인에 따라 제품에\n\n소프트웨어 위험관리에는 사이버보안에 대한 위험관리 항목이\n\n포함되어야 하며, 소프트웨어 위험관리와 동일한 방식으로 위험\n\n‘위해요인 식별’에서는 관련 자료(규격, 가이드라인, 국내외\n\n이상 사례 등)에 근거하여 의료기기의 정상 및 고장상태에서\n\n이미 알고 있거나 예측 가능한 의료기기 사이버보안 측면의\n\n‘위험산정’에서는 위해상황을 초래할 수 있는 예측 가능한\n\n- - 27 -\n위해요인\n\n구체적인 예시\n\n사용자 또는 환자에게\n\n발생 가능한 손상\n\n관련자료\n\n표 9.  위해요인 식별 예시\n\n식별한 각 위해요인에 대하여 위험관리 계획서에 정의한 위험\n\n식별한 모든 위험에 대하여 위험의 평가 결과를 ‘위험을\n\n허용할 수 없는 영역(unacceptable)’과‘합리적으로 실현할\n\n수 있는 가장 낮은 영역(As Low As Reasonably Practicable,\n\nALARP)’, ‘허용할 수 있는 영역(acceptable)’의 3단계 또는\n\n‘위험을 허용할 수 없는 영역(unacceptable)’과 ‘허용할 수\n\n**[표 시작]**\n\n| 위해요인 | 발생 가능한 |\n| --- | --- |\n**사용자의**\n\n**[표 끝]**\n\n- - 28 -\n다) 위험통제\n\n제조자는 위험평가 결과 중 ‘위험을 허용할 수 없는 영역\n\n(unacceptable)’과‘합리적으로 실현할 수 있는 가장 낮은 영역\n\n(ALARP)’을 허용 가능한 수준까지 감소시키기 위하여 위험\n\n통제 조치를 식별하고, <표 13>과 같이 위험통제 활동을 수행\n\n모든 위험통제 조치를 하고 검증한 뒤 위험관리 계획에서\n\n정의한 위험허용 기준을 사용하여 해당 의료기기에서 식별한\n\n전체 잔여위험이 허용 가능한지 아닌지를 결정하고 <표 14>와\n\n발생\n\n가능\n\n없음\n\n인증 기능 구현\n\n- - 29 -\n4) 사이버보안 적용 방법\n\n‘의료기기 사이버보안 요구사항 체크리스트’는 의료기기\n\n사이버보안 요구사항에 대한 적합성 여부를 확인할 수 있는 자료로\n\n제조자는 체크리스트의 질의 사항을 확인하여 요구사항의 적용\n\n사용되는 통신기술(유·무선 통신 방식 등), 사용환경(병원\n\n내/외 사용, 공용 네트워크망 사용 등) 등 통신 특성을 확인할\n\n수 있는 사항을 기재한다.  이를 기반으로 체크리스트에 따라\n\n요구사항 적용여부, 적합성 입증방법, 첨부자료 또는 문서번호를\n\n- - 30 -\n<예시> - 의료기기 사이버보안 요구사항 체크리스트\n\n< 의료기기 사이버보안 특성 기재 >\n\n1) 사용되는 통신 기술 : 유선 통신(LAN), 무선통신(Wi-fi, 블루투스)\n\n**[표 시작]**\n\n**무결성**\n**물리적**\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 |\n| 신뢰성 | ※ 피험자 수: 시험대상수 산출시 일반적인 고려사항 |\n| 발 | 행 | 일 2023년 12월 7일 |\n**- 임상연구에서 피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 수가 보장**\n**사용자**\n**가용성**\n| 발 | 행 | 인 | 박윤주 |\n| 편 집 위 원 장 이정림 | 1) 이상 사례 교육 |\n| 연구 참여 동의서 취득 | O | - | - | - |\n| 편 | 집 | 위 | 원 | 이원규, 박해대, 양승하, 한영민, 김건소, 채형래 |\n| 임상시험 의료기기 적용 | O | O | O | O |\n| 문 | 의 | 처 |\n| 소프트 | 평가지표 Baseline 수집 | (O) | O | - | - |\n| 평가지표 수집 및 분석2) | 2)2) | O | O | O | O |\n**2) 중대한 이상 의료기기 이상 반응 보고**\n| 데이터 | 시험보고서 |\n\n**[표 끝]**\n\n- - 31 -\n제조자는 기밀성에 대한 위험통제 수단이\n\n요구될 때, 통신 프로토콜의 컨트롤(control)/\n\n**[표 시작]**\n\n| 검증 및 | 시험보고서 |\n| --- | --- |\n| 피험자 수는 임상시험 방법에 따라 식약처의 ‘의료기기 임상시험 관련 통계기법 | : 시험군의 치료 전 대비 post-treatment 후 평균 식사장애 검사(EDE-Q) 변화량 |\n| 임상시험 디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고 | 시퀀싱(sequencing) 필드의 메시지를 보호 | (1) Eating Disorder Examination Questionnaire (EDE-Q) | 적용 |\n| 할 수 있다.  본 예시는 대표적인 예를 작성한 것으로 실제 시험규격에 대해 작성 | 해당 임상시험용 의료기기 및 대조시험용 의료기기의 품목명, 제조회사, 원재료, 모양, | Global Impression of |\n| 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | 유효성 | (AB-1234) |\n| 가이드라인’을 참고하여 임상시험 피험자 수 산출 방식을 적용한다.  피험자 수를 결정 | - 시험자는 시험책임자, 시험담당자, 임상시험 조정자를 포함한다. ",
        "original_sentence": "위해요인 식별 예시\n\n식별한 각 위해요인에 대하여 위험관리 계획서에 정의한 위험\n\n식별한 모든 위험에 대하여 위험의 평가 결과를 ‘위험을\n\n허용할 수 없는 영역(unacceptable)’과‘합리적으로 실현할\n\n수 있는 가장 낮은 영역(As Low As Reasonably Practicable,\n\nALARP)’, ‘허용할 수 있는 영역(acceptable)’의 3단계 또는\n\n‘위험을 허용할 수 없는 영역(unacceptable)’과 ‘허용할 수\n\n**[표 시작]**\n\n| 위해요인 | 발생 가능한 |\n| --- | --- |\n**사용자의**\n\n**[표 끝]**\n\n- - 28 -\n다) 위험통제\n\n제조자는 위험평가 결과 중 ‘위험을 허용할 수 없는 영역\n\n(unacceptable)’과‘합리적으로 실현할 수 있는 가장 낮은 영역\n\n(ALARP)’을 허용 가능한 수준까지 감소시키기 위하여 위험\n\n통제 조치를 식별하고, <표 13>과 같이 위험통제 활동을 수행\n\n모든 위험통제 조치를 하고 검증한 뒤 위험관리 계획에서\n\n정의한 위험허용 기준을 사용하여 해당 의료기기에서 식별한\n\n전체 잔여위험이 허용 가능한지 아닌지를 결정하고 <표 14>와\n\n발생\n\n가능\n\n없음\n\n인증 기능 구현\n\n- - 29 -\n4) 사이버보안 적용 방법\n\n‘의료기기 사이버보안 요구사항 체크리스트’는 의료기기\n\n사이버보안 요구사항에 대한 적합성 여부를 확인할 수 있는 자료로\n\n제조자는 체크리스트의 질의 사항을 확인하여 요구사항의 적용\n\n사용되는 통신기술(유·무선 통신 방식 등), 사용환경(병원\n\n내/외 사용, 공용 네트워크망 사용 등) 등 통신 특성을 확인할\n\n수 있는 사항을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_496",
      "text": "이를 기반으로 체크리스트에 따라\n\n요구사항 적용여부, 적합성 입증방법, 첨부자료 또는 문서번호를\n\n- - 30 -\n<예시> - 의료기기 사이버보안 요구사항 체크리스트\n\n< 의료기기 사이버보안 특성 기재 >\n\n1) 사용되는 통신 기술 : 유선 통신(LAN), 무선통신(Wi-fi, 블루투스)\n\n**[표 시작]**\n\n**무결성**\n**물리적**\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 |\n| 신뢰성 | ※ 피험자 수: 시험대상수 산출시 일반적인 고려사항 |\n| 발 | 행 | 일 2023년 12월 7일 |\n**- 임상연구에서 피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 수가 보장**\n**사용자**\n**가용성**\n| 발 | 행 | 인 | 박윤주 |\n| 편 집 위 원 장 이정림 | 1) 이상 사례 교육 |\n| 연구 참여 동의서 취득 | O | - | - | - |\n| 편 | 집 | 위 | 원 | 이원규, 박해대, 양승하, 한영민, 김건소, 채형래 |\n| 임상시험 의료기기 적용 | O | O | O | O |\n| 문 | 의 | 처 |\n| 소프트 | 평가지표 Baseline 수집 | (O) | O | - | - |\n| 평가지표 수집 및 분석2) | 2)2) | O | O | O | O |\n**2) 중대한 이상 의료기기 이상 반응 보고**\n| 데이터 | 시험보고서 |\n\n**[표 끝]**\n\n- - 31 -\n제조자는 기밀성에 대한 위험통제 수단이\n\n요구될 때, 통신 프로토콜의 컨트롤(control)/\n\n**[표 시작]**\n\n| 검증 및 | 시험보고서 |\n| --- | --- |\n| 피험자 수는 임상시험 방법에 따라 식약처의 ‘의료기기 임상시험 관련 통계기법 | : 시험군의 치료 전 대비 post-treatment 후 평균 식사장애 검사(EDE-Q) 변화량 |\n| 임상시험 디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고 | 시퀀싱(sequencing) 필드의 메시지를 보호 | (1) Eating Disorder Examination Questionnaire (EDE-Q) | 적용 |\n| 할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 495,
        "window_size": 3,
        "char_count": 1040,
        "word_count": 282,
        "page_number": 3,
        "window_text": "본 요구사항은 제품의 사이버보안 안전성 등급 및\n\n제품의 특성에 따라 적용한다.  해당 가이드라인에 따라 제품에\n\n소프트웨어 위험관리에는 사이버보안에 대한 위험관리 항목이\n\n포함되어야 하며, 소프트웨어 위험관리와 동일한 방식으로 위험\n\n‘위해요인 식별’에서는 관련 자료(규격, 가이드라인, 국내외\n\n이상 사례 등)에 근거하여 의료기기의 정상 및 고장상태에서\n\n이미 알고 있거나 예측 가능한 의료기기 사이버보안 측면의\n\n‘위험산정’에서는 위해상황을 초래할 수 있는 예측 가능한\n\n- - 27 -\n위해요인\n\n구체적인 예시\n\n사용자 또는 환자에게\n\n발생 가능한 손상\n\n관련자료\n\n표 9.  위해요인 식별 예시\n\n식별한 각 위해요인에 대하여 위험관리 계획서에 정의한 위험\n\n식별한 모든 위험에 대하여 위험의 평가 결과를 ‘위험을\n\n허용할 수 없는 영역(unacceptable)’과‘합리적으로 실현할\n\n수 있는 가장 낮은 영역(As Low As Reasonably Practicable,\n\nALARP)’, ‘허용할 수 있는 영역(acceptable)’의 3단계 또는\n\n‘위험을 허용할 수 없는 영역(unacceptable)’과 ‘허용할 수\n\n**[표 시작]**\n\n| 위해요인 | 발생 가능한 |\n| --- | --- |\n**사용자의**\n\n**[표 끝]**\n\n- - 28 -\n다) 위험통제\n\n제조자는 위험평가 결과 중 ‘위험을 허용할 수 없는 영역\n\n(unacceptable)’과‘합리적으로 실현할 수 있는 가장 낮은 영역\n\n(ALARP)’을 허용 가능한 수준까지 감소시키기 위하여 위험\n\n통제 조치를 식별하고, <표 13>과 같이 위험통제 활동을 수행\n\n모든 위험통제 조치를 하고 검증한 뒤 위험관리 계획에서\n\n정의한 위험허용 기준을 사용하여 해당 의료기기에서 식별한\n\n전체 잔여위험이 허용 가능한지 아닌지를 결정하고 <표 14>와\n\n발생\n\n가능\n\n없음\n\n인증 기능 구현\n\n- - 29 -\n4) 사이버보안 적용 방법\n\n‘의료기기 사이버보안 요구사항 체크리스트’는 의료기기\n\n사이버보안 요구사항에 대한 적합성 여부를 확인할 수 있는 자료로\n\n제조자는 체크리스트의 질의 사항을 확인하여 요구사항의 적용\n\n사용되는 통신기술(유·무선 통신 방식 등), 사용환경(병원\n\n내/외 사용, 공용 네트워크망 사용 등) 등 통신 특성을 확인할\n\n수 있는 사항을 기재한다.  이를 기반으로 체크리스트에 따라\n\n요구사항 적용여부, 적합성 입증방법, 첨부자료 또는 문서번호를\n\n- - 30 -\n<예시> - 의료기기 사이버보안 요구사항 체크리스트\n\n< 의료기기 사이버보안 특성 기재 >\n\n1) 사용되는 통신 기술 : 유선 통신(LAN), 무선통신(Wi-fi, 블루투스)\n\n**[표 시작]**\n\n**무결성**\n**물리적**\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 |\n| 신뢰성 | ※ 피험자 수: 시험대상수 산출시 일반적인 고려사항 |\n| 발 | 행 | 일 2023년 12월 7일 |\n**- 임상연구에서 피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 수가 보장**\n**사용자**\n**가용성**\n| 발 | 행 | 인 | 박윤주 |\n| 편 집 위 원 장 이정림 | 1) 이상 사례 교육 |\n| 연구 참여 동의서 취득 | O | - | - | - |\n| 편 | 집 | 위 | 원 | 이원규, 박해대, 양승하, 한영민, 김건소, 채형래 |\n| 임상시험 의료기기 적용 | O | O | O | O |\n| 문 | 의 | 처 |\n| 소프트 | 평가지표 Baseline 수집 | (O) | O | - | - |\n| 평가지표 수집 및 분석2) | 2)2) | O | O | O | O |\n**2) 중대한 이상 의료기기 이상 반응 보고**\n| 데이터 | 시험보고서 |\n\n**[표 끝]**\n\n- - 31 -\n제조자는 기밀성에 대한 위험통제 수단이\n\n요구될 때, 통신 프로토콜의 컨트롤(control)/\n\n**[표 시작]**\n\n| 검증 및 | 시험보고서 |\n| --- | --- |\n| 피험자 수는 임상시험 방법에 따라 식약처의 ‘의료기기 임상시험 관련 통계기법 | : 시험군의 치료 전 대비 post-treatment 후 평균 식사장애 검사(EDE-Q) 변화량 |\n| 임상시험 디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고 | 시퀀싱(sequencing) 필드의 메시지를 보호 | (1) Eating Disorder Examination Questionnaire (EDE-Q) | 적용 |\n| 할 수 있다.  본 예시는 대표적인 예를 작성한 것으로 실제 시험규격에 대해 작성 | 해당 임상시험용 의료기기 및 대조시험용 의료기기의 품목명, 제조회사, 원재료, 모양, | Global Impression of |\n| 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | 유효성 | (AB-1234) |\n| 가이드라인’을 참고하여 임상시험 피험자 수 산출 방식을 적용한다.  피험자 수를 결정 | - 시험자는 시험책임자, 시험담당자, 임상시험 조정자를 포함한다.  | 3) 스크리닝 시점에 BMI 가 17kg/㎡미만, 40kg/㎡이상인 자 |\n| 그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있다. ",
        "original_sentence": "이를 기반으로 체크리스트에 따라\n\n요구사항 적용여부, 적합성 입증방법, 첨부자료 또는 문서번호를\n\n- - 30 -\n<예시> - 의료기기 사이버보안 요구사항 체크리스트\n\n< 의료기기 사이버보안 특성 기재 >\n\n1) 사용되는 통신 기술 : 유선 통신(LAN), 무선통신(Wi-fi, 블루투스)\n\n**[표 시작]**\n\n**무결성**\n**물리적**\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 |\n| 신뢰성 | ※ 피험자 수: 시험대상수 산출시 일반적인 고려사항 |\n| 발 | 행 | 일 2023년 12월 7일 |\n**- 임상연구에서 피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 수가 보장**\n**사용자**\n**가용성**\n| 발 | 행 | 인 | 박윤주 |\n| 편 집 위 원 장 이정림 | 1) 이상 사례 교육 |\n| 연구 참여 동의서 취득 | O | - | - | - |\n| 편 | 집 | 위 | 원 | 이원규, 박해대, 양승하, 한영민, 김건소, 채형래 |\n| 임상시험 의료기기 적용 | O | O | O | O |\n| 문 | 의 | 처 |\n| 소프트 | 평가지표 Baseline 수집 | (O) | O | - | - |\n| 평가지표 수집 및 분석2) | 2)2) | O | O | O | O |\n**2) 중대한 이상 의료기기 이상 반응 보고**\n| 데이터 | 시험보고서 |\n\n**[표 끝]**\n\n- - 31 -\n제조자는 기밀성에 대한 위험통제 수단이\n\n요구될 때, 통신 프로토콜의 컨트롤(control)/\n\n**[표 시작]**\n\n| 검증 및 | 시험보고서 |\n| --- | --- |\n| 피험자 수는 임상시험 방법에 따라 식약처의 ‘의료기기 임상시험 관련 통계기법 | : 시험군의 치료 전 대비 post-treatment 후 평균 식사장애 검사(EDE-Q) 변화량 |\n| 임상시험 디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고 | 시퀀싱(sequencing) 필드의 메시지를 보호 | (1) Eating Disorder Examination Questionnaire (EDE-Q) | 적용 |\n| 할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_497",
      "text": "본 예시는 대표적인 예를 작성한 것으로 실제 시험규격에 대해 작성 | 해당 임상시험용 의료기기 및 대조시험용 의료기기의 품목명, 제조회사, 원재료, 모양, | Global Impression of |\n| 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | 유효성 | (AB-1234) |\n| 가이드라인’을 참고하여 임상시험 피험자 수 산출 방식을 적용한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 496,
        "window_size": 3,
        "char_count": 215,
        "word_count": 50,
        "page_number": 26,
        "window_text": "해당 가이드라인에 따라 제품에\n\n소프트웨어 위험관리에는 사이버보안에 대한 위험관리 항목이\n\n포함되어야 하며, 소프트웨어 위험관리와 동일한 방식으로 위험\n\n‘위해요인 식별’에서는 관련 자료(규격, 가이드라인, 국내외\n\n이상 사례 등)에 근거하여 의료기기의 정상 및 고장상태에서\n\n이미 알고 있거나 예측 가능한 의료기기 사이버보안 측면의\n\n‘위험산정’에서는 위해상황을 초래할 수 있는 예측 가능한\n\n- - 27 -\n위해요인\n\n구체적인 예시\n\n사용자 또는 환자에게\n\n발생 가능한 손상\n\n관련자료\n\n표 9.  위해요인 식별 예시\n\n식별한 각 위해요인에 대하여 위험관리 계획서에 정의한 위험\n\n식별한 모든 위험에 대하여 위험의 평가 결과를 ‘위험을\n\n허용할 수 없는 영역(unacceptable)’과‘합리적으로 실현할\n\n수 있는 가장 낮은 영역(As Low As Reasonably Practicable,\n\nALARP)’, ‘허용할 수 있는 영역(acceptable)’의 3단계 또는\n\n‘위험을 허용할 수 없는 영역(unacceptable)’과 ‘허용할 수\n\n**[표 시작]**\n\n| 위해요인 | 발생 가능한 |\n| --- | --- |\n**사용자의**\n\n**[표 끝]**\n\n- - 28 -\n다) 위험통제\n\n제조자는 위험평가 결과 중 ‘위험을 허용할 수 없는 영역\n\n(unacceptable)’과‘합리적으로 실현할 수 있는 가장 낮은 영역\n\n(ALARP)’을 허용 가능한 수준까지 감소시키기 위하여 위험\n\n통제 조치를 식별하고, <표 13>과 같이 위험통제 활동을 수행\n\n모든 위험통제 조치를 하고 검증한 뒤 위험관리 계획에서\n\n정의한 위험허용 기준을 사용하여 해당 의료기기에서 식별한\n\n전체 잔여위험이 허용 가능한지 아닌지를 결정하고 <표 14>와\n\n발생\n\n가능\n\n없음\n\n인증 기능 구현\n\n- - 29 -\n4) 사이버보안 적용 방법\n\n‘의료기기 사이버보안 요구사항 체크리스트’는 의료기기\n\n사이버보안 요구사항에 대한 적합성 여부를 확인할 수 있는 자료로\n\n제조자는 체크리스트의 질의 사항을 확인하여 요구사항의 적용\n\n사용되는 통신기술(유·무선 통신 방식 등), 사용환경(병원\n\n내/외 사용, 공용 네트워크망 사용 등) 등 통신 특성을 확인할\n\n수 있는 사항을 기재한다.  이를 기반으로 체크리스트에 따라\n\n요구사항 적용여부, 적합성 입증방법, 첨부자료 또는 문서번호를\n\n- - 30 -\n<예시> - 의료기기 사이버보안 요구사항 체크리스트\n\n< 의료기기 사이버보안 특성 기재 >\n\n1) 사용되는 통신 기술 : 유선 통신(LAN), 무선통신(Wi-fi, 블루투스)\n\n**[표 시작]**\n\n**무결성**\n**물리적**\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 |\n| 신뢰성 | ※ 피험자 수: 시험대상수 산출시 일반적인 고려사항 |\n| 발 | 행 | 일 2023년 12월 7일 |\n**- 임상연구에서 피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 수가 보장**\n**사용자**\n**가용성**\n| 발 | 행 | 인 | 박윤주 |\n| 편 집 위 원 장 이정림 | 1) 이상 사례 교육 |\n| 연구 참여 동의서 취득 | O | - | - | - |\n| 편 | 집 | 위 | 원 | 이원규, 박해대, 양승하, 한영민, 김건소, 채형래 |\n| 임상시험 의료기기 적용 | O | O | O | O |\n| 문 | 의 | 처 |\n| 소프트 | 평가지표 Baseline 수집 | (O) | O | - | - |\n| 평가지표 수집 및 분석2) | 2)2) | O | O | O | O |\n**2) 중대한 이상 의료기기 이상 반응 보고**\n| 데이터 | 시험보고서 |\n\n**[표 끝]**\n\n- - 31 -\n제조자는 기밀성에 대한 위험통제 수단이\n\n요구될 때, 통신 프로토콜의 컨트롤(control)/\n\n**[표 시작]**\n\n| 검증 및 | 시험보고서 |\n| --- | --- |\n| 피험자 수는 임상시험 방법에 따라 식약처의 ‘의료기기 임상시험 관련 통계기법 | : 시험군의 치료 전 대비 post-treatment 후 평균 식사장애 검사(EDE-Q) 변화량 |\n| 임상시험 디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고 | 시퀀싱(sequencing) 필드의 메시지를 보호 | (1) Eating Disorder Examination Questionnaire (EDE-Q) | 적용 |\n| 할 수 있다.  본 예시는 대표적인 예를 작성한 것으로 실제 시험규격에 대해 작성 | 해당 임상시험용 의료기기 및 대조시험용 의료기기의 품목명, 제조회사, 원재료, 모양, | Global Impression of |\n| 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | 유효성 | (AB-1234) |\n| 가이드라인’을 참고하여 임상시험 피험자 수 산출 방식을 적용한다.  피험자 수를 결정 | - 시험자는 시험책임자, 시험담당자, 임상시험 조정자를 포함한다.  | 3) 스크리닝 시점에 BMI 가 17kg/㎡미만, 40kg/㎡이상인 자 |\n| 그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있다.  피험자 배정과 처리 | 1) 방문 1 (스크리닝 및 검사일, Screening) | 피험자의 모집 기간, 임상 관찰 및 시험 수행 기간, 통계 처리 기간, 결과보고서 작성 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례기록서 | 식약처장은 [의료법]에 따른 의료기관 중 임상시험에 필요한 시설, 인력 및 기구를 | 임상시험용 의료기기 관리자는 임상시험기관에서 임상시험용 해당 의료기기를 | 시험책임자는 의료기기법 시행규칙 제24조 제1항 제4호의 규정에 따라 임상 | : 선정기준 모두를 만족하는 자 | 나) 회원가입 및 초기 평가를 시행한다. ",
        "original_sentence": "본 예시는 대표적인 예를 작성한 것으로 실제 시험규격에 대해 작성 | 해당 임상시험용 의료기기 및 대조시험용 의료기기의 품목명, 제조회사, 원재료, 모양, | Global Impression of |\n| 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | 유효성 | (AB-1234) |\n| 가이드라인’을 참고하여 임상시험 피험자 수 산출 방식을 적용한다. "
      }
    },
    {
      "chunk_id": "chunk_498",
      "text": "피험자 수를 결정 | - 시험자는 시험책임자, 시험담당자, 임상시험 조정자를 포함한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 497,
        "window_size": 3,
        "char_count": 49,
        "word_count": 11,
        "page_number": 3,
        "window_text": "위해요인 식별 예시\n\n식별한 각 위해요인에 대하여 위험관리 계획서에 정의한 위험\n\n식별한 모든 위험에 대하여 위험의 평가 결과를 ‘위험을\n\n허용할 수 없는 영역(unacceptable)’과‘합리적으로 실현할\n\n수 있는 가장 낮은 영역(As Low As Reasonably Practicable,\n\nALARP)’, ‘허용할 수 있는 영역(acceptable)’의 3단계 또는\n\n‘위험을 허용할 수 없는 영역(unacceptable)’과 ‘허용할 수\n\n**[표 시작]**\n\n| 위해요인 | 발생 가능한 |\n| --- | --- |\n**사용자의**\n\n**[표 끝]**\n\n- - 28 -\n다) 위험통제\n\n제조자는 위험평가 결과 중 ‘위험을 허용할 수 없는 영역\n\n(unacceptable)’과‘합리적으로 실현할 수 있는 가장 낮은 영역\n\n(ALARP)’을 허용 가능한 수준까지 감소시키기 위하여 위험\n\n통제 조치를 식별하고, <표 13>과 같이 위험통제 활동을 수행\n\n모든 위험통제 조치를 하고 검증한 뒤 위험관리 계획에서\n\n정의한 위험허용 기준을 사용하여 해당 의료기기에서 식별한\n\n전체 잔여위험이 허용 가능한지 아닌지를 결정하고 <표 14>와\n\n발생\n\n가능\n\n없음\n\n인증 기능 구현\n\n- - 29 -\n4) 사이버보안 적용 방법\n\n‘의료기기 사이버보안 요구사항 체크리스트’는 의료기기\n\n사이버보안 요구사항에 대한 적합성 여부를 확인할 수 있는 자료로\n\n제조자는 체크리스트의 질의 사항을 확인하여 요구사항의 적용\n\n사용되는 통신기술(유·무선 통신 방식 등), 사용환경(병원\n\n내/외 사용, 공용 네트워크망 사용 등) 등 통신 특성을 확인할\n\n수 있는 사항을 기재한다.  이를 기반으로 체크리스트에 따라\n\n요구사항 적용여부, 적합성 입증방법, 첨부자료 또는 문서번호를\n\n- - 30 -\n<예시> - 의료기기 사이버보안 요구사항 체크리스트\n\n< 의료기기 사이버보안 특성 기재 >\n\n1) 사용되는 통신 기술 : 유선 통신(LAN), 무선통신(Wi-fi, 블루투스)\n\n**[표 시작]**\n\n**무결성**\n**물리적**\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 |\n| 신뢰성 | ※ 피험자 수: 시험대상수 산출시 일반적인 고려사항 |\n| 발 | 행 | 일 2023년 12월 7일 |\n**- 임상연구에서 피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 수가 보장**\n**사용자**\n**가용성**\n| 발 | 행 | 인 | 박윤주 |\n| 편 집 위 원 장 이정림 | 1) 이상 사례 교육 |\n| 연구 참여 동의서 취득 | O | - | - | - |\n| 편 | 집 | 위 | 원 | 이원규, 박해대, 양승하, 한영민, 김건소, 채형래 |\n| 임상시험 의료기기 적용 | O | O | O | O |\n| 문 | 의 | 처 |\n| 소프트 | 평가지표 Baseline 수집 | (O) | O | - | - |\n| 평가지표 수집 및 분석2) | 2)2) | O | O | O | O |\n**2) 중대한 이상 의료기기 이상 반응 보고**\n| 데이터 | 시험보고서 |\n\n**[표 끝]**\n\n- - 31 -\n제조자는 기밀성에 대한 위험통제 수단이\n\n요구될 때, 통신 프로토콜의 컨트롤(control)/\n\n**[표 시작]**\n\n| 검증 및 | 시험보고서 |\n| --- | --- |\n| 피험자 수는 임상시험 방법에 따라 식약처의 ‘의료기기 임상시험 관련 통계기법 | : 시험군의 치료 전 대비 post-treatment 후 평균 식사장애 검사(EDE-Q) 변화량 |\n| 임상시험 디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고 | 시퀀싱(sequencing) 필드의 메시지를 보호 | (1) Eating Disorder Examination Questionnaire (EDE-Q) | 적용 |\n| 할 수 있다.  본 예시는 대표적인 예를 작성한 것으로 실제 시험규격에 대해 작성 | 해당 임상시험용 의료기기 및 대조시험용 의료기기의 품목명, 제조회사, 원재료, 모양, | Global Impression of |\n| 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | 유효성 | (AB-1234) |\n| 가이드라인’을 참고하여 임상시험 피험자 수 산출 방식을 적용한다.  피험자 수를 결정 | - 시험자는 시험책임자, 시험담당자, 임상시험 조정자를 포함한다.  | 3) 스크리닝 시점에 BMI 가 17kg/㎡미만, 40kg/㎡이상인 자 |\n| 그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있다.  피험자 배정과 처리 | 1) 방문 1 (스크리닝 및 검사일, Screening) | 피험자의 모집 기간, 임상 관찰 및 시험 수행 기간, 통계 처리 기간, 결과보고서 작성 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례기록서 | 식약처장은 [의료법]에 따른 의료기관 중 임상시험에 필요한 시설, 인력 및 기구를 | 임상시험용 의료기기 관리자는 임상시험기관에서 임상시험용 해당 의료기기를 | 시험책임자는 의료기기법 시행규칙 제24조 제1항 제4호의 규정에 따라 임상 | : 선정기준 모두를 만족하는 자 | 나) 회원가입 및 초기 평가를 시행한다.  | 하는 내용이 포함되어서는 안된다. ",
        "original_sentence": "피험자 수를 결정 | - 시험자는 시험책임자, 시험담당자, 임상시험 조정자를 포함한다. "
      }
    },
    {
      "chunk_id": "chunk_499",
      "text": "| 3) 스크리닝 시점에 BMI 가 17kg/㎡미만, 40kg/㎡이상인 자 |\n| 그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 498,
        "window_size": 3,
        "char_count": 82,
        "word_count": 21,
        "page_number": 19,
        "window_text": "이를 기반으로 체크리스트에 따라\n\n요구사항 적용여부, 적합성 입증방법, 첨부자료 또는 문서번호를\n\n- - 30 -\n<예시> - 의료기기 사이버보안 요구사항 체크리스트\n\n< 의료기기 사이버보안 특성 기재 >\n\n1) 사용되는 통신 기술 : 유선 통신(LAN), 무선통신(Wi-fi, 블루투스)\n\n**[표 시작]**\n\n**무결성**\n**물리적**\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 |\n| 신뢰성 | ※ 피험자 수: 시험대상수 산출시 일반적인 고려사항 |\n| 발 | 행 | 일 2023년 12월 7일 |\n**- 임상연구에서 피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 수가 보장**\n**사용자**\n**가용성**\n| 발 | 행 | 인 | 박윤주 |\n| 편 집 위 원 장 이정림 | 1) 이상 사례 교육 |\n| 연구 참여 동의서 취득 | O | - | - | - |\n| 편 | 집 | 위 | 원 | 이원규, 박해대, 양승하, 한영민, 김건소, 채형래 |\n| 임상시험 의료기기 적용 | O | O | O | O |\n| 문 | 의 | 처 |\n| 소프트 | 평가지표 Baseline 수집 | (O) | O | - | - |\n| 평가지표 수집 및 분석2) | 2)2) | O | O | O | O |\n**2) 중대한 이상 의료기기 이상 반응 보고**\n| 데이터 | 시험보고서 |\n\n**[표 끝]**\n\n- - 31 -\n제조자는 기밀성에 대한 위험통제 수단이\n\n요구될 때, 통신 프로토콜의 컨트롤(control)/\n\n**[표 시작]**\n\n| 검증 및 | 시험보고서 |\n| --- | --- |\n| 피험자 수는 임상시험 방법에 따라 식약처의 ‘의료기기 임상시험 관련 통계기법 | : 시험군의 치료 전 대비 post-treatment 후 평균 식사장애 검사(EDE-Q) 변화량 |\n| 임상시험 디자인에서 많이 사용되는 설계방법에 대한 내용을 참고하여 선택하고 | 시퀀싱(sequencing) 필드의 메시지를 보호 | (1) Eating Disorder Examination Questionnaire (EDE-Q) | 적용 |\n| 할 수 있다.  본 예시는 대표적인 예를 작성한 것으로 실제 시험규격에 대해 작성 | 해당 임상시험용 의료기기 및 대조시험용 의료기기의 품목명, 제조회사, 원재료, 모양, | Global Impression of |\n| 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | 유효성 | (AB-1234) |\n| 가이드라인’을 참고하여 임상시험 피험자 수 산출 방식을 적용한다.  피험자 수를 결정 | - 시험자는 시험책임자, 시험담당자, 임상시험 조정자를 포함한다.  | 3) 스크리닝 시점에 BMI 가 17kg/㎡미만, 40kg/㎡이상인 자 |\n| 그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있다.  피험자 배정과 처리 | 1) 방문 1 (스크리닝 및 검사일, Screening) | 피험자의 모집 기간, 임상 관찰 및 시험 수행 기간, 통계 처리 기간, 결과보고서 작성 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례기록서 | 식약처장은 [의료법]에 따른 의료기관 중 임상시험에 필요한 시설, 인력 및 기구를 | 임상시험용 의료기기 관리자는 임상시험기관에서 임상시험용 해당 의료기기를 | 시험책임자는 의료기기법 시행규칙 제24조 제1항 제4호의 규정에 따라 임상 | : 선정기준 모두를 만족하는 자 | 나) 회원가입 및 초기 평가를 시행한다.  | 하는 내용이 포함되어서는 안된다.  | (CGI-I) 평균 점수 | - 시험군 혹은 대조군에 무작위배정을 통해 배치한다. ",
        "original_sentence": "| 3) 스크리닝 시점에 BMI 가 17kg/㎡미만, 40kg/㎡이상인 자 |\n| 그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_500",
      "text": "피험자 배정과 처리 | 1) 방문 1 (스크리닝 및 검사일, Screening) | 피험자의 모집 기간, 임상 관찰 및 시험 수행 기간, 통계 처리 기간, 결과보고서 작성 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례기록서 | 식약처장은 [의료법]에 따른 의료기관 중 임상시험에 필요한 시설, 인력 및 기구를 | 임상시험용 의료기기 관리자는 임상시험기관에서 임상시험용 해당 의료기기를 | 시험책임자는 의료기기법 시행규칙 제24조 제1항 제4호의 규정에 따라 임상 | : 선정기준 모두를 만족하는 자 | 나) 회원가입 및 초기 평가를 시행한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 499,
        "window_size": 3,
        "char_count": 322,
        "word_count": 80,
        "page_number": 19,
        "window_text": "본 예시는 대표적인 예를 작성한 것으로 실제 시험규격에 대해 작성 | 해당 임상시험용 의료기기 및 대조시험용 의료기기의 품목명, 제조회사, 원재료, 모양, | Global Impression of |\n| 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | 유효성 | (AB-1234) |\n| 가이드라인’을 참고하여 임상시험 피험자 수 산출 방식을 적용한다.  피험자 수를 결정 | - 시험자는 시험책임자, 시험담당자, 임상시험 조정자를 포함한다.  | 3) 스크리닝 시점에 BMI 가 17kg/㎡미만, 40kg/㎡이상인 자 |\n| 그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있다.  피험자 배정과 처리 | 1) 방문 1 (스크리닝 및 검사일, Screening) | 피험자의 모집 기간, 임상 관찰 및 시험 수행 기간, 통계 처리 기간, 결과보고서 작성 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례기록서 | 식약처장은 [의료법]에 따른 의료기관 중 임상시험에 필요한 시설, 인력 및 기구를 | 임상시험용 의료기기 관리자는 임상시험기관에서 임상시험용 해당 의료기기를 | 시험책임자는 의료기기법 시행규칙 제24조 제1항 제4호의 규정에 따라 임상 | : 선정기준 모두를 만족하는 자 | 나) 회원가입 및 초기 평가를 시행한다.  | 하는 내용이 포함되어서는 안된다.  | (CGI-I) 평균 점수 | - 시험군 혹은 대조군에 무작위배정을 통해 배치한다.  | - 계획서 순응 임상시험대상자군(Per-protocol Set, PPS) | 분석한다. ",
        "original_sentence": "피험자 배정과 처리 | 1) 방문 1 (스크리닝 및 검사일, Screening) | 피험자의 모집 기간, 임상 관찰 및 시험 수행 기간, 통계 처리 기간, 결과보고서 작성 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례기록서 | 식약처장은 [의료법]에 따른 의료기관 중 임상시험에 필요한 시설, 인력 및 기구를 | 임상시험용 의료기기 관리자는 임상시험기관에서 임상시험용 해당 의료기기를 | 시험책임자는 의료기기법 시행규칙 제24조 제1항 제4호의 규정에 따라 임상 | : 선정기준 모두를 만족하는 자 | 나) 회원가입 및 초기 평가를 시행한다. "
      }
    },
    {
      "chunk_id": "chunk_501",
      "text": "| 하는 내용이 포함되어서는 안된다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 500,
        "window_size": 3,
        "char_count": 21,
        "word_count": 5,
        "page_number": 15,
        "window_text": "피험자 수를 결정 | - 시험자는 시험책임자, 시험담당자, 임상시험 조정자를 포함한다.  | 3) 스크리닝 시점에 BMI 가 17kg/㎡미만, 40kg/㎡이상인 자 |\n| 그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있다.  피험자 배정과 처리 | 1) 방문 1 (스크리닝 및 검사일, Screening) | 피험자의 모집 기간, 임상 관찰 및 시험 수행 기간, 통계 처리 기간, 결과보고서 작성 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례기록서 | 식약처장은 [의료법]에 따른 의료기관 중 임상시험에 필요한 시설, 인력 및 기구를 | 임상시험용 의료기기 관리자는 임상시험기관에서 임상시험용 해당 의료기기를 | 시험책임자는 의료기기법 시행규칙 제24조 제1항 제4호의 규정에 따라 임상 | : 선정기준 모두를 만족하는 자 | 나) 회원가입 및 초기 평가를 시행한다.  | 하는 내용이 포함되어서는 안된다.  | (CGI-I) 평균 점수 | - 시험군 혹은 대조군에 무작위배정을 통해 배치한다.  | - 계획서 순응 임상시험대상자군(Per-protocol Set, PPS) | 분석한다.  | 하거나 암호화의 키 관련 자료가 손상되는 | 제조자는 새로운 사이버보안 취약성에 대응할 |\n| 구조, 성능 등을 구체적으로 기재하도록 한다. ",
        "original_sentence": "| 하는 내용이 포함되어서는 안된다. "
      }
    },
    {
      "chunk_id": "chunk_502",
      "text": "| (CGI-I) 평균 점수 | - 시험군 혹은 대조군에 무작위배정을 통해 배치한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 501,
        "window_size": 3,
        "char_count": 48,
        "word_count": 12,
        "page_number": 15,
        "window_text": "| 3) 스크리닝 시점에 BMI 가 17kg/㎡미만, 40kg/㎡이상인 자 |\n| 그 외 임상시험의 목적에 따라 다른 디자인을 사용할 수도 있다.  피험자 배정과 처리 | 1) 방문 1 (스크리닝 및 검사일, Screening) | 피험자의 모집 기간, 임상 관찰 및 시험 수행 기간, 통계 처리 기간, 결과보고서 작성 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례기록서 | 식약처장은 [의료법]에 따른 의료기관 중 임상시험에 필요한 시설, 인력 및 기구를 | 임상시험용 의료기기 관리자는 임상시험기관에서 임상시험용 해당 의료기기를 | 시험책임자는 의료기기법 시행규칙 제24조 제1항 제4호의 규정에 따라 임상 | : 선정기준 모두를 만족하는 자 | 나) 회원가입 및 초기 평가를 시행한다.  | 하는 내용이 포함되어서는 안된다.  | (CGI-I) 평균 점수 | - 시험군 혹은 대조군에 무작위배정을 통해 배치한다.  | - 계획서 순응 임상시험대상자군(Per-protocol Set, PPS) | 분석한다.  | 하거나 암호화의 키 관련 자료가 손상되는 | 제조자는 새로운 사이버보안 취약성에 대응할 |\n| 구조, 성능 등을 구체적으로 기재하도록 한다.  | - 해당 의료기기의 임상시험에 따른 유효성 평가는 사용된 모든 의료기기를 | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 및 | armacology, 83(8), 1636–1642. ",
        "original_sentence": "| (CGI-I) 평균 점수 | - 시험군 혹은 대조군에 무작위배정을 통해 배치한다. "
      }
    },
    {
      "chunk_id": "chunk_503",
      "text": "| - 계획서 순응 임상시험대상자군(Per-protocol Set, PPS) | 분석한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 502,
        "window_size": 3,
        "char_count": 51,
        "word_count": 9,
        "page_number": 15,
        "window_text": "피험자 배정과 처리 | 1) 방문 1 (스크리닝 및 검사일, Screening) | 피험자의 모집 기간, 임상 관찰 및 시험 수행 기간, 통계 처리 기간, 결과보고서 작성 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례기록서 | 식약처장은 [의료법]에 따른 의료기관 중 임상시험에 필요한 시설, 인력 및 기구를 | 임상시험용 의료기기 관리자는 임상시험기관에서 임상시험용 해당 의료기기를 | 시험책임자는 의료기기법 시행규칙 제24조 제1항 제4호의 규정에 따라 임상 | : 선정기준 모두를 만족하는 자 | 나) 회원가입 및 초기 평가를 시행한다.  | 하는 내용이 포함되어서는 안된다.  | (CGI-I) 평균 점수 | - 시험군 혹은 대조군에 무작위배정을 통해 배치한다.  | - 계획서 순응 임상시험대상자군(Per-protocol Set, PPS) | 분석한다.  | 하거나 암호화의 키 관련 자료가 손상되는 | 제조자는 새로운 사이버보안 취약성에 대응할 |\n| 구조, 성능 등을 구체적으로 기재하도록 한다.  | - 해당 의료기기의 임상시험에 따른 유효성 평가는 사용된 모든 의료기기를 | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 및 | armacology, 83(8), 1636–1642.  | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상반응 등에 대하여 임상 | 이상사례(의료기기이상반응, 중대한 이상반응/의료기기이상반응 포함)의 발생 시 | Mental Health & Social Work, 43(3), 58-81. ",
        "original_sentence": "| - 계획서 순응 임상시험대상자군(Per-protocol Set, PPS) | 분석한다. "
      }
    },
    {
      "chunk_id": "chunk_504",
      "text": "| 하거나 암호화의 키 관련 자료가 손상되는 | 제조자는 새로운 사이버보안 취약성에 대응할 |\n| 구조, 성능 등을 구체적으로 기재하도록 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 503,
        "window_size": 3,
        "char_count": 81,
        "word_count": 21,
        "page_number": 28,
        "window_text": "| 하는 내용이 포함되어서는 안된다.  | (CGI-I) 평균 점수 | - 시험군 혹은 대조군에 무작위배정을 통해 배치한다.  | - 계획서 순응 임상시험대상자군(Per-protocol Set, PPS) | 분석한다.  | 하거나 암호화의 키 관련 자료가 손상되는 | 제조자는 새로운 사이버보안 취약성에 대응할 |\n| 구조, 성능 등을 구체적으로 기재하도록 한다.  | - 해당 의료기기의 임상시험에 따른 유효성 평가는 사용된 모든 의료기기를 | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 및 | armacology, 83(8), 1636–1642.  | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상반응 등에 대하여 임상 | 이상사례(의료기기이상반응, 중대한 이상반응/의료기기이상반응 포함)의 발생 시 | Mental Health & Social Work, 43(3), 58-81.  | Improvement (CGI-I) 평균 | : 대조군의 치료 전 대비 post-treatment 후 평균 식사장애 검사(EDE-Q) 변화량 |\n| 시에는 해당 제품의 특성 및 주요 기능을 고려하여 작성하여야 한다. ",
        "original_sentence": "| 하거나 암호화의 키 관련 자료가 손상되는 | 제조자는 새로운 사이버보안 취약성에 대응할 |\n| 구조, 성능 등을 구체적으로 기재하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_505",
      "text": "| - 해당 의료기기의 임상시험에 따른 유효성 평가는 사용된 모든 의료기기를 | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 및 | armacology, 83(8), 1636–1642. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 504,
        "window_size": 3,
        "char_count": 122,
        "word_count": 25,
        "page_number": 18,
        "window_text": "| (CGI-I) 평균 점수 | - 시험군 혹은 대조군에 무작위배정을 통해 배치한다.  | - 계획서 순응 임상시험대상자군(Per-protocol Set, PPS) | 분석한다.  | 하거나 암호화의 키 관련 자료가 손상되는 | 제조자는 새로운 사이버보안 취약성에 대응할 |\n| 구조, 성능 등을 구체적으로 기재하도록 한다.  | - 해당 의료기기의 임상시험에 따른 유효성 평가는 사용된 모든 의료기기를 | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 및 | armacology, 83(8), 1636–1642.  | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상반응 등에 대하여 임상 | 이상사례(의료기기이상반응, 중대한 이상반응/의료기기이상반응 포함)의 발생 시 | Mental Health & Social Work, 43(3), 58-81.  | Improvement (CGI-I) 평균 | : 대조군의 치료 전 대비 post-treatment 후 평균 식사장애 검사(EDE-Q) 변화량 |\n| 시에는 해당 제품의 특성 및 주요 기능을 고려하여 작성하여야 한다.  | 하기 위해서는 사전 정보가 필요한데, 여기에 포함되어야 할 필수 정보로는 다음이 있다. ",
        "original_sentence": "| - 해당 의료기기의 임상시험에 따른 유효성 평가는 사용된 모든 의료기기를 | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 및 | armacology, 83(8), 1636–1642. "
      }
    },
    {
      "chunk_id": "chunk_506",
      "text": "| 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상반응 등에 대하여 임상 | 이상사례(의료기기이상반응, 중대한 이상반응/의료기기이상반응 포함)의 발생 시 | Mental Health & Social Work, 43(3), 58-81. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 505,
        "window_size": 3,
        "char_count": 135,
        "word_count": 27,
        "page_number": 28,
        "window_text": "| - 계획서 순응 임상시험대상자군(Per-protocol Set, PPS) | 분석한다.  | 하거나 암호화의 키 관련 자료가 손상되는 | 제조자는 새로운 사이버보안 취약성에 대응할 |\n| 구조, 성능 등을 구체적으로 기재하도록 한다.  | - 해당 의료기기의 임상시험에 따른 유효성 평가는 사용된 모든 의료기기를 | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 및 | armacology, 83(8), 1636–1642.  | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상반응 등에 대하여 임상 | 이상사례(의료기기이상반응, 중대한 이상반응/의료기기이상반응 포함)의 발생 시 | Mental Health & Social Work, 43(3), 58-81.  | Improvement (CGI-I) 평균 | : 대조군의 치료 전 대비 post-treatment 후 평균 식사장애 검사(EDE-Q) 변화량 |\n| 시에는 해당 제품의 특성 및 주요 기능을 고려하여 작성하여야 한다.  | 하기 위해서는 사전 정보가 필요한데, 여기에 포함되어야 할 필수 정보로는 다음이 있다.  | - 임상시험 전, 중, 후에 관찰해야 할 항목들을 나열한다. ",
        "original_sentence": "| 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상반응 등에 대하여 임상 | 이상사례(의료기기이상반응, 중대한 이상반응/의료기기이상반응 포함)의 발생 시 | Mental Health & Social Work, 43(3), 58-81. "
      }
    },
    {
      "chunk_id": "chunk_507",
      "text": "| Improvement (CGI-I) 평균 | : 대조군의 치료 전 대비 post-treatment 후 평균 식사장애 검사(EDE-Q) 변화량 |\n| 시에는 해당 제품의 특성 및 주요 기능을 고려하여 작성하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 506,
        "window_size": 3,
        "char_count": 125,
        "word_count": 28,
        "page_number": 34,
        "window_text": "| 하거나 암호화의 키 관련 자료가 손상되는 | 제조자는 새로운 사이버보안 취약성에 대응할 |\n| 구조, 성능 등을 구체적으로 기재하도록 한다.  | - 해당 의료기기의 임상시험에 따른 유효성 평가는 사용된 모든 의료기기를 | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 및 | armacology, 83(8), 1636–1642.  | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상반응 등에 대하여 임상 | 이상사례(의료기기이상반응, 중대한 이상반응/의료기기이상반응 포함)의 발생 시 | Mental Health & Social Work, 43(3), 58-81.  | Improvement (CGI-I) 평균 | : 대조군의 치료 전 대비 post-treatment 후 평균 식사장애 검사(EDE-Q) 변화량 |\n| 시에는 해당 제품의 특성 및 주요 기능을 고려하여 작성하여야 한다.  | 하기 위해서는 사전 정보가 필요한데, 여기에 포함되어야 할 필수 정보로는 다음이 있다.  | - 임상시험 전, 중, 후에 관찰해야 할 항목들을 나열한다.  | 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 | 소프트웨어 |\n**기술하는 것을 말하며, 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의**\n| - 부작용, 이상반응 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람 |\n| 보관, 관리하는 임상의, 의료기사 또는 간호사 등으로 임상시험기관의 장이 지정한 | 시험을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화할 때, 헬싱키 선언에 |\n**- 피험자(Subject)란 임상시험에 참여하는 임상시험용 또는 대조시험용 의료기기의**\n**요원을 지정하여야 한다. ",
        "original_sentence": "| Improvement (CGI-I) 평균 | : 대조군의 치료 전 대비 post-treatment 후 평균 식사장애 검사(EDE-Q) 변화량 |\n| 시에는 해당 제품의 특성 및 주요 기능을 고려하여 작성하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_508",
      "text": "| 하기 위해서는 사전 정보가 필요한데, 여기에 포함되어야 할 필수 정보로는 다음이 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 507,
        "window_size": 3,
        "char_count": 51,
        "word_count": 13,
        "page_number": 34,
        "window_text": "| - 해당 의료기기의 임상시험에 따른 유효성 평가는 사용된 모든 의료기기를 | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 및 | armacology, 83(8), 1636–1642.  | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상반응 등에 대하여 임상 | 이상사례(의료기기이상반응, 중대한 이상반응/의료기기이상반응 포함)의 발생 시 | Mental Health & Social Work, 43(3), 58-81.  | Improvement (CGI-I) 평균 | : 대조군의 치료 전 대비 post-treatment 후 평균 식사장애 검사(EDE-Q) 변화량 |\n| 시에는 해당 제품의 특성 및 주요 기능을 고려하여 작성하여야 한다.  | 하기 위해서는 사전 정보가 필요한데, 여기에 포함되어야 할 필수 정보로는 다음이 있다.  | - 임상시험 전, 중, 후에 관찰해야 할 항목들을 나열한다.  | 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 | 소프트웨어 |\n**기술하는 것을 말하며, 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의**\n| - 부작용, 이상반응 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람 |\n| 보관, 관리하는 임상의, 의료기사 또는 간호사 등으로 임상시험기관의 장이 지정한 | 시험을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화할 때, 헬싱키 선언에 |\n**- 피험자(Subject)란 임상시험에 참여하는 임상시험용 또는 대조시험용 의료기기의**\n**요원을 지정하여야 한다.  임상시험 모니터요원의 선정, 자격기준, 수행임무 등에**\n**대한 사항은 「의료기기법 시행규칙」별표3 “의료기기의 임상시험 관리기준” 제8호**\n| 1) 스크리닝 및 검사일은 치료 시작일 전 28일 이내에 시작한다. ",
        "original_sentence": "| 하기 위해서는 사전 정보가 필요한데, 여기에 포함되어야 할 필수 정보로는 다음이 있다. "
      }
    },
    {
      "chunk_id": "chunk_509",
      "text": "| - 임상시험 전, 중, 후에 관찰해야 할 항목들을 나열한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 508,
        "window_size": 3,
        "char_count": 36,
        "word_count": 10,
        "page_number": 7,
        "window_text": "| 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상반응 등에 대하여 임상 | 이상사례(의료기기이상반응, 중대한 이상반응/의료기기이상반응 포함)의 발생 시 | Mental Health & Social Work, 43(3), 58-81.  | Improvement (CGI-I) 평균 | : 대조군의 치료 전 대비 post-treatment 후 평균 식사장애 검사(EDE-Q) 변화량 |\n| 시에는 해당 제품의 특성 및 주요 기능을 고려하여 작성하여야 한다.  | 하기 위해서는 사전 정보가 필요한데, 여기에 포함되어야 할 필수 정보로는 다음이 있다.  | - 임상시험 전, 중, 후에 관찰해야 할 항목들을 나열한다.  | 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 | 소프트웨어 |\n**기술하는 것을 말하며, 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의**\n| - 부작용, 이상반응 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람 |\n| 보관, 관리하는 임상의, 의료기사 또는 간호사 등으로 임상시험기관의 장이 지정한 | 시험을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화할 때, 헬싱키 선언에 |\n**- 피험자(Subject)란 임상시험에 참여하는 임상시험용 또는 대조시험용 의료기기의**\n**요원을 지정하여야 한다.  임상시험 모니터요원의 선정, 자격기준, 수행임무 등에**\n**대한 사항은 「의료기기법 시행규칙」별표3 “의료기기의 임상시험 관리기준” 제8호**\n| 1) 스크리닝 및 검사일은 치료 시작일 전 28일 이내에 시작한다.  | 2) 수집하는 지표에 따라 수집이 다를 경우 나누어 표현한다. ",
        "original_sentence": "| - 임상시험 전, 중, 후에 관찰해야 할 항목들을 나열한다. "
      }
    },
    {
      "chunk_id": "chunk_510",
      "text": "| 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 | 소프트웨어 |\n**기술하는 것을 말하며, 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의**\n| - 부작용, 이상반응 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람 |\n| 보관, 관리하는 임상의, 의료기사 또는 간호사 등으로 임상시험기관의 장이 지정한 | 시험을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화할 때, 헬싱키 선언에 |\n**- 피험자(Subject)란 임상시험에 참여하는 임상시험용 또는 대조시험용 의료기기의**\n**요원을 지정하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 509,
        "window_size": 3,
        "char_count": 355,
        "word_count": 84,
        "page_number": 3,
        "window_text": "| Improvement (CGI-I) 평균 | : 대조군의 치료 전 대비 post-treatment 후 평균 식사장애 검사(EDE-Q) 변화량 |\n| 시에는 해당 제품의 특성 및 주요 기능을 고려하여 작성하여야 한다.  | 하기 위해서는 사전 정보가 필요한데, 여기에 포함되어야 할 필수 정보로는 다음이 있다.  | - 임상시험 전, 중, 후에 관찰해야 할 항목들을 나열한다.  | 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 | 소프트웨어 |\n**기술하는 것을 말하며, 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의**\n| - 부작용, 이상반응 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람 |\n| 보관, 관리하는 임상의, 의료기사 또는 간호사 등으로 임상시험기관의 장이 지정한 | 시험을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화할 때, 헬싱키 선언에 |\n**- 피험자(Subject)란 임상시험에 참여하는 임상시험용 또는 대조시험용 의료기기의**\n**요원을 지정하여야 한다.  임상시험 모니터요원의 선정, 자격기준, 수행임무 등에**\n**대한 사항은 「의료기기법 시행규칙」별표3 “의료기기의 임상시험 관리기준” 제8호**\n| 1) 스크리닝 및 검사일은 치료 시작일 전 28일 이내에 시작한다.  | 2) 수집하는 지표에 따라 수집이 다를 경우 나누어 표현한다.  | 3) 섭식장애 개선 디지털치료기기 제품의 치료 기간에 따라 전체 치료 기간은 변경될 수 있다. ",
        "original_sentence": "| 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 | 소프트웨어 |\n**기술하는 것을 말하며, 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의**\n| - 부작용, 이상반응 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람 |\n| 보관, 관리하는 임상의, 의료기사 또는 간호사 등으로 임상시험기관의 장이 지정한 | 시험을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화할 때, 헬싱키 선언에 |\n**- 피험자(Subject)란 임상시험에 참여하는 임상시험용 또는 대조시험용 의료기기의**\n**요원을 지정하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_511",
      "text": "임상시험 모니터요원의 선정, 자격기준, 수행임무 등에**\n**대한 사항은 「의료기기법 시행규칙」별표3 “의료기기의 임상시험 관리기준” 제8호**\n| 1) 스크리닝 및 검사일은 치료 시작일 전 28일 이내에 시작한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 510,
        "window_size": 3,
        "char_count": 121,
        "word_count": 25,
        "page_number": 3,
        "window_text": "| 하기 위해서는 사전 정보가 필요한데, 여기에 포함되어야 할 필수 정보로는 다음이 있다.  | - 임상시험 전, 중, 후에 관찰해야 할 항목들을 나열한다.  | 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 | 소프트웨어 |\n**기술하는 것을 말하며, 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의**\n| - 부작용, 이상반응 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람 |\n| 보관, 관리하는 임상의, 의료기사 또는 간호사 등으로 임상시험기관의 장이 지정한 | 시험을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화할 때, 헬싱키 선언에 |\n**- 피험자(Subject)란 임상시험에 참여하는 임상시험용 또는 대조시험용 의료기기의**\n**요원을 지정하여야 한다.  임상시험 모니터요원의 선정, 자격기준, 수행임무 등에**\n**대한 사항은 「의료기기법 시행규칙」별표3 “의료기기의 임상시험 관리기준” 제8호**\n| 1) 스크리닝 및 검사일은 치료 시작일 전 28일 이내에 시작한다.  | 2) 수집하는 지표에 따라 수집이 다를 경우 나누어 표현한다.  | 3) 섭식장애 개선 디지털치료기기 제품의 치료 기간에 따라 전체 치료 기간은 변경될 수 있다.  | 4) 임상시험 설계에 따른 선택사항이므로 치료 기간 종료 후 추적관찰 기간은 변경될 수 있다. ",
        "original_sentence": "임상시험 모니터요원의 선정, 자격기준, 수행임무 등에**\n**대한 사항은 「의료기기법 시행규칙」별표3 “의료기기의 임상시험 관리기준” 제8호**\n| 1) 스크리닝 및 검사일은 치료 시작일 전 28일 이내에 시작한다. "
      }
    },
    {
      "chunk_id": "chunk_512",
      "text": "| 2) 수집하는 지표에 따라 수집이 다를 경우 나누어 표현한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 511,
        "window_size": 3,
        "char_count": 37,
        "word_count": 10,
        "page_number": 9,
        "window_text": "| - 임상시험 전, 중, 후에 관찰해야 할 항목들을 나열한다.  | 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 | 소프트웨어 |\n**기술하는 것을 말하며, 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의**\n| - 부작용, 이상반응 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람 |\n| 보관, 관리하는 임상의, 의료기사 또는 간호사 등으로 임상시험기관의 장이 지정한 | 시험을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화할 때, 헬싱키 선언에 |\n**- 피험자(Subject)란 임상시험에 참여하는 임상시험용 또는 대조시험용 의료기기의**\n**요원을 지정하여야 한다.  임상시험 모니터요원의 선정, 자격기준, 수행임무 등에**\n**대한 사항은 「의료기기법 시행규칙」별표3 “의료기기의 임상시험 관리기준” 제8호**\n| 1) 스크리닝 및 검사일은 치료 시작일 전 28일 이내에 시작한다.  | 2) 수집하는 지표에 따라 수집이 다를 경우 나누어 표현한다.  | 3) 섭식장애 개선 디지털치료기기 제품의 치료 기간에 따라 전체 치료 기간은 변경될 수 있다.  | 4) 임상시험 설계에 따른 선택사항이므로 치료 기간 종료 후 추적관찰 기간은 변경될 수 있다.  | 시험보고서 |\n| 1) 과거에 섭식장애 치료를 위하여 인지행동치료를 받아본 자 | 아래와 같다. ",
        "original_sentence": "| 2) 수집하는 지표에 따라 수집이 다를 경우 나누어 표현한다. "
      }
    },
    {
      "chunk_id": "chunk_513",
      "text": "| 3) 섭식장애 개선 디지털치료기기 제품의 치료 기간에 따라 전체 치료 기간은 변경될 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 512,
        "window_size": 3,
        "char_count": 55,
        "word_count": 15,
        "page_number": 1,
        "window_text": "| 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 | 소프트웨어 |\n**기술하는 것을 말하며, 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의**\n| - 부작용, 이상반응 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람 |\n| 보관, 관리하는 임상의, 의료기사 또는 간호사 등으로 임상시험기관의 장이 지정한 | 시험을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화할 때, 헬싱키 선언에 |\n**- 피험자(Subject)란 임상시험에 참여하는 임상시험용 또는 대조시험용 의료기기의**\n**요원을 지정하여야 한다.  임상시험 모니터요원의 선정, 자격기준, 수행임무 등에**\n**대한 사항은 「의료기기법 시행규칙」별표3 “의료기기의 임상시험 관리기준” 제8호**\n| 1) 스크리닝 및 검사일은 치료 시작일 전 28일 이내에 시작한다.  | 2) 수집하는 지표에 따라 수집이 다를 경우 나누어 표현한다.  | 3) 섭식장애 개선 디지털치료기기 제품의 치료 기간에 따라 전체 치료 기간은 변경될 수 있다.  | 4) 임상시험 설계에 따른 선택사항이므로 치료 기간 종료 후 추적관찰 기간은 변경될 수 있다.  | 시험보고서 |\n| 1) 과거에 섭식장애 치료를 위하여 인지행동치료를 받아본 자 | 아래와 같다.  | 디지털치료기기를 설치한다. ",
        "original_sentence": "| 3) 섭식장애 개선 디지털치료기기 제품의 치료 기간에 따라 전체 치료 기간은 변경될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_514",
      "text": "| 4) 임상시험 설계에 따른 선택사항이므로 치료 기간 종료 후 추적관찰 기간은 변경될 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 513,
        "window_size": 3,
        "char_count": 55,
        "word_count": 15,
        "page_number": 3,
        "window_text": "임상시험 모니터요원의 선정, 자격기준, 수행임무 등에**\n**대한 사항은 「의료기기법 시행규칙」별표3 “의료기기의 임상시험 관리기준” 제8호**\n| 1) 스크리닝 및 검사일은 치료 시작일 전 28일 이내에 시작한다.  | 2) 수집하는 지표에 따라 수집이 다를 경우 나누어 표현한다.  | 3) 섭식장애 개선 디지털치료기기 제품의 치료 기간에 따라 전체 치료 기간은 변경될 수 있다.  | 4) 임상시험 설계에 따른 선택사항이므로 치료 기간 종료 후 추적관찰 기간은 변경될 수 있다.  | 시험보고서 |\n| 1) 과거에 섭식장애 치료를 위하여 인지행동치료를 받아본 자 | 아래와 같다.  | 디지털치료기기를 설치한다.  | (기타 심리적 장애와 연관된 구토) |\n| (3) 병용약물: 복용 여부 및 종류 | (4) The EuroQol Visual Analogue Scale (EQ-VAS) | 가설은 아래와 같다. ",
        "original_sentence": "| 4) 임상시험 설계에 따른 선택사항이므로 치료 기간 종료 후 추적관찰 기간은 변경될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_515",
      "text": "| 시험보고서 |\n| 1) 과거에 섭식장애 치료를 위하여 인지행동치료를 받아본 자 | 아래와 같다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 514,
        "window_size": 3,
        "char_count": 56,
        "word_count": 15,
        "page_number": 19,
        "window_text": "| 2) 수집하는 지표에 따라 수집이 다를 경우 나누어 표현한다.  | 3) 섭식장애 개선 디지털치료기기 제품의 치료 기간에 따라 전체 치료 기간은 변경될 수 있다.  | 4) 임상시험 설계에 따른 선택사항이므로 치료 기간 종료 후 추적관찰 기간은 변경될 수 있다.  | 시험보고서 |\n| 1) 과거에 섭식장애 치료를 위하여 인지행동치료를 받아본 자 | 아래와 같다.  | 디지털치료기기를 설치한다.  | (기타 심리적 장애와 연관된 구토) |\n| (3) 병용약물: 복용 여부 및 종류 | (4) The EuroQol Visual Analogue Scale (EQ-VAS) | 가설은 아래와 같다.  | 열람자, 해제 후 조치사항 등에 대한 문서를 기록·보관한다. ",
        "original_sentence": "| 시험보고서 |\n| 1) 과거에 섭식장애 치료를 위하여 인지행동치료를 받아본 자 | 아래와 같다. "
      }
    },
    {
      "chunk_id": "chunk_516",
      "text": "| 디지털치료기기를 설치한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 515,
        "window_size": 3,
        "char_count": 17,
        "word_count": 3,
        "page_number": 15,
        "window_text": "| 3) 섭식장애 개선 디지털치료기기 제품의 치료 기간에 따라 전체 치료 기간은 변경될 수 있다.  | 4) 임상시험 설계에 따른 선택사항이므로 치료 기간 종료 후 추적관찰 기간은 변경될 수 있다.  | 시험보고서 |\n| 1) 과거에 섭식장애 치료를 위하여 인지행동치료를 받아본 자 | 아래와 같다.  | 디지털치료기기를 설치한다.  | (기타 심리적 장애와 연관된 구토) |\n| (3) 병용약물: 복용 여부 및 종류 | (4) The EuroQol Visual Analogue Scale (EQ-VAS) | 가설은 아래와 같다.  | 열람자, 해제 후 조치사항 등에 대한 문서를 기록·보관한다.  | (AB-1234) |\n| - 안전성 자료(Safety Set, SS) | 위한 통계처리 시 삽입할 수 있다. ",
        "original_sentence": "| 디지털치료기기를 설치한다. "
      }
    },
    {
      "chunk_id": "chunk_517",
      "text": "| (기타 심리적 장애와 연관된 구토) |\n| (3) 병용약물: 복용 여부 및 종류 | (4) The EuroQol Visual Analogue Scale (EQ-VAS) | 가설은 아래와 같다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 516,
        "window_size": 3,
        "char_count": 110,
        "word_count": 26,
        "page_number": 3,
        "window_text": "| 4) 임상시험 설계에 따른 선택사항이므로 치료 기간 종료 후 추적관찰 기간은 변경될 수 있다.  | 시험보고서 |\n| 1) 과거에 섭식장애 치료를 위하여 인지행동치료를 받아본 자 | 아래와 같다.  | 디지털치료기기를 설치한다.  | (기타 심리적 장애와 연관된 구토) |\n| (3) 병용약물: 복용 여부 및 종류 | (4) The EuroQol Visual Analogue Scale (EQ-VAS) | 가설은 아래와 같다.  | 열람자, 해제 후 조치사항 등에 대한 문서를 기록·보관한다.  | (AB-1234) |\n| - 안전성 자료(Safety Set, SS) | 위한 통계처리 시 삽입할 수 있다.  | 대해 이미 알려진 정보와 일관된 양상을 보이는 경우 | 장애와 연관된 구토) |\n| tice Review, 11, 133 - 143. ",
        "original_sentence": "| (기타 심리적 장애와 연관된 구토) |\n| (3) 병용약물: 복용 여부 및 종류 | (4) The EuroQol Visual Analogue Scale (EQ-VAS) | 가설은 아래와 같다. "
      }
    },
    {
      "chunk_id": "chunk_518",
      "text": "| 열람자, 해제 후 조치사항 등에 대한 문서를 기록·보관한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 517,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 3,
        "window_text": "| 시험보고서 |\n| 1) 과거에 섭식장애 치료를 위하여 인지행동치료를 받아본 자 | 아래와 같다.  | 디지털치료기기를 설치한다.  | (기타 심리적 장애와 연관된 구토) |\n| (3) 병용약물: 복용 여부 및 종류 | (4) The EuroQol Visual Analogue Scale (EQ-VAS) | 가설은 아래와 같다.  | 열람자, 해제 후 조치사항 등에 대한 문서를 기록·보관한다.  | (AB-1234) |\n| - 안전성 자료(Safety Set, SS) | 위한 통계처리 시 삽입할 수 있다.  | 대해 이미 알려진 정보와 일관된 양상을 보이는 경우 | 장애와 연관된 구토) |\n| tice Review, 11, 133 - 143.  | 대응 계획을 수립하여야 한다. ",
        "original_sentence": "| 열람자, 해제 후 조치사항 등에 대한 문서를 기록·보관한다. "
      }
    },
    {
      "chunk_id": "chunk_519",
      "text": "| (AB-1234) |\n| - 안전성 자료(Safety Set, SS) | 위한 통계처리 시 삽입할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 518,
        "window_size": 3,
        "char_count": 63,
        "word_count": 16,
        "page_number": 9,
        "window_text": "| 디지털치료기기를 설치한다.  | (기타 심리적 장애와 연관된 구토) |\n| (3) 병용약물: 복용 여부 및 종류 | (4) The EuroQol Visual Analogue Scale (EQ-VAS) | 가설은 아래와 같다.  | 열람자, 해제 후 조치사항 등에 대한 문서를 기록·보관한다.  | (AB-1234) |\n| - 안전성 자료(Safety Set, SS) | 위한 통계처리 시 삽입할 수 있다.  | 대해 이미 알려진 정보와 일관된 양상을 보이는 경우 | 장애와 연관된 구토) |\n| tice Review, 11, 133 - 143.  | 대응 계획을 수립하여야 한다.  | 유효성 |\n\n**[표 끝]**\n\n소프트웨어\n\n- - 32 -\n※ 예: 보안이 보장되지 않은(unsecure) 운영\n\n체제 버전에서 운영되는 의료기기 소프트웨어\n\n확인 자료\n\n- - 33 -\n5) 허가·인증 변경 시 제출자료\n\n사이버 보안에 영향을 미치는 변경(통신방법의 변경/추가,\n\n운영체제의 변경/추가, 통신 목적 변경/추가 등)이 포함된 경우\n\n에는 「의료기기 허가·신고·심사 등에 관한 규정」(식약처\n\n고시) 제19조의2(의료기기 소프트웨어 허가ㆍ인증ㆍ신고의 변경\n\n처리)에 따라, 소프트웨어 업그레이드에 해당되므로 변경허가‧\n\n이 경우에는 신규 허가와 마찬가지로 ‘의료기기 소프트웨어\n\n적합성 확인보고서’, ‘의료기기 사이버보안 요구사항 체크\n\n리스트’와 체크리스트의 요구사항을 실제로 검증 또는 검증을\n\n대체한 사유를 확인할 수 있는 자료(소프트웨어 검증 및 유효성\n\n확인자료, 성능시험성적서, 위험관리문서 등)를 제출하여야\n\n- - 34 -\n<!-- PAGE_41 -->\n##### 3. ",
        "original_sentence": "| (AB-1234) |\n| - 안전성 자료(Safety Set, SS) | 위한 통계처리 시 삽입할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_520",
      "text": "| 대해 이미 알려진 정보와 일관된 양상을 보이는 경우 | 장애와 연관된 구토) |\n| tice Review, 11, 133 - 143. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 519,
        "window_size": 3,
        "char_count": 77,
        "word_count": 21,
        "page_number": 54,
        "window_text": "| (기타 심리적 장애와 연관된 구토) |\n| (3) 병용약물: 복용 여부 및 종류 | (4) The EuroQol Visual Analogue Scale (EQ-VAS) | 가설은 아래와 같다.  | 열람자, 해제 후 조치사항 등에 대한 문서를 기록·보관한다.  | (AB-1234) |\n| - 안전성 자료(Safety Set, SS) | 위한 통계처리 시 삽입할 수 있다.  | 대해 이미 알려진 정보와 일관된 양상을 보이는 경우 | 장애와 연관된 구토) |\n| tice Review, 11, 133 - 143.  | 대응 계획을 수립하여야 한다.  | 유효성 |\n\n**[표 끝]**\n\n소프트웨어\n\n- - 32 -\n※ 예: 보안이 보장되지 않은(unsecure) 운영\n\n체제 버전에서 운영되는 의료기기 소프트웨어\n\n확인 자료\n\n- - 33 -\n5) 허가·인증 변경 시 제출자료\n\n사이버 보안에 영향을 미치는 변경(통신방법의 변경/추가,\n\n운영체제의 변경/추가, 통신 목적 변경/추가 등)이 포함된 경우\n\n에는 「의료기기 허가·신고·심사 등에 관한 규정」(식약처\n\n고시) 제19조의2(의료기기 소프트웨어 허가ㆍ인증ㆍ신고의 변경\n\n처리)에 따라, 소프트웨어 업그레이드에 해당되므로 변경허가‧\n\n이 경우에는 신규 허가와 마찬가지로 ‘의료기기 소프트웨어\n\n적합성 확인보고서’, ‘의료기기 사이버보안 요구사항 체크\n\n리스트’와 체크리스트의 요구사항을 실제로 검증 또는 검증을\n\n대체한 사유를 확인할 수 있는 자료(소프트웨어 검증 및 유효성\n\n확인자료, 성능시험성적서, 위험관리문서 등)를 제출하여야\n\n- - 34 -\n<!-- PAGE_41 -->\n##### 3.  성능 평가 항목\n\n섭식장애 개선 디지털치료기기의 성능 평가 항목은 제품의 주요\n\n기능을 근거로 설정하며, 시험 기준 및 시험 방법은 제품의 특성을\n\n고려하여 가능한 정량적이고 구체적으로 작성한다.\n\n",
        "original_sentence": "| 대해 이미 알려진 정보와 일관된 양상을 보이는 경우 | 장애와 연관된 구토) |\n| tice Review, 11, 133 - 143. "
      }
    },
    {
      "chunk_id": "chunk_521",
      "text": "| 대응 계획을 수립하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 520,
        "window_size": 3,
        "char_count": 19,
        "word_count": 5,
        "page_number": 15,
        "window_text": "| 열람자, 해제 후 조치사항 등에 대한 문서를 기록·보관한다.  | (AB-1234) |\n| - 안전성 자료(Safety Set, SS) | 위한 통계처리 시 삽입할 수 있다.  | 대해 이미 알려진 정보와 일관된 양상을 보이는 경우 | 장애와 연관된 구토) |\n| tice Review, 11, 133 - 143.  | 대응 계획을 수립하여야 한다.  | 유효성 |\n\n**[표 끝]**\n\n소프트웨어\n\n- - 32 -\n※ 예: 보안이 보장되지 않은(unsecure) 운영\n\n체제 버전에서 운영되는 의료기기 소프트웨어\n\n확인 자료\n\n- - 33 -\n5) 허가·인증 변경 시 제출자료\n\n사이버 보안에 영향을 미치는 변경(통신방법의 변경/추가,\n\n운영체제의 변경/추가, 통신 목적 변경/추가 등)이 포함된 경우\n\n에는 「의료기기 허가·신고·심사 등에 관한 규정」(식약처\n\n고시) 제19조의2(의료기기 소프트웨어 허가ㆍ인증ㆍ신고의 변경\n\n처리)에 따라, 소프트웨어 업그레이드에 해당되므로 변경허가‧\n\n이 경우에는 신규 허가와 마찬가지로 ‘의료기기 소프트웨어\n\n적합성 확인보고서’, ‘의료기기 사이버보안 요구사항 체크\n\n리스트’와 체크리스트의 요구사항을 실제로 검증 또는 검증을\n\n대체한 사유를 확인할 수 있는 자료(소프트웨어 검증 및 유효성\n\n확인자료, 성능시험성적서, 위험관리문서 등)를 제출하여야\n\n- - 34 -\n<!-- PAGE_41 -->\n##### 3.  성능 평가 항목\n\n섭식장애 개선 디지털치료기기의 성능 평가 항목은 제품의 주요\n\n기능을 근거로 설정하며, 시험 기준 및 시험 방법은 제품의 특성을\n\n고려하여 가능한 정량적이고 구체적으로 작성한다.\n\n - - 35 -\n본 예시는 이해를 돕기 위하여 작성된 것으로 실제 신청하려는 제품의 내용과 상이\n\n예시)\n\n- - 36 -\n<!-- PAGE_43 -->\n### Ⅲ\n\n<!-- PAGE_43 -->\n### 임상시험계획서 작성 시 고려사항 및 예시\n\n「의료기기법 시행규칙」제20조(임상시험계획의 승인 등) 제2항에 따라\n\n임상시험계획서에 포함되어야 할 사항은 다음과 같다.\n\n",
        "original_sentence": "| 대응 계획을 수립하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_522",
      "text": "| 유효성 |\n\n**[표 끝]**\n\n소프트웨어\n\n- - 32 -\n※ 예: 보안이 보장되지 않은(unsecure) 운영\n\n체제 버전에서 운영되는 의료기기 소프트웨어\n\n확인 자료\n\n- - 33 -\n5) 허가·인증 변경 시 제출자료\n\n사이버 보안에 영향을 미치는 변경(통신방법의 변경/추가,\n\n운영체제의 변경/추가, 통신 목적 변경/추가 등)이 포함된 경우\n\n에는 「의료기기 허가·신고·심사 등에 관한 규정」(식약처\n\n고시) 제19조의2(의료기기 소프트웨어 허가ㆍ인증ㆍ신고의 변경\n\n처리)에 따라, 소프트웨어 업그레이드에 해당되므로 변경허가‧\n\n이 경우에는 신규 허가와 마찬가지로 ‘의료기기 소프트웨어\n\n적합성 확인보고서’, ‘의료기기 사이버보안 요구사항 체크\n\n리스트’와 체크리스트의 요구사항을 실제로 검증 또는 검증을\n\n대체한 사유를 확인할 수 있는 자료(소프트웨어 검증 및 유효성\n\n확인자료, 성능시험성적서, 위험관리문서 등)를 제출하여야\n\n- - 34 -\n<!-- PAGE_41 -->\n##### 3. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 521,
        "window_size": 3,
        "char_count": 506,
        "word_count": 106,
        "page_number": 41,
        "window_text": "| (AB-1234) |\n| - 안전성 자료(Safety Set, SS) | 위한 통계처리 시 삽입할 수 있다.  | 대해 이미 알려진 정보와 일관된 양상을 보이는 경우 | 장애와 연관된 구토) |\n| tice Review, 11, 133 - 143.  | 대응 계획을 수립하여야 한다.  | 유효성 |\n\n**[표 끝]**\n\n소프트웨어\n\n- - 32 -\n※ 예: 보안이 보장되지 않은(unsecure) 운영\n\n체제 버전에서 운영되는 의료기기 소프트웨어\n\n확인 자료\n\n- - 33 -\n5) 허가·인증 변경 시 제출자료\n\n사이버 보안에 영향을 미치는 변경(통신방법의 변경/추가,\n\n운영체제의 변경/추가, 통신 목적 변경/추가 등)이 포함된 경우\n\n에는 「의료기기 허가·신고·심사 등에 관한 규정」(식약처\n\n고시) 제19조의2(의료기기 소프트웨어 허가ㆍ인증ㆍ신고의 변경\n\n처리)에 따라, 소프트웨어 업그레이드에 해당되므로 변경허가‧\n\n이 경우에는 신규 허가와 마찬가지로 ‘의료기기 소프트웨어\n\n적합성 확인보고서’, ‘의료기기 사이버보안 요구사항 체크\n\n리스트’와 체크리스트의 요구사항을 실제로 검증 또는 검증을\n\n대체한 사유를 확인할 수 있는 자료(소프트웨어 검증 및 유효성\n\n확인자료, 성능시험성적서, 위험관리문서 등)를 제출하여야\n\n- - 34 -\n<!-- PAGE_41 -->\n##### 3.  성능 평가 항목\n\n섭식장애 개선 디지털치료기기의 성능 평가 항목은 제품의 주요\n\n기능을 근거로 설정하며, 시험 기준 및 시험 방법은 제품의 특성을\n\n고려하여 가능한 정량적이고 구체적으로 작성한다.\n\n - - 35 -\n본 예시는 이해를 돕기 위하여 작성된 것으로 실제 신청하려는 제품의 내용과 상이\n\n예시)\n\n- - 36 -\n<!-- PAGE_43 -->\n### Ⅲ\n\n<!-- PAGE_43 -->\n### 임상시험계획서 작성 시 고려사항 및 예시\n\n「의료기기법 시행규칙」제20조(임상시험계획의 승인 등) 제2항에 따라\n\n임상시험계획서에 포함되어야 할 사항은 다음과 같다.\n\n - 1. ",
        "original_sentence": "| 유효성 |\n\n**[표 끝]**\n\n소프트웨어\n\n- - 32 -\n※ 예: 보안이 보장되지 않은(unsecure) 운영\n\n체제 버전에서 운영되는 의료기기 소프트웨어\n\n확인 자료\n\n- - 33 -\n5) 허가·인증 변경 시 제출자료\n\n사이버 보안에 영향을 미치는 변경(통신방법의 변경/추가,\n\n운영체제의 변경/추가, 통신 목적 변경/추가 등)이 포함된 경우\n\n에는 「의료기기 허가·신고·심사 등에 관한 규정」(식약처\n\n고시) 제19조의2(의료기기 소프트웨어 허가ㆍ인증ㆍ신고의 변경\n\n처리)에 따라, 소프트웨어 업그레이드에 해당되므로 변경허가‧\n\n이 경우에는 신규 허가와 마찬가지로 ‘의료기기 소프트웨어\n\n적합성 확인보고서’, ‘의료기기 사이버보안 요구사항 체크\n\n리스트’와 체크리스트의 요구사항을 실제로 검증 또는 검증을\n\n대체한 사유를 확인할 수 있는 자료(소프트웨어 검증 및 유효성\n\n확인자료, 성능시험성적서, 위험관리문서 등)를 제출하여야\n\n- - 34 -\n<!-- PAGE_41 -->\n##### 3. "
      }
    },
    {
      "chunk_id": "chunk_523",
      "text": "성능 평가 항목\n\n섭식장애 개선 디지털치료기기의 성능 평가 항목은 제품의 주요\n\n기능을 근거로 설정하며, 시험 기준 및 시험 방법은 제품의 특성을\n\n고려하여 가능한 정량적이고 구체적으로 작성한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 522,
        "window_size": 3,
        "char_count": 111,
        "word_count": 26,
        "page_number": 1,
        "window_text": "| 대해 이미 알려진 정보와 일관된 양상을 보이는 경우 | 장애와 연관된 구토) |\n| tice Review, 11, 133 - 143.  | 대응 계획을 수립하여야 한다.  | 유효성 |\n\n**[표 끝]**\n\n소프트웨어\n\n- - 32 -\n※ 예: 보안이 보장되지 않은(unsecure) 운영\n\n체제 버전에서 운영되는 의료기기 소프트웨어\n\n확인 자료\n\n- - 33 -\n5) 허가·인증 변경 시 제출자료\n\n사이버 보안에 영향을 미치는 변경(통신방법의 변경/추가,\n\n운영체제의 변경/추가, 통신 목적 변경/추가 등)이 포함된 경우\n\n에는 「의료기기 허가·신고·심사 등에 관한 규정」(식약처\n\n고시) 제19조의2(의료기기 소프트웨어 허가ㆍ인증ㆍ신고의 변경\n\n처리)에 따라, 소프트웨어 업그레이드에 해당되므로 변경허가‧\n\n이 경우에는 신규 허가와 마찬가지로 ‘의료기기 소프트웨어\n\n적합성 확인보고서’, ‘의료기기 사이버보안 요구사항 체크\n\n리스트’와 체크리스트의 요구사항을 실제로 검증 또는 검증을\n\n대체한 사유를 확인할 수 있는 자료(소프트웨어 검증 및 유효성\n\n확인자료, 성능시험성적서, 위험관리문서 등)를 제출하여야\n\n- - 34 -\n<!-- PAGE_41 -->\n##### 3.  성능 평가 항목\n\n섭식장애 개선 디지털치료기기의 성능 평가 항목은 제품의 주요\n\n기능을 근거로 설정하며, 시험 기준 및 시험 방법은 제품의 특성을\n\n고려하여 가능한 정량적이고 구체적으로 작성한다.\n\n - - 35 -\n본 예시는 이해를 돕기 위하여 작성된 것으로 실제 신청하려는 제품의 내용과 상이\n\n예시)\n\n- - 36 -\n<!-- PAGE_43 -->\n### Ⅲ\n\n<!-- PAGE_43 -->\n### 임상시험계획서 작성 시 고려사항 및 예시\n\n「의료기기법 시행규칙」제20조(임상시험계획의 승인 등) 제2항에 따라\n\n임상시험계획서에 포함되어야 할 사항은 다음과 같다.\n\n - 1.  임상시험의 제목\n- 2. ",
        "original_sentence": "성능 평가 항목\n\n섭식장애 개선 디지털치료기기의 성능 평가 항목은 제품의 주요\n\n기능을 근거로 설정하며, 시험 기준 및 시험 방법은 제품의 특성을\n\n고려하여 가능한 정량적이고 구체적으로 작성한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_524",
      "text": "- - 35 -\n본 예시는 이해를 돕기 위하여 작성된 것으로 실제 신청하려는 제품의 내용과 상이\n\n예시)\n\n- - 36 -\n<!-- PAGE_43 -->\n### Ⅲ\n\n<!-- PAGE_43 -->\n### 임상시험계획서 작성 시 고려사항 및 예시\n\n「의료기기법 시행규칙」제20조(임상시험계획의 승인 등) 제2항에 따라\n\n임상시험계획서에 포함되어야 할 사항은 다음과 같다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 523,
        "window_size": 3,
        "char_count": 208,
        "word_count": 48,
        "page_number": 43,
        "window_text": "| 대응 계획을 수립하여야 한다.  | 유효성 |\n\n**[표 끝]**\n\n소프트웨어\n\n- - 32 -\n※ 예: 보안이 보장되지 않은(unsecure) 운영\n\n체제 버전에서 운영되는 의료기기 소프트웨어\n\n확인 자료\n\n- - 33 -\n5) 허가·인증 변경 시 제출자료\n\n사이버 보안에 영향을 미치는 변경(통신방법의 변경/추가,\n\n운영체제의 변경/추가, 통신 목적 변경/추가 등)이 포함된 경우\n\n에는 「의료기기 허가·신고·심사 등에 관한 규정」(식약처\n\n고시) 제19조의2(의료기기 소프트웨어 허가ㆍ인증ㆍ신고의 변경\n\n처리)에 따라, 소프트웨어 업그레이드에 해당되므로 변경허가‧\n\n이 경우에는 신규 허가와 마찬가지로 ‘의료기기 소프트웨어\n\n적합성 확인보고서’, ‘의료기기 사이버보안 요구사항 체크\n\n리스트’와 체크리스트의 요구사항을 실제로 검증 또는 검증을\n\n대체한 사유를 확인할 수 있는 자료(소프트웨어 검증 및 유효성\n\n확인자료, 성능시험성적서, 위험관리문서 등)를 제출하여야\n\n- - 34 -\n<!-- PAGE_41 -->\n##### 3.  성능 평가 항목\n\n섭식장애 개선 디지털치료기기의 성능 평가 항목은 제품의 주요\n\n기능을 근거로 설정하며, 시험 기준 및 시험 방법은 제품의 특성을\n\n고려하여 가능한 정량적이고 구체적으로 작성한다.\n\n - - 35 -\n본 예시는 이해를 돕기 위하여 작성된 것으로 실제 신청하려는 제품의 내용과 상이\n\n예시)\n\n- - 36 -\n<!-- PAGE_43 -->\n### Ⅲ\n\n<!-- PAGE_43 -->\n### 임상시험계획서 작성 시 고려사항 및 예시\n\n「의료기기법 시행규칙」제20조(임상시험계획의 승인 등) 제2항에 따라\n\n임상시험계획서에 포함되어야 할 사항은 다음과 같다.\n\n - 1.  임상시험의 제목\n- 2.  임상시험기관의 명칭 및 소재지\n- 3. ",
        "original_sentence": "- - 35 -\n본 예시는 이해를 돕기 위하여 작성된 것으로 실제 신청하려는 제품의 내용과 상이\n\n예시)\n\n- - 36 -\n<!-- PAGE_43 -->\n### Ⅲ\n\n<!-- PAGE_43 -->\n### 임상시험계획서 작성 시 고려사항 및 예시\n\n「의료기기법 시행규칙」제20조(임상시험계획의 승인 등) 제2항에 따라\n\n임상시험계획서에 포함되어야 할 사항은 다음과 같다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_525",
      "text": "- 1. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 524,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 19,
        "window_text": "| 유효성 |\n\n**[표 끝]**\n\n소프트웨어\n\n- - 32 -\n※ 예: 보안이 보장되지 않은(unsecure) 운영\n\n체제 버전에서 운영되는 의료기기 소프트웨어\n\n확인 자료\n\n- - 33 -\n5) 허가·인증 변경 시 제출자료\n\n사이버 보안에 영향을 미치는 변경(통신방법의 변경/추가,\n\n운영체제의 변경/추가, 통신 목적 변경/추가 등)이 포함된 경우\n\n에는 「의료기기 허가·신고·심사 등에 관한 규정」(식약처\n\n고시) 제19조의2(의료기기 소프트웨어 허가ㆍ인증ㆍ신고의 변경\n\n처리)에 따라, 소프트웨어 업그레이드에 해당되므로 변경허가‧\n\n이 경우에는 신규 허가와 마찬가지로 ‘의료기기 소프트웨어\n\n적합성 확인보고서’, ‘의료기기 사이버보안 요구사항 체크\n\n리스트’와 체크리스트의 요구사항을 실제로 검증 또는 검증을\n\n대체한 사유를 확인할 수 있는 자료(소프트웨어 검증 및 유효성\n\n확인자료, 성능시험성적서, 위험관리문서 등)를 제출하여야\n\n- - 34 -\n<!-- PAGE_41 -->\n##### 3.  성능 평가 항목\n\n섭식장애 개선 디지털치료기기의 성능 평가 항목은 제품의 주요\n\n기능을 근거로 설정하며, 시험 기준 및 시험 방법은 제품의 특성을\n\n고려하여 가능한 정량적이고 구체적으로 작성한다.\n\n - - 35 -\n본 예시는 이해를 돕기 위하여 작성된 것으로 실제 신청하려는 제품의 내용과 상이\n\n예시)\n\n- - 36 -\n<!-- PAGE_43 -->\n### Ⅲ\n\n<!-- PAGE_43 -->\n### 임상시험계획서 작성 시 고려사항 및 예시\n\n「의료기기법 시행규칙」제20조(임상시험계획의 승인 등) 제2항에 따라\n\n임상시험계획서에 포함되어야 할 사항은 다음과 같다.\n\n - 1.  임상시험의 제목\n- 2.  임상시험기관의 명칭 및 소재지\n- 3.  임상시험의 책임자ㆍ담당자 및 공동연구자의 성명 및 직명\n- 4. ",
        "original_sentence": "- 1. "
      }
    },
    {
      "chunk_id": "chunk_526",
      "text": "임상시험의 제목\n- 2. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 525,
        "window_size": 3,
        "char_count": 14,
        "word_count": 4,
        "page_number": 7,
        "window_text": "성능 평가 항목\n\n섭식장애 개선 디지털치료기기의 성능 평가 항목은 제품의 주요\n\n기능을 근거로 설정하며, 시험 기준 및 시험 방법은 제품의 특성을\n\n고려하여 가능한 정량적이고 구체적으로 작성한다.\n\n - - 35 -\n본 예시는 이해를 돕기 위하여 작성된 것으로 실제 신청하려는 제품의 내용과 상이\n\n예시)\n\n- - 36 -\n<!-- PAGE_43 -->\n### Ⅲ\n\n<!-- PAGE_43 -->\n### 임상시험계획서 작성 시 고려사항 및 예시\n\n「의료기기법 시행규칙」제20조(임상시험계획의 승인 등) 제2항에 따라\n\n임상시험계획서에 포함되어야 할 사항은 다음과 같다.\n\n - 1.  임상시험의 제목\n- 2.  임상시험기관의 명칭 및 소재지\n- 3.  임상시험의 책임자ㆍ담당자 및 공동연구자의 성명 및 직명\n- 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n- 5. ",
        "original_sentence": "임상시험의 제목\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_527",
      "text": "임상시험기관의 명칭 및 소재지\n- 3. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 526,
        "window_size": 3,
        "char_count": 22,
        "word_count": 6,
        "page_number": 3,
        "window_text": "- - 35 -\n본 예시는 이해를 돕기 위하여 작성된 것으로 실제 신청하려는 제품의 내용과 상이\n\n예시)\n\n- - 36 -\n<!-- PAGE_43 -->\n### Ⅲ\n\n<!-- PAGE_43 -->\n### 임상시험계획서 작성 시 고려사항 및 예시\n\n「의료기기법 시행규칙」제20조(임상시험계획의 승인 등) 제2항에 따라\n\n임상시험계획서에 포함되어야 할 사항은 다음과 같다.\n\n - 1.  임상시험의 제목\n- 2.  임상시험기관의 명칭 및 소재지\n- 3.  임상시험의 책임자ㆍ담당자 및 공동연구자의 성명 및 직명\n- 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n- 5.  임상시험을 하려는 자의 성명 및 주소\n- 6. ",
        "original_sentence": "임상시험기관의 명칭 및 소재지\n- 3. "
      }
    },
    {
      "chunk_id": "chunk_528",
      "text": "임상시험의 책임자ㆍ담당자 및 공동연구자의 성명 및 직명\n- 4. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 527,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 3,
        "window_text": "- 1.  임상시험의 제목\n- 2.  임상시험기관의 명칭 및 소재지\n- 3.  임상시험의 책임자ㆍ담당자 및 공동연구자의 성명 및 직명\n- 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n- 5.  임상시험을 하려는 자의 성명 및 주소\n- 6.  임상시험의 목적 및 배경\n- 7. ",
        "original_sentence": "임상시험의 책임자ㆍ담당자 및 공동연구자의 성명 및 직명\n- 4. "
      }
    },
    {
      "chunk_id": "chunk_529",
      "text": "임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n- 5. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 528,
        "window_size": 3,
        "char_count": 35,
        "word_count": 9,
        "page_number": 26,
        "window_text": "임상시험의 제목\n- 2.  임상시험기관의 명칭 및 소재지\n- 3.  임상시험의 책임자ㆍ담당자 및 공동연구자의 성명 및 직명\n- 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n- 5.  임상시험을 하려는 자의 성명 및 주소\n- 6.  임상시험의 목적 및 배경\n- 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다)\n- 8. ",
        "original_sentence": "임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n- 5. "
      }
    },
    {
      "chunk_id": "chunk_530",
      "text": "임상시험을 하려는 자의 성명 및 주소\n- 6. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 529,
        "window_size": 3,
        "char_count": 26,
        "word_count": 8,
        "page_number": 27,
        "window_text": "임상시험기관의 명칭 및 소재지\n- 3.  임상시험의 책임자ㆍ담당자 및 공동연구자의 성명 및 직명\n- 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n- 5.  임상시험을 하려는 자의 성명 및 주소\n- 6.  임상시험의 목적 및 배경\n- 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다)\n- 8.  임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되어 임상시험에\n- 9. ",
        "original_sentence": "임상시험을 하려는 자의 성명 및 주소\n- 6. "
      }
    },
    {
      "chunk_id": "chunk_531",
      "text": "임상시험의 목적 및 배경\n- 7. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 530,
        "window_size": 3,
        "char_count": 19,
        "word_count": 6,
        "page_number": 7,
        "window_text": "임상시험의 책임자ㆍ담당자 및 공동연구자의 성명 및 직명\n- 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n- 5.  임상시험을 하려는 자의 성명 및 주소\n- 6.  임상시험의 목적 및 배경\n- 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다)\n- 8.  임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되어 임상시험에\n- 9.  임상시험기간\n- 10. ",
        "original_sentence": "임상시험의 목적 및 배경\n- 7. "
      }
    },
    {
      "chunk_id": "chunk_532",
      "text": "임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다)\n- 8. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 531,
        "window_size": 3,
        "char_count": 45,
        "word_count": 9,
        "page_number": 7,
        "window_text": "임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n- 5.  임상시험을 하려는 자의 성명 및 주소\n- 6.  임상시험의 목적 및 배경\n- 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다)\n- 8.  임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되어 임상시험에\n- 9.  임상시험기간\n- 10.  임상시험방법(사용량ㆍ사용방법ㆍ사용기간ㆍ병용요법 등을 포함한다)\n- 11. ",
        "original_sentence": "임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다)\n- 8. "
      }
    },
    {
      "chunk_id": "chunk_533",
      "text": "임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되어 임상시험에\n- 9. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 532,
        "window_size": 3,
        "char_count": 44,
        "word_count": 10,
        "page_number": 27,
        "window_text": "임상시험을 하려는 자의 성명 및 주소\n- 6.  임상시험의 목적 및 배경\n- 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다)\n- 8.  임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되어 임상시험에\n- 9.  임상시험기간\n- 10.  임상시험방법(사용량ㆍ사용방법ㆍ사용기간ㆍ병용요법 등을 포함한다)\n- 11.  관찰항목ㆍ임상검사항목 및 관찰검사방법\n- 12. ",
        "original_sentence": "임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되어 임상시험에\n- 9. "
      }
    },
    {
      "chunk_id": "chunk_534",
      "text": "임상시험기간\n- 10. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 533,
        "window_size": 3,
        "char_count": 13,
        "word_count": 3,
        "page_number": 19,
        "window_text": "임상시험의 목적 및 배경\n- 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다)\n- 8.  임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되어 임상시험에\n- 9.  임상시험기간\n- 10.  임상시험방법(사용량ㆍ사용방법ㆍ사용기간ㆍ병용요법 등을 포함한다)\n- 11.  관찰항목ㆍ임상검사항목 및 관찰검사방법\n- 12.  예측되는 부작용 및 사용 시 주의사항\n- 13. ",
        "original_sentence": "임상시험기간\n- 10. "
      }
    },
    {
      "chunk_id": "chunk_535",
      "text": "임상시험방법(사용량ㆍ사용방법ㆍ사용기간ㆍ병용요법 등을 포함한다)\n- 11. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 534,
        "window_size": 3,
        "char_count": 41,
        "word_count": 5,
        "page_number": 19,
        "window_text": "임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다)\n- 8.  임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되어 임상시험에\n- 9.  임상시험기간\n- 10.  임상시험방법(사용량ㆍ사용방법ㆍ사용기간ㆍ병용요법 등을 포함한다)\n- 11.  관찰항목ㆍ임상검사항목 및 관찰검사방법\n- 12.  예측되는 부작용 및 사용 시 주의사항\n- 13.  중지ㆍ탈락 기준\n- 14. ",
        "original_sentence": "임상시험방법(사용량ㆍ사용방법ㆍ사용기간ㆍ병용요법 등을 포함한다)\n- 11. "
      }
    },
    {
      "chunk_id": "chunk_536",
      "text": "관찰항목ㆍ임상검사항목 및 관찰검사방법\n- 12. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 535,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 3,
        "window_text": "임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되어 임상시험에\n- 9.  임상시험기간\n- 10.  임상시험방법(사용량ㆍ사용방법ㆍ사용기간ㆍ병용요법 등을 포함한다)\n- 11.  관찰항목ㆍ임상검사항목 및 관찰검사방법\n- 12.  예측되는 부작용 및 사용 시 주의사항\n- 13.  중지ㆍ탈락 기준\n- 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 따른다)\n- 15. ",
        "original_sentence": "관찰항목ㆍ임상검사항목 및 관찰검사방법\n- 12. "
      }
    },
    {
      "chunk_id": "chunk_537",
      "text": "예측되는 부작용 및 사용 시 주의사항\n- 13. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 536,
        "window_size": 3,
        "char_count": 27,
        "word_count": 8,
        "page_number": 3,
        "window_text": "임상시험기간\n- 10.  임상시험방법(사용량ㆍ사용방법ㆍ사용기간ㆍ병용요법 등을 포함한다)\n- 11.  관찰항목ㆍ임상검사항목 및 관찰검사방법\n- 12.  예측되는 부작용 및 사용 시 주의사항\n- 13.  중지ㆍ탈락 기준\n- 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 따른다)\n- 15.  부작용을 포함한 안전성의 평가기준ㆍ평가방법 및 보고방법\n- 16. ",
        "original_sentence": "예측되는 부작용 및 사용 시 주의사항\n- 13. "
      }
    },
    {
      "chunk_id": "chunk_538",
      "text": "중지ㆍ탈락 기준\n- 14. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 537,
        "window_size": 3,
        "char_count": 15,
        "word_count": 4,
        "page_number": 19,
        "window_text": "임상시험방법(사용량ㆍ사용방법ㆍ사용기간ㆍ병용요법 등을 포함한다)\n- 11.  관찰항목ㆍ임상검사항목 및 관찰검사방법\n- 12.  예측되는 부작용 및 사용 시 주의사항\n- 13.  중지ㆍ탈락 기준\n- 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 따른다)\n- 15.  부작용을 포함한 안전성의 평가기준ㆍ평가방법 및 보고방법\n- 16.  피험자동의서 서식\n- 17. ",
        "original_sentence": "중지ㆍ탈락 기준\n- 14. "
      }
    },
    {
      "chunk_id": "chunk_539",
      "text": "유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 따른다)\n- 15. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 538,
        "window_size": 3,
        "char_count": 42,
        "word_count": 8,
        "page_number": 18,
        "window_text": "관찰항목ㆍ임상검사항목 및 관찰검사방법\n- 12.  예측되는 부작용 및 사용 시 주의사항\n- 13.  중지ㆍ탈락 기준\n- 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 따른다)\n- 15.  부작용을 포함한 안전성의 평가기준ㆍ평가방법 및 보고방법\n- 16.  피험자동의서 서식\n- 17.  피해자 보상에 대한 규약\n- 18. ",
        "original_sentence": "유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 따른다)\n- 15. "
      }
    },
    {
      "chunk_id": "chunk_540",
      "text": "부작용을 포함한 안전성의 평가기준ㆍ평가방법 및 보고방법\n- 16. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 539,
        "window_size": 3,
        "char_count": 37,
        "word_count": 8,
        "page_number": 19,
        "window_text": "예측되는 부작용 및 사용 시 주의사항\n- 13.  중지ㆍ탈락 기준\n- 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 따른다)\n- 15.  부작용을 포함한 안전성의 평가기준ㆍ평가방법 및 보고방법\n- 16.  피험자동의서 서식\n- 17.  피해자 보상에 대한 규약\n- 18.  임상시험 후 피험자의 진료에 관한 사항\n- 19. ",
        "original_sentence": "부작용을 포함한 안전성의 평가기준ㆍ평가방법 및 보고방법\n- 16. "
      }
    },
    {
      "chunk_id": "chunk_541",
      "text": "피험자동의서 서식\n- 17. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 540,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 19,
        "window_text": "중지ㆍ탈락 기준\n- 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 따른다)\n- 15.  부작용을 포함한 안전성의 평가기준ㆍ평가방법 및 보고방법\n- 16.  피험자동의서 서식\n- 17.  피해자 보상에 대한 규약\n- 18.  임상시험 후 피험자의 진료에 관한 사항\n- 19.  피험자의 안전보호에 관한 대책\n- 20. ",
        "original_sentence": "피험자동의서 서식\n- 17. "
      }
    },
    {
      "chunk_id": "chunk_542",
      "text": "피해자 보상에 대한 규약\n- 18. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 541,
        "window_size": 3,
        "char_count": 20,
        "word_count": 6,
        "page_number": 19,
        "window_text": "유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 따른다)\n- 15.  부작용을 포함한 안전성의 평가기준ㆍ평가방법 및 보고방법\n- 16.  피험자동의서 서식\n- 17.  피해자 보상에 대한 규약\n- 18.  임상시험 후 피험자의 진료에 관한 사항\n- 19.  피험자의 안전보호에 관한 대책\n- 20.  그 밖에 임상시험을 안전하고 과학적으로 실시하기 위하여 필요한 사항\n- - 37 -\n<!-- PAGE_44 -->\n##### 1. ",
        "original_sentence": "피해자 보상에 대한 규약\n- 18. "
      }
    },
    {
      "chunk_id": "chunk_543",
      "text": "임상시험 후 피험자의 진료에 관한 사항\n- 19. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 542,
        "window_size": 3,
        "char_count": 28,
        "word_count": 8,
        "page_number": 3,
        "window_text": "부작용을 포함한 안전성의 평가기준ㆍ평가방법 및 보고방법\n- 16.  피험자동의서 서식\n- 17.  피해자 보상에 대한 규약\n- 18.  임상시험 후 피험자의 진료에 관한 사항\n- 19.  피험자의 안전보호에 관한 대책\n- 20.  그 밖에 임상시험을 안전하고 과학적으로 실시하기 위하여 필요한 사항\n- - 37 -\n<!-- PAGE_44 -->\n##### 1.  임상시험의 제목\n\n**[표 시작]**\n\n| 임상시험 의뢰자는 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 | 임상시험 방법은 해당 의료기기에 대한 모양, 구조 및 사용 전 준비사항, 피험자에 |\n| --- | --- |\n**임상시험용 ‘섭식장애 개선 디지털치료기기’의 안전성과 유효성을 증명하고자**\n**임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료 방법 등을 제공**\n\n**[표 끝]**\n\n[예시]\n\n섭식장애 진단환자의 섭식장애 증상을 개선하기 위해서 사용되는\n\nOOO 디지털치료기기의 안전성 및 유효성을 평가하기 위한 전향적\n\n[F50.4] Overeating associated with other psychological disturbances\n\n[F50.5] Vomiting associated with other psychological disturbances\n\n- - 38 -\n[F50.8] Other eating disorders (기타 식사장애)\n\n[F50.9] Eating disorder, unspecified (상세불명의 식사장애)\n\n2) 의료기기의 사용 목적 : 환자의 섭식장애 증상을 정량적으로 개선\n\n- - 39 -\n<!-- PAGE_46 -->\n##### 2. ",
        "original_sentence": "임상시험 후 피험자의 진료에 관한 사항\n- 19. "
      }
    },
    {
      "chunk_id": "chunk_544",
      "text": "피험자의 안전보호에 관한 대책\n- 20. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 543,
        "window_size": 3,
        "char_count": 23,
        "word_count": 6,
        "page_number": 9,
        "window_text": "피험자동의서 서식\n- 17.  피해자 보상에 대한 규약\n- 18.  임상시험 후 피험자의 진료에 관한 사항\n- 19.  피험자의 안전보호에 관한 대책\n- 20.  그 밖에 임상시험을 안전하고 과학적으로 실시하기 위하여 필요한 사항\n- - 37 -\n<!-- PAGE_44 -->\n##### 1.  임상시험의 제목\n\n**[표 시작]**\n\n| 임상시험 의뢰자는 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 | 임상시험 방법은 해당 의료기기에 대한 모양, 구조 및 사용 전 준비사항, 피험자에 |\n| --- | --- |\n**임상시험용 ‘섭식장애 개선 디지털치료기기’의 안전성과 유효성을 증명하고자**\n**임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료 방법 등을 제공**\n\n**[표 끝]**\n\n[예시]\n\n섭식장애 진단환자의 섭식장애 증상을 개선하기 위해서 사용되는\n\nOOO 디지털치료기기의 안전성 및 유효성을 평가하기 위한 전향적\n\n[F50.4] Overeating associated with other psychological disturbances\n\n[F50.5] Vomiting associated with other psychological disturbances\n\n- - 38 -\n[F50.8] Other eating disorders (기타 식사장애)\n\n[F50.9] Eating disorder, unspecified (상세불명의 식사장애)\n\n2) 의료기기의 사용 목적 : 환자의 섭식장애 증상을 정량적으로 개선\n\n- - 39 -\n<!-- PAGE_46 -->\n##### 2.  임상시험기관의 명칭 및 소재지\n\n임상시험\n\n- - 40 -\n<!-- PAGE_47 -->\n##### 3. ",
        "original_sentence": "피험자의 안전보호에 관한 대책\n- 20. "
      }
    },
    {
      "chunk_id": "chunk_545",
      "text": "그 밖에 임상시험을 안전하고 과학적으로 실시하기 위하여 필요한 사항\n- - 37 -\n<!-- PAGE_44 -->\n##### 1. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 544,
        "window_size": 3,
        "char_count": 73,
        "word_count": 18,
        "page_number": 44,
        "window_text": "피해자 보상에 대한 규약\n- 18.  임상시험 후 피험자의 진료에 관한 사항\n- 19.  피험자의 안전보호에 관한 대책\n- 20.  그 밖에 임상시험을 안전하고 과학적으로 실시하기 위하여 필요한 사항\n- - 37 -\n<!-- PAGE_44 -->\n##### 1.  임상시험의 제목\n\n**[표 시작]**\n\n| 임상시험 의뢰자는 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 | 임상시험 방법은 해당 의료기기에 대한 모양, 구조 및 사용 전 준비사항, 피험자에 |\n| --- | --- |\n**임상시험용 ‘섭식장애 개선 디지털치료기기’의 안전성과 유효성을 증명하고자**\n**임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료 방법 등을 제공**\n\n**[표 끝]**\n\n[예시]\n\n섭식장애 진단환자의 섭식장애 증상을 개선하기 위해서 사용되는\n\nOOO 디지털치료기기의 안전성 및 유효성을 평가하기 위한 전향적\n\n[F50.4] Overeating associated with other psychological disturbances\n\n[F50.5] Vomiting associated with other psychological disturbances\n\n- - 38 -\n[F50.8] Other eating disorders (기타 식사장애)\n\n[F50.9] Eating disorder, unspecified (상세불명의 식사장애)\n\n2) 의료기기의 사용 목적 : 환자의 섭식장애 증상을 정량적으로 개선\n\n- - 39 -\n<!-- PAGE_46 -->\n##### 2.  임상시험기관의 명칭 및 소재지\n\n임상시험\n\n- - 40 -\n<!-- PAGE_47 -->\n##### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n- 가. ",
        "original_sentence": "그 밖에 임상시험을 안전하고 과학적으로 실시하기 위하여 필요한 사항\n- - 37 -\n<!-- PAGE_44 -->\n##### 1. "
      }
    },
    {
      "chunk_id": "chunk_546",
      "text": "임상시험의 제목\n\n**[표 시작]**\n\n| 임상시험 의뢰자는 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 | 임상시험 방법은 해당 의료기기에 대한 모양, 구조 및 사용 전 준비사항, 피험자에 |\n| --- | --- |\n**임상시험용 ‘섭식장애 개선 디지털치료기기’의 안전성과 유효성을 증명하고자**\n**임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료 방법 등을 제공**\n\n**[표 끝]**\n\n[예시]\n\n섭식장애 진단환자의 섭식장애 증상을 개선하기 위해서 사용되는\n\nOOO 디지털치료기기의 안전성 및 유효성을 평가하기 위한 전향적\n\n[F50.4] Overeating associated with other psychological disturbances\n\n[F50.5] Vomiting associated with other psychological disturbances\n\n- - 38 -\n[F50.8] Other eating disorders (기타 식사장애)\n\n[F50.9] Eating disorder, unspecified (상세불명의 식사장애)\n\n2) 의료기기의 사용 목적 : 환자의 섭식장애 증상을 정량적으로 개선\n\n- - 39 -\n<!-- PAGE_46 -->\n##### 2. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 545,
        "window_size": 3,
        "char_count": 630,
        "word_count": 121,
        "page_number": 46,
        "window_text": "임상시험 후 피험자의 진료에 관한 사항\n- 19.  피험자의 안전보호에 관한 대책\n- 20.  그 밖에 임상시험을 안전하고 과학적으로 실시하기 위하여 필요한 사항\n- - 37 -\n<!-- PAGE_44 -->\n##### 1.  임상시험의 제목\n\n**[표 시작]**\n\n| 임상시험 의뢰자는 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 | 임상시험 방법은 해당 의료기기에 대한 모양, 구조 및 사용 전 준비사항, 피험자에 |\n| --- | --- |\n**임상시험용 ‘섭식장애 개선 디지털치료기기’의 안전성과 유효성을 증명하고자**\n**임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료 방법 등을 제공**\n\n**[표 끝]**\n\n[예시]\n\n섭식장애 진단환자의 섭식장애 증상을 개선하기 위해서 사용되는\n\nOOO 디지털치료기기의 안전성 및 유효성을 평가하기 위한 전향적\n\n[F50.4] Overeating associated with other psychological disturbances\n\n[F50.5] Vomiting associated with other psychological disturbances\n\n- - 38 -\n[F50.8] Other eating disorders (기타 식사장애)\n\n[F50.9] Eating disorder, unspecified (상세불명의 식사장애)\n\n2) 의료기기의 사용 목적 : 환자의 섭식장애 증상을 정량적으로 개선\n\n- - 39 -\n<!-- PAGE_46 -->\n##### 2.  임상시험기관의 명칭 및 소재지\n\n임상시험\n\n- - 40 -\n<!-- PAGE_47 -->\n##### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n- 가.  시험책임자\n- 나. ",
        "original_sentence": "임상시험의 제목\n\n**[표 시작]**\n\n| 임상시험 의뢰자는 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 | 임상시험 방법은 해당 의료기기에 대한 모양, 구조 및 사용 전 준비사항, 피험자에 |\n| --- | --- |\n**임상시험용 ‘섭식장애 개선 디지털치료기기’의 안전성과 유효성을 증명하고자**\n**임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료 방법 등을 제공**\n\n**[표 끝]**\n\n[예시]\n\n섭식장애 진단환자의 섭식장애 증상을 개선하기 위해서 사용되는\n\nOOO 디지털치료기기의 안전성 및 유효성을 평가하기 위한 전향적\n\n[F50.4] Overeating associated with other psychological disturbances\n\n[F50.5] Vomiting associated with other psychological disturbances\n\n- - 38 -\n[F50.8] Other eating disorders (기타 식사장애)\n\n[F50.9] Eating disorder, unspecified (상세불명의 식사장애)\n\n2) 의료기기의 사용 목적 : 환자의 섭식장애 증상을 정량적으로 개선\n\n- - 39 -\n<!-- PAGE_46 -->\n##### 2. "
      }
    },
    {
      "chunk_id": "chunk_547",
      "text": "임상시험기관의 명칭 및 소재지\n\n임상시험\n\n- - 40 -\n<!-- PAGE_47 -->\n##### 3. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 546,
        "window_size": 3,
        "char_count": 59,
        "word_count": 14,
        "page_number": 47,
        "window_text": "피험자의 안전보호에 관한 대책\n- 20.  그 밖에 임상시험을 안전하고 과학적으로 실시하기 위하여 필요한 사항\n- - 37 -\n<!-- PAGE_44 -->\n##### 1.  임상시험의 제목\n\n**[표 시작]**\n\n| 임상시험 의뢰자는 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 | 임상시험 방법은 해당 의료기기에 대한 모양, 구조 및 사용 전 준비사항, 피험자에 |\n| --- | --- |\n**임상시험용 ‘섭식장애 개선 디지털치료기기’의 안전성과 유효성을 증명하고자**\n**임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료 방법 등을 제공**\n\n**[표 끝]**\n\n[예시]\n\n섭식장애 진단환자의 섭식장애 증상을 개선하기 위해서 사용되는\n\nOOO 디지털치료기기의 안전성 및 유효성을 평가하기 위한 전향적\n\n[F50.4] Overeating associated with other psychological disturbances\n\n[F50.5] Vomiting associated with other psychological disturbances\n\n- - 38 -\n[F50.8] Other eating disorders (기타 식사장애)\n\n[F50.9] Eating disorder, unspecified (상세불명의 식사장애)\n\n2) 의료기기의 사용 목적 : 환자의 섭식장애 증상을 정량적으로 개선\n\n- - 39 -\n<!-- PAGE_46 -->\n##### 2.  임상시험기관의 명칭 및 소재지\n\n임상시험\n\n- - 40 -\n<!-- PAGE_47 -->\n##### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n- 가.  시험책임자\n- 나.  시험담당자\n- 다. ",
        "original_sentence": "임상시험기관의 명칭 및 소재지\n\n임상시험\n\n- - 40 -\n<!-- PAGE_47 -->\n##### 3. "
      }
    },
    {
      "chunk_id": "chunk_548",
      "text": "임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n- 가. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 547,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 3,
        "window_text": "그 밖에 임상시험을 안전하고 과학적으로 실시하기 위하여 필요한 사항\n- - 37 -\n<!-- PAGE_44 -->\n##### 1.  임상시험의 제목\n\n**[표 시작]**\n\n| 임상시험 의뢰자는 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 | 임상시험 방법은 해당 의료기기에 대한 모양, 구조 및 사용 전 준비사항, 피험자에 |\n| --- | --- |\n**임상시험용 ‘섭식장애 개선 디지털치료기기’의 안전성과 유효성을 증명하고자**\n**임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료 방법 등을 제공**\n\n**[표 끝]**\n\n[예시]\n\n섭식장애 진단환자의 섭식장애 증상을 개선하기 위해서 사용되는\n\nOOO 디지털치료기기의 안전성 및 유효성을 평가하기 위한 전향적\n\n[F50.4] Overeating associated with other psychological disturbances\n\n[F50.5] Vomiting associated with other psychological disturbances\n\n- - 38 -\n[F50.8] Other eating disorders (기타 식사장애)\n\n[F50.9] Eating disorder, unspecified (상세불명의 식사장애)\n\n2) 의료기기의 사용 목적 : 환자의 섭식장애 증상을 정량적으로 개선\n\n- - 39 -\n<!-- PAGE_46 -->\n##### 2.  임상시험기관의 명칭 및 소재지\n\n임상시험\n\n- - 40 -\n<!-- PAGE_47 -->\n##### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n- 가.  시험책임자\n- 나.  시험담당자\n- 다.  공동연구자\n- 라. ",
        "original_sentence": "임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_549",
      "text": "시험책임자\n- 나. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 548,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 35,
        "window_text": "임상시험의 제목\n\n**[표 시작]**\n\n| 임상시험 의뢰자는 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 | 임상시험 방법은 해당 의료기기에 대한 모양, 구조 및 사용 전 준비사항, 피험자에 |\n| --- | --- |\n**임상시험용 ‘섭식장애 개선 디지털치료기기’의 안전성과 유효성을 증명하고자**\n**임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료 방법 등을 제공**\n\n**[표 끝]**\n\n[예시]\n\n섭식장애 진단환자의 섭식장애 증상을 개선하기 위해서 사용되는\n\nOOO 디지털치료기기의 안전성 및 유효성을 평가하기 위한 전향적\n\n[F50.4] Overeating associated with other psychological disturbances\n\n[F50.5] Vomiting associated with other psychological disturbances\n\n- - 38 -\n[F50.8] Other eating disorders (기타 식사장애)\n\n[F50.9] Eating disorder, unspecified (상세불명의 식사장애)\n\n2) 의료기기의 사용 목적 : 환자의 섭식장애 증상을 정량적으로 개선\n\n- - 39 -\n<!-- PAGE_46 -->\n##### 2.  임상시험기관의 명칭 및 소재지\n\n임상시험\n\n- - 40 -\n<!-- PAGE_47 -->\n##### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n- 가.  시험책임자\n- 나.  시험담당자\n- 다.  공동연구자\n- 라.  임상시험 조정자\n- - 41 -\n<!-- PAGE_48 -->\n##### 4. ",
        "original_sentence": "시험책임자\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_550",
      "text": "시험담당자\n- 다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 549,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 3,
        "window_text": "임상시험기관의 명칭 및 소재지\n\n임상시험\n\n- - 40 -\n<!-- PAGE_47 -->\n##### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n- 가.  시험책임자\n- 나.  시험담당자\n- 다.  공동연구자\n- 라.  임상시험 조정자\n- - 41 -\n<!-- PAGE_48 -->\n##### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n의료기기 관리자\n\n- - 42 -\n<!-- PAGE_49 -->\n##### 5. ",
        "original_sentence": "시험담당자\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_551",
      "text": "공동연구자\n- 라. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 550,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 72,
        "window_text": "임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n- 가.  시험책임자\n- 나.  시험담당자\n- 다.  공동연구자\n- 라.  임상시험 조정자\n- - 41 -\n<!-- PAGE_48 -->\n##### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n의료기기 관리자\n\n- - 42 -\n<!-- PAGE_49 -->\n##### 5.  임상시험을 하려는 자의 성명 및 주소\n\n- 가. ",
        "original_sentence": "공동연구자\n- 라. "
      }
    },
    {
      "chunk_id": "chunk_552",
      "text": "임상시험 조정자\n- - 41 -\n<!-- PAGE_48 -->\n##### 4. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 551,
        "window_size": 3,
        "char_count": 44,
        "word_count": 11,
        "page_number": 48,
        "window_text": "시험책임자\n- 나.  시험담당자\n- 다.  공동연구자\n- 라.  임상시험 조정자\n- - 41 -\n<!-- PAGE_48 -->\n##### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n의료기기 관리자\n\n- - 42 -\n<!-- PAGE_49 -->\n##### 5.  임상시험을 하려는 자의 성명 및 주소\n\n- 가.  의뢰자\n- 나. ",
        "original_sentence": "임상시험 조정자\n- - 41 -\n<!-- PAGE_48 -->\n##### 4. "
      }
    },
    {
      "chunk_id": "chunk_553",
      "text": "임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n의료기기 관리자\n\n- - 42 -\n<!-- PAGE_49 -->\n##### 5. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 552,
        "window_size": 3,
        "char_count": 76,
        "word_count": 18,
        "page_number": 49,
        "window_text": "시험담당자\n- 다.  공동연구자\n- 라.  임상시험 조정자\n- - 41 -\n<!-- PAGE_48 -->\n##### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n의료기기 관리자\n\n- - 42 -\n<!-- PAGE_49 -->\n##### 5.  임상시험을 하려는 자의 성명 및 주소\n\n- 가.  의뢰자\n- 나.  모니터요원\n- 다. ",
        "original_sentence": "임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n의료기기 관리자\n\n- - 42 -\n<!-- PAGE_49 -->\n##### 5. "
      }
    },
    {
      "chunk_id": "chunk_554",
      "text": "임상시험을 하려는 자의 성명 및 주소\n\n- 가. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 553,
        "window_size": 3,
        "char_count": 27,
        "word_count": 8,
        "page_number": 30,
        "window_text": "공동연구자\n- 라.  임상시험 조정자\n- - 41 -\n<!-- PAGE_48 -->\n##### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n의료기기 관리자\n\n- - 42 -\n<!-- PAGE_49 -->\n##### 5.  임상시험을 하려는 자의 성명 및 주소\n\n- 가.  의뢰자\n- 나.  모니터요원\n- 다.  임상시험 수탁업체\n※ 임상시험 수탁기관(CRO: Contact Research Organization)이 있는 경우 해당\n\n- - 43 -\n<!-- PAGE_50 -->\n##### 6. ",
        "original_sentence": "임상시험을 하려는 자의 성명 및 주소\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_555",
      "text": "의뢰자\n- 나. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 554,
        "window_size": 3,
        "char_count": 9,
        "word_count": 3,
        "page_number": 72,
        "window_text": "임상시험 조정자\n- - 41 -\n<!-- PAGE_48 -->\n##### 4.  임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n의료기기 관리자\n\n- - 42 -\n<!-- PAGE_49 -->\n##### 5.  임상시험을 하려는 자의 성명 및 주소\n\n- 가.  의뢰자\n- 나.  모니터요원\n- 다.  임상시험 수탁업체\n※ 임상시험 수탁기관(CRO: Contact Research Organization)이 있는 경우 해당\n\n- - 43 -\n<!-- PAGE_50 -->\n##### 6.  임상시험의 목적 및 배경\n\n- 가. ",
        "original_sentence": "의뢰자\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_556",
      "text": "모니터요원\n- 다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 555,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 72,
        "window_text": "임상시험용 의료기기를 관리하는 관리자의 성명 및 직명\n\n의료기기 관리자\n\n- - 42 -\n<!-- PAGE_49 -->\n##### 5.  임상시험을 하려는 자의 성명 및 주소\n\n- 가.  의뢰자\n- 나.  모니터요원\n- 다.  임상시험 수탁업체\n※ 임상시험 수탁기관(CRO: Contact Research Organization)이 있는 경우 해당\n\n- - 43 -\n<!-- PAGE_50 -->\n##### 6.  임상시험의 목적 및 배경\n\n- 가.  임상시험의 목적\n1) 임상시험용 디지털치료기기의 섭식장애 치료에 대한 안전성 평가\n\n2) 임상시험용 디지털치료기기의 섭식장애 치료에 대한 유효성 평가\n\n최근 섭식장애로 치료받는 환자가 증가하는 추세로 섭식장애를 치료\n\n하는 방법 또한 많은 주목을 받고 있다. ",
        "original_sentence": "모니터요원\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_557",
      "text": "임상시험 수탁업체\n※ 임상시험 수탁기관(CRO: Contact Research Organization)이 있는 경우 해당\n\n- - 43 -\n<!-- PAGE_50 -->\n##### 6. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 556,
        "window_size": 3,
        "char_count": 104,
        "word_count": 20,
        "page_number": 50,
        "window_text": "임상시험을 하려는 자의 성명 및 주소\n\n- 가.  의뢰자\n- 나.  모니터요원\n- 다.  임상시험 수탁업체\n※ 임상시험 수탁기관(CRO: Contact Research Organization)이 있는 경우 해당\n\n- - 43 -\n<!-- PAGE_50 -->\n##### 6.  임상시험의 목적 및 배경\n\n- 가.  임상시험의 목적\n1) 임상시험용 디지털치료기기의 섭식장애 치료에 대한 안전성 평가\n\n2) 임상시험용 디지털치료기기의 섭식장애 치료에 대한 유효성 평가\n\n최근 섭식장애로 치료받는 환자가 증가하는 추세로 섭식장애를 치료\n\n하는 방법 또한 많은 주목을 받고 있다.  임상에서 섭식장애 환자에게\n\n주로 사용되는 치료는 비약물 치료이며, 그중에서도 인지행동치료가\n\n가장 널리 사용되고 있다. ",
        "original_sentence": "임상시험 수탁업체\n※ 임상시험 수탁기관(CRO: Contact Research Organization)이 있는 경우 해당\n\n- - 43 -\n<!-- PAGE_50 -->\n##### 6. "
      }
    },
    {
      "chunk_id": "chunk_558",
      "text": "임상시험의 목적 및 배경\n\n- 가. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 557,
        "window_size": 3,
        "char_count": 20,
        "word_count": 6,
        "page_number": 7,
        "window_text": "의뢰자\n- 나.  모니터요원\n- 다.  임상시험 수탁업체\n※ 임상시험 수탁기관(CRO: Contact Research Organization)이 있는 경우 해당\n\n- - 43 -\n<!-- PAGE_50 -->\n##### 6.  임상시험의 목적 및 배경\n\n- 가.  임상시험의 목적\n1) 임상시험용 디지털치료기기의 섭식장애 치료에 대한 안전성 평가\n\n2) 임상시험용 디지털치료기기의 섭식장애 치료에 대한 유효성 평가\n\n최근 섭식장애로 치료받는 환자가 증가하는 추세로 섭식장애를 치료\n\n하는 방법 또한 많은 주목을 받고 있다.  임상에서 섭식장애 환자에게\n\n주로 사용되는 치료는 비약물 치료이며, 그중에서도 인지행동치료가\n\n가장 널리 사용되고 있다.  선행연구에 의하면, 섭식장애를 진단받은\n\n환자를 대상으로 비약물적 중재와 약물적 중재의 효과를 비교한\n\n연구에서 약물적 중재보다 비약물적 중재를 적용한 군이 오히려 폭식\n\n증상 감소에 효과적인 것으로 보고된 바 있으며(Vocks et al., 2010),\n\n비약물적 중재가 식이에 대한 태도를 긍정적으로 변화시키는 것으로\n\n나타났다(Yun&Kim, 2018).\n\n",
        "original_sentence": "임상시험의 목적 및 배경\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_559",
      "text": "임상시험의 목적\n1) 임상시험용 디지털치료기기의 섭식장애 치료에 대한 안전성 평가\n\n2) 임상시험용 디지털치료기기의 섭식장애 치료에 대한 유효성 평가\n\n최근 섭식장애로 치료받는 환자가 증가하는 추세로 섭식장애를 치료\n\n하는 방법 또한 많은 주목을 받고 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 558,
        "window_size": 3,
        "char_count": 145,
        "word_count": 33,
        "page_number": 7,
        "window_text": "모니터요원\n- 다.  임상시험 수탁업체\n※ 임상시험 수탁기관(CRO: Contact Research Organization)이 있는 경우 해당\n\n- - 43 -\n<!-- PAGE_50 -->\n##### 6.  임상시험의 목적 및 배경\n\n- 가.  임상시험의 목적\n1) 임상시험용 디지털치료기기의 섭식장애 치료에 대한 안전성 평가\n\n2) 임상시험용 디지털치료기기의 섭식장애 치료에 대한 유효성 평가\n\n최근 섭식장애로 치료받는 환자가 증가하는 추세로 섭식장애를 치료\n\n하는 방법 또한 많은 주목을 받고 있다.  임상에서 섭식장애 환자에게\n\n주로 사용되는 치료는 비약물 치료이며, 그중에서도 인지행동치료가\n\n가장 널리 사용되고 있다.  선행연구에 의하면, 섭식장애를 진단받은\n\n환자를 대상으로 비약물적 중재와 약물적 중재의 효과를 비교한\n\n연구에서 약물적 중재보다 비약물적 중재를 적용한 군이 오히려 폭식\n\n증상 감소에 효과적인 것으로 보고된 바 있으며(Vocks et al., 2010),\n\n비약물적 중재가 식이에 대한 태도를 긍정적으로 변화시키는 것으로\n\n나타났다(Yun&Kim, 2018).\n\n 섭식장애 인지행동치료 등 비약물 치료 효과가 미비한 경우, 필요\n\n하다면 약물치료를 통해 섭식장애를 개선할 수 있다.\n\n",
        "original_sentence": "임상시험의 목적\n1) 임상시험용 디지털치료기기의 섭식장애 치료에 대한 안전성 평가\n\n2) 임상시험용 디지털치료기기의 섭식장애 치료에 대한 유효성 평가\n\n최근 섭식장애로 치료받는 환자가 증가하는 추세로 섭식장애를 치료\n\n하는 방법 또한 많은 주목을 받고 있다. "
      }
    },
    {
      "chunk_id": "chunk_560",
      "text": "임상에서 섭식장애 환자에게\n\n주로 사용되는 치료는 비약물 치료이며, 그중에서도 인지행동치료가\n\n가장 널리 사용되고 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 559,
        "window_size": 3,
        "char_count": 68,
        "word_count": 14,
        "page_number": 15,
        "window_text": "임상시험 수탁업체\n※ 임상시험 수탁기관(CRO: Contact Research Organization)이 있는 경우 해당\n\n- - 43 -\n<!-- PAGE_50 -->\n##### 6.  임상시험의 목적 및 배경\n\n- 가.  임상시험의 목적\n1) 임상시험용 디지털치료기기의 섭식장애 치료에 대한 안전성 평가\n\n2) 임상시험용 디지털치료기기의 섭식장애 치료에 대한 유효성 평가\n\n최근 섭식장애로 치료받는 환자가 증가하는 추세로 섭식장애를 치료\n\n하는 방법 또한 많은 주목을 받고 있다.  임상에서 섭식장애 환자에게\n\n주로 사용되는 치료는 비약물 치료이며, 그중에서도 인지행동치료가\n\n가장 널리 사용되고 있다.  선행연구에 의하면, 섭식장애를 진단받은\n\n환자를 대상으로 비약물적 중재와 약물적 중재의 효과를 비교한\n\n연구에서 약물적 중재보다 비약물적 중재를 적용한 군이 오히려 폭식\n\n증상 감소에 효과적인 것으로 보고된 바 있으며(Vocks et al., 2010),\n\n비약물적 중재가 식이에 대한 태도를 긍정적으로 변화시키는 것으로\n\n나타났다(Yun&Kim, 2018).\n\n 섭식장애 인지행동치료 등 비약물 치료 효과가 미비한 경우, 필요\n\n하다면 약물치료를 통해 섭식장애를 개선할 수 있다.\n\n - - 44 -\n최근 디지털 기반 섭식장애 치료는 웹 또는 스마트폰 앱 기반으로\n\n인지행동치료를 시행한다. ",
        "original_sentence": "임상에서 섭식장애 환자에게\n\n주로 사용되는 치료는 비약물 치료이며, 그중에서도 인지행동치료가\n\n가장 널리 사용되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_561",
      "text": "선행연구에 의하면, 섭식장애를 진단받은\n\n환자를 대상으로 비약물적 중재와 약물적 중재의 효과를 비교한\n\n연구에서 약물적 중재보다 비약물적 중재를 적용한 군이 오히려 폭식\n\n증상 감소에 효과적인 것으로 보고된 바 있으며(Vocks et al., 2010),\n\n비약물적 중재가 식이에 대한 태도를 긍정적으로 변화시키는 것으로\n\n나타났다(Yun&Kim, 2018).\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 560,
        "window_size": 3,
        "char_count": 203,
        "word_count": 41,
        "page_number": 15,
        "window_text": "임상시험의 목적 및 배경\n\n- 가.  임상시험의 목적\n1) 임상시험용 디지털치료기기의 섭식장애 치료에 대한 안전성 평가\n\n2) 임상시험용 디지털치료기기의 섭식장애 치료에 대한 유효성 평가\n\n최근 섭식장애로 치료받는 환자가 증가하는 추세로 섭식장애를 치료\n\n하는 방법 또한 많은 주목을 받고 있다.  임상에서 섭식장애 환자에게\n\n주로 사용되는 치료는 비약물 치료이며, 그중에서도 인지행동치료가\n\n가장 널리 사용되고 있다.  선행연구에 의하면, 섭식장애를 진단받은\n\n환자를 대상으로 비약물적 중재와 약물적 중재의 효과를 비교한\n\n연구에서 약물적 중재보다 비약물적 중재를 적용한 군이 오히려 폭식\n\n증상 감소에 효과적인 것으로 보고된 바 있으며(Vocks et al., 2010),\n\n비약물적 중재가 식이에 대한 태도를 긍정적으로 변화시키는 것으로\n\n나타났다(Yun&Kim, 2018).\n\n 섭식장애 인지행동치료 등 비약물 치료 효과가 미비한 경우, 필요\n\n하다면 약물치료를 통해 섭식장애를 개선할 수 있다.\n\n - - 44 -\n최근 디지털 기반 섭식장애 치료는 웹 또는 스마트폰 앱 기반으로\n\n인지행동치료를 시행한다.  이를 통해 환자들이 직접 집에서 컴퓨터,\n\n혹은 스마트폰을 이용하여 치료를 시행 받을 수 있으므로 시·공간의\n\n제약에서 자유롭게 될 것이며, 치료 대부분을 환자가 프로그램을 통해\n\n수행하고 피드백을 받을 수 있으므로 치료자 관점에서 비용 대비\n\n효용성 또한 증가하게 될 것으로 기대된다.\n\n",
        "original_sentence": "선행연구에 의하면, 섭식장애를 진단받은\n\n환자를 대상으로 비약물적 중재와 약물적 중재의 효과를 비교한\n\n연구에서 약물적 중재보다 비약물적 중재를 적용한 군이 오히려 폭식\n\n증상 감소에 효과적인 것으로 보고된 바 있으며(Vocks et al., 2010),\n\n비약물적 중재가 식이에 대한 태도를 긍정적으로 변화시키는 것으로\n\n나타났다(Yun&Kim, 2018).\n\n"
      }
    },
    {
      "chunk_id": "chunk_562",
      "text": "섭식장애 인지행동치료 등 비약물 치료 효과가 미비한 경우, 필요\n\n하다면 약물치료를 통해 섭식장애를 개선할 수 있다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 561,
        "window_size": 3,
        "char_count": 67,
        "word_count": 16,
        "page_number": 34,
        "window_text": "임상시험의 목적\n1) 임상시험용 디지털치료기기의 섭식장애 치료에 대한 안전성 평가\n\n2) 임상시험용 디지털치료기기의 섭식장애 치료에 대한 유효성 평가\n\n최근 섭식장애로 치료받는 환자가 증가하는 추세로 섭식장애를 치료\n\n하는 방법 또한 많은 주목을 받고 있다.  임상에서 섭식장애 환자에게\n\n주로 사용되는 치료는 비약물 치료이며, 그중에서도 인지행동치료가\n\n가장 널리 사용되고 있다.  선행연구에 의하면, 섭식장애를 진단받은\n\n환자를 대상으로 비약물적 중재와 약물적 중재의 효과를 비교한\n\n연구에서 약물적 중재보다 비약물적 중재를 적용한 군이 오히려 폭식\n\n증상 감소에 효과적인 것으로 보고된 바 있으며(Vocks et al., 2010),\n\n비약물적 중재가 식이에 대한 태도를 긍정적으로 변화시키는 것으로\n\n나타났다(Yun&Kim, 2018).\n\n 섭식장애 인지행동치료 등 비약물 치료 효과가 미비한 경우, 필요\n\n하다면 약물치료를 통해 섭식장애를 개선할 수 있다.\n\n - - 44 -\n최근 디지털 기반 섭식장애 치료는 웹 또는 스마트폰 앱 기반으로\n\n인지행동치료를 시행한다.  이를 통해 환자들이 직접 집에서 컴퓨터,\n\n혹은 스마트폰을 이용하여 치료를 시행 받을 수 있으므로 시·공간의\n\n제약에서 자유롭게 될 것이며, 치료 대부분을 환자가 프로그램을 통해\n\n수행하고 피드백을 받을 수 있으므로 치료자 관점에서 비용 대비\n\n효용성 또한 증가하게 될 것으로 기대된다.\n\n 섭식장애 인지행동치료의 효과에 관한 여러 연구 결과가 발표되고\n\n있다. ",
        "original_sentence": "섭식장애 인지행동치료 등 비약물 치료 효과가 미비한 경우, 필요\n\n하다면 약물치료를 통해 섭식장애를 개선할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_563",
      "text": "- - 44 -\n최근 디지털 기반 섭식장애 치료는 웹 또는 스마트폰 앱 기반으로\n\n인지행동치료를 시행한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 562,
        "window_size": 3,
        "char_count": 60,
        "word_count": 16,
        "page_number": 26,
        "window_text": "임상에서 섭식장애 환자에게\n\n주로 사용되는 치료는 비약물 치료이며, 그중에서도 인지행동치료가\n\n가장 널리 사용되고 있다.  선행연구에 의하면, 섭식장애를 진단받은\n\n환자를 대상으로 비약물적 중재와 약물적 중재의 효과를 비교한\n\n연구에서 약물적 중재보다 비약물적 중재를 적용한 군이 오히려 폭식\n\n증상 감소에 효과적인 것으로 보고된 바 있으며(Vocks et al., 2010),\n\n비약물적 중재가 식이에 대한 태도를 긍정적으로 변화시키는 것으로\n\n나타났다(Yun&Kim, 2018).\n\n 섭식장애 인지행동치료 등 비약물 치료 효과가 미비한 경우, 필요\n\n하다면 약물치료를 통해 섭식장애를 개선할 수 있다.\n\n - - 44 -\n최근 디지털 기반 섭식장애 치료는 웹 또는 스마트폰 앱 기반으로\n\n인지행동치료를 시행한다.  이를 통해 환자들이 직접 집에서 컴퓨터,\n\n혹은 스마트폰을 이용하여 치료를 시행 받을 수 있으므로 시·공간의\n\n제약에서 자유롭게 될 것이며, 치료 대부분을 환자가 프로그램을 통해\n\n수행하고 피드백을 받을 수 있으므로 치료자 관점에서 비용 대비\n\n효용성 또한 증가하게 될 것으로 기대된다.\n\n 섭식장애 인지행동치료의 효과에 관한 여러 연구 결과가 발표되고\n\n있다.  특히, 최근 연구들은 단순히 섭식장애 인지행동치료를 디지털\n\n환경으로 옮기는 것에서 발전하여, 애플리케이션을 통하여 환자에게\n\n바로 피드백을 제공함으로써 의사나 치료자가 직접적인 가이드를 주지\n\n않더라도 치료 효과를 볼 수 있게 하는 “디지털치료기기(Digital\n\nTherapeutics, DTx)”의 개념을 추구하고 있다.\n\n",
        "original_sentence": "- - 44 -\n최근 디지털 기반 섭식장애 치료는 웹 또는 스마트폰 앱 기반으로\n\n인지행동치료를 시행한다. "
      }
    },
    {
      "chunk_id": "chunk_564",
      "text": "이를 통해 환자들이 직접 집에서 컴퓨터,\n\n혹은 스마트폰을 이용하여 치료를 시행 받을 수 있으므로 시·공간의\n\n제약에서 자유롭게 될 것이며, 치료 대부분을 환자가 프로그램을 통해\n\n수행하고 피드백을 받을 수 있으므로 치료자 관점에서 비용 대비\n\n효용성 또한 증가하게 될 것으로 기대된다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 563,
        "window_size": 3,
        "char_count": 162,
        "word_count": 39,
        "page_number": 15,
        "window_text": "선행연구에 의하면, 섭식장애를 진단받은\n\n환자를 대상으로 비약물적 중재와 약물적 중재의 효과를 비교한\n\n연구에서 약물적 중재보다 비약물적 중재를 적용한 군이 오히려 폭식\n\n증상 감소에 효과적인 것으로 보고된 바 있으며(Vocks et al., 2010),\n\n비약물적 중재가 식이에 대한 태도를 긍정적으로 변화시키는 것으로\n\n나타났다(Yun&Kim, 2018).\n\n 섭식장애 인지행동치료 등 비약물 치료 효과가 미비한 경우, 필요\n\n하다면 약물치료를 통해 섭식장애를 개선할 수 있다.\n\n - - 44 -\n최근 디지털 기반 섭식장애 치료는 웹 또는 스마트폰 앱 기반으로\n\n인지행동치료를 시행한다.  이를 통해 환자들이 직접 집에서 컴퓨터,\n\n혹은 스마트폰을 이용하여 치료를 시행 받을 수 있으므로 시·공간의\n\n제약에서 자유롭게 될 것이며, 치료 대부분을 환자가 프로그램을 통해\n\n수행하고 피드백을 받을 수 있으므로 치료자 관점에서 비용 대비\n\n효용성 또한 증가하게 될 것으로 기대된다.\n\n 섭식장애 인지행동치료의 효과에 관한 여러 연구 결과가 발표되고\n\n있다.  특히, 최근 연구들은 단순히 섭식장애 인지행동치료를 디지털\n\n환경으로 옮기는 것에서 발전하여, 애플리케이션을 통하여 환자에게\n\n바로 피드백을 제공함으로써 의사나 치료자가 직접적인 가이드를 주지\n\n않더라도 치료 효과를 볼 수 있게 하는 “디지털치료기기(Digital\n\nTherapeutics, DTx)”의 개념을 추구하고 있다.\n\n 본 임상시험을 통해 섭식장애 환자들을 대상으로 개발된 섭식장애\n\n개선 디지털치료기기의 작용기전에 대한 안전성(safety)과 유효성\n\n(effectiveness)을 검증하고자 한다.\n\n",
        "original_sentence": "이를 통해 환자들이 직접 집에서 컴퓨터,\n\n혹은 스마트폰을 이용하여 치료를 시행 받을 수 있으므로 시·공간의\n\n제약에서 자유롭게 될 것이며, 치료 대부분을 환자가 프로그램을 통해\n\n수행하고 피드백을 받을 수 있으므로 치료자 관점에서 비용 대비\n\n효용성 또한 증가하게 될 것으로 기대된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_565",
      "text": "섭식장애 인지행동치료의 효과에 관한 여러 연구 결과가 발표되고\n\n있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 564,
        "window_size": 3,
        "char_count": 40,
        "word_count": 9,
        "page_number": 34,
        "window_text": "섭식장애 인지행동치료 등 비약물 치료 효과가 미비한 경우, 필요\n\n하다면 약물치료를 통해 섭식장애를 개선할 수 있다.\n\n - - 44 -\n최근 디지털 기반 섭식장애 치료는 웹 또는 스마트폰 앱 기반으로\n\n인지행동치료를 시행한다.  이를 통해 환자들이 직접 집에서 컴퓨터,\n\n혹은 스마트폰을 이용하여 치료를 시행 받을 수 있으므로 시·공간의\n\n제약에서 자유롭게 될 것이며, 치료 대부분을 환자가 프로그램을 통해\n\n수행하고 피드백을 받을 수 있으므로 치료자 관점에서 비용 대비\n\n효용성 또한 증가하게 될 것으로 기대된다.\n\n 섭식장애 인지행동치료의 효과에 관한 여러 연구 결과가 발표되고\n\n있다.  특히, 최근 연구들은 단순히 섭식장애 인지행동치료를 디지털\n\n환경으로 옮기는 것에서 발전하여, 애플리케이션을 통하여 환자에게\n\n바로 피드백을 제공함으로써 의사나 치료자가 직접적인 가이드를 주지\n\n않더라도 치료 효과를 볼 수 있게 하는 “디지털치료기기(Digital\n\nTherapeutics, DTx)”의 개념을 추구하고 있다.\n\n 본 임상시험을 통해 섭식장애 환자들을 대상으로 개발된 섭식장애\n\n개선 디지털치료기기의 작용기전에 대한 안전성(safety)과 유효성\n\n(effectiveness)을 검증하고자 한다.\n\n - - 45 -\n- 나. ",
        "original_sentence": "섭식장애 인지행동치료의 효과에 관한 여러 연구 결과가 발표되고\n\n있다. "
      }
    },
    {
      "chunk_id": "chunk_566",
      "text": "특히, 최근 연구들은 단순히 섭식장애 인지행동치료를 디지털\n\n환경으로 옮기는 것에서 발전하여, 애플리케이션을 통하여 환자에게\n\n바로 피드백을 제공함으로써 의사나 치료자가 직접적인 가이드를 주지\n\n않더라도 치료 효과를 볼 수 있게 하는 “디지털치료기기(Digital\n\nTherapeutics, DTx)”의 개념을 추구하고 있다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 565,
        "window_size": 3,
        "char_count": 184,
        "word_count": 35,
        "page_number": 116,
        "window_text": "- - 44 -\n최근 디지털 기반 섭식장애 치료는 웹 또는 스마트폰 앱 기반으로\n\n인지행동치료를 시행한다.  이를 통해 환자들이 직접 집에서 컴퓨터,\n\n혹은 스마트폰을 이용하여 치료를 시행 받을 수 있으므로 시·공간의\n\n제약에서 자유롭게 될 것이며, 치료 대부분을 환자가 프로그램을 통해\n\n수행하고 피드백을 받을 수 있으므로 치료자 관점에서 비용 대비\n\n효용성 또한 증가하게 될 것으로 기대된다.\n\n 섭식장애 인지행동치료의 효과에 관한 여러 연구 결과가 발표되고\n\n있다.  특히, 최근 연구들은 단순히 섭식장애 인지행동치료를 디지털\n\n환경으로 옮기는 것에서 발전하여, 애플리케이션을 통하여 환자에게\n\n바로 피드백을 제공함으로써 의사나 치료자가 직접적인 가이드를 주지\n\n않더라도 치료 효과를 볼 수 있게 하는 “디지털치료기기(Digital\n\nTherapeutics, DTx)”의 개념을 추구하고 있다.\n\n 본 임상시험을 통해 섭식장애 환자들을 대상으로 개발된 섭식장애\n\n개선 디지털치료기기의 작용기전에 대한 안전성(safety)과 유효성\n\n(effectiveness)을 검증하고자 한다.\n\n - - 45 -\n- 나.  임상시험의 배경\n디지털치료기기란 질병이나 장애를 예방, 관리, 치료하기 위해 환자에게\n\n근거 기반의 치료적 중재(evidence-based therapeutic intervention)를 제공\n\n하는 고도화된 소프트웨어 의료기기를 가리킨다.\n\n",
        "original_sentence": "특히, 최근 연구들은 단순히 섭식장애 인지행동치료를 디지털\n\n환경으로 옮기는 것에서 발전하여, 애플리케이션을 통하여 환자에게\n\n바로 피드백을 제공함으로써 의사나 치료자가 직접적인 가이드를 주지\n\n않더라도 치료 효과를 볼 수 있게 하는 “디지털치료기기(Digital\n\nTherapeutics, DTx)”의 개념을 추구하고 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_567",
      "text": "본 임상시험을 통해 섭식장애 환자들을 대상으로 개발된 섭식장애\n\n개선 디지털치료기기의 작용기전에 대한 안전성(safety)과 유효성\n\n(effectiveness)을 검증하고자 한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 566,
        "window_size": 3,
        "char_count": 103,
        "word_count": 17,
        "page_number": 15,
        "window_text": "이를 통해 환자들이 직접 집에서 컴퓨터,\n\n혹은 스마트폰을 이용하여 치료를 시행 받을 수 있으므로 시·공간의\n\n제약에서 자유롭게 될 것이며, 치료 대부분을 환자가 프로그램을 통해\n\n수행하고 피드백을 받을 수 있으므로 치료자 관점에서 비용 대비\n\n효용성 또한 증가하게 될 것으로 기대된다.\n\n 섭식장애 인지행동치료의 효과에 관한 여러 연구 결과가 발표되고\n\n있다.  특히, 최근 연구들은 단순히 섭식장애 인지행동치료를 디지털\n\n환경으로 옮기는 것에서 발전하여, 애플리케이션을 통하여 환자에게\n\n바로 피드백을 제공함으로써 의사나 치료자가 직접적인 가이드를 주지\n\n않더라도 치료 효과를 볼 수 있게 하는 “디지털치료기기(Digital\n\nTherapeutics, DTx)”의 개념을 추구하고 있다.\n\n 본 임상시험을 통해 섭식장애 환자들을 대상으로 개발된 섭식장애\n\n개선 디지털치료기기의 작용기전에 대한 안전성(safety)과 유효성\n\n(effectiveness)을 검증하고자 한다.\n\n - - 45 -\n- 나.  임상시험의 배경\n디지털치료기기란 질병이나 장애를 예방, 관리, 치료하기 위해 환자에게\n\n근거 기반의 치료적 중재(evidence-based therapeutic intervention)를 제공\n\n하는 고도화된 소프트웨어 의료기기를 가리킨다.\n\n 디지털치료기기를 통한 인지행동치료의 제공은 디지털치료기기의 최\n\n첨단 접근방식을 통해 환자 개인별로 단계적인 치료를 가능하게 하며,\n\n시간 및 공간 제약 없이 인지행동치료를 가능하게 하여 치료 효과를 높\n\n이며, 더 많은 환자에게 치료 기회를 줄 수 있다는 장점이 있다.\n\n",
        "original_sentence": "본 임상시험을 통해 섭식장애 환자들을 대상으로 개발된 섭식장애\n\n개선 디지털치료기기의 작용기전에 대한 안전성(safety)과 유효성\n\n(effectiveness)을 검증하고자 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_568",
      "text": "- - 45 -\n- 나. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 567,
        "window_size": 3,
        "char_count": 14,
        "word_count": 6,
        "page_number": 26,
        "window_text": "섭식장애 인지행동치료의 효과에 관한 여러 연구 결과가 발표되고\n\n있다.  특히, 최근 연구들은 단순히 섭식장애 인지행동치료를 디지털\n\n환경으로 옮기는 것에서 발전하여, 애플리케이션을 통하여 환자에게\n\n바로 피드백을 제공함으로써 의사나 치료자가 직접적인 가이드를 주지\n\n않더라도 치료 효과를 볼 수 있게 하는 “디지털치료기기(Digital\n\nTherapeutics, DTx)”의 개념을 추구하고 있다.\n\n 본 임상시험을 통해 섭식장애 환자들을 대상으로 개발된 섭식장애\n\n개선 디지털치료기기의 작용기전에 대한 안전성(safety)과 유효성\n\n(effectiveness)을 검증하고자 한다.\n\n - - 45 -\n- 나.  임상시험의 배경\n디지털치료기기란 질병이나 장애를 예방, 관리, 치료하기 위해 환자에게\n\n근거 기반의 치료적 중재(evidence-based therapeutic intervention)를 제공\n\n하는 고도화된 소프트웨어 의료기기를 가리킨다.\n\n 디지털치료기기를 통한 인지행동치료의 제공은 디지털치료기기의 최\n\n첨단 접근방식을 통해 환자 개인별로 단계적인 치료를 가능하게 하며,\n\n시간 및 공간 제약 없이 인지행동치료를 가능하게 하여 치료 효과를 높\n\n이며, 더 많은 환자에게 치료 기회를 줄 수 있다는 장점이 있다.\n\n 선행연구에 따르면, 폭식장애 환자를 대상으로 16주간 인터넷 기반\n\n중재 프로그램을 시행하였다. ",
        "original_sentence": "- - 45 -\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_569",
      "text": "임상시험의 배경\n디지털치료기기란 질병이나 장애를 예방, 관리, 치료하기 위해 환자에게\n\n근거 기반의 치료적 중재(evidence-based therapeutic intervention)를 제공\n\n하는 고도화된 소프트웨어 의료기기를 가리킨다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 568,
        "window_size": 3,
        "char_count": 136,
        "word_count": 22,
        "page_number": 15,
        "window_text": "특히, 최근 연구들은 단순히 섭식장애 인지행동치료를 디지털\n\n환경으로 옮기는 것에서 발전하여, 애플리케이션을 통하여 환자에게\n\n바로 피드백을 제공함으로써 의사나 치료자가 직접적인 가이드를 주지\n\n않더라도 치료 효과를 볼 수 있게 하는 “디지털치료기기(Digital\n\nTherapeutics, DTx)”의 개념을 추구하고 있다.\n\n 본 임상시험을 통해 섭식장애 환자들을 대상으로 개발된 섭식장애\n\n개선 디지털치료기기의 작용기전에 대한 안전성(safety)과 유효성\n\n(effectiveness)을 검증하고자 한다.\n\n - - 45 -\n- 나.  임상시험의 배경\n디지털치료기기란 질병이나 장애를 예방, 관리, 치료하기 위해 환자에게\n\n근거 기반의 치료적 중재(evidence-based therapeutic intervention)를 제공\n\n하는 고도화된 소프트웨어 의료기기를 가리킨다.\n\n 디지털치료기기를 통한 인지행동치료의 제공은 디지털치료기기의 최\n\n첨단 접근방식을 통해 환자 개인별로 단계적인 치료를 가능하게 하며,\n\n시간 및 공간 제약 없이 인지행동치료를 가능하게 하여 치료 효과를 높\n\n이며, 더 많은 환자에게 치료 기회를 줄 수 있다는 장점이 있다.\n\n 선행연구에 따르면, 폭식장애 환자를 대상으로 16주간 인터넷 기반\n\n중재 프로그램을 시행하였다.  해당 연구는 인지행동 대면 치료 및\n\n자조 요법을 포함한 디지털 인지행동치료 프로그램이 마련되었고, 글\n\n쓰기 과제, 임상심리사로부터의 피드백, 활동 일기, 심리 교육 등으로\n\n구성되었다. ",
        "original_sentence": "임상시험의 배경\n디지털치료기기란 질병이나 장애를 예방, 관리, 치료하기 위해 환자에게\n\n근거 기반의 치료적 중재(evidence-based therapeutic intervention)를 제공\n\n하는 고도화된 소프트웨어 의료기기를 가리킨다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_570",
      "text": "디지털치료기기를 통한 인지행동치료의 제공은 디지털치료기기의 최\n\n첨단 접근방식을 통해 환자 개인별로 단계적인 치료를 가능하게 하며,\n\n시간 및 공간 제약 없이 인지행동치료를 가능하게 하여 치료 효과를 높\n\n이며, 더 많은 환자에게 치료 기회를 줄 수 있다는 장점이 있다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 569,
        "window_size": 3,
        "char_count": 153,
        "word_count": 37,
        "page_number": 15,
        "window_text": "본 임상시험을 통해 섭식장애 환자들을 대상으로 개발된 섭식장애\n\n개선 디지털치료기기의 작용기전에 대한 안전성(safety)과 유효성\n\n(effectiveness)을 검증하고자 한다.\n\n - - 45 -\n- 나.  임상시험의 배경\n디지털치료기기란 질병이나 장애를 예방, 관리, 치료하기 위해 환자에게\n\n근거 기반의 치료적 중재(evidence-based therapeutic intervention)를 제공\n\n하는 고도화된 소프트웨어 의료기기를 가리킨다.\n\n 디지털치료기기를 통한 인지행동치료의 제공은 디지털치료기기의 최\n\n첨단 접근방식을 통해 환자 개인별로 단계적인 치료를 가능하게 하며,\n\n시간 및 공간 제약 없이 인지행동치료를 가능하게 하여 치료 효과를 높\n\n이며, 더 많은 환자에게 치료 기회를 줄 수 있다는 장점이 있다.\n\n 선행연구에 따르면, 폭식장애 환자를 대상으로 16주간 인터넷 기반\n\n중재 프로그램을 시행하였다.  해당 연구는 인지행동 대면 치료 및\n\n자조 요법을 포함한 디지털 인지행동치료 프로그램이 마련되었고, 글\n\n쓰기 과제, 임상심리사로부터의 피드백, 활동 일기, 심리 교육 등으로\n\n구성되었다.  위 연구는 폭식 횟수 감소 등 폭식장애 증상 완화,\n\nEDE-Q 척도 감소 또는 유지, 우울 증상 완화 등의 긍정적 결과를\n\n보였다(Wagner et al., 2016).\n\n",
        "original_sentence": "디지털치료기기를 통한 인지행동치료의 제공은 디지털치료기기의 최\n\n첨단 접근방식을 통해 환자 개인별로 단계적인 치료를 가능하게 하며,\n\n시간 및 공간 제약 없이 인지행동치료를 가능하게 하여 치료 효과를 높\n\n이며, 더 많은 환자에게 치료 기회를 줄 수 있다는 장점이 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_571",
      "text": "선행연구에 따르면, 폭식장애 환자를 대상으로 16주간 인터넷 기반\n\n중재 프로그램을 시행하였다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 570,
        "window_size": 3,
        "char_count": 54,
        "word_count": 11,
        "page_number": 15,
        "window_text": "- - 45 -\n- 나.  임상시험의 배경\n디지털치료기기란 질병이나 장애를 예방, 관리, 치료하기 위해 환자에게\n\n근거 기반의 치료적 중재(evidence-based therapeutic intervention)를 제공\n\n하는 고도화된 소프트웨어 의료기기를 가리킨다.\n\n 디지털치료기기를 통한 인지행동치료의 제공은 디지털치료기기의 최\n\n첨단 접근방식을 통해 환자 개인별로 단계적인 치료를 가능하게 하며,\n\n시간 및 공간 제약 없이 인지행동치료를 가능하게 하여 치료 효과를 높\n\n이며, 더 많은 환자에게 치료 기회를 줄 수 있다는 장점이 있다.\n\n 선행연구에 따르면, 폭식장애 환자를 대상으로 16주간 인터넷 기반\n\n중재 프로그램을 시행하였다.  해당 연구는 인지행동 대면 치료 및\n\n자조 요법을 포함한 디지털 인지행동치료 프로그램이 마련되었고, 글\n\n쓰기 과제, 임상심리사로부터의 피드백, 활동 일기, 심리 교육 등으로\n\n구성되었다.  위 연구는 폭식 횟수 감소 등 폭식장애 증상 완화,\n\nEDE-Q 척도 감소 또는 유지, 우울 증상 완화 등의 긍정적 결과를\n\n보였다(Wagner et al., 2016).\n\n 또한, 디지털 기반 섭식장애 치료는 섭식장애 환자들의 건강 개선에\n\n효과적인 것으로 입증되었다(terHuurne et al., 2015). ",
        "original_sentence": "선행연구에 따르면, 폭식장애 환자를 대상으로 16주간 인터넷 기반\n\n중재 프로그램을 시행하였다. "
      }
    },
    {
      "chunk_id": "chunk_572",
      "text": "해당 연구는 인지행동 대면 치료 및\n\n자조 요법을 포함한 디지털 인지행동치료 프로그램이 마련되었고, 글\n\n쓰기 과제, 임상심리사로부터의 피드백, 활동 일기, 심리 교육 등으로\n\n구성되었다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 571,
        "window_size": 3,
        "char_count": 106,
        "word_count": 24,
        "page_number": 30,
        "window_text": "임상시험의 배경\n디지털치료기기란 질병이나 장애를 예방, 관리, 치료하기 위해 환자에게\n\n근거 기반의 치료적 중재(evidence-based therapeutic intervention)를 제공\n\n하는 고도화된 소프트웨어 의료기기를 가리킨다.\n\n 디지털치료기기를 통한 인지행동치료의 제공은 디지털치료기기의 최\n\n첨단 접근방식을 통해 환자 개인별로 단계적인 치료를 가능하게 하며,\n\n시간 및 공간 제약 없이 인지행동치료를 가능하게 하여 치료 효과를 높\n\n이며, 더 많은 환자에게 치료 기회를 줄 수 있다는 장점이 있다.\n\n 선행연구에 따르면, 폭식장애 환자를 대상으로 16주간 인터넷 기반\n\n중재 프로그램을 시행하였다.  해당 연구는 인지행동 대면 치료 및\n\n자조 요법을 포함한 디지털 인지행동치료 프로그램이 마련되었고, 글\n\n쓰기 과제, 임상심리사로부터의 피드백, 활동 일기, 심리 교육 등으로\n\n구성되었다.  위 연구는 폭식 횟수 감소 등 폭식장애 증상 완화,\n\nEDE-Q 척도 감소 또는 유지, 우울 증상 완화 등의 긍정적 결과를\n\n보였다(Wagner et al., 2016).\n\n 또한, 디지털 기반 섭식장애 치료는 섭식장애 환자들의 건강 개선에\n\n효과적인 것으로 입증되었다(terHuurne et al., 2015).  해당 연구에서는\n\n섭식장애를 겪고 있는 여성 환자 총 214명 대상으로 웹 기반의 인지\n\n행동치료(CBT) 중재를 수행했다. ",
        "original_sentence": "해당 연구는 인지행동 대면 치료 및\n\n자조 요법을 포함한 디지털 인지행동치료 프로그램이 마련되었고, 글\n\n쓰기 과제, 임상심리사로부터의 피드백, 활동 일기, 심리 교육 등으로\n\n구성되었다. "
      }
    },
    {
      "chunk_id": "chunk_573",
      "text": "위 연구는 폭식 횟수 감소 등 폭식장애 증상 완화,\n\nEDE-Q 척도 감소 또는 유지, 우울 증상 완화 등의 긍정적 결과를\n\n보였다(Wagner et al., 2016).\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 572,
        "window_size": 3,
        "char_count": 97,
        "word_count": 24,
        "page_number": 17,
        "window_text": "디지털치료기기를 통한 인지행동치료의 제공은 디지털치료기기의 최\n\n첨단 접근방식을 통해 환자 개인별로 단계적인 치료를 가능하게 하며,\n\n시간 및 공간 제약 없이 인지행동치료를 가능하게 하여 치료 효과를 높\n\n이며, 더 많은 환자에게 치료 기회를 줄 수 있다는 장점이 있다.\n\n 선행연구에 따르면, 폭식장애 환자를 대상으로 16주간 인터넷 기반\n\n중재 프로그램을 시행하였다.  해당 연구는 인지행동 대면 치료 및\n\n자조 요법을 포함한 디지털 인지행동치료 프로그램이 마련되었고, 글\n\n쓰기 과제, 임상심리사로부터의 피드백, 활동 일기, 심리 교육 등으로\n\n구성되었다.  위 연구는 폭식 횟수 감소 등 폭식장애 증상 완화,\n\nEDE-Q 척도 감소 또는 유지, 우울 증상 완화 등의 긍정적 결과를\n\n보였다(Wagner et al., 2016).\n\n 또한, 디지털 기반 섭식장애 치료는 섭식장애 환자들의 건강 개선에\n\n효과적인 것으로 입증되었다(terHuurne et al., 2015).  해당 연구에서는\n\n섭식장애를 겪고 있는 여성 환자 총 214명 대상으로 웹 기반의 인지\n\n행동치료(CBT) 중재를 수행했다.  웹 기반 애플리케이션은 21개의\n\n세션과 10개의 과제로 구성되었으며, 참가자들은 하루 약 20분 정도의\n\n중재를\n\n받았다.\n\n",
        "original_sentence": "위 연구는 폭식 횟수 감소 등 폭식장애 증상 완화,\n\nEDE-Q 척도 감소 또는 유지, 우울 증상 완화 등의 긍정적 결과를\n\n보였다(Wagner et al., 2016).\n\n"
      }
    },
    {
      "chunk_id": "chunk_574",
      "text": "또한, 디지털 기반 섭식장애 치료는 섭식장애 환자들의 건강 개선에\n\n효과적인 것으로 입증되었다(terHuurne et al., 2015). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 573,
        "window_size": 3,
        "char_count": 78,
        "word_count": 15,
        "page_number": 15,
        "window_text": "선행연구에 따르면, 폭식장애 환자를 대상으로 16주간 인터넷 기반\n\n중재 프로그램을 시행하였다.  해당 연구는 인지행동 대면 치료 및\n\n자조 요법을 포함한 디지털 인지행동치료 프로그램이 마련되었고, 글\n\n쓰기 과제, 임상심리사로부터의 피드백, 활동 일기, 심리 교육 등으로\n\n구성되었다.  위 연구는 폭식 횟수 감소 등 폭식장애 증상 완화,\n\nEDE-Q 척도 감소 또는 유지, 우울 증상 완화 등의 긍정적 결과를\n\n보였다(Wagner et al., 2016).\n\n 또한, 디지털 기반 섭식장애 치료는 섭식장애 환자들의 건강 개선에\n\n효과적인 것으로 입증되었다(terHuurne et al., 2015).  해당 연구에서는\n\n섭식장애를 겪고 있는 여성 환자 총 214명 대상으로 웹 기반의 인지\n\n행동치료(CBT) 중재를 수행했다.  웹 기반 애플리케이션은 21개의\n\n세션과 10개의 과제로 구성되었으며, 참가자들은 하루 약 20분 정도의\n\n중재를\n\n받았다.\n\n 일차\n\n유효성\n\n변수는\n\nEDE-Q(Eating\n\nDisorder\n\nExamination-Questionnaire), 이차 유효성 변수는 BAT(Body Attitude\n\nTest)가 사용되었다. ",
        "original_sentence": "또한, 디지털 기반 섭식장애 치료는 섭식장애 환자들의 건강 개선에\n\n효과적인 것으로 입증되었다(terHuurne et al., 2015). "
      }
    },
    {
      "chunk_id": "chunk_575",
      "text": "해당 연구에서는\n\n섭식장애를 겪고 있는 여성 환자 총 214명 대상으로 웹 기반의 인지\n\n행동치료(CBT) 중재를 수행했다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 574,
        "window_size": 3,
        "char_count": 70,
        "word_count": 16,
        "page_number": 9,
        "window_text": "해당 연구는 인지행동 대면 치료 및\n\n자조 요법을 포함한 디지털 인지행동치료 프로그램이 마련되었고, 글\n\n쓰기 과제, 임상심리사로부터의 피드백, 활동 일기, 심리 교육 등으로\n\n구성되었다.  위 연구는 폭식 횟수 감소 등 폭식장애 증상 완화,\n\nEDE-Q 척도 감소 또는 유지, 우울 증상 완화 등의 긍정적 결과를\n\n보였다(Wagner et al., 2016).\n\n 또한, 디지털 기반 섭식장애 치료는 섭식장애 환자들의 건강 개선에\n\n효과적인 것으로 입증되었다(terHuurne et al., 2015).  해당 연구에서는\n\n섭식장애를 겪고 있는 여성 환자 총 214명 대상으로 웹 기반의 인지\n\n행동치료(CBT) 중재를 수행했다.  웹 기반 애플리케이션은 21개의\n\n세션과 10개의 과제로 구성되었으며, 참가자들은 하루 약 20분 정도의\n\n중재를\n\n받았다.\n\n 일차\n\n유효성\n\n변수는\n\nEDE-Q(Eating\n\nDisorder\n\nExamination-Questionnaire), 이차 유효성 변수는 BAT(Body Attitude\n\nTest)가 사용되었다.  결과적으로 환자들은 신체 및 정신 건강, 자존감\n\n- - 46 -\n등이 크게 상승한 것을 알 수 있었다.\n\n",
        "original_sentence": "해당 연구에서는\n\n섭식장애를 겪고 있는 여성 환자 총 214명 대상으로 웹 기반의 인지\n\n행동치료(CBT) 중재를 수행했다. "
      }
    },
    {
      "chunk_id": "chunk_576",
      "text": "웹 기반 애플리케이션은 21개의\n\n세션과 10개의 과제로 구성되었으며, 참가자들은 하루 약 20분 정도의\n\n중재를\n\n받았다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 575,
        "window_size": 3,
        "char_count": 71,
        "word_count": 15,
        "page_number": 9,
        "window_text": "위 연구는 폭식 횟수 감소 등 폭식장애 증상 완화,\n\nEDE-Q 척도 감소 또는 유지, 우울 증상 완화 등의 긍정적 결과를\n\n보였다(Wagner et al., 2016).\n\n 또한, 디지털 기반 섭식장애 치료는 섭식장애 환자들의 건강 개선에\n\n효과적인 것으로 입증되었다(terHuurne et al., 2015).  해당 연구에서는\n\n섭식장애를 겪고 있는 여성 환자 총 214명 대상으로 웹 기반의 인지\n\n행동치료(CBT) 중재를 수행했다.  웹 기반 애플리케이션은 21개의\n\n세션과 10개의 과제로 구성되었으며, 참가자들은 하루 약 20분 정도의\n\n중재를\n\n받았다.\n\n 일차\n\n유효성\n\n변수는\n\nEDE-Q(Eating\n\nDisorder\n\nExamination-Questionnaire), 이차 유효성 변수는 BAT(Body Attitude\n\nTest)가 사용되었다.  결과적으로 환자들은 신체 및 정신 건강, 자존감\n\n- - 46 -\n등이 크게 상승한 것을 알 수 있었다.\n\n 이러한 디지털치료기기는 기존의 섭식장애 개선을 위한 웰니스\n\n프로그램과 다음과 같은 차이점을 가진다. ",
        "original_sentence": "웹 기반 애플리케이션은 21개의\n\n세션과 10개의 과제로 구성되었으며, 참가자들은 하루 약 20분 정도의\n\n중재를\n\n받았다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_577",
      "text": "일차\n\n유효성\n\n변수는\n\nEDE-Q(Eating\n\nDisorder\n\nExamination-Questionnaire), 이차 유효성 변수는 BAT(Body Attitude\n\nTest)가 사용되었다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 576,
        "window_size": 3,
        "char_count": 110,
        "word_count": 13,
        "page_number": 7,
        "window_text": "또한, 디지털 기반 섭식장애 치료는 섭식장애 환자들의 건강 개선에\n\n효과적인 것으로 입증되었다(terHuurne et al., 2015).  해당 연구에서는\n\n섭식장애를 겪고 있는 여성 환자 총 214명 대상으로 웹 기반의 인지\n\n행동치료(CBT) 중재를 수행했다.  웹 기반 애플리케이션은 21개의\n\n세션과 10개의 과제로 구성되었으며, 참가자들은 하루 약 20분 정도의\n\n중재를\n\n받았다.\n\n 일차\n\n유효성\n\n변수는\n\nEDE-Q(Eating\n\nDisorder\n\nExamination-Questionnaire), 이차 유효성 변수는 BAT(Body Attitude\n\nTest)가 사용되었다.  결과적으로 환자들은 신체 및 정신 건강, 자존감\n\n- - 46 -\n등이 크게 상승한 것을 알 수 있었다.\n\n 이러한 디지털치료기기는 기존의 섭식장애 개선을 위한 웰니스\n\n프로그램과 다음과 같은 차이점을 가진다.  첫째, 일방적인 콘텐츠\n\n제공을 넘어 쌍방향적인 피드백을 제공한다. ",
        "original_sentence": "일차\n\n유효성\n\n변수는\n\nEDE-Q(Eating\n\nDisorder\n\nExamination-Questionnaire), 이차 유효성 변수는 BAT(Body Attitude\n\nTest)가 사용되었다. "
      }
    },
    {
      "chunk_id": "chunk_578",
      "text": "결과적으로 환자들은 신체 및 정신 건강, 자존감\n\n- - 46 -\n등이 크게 상승한 것을 알 수 있었다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 577,
        "window_size": 3,
        "char_count": 60,
        "word_count": 18,
        "page_number": 15,
        "window_text": "해당 연구에서는\n\n섭식장애를 겪고 있는 여성 환자 총 214명 대상으로 웹 기반의 인지\n\n행동치료(CBT) 중재를 수행했다.  웹 기반 애플리케이션은 21개의\n\n세션과 10개의 과제로 구성되었으며, 참가자들은 하루 약 20분 정도의\n\n중재를\n\n받았다.\n\n 일차\n\n유효성\n\n변수는\n\nEDE-Q(Eating\n\nDisorder\n\nExamination-Questionnaire), 이차 유효성 변수는 BAT(Body Attitude\n\nTest)가 사용되었다.  결과적으로 환자들은 신체 및 정신 건강, 자존감\n\n- - 46 -\n등이 크게 상승한 것을 알 수 있었다.\n\n 이러한 디지털치료기기는 기존의 섭식장애 개선을 위한 웰니스\n\n프로그램과 다음과 같은 차이점을 가진다.  첫째, 일방적인 콘텐츠\n\n제공을 넘어 쌍방향적인 피드백을 제공한다.  대상자의 섭식장애 증상에\n\n대한 변수를 지속해서 수집하고, 이에 대해 다음 목표를 제시함으로써\n\n치료 효과를 극대화한다. ",
        "original_sentence": "결과적으로 환자들은 신체 및 정신 건강, 자존감\n\n- - 46 -\n등이 크게 상승한 것을 알 수 있었다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_579",
      "text": "이러한 디지털치료기기는 기존의 섭식장애 개선을 위한 웰니스\n\n프로그램과 다음과 같은 차이점을 가진다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 578,
        "window_size": 3,
        "char_count": 57,
        "word_count": 12,
        "page_number": 7,
        "window_text": "웹 기반 애플리케이션은 21개의\n\n세션과 10개의 과제로 구성되었으며, 참가자들은 하루 약 20분 정도의\n\n중재를\n\n받았다.\n\n 일차\n\n유효성\n\n변수는\n\nEDE-Q(Eating\n\nDisorder\n\nExamination-Questionnaire), 이차 유효성 변수는 BAT(Body Attitude\n\nTest)가 사용되었다.  결과적으로 환자들은 신체 및 정신 건강, 자존감\n\n- - 46 -\n등이 크게 상승한 것을 알 수 있었다.\n\n 이러한 디지털치료기기는 기존의 섭식장애 개선을 위한 웰니스\n\n프로그램과 다음과 같은 차이점을 가진다.  첫째, 일방적인 콘텐츠\n\n제공을 넘어 쌍방향적인 피드백을 제공한다.  대상자의 섭식장애 증상에\n\n대한 변수를 지속해서 수집하고, 이에 대해 다음 목표를 제시함으로써\n\n치료 효과를 극대화한다.  이 과정에서 피험자는 단순히 콘텐츠를 소비\n\n하는 것을 넘어서, 스스로 콘텐츠에 참여하고 있다는 느낌을 받을 수\n\n있다. ",
        "original_sentence": "이러한 디지털치료기기는 기존의 섭식장애 개선을 위한 웰니스\n\n프로그램과 다음과 같은 차이점을 가진다. "
      }
    },
    {
      "chunk_id": "chunk_580",
      "text": "첫째, 일방적인 콘텐츠\n\n제공을 넘어 쌍방향적인 피드백을 제공한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 579,
        "window_size": 3,
        "char_count": 38,
        "word_count": 8,
        "page_number": 15,
        "window_text": "일차\n\n유효성\n\n변수는\n\nEDE-Q(Eating\n\nDisorder\n\nExamination-Questionnaire), 이차 유효성 변수는 BAT(Body Attitude\n\nTest)가 사용되었다.  결과적으로 환자들은 신체 및 정신 건강, 자존감\n\n- - 46 -\n등이 크게 상승한 것을 알 수 있었다.\n\n 이러한 디지털치료기기는 기존의 섭식장애 개선을 위한 웰니스\n\n프로그램과 다음과 같은 차이점을 가진다.  첫째, 일방적인 콘텐츠\n\n제공을 넘어 쌍방향적인 피드백을 제공한다.  대상자의 섭식장애 증상에\n\n대한 변수를 지속해서 수집하고, 이에 대해 다음 목표를 제시함으로써\n\n치료 효과를 극대화한다.  이 과정에서 피험자는 단순히 콘텐츠를 소비\n\n하는 것을 넘어서, 스스로 콘텐츠에 참여하고 있다는 느낌을 받을 수\n\n있다.  둘째, 피험자 맞춤형 콘텐츠 제공이 가능하다. ",
        "original_sentence": "첫째, 일방적인 콘텐츠\n\n제공을 넘어 쌍방향적인 피드백을 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_581",
      "text": "대상자의 섭식장애 증상에\n\n대한 변수를 지속해서 수집하고, 이에 대해 다음 목표를 제시함으로써\n\n치료 효과를 극대화한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 580,
        "window_size": 3,
        "char_count": 68,
        "word_count": 15,
        "page_number": 7,
        "window_text": "결과적으로 환자들은 신체 및 정신 건강, 자존감\n\n- - 46 -\n등이 크게 상승한 것을 알 수 있었다.\n\n 이러한 디지털치료기기는 기존의 섭식장애 개선을 위한 웰니스\n\n프로그램과 다음과 같은 차이점을 가진다.  첫째, 일방적인 콘텐츠\n\n제공을 넘어 쌍방향적인 피드백을 제공한다.  대상자의 섭식장애 증상에\n\n대한 변수를 지속해서 수집하고, 이에 대해 다음 목표를 제시함으로써\n\n치료 효과를 극대화한다.  이 과정에서 피험자는 단순히 콘텐츠를 소비\n\n하는 것을 넘어서, 스스로 콘텐츠에 참여하고 있다는 느낌을 받을 수\n\n있다.  둘째, 피험자 맞춤형 콘텐츠 제공이 가능하다.  모든 콘텐츠를\n\n같은 비율로 제공하는 것에 그치지 않고 피험자의 정보를 수집함으로써\n\n취약한 부분에 대한 집중적인 맞춤형 콘텐츠 제공을 하는 것이 가능\n\n하다. ",
        "original_sentence": "대상자의 섭식장애 증상에\n\n대한 변수를 지속해서 수집하고, 이에 대해 다음 목표를 제시함으로써\n\n치료 효과를 극대화한다. "
      }
    },
    {
      "chunk_id": "chunk_582",
      "text": "이 과정에서 피험자는 단순히 콘텐츠를 소비\n\n하는 것을 넘어서, 스스로 콘텐츠에 참여하고 있다는 느낌을 받을 수\n\n있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 581,
        "window_size": 3,
        "char_count": 68,
        "word_count": 17,
        "page_number": 34,
        "window_text": "이러한 디지털치료기기는 기존의 섭식장애 개선을 위한 웰니스\n\n프로그램과 다음과 같은 차이점을 가진다.  첫째, 일방적인 콘텐츠\n\n제공을 넘어 쌍방향적인 피드백을 제공한다.  대상자의 섭식장애 증상에\n\n대한 변수를 지속해서 수집하고, 이에 대해 다음 목표를 제시함으로써\n\n치료 효과를 극대화한다.  이 과정에서 피험자는 단순히 콘텐츠를 소비\n\n하는 것을 넘어서, 스스로 콘텐츠에 참여하고 있다는 느낌을 받을 수\n\n있다.  둘째, 피험자 맞춤형 콘텐츠 제공이 가능하다.  모든 콘텐츠를\n\n같은 비율로 제공하는 것에 그치지 않고 피험자의 정보를 수집함으로써\n\n취약한 부분에 대한 집중적인 맞춤형 콘텐츠 제공을 하는 것이 가능\n\n하다.  셋째, 일정 시간 동안의 꾸준한 사용을 독려하며 치료 효과에\n\n대한 모니터링이 가능하다. ",
        "original_sentence": "이 과정에서 피험자는 단순히 콘텐츠를 소비\n\n하는 것을 넘어서, 스스로 콘텐츠에 참여하고 있다는 느낌을 받을 수\n\n있다. "
      }
    },
    {
      "chunk_id": "chunk_583",
      "text": "둘째, 피험자 맞춤형 콘텐츠 제공이 가능하다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 582,
        "window_size": 3,
        "char_count": 26,
        "word_count": 6,
        "page_number": 34,
        "window_text": "첫째, 일방적인 콘텐츠\n\n제공을 넘어 쌍방향적인 피드백을 제공한다.  대상자의 섭식장애 증상에\n\n대한 변수를 지속해서 수집하고, 이에 대해 다음 목표를 제시함으로써\n\n치료 효과를 극대화한다.  이 과정에서 피험자는 단순히 콘텐츠를 소비\n\n하는 것을 넘어서, 스스로 콘텐츠에 참여하고 있다는 느낌을 받을 수\n\n있다.  둘째, 피험자 맞춤형 콘텐츠 제공이 가능하다.  모든 콘텐츠를\n\n같은 비율로 제공하는 것에 그치지 않고 피험자의 정보를 수집함으로써\n\n취약한 부분에 대한 집중적인 맞춤형 콘텐츠 제공을 하는 것이 가능\n\n하다.  셋째, 일정 시간 동안의 꾸준한 사용을 독려하며 치료 효과에\n\n대한 모니터링이 가능하다.  일반적으로 디지털치료기기는 모든 콘텐츠를\n\n한 번에 제공하지 않고 일정 기간 순차적으로 콘텐츠 제공하여 사용\n\n기간을 조정한다. ",
        "original_sentence": "둘째, 피험자 맞춤형 콘텐츠 제공이 가능하다. "
      }
    },
    {
      "chunk_id": "chunk_584",
      "text": "모든 콘텐츠를\n\n같은 비율로 제공하는 것에 그치지 않고 피험자의 정보를 수집함으로써\n\n취약한 부분에 대한 집중적인 맞춤형 콘텐츠 제공을 하는 것이 가능\n\n하다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 583,
        "window_size": 3,
        "char_count": 90,
        "word_count": 22,
        "page_number": 34,
        "window_text": "대상자의 섭식장애 증상에\n\n대한 변수를 지속해서 수집하고, 이에 대해 다음 목표를 제시함으로써\n\n치료 효과를 극대화한다.  이 과정에서 피험자는 단순히 콘텐츠를 소비\n\n하는 것을 넘어서, 스스로 콘텐츠에 참여하고 있다는 느낌을 받을 수\n\n있다.  둘째, 피험자 맞춤형 콘텐츠 제공이 가능하다.  모든 콘텐츠를\n\n같은 비율로 제공하는 것에 그치지 않고 피험자의 정보를 수집함으로써\n\n취약한 부분에 대한 집중적인 맞춤형 콘텐츠 제공을 하는 것이 가능\n\n하다.  셋째, 일정 시간 동안의 꾸준한 사용을 독려하며 치료 효과에\n\n대한 모니터링이 가능하다.  일반적으로 디지털치료기기는 모든 콘텐츠를\n\n한 번에 제공하지 않고 일정 기간 순차적으로 콘텐츠 제공하여 사용\n\n기간을 조정한다.  피험자들은 치료 기간 중 섭식장애 증상이 어떻게\n\n변화하는지 실제 체감하고, 또한 디지털치료기기를 통한 모니터링을\n\n받을 수 있어 치료 동기 부여에 긍정적으로 작용할 수 있다.\n\n",
        "original_sentence": "모든 콘텐츠를\n\n같은 비율로 제공하는 것에 그치지 않고 피험자의 정보를 수집함으로써\n\n취약한 부분에 대한 집중적인 맞춤형 콘텐츠 제공을 하는 것이 가능\n\n하다. "
      }
    },
    {
      "chunk_id": "chunk_585",
      "text": "셋째, 일정 시간 동안의 꾸준한 사용을 독려하며 치료 효과에\n\n대한 모니터링이 가능하다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 584,
        "window_size": 3,
        "char_count": 50,
        "word_count": 12,
        "page_number": 30,
        "window_text": "이 과정에서 피험자는 단순히 콘텐츠를 소비\n\n하는 것을 넘어서, 스스로 콘텐츠에 참여하고 있다는 느낌을 받을 수\n\n있다.  둘째, 피험자 맞춤형 콘텐츠 제공이 가능하다.  모든 콘텐츠를\n\n같은 비율로 제공하는 것에 그치지 않고 피험자의 정보를 수집함으로써\n\n취약한 부분에 대한 집중적인 맞춤형 콘텐츠 제공을 하는 것이 가능\n\n하다.  셋째, 일정 시간 동안의 꾸준한 사용을 독려하며 치료 효과에\n\n대한 모니터링이 가능하다.  일반적으로 디지털치료기기는 모든 콘텐츠를\n\n한 번에 제공하지 않고 일정 기간 순차적으로 콘텐츠 제공하여 사용\n\n기간을 조정한다.  피험자들은 치료 기간 중 섭식장애 증상이 어떻게\n\n변화하는지 실제 체감하고, 또한 디지털치료기기를 통한 모니터링을\n\n받을 수 있어 치료 동기 부여에 긍정적으로 작용할 수 있다.\n\n 본 연구에서는 국내에서 개발된 디지털 섭식장애 인지행동치료\n\n애플리케이션을 무작위배정 임상시험을 통해 효과성과 안전성 검증을\n\n함으로써 해당 애플리케이션을 실제 국내 임상에서 활용할 수 있는지\n\n확인을 할 수 있으며 국내 섭식장애 환자들에게 새로운 치료의 선택지를\n\n열어주고자 한다.\n\n",
        "original_sentence": "셋째, 일정 시간 동안의 꾸준한 사용을 독려하며 치료 효과에\n\n대한 모니터링이 가능하다. "
      }
    },
    {
      "chunk_id": "chunk_586",
      "text": "일반적으로 디지털치료기기는 모든 콘텐츠를\n\n한 번에 제공하지 않고 일정 기간 순차적으로 콘텐츠 제공하여 사용\n\n기간을 조정한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 585,
        "window_size": 3,
        "char_count": 72,
        "word_count": 16,
        "page_number": 7,
        "window_text": "둘째, 피험자 맞춤형 콘텐츠 제공이 가능하다.  모든 콘텐츠를\n\n같은 비율로 제공하는 것에 그치지 않고 피험자의 정보를 수집함으로써\n\n취약한 부분에 대한 집중적인 맞춤형 콘텐츠 제공을 하는 것이 가능\n\n하다.  셋째, 일정 시간 동안의 꾸준한 사용을 독려하며 치료 효과에\n\n대한 모니터링이 가능하다.  일반적으로 디지털치료기기는 모든 콘텐츠를\n\n한 번에 제공하지 않고 일정 기간 순차적으로 콘텐츠 제공하여 사용\n\n기간을 조정한다.  피험자들은 치료 기간 중 섭식장애 증상이 어떻게\n\n변화하는지 실제 체감하고, 또한 디지털치료기기를 통한 모니터링을\n\n받을 수 있어 치료 동기 부여에 긍정적으로 작용할 수 있다.\n\n 본 연구에서는 국내에서 개발된 디지털 섭식장애 인지행동치료\n\n애플리케이션을 무작위배정 임상시험을 통해 효과성과 안전성 검증을\n\n함으로써 해당 애플리케이션을 실제 국내 임상에서 활용할 수 있는지\n\n확인을 할 수 있으며 국내 섭식장애 환자들에게 새로운 치료의 선택지를\n\n열어주고자 한다.\n\n - - 47 -\n- 7. ",
        "original_sentence": "일반적으로 디지털치료기기는 모든 콘텐츠를\n\n한 번에 제공하지 않고 일정 기간 순차적으로 콘텐츠 제공하여 사용\n\n기간을 조정한다. "
      }
    },
    {
      "chunk_id": "chunk_587",
      "text": "피험자들은 치료 기간 중 섭식장애 증상이 어떻게\n\n변화하는지 실제 체감하고, 또한 디지털치료기기를 통한 모니터링을\n\n받을 수 있어 치료 동기 부여에 긍정적으로 작용할 수 있다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 586,
        "window_size": 3,
        "char_count": 100,
        "word_count": 24,
        "page_number": 35,
        "window_text": "모든 콘텐츠를\n\n같은 비율로 제공하는 것에 그치지 않고 피험자의 정보를 수집함으로써\n\n취약한 부분에 대한 집중적인 맞춤형 콘텐츠 제공을 하는 것이 가능\n\n하다.  셋째, 일정 시간 동안의 꾸준한 사용을 독려하며 치료 효과에\n\n대한 모니터링이 가능하다.  일반적으로 디지털치료기기는 모든 콘텐츠를\n\n한 번에 제공하지 않고 일정 기간 순차적으로 콘텐츠 제공하여 사용\n\n기간을 조정한다.  피험자들은 치료 기간 중 섭식장애 증상이 어떻게\n\n변화하는지 실제 체감하고, 또한 디지털치료기기를 통한 모니터링을\n\n받을 수 있어 치료 동기 부여에 긍정적으로 작용할 수 있다.\n\n 본 연구에서는 국내에서 개발된 디지털 섭식장애 인지행동치료\n\n애플리케이션을 무작위배정 임상시험을 통해 효과성과 안전성 검증을\n\n함으로써 해당 애플리케이션을 실제 국내 임상에서 활용할 수 있는지\n\n확인을 할 수 있으며 국내 섭식장애 환자들에게 새로운 치료의 선택지를\n\n열어주고자 한다.\n\n - - 47 -\n- 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증 포함)\n- 가. ",
        "original_sentence": "피험자들은 치료 기간 중 섭식장애 증상이 어떻게\n\n변화하는지 실제 체감하고, 또한 디지털치료기기를 통한 모니터링을\n\n받을 수 있어 치료 동기 부여에 긍정적으로 작용할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_588",
      "text": "본 연구에서는 국내에서 개발된 디지털 섭식장애 인지행동치료\n\n애플리케이션을 무작위배정 임상시험을 통해 효과성과 안전성 검증을\n\n함으로써 해당 애플리케이션을 실제 국내 임상에서 활용할 수 있는지\n\n확인을 할 수 있으며 국내 섭식장애 환자들에게 새로운 치료의 선택지를\n\n열어주고자 한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 587,
        "window_size": 3,
        "char_count": 160,
        "word_count": 35,
        "page_number": 27,
        "window_text": "셋째, 일정 시간 동안의 꾸준한 사용을 독려하며 치료 효과에\n\n대한 모니터링이 가능하다.  일반적으로 디지털치료기기는 모든 콘텐츠를\n\n한 번에 제공하지 않고 일정 기간 순차적으로 콘텐츠 제공하여 사용\n\n기간을 조정한다.  피험자들은 치료 기간 중 섭식장애 증상이 어떻게\n\n변화하는지 실제 체감하고, 또한 디지털치료기기를 통한 모니터링을\n\n받을 수 있어 치료 동기 부여에 긍정적으로 작용할 수 있다.\n\n 본 연구에서는 국내에서 개발된 디지털 섭식장애 인지행동치료\n\n애플리케이션을 무작위배정 임상시험을 통해 효과성과 안전성 검증을\n\n함으로써 해당 애플리케이션을 실제 국내 임상에서 활용할 수 있는지\n\n확인을 할 수 있으며 국내 섭식장애 환자들에게 새로운 치료의 선택지를\n\n열어주고자 한다.\n\n - - 47 -\n- 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증 포함)\n- 가.  임상시험용 의료기기 사용 목적\n[예시]\n\n[사용 목적]\n\n모바일 애플리케이션 형태의 섭식장애 인지행동치료 기반, 혹은 이와\n\n유사한 과학적 근거를 가진 섭식장애의 비약물적인 치료에 근간한\n\n콘텐츠를 범용 장비(스마트폰 또는 태블릿 PC)를 통해 제공하는 소프트\n\n웨어 의료기기이다. ",
        "original_sentence": "본 연구에서는 국내에서 개발된 디지털 섭식장애 인지행동치료\n\n애플리케이션을 무작위배정 임상시험을 통해 효과성과 안전성 검증을\n\n함으로써 해당 애플리케이션을 실제 국내 임상에서 활용할 수 있는지\n\n확인을 할 수 있으며 국내 섭식장애 환자들에게 새로운 치료의 선택지를\n\n열어주고자 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_589",
      "text": "- - 47 -\n- 7. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 588,
        "window_size": 3,
        "char_count": 14,
        "word_count": 6,
        "page_number": 26,
        "window_text": "일반적으로 디지털치료기기는 모든 콘텐츠를\n\n한 번에 제공하지 않고 일정 기간 순차적으로 콘텐츠 제공하여 사용\n\n기간을 조정한다.  피험자들은 치료 기간 중 섭식장애 증상이 어떻게\n\n변화하는지 실제 체감하고, 또한 디지털치료기기를 통한 모니터링을\n\n받을 수 있어 치료 동기 부여에 긍정적으로 작용할 수 있다.\n\n 본 연구에서는 국내에서 개발된 디지털 섭식장애 인지행동치료\n\n애플리케이션을 무작위배정 임상시험을 통해 효과성과 안전성 검증을\n\n함으로써 해당 애플리케이션을 실제 국내 임상에서 활용할 수 있는지\n\n확인을 할 수 있으며 국내 섭식장애 환자들에게 새로운 치료의 선택지를\n\n열어주고자 한다.\n\n - - 47 -\n- 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증 포함)\n- 가.  임상시험용 의료기기 사용 목적\n[예시]\n\n[사용 목적]\n\n모바일 애플리케이션 형태의 섭식장애 인지행동치료 기반, 혹은 이와\n\n유사한 과학적 근거를 가진 섭식장애의 비약물적인 치료에 근간한\n\n콘텐츠를 범용 장비(스마트폰 또는 태블릿 PC)를 통해 제공하는 소프트\n\n웨어 의료기기이다.  임상시험용 기기는 섭식장애 인지행동치료(CBT)\n\n혹은 이와 유사한 과학적 근거를 가진 섭식장애의 비약물적인 치료를\n\n제공하여 대조군 대비 섭식장애 증상을 개선하는 것을 목표로 한다.\n\n",
        "original_sentence": "- - 47 -\n- 7. "
      }
    },
    {
      "chunk_id": "chunk_590",
      "text": "임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증 포함)\n- 가. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 589,
        "window_size": 3,
        "char_count": 42,
        "word_count": 9,
        "page_number": 7,
        "window_text": "피험자들은 치료 기간 중 섭식장애 증상이 어떻게\n\n변화하는지 실제 체감하고, 또한 디지털치료기기를 통한 모니터링을\n\n받을 수 있어 치료 동기 부여에 긍정적으로 작용할 수 있다.\n\n 본 연구에서는 국내에서 개발된 디지털 섭식장애 인지행동치료\n\n애플리케이션을 무작위배정 임상시험을 통해 효과성과 안전성 검증을\n\n함으로써 해당 애플리케이션을 실제 국내 임상에서 활용할 수 있는지\n\n확인을 할 수 있으며 국내 섭식장애 환자들에게 새로운 치료의 선택지를\n\n열어주고자 한다.\n\n - - 47 -\n- 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증 포함)\n- 가.  임상시험용 의료기기 사용 목적\n[예시]\n\n[사용 목적]\n\n모바일 애플리케이션 형태의 섭식장애 인지행동치료 기반, 혹은 이와\n\n유사한 과학적 근거를 가진 섭식장애의 비약물적인 치료에 근간한\n\n콘텐츠를 범용 장비(스마트폰 또는 태블릿 PC)를 통해 제공하는 소프트\n\n웨어 의료기기이다.  임상시험용 기기는 섭식장애 인지행동치료(CBT)\n\n혹은 이와 유사한 과학적 근거를 가진 섭식장애의 비약물적인 치료를\n\n제공하여 대조군 대비 섭식장애 증상을 개선하는 것을 목표로 한다.\n\n 본 의료기기는 의사에게 섭식장애* 진단을 받은 환자를 대상으로\n\n하며, 추후 추가적인 적응증 확대는 가능하나 섭식장애에 대한 의사\n\n진단을 기반으로 한다.\n\n",
        "original_sentence": "임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증 포함)\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_591",
      "text": "임상시험용 의료기기 사용 목적\n[예시]\n\n[사용 목적]\n\n모바일 애플리케이션 형태의 섭식장애 인지행동치료 기반, 혹은 이와\n\n유사한 과학적 근거를 가진 섭식장애의 비약물적인 치료에 근간한\n\n콘텐츠를 범용 장비(스마트폰 또는 태블릿 PC)를 통해 제공하는 소프트\n\n웨어 의료기기이다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 590,
        "window_size": 3,
        "char_count": 158,
        "word_count": 34,
        "page_number": 7,
        "window_text": "본 연구에서는 국내에서 개발된 디지털 섭식장애 인지행동치료\n\n애플리케이션을 무작위배정 임상시험을 통해 효과성과 안전성 검증을\n\n함으로써 해당 애플리케이션을 실제 국내 임상에서 활용할 수 있는지\n\n확인을 할 수 있으며 국내 섭식장애 환자들에게 새로운 치료의 선택지를\n\n열어주고자 한다.\n\n - - 47 -\n- 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증 포함)\n- 가.  임상시험용 의료기기 사용 목적\n[예시]\n\n[사용 목적]\n\n모바일 애플리케이션 형태의 섭식장애 인지행동치료 기반, 혹은 이와\n\n유사한 과학적 근거를 가진 섭식장애의 비약물적인 치료에 근간한\n\n콘텐츠를 범용 장비(스마트폰 또는 태블릿 PC)를 통해 제공하는 소프트\n\n웨어 의료기기이다.  임상시험용 기기는 섭식장애 인지행동치료(CBT)\n\n혹은 이와 유사한 과학적 근거를 가진 섭식장애의 비약물적인 치료를\n\n제공하여 대조군 대비 섭식장애 증상을 개선하는 것을 목표로 한다.\n\n 본 의료기기는 의사에게 섭식장애* 진단을 받은 환자를 대상으로\n\n하며, 추후 추가적인 적응증 확대는 가능하나 섭식장애에 대한 의사\n\n진단을 기반으로 한다.\n\n [F50.4] Overeating associated with other psychological disturbances (기타 심리적\n\n[F50.5] Vomiting associated with other psychological disturbances (기타 심리적\n\n- - 48 -\n[F50.8] Other eating disorders (기타 식사장애)\n\n[F50.9] Eating disorder, unspecified (상세불명의 식사장애)\n\n- - 49 -\n- 나. ",
        "original_sentence": "임상시험용 의료기기 사용 목적\n[예시]\n\n[사용 목적]\n\n모바일 애플리케이션 형태의 섭식장애 인지행동치료 기반, 혹은 이와\n\n유사한 과학적 근거를 가진 섭식장애의 비약물적인 치료에 근간한\n\n콘텐츠를 범용 장비(스마트폰 또는 태블릿 PC)를 통해 제공하는 소프트\n\n웨어 의료기기이다. "
      }
    },
    {
      "chunk_id": "chunk_592",
      "text": "임상시험용 기기는 섭식장애 인지행동치료(CBT)\n\n혹은 이와 유사한 과학적 근거를 가진 섭식장애의 비약물적인 치료를\n\n제공하여 대조군 대비 섭식장애 증상을 개선하는 것을 목표로 한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 591,
        "window_size": 3,
        "char_count": 104,
        "word_count": 22,
        "page_number": 35,
        "window_text": "- - 47 -\n- 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증 포함)\n- 가.  임상시험용 의료기기 사용 목적\n[예시]\n\n[사용 목적]\n\n모바일 애플리케이션 형태의 섭식장애 인지행동치료 기반, 혹은 이와\n\n유사한 과학적 근거를 가진 섭식장애의 비약물적인 치료에 근간한\n\n콘텐츠를 범용 장비(스마트폰 또는 태블릿 PC)를 통해 제공하는 소프트\n\n웨어 의료기기이다.  임상시험용 기기는 섭식장애 인지행동치료(CBT)\n\n혹은 이와 유사한 과학적 근거를 가진 섭식장애의 비약물적인 치료를\n\n제공하여 대조군 대비 섭식장애 증상을 개선하는 것을 목표로 한다.\n\n 본 의료기기는 의사에게 섭식장애* 진단을 받은 환자를 대상으로\n\n하며, 추후 추가적인 적응증 확대는 가능하나 섭식장애에 대한 의사\n\n진단을 기반으로 한다.\n\n [F50.4] Overeating associated with other psychological disturbances (기타 심리적\n\n[F50.5] Vomiting associated with other psychological disturbances (기타 심리적\n\n- - 48 -\n[F50.8] Other eating disorders (기타 식사장애)\n\n[F50.9] Eating disorder, unspecified (상세불명의 식사장애)\n\n- - 49 -\n- 나.  임상시험용 의료기기 정보\n- - 품목명(품목분류번호, 등급): 인지치료소프트웨어(E06060.02, 2등급)\n※ 대조 시험용 의료기기의 구체적인 정보를 ‘가)’를 참고하여 작성한다. ",
        "original_sentence": "임상시험용 기기는 섭식장애 인지행동치료(CBT)\n\n혹은 이와 유사한 과학적 근거를 가진 섭식장애의 비약물적인 치료를\n\n제공하여 대조군 대비 섭식장애 증상을 개선하는 것을 목표로 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_593",
      "text": "본 의료기기는 의사에게 섭식장애* 진단을 받은 환자를 대상으로\n\n하며, 추후 추가적인 적응증 확대는 가능하나 섭식장애에 대한 의사\n\n진단을 기반으로 한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 592,
        "window_size": 3,
        "char_count": 88,
        "word_count": 20,
        "page_number": 15,
        "window_text": "임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증 포함)\n- 가.  임상시험용 의료기기 사용 목적\n[예시]\n\n[사용 목적]\n\n모바일 애플리케이션 형태의 섭식장애 인지행동치료 기반, 혹은 이와\n\n유사한 과학적 근거를 가진 섭식장애의 비약물적인 치료에 근간한\n\n콘텐츠를 범용 장비(스마트폰 또는 태블릿 PC)를 통해 제공하는 소프트\n\n웨어 의료기기이다.  임상시험용 기기는 섭식장애 인지행동치료(CBT)\n\n혹은 이와 유사한 과학적 근거를 가진 섭식장애의 비약물적인 치료를\n\n제공하여 대조군 대비 섭식장애 증상을 개선하는 것을 목표로 한다.\n\n 본 의료기기는 의사에게 섭식장애* 진단을 받은 환자를 대상으로\n\n하며, 추후 추가적인 적응증 확대는 가능하나 섭식장애에 대한 의사\n\n진단을 기반으로 한다.\n\n [F50.4] Overeating associated with other psychological disturbances (기타 심리적\n\n[F50.5] Vomiting associated with other psychological disturbances (기타 심리적\n\n- - 48 -\n[F50.8] Other eating disorders (기타 식사장애)\n\n[F50.9] Eating disorder, unspecified (상세불명의 식사장애)\n\n- - 49 -\n- 나.  임상시험용 의료기기 정보\n- - 품목명(품목분류번호, 등급): 인지치료소프트웨어(E06060.02, 2등급)\n※ 대조 시험용 의료기기의 구체적인 정보를 ‘가)’를 참고하여 작성한다.  대조\n\n시험용 의료기기가 설정되지 않았을 경우 생략할 수 있으며, 설정하지\n\n- 다. ",
        "original_sentence": "본 의료기기는 의사에게 섭식장애* 진단을 받은 환자를 대상으로\n\n하며, 추후 추가적인 적응증 확대는 가능하나 섭식장애에 대한 의사\n\n진단을 기반으로 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_594",
      "text": "[F50.4] Overeating associated with other psychological disturbances (기타 심리적\n\n[F50.5] Vomiting associated with other psychological disturbances (기타 심리적\n\n- - 48 -\n[F50.8] Other eating disorders (기타 식사장애)\n\n[F50.9] Eating disorder, unspecified (상세불명의 식사장애)\n\n- - 49 -\n- 나. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 593,
        "window_size": 3,
        "char_count": 268,
        "word_count": 40,
        "page_number": 26,
        "window_text": "임상시험용 의료기기 사용 목적\n[예시]\n\n[사용 목적]\n\n모바일 애플리케이션 형태의 섭식장애 인지행동치료 기반, 혹은 이와\n\n유사한 과학적 근거를 가진 섭식장애의 비약물적인 치료에 근간한\n\n콘텐츠를 범용 장비(스마트폰 또는 태블릿 PC)를 통해 제공하는 소프트\n\n웨어 의료기기이다.  임상시험용 기기는 섭식장애 인지행동치료(CBT)\n\n혹은 이와 유사한 과학적 근거를 가진 섭식장애의 비약물적인 치료를\n\n제공하여 대조군 대비 섭식장애 증상을 개선하는 것을 목표로 한다.\n\n 본 의료기기는 의사에게 섭식장애* 진단을 받은 환자를 대상으로\n\n하며, 추후 추가적인 적응증 확대는 가능하나 섭식장애에 대한 의사\n\n진단을 기반으로 한다.\n\n [F50.4] Overeating associated with other psychological disturbances (기타 심리적\n\n[F50.5] Vomiting associated with other psychological disturbances (기타 심리적\n\n- - 48 -\n[F50.8] Other eating disorders (기타 식사장애)\n\n[F50.9] Eating disorder, unspecified (상세불명의 식사장애)\n\n- - 49 -\n- 나.  임상시험용 의료기기 정보\n- - 품목명(품목분류번호, 등급): 인지치료소프트웨어(E06060.02, 2등급)\n※ 대조 시험용 의료기기의 구체적인 정보를 ‘가)’를 참고하여 작성한다.  대조\n\n시험용 의료기기가 설정되지 않았을 경우 생략할 수 있으며, 설정하지\n\n- 다.  임상시험용 의료기기 사용 방법\n- - 치료에 앞서 범용장비(스마트폰, 태블릿, PC 등)에 OOO\n- - 50 -\n2) 사용 방법\n\n가) OOO 디지털치료기기를 실행한다.\n\n",
        "original_sentence": "[F50.4] Overeating associated with other psychological disturbances (기타 심리적\n\n[F50.5] Vomiting associated with other psychological disturbances (기타 심리적\n\n- - 48 -\n[F50.8] Other eating disorders (기타 식사장애)\n\n[F50.9] Eating disorder, unspecified (상세불명의 식사장애)\n\n- - 49 -\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_595",
      "text": "임상시험용 의료기기 정보\n- - 품목명(품목분류번호, 등급): 인지치료소프트웨어(E06060.02, 2등급)\n※ 대조 시험용 의료기기의 구체적인 정보를 ‘가)’를 참고하여 작성한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 594,
        "window_size": 3,
        "char_count": 102,
        "word_count": 18,
        "page_number": 7,
        "window_text": "임상시험용 기기는 섭식장애 인지행동치료(CBT)\n\n혹은 이와 유사한 과학적 근거를 가진 섭식장애의 비약물적인 치료를\n\n제공하여 대조군 대비 섭식장애 증상을 개선하는 것을 목표로 한다.\n\n 본 의료기기는 의사에게 섭식장애* 진단을 받은 환자를 대상으로\n\n하며, 추후 추가적인 적응증 확대는 가능하나 섭식장애에 대한 의사\n\n진단을 기반으로 한다.\n\n [F50.4] Overeating associated with other psychological disturbances (기타 심리적\n\n[F50.5] Vomiting associated with other psychological disturbances (기타 심리적\n\n- - 48 -\n[F50.8] Other eating disorders (기타 식사장애)\n\n[F50.9] Eating disorder, unspecified (상세불명의 식사장애)\n\n- - 49 -\n- 나.  임상시험용 의료기기 정보\n- - 품목명(품목분류번호, 등급): 인지치료소프트웨어(E06060.02, 2등급)\n※ 대조 시험용 의료기기의 구체적인 정보를 ‘가)’를 참고하여 작성한다.  대조\n\n시험용 의료기기가 설정되지 않았을 경우 생략할 수 있으며, 설정하지\n\n- 다.  임상시험용 의료기기 사용 방법\n- - 치료에 앞서 범용장비(스마트폰, 태블릿, PC 등)에 OOO\n- - 50 -\n2) 사용 방법\n\n가) OOO 디지털치료기기를 실행한다.\n\n : 성별, 나이, 섭식장애 치료 약물 복용 여부, 섭식장애 증상에\n\n대한 기초 평가(섭식장애 증상의 빈도, 섭식장애 증상으로 인한\n\n불편감, 우울을 포함한 기타 정신과적인 정도 등이 포함될 수\n\n다) 디지털치료기기를 통한 섭식장애와 관련된 인지 및 행동의\n\n교정은 식사일기(식사 시간, 함께 식사한 대상, 식사를 한 장소,\n\n식사 전의 배고픔 정도와 식사 후의 배부름 정도, 감정 등),\n\n라) 상술한 치료의 경우 환자의 순응도를 높이기 위한 전략이\n\n포함되어야 하며(콘텐츠 제공 방식의 다양화, 알림 제공, 보상\n\n방안 등을 포함) 환자가 입력한 정보에 따른 피드백이 제공\n\n되어야 하고 환자가 스스로 입력한 정보를 모니터링 할 수\n\n- - 51 -\n<!-- PAGE_58 -->\n##### 8. ",
        "original_sentence": "임상시험용 의료기기 정보\n- - 품목명(품목분류번호, 등급): 인지치료소프트웨어(E06060.02, 2등급)\n※ 대조 시험용 의료기기의 구체적인 정보를 ‘가)’를 참고하여 작성한다. "
      }
    },
    {
      "chunk_id": "chunk_596",
      "text": "대조\n\n시험용 의료기기가 설정되지 않았을 경우 생략할 수 있으며, 설정하지\n\n- 다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 595,
        "window_size": 3,
        "char_count": 48,
        "word_count": 12,
        "page_number": 27,
        "window_text": "본 의료기기는 의사에게 섭식장애* 진단을 받은 환자를 대상으로\n\n하며, 추후 추가적인 적응증 확대는 가능하나 섭식장애에 대한 의사\n\n진단을 기반으로 한다.\n\n [F50.4] Overeating associated with other psychological disturbances (기타 심리적\n\n[F50.5] Vomiting associated with other psychological disturbances (기타 심리적\n\n- - 48 -\n[F50.8] Other eating disorders (기타 식사장애)\n\n[F50.9] Eating disorder, unspecified (상세불명의 식사장애)\n\n- - 49 -\n- 나.  임상시험용 의료기기 정보\n- - 품목명(품목분류번호, 등급): 인지치료소프트웨어(E06060.02, 2등급)\n※ 대조 시험용 의료기기의 구체적인 정보를 ‘가)’를 참고하여 작성한다.  대조\n\n시험용 의료기기가 설정되지 않았을 경우 생략할 수 있으며, 설정하지\n\n- 다.  임상시험용 의료기기 사용 방법\n- - 치료에 앞서 범용장비(스마트폰, 태블릿, PC 등)에 OOO\n- - 50 -\n2) 사용 방법\n\n가) OOO 디지털치료기기를 실행한다.\n\n : 성별, 나이, 섭식장애 치료 약물 복용 여부, 섭식장애 증상에\n\n대한 기초 평가(섭식장애 증상의 빈도, 섭식장애 증상으로 인한\n\n불편감, 우울을 포함한 기타 정신과적인 정도 등이 포함될 수\n\n다) 디지털치료기기를 통한 섭식장애와 관련된 인지 및 행동의\n\n교정은 식사일기(식사 시간, 함께 식사한 대상, 식사를 한 장소,\n\n식사 전의 배고픔 정도와 식사 후의 배부름 정도, 감정 등),\n\n라) 상술한 치료의 경우 환자의 순응도를 높이기 위한 전략이\n\n포함되어야 하며(콘텐츠 제공 방식의 다양화, 알림 제공, 보상\n\n방안 등을 포함) 환자가 입력한 정보에 따른 피드백이 제공\n\n되어야 하고 환자가 스스로 입력한 정보를 모니터링 할 수\n\n- - 51 -\n<!-- PAGE_58 -->\n##### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n- - 52 -\n[예시]\n\n- 가. ",
        "original_sentence": "대조\n\n시험용 의료기기가 설정되지 않았을 경우 생략할 수 있으며, 설정하지\n\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_597",
      "text": "임상시험용 의료기기 사용 방법\n- - 치료에 앞서 범용장비(스마트폰, 태블릿, PC 등)에 OOO\n- - 50 -\n2) 사용 방법\n\n가) OOO 디지털치료기기를 실행한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 596,
        "window_size": 3,
        "char_count": 97,
        "word_count": 24,
        "page_number": 27,
        "window_text": "[F50.4] Overeating associated with other psychological disturbances (기타 심리적\n\n[F50.5] Vomiting associated with other psychological disturbances (기타 심리적\n\n- - 48 -\n[F50.8] Other eating disorders (기타 식사장애)\n\n[F50.9] Eating disorder, unspecified (상세불명의 식사장애)\n\n- - 49 -\n- 나.  임상시험용 의료기기 정보\n- - 품목명(품목분류번호, 등급): 인지치료소프트웨어(E06060.02, 2등급)\n※ 대조 시험용 의료기기의 구체적인 정보를 ‘가)’를 참고하여 작성한다.  대조\n\n시험용 의료기기가 설정되지 않았을 경우 생략할 수 있으며, 설정하지\n\n- 다.  임상시험용 의료기기 사용 방법\n- - 치료에 앞서 범용장비(스마트폰, 태블릿, PC 등)에 OOO\n- - 50 -\n2) 사용 방법\n\n가) OOO 디지털치료기기를 실행한다.\n\n : 성별, 나이, 섭식장애 치료 약물 복용 여부, 섭식장애 증상에\n\n대한 기초 평가(섭식장애 증상의 빈도, 섭식장애 증상으로 인한\n\n불편감, 우울을 포함한 기타 정신과적인 정도 등이 포함될 수\n\n다) 디지털치료기기를 통한 섭식장애와 관련된 인지 및 행동의\n\n교정은 식사일기(식사 시간, 함께 식사한 대상, 식사를 한 장소,\n\n식사 전의 배고픔 정도와 식사 후의 배부름 정도, 감정 등),\n\n라) 상술한 치료의 경우 환자의 순응도를 높이기 위한 전략이\n\n포함되어야 하며(콘텐츠 제공 방식의 다양화, 알림 제공, 보상\n\n방안 등을 포함) 환자가 입력한 정보에 따른 피드백이 제공\n\n되어야 하고 환자가 스스로 입력한 정보를 모니터링 할 수\n\n- - 51 -\n<!-- PAGE_58 -->\n##### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n- - 52 -\n[예시]\n\n- 가.  피험자 선정기준\n2) DSM-5의 섭식장애 진단기준을 만족하거나 ICD-10에 의거한 섭\n\n[F50.4] Overeating associated with other psychological disturbances (기타\n\n[F50.5] Vomiting associated with other psychological disturbances (기타\n\n3) 스마트폰을 이용하여 모바일 애플리케이션 사용에 어려움이 없는 자\n\n4) 본 임상시험에 대해 충분한 설명을 듣고 이해한 후, 자의로 참여를\n\n- 나. ",
        "original_sentence": "임상시험용 의료기기 사용 방법\n- - 치료에 앞서 범용장비(스마트폰, 태블릿, PC 등)에 OOO\n- - 50 -\n2) 사용 방법\n\n가) OOO 디지털치료기기를 실행한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_598",
      "text": ": 성별, 나이, 섭식장애 치료 약물 복용 여부, 섭식장애 증상에\n\n대한 기초 평가(섭식장애 증상의 빈도, 섭식장애 증상으로 인한\n\n불편감, 우울을 포함한 기타 정신과적인 정도 등이 포함될 수\n\n다) 디지털치료기기를 통한 섭식장애와 관련된 인지 및 행동의\n\n교정은 식사일기(식사 시간, 함께 식사한 대상, 식사를 한 장소,\n\n식사 전의 배고픔 정도와 식사 후의 배부름 정도, 감정 등),\n\n라) 상술한 치료의 경우 환자의 순응도를 높이기 위한 전략이\n\n포함되어야 하며(콘텐츠 제공 방식의 다양화, 알림 제공, 보상\n\n방안 등을 포함) 환자가 입력한 정보에 따른 피드백이 제공\n\n되어야 하고 환자가 스스로 입력한 정보를 모니터링 할 수\n\n- - 51 -\n<!-- PAGE_58 -->\n##### 8. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 597,
        "window_size": 3,
        "char_count": 391,
        "word_count": 98,
        "page_number": 58,
        "window_text": "임상시험용 의료기기 정보\n- - 품목명(품목분류번호, 등급): 인지치료소프트웨어(E06060.02, 2등급)\n※ 대조 시험용 의료기기의 구체적인 정보를 ‘가)’를 참고하여 작성한다.  대조\n\n시험용 의료기기가 설정되지 않았을 경우 생략할 수 있으며, 설정하지\n\n- 다.  임상시험용 의료기기 사용 방법\n- - 치료에 앞서 범용장비(스마트폰, 태블릿, PC 등)에 OOO\n- - 50 -\n2) 사용 방법\n\n가) OOO 디지털치료기기를 실행한다.\n\n : 성별, 나이, 섭식장애 치료 약물 복용 여부, 섭식장애 증상에\n\n대한 기초 평가(섭식장애 증상의 빈도, 섭식장애 증상으로 인한\n\n불편감, 우울을 포함한 기타 정신과적인 정도 등이 포함될 수\n\n다) 디지털치료기기를 통한 섭식장애와 관련된 인지 및 행동의\n\n교정은 식사일기(식사 시간, 함께 식사한 대상, 식사를 한 장소,\n\n식사 전의 배고픔 정도와 식사 후의 배부름 정도, 감정 등),\n\n라) 상술한 치료의 경우 환자의 순응도를 높이기 위한 전략이\n\n포함되어야 하며(콘텐츠 제공 방식의 다양화, 알림 제공, 보상\n\n방안 등을 포함) 환자가 입력한 정보에 따른 피드백이 제공\n\n되어야 하고 환자가 스스로 입력한 정보를 모니터링 할 수\n\n- - 51 -\n<!-- PAGE_58 -->\n##### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n- - 52 -\n[예시]\n\n- 가.  피험자 선정기준\n2) DSM-5의 섭식장애 진단기준을 만족하거나 ICD-10에 의거한 섭\n\n[F50.4] Overeating associated with other psychological disturbances (기타\n\n[F50.5] Vomiting associated with other psychological disturbances (기타\n\n3) 스마트폰을 이용하여 모바일 애플리케이션 사용에 어려움이 없는 자\n\n4) 본 임상시험에 대해 충분한 설명을 듣고 이해한 후, 자의로 참여를\n\n- 나.  피험자 제외기준\n: 제외기준 중 어느 하나라도 해당하는 항목이 있는 경우 본\n\n- - 53 -\n2) 비만대사 수술*(Bariatric surgery)의 과거 수술력이 있는 자\n\n* 조절형 위밴드술, 위소매 절제술, 담췌 우회술, 루와이 위우회술 등\n\n4) MINI(Mini international neuropsychiatric interview)에 의거한\n\n6) 자살 위험이 있거나 (C-SSRS 4점 이상) 최근 2주 이내에 자살을\n\n7) 활동적이고 진행중인 신체적 질환 (예:울혈성 심부전, 만성\n\n폐쇄성 폐질환, 급성 통증), 신경 장애 (예:뇌혈관 질환), 신경\n\n퇴행성 질환 (예:치매, 다발성 경화증)을 가진 자, 불안정한\n\n※ 피험자 선정기준 및 제외기준은 의료기기의 특성, 내용 구성 등을\n\n- - 54 -\n- 다. ",
        "original_sentence": ": 성별, 나이, 섭식장애 치료 약물 복용 여부, 섭식장애 증상에\n\n대한 기초 평가(섭식장애 증상의 빈도, 섭식장애 증상으로 인한\n\n불편감, 우울을 포함한 기타 정신과적인 정도 등이 포함될 수\n\n다) 디지털치료기기를 통한 섭식장애와 관련된 인지 및 행동의\n\n교정은 식사일기(식사 시간, 함께 식사한 대상, 식사를 한 장소,\n\n식사 전의 배고픔 정도와 식사 후의 배부름 정도, 감정 등),\n\n라) 상술한 치료의 경우 환자의 순응도를 높이기 위한 전략이\n\n포함되어야 하며(콘텐츠 제공 방식의 다양화, 알림 제공, 보상\n\n방안 등을 포함) 환자가 입력한 정보에 따른 피드백이 제공\n\n되어야 하고 환자가 스스로 입력한 정보를 모니터링 할 수\n\n- - 51 -\n<!-- PAGE_58 -->\n##### 8. "
      }
    },
    {
      "chunk_id": "chunk_599",
      "text": "피험자의 선정기준·제외기준·인원 및 그 근거\n\n- - 52 -\n[예시]\n\n- 가. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 598,
        "window_size": 3,
        "char_count": 46,
        "word_count": 12,
        "page_number": 9,
        "window_text": "대조\n\n시험용 의료기기가 설정되지 않았을 경우 생략할 수 있으며, 설정하지\n\n- 다.  임상시험용 의료기기 사용 방법\n- - 치료에 앞서 범용장비(스마트폰, 태블릿, PC 등)에 OOO\n- - 50 -\n2) 사용 방법\n\n가) OOO 디지털치료기기를 실행한다.\n\n : 성별, 나이, 섭식장애 치료 약물 복용 여부, 섭식장애 증상에\n\n대한 기초 평가(섭식장애 증상의 빈도, 섭식장애 증상으로 인한\n\n불편감, 우울을 포함한 기타 정신과적인 정도 등이 포함될 수\n\n다) 디지털치료기기를 통한 섭식장애와 관련된 인지 및 행동의\n\n교정은 식사일기(식사 시간, 함께 식사한 대상, 식사를 한 장소,\n\n식사 전의 배고픔 정도와 식사 후의 배부름 정도, 감정 등),\n\n라) 상술한 치료의 경우 환자의 순응도를 높이기 위한 전략이\n\n포함되어야 하며(콘텐츠 제공 방식의 다양화, 알림 제공, 보상\n\n방안 등을 포함) 환자가 입력한 정보에 따른 피드백이 제공\n\n되어야 하고 환자가 스스로 입력한 정보를 모니터링 할 수\n\n- - 51 -\n<!-- PAGE_58 -->\n##### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n- - 52 -\n[예시]\n\n- 가.  피험자 선정기준\n2) DSM-5의 섭식장애 진단기준을 만족하거나 ICD-10에 의거한 섭\n\n[F50.4] Overeating associated with other psychological disturbances (기타\n\n[F50.5] Vomiting associated with other psychological disturbances (기타\n\n3) 스마트폰을 이용하여 모바일 애플리케이션 사용에 어려움이 없는 자\n\n4) 본 임상시험에 대해 충분한 설명을 듣고 이해한 후, 자의로 참여를\n\n- 나.  피험자 제외기준\n: 제외기준 중 어느 하나라도 해당하는 항목이 있는 경우 본\n\n- - 53 -\n2) 비만대사 수술*(Bariatric surgery)의 과거 수술력이 있는 자\n\n* 조절형 위밴드술, 위소매 절제술, 담췌 우회술, 루와이 위우회술 등\n\n4) MINI(Mini international neuropsychiatric interview)에 의거한\n\n6) 자살 위험이 있거나 (C-SSRS 4점 이상) 최근 2주 이내에 자살을\n\n7) 활동적이고 진행중인 신체적 질환 (예:울혈성 심부전, 만성\n\n폐쇄성 폐질환, 급성 통증), 신경 장애 (예:뇌혈관 질환), 신경\n\n퇴행성 질환 (예:치매, 다발성 경화증)을 가진 자, 불안정한\n\n※ 피험자 선정기준 및 제외기준은 의료기기의 특성, 내용 구성 등을\n\n- - 54 -\n- 다.  목표대상자 수 및 그 근거\n※ 본 가이드라인에 작성된 산출 방법은 공개된 선행연구 결과를 기반으로 작성된\n\n예시이며, 목표 대상자 수는 개발 제품 특성과 탐색 임상시험 등 제품별 선행\n\n연구 결과에 따라 다르므로, 개발 제품의 선행연구 결과 및 참고문헌을\n\n기준으로 산출한다. ",
        "original_sentence": "피험자의 선정기준·제외기준·인원 및 그 근거\n\n- - 52 -\n[예시]\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_600",
      "text": "피험자 선정기준\n2) DSM-5의 섭식장애 진단기준을 만족하거나 ICD-10에 의거한 섭\n\n[F50.4] Overeating associated with other psychological disturbances (기타\n\n[F50.5] Vomiting associated with other psychological disturbances (기타\n\n3) 스마트폰을 이용하여 모바일 애플리케이션 사용에 어려움이 없는 자\n\n4) 본 임상시험에 대해 충분한 설명을 듣고 이해한 후, 자의로 참여를\n\n- 나. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 599,
        "window_size": 3,
        "char_count": 281,
        "word_count": 48,
        "page_number": 9,
        "window_text": "임상시험용 의료기기 사용 방법\n- - 치료에 앞서 범용장비(스마트폰, 태블릿, PC 등)에 OOO\n- - 50 -\n2) 사용 방법\n\n가) OOO 디지털치료기기를 실행한다.\n\n : 성별, 나이, 섭식장애 치료 약물 복용 여부, 섭식장애 증상에\n\n대한 기초 평가(섭식장애 증상의 빈도, 섭식장애 증상으로 인한\n\n불편감, 우울을 포함한 기타 정신과적인 정도 등이 포함될 수\n\n다) 디지털치료기기를 통한 섭식장애와 관련된 인지 및 행동의\n\n교정은 식사일기(식사 시간, 함께 식사한 대상, 식사를 한 장소,\n\n식사 전의 배고픔 정도와 식사 후의 배부름 정도, 감정 등),\n\n라) 상술한 치료의 경우 환자의 순응도를 높이기 위한 전략이\n\n포함되어야 하며(콘텐츠 제공 방식의 다양화, 알림 제공, 보상\n\n방안 등을 포함) 환자가 입력한 정보에 따른 피드백이 제공\n\n되어야 하고 환자가 스스로 입력한 정보를 모니터링 할 수\n\n- - 51 -\n<!-- PAGE_58 -->\n##### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n- - 52 -\n[예시]\n\n- 가.  피험자 선정기준\n2) DSM-5의 섭식장애 진단기준을 만족하거나 ICD-10에 의거한 섭\n\n[F50.4] Overeating associated with other psychological disturbances (기타\n\n[F50.5] Vomiting associated with other psychological disturbances (기타\n\n3) 스마트폰을 이용하여 모바일 애플리케이션 사용에 어려움이 없는 자\n\n4) 본 임상시험에 대해 충분한 설명을 듣고 이해한 후, 자의로 참여를\n\n- 나.  피험자 제외기준\n: 제외기준 중 어느 하나라도 해당하는 항목이 있는 경우 본\n\n- - 53 -\n2) 비만대사 수술*(Bariatric surgery)의 과거 수술력이 있는 자\n\n* 조절형 위밴드술, 위소매 절제술, 담췌 우회술, 루와이 위우회술 등\n\n4) MINI(Mini international neuropsychiatric interview)에 의거한\n\n6) 자살 위험이 있거나 (C-SSRS 4점 이상) 최근 2주 이내에 자살을\n\n7) 활동적이고 진행중인 신체적 질환 (예:울혈성 심부전, 만성\n\n폐쇄성 폐질환, 급성 통증), 신경 장애 (예:뇌혈관 질환), 신경\n\n퇴행성 질환 (예:치매, 다발성 경화증)을 가진 자, 불안정한\n\n※ 피험자 선정기준 및 제외기준은 의료기기의 특성, 내용 구성 등을\n\n- - 54 -\n- 다.  목표대상자 수 및 그 근거\n※ 본 가이드라인에 작성된 산출 방법은 공개된 선행연구 결과를 기반으로 작성된\n\n예시이며, 목표 대상자 수는 개발 제품 특성과 탐색 임상시험 등 제품별 선행\n\n연구 결과에 따라 다르므로, 개발 제품의 선행연구 결과 및 참고문헌을\n\n기준으로 산출한다.  이때, 그 근거(가설, 변수, 성공기준)를 함께 제시하여야\n\n본 시험의 일차목적: 섭식장애 환자에서 베이스라인 (사용 전)\n\n대비 8 주 시점의 식사장애 검사(EDE-Q)의 변화량이 기존\n\n치료군 대비 의료기기 사용군에서 비열등하게 개선되었는지\n\n확증하는 것이다. ",
        "original_sentence": "피험자 선정기준\n2) DSM-5의 섭식장애 진단기준을 만족하거나 ICD-10에 의거한 섭\n\n[F50.4] Overeating associated with other psychological disturbances (기타\n\n[F50.5] Vomiting associated with other psychological disturbances (기타\n\n3) 스마트폰을 이용하여 모바일 애플리케이션 사용에 어려움이 없는 자\n\n4) 본 임상시험에 대해 충분한 설명을 듣고 이해한 후, 자의로 참여를\n\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_601",
      "text": "피험자 제외기준\n: 제외기준 중 어느 하나라도 해당하는 항목이 있는 경우 본\n\n- - 53 -\n2) 비만대사 수술*(Bariatric surgery)의 과거 수술력이 있는 자\n\n* 조절형 위밴드술, 위소매 절제술, 담췌 우회술, 루와이 위우회술 등\n\n4) MINI(Mini international neuropsychiatric interview)에 의거한\n\n6) 자살 위험이 있거나 (C-SSRS 4점 이상) 최근 2주 이내에 자살을\n\n7) 활동적이고 진행중인 신체적 질환 (예:울혈성 심부전, 만성\n\n폐쇄성 폐질환, 급성 통증), 신경 장애 (예:뇌혈관 질환), 신경\n\n퇴행성 질환 (예:치매, 다발성 경화증)을 가진 자, 불안정한\n\n※ 피험자 선정기준 및 제외기준은 의료기기의 특성, 내용 구성 등을\n\n- - 54 -\n- 다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 600,
        "window_size": 3,
        "char_count": 410,
        "word_count": 92,
        "page_number": 7,
        "window_text": ": 성별, 나이, 섭식장애 치료 약물 복용 여부, 섭식장애 증상에\n\n대한 기초 평가(섭식장애 증상의 빈도, 섭식장애 증상으로 인한\n\n불편감, 우울을 포함한 기타 정신과적인 정도 등이 포함될 수\n\n다) 디지털치료기기를 통한 섭식장애와 관련된 인지 및 행동의\n\n교정은 식사일기(식사 시간, 함께 식사한 대상, 식사를 한 장소,\n\n식사 전의 배고픔 정도와 식사 후의 배부름 정도, 감정 등),\n\n라) 상술한 치료의 경우 환자의 순응도를 높이기 위한 전략이\n\n포함되어야 하며(콘텐츠 제공 방식의 다양화, 알림 제공, 보상\n\n방안 등을 포함) 환자가 입력한 정보에 따른 피드백이 제공\n\n되어야 하고 환자가 스스로 입력한 정보를 모니터링 할 수\n\n- - 51 -\n<!-- PAGE_58 -->\n##### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n- - 52 -\n[예시]\n\n- 가.  피험자 선정기준\n2) DSM-5의 섭식장애 진단기준을 만족하거나 ICD-10에 의거한 섭\n\n[F50.4] Overeating associated with other psychological disturbances (기타\n\n[F50.5] Vomiting associated with other psychological disturbances (기타\n\n3) 스마트폰을 이용하여 모바일 애플리케이션 사용에 어려움이 없는 자\n\n4) 본 임상시험에 대해 충분한 설명을 듣고 이해한 후, 자의로 참여를\n\n- 나.  피험자 제외기준\n: 제외기준 중 어느 하나라도 해당하는 항목이 있는 경우 본\n\n- - 53 -\n2) 비만대사 수술*(Bariatric surgery)의 과거 수술력이 있는 자\n\n* 조절형 위밴드술, 위소매 절제술, 담췌 우회술, 루와이 위우회술 등\n\n4) MINI(Mini international neuropsychiatric interview)에 의거한\n\n6) 자살 위험이 있거나 (C-SSRS 4점 이상) 최근 2주 이내에 자살을\n\n7) 활동적이고 진행중인 신체적 질환 (예:울혈성 심부전, 만성\n\n폐쇄성 폐질환, 급성 통증), 신경 장애 (예:뇌혈관 질환), 신경\n\n퇴행성 질환 (예:치매, 다발성 경화증)을 가진 자, 불안정한\n\n※ 피험자 선정기준 및 제외기준은 의료기기의 특성, 내용 구성 등을\n\n- - 54 -\n- 다.  목표대상자 수 및 그 근거\n※ 본 가이드라인에 작성된 산출 방법은 공개된 선행연구 결과를 기반으로 작성된\n\n예시이며, 목표 대상자 수는 개발 제품 특성과 탐색 임상시험 등 제품별 선행\n\n연구 결과에 따라 다르므로, 개발 제품의 선행연구 결과 및 참고문헌을\n\n기준으로 산출한다.  이때, 그 근거(가설, 변수, 성공기준)를 함께 제시하여야\n\n본 시험의 일차목적: 섭식장애 환자에서 베이스라인 (사용 전)\n\n대비 8 주 시점의 식사장애 검사(EDE-Q)의 변화량이 기존\n\n치료군 대비 의료기기 사용군에서 비열등하게 개선되었는지\n\n확증하는 것이다.  변화량은 치료 시작 전 평가지표 Baseline\n\n조사에서 수집한 정보와 Post-treatment (의료기기 사용 8주 후\n\n시점) 조사에서 수집한 정보와의 차이를 의미하며, 이에 대한\n\n- - 55 -\n    ≥\n\n      \n\n※ 또한, 비열등성 허용 오차는 임상 근거에 기반하여 수치가 달라질 수 있으나,\n\n비열등성 허용오차는 Grilo et al. ",
        "original_sentence": "피험자 제외기준\n: 제외기준 중 어느 하나라도 해당하는 항목이 있는 경우 본\n\n- - 53 -\n2) 비만대사 수술*(Bariatric surgery)의 과거 수술력이 있는 자\n\n* 조절형 위밴드술, 위소매 절제술, 담췌 우회술, 루와이 위우회술 등\n\n4) MINI(Mini international neuropsychiatric interview)에 의거한\n\n6) 자살 위험이 있거나 (C-SSRS 4점 이상) 최근 2주 이내에 자살을\n\n7) 활동적이고 진행중인 신체적 질환 (예:울혈성 심부전, 만성\n\n폐쇄성 폐질환, 급성 통증), 신경 장애 (예:뇌혈관 질환), 신경\n\n퇴행성 질환 (예:치매, 다발성 경화증)을 가진 자, 불안정한\n\n※ 피험자 선정기준 및 제외기준은 의료기기의 특성, 내용 구성 등을\n\n- - 54 -\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_602",
      "text": "목표대상자 수 및 그 근거\n※ 본 가이드라인에 작성된 산출 방법은 공개된 선행연구 결과를 기반으로 작성된\n\n예시이며, 목표 대상자 수는 개발 제품 특성과 탐색 임상시험 등 제품별 선행\n\n연구 결과에 따라 다르므로, 개발 제품의 선행연구 결과 및 참고문헌을\n\n기준으로 산출한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 601,
        "window_size": 3,
        "char_count": 155,
        "word_count": 40,
        "page_number": 7,
        "window_text": "피험자의 선정기준·제외기준·인원 및 그 근거\n\n- - 52 -\n[예시]\n\n- 가.  피험자 선정기준\n2) DSM-5의 섭식장애 진단기준을 만족하거나 ICD-10에 의거한 섭\n\n[F50.4] Overeating associated with other psychological disturbances (기타\n\n[F50.5] Vomiting associated with other psychological disturbances (기타\n\n3) 스마트폰을 이용하여 모바일 애플리케이션 사용에 어려움이 없는 자\n\n4) 본 임상시험에 대해 충분한 설명을 듣고 이해한 후, 자의로 참여를\n\n- 나.  피험자 제외기준\n: 제외기준 중 어느 하나라도 해당하는 항목이 있는 경우 본\n\n- - 53 -\n2) 비만대사 수술*(Bariatric surgery)의 과거 수술력이 있는 자\n\n* 조절형 위밴드술, 위소매 절제술, 담췌 우회술, 루와이 위우회술 등\n\n4) MINI(Mini international neuropsychiatric interview)에 의거한\n\n6) 자살 위험이 있거나 (C-SSRS 4점 이상) 최근 2주 이내에 자살을\n\n7) 활동적이고 진행중인 신체적 질환 (예:울혈성 심부전, 만성\n\n폐쇄성 폐질환, 급성 통증), 신경 장애 (예:뇌혈관 질환), 신경\n\n퇴행성 질환 (예:치매, 다발성 경화증)을 가진 자, 불안정한\n\n※ 피험자 선정기준 및 제외기준은 의료기기의 특성, 내용 구성 등을\n\n- - 54 -\n- 다.  목표대상자 수 및 그 근거\n※ 본 가이드라인에 작성된 산출 방법은 공개된 선행연구 결과를 기반으로 작성된\n\n예시이며, 목표 대상자 수는 개발 제품 특성과 탐색 임상시험 등 제품별 선행\n\n연구 결과에 따라 다르므로, 개발 제품의 선행연구 결과 및 참고문헌을\n\n기준으로 산출한다.  이때, 그 근거(가설, 변수, 성공기준)를 함께 제시하여야\n\n본 시험의 일차목적: 섭식장애 환자에서 베이스라인 (사용 전)\n\n대비 8 주 시점의 식사장애 검사(EDE-Q)의 변화량이 기존\n\n치료군 대비 의료기기 사용군에서 비열등하게 개선되었는지\n\n확증하는 것이다.  변화량은 치료 시작 전 평가지표 Baseline\n\n조사에서 수집한 정보와 Post-treatment (의료기기 사용 8주 후\n\n시점) 조사에서 수집한 정보와의 차이를 의미하며, 이에 대한\n\n- - 55 -\n    ≥\n\n      \n\n※ 또한, 비열등성 허용 오차는 임상 근거에 기반하여 수치가 달라질 수 있으나,\n\n비열등성 허용오차는 Grilo et al.  (2022)에서의 대조군인\n\nplacebo군과 기존 BWL(Behavioral weight loss therapy) 과\n\n약물(naltrexone, bupropion) 처리군의 변화량 효과 차이를\n\n섭식장애 환자를 대상으로 한 기존 비교 임상연구를 검토한\n\n결과, 식사장애 검사(EDE-Q) 변화량은 다음 표와 같이 조사\n\n대조군의 baseline 대비 16주 시점에서의 식사장애 검사\n\n(EDE-Q) 변화량 차이는 –3.74이고 표준편차는 11.32이나\n\n본 임상시험의 치료기간은 8주로 참고문헌에 비해 짧으므로\n\n- - 56 -\n해당 효과의 50% 정도인 –1.87로 설정하였다.\n\n",
        "original_sentence": "목표대상자 수 및 그 근거\n※ 본 가이드라인에 작성된 산출 방법은 공개된 선행연구 결과를 기반으로 작성된\n\n예시이며, 목표 대상자 수는 개발 제품 특성과 탐색 임상시험 등 제품별 선행\n\n연구 결과에 따라 다르므로, 개발 제품의 선행연구 결과 및 참고문헌을\n\n기준으로 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_603",
      "text": "이때, 그 근거(가설, 변수, 성공기준)를 함께 제시하여야\n\n본 시험의 일차목적: 섭식장애 환자에서 베이스라인 (사용 전)\n\n대비 8 주 시점의 식사장애 검사(EDE-Q)의 변화량이 기존\n\n치료군 대비 의료기기 사용군에서 비열등하게 개선되었는지\n\n확증하는 것이다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 602,
        "window_size": 3,
        "char_count": 148,
        "word_count": 31,
        "page_number": 7,
        "window_text": "피험자 선정기준\n2) DSM-5의 섭식장애 진단기준을 만족하거나 ICD-10에 의거한 섭\n\n[F50.4] Overeating associated with other psychological disturbances (기타\n\n[F50.5] Vomiting associated with other psychological disturbances (기타\n\n3) 스마트폰을 이용하여 모바일 애플리케이션 사용에 어려움이 없는 자\n\n4) 본 임상시험에 대해 충분한 설명을 듣고 이해한 후, 자의로 참여를\n\n- 나.  피험자 제외기준\n: 제외기준 중 어느 하나라도 해당하는 항목이 있는 경우 본\n\n- - 53 -\n2) 비만대사 수술*(Bariatric surgery)의 과거 수술력이 있는 자\n\n* 조절형 위밴드술, 위소매 절제술, 담췌 우회술, 루와이 위우회술 등\n\n4) MINI(Mini international neuropsychiatric interview)에 의거한\n\n6) 자살 위험이 있거나 (C-SSRS 4점 이상) 최근 2주 이내에 자살을\n\n7) 활동적이고 진행중인 신체적 질환 (예:울혈성 심부전, 만성\n\n폐쇄성 폐질환, 급성 통증), 신경 장애 (예:뇌혈관 질환), 신경\n\n퇴행성 질환 (예:치매, 다발성 경화증)을 가진 자, 불안정한\n\n※ 피험자 선정기준 및 제외기준은 의료기기의 특성, 내용 구성 등을\n\n- - 54 -\n- 다.  목표대상자 수 및 그 근거\n※ 본 가이드라인에 작성된 산출 방법은 공개된 선행연구 결과를 기반으로 작성된\n\n예시이며, 목표 대상자 수는 개발 제품 특성과 탐색 임상시험 등 제품별 선행\n\n연구 결과에 따라 다르므로, 개발 제품의 선행연구 결과 및 참고문헌을\n\n기준으로 산출한다.  이때, 그 근거(가설, 변수, 성공기준)를 함께 제시하여야\n\n본 시험의 일차목적: 섭식장애 환자에서 베이스라인 (사용 전)\n\n대비 8 주 시점의 식사장애 검사(EDE-Q)의 변화량이 기존\n\n치료군 대비 의료기기 사용군에서 비열등하게 개선되었는지\n\n확증하는 것이다.  변화량은 치료 시작 전 평가지표 Baseline\n\n조사에서 수집한 정보와 Post-treatment (의료기기 사용 8주 후\n\n시점) 조사에서 수집한 정보와의 차이를 의미하며, 이에 대한\n\n- - 55 -\n    ≥\n\n      \n\n※ 또한, 비열등성 허용 오차는 임상 근거에 기반하여 수치가 달라질 수 있으나,\n\n비열등성 허용오차는 Grilo et al.  (2022)에서의 대조군인\n\nplacebo군과 기존 BWL(Behavioral weight loss therapy) 과\n\n약물(naltrexone, bupropion) 처리군의 변화량 효과 차이를\n\n섭식장애 환자를 대상으로 한 기존 비교 임상연구를 검토한\n\n결과, 식사장애 검사(EDE-Q) 변화량은 다음 표와 같이 조사\n\n대조군의 baseline 대비 16주 시점에서의 식사장애 검사\n\n(EDE-Q) 변화량 차이는 –3.74이고 표준편차는 11.32이나\n\n본 임상시험의 치료기간은 8주로 참고문헌에 비해 짧으므로\n\n- - 56 -\n해당 효과의 50% 정도인 –1.87로 설정하였다.\n\n 기존 대조군의 baseline 대비 16주 시점에서의 식사장애 검사\n\n(EDE-Q) 변화량 차이는 –12.79이고 표준편차는 8.24이나 위와\n\n각 군의 표준편차도 효과 평균과 동일하게 50% 반영하여\n\n각 4.1, 5.7로 설정하여 차이에 대한 합동표준편차는 5.0로\n\n두 참고문헌을 통해 8주 시점에서의 기존 대조군 대비\n\nplacebe 군 효과는 (-6.40)-(-1.87)=-4.53 정도로 추정되며, 비\n\n열등성 허용오차 (-기호)는 해당 효과의 절반 정도인 -2.26이다.\n\n",
        "original_sentence": "이때, 그 근거(가설, 변수, 성공기준)를 함께 제시하여야\n\n본 시험의 일차목적: 섭식장애 환자에서 베이스라인 (사용 전)\n\n대비 8 주 시점의 식사장애 검사(EDE-Q)의 변화량이 기존\n\n치료군 대비 의료기기 사용군에서 비열등하게 개선되었는지\n\n확증하는 것이다. "
      }
    },
    {
      "chunk_id": "chunk_604",
      "text": "변화량은 치료 시작 전 평가지표 Baseline\n\n조사에서 수집한 정보와 Post-treatment (의료기기 사용 8주 후\n\n시점) 조사에서 수집한 정보와의 차이를 의미하며, 이에 대한\n\n- - 55 -\n    ≥\n\n      \n\n※ 또한, 비열등성 허용 오차는 임상 근거에 기반하여 수치가 달라질 수 있으나,\n\n비열등성 허용오차는 Grilo et al. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 603,
        "window_size": 3,
        "char_count": 224,
        "word_count": 55,
        "page_number": 62,
        "window_text": "피험자 제외기준\n: 제외기준 중 어느 하나라도 해당하는 항목이 있는 경우 본\n\n- - 53 -\n2) 비만대사 수술*(Bariatric surgery)의 과거 수술력이 있는 자\n\n* 조절형 위밴드술, 위소매 절제술, 담췌 우회술, 루와이 위우회술 등\n\n4) MINI(Mini international neuropsychiatric interview)에 의거한\n\n6) 자살 위험이 있거나 (C-SSRS 4점 이상) 최근 2주 이내에 자살을\n\n7) 활동적이고 진행중인 신체적 질환 (예:울혈성 심부전, 만성\n\n폐쇄성 폐질환, 급성 통증), 신경 장애 (예:뇌혈관 질환), 신경\n\n퇴행성 질환 (예:치매, 다발성 경화증)을 가진 자, 불안정한\n\n※ 피험자 선정기준 및 제외기준은 의료기기의 특성, 내용 구성 등을\n\n- - 54 -\n- 다.  목표대상자 수 및 그 근거\n※ 본 가이드라인에 작성된 산출 방법은 공개된 선행연구 결과를 기반으로 작성된\n\n예시이며, 목표 대상자 수는 개발 제품 특성과 탐색 임상시험 등 제품별 선행\n\n연구 결과에 따라 다르므로, 개발 제품의 선행연구 결과 및 참고문헌을\n\n기준으로 산출한다.  이때, 그 근거(가설, 변수, 성공기준)를 함께 제시하여야\n\n본 시험의 일차목적: 섭식장애 환자에서 베이스라인 (사용 전)\n\n대비 8 주 시점의 식사장애 검사(EDE-Q)의 변화량이 기존\n\n치료군 대비 의료기기 사용군에서 비열등하게 개선되었는지\n\n확증하는 것이다.  변화량은 치료 시작 전 평가지표 Baseline\n\n조사에서 수집한 정보와 Post-treatment (의료기기 사용 8주 후\n\n시점) 조사에서 수집한 정보와의 차이를 의미하며, 이에 대한\n\n- - 55 -\n    ≥\n\n      \n\n※ 또한, 비열등성 허용 오차는 임상 근거에 기반하여 수치가 달라질 수 있으나,\n\n비열등성 허용오차는 Grilo et al.  (2022)에서의 대조군인\n\nplacebo군과 기존 BWL(Behavioral weight loss therapy) 과\n\n약물(naltrexone, bupropion) 처리군의 변화량 효과 차이를\n\n섭식장애 환자를 대상으로 한 기존 비교 임상연구를 검토한\n\n결과, 식사장애 검사(EDE-Q) 변화량은 다음 표와 같이 조사\n\n대조군의 baseline 대비 16주 시점에서의 식사장애 검사\n\n(EDE-Q) 변화량 차이는 –3.74이고 표준편차는 11.32이나\n\n본 임상시험의 치료기간은 8주로 참고문헌에 비해 짧으므로\n\n- - 56 -\n해당 효과의 50% 정도인 –1.87로 설정하였다.\n\n 기존 대조군의 baseline 대비 16주 시점에서의 식사장애 검사\n\n(EDE-Q) 변화량 차이는 –12.79이고 표준편차는 8.24이나 위와\n\n각 군의 표준편차도 효과 평균과 동일하게 50% 반영하여\n\n각 4.1, 5.7로 설정하여 차이에 대한 합동표준편차는 5.0로\n\n두 참고문헌을 통해 8주 시점에서의 기존 대조군 대비\n\nplacebe 군 효과는 (-6.40)-(-1.87)=-4.53 정도로 추정되며, 비\n\n열등성 허용오차 (-기호)는 해당 효과의 절반 정도인 -2.26이다.\n\n 선행연구인 Mond et al.",
        "original_sentence": "변화량은 치료 시작 전 평가지표 Baseline\n\n조사에서 수집한 정보와 Post-treatment (의료기기 사용 8주 후\n\n시점) 조사에서 수집한 정보와의 차이를 의미하며, 이에 대한\n\n- - 55 -\n    ≥\n\n      \n\n※ 또한, 비열등성 허용 오차는 임상 근거에 기반하여 수치가 달라질 수 있으나,\n\n비열등성 허용오차는 Grilo et al. "
      }
    },
    {
      "chunk_id": "chunk_605",
      "text": "(2022)에서의 대조군인\n\nplacebo군과 기존 BWL(Behavioral weight loss therapy) 과\n\n약물(naltrexone, bupropion) 처리군의 변화량 효과 차이를\n\n섭식장애 환자를 대상으로 한 기존 비교 임상연구를 검토한\n\n결과, 식사장애 검사(EDE-Q) 변화량은 다음 표와 같이 조사\n\n대조군의 baseline 대비 16주 시점에서의 식사장애 검사\n\n(EDE-Q) 변화량 차이는 –3.74이고 표준편차는 11.32이나\n\n본 임상시험의 치료기간은 8주로 참고문헌에 비해 짧으므로\n\n- - 56 -\n해당 효과의 50% 정도인 –1.87로 설정하였다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 604,
        "window_size": 3,
        "char_count": 328,
        "word_count": 61,
        "page_number": 9,
        "window_text": "목표대상자 수 및 그 근거\n※ 본 가이드라인에 작성된 산출 방법은 공개된 선행연구 결과를 기반으로 작성된\n\n예시이며, 목표 대상자 수는 개발 제품 특성과 탐색 임상시험 등 제품별 선행\n\n연구 결과에 따라 다르므로, 개발 제품의 선행연구 결과 및 참고문헌을\n\n기준으로 산출한다.  이때, 그 근거(가설, 변수, 성공기준)를 함께 제시하여야\n\n본 시험의 일차목적: 섭식장애 환자에서 베이스라인 (사용 전)\n\n대비 8 주 시점의 식사장애 검사(EDE-Q)의 변화량이 기존\n\n치료군 대비 의료기기 사용군에서 비열등하게 개선되었는지\n\n확증하는 것이다.  변화량은 치료 시작 전 평가지표 Baseline\n\n조사에서 수집한 정보와 Post-treatment (의료기기 사용 8주 후\n\n시점) 조사에서 수집한 정보와의 차이를 의미하며, 이에 대한\n\n- - 55 -\n    ≥\n\n      \n\n※ 또한, 비열등성 허용 오차는 임상 근거에 기반하여 수치가 달라질 수 있으나,\n\n비열등성 허용오차는 Grilo et al.  (2022)에서의 대조군인\n\nplacebo군과 기존 BWL(Behavioral weight loss therapy) 과\n\n약물(naltrexone, bupropion) 처리군의 변화량 효과 차이를\n\n섭식장애 환자를 대상으로 한 기존 비교 임상연구를 검토한\n\n결과, 식사장애 검사(EDE-Q) 변화량은 다음 표와 같이 조사\n\n대조군의 baseline 대비 16주 시점에서의 식사장애 검사\n\n(EDE-Q) 변화량 차이는 –3.74이고 표준편차는 11.32이나\n\n본 임상시험의 치료기간은 8주로 참고문헌에 비해 짧으므로\n\n- - 56 -\n해당 효과의 50% 정도인 –1.87로 설정하였다.\n\n 기존 대조군의 baseline 대비 16주 시점에서의 식사장애 검사\n\n(EDE-Q) 변화량 차이는 –12.79이고 표준편차는 8.24이나 위와\n\n각 군의 표준편차도 효과 평균과 동일하게 50% 반영하여\n\n각 4.1, 5.7로 설정하여 차이에 대한 합동표준편차는 5.0로\n\n두 참고문헌을 통해 8주 시점에서의 기존 대조군 대비\n\nplacebe 군 효과는 (-6.40)-(-1.87)=-4.53 정도로 추정되며, 비\n\n열등성 허용오차 (-기호)는 해당 효과의 절반 정도인 -2.26이다.\n\n 선행연구인 Mond et al. (2004), Mond et al.",
        "original_sentence": "(2022)에서의 대조군인\n\nplacebo군과 기존 BWL(Behavioral weight loss therapy) 과\n\n약물(naltrexone, bupropion) 처리군의 변화량 효과 차이를\n\n섭식장애 환자를 대상으로 한 기존 비교 임상연구를 검토한\n\n결과, 식사장애 검사(EDE-Q) 변화량은 다음 표와 같이 조사\n\n대조군의 baseline 대비 16주 시점에서의 식사장애 검사\n\n(EDE-Q) 변화량 차이는 –3.74이고 표준편차는 11.32이나\n\n본 임상시험의 치료기간은 8주로 참고문헌에 비해 짧으므로\n\n- - 56 -\n해당 효과의 50% 정도인 –1.87로 설정하였다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_606",
      "text": "기존 대조군의 baseline 대비 16주 시점에서의 식사장애 검사\n\n(EDE-Q) 변화량 차이는 –12.79이고 표준편차는 8.24이나 위와\n\n각 군의 표준편차도 효과 평균과 동일하게 50% 반영하여\n\n각 4.1, 5.7로 설정하여 차이에 대한 합동표준편차는 5.0로\n\n두 참고문헌을 통해 8주 시점에서의 기존 대조군 대비\n\nplacebe 군 효과는 (-6.40)-(-1.87)=-4.53 정도로 추정되며, 비\n\n열등성 허용오차 (-기호)는 해당 효과의 절반 정도인 -2.26이다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 605,
        "window_size": 3,
        "char_count": 272,
        "word_count": 54,
        "page_number": 19,
        "window_text": "이때, 그 근거(가설, 변수, 성공기준)를 함께 제시하여야\n\n본 시험의 일차목적: 섭식장애 환자에서 베이스라인 (사용 전)\n\n대비 8 주 시점의 식사장애 검사(EDE-Q)의 변화량이 기존\n\n치료군 대비 의료기기 사용군에서 비열등하게 개선되었는지\n\n확증하는 것이다.  변화량은 치료 시작 전 평가지표 Baseline\n\n조사에서 수집한 정보와 Post-treatment (의료기기 사용 8주 후\n\n시점) 조사에서 수집한 정보와의 차이를 의미하며, 이에 대한\n\n- - 55 -\n    ≥\n\n      \n\n※ 또한, 비열등성 허용 오차는 임상 근거에 기반하여 수치가 달라질 수 있으나,\n\n비열등성 허용오차는 Grilo et al.  (2022)에서의 대조군인\n\nplacebo군과 기존 BWL(Behavioral weight loss therapy) 과\n\n약물(naltrexone, bupropion) 처리군의 변화량 효과 차이를\n\n섭식장애 환자를 대상으로 한 기존 비교 임상연구를 검토한\n\n결과, 식사장애 검사(EDE-Q) 변화량은 다음 표와 같이 조사\n\n대조군의 baseline 대비 16주 시점에서의 식사장애 검사\n\n(EDE-Q) 변화량 차이는 –3.74이고 표준편차는 11.32이나\n\n본 임상시험의 치료기간은 8주로 참고문헌에 비해 짧으므로\n\n- - 56 -\n해당 효과의 50% 정도인 –1.87로 설정하였다.\n\n 기존 대조군의 baseline 대비 16주 시점에서의 식사장애 검사\n\n(EDE-Q) 변화량 차이는 –12.79이고 표준편차는 8.24이나 위와\n\n각 군의 표준편차도 효과 평균과 동일하게 50% 반영하여\n\n각 4.1, 5.7로 설정하여 차이에 대한 합동표준편차는 5.0로\n\n두 참고문헌을 통해 8주 시점에서의 기존 대조군 대비\n\nplacebe 군 효과는 (-6.40)-(-1.87)=-4.53 정도로 추정되며, 비\n\n열등성 허용오차 (-기호)는 해당 효과의 절반 정도인 -2.26이다.\n\n 선행연구인 Mond et al. (2004), Mond et al. (2008)의 연구에서\n\nEDE-Q에 대한 cut-off 값을 각각 2.3, 2.8이었던 점을 감안\n\n하여, 본 가이드라인의 비열등성 허용오차는 -2.5로 설정하고자\n\n이에 단측 유의수준 2.5%, 검정력 80%를 만족하는 데\n\n필요한 피험자 수(군당 1:1 배정)를 산출한 결과, 중도 탈락률\n\n5%를 고려하여 목표 피험자 수는 총 128명(군당 64명)으로\n\n두 군의 평균 차이 검정에 대한 피험자 수 산출 공식은\n\n- - 57 -\n \n\n  \n\n ×  ×      \n\n\n\n\n\n \n\n ×  ×   \n\n≈ \n\n- - 58 -\n피험자의 모집 기간, 임상 관찰 및 수행 기간, 통계분석 기간, 결과\n\n보고서 작성 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을\n\n고려하도록 한다.\n\n",
        "original_sentence": "기존 대조군의 baseline 대비 16주 시점에서의 식사장애 검사\n\n(EDE-Q) 변화량 차이는 –12.79이고 표준편차는 8.24이나 위와\n\n각 군의 표준편차도 효과 평균과 동일하게 50% 반영하여\n\n각 4.1, 5.7로 설정하여 차이에 대한 합동표준편차는 5.0로\n\n두 참고문헌을 통해 8주 시점에서의 기존 대조군 대비\n\nplacebe 군 효과는 (-6.40)-(-1.87)=-4.53 정도로 추정되며, 비\n\n열등성 허용오차 (-기호)는 해당 효과의 절반 정도인 -2.26이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_607",
      "text": "선행연구인 Mond et al.",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 606,
        "window_size": 3,
        "char_count": 17,
        "word_count": 4,
        "page_number": 62,
        "window_text": "변화량은 치료 시작 전 평가지표 Baseline\n\n조사에서 수집한 정보와 Post-treatment (의료기기 사용 8주 후\n\n시점) 조사에서 수집한 정보와의 차이를 의미하며, 이에 대한\n\n- - 55 -\n    ≥\n\n      \n\n※ 또한, 비열등성 허용 오차는 임상 근거에 기반하여 수치가 달라질 수 있으나,\n\n비열등성 허용오차는 Grilo et al.  (2022)에서의 대조군인\n\nplacebo군과 기존 BWL(Behavioral weight loss therapy) 과\n\n약물(naltrexone, bupropion) 처리군의 변화량 효과 차이를\n\n섭식장애 환자를 대상으로 한 기존 비교 임상연구를 검토한\n\n결과, 식사장애 검사(EDE-Q) 변화량은 다음 표와 같이 조사\n\n대조군의 baseline 대비 16주 시점에서의 식사장애 검사\n\n(EDE-Q) 변화량 차이는 –3.74이고 표준편차는 11.32이나\n\n본 임상시험의 치료기간은 8주로 참고문헌에 비해 짧으므로\n\n- - 56 -\n해당 효과의 50% 정도인 –1.87로 설정하였다.\n\n 기존 대조군의 baseline 대비 16주 시점에서의 식사장애 검사\n\n(EDE-Q) 변화량 차이는 –12.79이고 표준편차는 8.24이나 위와\n\n각 군의 표준편차도 효과 평균과 동일하게 50% 반영하여\n\n각 4.1, 5.7로 설정하여 차이에 대한 합동표준편차는 5.0로\n\n두 참고문헌을 통해 8주 시점에서의 기존 대조군 대비\n\nplacebe 군 효과는 (-6.40)-(-1.87)=-4.53 정도로 추정되며, 비\n\n열등성 허용오차 (-기호)는 해당 효과의 절반 정도인 -2.26이다.\n\n 선행연구인 Mond et al. (2004), Mond et al. (2008)의 연구에서\n\nEDE-Q에 대한 cut-off 값을 각각 2.3, 2.8이었던 점을 감안\n\n하여, 본 가이드라인의 비열등성 허용오차는 -2.5로 설정하고자\n\n이에 단측 유의수준 2.5%, 검정력 80%를 만족하는 데\n\n필요한 피험자 수(군당 1:1 배정)를 산출한 결과, 중도 탈락률\n\n5%를 고려하여 목표 피험자 수는 총 128명(군당 64명)으로\n\n두 군의 평균 차이 검정에 대한 피험자 수 산출 공식은\n\n- - 57 -\n \n\n  \n\n ×  ×      \n\n\n\n\n\n \n\n ×  ×   \n\n≈ \n\n- - 58 -\n피험자의 모집 기간, 임상 관찰 및 수행 기간, 통계분석 기간, 결과\n\n보고서 작성 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을\n\n고려하도록 한다.\n\n <!-- PAGE_65 -->\n##### 9. ",
        "original_sentence": "선행연구인 Mond et al."
      }
    },
    {
      "chunk_id": "chunk_608",
      "text": "(2004), Mond et al.",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 607,
        "window_size": 3,
        "char_count": 19,
        "word_count": 4,
        "page_number": 9,
        "window_text": "(2022)에서의 대조군인\n\nplacebo군과 기존 BWL(Behavioral weight loss therapy) 과\n\n약물(naltrexone, bupropion) 처리군의 변화량 효과 차이를\n\n섭식장애 환자를 대상으로 한 기존 비교 임상연구를 검토한\n\n결과, 식사장애 검사(EDE-Q) 변화량은 다음 표와 같이 조사\n\n대조군의 baseline 대비 16주 시점에서의 식사장애 검사\n\n(EDE-Q) 변화량 차이는 –3.74이고 표준편차는 11.32이나\n\n본 임상시험의 치료기간은 8주로 참고문헌에 비해 짧으므로\n\n- - 56 -\n해당 효과의 50% 정도인 –1.87로 설정하였다.\n\n 기존 대조군의 baseline 대비 16주 시점에서의 식사장애 검사\n\n(EDE-Q) 변화량 차이는 –12.79이고 표준편차는 8.24이나 위와\n\n각 군의 표준편차도 효과 평균과 동일하게 50% 반영하여\n\n각 4.1, 5.7로 설정하여 차이에 대한 합동표준편차는 5.0로\n\n두 참고문헌을 통해 8주 시점에서의 기존 대조군 대비\n\nplacebe 군 효과는 (-6.40)-(-1.87)=-4.53 정도로 추정되며, 비\n\n열등성 허용오차 (-기호)는 해당 효과의 절반 정도인 -2.26이다.\n\n 선행연구인 Mond et al. (2004), Mond et al. (2008)의 연구에서\n\nEDE-Q에 대한 cut-off 값을 각각 2.3, 2.8이었던 점을 감안\n\n하여, 본 가이드라인의 비열등성 허용오차는 -2.5로 설정하고자\n\n이에 단측 유의수준 2.5%, 검정력 80%를 만족하는 데\n\n필요한 피험자 수(군당 1:1 배정)를 산출한 결과, 중도 탈락률\n\n5%를 고려하여 목표 피험자 수는 총 128명(군당 64명)으로\n\n두 군의 평균 차이 검정에 대한 피험자 수 산출 공식은\n\n- - 57 -\n \n\n  \n\n ×  ×      \n\n\n\n\n\n \n\n ×  ×   \n\n≈ \n\n- - 58 -\n피험자의 모집 기간, 임상 관찰 및 수행 기간, 통계분석 기간, 결과\n\n보고서 작성 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을\n\n고려하도록 한다.\n\n <!-- PAGE_65 -->\n##### 9.  임상시험기간\n\n- - 59 -\n- 가. ",
        "original_sentence": "(2004), Mond et al."
      }
    },
    {
      "chunk_id": "chunk_609",
      "text": "(2008)의 연구에서\n\nEDE-Q에 대한 cut-off 값을 각각 2.3, 2.8이었던 점을 감안\n\n하여, 본 가이드라인의 비열등성 허용오차는 -2.5로 설정하고자\n\n이에 단측 유의수준 2.5%, 검정력 80%를 만족하는 데\n\n필요한 피험자 수(군당 1:1 배정)를 산출한 결과, 중도 탈락률\n\n5%를 고려하여 목표 피험자 수는 총 128명(군당 64명)으로\n\n두 군의 평균 차이 검정에 대한 피험자 수 산출 공식은\n\n- - 57 -\n \n\n  \n\n ×  ×      \n\n\n\n\n\n \n\n ×  ×   \n\n≈ \n\n- - 58 -\n피험자의 모집 기간, 임상 관찰 및 수행 기간, 통계분석 기간, 결과\n\n보고서 작성 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을\n\n고려하도록 한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 608,
        "window_size": 3,
        "char_count": 434,
        "word_count": 111,
        "page_number": 9,
        "window_text": "기존 대조군의 baseline 대비 16주 시점에서의 식사장애 검사\n\n(EDE-Q) 변화량 차이는 –12.79이고 표준편차는 8.24이나 위와\n\n각 군의 표준편차도 효과 평균과 동일하게 50% 반영하여\n\n각 4.1, 5.7로 설정하여 차이에 대한 합동표준편차는 5.0로\n\n두 참고문헌을 통해 8주 시점에서의 기존 대조군 대비\n\nplacebe 군 효과는 (-6.40)-(-1.87)=-4.53 정도로 추정되며, 비\n\n열등성 허용오차 (-기호)는 해당 효과의 절반 정도인 -2.26이다.\n\n 선행연구인 Mond et al. (2004), Mond et al. (2008)의 연구에서\n\nEDE-Q에 대한 cut-off 값을 각각 2.3, 2.8이었던 점을 감안\n\n하여, 본 가이드라인의 비열등성 허용오차는 -2.5로 설정하고자\n\n이에 단측 유의수준 2.5%, 검정력 80%를 만족하는 데\n\n필요한 피험자 수(군당 1:1 배정)를 산출한 결과, 중도 탈락률\n\n5%를 고려하여 목표 피험자 수는 총 128명(군당 64명)으로\n\n두 군의 평균 차이 검정에 대한 피험자 수 산출 공식은\n\n- - 57 -\n \n\n  \n\n ×  ×      \n\n\n\n\n\n \n\n ×  ×   \n\n≈ \n\n- - 58 -\n피험자의 모집 기간, 임상 관찰 및 수행 기간, 통계분석 기간, 결과\n\n보고서 작성 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을\n\n고려하도록 한다.\n\n <!-- PAGE_65 -->\n##### 9.  임상시험기간\n\n- - 59 -\n- 가.  시험방법\n가) 시험기기: 디지털 섭식장애 인지행동치료 애플리케이션 및\n\n- (예) 섭식장애 인지행동치료 등의 기능이 탑재된 애플리케이션\n※ 섭식장애 개선 디지털치료기기 허가 제품이 출시된 이후에는 기허가\n\n제품과 비교시험 하는 동등성 검정 혹은 비열등성 검정 등을 시행\n\n* 비열등성/동등성 시험(Non-inferiority, equivalence trial): 비교 연구에 있어\n\n대조기기와 비교해 시험기기의 성능이 열등하지 않음을 보이거나,\n\n3) 최소 3회의 외래 방문을 통한 조사: 방문 1(Screening/Baseline),\n\n- 10. ",
        "original_sentence": "(2008)의 연구에서\n\nEDE-Q에 대한 cut-off 값을 각각 2.3, 2.8이었던 점을 감안\n\n하여, 본 가이드라인의 비열등성 허용오차는 -2.5로 설정하고자\n\n이에 단측 유의수준 2.5%, 검정력 80%를 만족하는 데\n\n필요한 피험자 수(군당 1:1 배정)를 산출한 결과, 중도 탈락률\n\n5%를 고려하여 목표 피험자 수는 총 128명(군당 64명)으로\n\n두 군의 평균 차이 검정에 대한 피험자 수 산출 공식은\n\n- - 57 -\n \n\n  \n\n ×  ×      \n\n\n\n\n\n \n\n ×  ×   \n\n≈ \n\n- - 58 -\n피험자의 모집 기간, 임상 관찰 및 수행 기간, 통계분석 기간, 결과\n\n보고서 작성 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을\n\n고려하도록 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_610",
      "text": "<!-- PAGE_65 -->\n##### 9. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 609,
        "window_size": 3,
        "char_count": 26,
        "word_count": 5,
        "page_number": 65,
        "window_text": "선행연구인 Mond et al. (2004), Mond et al. (2008)의 연구에서\n\nEDE-Q에 대한 cut-off 값을 각각 2.3, 2.8이었던 점을 감안\n\n하여, 본 가이드라인의 비열등성 허용오차는 -2.5로 설정하고자\n\n이에 단측 유의수준 2.5%, 검정력 80%를 만족하는 데\n\n필요한 피험자 수(군당 1:1 배정)를 산출한 결과, 중도 탈락률\n\n5%를 고려하여 목표 피험자 수는 총 128명(군당 64명)으로\n\n두 군의 평균 차이 검정에 대한 피험자 수 산출 공식은\n\n- - 57 -\n \n\n  \n\n ×  ×      \n\n\n\n\n\n \n\n ×  ×   \n\n≈ \n\n- - 58 -\n피험자의 모집 기간, 임상 관찰 및 수행 기간, 통계분석 기간, 결과\n\n보고서 작성 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을\n\n고려하도록 한다.\n\n <!-- PAGE_65 -->\n##### 9.  임상시험기간\n\n- - 59 -\n- 가.  시험방법\n가) 시험기기: 디지털 섭식장애 인지행동치료 애플리케이션 및\n\n- (예) 섭식장애 인지행동치료 등의 기능이 탑재된 애플리케이션\n※ 섭식장애 개선 디지털치료기기 허가 제품이 출시된 이후에는 기허가\n\n제품과 비교시험 하는 동등성 검정 혹은 비열등성 검정 등을 시행\n\n* 비열등성/동등성 시험(Non-inferiority, equivalence trial): 비교 연구에 있어\n\n대조기기와 비교해 시험기기의 성능이 열등하지 않음을 보이거나,\n\n3) 최소 3회의 외래 방문을 통한 조사: 방문 1(Screening/Baseline),\n\n- 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n- - 60 -\n방문 3(Follow-up, 4주 후), 방문 5(Follow-up, 8주 후)\n\n※ 방문 2(Follow-up, 2주 후), 방문 4(Follow-up, 6주 후)는 전화를 통해\n\n시행하나, 필요시 애플리케이션, 이메일, 문자, SNS 등을 통해 수집할\n\n4) 층화무작위배정: 성별(남/여), 단일(다)기관, 시험군 및 대조군 1:1 배정\n\n- - 기관별로 내원한 환자 중 선정, 제외 기준에 따라 적합한\n- - 본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한\n내용을 피험자 본인 또는 대리인에게 설명하고, 피험자 또는\n\n대리인이 내용을 잘 이해한 것을 확인한 다음, 자유의사에 따른\n\n임상시험 참가의 동의를 문서로 받는다. ",
        "original_sentence": "<!-- PAGE_65 -->\n##### 9. "
      }
    },
    {
      "chunk_id": "chunk_611",
      "text": "임상시험기간\n\n- - 59 -\n- 가. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 610,
        "window_size": 3,
        "char_count": 22,
        "word_count": 7,
        "page_number": 26,
        "window_text": "(2004), Mond et al. (2008)의 연구에서\n\nEDE-Q에 대한 cut-off 값을 각각 2.3, 2.8이었던 점을 감안\n\n하여, 본 가이드라인의 비열등성 허용오차는 -2.5로 설정하고자\n\n이에 단측 유의수준 2.5%, 검정력 80%를 만족하는 데\n\n필요한 피험자 수(군당 1:1 배정)를 산출한 결과, 중도 탈락률\n\n5%를 고려하여 목표 피험자 수는 총 128명(군당 64명)으로\n\n두 군의 평균 차이 검정에 대한 피험자 수 산출 공식은\n\n- - 57 -\n \n\n  \n\n ×  ×      \n\n\n\n\n\n \n\n ×  ×   \n\n≈ \n\n- - 58 -\n피험자의 모집 기간, 임상 관찰 및 수행 기간, 통계분석 기간, 결과\n\n보고서 작성 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을\n\n고려하도록 한다.\n\n <!-- PAGE_65 -->\n##### 9.  임상시험기간\n\n- - 59 -\n- 가.  시험방법\n가) 시험기기: 디지털 섭식장애 인지행동치료 애플리케이션 및\n\n- (예) 섭식장애 인지행동치료 등의 기능이 탑재된 애플리케이션\n※ 섭식장애 개선 디지털치료기기 허가 제품이 출시된 이후에는 기허가\n\n제품과 비교시험 하는 동등성 검정 혹은 비열등성 검정 등을 시행\n\n* 비열등성/동등성 시험(Non-inferiority, equivalence trial): 비교 연구에 있어\n\n대조기기와 비교해 시험기기의 성능이 열등하지 않음을 보이거나,\n\n3) 최소 3회의 외래 방문을 통한 조사: 방문 1(Screening/Baseline),\n\n- 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n- - 60 -\n방문 3(Follow-up, 4주 후), 방문 5(Follow-up, 8주 후)\n\n※ 방문 2(Follow-up, 2주 후), 방문 4(Follow-up, 6주 후)는 전화를 통해\n\n시행하나, 필요시 애플리케이션, 이메일, 문자, SNS 등을 통해 수집할\n\n4) 층화무작위배정: 성별(남/여), 단일(다)기관, 시험군 및 대조군 1:1 배정\n\n- - 기관별로 내원한 환자 중 선정, 제외 기준에 따라 적합한\n- - 본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한\n내용을 피험자 본인 또는 대리인에게 설명하고, 피험자 또는\n\n대리인이 내용을 잘 이해한 것을 확인한 다음, 자유의사에 따른\n\n임상시험 참가의 동의를 문서로 받는다.  또한 동의에 서명한\n\n연월일을 기록하며, 동의서 사본을 환자에게 제공하여 환자가\n\n지속해서 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n",
        "original_sentence": "임상시험기간\n\n- - 59 -\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_612",
      "text": "시험방법\n가) 시험기기: 디지털 섭식장애 인지행동치료 애플리케이션 및\n\n- (예) 섭식장애 인지행동치료 등의 기능이 탑재된 애플리케이션\n※ 섭식장애 개선 디지털치료기기 허가 제품이 출시된 이후에는 기허가\n\n제품과 비교시험 하는 동등성 검정 혹은 비열등성 검정 등을 시행\n\n* 비열등성/동등성 시험(Non-inferiority, equivalence trial): 비교 연구에 있어\n\n대조기기와 비교해 시험기기의 성능이 열등하지 않음을 보이거나,\n\n3) 최소 3회의 외래 방문을 통한 조사: 방문 1(Screening/Baseline),\n\n- 10. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 611,
        "window_size": 3,
        "char_count": 307,
        "word_count": 61,
        "page_number": 30,
        "window_text": "(2008)의 연구에서\n\nEDE-Q에 대한 cut-off 값을 각각 2.3, 2.8이었던 점을 감안\n\n하여, 본 가이드라인의 비열등성 허용오차는 -2.5로 설정하고자\n\n이에 단측 유의수준 2.5%, 검정력 80%를 만족하는 데\n\n필요한 피험자 수(군당 1:1 배정)를 산출한 결과, 중도 탈락률\n\n5%를 고려하여 목표 피험자 수는 총 128명(군당 64명)으로\n\n두 군의 평균 차이 검정에 대한 피험자 수 산출 공식은\n\n- - 57 -\n \n\n  \n\n ×  ×      \n\n\n\n\n\n \n\n ×  ×   \n\n≈ \n\n- - 58 -\n피험자의 모집 기간, 임상 관찰 및 수행 기간, 통계분석 기간, 결과\n\n보고서 작성 기간, 임상시험심사위원회 심사 기간 등 충분한 기간을\n\n고려하도록 한다.\n\n <!-- PAGE_65 -->\n##### 9.  임상시험기간\n\n- - 59 -\n- 가.  시험방법\n가) 시험기기: 디지털 섭식장애 인지행동치료 애플리케이션 및\n\n- (예) 섭식장애 인지행동치료 등의 기능이 탑재된 애플리케이션\n※ 섭식장애 개선 디지털치료기기 허가 제품이 출시된 이후에는 기허가\n\n제품과 비교시험 하는 동등성 검정 혹은 비열등성 검정 등을 시행\n\n* 비열등성/동등성 시험(Non-inferiority, equivalence trial): 비교 연구에 있어\n\n대조기기와 비교해 시험기기의 성능이 열등하지 않음을 보이거나,\n\n3) 최소 3회의 외래 방문을 통한 조사: 방문 1(Screening/Baseline),\n\n- 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n- - 60 -\n방문 3(Follow-up, 4주 후), 방문 5(Follow-up, 8주 후)\n\n※ 방문 2(Follow-up, 2주 후), 방문 4(Follow-up, 6주 후)는 전화를 통해\n\n시행하나, 필요시 애플리케이션, 이메일, 문자, SNS 등을 통해 수집할\n\n4) 층화무작위배정: 성별(남/여), 단일(다)기관, 시험군 및 대조군 1:1 배정\n\n- - 기관별로 내원한 환자 중 선정, 제외 기준에 따라 적합한\n- - 본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한\n내용을 피험자 본인 또는 대리인에게 설명하고, 피험자 또는\n\n대리인이 내용을 잘 이해한 것을 확인한 다음, 자유의사에 따른\n\n임상시험 참가의 동의를 문서로 받는다.  또한 동의에 서명한\n\n연월일을 기록하며, 동의서 사본을 환자에게 제공하여 환자가\n\n지속해서 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n - - 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력\n등에 대하여 차트 확인 등을 통하여 점검하고 증례 기록서에\n\n- - 61 -\n라) 피험자 식별코드 부여\n\n- (1) 피험자에게 서명하고 동의를 받은 후 동의 취득 순서에 따라\n스크리닝 번호를 부여하며 피험자가 참여를 종료할 때까지\n\n- (2) 피험자 적합성 평가: 피험자 선정 및 제외 기준에 적합한지\n· 베이스라인 (사용 전) 대비 8주 시점의 식사장애 검사\n\n· 일차 유효성 평가지표를 통해 유효성을 검증하는 것이\n\n기본적인 원칙이지만, 이외 필요하면 변수를 이차 유효성\n\n· 과학적인 근거를 가진 변수이되, 기존 섭식장애 증상 개선\n\n- - 62 -\n측정도구\n\n설명\n\nEDE-Q는 총 28 개 문항으로 구성되어 있으며, 섭식장애의\n\n주요\n\n병리를\n\n측정하는\n\n식사제한, 식사관심, 체형관심,\n\n체중관심의\n\n4개\n\n하위요인으로\n\n구성되어\n\n있다. ",
        "original_sentence": "시험방법\n가) 시험기기: 디지털 섭식장애 인지행동치료 애플리케이션 및\n\n- (예) 섭식장애 인지행동치료 등의 기능이 탑재된 애플리케이션\n※ 섭식장애 개선 디지털치료기기 허가 제품이 출시된 이후에는 기허가\n\n제품과 비교시험 하는 동등성 검정 혹은 비열등성 검정 등을 시행\n\n* 비열등성/동등성 시험(Non-inferiority, equivalence trial): 비교 연구에 있어\n\n대조기기와 비교해 시험기기의 성능이 열등하지 않음을 보이거나,\n\n3) 최소 3회의 외래 방문을 통한 조사: 방문 1(Screening/Baseline),\n\n- 10. "
      }
    },
    {
      "chunk_id": "chunk_613",
      "text": "임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n- - 60 -\n방문 3(Follow-up, 4주 후), 방문 5(Follow-up, 8주 후)\n\n※ 방문 2(Follow-up, 2주 후), 방문 4(Follow-up, 6주 후)는 전화를 통해\n\n시행하나, 필요시 애플리케이션, 이메일, 문자, SNS 등을 통해 수집할\n\n4) 층화무작위배정: 성별(남/여), 단일(다)기관, 시험군 및 대조군 1:1 배정\n\n- - 기관별로 내원한 환자 중 선정, 제외 기준에 따라 적합한\n- - 본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한\n내용을 피험자 본인 또는 대리인에게 설명하고, 피험자 또는\n\n대리인이 내용을 잘 이해한 것을 확인한 다음, 자유의사에 따른\n\n임상시험 참가의 동의를 문서로 받는다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 612,
        "window_size": 3,
        "char_count": 397,
        "word_count": 86,
        "page_number": 26,
        "window_text": "<!-- PAGE_65 -->\n##### 9.  임상시험기간\n\n- - 59 -\n- 가.  시험방법\n가) 시험기기: 디지털 섭식장애 인지행동치료 애플리케이션 및\n\n- (예) 섭식장애 인지행동치료 등의 기능이 탑재된 애플리케이션\n※ 섭식장애 개선 디지털치료기기 허가 제품이 출시된 이후에는 기허가\n\n제품과 비교시험 하는 동등성 검정 혹은 비열등성 검정 등을 시행\n\n* 비열등성/동등성 시험(Non-inferiority, equivalence trial): 비교 연구에 있어\n\n대조기기와 비교해 시험기기의 성능이 열등하지 않음을 보이거나,\n\n3) 최소 3회의 외래 방문을 통한 조사: 방문 1(Screening/Baseline),\n\n- 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n- - 60 -\n방문 3(Follow-up, 4주 후), 방문 5(Follow-up, 8주 후)\n\n※ 방문 2(Follow-up, 2주 후), 방문 4(Follow-up, 6주 후)는 전화를 통해\n\n시행하나, 필요시 애플리케이션, 이메일, 문자, SNS 등을 통해 수집할\n\n4) 층화무작위배정: 성별(남/여), 단일(다)기관, 시험군 및 대조군 1:1 배정\n\n- - 기관별로 내원한 환자 중 선정, 제외 기준에 따라 적합한\n- - 본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한\n내용을 피험자 본인 또는 대리인에게 설명하고, 피험자 또는\n\n대리인이 내용을 잘 이해한 것을 확인한 다음, 자유의사에 따른\n\n임상시험 참가의 동의를 문서로 받는다.  또한 동의에 서명한\n\n연월일을 기록하며, 동의서 사본을 환자에게 제공하여 환자가\n\n지속해서 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n - - 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력\n등에 대하여 차트 확인 등을 통하여 점검하고 증례 기록서에\n\n- - 61 -\n라) 피험자 식별코드 부여\n\n- (1) 피험자에게 서명하고 동의를 받은 후 동의 취득 순서에 따라\n스크리닝 번호를 부여하며 피험자가 참여를 종료할 때까지\n\n- (2) 피험자 적합성 평가: 피험자 선정 및 제외 기준에 적합한지\n· 베이스라인 (사용 전) 대비 8주 시점의 식사장애 검사\n\n· 일차 유효성 평가지표를 통해 유효성을 검증하는 것이\n\n기본적인 원칙이지만, 이외 필요하면 변수를 이차 유효성\n\n· 과학적인 근거를 가진 변수이되, 기존 섭식장애 증상 개선\n\n- - 62 -\n측정도구\n\n설명\n\nEDE-Q는 총 28 개 문항으로 구성되어 있으며, 섭식장애의\n\n주요\n\n병리를\n\n측정하는\n\n식사제한, 식사관심, 체형관심,\n\n체중관심의\n\n4개\n\n하위요인으로\n\n구성되어\n\n있다.  점수가\n\n높을수록 섭식 행동 및 태도에 문제가 있는 것을 의미한다.\n\n",
        "original_sentence": "임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n- - 60 -\n방문 3(Follow-up, 4주 후), 방문 5(Follow-up, 8주 후)\n\n※ 방문 2(Follow-up, 2주 후), 방문 4(Follow-up, 6주 후)는 전화를 통해\n\n시행하나, 필요시 애플리케이션, 이메일, 문자, SNS 등을 통해 수집할\n\n4) 층화무작위배정: 성별(남/여), 단일(다)기관, 시험군 및 대조군 1:1 배정\n\n- - 기관별로 내원한 환자 중 선정, 제외 기준에 따라 적합한\n- - 본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한\n내용을 피험자 본인 또는 대리인에게 설명하고, 피험자 또는\n\n대리인이 내용을 잘 이해한 것을 확인한 다음, 자유의사에 따른\n\n임상시험 참가의 동의를 문서로 받는다. "
      }
    },
    {
      "chunk_id": "chunk_614",
      "text": "또한 동의에 서명한\n\n연월일을 기록하며, 동의서 사본을 환자에게 제공하여 환자가\n\n지속해서 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 613,
        "window_size": 3,
        "char_count": 82,
        "word_count": 19,
        "page_number": 15,
        "window_text": "임상시험기간\n\n- - 59 -\n- 가.  시험방법\n가) 시험기기: 디지털 섭식장애 인지행동치료 애플리케이션 및\n\n- (예) 섭식장애 인지행동치료 등의 기능이 탑재된 애플리케이션\n※ 섭식장애 개선 디지털치료기기 허가 제품이 출시된 이후에는 기허가\n\n제품과 비교시험 하는 동등성 검정 혹은 비열등성 검정 등을 시행\n\n* 비열등성/동등성 시험(Non-inferiority, equivalence trial): 비교 연구에 있어\n\n대조기기와 비교해 시험기기의 성능이 열등하지 않음을 보이거나,\n\n3) 최소 3회의 외래 방문을 통한 조사: 방문 1(Screening/Baseline),\n\n- 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n- - 60 -\n방문 3(Follow-up, 4주 후), 방문 5(Follow-up, 8주 후)\n\n※ 방문 2(Follow-up, 2주 후), 방문 4(Follow-up, 6주 후)는 전화를 통해\n\n시행하나, 필요시 애플리케이션, 이메일, 문자, SNS 등을 통해 수집할\n\n4) 층화무작위배정: 성별(남/여), 단일(다)기관, 시험군 및 대조군 1:1 배정\n\n- - 기관별로 내원한 환자 중 선정, 제외 기준에 따라 적합한\n- - 본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한\n내용을 피험자 본인 또는 대리인에게 설명하고, 피험자 또는\n\n대리인이 내용을 잘 이해한 것을 확인한 다음, 자유의사에 따른\n\n임상시험 참가의 동의를 문서로 받는다.  또한 동의에 서명한\n\n연월일을 기록하며, 동의서 사본을 환자에게 제공하여 환자가\n\n지속해서 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n - - 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력\n등에 대하여 차트 확인 등을 통하여 점검하고 증례 기록서에\n\n- - 61 -\n라) 피험자 식별코드 부여\n\n- (1) 피험자에게 서명하고 동의를 받은 후 동의 취득 순서에 따라\n스크리닝 번호를 부여하며 피험자가 참여를 종료할 때까지\n\n- (2) 피험자 적합성 평가: 피험자 선정 및 제외 기준에 적합한지\n· 베이스라인 (사용 전) 대비 8주 시점의 식사장애 검사\n\n· 일차 유효성 평가지표를 통해 유효성을 검증하는 것이\n\n기본적인 원칙이지만, 이외 필요하면 변수를 이차 유효성\n\n· 과학적인 근거를 가진 변수이되, 기존 섭식장애 증상 개선\n\n- - 62 -\n측정도구\n\n설명\n\nEDE-Q는 총 28 개 문항으로 구성되어 있으며, 섭식장애의\n\n주요\n\n병리를\n\n측정하는\n\n식사제한, 식사관심, 체형관심,\n\n체중관심의\n\n4개\n\n하위요인으로\n\n구성되어\n\n있다.  점수가\n\n높을수록 섭식 행동 및 태도에 문제가 있는 것을 의미한다.\n\n CIA 를 통해 섭식장애와 관련된 세 가지 주요 영역(개인적,\n\n사회적, 인지적)에 대한 이차적인 손상 정도를 평가한다.\n\n",
        "original_sentence": "또한 동의에 서명한\n\n연월일을 기록하며, 동의서 사본을 환자에게 제공하여 환자가\n\n지속해서 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_615",
      "text": "- - 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력\n등에 대하여 차트 확인 등을 통하여 점검하고 증례 기록서에\n\n- - 61 -\n라) 피험자 식별코드 부여\n\n- (1) 피험자에게 서명하고 동의를 받은 후 동의 취득 순서에 따라\n스크리닝 번호를 부여하며 피험자가 참여를 종료할 때까지\n\n- (2) 피험자 적합성 평가: 피험자 선정 및 제외 기준에 적합한지\n· 베이스라인 (사용 전) 대비 8주 시점의 식사장애 검사\n\n· 일차 유효성 평가지표를 통해 유효성을 검증하는 것이\n\n기본적인 원칙이지만, 이외 필요하면 변수를 이차 유효성\n\n· 과학적인 근거를 가진 변수이되, 기존 섭식장애 증상 개선\n\n- - 62 -\n측정도구\n\n설명\n\nEDE-Q는 총 28 개 문항으로 구성되어 있으며, 섭식장애의\n\n주요\n\n병리를\n\n측정하는\n\n식사제한, 식사관심, 체형관심,\n\n체중관심의\n\n4개\n\n하위요인으로\n\n구성되어\n\n있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 614,
        "window_size": 3,
        "char_count": 456,
        "word_count": 114,
        "page_number": 7,
        "window_text": "시험방법\n가) 시험기기: 디지털 섭식장애 인지행동치료 애플리케이션 및\n\n- (예) 섭식장애 인지행동치료 등의 기능이 탑재된 애플리케이션\n※ 섭식장애 개선 디지털치료기기 허가 제품이 출시된 이후에는 기허가\n\n제품과 비교시험 하는 동등성 검정 혹은 비열등성 검정 등을 시행\n\n* 비열등성/동등성 시험(Non-inferiority, equivalence trial): 비교 연구에 있어\n\n대조기기와 비교해 시험기기의 성능이 열등하지 않음을 보이거나,\n\n3) 최소 3회의 외래 방문을 통한 조사: 방문 1(Screening/Baseline),\n\n- 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n- - 60 -\n방문 3(Follow-up, 4주 후), 방문 5(Follow-up, 8주 후)\n\n※ 방문 2(Follow-up, 2주 후), 방문 4(Follow-up, 6주 후)는 전화를 통해\n\n시행하나, 필요시 애플리케이션, 이메일, 문자, SNS 등을 통해 수집할\n\n4) 층화무작위배정: 성별(남/여), 단일(다)기관, 시험군 및 대조군 1:1 배정\n\n- - 기관별로 내원한 환자 중 선정, 제외 기준에 따라 적합한\n- - 본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한\n내용을 피험자 본인 또는 대리인에게 설명하고, 피험자 또는\n\n대리인이 내용을 잘 이해한 것을 확인한 다음, 자유의사에 따른\n\n임상시험 참가의 동의를 문서로 받는다.  또한 동의에 서명한\n\n연월일을 기록하며, 동의서 사본을 환자에게 제공하여 환자가\n\n지속해서 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n - - 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력\n등에 대하여 차트 확인 등을 통하여 점검하고 증례 기록서에\n\n- - 61 -\n라) 피험자 식별코드 부여\n\n- (1) 피험자에게 서명하고 동의를 받은 후 동의 취득 순서에 따라\n스크리닝 번호를 부여하며 피험자가 참여를 종료할 때까지\n\n- (2) 피험자 적합성 평가: 피험자 선정 및 제외 기준에 적합한지\n· 베이스라인 (사용 전) 대비 8주 시점의 식사장애 검사\n\n· 일차 유효성 평가지표를 통해 유효성을 검증하는 것이\n\n기본적인 원칙이지만, 이외 필요하면 변수를 이차 유효성\n\n· 과학적인 근거를 가진 변수이되, 기존 섭식장애 증상 개선\n\n- - 62 -\n측정도구\n\n설명\n\nEDE-Q는 총 28 개 문항으로 구성되어 있으며, 섭식장애의\n\n주요\n\n병리를\n\n측정하는\n\n식사제한, 식사관심, 체형관심,\n\n체중관심의\n\n4개\n\n하위요인으로\n\n구성되어\n\n있다.  점수가\n\n높을수록 섭식 행동 및 태도에 문제가 있는 것을 의미한다.\n\n CIA 를 통해 섭식장애와 관련된 세 가지 주요 영역(개인적,\n\n사회적, 인지적)에 대한 이차적인 손상 정도를 평가한다.\n\n 점수가 높을수록 섭식장애로 인한 개인적, 사회적, 인지적\n\nPHQ-9를 통해 우울 증상을 평가한다. ",
        "original_sentence": "- - 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력\n등에 대하여 차트 확인 등을 통하여 점검하고 증례 기록서에\n\n- - 61 -\n라) 피험자 식별코드 부여\n\n- (1) 피험자에게 서명하고 동의를 받은 후 동의 취득 순서에 따라\n스크리닝 번호를 부여하며 피험자가 참여를 종료할 때까지\n\n- (2) 피험자 적합성 평가: 피험자 선정 및 제외 기준에 적합한지\n· 베이스라인 (사용 전) 대비 8주 시점의 식사장애 검사\n\n· 일차 유효성 평가지표를 통해 유효성을 검증하는 것이\n\n기본적인 원칙이지만, 이외 필요하면 변수를 이차 유효성\n\n· 과학적인 근거를 가진 변수이되, 기존 섭식장애 증상 개선\n\n- - 62 -\n측정도구\n\n설명\n\nEDE-Q는 총 28 개 문항으로 구성되어 있으며, 섭식장애의\n\n주요\n\n병리를\n\n측정하는\n\n식사제한, 식사관심, 체형관심,\n\n체중관심의\n\n4개\n\n하위요인으로\n\n구성되어\n\n있다. "
      }
    },
    {
      "chunk_id": "chunk_616",
      "text": "점수가\n\n높을수록 섭식 행동 및 태도에 문제가 있는 것을 의미한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 615,
        "window_size": 3,
        "char_count": 39,
        "word_count": 10,
        "page_number": 15,
        "window_text": "임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n- - 60 -\n방문 3(Follow-up, 4주 후), 방문 5(Follow-up, 8주 후)\n\n※ 방문 2(Follow-up, 2주 후), 방문 4(Follow-up, 6주 후)는 전화를 통해\n\n시행하나, 필요시 애플리케이션, 이메일, 문자, SNS 등을 통해 수집할\n\n4) 층화무작위배정: 성별(남/여), 단일(다)기관, 시험군 및 대조군 1:1 배정\n\n- - 기관별로 내원한 환자 중 선정, 제외 기준에 따라 적합한\n- - 본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한\n내용을 피험자 본인 또는 대리인에게 설명하고, 피험자 또는\n\n대리인이 내용을 잘 이해한 것을 확인한 다음, 자유의사에 따른\n\n임상시험 참가의 동의를 문서로 받는다.  또한 동의에 서명한\n\n연월일을 기록하며, 동의서 사본을 환자에게 제공하여 환자가\n\n지속해서 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n - - 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력\n등에 대하여 차트 확인 등을 통하여 점검하고 증례 기록서에\n\n- - 61 -\n라) 피험자 식별코드 부여\n\n- (1) 피험자에게 서명하고 동의를 받은 후 동의 취득 순서에 따라\n스크리닝 번호를 부여하며 피험자가 참여를 종료할 때까지\n\n- (2) 피험자 적합성 평가: 피험자 선정 및 제외 기준에 적합한지\n· 베이스라인 (사용 전) 대비 8주 시점의 식사장애 검사\n\n· 일차 유효성 평가지표를 통해 유효성을 검증하는 것이\n\n기본적인 원칙이지만, 이외 필요하면 변수를 이차 유효성\n\n· 과학적인 근거를 가진 변수이되, 기존 섭식장애 증상 개선\n\n- - 62 -\n측정도구\n\n설명\n\nEDE-Q는 총 28 개 문항으로 구성되어 있으며, 섭식장애의\n\n주요\n\n병리를\n\n측정하는\n\n식사제한, 식사관심, 체형관심,\n\n체중관심의\n\n4개\n\n하위요인으로\n\n구성되어\n\n있다.  점수가\n\n높을수록 섭식 행동 및 태도에 문제가 있는 것을 의미한다.\n\n CIA 를 통해 섭식장애와 관련된 세 가지 주요 영역(개인적,\n\n사회적, 인지적)에 대한 이차적인 손상 정도를 평가한다.\n\n 점수가 높을수록 섭식장애로 인한 개인적, 사회적, 인지적\n\nPHQ-9를 통해 우울 증상을 평가한다.  DSM-IV의 주요\n\n우울장애의 진단기준에 의거하여 지난 2주간의 무쾌감,\n\n우울감, 수면의 변화, 피로감, 식욕의 변화, 죄책감, 무가\n\n치감, 집중력 저하, 좌불안석 또는 쳐진 느낌, 자살사고의\n\n**[표 시작]**\n\n| 시하는 자, 임상시험심사위원회 및 식품의약품안전처장이 관계 | - 대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 | - 피험자가 임상시험 중 임상시험 참여 중단을 요구하거나 시험 | 구간을 제시한다. ",
        "original_sentence": "점수가\n\n높을수록 섭식 행동 및 태도에 문제가 있는 것을 의미한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_617",
      "text": "CIA 를 통해 섭식장애와 관련된 세 가지 주요 영역(개인적,\n\n사회적, 인지적)에 대한 이차적인 손상 정도를 평가한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 616,
        "window_size": 3,
        "char_count": 69,
        "word_count": 16,
        "page_number": 30,
        "window_text": "또한 동의에 서명한\n\n연월일을 기록하며, 동의서 사본을 환자에게 제공하여 환자가\n\n지속해서 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.\n\n - - 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력\n등에 대하여 차트 확인 등을 통하여 점검하고 증례 기록서에\n\n- - 61 -\n라) 피험자 식별코드 부여\n\n- (1) 피험자에게 서명하고 동의를 받은 후 동의 취득 순서에 따라\n스크리닝 번호를 부여하며 피험자가 참여를 종료할 때까지\n\n- (2) 피험자 적합성 평가: 피험자 선정 및 제외 기준에 적합한지\n· 베이스라인 (사용 전) 대비 8주 시점의 식사장애 검사\n\n· 일차 유효성 평가지표를 통해 유효성을 검증하는 것이\n\n기본적인 원칙이지만, 이외 필요하면 변수를 이차 유효성\n\n· 과학적인 근거를 가진 변수이되, 기존 섭식장애 증상 개선\n\n- - 62 -\n측정도구\n\n설명\n\nEDE-Q는 총 28 개 문항으로 구성되어 있으며, 섭식장애의\n\n주요\n\n병리를\n\n측정하는\n\n식사제한, 식사관심, 체형관심,\n\n체중관심의\n\n4개\n\n하위요인으로\n\n구성되어\n\n있다.  점수가\n\n높을수록 섭식 행동 및 태도에 문제가 있는 것을 의미한다.\n\n CIA 를 통해 섭식장애와 관련된 세 가지 주요 영역(개인적,\n\n사회적, 인지적)에 대한 이차적인 손상 정도를 평가한다.\n\n 점수가 높을수록 섭식장애로 인한 개인적, 사회적, 인지적\n\nPHQ-9를 통해 우울 증상을 평가한다.  DSM-IV의 주요\n\n우울장애의 진단기준에 의거하여 지난 2주간의 무쾌감,\n\n우울감, 수면의 변화, 피로감, 식욕의 변화, 죄책감, 무가\n\n치감, 집중력 저하, 좌불안석 또는 쳐진 느낌, 자살사고의\n\n**[표 시작]**\n\n| 시하는 자, 임상시험심사위원회 및 식품의약품안전처장이 관계 | - 대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 | - 피험자가 임상시험 중 임상시험 참여 중단을 요구하거나 시험 | 구간을 제시한다.  95% 신뢰구간 상한이 비열등성 마진(2.5)을 | 9 가지 문항으로 구성되어 있다. ",
        "original_sentence": "CIA 를 통해 섭식장애와 관련된 세 가지 주요 영역(개인적,\n\n사회적, 인지적)에 대한 이차적인 손상 정도를 평가한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_618",
      "text": "점수가 높을수록 섭식장애로 인한 개인적, 사회적, 인지적\n\nPHQ-9를 통해 우울 증상을 평가한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 617,
        "window_size": 3,
        "char_count": 56,
        "word_count": 12,
        "page_number": 28,
        "window_text": "- - 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력\n등에 대하여 차트 확인 등을 통하여 점검하고 증례 기록서에\n\n- - 61 -\n라) 피험자 식별코드 부여\n\n- (1) 피험자에게 서명하고 동의를 받은 후 동의 취득 순서에 따라\n스크리닝 번호를 부여하며 피험자가 참여를 종료할 때까지\n\n- (2) 피험자 적합성 평가: 피험자 선정 및 제외 기준에 적합한지\n· 베이스라인 (사용 전) 대비 8주 시점의 식사장애 검사\n\n· 일차 유효성 평가지표를 통해 유효성을 검증하는 것이\n\n기본적인 원칙이지만, 이외 필요하면 변수를 이차 유효성\n\n· 과학적인 근거를 가진 변수이되, 기존 섭식장애 증상 개선\n\n- - 62 -\n측정도구\n\n설명\n\nEDE-Q는 총 28 개 문항으로 구성되어 있으며, 섭식장애의\n\n주요\n\n병리를\n\n측정하는\n\n식사제한, 식사관심, 체형관심,\n\n체중관심의\n\n4개\n\n하위요인으로\n\n구성되어\n\n있다.  점수가\n\n높을수록 섭식 행동 및 태도에 문제가 있는 것을 의미한다.\n\n CIA 를 통해 섭식장애와 관련된 세 가지 주요 영역(개인적,\n\n사회적, 인지적)에 대한 이차적인 손상 정도를 평가한다.\n\n 점수가 높을수록 섭식장애로 인한 개인적, 사회적, 인지적\n\nPHQ-9를 통해 우울 증상을 평가한다.  DSM-IV의 주요\n\n우울장애의 진단기준에 의거하여 지난 2주간의 무쾌감,\n\n우울감, 수면의 변화, 피로감, 식욕의 변화, 죄책감, 무가\n\n치감, 집중력 저하, 좌불안석 또는 쳐진 느낌, 자살사고의\n\n**[표 시작]**\n\n| 시하는 자, 임상시험심사위원회 및 식품의약품안전처장이 관계 | - 대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 | - 피험자가 임상시험 중 임상시험 참여 중단을 요구하거나 시험 | 구간을 제시한다.  95% 신뢰구간 상한이 비열등성 마진(2.5)을 | 9 가지 문항으로 구성되어 있다.  점수가 높을수록 우울 |\n| --- | --- | --- | --- | --- |\n**쌍방향 웹반응시스템(Interactive Web Response System,**\n| 법령에 따라 임상시험의 실시 절차와 자료의 품질을 검증하기 | - 정해진 기간에 환자에게 해가 되지 않는 내용으로 과학적 근거에 | - 이상 반응이 다른 가능성이 있는 원인과 같은 수준으로 임상 | * 순응도란 치료 기간 내 총 노출된 모듈 횟수를 통해 평가한다. ",
        "original_sentence": "점수가 높을수록 섭식장애로 인한 개인적, 사회적, 인지적\n\nPHQ-9를 통해 우울 증상을 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_619",
      "text": "DSM-IV의 주요\n\n우울장애의 진단기준에 의거하여 지난 2주간의 무쾌감,\n\n우울감, 수면의 변화, 피로감, 식욕의 변화, 죄책감, 무가\n\n치감, 집중력 저하, 좌불안석 또는 쳐진 느낌, 자살사고의\n\n**[표 시작]**\n\n| 시하는 자, 임상시험심사위원회 및 식품의약품안전처장이 관계 | - 대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 | - 피험자가 임상시험 중 임상시험 참여 중단을 요구하거나 시험 | 구간을 제시한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 618,
        "window_size": 3,
        "char_count": 245,
        "word_count": 57,
        "page_number": 9,
        "window_text": "점수가\n\n높을수록 섭식 행동 및 태도에 문제가 있는 것을 의미한다.\n\n CIA 를 통해 섭식장애와 관련된 세 가지 주요 영역(개인적,\n\n사회적, 인지적)에 대한 이차적인 손상 정도를 평가한다.\n\n 점수가 높을수록 섭식장애로 인한 개인적, 사회적, 인지적\n\nPHQ-9를 통해 우울 증상을 평가한다.  DSM-IV의 주요\n\n우울장애의 진단기준에 의거하여 지난 2주간의 무쾌감,\n\n우울감, 수면의 변화, 피로감, 식욕의 변화, 죄책감, 무가\n\n치감, 집중력 저하, 좌불안석 또는 쳐진 느낌, 자살사고의\n\n**[표 시작]**\n\n| 시하는 자, 임상시험심사위원회 및 식품의약품안전처장이 관계 | - 대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 | - 피험자가 임상시험 중 임상시험 참여 중단을 요구하거나 시험 | 구간을 제시한다.  95% 신뢰구간 상한이 비열등성 마진(2.5)을 | 9 가지 문항으로 구성되어 있다.  점수가 높을수록 우울 |\n| --- | --- | --- | --- | --- |\n**쌍방향 웹반응시스템(Interactive Web Response System,**\n| 법령에 따라 임상시험의 실시 절차와 자료의 품질을 검증하기 | - 정해진 기간에 환자에게 해가 되지 않는 내용으로 과학적 근거에 | - 이상 반응이 다른 가능성이 있는 원인과 같은 수준으로 임상 | * 순응도란 치료 기간 내 총 노출된 모듈 횟수를 통해 평가한다.  총 | 포함하지 않으면 통계적으로 비열등하다고 판단한다. ",
        "original_sentence": "DSM-IV의 주요\n\n우울장애의 진단기준에 의거하여 지난 2주간의 무쾌감,\n\n우울감, 수면의 변화, 피로감, 식욕의 변화, 죄책감, 무가\n\n치감, 집중력 저하, 좌불안석 또는 쳐진 느낌, 자살사고의\n\n**[표 시작]**\n\n| 시하는 자, 임상시험심사위원회 및 식품의약품안전처장이 관계 | - 대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 | - 피험자가 임상시험 중 임상시험 참여 중단을 요구하거나 시험 | 구간을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_620",
      "text": "95% 신뢰구간 상한이 비열등성 마진(2.5)을 | 9 가지 문항으로 구성되어 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 619,
        "window_size": 3,
        "char_count": 48,
        "word_count": 11,
        "page_number": 9,
        "window_text": "CIA 를 통해 섭식장애와 관련된 세 가지 주요 영역(개인적,\n\n사회적, 인지적)에 대한 이차적인 손상 정도를 평가한다.\n\n 점수가 높을수록 섭식장애로 인한 개인적, 사회적, 인지적\n\nPHQ-9를 통해 우울 증상을 평가한다.  DSM-IV의 주요\n\n우울장애의 진단기준에 의거하여 지난 2주간의 무쾌감,\n\n우울감, 수면의 변화, 피로감, 식욕의 변화, 죄책감, 무가\n\n치감, 집중력 저하, 좌불안석 또는 쳐진 느낌, 자살사고의\n\n**[표 시작]**\n\n| 시하는 자, 임상시험심사위원회 및 식품의약품안전처장이 관계 | - 대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 | - 피험자가 임상시험 중 임상시험 참여 중단을 요구하거나 시험 | 구간을 제시한다.  95% 신뢰구간 상한이 비열등성 마진(2.5)을 | 9 가지 문항으로 구성되어 있다.  점수가 높을수록 우울 |\n| --- | --- | --- | --- | --- |\n**쌍방향 웹반응시스템(Interactive Web Response System,**\n| 법령에 따라 임상시험의 실시 절차와 자료의 품질을 검증하기 | - 정해진 기간에 환자에게 해가 되지 않는 내용으로 과학적 근거에 | - 이상 반응이 다른 가능성이 있는 원인과 같은 수준으로 임상 | * 순응도란 치료 기간 내 총 노출된 모듈 횟수를 통해 평가한다.  총 | 포함하지 않으면 통계적으로 비열등하다고 판단한다.  또한, |\n\n**[표 끝]**\n\nGAD-7은 범불안장애 환자를 선별 진단하기 위해 개발된\n\n선별평가도구로 불안 또는 걱정과 관련된 7가지 문항에\n\n대해 그 정도를 0점 (전혀 없었다)에서 3점(거의 매일\n\n괴로웠다.",
        "original_sentence": "95% 신뢰구간 상한이 비열등성 마진(2.5)을 | 9 가지 문항으로 구성되어 있다. "
      }
    },
    {
      "chunk_id": "chunk_621",
      "text": "점수가 높을수록 우울 |\n| --- | --- | --- | --- | --- |\n**쌍방향 웹반응시스템(Interactive Web Response System,**\n| 법령에 따라 임상시험의 실시 절차와 자료의 품질을 검증하기 | - 정해진 기간에 환자에게 해가 되지 않는 내용으로 과학적 근거에 | - 이상 반응이 다른 가능성이 있는 원인과 같은 수준으로 임상 | * 순응도란 치료 기간 내 총 노출된 모듈 횟수를 통해 평가한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 620,
        "window_size": 3,
        "char_count": 244,
        "word_count": 63,
        "page_number": 70,
        "window_text": "점수가 높을수록 섭식장애로 인한 개인적, 사회적, 인지적\n\nPHQ-9를 통해 우울 증상을 평가한다.  DSM-IV의 주요\n\n우울장애의 진단기준에 의거하여 지난 2주간의 무쾌감,\n\n우울감, 수면의 변화, 피로감, 식욕의 변화, 죄책감, 무가\n\n치감, 집중력 저하, 좌불안석 또는 쳐진 느낌, 자살사고의\n\n**[표 시작]**\n\n| 시하는 자, 임상시험심사위원회 및 식품의약품안전처장이 관계 | - 대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 | - 피험자가 임상시험 중 임상시험 참여 중단을 요구하거나 시험 | 구간을 제시한다.  95% 신뢰구간 상한이 비열등성 마진(2.5)을 | 9 가지 문항으로 구성되어 있다.  점수가 높을수록 우울 |\n| --- | --- | --- | --- | --- |\n**쌍방향 웹반응시스템(Interactive Web Response System,**\n| 법령에 따라 임상시험의 실시 절차와 자료의 품질을 검증하기 | - 정해진 기간에 환자에게 해가 되지 않는 내용으로 과학적 근거에 | - 이상 반응이 다른 가능성이 있는 원인과 같은 수준으로 임상 | * 순응도란 치료 기간 내 총 노출된 모듈 횟수를 통해 평가한다.  총 | 포함하지 않으면 통계적으로 비열등하다고 판단한다.  또한, |\n\n**[표 끝]**\n\nGAD-7은 범불안장애 환자를 선별 진단하기 위해 개발된\n\n선별평가도구로 불안 또는 걱정과 관련된 7가지 문항에\n\n대해 그 정도를 0점 (전혀 없었다)에서 3점(거의 매일\n\n괴로웠다. )까지 체크하여 불안 증상을 평가한다. ",
        "original_sentence": "점수가 높을수록 우울 |\n| --- | --- | --- | --- | --- |\n**쌍방향 웹반응시스템(Interactive Web Response System,**\n| 법령에 따라 임상시험의 실시 절차와 자료의 품질을 검증하기 | - 정해진 기간에 환자에게 해가 되지 않는 내용으로 과학적 근거에 | - 이상 반응이 다른 가능성이 있는 원인과 같은 수준으로 임상 | * 순응도란 치료 기간 내 총 노출된 모듈 횟수를 통해 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_622",
      "text": "총 | 포함하지 않으면 통계적으로 비열등하다고 판단한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 621,
        "window_size": 3,
        "char_count": 32,
        "word_count": 7,
        "page_number": 15,
        "window_text": "DSM-IV의 주요\n\n우울장애의 진단기준에 의거하여 지난 2주간의 무쾌감,\n\n우울감, 수면의 변화, 피로감, 식욕의 변화, 죄책감, 무가\n\n치감, 집중력 저하, 좌불안석 또는 쳐진 느낌, 자살사고의\n\n**[표 시작]**\n\n| 시하는 자, 임상시험심사위원회 및 식품의약품안전처장이 관계 | - 대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 | - 피험자가 임상시험 중 임상시험 참여 중단을 요구하거나 시험 | 구간을 제시한다.  95% 신뢰구간 상한이 비열등성 마진(2.5)을 | 9 가지 문항으로 구성되어 있다.  점수가 높을수록 우울 |\n| --- | --- | --- | --- | --- |\n**쌍방향 웹반응시스템(Interactive Web Response System,**\n| 법령에 따라 임상시험의 실시 절차와 자료의 품질을 검증하기 | - 정해진 기간에 환자에게 해가 되지 않는 내용으로 과학적 근거에 | - 이상 반응이 다른 가능성이 있는 원인과 같은 수준으로 임상 | * 순응도란 치료 기간 내 총 노출된 모듈 횟수를 통해 평가한다.  총 | 포함하지 않으면 통계적으로 비열등하다고 판단한다.  또한, |\n\n**[표 끝]**\n\nGAD-7은 범불안장애 환자를 선별 진단하기 위해 개발된\n\n선별평가도구로 불안 또는 걱정과 관련된 7가지 문항에\n\n대해 그 정도를 0점 (전혀 없었다)에서 3점(거의 매일\n\n괴로웠다. )까지 체크하여 불안 증상을 평가한다.  총점은\n\n0-21점 사이가 되며, 점수가 높을수록 불안 증상의 심각도가\n\nEQ-VAS는 일반적으로 사용되는 삶의 질 설문지 중 하나로,\n\n피험자의 전반적인 건강 상태를 0점에서 100점 척도로\n\n평가한다. ",
        "original_sentence": "총 | 포함하지 않으면 통계적으로 비열등하다고 판단한다. "
      }
    },
    {
      "chunk_id": "chunk_623",
      "text": "또한, |\n\n**[표 끝]**\n\nGAD-7은 범불안장애 환자를 선별 진단하기 위해 개발된\n\n선별평가도구로 불안 또는 걱정과 관련된 7가지 문항에\n\n대해 그 정도를 0점 (전혀 없었다)에서 3점(거의 매일\n\n괴로웠다.",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 622,
        "window_size": 3,
        "char_count": 120,
        "word_count": 27,
        "page_number": 15,
        "window_text": "95% 신뢰구간 상한이 비열등성 마진(2.5)을 | 9 가지 문항으로 구성되어 있다.  점수가 높을수록 우울 |\n| --- | --- | --- | --- | --- |\n**쌍방향 웹반응시스템(Interactive Web Response System,**\n| 법령에 따라 임상시험의 실시 절차와 자료의 품질을 검증하기 | - 정해진 기간에 환자에게 해가 되지 않는 내용으로 과학적 근거에 | - 이상 반응이 다른 가능성이 있는 원인과 같은 수준으로 임상 | * 순응도란 치료 기간 내 총 노출된 모듈 횟수를 통해 평가한다.  총 | 포함하지 않으면 통계적으로 비열등하다고 판단한다.  또한, |\n\n**[표 끝]**\n\nGAD-7은 범불안장애 환자를 선별 진단하기 위해 개발된\n\n선별평가도구로 불안 또는 걱정과 관련된 7가지 문항에\n\n대해 그 정도를 0점 (전혀 없었다)에서 3점(거의 매일\n\n괴로웠다. )까지 체크하여 불안 증상을 평가한다.  총점은\n\n0-21점 사이가 되며, 점수가 높을수록 불안 증상의 심각도가\n\nEQ-VAS는 일반적으로 사용되는 삶의 질 설문지 중 하나로,\n\n피험자의 전반적인 건강 상태를 0점에서 100점 척도로\n\n평가한다.  점수가 높을수록 전반적인 건강 상태가 좋다는\n\nCGI-S 는 피험자의 전반적인 질병 상태의 심각도를 평가\n\n하는 설문지로, 점수가 높을수록 질병 심각도가 높다는\n\n표 13. ",
        "original_sentence": "또한, |\n\n**[표 끝]**\n\nGAD-7은 범불안장애 환자를 선별 진단하기 위해 개발된\n\n선별평가도구로 불안 또는 걱정과 관련된 7가지 문항에\n\n대해 그 정도를 0점 (전혀 없었다)에서 3점(거의 매일\n\n괴로웠다."
      }
    },
    {
      "chunk_id": "chunk_624",
      "text": ")까지 체크하여 불안 증상을 평가한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 623,
        "window_size": 3,
        "char_count": 22,
        "word_count": 5,
        "page_number": 15,
        "window_text": "점수가 높을수록 우울 |\n| --- | --- | --- | --- | --- |\n**쌍방향 웹반응시스템(Interactive Web Response System,**\n| 법령에 따라 임상시험의 실시 절차와 자료의 품질을 검증하기 | - 정해진 기간에 환자에게 해가 되지 않는 내용으로 과학적 근거에 | - 이상 반응이 다른 가능성이 있는 원인과 같은 수준으로 임상 | * 순응도란 치료 기간 내 총 노출된 모듈 횟수를 통해 평가한다.  총 | 포함하지 않으면 통계적으로 비열등하다고 판단한다.  또한, |\n\n**[표 끝]**\n\nGAD-7은 범불안장애 환자를 선별 진단하기 위해 개발된\n\n선별평가도구로 불안 또는 걱정과 관련된 7가지 문항에\n\n대해 그 정도를 0점 (전혀 없었다)에서 3점(거의 매일\n\n괴로웠다. )까지 체크하여 불안 증상을 평가한다.  총점은\n\n0-21점 사이가 되며, 점수가 높을수록 불안 증상의 심각도가\n\nEQ-VAS는 일반적으로 사용되는 삶의 질 설문지 중 하나로,\n\n피험자의 전반적인 건강 상태를 0점에서 100점 척도로\n\n평가한다.  점수가 높을수록 전반적인 건강 상태가 좋다는\n\nCGI-S 는 피험자의 전반적인 질병 상태의 심각도를 평가\n\n하는 설문지로, 점수가 높을수록 질병 심각도가 높다는\n\n표 13.  섭식장애 이차 유효성 평가 지표 측정도구 예시\n\n- - 63 -\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록\n\n- - 각 관찰 항목에 대한 평가 도구 및 평가 방법에 대한 자세한\n측정도구\n\n설명\n\n4주, 8주 시점의 Clinical\n\n- (1) Clinical Global Impression of Improvement (CGI-I)\nCGI-I 는 피험자의 전반적인 건강상태의 개선 정도를 평가\n\n하는 설문지로, 시험자는 피험자의 건강상태의 개선 또는\n\n악화 정도를 7점 척도로 평가하며, 점수가 낮을수록 개선도가\n\n앱을 통해 수집된 자기 모니터링 식사일기를 통하여 피험자의\n\n베이스라인 (사용 전) 대비 임상시험용 의료기기 사용 후 8 주\n\n- - 64 -\n- 나. ",
        "original_sentence": ")까지 체크하여 불안 증상을 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_625",
      "text": "총점은\n\n0-21점 사이가 되며, 점수가 높을수록 불안 증상의 심각도가\n\nEQ-VAS는 일반적으로 사용되는 삶의 질 설문지 중 하나로,\n\n피험자의 전반적인 건강 상태를 0점에서 100점 척도로\n\n평가한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 624,
        "window_size": 3,
        "char_count": 115,
        "word_count": 25,
        "page_number": 9,
        "window_text": "총 | 포함하지 않으면 통계적으로 비열등하다고 판단한다.  또한, |\n\n**[표 끝]**\n\nGAD-7은 범불안장애 환자를 선별 진단하기 위해 개발된\n\n선별평가도구로 불안 또는 걱정과 관련된 7가지 문항에\n\n대해 그 정도를 0점 (전혀 없었다)에서 3점(거의 매일\n\n괴로웠다. )까지 체크하여 불안 증상을 평가한다.  총점은\n\n0-21점 사이가 되며, 점수가 높을수록 불안 증상의 심각도가\n\nEQ-VAS는 일반적으로 사용되는 삶의 질 설문지 중 하나로,\n\n피험자의 전반적인 건강 상태를 0점에서 100점 척도로\n\n평가한다.  점수가 높을수록 전반적인 건강 상태가 좋다는\n\nCGI-S 는 피험자의 전반적인 질병 상태의 심각도를 평가\n\n하는 설문지로, 점수가 높을수록 질병 심각도가 높다는\n\n표 13.  섭식장애 이차 유효성 평가 지표 측정도구 예시\n\n- - 63 -\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록\n\n- - 각 관찰 항목에 대한 평가 도구 및 평가 방법에 대한 자세한\n측정도구\n\n설명\n\n4주, 8주 시점의 Clinical\n\n- (1) Clinical Global Impression of Improvement (CGI-I)\nCGI-I 는 피험자의 전반적인 건강상태의 개선 정도를 평가\n\n하는 설문지로, 시험자는 피험자의 건강상태의 개선 또는\n\n악화 정도를 7점 척도로 평가하며, 점수가 낮을수록 개선도가\n\n앱을 통해 수집된 자기 모니터링 식사일기를 통하여 피험자의\n\n베이스라인 (사용 전) 대비 임상시험용 의료기기 사용 후 8 주\n\n- - 64 -\n- 나.  설계 방법\n[예시]\n\n- - 연구자는 선정제외기준에 합격한 피험자의 순서대로 배정일에\n- - 본 연구와 독립된 통계학자가 SAS 통계 패키지를 가지고 층화\n순열화 블록 무작위배정법(stratified permuted block randomization)을\n\n- - 연구의 특성상 단일맹검을 지향하되, 필요하면 비맹검 임상시험을\n- - 단일맹검인 경우, 임상시험 도중 응급상황 발생 등으로 인하여\n피험자의 눈가림을 해제할 수 있다. ",
        "original_sentence": "총점은\n\n0-21점 사이가 되며, 점수가 높을수록 불안 증상의 심각도가\n\nEQ-VAS는 일반적으로 사용되는 삶의 질 설문지 중 하나로,\n\n피험자의 전반적인 건강 상태를 0점에서 100점 척도로\n\n평가한다. "
      }
    },
    {
      "chunk_id": "chunk_626",
      "text": "점수가 높을수록 전반적인 건강 상태가 좋다는\n\nCGI-S 는 피험자의 전반적인 질병 상태의 심각도를 평가\n\n하는 설문지로, 점수가 높을수록 질병 심각도가 높다는\n\n표 13. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 625,
        "window_size": 3,
        "char_count": 97,
        "word_count": 23,
        "page_number": 35,
        "window_text": "또한, |\n\n**[표 끝]**\n\nGAD-7은 범불안장애 환자를 선별 진단하기 위해 개발된\n\n선별평가도구로 불안 또는 걱정과 관련된 7가지 문항에\n\n대해 그 정도를 0점 (전혀 없었다)에서 3점(거의 매일\n\n괴로웠다. )까지 체크하여 불안 증상을 평가한다.  총점은\n\n0-21점 사이가 되며, 점수가 높을수록 불안 증상의 심각도가\n\nEQ-VAS는 일반적으로 사용되는 삶의 질 설문지 중 하나로,\n\n피험자의 전반적인 건강 상태를 0점에서 100점 척도로\n\n평가한다.  점수가 높을수록 전반적인 건강 상태가 좋다는\n\nCGI-S 는 피험자의 전반적인 질병 상태의 심각도를 평가\n\n하는 설문지로, 점수가 높을수록 질병 심각도가 높다는\n\n표 13.  섭식장애 이차 유효성 평가 지표 측정도구 예시\n\n- - 63 -\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록\n\n- - 각 관찰 항목에 대한 평가 도구 및 평가 방법에 대한 자세한\n측정도구\n\n설명\n\n4주, 8주 시점의 Clinical\n\n- (1) Clinical Global Impression of Improvement (CGI-I)\nCGI-I 는 피험자의 전반적인 건강상태의 개선 정도를 평가\n\n하는 설문지로, 시험자는 피험자의 건강상태의 개선 또는\n\n악화 정도를 7점 척도로 평가하며, 점수가 낮을수록 개선도가\n\n앱을 통해 수집된 자기 모니터링 식사일기를 통하여 피험자의\n\n베이스라인 (사용 전) 대비 임상시험용 의료기기 사용 후 8 주\n\n- - 64 -\n- 나.  설계 방법\n[예시]\n\n- - 연구자는 선정제외기준에 합격한 피험자의 순서대로 배정일에\n- - 본 연구와 독립된 통계학자가 SAS 통계 패키지를 가지고 층화\n순열화 블록 무작위배정법(stratified permuted block randomization)을\n\n- - 연구의 특성상 단일맹검을 지향하되, 필요하면 비맹검 임상시험을\n- - 단일맹검인 경우, 임상시험 도중 응급상황 발생 등으로 인하여\n피험자의 눈가림을 해제할 수 있다.  이 경우, 사유와 해제일,\n\n- - 65 -\n<!-- PAGE_72 -->\n##### 11. ",
        "original_sentence": "점수가 높을수록 전반적인 건강 상태가 좋다는\n\nCGI-S 는 피험자의 전반적인 질병 상태의 심각도를 평가\n\n하는 설문지로, 점수가 높을수록 질병 심각도가 높다는\n\n표 13. "
      }
    },
    {
      "chunk_id": "chunk_627",
      "text": "섭식장애 이차 유효성 평가 지표 측정도구 예시\n\n- - 63 -\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록\n\n- - 각 관찰 항목에 대한 평가 도구 및 평가 방법에 대한 자세한\n측정도구\n\n설명\n\n4주, 8주 시점의 Clinical\n\n- (1) Clinical Global Impression of Improvement (CGI-I)\nCGI-I 는 피험자의 전반적인 건강상태의 개선 정도를 평가\n\n하는 설문지로, 시험자는 피험자의 건강상태의 개선 또는\n\n악화 정도를 7점 척도로 평가하며, 점수가 낮을수록 개선도가\n\n앱을 통해 수집된 자기 모니터링 식사일기를 통하여 피험자의\n\n베이스라인 (사용 전) 대비 임상시험용 의료기기 사용 후 8 주\n\n- - 64 -\n- 나. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 626,
        "window_size": 3,
        "char_count": 451,
        "word_count": 110,
        "page_number": 7,
        "window_text": ")까지 체크하여 불안 증상을 평가한다.  총점은\n\n0-21점 사이가 되며, 점수가 높을수록 불안 증상의 심각도가\n\nEQ-VAS는 일반적으로 사용되는 삶의 질 설문지 중 하나로,\n\n피험자의 전반적인 건강 상태를 0점에서 100점 척도로\n\n평가한다.  점수가 높을수록 전반적인 건강 상태가 좋다는\n\nCGI-S 는 피험자의 전반적인 질병 상태의 심각도를 평가\n\n하는 설문지로, 점수가 높을수록 질병 심각도가 높다는\n\n표 13.  섭식장애 이차 유효성 평가 지표 측정도구 예시\n\n- - 63 -\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록\n\n- - 각 관찰 항목에 대한 평가 도구 및 평가 방법에 대한 자세한\n측정도구\n\n설명\n\n4주, 8주 시점의 Clinical\n\n- (1) Clinical Global Impression of Improvement (CGI-I)\nCGI-I 는 피험자의 전반적인 건강상태의 개선 정도를 평가\n\n하는 설문지로, 시험자는 피험자의 건강상태의 개선 또는\n\n악화 정도를 7점 척도로 평가하며, 점수가 낮을수록 개선도가\n\n앱을 통해 수집된 자기 모니터링 식사일기를 통하여 피험자의\n\n베이스라인 (사용 전) 대비 임상시험용 의료기기 사용 후 8 주\n\n- - 64 -\n- 나.  설계 방법\n[예시]\n\n- - 연구자는 선정제외기준에 합격한 피험자의 순서대로 배정일에\n- - 본 연구와 독립된 통계학자가 SAS 통계 패키지를 가지고 층화\n순열화 블록 무작위배정법(stratified permuted block randomization)을\n\n- - 연구의 특성상 단일맹검을 지향하되, 필요하면 비맹검 임상시험을\n- - 단일맹검인 경우, 임상시험 도중 응급상황 발생 등으로 인하여\n피험자의 눈가림을 해제할 수 있다.  이 경우, 사유와 해제일,\n\n- - 65 -\n<!-- PAGE_72 -->\n##### 11.  관찰항목·임상검사항목 및 관찰검사방법\n\n[예시]\n\n- 가. ",
        "original_sentence": "섭식장애 이차 유효성 평가 지표 측정도구 예시\n\n- - 63 -\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록\n\n- - 각 관찰 항목에 대한 평가 도구 및 평가 방법에 대한 자세한\n측정도구\n\n설명\n\n4주, 8주 시점의 Clinical\n\n- (1) Clinical Global Impression of Improvement (CGI-I)\nCGI-I 는 피험자의 전반적인 건강상태의 개선 정도를 평가\n\n하는 설문지로, 시험자는 피험자의 건강상태의 개선 또는\n\n악화 정도를 7점 척도로 평가하며, 점수가 낮을수록 개선도가\n\n앱을 통해 수집된 자기 모니터링 식사일기를 통하여 피험자의\n\n베이스라인 (사용 전) 대비 임상시험용 의료기기 사용 후 8 주\n\n- - 64 -\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_628",
      "text": "설계 방법\n[예시]\n\n- - 연구자는 선정제외기준에 합격한 피험자의 순서대로 배정일에\n- - 본 연구와 독립된 통계학자가 SAS 통계 패키지를 가지고 층화\n순열화 블록 무작위배정법(stratified permuted block randomization)을\n\n- - 연구의 특성상 단일맹검을 지향하되, 필요하면 비맹검 임상시험을\n- - 단일맹검인 경우, 임상시험 도중 응급상황 발생 등으로 인하여\n피험자의 눈가림을 해제할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 627,
        "window_size": 3,
        "char_count": 241,
        "word_count": 52,
        "page_number": 31,
        "window_text": "총점은\n\n0-21점 사이가 되며, 점수가 높을수록 불안 증상의 심각도가\n\nEQ-VAS는 일반적으로 사용되는 삶의 질 설문지 중 하나로,\n\n피험자의 전반적인 건강 상태를 0점에서 100점 척도로\n\n평가한다.  점수가 높을수록 전반적인 건강 상태가 좋다는\n\nCGI-S 는 피험자의 전반적인 질병 상태의 심각도를 평가\n\n하는 설문지로, 점수가 높을수록 질병 심각도가 높다는\n\n표 13.  섭식장애 이차 유효성 평가 지표 측정도구 예시\n\n- - 63 -\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록\n\n- - 각 관찰 항목에 대한 평가 도구 및 평가 방법에 대한 자세한\n측정도구\n\n설명\n\n4주, 8주 시점의 Clinical\n\n- (1) Clinical Global Impression of Improvement (CGI-I)\nCGI-I 는 피험자의 전반적인 건강상태의 개선 정도를 평가\n\n하는 설문지로, 시험자는 피험자의 건강상태의 개선 또는\n\n악화 정도를 7점 척도로 평가하며, 점수가 낮을수록 개선도가\n\n앱을 통해 수집된 자기 모니터링 식사일기를 통하여 피험자의\n\n베이스라인 (사용 전) 대비 임상시험용 의료기기 사용 후 8 주\n\n- - 64 -\n- 나.  설계 방법\n[예시]\n\n- - 연구자는 선정제외기준에 합격한 피험자의 순서대로 배정일에\n- - 본 연구와 독립된 통계학자가 SAS 통계 패키지를 가지고 층화\n순열화 블록 무작위배정법(stratified permuted block randomization)을\n\n- - 연구의 특성상 단일맹검을 지향하되, 필요하면 비맹검 임상시험을\n- - 단일맹검인 경우, 임상시험 도중 응급상황 발생 등으로 인하여\n피험자의 눈가림을 해제할 수 있다.  이 경우, 사유와 해제일,\n\n- - 65 -\n<!-- PAGE_72 -->\n##### 11.  관찰항목·임상검사항목 및 관찰검사방법\n\n[예시]\n\n- 가.  임상시험 일정표\n- - 66 -\n- 나. ",
        "original_sentence": "설계 방법\n[예시]\n\n- - 연구자는 선정제외기준에 합격한 피험자의 순서대로 배정일에\n- - 본 연구와 독립된 통계학자가 SAS 통계 패키지를 가지고 층화\n순열화 블록 무작위배정법(stratified permuted block randomization)을\n\n- - 연구의 특성상 단일맹검을 지향하되, 필요하면 비맹검 임상시험을\n- - 단일맹검인 경우, 임상시험 도중 응급상황 발생 등으로 인하여\n피험자의 눈가림을 해제할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_629",
      "text": "이 경우, 사유와 해제일,\n\n- - 65 -\n<!-- PAGE_72 -->\n##### 11. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 628,
        "window_size": 3,
        "char_count": 52,
        "word_count": 13,
        "page_number": 72,
        "window_text": "점수가 높을수록 전반적인 건강 상태가 좋다는\n\nCGI-S 는 피험자의 전반적인 질병 상태의 심각도를 평가\n\n하는 설문지로, 점수가 높을수록 질병 심각도가 높다는\n\n표 13.  섭식장애 이차 유효성 평가 지표 측정도구 예시\n\n- - 63 -\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록\n\n- - 각 관찰 항목에 대한 평가 도구 및 평가 방법에 대한 자세한\n측정도구\n\n설명\n\n4주, 8주 시점의 Clinical\n\n- (1) Clinical Global Impression of Improvement (CGI-I)\nCGI-I 는 피험자의 전반적인 건강상태의 개선 정도를 평가\n\n하는 설문지로, 시험자는 피험자의 건강상태의 개선 또는\n\n악화 정도를 7점 척도로 평가하며, 점수가 낮을수록 개선도가\n\n앱을 통해 수집된 자기 모니터링 식사일기를 통하여 피험자의\n\n베이스라인 (사용 전) 대비 임상시험용 의료기기 사용 후 8 주\n\n- - 64 -\n- 나.  설계 방법\n[예시]\n\n- - 연구자는 선정제외기준에 합격한 피험자의 순서대로 배정일에\n- - 본 연구와 독립된 통계학자가 SAS 통계 패키지를 가지고 층화\n순열화 블록 무작위배정법(stratified permuted block randomization)을\n\n- - 연구의 특성상 단일맹검을 지향하되, 필요하면 비맹검 임상시험을\n- - 단일맹검인 경우, 임상시험 도중 응급상황 발생 등으로 인하여\n피험자의 눈가림을 해제할 수 있다.  이 경우, 사유와 해제일,\n\n- - 65 -\n<!-- PAGE_72 -->\n##### 11.  관찰항목·임상검사항목 및 관찰검사방법\n\n[예시]\n\n- 가.  임상시험 일정표\n- - 66 -\n- 나.  임상시험 절차\n[예시]\n\n- - 임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여\n대상자 또는 법정대리인에게 상세히 설명한다. ",
        "original_sentence": "이 경우, 사유와 해제일,\n\n- - 65 -\n<!-- PAGE_72 -->\n##### 11. "
      }
    },
    {
      "chunk_id": "chunk_630",
      "text": "관찰항목·임상검사항목 및 관찰검사방법\n\n[예시]\n\n- 가. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 629,
        "window_size": 3,
        "char_count": 33,
        "word_count": 6,
        "page_number": 3,
        "window_text": "섭식장애 이차 유효성 평가 지표 측정도구 예시\n\n- - 63 -\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록\n\n- - 각 관찰 항목에 대한 평가 도구 및 평가 방법에 대한 자세한\n측정도구\n\n설명\n\n4주, 8주 시점의 Clinical\n\n- (1) Clinical Global Impression of Improvement (CGI-I)\nCGI-I 는 피험자의 전반적인 건강상태의 개선 정도를 평가\n\n하는 설문지로, 시험자는 피험자의 건강상태의 개선 또는\n\n악화 정도를 7점 척도로 평가하며, 점수가 낮을수록 개선도가\n\n앱을 통해 수집된 자기 모니터링 식사일기를 통하여 피험자의\n\n베이스라인 (사용 전) 대비 임상시험용 의료기기 사용 후 8 주\n\n- - 64 -\n- 나.  설계 방법\n[예시]\n\n- - 연구자는 선정제외기준에 합격한 피험자의 순서대로 배정일에\n- - 본 연구와 독립된 통계학자가 SAS 통계 패키지를 가지고 층화\n순열화 블록 무작위배정법(stratified permuted block randomization)을\n\n- - 연구의 특성상 단일맹검을 지향하되, 필요하면 비맹검 임상시험을\n- - 단일맹검인 경우, 임상시험 도중 응급상황 발생 등으로 인하여\n피험자의 눈가림을 해제할 수 있다.  이 경우, 사유와 해제일,\n\n- - 65 -\n<!-- PAGE_72 -->\n##### 11.  관찰항목·임상검사항목 및 관찰검사방법\n\n[예시]\n\n- 가.  임상시험 일정표\n- - 66 -\n- 나.  임상시험 절차\n[예시]\n\n- - 임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여\n대상자 또는 법정대리인에게 상세히 설명한다.  서명 일자를\n\n정확히 기재하여야 하며, 작성된 동의서 원본은 시험자가 보관\n\n하고 사본은 시험대상자 또는 법정대리인에게 내준다. ",
        "original_sentence": "관찰항목·임상검사항목 및 관찰검사방법\n\n[예시]\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_631",
      "text": "임상시험 일정표\n- - 66 -\n- 나. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 630,
        "window_size": 3,
        "char_count": 23,
        "word_count": 8,
        "page_number": 27,
        "window_text": "설계 방법\n[예시]\n\n- - 연구자는 선정제외기준에 합격한 피험자의 순서대로 배정일에\n- - 본 연구와 독립된 통계학자가 SAS 통계 패키지를 가지고 층화\n순열화 블록 무작위배정법(stratified permuted block randomization)을\n\n- - 연구의 특성상 단일맹검을 지향하되, 필요하면 비맹검 임상시험을\n- - 단일맹검인 경우, 임상시험 도중 응급상황 발생 등으로 인하여\n피험자의 눈가림을 해제할 수 있다.  이 경우, 사유와 해제일,\n\n- - 65 -\n<!-- PAGE_72 -->\n##### 11.  관찰항목·임상검사항목 및 관찰검사방법\n\n[예시]\n\n- 가.  임상시험 일정표\n- - 66 -\n- 나.  임상시험 절차\n[예시]\n\n- - 임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여\n대상자 또는 법정대리인에게 상세히 설명한다.  서명 일자를\n\n정확히 기재하여야 하며, 작성된 동의서 원본은 시험자가 보관\n\n하고 사본은 시험대상자 또는 법정대리인에게 내준다.  대상자\n\n에게 동의를 받은 후 동의 취득 순서에 따라 스크리닝 번호를\n\n- - 인구학적 정보로 대상자 이니셜, 만 나이, 성별, 직업을 조사\n하며 기초 문진에 필요한 환자들의 의학적 특성에 대한 정보\n\n- - 피험자 선정을 위한 식사장애 검사(EDE-Q) 조사 정보를\n- - 필요하면 본 단계에서 수집한 정보를 Baseline 지표로 활용할\n- - 67 -\n마) 과거 병력 조사\n\n- - 병력 등을 문진과 과거 진료 기록을 통해 조사한다.\n",
        "original_sentence": "임상시험 일정표\n- - 66 -\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_632",
      "text": "임상시험 절차\n[예시]\n\n- - 임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여\n대상자 또는 법정대리인에게 상세히 설명한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 631,
        "window_size": 3,
        "char_count": 77,
        "word_count": 18,
        "page_number": 7,
        "window_text": "이 경우, 사유와 해제일,\n\n- - 65 -\n<!-- PAGE_72 -->\n##### 11.  관찰항목·임상검사항목 및 관찰검사방법\n\n[예시]\n\n- 가.  임상시험 일정표\n- - 66 -\n- 나.  임상시험 절차\n[예시]\n\n- - 임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여\n대상자 또는 법정대리인에게 상세히 설명한다.  서명 일자를\n\n정확히 기재하여야 하며, 작성된 동의서 원본은 시험자가 보관\n\n하고 사본은 시험대상자 또는 법정대리인에게 내준다.  대상자\n\n에게 동의를 받은 후 동의 취득 순서에 따라 스크리닝 번호를\n\n- - 인구학적 정보로 대상자 이니셜, 만 나이, 성별, 직업을 조사\n하며 기초 문진에 필요한 환자들의 의학적 특성에 대한 정보\n\n- - 피험자 선정을 위한 식사장애 검사(EDE-Q) 조사 정보를\n- - 필요하면 본 단계에서 수집한 정보를 Baseline 지표로 활용할\n- - 67 -\n마) 과거 병력 조사\n\n- - 병력 등을 문진과 과거 진료 기록을 통해 조사한다.\n - - 병력조사에 포함되어야 하는 내용은 다음과 같다. ",
        "original_sentence": "임상시험 절차\n[예시]\n\n- - 임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여\n대상자 또는 법정대리인에게 상세히 설명한다. "
      }
    },
    {
      "chunk_id": "chunk_633",
      "text": "서명 일자를\n\n정확히 기재하여야 하며, 작성된 동의서 원본은 시험자가 보관\n\n하고 사본은 시험대상자 또는 법정대리인에게 내준다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 632,
        "window_size": 3,
        "char_count": 72,
        "word_count": 16,
        "page_number": 34,
        "window_text": "관찰항목·임상검사항목 및 관찰검사방법\n\n[예시]\n\n- 가.  임상시험 일정표\n- - 66 -\n- 나.  임상시험 절차\n[예시]\n\n- - 임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여\n대상자 또는 법정대리인에게 상세히 설명한다.  서명 일자를\n\n정확히 기재하여야 하며, 작성된 동의서 원본은 시험자가 보관\n\n하고 사본은 시험대상자 또는 법정대리인에게 내준다.  대상자\n\n에게 동의를 받은 후 동의 취득 순서에 따라 스크리닝 번호를\n\n- - 인구학적 정보로 대상자 이니셜, 만 나이, 성별, 직업을 조사\n하며 기초 문진에 필요한 환자들의 의학적 특성에 대한 정보\n\n- - 피험자 선정을 위한 식사장애 검사(EDE-Q) 조사 정보를\n- - 필요하면 본 단계에서 수집한 정보를 Baseline 지표로 활용할\n- - 67 -\n마) 과거 병력 조사\n\n- - 병력 등을 문진과 과거 진료 기록을 통해 조사한다.\n - - 병력조사에 포함되어야 하는 내용은 다음과 같다.  치매, 인지\n기능 장애, 정신증, 양극성 장애 및 현재 주요 우울 삽화\n\n(current major depressive episode) 등 스크리닝 확인해야 할\n\n질병군 등의 과거력 및 현 병력, 발생 시기, 치료와 진행 여부\n\n- - 동의서 취득일 기준으로 최근 5년 이내 과거 및 현재 병력을\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 일차 유효성 평가지표, 이차 임상 변수를 평가하기 위해 식사장애\n검사(EDE-Q)를 작성하도록 하여 지참하게 하거나, 애플리케이션\n\n- - 필요에 따라 방문 1(스크리닝 단계)에서 측정한 식사장애 검사\n- - 68 -\n(EDE-Q)를 Baseline 지표로 활용할 수 있다.\n\n",
        "original_sentence": "서명 일자를\n\n정확히 기재하여야 하며, 작성된 동의서 원본은 시험자가 보관\n\n하고 사본은 시험대상자 또는 법정대리인에게 내준다. "
      }
    },
    {
      "chunk_id": "chunk_634",
      "text": "대상자\n\n에게 동의를 받은 후 동의 취득 순서에 따라 스크리닝 번호를\n\n- - 인구학적 정보로 대상자 이니셜, 만 나이, 성별, 직업을 조사\n하며 기초 문진에 필요한 환자들의 의학적 특성에 대한 정보\n\n- - 피험자 선정을 위한 식사장애 검사(EDE-Q) 조사 정보를\n- - 필요하면 본 단계에서 수집한 정보를 Baseline 지표로 활용할\n- - 67 -\n마) 과거 병력 조사\n\n- - 병력 등을 문진과 과거 진료 기록을 통해 조사한다.\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 633,
        "window_size": 3,
        "char_count": 246,
        "word_count": 68,
        "page_number": 26,
        "window_text": "임상시험 일정표\n- - 66 -\n- 나.  임상시험 절차\n[예시]\n\n- - 임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여\n대상자 또는 법정대리인에게 상세히 설명한다.  서명 일자를\n\n정확히 기재하여야 하며, 작성된 동의서 원본은 시험자가 보관\n\n하고 사본은 시험대상자 또는 법정대리인에게 내준다.  대상자\n\n에게 동의를 받은 후 동의 취득 순서에 따라 스크리닝 번호를\n\n- - 인구학적 정보로 대상자 이니셜, 만 나이, 성별, 직업을 조사\n하며 기초 문진에 필요한 환자들의 의학적 특성에 대한 정보\n\n- - 피험자 선정을 위한 식사장애 검사(EDE-Q) 조사 정보를\n- - 필요하면 본 단계에서 수집한 정보를 Baseline 지표로 활용할\n- - 67 -\n마) 과거 병력 조사\n\n- - 병력 등을 문진과 과거 진료 기록을 통해 조사한다.\n - - 병력조사에 포함되어야 하는 내용은 다음과 같다.  치매, 인지\n기능 장애, 정신증, 양극성 장애 및 현재 주요 우울 삽화\n\n(current major depressive episode) 등 스크리닝 확인해야 할\n\n질병군 등의 과거력 및 현 병력, 발생 시기, 치료와 진행 여부\n\n- - 동의서 취득일 기준으로 최근 5년 이내 과거 및 현재 병력을\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 일차 유효성 평가지표, 이차 임상 변수를 평가하기 위해 식사장애\n검사(EDE-Q)를 작성하도록 하여 지참하게 하거나, 애플리케이션\n\n- - 필요에 따라 방문 1(스크리닝 단계)에서 측정한 식사장애 검사\n- - 68 -\n(EDE-Q)를 Baseline 지표로 활용할 수 있다.\n\n 나) 무작위배정\n\n- - 회원가입 및 초기 증상평가를 시행한다(기본 입력 정보: 성별,\n나이, 섭식장애 증상의 정도, 섭식장애 증상으로 인한 행동의\n\n- - 정해진 기간에 상술 된 방식으로 디지털치료기기 콘텐츠를\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 진찰을 통해 관찰하고, 임상시험용\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 69 -\n기간, 목적을 확인한다.\n\n",
        "original_sentence": "대상자\n\n에게 동의를 받은 후 동의 취득 순서에 따라 스크리닝 번호를\n\n- - 인구학적 정보로 대상자 이니셜, 만 나이, 성별, 직업을 조사\n하며 기초 문진에 필요한 환자들의 의학적 특성에 대한 정보\n\n- - 피험자 선정을 위한 식사장애 검사(EDE-Q) 조사 정보를\n- - 필요하면 본 단계에서 수집한 정보를 Baseline 지표로 활용할\n- - 67 -\n마) 과거 병력 조사\n\n- - 병력 등을 문진과 과거 진료 기록을 통해 조사한다.\n"
      }
    },
    {
      "chunk_id": "chunk_635",
      "text": "- - 병력조사에 포함되어야 하는 내용은 다음과 같다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 634,
        "window_size": 3,
        "char_count": 31,
        "word_count": 8,
        "page_number": 15,
        "window_text": "임상시험 절차\n[예시]\n\n- - 임상시험에 들어가기 전, 본 임상시험의 목적과 내용에 대하여\n대상자 또는 법정대리인에게 상세히 설명한다.  서명 일자를\n\n정확히 기재하여야 하며, 작성된 동의서 원본은 시험자가 보관\n\n하고 사본은 시험대상자 또는 법정대리인에게 내준다.  대상자\n\n에게 동의를 받은 후 동의 취득 순서에 따라 스크리닝 번호를\n\n- - 인구학적 정보로 대상자 이니셜, 만 나이, 성별, 직업을 조사\n하며 기초 문진에 필요한 환자들의 의학적 특성에 대한 정보\n\n- - 피험자 선정을 위한 식사장애 검사(EDE-Q) 조사 정보를\n- - 필요하면 본 단계에서 수집한 정보를 Baseline 지표로 활용할\n- - 67 -\n마) 과거 병력 조사\n\n- - 병력 등을 문진과 과거 진료 기록을 통해 조사한다.\n - - 병력조사에 포함되어야 하는 내용은 다음과 같다.  치매, 인지\n기능 장애, 정신증, 양극성 장애 및 현재 주요 우울 삽화\n\n(current major depressive episode) 등 스크리닝 확인해야 할\n\n질병군 등의 과거력 및 현 병력, 발생 시기, 치료와 진행 여부\n\n- - 동의서 취득일 기준으로 최근 5년 이내 과거 및 현재 병력을\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 일차 유효성 평가지표, 이차 임상 변수를 평가하기 위해 식사장애\n검사(EDE-Q)를 작성하도록 하여 지참하게 하거나, 애플리케이션\n\n- - 필요에 따라 방문 1(스크리닝 단계)에서 측정한 식사장애 검사\n- - 68 -\n(EDE-Q)를 Baseline 지표로 활용할 수 있다.\n\n 나) 무작위배정\n\n- - 회원가입 및 초기 증상평가를 시행한다(기본 입력 정보: 성별,\n나이, 섭식장애 증상의 정도, 섭식장애 증상으로 인한 행동의\n\n- - 정해진 기간에 상술 된 방식으로 디지털치료기기 콘텐츠를\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 진찰을 통해 관찰하고, 임상시험용\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 69 -\n기간, 목적을 확인한다.\n\n 사) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 치료 후 평가 및 일차 유효성 평가지표, 이차 유효성 평가지표의\n변화를 검증하기 위해 섭식장애 평가 항목 및 해당하는 자가\n\n보고 척도를 작성하도록 하여 지참하게 하거나, 애플리케이션을\n\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 70 -\n기간, 목적을 확인한다.\n\n",
        "original_sentence": "- - 병력조사에 포함되어야 하는 내용은 다음과 같다. "
      }
    },
    {
      "chunk_id": "chunk_636",
      "text": "치매, 인지\n기능 장애, 정신증, 양극성 장애 및 현재 주요 우울 삽화\n\n(current major depressive episode) 등 스크리닝 확인해야 할\n\n질병군 등의 과거력 및 현 병력, 발생 시기, 치료와 진행 여부\n\n- - 동의서 취득일 기준으로 최근 5년 이내 과거 및 현재 병력을\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 일차 유효성 평가지표, 이차 임상 변수를 평가하기 위해 식사장애\n검사(EDE-Q)를 작성하도록 하여 지참하게 하거나, 애플리케이션\n\n- - 필요에 따라 방문 1(스크리닝 단계)에서 측정한 식사장애 검사\n- - 68 -\n(EDE-Q)를 Baseline 지표로 활용할 수 있다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 635,
        "window_size": 3,
        "char_count": 399,
        "word_count": 99,
        "page_number": 30,
        "window_text": "서명 일자를\n\n정확히 기재하여야 하며, 작성된 동의서 원본은 시험자가 보관\n\n하고 사본은 시험대상자 또는 법정대리인에게 내준다.  대상자\n\n에게 동의를 받은 후 동의 취득 순서에 따라 스크리닝 번호를\n\n- - 인구학적 정보로 대상자 이니셜, 만 나이, 성별, 직업을 조사\n하며 기초 문진에 필요한 환자들의 의학적 특성에 대한 정보\n\n- - 피험자 선정을 위한 식사장애 검사(EDE-Q) 조사 정보를\n- - 필요하면 본 단계에서 수집한 정보를 Baseline 지표로 활용할\n- - 67 -\n마) 과거 병력 조사\n\n- - 병력 등을 문진과 과거 진료 기록을 통해 조사한다.\n - - 병력조사에 포함되어야 하는 내용은 다음과 같다.  치매, 인지\n기능 장애, 정신증, 양극성 장애 및 현재 주요 우울 삽화\n\n(current major depressive episode) 등 스크리닝 확인해야 할\n\n질병군 등의 과거력 및 현 병력, 발생 시기, 치료와 진행 여부\n\n- - 동의서 취득일 기준으로 최근 5년 이내 과거 및 현재 병력을\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 일차 유효성 평가지표, 이차 임상 변수를 평가하기 위해 식사장애\n검사(EDE-Q)를 작성하도록 하여 지참하게 하거나, 애플리케이션\n\n- - 필요에 따라 방문 1(스크리닝 단계)에서 측정한 식사장애 검사\n- - 68 -\n(EDE-Q)를 Baseline 지표로 활용할 수 있다.\n\n 나) 무작위배정\n\n- - 회원가입 및 초기 증상평가를 시행한다(기본 입력 정보: 성별,\n나이, 섭식장애 증상의 정도, 섭식장애 증상으로 인한 행동의\n\n- - 정해진 기간에 상술 된 방식으로 디지털치료기기 콘텐츠를\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 진찰을 통해 관찰하고, 임상시험용\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 69 -\n기간, 목적을 확인한다.\n\n 사) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 치료 후 평가 및 일차 유효성 평가지표, 이차 유효성 평가지표의\n변화를 검증하기 위해 섭식장애 평가 항목 및 해당하는 자가\n\n보고 척도를 작성하도록 하여 지참하게 하거나, 애플리케이션을\n\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 70 -\n기간, 목적을 확인한다.\n\n 라) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 장기 효과 확인을 위한 일차 유효성 평가지표, 이차 유효성\n평가지표의 변화를 검증하기 위해 섭식장애 평가 항목 및\n\n해당하는 자가 보고 척도를 작성하도록 하여 지참하게 하거나,\n\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 71 -\n기간, 목적을 확인한다.\n\n",
        "original_sentence": "치매, 인지\n기능 장애, 정신증, 양극성 장애 및 현재 주요 우울 삽화\n\n(current major depressive episode) 등 스크리닝 확인해야 할\n\n질병군 등의 과거력 및 현 병력, 발생 시기, 치료와 진행 여부\n\n- - 동의서 취득일 기준으로 최근 5년 이내 과거 및 현재 병력을\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 일차 유효성 평가지표, 이차 임상 변수를 평가하기 위해 식사장애\n검사(EDE-Q)를 작성하도록 하여 지참하게 하거나, 애플리케이션\n\n- - 필요에 따라 방문 1(스크리닝 단계)에서 측정한 식사장애 검사\n- - 68 -\n(EDE-Q)를 Baseline 지표로 활용할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_637",
      "text": "나) 무작위배정\n\n- - 회원가입 및 초기 증상평가를 시행한다(기본 입력 정보: 성별,\n나이, 섭식장애 증상의 정도, 섭식장애 증상으로 인한 행동의\n\n- - 정해진 기간에 상술 된 방식으로 디지털치료기기 콘텐츠를\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 진찰을 통해 관찰하고, 임상시험용\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 69 -\n기간, 목적을 확인한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 636,
        "window_size": 3,
        "char_count": 333,
        "word_count": 83,
        "page_number": 30,
        "window_text": "대상자\n\n에게 동의를 받은 후 동의 취득 순서에 따라 스크리닝 번호를\n\n- - 인구학적 정보로 대상자 이니셜, 만 나이, 성별, 직업을 조사\n하며 기초 문진에 필요한 환자들의 의학적 특성에 대한 정보\n\n- - 피험자 선정을 위한 식사장애 검사(EDE-Q) 조사 정보를\n- - 필요하면 본 단계에서 수집한 정보를 Baseline 지표로 활용할\n- - 67 -\n마) 과거 병력 조사\n\n- - 병력 등을 문진과 과거 진료 기록을 통해 조사한다.\n - - 병력조사에 포함되어야 하는 내용은 다음과 같다.  치매, 인지\n기능 장애, 정신증, 양극성 장애 및 현재 주요 우울 삽화\n\n(current major depressive episode) 등 스크리닝 확인해야 할\n\n질병군 등의 과거력 및 현 병력, 발생 시기, 치료와 진행 여부\n\n- - 동의서 취득일 기준으로 최근 5년 이내 과거 및 현재 병력을\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 일차 유효성 평가지표, 이차 임상 변수를 평가하기 위해 식사장애\n검사(EDE-Q)를 작성하도록 하여 지참하게 하거나, 애플리케이션\n\n- - 필요에 따라 방문 1(스크리닝 단계)에서 측정한 식사장애 검사\n- - 68 -\n(EDE-Q)를 Baseline 지표로 활용할 수 있다.\n\n 나) 무작위배정\n\n- - 회원가입 및 초기 증상평가를 시행한다(기본 입력 정보: 성별,\n나이, 섭식장애 증상의 정도, 섭식장애 증상으로 인한 행동의\n\n- - 정해진 기간에 상술 된 방식으로 디지털치료기기 콘텐츠를\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 진찰을 통해 관찰하고, 임상시험용\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 69 -\n기간, 목적을 확인한다.\n\n 사) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 치료 후 평가 및 일차 유효성 평가지표, 이차 유효성 평가지표의\n변화를 검증하기 위해 섭식장애 평가 항목 및 해당하는 자가\n\n보고 척도를 작성하도록 하여 지참하게 하거나, 애플리케이션을\n\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 70 -\n기간, 목적을 확인한다.\n\n 라) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 장기 효과 확인을 위한 일차 유효성 평가지표, 이차 유효성\n평가지표의 변화를 검증하기 위해 섭식장애 평가 항목 및\n\n해당하는 자가 보고 척도를 작성하도록 하여 지참하게 하거나,\n\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 71 -\n기간, 목적을 확인한다.\n\n 라) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 72 -\n<!-- PAGE_79 -->\n##### 12. ",
        "original_sentence": "나) 무작위배정\n\n- - 회원가입 및 초기 증상평가를 시행한다(기본 입력 정보: 성별,\n나이, 섭식장애 증상의 정도, 섭식장애 증상으로 인한 행동의\n\n- - 정해진 기간에 상술 된 방식으로 디지털치료기기 콘텐츠를\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 진찰을 통해 관찰하고, 임상시험용\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 69 -\n기간, 목적을 확인한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_638",
      "text": "사) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 치료 후 평가 및 일차 유효성 평가지표, 이차 유효성 평가지표의\n변화를 검증하기 위해 섭식장애 평가 항목 및 해당하는 자가\n\n보고 척도를 작성하도록 하여 지참하게 하거나, 애플리케이션을\n\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 70 -\n기간, 목적을 확인한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 637,
        "window_size": 3,
        "char_count": 407,
        "word_count": 103,
        "page_number": 30,
        "window_text": "- - 병력조사에 포함되어야 하는 내용은 다음과 같다.  치매, 인지\n기능 장애, 정신증, 양극성 장애 및 현재 주요 우울 삽화\n\n(current major depressive episode) 등 스크리닝 확인해야 할\n\n질병군 등의 과거력 및 현 병력, 발생 시기, 치료와 진행 여부\n\n- - 동의서 취득일 기준으로 최근 5년 이내 과거 및 현재 병력을\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 일차 유효성 평가지표, 이차 임상 변수를 평가하기 위해 식사장애\n검사(EDE-Q)를 작성하도록 하여 지참하게 하거나, 애플리케이션\n\n- - 필요에 따라 방문 1(스크리닝 단계)에서 측정한 식사장애 검사\n- - 68 -\n(EDE-Q)를 Baseline 지표로 활용할 수 있다.\n\n 나) 무작위배정\n\n- - 회원가입 및 초기 증상평가를 시행한다(기본 입력 정보: 성별,\n나이, 섭식장애 증상의 정도, 섭식장애 증상으로 인한 행동의\n\n- - 정해진 기간에 상술 된 방식으로 디지털치료기기 콘텐츠를\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 진찰을 통해 관찰하고, 임상시험용\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 69 -\n기간, 목적을 확인한다.\n\n 사) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 치료 후 평가 및 일차 유효성 평가지표, 이차 유효성 평가지표의\n변화를 검증하기 위해 섭식장애 평가 항목 및 해당하는 자가\n\n보고 척도를 작성하도록 하여 지참하게 하거나, 애플리케이션을\n\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 70 -\n기간, 목적을 확인한다.\n\n 라) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 장기 효과 확인을 위한 일차 유효성 평가지표, 이차 유효성\n평가지표의 변화를 검증하기 위해 섭식장애 평가 항목 및\n\n해당하는 자가 보고 척도를 작성하도록 하여 지참하게 하거나,\n\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 71 -\n기간, 목적을 확인한다.\n\n 라) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 72 -\n<!-- PAGE_79 -->\n##### 12.  예측되는 부작용 및 사용 시 주의사항\n\n[예시]\n\n- 가. ",
        "original_sentence": "사) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 치료 후 평가 및 일차 유효성 평가지표, 이차 유효성 평가지표의\n변화를 검증하기 위해 섭식장애 평가 항목 및 해당하는 자가\n\n보고 척도를 작성하도록 하여 지참하게 하거나, 애플리케이션을\n\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 70 -\n기간, 목적을 확인한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_639",
      "text": "라) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 장기 효과 확인을 위한 일차 유효성 평가지표, 이차 유효성\n평가지표의 변화를 검증하기 위해 섭식장애 평가 항목 및\n\n해당하는 자가 보고 척도를 작성하도록 하여 지참하게 하거나,\n\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 71 -\n기간, 목적을 확인한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 638,
        "window_size": 3,
        "char_count": 402,
        "word_count": 102,
        "page_number": 30,
        "window_text": "치매, 인지\n기능 장애, 정신증, 양극성 장애 및 현재 주요 우울 삽화\n\n(current major depressive episode) 등 스크리닝 확인해야 할\n\n질병군 등의 과거력 및 현 병력, 발생 시기, 치료와 진행 여부\n\n- - 동의서 취득일 기준으로 최근 5년 이내 과거 및 현재 병력을\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 일차 유효성 평가지표, 이차 임상 변수를 평가하기 위해 식사장애\n검사(EDE-Q)를 작성하도록 하여 지참하게 하거나, 애플리케이션\n\n- - 필요에 따라 방문 1(스크리닝 단계)에서 측정한 식사장애 검사\n- - 68 -\n(EDE-Q)를 Baseline 지표로 활용할 수 있다.\n\n 나) 무작위배정\n\n- - 회원가입 및 초기 증상평가를 시행한다(기본 입력 정보: 성별,\n나이, 섭식장애 증상의 정도, 섭식장애 증상으로 인한 행동의\n\n- - 정해진 기간에 상술 된 방식으로 디지털치료기기 콘텐츠를\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 진찰을 통해 관찰하고, 임상시험용\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 69 -\n기간, 목적을 확인한다.\n\n 사) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 치료 후 평가 및 일차 유효성 평가지표, 이차 유효성 평가지표의\n변화를 검증하기 위해 섭식장애 평가 항목 및 해당하는 자가\n\n보고 척도를 작성하도록 하여 지참하게 하거나, 애플리케이션을\n\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 70 -\n기간, 목적을 확인한다.\n\n 라) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 장기 효과 확인을 위한 일차 유효성 평가지표, 이차 유효성\n평가지표의 변화를 검증하기 위해 섭식장애 평가 항목 및\n\n해당하는 자가 보고 척도를 작성하도록 하여 지참하게 하거나,\n\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 71 -\n기간, 목적을 확인한다.\n\n 라) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 72 -\n<!-- PAGE_79 -->\n##### 12.  예측되는 부작용 및 사용 시 주의사항\n\n[예시]\n\n- 가.  예측되는 부작용\n본 연구에서 적용하는 치료는 디지털 섭식장애 인지행동치료(CBT),\n\n혹은 이에 상응하는 과학적 근거를 가진 섭식장애의 비약물적인 치료이다.\n\n",
        "original_sentence": "라) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 장기 효과 확인을 위한 일차 유효성 평가지표, 이차 유효성\n평가지표의 변화를 검증하기 위해 섭식장애 평가 항목 및\n\n해당하는 자가 보고 척도를 작성하도록 하여 지참하게 하거나,\n\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 71 -\n기간, 목적을 확인한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_640",
      "text": "라) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 72 -\n<!-- PAGE_79 -->\n##### 12. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 639,
        "window_size": 3,
        "char_count": 85,
        "word_count": 22,
        "page_number": 79,
        "window_text": "나) 무작위배정\n\n- - 회원가입 및 초기 증상평가를 시행한다(기본 입력 정보: 성별,\n나이, 섭식장애 증상의 정도, 섭식장애 증상으로 인한 행동의\n\n- - 정해진 기간에 상술 된 방식으로 디지털치료기기 콘텐츠를\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 진찰을 통해 관찰하고, 임상시험용\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 69 -\n기간, 목적을 확인한다.\n\n 사) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 치료 후 평가 및 일차 유효성 평가지표, 이차 유효성 평가지표의\n변화를 검증하기 위해 섭식장애 평가 항목 및 해당하는 자가\n\n보고 척도를 작성하도록 하여 지참하게 하거나, 애플리케이션을\n\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 70 -\n기간, 목적을 확인한다.\n\n 라) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 장기 효과 확인을 위한 일차 유효성 평가지표, 이차 유효성\n평가지표의 변화를 검증하기 위해 섭식장애 평가 항목 및\n\n해당하는 자가 보고 척도를 작성하도록 하여 지참하게 하거나,\n\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 71 -\n기간, 목적을 확인한다.\n\n 라) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 72 -\n<!-- PAGE_79 -->\n##### 12.  예측되는 부작용 및 사용 시 주의사항\n\n[예시]\n\n- 가.  예측되는 부작용\n본 연구에서 적용하는 치료는 디지털 섭식장애 인지행동치료(CBT),\n\n혹은 이에 상응하는 과학적 근거를 가진 섭식장애의 비약물적인 치료이다.\n\n 섭식장애 인지행동치료 및 기타 비약물적인 치료의 경우 행동 요법\n\n또는 인지 요법을 포함한 교육 이외 침습적이거나 환자에게 유해를\n\n끼칠 수 있는 내용은 포함되어 있지 않다. ",
        "original_sentence": "라) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 72 -\n<!-- PAGE_79 -->\n##### 12. "
      }
    },
    {
      "chunk_id": "chunk_641",
      "text": "예측되는 부작용 및 사용 시 주의사항\n\n[예시]\n\n- 가. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 640,
        "window_size": 3,
        "char_count": 33,
        "word_count": 9,
        "page_number": 3,
        "window_text": "사) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 치료 후 평가 및 일차 유효성 평가지표, 이차 유효성 평가지표의\n변화를 검증하기 위해 섭식장애 평가 항목 및 해당하는 자가\n\n보고 척도를 작성하도록 하여 지참하게 하거나, 애플리케이션을\n\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 70 -\n기간, 목적을 확인한다.\n\n 라) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 장기 효과 확인을 위한 일차 유효성 평가지표, 이차 유효성\n평가지표의 변화를 검증하기 위해 섭식장애 평가 항목 및\n\n해당하는 자가 보고 척도를 작성하도록 하여 지참하게 하거나,\n\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 71 -\n기간, 목적을 확인한다.\n\n 라) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 72 -\n<!-- PAGE_79 -->\n##### 12.  예측되는 부작용 및 사용 시 주의사항\n\n[예시]\n\n- 가.  예측되는 부작용\n본 연구에서 적용하는 치료는 디지털 섭식장애 인지행동치료(CBT),\n\n혹은 이에 상응하는 과학적 근거를 가진 섭식장애의 비약물적인 치료이다.\n\n 섭식장애 인지행동치료 및 기타 비약물적인 치료의 경우 행동 요법\n\n또는 인지 요법을 포함한 교육 이외 침습적이거나 환자에게 유해를\n\n끼칠 수 있는 내용은 포함되어 있지 않다.  다만, 일반적인 섭식장애\n\n인지행동치료의 부작용 정도에 대한 부작용 또는 범용장비 사용으로\n\n인한 부작용을 예상할 수 있고, 이는 다음과 같다.\n\n",
        "original_sentence": "예측되는 부작용 및 사용 시 주의사항\n\n[예시]\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_642",
      "text": "예측되는 부작용\n본 연구에서 적용하는 치료는 디지털 섭식장애 인지행동치료(CBT),\n\n혹은 이에 상응하는 과학적 근거를 가진 섭식장애의 비약물적인 치료이다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 641,
        "window_size": 3,
        "char_count": 89,
        "word_count": 18,
        "page_number": 28,
        "window_text": "라) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 장기 효과 확인을 위한 일차 유효성 평가지표, 이차 유효성\n평가지표의 변화를 검증하기 위해 섭식장애 평가 항목 및\n\n해당하는 자가 보고 척도를 작성하도록 하여 지참하게 하거나,\n\n- - 시험자는 임상시험에 사용되는 의료기기 사용 후 나타나는\n이상 반응 여부를 방문일에 피험자에 대한 진찰을 통해 관찰\n\n하고, 임상시험용 의료기기와의 인과관계에 대하여 증례 기록지에\n\n※ 단, 이상 반응 여부는 필요하면 온라인(앱, 이메일, 문자, SNS 등)으로\n\n- - 병용약물은 동의서 취득일 기준으로 최근 3개월 이내에 복용\n하였거나 유지 중인 약물을 조사하며 성분명, 용법, 용량, 투여\n\n- - 71 -\n기간, 목적을 확인한다.\n\n 라) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 72 -\n<!-- PAGE_79 -->\n##### 12.  예측되는 부작용 및 사용 시 주의사항\n\n[예시]\n\n- 가.  예측되는 부작용\n본 연구에서 적용하는 치료는 디지털 섭식장애 인지행동치료(CBT),\n\n혹은 이에 상응하는 과학적 근거를 가진 섭식장애의 비약물적인 치료이다.\n\n 섭식장애 인지행동치료 및 기타 비약물적인 치료의 경우 행동 요법\n\n또는 인지 요법을 포함한 교육 이외 침습적이거나 환자에게 유해를\n\n끼칠 수 있는 내용은 포함되어 있지 않다.  다만, 일반적인 섭식장애\n\n인지행동치료의 부작용 정도에 대한 부작용 또는 범용장비 사용으로\n\n인한 부작용을 예상할 수 있고, 이는 다음과 같다.\n\n 1) 섭식장애 인지행동치료의 행동 요법 중 노출 치료의 경우, 섭식\n\n장애 증상의 발생 및 악화가 나타날 수 있다. ",
        "original_sentence": "예측되는 부작용\n본 연구에서 적용하는 치료는 디지털 섭식장애 인지행동치료(CBT),\n\n혹은 이에 상응하는 과학적 근거를 가진 섭식장애의 비약물적인 치료이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_643",
      "text": "섭식장애 인지행동치료 및 기타 비약물적인 치료의 경우 행동 요법\n\n또는 인지 요법을 포함한 교육 이외 침습적이거나 환자에게 유해를\n\n끼칠 수 있는 내용은 포함되어 있지 않다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 642,
        "window_size": 3,
        "char_count": 98,
        "word_count": 25,
        "page_number": 30,
        "window_text": "라) 순응도 조사\n\n- - 치료 기간에 애플리케이션 사용도 및 콘텐츠 이용도를 수집하여\n- - 72 -\n<!-- PAGE_79 -->\n##### 12.  예측되는 부작용 및 사용 시 주의사항\n\n[예시]\n\n- 가.  예측되는 부작용\n본 연구에서 적용하는 치료는 디지털 섭식장애 인지행동치료(CBT),\n\n혹은 이에 상응하는 과학적 근거를 가진 섭식장애의 비약물적인 치료이다.\n\n 섭식장애 인지행동치료 및 기타 비약물적인 치료의 경우 행동 요법\n\n또는 인지 요법을 포함한 교육 이외 침습적이거나 환자에게 유해를\n\n끼칠 수 있는 내용은 포함되어 있지 않다.  다만, 일반적인 섭식장애\n\n인지행동치료의 부작용 정도에 대한 부작용 또는 범용장비 사용으로\n\n인한 부작용을 예상할 수 있고, 이는 다음과 같다.\n\n 1) 섭식장애 인지행동치료의 행동 요법 중 노출 치료의 경우, 섭식\n\n장애 증상의 발생 및 악화가 나타날 수 있다.  섭식장애 이외 기타\n\n정신과적인 증상의 악화 위험이 큰 사람, 특히 자살 생각을 하는\n\n사람의 경우 임상시험에서 배제함으로써 위험도를 최소화할 수\n\n있다. ",
        "original_sentence": "섭식장애 인지행동치료 및 기타 비약물적인 치료의 경우 행동 요법\n\n또는 인지 요법을 포함한 교육 이외 침습적이거나 환자에게 유해를\n\n끼칠 수 있는 내용은 포함되어 있지 않다. "
      }
    },
    {
      "chunk_id": "chunk_644",
      "text": "다만, 일반적인 섭식장애\n\n인지행동치료의 부작용 정도에 대한 부작용 또는 범용장비 사용으로\n\n인한 부작용을 예상할 수 있고, 이는 다음과 같다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 643,
        "window_size": 3,
        "char_count": 82,
        "word_count": 19,
        "page_number": 30,
        "window_text": "예측되는 부작용 및 사용 시 주의사항\n\n[예시]\n\n- 가.  예측되는 부작용\n본 연구에서 적용하는 치료는 디지털 섭식장애 인지행동치료(CBT),\n\n혹은 이에 상응하는 과학적 근거를 가진 섭식장애의 비약물적인 치료이다.\n\n 섭식장애 인지행동치료 및 기타 비약물적인 치료의 경우 행동 요법\n\n또는 인지 요법을 포함한 교육 이외 침습적이거나 환자에게 유해를\n\n끼칠 수 있는 내용은 포함되어 있지 않다.  다만, 일반적인 섭식장애\n\n인지행동치료의 부작용 정도에 대한 부작용 또는 범용장비 사용으로\n\n인한 부작용을 예상할 수 있고, 이는 다음과 같다.\n\n 1) 섭식장애 인지행동치료의 행동 요법 중 노출 치료의 경우, 섭식\n\n장애 증상의 발생 및 악화가 나타날 수 있다.  섭식장애 이외 기타\n\n정신과적인 증상의 악화 위험이 큰 사람, 특히 자살 생각을 하는\n\n사람의 경우 임상시험에서 배제함으로써 위험도를 최소화할 수\n\n있다.  이 외에도 치료 시작 시점에서 일시적인 불안감, 악화감이\n\n나타날 수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통\n\n하여 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.\n\n",
        "original_sentence": "다만, 일반적인 섭식장애\n\n인지행동치료의 부작용 정도에 대한 부작용 또는 범용장비 사용으로\n\n인한 부작용을 예상할 수 있고, 이는 다음과 같다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_645",
      "text": "1) 섭식장애 인지행동치료의 행동 요법 중 노출 치료의 경우, 섭식\n\n장애 증상의 발생 및 악화가 나타날 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 644,
        "window_size": 3,
        "char_count": 65,
        "word_count": 18,
        "page_number": 19,
        "window_text": "예측되는 부작용\n본 연구에서 적용하는 치료는 디지털 섭식장애 인지행동치료(CBT),\n\n혹은 이에 상응하는 과학적 근거를 가진 섭식장애의 비약물적인 치료이다.\n\n 섭식장애 인지행동치료 및 기타 비약물적인 치료의 경우 행동 요법\n\n또는 인지 요법을 포함한 교육 이외 침습적이거나 환자에게 유해를\n\n끼칠 수 있는 내용은 포함되어 있지 않다.  다만, 일반적인 섭식장애\n\n인지행동치료의 부작용 정도에 대한 부작용 또는 범용장비 사용으로\n\n인한 부작용을 예상할 수 있고, 이는 다음과 같다.\n\n 1) 섭식장애 인지행동치료의 행동 요법 중 노출 치료의 경우, 섭식\n\n장애 증상의 발생 및 악화가 나타날 수 있다.  섭식장애 이외 기타\n\n정신과적인 증상의 악화 위험이 큰 사람, 특히 자살 생각을 하는\n\n사람의 경우 임상시험에서 배제함으로써 위험도를 최소화할 수\n\n있다.  이 외에도 치료 시작 시점에서 일시적인 불안감, 악화감이\n\n나타날 수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통\n\n하여 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.\n\n 2) 섭식장애 인지행동치료의 인지 요법 중 왜곡된 인지 교정의 경우\n\n역기능적인 사고의 탐색 및 교정의 과정에서 일시적인 불안감\n\n- - 73 -\n악화를 가져올 수 있다. ",
        "original_sentence": "1) 섭식장애 인지행동치료의 행동 요법 중 노출 치료의 경우, 섭식\n\n장애 증상의 발생 및 악화가 나타날 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_646",
      "text": "섭식장애 이외 기타\n\n정신과적인 증상의 악화 위험이 큰 사람, 특히 자살 생각을 하는\n\n사람의 경우 임상시험에서 배제함으로써 위험도를 최소화할 수\n\n있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 645,
        "window_size": 3,
        "char_count": 87,
        "word_count": 21,
        "page_number": 30,
        "window_text": "섭식장애 인지행동치료 및 기타 비약물적인 치료의 경우 행동 요법\n\n또는 인지 요법을 포함한 교육 이외 침습적이거나 환자에게 유해를\n\n끼칠 수 있는 내용은 포함되어 있지 않다.  다만, 일반적인 섭식장애\n\n인지행동치료의 부작용 정도에 대한 부작용 또는 범용장비 사용으로\n\n인한 부작용을 예상할 수 있고, 이는 다음과 같다.\n\n 1) 섭식장애 인지행동치료의 행동 요법 중 노출 치료의 경우, 섭식\n\n장애 증상의 발생 및 악화가 나타날 수 있다.  섭식장애 이외 기타\n\n정신과적인 증상의 악화 위험이 큰 사람, 특히 자살 생각을 하는\n\n사람의 경우 임상시험에서 배제함으로써 위험도를 최소화할 수\n\n있다.  이 외에도 치료 시작 시점에서 일시적인 불안감, 악화감이\n\n나타날 수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통\n\n하여 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.\n\n 2) 섭식장애 인지행동치료의 인지 요법 중 왜곡된 인지 교정의 경우\n\n역기능적인 사고의 탐색 및 교정의 과정에서 일시적인 불안감\n\n- - 73 -\n악화를 가져올 수 있다.  상술한 것과 같이 선정 및 제외 기준을\n\n활용하여 위험도를 최소화하며, 실험에 참여한 환자들을 대상\n\n으로는 치료 시작 시점에서 일시적인 불안감 악화가 나타날\n\n수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통하여\n\n3) 섭식장애 개선 디지털 치료를 위한 범용 장비(스마트폰 또는\n\n태블릿 PC 등) 사용으로 두통, 눈의 피로, 눈 또는 근육경련, 눈의\n\n불수의운동, 메스꺼움, 어지럼증, 머리 또는 눈의 불쾌감 또는 통증,\n\n졸림, 피로감과 같은 부작용이 발생할 수 있다. ",
        "original_sentence": "섭식장애 이외 기타\n\n정신과적인 증상의 악화 위험이 큰 사람, 특히 자살 생각을 하는\n\n사람의 경우 임상시험에서 배제함으로써 위험도를 최소화할 수\n\n있다. "
      }
    },
    {
      "chunk_id": "chunk_647",
      "text": "이 외에도 치료 시작 시점에서 일시적인 불안감, 악화감이\n\n나타날 수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통\n\n하여 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 646,
        "window_size": 3,
        "char_count": 107,
        "word_count": 26,
        "page_number": 9,
        "window_text": "다만, 일반적인 섭식장애\n\n인지행동치료의 부작용 정도에 대한 부작용 또는 범용장비 사용으로\n\n인한 부작용을 예상할 수 있고, 이는 다음과 같다.\n\n 1) 섭식장애 인지행동치료의 행동 요법 중 노출 치료의 경우, 섭식\n\n장애 증상의 발생 및 악화가 나타날 수 있다.  섭식장애 이외 기타\n\n정신과적인 증상의 악화 위험이 큰 사람, 특히 자살 생각을 하는\n\n사람의 경우 임상시험에서 배제함으로써 위험도를 최소화할 수\n\n있다.  이 외에도 치료 시작 시점에서 일시적인 불안감, 악화감이\n\n나타날 수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통\n\n하여 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.\n\n 2) 섭식장애 인지행동치료의 인지 요법 중 왜곡된 인지 교정의 경우\n\n역기능적인 사고의 탐색 및 교정의 과정에서 일시적인 불안감\n\n- - 73 -\n악화를 가져올 수 있다.  상술한 것과 같이 선정 및 제외 기준을\n\n활용하여 위험도를 최소화하며, 실험에 참여한 환자들을 대상\n\n으로는 치료 시작 시점에서 일시적인 불안감 악화가 나타날\n\n수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통하여\n\n3) 섭식장애 개선 디지털 치료를 위한 범용 장비(스마트폰 또는\n\n태블릿 PC 등) 사용으로 두통, 눈의 피로, 눈 또는 근육경련, 눈의\n\n불수의운동, 메스꺼움, 어지럼증, 머리 또는 눈의 불쾌감 또는 통증,\n\n졸림, 피로감과 같은 부작용이 발생할 수 있다.  해당 경우 24시간\n\n연락 가능한 연구자 번호를 통하여 즉시 상담과 필요하면 의료진\n\n본 연구에서 진행되는 평가는 자가 보고 설문지, 면담 등 모두\n\n비침습적인 검사로 이루어져 있으므로 예측되는 부작용은 없다.\n\n",
        "original_sentence": "이 외에도 치료 시작 시점에서 일시적인 불안감, 악화감이\n\n나타날 수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통\n\n하여 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_648",
      "text": "2) 섭식장애 인지행동치료의 인지 요법 중 왜곡된 인지 교정의 경우\n\n역기능적인 사고의 탐색 및 교정의 과정에서 일시적인 불안감\n\n- - 73 -\n악화를 가져올 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 647,
        "window_size": 3,
        "char_count": 96,
        "word_count": 26,
        "page_number": 9,
        "window_text": "1) 섭식장애 인지행동치료의 행동 요법 중 노출 치료의 경우, 섭식\n\n장애 증상의 발생 및 악화가 나타날 수 있다.  섭식장애 이외 기타\n\n정신과적인 증상의 악화 위험이 큰 사람, 특히 자살 생각을 하는\n\n사람의 경우 임상시험에서 배제함으로써 위험도를 최소화할 수\n\n있다.  이 외에도 치료 시작 시점에서 일시적인 불안감, 악화감이\n\n나타날 수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통\n\n하여 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.\n\n 2) 섭식장애 인지행동치료의 인지 요법 중 왜곡된 인지 교정의 경우\n\n역기능적인 사고의 탐색 및 교정의 과정에서 일시적인 불안감\n\n- - 73 -\n악화를 가져올 수 있다.  상술한 것과 같이 선정 및 제외 기준을\n\n활용하여 위험도를 최소화하며, 실험에 참여한 환자들을 대상\n\n으로는 치료 시작 시점에서 일시적인 불안감 악화가 나타날\n\n수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통하여\n\n3) 섭식장애 개선 디지털 치료를 위한 범용 장비(스마트폰 또는\n\n태블릿 PC 등) 사용으로 두통, 눈의 피로, 눈 또는 근육경련, 눈의\n\n불수의운동, 메스꺼움, 어지럼증, 머리 또는 눈의 불쾌감 또는 통증,\n\n졸림, 피로감과 같은 부작용이 발생할 수 있다.  해당 경우 24시간\n\n연락 가능한 연구자 번호를 통하여 즉시 상담과 필요하면 의료진\n\n본 연구에서 진행되는 평가는 자가 보고 설문지, 면담 등 모두\n\n비침습적인 검사로 이루어져 있으므로 예측되는 부작용은 없다.\n\n - 나. ",
        "original_sentence": "2) 섭식장애 인지행동치료의 인지 요법 중 왜곡된 인지 교정의 경우\n\n역기능적인 사고의 탐색 및 교정의 과정에서 일시적인 불안감\n\n- - 73 -\n악화를 가져올 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_649",
      "text": "상술한 것과 같이 선정 및 제외 기준을\n\n활용하여 위험도를 최소화하며, 실험에 참여한 환자들을 대상\n\n으로는 치료 시작 시점에서 일시적인 불안감 악화가 나타날\n\n수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통하여\n\n3) 섭식장애 개선 디지털 치료를 위한 범용 장비(스마트폰 또는\n\n태블릿 PC 등) 사용으로 두통, 눈의 피로, 눈 또는 근육경련, 눈의\n\n불수의운동, 메스꺼움, 어지럼증, 머리 또는 눈의 불쾌감 또는 통증,\n\n졸림, 피로감과 같은 부작용이 발생할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 648,
        "window_size": 3,
        "char_count": 271,
        "word_count": 67,
        "page_number": 15,
        "window_text": "섭식장애 이외 기타\n\n정신과적인 증상의 악화 위험이 큰 사람, 특히 자살 생각을 하는\n\n사람의 경우 임상시험에서 배제함으로써 위험도를 최소화할 수\n\n있다.  이 외에도 치료 시작 시점에서 일시적인 불안감, 악화감이\n\n나타날 수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통\n\n하여 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.\n\n 2) 섭식장애 인지행동치료의 인지 요법 중 왜곡된 인지 교정의 경우\n\n역기능적인 사고의 탐색 및 교정의 과정에서 일시적인 불안감\n\n- - 73 -\n악화를 가져올 수 있다.  상술한 것과 같이 선정 및 제외 기준을\n\n활용하여 위험도를 최소화하며, 실험에 참여한 환자들을 대상\n\n으로는 치료 시작 시점에서 일시적인 불안감 악화가 나타날\n\n수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통하여\n\n3) 섭식장애 개선 디지털 치료를 위한 범용 장비(스마트폰 또는\n\n태블릿 PC 등) 사용으로 두통, 눈의 피로, 눈 또는 근육경련, 눈의\n\n불수의운동, 메스꺼움, 어지럼증, 머리 또는 눈의 불쾌감 또는 통증,\n\n졸림, 피로감과 같은 부작용이 발생할 수 있다.  해당 경우 24시간\n\n연락 가능한 연구자 번호를 통하여 즉시 상담과 필요하면 의료진\n\n본 연구에서 진행되는 평가는 자가 보고 설문지, 면담 등 모두\n\n비침습적인 검사로 이루어져 있으므로 예측되는 부작용은 없다.\n\n - 나.  사용 시 주의사항\n본 연구에서 적용하는 섭식장애 개선 디지털치료기기의 부작용,\n\n일반적 주의, 적용상의 주의는 다음과 같다.\n\n",
        "original_sentence": "상술한 것과 같이 선정 및 제외 기준을\n\n활용하여 위험도를 최소화하며, 실험에 참여한 환자들을 대상\n\n으로는 치료 시작 시점에서 일시적인 불안감 악화가 나타날\n\n수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통하여\n\n3) 섭식장애 개선 디지털 치료를 위한 범용 장비(스마트폰 또는\n\n태블릿 PC 등) 사용으로 두통, 눈의 피로, 눈 또는 근육경련, 눈의\n\n불수의운동, 메스꺼움, 어지럼증, 머리 또는 눈의 불쾌감 또는 통증,\n\n졸림, 피로감과 같은 부작용이 발생할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_650",
      "text": "해당 경우 24시간\n\n연락 가능한 연구자 번호를 통하여 즉시 상담과 필요하면 의료진\n\n본 연구에서 진행되는 평가는 자가 보고 설문지, 면담 등 모두\n\n비침습적인 검사로 이루어져 있으므로 예측되는 부작용은 없다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 649,
        "window_size": 3,
        "char_count": 119,
        "word_count": 29,
        "page_number": 9,
        "window_text": "이 외에도 치료 시작 시점에서 일시적인 불안감, 악화감이\n\n나타날 수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통\n\n하여 즉시 상담과 필요하면 의료진 연결이 가능하도록 조치한다.\n\n 2) 섭식장애 인지행동치료의 인지 요법 중 왜곡된 인지 교정의 경우\n\n역기능적인 사고의 탐색 및 교정의 과정에서 일시적인 불안감\n\n- - 73 -\n악화를 가져올 수 있다.  상술한 것과 같이 선정 및 제외 기준을\n\n활용하여 위험도를 최소화하며, 실험에 참여한 환자들을 대상\n\n으로는 치료 시작 시점에서 일시적인 불안감 악화가 나타날\n\n수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통하여\n\n3) 섭식장애 개선 디지털 치료를 위한 범용 장비(스마트폰 또는\n\n태블릿 PC 등) 사용으로 두통, 눈의 피로, 눈 또는 근육경련, 눈의\n\n불수의운동, 메스꺼움, 어지럼증, 머리 또는 눈의 불쾌감 또는 통증,\n\n졸림, 피로감과 같은 부작용이 발생할 수 있다.  해당 경우 24시간\n\n연락 가능한 연구자 번호를 통하여 즉시 상담과 필요하면 의료진\n\n본 연구에서 진행되는 평가는 자가 보고 설문지, 면담 등 모두\n\n비침습적인 검사로 이루어져 있으므로 예측되는 부작용은 없다.\n\n - 나.  사용 시 주의사항\n본 연구에서 적용하는 섭식장애 개선 디지털치료기기의 부작용,\n\n일반적 주의, 적용상의 주의는 다음과 같다.\n\n 본 제품을 사용한 후 제품에 대한 부적합 반응이 전부 배제될\n\n사이버 보안과 관련된 사고 발생 시 임상시험 관리자 긴급\n\n- - 74 -\n번호로 연락하고 관리자가 조치할 때까지 대기한다.\n\n",
        "original_sentence": "해당 경우 24시간\n\n연락 가능한 연구자 번호를 통하여 즉시 상담과 필요하면 의료진\n\n본 연구에서 진행되는 평가는 자가 보고 설문지, 면담 등 모두\n\n비침습적인 검사로 이루어져 있으므로 예측되는 부작용은 없다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_651",
      "text": "- 나. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 650,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 72,
        "window_text": "2) 섭식장애 인지행동치료의 인지 요법 중 왜곡된 인지 교정의 경우\n\n역기능적인 사고의 탐색 및 교정의 과정에서 일시적인 불안감\n\n- - 73 -\n악화를 가져올 수 있다.  상술한 것과 같이 선정 및 제외 기준을\n\n활용하여 위험도를 최소화하며, 실험에 참여한 환자들을 대상\n\n으로는 치료 시작 시점에서 일시적인 불안감 악화가 나타날\n\n수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통하여\n\n3) 섭식장애 개선 디지털 치료를 위한 범용 장비(스마트폰 또는\n\n태블릿 PC 등) 사용으로 두통, 눈의 피로, 눈 또는 근육경련, 눈의\n\n불수의운동, 메스꺼움, 어지럼증, 머리 또는 눈의 불쾌감 또는 통증,\n\n졸림, 피로감과 같은 부작용이 발생할 수 있다.  해당 경우 24시간\n\n연락 가능한 연구자 번호를 통하여 즉시 상담과 필요하면 의료진\n\n본 연구에서 진행되는 평가는 자가 보고 설문지, 면담 등 모두\n\n비침습적인 검사로 이루어져 있으므로 예측되는 부작용은 없다.\n\n - 나.  사용 시 주의사항\n본 연구에서 적용하는 섭식장애 개선 디지털치료기기의 부작용,\n\n일반적 주의, 적용상의 주의는 다음과 같다.\n\n 본 제품을 사용한 후 제품에 대한 부적합 반응이 전부 배제될\n\n사이버 보안과 관련된 사고 발생 시 임상시험 관리자 긴급\n\n- - 74 -\n번호로 연락하고 관리자가 조치할 때까지 대기한다.\n\n 7) 적용상의 주의\n\n사용 시간, 사용 횟수, 결과 작성 등 임상시험 책임자와 담당자가\n\n- - 75 -\n<!-- PAGE_82 -->\n##### 13. ",
        "original_sentence": "- 나. "
      }
    },
    {
      "chunk_id": "chunk_652",
      "text": "사용 시 주의사항\n본 연구에서 적용하는 섭식장애 개선 디지털치료기기의 부작용,\n\n일반적 주의, 적용상의 주의는 다음과 같다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 651,
        "window_size": 3,
        "char_count": 71,
        "word_count": 16,
        "page_number": 1,
        "window_text": "상술한 것과 같이 선정 및 제외 기준을\n\n활용하여 위험도를 최소화하며, 실험에 참여한 환자들을 대상\n\n으로는 치료 시작 시점에서 일시적인 불안감 악화가 나타날\n\n수 있음을 알리고, 24시간 연락 가능한 연구자 번호를 통하여\n\n3) 섭식장애 개선 디지털 치료를 위한 범용 장비(스마트폰 또는\n\n태블릿 PC 등) 사용으로 두통, 눈의 피로, 눈 또는 근육경련, 눈의\n\n불수의운동, 메스꺼움, 어지럼증, 머리 또는 눈의 불쾌감 또는 통증,\n\n졸림, 피로감과 같은 부작용이 발생할 수 있다.  해당 경우 24시간\n\n연락 가능한 연구자 번호를 통하여 즉시 상담과 필요하면 의료진\n\n본 연구에서 진행되는 평가는 자가 보고 설문지, 면담 등 모두\n\n비침습적인 검사로 이루어져 있으므로 예측되는 부작용은 없다.\n\n - 나.  사용 시 주의사항\n본 연구에서 적용하는 섭식장애 개선 디지털치료기기의 부작용,\n\n일반적 주의, 적용상의 주의는 다음과 같다.\n\n 본 제품을 사용한 후 제품에 대한 부적합 반응이 전부 배제될\n\n사이버 보안과 관련된 사고 발생 시 임상시험 관리자 긴급\n\n- - 74 -\n번호로 연락하고 관리자가 조치할 때까지 대기한다.\n\n 7) 적용상의 주의\n\n사용 시간, 사용 횟수, 결과 작성 등 임상시험 책임자와 담당자가\n\n- - 75 -\n<!-- PAGE_82 -->\n##### 13.  중지·탈락 기준\n\n[예시]\n\n- 가. ",
        "original_sentence": "사용 시 주의사항\n본 연구에서 적용하는 섭식장애 개선 디지털치료기기의 부작용,\n\n일반적 주의, 적용상의 주의는 다음과 같다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_653",
      "text": "본 제품을 사용한 후 제품에 대한 부적합 반응이 전부 배제될\n\n사이버 보안과 관련된 사고 발생 시 임상시험 관리자 긴급\n\n- - 74 -\n번호로 연락하고 관리자가 조치할 때까지 대기한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 652,
        "window_size": 3,
        "char_count": 106,
        "word_count": 29,
        "page_number": 30,
        "window_text": "해당 경우 24시간\n\n연락 가능한 연구자 번호를 통하여 즉시 상담과 필요하면 의료진\n\n본 연구에서 진행되는 평가는 자가 보고 설문지, 면담 등 모두\n\n비침습적인 검사로 이루어져 있으므로 예측되는 부작용은 없다.\n\n - 나.  사용 시 주의사항\n본 연구에서 적용하는 섭식장애 개선 디지털치료기기의 부작용,\n\n일반적 주의, 적용상의 주의는 다음과 같다.\n\n 본 제품을 사용한 후 제품에 대한 부적합 반응이 전부 배제될\n\n사이버 보안과 관련된 사고 발생 시 임상시험 관리자 긴급\n\n- - 74 -\n번호로 연락하고 관리자가 조치할 때까지 대기한다.\n\n 7) 적용상의 주의\n\n사용 시간, 사용 횟수, 결과 작성 등 임상시험 책임자와 담당자가\n\n- - 75 -\n<!-- PAGE_82 -->\n##### 13.  중지·탈락 기준\n\n[예시]\n\n- 가.  중지\n- - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n- - 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는\n- - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n- - 중지 시점까지의 검사 결과 관련 자료는 성능과 안전성 평가를\n- - 76 -\n- - 임상시험을 통해 얻은 자료는 성능 및 안전성 분석을 위한\n데이터가 정해져야 하며, 만약 자료에 결함이 생기면 적절한\n\n보정 방법을 임상시험계획에서 제시하고 보정 후 분석을 시행\n\n- - 동의를 철회하였으면 해당 시점 이후의 수집된 피험자의 정\n- 나. ",
        "original_sentence": "본 제품을 사용한 후 제품에 대한 부적합 반응이 전부 배제될\n\n사이버 보안과 관련된 사고 발생 시 임상시험 관리자 긴급\n\n- - 74 -\n번호로 연락하고 관리자가 조치할 때까지 대기한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_654",
      "text": "7) 적용상의 주의\n\n사용 시간, 사용 횟수, 결과 작성 등 임상시험 책임자와 담당자가\n\n- - 75 -\n<!-- PAGE_82 -->\n##### 13. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 653,
        "window_size": 3,
        "char_count": 86,
        "word_count": 22,
        "page_number": 82,
        "window_text": "- 나.  사용 시 주의사항\n본 연구에서 적용하는 섭식장애 개선 디지털치료기기의 부작용,\n\n일반적 주의, 적용상의 주의는 다음과 같다.\n\n 본 제품을 사용한 후 제품에 대한 부적합 반응이 전부 배제될\n\n사이버 보안과 관련된 사고 발생 시 임상시험 관리자 긴급\n\n- - 74 -\n번호로 연락하고 관리자가 조치할 때까지 대기한다.\n\n 7) 적용상의 주의\n\n사용 시간, 사용 횟수, 결과 작성 등 임상시험 책임자와 담당자가\n\n- - 75 -\n<!-- PAGE_82 -->\n##### 13.  중지·탈락 기준\n\n[예시]\n\n- 가.  중지\n- - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n- - 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는\n- - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n- - 중지 시점까지의 검사 결과 관련 자료는 성능과 안전성 평가를\n- - 76 -\n- - 임상시험을 통해 얻은 자료는 성능 및 안전성 분석을 위한\n데이터가 정해져야 하며, 만약 자료에 결함이 생기면 적절한\n\n보정 방법을 임상시험계획에서 제시하고 보정 후 분석을 시행\n\n- - 동의를 철회하였으면 해당 시점 이후의 수집된 피험자의 정\n- 나.  탈락\n: 시험자는 다음과 같은 경우에 연구 참여 대상자를 시험에서\n\n- - 피험자의 부작용(예: 두통, 눈의 피로, 눈 또는 근육경련, 눈의\n불수의운동, 메스꺼움, 어지럼증 등)으로 인하여 임상시험 책임자\n\n- - 피험자가 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n- - 피험자의 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n- - 임상시험 중 선정/제외 기준 위반 등 중대한 계획서 위반\n- - 77 -\n- - 기타 사유로 인하여 임상시험 책임자 또는 담당자가 임상\n시험을 중지해야 한다고 판단한 경우\n\n- - 섭식장애 연관 증상이 지나치게 악화되어 다른 정신과적 건강\n- - 중도 탈락 시, 시험자는 대상자의 임상시험 조기 탈락의 주요\n사유를 평가하여 증례 기록서 임상시험 완료 항목에 해당 정보를\n\n- - 참여 중단 의사를 밝히지 않고 방문에 출석하지 않아 현재\n상태가 불분명한 대상자의 경우에 시험자는 대상자와 전화\n\n- - 78 -\n- 14. ",
        "original_sentence": "7) 적용상의 주의\n\n사용 시간, 사용 횟수, 결과 작성 등 임상시험 책임자와 담당자가\n\n- - 75 -\n<!-- PAGE_82 -->\n##### 13. "
      }
    },
    {
      "chunk_id": "chunk_655",
      "text": "중지·탈락 기준\n\n[예시]\n\n- 가. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 654,
        "window_size": 3,
        "char_count": 21,
        "word_count": 5,
        "page_number": 44,
        "window_text": "사용 시 주의사항\n본 연구에서 적용하는 섭식장애 개선 디지털치료기기의 부작용,\n\n일반적 주의, 적용상의 주의는 다음과 같다.\n\n 본 제품을 사용한 후 제품에 대한 부적합 반응이 전부 배제될\n\n사이버 보안과 관련된 사고 발생 시 임상시험 관리자 긴급\n\n- - 74 -\n번호로 연락하고 관리자가 조치할 때까지 대기한다.\n\n 7) 적용상의 주의\n\n사용 시간, 사용 횟수, 결과 작성 등 임상시험 책임자와 담당자가\n\n- - 75 -\n<!-- PAGE_82 -->\n##### 13.  중지·탈락 기준\n\n[예시]\n\n- 가.  중지\n- - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n- - 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는\n- - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n- - 중지 시점까지의 검사 결과 관련 자료는 성능과 안전성 평가를\n- - 76 -\n- - 임상시험을 통해 얻은 자료는 성능 및 안전성 분석을 위한\n데이터가 정해져야 하며, 만약 자료에 결함이 생기면 적절한\n\n보정 방법을 임상시험계획에서 제시하고 보정 후 분석을 시행\n\n- - 동의를 철회하였으면 해당 시점 이후의 수집된 피험자의 정\n- 나.  탈락\n: 시험자는 다음과 같은 경우에 연구 참여 대상자를 시험에서\n\n- - 피험자의 부작용(예: 두통, 눈의 피로, 눈 또는 근육경련, 눈의\n불수의운동, 메스꺼움, 어지럼증 등)으로 인하여 임상시험 책임자\n\n- - 피험자가 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n- - 피험자의 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n- - 임상시험 중 선정/제외 기준 위반 등 중대한 계획서 위반\n- - 77 -\n- - 기타 사유로 인하여 임상시험 책임자 또는 담당자가 임상\n시험을 중지해야 한다고 판단한 경우\n\n- - 섭식장애 연관 증상이 지나치게 악화되어 다른 정신과적 건강\n- - 중도 탈락 시, 시험자는 대상자의 임상시험 조기 탈락의 주요\n사유를 평가하여 증례 기록서 임상시험 완료 항목에 해당 정보를\n\n- - 참여 중단 의사를 밝히지 않고 방문에 출석하지 않아 현재\n상태가 불분명한 대상자의 경우에 시험자는 대상자와 전화\n\n- - 78 -\n- 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 의함)\n- 가. ",
        "original_sentence": "중지·탈락 기준\n\n[예시]\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_656",
      "text": "중지\n- - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n- - 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는\n- - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n- - 중지 시점까지의 검사 결과 관련 자료는 성능과 안전성 평가를\n- - 76 -\n- - 임상시험을 통해 얻은 자료는 성능 및 안전성 분석을 위한\n데이터가 정해져야 하며, 만약 자료에 결함이 생기면 적절한\n\n보정 방법을 임상시험계획에서 제시하고 보정 후 분석을 시행\n\n- - 동의를 철회하였으면 해당 시점 이후의 수집된 피험자의 정\n- 나. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 655,
        "window_size": 3,
        "char_count": 306,
        "word_count": 81,
        "page_number": 35,
        "window_text": "본 제품을 사용한 후 제품에 대한 부적합 반응이 전부 배제될\n\n사이버 보안과 관련된 사고 발생 시 임상시험 관리자 긴급\n\n- - 74 -\n번호로 연락하고 관리자가 조치할 때까지 대기한다.\n\n 7) 적용상의 주의\n\n사용 시간, 사용 횟수, 결과 작성 등 임상시험 책임자와 담당자가\n\n- - 75 -\n<!-- PAGE_82 -->\n##### 13.  중지·탈락 기준\n\n[예시]\n\n- 가.  중지\n- - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n- - 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는\n- - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n- - 중지 시점까지의 검사 결과 관련 자료는 성능과 안전성 평가를\n- - 76 -\n- - 임상시험을 통해 얻은 자료는 성능 및 안전성 분석을 위한\n데이터가 정해져야 하며, 만약 자료에 결함이 생기면 적절한\n\n보정 방법을 임상시험계획에서 제시하고 보정 후 분석을 시행\n\n- - 동의를 철회하였으면 해당 시점 이후의 수집된 피험자의 정\n- 나.  탈락\n: 시험자는 다음과 같은 경우에 연구 참여 대상자를 시험에서\n\n- - 피험자의 부작용(예: 두통, 눈의 피로, 눈 또는 근육경련, 눈의\n불수의운동, 메스꺼움, 어지럼증 등)으로 인하여 임상시험 책임자\n\n- - 피험자가 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n- - 피험자의 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n- - 임상시험 중 선정/제외 기준 위반 등 중대한 계획서 위반\n- - 77 -\n- - 기타 사유로 인하여 임상시험 책임자 또는 담당자가 임상\n시험을 중지해야 한다고 판단한 경우\n\n- - 섭식장애 연관 증상이 지나치게 악화되어 다른 정신과적 건강\n- - 중도 탈락 시, 시험자는 대상자의 임상시험 조기 탈락의 주요\n사유를 평가하여 증례 기록서 임상시험 완료 항목에 해당 정보를\n\n- - 참여 중단 의사를 밝히지 않고 방문에 출석하지 않아 현재\n상태가 불분명한 대상자의 경우에 시험자는 대상자와 전화\n\n- - 78 -\n- 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 의함)\n- 가.  유효성의 평가 기준\n[일차 유효성 평가변수]\n\n[이차 유효성 평가변수]\n\n1) 베이스라인 (사용 전) 대비 4주, 8주 시점의 하기 지표 변화량\n\n- - 79 -\n- (5) Clinical Global Impression of Severity (CGI-S)\n2) 4주, 8주 시점의 Clinical Global Impression of Improvement\n\n- - 80 -\n- 나. ",
        "original_sentence": "중지\n- - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n- - 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는\n- - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n- - 중지 시점까지의 검사 결과 관련 자료는 성능과 안전성 평가를\n- - 76 -\n- - 임상시험을 통해 얻은 자료는 성능 및 안전성 분석을 위한\n데이터가 정해져야 하며, 만약 자료에 결함이 생기면 적절한\n\n보정 방법을 임상시험계획에서 제시하고 보정 후 분석을 시행\n\n- - 동의를 철회하였으면 해당 시점 이후의 수집된 피험자의 정\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_657",
      "text": "탈락\n: 시험자는 다음과 같은 경우에 연구 참여 대상자를 시험에서\n\n- - 피험자의 부작용(예: 두통, 눈의 피로, 눈 또는 근육경련, 눈의\n불수의운동, 메스꺼움, 어지럼증 등)으로 인하여 임상시험 책임자\n\n- - 피험자가 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n- - 피험자의 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n- - 임상시험 중 선정/제외 기준 위반 등 중대한 계획서 위반\n- - 77 -\n- - 기타 사유로 인하여 임상시험 책임자 또는 담당자가 임상\n시험을 중지해야 한다고 판단한 경우\n\n- - 섭식장애 연관 증상이 지나치게 악화되어 다른 정신과적 건강\n- - 중도 탈락 시, 시험자는 대상자의 임상시험 조기 탈락의 주요\n사유를 평가하여 증례 기록서 임상시험 완료 항목에 해당 정보를\n\n- - 참여 중단 의사를 밝히지 않고 방문에 출석하지 않아 현재\n상태가 불분명한 대상자의 경우에 시험자는 대상자와 전화\n\n- - 78 -\n- 14. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 656,
        "window_size": 3,
        "char_count": 485,
        "word_count": 132,
        "page_number": 35,
        "window_text": "7) 적용상의 주의\n\n사용 시간, 사용 횟수, 결과 작성 등 임상시험 책임자와 담당자가\n\n- - 75 -\n<!-- PAGE_82 -->\n##### 13.  중지·탈락 기준\n\n[예시]\n\n- 가.  중지\n- - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n- - 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는\n- - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n- - 중지 시점까지의 검사 결과 관련 자료는 성능과 안전성 평가를\n- - 76 -\n- - 임상시험을 통해 얻은 자료는 성능 및 안전성 분석을 위한\n데이터가 정해져야 하며, 만약 자료에 결함이 생기면 적절한\n\n보정 방법을 임상시험계획에서 제시하고 보정 후 분석을 시행\n\n- - 동의를 철회하였으면 해당 시점 이후의 수집된 피험자의 정\n- 나.  탈락\n: 시험자는 다음과 같은 경우에 연구 참여 대상자를 시험에서\n\n- - 피험자의 부작용(예: 두통, 눈의 피로, 눈 또는 근육경련, 눈의\n불수의운동, 메스꺼움, 어지럼증 등)으로 인하여 임상시험 책임자\n\n- - 피험자가 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n- - 피험자의 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n- - 임상시험 중 선정/제외 기준 위반 등 중대한 계획서 위반\n- - 77 -\n- - 기타 사유로 인하여 임상시험 책임자 또는 담당자가 임상\n시험을 중지해야 한다고 판단한 경우\n\n- - 섭식장애 연관 증상이 지나치게 악화되어 다른 정신과적 건강\n- - 중도 탈락 시, 시험자는 대상자의 임상시험 조기 탈락의 주요\n사유를 평가하여 증례 기록서 임상시험 완료 항목에 해당 정보를\n\n- - 참여 중단 의사를 밝히지 않고 방문에 출석하지 않아 현재\n상태가 불분명한 대상자의 경우에 시험자는 대상자와 전화\n\n- - 78 -\n- 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 의함)\n- 가.  유효성의 평가 기준\n[일차 유효성 평가변수]\n\n[이차 유효성 평가변수]\n\n1) 베이스라인 (사용 전) 대비 4주, 8주 시점의 하기 지표 변화량\n\n- - 79 -\n- (5) Clinical Global Impression of Severity (CGI-S)\n2) 4주, 8주 시점의 Clinical Global Impression of Improvement\n\n- - 80 -\n- 나.  검사방법\n1) Eating Disorder Examination Questionnaire (EDE-Q)\n\nEDE-Q는 총 28개 문항으로 구성된 자가 설문지이며, 섭식장애의\n\n주요 병리를 측정하는 식사제한, 식사관심, 체형관심, 체중관심의\n\n4개 하위요인으로 구성되어 있다. ",
        "original_sentence": "탈락\n: 시험자는 다음과 같은 경우에 연구 참여 대상자를 시험에서\n\n- - 피험자의 부작용(예: 두통, 눈의 피로, 눈 또는 근육경련, 눈의\n불수의운동, 메스꺼움, 어지럼증 등)으로 인하여 임상시험 책임자\n\n- - 피험자가 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n- - 피험자의 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n- - 임상시험 중 선정/제외 기준 위반 등 중대한 계획서 위반\n- - 77 -\n- - 기타 사유로 인하여 임상시험 책임자 또는 담당자가 임상\n시험을 중지해야 한다고 판단한 경우\n\n- - 섭식장애 연관 증상이 지나치게 악화되어 다른 정신과적 건강\n- - 중도 탈락 시, 시험자는 대상자의 임상시험 조기 탈락의 주요\n사유를 평가하여 증례 기록서 임상시험 완료 항목에 해당 정보를\n\n- - 참여 중단 의사를 밝히지 않고 방문에 출석하지 않아 현재\n상태가 불분명한 대상자의 경우에 시험자는 대상자와 전화\n\n- - 78 -\n- 14. "
      }
    },
    {
      "chunk_id": "chunk_658",
      "text": "유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 의함)\n- 가. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 657,
        "window_size": 3,
        "char_count": 40,
        "word_count": 8,
        "page_number": 18,
        "window_text": "중지·탈락 기준\n\n[예시]\n\n- 가.  중지\n- - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n- - 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는\n- - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n- - 중지 시점까지의 검사 결과 관련 자료는 성능과 안전성 평가를\n- - 76 -\n- - 임상시험을 통해 얻은 자료는 성능 및 안전성 분석을 위한\n데이터가 정해져야 하며, 만약 자료에 결함이 생기면 적절한\n\n보정 방법을 임상시험계획에서 제시하고 보정 후 분석을 시행\n\n- - 동의를 철회하였으면 해당 시점 이후의 수집된 피험자의 정\n- 나.  탈락\n: 시험자는 다음과 같은 경우에 연구 참여 대상자를 시험에서\n\n- - 피험자의 부작용(예: 두통, 눈의 피로, 눈 또는 근육경련, 눈의\n불수의운동, 메스꺼움, 어지럼증 등)으로 인하여 임상시험 책임자\n\n- - 피험자가 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n- - 피험자의 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n- - 임상시험 중 선정/제외 기준 위반 등 중대한 계획서 위반\n- - 77 -\n- - 기타 사유로 인하여 임상시험 책임자 또는 담당자가 임상\n시험을 중지해야 한다고 판단한 경우\n\n- - 섭식장애 연관 증상이 지나치게 악화되어 다른 정신과적 건강\n- - 중도 탈락 시, 시험자는 대상자의 임상시험 조기 탈락의 주요\n사유를 평가하여 증례 기록서 임상시험 완료 항목에 해당 정보를\n\n- - 참여 중단 의사를 밝히지 않고 방문에 출석하지 않아 현재\n상태가 불분명한 대상자의 경우에 시험자는 대상자와 전화\n\n- - 78 -\n- 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 의함)\n- 가.  유효성의 평가 기준\n[일차 유효성 평가변수]\n\n[이차 유효성 평가변수]\n\n1) 베이스라인 (사용 전) 대비 4주, 8주 시점의 하기 지표 변화량\n\n- - 79 -\n- (5) Clinical Global Impression of Severity (CGI-S)\n2) 4주, 8주 시점의 Clinical Global Impression of Improvement\n\n- - 80 -\n- 나.  검사방법\n1) Eating Disorder Examination Questionnaire (EDE-Q)\n\nEDE-Q는 총 28개 문항으로 구성된 자가 설문지이며, 섭식장애의\n\n주요 병리를 측정하는 식사제한, 식사관심, 체형관심, 체중관심의\n\n4개 하위요인으로 구성되어 있다.  빈도를 묻는 문항을 제외하고 지\n\n난 4주간의 증상을 0점에서 6점까지 7점 척도로 평가한다. ",
        "original_sentence": "유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 의함)\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_659",
      "text": "유효성의 평가 기준\n[일차 유효성 평가변수]\n\n[이차 유효성 평가변수]\n\n1) 베이스라인 (사용 전) 대비 4주, 8주 시점의 하기 지표 변화량\n\n- - 79 -\n- (5) Clinical Global Impression of Severity (CGI-S)\n2) 4주, 8주 시점의 Clinical Global Impression of Improvement\n\n- - 80 -\n- 나. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 658,
        "window_size": 3,
        "char_count": 215,
        "word_count": 47,
        "page_number": 7,
        "window_text": "중지\n- - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n- - 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는\n- - 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기 종료\n- - 중지 시점까지의 검사 결과 관련 자료는 성능과 안전성 평가를\n- - 76 -\n- - 임상시험을 통해 얻은 자료는 성능 및 안전성 분석을 위한\n데이터가 정해져야 하며, 만약 자료에 결함이 생기면 적절한\n\n보정 방법을 임상시험계획에서 제시하고 보정 후 분석을 시행\n\n- - 동의를 철회하였으면 해당 시점 이후의 수집된 피험자의 정\n- 나.  탈락\n: 시험자는 다음과 같은 경우에 연구 참여 대상자를 시험에서\n\n- - 피험자의 부작용(예: 두통, 눈의 피로, 눈 또는 근육경련, 눈의\n불수의운동, 메스꺼움, 어지럼증 등)으로 인하여 임상시험 책임자\n\n- - 피험자가 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n- - 피험자의 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n- - 임상시험 중 선정/제외 기준 위반 등 중대한 계획서 위반\n- - 77 -\n- - 기타 사유로 인하여 임상시험 책임자 또는 담당자가 임상\n시험을 중지해야 한다고 판단한 경우\n\n- - 섭식장애 연관 증상이 지나치게 악화되어 다른 정신과적 건강\n- - 중도 탈락 시, 시험자는 대상자의 임상시험 조기 탈락의 주요\n사유를 평가하여 증례 기록서 임상시험 완료 항목에 해당 정보를\n\n- - 참여 중단 의사를 밝히지 않고 방문에 출석하지 않아 현재\n상태가 불분명한 대상자의 경우에 시험자는 대상자와 전화\n\n- - 78 -\n- 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 의함)\n- 가.  유효성의 평가 기준\n[일차 유효성 평가변수]\n\n[이차 유효성 평가변수]\n\n1) 베이스라인 (사용 전) 대비 4주, 8주 시점의 하기 지표 변화량\n\n- - 79 -\n- (5) Clinical Global Impression of Severity (CGI-S)\n2) 4주, 8주 시점의 Clinical Global Impression of Improvement\n\n- - 80 -\n- 나.  검사방법\n1) Eating Disorder Examination Questionnaire (EDE-Q)\n\nEDE-Q는 총 28개 문항으로 구성된 자가 설문지이며, 섭식장애의\n\n주요 병리를 측정하는 식사제한, 식사관심, 체형관심, 체중관심의\n\n4개 하위요인으로 구성되어 있다.  빈도를 묻는 문항을 제외하고 지\n\n난 4주간의 증상을 0점에서 6점까지 7점 척도로 평가한다.  점수가\n\n높을수록 섭식 행동 및 태도에 문제가 있는 것을 의미한다 (Bang,\n\n본 연구에서는 방문 1, 방문3, 방문 5에 EDE-Q 척도 평가를 수행\n\n할 예정이고 일차 유효성 평가는 EDE-Q로 평가할 예정이다. ",
        "original_sentence": "유효성의 평가 기준\n[일차 유효성 평가변수]\n\n[이차 유효성 평가변수]\n\n1) 베이스라인 (사용 전) 대비 4주, 8주 시점의 하기 지표 변화량\n\n- - 79 -\n- (5) Clinical Global Impression of Severity (CGI-S)\n2) 4주, 8주 시점의 Clinical Global Impression of Improvement\n\n- - 80 -\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_660",
      "text": "검사방법\n1) Eating Disorder Examination Questionnaire (EDE-Q)\n\nEDE-Q는 총 28개 문항으로 구성된 자가 설문지이며, 섭식장애의\n\n주요 병리를 측정하는 식사제한, 식사관심, 체형관심, 체중관심의\n\n4개 하위요인으로 구성되어 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 659,
        "window_size": 3,
        "char_count": 154,
        "word_count": 26,
        "page_number": 18,
        "window_text": "탈락\n: 시험자는 다음과 같은 경우에 연구 참여 대상자를 시험에서\n\n- - 피험자의 부작용(예: 두통, 눈의 피로, 눈 또는 근육경련, 눈의\n불수의운동, 메스꺼움, 어지럼증 등)으로 인하여 임상시험 책임자\n\n- - 피험자가 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n- - 피험자의 임상시험 중 임상시험용 의료기기 비교 평가하는 데\n- - 임상시험 중 선정/제외 기준 위반 등 중대한 계획서 위반\n- - 77 -\n- - 기타 사유로 인하여 임상시험 책임자 또는 담당자가 임상\n시험을 중지해야 한다고 판단한 경우\n\n- - 섭식장애 연관 증상이 지나치게 악화되어 다른 정신과적 건강\n- - 중도 탈락 시, 시험자는 대상자의 임상시험 조기 탈락의 주요\n사유를 평가하여 증례 기록서 임상시험 완료 항목에 해당 정보를\n\n- - 참여 중단 의사를 밝히지 않고 방문에 출석하지 않아 현재\n상태가 불분명한 대상자의 경우에 시험자는 대상자와 전화\n\n- - 78 -\n- 14.  유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 의함)\n- 가.  유효성의 평가 기준\n[일차 유효성 평가변수]\n\n[이차 유효성 평가변수]\n\n1) 베이스라인 (사용 전) 대비 4주, 8주 시점의 하기 지표 변화량\n\n- - 79 -\n- (5) Clinical Global Impression of Severity (CGI-S)\n2) 4주, 8주 시점의 Clinical Global Impression of Improvement\n\n- - 80 -\n- 나.  검사방법\n1) Eating Disorder Examination Questionnaire (EDE-Q)\n\nEDE-Q는 총 28개 문항으로 구성된 자가 설문지이며, 섭식장애의\n\n주요 병리를 측정하는 식사제한, 식사관심, 체형관심, 체중관심의\n\n4개 하위요인으로 구성되어 있다.  빈도를 묻는 문항을 제외하고 지\n\n난 4주간의 증상을 0점에서 6점까지 7점 척도로 평가한다.  점수가\n\n높을수록 섭식 행동 및 태도에 문제가 있는 것을 의미한다 (Bang,\n\n본 연구에서는 방문 1, 방문3, 방문 5에 EDE-Q 척도 평가를 수행\n\n할 예정이고 일차 유효성 평가는 EDE-Q로 평가할 예정이다.  측정\n\nCIA를 통해 섭식장애와 관련된 세 가지 주요 영역(개인적, 사회적,\n\n인지적)에 대한 이차적인 손상정도를 평가한다. ",
        "original_sentence": "검사방법\n1) Eating Disorder Examination Questionnaire (EDE-Q)\n\nEDE-Q는 총 28개 문항으로 구성된 자가 설문지이며, 섭식장애의\n\n주요 병리를 측정하는 식사제한, 식사관심, 체형관심, 체중관심의\n\n4개 하위요인으로 구성되어 있다. "
      }
    },
    {
      "chunk_id": "chunk_661",
      "text": "빈도를 묻는 문항을 제외하고 지\n\n난 4주간의 증상을 0점에서 6점까지 7점 척도로 평가한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 660,
        "window_size": 3,
        "char_count": 53,
        "word_count": 13,
        "page_number": 26,
        "window_text": "유효성의 평가기준, 평가방법 및 해석방법(통계분석방법에 의함)\n- 가.  유효성의 평가 기준\n[일차 유효성 평가변수]\n\n[이차 유효성 평가변수]\n\n1) 베이스라인 (사용 전) 대비 4주, 8주 시점의 하기 지표 변화량\n\n- - 79 -\n- (5) Clinical Global Impression of Severity (CGI-S)\n2) 4주, 8주 시점의 Clinical Global Impression of Improvement\n\n- - 80 -\n- 나.  검사방법\n1) Eating Disorder Examination Questionnaire (EDE-Q)\n\nEDE-Q는 총 28개 문항으로 구성된 자가 설문지이며, 섭식장애의\n\n주요 병리를 측정하는 식사제한, 식사관심, 체형관심, 체중관심의\n\n4개 하위요인으로 구성되어 있다.  빈도를 묻는 문항을 제외하고 지\n\n난 4주간의 증상을 0점에서 6점까지 7점 척도로 평가한다.  점수가\n\n높을수록 섭식 행동 및 태도에 문제가 있는 것을 의미한다 (Bang,\n\n본 연구에서는 방문 1, 방문3, 방문 5에 EDE-Q 척도 평가를 수행\n\n할 예정이고 일차 유효성 평가는 EDE-Q로 평가할 예정이다.  측정\n\nCIA를 통해 섭식장애와 관련된 세 가지 주요 영역(개인적, 사회적,\n\n인지적)에 대한 이차적인 손상정도를 평가한다.  CIA는 총 16개 문항의\n\n짧은 자기보고형 평가도구로, 0점에서 3점까지 4점 척도로 평가한다.\n\n",
        "original_sentence": "빈도를 묻는 문항을 제외하고 지\n\n난 4주간의 증상을 0점에서 6점까지 7점 척도로 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_662",
      "text": "점수가\n\n높을수록 섭식 행동 및 태도에 문제가 있는 것을 의미한다 (Bang,\n\n본 연구에서는 방문 1, 방문3, 방문 5에 EDE-Q 척도 평가를 수행\n\n할 예정이고 일차 유효성 평가는 EDE-Q로 평가할 예정이다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 661,
        "window_size": 3,
        "char_count": 122,
        "word_count": 30,
        "page_number": 30,
        "window_text": "유효성의 평가 기준\n[일차 유효성 평가변수]\n\n[이차 유효성 평가변수]\n\n1) 베이스라인 (사용 전) 대비 4주, 8주 시점의 하기 지표 변화량\n\n- - 79 -\n- (5) Clinical Global Impression of Severity (CGI-S)\n2) 4주, 8주 시점의 Clinical Global Impression of Improvement\n\n- - 80 -\n- 나.  검사방법\n1) Eating Disorder Examination Questionnaire (EDE-Q)\n\nEDE-Q는 총 28개 문항으로 구성된 자가 설문지이며, 섭식장애의\n\n주요 병리를 측정하는 식사제한, 식사관심, 체형관심, 체중관심의\n\n4개 하위요인으로 구성되어 있다.  빈도를 묻는 문항을 제외하고 지\n\n난 4주간의 증상을 0점에서 6점까지 7점 척도로 평가한다.  점수가\n\n높을수록 섭식 행동 및 태도에 문제가 있는 것을 의미한다 (Bang,\n\n본 연구에서는 방문 1, 방문3, 방문 5에 EDE-Q 척도 평가를 수행\n\n할 예정이고 일차 유효성 평가는 EDE-Q로 평가할 예정이다.  측정\n\nCIA를 통해 섭식장애와 관련된 세 가지 주요 영역(개인적, 사회적,\n\n인지적)에 대한 이차적인 손상정도를 평가한다.  CIA는 총 16개 문항의\n\n짧은 자기보고형 평가도구로, 0점에서 3점까지 4점 척도로 평가한다.\n\n 점수가 높을수록 섭식장애로 인한 개인적, 사회적, 인지적 손상이\n\nPHQ-9를 통해 우울 증상을 평가한다. ",
        "original_sentence": "점수가\n\n높을수록 섭식 행동 및 태도에 문제가 있는 것을 의미한다 (Bang,\n\n본 연구에서는 방문 1, 방문3, 방문 5에 EDE-Q 척도 평가를 수행\n\n할 예정이고 일차 유효성 평가는 EDE-Q로 평가할 예정이다. "
      }
    },
    {
      "chunk_id": "chunk_663",
      "text": "측정\n\nCIA를 통해 섭식장애와 관련된 세 가지 주요 영역(개인적, 사회적,\n\n인지적)에 대한 이차적인 손상정도를 평가한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 662,
        "window_size": 3,
        "char_count": 70,
        "word_count": 15,
        "page_number": 31,
        "window_text": "검사방법\n1) Eating Disorder Examination Questionnaire (EDE-Q)\n\nEDE-Q는 총 28개 문항으로 구성된 자가 설문지이며, 섭식장애의\n\n주요 병리를 측정하는 식사제한, 식사관심, 체형관심, 체중관심의\n\n4개 하위요인으로 구성되어 있다.  빈도를 묻는 문항을 제외하고 지\n\n난 4주간의 증상을 0점에서 6점까지 7점 척도로 평가한다.  점수가\n\n높을수록 섭식 행동 및 태도에 문제가 있는 것을 의미한다 (Bang,\n\n본 연구에서는 방문 1, 방문3, 방문 5에 EDE-Q 척도 평가를 수행\n\n할 예정이고 일차 유효성 평가는 EDE-Q로 평가할 예정이다.  측정\n\nCIA를 통해 섭식장애와 관련된 세 가지 주요 영역(개인적, 사회적,\n\n인지적)에 대한 이차적인 손상정도를 평가한다.  CIA는 총 16개 문항의\n\n짧은 자기보고형 평가도구로, 0점에서 3점까지 4점 척도로 평가한다.\n\n 점수가 높을수록 섭식장애로 인한 개인적, 사회적, 인지적 손상이\n\nPHQ-9를 통해 우울 증상을 평가한다.  DSM-IV의 주요우울장애의\n\n진단기준에 의거하여 지난 2주간의 무쾌감, 우울감, 수면의 변화,\n\n피로감, 식욕의 변화, 죄책감, 무가치감, 집중력 저하, 좌불안석 또는\n\n- - 81 -\n쳐진 느낌, 자살사고의 9가지 문항으로 구성되어 있다. ",
        "original_sentence": "측정\n\nCIA를 통해 섭식장애와 관련된 세 가지 주요 영역(개인적, 사회적,\n\n인지적)에 대한 이차적인 손상정도를 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_664",
      "text": "CIA는 총 16개 문항의\n\n짧은 자기보고형 평가도구로, 0점에서 3점까지 4점 척도로 평가한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 663,
        "window_size": 3,
        "char_count": 56,
        "word_count": 12,
        "page_number": 19,
        "window_text": "빈도를 묻는 문항을 제외하고 지\n\n난 4주간의 증상을 0점에서 6점까지 7점 척도로 평가한다.  점수가\n\n높을수록 섭식 행동 및 태도에 문제가 있는 것을 의미한다 (Bang,\n\n본 연구에서는 방문 1, 방문3, 방문 5에 EDE-Q 척도 평가를 수행\n\n할 예정이고 일차 유효성 평가는 EDE-Q로 평가할 예정이다.  측정\n\nCIA를 통해 섭식장애와 관련된 세 가지 주요 영역(개인적, 사회적,\n\n인지적)에 대한 이차적인 손상정도를 평가한다.  CIA는 총 16개 문항의\n\n짧은 자기보고형 평가도구로, 0점에서 3점까지 4점 척도로 평가한다.\n\n 점수가 높을수록 섭식장애로 인한 개인적, 사회적, 인지적 손상이\n\nPHQ-9를 통해 우울 증상을 평가한다.  DSM-IV의 주요우울장애의\n\n진단기준에 의거하여 지난 2주간의 무쾌감, 우울감, 수면의 변화,\n\n피로감, 식욕의 변화, 죄책감, 무가치감, 집중력 저하, 좌불안석 또는\n\n- - 81 -\n쳐진 느낌, 자살사고의 9가지 문항으로 구성되어 있다.  각각의\n\n요소는 0점 (전혀없음)에서 3점(거의 매일)으로 구성되어 총점은\n\n0-27점 사이가 된다. ",
        "original_sentence": "CIA는 총 16개 문항의\n\n짧은 자기보고형 평가도구로, 0점에서 3점까지 4점 척도로 평가한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_665",
      "text": "점수가 높을수록 섭식장애로 인한 개인적, 사회적, 인지적 손상이\n\nPHQ-9를 통해 우울 증상을 평가한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 664,
        "window_size": 3,
        "char_count": 60,
        "word_count": 13,
        "page_number": 28,
        "window_text": "점수가\n\n높을수록 섭식 행동 및 태도에 문제가 있는 것을 의미한다 (Bang,\n\n본 연구에서는 방문 1, 방문3, 방문 5에 EDE-Q 척도 평가를 수행\n\n할 예정이고 일차 유효성 평가는 EDE-Q로 평가할 예정이다.  측정\n\nCIA를 통해 섭식장애와 관련된 세 가지 주요 영역(개인적, 사회적,\n\n인지적)에 대한 이차적인 손상정도를 평가한다.  CIA는 총 16개 문항의\n\n짧은 자기보고형 평가도구로, 0점에서 3점까지 4점 척도로 평가한다.\n\n 점수가 높을수록 섭식장애로 인한 개인적, 사회적, 인지적 손상이\n\nPHQ-9를 통해 우울 증상을 평가한다.  DSM-IV의 주요우울장애의\n\n진단기준에 의거하여 지난 2주간의 무쾌감, 우울감, 수면의 변화,\n\n피로감, 식욕의 변화, 죄책감, 무가치감, 집중력 저하, 좌불안석 또는\n\n- - 81 -\n쳐진 느낌, 자살사고의 9가지 문항으로 구성되어 있다.  각각의\n\n요소는 0점 (전혀없음)에서 3점(거의 매일)으로 구성되어 총점은\n\n0-27점 사이가 된다.  점수가 높을수록 우울 증상이 심각하다는 것을\n\nGAD-7은 범불안장애 환자를 선별 진단하기 위해 개발된 선별평\n\n가도구로 불안 또는 걱정과 관련된 7가지 문항에 대해 그 정도를\n\n0점 (전혀 없었다)에서 3점(거의 매일 괴로웠다.",
        "original_sentence": "점수가 높을수록 섭식장애로 인한 개인적, 사회적, 인지적 손상이\n\nPHQ-9를 통해 우울 증상을 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_666",
      "text": "DSM-IV의 주요우울장애의\n\n진단기준에 의거하여 지난 2주간의 무쾌감, 우울감, 수면의 변화,\n\n피로감, 식욕의 변화, 죄책감, 무가치감, 집중력 저하, 좌불안석 또는\n\n- - 81 -\n쳐진 느낌, 자살사고의 9가지 문항으로 구성되어 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 665,
        "window_size": 3,
        "char_count": 136,
        "word_count": 30,
        "page_number": 9,
        "window_text": "측정\n\nCIA를 통해 섭식장애와 관련된 세 가지 주요 영역(개인적, 사회적,\n\n인지적)에 대한 이차적인 손상정도를 평가한다.  CIA는 총 16개 문항의\n\n짧은 자기보고형 평가도구로, 0점에서 3점까지 4점 척도로 평가한다.\n\n 점수가 높을수록 섭식장애로 인한 개인적, 사회적, 인지적 손상이\n\nPHQ-9를 통해 우울 증상을 평가한다.  DSM-IV의 주요우울장애의\n\n진단기준에 의거하여 지난 2주간의 무쾌감, 우울감, 수면의 변화,\n\n피로감, 식욕의 변화, 죄책감, 무가치감, 집중력 저하, 좌불안석 또는\n\n- - 81 -\n쳐진 느낌, 자살사고의 9가지 문항으로 구성되어 있다.  각각의\n\n요소는 0점 (전혀없음)에서 3점(거의 매일)으로 구성되어 총점은\n\n0-27점 사이가 된다.  점수가 높을수록 우울 증상이 심각하다는 것을\n\nGAD-7은 범불안장애 환자를 선별 진단하기 위해 개발된 선별평\n\n가도구로 불안 또는 걱정과 관련된 7가지 문항에 대해 그 정도를\n\n0점 (전혀 없었다)에서 3점(거의 매일 괴로웠다. )까지 체크하여 불안\n\n증상을 평가한다. ",
        "original_sentence": "DSM-IV의 주요우울장애의\n\n진단기준에 의거하여 지난 2주간의 무쾌감, 우울감, 수면의 변화,\n\n피로감, 식욕의 변화, 죄책감, 무가치감, 집중력 저하, 좌불안석 또는\n\n- - 81 -\n쳐진 느낌, 자살사고의 9가지 문항으로 구성되어 있다. "
      }
    },
    {
      "chunk_id": "chunk_667",
      "text": "각각의\n\n요소는 0점 (전혀없음)에서 3점(거의 매일)으로 구성되어 총점은\n\n0-27점 사이가 된다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 666,
        "window_size": 3,
        "char_count": 57,
        "word_count": 11,
        "page_number": 9,
        "window_text": "CIA는 총 16개 문항의\n\n짧은 자기보고형 평가도구로, 0점에서 3점까지 4점 척도로 평가한다.\n\n 점수가 높을수록 섭식장애로 인한 개인적, 사회적, 인지적 손상이\n\nPHQ-9를 통해 우울 증상을 평가한다.  DSM-IV의 주요우울장애의\n\n진단기준에 의거하여 지난 2주간의 무쾌감, 우울감, 수면의 변화,\n\n피로감, 식욕의 변화, 죄책감, 무가치감, 집중력 저하, 좌불안석 또는\n\n- - 81 -\n쳐진 느낌, 자살사고의 9가지 문항으로 구성되어 있다.  각각의\n\n요소는 0점 (전혀없음)에서 3점(거의 매일)으로 구성되어 총점은\n\n0-27점 사이가 된다.  점수가 높을수록 우울 증상이 심각하다는 것을\n\nGAD-7은 범불안장애 환자를 선별 진단하기 위해 개발된 선별평\n\n가도구로 불안 또는 걱정과 관련된 7가지 문항에 대해 그 정도를\n\n0점 (전혀 없었다)에서 3점(거의 매일 괴로웠다. )까지 체크하여 불안\n\n증상을 평가한다.  총점은 0-21점 사이가 되며, 점수가 높을수록 불안\n\n증상의 심각도가 높고 기능저하도 심한 것을 의미한다(Kim,Park et\n\nEQ-VAS는 일반적으로 사용되는 삶의 질 설문지 중 하나로, 피험자의\n\n전반적인 건강 상태를 0점에서 100점 척도로 평가한다. ",
        "original_sentence": "각각의\n\n요소는 0점 (전혀없음)에서 3점(거의 매일)으로 구성되어 총점은\n\n0-27점 사이가 된다. "
      }
    },
    {
      "chunk_id": "chunk_668",
      "text": "점수가 높을수록 우울 증상이 심각하다는 것을\n\nGAD-7은 범불안장애 환자를 선별 진단하기 위해 개발된 선별평\n\n가도구로 불안 또는 걱정과 관련된 7가지 문항에 대해 그 정도를\n\n0점 (전혀 없었다)에서 3점(거의 매일 괴로웠다.",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 667,
        "window_size": 3,
        "char_count": 128,
        "word_count": 30,
        "page_number": 15,
        "window_text": "점수가 높을수록 섭식장애로 인한 개인적, 사회적, 인지적 손상이\n\nPHQ-9를 통해 우울 증상을 평가한다.  DSM-IV의 주요우울장애의\n\n진단기준에 의거하여 지난 2주간의 무쾌감, 우울감, 수면의 변화,\n\n피로감, 식욕의 변화, 죄책감, 무가치감, 집중력 저하, 좌불안석 또는\n\n- - 81 -\n쳐진 느낌, 자살사고의 9가지 문항으로 구성되어 있다.  각각의\n\n요소는 0점 (전혀없음)에서 3점(거의 매일)으로 구성되어 총점은\n\n0-27점 사이가 된다.  점수가 높을수록 우울 증상이 심각하다는 것을\n\nGAD-7은 범불안장애 환자를 선별 진단하기 위해 개발된 선별평\n\n가도구로 불안 또는 걱정과 관련된 7가지 문항에 대해 그 정도를\n\n0점 (전혀 없었다)에서 3점(거의 매일 괴로웠다. )까지 체크하여 불안\n\n증상을 평가한다.  총점은 0-21점 사이가 되며, 점수가 높을수록 불안\n\n증상의 심각도가 높고 기능저하도 심한 것을 의미한다(Kim,Park et\n\nEQ-VAS는 일반적으로 사용되는 삶의 질 설문지 중 하나로, 피험자의\n\n전반적인 건강 상태를 0점에서 100점 척도로 평가한다.  점수가\n\n높을수록\n\n전반적인\n\n건강\n\n상태가\n\n좋다는\n\n것을\n\n의미한다\n\nCGI-I는 피험자의 전반적인 건강상태의 개선 정도를 평가하는\n\n설문지로, 4주 (방문 3), 8주 (방문 5) 시점에 평가한다. ",
        "original_sentence": "점수가 높을수록 우울 증상이 심각하다는 것을\n\nGAD-7은 범불안장애 환자를 선별 진단하기 위해 개발된 선별평\n\n가도구로 불안 또는 걱정과 관련된 7가지 문항에 대해 그 정도를\n\n0점 (전혀 없었다)에서 3점(거의 매일 괴로웠다."
      }
    },
    {
      "chunk_id": "chunk_669",
      "text": ")까지 체크하여 불안\n\n증상을 평가한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 668,
        "window_size": 3,
        "char_count": 23,
        "word_count": 5,
        "page_number": 15,
        "window_text": "DSM-IV의 주요우울장애의\n\n진단기준에 의거하여 지난 2주간의 무쾌감, 우울감, 수면의 변화,\n\n피로감, 식욕의 변화, 죄책감, 무가치감, 집중력 저하, 좌불안석 또는\n\n- - 81 -\n쳐진 느낌, 자살사고의 9가지 문항으로 구성되어 있다.  각각의\n\n요소는 0점 (전혀없음)에서 3점(거의 매일)으로 구성되어 총점은\n\n0-27점 사이가 된다.  점수가 높을수록 우울 증상이 심각하다는 것을\n\nGAD-7은 범불안장애 환자를 선별 진단하기 위해 개발된 선별평\n\n가도구로 불안 또는 걱정과 관련된 7가지 문항에 대해 그 정도를\n\n0점 (전혀 없었다)에서 3점(거의 매일 괴로웠다. )까지 체크하여 불안\n\n증상을 평가한다.  총점은 0-21점 사이가 되며, 점수가 높을수록 불안\n\n증상의 심각도가 높고 기능저하도 심한 것을 의미한다(Kim,Park et\n\nEQ-VAS는 일반적으로 사용되는 삶의 질 설문지 중 하나로, 피험자의\n\n전반적인 건강 상태를 0점에서 100점 척도로 평가한다.  점수가\n\n높을수록\n\n전반적인\n\n건강\n\n상태가\n\n좋다는\n\n것을\n\n의미한다\n\nCGI-I는 피험자의 전반적인 건강상태의 개선 정도를 평가하는\n\n설문지로, 4주 (방문 3), 8주 (방문 5) 시점에 평가한다.  시험자는\n\n피험자의 건강상태의 개선 또는 악화 정도를 7점 척도로 평가하며,\n\n- - 82 -\n점수가 낮을수록 개선도가 높다는 것을 의미한다(Busner&Targum,\n\n2007).\n\n",
        "original_sentence": ")까지 체크하여 불안\n\n증상을 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_670",
      "text": "총점은 0-21점 사이가 되며, 점수가 높을수록 불안\n\n증상의 심각도가 높고 기능저하도 심한 것을 의미한다(Kim,Park et\n\nEQ-VAS는 일반적으로 사용되는 삶의 질 설문지 중 하나로, 피험자의\n\n전반적인 건강 상태를 0점에서 100점 척도로 평가한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 669,
        "window_size": 3,
        "char_count": 146,
        "word_count": 31,
        "page_number": 9,
        "window_text": "각각의\n\n요소는 0점 (전혀없음)에서 3점(거의 매일)으로 구성되어 총점은\n\n0-27점 사이가 된다.  점수가 높을수록 우울 증상이 심각하다는 것을\n\nGAD-7은 범불안장애 환자를 선별 진단하기 위해 개발된 선별평\n\n가도구로 불안 또는 걱정과 관련된 7가지 문항에 대해 그 정도를\n\n0점 (전혀 없었다)에서 3점(거의 매일 괴로웠다. )까지 체크하여 불안\n\n증상을 평가한다.  총점은 0-21점 사이가 되며, 점수가 높을수록 불안\n\n증상의 심각도가 높고 기능저하도 심한 것을 의미한다(Kim,Park et\n\nEQ-VAS는 일반적으로 사용되는 삶의 질 설문지 중 하나로, 피험자의\n\n전반적인 건강 상태를 0점에서 100점 척도로 평가한다.  점수가\n\n높을수록\n\n전반적인\n\n건강\n\n상태가\n\n좋다는\n\n것을\n\n의미한다\n\nCGI-I는 피험자의 전반적인 건강상태의 개선 정도를 평가하는\n\n설문지로, 4주 (방문 3), 8주 (방문 5) 시점에 평가한다.  시험자는\n\n피험자의 건강상태의 개선 또는 악화 정도를 7점 척도로 평가하며,\n\n- - 82 -\n점수가 낮을수록 개선도가 높다는 것을 의미한다(Busner&Targum,\n\n2007).\n\n CGI-S는 피험자의 전반적인 질병 상태의 심각도를 평가하는 설문지로,\n\n베이스라인, 4주 (방문 3), 8주 (방문 5) 시점에 평가한다. ",
        "original_sentence": "총점은 0-21점 사이가 되며, 점수가 높을수록 불안\n\n증상의 심각도가 높고 기능저하도 심한 것을 의미한다(Kim,Park et\n\nEQ-VAS는 일반적으로 사용되는 삶의 질 설문지 중 하나로, 피험자의\n\n전반적인 건강 상태를 0점에서 100점 척도로 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_671",
      "text": "점수가\n\n높을수록\n\n전반적인\n\n건강\n\n상태가\n\n좋다는\n\n것을\n\n의미한다\n\nCGI-I는 피험자의 전반적인 건강상태의 개선 정도를 평가하는\n\n설문지로, 4주 (방문 3), 8주 (방문 5) 시점에 평가한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 670,
        "window_size": 3,
        "char_count": 114,
        "word_count": 24,
        "page_number": 35,
        "window_text": "점수가 높을수록 우울 증상이 심각하다는 것을\n\nGAD-7은 범불안장애 환자를 선별 진단하기 위해 개발된 선별평\n\n가도구로 불안 또는 걱정과 관련된 7가지 문항에 대해 그 정도를\n\n0점 (전혀 없었다)에서 3점(거의 매일 괴로웠다. )까지 체크하여 불안\n\n증상을 평가한다.  총점은 0-21점 사이가 되며, 점수가 높을수록 불안\n\n증상의 심각도가 높고 기능저하도 심한 것을 의미한다(Kim,Park et\n\nEQ-VAS는 일반적으로 사용되는 삶의 질 설문지 중 하나로, 피험자의\n\n전반적인 건강 상태를 0점에서 100점 척도로 평가한다.  점수가\n\n높을수록\n\n전반적인\n\n건강\n\n상태가\n\n좋다는\n\n것을\n\n의미한다\n\nCGI-I는 피험자의 전반적인 건강상태의 개선 정도를 평가하는\n\n설문지로, 4주 (방문 3), 8주 (방문 5) 시점에 평가한다.  시험자는\n\n피험자의 건강상태의 개선 또는 악화 정도를 7점 척도로 평가하며,\n\n- - 82 -\n점수가 낮을수록 개선도가 높다는 것을 의미한다(Busner&Targum,\n\n2007).\n\n CGI-S는 피험자의 전반적인 질병 상태의 심각도를 평가하는 설문지로,\n\n베이스라인, 4주 (방문 3), 8주 (방문 5) 시점에 평가한다.  시험자는\n\n높을수록 질병 심각도가 높다는 것을 의미한다(Busner&Targum,\n\nFollow-up 후 4주, 8주 시점에 폭식 횟수 0회 달성 여부 및 치료 전\n\n- - 83 -\n- 다. ",
        "original_sentence": "점수가\n\n높을수록\n\n전반적인\n\n건강\n\n상태가\n\n좋다는\n\n것을\n\n의미한다\n\nCGI-I는 피험자의 전반적인 건강상태의 개선 정도를 평가하는\n\n설문지로, 4주 (방문 3), 8주 (방문 5) 시점에 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_672",
      "text": "시험자는\n\n피험자의 건강상태의 개선 또는 악화 정도를 7점 척도로 평가하며,\n\n- - 82 -\n점수가 낮을수록 개선도가 높다는 것을 의미한다(Busner&Targum,\n\n2007).\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 671,
        "window_size": 3,
        "char_count": 103,
        "word_count": 21,
        "page_number": 9,
        "window_text": ")까지 체크하여 불안\n\n증상을 평가한다.  총점은 0-21점 사이가 되며, 점수가 높을수록 불안\n\n증상의 심각도가 높고 기능저하도 심한 것을 의미한다(Kim,Park et\n\nEQ-VAS는 일반적으로 사용되는 삶의 질 설문지 중 하나로, 피험자의\n\n전반적인 건강 상태를 0점에서 100점 척도로 평가한다.  점수가\n\n높을수록\n\n전반적인\n\n건강\n\n상태가\n\n좋다는\n\n것을\n\n의미한다\n\nCGI-I는 피험자의 전반적인 건강상태의 개선 정도를 평가하는\n\n설문지로, 4주 (방문 3), 8주 (방문 5) 시점에 평가한다.  시험자는\n\n피험자의 건강상태의 개선 또는 악화 정도를 7점 척도로 평가하며,\n\n- - 82 -\n점수가 낮을수록 개선도가 높다는 것을 의미한다(Busner&Targum,\n\n2007).\n\n CGI-S는 피험자의 전반적인 질병 상태의 심각도를 평가하는 설문지로,\n\n베이스라인, 4주 (방문 3), 8주 (방문 5) 시점에 평가한다.  시험자는\n\n높을수록 질병 심각도가 높다는 것을 의미한다(Busner&Targum,\n\nFollow-up 후 4주, 8주 시점에 폭식 횟수 0회 달성 여부 및 치료 전\n\n- - 83 -\n- 다.  통계분석방법\n1) 분석대상군\n\n모든 분석 대상자군(FAS)에 속한 피험자이면서 임상시험\n\n일정대로 모든 수행을 완료하고, 아래의 주요한 임상시험계획\n\n위반이 없는 피험자로 정의한다. ",
        "original_sentence": "시험자는\n\n피험자의 건강상태의 개선 또는 악화 정도를 7점 척도로 평가하며,\n\n- - 82 -\n점수가 낮을수록 개선도가 높다는 것을 의미한다(Busner&Targum,\n\n2007).\n\n"
      }
    },
    {
      "chunk_id": "chunk_673",
      "text": "CGI-S는 피험자의 전반적인 질병 상태의 심각도를 평가하는 설문지로,\n\n베이스라인, 4주 (방문 3), 8주 (방문 5) 시점에 평가한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 672,
        "window_size": 3,
        "char_count": 79,
        "word_count": 17,
        "page_number": 26,
        "window_text": "총점은 0-21점 사이가 되며, 점수가 높을수록 불안\n\n증상의 심각도가 높고 기능저하도 심한 것을 의미한다(Kim,Park et\n\nEQ-VAS는 일반적으로 사용되는 삶의 질 설문지 중 하나로, 피험자의\n\n전반적인 건강 상태를 0점에서 100점 척도로 평가한다.  점수가\n\n높을수록\n\n전반적인\n\n건강\n\n상태가\n\n좋다는\n\n것을\n\n의미한다\n\nCGI-I는 피험자의 전반적인 건강상태의 개선 정도를 평가하는\n\n설문지로, 4주 (방문 3), 8주 (방문 5) 시점에 평가한다.  시험자는\n\n피험자의 건강상태의 개선 또는 악화 정도를 7점 척도로 평가하며,\n\n- - 82 -\n점수가 낮을수록 개선도가 높다는 것을 의미한다(Busner&Targum,\n\n2007).\n\n CGI-S는 피험자의 전반적인 질병 상태의 심각도를 평가하는 설문지로,\n\n베이스라인, 4주 (방문 3), 8주 (방문 5) 시점에 평가한다.  시험자는\n\n높을수록 질병 심각도가 높다는 것을 의미한다(Busner&Targum,\n\nFollow-up 후 4주, 8주 시점에 폭식 횟수 0회 달성 여부 및 치료 전\n\n- - 83 -\n- 다.  통계분석방법\n1) 분석대상군\n\n모든 분석 대상자군(FAS)에 속한 피험자이면서 임상시험\n\n일정대로 모든 수행을 완료하고, 아래의 주요한 임상시험계획\n\n위반이 없는 피험자로 정의한다.  1차/2차 유효성 평가는 계획서\n\n- (4) 임상시험 참여 중 심적/신체적 환경 변화로 있는 것으로 판\n모듈 횟수 중 75% 미만(예, 총 6주의 경우 4주 미만)으로 노출된\n\n배정된 대로 분석(Intention-to-treat, ITT) 원칙을 따르며,\n\n무작위배정된 모든 피험자군 중 주요한 선정기준을 위배하거나\n\n무작위배정된 후 섭식장애 개선 디지털치료기기를 로그인 하여,\n\n한 번이라도 사용한 로그가 존재하지 않거나, 무작위배정 이후\n\n일차 유효성 평가자료가 전무한 경우는 제외한다. ",
        "original_sentence": "CGI-S는 피험자의 전반적인 질병 상태의 심각도를 평가하는 설문지로,\n\n베이스라인, 4주 (방문 3), 8주 (방문 5) 시점에 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_674",
      "text": "시험자는\n\n높을수록 질병 심각도가 높다는 것을 의미한다(Busner&Targum,\n\nFollow-up 후 4주, 8주 시점에 폭식 횟수 0회 달성 여부 및 치료 전\n\n- - 83 -\n- 다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 673,
        "window_size": 3,
        "char_count": 107,
        "word_count": 26,
        "page_number": 30,
        "window_text": "점수가\n\n높을수록\n\n전반적인\n\n건강\n\n상태가\n\n좋다는\n\n것을\n\n의미한다\n\nCGI-I는 피험자의 전반적인 건강상태의 개선 정도를 평가하는\n\n설문지로, 4주 (방문 3), 8주 (방문 5) 시점에 평가한다.  시험자는\n\n피험자의 건강상태의 개선 또는 악화 정도를 7점 척도로 평가하며,\n\n- - 82 -\n점수가 낮을수록 개선도가 높다는 것을 의미한다(Busner&Targum,\n\n2007).\n\n CGI-S는 피험자의 전반적인 질병 상태의 심각도를 평가하는 설문지로,\n\n베이스라인, 4주 (방문 3), 8주 (방문 5) 시점에 평가한다.  시험자는\n\n높을수록 질병 심각도가 높다는 것을 의미한다(Busner&Targum,\n\nFollow-up 후 4주, 8주 시점에 폭식 횟수 0회 달성 여부 및 치료 전\n\n- - 83 -\n- 다.  통계분석방법\n1) 분석대상군\n\n모든 분석 대상자군(FAS)에 속한 피험자이면서 임상시험\n\n일정대로 모든 수행을 완료하고, 아래의 주요한 임상시험계획\n\n위반이 없는 피험자로 정의한다.  1차/2차 유효성 평가는 계획서\n\n- (4) 임상시험 참여 중 심적/신체적 환경 변화로 있는 것으로 판\n모듈 횟수 중 75% 미만(예, 총 6주의 경우 4주 미만)으로 노출된\n\n배정된 대로 분석(Intention-to-treat, ITT) 원칙을 따르며,\n\n무작위배정된 모든 피험자군 중 주요한 선정기준을 위배하거나\n\n무작위배정된 후 섭식장애 개선 디지털치료기기를 로그인 하여,\n\n한 번이라도 사용한 로그가 존재하지 않거나, 무작위배정 이후\n\n일차 유효성 평가자료가 전무한 경우는 제외한다.  1차/2차\n\n유효성 평가는 모든 분석 대상자군(Full Analysis Set, FAS)를\n\n- - 84 -\n섭식장애 개선 디지털치료기기로 한 번이라도 치료를 받은\n\n모든 피험자로 정의한다. ",
        "original_sentence": "시험자는\n\n높을수록 질병 심각도가 높다는 것을 의미한다(Busner&Targum,\n\nFollow-up 후 4주, 8주 시점에 폭식 횟수 0회 달성 여부 및 치료 전\n\n- - 83 -\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_675",
      "text": "통계분석방법\n1) 분석대상군\n\n모든 분석 대상자군(FAS)에 속한 피험자이면서 임상시험\n\n일정대로 모든 수행을 완료하고, 아래의 주요한 임상시험계획\n\n위반이 없는 피험자로 정의한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 674,
        "window_size": 3,
        "char_count": 102,
        "word_count": 20,
        "page_number": 19,
        "window_text": "시험자는\n\n피험자의 건강상태의 개선 또는 악화 정도를 7점 척도로 평가하며,\n\n- - 82 -\n점수가 낮을수록 개선도가 높다는 것을 의미한다(Busner&Targum,\n\n2007).\n\n CGI-S는 피험자의 전반적인 질병 상태의 심각도를 평가하는 설문지로,\n\n베이스라인, 4주 (방문 3), 8주 (방문 5) 시점에 평가한다.  시험자는\n\n높을수록 질병 심각도가 높다는 것을 의미한다(Busner&Targum,\n\nFollow-up 후 4주, 8주 시점에 폭식 횟수 0회 달성 여부 및 치료 전\n\n- - 83 -\n- 다.  통계분석방법\n1) 분석대상군\n\n모든 분석 대상자군(FAS)에 속한 피험자이면서 임상시험\n\n일정대로 모든 수행을 완료하고, 아래의 주요한 임상시험계획\n\n위반이 없는 피험자로 정의한다.  1차/2차 유효성 평가는 계획서\n\n- (4) 임상시험 참여 중 심적/신체적 환경 변화로 있는 것으로 판\n모듈 횟수 중 75% 미만(예, 총 6주의 경우 4주 미만)으로 노출된\n\n배정된 대로 분석(Intention-to-treat, ITT) 원칙을 따르며,\n\n무작위배정된 모든 피험자군 중 주요한 선정기준을 위배하거나\n\n무작위배정된 후 섭식장애 개선 디지털치료기기를 로그인 하여,\n\n한 번이라도 사용한 로그가 존재하지 않거나, 무작위배정 이후\n\n일차 유효성 평가자료가 전무한 경우는 제외한다.  1차/2차\n\n유효성 평가는 모든 분석 대상자군(Full Analysis Set, FAS)를\n\n- - 84 -\n섭식장애 개선 디지털치료기기로 한 번이라도 치료를 받은\n\n모든 피험자로 정의한다.  안전성 평가는 안전성 자료를 대상으로\n\n- - 치료 전 대비 Follow-up 후 8주 시점의 식사장애 검사(EDE-Q)\n: 해당 시점에서의 Post-treatment 후 치료군별 기술통계량(평\n\n: Post-treatment 후 변화량의 군간 차이 검정은 기저치를\n\n공변량으로 한 공분산분석(ANCOVA)을 적용한다. ",
        "original_sentence": "통계분석방법\n1) 분석대상군\n\n모든 분석 대상자군(FAS)에 속한 피험자이면서 임상시험\n\n일정대로 모든 수행을 완료하고, 아래의 주요한 임상시험계획\n\n위반이 없는 피험자로 정의한다. "
      }
    },
    {
      "chunk_id": "chunk_676",
      "text": "1차/2차 유효성 평가는 계획서\n\n- (4) 임상시험 참여 중 심적/신체적 환경 변화로 있는 것으로 판\n모듈 횟수 중 75% 미만(예, 총 6주의 경우 4주 미만)으로 노출된\n\n배정된 대로 분석(Intention-to-treat, ITT) 원칙을 따르며,\n\n무작위배정된 모든 피험자군 중 주요한 선정기준을 위배하거나\n\n무작위배정된 후 섭식장애 개선 디지털치료기기를 로그인 하여,\n\n한 번이라도 사용한 로그가 존재하지 않거나, 무작위배정 이후\n\n일차 유효성 평가자료가 전무한 경우는 제외한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 675,
        "window_size": 3,
        "char_count": 275,
        "word_count": 60,
        "page_number": 7,
        "window_text": "CGI-S는 피험자의 전반적인 질병 상태의 심각도를 평가하는 설문지로,\n\n베이스라인, 4주 (방문 3), 8주 (방문 5) 시점에 평가한다.  시험자는\n\n높을수록 질병 심각도가 높다는 것을 의미한다(Busner&Targum,\n\nFollow-up 후 4주, 8주 시점에 폭식 횟수 0회 달성 여부 및 치료 전\n\n- - 83 -\n- 다.  통계분석방법\n1) 분석대상군\n\n모든 분석 대상자군(FAS)에 속한 피험자이면서 임상시험\n\n일정대로 모든 수행을 완료하고, 아래의 주요한 임상시험계획\n\n위반이 없는 피험자로 정의한다.  1차/2차 유효성 평가는 계획서\n\n- (4) 임상시험 참여 중 심적/신체적 환경 변화로 있는 것으로 판\n모듈 횟수 중 75% 미만(예, 총 6주의 경우 4주 미만)으로 노출된\n\n배정된 대로 분석(Intention-to-treat, ITT) 원칙을 따르며,\n\n무작위배정된 모든 피험자군 중 주요한 선정기준을 위배하거나\n\n무작위배정된 후 섭식장애 개선 디지털치료기기를 로그인 하여,\n\n한 번이라도 사용한 로그가 존재하지 않거나, 무작위배정 이후\n\n일차 유효성 평가자료가 전무한 경우는 제외한다.  1차/2차\n\n유효성 평가는 모든 분석 대상자군(Full Analysis Set, FAS)를\n\n- - 84 -\n섭식장애 개선 디지털치료기기로 한 번이라도 치료를 받은\n\n모든 피험자로 정의한다.  안전성 평가는 안전성 자료를 대상으로\n\n- - 치료 전 대비 Follow-up 후 8주 시점의 식사장애 검사(EDE-Q)\n: 해당 시점에서의 Post-treatment 후 치료군별 기술통계량(평\n\n: Post-treatment 후 변화량의 군간 차이 검정은 기저치를\n\n공변량으로 한 공분산분석(ANCOVA)을 적용한다.  다른 변수를\n\n통제한 후 배정군 간 평균 변화량에 대한 양측 95% 신뢰\n\n1) 치료 전 대비 Follow-up 후 4주, 8주 시점의 하기 지표 변화량\n\n: CIA, PHQ-9, GAD-7, EQ-VAS, CGI-S 지표를 통해 변화량을\n\n2) 4주, 8주 시점의 Clinical Global Impression of Improvement\n\n3) 치료 전 대비 Follow-up 후 4주, 8주 시점의 폭식 횟수를 0회\n\n- - 85 -\n4) 결측값 처리\n\n- - 모든 분석 대상자군(Full Analysis Set, FAS)에서 중도 탈락 등의\n사유로 치료 후 시점에서 발생하는 결측치는 일차/이차 유효성\n\n평가변수에 대해서는 마지막 관측값 선행 대체법(Last Observation\n\nCarried Forward, LOCF)으로 대치한다. ",
        "original_sentence": "1차/2차 유효성 평가는 계획서\n\n- (4) 임상시험 참여 중 심적/신체적 환경 변화로 있는 것으로 판\n모듈 횟수 중 75% 미만(예, 총 6주의 경우 4주 미만)으로 노출된\n\n배정된 대로 분석(Intention-to-treat, ITT) 원칙을 따르며,\n\n무작위배정된 모든 피험자군 중 주요한 선정기준을 위배하거나\n\n무작위배정된 후 섭식장애 개선 디지털치료기기를 로그인 하여,\n\n한 번이라도 사용한 로그가 존재하지 않거나, 무작위배정 이후\n\n일차 유효성 평가자료가 전무한 경우는 제외한다. "
      }
    },
    {
      "chunk_id": "chunk_677",
      "text": "1차/2차\n\n유효성 평가는 모든 분석 대상자군(Full Analysis Set, FAS)를\n\n- - 84 -\n섭식장애 개선 디지털치료기기로 한 번이라도 치료를 받은\n\n모든 피험자로 정의한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 676,
        "window_size": 3,
        "char_count": 107,
        "word_count": 23,
        "page_number": 7,
        "window_text": "시험자는\n\n높을수록 질병 심각도가 높다는 것을 의미한다(Busner&Targum,\n\nFollow-up 후 4주, 8주 시점에 폭식 횟수 0회 달성 여부 및 치료 전\n\n- - 83 -\n- 다.  통계분석방법\n1) 분석대상군\n\n모든 분석 대상자군(FAS)에 속한 피험자이면서 임상시험\n\n일정대로 모든 수행을 완료하고, 아래의 주요한 임상시험계획\n\n위반이 없는 피험자로 정의한다.  1차/2차 유효성 평가는 계획서\n\n- (4) 임상시험 참여 중 심적/신체적 환경 변화로 있는 것으로 판\n모듈 횟수 중 75% 미만(예, 총 6주의 경우 4주 미만)으로 노출된\n\n배정된 대로 분석(Intention-to-treat, ITT) 원칙을 따르며,\n\n무작위배정된 모든 피험자군 중 주요한 선정기준을 위배하거나\n\n무작위배정된 후 섭식장애 개선 디지털치료기기를 로그인 하여,\n\n한 번이라도 사용한 로그가 존재하지 않거나, 무작위배정 이후\n\n일차 유효성 평가자료가 전무한 경우는 제외한다.  1차/2차\n\n유효성 평가는 모든 분석 대상자군(Full Analysis Set, FAS)를\n\n- - 84 -\n섭식장애 개선 디지털치료기기로 한 번이라도 치료를 받은\n\n모든 피험자로 정의한다.  안전성 평가는 안전성 자료를 대상으로\n\n- - 치료 전 대비 Follow-up 후 8주 시점의 식사장애 검사(EDE-Q)\n: 해당 시점에서의 Post-treatment 후 치료군별 기술통계량(평\n\n: Post-treatment 후 변화량의 군간 차이 검정은 기저치를\n\n공변량으로 한 공분산분석(ANCOVA)을 적용한다.  다른 변수를\n\n통제한 후 배정군 간 평균 변화량에 대한 양측 95% 신뢰\n\n1) 치료 전 대비 Follow-up 후 4주, 8주 시점의 하기 지표 변화량\n\n: CIA, PHQ-9, GAD-7, EQ-VAS, CGI-S 지표를 통해 변화량을\n\n2) 4주, 8주 시점의 Clinical Global Impression of Improvement\n\n3) 치료 전 대비 Follow-up 후 4주, 8주 시점의 폭식 횟수를 0회\n\n- - 85 -\n4) 결측값 처리\n\n- - 모든 분석 대상자군(Full Analysis Set, FAS)에서 중도 탈락 등의\n사유로 치료 후 시점에서 발생하는 결측치는 일차/이차 유효성\n\n평가변수에 대해서는 마지막 관측값 선행 대체법(Last Observation\n\nCarried Forward, LOCF)으로 대치한다.  그 외 자료는 대치 처리\n\n- - 일차 유효성 평가변수는 피험자의 하위집단(성별, 연령별 등)에\n따라 차이가 있는지 탐색적으로 확인하기 위해 하위 분석을\n\n- - 일차 유효성 평가 결과가 기관에 따라 차이가 있는지를 확인\n하기 위해 기관 및 기관과 그룹 간 상호작용을 공분산 분석\n\n모형에 포함하여 기관에 따른 군간 차이가 있는지 분석하여\n\n- - 대치 처리하지 않고 결측치를 고려한 반복측정혼합모형을\n적용하여 주요 결과와 차이가 있는지 탐색적으로 분석하여\n\n- - 86 -\n<!-- PAGE_93 -->\n##### 15. ",
        "original_sentence": "1차/2차\n\n유효성 평가는 모든 분석 대상자군(Full Analysis Set, FAS)를\n\n- - 84 -\n섭식장애 개선 디지털치료기기로 한 번이라도 치료를 받은\n\n모든 피험자로 정의한다. "
      }
    },
    {
      "chunk_id": "chunk_678",
      "text": "안전성 평가는 안전성 자료를 대상으로\n\n- - 치료 전 대비 Follow-up 후 8주 시점의 식사장애 검사(EDE-Q)\n: 해당 시점에서의 Post-treatment 후 치료군별 기술통계량(평\n\n: Post-treatment 후 변화량의 군간 차이 검정은 기저치를\n\n공변량으로 한 공분산분석(ANCOVA)을 적용한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 677,
        "window_size": 3,
        "char_count": 179,
        "word_count": 35,
        "page_number": 28,
        "window_text": "통계분석방법\n1) 분석대상군\n\n모든 분석 대상자군(FAS)에 속한 피험자이면서 임상시험\n\n일정대로 모든 수행을 완료하고, 아래의 주요한 임상시험계획\n\n위반이 없는 피험자로 정의한다.  1차/2차 유효성 평가는 계획서\n\n- (4) 임상시험 참여 중 심적/신체적 환경 변화로 있는 것으로 판\n모듈 횟수 중 75% 미만(예, 총 6주의 경우 4주 미만)으로 노출된\n\n배정된 대로 분석(Intention-to-treat, ITT) 원칙을 따르며,\n\n무작위배정된 모든 피험자군 중 주요한 선정기준을 위배하거나\n\n무작위배정된 후 섭식장애 개선 디지털치료기기를 로그인 하여,\n\n한 번이라도 사용한 로그가 존재하지 않거나, 무작위배정 이후\n\n일차 유효성 평가자료가 전무한 경우는 제외한다.  1차/2차\n\n유효성 평가는 모든 분석 대상자군(Full Analysis Set, FAS)를\n\n- - 84 -\n섭식장애 개선 디지털치료기기로 한 번이라도 치료를 받은\n\n모든 피험자로 정의한다.  안전성 평가는 안전성 자료를 대상으로\n\n- - 치료 전 대비 Follow-up 후 8주 시점의 식사장애 검사(EDE-Q)\n: 해당 시점에서의 Post-treatment 후 치료군별 기술통계량(평\n\n: Post-treatment 후 변화량의 군간 차이 검정은 기저치를\n\n공변량으로 한 공분산분석(ANCOVA)을 적용한다.  다른 변수를\n\n통제한 후 배정군 간 평균 변화량에 대한 양측 95% 신뢰\n\n1) 치료 전 대비 Follow-up 후 4주, 8주 시점의 하기 지표 변화량\n\n: CIA, PHQ-9, GAD-7, EQ-VAS, CGI-S 지표를 통해 변화량을\n\n2) 4주, 8주 시점의 Clinical Global Impression of Improvement\n\n3) 치료 전 대비 Follow-up 후 4주, 8주 시점의 폭식 횟수를 0회\n\n- - 85 -\n4) 결측값 처리\n\n- - 모든 분석 대상자군(Full Analysis Set, FAS)에서 중도 탈락 등의\n사유로 치료 후 시점에서 발생하는 결측치는 일차/이차 유효성\n\n평가변수에 대해서는 마지막 관측값 선행 대체법(Last Observation\n\nCarried Forward, LOCF)으로 대치한다.  그 외 자료는 대치 처리\n\n- - 일차 유효성 평가변수는 피험자의 하위집단(성별, 연령별 등)에\n따라 차이가 있는지 탐색적으로 확인하기 위해 하위 분석을\n\n- - 일차 유효성 평가 결과가 기관에 따라 차이가 있는지를 확인\n하기 위해 기관 및 기관과 그룹 간 상호작용을 공분산 분석\n\n모형에 포함하여 기관에 따른 군간 차이가 있는지 분석하여\n\n- - 대치 처리하지 않고 결측치를 고려한 반복측정혼합모형을\n적용하여 주요 결과와 차이가 있는지 탐색적으로 분석하여\n\n- - 86 -\n<!-- PAGE_93 -->\n##### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n- 가. ",
        "original_sentence": "안전성 평가는 안전성 자료를 대상으로\n\n- - 치료 전 대비 Follow-up 후 8주 시점의 식사장애 검사(EDE-Q)\n: 해당 시점에서의 Post-treatment 후 치료군별 기술통계량(평\n\n: Post-treatment 후 변화량의 군간 차이 검정은 기저치를\n\n공변량으로 한 공분산분석(ANCOVA)을 적용한다. "
      }
    },
    {
      "chunk_id": "chunk_679",
      "text": "다른 변수를\n\n통제한 후 배정군 간 평균 변화량에 대한 양측 95% 신뢰\n\n1) 치료 전 대비 Follow-up 후 4주, 8주 시점의 하기 지표 변화량\n\n: CIA, PHQ-9, GAD-7, EQ-VAS, CGI-S 지표를 통해 변화량을\n\n2) 4주, 8주 시점의 Clinical Global Impression of Improvement\n\n3) 치료 전 대비 Follow-up 후 4주, 8주 시점의 폭식 횟수를 0회\n\n- - 85 -\n4) 결측값 처리\n\n- - 모든 분석 대상자군(Full Analysis Set, FAS)에서 중도 탈락 등의\n사유로 치료 후 시점에서 발생하는 결측치는 일차/이차 유효성\n\n평가변수에 대해서는 마지막 관측값 선행 대체법(Last Observation\n\nCarried Forward, LOCF)으로 대치한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 678,
        "window_size": 3,
        "char_count": 417,
        "word_count": 91,
        "page_number": 19,
        "window_text": "1차/2차 유효성 평가는 계획서\n\n- (4) 임상시험 참여 중 심적/신체적 환경 변화로 있는 것으로 판\n모듈 횟수 중 75% 미만(예, 총 6주의 경우 4주 미만)으로 노출된\n\n배정된 대로 분석(Intention-to-treat, ITT) 원칙을 따르며,\n\n무작위배정된 모든 피험자군 중 주요한 선정기준을 위배하거나\n\n무작위배정된 후 섭식장애 개선 디지털치료기기를 로그인 하여,\n\n한 번이라도 사용한 로그가 존재하지 않거나, 무작위배정 이후\n\n일차 유효성 평가자료가 전무한 경우는 제외한다.  1차/2차\n\n유효성 평가는 모든 분석 대상자군(Full Analysis Set, FAS)를\n\n- - 84 -\n섭식장애 개선 디지털치료기기로 한 번이라도 치료를 받은\n\n모든 피험자로 정의한다.  안전성 평가는 안전성 자료를 대상으로\n\n- - 치료 전 대비 Follow-up 후 8주 시점의 식사장애 검사(EDE-Q)\n: 해당 시점에서의 Post-treatment 후 치료군별 기술통계량(평\n\n: Post-treatment 후 변화량의 군간 차이 검정은 기저치를\n\n공변량으로 한 공분산분석(ANCOVA)을 적용한다.  다른 변수를\n\n통제한 후 배정군 간 평균 변화량에 대한 양측 95% 신뢰\n\n1) 치료 전 대비 Follow-up 후 4주, 8주 시점의 하기 지표 변화량\n\n: CIA, PHQ-9, GAD-7, EQ-VAS, CGI-S 지표를 통해 변화량을\n\n2) 4주, 8주 시점의 Clinical Global Impression of Improvement\n\n3) 치료 전 대비 Follow-up 후 4주, 8주 시점의 폭식 횟수를 0회\n\n- - 85 -\n4) 결측값 처리\n\n- - 모든 분석 대상자군(Full Analysis Set, FAS)에서 중도 탈락 등의\n사유로 치료 후 시점에서 발생하는 결측치는 일차/이차 유효성\n\n평가변수에 대해서는 마지막 관측값 선행 대체법(Last Observation\n\nCarried Forward, LOCF)으로 대치한다.  그 외 자료는 대치 처리\n\n- - 일차 유효성 평가변수는 피험자의 하위집단(성별, 연령별 등)에\n따라 차이가 있는지 탐색적으로 확인하기 위해 하위 분석을\n\n- - 일차 유효성 평가 결과가 기관에 따라 차이가 있는지를 확인\n하기 위해 기관 및 기관과 그룹 간 상호작용을 공분산 분석\n\n모형에 포함하여 기관에 따른 군간 차이가 있는지 분석하여\n\n- - 대치 처리하지 않고 결측치를 고려한 반복측정혼합모형을\n적용하여 주요 결과와 차이가 있는지 탐색적으로 분석하여\n\n- - 86 -\n<!-- PAGE_93 -->\n##### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n- 가.  피험자 안전성\n본 임상시험은 저위험(low-risk) 치료용 의료기기의 임상적 평가\n\n이므로 피험자가 직접적으로 받는 인체의 위해도가 없을 수도 있다.\n\n",
        "original_sentence": "다른 변수를\n\n통제한 후 배정군 간 평균 변화량에 대한 양측 95% 신뢰\n\n1) 치료 전 대비 Follow-up 후 4주, 8주 시점의 하기 지표 변화량\n\n: CIA, PHQ-9, GAD-7, EQ-VAS, CGI-S 지표를 통해 변화량을\n\n2) 4주, 8주 시점의 Clinical Global Impression of Improvement\n\n3) 치료 전 대비 Follow-up 후 4주, 8주 시점의 폭식 횟수를 0회\n\n- - 85 -\n4) 결측값 처리\n\n- - 모든 분석 대상자군(Full Analysis Set, FAS)에서 중도 탈락 등의\n사유로 치료 후 시점에서 발생하는 결측치는 일차/이차 유효성\n\n평가변수에 대해서는 마지막 관측값 선행 대체법(Last Observation\n\nCarried Forward, LOCF)으로 대치한다. "
      }
    },
    {
      "chunk_id": "chunk_680",
      "text": "그 외 자료는 대치 처리\n\n- - 일차 유효성 평가변수는 피험자의 하위집단(성별, 연령별 등)에\n따라 차이가 있는지 탐색적으로 확인하기 위해 하위 분석을\n\n- - 일차 유효성 평가 결과가 기관에 따라 차이가 있는지를 확인\n하기 위해 기관 및 기관과 그룹 간 상호작용을 공분산 분석\n\n모형에 포함하여 기관에 따른 군간 차이가 있는지 분석하여\n\n- - 대치 처리하지 않고 결측치를 고려한 반복측정혼합모형을\n적용하여 주요 결과와 차이가 있는지 탐색적으로 분석하여\n\n- - 86 -\n<!-- PAGE_93 -->\n##### 15. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 679,
        "window_size": 3,
        "char_count": 293,
        "word_count": 75,
        "page_number": 93,
        "window_text": "1차/2차\n\n유효성 평가는 모든 분석 대상자군(Full Analysis Set, FAS)를\n\n- - 84 -\n섭식장애 개선 디지털치료기기로 한 번이라도 치료를 받은\n\n모든 피험자로 정의한다.  안전성 평가는 안전성 자료를 대상으로\n\n- - 치료 전 대비 Follow-up 후 8주 시점의 식사장애 검사(EDE-Q)\n: 해당 시점에서의 Post-treatment 후 치료군별 기술통계량(평\n\n: Post-treatment 후 변화량의 군간 차이 검정은 기저치를\n\n공변량으로 한 공분산분석(ANCOVA)을 적용한다.  다른 변수를\n\n통제한 후 배정군 간 평균 변화량에 대한 양측 95% 신뢰\n\n1) 치료 전 대비 Follow-up 후 4주, 8주 시점의 하기 지표 변화량\n\n: CIA, PHQ-9, GAD-7, EQ-VAS, CGI-S 지표를 통해 변화량을\n\n2) 4주, 8주 시점의 Clinical Global Impression of Improvement\n\n3) 치료 전 대비 Follow-up 후 4주, 8주 시점의 폭식 횟수를 0회\n\n- - 85 -\n4) 결측값 처리\n\n- - 모든 분석 대상자군(Full Analysis Set, FAS)에서 중도 탈락 등의\n사유로 치료 후 시점에서 발생하는 결측치는 일차/이차 유효성\n\n평가변수에 대해서는 마지막 관측값 선행 대체법(Last Observation\n\nCarried Forward, LOCF)으로 대치한다.  그 외 자료는 대치 처리\n\n- - 일차 유효성 평가변수는 피험자의 하위집단(성별, 연령별 등)에\n따라 차이가 있는지 탐색적으로 확인하기 위해 하위 분석을\n\n- - 일차 유효성 평가 결과가 기관에 따라 차이가 있는지를 확인\n하기 위해 기관 및 기관과 그룹 간 상호작용을 공분산 분석\n\n모형에 포함하여 기관에 따른 군간 차이가 있는지 분석하여\n\n- - 대치 처리하지 않고 결측치를 고려한 반복측정혼합모형을\n적용하여 주요 결과와 차이가 있는지 탐색적으로 분석하여\n\n- - 86 -\n<!-- PAGE_93 -->\n##### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n- 가.  피험자 안전성\n본 임상시험은 저위험(low-risk) 치료용 의료기기의 임상적 평가\n\n이므로 피험자가 직접적으로 받는 인체의 위해도가 없을 수도 있다.\n\n 하지만, 치료 도중 피험자한테 문제(예: 낮 시간 졸음이 과도한 현상 등)가\n\n발생하면 임상시험 담당 연구진에게 연락할 수 있는 긴급 연락망을\n\n제공하고, 디지털 기기(애플리케이션) 사용 관련한 문제(예: 버그 문제,\n\n로그인 실패 등)가 발생하면 회사 측 고객센터로 연락할 수 있는\n\n별도의 연락망을 제공한다. ",
        "original_sentence": "그 외 자료는 대치 처리\n\n- - 일차 유효성 평가변수는 피험자의 하위집단(성별, 연령별 등)에\n따라 차이가 있는지 탐색적으로 확인하기 위해 하위 분석을\n\n- - 일차 유효성 평가 결과가 기관에 따라 차이가 있는지를 확인\n하기 위해 기관 및 기관과 그룹 간 상호작용을 공분산 분석\n\n모형에 포함하여 기관에 따른 군간 차이가 있는지 분석하여\n\n- - 대치 처리하지 않고 결측치를 고려한 반복측정혼합모형을\n적용하여 주요 결과와 차이가 있는지 탐색적으로 분석하여\n\n- - 86 -\n<!-- PAGE_93 -->\n##### 15. "
      }
    },
    {
      "chunk_id": "chunk_681",
      "text": "부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n- 가. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 680,
        "window_size": 3,
        "char_count": 37,
        "word_count": 8,
        "page_number": 30,
        "window_text": "안전성 평가는 안전성 자료를 대상으로\n\n- - 치료 전 대비 Follow-up 후 8주 시점의 식사장애 검사(EDE-Q)\n: 해당 시점에서의 Post-treatment 후 치료군별 기술통계량(평\n\n: Post-treatment 후 변화량의 군간 차이 검정은 기저치를\n\n공변량으로 한 공분산분석(ANCOVA)을 적용한다.  다른 변수를\n\n통제한 후 배정군 간 평균 변화량에 대한 양측 95% 신뢰\n\n1) 치료 전 대비 Follow-up 후 4주, 8주 시점의 하기 지표 변화량\n\n: CIA, PHQ-9, GAD-7, EQ-VAS, CGI-S 지표를 통해 변화량을\n\n2) 4주, 8주 시점의 Clinical Global Impression of Improvement\n\n3) 치료 전 대비 Follow-up 후 4주, 8주 시점의 폭식 횟수를 0회\n\n- - 85 -\n4) 결측값 처리\n\n- - 모든 분석 대상자군(Full Analysis Set, FAS)에서 중도 탈락 등의\n사유로 치료 후 시점에서 발생하는 결측치는 일차/이차 유효성\n\n평가변수에 대해서는 마지막 관측값 선행 대체법(Last Observation\n\nCarried Forward, LOCF)으로 대치한다.  그 외 자료는 대치 처리\n\n- - 일차 유효성 평가변수는 피험자의 하위집단(성별, 연령별 등)에\n따라 차이가 있는지 탐색적으로 확인하기 위해 하위 분석을\n\n- - 일차 유효성 평가 결과가 기관에 따라 차이가 있는지를 확인\n하기 위해 기관 및 기관과 그룹 간 상호작용을 공분산 분석\n\n모형에 포함하여 기관에 따른 군간 차이가 있는지 분석하여\n\n- - 대치 처리하지 않고 결측치를 고려한 반복측정혼합모형을\n적용하여 주요 결과와 차이가 있는지 탐색적으로 분석하여\n\n- - 86 -\n<!-- PAGE_93 -->\n##### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n- 가.  피험자 안전성\n본 임상시험은 저위험(low-risk) 치료용 의료기기의 임상적 평가\n\n이므로 피험자가 직접적으로 받는 인체의 위해도가 없을 수도 있다.\n\n 하지만, 치료 도중 피험자한테 문제(예: 낮 시간 졸음이 과도한 현상 등)가\n\n발생하면 임상시험 담당 연구진에게 연락할 수 있는 긴급 연락망을\n\n제공하고, 디지털 기기(애플리케이션) 사용 관련한 문제(예: 버그 문제,\n\n로그인 실패 등)가 발생하면 회사 측 고객센터로 연락할 수 있는\n\n별도의 연락망을 제공한다.  긴급 연락망과 방문을 통해 이상 반응을\n\n수집한다.\n\n",
        "original_sentence": "부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_682",
      "text": "피험자 안전성\n본 임상시험은 저위험(low-risk) 치료용 의료기기의 임상적 평가\n\n이므로 피험자가 직접적으로 받는 인체의 위해도가 없을 수도 있다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 681,
        "window_size": 3,
        "char_count": 86,
        "word_count": 18,
        "page_number": 27,
        "window_text": "다른 변수를\n\n통제한 후 배정군 간 평균 변화량에 대한 양측 95% 신뢰\n\n1) 치료 전 대비 Follow-up 후 4주, 8주 시점의 하기 지표 변화량\n\n: CIA, PHQ-9, GAD-7, EQ-VAS, CGI-S 지표를 통해 변화량을\n\n2) 4주, 8주 시점의 Clinical Global Impression of Improvement\n\n3) 치료 전 대비 Follow-up 후 4주, 8주 시점의 폭식 횟수를 0회\n\n- - 85 -\n4) 결측값 처리\n\n- - 모든 분석 대상자군(Full Analysis Set, FAS)에서 중도 탈락 등의\n사유로 치료 후 시점에서 발생하는 결측치는 일차/이차 유효성\n\n평가변수에 대해서는 마지막 관측값 선행 대체법(Last Observation\n\nCarried Forward, LOCF)으로 대치한다.  그 외 자료는 대치 처리\n\n- - 일차 유효성 평가변수는 피험자의 하위집단(성별, 연령별 등)에\n따라 차이가 있는지 탐색적으로 확인하기 위해 하위 분석을\n\n- - 일차 유효성 평가 결과가 기관에 따라 차이가 있는지를 확인\n하기 위해 기관 및 기관과 그룹 간 상호작용을 공분산 분석\n\n모형에 포함하여 기관에 따른 군간 차이가 있는지 분석하여\n\n- - 대치 처리하지 않고 결측치를 고려한 반복측정혼합모형을\n적용하여 주요 결과와 차이가 있는지 탐색적으로 분석하여\n\n- - 86 -\n<!-- PAGE_93 -->\n##### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n- 가.  피험자 안전성\n본 임상시험은 저위험(low-risk) 치료용 의료기기의 임상적 평가\n\n이므로 피험자가 직접적으로 받는 인체의 위해도가 없을 수도 있다.\n\n 하지만, 치료 도중 피험자한테 문제(예: 낮 시간 졸음이 과도한 현상 등)가\n\n발생하면 임상시험 담당 연구진에게 연락할 수 있는 긴급 연락망을\n\n제공하고, 디지털 기기(애플리케이션) 사용 관련한 문제(예: 버그 문제,\n\n로그인 실패 등)가 발생하면 회사 측 고객센터로 연락할 수 있는\n\n별도의 연락망을 제공한다.  긴급 연락망과 방문을 통해 이상 반응을\n\n수집한다.\n\n - 나. ",
        "original_sentence": "피험자 안전성\n본 임상시험은 저위험(low-risk) 치료용 의료기기의 임상적 평가\n\n이므로 피험자가 직접적으로 받는 인체의 위해도가 없을 수도 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_683",
      "text": "하지만, 치료 도중 피험자한테 문제(예: 낮 시간 졸음이 과도한 현상 등)가\n\n발생하면 임상시험 담당 연구진에게 연락할 수 있는 긴급 연락망을\n\n제공하고, 디지털 기기(애플리케이션) 사용 관련한 문제(예: 버그 문제,\n\n로그인 실패 등)가 발생하면 회사 측 고객센터로 연락할 수 있는\n\n별도의 연락망을 제공한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 682,
        "window_size": 3,
        "char_count": 175,
        "word_count": 41,
        "page_number": 34,
        "window_text": "그 외 자료는 대치 처리\n\n- - 일차 유효성 평가변수는 피험자의 하위집단(성별, 연령별 등)에\n따라 차이가 있는지 탐색적으로 확인하기 위해 하위 분석을\n\n- - 일차 유효성 평가 결과가 기관에 따라 차이가 있는지를 확인\n하기 위해 기관 및 기관과 그룹 간 상호작용을 공분산 분석\n\n모형에 포함하여 기관에 따른 군간 차이가 있는지 분석하여\n\n- - 대치 처리하지 않고 결측치를 고려한 반복측정혼합모형을\n적용하여 주요 결과와 차이가 있는지 탐색적으로 분석하여\n\n- - 86 -\n<!-- PAGE_93 -->\n##### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n- 가.  피험자 안전성\n본 임상시험은 저위험(low-risk) 치료용 의료기기의 임상적 평가\n\n이므로 피험자가 직접적으로 받는 인체의 위해도가 없을 수도 있다.\n\n 하지만, 치료 도중 피험자한테 문제(예: 낮 시간 졸음이 과도한 현상 등)가\n\n발생하면 임상시험 담당 연구진에게 연락할 수 있는 긴급 연락망을\n\n제공하고, 디지털 기기(애플리케이션) 사용 관련한 문제(예: 버그 문제,\n\n로그인 실패 등)가 발생하면 회사 측 고객센터로 연락할 수 있는\n\n별도의 연락망을 제공한다.  긴급 연락망과 방문을 통해 이상 반응을\n\n수집한다.\n\n - 나.  시험자 안전성\n해당 임상시험용 의료기기는 소프트웨어에 속하며 비침습적이며 짧은\n\n기간 동안 임상시험에 참여하기 때문에 안전에 대한 위험은 없다고\n\n할 수 있다.\n\n",
        "original_sentence": "하지만, 치료 도중 피험자한테 문제(예: 낮 시간 졸음이 과도한 현상 등)가\n\n발생하면 임상시험 담당 연구진에게 연락할 수 있는 긴급 연락망을\n\n제공하고, 디지털 기기(애플리케이션) 사용 관련한 문제(예: 버그 문제,\n\n로그인 실패 등)가 발생하면 회사 측 고객센터로 연락할 수 있는\n\n별도의 연락망을 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_684",
      "text": "긴급 연락망과 방문을 통해 이상 반응을\n\n수집한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 683,
        "window_size": 3,
        "char_count": 30,
        "word_count": 7,
        "page_number": 15,
        "window_text": "부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n- 가.  피험자 안전성\n본 임상시험은 저위험(low-risk) 치료용 의료기기의 임상적 평가\n\n이므로 피험자가 직접적으로 받는 인체의 위해도가 없을 수도 있다.\n\n 하지만, 치료 도중 피험자한테 문제(예: 낮 시간 졸음이 과도한 현상 등)가\n\n발생하면 임상시험 담당 연구진에게 연락할 수 있는 긴급 연락망을\n\n제공하고, 디지털 기기(애플리케이션) 사용 관련한 문제(예: 버그 문제,\n\n로그인 실패 등)가 발생하면 회사 측 고객센터로 연락할 수 있는\n\n별도의 연락망을 제공한다.  긴급 연락망과 방문을 통해 이상 반응을\n\n수집한다.\n\n - 나.  시험자 안전성\n해당 임상시험용 의료기기는 소프트웨어에 속하며 비침습적이며 짧은\n\n기간 동안 임상시험에 참여하기 때문에 안전에 대한 위험은 없다고\n\n할 수 있다.\n\n - - 87 -\n- 다. ",
        "original_sentence": "긴급 연락망과 방문을 통해 이상 반응을\n\n수집한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_685",
      "text": "- 나. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 684,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 72,
        "window_text": "피험자 안전성\n본 임상시험은 저위험(low-risk) 치료용 의료기기의 임상적 평가\n\n이므로 피험자가 직접적으로 받는 인체의 위해도가 없을 수도 있다.\n\n 하지만, 치료 도중 피험자한테 문제(예: 낮 시간 졸음이 과도한 현상 등)가\n\n발생하면 임상시험 담당 연구진에게 연락할 수 있는 긴급 연락망을\n\n제공하고, 디지털 기기(애플리케이션) 사용 관련한 문제(예: 버그 문제,\n\n로그인 실패 등)가 발생하면 회사 측 고객센터로 연락할 수 있는\n\n별도의 연락망을 제공한다.  긴급 연락망과 방문을 통해 이상 반응을\n\n수집한다.\n\n - 나.  시험자 안전성\n해당 임상시험용 의료기기는 소프트웨어에 속하며 비침습적이며 짧은\n\n기간 동안 임상시험에 참여하기 때문에 안전에 대한 위험은 없다고\n\n할 수 있다.\n\n - - 87 -\n- 다.  이상 사례의 정의\n1) 이상 사례(Adverse Event, AE)란 임상시험 중 피험자에게 발생한\n\n모든 의도하지 않은 증후(sign), 증상(symptom) 또는 질병을 말하며,\n\n해당 임상시험용 의료기기와 반드시 인과관계를 가져야 하는 것은\n\n2) 의료기기 이상 반응(Adverse Device Effect, ADE)이란 임상시험용\n\n의료기기로 인하여 발생한 모든 유해하고 의도하지 않은 반응으로서\n\n- 라. ",
        "original_sentence": "- 나. "
      }
    },
    {
      "chunk_id": "chunk_686",
      "text": "시험자 안전성\n해당 임상시험용 의료기기는 소프트웨어에 속하며 비침습적이며 짧은\n\n기간 동안 임상시험에 참여하기 때문에 안전에 대한 위험은 없다고\n\n할 수 있다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 685,
        "window_size": 3,
        "char_count": 91,
        "word_count": 21,
        "page_number": 9,
        "window_text": "하지만, 치료 도중 피험자한테 문제(예: 낮 시간 졸음이 과도한 현상 등)가\n\n발생하면 임상시험 담당 연구진에게 연락할 수 있는 긴급 연락망을\n\n제공하고, 디지털 기기(애플리케이션) 사용 관련한 문제(예: 버그 문제,\n\n로그인 실패 등)가 발생하면 회사 측 고객센터로 연락할 수 있는\n\n별도의 연락망을 제공한다.  긴급 연락망과 방문을 통해 이상 반응을\n\n수집한다.\n\n - 나.  시험자 안전성\n해당 임상시험용 의료기기는 소프트웨어에 속하며 비침습적이며 짧은\n\n기간 동안 임상시험에 참여하기 때문에 안전에 대한 위험은 없다고\n\n할 수 있다.\n\n - - 87 -\n- 다.  이상 사례의 정의\n1) 이상 사례(Adverse Event, AE)란 임상시험 중 피험자에게 발생한\n\n모든 의도하지 않은 증후(sign), 증상(symptom) 또는 질병을 말하며,\n\n해당 임상시험용 의료기기와 반드시 인과관계를 가져야 하는 것은\n\n2) 의료기기 이상 반응(Adverse Device Effect, ADE)이란 임상시험용\n\n의료기기로 인하여 발생한 모든 유해하고 의도하지 않은 반응으로서\n\n- 라.  이상 사례의 평가\n이상 사례 발현 시 임상시험용 의료기기와의 관련성 여부는\n\n시험자가 다음 기준에 의하여 평가하며, 시험자의 의견을 기술\n\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적\n- - 이상 반응이 다른 어떤 이유보다 임상시험용 의료기기의 사용\n- - 이상 반응이 임상시험용 의료기기 또는 동일 계열의 의료기기에\n- - 88 -\n- ○ 관련성이 많음(Probably related)\n- - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n- - 이상 반응이 다른 원인보다 임상시험용 의료기기의 사용으로\n- - 임상시험용 의료기기의 사용 중단으로 이상 반응이 사라지는\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n- - 임상시험용 의료기기의 사용 중단으로(실시된 경우) 이상\n- - 임상시험용 의료기기의 사용 중단 결과(실시된 경우)가 음성\n- - 임상시험용 의료기기의 재사용(실시된 경우) 결과가 음성이거나\n- - 89 -\n- ○ 관련성이 없음(Definitely not related)\n- - 임상시험용 의료기기를 사용하지 않은 경우\n- - 임상시험용 의료기기의 사용과 이상 반응 발현과의 시간적\n- - 정보가 불충분하거나 상충하여 판단할 수 없고 이를 보완\n- 마. ",
        "original_sentence": "시험자 안전성\n해당 임상시험용 의료기기는 소프트웨어에 속하며 비침습적이며 짧은\n\n기간 동안 임상시험에 참여하기 때문에 안전에 대한 위험은 없다고\n\n할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_687",
      "text": "- - 87 -\n- 다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 686,
        "window_size": 3,
        "char_count": 14,
        "word_count": 6,
        "page_number": 27,
        "window_text": "긴급 연락망과 방문을 통해 이상 반응을\n\n수집한다.\n\n - 나.  시험자 안전성\n해당 임상시험용 의료기기는 소프트웨어에 속하며 비침습적이며 짧은\n\n기간 동안 임상시험에 참여하기 때문에 안전에 대한 위험은 없다고\n\n할 수 있다.\n\n - - 87 -\n- 다.  이상 사례의 정의\n1) 이상 사례(Adverse Event, AE)란 임상시험 중 피험자에게 발생한\n\n모든 의도하지 않은 증후(sign), 증상(symptom) 또는 질병을 말하며,\n\n해당 임상시험용 의료기기와 반드시 인과관계를 가져야 하는 것은\n\n2) 의료기기 이상 반응(Adverse Device Effect, ADE)이란 임상시험용\n\n의료기기로 인하여 발생한 모든 유해하고 의도하지 않은 반응으로서\n\n- 라.  이상 사례의 평가\n이상 사례 발현 시 임상시험용 의료기기와의 관련성 여부는\n\n시험자가 다음 기준에 의하여 평가하며, 시험자의 의견을 기술\n\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적\n- - 이상 반응이 다른 어떤 이유보다 임상시험용 의료기기의 사용\n- - 이상 반응이 임상시험용 의료기기 또는 동일 계열의 의료기기에\n- - 88 -\n- ○ 관련성이 많음(Probably related)\n- - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n- - 이상 반응이 다른 원인보다 임상시험용 의료기기의 사용으로\n- - 임상시험용 의료기기의 사용 중단으로 이상 반응이 사라지는\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n- - 임상시험용 의료기기의 사용 중단으로(실시된 경우) 이상\n- - 임상시험용 의료기기의 사용 중단 결과(실시된 경우)가 음성\n- - 임상시험용 의료기기의 재사용(실시된 경우) 결과가 음성이거나\n- - 89 -\n- ○ 관련성이 없음(Definitely not related)\n- - 임상시험용 의료기기를 사용하지 않은 경우\n- - 임상시험용 의료기기의 사용과 이상 반응 발현과의 시간적\n- - 정보가 불충분하거나 상충하여 판단할 수 없고 이를 보완\n- 마.  안전성의 평가 기준\n본 임상시험에서 이상 반응은 임상시험 시작 전에 관찰되지 않은\n\n증상이 발생하는 모든 바람직하지 않은 의학적ㆍ물리적 소견을 이상\n\n반응으로 분류한다. ",
        "original_sentence": "- - 87 -\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_688",
      "text": "이상 사례의 정의\n1) 이상 사례(Adverse Event, AE)란 임상시험 중 피험자에게 발생한\n\n모든 의도하지 않은 증후(sign), 증상(symptom) 또는 질병을 말하며,\n\n해당 임상시험용 의료기기와 반드시 인과관계를 가져야 하는 것은\n\n2) 의료기기 이상 반응(Adverse Device Effect, ADE)이란 임상시험용\n\n의료기기로 인하여 발생한 모든 유해하고 의도하지 않은 반응으로서\n\n- 라. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 687,
        "window_size": 3,
        "char_count": 232,
        "word_count": 46,
        "page_number": 19,
        "window_text": "- 나.  시험자 안전성\n해당 임상시험용 의료기기는 소프트웨어에 속하며 비침습적이며 짧은\n\n기간 동안 임상시험에 참여하기 때문에 안전에 대한 위험은 없다고\n\n할 수 있다.\n\n - - 87 -\n- 다.  이상 사례의 정의\n1) 이상 사례(Adverse Event, AE)란 임상시험 중 피험자에게 발생한\n\n모든 의도하지 않은 증후(sign), 증상(symptom) 또는 질병을 말하며,\n\n해당 임상시험용 의료기기와 반드시 인과관계를 가져야 하는 것은\n\n2) 의료기기 이상 반응(Adverse Device Effect, ADE)이란 임상시험용\n\n의료기기로 인하여 발생한 모든 유해하고 의도하지 않은 반응으로서\n\n- 라.  이상 사례의 평가\n이상 사례 발현 시 임상시험용 의료기기와의 관련성 여부는\n\n시험자가 다음 기준에 의하여 평가하며, 시험자의 의견을 기술\n\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적\n- - 이상 반응이 다른 어떤 이유보다 임상시험용 의료기기의 사용\n- - 이상 반응이 임상시험용 의료기기 또는 동일 계열의 의료기기에\n- - 88 -\n- ○ 관련성이 많음(Probably related)\n- - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n- - 이상 반응이 다른 원인보다 임상시험용 의료기기의 사용으로\n- - 임상시험용 의료기기의 사용 중단으로 이상 반응이 사라지는\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n- - 임상시험용 의료기기의 사용 중단으로(실시된 경우) 이상\n- - 임상시험용 의료기기의 사용 중단 결과(실시된 경우)가 음성\n- - 임상시험용 의료기기의 재사용(실시된 경우) 결과가 음성이거나\n- - 89 -\n- ○ 관련성이 없음(Definitely not related)\n- - 임상시험용 의료기기를 사용하지 않은 경우\n- - 임상시험용 의료기기의 사용과 이상 반응 발현과의 시간적\n- - 정보가 불충분하거나 상충하여 판단할 수 없고 이를 보완\n- 마.  안전성의 평가 기준\n본 임상시험에서 이상 반응은 임상시험 시작 전에 관찰되지 않은\n\n증상이 발생하는 모든 바람직하지 않은 의학적ㆍ물리적 소견을 이상\n\n반응으로 분류한다.  예측되는 부작용도 이상 반응으로 분류한다.\n\n",
        "original_sentence": "이상 사례의 정의\n1) 이상 사례(Adverse Event, AE)란 임상시험 중 피험자에게 발생한\n\n모든 의도하지 않은 증후(sign), 증상(symptom) 또는 질병을 말하며,\n\n해당 임상시험용 의료기기와 반드시 인과관계를 가져야 하는 것은\n\n2) 의료기기 이상 반응(Adverse Device Effect, ADE)이란 임상시험용\n\n의료기기로 인하여 발생한 모든 유해하고 의도하지 않은 반응으로서\n\n- 라. "
      }
    },
    {
      "chunk_id": "chunk_689",
      "text": "이상 사례의 평가\n이상 사례 발현 시 임상시험용 의료기기와의 관련성 여부는\n\n시험자가 다음 기준에 의하여 평가하며, 시험자의 의견을 기술\n\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적\n- - 이상 반응이 다른 어떤 이유보다 임상시험용 의료기기의 사용\n- - 이상 반응이 임상시험용 의료기기 또는 동일 계열의 의료기기에\n- - 88 -\n- ○ 관련성이 많음(Probably related)\n- - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n- - 이상 반응이 다른 원인보다 임상시험용 의료기기의 사용으로\n- - 임상시험용 의료기기의 사용 중단으로 이상 반응이 사라지는\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n- - 임상시험용 의료기기의 사용 중단으로(실시된 경우) 이상\n- - 임상시험용 의료기기의 사용 중단 결과(실시된 경우)가 음성\n- - 임상시험용 의료기기의 재사용(실시된 경우) 결과가 음성이거나\n- - 89 -\n- ○ 관련성이 없음(Definitely not related)\n- - 임상시험용 의료기기를 사용하지 않은 경우\n- - 임상시험용 의료기기의 사용과 이상 반응 발현과의 시간적\n- - 정보가 불충분하거나 상충하여 판단할 수 없고 이를 보완\n- 마. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 688,
        "window_size": 3,
        "char_count": 664,
        "word_count": 166,
        "page_number": 3,
        "window_text": "시험자 안전성\n해당 임상시험용 의료기기는 소프트웨어에 속하며 비침습적이며 짧은\n\n기간 동안 임상시험에 참여하기 때문에 안전에 대한 위험은 없다고\n\n할 수 있다.\n\n - - 87 -\n- 다.  이상 사례의 정의\n1) 이상 사례(Adverse Event, AE)란 임상시험 중 피험자에게 발생한\n\n모든 의도하지 않은 증후(sign), 증상(symptom) 또는 질병을 말하며,\n\n해당 임상시험용 의료기기와 반드시 인과관계를 가져야 하는 것은\n\n2) 의료기기 이상 반응(Adverse Device Effect, ADE)이란 임상시험용\n\n의료기기로 인하여 발생한 모든 유해하고 의도하지 않은 반응으로서\n\n- 라.  이상 사례의 평가\n이상 사례 발현 시 임상시험용 의료기기와의 관련성 여부는\n\n시험자가 다음 기준에 의하여 평가하며, 시험자의 의견을 기술\n\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적\n- - 이상 반응이 다른 어떤 이유보다 임상시험용 의료기기의 사용\n- - 이상 반응이 임상시험용 의료기기 또는 동일 계열의 의료기기에\n- - 88 -\n- ○ 관련성이 많음(Probably related)\n- - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n- - 이상 반응이 다른 원인보다 임상시험용 의료기기의 사용으로\n- - 임상시험용 의료기기의 사용 중단으로 이상 반응이 사라지는\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n- - 임상시험용 의료기기의 사용 중단으로(실시된 경우) 이상\n- - 임상시험용 의료기기의 사용 중단 결과(실시된 경우)가 음성\n- - 임상시험용 의료기기의 재사용(실시된 경우) 결과가 음성이거나\n- - 89 -\n- ○ 관련성이 없음(Definitely not related)\n- - 임상시험용 의료기기를 사용하지 않은 경우\n- - 임상시험용 의료기기의 사용과 이상 반응 발현과의 시간적\n- - 정보가 불충분하거나 상충하여 판단할 수 없고 이를 보완\n- 마.  안전성의 평가 기준\n본 임상시험에서 이상 반응은 임상시험 시작 전에 관찰되지 않은\n\n증상이 발생하는 모든 바람직하지 않은 의학적ㆍ물리적 소견을 이상\n\n반응으로 분류한다.  예측되는 부작용도 이상 반응으로 분류한다.\n\n - 바. ",
        "original_sentence": "이상 사례의 평가\n이상 사례 발현 시 임상시험용 의료기기와의 관련성 여부는\n\n시험자가 다음 기준에 의하여 평가하며, 시험자의 의견을 기술\n\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적\n- - 이상 반응이 다른 어떤 이유보다 임상시험용 의료기기의 사용\n- - 이상 반응이 임상시험용 의료기기 또는 동일 계열의 의료기기에\n- - 88 -\n- ○ 관련성이 많음(Probably related)\n- - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n- - 이상 반응이 다른 원인보다 임상시험용 의료기기의 사용으로\n- - 임상시험용 의료기기의 사용 중단으로 이상 반응이 사라지는\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n- - 임상시험용 의료기기의 사용 중단으로(실시된 경우) 이상\n- - 임상시험용 의료기기의 사용 중단 결과(실시된 경우)가 음성\n- - 임상시험용 의료기기의 재사용(실시된 경우) 결과가 음성이거나\n- - 89 -\n- ○ 관련성이 없음(Definitely not related)\n- - 임상시험용 의료기기를 사용하지 않은 경우\n- - 임상시험용 의료기기의 사용과 이상 반응 발현과의 시간적\n- - 정보가 불충분하거나 상충하여 판단할 수 없고 이를 보완\n- 마. "
      }
    },
    {
      "chunk_id": "chunk_690",
      "text": "안전성의 평가 기준\n본 임상시험에서 이상 반응은 임상시험 시작 전에 관찰되지 않은\n\n증상이 발생하는 모든 바람직하지 않은 의학적ㆍ물리적 소견을 이상\n\n반응으로 분류한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 689,
        "window_size": 3,
        "char_count": 95,
        "word_count": 22,
        "page_number": 30,
        "window_text": "- - 87 -\n- 다.  이상 사례의 정의\n1) 이상 사례(Adverse Event, AE)란 임상시험 중 피험자에게 발생한\n\n모든 의도하지 않은 증후(sign), 증상(symptom) 또는 질병을 말하며,\n\n해당 임상시험용 의료기기와 반드시 인과관계를 가져야 하는 것은\n\n2) 의료기기 이상 반응(Adverse Device Effect, ADE)이란 임상시험용\n\n의료기기로 인하여 발생한 모든 유해하고 의도하지 않은 반응으로서\n\n- 라.  이상 사례의 평가\n이상 사례 발현 시 임상시험용 의료기기와의 관련성 여부는\n\n시험자가 다음 기준에 의하여 평가하며, 시험자의 의견을 기술\n\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적\n- - 이상 반응이 다른 어떤 이유보다 임상시험용 의료기기의 사용\n- - 이상 반응이 임상시험용 의료기기 또는 동일 계열의 의료기기에\n- - 88 -\n- ○ 관련성이 많음(Probably related)\n- - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n- - 이상 반응이 다른 원인보다 임상시험용 의료기기의 사용으로\n- - 임상시험용 의료기기의 사용 중단으로 이상 반응이 사라지는\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n- - 임상시험용 의료기기의 사용 중단으로(실시된 경우) 이상\n- - 임상시험용 의료기기의 사용 중단 결과(실시된 경우)가 음성\n- - 임상시험용 의료기기의 재사용(실시된 경우) 결과가 음성이거나\n- - 89 -\n- ○ 관련성이 없음(Definitely not related)\n- - 임상시험용 의료기기를 사용하지 않은 경우\n- - 임상시험용 의료기기의 사용과 이상 반응 발현과의 시간적\n- - 정보가 불충분하거나 상충하여 판단할 수 없고 이를 보완\n- 마.  안전성의 평가 기준\n본 임상시험에서 이상 반응은 임상시험 시작 전에 관찰되지 않은\n\n증상이 발생하는 모든 바람직하지 않은 의학적ㆍ물리적 소견을 이상\n\n반응으로 분류한다.  예측되는 부작용도 이상 반응으로 분류한다.\n\n - 바.  이상 사례 보고 방법\n- ○ 시험책임자는 시험담당자 또는 임상의 등에게 임상시험용 의료\n기기 사용 후 나타날 수 있는 모든 이상 사례에 대하여 교육을\n\n하고 사용 후 나타나는 모든 현상에 대하여 보고하도록 교육을\n\n※\n\n본 내용은「의료기기법 시행규칙」별표 3“의료기기 임상시험 관리기준” 제8호\n\n- ○ 이외에도 시험자가 중대하다고 간주하거나, 임상시험용 의료\n- - 90 -\n기기와의 사용과 연관 지을 수 있는 유의한 위험, 금기, 부작용,\n\n주의사항을 시사하는 사건 등도 중대한 이상 사례/의료기기\n\n이상 반응으로 기록하고 사망을 초래하거나 생명을 위협할\n\n때는 의뢰자가 이 사실을 보고받거나 알게 된 날로부터 7일\n\n이내, 이 경우 상세한 정보를 최초 보고일로부터 8일 이내에\n\n추가로 보고 하여야 한다. ",
        "original_sentence": "안전성의 평가 기준\n본 임상시험에서 이상 반응은 임상시험 시작 전에 관찰되지 않은\n\n증상이 발생하는 모든 바람직하지 않은 의학적ㆍ물리적 소견을 이상\n\n반응으로 분류한다. "
      }
    },
    {
      "chunk_id": "chunk_691",
      "text": "예측되는 부작용도 이상 반응으로 분류한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 690,
        "window_size": 3,
        "char_count": 25,
        "word_count": 5,
        "page_number": 15,
        "window_text": "이상 사례의 정의\n1) 이상 사례(Adverse Event, AE)란 임상시험 중 피험자에게 발생한\n\n모든 의도하지 않은 증후(sign), 증상(symptom) 또는 질병을 말하며,\n\n해당 임상시험용 의료기기와 반드시 인과관계를 가져야 하는 것은\n\n2) 의료기기 이상 반응(Adverse Device Effect, ADE)이란 임상시험용\n\n의료기기로 인하여 발생한 모든 유해하고 의도하지 않은 반응으로서\n\n- 라.  이상 사례의 평가\n이상 사례 발현 시 임상시험용 의료기기와의 관련성 여부는\n\n시험자가 다음 기준에 의하여 평가하며, 시험자의 의견을 기술\n\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적\n- - 이상 반응이 다른 어떤 이유보다 임상시험용 의료기기의 사용\n- - 이상 반응이 임상시험용 의료기기 또는 동일 계열의 의료기기에\n- - 88 -\n- ○ 관련성이 많음(Probably related)\n- - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n- - 이상 반응이 다른 원인보다 임상시험용 의료기기의 사용으로\n- - 임상시험용 의료기기의 사용 중단으로 이상 반응이 사라지는\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n- - 임상시험용 의료기기의 사용 중단으로(실시된 경우) 이상\n- - 임상시험용 의료기기의 사용 중단 결과(실시된 경우)가 음성\n- - 임상시험용 의료기기의 재사용(실시된 경우) 결과가 음성이거나\n- - 89 -\n- ○ 관련성이 없음(Definitely not related)\n- - 임상시험용 의료기기를 사용하지 않은 경우\n- - 임상시험용 의료기기의 사용과 이상 반응 발현과의 시간적\n- - 정보가 불충분하거나 상충하여 판단할 수 없고 이를 보완\n- 마.  안전성의 평가 기준\n본 임상시험에서 이상 반응은 임상시험 시작 전에 관찰되지 않은\n\n증상이 발생하는 모든 바람직하지 않은 의학적ㆍ물리적 소견을 이상\n\n반응으로 분류한다.  예측되는 부작용도 이상 반응으로 분류한다.\n\n - 바.  이상 사례 보고 방법\n- ○ 시험책임자는 시험담당자 또는 임상의 등에게 임상시험용 의료\n기기 사용 후 나타날 수 있는 모든 이상 사례에 대하여 교육을\n\n하고 사용 후 나타나는 모든 현상에 대하여 보고하도록 교육을\n\n※\n\n본 내용은「의료기기법 시행규칙」별표 3“의료기기 임상시험 관리기준” 제8호\n\n- ○ 이외에도 시험자가 중대하다고 간주하거나, 임상시험용 의료\n- - 90 -\n기기와의 사용과 연관 지을 수 있는 유의한 위험, 금기, 부작용,\n\n주의사항을 시사하는 사건 등도 중대한 이상 사례/의료기기\n\n이상 반응으로 기록하고 사망을 초래하거나 생명을 위협할\n\n때는 의뢰자가 이 사실을 보고받거나 알게 된 날로부터 7일\n\n이내, 이 경우 상세한 정보를 최초 보고일로부터 8일 이내에\n\n추가로 보고 하여야 한다.  그 밖의 중대하거나 예상하지 못한\n\n모든 이상 반응이 나타났을 때 의뢰자가 이 사실을 보고\n\n- - 91 -\n<!-- PAGE_98 -->\n##### 16. ",
        "original_sentence": "예측되는 부작용도 이상 반응으로 분류한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_692",
      "text": "- 바. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 691,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 72,
        "window_text": "이상 사례의 평가\n이상 사례 발현 시 임상시험용 의료기기와의 관련성 여부는\n\n시험자가 다음 기준에 의하여 평가하며, 시험자의 의견을 기술\n\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적\n- - 이상 반응이 다른 어떤 이유보다 임상시험용 의료기기의 사용\n- - 이상 반응이 임상시험용 의료기기 또는 동일 계열의 의료기기에\n- - 88 -\n- ○ 관련성이 많음(Probably related)\n- - 임상시험용 의료기기를 사용하였다는 증거가 있는 경우\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n- - 이상 반응이 다른 원인보다 임상시험용 의료기기의 사용으로\n- - 임상시험용 의료기기의 사용 중단으로 이상 반응이 사라지는\n- - 임상시험용 의료기기의 사용과 이상 반응 발현의 시간적 순서가\n- - 임상시험용 의료기기의 사용 중단으로(실시된 경우) 이상\n- - 임상시험용 의료기기의 사용 중단 결과(실시된 경우)가 음성\n- - 임상시험용 의료기기의 재사용(실시된 경우) 결과가 음성이거나\n- - 89 -\n- ○ 관련성이 없음(Definitely not related)\n- - 임상시험용 의료기기를 사용하지 않은 경우\n- - 임상시험용 의료기기의 사용과 이상 반응 발현과의 시간적\n- - 정보가 불충분하거나 상충하여 판단할 수 없고 이를 보완\n- 마.  안전성의 평가 기준\n본 임상시험에서 이상 반응은 임상시험 시작 전에 관찰되지 않은\n\n증상이 발생하는 모든 바람직하지 않은 의학적ㆍ물리적 소견을 이상\n\n반응으로 분류한다.  예측되는 부작용도 이상 반응으로 분류한다.\n\n - 바.  이상 사례 보고 방법\n- ○ 시험책임자는 시험담당자 또는 임상의 등에게 임상시험용 의료\n기기 사용 후 나타날 수 있는 모든 이상 사례에 대하여 교육을\n\n하고 사용 후 나타나는 모든 현상에 대하여 보고하도록 교육을\n\n※\n\n본 내용은「의료기기법 시행규칙」별표 3“의료기기 임상시험 관리기준” 제8호\n\n- ○ 이외에도 시험자가 중대하다고 간주하거나, 임상시험용 의료\n- - 90 -\n기기와의 사용과 연관 지을 수 있는 유의한 위험, 금기, 부작용,\n\n주의사항을 시사하는 사건 등도 중대한 이상 사례/의료기기\n\n이상 반응으로 기록하고 사망을 초래하거나 생명을 위협할\n\n때는 의뢰자가 이 사실을 보고받거나 알게 된 날로부터 7일\n\n이내, 이 경우 상세한 정보를 최초 보고일로부터 8일 이내에\n\n추가로 보고 하여야 한다.  그 밖의 중대하거나 예상하지 못한\n\n모든 이상 반응이 나타났을 때 의뢰자가 이 사실을 보고\n\n- - 91 -\n<!-- PAGE_98 -->\n##### 16.  피험자 동의서 서식\n\n- 가. ",
        "original_sentence": "- 바. "
      }
    },
    {
      "chunk_id": "chunk_693",
      "text": "이상 사례 보고 방법\n- ○ 시험책임자는 시험담당자 또는 임상의 등에게 임상시험용 의료\n기기 사용 후 나타날 수 있는 모든 이상 사례에 대하여 교육을\n\n하고 사용 후 나타나는 모든 현상에 대하여 보고하도록 교육을\n\n※\n\n본 내용은「의료기기법 시행규칙」별표 3“의료기기 임상시험 관리기준” 제8호\n\n- ○ 이외에도 시험자가 중대하다고 간주하거나, 임상시험용 의료\n- - 90 -\n기기와의 사용과 연관 지을 수 있는 유의한 위험, 금기, 부작용,\n\n주의사항을 시사하는 사건 등도 중대한 이상 사례/의료기기\n\n이상 반응으로 기록하고 사망을 초래하거나 생명을 위협할\n\n때는 의뢰자가 이 사실을 보고받거나 알게 된 날로부터 7일\n\n이내, 이 경우 상세한 정보를 최초 보고일로부터 8일 이내에\n\n추가로 보고 하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 692,
        "window_size": 3,
        "char_count": 398,
        "word_count": 99,
        "page_number": 3,
        "window_text": "안전성의 평가 기준\n본 임상시험에서 이상 반응은 임상시험 시작 전에 관찰되지 않은\n\n증상이 발생하는 모든 바람직하지 않은 의학적ㆍ물리적 소견을 이상\n\n반응으로 분류한다.  예측되는 부작용도 이상 반응으로 분류한다.\n\n - 바.  이상 사례 보고 방법\n- ○ 시험책임자는 시험담당자 또는 임상의 등에게 임상시험용 의료\n기기 사용 후 나타날 수 있는 모든 이상 사례에 대하여 교육을\n\n하고 사용 후 나타나는 모든 현상에 대하여 보고하도록 교육을\n\n※\n\n본 내용은「의료기기법 시행규칙」별표 3“의료기기 임상시험 관리기준” 제8호\n\n- ○ 이외에도 시험자가 중대하다고 간주하거나, 임상시험용 의료\n- - 90 -\n기기와의 사용과 연관 지을 수 있는 유의한 위험, 금기, 부작용,\n\n주의사항을 시사하는 사건 등도 중대한 이상 사례/의료기기\n\n이상 반응으로 기록하고 사망을 초래하거나 생명을 위협할\n\n때는 의뢰자가 이 사실을 보고받거나 알게 된 날로부터 7일\n\n이내, 이 경우 상세한 정보를 최초 보고일로부터 8일 이내에\n\n추가로 보고 하여야 한다.  그 밖의 중대하거나 예상하지 못한\n\n모든 이상 반응이 나타났을 때 의뢰자가 이 사실을 보고\n\n- - 91 -\n<!-- PAGE_98 -->\n##### 16.  피험자 동의서 서식\n\n- 가.  피험자 동의서에 반드시 포함되어야 하는 사항\n3) 임상시험용 의료기기에 관한 정보 및 시험군 또는 대조군에\n\n4) 침습적 시술(invasive procedure)을 포함하여 임상시험에서 피험자가\n\n8) 기대되는 이익이 있거나 피험자에게 기대되는 이익이 없을 경우\n\n9) 피험자가 선택할 수 있는 다른 치료방법이나 종류 및 그 치료\n\n방법의 잠재적 위험과 이익\n\n- - 92 -\n10) 임상시험과 관련한 손상이 발생하였을 경우 피험자에게 주어질\n\n보상이나 치료방법\n\n11) 피험자가 임상시험에 참여함으로써 받게 될 금전적 보상이 있는\n\n경우 예상 금액 및 이 금액이 임상시험 참여의 정도나 기간에\n\n13) 피험자의 임상시험 참여 여부 결정은 자발적이어야 하며, 피험자가\n\n원래 받을 수 있는 이익에 대한 손실 없이 임상시험의 참여를\n\n거부하거나 임상시험 도중 언제라도 참여를 포기할 수 있다는\n\n14) 제8호 항목에 따른 모니터 요원, 제8호 항목에 따른 점검을 실\n\n위하여 피험자의 신상에 관한 비밀이 보호되는 범위에서 피험자의\n\n의무기록을 열람할 수 있다는 사실과 피험자 또는 피험자 대리인의\n\n15) 피험자의 신상을 파악할 수 있는 기록은 비밀로 보호될 것이며\n\n임상시험의 결과가 출관될 경우 피험자의 신상은 비밀로 보호\n\n16) 피험자의 임상시험 계속 참여 여부에 영향을 줄 수 있는 새로운\n\n정보를 취득하면 적시에 피험자 또는 피험자의 대리인에게 알릴\n\n17) 임상시험과 피험자의 권익에 관하여 추가적인 정보를 얻고자\n\n- - 93 -\n하거나 임상시험과 관련이 있는 손상이 발생하면 연락해야 하는\n\n사람\n\n18) 임상시험 도중 피험자의 임상시험 참여가 중지되는 경우 및 그\n\n- 나. ",
        "original_sentence": "이상 사례 보고 방법\n- ○ 시험책임자는 시험담당자 또는 임상의 등에게 임상시험용 의료\n기기 사용 후 나타날 수 있는 모든 이상 사례에 대하여 교육을\n\n하고 사용 후 나타나는 모든 현상에 대하여 보고하도록 교육을\n\n※\n\n본 내용은「의료기기법 시행규칙」별표 3“의료기기 임상시험 관리기준” 제8호\n\n- ○ 이외에도 시험자가 중대하다고 간주하거나, 임상시험용 의료\n- - 90 -\n기기와의 사용과 연관 지을 수 있는 유의한 위험, 금기, 부작용,\n\n주의사항을 시사하는 사건 등도 중대한 이상 사례/의료기기\n\n이상 반응으로 기록하고 사망을 초래하거나 생명을 위협할\n\n때는 의뢰자가 이 사실을 보고받거나 알게 된 날로부터 7일\n\n이내, 이 경우 상세한 정보를 최초 보고일로부터 8일 이내에\n\n추가로 보고 하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_694",
      "text": "그 밖의 중대하거나 예상하지 못한\n\n모든 이상 반응이 나타났을 때 의뢰자가 이 사실을 보고\n\n- - 91 -\n<!-- PAGE_98 -->\n##### 16. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 693,
        "window_size": 3,
        "char_count": 88,
        "word_count": 23,
        "page_number": 98,
        "window_text": "예측되는 부작용도 이상 반응으로 분류한다.\n\n - 바.  이상 사례 보고 방법\n- ○ 시험책임자는 시험담당자 또는 임상의 등에게 임상시험용 의료\n기기 사용 후 나타날 수 있는 모든 이상 사례에 대하여 교육을\n\n하고 사용 후 나타나는 모든 현상에 대하여 보고하도록 교육을\n\n※\n\n본 내용은「의료기기법 시행규칙」별표 3“의료기기 임상시험 관리기준” 제8호\n\n- ○ 이외에도 시험자가 중대하다고 간주하거나, 임상시험용 의료\n- - 90 -\n기기와의 사용과 연관 지을 수 있는 유의한 위험, 금기, 부작용,\n\n주의사항을 시사하는 사건 등도 중대한 이상 사례/의료기기\n\n이상 반응으로 기록하고 사망을 초래하거나 생명을 위협할\n\n때는 의뢰자가 이 사실을 보고받거나 알게 된 날로부터 7일\n\n이내, 이 경우 상세한 정보를 최초 보고일로부터 8일 이내에\n\n추가로 보고 하여야 한다.  그 밖의 중대하거나 예상하지 못한\n\n모든 이상 반응이 나타났을 때 의뢰자가 이 사실을 보고\n\n- - 91 -\n<!-- PAGE_98 -->\n##### 16.  피험자 동의서 서식\n\n- 가.  피험자 동의서에 반드시 포함되어야 하는 사항\n3) 임상시험용 의료기기에 관한 정보 및 시험군 또는 대조군에\n\n4) 침습적 시술(invasive procedure)을 포함하여 임상시험에서 피험자가\n\n8) 기대되는 이익이 있거나 피험자에게 기대되는 이익이 없을 경우\n\n9) 피험자가 선택할 수 있는 다른 치료방법이나 종류 및 그 치료\n\n방법의 잠재적 위험과 이익\n\n- - 92 -\n10) 임상시험과 관련한 손상이 발생하였을 경우 피험자에게 주어질\n\n보상이나 치료방법\n\n11) 피험자가 임상시험에 참여함으로써 받게 될 금전적 보상이 있는\n\n경우 예상 금액 및 이 금액이 임상시험 참여의 정도나 기간에\n\n13) 피험자의 임상시험 참여 여부 결정은 자발적이어야 하며, 피험자가\n\n원래 받을 수 있는 이익에 대한 손실 없이 임상시험의 참여를\n\n거부하거나 임상시험 도중 언제라도 참여를 포기할 수 있다는\n\n14) 제8호 항목에 따른 모니터 요원, 제8호 항목에 따른 점검을 실\n\n위하여 피험자의 신상에 관한 비밀이 보호되는 범위에서 피험자의\n\n의무기록을 열람할 수 있다는 사실과 피험자 또는 피험자 대리인의\n\n15) 피험자의 신상을 파악할 수 있는 기록은 비밀로 보호될 것이며\n\n임상시험의 결과가 출관될 경우 피험자의 신상은 비밀로 보호\n\n16) 피험자의 임상시험 계속 참여 여부에 영향을 줄 수 있는 새로운\n\n정보를 취득하면 적시에 피험자 또는 피험자의 대리인에게 알릴\n\n17) 임상시험과 피험자의 권익에 관하여 추가적인 정보를 얻고자\n\n- - 93 -\n하거나 임상시험과 관련이 있는 손상이 발생하면 연락해야 하는\n\n사람\n\n18) 임상시험 도중 피험자의 임상시험 참여가 중지되는 경우 및 그\n\n- 나.  피험자 동의의 일반적 요건\n1) 연구자는 연구를 시작하기 전에 임상시험심사위원회(Institutional\n\nReview Board, IRB)로부터 피험자에게 제공될 설명서 및 동의서,\n\n2) 연구자는 임상시험심사위원회 승인 직인이 찍힌 동의서 등을\n\n피험자 또는 피험자의 대리인에게 제공해야 하며, 피험자(또는\n\n대리인)와 동의를 받은 책임연구자(또는 책임연구자의 위임을 받은\n\n자)는 동의서 서식에 서명하고, 자필로 해당 날짜를 기재하여야\n\n3) 연구자는 서명된 동의서를 보관해야 하며, 사본을 피험자(또는\n\n4) 동의서를 받는 과정에서 연구자는 피험자 또는 대리인에게 강제나\n\n부당한 영향을 미치지 않아야 하며, 피험자 또는 대리인이 연구의\n\n모든 정보를 이해할 수 있는 용어 및 언어로 작성된 동의서 등을\n\n제공하여 설명하고 질문에 대하여 대답한 후 충분히 생각할\n\n- - 94 -\n5) 피험자 동의서에는 피험자 또는 대리인의 법적 권리를 포기나\n\n제한, 연구자/의뢰자/기관 및 기관장의 과실 책임의 면제를 암시\n\n6) 피험자의 동의에 영향을 줄 수 있는 새로운 연구 관련정보가\n\n수집되면 동의서 서식, 피험자 설명서 및 기타 문서화된 정보는\n\n이에 따라 수정되어야 하며, 사용 전에 반드시 위원회의 승인을\n\n받아야 한다. ",
        "original_sentence": "그 밖의 중대하거나 예상하지 못한\n\n모든 이상 반응이 나타났을 때 의뢰자가 이 사실을 보고\n\n- - 91 -\n<!-- PAGE_98 -->\n##### 16. "
      }
    },
    {
      "chunk_id": "chunk_695",
      "text": "피험자 동의서 서식\n\n- 가. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 694,
        "window_size": 3,
        "char_count": 17,
        "word_count": 5,
        "page_number": 35,
        "window_text": "- 바.  이상 사례 보고 방법\n- ○ 시험책임자는 시험담당자 또는 임상의 등에게 임상시험용 의료\n기기 사용 후 나타날 수 있는 모든 이상 사례에 대하여 교육을\n\n하고 사용 후 나타나는 모든 현상에 대하여 보고하도록 교육을\n\n※\n\n본 내용은「의료기기법 시행규칙」별표 3“의료기기 임상시험 관리기준” 제8호\n\n- ○ 이외에도 시험자가 중대하다고 간주하거나, 임상시험용 의료\n- - 90 -\n기기와의 사용과 연관 지을 수 있는 유의한 위험, 금기, 부작용,\n\n주의사항을 시사하는 사건 등도 중대한 이상 사례/의료기기\n\n이상 반응으로 기록하고 사망을 초래하거나 생명을 위협할\n\n때는 의뢰자가 이 사실을 보고받거나 알게 된 날로부터 7일\n\n이내, 이 경우 상세한 정보를 최초 보고일로부터 8일 이내에\n\n추가로 보고 하여야 한다.  그 밖의 중대하거나 예상하지 못한\n\n모든 이상 반응이 나타났을 때 의뢰자가 이 사실을 보고\n\n- - 91 -\n<!-- PAGE_98 -->\n##### 16.  피험자 동의서 서식\n\n- 가.  피험자 동의서에 반드시 포함되어야 하는 사항\n3) 임상시험용 의료기기에 관한 정보 및 시험군 또는 대조군에\n\n4) 침습적 시술(invasive procedure)을 포함하여 임상시험에서 피험자가\n\n8) 기대되는 이익이 있거나 피험자에게 기대되는 이익이 없을 경우\n\n9) 피험자가 선택할 수 있는 다른 치료방법이나 종류 및 그 치료\n\n방법의 잠재적 위험과 이익\n\n- - 92 -\n10) 임상시험과 관련한 손상이 발생하였을 경우 피험자에게 주어질\n\n보상이나 치료방법\n\n11) 피험자가 임상시험에 참여함으로써 받게 될 금전적 보상이 있는\n\n경우 예상 금액 및 이 금액이 임상시험 참여의 정도나 기간에\n\n13) 피험자의 임상시험 참여 여부 결정은 자발적이어야 하며, 피험자가\n\n원래 받을 수 있는 이익에 대한 손실 없이 임상시험의 참여를\n\n거부하거나 임상시험 도중 언제라도 참여를 포기할 수 있다는\n\n14) 제8호 항목에 따른 모니터 요원, 제8호 항목에 따른 점검을 실\n\n위하여 피험자의 신상에 관한 비밀이 보호되는 범위에서 피험자의\n\n의무기록을 열람할 수 있다는 사실과 피험자 또는 피험자 대리인의\n\n15) 피험자의 신상을 파악할 수 있는 기록은 비밀로 보호될 것이며\n\n임상시험의 결과가 출관될 경우 피험자의 신상은 비밀로 보호\n\n16) 피험자의 임상시험 계속 참여 여부에 영향을 줄 수 있는 새로운\n\n정보를 취득하면 적시에 피험자 또는 피험자의 대리인에게 알릴\n\n17) 임상시험과 피험자의 권익에 관하여 추가적인 정보를 얻고자\n\n- - 93 -\n하거나 임상시험과 관련이 있는 손상이 발생하면 연락해야 하는\n\n사람\n\n18) 임상시험 도중 피험자의 임상시험 참여가 중지되는 경우 및 그\n\n- 나.  피험자 동의의 일반적 요건\n1) 연구자는 연구를 시작하기 전에 임상시험심사위원회(Institutional\n\nReview Board, IRB)로부터 피험자에게 제공될 설명서 및 동의서,\n\n2) 연구자는 임상시험심사위원회 승인 직인이 찍힌 동의서 등을\n\n피험자 또는 피험자의 대리인에게 제공해야 하며, 피험자(또는\n\n대리인)와 동의를 받은 책임연구자(또는 책임연구자의 위임을 받은\n\n자)는 동의서 서식에 서명하고, 자필로 해당 날짜를 기재하여야\n\n3) 연구자는 서명된 동의서를 보관해야 하며, 사본을 피험자(또는\n\n4) 동의서를 받는 과정에서 연구자는 피험자 또는 대리인에게 강제나\n\n부당한 영향을 미치지 않아야 하며, 피험자 또는 대리인이 연구의\n\n모든 정보를 이해할 수 있는 용어 및 언어로 작성된 동의서 등을\n\n제공하여 설명하고 질문에 대하여 대답한 후 충분히 생각할\n\n- - 94 -\n5) 피험자 동의서에는 피험자 또는 대리인의 법적 권리를 포기나\n\n제한, 연구자/의뢰자/기관 및 기관장의 과실 책임의 면제를 암시\n\n6) 피험자의 동의에 영향을 줄 수 있는 새로운 연구 관련정보가\n\n수집되면 동의서 서식, 피험자 설명서 및 기타 문서화된 정보는\n\n이에 따라 수정되어야 하며, 사용 전에 반드시 위원회의 승인을\n\n받아야 한다.  피험자의 지속적인 연구 참여 의지에 영향을 줄 경우\n\n연구 책임자는 피험자 또는 대리인에게 즉시 알리고, 이러한\n\n7) 피험자 또는 대리인이 동의서 등을 읽을 수 없는 경우에는 공정한\n\n- 다. ",
        "original_sentence": "피험자 동의서 서식\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_696",
      "text": "피험자 동의서에 반드시 포함되어야 하는 사항\n3) 임상시험용 의료기기에 관한 정보 및 시험군 또는 대조군에\n\n4) 침습적 시술(invasive procedure)을 포함하여 임상시험에서 피험자가\n\n8) 기대되는 이익이 있거나 피험자에게 기대되는 이익이 없을 경우\n\n9) 피험자가 선택할 수 있는 다른 치료방법이나 종류 및 그 치료\n\n방법의 잠재적 위험과 이익\n\n- - 92 -\n10) 임상시험과 관련한 손상이 발생하였을 경우 피험자에게 주어질\n\n보상이나 치료방법\n\n11) 피험자가 임상시험에 참여함으로써 받게 될 금전적 보상이 있는\n\n경우 예상 금액 및 이 금액이 임상시험 참여의 정도나 기간에\n\n13) 피험자의 임상시험 참여 여부 결정은 자발적이어야 하며, 피험자가\n\n원래 받을 수 있는 이익에 대한 손실 없이 임상시험의 참여를\n\n거부하거나 임상시험 도중 언제라도 참여를 포기할 수 있다는\n\n14) 제8호 항목에 따른 모니터 요원, 제8호 항목에 따른 점검을 실\n\n위하여 피험자의 신상에 관한 비밀이 보호되는 범위에서 피험자의\n\n의무기록을 열람할 수 있다는 사실과 피험자 또는 피험자 대리인의\n\n15) 피험자의 신상을 파악할 수 있는 기록은 비밀로 보호될 것이며\n\n임상시험의 결과가 출관될 경우 피험자의 신상은 비밀로 보호\n\n16) 피험자의 임상시험 계속 참여 여부에 영향을 줄 수 있는 새로운\n\n정보를 취득하면 적시에 피험자 또는 피험자의 대리인에게 알릴\n\n17) 임상시험과 피험자의 권익에 관하여 추가적인 정보를 얻고자\n\n- - 93 -\n하거나 임상시험과 관련이 있는 손상이 발생하면 연락해야 하는\n\n사람\n\n18) 임상시험 도중 피험자의 임상시험 참여가 중지되는 경우 및 그\n\n- 나. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 695,
        "window_size": 3,
        "char_count": 835,
        "word_count": 204,
        "page_number": 3,
        "window_text": "이상 사례 보고 방법\n- ○ 시험책임자는 시험담당자 또는 임상의 등에게 임상시험용 의료\n기기 사용 후 나타날 수 있는 모든 이상 사례에 대하여 교육을\n\n하고 사용 후 나타나는 모든 현상에 대하여 보고하도록 교육을\n\n※\n\n본 내용은「의료기기법 시행규칙」별표 3“의료기기 임상시험 관리기준” 제8호\n\n- ○ 이외에도 시험자가 중대하다고 간주하거나, 임상시험용 의료\n- - 90 -\n기기와의 사용과 연관 지을 수 있는 유의한 위험, 금기, 부작용,\n\n주의사항을 시사하는 사건 등도 중대한 이상 사례/의료기기\n\n이상 반응으로 기록하고 사망을 초래하거나 생명을 위협할\n\n때는 의뢰자가 이 사실을 보고받거나 알게 된 날로부터 7일\n\n이내, 이 경우 상세한 정보를 최초 보고일로부터 8일 이내에\n\n추가로 보고 하여야 한다.  그 밖의 중대하거나 예상하지 못한\n\n모든 이상 반응이 나타났을 때 의뢰자가 이 사실을 보고\n\n- - 91 -\n<!-- PAGE_98 -->\n##### 16.  피험자 동의서 서식\n\n- 가.  피험자 동의서에 반드시 포함되어야 하는 사항\n3) 임상시험용 의료기기에 관한 정보 및 시험군 또는 대조군에\n\n4) 침습적 시술(invasive procedure)을 포함하여 임상시험에서 피험자가\n\n8) 기대되는 이익이 있거나 피험자에게 기대되는 이익이 없을 경우\n\n9) 피험자가 선택할 수 있는 다른 치료방법이나 종류 및 그 치료\n\n방법의 잠재적 위험과 이익\n\n- - 92 -\n10) 임상시험과 관련한 손상이 발생하였을 경우 피험자에게 주어질\n\n보상이나 치료방법\n\n11) 피험자가 임상시험에 참여함으로써 받게 될 금전적 보상이 있는\n\n경우 예상 금액 및 이 금액이 임상시험 참여의 정도나 기간에\n\n13) 피험자의 임상시험 참여 여부 결정은 자발적이어야 하며, 피험자가\n\n원래 받을 수 있는 이익에 대한 손실 없이 임상시험의 참여를\n\n거부하거나 임상시험 도중 언제라도 참여를 포기할 수 있다는\n\n14) 제8호 항목에 따른 모니터 요원, 제8호 항목에 따른 점검을 실\n\n위하여 피험자의 신상에 관한 비밀이 보호되는 범위에서 피험자의\n\n의무기록을 열람할 수 있다는 사실과 피험자 또는 피험자 대리인의\n\n15) 피험자의 신상을 파악할 수 있는 기록은 비밀로 보호될 것이며\n\n임상시험의 결과가 출관될 경우 피험자의 신상은 비밀로 보호\n\n16) 피험자의 임상시험 계속 참여 여부에 영향을 줄 수 있는 새로운\n\n정보를 취득하면 적시에 피험자 또는 피험자의 대리인에게 알릴\n\n17) 임상시험과 피험자의 권익에 관하여 추가적인 정보를 얻고자\n\n- - 93 -\n하거나 임상시험과 관련이 있는 손상이 발생하면 연락해야 하는\n\n사람\n\n18) 임상시험 도중 피험자의 임상시험 참여가 중지되는 경우 및 그\n\n- 나.  피험자 동의의 일반적 요건\n1) 연구자는 연구를 시작하기 전에 임상시험심사위원회(Institutional\n\nReview Board, IRB)로부터 피험자에게 제공될 설명서 및 동의서,\n\n2) 연구자는 임상시험심사위원회 승인 직인이 찍힌 동의서 등을\n\n피험자 또는 피험자의 대리인에게 제공해야 하며, 피험자(또는\n\n대리인)와 동의를 받은 책임연구자(또는 책임연구자의 위임을 받은\n\n자)는 동의서 서식에 서명하고, 자필로 해당 날짜를 기재하여야\n\n3) 연구자는 서명된 동의서를 보관해야 하며, 사본을 피험자(또는\n\n4) 동의서를 받는 과정에서 연구자는 피험자 또는 대리인에게 강제나\n\n부당한 영향을 미치지 않아야 하며, 피험자 또는 대리인이 연구의\n\n모든 정보를 이해할 수 있는 용어 및 언어로 작성된 동의서 등을\n\n제공하여 설명하고 질문에 대하여 대답한 후 충분히 생각할\n\n- - 94 -\n5) 피험자 동의서에는 피험자 또는 대리인의 법적 권리를 포기나\n\n제한, 연구자/의뢰자/기관 및 기관장의 과실 책임의 면제를 암시\n\n6) 피험자의 동의에 영향을 줄 수 있는 새로운 연구 관련정보가\n\n수집되면 동의서 서식, 피험자 설명서 및 기타 문서화된 정보는\n\n이에 따라 수정되어야 하며, 사용 전에 반드시 위원회의 승인을\n\n받아야 한다.  피험자의 지속적인 연구 참여 의지에 영향을 줄 경우\n\n연구 책임자는 피험자 또는 대리인에게 즉시 알리고, 이러한\n\n7) 피험자 또는 대리인이 동의서 등을 읽을 수 없는 경우에는 공정한\n\n- 다.  임상시험 실시 도중 피험자 설명문 등이 변경되었을 때 재동의\n임상시험 실시 도중 동의서 서식이 변경되거나, 피험자에게 제공된\n\n문서 정보의 변경이 있는 경우에는 변경일 기준 다음 방문일에 변경\n\n내용을 피험자에게 충분히 설명하고, 시험책임자(또는 시험담당의사)와\n\n피험자는 변경동의서에 서명하고 해당 날짜를 자필로 적어야 한다.\n\n",
        "original_sentence": "피험자 동의서에 반드시 포함되어야 하는 사항\n3) 임상시험용 의료기기에 관한 정보 및 시험군 또는 대조군에\n\n4) 침습적 시술(invasive procedure)을 포함하여 임상시험에서 피험자가\n\n8) 기대되는 이익이 있거나 피험자에게 기대되는 이익이 없을 경우\n\n9) 피험자가 선택할 수 있는 다른 치료방법이나 종류 및 그 치료\n\n방법의 잠재적 위험과 이익\n\n- - 92 -\n10) 임상시험과 관련한 손상이 발생하였을 경우 피험자에게 주어질\n\n보상이나 치료방법\n\n11) 피험자가 임상시험에 참여함으로써 받게 될 금전적 보상이 있는\n\n경우 예상 금액 및 이 금액이 임상시험 참여의 정도나 기간에\n\n13) 피험자의 임상시험 참여 여부 결정은 자발적이어야 하며, 피험자가\n\n원래 받을 수 있는 이익에 대한 손실 없이 임상시험의 참여를\n\n거부하거나 임상시험 도중 언제라도 참여를 포기할 수 있다는\n\n14) 제8호 항목에 따른 모니터 요원, 제8호 항목에 따른 점검을 실\n\n위하여 피험자의 신상에 관한 비밀이 보호되는 범위에서 피험자의\n\n의무기록을 열람할 수 있다는 사실과 피험자 또는 피험자 대리인의\n\n15) 피험자의 신상을 파악할 수 있는 기록은 비밀로 보호될 것이며\n\n임상시험의 결과가 출관될 경우 피험자의 신상은 비밀로 보호\n\n16) 피험자의 임상시험 계속 참여 여부에 영향을 줄 수 있는 새로운\n\n정보를 취득하면 적시에 피험자 또는 피험자의 대리인에게 알릴\n\n17) 임상시험과 피험자의 권익에 관하여 추가적인 정보를 얻고자\n\n- - 93 -\n하거나 임상시험과 관련이 있는 손상이 발생하면 연락해야 하는\n\n사람\n\n18) 임상시험 도중 피험자의 임상시험 참여가 중지되는 경우 및 그\n\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_697",
      "text": "피험자 동의의 일반적 요건\n1) 연구자는 연구를 시작하기 전에 임상시험심사위원회(Institutional\n\nReview Board, IRB)로부터 피험자에게 제공될 설명서 및 동의서,\n\n2) 연구자는 임상시험심사위원회 승인 직인이 찍힌 동의서 등을\n\n피험자 또는 피험자의 대리인에게 제공해야 하며, 피험자(또는\n\n대리인)와 동의를 받은 책임연구자(또는 책임연구자의 위임을 받은\n\n자)는 동의서 서식에 서명하고, 자필로 해당 날짜를 기재하여야\n\n3) 연구자는 서명된 동의서를 보관해야 하며, 사본을 피험자(또는\n\n4) 동의서를 받는 과정에서 연구자는 피험자 또는 대리인에게 강제나\n\n부당한 영향을 미치지 않아야 하며, 피험자 또는 대리인이 연구의\n\n모든 정보를 이해할 수 있는 용어 및 언어로 작성된 동의서 등을\n\n제공하여 설명하고 질문에 대하여 대답한 후 충분히 생각할\n\n- - 94 -\n5) 피험자 동의서에는 피험자 또는 대리인의 법적 권리를 포기나\n\n제한, 연구자/의뢰자/기관 및 기관장의 과실 책임의 면제를 암시\n\n6) 피험자의 동의에 영향을 줄 수 있는 새로운 연구 관련정보가\n\n수집되면 동의서 서식, 피험자 설명서 및 기타 문서화된 정보는\n\n이에 따라 수정되어야 하며, 사용 전에 반드시 위원회의 승인을\n\n받아야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 696,
        "window_size": 3,
        "char_count": 632,
        "word_count": 144,
        "page_number": 19,
        "window_text": "그 밖의 중대하거나 예상하지 못한\n\n모든 이상 반응이 나타났을 때 의뢰자가 이 사실을 보고\n\n- - 91 -\n<!-- PAGE_98 -->\n##### 16.  피험자 동의서 서식\n\n- 가.  피험자 동의서에 반드시 포함되어야 하는 사항\n3) 임상시험용 의료기기에 관한 정보 및 시험군 또는 대조군에\n\n4) 침습적 시술(invasive procedure)을 포함하여 임상시험에서 피험자가\n\n8) 기대되는 이익이 있거나 피험자에게 기대되는 이익이 없을 경우\n\n9) 피험자가 선택할 수 있는 다른 치료방법이나 종류 및 그 치료\n\n방법의 잠재적 위험과 이익\n\n- - 92 -\n10) 임상시험과 관련한 손상이 발생하였을 경우 피험자에게 주어질\n\n보상이나 치료방법\n\n11) 피험자가 임상시험에 참여함으로써 받게 될 금전적 보상이 있는\n\n경우 예상 금액 및 이 금액이 임상시험 참여의 정도나 기간에\n\n13) 피험자의 임상시험 참여 여부 결정은 자발적이어야 하며, 피험자가\n\n원래 받을 수 있는 이익에 대한 손실 없이 임상시험의 참여를\n\n거부하거나 임상시험 도중 언제라도 참여를 포기할 수 있다는\n\n14) 제8호 항목에 따른 모니터 요원, 제8호 항목에 따른 점검을 실\n\n위하여 피험자의 신상에 관한 비밀이 보호되는 범위에서 피험자의\n\n의무기록을 열람할 수 있다는 사실과 피험자 또는 피험자 대리인의\n\n15) 피험자의 신상을 파악할 수 있는 기록은 비밀로 보호될 것이며\n\n임상시험의 결과가 출관될 경우 피험자의 신상은 비밀로 보호\n\n16) 피험자의 임상시험 계속 참여 여부에 영향을 줄 수 있는 새로운\n\n정보를 취득하면 적시에 피험자 또는 피험자의 대리인에게 알릴\n\n17) 임상시험과 피험자의 권익에 관하여 추가적인 정보를 얻고자\n\n- - 93 -\n하거나 임상시험과 관련이 있는 손상이 발생하면 연락해야 하는\n\n사람\n\n18) 임상시험 도중 피험자의 임상시험 참여가 중지되는 경우 및 그\n\n- 나.  피험자 동의의 일반적 요건\n1) 연구자는 연구를 시작하기 전에 임상시험심사위원회(Institutional\n\nReview Board, IRB)로부터 피험자에게 제공될 설명서 및 동의서,\n\n2) 연구자는 임상시험심사위원회 승인 직인이 찍힌 동의서 등을\n\n피험자 또는 피험자의 대리인에게 제공해야 하며, 피험자(또는\n\n대리인)와 동의를 받은 책임연구자(또는 책임연구자의 위임을 받은\n\n자)는 동의서 서식에 서명하고, 자필로 해당 날짜를 기재하여야\n\n3) 연구자는 서명된 동의서를 보관해야 하며, 사본을 피험자(또는\n\n4) 동의서를 받는 과정에서 연구자는 피험자 또는 대리인에게 강제나\n\n부당한 영향을 미치지 않아야 하며, 피험자 또는 대리인이 연구의\n\n모든 정보를 이해할 수 있는 용어 및 언어로 작성된 동의서 등을\n\n제공하여 설명하고 질문에 대하여 대답한 후 충분히 생각할\n\n- - 94 -\n5) 피험자 동의서에는 피험자 또는 대리인의 법적 권리를 포기나\n\n제한, 연구자/의뢰자/기관 및 기관장의 과실 책임의 면제를 암시\n\n6) 피험자의 동의에 영향을 줄 수 있는 새로운 연구 관련정보가\n\n수집되면 동의서 서식, 피험자 설명서 및 기타 문서화된 정보는\n\n이에 따라 수정되어야 하며, 사용 전에 반드시 위원회의 승인을\n\n받아야 한다.  피험자의 지속적인 연구 참여 의지에 영향을 줄 경우\n\n연구 책임자는 피험자 또는 대리인에게 즉시 알리고, 이러한\n\n7) 피험자 또는 대리인이 동의서 등을 읽을 수 없는 경우에는 공정한\n\n- 다.  임상시험 실시 도중 피험자 설명문 등이 변경되었을 때 재동의\n임상시험 실시 도중 동의서 서식이 변경되거나, 피험자에게 제공된\n\n문서 정보의 변경이 있는 경우에는 변경일 기준 다음 방문일에 변경\n\n내용을 피험자에게 충분히 설명하고, 시험책임자(또는 시험담당의사)와\n\n피험자는 변경동의서에 서명하고 해당 날짜를 자필로 적어야 한다.\n\n - 라. ",
        "original_sentence": "피험자 동의의 일반적 요건\n1) 연구자는 연구를 시작하기 전에 임상시험심사위원회(Institutional\n\nReview Board, IRB)로부터 피험자에게 제공될 설명서 및 동의서,\n\n2) 연구자는 임상시험심사위원회 승인 직인이 찍힌 동의서 등을\n\n피험자 또는 피험자의 대리인에게 제공해야 하며, 피험자(또는\n\n대리인)와 동의를 받은 책임연구자(또는 책임연구자의 위임을 받은\n\n자)는 동의서 서식에 서명하고, 자필로 해당 날짜를 기재하여야\n\n3) 연구자는 서명된 동의서를 보관해야 하며, 사본을 피험자(또는\n\n4) 동의서를 받는 과정에서 연구자는 피험자 또는 대리인에게 강제나\n\n부당한 영향을 미치지 않아야 하며, 피험자 또는 대리인이 연구의\n\n모든 정보를 이해할 수 있는 용어 및 언어로 작성된 동의서 등을\n\n제공하여 설명하고 질문에 대하여 대답한 후 충분히 생각할\n\n- - 94 -\n5) 피험자 동의서에는 피험자 또는 대리인의 법적 권리를 포기나\n\n제한, 연구자/의뢰자/기관 및 기관장의 과실 책임의 면제를 암시\n\n6) 피험자의 동의에 영향을 줄 수 있는 새로운 연구 관련정보가\n\n수집되면 동의서 서식, 피험자 설명서 및 기타 문서화된 정보는\n\n이에 따라 수정되어야 하며, 사용 전에 반드시 위원회의 승인을\n\n받아야 한다. "
      }
    },
    {
      "chunk_id": "chunk_698",
      "text": "피험자의 지속적인 연구 참여 의지에 영향을 줄 경우\n\n연구 책임자는 피험자 또는 대리인에게 즉시 알리고, 이러한\n\n7) 피험자 또는 대리인이 동의서 등을 읽을 수 없는 경우에는 공정한\n\n- 다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 697,
        "window_size": 3,
        "char_count": 109,
        "word_count": 29,
        "page_number": 34,
        "window_text": "피험자 동의서 서식\n\n- 가.  피험자 동의서에 반드시 포함되어야 하는 사항\n3) 임상시험용 의료기기에 관한 정보 및 시험군 또는 대조군에\n\n4) 침습적 시술(invasive procedure)을 포함하여 임상시험에서 피험자가\n\n8) 기대되는 이익이 있거나 피험자에게 기대되는 이익이 없을 경우\n\n9) 피험자가 선택할 수 있는 다른 치료방법이나 종류 및 그 치료\n\n방법의 잠재적 위험과 이익\n\n- - 92 -\n10) 임상시험과 관련한 손상이 발생하였을 경우 피험자에게 주어질\n\n보상이나 치료방법\n\n11) 피험자가 임상시험에 참여함으로써 받게 될 금전적 보상이 있는\n\n경우 예상 금액 및 이 금액이 임상시험 참여의 정도나 기간에\n\n13) 피험자의 임상시험 참여 여부 결정은 자발적이어야 하며, 피험자가\n\n원래 받을 수 있는 이익에 대한 손실 없이 임상시험의 참여를\n\n거부하거나 임상시험 도중 언제라도 참여를 포기할 수 있다는\n\n14) 제8호 항목에 따른 모니터 요원, 제8호 항목에 따른 점검을 실\n\n위하여 피험자의 신상에 관한 비밀이 보호되는 범위에서 피험자의\n\n의무기록을 열람할 수 있다는 사실과 피험자 또는 피험자 대리인의\n\n15) 피험자의 신상을 파악할 수 있는 기록은 비밀로 보호될 것이며\n\n임상시험의 결과가 출관될 경우 피험자의 신상은 비밀로 보호\n\n16) 피험자의 임상시험 계속 참여 여부에 영향을 줄 수 있는 새로운\n\n정보를 취득하면 적시에 피험자 또는 피험자의 대리인에게 알릴\n\n17) 임상시험과 피험자의 권익에 관하여 추가적인 정보를 얻고자\n\n- - 93 -\n하거나 임상시험과 관련이 있는 손상이 발생하면 연락해야 하는\n\n사람\n\n18) 임상시험 도중 피험자의 임상시험 참여가 중지되는 경우 및 그\n\n- 나.  피험자 동의의 일반적 요건\n1) 연구자는 연구를 시작하기 전에 임상시험심사위원회(Institutional\n\nReview Board, IRB)로부터 피험자에게 제공될 설명서 및 동의서,\n\n2) 연구자는 임상시험심사위원회 승인 직인이 찍힌 동의서 등을\n\n피험자 또는 피험자의 대리인에게 제공해야 하며, 피험자(또는\n\n대리인)와 동의를 받은 책임연구자(또는 책임연구자의 위임을 받은\n\n자)는 동의서 서식에 서명하고, 자필로 해당 날짜를 기재하여야\n\n3) 연구자는 서명된 동의서를 보관해야 하며, 사본을 피험자(또는\n\n4) 동의서를 받는 과정에서 연구자는 피험자 또는 대리인에게 강제나\n\n부당한 영향을 미치지 않아야 하며, 피험자 또는 대리인이 연구의\n\n모든 정보를 이해할 수 있는 용어 및 언어로 작성된 동의서 등을\n\n제공하여 설명하고 질문에 대하여 대답한 후 충분히 생각할\n\n- - 94 -\n5) 피험자 동의서에는 피험자 또는 대리인의 법적 권리를 포기나\n\n제한, 연구자/의뢰자/기관 및 기관장의 과실 책임의 면제를 암시\n\n6) 피험자의 동의에 영향을 줄 수 있는 새로운 연구 관련정보가\n\n수집되면 동의서 서식, 피험자 설명서 및 기타 문서화된 정보는\n\n이에 따라 수정되어야 하며, 사용 전에 반드시 위원회의 승인을\n\n받아야 한다.  피험자의 지속적인 연구 참여 의지에 영향을 줄 경우\n\n연구 책임자는 피험자 또는 대리인에게 즉시 알리고, 이러한\n\n7) 피험자 또는 대리인이 동의서 등을 읽을 수 없는 경우에는 공정한\n\n- 다.  임상시험 실시 도중 피험자 설명문 등이 변경되었을 때 재동의\n임상시험 실시 도중 동의서 서식이 변경되거나, 피험자에게 제공된\n\n문서 정보의 변경이 있는 경우에는 변경일 기준 다음 방문일에 변경\n\n내용을 피험자에게 충분히 설명하고, 시험책임자(또는 시험담당의사)와\n\n피험자는 변경동의서에 서명하고 해당 날짜를 자필로 적어야 한다.\n\n - 라.  피험자의 대리인이 피험자를 대신하여 임상시험 참여에 동의\n피험자의 이해능력, 의사표현능력의 결여 등의 사유로 동의를 받을\n\n수 없는 경우에는 대리인의 동의를 받을 수 있으며, 이와 같은 경우\n\n에도 피험자는 피험자 자신이 이해할 수 있는 정도까지 임상시험에\n\n관한 정보를 제공 받아야하며, 가능하다면 피험자는 동의서 서식에\n\n- - 95 -\n서명하고 자필로 날짜를 기재하여야 한다. ",
        "original_sentence": "피험자의 지속적인 연구 참여 의지에 영향을 줄 경우\n\n연구 책임자는 피험자 또는 대리인에게 즉시 알리고, 이러한\n\n7) 피험자 또는 대리인이 동의서 등을 읽을 수 없는 경우에는 공정한\n\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_699",
      "text": "임상시험 실시 도중 피험자 설명문 등이 변경되었을 때 재동의\n임상시험 실시 도중 동의서 서식이 변경되거나, 피험자에게 제공된\n\n문서 정보의 변경이 있는 경우에는 변경일 기준 다음 방문일에 변경\n\n내용을 피험자에게 충분히 설명하고, 시험책임자(또는 시험담당의사)와\n\n피험자는 변경동의서에 서명하고 해당 날짜를 자필로 적어야 한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 698,
        "window_size": 3,
        "char_count": 185,
        "word_count": 41,
        "page_number": 32,
        "window_text": "피험자 동의서에 반드시 포함되어야 하는 사항\n3) 임상시험용 의료기기에 관한 정보 및 시험군 또는 대조군에\n\n4) 침습적 시술(invasive procedure)을 포함하여 임상시험에서 피험자가\n\n8) 기대되는 이익이 있거나 피험자에게 기대되는 이익이 없을 경우\n\n9) 피험자가 선택할 수 있는 다른 치료방법이나 종류 및 그 치료\n\n방법의 잠재적 위험과 이익\n\n- - 92 -\n10) 임상시험과 관련한 손상이 발생하였을 경우 피험자에게 주어질\n\n보상이나 치료방법\n\n11) 피험자가 임상시험에 참여함으로써 받게 될 금전적 보상이 있는\n\n경우 예상 금액 및 이 금액이 임상시험 참여의 정도나 기간에\n\n13) 피험자의 임상시험 참여 여부 결정은 자발적이어야 하며, 피험자가\n\n원래 받을 수 있는 이익에 대한 손실 없이 임상시험의 참여를\n\n거부하거나 임상시험 도중 언제라도 참여를 포기할 수 있다는\n\n14) 제8호 항목에 따른 모니터 요원, 제8호 항목에 따른 점검을 실\n\n위하여 피험자의 신상에 관한 비밀이 보호되는 범위에서 피험자의\n\n의무기록을 열람할 수 있다는 사실과 피험자 또는 피험자 대리인의\n\n15) 피험자의 신상을 파악할 수 있는 기록은 비밀로 보호될 것이며\n\n임상시험의 결과가 출관될 경우 피험자의 신상은 비밀로 보호\n\n16) 피험자의 임상시험 계속 참여 여부에 영향을 줄 수 있는 새로운\n\n정보를 취득하면 적시에 피험자 또는 피험자의 대리인에게 알릴\n\n17) 임상시험과 피험자의 권익에 관하여 추가적인 정보를 얻고자\n\n- - 93 -\n하거나 임상시험과 관련이 있는 손상이 발생하면 연락해야 하는\n\n사람\n\n18) 임상시험 도중 피험자의 임상시험 참여가 중지되는 경우 및 그\n\n- 나.  피험자 동의의 일반적 요건\n1) 연구자는 연구를 시작하기 전에 임상시험심사위원회(Institutional\n\nReview Board, IRB)로부터 피험자에게 제공될 설명서 및 동의서,\n\n2) 연구자는 임상시험심사위원회 승인 직인이 찍힌 동의서 등을\n\n피험자 또는 피험자의 대리인에게 제공해야 하며, 피험자(또는\n\n대리인)와 동의를 받은 책임연구자(또는 책임연구자의 위임을 받은\n\n자)는 동의서 서식에 서명하고, 자필로 해당 날짜를 기재하여야\n\n3) 연구자는 서명된 동의서를 보관해야 하며, 사본을 피험자(또는\n\n4) 동의서를 받는 과정에서 연구자는 피험자 또는 대리인에게 강제나\n\n부당한 영향을 미치지 않아야 하며, 피험자 또는 대리인이 연구의\n\n모든 정보를 이해할 수 있는 용어 및 언어로 작성된 동의서 등을\n\n제공하여 설명하고 질문에 대하여 대답한 후 충분히 생각할\n\n- - 94 -\n5) 피험자 동의서에는 피험자 또는 대리인의 법적 권리를 포기나\n\n제한, 연구자/의뢰자/기관 및 기관장의 과실 책임의 면제를 암시\n\n6) 피험자의 동의에 영향을 줄 수 있는 새로운 연구 관련정보가\n\n수집되면 동의서 서식, 피험자 설명서 및 기타 문서화된 정보는\n\n이에 따라 수정되어야 하며, 사용 전에 반드시 위원회의 승인을\n\n받아야 한다.  피험자의 지속적인 연구 참여 의지에 영향을 줄 경우\n\n연구 책임자는 피험자 또는 대리인에게 즉시 알리고, 이러한\n\n7) 피험자 또는 대리인이 동의서 등을 읽을 수 없는 경우에는 공정한\n\n- 다.  임상시험 실시 도중 피험자 설명문 등이 변경되었을 때 재동의\n임상시험 실시 도중 동의서 서식이 변경되거나, 피험자에게 제공된\n\n문서 정보의 변경이 있는 경우에는 변경일 기준 다음 방문일에 변경\n\n내용을 피험자에게 충분히 설명하고, 시험책임자(또는 시험담당의사)와\n\n피험자는 변경동의서에 서명하고 해당 날짜를 자필로 적어야 한다.\n\n - 라.  피험자의 대리인이 피험자를 대신하여 임상시험 참여에 동의\n피험자의 이해능력, 의사표현능력의 결여 등의 사유로 동의를 받을\n\n수 없는 경우에는 대리인의 동의를 받을 수 있으며, 이와 같은 경우\n\n에도 피험자는 피험자 자신이 이해할 수 있는 정도까지 임상시험에\n\n관한 정보를 제공 받아야하며, 가능하다면 피험자는 동의서 서식에\n\n- - 95 -\n서명하고 자필로 날짜를 기재하여야 한다.  또한, 피험자의 대리인임을\n\n확인할 수 있는 근거자료 등을 확보하고, 피험자 동의 설명서 등에\n\n대리인의 동의 사유를 구체적으로 기술할 것을 권장한다.\n\n",
        "original_sentence": "임상시험 실시 도중 피험자 설명문 등이 변경되었을 때 재동의\n임상시험 실시 도중 동의서 서식이 변경되거나, 피험자에게 제공된\n\n문서 정보의 변경이 있는 경우에는 변경일 기준 다음 방문일에 변경\n\n내용을 피험자에게 충분히 설명하고, 시험책임자(또는 시험담당의사)와\n\n피험자는 변경동의서에 서명하고 해당 날짜를 자필로 적어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_700",
      "text": "- 라. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 699,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 72,
        "window_text": "피험자 동의의 일반적 요건\n1) 연구자는 연구를 시작하기 전에 임상시험심사위원회(Institutional\n\nReview Board, IRB)로부터 피험자에게 제공될 설명서 및 동의서,\n\n2) 연구자는 임상시험심사위원회 승인 직인이 찍힌 동의서 등을\n\n피험자 또는 피험자의 대리인에게 제공해야 하며, 피험자(또는\n\n대리인)와 동의를 받은 책임연구자(또는 책임연구자의 위임을 받은\n\n자)는 동의서 서식에 서명하고, 자필로 해당 날짜를 기재하여야\n\n3) 연구자는 서명된 동의서를 보관해야 하며, 사본을 피험자(또는\n\n4) 동의서를 받는 과정에서 연구자는 피험자 또는 대리인에게 강제나\n\n부당한 영향을 미치지 않아야 하며, 피험자 또는 대리인이 연구의\n\n모든 정보를 이해할 수 있는 용어 및 언어로 작성된 동의서 등을\n\n제공하여 설명하고 질문에 대하여 대답한 후 충분히 생각할\n\n- - 94 -\n5) 피험자 동의서에는 피험자 또는 대리인의 법적 권리를 포기나\n\n제한, 연구자/의뢰자/기관 및 기관장의 과실 책임의 면제를 암시\n\n6) 피험자의 동의에 영향을 줄 수 있는 새로운 연구 관련정보가\n\n수집되면 동의서 서식, 피험자 설명서 및 기타 문서화된 정보는\n\n이에 따라 수정되어야 하며, 사용 전에 반드시 위원회의 승인을\n\n받아야 한다.  피험자의 지속적인 연구 참여 의지에 영향을 줄 경우\n\n연구 책임자는 피험자 또는 대리인에게 즉시 알리고, 이러한\n\n7) 피험자 또는 대리인이 동의서 등을 읽을 수 없는 경우에는 공정한\n\n- 다.  임상시험 실시 도중 피험자 설명문 등이 변경되었을 때 재동의\n임상시험 실시 도중 동의서 서식이 변경되거나, 피험자에게 제공된\n\n문서 정보의 변경이 있는 경우에는 변경일 기준 다음 방문일에 변경\n\n내용을 피험자에게 충분히 설명하고, 시험책임자(또는 시험담당의사)와\n\n피험자는 변경동의서에 서명하고 해당 날짜를 자필로 적어야 한다.\n\n - 라.  피험자의 대리인이 피험자를 대신하여 임상시험 참여에 동의\n피험자의 이해능력, 의사표현능력의 결여 등의 사유로 동의를 받을\n\n수 없는 경우에는 대리인의 동의를 받을 수 있으며, 이와 같은 경우\n\n에도 피험자는 피험자 자신이 이해할 수 있는 정도까지 임상시험에\n\n관한 정보를 제공 받아야하며, 가능하다면 피험자는 동의서 서식에\n\n- - 95 -\n서명하고 자필로 날짜를 기재하여야 한다.  또한, 피험자의 대리인임을\n\n확인할 수 있는 근거자료 등을 확보하고, 피험자 동의 설명서 등에\n\n대리인의 동의 사유를 구체적으로 기술할 것을 권장한다.\n\n - - 96 -\n<!-- PAGE_103 -->\n##### 17. ",
        "original_sentence": "- 라. "
      }
    },
    {
      "chunk_id": "chunk_701",
      "text": "피험자의 대리인이 피험자를 대신하여 임상시험 참여에 동의\n피험자의 이해능력, 의사표현능력의 결여 등의 사유로 동의를 받을\n\n수 없는 경우에는 대리인의 동의를 받을 수 있으며, 이와 같은 경우\n\n에도 피험자는 피험자 자신이 이해할 수 있는 정도까지 임상시험에\n\n관한 정보를 제공 받아야하며, 가능하다면 피험자는 동의서 서식에\n\n- - 95 -\n서명하고 자필로 날짜를 기재하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 700,
        "window_size": 3,
        "char_count": 214,
        "word_count": 52,
        "page_number": 35,
        "window_text": "피험자의 지속적인 연구 참여 의지에 영향을 줄 경우\n\n연구 책임자는 피험자 또는 대리인에게 즉시 알리고, 이러한\n\n7) 피험자 또는 대리인이 동의서 등을 읽을 수 없는 경우에는 공정한\n\n- 다.  임상시험 실시 도중 피험자 설명문 등이 변경되었을 때 재동의\n임상시험 실시 도중 동의서 서식이 변경되거나, 피험자에게 제공된\n\n문서 정보의 변경이 있는 경우에는 변경일 기준 다음 방문일에 변경\n\n내용을 피험자에게 충분히 설명하고, 시험책임자(또는 시험담당의사)와\n\n피험자는 변경동의서에 서명하고 해당 날짜를 자필로 적어야 한다.\n\n - 라.  피험자의 대리인이 피험자를 대신하여 임상시험 참여에 동의\n피험자의 이해능력, 의사표현능력의 결여 등의 사유로 동의를 받을\n\n수 없는 경우에는 대리인의 동의를 받을 수 있으며, 이와 같은 경우\n\n에도 피험자는 피험자 자신이 이해할 수 있는 정도까지 임상시험에\n\n관한 정보를 제공 받아야하며, 가능하다면 피험자는 동의서 서식에\n\n- - 95 -\n서명하고 자필로 날짜를 기재하여야 한다.  또한, 피험자의 대리인임을\n\n확인할 수 있는 근거자료 등을 확보하고, 피험자 동의 설명서 등에\n\n대리인의 동의 사유를 구체적으로 기술할 것을 권장한다.\n\n - - 96 -\n<!-- PAGE_103 -->\n##### 17.  피해자 보상에 대한 규약\n\n임상시험용 의료기기가 직접적 원인이 되어 피험자에게 손상이\n\n발생하여 응급조치가 필요한 경우 시험책임자가 가입한 보험에 의해\n\n보상한다. ",
        "original_sentence": "피험자의 대리인이 피험자를 대신하여 임상시험 참여에 동의\n피험자의 이해능력, 의사표현능력의 결여 등의 사유로 동의를 받을\n\n수 없는 경우에는 대리인의 동의를 받을 수 있으며, 이와 같은 경우\n\n에도 피험자는 피험자 자신이 이해할 수 있는 정도까지 임상시험에\n\n관한 정보를 제공 받아야하며, 가능하다면 피험자는 동의서 서식에\n\n- - 95 -\n서명하고 자필로 날짜를 기재하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_702",
      "text": "또한, 피험자의 대리인임을\n\n확인할 수 있는 근거자료 등을 확보하고, 피험자 동의 설명서 등에\n\n대리인의 동의 사유를 구체적으로 기술할 것을 권장한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 701,
        "window_size": 3,
        "char_count": 86,
        "word_count": 20,
        "page_number": 28,
        "window_text": "임상시험 실시 도중 피험자 설명문 등이 변경되었을 때 재동의\n임상시험 실시 도중 동의서 서식이 변경되거나, 피험자에게 제공된\n\n문서 정보의 변경이 있는 경우에는 변경일 기준 다음 방문일에 변경\n\n내용을 피험자에게 충분히 설명하고, 시험책임자(또는 시험담당의사)와\n\n피험자는 변경동의서에 서명하고 해당 날짜를 자필로 적어야 한다.\n\n - 라.  피험자의 대리인이 피험자를 대신하여 임상시험 참여에 동의\n피험자의 이해능력, 의사표현능력의 결여 등의 사유로 동의를 받을\n\n수 없는 경우에는 대리인의 동의를 받을 수 있으며, 이와 같은 경우\n\n에도 피험자는 피험자 자신이 이해할 수 있는 정도까지 임상시험에\n\n관한 정보를 제공 받아야하며, 가능하다면 피험자는 동의서 서식에\n\n- - 95 -\n서명하고 자필로 날짜를 기재하여야 한다.  또한, 피험자의 대리인임을\n\n확인할 수 있는 근거자료 등을 확보하고, 피험자 동의 설명서 등에\n\n대리인의 동의 사유를 구체적으로 기술할 것을 권장한다.\n\n - - 96 -\n<!-- PAGE_103 -->\n##### 17.  피해자 보상에 대한 규약\n\n임상시험용 의료기기가 직접적 원인이 되어 피험자에게 손상이\n\n발생하여 응급조치가 필요한 경우 시험책임자가 가입한 보험에 의해\n\n보상한다.  본 임상시험과 관련이 없는 부작용이 발생한 경우에도 해당\n\n과와의 긴밀한 협조를 통하여 신속한 검사와 처치를 시행한다.\n\n",
        "original_sentence": "또한, 피험자의 대리인임을\n\n확인할 수 있는 근거자료 등을 확보하고, 피험자 동의 설명서 등에\n\n대리인의 동의 사유를 구체적으로 기술할 것을 권장한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_703",
      "text": "- - 96 -\n<!-- PAGE_103 -->\n##### 17. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 702,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 103,
        "window_text": "- 라.  피험자의 대리인이 피험자를 대신하여 임상시험 참여에 동의\n피험자의 이해능력, 의사표현능력의 결여 등의 사유로 동의를 받을\n\n수 없는 경우에는 대리인의 동의를 받을 수 있으며, 이와 같은 경우\n\n에도 피험자는 피험자 자신이 이해할 수 있는 정도까지 임상시험에\n\n관한 정보를 제공 받아야하며, 가능하다면 피험자는 동의서 서식에\n\n- - 95 -\n서명하고 자필로 날짜를 기재하여야 한다.  또한, 피험자의 대리인임을\n\n확인할 수 있는 근거자료 등을 확보하고, 피험자 동의 설명서 등에\n\n대리인의 동의 사유를 구체적으로 기술할 것을 권장한다.\n\n - - 96 -\n<!-- PAGE_103 -->\n##### 17.  피해자 보상에 대한 규약\n\n임상시험용 의료기기가 직접적 원인이 되어 피험자에게 손상이\n\n발생하여 응급조치가 필요한 경우 시험책임자가 가입한 보험에 의해\n\n보상한다.  본 임상시험과 관련이 없는 부작용이 발생한 경우에도 해당\n\n과와의 긴밀한 협조를 통하여 신속한 검사와 처치를 시행한다.\n\n 예상된 의료기기 이상반응에 대하여 당사자들 간에 미리 합의한\n\n보상액 또는 조치가 있는 경우, 당해 기준에 따라 이를 보상한다. ",
        "original_sentence": "- - 96 -\n<!-- PAGE_103 -->\n##### 17. "
      }
    },
    {
      "chunk_id": "chunk_704",
      "text": "피해자 보상에 대한 규약\n\n임상시험용 의료기기가 직접적 원인이 되어 피험자에게 손상이\n\n발생하여 응급조치가 필요한 경우 시험책임자가 가입한 보험에 의해\n\n보상한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 703,
        "window_size": 3,
        "char_count": 92,
        "word_count": 20,
        "page_number": 27,
        "window_text": "피험자의 대리인이 피험자를 대신하여 임상시험 참여에 동의\n피험자의 이해능력, 의사표현능력의 결여 등의 사유로 동의를 받을\n\n수 없는 경우에는 대리인의 동의를 받을 수 있으며, 이와 같은 경우\n\n에도 피험자는 피험자 자신이 이해할 수 있는 정도까지 임상시험에\n\n관한 정보를 제공 받아야하며, 가능하다면 피험자는 동의서 서식에\n\n- - 95 -\n서명하고 자필로 날짜를 기재하여야 한다.  또한, 피험자의 대리인임을\n\n확인할 수 있는 근거자료 등을 확보하고, 피험자 동의 설명서 등에\n\n대리인의 동의 사유를 구체적으로 기술할 것을 권장한다.\n\n - - 96 -\n<!-- PAGE_103 -->\n##### 17.  피해자 보상에 대한 규약\n\n임상시험용 의료기기가 직접적 원인이 되어 피험자에게 손상이\n\n발생하여 응급조치가 필요한 경우 시험책임자가 가입한 보험에 의해\n\n보상한다.  본 임상시험과 관련이 없는 부작용이 발생한 경우에도 해당\n\n과와의 긴밀한 협조를 통하여 신속한 검사와 처치를 시행한다.\n\n 예상된 의료기기 이상반응에 대하여 당사자들 간에 미리 합의한\n\n보상액 또는 조치가 있는 경우, 당해 기준에 따라 이를 보상한다.  그\n\n외의 경우에는 신체손상의 정도, 성격, 지속기간, 유사사례 등을 종합적\n\n으로 고려하여 당사자들 간에 합의한 보상방법에 따라 이를 보상한다.\n\n",
        "original_sentence": "피해자 보상에 대한 규약\n\n임상시험용 의료기기가 직접적 원인이 되어 피험자에게 손상이\n\n발생하여 응급조치가 필요한 경우 시험책임자가 가입한 보험에 의해\n\n보상한다. "
      }
    },
    {
      "chunk_id": "chunk_705",
      "text": "본 임상시험과 관련이 없는 부작용이 발생한 경우에도 해당\n\n과와의 긴밀한 협조를 통하여 신속한 검사와 처치를 시행한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 704,
        "window_size": 3,
        "char_count": 68,
        "word_count": 16,
        "page_number": 34,
        "window_text": "또한, 피험자의 대리인임을\n\n확인할 수 있는 근거자료 등을 확보하고, 피험자 동의 설명서 등에\n\n대리인의 동의 사유를 구체적으로 기술할 것을 권장한다.\n\n - - 96 -\n<!-- PAGE_103 -->\n##### 17.  피해자 보상에 대한 규약\n\n임상시험용 의료기기가 직접적 원인이 되어 피험자에게 손상이\n\n발생하여 응급조치가 필요한 경우 시험책임자가 가입한 보험에 의해\n\n보상한다.  본 임상시험과 관련이 없는 부작용이 발생한 경우에도 해당\n\n과와의 긴밀한 협조를 통하여 신속한 검사와 처치를 시행한다.\n\n 예상된 의료기기 이상반응에 대하여 당사자들 간에 미리 합의한\n\n보상액 또는 조치가 있는 경우, 당해 기준에 따라 이를 보상한다.  그\n\n외의 경우에는 신체손상의 정도, 성격, 지속기간, 유사사례 등을 종합적\n\n으로 고려하여 당사자들 간에 합의한 보상방법에 따라 이를 보상한다.\n\n 당사자들 간에 전항의 합의가 이루어지지 아니한 경우에는, 법원의\n\n판결 및 이에 준하는 결정의 확정내용에 따라 보상한다.\n\n",
        "original_sentence": "본 임상시험과 관련이 없는 부작용이 발생한 경우에도 해당\n\n과와의 긴밀한 협조를 통하여 신속한 검사와 처치를 시행한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_706",
      "text": "예상된 의료기기 이상반응에 대하여 당사자들 간에 미리 합의한\n\n보상액 또는 조치가 있는 경우, 당해 기준에 따라 이를 보상한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 705,
        "window_size": 3,
        "char_count": 72,
        "word_count": 18,
        "page_number": 27,
        "window_text": "- - 96 -\n<!-- PAGE_103 -->\n##### 17.  피해자 보상에 대한 규약\n\n임상시험용 의료기기가 직접적 원인이 되어 피험자에게 손상이\n\n발생하여 응급조치가 필요한 경우 시험책임자가 가입한 보험에 의해\n\n보상한다.  본 임상시험과 관련이 없는 부작용이 발생한 경우에도 해당\n\n과와의 긴밀한 협조를 통하여 신속한 검사와 처치를 시행한다.\n\n 예상된 의료기기 이상반응에 대하여 당사자들 간에 미리 합의한\n\n보상액 또는 조치가 있는 경우, 당해 기준에 따라 이를 보상한다.  그\n\n외의 경우에는 신체손상의 정도, 성격, 지속기간, 유사사례 등을 종합적\n\n으로 고려하여 당사자들 간에 합의한 보상방법에 따라 이를 보상한다.\n\n 당사자들 간에 전항의 합의가 이루어지지 아니한 경우에는, 법원의\n\n판결 및 이에 준하는 결정의 확정내용에 따라 보상한다.\n\n - - 97 -\n<!-- PAGE_104 -->\n##### 18. ",
        "original_sentence": "예상된 의료기기 이상반응에 대하여 당사자들 간에 미리 합의한\n\n보상액 또는 조치가 있는 경우, 당해 기준에 따라 이를 보상한다. "
      }
    },
    {
      "chunk_id": "chunk_707",
      "text": "그\n\n외의 경우에는 신체손상의 정도, 성격, 지속기간, 유사사례 등을 종합적\n\n으로 고려하여 당사자들 간에 합의한 보상방법에 따라 이를 보상한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 706,
        "window_size": 3,
        "char_count": 83,
        "word_count": 19,
        "page_number": 34,
        "window_text": "피해자 보상에 대한 규약\n\n임상시험용 의료기기가 직접적 원인이 되어 피험자에게 손상이\n\n발생하여 응급조치가 필요한 경우 시험책임자가 가입한 보험에 의해\n\n보상한다.  본 임상시험과 관련이 없는 부작용이 발생한 경우에도 해당\n\n과와의 긴밀한 협조를 통하여 신속한 검사와 처치를 시행한다.\n\n 예상된 의료기기 이상반응에 대하여 당사자들 간에 미리 합의한\n\n보상액 또는 조치가 있는 경우, 당해 기준에 따라 이를 보상한다.  그\n\n외의 경우에는 신체손상의 정도, 성격, 지속기간, 유사사례 등을 종합적\n\n으로 고려하여 당사자들 간에 합의한 보상방법에 따라 이를 보상한다.\n\n 당사자들 간에 전항의 합의가 이루어지지 아니한 경우에는, 법원의\n\n판결 및 이에 준하는 결정의 확정내용에 따라 보상한다.\n\n - - 97 -\n<!-- PAGE_104 -->\n##### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 OO병원\n\n에서 진행하던 치료절차가 임상시험 참여 전과 다름없이 진행되며,\n\n이후의 치료비는 피험자가 지불하여야 한다. ",
        "original_sentence": "그\n\n외의 경우에는 신체손상의 정도, 성격, 지속기간, 유사사례 등을 종합적\n\n으로 고려하여 당사자들 간에 합의한 보상방법에 따라 이를 보상한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_708",
      "text": "당사자들 간에 전항의 합의가 이루어지지 아니한 경우에는, 법원의\n\n판결 및 이에 준하는 결정의 확정내용에 따라 보상한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 707,
        "window_size": 3,
        "char_count": 69,
        "word_count": 16,
        "page_number": 30,
        "window_text": "본 임상시험과 관련이 없는 부작용이 발생한 경우에도 해당\n\n과와의 긴밀한 협조를 통하여 신속한 검사와 처치를 시행한다.\n\n 예상된 의료기기 이상반응에 대하여 당사자들 간에 미리 합의한\n\n보상액 또는 조치가 있는 경우, 당해 기준에 따라 이를 보상한다.  그\n\n외의 경우에는 신체손상의 정도, 성격, 지속기간, 유사사례 등을 종합적\n\n으로 고려하여 당사자들 간에 합의한 보상방법에 따라 이를 보상한다.\n\n 당사자들 간에 전항의 합의가 이루어지지 아니한 경우에는, 법원의\n\n판결 및 이에 준하는 결정의 확정내용에 따라 보상한다.\n\n - - 97 -\n<!-- PAGE_104 -->\n##### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 OO병원\n\n에서 진행하던 치료절차가 임상시험 참여 전과 다름없이 진행되며,\n\n이후의 치료비는 피험자가 지불하여야 한다.  다만, 부작용 발생 시\n\n임상시험에 사용된 의료기기와의 인과관계 유무를 확인한 후, 본\n\n임상시험에 사용된 의료기기로 인하여 부작용이 발생한 경우 ㈜OOO\n\n에서 치료에 관한 부작용이 소실될 때까지 치료비를 지불한다.\n\n",
        "original_sentence": "당사자들 간에 전항의 합의가 이루어지지 아니한 경우에는, 법원의\n\n판결 및 이에 준하는 결정의 확정내용에 따라 보상한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_709",
      "text": "- - 97 -\n<!-- PAGE_104 -->\n##### 18. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 708,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 104,
        "window_text": "예상된 의료기기 이상반응에 대하여 당사자들 간에 미리 합의한\n\n보상액 또는 조치가 있는 경우, 당해 기준에 따라 이를 보상한다.  그\n\n외의 경우에는 신체손상의 정도, 성격, 지속기간, 유사사례 등을 종합적\n\n으로 고려하여 당사자들 간에 합의한 보상방법에 따라 이를 보상한다.\n\n 당사자들 간에 전항의 합의가 이루어지지 아니한 경우에는, 법원의\n\n판결 및 이에 준하는 결정의 확정내용에 따라 보상한다.\n\n - - 97 -\n<!-- PAGE_104 -->\n##### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 OO병원\n\n에서 진행하던 치료절차가 임상시험 참여 전과 다름없이 진행되며,\n\n이후의 치료비는 피험자가 지불하여야 한다.  다만, 부작용 발생 시\n\n임상시험에 사용된 의료기기와의 인과관계 유무를 확인한 후, 본\n\n임상시험에 사용된 의료기기로 인하여 부작용이 발생한 경우 ㈜OOO\n\n에서 치료에 관한 부작용이 소실될 때까지 치료비를 지불한다.\n\n - - 98 -\n<!-- PAGE_105 -->\n##### 19. ",
        "original_sentence": "- - 97 -\n<!-- PAGE_104 -->\n##### 18. "
      }
    },
    {
      "chunk_id": "chunk_710",
      "text": "임상시험 후 피험자의 진료에 관한 사항\n\n본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 OO병원\n\n에서 진행하던 치료절차가 임상시험 참여 전과 다름없이 진행되며,\n\n이후의 치료비는 피험자가 지불하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 709,
        "window_size": 3,
        "char_count": 121,
        "word_count": 28,
        "page_number": 3,
        "window_text": "그\n\n외의 경우에는 신체손상의 정도, 성격, 지속기간, 유사사례 등을 종합적\n\n으로 고려하여 당사자들 간에 합의한 보상방법에 따라 이를 보상한다.\n\n 당사자들 간에 전항의 합의가 이루어지지 아니한 경우에는, 법원의\n\n판결 및 이에 준하는 결정의 확정내용에 따라 보상한다.\n\n - - 97 -\n<!-- PAGE_104 -->\n##### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 OO병원\n\n에서 진행하던 치료절차가 임상시험 참여 전과 다름없이 진행되며,\n\n이후의 치료비는 피험자가 지불하여야 한다.  다만, 부작용 발생 시\n\n임상시험에 사용된 의료기기와의 인과관계 유무를 확인한 후, 본\n\n임상시험에 사용된 의료기기로 인하여 부작용이 발생한 경우 ㈜OOO\n\n에서 치료에 관한 부작용이 소실될 때까지 치료비를 지불한다.\n\n - - 98 -\n<!-- PAGE_105 -->\n##### 19.  피험자의 안전보호에 대한 대책\n\n- 가. ",
        "original_sentence": "임상시험 후 피험자의 진료에 관한 사항\n\n본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 OO병원\n\n에서 진행하던 치료절차가 임상시험 참여 전과 다름없이 진행되며,\n\n이후의 치료비는 피험자가 지불하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_711",
      "text": "다만, 부작용 발생 시\n\n임상시험에 사용된 의료기기와의 인과관계 유무를 확인한 후, 본\n\n임상시험에 사용된 의료기기로 인하여 부작용이 발생한 경우 ㈜OOO\n\n에서 치료에 관한 부작용이 소실될 때까지 치료비를 지불한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 710,
        "window_size": 3,
        "char_count": 123,
        "word_count": 28,
        "page_number": 27,
        "window_text": "당사자들 간에 전항의 합의가 이루어지지 아니한 경우에는, 법원의\n\n판결 및 이에 준하는 결정의 확정내용에 따라 보상한다.\n\n - - 97 -\n<!-- PAGE_104 -->\n##### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 OO병원\n\n에서 진행하던 치료절차가 임상시험 참여 전과 다름없이 진행되며,\n\n이후의 치료비는 피험자가 지불하여야 한다.  다만, 부작용 발생 시\n\n임상시험에 사용된 의료기기와의 인과관계 유무를 확인한 후, 본\n\n임상시험에 사용된 의료기기로 인하여 부작용이 발생한 경우 ㈜OOO\n\n에서 치료에 관한 부작용이 소실될 때까지 치료비를 지불한다.\n\n - - 98 -\n<!-- PAGE_105 -->\n##### 19.  피험자의 안전보호에 대한 대책\n\n- 가.  임상시험 실시기관\n임상시험 실시기관의 장은 해당 임상시험의 실시에 필요한 임상\n\n시험실, 설비와 전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를\n\n취할 수 있도록 하는 등 해당 임상시험을 적절하게 실시할 수 있도록\n\n하여야 한다.\n\n",
        "original_sentence": "다만, 부작용 발생 시\n\n임상시험에 사용된 의료기기와의 인과관계 유무를 확인한 후, 본\n\n임상시험에 사용된 의료기기로 인하여 부작용이 발생한 경우 ㈜OOO\n\n에서 치료에 관한 부작용이 소실될 때까지 치료비를 지불한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_712",
      "text": "- - 98 -\n<!-- PAGE_105 -->\n##### 19. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 711,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 105,
        "window_text": "- - 97 -\n<!-- PAGE_104 -->\n##### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 OO병원\n\n에서 진행하던 치료절차가 임상시험 참여 전과 다름없이 진행되며,\n\n이후의 치료비는 피험자가 지불하여야 한다.  다만, 부작용 발생 시\n\n임상시험에 사용된 의료기기와의 인과관계 유무를 확인한 후, 본\n\n임상시험에 사용된 의료기기로 인하여 부작용이 발생한 경우 ㈜OOO\n\n에서 치료에 관한 부작용이 소실될 때까지 치료비를 지불한다.\n\n - - 98 -\n<!-- PAGE_105 -->\n##### 19.  피험자의 안전보호에 대한 대책\n\n- 가.  임상시험 실시기관\n임상시험 실시기관의 장은 해당 임상시험의 실시에 필요한 임상\n\n시험실, 설비와 전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를\n\n취할 수 있도록 하는 등 해당 임상시험을 적절하게 실시할 수 있도록\n\n하여야 한다.\n\n - 나. ",
        "original_sentence": "- - 98 -\n<!-- PAGE_105 -->\n##### 19. "
      }
    },
    {
      "chunk_id": "chunk_713",
      "text": "피험자의 안전보호에 대한 대책\n\n- 가. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 712,
        "window_size": 3,
        "char_count": 23,
        "word_count": 6,
        "page_number": 30,
        "window_text": "임상시험 후 피험자의 진료에 관한 사항\n\n본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 OO병원\n\n에서 진행하던 치료절차가 임상시험 참여 전과 다름없이 진행되며,\n\n이후의 치료비는 피험자가 지불하여야 한다.  다만, 부작용 발생 시\n\n임상시험에 사용된 의료기기와의 인과관계 유무를 확인한 후, 본\n\n임상시험에 사용된 의료기기로 인하여 부작용이 발생한 경우 ㈜OOO\n\n에서 치료에 관한 부작용이 소실될 때까지 치료비를 지불한다.\n\n - - 98 -\n<!-- PAGE_105 -->\n##### 19.  피험자의 안전보호에 대한 대책\n\n- 가.  임상시험 실시기관\n임상시험 실시기관의 장은 해당 임상시험의 실시에 필요한 임상\n\n시험실, 설비와 전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를\n\n취할 수 있도록 하는 등 해당 임상시험을 적절하게 실시할 수 있도록\n\n하여야 한다.\n\n - 나.  임상시험심사위원회\n1) 임상시험심사위원회는 국내 법규/관례에 따라 구성되어 있어야\n\n한다. ",
        "original_sentence": "피험자의 안전보호에 대한 대책\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_714",
      "text": "임상시험 실시기관\n임상시험 실시기관의 장은 해당 임상시험의 실시에 필요한 임상\n\n시험실, 설비와 전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를\n\n취할 수 있도록 하는 등 해당 임상시험을 적절하게 실시할 수 있도록\n\n하여야 한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 713,
        "window_size": 3,
        "char_count": 132,
        "word_count": 33,
        "page_number": 35,
        "window_text": "다만, 부작용 발생 시\n\n임상시험에 사용된 의료기기와의 인과관계 유무를 확인한 후, 본\n\n임상시험에 사용된 의료기기로 인하여 부작용이 발생한 경우 ㈜OOO\n\n에서 치료에 관한 부작용이 소실될 때까지 치료비를 지불한다.\n\n - - 98 -\n<!-- PAGE_105 -->\n##### 19.  피험자의 안전보호에 대한 대책\n\n- 가.  임상시험 실시기관\n임상시험 실시기관의 장은 해당 임상시험의 실시에 필요한 임상\n\n시험실, 설비와 전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를\n\n취할 수 있도록 하는 등 해당 임상시험을 적절하게 실시할 수 있도록\n\n하여야 한다.\n\n - 나.  임상시험심사위원회\n1) 임상시험심사위원회는 국내 법규/관례에 따라 구성되어 있어야\n\n한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를 보호해야\n\n하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에는\n\n2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가\n\n동의가 적절하게 얻어지지 않았거나 임상시험이 임상시험계획서에\n\n따라 진행되지 않은 경우 또는 중대한 이상반응/의료기기 이상\n\n반응이 나타난 경우에는 임상시험의 일부 또는 전부에 대하여\n\n- - 99 -\n- 다. ",
        "original_sentence": "임상시험 실시기관\n임상시험 실시기관의 장은 해당 임상시험의 실시에 필요한 임상\n\n시험실, 설비와 전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를\n\n취할 수 있도록 하는 등 해당 임상시험을 적절하게 실시할 수 있도록\n\n하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_715",
      "text": "- 나. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 714,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 72,
        "window_text": "- - 98 -\n<!-- PAGE_105 -->\n##### 19.  피험자의 안전보호에 대한 대책\n\n- 가.  임상시험 실시기관\n임상시험 실시기관의 장은 해당 임상시험의 실시에 필요한 임상\n\n시험실, 설비와 전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를\n\n취할 수 있도록 하는 등 해당 임상시험을 적절하게 실시할 수 있도록\n\n하여야 한다.\n\n - 나.  임상시험심사위원회\n1) 임상시험심사위원회는 국내 법규/관례에 따라 구성되어 있어야\n\n한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를 보호해야\n\n하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에는\n\n2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가\n\n동의가 적절하게 얻어지지 않았거나 임상시험이 임상시험계획서에\n\n따라 진행되지 않은 경우 또는 중대한 이상반응/의료기기 이상\n\n반응이 나타난 경우에는 임상시험의 일부 또는 전부에 대하여\n\n- - 99 -\n- 다.  시험자\n1) 시험자(Investigator)란 시험책임자, 시험담당자, 임상시험조정자를\n\n말한다. ",
        "original_sentence": "- 나. "
      }
    },
    {
      "chunk_id": "chunk_716",
      "text": "임상시험심사위원회\n1) 임상시험심사위원회는 국내 법규/관례에 따라 구성되어 있어야\n\n한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 715,
        "window_size": 3,
        "char_count": 51,
        "word_count": 9,
        "page_number": 15,
        "window_text": "피험자의 안전보호에 대한 대책\n\n- 가.  임상시험 실시기관\n임상시험 실시기관의 장은 해당 임상시험의 실시에 필요한 임상\n\n시험실, 설비와 전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를\n\n취할 수 있도록 하는 등 해당 임상시험을 적절하게 실시할 수 있도록\n\n하여야 한다.\n\n - 나.  임상시험심사위원회\n1) 임상시험심사위원회는 국내 법규/관례에 따라 구성되어 있어야\n\n한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를 보호해야\n\n하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에는\n\n2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가\n\n동의가 적절하게 얻어지지 않았거나 임상시험이 임상시험계획서에\n\n따라 진행되지 않은 경우 또는 중대한 이상반응/의료기기 이상\n\n반응이 나타난 경우에는 임상시험의 일부 또는 전부에 대하여\n\n- - 99 -\n- 다.  시험자\n1) 시험자(Investigator)란 시험책임자, 시험담당자, 임상시험조정자를\n\n말한다.  시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식\n\n품의약품 안전청장의 승인을 득한 임상시험 계획서를 준수하여\n\n2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미\n\n있는 시험실적 검사치의 이상을 포함하여 임상시험에서 발생한\n\n모든 이상반응에 대해 피험자가 적절한 의학적 처치를 받을 수\n\n있도록 조치하여야 하고, 시험자가 알게 된 피험자의 병발질환에\n\n대해 의학적 처치가 필요한 경우 이를 피험자에게 알려주어야 한다.\n\n",
        "original_sentence": "임상시험심사위원회\n1) 임상시험심사위원회는 국내 법규/관례에 따라 구성되어 있어야\n\n한다. "
      }
    },
    {
      "chunk_id": "chunk_717",
      "text": "임상시험심사위원회는 피험자의 권리, 안전, 복지를 보호해야\n\n하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에는\n\n2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가\n\n동의가 적절하게 얻어지지 않았거나 임상시험이 임상시험계획서에\n\n따라 진행되지 않은 경우 또는 중대한 이상반응/의료기기 이상\n\n반응이 나타난 경우에는 임상시험의 일부 또는 전부에 대하여\n\n- - 99 -\n- 다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 716,
        "window_size": 3,
        "char_count": 226,
        "word_count": 49,
        "page_number": 30,
        "window_text": "임상시험 실시기관\n임상시험 실시기관의 장은 해당 임상시험의 실시에 필요한 임상\n\n시험실, 설비와 전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를\n\n취할 수 있도록 하는 등 해당 임상시험을 적절하게 실시할 수 있도록\n\n하여야 한다.\n\n - 나.  임상시험심사위원회\n1) 임상시험심사위원회는 국내 법규/관례에 따라 구성되어 있어야\n\n한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를 보호해야\n\n하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에는\n\n2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가\n\n동의가 적절하게 얻어지지 않았거나 임상시험이 임상시험계획서에\n\n따라 진행되지 않은 경우 또는 중대한 이상반응/의료기기 이상\n\n반응이 나타난 경우에는 임상시험의 일부 또는 전부에 대하여\n\n- - 99 -\n- 다.  시험자\n1) 시험자(Investigator)란 시험책임자, 시험담당자, 임상시험조정자를\n\n말한다.  시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식\n\n품의약품 안전청장의 승인을 득한 임상시험 계획서를 준수하여\n\n2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미\n\n있는 시험실적 검사치의 이상을 포함하여 임상시험에서 발생한\n\n모든 이상반응에 대해 피험자가 적절한 의학적 처치를 받을 수\n\n있도록 조치하여야 하고, 시험자가 알게 된 피험자의 병발질환에\n\n대해 의학적 처치가 필요한 경우 이를 피험자에게 알려주어야 한다.\n\n 3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의\n\n- 라. ",
        "original_sentence": "임상시험심사위원회는 피험자의 권리, 안전, 복지를 보호해야\n\n하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에는\n\n2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가\n\n동의가 적절하게 얻어지지 않았거나 임상시험이 임상시험계획서에\n\n따라 진행되지 않은 경우 또는 중대한 이상반응/의료기기 이상\n\n반응이 나타난 경우에는 임상시험의 일부 또는 전부에 대하여\n\n- - 99 -\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_718",
      "text": "시험자\n1) 시험자(Investigator)란 시험책임자, 시험담당자, 임상시험조정자를\n\n말한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 717,
        "window_size": 3,
        "char_count": 55,
        "word_count": 7,
        "page_number": 3,
        "window_text": "- 나.  임상시험심사위원회\n1) 임상시험심사위원회는 국내 법규/관례에 따라 구성되어 있어야\n\n한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를 보호해야\n\n하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에는\n\n2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가\n\n동의가 적절하게 얻어지지 않았거나 임상시험이 임상시험계획서에\n\n따라 진행되지 않은 경우 또는 중대한 이상반응/의료기기 이상\n\n반응이 나타난 경우에는 임상시험의 일부 또는 전부에 대하여\n\n- - 99 -\n- 다.  시험자\n1) 시험자(Investigator)란 시험책임자, 시험담당자, 임상시험조정자를\n\n말한다.  시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식\n\n품의약품 안전청장의 승인을 득한 임상시험 계획서를 준수하여\n\n2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미\n\n있는 시험실적 검사치의 이상을 포함하여 임상시험에서 발생한\n\n모든 이상반응에 대해 피험자가 적절한 의학적 처치를 받을 수\n\n있도록 조치하여야 하고, 시험자가 알게 된 피험자의 병발질환에\n\n대해 의학적 처치가 필요한 경우 이를 피험자에게 알려주어야 한다.\n\n 3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의\n\n- 라.  의뢰자\n1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로\n\n통상의료기기 임상시험의 경우 의료기기 제조업자(수입자를 포함\n\n2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상\n\n3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수,\n\n임상시험의 종류와 복잡성, 피험자에게 미칠 수 있는 잠재적인\n\n위험의 정도 및 이미 확인된 임상시험 실시상의 문제점 등에 따라\n\n- - 100 -\n- 마. ",
        "original_sentence": "시험자\n1) 시험자(Investigator)란 시험책임자, 시험담당자, 임상시험조정자를\n\n말한다. "
      }
    },
    {
      "chunk_id": "chunk_719",
      "text": "시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식\n\n품의약품 안전청장의 승인을 득한 임상시험 계획서를 준수하여\n\n2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미\n\n있는 시험실적 검사치의 이상을 포함하여 임상시험에서 발생한\n\n모든 이상반응에 대해 피험자가 적절한 의학적 처치를 받을 수\n\n있도록 조치하여야 하고, 시험자가 알게 된 피험자의 병발질환에\n\n대해 의학적 처치가 필요한 경우 이를 피험자에게 알려주어야 한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 718,
        "window_size": 3,
        "char_count": 246,
        "word_count": 55,
        "page_number": 30,
        "window_text": "임상시험심사위원회\n1) 임상시험심사위원회는 국내 법규/관례에 따라 구성되어 있어야\n\n한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를 보호해야\n\n하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에는\n\n2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가\n\n동의가 적절하게 얻어지지 않았거나 임상시험이 임상시험계획서에\n\n따라 진행되지 않은 경우 또는 중대한 이상반응/의료기기 이상\n\n반응이 나타난 경우에는 임상시험의 일부 또는 전부에 대하여\n\n- - 99 -\n- 다.  시험자\n1) 시험자(Investigator)란 시험책임자, 시험담당자, 임상시험조정자를\n\n말한다.  시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식\n\n품의약품 안전청장의 승인을 득한 임상시험 계획서를 준수하여\n\n2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미\n\n있는 시험실적 검사치의 이상을 포함하여 임상시험에서 발생한\n\n모든 이상반응에 대해 피험자가 적절한 의학적 처치를 받을 수\n\n있도록 조치하여야 하고, 시험자가 알게 된 피험자의 병발질환에\n\n대해 의학적 처치가 필요한 경우 이를 피험자에게 알려주어야 한다.\n\n 3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의\n\n- 라.  의뢰자\n1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로\n\n통상의료기기 임상시험의 경우 의료기기 제조업자(수입자를 포함\n\n2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상\n\n3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수,\n\n임상시험의 종류와 복잡성, 피험자에게 미칠 수 있는 잠재적인\n\n위험의 정도 및 이미 확인된 임상시험 실시상의 문제점 등에 따라\n\n- - 100 -\n- 마.  모니터링\n1) 모니터링(Monitoring)이란 임상시험 진행 과정을 감독하고, 해당\n\n임상시험이 임상시험계획서, 표준작업지침서, 임상시험 실시 기준\n\n및 관련 규정에 따라 실시, 기록되는지 여부를 검토, 확인하는\n\n2) 임상시험에 대한 모니터링은 임상시험모니터요원의 정기적인\n\n임상시험 실시기관 방문과 전화 등을 통해서 이루어질 것이다.\n\n",
        "original_sentence": "시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식\n\n품의약품 안전청장의 승인을 득한 임상시험 계획서를 준수하여\n\n2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미\n\n있는 시험실적 검사치의 이상을 포함하여 임상시험에서 발생한\n\n모든 이상반응에 대해 피험자가 적절한 의학적 처치를 받을 수\n\n있도록 조치하여야 하고, 시험자가 알게 된 피험자의 병발질환에\n\n대해 의학적 처치가 필요한 경우 이를 피험자에게 알려주어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_720",
      "text": "3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의\n\n- 라. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 719,
        "window_size": 3,
        "char_count": 45,
        "word_count": 11,
        "page_number": 26,
        "window_text": "임상시험심사위원회는 피험자의 권리, 안전, 복지를 보호해야\n\n하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에는\n\n2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가\n\n동의가 적절하게 얻어지지 않았거나 임상시험이 임상시험계획서에\n\n따라 진행되지 않은 경우 또는 중대한 이상반응/의료기기 이상\n\n반응이 나타난 경우에는 임상시험의 일부 또는 전부에 대하여\n\n- - 99 -\n- 다.  시험자\n1) 시험자(Investigator)란 시험책임자, 시험담당자, 임상시험조정자를\n\n말한다.  시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식\n\n품의약품 안전청장의 승인을 득한 임상시험 계획서를 준수하여\n\n2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미\n\n있는 시험실적 검사치의 이상을 포함하여 임상시험에서 발생한\n\n모든 이상반응에 대해 피험자가 적절한 의학적 처치를 받을 수\n\n있도록 조치하여야 하고, 시험자가 알게 된 피험자의 병발질환에\n\n대해 의학적 처치가 필요한 경우 이를 피험자에게 알려주어야 한다.\n\n 3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의\n\n- 라.  의뢰자\n1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로\n\n통상의료기기 임상시험의 경우 의료기기 제조업자(수입자를 포함\n\n2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상\n\n3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수,\n\n임상시험의 종류와 복잡성, 피험자에게 미칠 수 있는 잠재적인\n\n위험의 정도 및 이미 확인된 임상시험 실시상의 문제점 등에 따라\n\n- - 100 -\n- 마.  모니터링\n1) 모니터링(Monitoring)이란 임상시험 진행 과정을 감독하고, 해당\n\n임상시험이 임상시험계획서, 표준작업지침서, 임상시험 실시 기준\n\n및 관련 규정에 따라 실시, 기록되는지 여부를 검토, 확인하는\n\n2) 임상시험에 대한 모니터링은 임상시험모니터요원의 정기적인\n\n임상시험 실시기관 방문과 전화 등을 통해서 이루어질 것이다.\n\n 방문 시 모니터는 환자기록 원본, 임상시험용 의료기기 관리 기록,\n\n3) 또한 임상시험모니터 요원은 임상시험 진행과정을 잘 살피고,\n\n- 바. ",
        "original_sentence": "3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의\n\n- 라. "
      }
    },
    {
      "chunk_id": "chunk_721",
      "text": "의뢰자\n1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로\n\n통상의료기기 임상시험의 경우 의료기기 제조업자(수입자를 포함\n\n2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상\n\n3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수,\n\n임상시험의 종류와 복잡성, 피험자에게 미칠 수 있는 잠재적인\n\n위험의 정도 및 이미 확인된 임상시험 실시상의 문제점 등에 따라\n\n- - 100 -\n- 마. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 720,
        "window_size": 3,
        "char_count": 243,
        "word_count": 59,
        "page_number": 19,
        "window_text": "시험자\n1) 시험자(Investigator)란 시험책임자, 시험담당자, 임상시험조정자를\n\n말한다.  시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식\n\n품의약품 안전청장의 승인을 득한 임상시험 계획서를 준수하여\n\n2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미\n\n있는 시험실적 검사치의 이상을 포함하여 임상시험에서 발생한\n\n모든 이상반응에 대해 피험자가 적절한 의학적 처치를 받을 수\n\n있도록 조치하여야 하고, 시험자가 알게 된 피험자의 병발질환에\n\n대해 의학적 처치가 필요한 경우 이를 피험자에게 알려주어야 한다.\n\n 3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의\n\n- 라.  의뢰자\n1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로\n\n통상의료기기 임상시험의 경우 의료기기 제조업자(수입자를 포함\n\n2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상\n\n3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수,\n\n임상시험의 종류와 복잡성, 피험자에게 미칠 수 있는 잠재적인\n\n위험의 정도 및 이미 확인된 임상시험 실시상의 문제점 등에 따라\n\n- - 100 -\n- 마.  모니터링\n1) 모니터링(Monitoring)이란 임상시험 진행 과정을 감독하고, 해당\n\n임상시험이 임상시험계획서, 표준작업지침서, 임상시험 실시 기준\n\n및 관련 규정에 따라 실시, 기록되는지 여부를 검토, 확인하는\n\n2) 임상시험에 대한 모니터링은 임상시험모니터요원의 정기적인\n\n임상시험 실시기관 방문과 전화 등을 통해서 이루어질 것이다.\n\n 방문 시 모니터는 환자기록 원본, 임상시험용 의료기기 관리 기록,\n\n3) 또한 임상시험모니터 요원은 임상시험 진행과정을 잘 살피고,\n\n- 바.  임상시험계획서의 변경\n1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장으로\n\n부터 승인받은 후, 시험절차가 광범위해지거나 위험도가 높아지\n\n거나 피험자 선정기준에 변화가 있거나 추가적인 안전성 정보로\n\n인해 임사시험계획서를 변경하는 경우에는 임상시험심사위원회\n\n2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용\n\n3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한\n\n경우를 제외하고는, 임상시험심사위원회 및 식품의약품안전처장의\n\n변경 승인 이전에는 계획서와 다르게 임상시험을 실시하여서는\n\n- - 101 -\n안 된다. ",
        "original_sentence": "의뢰자\n1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로\n\n통상의료기기 임상시험의 경우 의료기기 제조업자(수입자를 포함\n\n2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상\n\n3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수,\n\n임상시험의 종류와 복잡성, 피험자에게 미칠 수 있는 잠재적인\n\n위험의 정도 및 이미 확인된 임상시험 실시상의 문제점 등에 따라\n\n- - 100 -\n- 마. "
      }
    },
    {
      "chunk_id": "chunk_722",
      "text": "모니터링\n1) 모니터링(Monitoring)이란 임상시험 진행 과정을 감독하고, 해당\n\n임상시험이 임상시험계획서, 표준작업지침서, 임상시험 실시 기준\n\n및 관련 규정에 따라 실시, 기록되는지 여부를 검토, 확인하는\n\n2) 임상시험에 대한 모니터링은 임상시험모니터요원의 정기적인\n\n임상시험 실시기관 방문과 전화 등을 통해서 이루어질 것이다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 721,
        "window_size": 3,
        "char_count": 191,
        "word_count": 37,
        "page_number": 19,
        "window_text": "시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식\n\n품의약품 안전청장의 승인을 득한 임상시험 계획서를 준수하여\n\n2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미\n\n있는 시험실적 검사치의 이상을 포함하여 임상시험에서 발생한\n\n모든 이상반응에 대해 피험자가 적절한 의학적 처치를 받을 수\n\n있도록 조치하여야 하고, 시험자가 알게 된 피험자의 병발질환에\n\n대해 의학적 처치가 필요한 경우 이를 피험자에게 알려주어야 한다.\n\n 3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의\n\n- 라.  의뢰자\n1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로\n\n통상의료기기 임상시험의 경우 의료기기 제조업자(수입자를 포함\n\n2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상\n\n3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수,\n\n임상시험의 종류와 복잡성, 피험자에게 미칠 수 있는 잠재적인\n\n위험의 정도 및 이미 확인된 임상시험 실시상의 문제점 등에 따라\n\n- - 100 -\n- 마.  모니터링\n1) 모니터링(Monitoring)이란 임상시험 진행 과정을 감독하고, 해당\n\n임상시험이 임상시험계획서, 표준작업지침서, 임상시험 실시 기준\n\n및 관련 규정에 따라 실시, 기록되는지 여부를 검토, 확인하는\n\n2) 임상시험에 대한 모니터링은 임상시험모니터요원의 정기적인\n\n임상시험 실시기관 방문과 전화 등을 통해서 이루어질 것이다.\n\n 방문 시 모니터는 환자기록 원본, 임상시험용 의료기기 관리 기록,\n\n3) 또한 임상시험모니터 요원은 임상시험 진행과정을 잘 살피고,\n\n- 바.  임상시험계획서의 변경\n1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장으로\n\n부터 승인받은 후, 시험절차가 광범위해지거나 위험도가 높아지\n\n거나 피험자 선정기준에 변화가 있거나 추가적인 안전성 정보로\n\n인해 임사시험계획서를 변경하는 경우에는 임상시험심사위원회\n\n2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용\n\n3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한\n\n경우를 제외하고는, 임상시험심사위원회 및 식품의약품안전처장의\n\n변경 승인 이전에는 계획서와 다르게 임상시험을 실시하여서는\n\n- - 101 -\n안 된다.  만일 피험자에게 발생한 즉각적 위험요소를 제거하기\n\n위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험\n\n계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에\n\n대하여 임상시험심사위원회(사후검토 승인을 위함), 의뢰자, 식품\n\n의약품안전처장에게 제출하여야 한다. ",
        "original_sentence": "모니터링\n1) 모니터링(Monitoring)이란 임상시험 진행 과정을 감독하고, 해당\n\n임상시험이 임상시험계획서, 표준작업지침서, 임상시험 실시 기준\n\n및 관련 규정에 따라 실시, 기록되는지 여부를 검토, 확인하는\n\n2) 임상시험에 대한 모니터링은 임상시험모니터요원의 정기적인\n\n임상시험 실시기관 방문과 전화 등을 통해서 이루어질 것이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_723",
      "text": "방문 시 모니터는 환자기록 원본, 임상시험용 의료기기 관리 기록,\n\n3) 또한 임상시험모니터 요원은 임상시험 진행과정을 잘 살피고,\n\n- 바. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 722,
        "window_size": 3,
        "char_count": 80,
        "word_count": 19,
        "page_number": 15,
        "window_text": "3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의\n\n- 라.  의뢰자\n1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로\n\n통상의료기기 임상시험의 경우 의료기기 제조업자(수입자를 포함\n\n2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상\n\n3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수,\n\n임상시험의 종류와 복잡성, 피험자에게 미칠 수 있는 잠재적인\n\n위험의 정도 및 이미 확인된 임상시험 실시상의 문제점 등에 따라\n\n- - 100 -\n- 마.  모니터링\n1) 모니터링(Monitoring)이란 임상시험 진행 과정을 감독하고, 해당\n\n임상시험이 임상시험계획서, 표준작업지침서, 임상시험 실시 기준\n\n및 관련 규정에 따라 실시, 기록되는지 여부를 검토, 확인하는\n\n2) 임상시험에 대한 모니터링은 임상시험모니터요원의 정기적인\n\n임상시험 실시기관 방문과 전화 등을 통해서 이루어질 것이다.\n\n 방문 시 모니터는 환자기록 원본, 임상시험용 의료기기 관리 기록,\n\n3) 또한 임상시험모니터 요원은 임상시험 진행과정을 잘 살피고,\n\n- 바.  임상시험계획서의 변경\n1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장으로\n\n부터 승인받은 후, 시험절차가 광범위해지거나 위험도가 높아지\n\n거나 피험자 선정기준에 변화가 있거나 추가적인 안전성 정보로\n\n인해 임사시험계획서를 변경하는 경우에는 임상시험심사위원회\n\n2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용\n\n3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한\n\n경우를 제외하고는, 임상시험심사위원회 및 식품의약품안전처장의\n\n변경 승인 이전에는 계획서와 다르게 임상시험을 실시하여서는\n\n- - 101 -\n안 된다.  만일 피험자에게 발생한 즉각적 위험요소를 제거하기\n\n위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험\n\n계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에\n\n대하여 임상시험심사위원회(사후검토 승인을 위함), 의뢰자, 식품\n\n의약품안전처장에게 제출하여야 한다.  그리고 임상시험심사위원회\n\n4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이\n\n- 사. ",
        "original_sentence": "방문 시 모니터는 환자기록 원본, 임상시험용 의료기기 관리 기록,\n\n3) 또한 임상시험모니터 요원은 임상시험 진행과정을 잘 살피고,\n\n- 바. "
      }
    },
    {
      "chunk_id": "chunk_724",
      "text": "임상시험계획서의 변경\n1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장으로\n\n부터 승인받은 후, 시험절차가 광범위해지거나 위험도가 높아지\n\n거나 피험자 선정기준에 변화가 있거나 추가적인 안전성 정보로\n\n인해 임사시험계획서를 변경하는 경우에는 임상시험심사위원회\n\n2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용\n\n3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한\n\n경우를 제외하고는, 임상시험심사위원회 및 식품의약품안전처장의\n\n변경 승인 이전에는 계획서와 다르게 임상시험을 실시하여서는\n\n- - 101 -\n안 된다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 723,
        "window_size": 3,
        "char_count": 316,
        "word_count": 64,
        "page_number": 19,
        "window_text": "의뢰자\n1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로\n\n통상의료기기 임상시험의 경우 의료기기 제조업자(수입자를 포함\n\n2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상\n\n3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수,\n\n임상시험의 종류와 복잡성, 피험자에게 미칠 수 있는 잠재적인\n\n위험의 정도 및 이미 확인된 임상시험 실시상의 문제점 등에 따라\n\n- - 100 -\n- 마.  모니터링\n1) 모니터링(Monitoring)이란 임상시험 진행 과정을 감독하고, 해당\n\n임상시험이 임상시험계획서, 표준작업지침서, 임상시험 실시 기준\n\n및 관련 규정에 따라 실시, 기록되는지 여부를 검토, 확인하는\n\n2) 임상시험에 대한 모니터링은 임상시험모니터요원의 정기적인\n\n임상시험 실시기관 방문과 전화 등을 통해서 이루어질 것이다.\n\n 방문 시 모니터는 환자기록 원본, 임상시험용 의료기기 관리 기록,\n\n3) 또한 임상시험모니터 요원은 임상시험 진행과정을 잘 살피고,\n\n- 바.  임상시험계획서의 변경\n1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장으로\n\n부터 승인받은 후, 시험절차가 광범위해지거나 위험도가 높아지\n\n거나 피험자 선정기준에 변화가 있거나 추가적인 안전성 정보로\n\n인해 임사시험계획서를 변경하는 경우에는 임상시험심사위원회\n\n2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용\n\n3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한\n\n경우를 제외하고는, 임상시험심사위원회 및 식품의약품안전처장의\n\n변경 승인 이전에는 계획서와 다르게 임상시험을 실시하여서는\n\n- - 101 -\n안 된다.  만일 피험자에게 발생한 즉각적 위험요소를 제거하기\n\n위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험\n\n계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에\n\n대하여 임상시험심사위원회(사후검토 승인을 위함), 의뢰자, 식품\n\n의약품안전처장에게 제출하여야 한다.  그리고 임상시험심사위원회\n\n4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이\n\n- 사.  피험자 동의\n1) 피험자 동의(Informed consent)라 함은 피험자가 임상시험 참여\n\n유무를 결정하기 전에 피험자를 위한 설명서를 통해 해당 임상\n\n시험과 관련된 모든 정보를 제공받고, 서명과 서명 날짜가 포함된\n\n문서를 통해 본인이 자발적으로 임상시험에 참여함을 확인하는\n\n2) 피험자 본인 또는 대리인이 동의서 서식, 피험자 설명서 및 기타\n\n문서화된 정보를 읽을 수 없는 경우에는 공정한 입회자가 동의를\n\n3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의\n\n세부 사항에 대해 질문하고 해당 임상시험의 참여 여부를 결정\n\n할 수 있도록 충분한 시간과 기회를 주어야 하며, 모든 임상시험\n\n관련 질문에 대해 피험자 또는 대리인이 만족할 수 있도록 대답\n\n- - 102 -\n- 아. ",
        "original_sentence": "임상시험계획서의 변경\n1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장으로\n\n부터 승인받은 후, 시험절차가 광범위해지거나 위험도가 높아지\n\n거나 피험자 선정기준에 변화가 있거나 추가적인 안전성 정보로\n\n인해 임사시험계획서를 변경하는 경우에는 임상시험심사위원회\n\n2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용\n\n3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한\n\n경우를 제외하고는, 임상시험심사위원회 및 식품의약품안전처장의\n\n변경 승인 이전에는 계획서와 다르게 임상시험을 실시하여서는\n\n- - 101 -\n안 된다. "
      }
    },
    {
      "chunk_id": "chunk_725",
      "text": "만일 피험자에게 발생한 즉각적 위험요소를 제거하기\n\n위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험\n\n계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에\n\n대하여 임상시험심사위원회(사후검토 승인을 위함), 의뢰자, 식품\n\n의약품안전처장에게 제출하여야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 724,
        "window_size": 3,
        "char_count": 155,
        "word_count": 31,
        "page_number": 30,
        "window_text": "모니터링\n1) 모니터링(Monitoring)이란 임상시험 진행 과정을 감독하고, 해당\n\n임상시험이 임상시험계획서, 표준작업지침서, 임상시험 실시 기준\n\n및 관련 규정에 따라 실시, 기록되는지 여부를 검토, 확인하는\n\n2) 임상시험에 대한 모니터링은 임상시험모니터요원의 정기적인\n\n임상시험 실시기관 방문과 전화 등을 통해서 이루어질 것이다.\n\n 방문 시 모니터는 환자기록 원본, 임상시험용 의료기기 관리 기록,\n\n3) 또한 임상시험모니터 요원은 임상시험 진행과정을 잘 살피고,\n\n- 바.  임상시험계획서의 변경\n1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장으로\n\n부터 승인받은 후, 시험절차가 광범위해지거나 위험도가 높아지\n\n거나 피험자 선정기준에 변화가 있거나 추가적인 안전성 정보로\n\n인해 임사시험계획서를 변경하는 경우에는 임상시험심사위원회\n\n2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용\n\n3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한\n\n경우를 제외하고는, 임상시험심사위원회 및 식품의약품안전처장의\n\n변경 승인 이전에는 계획서와 다르게 임상시험을 실시하여서는\n\n- - 101 -\n안 된다.  만일 피험자에게 발생한 즉각적 위험요소를 제거하기\n\n위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험\n\n계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에\n\n대하여 임상시험심사위원회(사후검토 승인을 위함), 의뢰자, 식품\n\n의약품안전처장에게 제출하여야 한다.  그리고 임상시험심사위원회\n\n4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이\n\n- 사.  피험자 동의\n1) 피험자 동의(Informed consent)라 함은 피험자가 임상시험 참여\n\n유무를 결정하기 전에 피험자를 위한 설명서를 통해 해당 임상\n\n시험과 관련된 모든 정보를 제공받고, 서명과 서명 날짜가 포함된\n\n문서를 통해 본인이 자발적으로 임상시험에 참여함을 확인하는\n\n2) 피험자 본인 또는 대리인이 동의서 서식, 피험자 설명서 및 기타\n\n문서화된 정보를 읽을 수 없는 경우에는 공정한 입회자가 동의를\n\n3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의\n\n세부 사항에 대해 질문하고 해당 임상시험의 참여 여부를 결정\n\n할 수 있도록 충분한 시간과 기회를 주어야 하며, 모든 임상시험\n\n관련 질문에 대해 피험자 또는 대리인이 만족할 수 있도록 대답\n\n- - 102 -\n- 아.  피험자 기록의 비밀보장\n1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며,\n\n임상시험의 결과가 출관 될 경우에도 피험자의 신원을 비밀상태로\n\n2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의\n\n모니터링과 점검 및 진행사항 관리를 위한 목적으로 피험자의\n\n기록을 열람할 수 있다. ",
        "original_sentence": "만일 피험자에게 발생한 즉각적 위험요소를 제거하기\n\n위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험\n\n계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에\n\n대하여 임상시험심사위원회(사후검토 승인을 위함), 의뢰자, 식품\n\n의약품안전처장에게 제출하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_726",
      "text": "그리고 임상시험심사위원회\n\n4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이\n\n- 사. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 725,
        "window_size": 3,
        "char_count": 57,
        "word_count": 13,
        "page_number": 26,
        "window_text": "방문 시 모니터는 환자기록 원본, 임상시험용 의료기기 관리 기록,\n\n3) 또한 임상시험모니터 요원은 임상시험 진행과정을 잘 살피고,\n\n- 바.  임상시험계획서의 변경\n1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장으로\n\n부터 승인받은 후, 시험절차가 광범위해지거나 위험도가 높아지\n\n거나 피험자 선정기준에 변화가 있거나 추가적인 안전성 정보로\n\n인해 임사시험계획서를 변경하는 경우에는 임상시험심사위원회\n\n2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용\n\n3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한\n\n경우를 제외하고는, 임상시험심사위원회 및 식품의약품안전처장의\n\n변경 승인 이전에는 계획서와 다르게 임상시험을 실시하여서는\n\n- - 101 -\n안 된다.  만일 피험자에게 발생한 즉각적 위험요소를 제거하기\n\n위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험\n\n계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에\n\n대하여 임상시험심사위원회(사후검토 승인을 위함), 의뢰자, 식품\n\n의약품안전처장에게 제출하여야 한다.  그리고 임상시험심사위원회\n\n4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이\n\n- 사.  피험자 동의\n1) 피험자 동의(Informed consent)라 함은 피험자가 임상시험 참여\n\n유무를 결정하기 전에 피험자를 위한 설명서를 통해 해당 임상\n\n시험과 관련된 모든 정보를 제공받고, 서명과 서명 날짜가 포함된\n\n문서를 통해 본인이 자발적으로 임상시험에 참여함을 확인하는\n\n2) 피험자 본인 또는 대리인이 동의서 서식, 피험자 설명서 및 기타\n\n문서화된 정보를 읽을 수 없는 경우에는 공정한 입회자가 동의를\n\n3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의\n\n세부 사항에 대해 질문하고 해당 임상시험의 참여 여부를 결정\n\n할 수 있도록 충분한 시간과 기회를 주어야 하며, 모든 임상시험\n\n관련 질문에 대해 피험자 또는 대리인이 만족할 수 있도록 대답\n\n- - 102 -\n- 아.  피험자 기록의 비밀보장\n1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며,\n\n임상시험의 결과가 출관 될 경우에도 피험자의 신원을 비밀상태로\n\n2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의\n\n모니터링과 점검 및 진행사항 관리를 위한 목적으로 피험자의\n\n기록을 열람할 수 있다.  시험자는 본 임상시험 계획서에 서명함\n\n으로써, 국내의 법규와 윤리적 측면에서 임상시험 의뢰자 또는\n\n모니터 및 점검자가 피험자의 차트와 증례기록서 기록을 검증하기\n\n위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.\n\n",
        "original_sentence": "그리고 임상시험심사위원회\n\n4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이\n\n- 사. "
      }
    },
    {
      "chunk_id": "chunk_727",
      "text": "피험자 동의\n1) 피험자 동의(Informed consent)라 함은 피험자가 임상시험 참여\n\n유무를 결정하기 전에 피험자를 위한 설명서를 통해 해당 임상\n\n시험과 관련된 모든 정보를 제공받고, 서명과 서명 날짜가 포함된\n\n문서를 통해 본인이 자발적으로 임상시험에 참여함을 확인하는\n\n2) 피험자 본인 또는 대리인이 동의서 서식, 피험자 설명서 및 기타\n\n문서화된 정보를 읽을 수 없는 경우에는 공정한 입회자가 동의를\n\n3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의\n\n세부 사항에 대해 질문하고 해당 임상시험의 참여 여부를 결정\n\n할 수 있도록 충분한 시간과 기회를 주어야 하며, 모든 임상시험\n\n관련 질문에 대해 피험자 또는 대리인이 만족할 수 있도록 대답\n\n- - 102 -\n- 아. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 726,
        "window_size": 3,
        "char_count": 395,
        "word_count": 99,
        "page_number": 19,
        "window_text": "임상시험계획서의 변경\n1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장으로\n\n부터 승인받은 후, 시험절차가 광범위해지거나 위험도가 높아지\n\n거나 피험자 선정기준에 변화가 있거나 추가적인 안전성 정보로\n\n인해 임사시험계획서를 변경하는 경우에는 임상시험심사위원회\n\n2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용\n\n3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한\n\n경우를 제외하고는, 임상시험심사위원회 및 식품의약품안전처장의\n\n변경 승인 이전에는 계획서와 다르게 임상시험을 실시하여서는\n\n- - 101 -\n안 된다.  만일 피험자에게 발생한 즉각적 위험요소를 제거하기\n\n위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험\n\n계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에\n\n대하여 임상시험심사위원회(사후검토 승인을 위함), 의뢰자, 식품\n\n의약품안전처장에게 제출하여야 한다.  그리고 임상시험심사위원회\n\n4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이\n\n- 사.  피험자 동의\n1) 피험자 동의(Informed consent)라 함은 피험자가 임상시험 참여\n\n유무를 결정하기 전에 피험자를 위한 설명서를 통해 해당 임상\n\n시험과 관련된 모든 정보를 제공받고, 서명과 서명 날짜가 포함된\n\n문서를 통해 본인이 자발적으로 임상시험에 참여함을 확인하는\n\n2) 피험자 본인 또는 대리인이 동의서 서식, 피험자 설명서 및 기타\n\n문서화된 정보를 읽을 수 없는 경우에는 공정한 입회자가 동의를\n\n3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의\n\n세부 사항에 대해 질문하고 해당 임상시험의 참여 여부를 결정\n\n할 수 있도록 충분한 시간과 기회를 주어야 하며, 모든 임상시험\n\n관련 질문에 대해 피험자 또는 대리인이 만족할 수 있도록 대답\n\n- - 102 -\n- 아.  피험자 기록의 비밀보장\n1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며,\n\n임상시험의 결과가 출관 될 경우에도 피험자의 신원을 비밀상태로\n\n2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의\n\n모니터링과 점검 및 진행사항 관리를 위한 목적으로 피험자의\n\n기록을 열람할 수 있다.  시험자는 본 임상시험 계획서에 서명함\n\n으로써, 국내의 법규와 윤리적 측면에서 임상시험 의뢰자 또는\n\n모니터 및 점검자가 피험자의 차트와 증례기록서 기록을 검증하기\n\n위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.\n\n 3) 증례기록서 등 임상시험에 관련된 모든 서류에는 피험자 이름이\n\n아닌 피험자 식별코드(일반적으로 피험자 이니셜)로 기록하고\n\n- 자. ",
        "original_sentence": "피험자 동의\n1) 피험자 동의(Informed consent)라 함은 피험자가 임상시험 참여\n\n유무를 결정하기 전에 피험자를 위한 설명서를 통해 해당 임상\n\n시험과 관련된 모든 정보를 제공받고, 서명과 서명 날짜가 포함된\n\n문서를 통해 본인이 자발적으로 임상시험에 참여함을 확인하는\n\n2) 피험자 본인 또는 대리인이 동의서 서식, 피험자 설명서 및 기타\n\n문서화된 정보를 읽을 수 없는 경우에는 공정한 입회자가 동의를\n\n3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의\n\n세부 사항에 대해 질문하고 해당 임상시험의 참여 여부를 결정\n\n할 수 있도록 충분한 시간과 기회를 주어야 하며, 모든 임상시험\n\n관련 질문에 대해 피험자 또는 대리인이 만족할 수 있도록 대답\n\n- - 102 -\n- 아. "
      }
    },
    {
      "chunk_id": "chunk_728",
      "text": "피험자 기록의 비밀보장\n1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며,\n\n임상시험의 결과가 출관 될 경우에도 피험자의 신원을 비밀상태로\n\n2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의\n\n모니터링과 점검 및 진행사항 관리를 위한 목적으로 피험자의\n\n기록을 열람할 수 있다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 727,
        "window_size": 3,
        "char_count": 176,
        "word_count": 43,
        "page_number": 19,
        "window_text": "만일 피험자에게 발생한 즉각적 위험요소를 제거하기\n\n위해 임상시험심사위원회의 승인을 얻기 전에 이러한 임상시험\n\n계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에\n\n대하여 임상시험심사위원회(사후검토 승인을 위함), 의뢰자, 식품\n\n의약품안전처장에게 제출하여야 한다.  그리고 임상시험심사위원회\n\n4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이\n\n- 사.  피험자 동의\n1) 피험자 동의(Informed consent)라 함은 피험자가 임상시험 참여\n\n유무를 결정하기 전에 피험자를 위한 설명서를 통해 해당 임상\n\n시험과 관련된 모든 정보를 제공받고, 서명과 서명 날짜가 포함된\n\n문서를 통해 본인이 자발적으로 임상시험에 참여함을 확인하는\n\n2) 피험자 본인 또는 대리인이 동의서 서식, 피험자 설명서 및 기타\n\n문서화된 정보를 읽을 수 없는 경우에는 공정한 입회자가 동의를\n\n3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의\n\n세부 사항에 대해 질문하고 해당 임상시험의 참여 여부를 결정\n\n할 수 있도록 충분한 시간과 기회를 주어야 하며, 모든 임상시험\n\n관련 질문에 대해 피험자 또는 대리인이 만족할 수 있도록 대답\n\n- - 102 -\n- 아.  피험자 기록의 비밀보장\n1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며,\n\n임상시험의 결과가 출관 될 경우에도 피험자의 신원을 비밀상태로\n\n2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의\n\n모니터링과 점검 및 진행사항 관리를 위한 목적으로 피험자의\n\n기록을 열람할 수 있다.  시험자는 본 임상시험 계획서에 서명함\n\n으로써, 국내의 법규와 윤리적 측면에서 임상시험 의뢰자 또는\n\n모니터 및 점검자가 피험자의 차트와 증례기록서 기록을 검증하기\n\n위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.\n\n 3) 증례기록서 등 임상시험에 관련된 모든 서류에는 피험자 이름이\n\n아닌 피험자 식별코드(일반적으로 피험자 이니셜)로 기록하고\n\n- 자.  기록의 보존\n1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하\n\n여야 하며 보안을 유지하도록 한다. ",
        "original_sentence": "피험자 기록의 비밀보장\n1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며,\n\n임상시험의 결과가 출관 될 경우에도 피험자의 신원을 비밀상태로\n\n2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의\n\n모니터링과 점검 및 진행사항 관리를 위한 목적으로 피험자의\n\n기록을 열람할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_729",
      "text": "시험자는 본 임상시험 계획서에 서명함\n\n으로써, 국내의 법규와 윤리적 측면에서 임상시험 의뢰자 또는\n\n모니터 및 점검자가 피험자의 차트와 증례기록서 기록을 검증하기\n\n위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 728,
        "window_size": 3,
        "char_count": 128,
        "word_count": 29,
        "page_number": 27,
        "window_text": "그리고 임상시험심사위원회\n\n4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이\n\n- 사.  피험자 동의\n1) 피험자 동의(Informed consent)라 함은 피험자가 임상시험 참여\n\n유무를 결정하기 전에 피험자를 위한 설명서를 통해 해당 임상\n\n시험과 관련된 모든 정보를 제공받고, 서명과 서명 날짜가 포함된\n\n문서를 통해 본인이 자발적으로 임상시험에 참여함을 확인하는\n\n2) 피험자 본인 또는 대리인이 동의서 서식, 피험자 설명서 및 기타\n\n문서화된 정보를 읽을 수 없는 경우에는 공정한 입회자가 동의를\n\n3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의\n\n세부 사항에 대해 질문하고 해당 임상시험의 참여 여부를 결정\n\n할 수 있도록 충분한 시간과 기회를 주어야 하며, 모든 임상시험\n\n관련 질문에 대해 피험자 또는 대리인이 만족할 수 있도록 대답\n\n- - 102 -\n- 아.  피험자 기록의 비밀보장\n1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며,\n\n임상시험의 결과가 출관 될 경우에도 피험자의 신원을 비밀상태로\n\n2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의\n\n모니터링과 점검 및 진행사항 관리를 위한 목적으로 피험자의\n\n기록을 열람할 수 있다.  시험자는 본 임상시험 계획서에 서명함\n\n으로써, 국내의 법규와 윤리적 측면에서 임상시험 의뢰자 또는\n\n모니터 및 점검자가 피험자의 차트와 증례기록서 기록을 검증하기\n\n위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.\n\n 3) 증례기록서 등 임상시험에 관련된 모든 서류에는 피험자 이름이\n\n아닌 피험자 식별코드(일반적으로 피험자 이니셜)로 기록하고\n\n- 자.  기록의 보존\n1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하\n\n여야 하며 보안을 유지하도록 한다.  제조허가/수입허가 또는 그\n\n변경 허가를 위한 임상시험 관련 자료는 허가일로부터 3년간\n\n보존하도록 하고, 그 밖의 임상시험 관련 자료는 임상시험이 끝난\n\n날부터 3년간 보존하도록 한다. ",
        "original_sentence": "시험자는 본 임상시험 계획서에 서명함\n\n으로써, 국내의 법규와 윤리적 측면에서 임상시험 의뢰자 또는\n\n모니터 및 점검자가 피험자의 차트와 증례기록서 기록을 검증하기\n\n위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_730",
      "text": "3) 증례기록서 등 임상시험에 관련된 모든 서류에는 피험자 이름이\n\n아닌 피험자 식별코드(일반적으로 피험자 이니셜)로 기록하고\n\n- 자. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 729,
        "window_size": 3,
        "char_count": 77,
        "word_count": 17,
        "page_number": 26,
        "window_text": "피험자 동의\n1) 피험자 동의(Informed consent)라 함은 피험자가 임상시험 참여\n\n유무를 결정하기 전에 피험자를 위한 설명서를 통해 해당 임상\n\n시험과 관련된 모든 정보를 제공받고, 서명과 서명 날짜가 포함된\n\n문서를 통해 본인이 자발적으로 임상시험에 참여함을 확인하는\n\n2) 피험자 본인 또는 대리인이 동의서 서식, 피험자 설명서 및 기타\n\n문서화된 정보를 읽을 수 없는 경우에는 공정한 입회자가 동의를\n\n3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의\n\n세부 사항에 대해 질문하고 해당 임상시험의 참여 여부를 결정\n\n할 수 있도록 충분한 시간과 기회를 주어야 하며, 모든 임상시험\n\n관련 질문에 대해 피험자 또는 대리인이 만족할 수 있도록 대답\n\n- - 102 -\n- 아.  피험자 기록의 비밀보장\n1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며,\n\n임상시험의 결과가 출관 될 경우에도 피험자의 신원을 비밀상태로\n\n2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의\n\n모니터링과 점검 및 진행사항 관리를 위한 목적으로 피험자의\n\n기록을 열람할 수 있다.  시험자는 본 임상시험 계획서에 서명함\n\n으로써, 국내의 법규와 윤리적 측면에서 임상시험 의뢰자 또는\n\n모니터 및 점검자가 피험자의 차트와 증례기록서 기록을 검증하기\n\n위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.\n\n 3) 증례기록서 등 임상시험에 관련된 모든 서류에는 피험자 이름이\n\n아닌 피험자 식별코드(일반적으로 피험자 이니셜)로 기록하고\n\n- 자.  기록의 보존\n1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하\n\n여야 하며 보안을 유지하도록 한다.  제조허가/수입허가 또는 그\n\n변경 허가를 위한 임상시험 관련 자료는 허가일로부터 3년간\n\n보존하도록 하고, 그 밖의 임상시험 관련 자료는 임상시험이 끝난\n\n날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이\n\n지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을\n\n- - 103 -\n- 20. ",
        "original_sentence": "3) 증례기록서 등 임상시험에 관련된 모든 서류에는 피험자 이름이\n\n아닌 피험자 식별코드(일반적으로 피험자 이니셜)로 기록하고\n\n- 자. "
      }
    },
    {
      "chunk_id": "chunk_731",
      "text": "기록의 보존\n1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하\n\n여야 하며 보안을 유지하도록 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 730,
        "window_size": 3,
        "char_count": 66,
        "word_count": 18,
        "page_number": 19,
        "window_text": "피험자 기록의 비밀보장\n1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며,\n\n임상시험의 결과가 출관 될 경우에도 피험자의 신원을 비밀상태로\n\n2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의\n\n모니터링과 점검 및 진행사항 관리를 위한 목적으로 피험자의\n\n기록을 열람할 수 있다.  시험자는 본 임상시험 계획서에 서명함\n\n으로써, 국내의 법규와 윤리적 측면에서 임상시험 의뢰자 또는\n\n모니터 및 점검자가 피험자의 차트와 증례기록서 기록을 검증하기\n\n위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.\n\n 3) 증례기록서 등 임상시험에 관련된 모든 서류에는 피험자 이름이\n\n아닌 피험자 식별코드(일반적으로 피험자 이니셜)로 기록하고\n\n- 자.  기록의 보존\n1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하\n\n여야 하며 보안을 유지하도록 한다.  제조허가/수입허가 또는 그\n\n변경 허가를 위한 임상시험 관련 자료는 허가일로부터 3년간\n\n보존하도록 하고, 그 밖의 임상시험 관련 자료는 임상시험이 끝난\n\n날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이\n\n지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을\n\n- - 103 -\n- 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n[예시]\n\n- 가. ",
        "original_sentence": "기록의 보존\n1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하\n\n여야 하며 보안을 유지하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_732",
      "text": "제조허가/수입허가 또는 그\n\n변경 허가를 위한 임상시험 관련 자료는 허가일로부터 3년간\n\n보존하도록 하고, 그 밖의 임상시험 관련 자료는 임상시험이 끝난\n\n날부터 3년간 보존하도록 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 731,
        "window_size": 3,
        "char_count": 105,
        "word_count": 24,
        "page_number": 26,
        "window_text": "시험자는 본 임상시험 계획서에 서명함\n\n으로써, 국내의 법규와 윤리적 측면에서 임상시험 의뢰자 또는\n\n모니터 및 점검자가 피험자의 차트와 증례기록서 기록을 검증하기\n\n위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.\n\n 3) 증례기록서 등 임상시험에 관련된 모든 서류에는 피험자 이름이\n\n아닌 피험자 식별코드(일반적으로 피험자 이니셜)로 기록하고\n\n- 자.  기록의 보존\n1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하\n\n여야 하며 보안을 유지하도록 한다.  제조허가/수입허가 또는 그\n\n변경 허가를 위한 임상시험 관련 자료는 허가일로부터 3년간\n\n보존하도록 하고, 그 밖의 임상시험 관련 자료는 임상시험이 끝난\n\n날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이\n\n지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을\n\n- - 103 -\n- 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n[예시]\n\n- 가.  자료 처리\n본 임상시험에 관련된 모니터 및 점검자는 본 임상시험의 모니\n\n터링과 점검 및 진행사항 관리를 위한 목적으로 대상자의 기록을\n\n임상시험용 의료기기와 연관된 유의한 위험, 금기, 부작용, 주의\n\n사항을 시사하는 사건 등을 포함하며, 발생시간, 정도, 처치, 경과,\n\n임상시험용 의료기기와의 인과관계 등에 대한 정보를 증례기록서에\n\n- 나. ",
        "original_sentence": "제조허가/수입허가 또는 그\n\n변경 허가를 위한 임상시험 관련 자료는 허가일로부터 3년간\n\n보존하도록 하고, 그 밖의 임상시험 관련 자료는 임상시험이 끝난\n\n날부터 3년간 보존하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_733",
      "text": "다만, 식품의약품안전처장이\n\n지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을\n\n- - 103 -\n- 20. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 732,
        "window_size": 3,
        "char_count": 67,
        "word_count": 14,
        "page_number": 30,
        "window_text": "3) 증례기록서 등 임상시험에 관련된 모든 서류에는 피험자 이름이\n\n아닌 피험자 식별코드(일반적으로 피험자 이니셜)로 기록하고\n\n- 자.  기록의 보존\n1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하\n\n여야 하며 보안을 유지하도록 한다.  제조허가/수입허가 또는 그\n\n변경 허가를 위한 임상시험 관련 자료는 허가일로부터 3년간\n\n보존하도록 하고, 그 밖의 임상시험 관련 자료는 임상시험이 끝난\n\n날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이\n\n지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을\n\n- - 103 -\n- 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n[예시]\n\n- 가.  자료 처리\n본 임상시험에 관련된 모니터 및 점검자는 본 임상시험의 모니\n\n터링과 점검 및 진행사항 관리를 위한 목적으로 대상자의 기록을\n\n임상시험용 의료기기와 연관된 유의한 위험, 금기, 부작용, 주의\n\n사항을 시사하는 사건 등을 포함하며, 발생시간, 정도, 처치, 경과,\n\n임상시험용 의료기기와의 인과관계 등에 대한 정보를 증례기록서에\n\n- 나.  법규준수\n시험자는 서명록에 서명함으로써, 본 임상시험계획서, 의료기기\n\n임상시험 관리기준, 국내의 모든 관련 법규와 임상시험 수행에 관련\n\n된 규칙 및 규정에 따라서 효과적이고 성실하게 연구를 수행할 것에\n\n동의하게 된다. ",
        "original_sentence": "다만, 식품의약품안전처장이\n\n지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을\n\n- - 103 -\n- 20. "
      }
    },
    {
      "chunk_id": "chunk_734",
      "text": "그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n[예시]\n\n- 가. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 733,
        "window_size": 3,
        "char_count": 47,
        "word_count": 12,
        "page_number": 3,
        "window_text": "기록의 보존\n1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하\n\n여야 하며 보안을 유지하도록 한다.  제조허가/수입허가 또는 그\n\n변경 허가를 위한 임상시험 관련 자료는 허가일로부터 3년간\n\n보존하도록 하고, 그 밖의 임상시험 관련 자료는 임상시험이 끝난\n\n날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이\n\n지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을\n\n- - 103 -\n- 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n[예시]\n\n- 가.  자료 처리\n본 임상시험에 관련된 모니터 및 점검자는 본 임상시험의 모니\n\n터링과 점검 및 진행사항 관리를 위한 목적으로 대상자의 기록을\n\n임상시험용 의료기기와 연관된 유의한 위험, 금기, 부작용, 주의\n\n사항을 시사하는 사건 등을 포함하며, 발생시간, 정도, 처치, 경과,\n\n임상시험용 의료기기와의 인과관계 등에 대한 정보를 증례기록서에\n\n- 나.  법규준수\n시험자는 서명록에 서명함으로써, 본 임상시험계획서, 의료기기\n\n임상시험 관리기준, 국내의 모든 관련 법규와 임상시험 수행에 관련\n\n된 규칙 및 규정에 따라서 효과적이고 성실하게 연구를 수행할 것에\n\n동의하게 된다.  임상시험 담당자 및 참여 연구진은 임상시험계획을\n\n- - 104 -\n정확히 분석, 숙지하도록 하며 시험책임자는 예기치 않은 이상반응\n\n등의 출현에 대한 충분한 대처와 필요에 따른 보고, 시험참여 연구진에\n\n대한 충분한 교육 등 사전조치를 취한다. ",
        "original_sentence": "그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n[예시]\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_735",
      "text": "자료 처리\n본 임상시험에 관련된 모니터 및 점검자는 본 임상시험의 모니\n\n터링과 점검 및 진행사항 관리를 위한 목적으로 대상자의 기록을\n\n임상시험용 의료기기와 연관된 유의한 위험, 금기, 부작용, 주의\n\n사항을 시사하는 사건 등을 포함하며, 발생시간, 정도, 처치, 경과,\n\n임상시험용 의료기기와의 인과관계 등에 대한 정보를 증례기록서에\n\n- 나. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 734,
        "window_size": 3,
        "char_count": 195,
        "word_count": 46,
        "page_number": 30,
        "window_text": "제조허가/수입허가 또는 그\n\n변경 허가를 위한 임상시험 관련 자료는 허가일로부터 3년간\n\n보존하도록 하고, 그 밖의 임상시험 관련 자료는 임상시험이 끝난\n\n날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이\n\n지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을\n\n- - 103 -\n- 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n[예시]\n\n- 가.  자료 처리\n본 임상시험에 관련된 모니터 및 점검자는 본 임상시험의 모니\n\n터링과 점검 및 진행사항 관리를 위한 목적으로 대상자의 기록을\n\n임상시험용 의료기기와 연관된 유의한 위험, 금기, 부작용, 주의\n\n사항을 시사하는 사건 등을 포함하며, 발생시간, 정도, 처치, 경과,\n\n임상시험용 의료기기와의 인과관계 등에 대한 정보를 증례기록서에\n\n- 나.  법규준수\n시험자는 서명록에 서명함으로써, 본 임상시험계획서, 의료기기\n\n임상시험 관리기준, 국내의 모든 관련 법규와 임상시험 수행에 관련\n\n된 규칙 및 규정에 따라서 효과적이고 성실하게 연구를 수행할 것에\n\n동의하게 된다.  임상시험 담당자 및 참여 연구진은 임상시험계획을\n\n- - 104 -\n정확히 분석, 숙지하도록 하며 시험책임자는 예기치 않은 이상반응\n\n등의 출현에 대한 충분한 대처와 필요에 따른 보고, 시험참여 연구진에\n\n대한 충분한 교육 등 사전조치를 취한다.  임상시험의 진행은 의료기기\n\n임상시험 관리 기준에 합당하게 진행한다.\n\n",
        "original_sentence": "자료 처리\n본 임상시험에 관련된 모니터 및 점검자는 본 임상시험의 모니\n\n터링과 점검 및 진행사항 관리를 위한 목적으로 대상자의 기록을\n\n임상시험용 의료기기와 연관된 유의한 위험, 금기, 부작용, 주의\n\n사항을 시사하는 사건 등을 포함하며, 발생시간, 정도, 처치, 경과,\n\n임상시험용 의료기기와의 인과관계 등에 대한 정보를 증례기록서에\n\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_736",
      "text": "법규준수\n시험자는 서명록에 서명함으로써, 본 임상시험계획서, 의료기기\n\n임상시험 관리기준, 국내의 모든 관련 법규와 임상시험 수행에 관련\n\n된 규칙 및 규정에 따라서 효과적이고 성실하게 연구를 수행할 것에\n\n동의하게 된다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 735,
        "window_size": 3,
        "char_count": 125,
        "word_count": 28,
        "page_number": 27,
        "window_text": "다만, 식품의약품안전처장이\n\n지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을\n\n- - 103 -\n- 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n[예시]\n\n- 가.  자료 처리\n본 임상시험에 관련된 모니터 및 점검자는 본 임상시험의 모니\n\n터링과 점검 및 진행사항 관리를 위한 목적으로 대상자의 기록을\n\n임상시험용 의료기기와 연관된 유의한 위험, 금기, 부작용, 주의\n\n사항을 시사하는 사건 등을 포함하며, 발생시간, 정도, 처치, 경과,\n\n임상시험용 의료기기와의 인과관계 등에 대한 정보를 증례기록서에\n\n- 나.  법규준수\n시험자는 서명록에 서명함으로써, 본 임상시험계획서, 의료기기\n\n임상시험 관리기준, 국내의 모든 관련 법규와 임상시험 수행에 관련\n\n된 규칙 및 규정에 따라서 효과적이고 성실하게 연구를 수행할 것에\n\n동의하게 된다.  임상시험 담당자 및 참여 연구진은 임상시험계획을\n\n- - 104 -\n정확히 분석, 숙지하도록 하며 시험책임자는 예기치 않은 이상반응\n\n등의 출현에 대한 충분한 대처와 필요에 따른 보고, 시험참여 연구진에\n\n대한 충분한 교육 등 사전조치를 취한다.  임상시험의 진행은 의료기기\n\n임상시험 관리 기준에 합당하게 진행한다.\n\n - 다. ",
        "original_sentence": "법규준수\n시험자는 서명록에 서명함으로써, 본 임상시험계획서, 의료기기\n\n임상시험 관리기준, 국내의 모든 관련 법규와 임상시험 수행에 관련\n\n된 규칙 및 규정에 따라서 효과적이고 성실하게 연구를 수행할 것에\n\n동의하게 된다. "
      }
    },
    {
      "chunk_id": "chunk_737",
      "text": "임상시험 담당자 및 참여 연구진은 임상시험계획을\n\n- - 104 -\n정확히 분석, 숙지하도록 하며 시험책임자는 예기치 않은 이상반응\n\n등의 출현에 대한 충분한 대처와 필요에 따른 보고, 시험참여 연구진에\n\n대한 충분한 교육 등 사전조치를 취한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 736,
        "window_size": 3,
        "char_count": 138,
        "word_count": 34,
        "page_number": 3,
        "window_text": "그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n[예시]\n\n- 가.  자료 처리\n본 임상시험에 관련된 모니터 및 점검자는 본 임상시험의 모니\n\n터링과 점검 및 진행사항 관리를 위한 목적으로 대상자의 기록을\n\n임상시험용 의료기기와 연관된 유의한 위험, 금기, 부작용, 주의\n\n사항을 시사하는 사건 등을 포함하며, 발생시간, 정도, 처치, 경과,\n\n임상시험용 의료기기와의 인과관계 등에 대한 정보를 증례기록서에\n\n- 나.  법규준수\n시험자는 서명록에 서명함으로써, 본 임상시험계획서, 의료기기\n\n임상시험 관리기준, 국내의 모든 관련 법규와 임상시험 수행에 관련\n\n된 규칙 및 규정에 따라서 효과적이고 성실하게 연구를 수행할 것에\n\n동의하게 된다.  임상시험 담당자 및 참여 연구진은 임상시험계획을\n\n- - 104 -\n정확히 분석, 숙지하도록 하며 시험책임자는 예기치 않은 이상반응\n\n등의 출현에 대한 충분한 대처와 필요에 따른 보고, 시험참여 연구진에\n\n대한 충분한 교육 등 사전조치를 취한다.  임상시험의 진행은 의료기기\n\n임상시험 관리 기준에 합당하게 진행한다.\n\n - 다.  임상시험 자료의 보관 및 열람\n임상시험 자료는 기밀로 보관되고 열람은 본 임상시험의 모니터링\n\n과 점검 및 진행 사항 관리를 위한 목적으로 대상자의 기록을 열람할\n\n수 있다.\n\n",
        "original_sentence": "임상시험 담당자 및 참여 연구진은 임상시험계획을\n\n- - 104 -\n정확히 분석, 숙지하도록 하며 시험책임자는 예기치 않은 이상반응\n\n등의 출현에 대한 충분한 대처와 필요에 따른 보고, 시험참여 연구진에\n\n대한 충분한 교육 등 사전조치를 취한다. "
      }
    },
    {
      "chunk_id": "chunk_738",
      "text": "임상시험의 진행은 의료기기\n\n임상시험 관리 기준에 합당하게 진행한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 737,
        "window_size": 3,
        "char_count": 40,
        "word_count": 8,
        "page_number": 15,
        "window_text": "자료 처리\n본 임상시험에 관련된 모니터 및 점검자는 본 임상시험의 모니\n\n터링과 점검 및 진행사항 관리를 위한 목적으로 대상자의 기록을\n\n임상시험용 의료기기와 연관된 유의한 위험, 금기, 부작용, 주의\n\n사항을 시사하는 사건 등을 포함하며, 발생시간, 정도, 처치, 경과,\n\n임상시험용 의료기기와의 인과관계 등에 대한 정보를 증례기록서에\n\n- 나.  법규준수\n시험자는 서명록에 서명함으로써, 본 임상시험계획서, 의료기기\n\n임상시험 관리기준, 국내의 모든 관련 법규와 임상시험 수행에 관련\n\n된 규칙 및 규정에 따라서 효과적이고 성실하게 연구를 수행할 것에\n\n동의하게 된다.  임상시험 담당자 및 참여 연구진은 임상시험계획을\n\n- - 104 -\n정확히 분석, 숙지하도록 하며 시험책임자는 예기치 않은 이상반응\n\n등의 출현에 대한 충분한 대처와 필요에 따른 보고, 시험참여 연구진에\n\n대한 충분한 교육 등 사전조치를 취한다.  임상시험의 진행은 의료기기\n\n임상시험 관리 기준에 합당하게 진행한다.\n\n - 다.  임상시험 자료의 보관 및 열람\n임상시험 자료는 기밀로 보관되고 열람은 본 임상시험의 모니터링\n\n과 점검 및 진행 사항 관리를 위한 목적으로 대상자의 기록을 열람할\n\n수 있다.\n\n - 라. ",
        "original_sentence": "임상시험의 진행은 의료기기\n\n임상시험 관리 기준에 합당하게 진행한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_739",
      "text": "- 다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 738,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 72,
        "window_text": "법규준수\n시험자는 서명록에 서명함으로써, 본 임상시험계획서, 의료기기\n\n임상시험 관리기준, 국내의 모든 관련 법규와 임상시험 수행에 관련\n\n된 규칙 및 규정에 따라서 효과적이고 성실하게 연구를 수행할 것에\n\n동의하게 된다.  임상시험 담당자 및 참여 연구진은 임상시험계획을\n\n- - 104 -\n정확히 분석, 숙지하도록 하며 시험책임자는 예기치 않은 이상반응\n\n등의 출현에 대한 충분한 대처와 필요에 따른 보고, 시험참여 연구진에\n\n대한 충분한 교육 등 사전조치를 취한다.  임상시험의 진행은 의료기기\n\n임상시험 관리 기준에 합당하게 진행한다.\n\n - 다.  임상시험 자료의 보관 및 열람\n임상시험 자료는 기밀로 보관되고 열람은 본 임상시험의 모니터링\n\n과 점검 및 진행 사항 관리를 위한 목적으로 대상자의 기록을 열람할\n\n수 있다.\n\n - 라.  점검 및 실태조사\n임상시험의 중요도, 대상자 수, 임상시험의 종류와 복잡성, 대상자\n\n에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n실시상의 문제점 등에 따라 결정된다.\n\n",
        "original_sentence": "- 다. "
      }
    },
    {
      "chunk_id": "chunk_740",
      "text": "임상시험 자료의 보관 및 열람\n임상시험 자료는 기밀로 보관되고 열람은 본 임상시험의 모니터링\n\n과 점검 및 진행 사항 관리를 위한 목적으로 대상자의 기록을 열람할\n\n수 있다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 739,
        "window_size": 3,
        "char_count": 99,
        "word_count": 26,
        "page_number": 30,
        "window_text": "임상시험 담당자 및 참여 연구진은 임상시험계획을\n\n- - 104 -\n정확히 분석, 숙지하도록 하며 시험책임자는 예기치 않은 이상반응\n\n등의 출현에 대한 충분한 대처와 필요에 따른 보고, 시험참여 연구진에\n\n대한 충분한 교육 등 사전조치를 취한다.  임상시험의 진행은 의료기기\n\n임상시험 관리 기준에 합당하게 진행한다.\n\n - 다.  임상시험 자료의 보관 및 열람\n임상시험 자료는 기밀로 보관되고 열람은 본 임상시험의 모니터링\n\n과 점검 및 진행 사항 관리를 위한 목적으로 대상자의 기록을 열람할\n\n수 있다.\n\n - 라.  점검 및 실태조사\n임상시험의 중요도, 대상자 수, 임상시험의 종류와 복잡성, 대상자\n\n에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n실시상의 문제점 등에 따라 결정된다.\n\n - 마. ",
        "original_sentence": "임상시험 자료의 보관 및 열람\n임상시험 자료는 기밀로 보관되고 열람은 본 임상시험의 모니터링\n\n과 점검 및 진행 사항 관리를 위한 목적으로 대상자의 기록을 열람할\n\n수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_741",
      "text": "- 라. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 740,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 72,
        "window_text": "임상시험의 진행은 의료기기\n\n임상시험 관리 기준에 합당하게 진행한다.\n\n - 다.  임상시험 자료의 보관 및 열람\n임상시험 자료는 기밀로 보관되고 열람은 본 임상시험의 모니터링\n\n과 점검 및 진행 사항 관리를 위한 목적으로 대상자의 기록을 열람할\n\n수 있다.\n\n - 라.  점검 및 실태조사\n임상시험의 중요도, 대상자 수, 임상시험의 종류와 복잡성, 대상자\n\n에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n실시상의 문제점 등에 따라 결정된다.\n\n - 마.  임상시험용 의료기기의 사용 및 관리\n임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가\n\n관리한다. ",
        "original_sentence": "- 라. "
      }
    },
    {
      "chunk_id": "chunk_742",
      "text": "점검 및 실태조사\n임상시험의 중요도, 대상자 수, 임상시험의 종류와 복잡성, 대상자\n\n에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n실시상의 문제점 등에 따라 결정된다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 741,
        "window_size": 3,
        "char_count": 108,
        "word_count": 27,
        "page_number": 30,
        "window_text": "- 다.  임상시험 자료의 보관 및 열람\n임상시험 자료는 기밀로 보관되고 열람은 본 임상시험의 모니터링\n\n과 점검 및 진행 사항 관리를 위한 목적으로 대상자의 기록을 열람할\n\n수 있다.\n\n - 라.  점검 및 실태조사\n임상시험의 중요도, 대상자 수, 임상시험의 종류와 복잡성, 대상자\n\n에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n실시상의 문제점 등에 따라 결정된다.\n\n - 마.  임상시험용 의료기기의 사용 및 관리\n임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가\n\n관리한다.  임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급,\n\n저장하며 “임상시험용”이라는 문구가 있어야 한다. ",
        "original_sentence": "점검 및 실태조사\n임상시험의 중요도, 대상자 수, 임상시험의 종류와 복잡성, 대상자\n\n에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n실시상의 문제점 등에 따라 결정된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_743",
      "text": "- 마. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 742,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 72,
        "window_text": "임상시험 자료의 보관 및 열람\n임상시험 자료는 기밀로 보관되고 열람은 본 임상시험의 모니터링\n\n과 점검 및 진행 사항 관리를 위한 목적으로 대상자의 기록을 열람할\n\n수 있다.\n\n - 라.  점검 및 실태조사\n임상시험의 중요도, 대상자 수, 임상시험의 종류와 복잡성, 대상자\n\n에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n실시상의 문제점 등에 따라 결정된다.\n\n - 마.  임상시험용 의료기기의 사용 및 관리\n임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가\n\n관리한다.  임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급,\n\n저장하며 “임상시험용”이라는 문구가 있어야 한다.  임상시험용\n\n의료기기 관리자는 임상시험에 사용되는 의료기기에 대해 인수, 재고\n\n관리, 반납 등의 업무를 수행하고 관련 기록을 유지하여야 한다.\n\n",
        "original_sentence": "- 마. "
      }
    },
    {
      "chunk_id": "chunk_744",
      "text": "임상시험용 의료기기의 사용 및 관리\n임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가\n\n관리한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 743,
        "window_size": 3,
        "char_count": 62,
        "word_count": 13,
        "page_number": 27,
        "window_text": "- 라.  점검 및 실태조사\n임상시험의 중요도, 대상자 수, 임상시험의 종류와 복잡성, 대상자\n\n에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n실시상의 문제점 등에 따라 결정된다.\n\n - 마.  임상시험용 의료기기의 사용 및 관리\n임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가\n\n관리한다.  임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급,\n\n저장하며 “임상시험용”이라는 문구가 있어야 한다.  임상시험용\n\n의료기기 관리자는 임상시험에 사용되는 의료기기에 대해 인수, 재고\n\n관리, 반납 등의 업무를 수행하고 관련 기록을 유지하여야 한다.\n\n - - 105 -\n- 바. ",
        "original_sentence": "임상시험용 의료기기의 사용 및 관리\n임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가\n\n관리한다. "
      }
    },
    {
      "chunk_id": "chunk_745",
      "text": "임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급,\n\n저장하며 “임상시험용”이라는 문구가 있어야 한다. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 744,
        "window_size": 3,
        "char_count": 62,
        "word_count": 12,
        "page_number": 3,
        "window_text": "점검 및 실태조사\n임상시험의 중요도, 대상자 수, 임상시험의 종류와 복잡성, 대상자\n\n에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n실시상의 문제점 등에 따라 결정된다.\n\n - 마.  임상시험용 의료기기의 사용 및 관리\n임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가\n\n관리한다.  임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급,\n\n저장하며 “임상시험용”이라는 문구가 있어야 한다.  임상시험용\n\n의료기기 관리자는 임상시험에 사용되는 의료기기에 대해 인수, 재고\n\n관리, 반납 등의 업무를 수행하고 관련 기록을 유지하여야 한다.\n\n - - 105 -\n- 바.  임상시험용 의료기기의 공급과 취급\n1) 의뢰자는 임상시험계획서에 대한 심사위원회와 청장의 승인을\n\n얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는\n\n2) 의뢰자는 관리자 등이 임상시험용 의료기기를 취급하고 보관하는\n\n방법에 대해 문서화된 절차를 가지고 있어야 하며, 이 절차에는\n\n적절하고 안전한 수, 취급, 보관, 미사용 임상시험용 의료기기의\n\n피험자로부터의 반납 및 의뢰자에 대한 반납 등에 대한 방법이\n\n3) 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에\n\n4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나\n\n임상시험의 종료 또는 사용기간의 만료 등에 의한 임상시험용\n\n- - 106 -\n<!-- PAGE_113 -->\n### Ⅳ\n\n<!-- PAGE_113 -->\n### 참고문헌\n\n- 1. ",
        "original_sentence": "임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급,\n\n저장하며 “임상시험용”이라는 문구가 있어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_746",
      "text": "임상시험용\n\n의료기기 관리자는 임상시험에 사용되는 의료기기에 대해 인수, 재고\n\n관리, 반납 등의 업무를 수행하고 관련 기록을 유지하여야 한다.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 745,
        "window_size": 3,
        "char_count": 82,
        "word_count": 18,
        "page_number": 27,
        "window_text": "- 마.  임상시험용 의료기기의 사용 및 관리\n임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가\n\n관리한다.  임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급,\n\n저장하며 “임상시험용”이라는 문구가 있어야 한다.  임상시험용\n\n의료기기 관리자는 임상시험에 사용되는 의료기기에 대해 인수, 재고\n\n관리, 반납 등의 업무를 수행하고 관련 기록을 유지하여야 한다.\n\n - - 105 -\n- 바.  임상시험용 의료기기의 공급과 취급\n1) 의뢰자는 임상시험계획서에 대한 심사위원회와 청장의 승인을\n\n얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는\n\n2) 의뢰자는 관리자 등이 임상시험용 의료기기를 취급하고 보관하는\n\n방법에 대해 문서화된 절차를 가지고 있어야 하며, 이 절차에는\n\n적절하고 안전한 수, 취급, 보관, 미사용 임상시험용 의료기기의\n\n피험자로부터의 반납 및 의뢰자에 대한 반납 등에 대한 방법이\n\n3) 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에\n\n4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나\n\n임상시험의 종료 또는 사용기간의 만료 등에 의한 임상시험용\n\n- - 106 -\n<!-- PAGE_113 -->\n### Ⅳ\n\n<!-- PAGE_113 -->\n### 참고문헌\n\n- 1.  박용우. ",
        "original_sentence": "임상시험용\n\n의료기기 관리자는 임상시험에 사용되는 의료기기에 대해 인수, 재고\n\n관리, 반납 등의 업무를 수행하고 관련 기록을 유지하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_747",
      "text": "- - 105 -\n- 바. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 746,
        "window_size": 3,
        "char_count": 15,
        "word_count": 6,
        "page_number": 19,
        "window_text": "임상시험용 의료기기의 사용 및 관리\n임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가\n\n관리한다.  임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급,\n\n저장하며 “임상시험용”이라는 문구가 있어야 한다.  임상시험용\n\n의료기기 관리자는 임상시험에 사용되는 의료기기에 대해 인수, 재고\n\n관리, 반납 등의 업무를 수행하고 관련 기록을 유지하여야 한다.\n\n - - 105 -\n- 바.  임상시험용 의료기기의 공급과 취급\n1) 의뢰자는 임상시험계획서에 대한 심사위원회와 청장의 승인을\n\n얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는\n\n2) 의뢰자는 관리자 등이 임상시험용 의료기기를 취급하고 보관하는\n\n방법에 대해 문서화된 절차를 가지고 있어야 하며, 이 절차에는\n\n적절하고 안전한 수, 취급, 보관, 미사용 임상시험용 의료기기의\n\n피험자로부터의 반납 및 의뢰자에 대한 반납 등에 대한 방법이\n\n3) 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에\n\n4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나\n\n임상시험의 종료 또는 사용기간의 만료 등에 의한 임상시험용\n\n- - 106 -\n<!-- PAGE_113 -->\n### Ⅳ\n\n<!-- PAGE_113 -->\n### 참고문헌\n\n- 1.  박용우.  (2000). ",
        "original_sentence": "- - 105 -\n- 바. "
      }
    },
    {
      "chunk_id": "chunk_748",
      "text": "임상시험용 의료기기의 공급과 취급\n1) 의뢰자는 임상시험계획서에 대한 심사위원회와 청장의 승인을\n\n얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는\n\n2) 의뢰자는 관리자 등이 임상시험용 의료기기를 취급하고 보관하는\n\n방법에 대해 문서화된 절차를 가지고 있어야 하며, 이 절차에는\n\n적절하고 안전한 수, 취급, 보관, 미사용 임상시험용 의료기기의\n\n피험자로부터의 반납 및 의뢰자에 대한 반납 등에 대한 방법이\n\n3) 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에\n\n4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나\n\n임상시험의 종료 또는 사용기간의 만료 등에 의한 임상시험용\n\n- - 106 -\n<!-- PAGE_113 -->\n### Ⅳ\n\n<!-- PAGE_113 -->\n### 참고문헌\n\n- 1. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 747,
        "window_size": 3,
        "char_count": 452,
        "word_count": 98,
        "page_number": 113,
        "window_text": "임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급,\n\n저장하며 “임상시험용”이라는 문구가 있어야 한다.  임상시험용\n\n의료기기 관리자는 임상시험에 사용되는 의료기기에 대해 인수, 재고\n\n관리, 반납 등의 업무를 수행하고 관련 기록을 유지하여야 한다.\n\n - - 105 -\n- 바.  임상시험용 의료기기의 공급과 취급\n1) 의뢰자는 임상시험계획서에 대한 심사위원회와 청장의 승인을\n\n얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는\n\n2) 의뢰자는 관리자 등이 임상시험용 의료기기를 취급하고 보관하는\n\n방법에 대해 문서화된 절차를 가지고 있어야 하며, 이 절차에는\n\n적절하고 안전한 수, 취급, 보관, 미사용 임상시험용 의료기기의\n\n피험자로부터의 반납 및 의뢰자에 대한 반납 등에 대한 방법이\n\n3) 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에\n\n4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나\n\n임상시험의 종료 또는 사용기간의 만료 등에 의한 임상시험용\n\n- - 106 -\n<!-- PAGE_113 -->\n### Ⅳ\n\n<!-- PAGE_113 -->\n### 참고문헌\n\n- 1.  박용우.  (2000).  섭식장애. ",
        "original_sentence": "임상시험용 의료기기의 공급과 취급\n1) 의뢰자는 임상시험계획서에 대한 심사위원회와 청장의 승인을\n\n얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는\n\n2) 의뢰자는 관리자 등이 임상시험용 의료기기를 취급하고 보관하는\n\n방법에 대해 문서화된 절차를 가지고 있어야 하며, 이 절차에는\n\n적절하고 안전한 수, 취급, 보관, 미사용 임상시험용 의료기기의\n\n피험자로부터의 반납 및 의뢰자에 대한 반납 등에 대한 방법이\n\n3) 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에\n\n4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나\n\n임상시험의 종료 또는 사용기간의 만료 등에 의한 임상시험용\n\n- - 106 -\n<!-- PAGE_113 -->\n### Ⅳ\n\n<!-- PAGE_113 -->\n### 참고문헌\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_749",
      "text": "박용우. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 748,
        "window_size": 3,
        "char_count": 5,
        "word_count": 1,
        "page_number": 113,
        "window_text": "임상시험용\n\n의료기기 관리자는 임상시험에 사용되는 의료기기에 대해 인수, 재고\n\n관리, 반납 등의 업무를 수행하고 관련 기록을 유지하여야 한다.\n\n - - 105 -\n- 바.  임상시험용 의료기기의 공급과 취급\n1) 의뢰자는 임상시험계획서에 대한 심사위원회와 청장의 승인을\n\n얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는\n\n2) 의뢰자는 관리자 등이 임상시험용 의료기기를 취급하고 보관하는\n\n방법에 대해 문서화된 절차를 가지고 있어야 하며, 이 절차에는\n\n적절하고 안전한 수, 취급, 보관, 미사용 임상시험용 의료기기의\n\n피험자로부터의 반납 및 의뢰자에 대한 반납 등에 대한 방법이\n\n3) 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에\n\n4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나\n\n임상시험의 종료 또는 사용기간의 만료 등에 의한 임상시험용\n\n- - 106 -\n<!-- PAGE_113 -->\n### Ⅳ\n\n<!-- PAGE_113 -->\n### 참고문헌\n\n- 1.  박용우.  (2000).  섭식장애.  가정의학회지, 21(3), 315-324.\n",
        "original_sentence": "박용우. "
      }
    },
    {
      "chunk_id": "chunk_750",
      "text": "(2000). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 749,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "- - 105 -\n- 바.  임상시험용 의료기기의 공급과 취급\n1) 의뢰자는 임상시험계획서에 대한 심사위원회와 청장의 승인을\n\n얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는\n\n2) 의뢰자는 관리자 등이 임상시험용 의료기기를 취급하고 보관하는\n\n방법에 대해 문서화된 절차를 가지고 있어야 하며, 이 절차에는\n\n적절하고 안전한 수, 취급, 보관, 미사용 임상시험용 의료기기의\n\n피험자로부터의 반납 및 의뢰자에 대한 반납 등에 대한 방법이\n\n3) 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에\n\n4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나\n\n임상시험의 종료 또는 사용기간의 만료 등에 의한 임상시험용\n\n- - 106 -\n<!-- PAGE_113 -->\n### Ⅳ\n\n<!-- PAGE_113 -->\n### 참고문헌\n\n- 1.  박용우.  (2000).  섭식장애.  가정의학회지, 21(3), 315-324.\n - 2. ",
        "original_sentence": "(2000). "
      }
    },
    {
      "chunk_id": "chunk_751",
      "text": "섭식장애. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 750,
        "window_size": 3,
        "char_count": 6,
        "word_count": 1,
        "page_number": 113,
        "window_text": "임상시험용 의료기기의 공급과 취급\n1) 의뢰자는 임상시험계획서에 대한 심사위원회와 청장의 승인을\n\n얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는\n\n2) 의뢰자는 관리자 등이 임상시험용 의료기기를 취급하고 보관하는\n\n방법에 대해 문서화된 절차를 가지고 있어야 하며, 이 절차에는\n\n적절하고 안전한 수, 취급, 보관, 미사용 임상시험용 의료기기의\n\n피험자로부터의 반납 및 의뢰자에 대한 반납 등에 대한 방법이\n\n3) 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에\n\n4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나\n\n임상시험의 종료 또는 사용기간의 만료 등에 의한 임상시험용\n\n- - 106 -\n<!-- PAGE_113 -->\n### Ⅳ\n\n<!-- PAGE_113 -->\n### 참고문헌\n\n- 1.  박용우.  (2000).  섭식장애.  가정의학회지, 21(3), 315-324.\n - 2.  Neumark-Sztainer D., Hannan PJ. ",
        "original_sentence": "섭식장애. "
      }
    },
    {
      "chunk_id": "chunk_752",
      "text": "가정의학회지, 21(3), 315-324.\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 751,
        "window_size": 3,
        "char_count": 24,
        "word_count": 3,
        "page_number": 9,
        "window_text": "박용우.  (2000).  섭식장애.  가정의학회지, 21(3), 315-324.\n - 2.  Neumark-Sztainer D., Hannan PJ.  (2000). ",
        "original_sentence": "가정의학회지, 21(3), 315-324.\n"
      }
    },
    {
      "chunk_id": "chunk_753",
      "text": "- 2. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 752,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 9,
        "window_text": "(2000).  섭식장애.  가정의학회지, 21(3), 315-324.\n - 2.  Neumark-Sztainer D., Hannan PJ.  (2000).  Weight-related behaviors among adolescent girls a\n- 3. ",
        "original_sentence": "- 2. "
      }
    },
    {
      "chunk_id": "chunk_754",
      "text": "Neumark-Sztainer D., Hannan PJ. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 753,
        "window_size": 3,
        "char_count": 32,
        "word_count": 4,
        "page_number": 62,
        "window_text": "섭식장애.  가정의학회지, 21(3), 315-324.\n - 2.  Neumark-Sztainer D., Hannan PJ.  (2000).  Weight-related behaviors among adolescent girls a\n- 3.  Whitehouse, A. M., Cooper, P. J., Vize, C. V., Hill, C., & Vogel, L. ",
        "original_sentence": "Neumark-Sztainer D., Hannan PJ. "
      }
    },
    {
      "chunk_id": "chunk_755",
      "text": "(2000). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 754,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "가정의학회지, 21(3), 315-324.\n - 2.  Neumark-Sztainer D., Hannan PJ.  (2000).  Weight-related behaviors among adolescent girls a\n- 3.  Whitehouse, A. M., Cooper, P. J., Vize, C. V., Hill, C., & Vogel, L.  (1992). ",
        "original_sentence": "(2000). "
      }
    },
    {
      "chunk_id": "chunk_756",
      "text": "Weight-related behaviors among adolescent girls a\n- 3. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 755,
        "window_size": 3,
        "char_count": 55,
        "word_count": 8,
        "page_number": 62,
        "window_text": "- 2.  Neumark-Sztainer D., Hannan PJ.  (2000).  Weight-related behaviors among adolescent girls a\n- 3.  Whitehouse, A. M., Cooper, P. J., Vize, C. V., Hill, C., & Vogel, L.  (1992).  Prevalence of eat\ning disorders in three Cambridge general practices: hidden and conspicuous morbidity. ",
        "original_sentence": "Weight-related behaviors among adolescent girls a\n- 3. "
      }
    },
    {
      "chunk_id": "chunk_757",
      "text": "Whitehouse, A. M., Cooper, P. J., Vize, C. V., Hill, C., & Vogel, L. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 756,
        "window_size": 3,
        "char_count": 69,
        "word_count": 14,
        "page_number": 113,
        "window_text": "Neumark-Sztainer D., Hannan PJ.  (2000).  Weight-related behaviors among adolescent girls a\n- 3.  Whitehouse, A. M., Cooper, P. J., Vize, C. V., Hill, C., & Vogel, L.  (1992).  Prevalence of eat\ning disorders in three Cambridge general practices: hidden and conspicuous morbidity.  The\n\nBritish journal of general practice : the journal of the Royal College of General Practitioner\n\n- 4. ",
        "original_sentence": "Whitehouse, A. M., Cooper, P. J., Vize, C. V., Hill, C., & Vogel, L. "
      }
    },
    {
      "chunk_id": "chunk_758",
      "text": "(1992). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 757,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "(2000).  Weight-related behaviors among adolescent girls a\n- 3.  Whitehouse, A. M., Cooper, P. J., Vize, C. V., Hill, C., & Vogel, L.  (1992).  Prevalence of eat\ning disorders in three Cambridge general practices: hidden and conspicuous morbidity.  The\n\nBritish journal of general practice : the journal of the Royal College of General Practitioner\n\n- 4.  Youl-Ri Kim. ",
        "original_sentence": "(1992). "
      }
    },
    {
      "chunk_id": "chunk_759",
      "text": "Prevalence of eat\ning disorders in three Cambridge general practices: hidden and conspicuous morbidity. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 758,
        "window_size": 3,
        "char_count": 104,
        "word_count": 14,
        "page_number": 9,
        "window_text": "Weight-related behaviors among adolescent girls a\n- 3.  Whitehouse, A. M., Cooper, P. J., Vize, C. V., Hill, C., & Vogel, L.  (1992).  Prevalence of eat\ning disorders in three Cambridge general practices: hidden and conspicuous morbidity.  The\n\nBritish journal of general practice : the journal of the Royal College of General Practitioner\n\n- 4.  Youl-Ri Kim.  (2018). ",
        "original_sentence": "Prevalence of eat\ning disorders in three Cambridge general practices: hidden and conspicuous morbidity. "
      }
    },
    {
      "chunk_id": "chunk_760",
      "text": "The\n\nBritish journal of general practice : the journal of the Royal College of General Practitioner\n\n- 4. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 759,
        "window_size": 3,
        "char_count": 106,
        "word_count": 18,
        "page_number": 62,
        "window_text": "Whitehouse, A. M., Cooper, P. J., Vize, C. V., Hill, C., & Vogel, L.  (1992).  Prevalence of eat\ning disorders in three Cambridge general practices: hidden and conspicuous morbidity.  The\n\nBritish journal of general practice : the journal of the Royal College of General Practitioner\n\n- 4.  Youl-Ri Kim.  (2018).  Medical complications and management of eating disorders. ",
        "original_sentence": "The\n\nBritish journal of general practice : the journal of the Royal College of General Practitioner\n\n- 4. "
      }
    },
    {
      "chunk_id": "chunk_761",
      "text": "Youl-Ri Kim. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 760,
        "window_size": 3,
        "char_count": 13,
        "word_count": 2,
        "page_number": 72,
        "window_text": "(1992).  Prevalence of eat\ning disorders in three Cambridge general practices: hidden and conspicuous morbidity.  The\n\nBritish journal of general practice : the journal of the Royal College of General Practitioner\n\n- 4.  Youl-Ri Kim.  (2018).  Medical complications and management of eating disorders.  J Korean M\n- 5. ",
        "original_sentence": "Youl-Ri Kim. "
      }
    },
    {
      "chunk_id": "chunk_762",
      "text": "(2018). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 761,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "Prevalence of eat\ning disorders in three Cambridge general practices: hidden and conspicuous morbidity.  The\n\nBritish journal of general practice : the journal of the Royal College of General Practitioner\n\n- 4.  Youl-Ri Kim.  (2018).  Medical complications and management of eating disorders.  J Korean M\n- 5.  Auger, N., Potter, B. J., Ukah, U. V., Low, N., Israël, M., Steiger, H., Healy-Profitós, J., & P\naradis, G. ",
        "original_sentence": "(2018). "
      }
    },
    {
      "chunk_id": "chunk_763",
      "text": "Medical complications and management of eating disorders. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 762,
        "window_size": 3,
        "char_count": 58,
        "word_count": 7,
        "page_number": 62,
        "window_text": "The\n\nBritish journal of general practice : the journal of the Royal College of General Practitioner\n\n- 4.  Youl-Ri Kim.  (2018).  Medical complications and management of eating disorders.  J Korean M\n- 5.  Auger, N., Potter, B. J., Ukah, U. V., Low, N., Israël, M., Steiger, H., Healy-Profitós, J., & P\naradis, G.  (2021). ",
        "original_sentence": "Medical complications and management of eating disorders. "
      }
    },
    {
      "chunk_id": "chunk_764",
      "text": "J Korean M\n- 5. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 763,
        "window_size": 3,
        "char_count": 16,
        "word_count": 5,
        "page_number": 26,
        "window_text": "Youl-Ri Kim.  (2018).  Medical complications and management of eating disorders.  J Korean M\n- 5.  Auger, N., Potter, B. J., Ukah, U. V., Low, N., Israël, M., Steiger, H., Healy-Profitós, J., & P\naradis, G.  (2021).  Anorexia nervosa and the long-term risk of mortality in women. ",
        "original_sentence": "J Korean M\n- 5. "
      }
    },
    {
      "chunk_id": "chunk_765",
      "text": "Auger, N., Potter, B. J., Ukah, U. V., Low, N., Israël, M., Steiger, H., Healy-Profitós, J., & P\naradis, G. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 764,
        "window_size": 3,
        "char_count": 108,
        "word_count": 20,
        "page_number": 113,
        "window_text": "(2018).  Medical complications and management of eating disorders.  J Korean M\n- 5.  Auger, N., Potter, B. J., Ukah, U. V., Low, N., Israël, M., Steiger, H., Healy-Profitós, J., & P\naradis, G.  (2021).  Anorexia nervosa and the long-term risk of mortality in women.  World ps\n\n- 6. ",
        "original_sentence": "Auger, N., Potter, B. J., Ukah, U. V., Low, N., Israël, M., Steiger, H., Healy-Profitós, J., & P\naradis, G. "
      }
    },
    {
      "chunk_id": "chunk_766",
      "text": "(2021). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 765,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "Medical complications and management of eating disorders.  J Korean M\n- 5.  Auger, N., Potter, B. J., Ukah, U. V., Low, N., Israël, M., Steiger, H., Healy-Profitós, J., & P\naradis, G.  (2021).  Anorexia nervosa and the long-term risk of mortality in women.  World ps\n\n- 6.  Nielsen, S., & Vilmar, J. W. ",
        "original_sentence": "(2021). "
      }
    },
    {
      "chunk_id": "chunk_767",
      "text": "Anorexia nervosa and the long-term risk of mortality in women. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 766,
        "window_size": 3,
        "char_count": 63,
        "word_count": 10,
        "page_number": 62,
        "window_text": "J Korean M\n- 5.  Auger, N., Potter, B. J., Ukah, U. V., Low, N., Israël, M., Steiger, H., Healy-Profitós, J., & P\naradis, G.  (2021).  Anorexia nervosa and the long-term risk of mortality in women.  World ps\n\n- 6.  Nielsen, S., & Vilmar, J. W.  (2021). ",
        "original_sentence": "Anorexia nervosa and the long-term risk of mortality in women. "
      }
    },
    {
      "chunk_id": "chunk_768",
      "text": "World ps\n\n- 6. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 767,
        "window_size": 3,
        "char_count": 15,
        "word_count": 4,
        "page_number": 27,
        "window_text": "Auger, N., Potter, B. J., Ukah, U. V., Low, N., Israël, M., Steiger, H., Healy-Profitós, J., & P\naradis, G.  (2021).  Anorexia nervosa and the long-term risk of mortality in women.  World ps\n\n- 6.  Nielsen, S., & Vilmar, J. W.  (2021).  What can we learn about eating disorder mortality from\neating disorder diagnoses at initial assessment? ",
        "original_sentence": "World ps\n\n- 6. "
      }
    },
    {
      "chunk_id": "chunk_769",
      "text": "Nielsen, S., & Vilmar, J. W. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 768,
        "window_size": 3,
        "char_count": 29,
        "word_count": 6,
        "page_number": 62,
        "window_text": "(2021).  Anorexia nervosa and the long-term risk of mortality in women.  World ps\n\n- 6.  Nielsen, S., & Vilmar, J. W.  (2021).  What can we learn about eating disorder mortality from\neating disorder diagnoses at initial assessment?  A Danish nationwide register follow-up stud\n\ny using record linkage, encompassing 45 years (1970-2014). ",
        "original_sentence": "Nielsen, S., & Vilmar, J. W. "
      }
    },
    {
      "chunk_id": "chunk_770",
      "text": "(2021). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 769,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "Anorexia nervosa and the long-term risk of mortality in women.  World ps\n\n- 6.  Nielsen, S., & Vilmar, J. W.  (2021).  What can we learn about eating disorder mortality from\neating disorder diagnoses at initial assessment?  A Danish nationwide register follow-up stud\n\ny using record linkage, encompassing 45 years (1970-2014).  Psychiatry research, 303, 1140\n\n- 7. ",
        "original_sentence": "(2021). "
      }
    },
    {
      "chunk_id": "chunk_771",
      "text": "What can we learn about eating disorder mortality from\neating disorder diagnoses at initial assessment? ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 770,
        "window_size": 3,
        "char_count": 104,
        "word_count": 15,
        "page_number": 9,
        "window_text": "World ps\n\n- 6.  Nielsen, S., & Vilmar, J. W.  (2021).  What can we learn about eating disorder mortality from\neating disorder diagnoses at initial assessment?  A Danish nationwide register follow-up stud\n\ny using record linkage, encompassing 45 years (1970-2014).  Psychiatry research, 303, 1140\n\n- 7.  Tith RM., Paradis G., Potter BJ., et al. ",
        "original_sentence": "What can we learn about eating disorder mortality from\neating disorder diagnoses at initial assessment? "
      }
    },
    {
      "chunk_id": "chunk_772",
      "text": "A Danish nationwide register follow-up stud\n\ny using record linkage, encompassing 45 years (1970-2014). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 771,
        "window_size": 3,
        "char_count": 104,
        "word_count": 14,
        "page_number": 62,
        "window_text": "Nielsen, S., & Vilmar, J. W.  (2021).  What can we learn about eating disorder mortality from\neating disorder diagnoses at initial assessment?  A Danish nationwide register follow-up stud\n\ny using record linkage, encompassing 45 years (1970-2014).  Psychiatry research, 303, 1140\n\n- 7.  Tith RM., Paradis G., Potter BJ., et al.  (2020). ",
        "original_sentence": "A Danish nationwide register follow-up stud\n\ny using record linkage, encompassing 45 years (1970-2014). "
      }
    },
    {
      "chunk_id": "chunk_773",
      "text": "Psychiatry research, 303, 1140\n\n- 7. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 772,
        "window_size": 3,
        "char_count": 37,
        "word_count": 6,
        "page_number": 19,
        "window_text": "(2021).  What can we learn about eating disorder mortality from\neating disorder diagnoses at initial assessment?  A Danish nationwide register follow-up stud\n\ny using record linkage, encompassing 45 years (1970-2014).  Psychiatry research, 303, 1140\n\n- 7.  Tith RM., Paradis G., Potter BJ., et al.  (2020).  Association of bulimia nervosa with long-term\n- 8. van Hoeken D., Hoek HW. ",
        "original_sentence": "Psychiatry research, 303, 1140\n\n- 7. "
      }
    },
    {
      "chunk_id": "chunk_774",
      "text": "Tith RM., Paradis G., Potter BJ., et al. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 773,
        "window_size": 3,
        "char_count": 41,
        "word_count": 8,
        "page_number": 113,
        "window_text": "What can we learn about eating disorder mortality from\neating disorder diagnoses at initial assessment?  A Danish nationwide register follow-up stud\n\ny using record linkage, encompassing 45 years (1970-2014).  Psychiatry research, 303, 1140\n\n- 7.  Tith RM., Paradis G., Potter BJ., et al.  (2020).  Association of bulimia nervosa with long-term\n- 8. van Hoeken D., Hoek HW.  (2020). ",
        "original_sentence": "Tith RM., Paradis G., Potter BJ., et al. "
      }
    },
    {
      "chunk_id": "chunk_775",
      "text": "(2020). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 774,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "A Danish nationwide register follow-up stud\n\ny using record linkage, encompassing 45 years (1970-2014).  Psychiatry research, 303, 1140\n\n- 7.  Tith RM., Paradis G., Potter BJ., et al.  (2020).  Association of bulimia nervosa with long-term\n- 8. van Hoeken D., Hoek HW.  (2020).  Review of the burden of eating disorders: mortality, disab\n- 9. ",
        "original_sentence": "(2020). "
      }
    },
    {
      "chunk_id": "chunk_776",
      "text": "Association of bulimia nervosa with long-term\n- 8. van Hoeken D., Hoek HW. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 775,
        "window_size": 3,
        "char_count": 75,
        "word_count": 13,
        "page_number": 28,
        "window_text": "Psychiatry research, 303, 1140\n\n- 7.  Tith RM., Paradis G., Potter BJ., et al.  (2020).  Association of bulimia nervosa with long-term\n- 8. van Hoeken D., Hoek HW.  (2020).  Review of the burden of eating disorders: mortality, disab\n- 9.  Kong, S., Kim, J., & Bae, J. ",
        "original_sentence": "Association of bulimia nervosa with long-term\n- 8. van Hoeken D., Hoek HW. "
      }
    },
    {
      "chunk_id": "chunk_777",
      "text": "(2020). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 776,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "Tith RM., Paradis G., Potter BJ., et al.  (2020).  Association of bulimia nervosa with long-term\n- 8. van Hoeken D., Hoek HW.  (2020).  Review of the burden of eating disorders: mortality, disab\n- 9.  Kong, S., Kim, J., & Bae, J.  (2000). ",
        "original_sentence": "(2020). "
      }
    },
    {
      "chunk_id": "chunk_778",
      "text": "Review of the burden of eating disorders: mortality, disab\n- 9. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 777,
        "window_size": 3,
        "char_count": 64,
        "word_count": 11,
        "page_number": 9,
        "window_text": "(2020).  Association of bulimia nervosa with long-term\n- 8. van Hoeken D., Hoek HW.  (2020).  Review of the burden of eating disorders: mortality, disab\n- 9.  Kong, S., Kim, J., & Bae, J.  (2000).  Effects of cognitive-behavioral group therapy for binge\n- 10. ",
        "original_sentence": "Review of the burden of eating disorders: mortality, disab\n- 9. "
      }
    },
    {
      "chunk_id": "chunk_779",
      "text": "Kong, S., Kim, J., & Bae, J. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 778,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 62,
        "window_text": "Association of bulimia nervosa with long-term\n- 8. van Hoeken D., Hoek HW.  (2020).  Review of the burden of eating disorders: mortality, disab\n- 9.  Kong, S., Kim, J., & Bae, J.  (2000).  Effects of cognitive-behavioral group therapy for binge\n- 10.  Reas, D. L., & Grilo, C. M. ",
        "original_sentence": "Kong, S., Kim, J., & Bae, J. "
      }
    },
    {
      "chunk_id": "chunk_780",
      "text": "(2000). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 779,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "(2020).  Review of the burden of eating disorders: mortality, disab\n- 9.  Kong, S., Kim, J., & Bae, J.  (2000).  Effects of cognitive-behavioral group therapy for binge\n- 10.  Reas, D. L., & Grilo, C. M.  (2008). ",
        "original_sentence": "(2000). "
      }
    },
    {
      "chunk_id": "chunk_781",
      "text": "Effects of cognitive-behavioral group therapy for binge\n- 10. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 780,
        "window_size": 3,
        "char_count": 62,
        "word_count": 9,
        "page_number": 9,
        "window_text": "Review of the burden of eating disorders: mortality, disab\n- 9.  Kong, S., Kim, J., & Bae, J.  (2000).  Effects of cognitive-behavioral group therapy for binge\n- 10.  Reas, D. L., & Grilo, C. M.  (2008).  Review and meta-analysis of pharmacotherapy for binge\n- 11. ",
        "original_sentence": "Effects of cognitive-behavioral group therapy for binge\n- 10. "
      }
    },
    {
      "chunk_id": "chunk_782",
      "text": "Reas, D. L., & Grilo, C. M. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 781,
        "window_size": 3,
        "char_count": 28,
        "word_count": 7,
        "page_number": 113,
        "window_text": "Kong, S., Kim, J., & Bae, J.  (2000).  Effects of cognitive-behavioral group therapy for binge\n- 10.  Reas, D. L., & Grilo, C. M.  (2008).  Review and meta-analysis of pharmacotherapy for binge\n- 11.  Kwon, H. I. ",
        "original_sentence": "Reas, D. L., & Grilo, C. M. "
      }
    },
    {
      "chunk_id": "chunk_783",
      "text": "(2008). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 782,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "(2000).  Effects of cognitive-behavioral group therapy for binge\n- 10.  Reas, D. L., & Grilo, C. M.  (2008).  Review and meta-analysis of pharmacotherapy for binge\n- 11.  Kwon, H. I.  & Kwon, J. H. ",
        "original_sentence": "(2008). "
      }
    },
    {
      "chunk_id": "chunk_784",
      "text": "Review and meta-analysis of pharmacotherapy for binge\n- 11. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 783,
        "window_size": 3,
        "char_count": 60,
        "word_count": 9,
        "page_number": 9,
        "window_text": "Effects of cognitive-behavioral group therapy for binge\n- 10.  Reas, D. L., & Grilo, C. M.  (2008).  Review and meta-analysis of pharmacotherapy for binge\n- 11.  Kwon, H. I.  & Kwon, J. H.  (2003). ",
        "original_sentence": "Review and meta-analysis of pharmacotherapy for binge\n- 11. "
      }
    },
    {
      "chunk_id": "chunk_785",
      "text": "Kwon, H. I. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 784,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 62,
        "window_text": "Reas, D. L., & Grilo, C. M.  (2008).  Review and meta-analysis of pharmacotherapy for binge\n- 11.  Kwon, H. I.  & Kwon, J. H.  (2003).  The effects of cognitive-behavioral treatment of college\n- 12. ",
        "original_sentence": "Kwon, H. I. "
      }
    },
    {
      "chunk_id": "chunk_786",
      "text": "& Kwon, J. H. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 785,
        "window_size": 3,
        "char_count": 14,
        "word_count": 4,
        "page_number": 62,
        "window_text": "(2008).  Review and meta-analysis of pharmacotherapy for binge\n- 11.  Kwon, H. I.  & Kwon, J. H.  (2003).  The effects of cognitive-behavioral treatment of college\n- 12.  Wilfley, D. E., Agras, W. S., Telch, C. F., Rossiter, E. M., Schneider, J. A., Cole, … Raebur\nn, S. D. ",
        "original_sentence": "& Kwon, J. H. "
      }
    },
    {
      "chunk_id": "chunk_787",
      "text": "(2003). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 786,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "Review and meta-analysis of pharmacotherapy for binge\n- 11.  Kwon, H. I.  & Kwon, J. H.  (2003).  The effects of cognitive-behavioral treatment of college\n- 12.  Wilfley, D. E., Agras, W. S., Telch, C. F., Rossiter, E. M., Schneider, J. A., Cole, … Raebur\nn, S. D.  (1993). ",
        "original_sentence": "(2003). "
      }
    },
    {
      "chunk_id": "chunk_788",
      "text": "The effects of cognitive-behavioral treatment of college\n- 12. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 787,
        "window_size": 3,
        "char_count": 63,
        "word_count": 9,
        "page_number": 62,
        "window_text": "Kwon, H. I.  & Kwon, J. H.  (2003).  The effects of cognitive-behavioral treatment of college\n- 12.  Wilfley, D. E., Agras, W. S., Telch, C. F., Rossiter, E. M., Schneider, J. A., Cole, … Raebur\nn, S. D.  (1993).  Group cognitive-behavioral therapy and group interpersonal psychotherapy\n\nfor the nonpurging bulimic individual: A controlled comparison. ",
        "original_sentence": "The effects of cognitive-behavioral treatment of college\n- 12. "
      }
    },
    {
      "chunk_id": "chunk_789",
      "text": "Wilfley, D. E., Agras, W. S., Telch, C. F., Rossiter, E. M., Schneider, J. A., Cole, … Raebur\nn, S. D. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 788,
        "window_size": 3,
        "char_count": 103,
        "word_count": 21,
        "page_number": 113,
        "window_text": "& Kwon, J. H.  (2003).  The effects of cognitive-behavioral treatment of college\n- 12.  Wilfley, D. E., Agras, W. S., Telch, C. F., Rossiter, E. M., Schneider, J. A., Cole, … Raebur\nn, S. D.  (1993).  Group cognitive-behavioral therapy and group interpersonal psychotherapy\n\nfor the nonpurging bulimic individual: A controlled comparison.  Journal of Consulting and Cl\n\n- 13. ",
        "original_sentence": "Wilfley, D. E., Agras, W. S., Telch, C. F., Rossiter, E. M., Schneider, J. A., Cole, … Raebur\nn, S. D. "
      }
    },
    {
      "chunk_id": "chunk_790",
      "text": "(1993). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 789,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 19,
        "window_text": "(2003).  The effects of cognitive-behavioral treatment of college\n- 12.  Wilfley, D. E., Agras, W. S., Telch, C. F., Rossiter, E. M., Schneider, J. A., Cole, … Raebur\nn, S. D.  (1993).  Group cognitive-behavioral therapy and group interpersonal psychotherapy\n\nfor the nonpurging bulimic individual: A controlled comparison.  Journal of Consulting and Cl\n\n- 13.  Park, N. R., & Son, C. N. ",
        "original_sentence": "(1993). "
      }
    },
    {
      "chunk_id": "chunk_791",
      "text": "Group cognitive-behavioral therapy and group interpersonal psychotherapy\n\nfor the nonpurging bulimic individual: A controlled comparison. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 790,
        "window_size": 3,
        "char_count": 138,
        "word_count": 15,
        "page_number": 9,
        "window_text": "The effects of cognitive-behavioral treatment of college\n- 12.  Wilfley, D. E., Agras, W. S., Telch, C. F., Rossiter, E. M., Schneider, J. A., Cole, … Raebur\nn, S. D.  (1993).  Group cognitive-behavioral therapy and group interpersonal psychotherapy\n\nfor the nonpurging bulimic individual: A controlled comparison.  Journal of Consulting and Cl\n\n- 13.  Park, N. R., & Son, C. N.  (2012). ",
        "original_sentence": "Group cognitive-behavioral therapy and group interpersonal psychotherapy\n\nfor the nonpurging bulimic individual: A controlled comparison. "
      }
    },
    {
      "chunk_id": "chunk_792",
      "text": "Journal of Consulting and Cl\n\n- 13. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 791,
        "window_size": 3,
        "char_count": 36,
        "word_count": 7,
        "page_number": 19,
        "window_text": "Wilfley, D. E., Agras, W. S., Telch, C. F., Rossiter, E. M., Schneider, J. A., Cole, … Raebur\nn, S. D.  (1993).  Group cognitive-behavioral therapy and group interpersonal psychotherapy\n\nfor the nonpurging bulimic individual: A controlled comparison.  Journal of Consulting and Cl\n\n- 13.  Park, N. R., & Son, C. N.  (2012).  Characteristics of binge eating disorder and the effective\nness of cognitive behavioral therapy with college students prone to BED. ",
        "original_sentence": "Journal of Consulting and Cl\n\n- 13. "
      }
    },
    {
      "chunk_id": "chunk_793",
      "text": "Park, N. R., & Son, C. N. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 792,
        "window_size": 3,
        "char_count": 26,
        "word_count": 7,
        "page_number": 62,
        "window_text": "(1993).  Group cognitive-behavioral therapy and group interpersonal psychotherapy\n\nfor the nonpurging bulimic individual: A controlled comparison.  Journal of Consulting and Cl\n\n- 13.  Park, N. R., & Son, C. N.  (2012).  Characteristics of binge eating disorder and the effective\nness of cognitive behavioral therapy with college students prone to BED.  The Korean Jour\n\n- 14. ",
        "original_sentence": "Park, N. R., & Son, C. N. "
      }
    },
    {
      "chunk_id": "chunk_794",
      "text": "(2012). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 793,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "Group cognitive-behavioral therapy and group interpersonal psychotherapy\n\nfor the nonpurging bulimic individual: A controlled comparison.  Journal of Consulting and Cl\n\n- 13.  Park, N. R., & Son, C. N.  (2012).  Characteristics of binge eating disorder and the effective\nness of cognitive behavioral therapy with college students prone to BED.  The Korean Jour\n\n- 14.  Baer, R. A., Fischer, S., & Huss, D. B. ",
        "original_sentence": "(2012). "
      }
    },
    {
      "chunk_id": "chunk_795",
      "text": "Characteristics of binge eating disorder and the effective\nness of cognitive behavioral therapy with college students prone to BED. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 794,
        "window_size": 3,
        "char_count": 132,
        "word_count": 19,
        "page_number": 9,
        "window_text": "Journal of Consulting and Cl\n\n- 13.  Park, N. R., & Son, C. N.  (2012).  Characteristics of binge eating disorder and the effective\nness of cognitive behavioral therapy with college students prone to BED.  The Korean Jour\n\n- 14.  Baer, R. A., Fischer, S., & Huss, D. B.  (2005). ",
        "original_sentence": "Characteristics of binge eating disorder and the effective\nness of cognitive behavioral therapy with college students prone to BED. "
      }
    },
    {
      "chunk_id": "chunk_796",
      "text": "The Korean Jour\n\n- 14. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 795,
        "window_size": 3,
        "char_count": 23,
        "word_count": 5,
        "page_number": 19,
        "window_text": "Park, N. R., & Son, C. N.  (2012).  Characteristics of binge eating disorder and the effective\nness of cognitive behavioral therapy with college students prone to BED.  The Korean Jour\n\n- 14.  Baer, R. A., Fischer, S., & Huss, D. B.  (2005).  Mindfulness-based cognitive therapy applied\n- 15. ",
        "original_sentence": "The Korean Jour\n\n- 14. "
      }
    },
    {
      "chunk_id": "chunk_797",
      "text": "Baer, R. A., Fischer, S., & Huss, D. B. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 796,
        "window_size": 3,
        "char_count": 40,
        "word_count": 9,
        "page_number": 113,
        "window_text": "(2012).  Characteristics of binge eating disorder and the effective\nness of cognitive behavioral therapy with college students prone to BED.  The Korean Jour\n\n- 14.  Baer, R. A., Fischer, S., & Huss, D. B.  (2005).  Mindfulness-based cognitive therapy applied\n- 15.  Kristeller, J. L., & Hallett, C. B. ",
        "original_sentence": "Baer, R. A., Fischer, S., & Huss, D. B. "
      }
    },
    {
      "chunk_id": "chunk_798",
      "text": "(2005). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 797,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "Characteristics of binge eating disorder and the effective\nness of cognitive behavioral therapy with college students prone to BED.  The Korean Jour\n\n- 14.  Baer, R. A., Fischer, S., & Huss, D. B.  (2005).  Mindfulness-based cognitive therapy applied\n- 15.  Kristeller, J. L., & Hallett, C. B.  (1999). ",
        "original_sentence": "(2005). "
      }
    },
    {
      "chunk_id": "chunk_799",
      "text": "Mindfulness-based cognitive therapy applied\n- 15. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 798,
        "window_size": 3,
        "char_count": 50,
        "word_count": 6,
        "page_number": 9,
        "window_text": "The Korean Jour\n\n- 14.  Baer, R. A., Fischer, S., & Huss, D. B.  (2005).  Mindfulness-based cognitive therapy applied\n- 15.  Kristeller, J. L., & Hallett, C. B.  (1999).  An Exploratory Study of a Meditation-based Interv\n- 16. ",
        "original_sentence": "Mindfulness-based cognitive therapy applied\n- 15. "
      }
    },
    {
      "chunk_id": "chunk_800",
      "text": "Kristeller, J. L., & Hallett, C. B. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 799,
        "window_size": 3,
        "char_count": 36,
        "word_count": 7,
        "page_number": 113,
        "window_text": "Baer, R. A., Fischer, S., & Huss, D. B.  (2005).  Mindfulness-based cognitive therapy applied\n- 15.  Kristeller, J. L., & Hallett, C. B.  (1999).  An Exploratory Study of a Meditation-based Interv\n- 16.  Smith, B.W., Shelley, B.M., Leahigh, L., & Vanleit, B.J. ",
        "original_sentence": "Kristeller, J. L., & Hallett, C. B. "
      }
    },
    {
      "chunk_id": "chunk_801",
      "text": "(1999). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 800,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 19,
        "window_text": "(2005).  Mindfulness-based cognitive therapy applied\n- 15.  Kristeller, J. L., & Hallett, C. B.  (1999).  An Exploratory Study of a Meditation-based Interv\n- 16.  Smith, B.W., Shelley, B.M., Leahigh, L., & Vanleit, B.J.  (2006). ",
        "original_sentence": "(1999). "
      }
    },
    {
      "chunk_id": "chunk_802",
      "text": "An Exploratory Study of a Meditation-based Interv\n- 16. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 801,
        "window_size": 3,
        "char_count": 56,
        "word_count": 9,
        "page_number": 62,
        "window_text": "Mindfulness-based cognitive therapy applied\n- 15.  Kristeller, J. L., & Hallett, C. B.  (1999).  An Exploratory Study of a Meditation-based Interv\n- 16.  Smith, B.W., Shelley, B.M., Leahigh, L., & Vanleit, B.J.  (2006).  A Preliminary Study of the\nEffects of a Modified Mindfulness Intervention on Binge Eating. ",
        "original_sentence": "An Exploratory Study of a Meditation-based Interv\n- 16. "
      }
    },
    {
      "chunk_id": "chunk_803",
      "text": "Smith, B.W., Shelley, B.M., Leahigh, L., & Vanleit, B.J. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 802,
        "window_size": 3,
        "char_count": 57,
        "word_count": 9,
        "page_number": 62,
        "window_text": "Kristeller, J. L., & Hallett, C. B.  (1999).  An Exploratory Study of a Meditation-based Interv\n- 16.  Smith, B.W., Shelley, B.M., Leahigh, L., & Vanleit, B.J.  (2006).  A Preliminary Study of the\nEffects of a Modified Mindfulness Intervention on Binge Eating.  Complementary Health Prac\n\n- - 107 -\n- 17. ",
        "original_sentence": "Smith, B.W., Shelley, B.M., Leahigh, L., & Vanleit, B.J. "
      }
    },
    {
      "chunk_id": "chunk_804",
      "text": "(2006). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 803,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "(1999).  An Exploratory Study of a Meditation-based Interv\n- 16.  Smith, B.W., Shelley, B.M., Leahigh, L., & Vanleit, B.J.  (2006).  A Preliminary Study of the\nEffects of a Modified Mindfulness Intervention on Binge Eating.  Complementary Health Prac\n\n- - 107 -\n- 17.  Kim, J. H. ",
        "original_sentence": "(2006). "
      }
    },
    {
      "chunk_id": "chunk_805",
      "text": "A Preliminary Study of the\nEffects of a Modified Mindfulness Intervention on Binge Eating. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 804,
        "window_size": 3,
        "char_count": 91,
        "word_count": 14,
        "page_number": 62,
        "window_text": "An Exploratory Study of a Meditation-based Interv\n- 16.  Smith, B.W., Shelley, B.M., Leahigh, L., & Vanleit, B.J.  (2006).  A Preliminary Study of the\nEffects of a Modified Mindfulness Intervention on Binge Eating.  Complementary Health Prac\n\n- - 107 -\n- 17.  Kim, J. H.  (2004). ",
        "original_sentence": "A Preliminary Study of the\nEffects of a Modified Mindfulness Intervention on Binge Eating. "
      }
    },
    {
      "chunk_id": "chunk_806",
      "text": "Complementary Health Prac\n\n- - 107 -\n- 17. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 805,
        "window_size": 3,
        "char_count": 43,
        "word_count": 9,
        "page_number": 19,
        "window_text": "Smith, B.W., Shelley, B.M., Leahigh, L., & Vanleit, B.J.  (2006).  A Preliminary Study of the\nEffects of a Modified Mindfulness Intervention on Binge Eating.  Complementary Health Prac\n\n- - 107 -\n- 17.  Kim, J. H.  (2004).  Types of mindfulness meditation and their implications for cognitive beha\nvioral therapy. ",
        "original_sentence": "Complementary Health Prac\n\n- - 107 -\n- 17. "
      }
    },
    {
      "chunk_id": "chunk_807",
      "text": "Kim, J. H. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 806,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 114,
        "window_text": "(2006).  A Preliminary Study of the\nEffects of a Modified Mindfulness Intervention on Binge Eating.  Complementary Health Prac\n\n- - 107 -\n- 17.  Kim, J. H.  (2004).  Types of mindfulness meditation and their implications for cognitive beha\nvioral therapy.  Cognitive Behavior Therapy in Korea, 4(2), 27-44.\n\n",
        "original_sentence": "Kim, J. H. "
      }
    },
    {
      "chunk_id": "chunk_808",
      "text": "(2004). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 807,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "A Preliminary Study of the\nEffects of a Modified Mindfulness Intervention on Binge Eating.  Complementary Health Prac\n\n- - 107 -\n- 17.  Kim, J. H.  (2004).  Types of mindfulness meditation and their implications for cognitive beha\nvioral therapy.  Cognitive Behavior Therapy in Korea, 4(2), 27-44.\n\n - 18. ",
        "original_sentence": "(2004). "
      }
    },
    {
      "chunk_id": "chunk_809",
      "text": "Types of mindfulness meditation and their implications for cognitive beha\nvioral therapy. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 808,
        "window_size": 3,
        "char_count": 90,
        "word_count": 12,
        "page_number": 62,
        "window_text": "Complementary Health Prac\n\n- - 107 -\n- 17.  Kim, J. H.  (2004).  Types of mindfulness meditation and their implications for cognitive beha\nvioral therapy.  Cognitive Behavior Therapy in Korea, 4(2), 27-44.\n\n - 18.  Lee, S. J., & Kim, M. ",
        "original_sentence": "Types of mindfulness meditation and their implications for cognitive beha\nvioral therapy. "
      }
    },
    {
      "chunk_id": "chunk_810",
      "text": "Cognitive Behavior Therapy in Korea, 4(2), 27-44.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 809,
        "window_size": 3,
        "char_count": 51,
        "word_count": 7,
        "page_number": 9,
        "window_text": "Kim, J. H.  (2004).  Types of mindfulness meditation and their implications for cognitive beha\nvioral therapy.  Cognitive Behavior Therapy in Korea, 4(2), 27-44.\n\n - 18.  Lee, S. J., & Kim, M.  (2015). ",
        "original_sentence": "Cognitive Behavior Therapy in Korea, 4(2), 27-44.\n\n"
      }
    },
    {
      "chunk_id": "chunk_811",
      "text": "- 18. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 810,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 19,
        "window_text": "(2004).  Types of mindfulness meditation and their implications for cognitive beha\nvioral therapy.  Cognitive Behavior Therapy in Korea, 4(2), 27-44.\n\n - 18.  Lee, S. J., & Kim, M.  (2015).  The effects of mindfulness meditation on binge eating, body\ndissatisfaction, depression and anger in patients with eating disorders: A preliminary study.\n\n",
        "original_sentence": "- 18. "
      }
    },
    {
      "chunk_id": "chunk_812",
      "text": "Lee, S. J., & Kim, M. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 811,
        "window_size": 3,
        "char_count": 22,
        "word_count": 6,
        "page_number": 114,
        "window_text": "Types of mindfulness meditation and their implications for cognitive beha\nvioral therapy.  Cognitive Behavior Therapy in Korea, 4(2), 27-44.\n\n - 18.  Lee, S. J., & Kim, M.  (2015).  The effects of mindfulness meditation on binge eating, body\ndissatisfaction, depression and anger in patients with eating disorders: A preliminary study.\n\n - 19. ",
        "original_sentence": "Lee, S. J., & Kim, M. "
      }
    },
    {
      "chunk_id": "chunk_813",
      "text": "(2015). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 812,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "Cognitive Behavior Therapy in Korea, 4(2), 27-44.\n\n - 18.  Lee, S. J., & Kim, M.  (2015).  The effects of mindfulness meditation on binge eating, body\ndissatisfaction, depression and anger in patients with eating disorders: A preliminary study.\n\n - 19.  Kim, S. H. ",
        "original_sentence": "(2015). "
      }
    },
    {
      "chunk_id": "chunk_814",
      "text": "The effects of mindfulness meditation on binge eating, body\ndissatisfaction, depression and anger in patients with eating disorders: A preliminary study.\n\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 813,
        "window_size": 3,
        "char_count": 155,
        "word_count": 21,
        "page_number": 62,
        "window_text": "- 18.  Lee, S. J., & Kim, M.  (2015).  The effects of mindfulness meditation on binge eating, body\ndissatisfaction, depression and anger in patients with eating disorders: A preliminary study.\n\n - 19.  Kim, S. H.  & Jo, M. J. ",
        "original_sentence": "The effects of mindfulness meditation on binge eating, body\ndissatisfaction, depression and anger in patients with eating disorders: A preliminary study.\n\n"
      }
    },
    {
      "chunk_id": "chunk_815",
      "text": "- 19. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 814,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 19,
        "window_text": "Lee, S. J., & Kim, M.  (2015).  The effects of mindfulness meditation on binge eating, body\ndissatisfaction, depression and anger in patients with eating disorders: A preliminary study.\n\n - 19.  Kim, S. H.  & Jo, M. J.  (2014). ",
        "original_sentence": "- 19. "
      }
    },
    {
      "chunk_id": "chunk_816",
      "text": "Kim, S. H. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 815,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 114,
        "window_text": "(2015).  The effects of mindfulness meditation on binge eating, body\ndissatisfaction, depression and anger in patients with eating disorders: A preliminary study.\n\n - 19.  Kim, S. H.  & Jo, M. J.  (2014).  Effect of clinical art therapy on self-esteem and depression\nof eating disorder patients. ",
        "original_sentence": "Kim, S. H. "
      }
    },
    {
      "chunk_id": "chunk_817",
      "text": "& Jo, M. J. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 816,
        "window_size": 3,
        "char_count": 12,
        "word_count": 4,
        "page_number": 114,
        "window_text": "The effects of mindfulness meditation on binge eating, body\ndissatisfaction, depression and anger in patients with eating disorders: A preliminary study.\n\n - 19.  Kim, S. H.  & Jo, M. J.  (2014).  Effect of clinical art therapy on self-esteem and depression\nof eating disorder patients.  Journal of The Korean Academy of Clinical Art Therapy, 9(2),\n\n- 20. ",
        "original_sentence": "& Jo, M. J. "
      }
    },
    {
      "chunk_id": "chunk_818",
      "text": "(2014). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 817,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "- 19.  Kim, S. H.  & Jo, M. J.  (2014).  Effect of clinical art therapy on self-esteem and depression\nof eating disorder patients.  Journal of The Korean Academy of Clinical Art Therapy, 9(2),\n\n- 20.  Han, J. H. ",
        "original_sentence": "(2014). "
      }
    },
    {
      "chunk_id": "chunk_819",
      "text": "Effect of clinical art therapy on self-esteem and depression\nof eating disorder patients. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 818,
        "window_size": 3,
        "char_count": 90,
        "word_count": 13,
        "page_number": 9,
        "window_text": "Kim, S. H.  & Jo, M. J.  (2014).  Effect of clinical art therapy on self-esteem and depression\nof eating disorder patients.  Journal of The Korean Academy of Clinical Art Therapy, 9(2),\n\n- 20.  Han, J. H.  (2003). ",
        "original_sentence": "Effect of clinical art therapy on self-esteem and depression\nof eating disorder patients. "
      }
    },
    {
      "chunk_id": "chunk_820",
      "text": "Journal of The Korean Academy of Clinical Art Therapy, 9(2),\n\n- 20. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 819,
        "window_size": 3,
        "char_count": 68,
        "word_count": 12,
        "page_number": 62,
        "window_text": "& Jo, M. J.  (2014).  Effect of clinical art therapy on self-esteem and depression\nof eating disorder patients.  Journal of The Korean Academy of Clinical Art Therapy, 9(2),\n\n- 20.  Han, J. H.  (2003).  Effect of cognitive-behavioral group therapy of bulimia nervosa. ",
        "original_sentence": "Journal of The Korean Academy of Clinical Art Therapy, 9(2),\n\n- 20. "
      }
    },
    {
      "chunk_id": "chunk_821",
      "text": "Han, J. H. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 820,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 62,
        "window_text": "(2014).  Effect of clinical art therapy on self-esteem and depression\nof eating disorder patients.  Journal of The Korean Academy of Clinical Art Therapy, 9(2),\n\n- 20.  Han, J. H.  (2003).  Effect of cognitive-behavioral group therapy of bulimia nervosa.  Unpublis\n- 21. ",
        "original_sentence": "Han, J. H. "
      }
    },
    {
      "chunk_id": "chunk_822",
      "text": "(2003). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 821,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "Effect of clinical art therapy on self-esteem and depression\nof eating disorder patients.  Journal of The Korean Academy of Clinical Art Therapy, 9(2),\n\n- 20.  Han, J. H.  (2003).  Effect of cognitive-behavioral group therapy of bulimia nervosa.  Unpublis\n- 21.  Vocks, S., Tuschen Caffier, B., Pietrowsky, R., Rustenbach, S. J., Kersting, A., & Herpertz,\nS. ",
        "original_sentence": "(2003). "
      }
    },
    {
      "chunk_id": "chunk_823",
      "text": "Effect of cognitive-behavioral group therapy of bulimia nervosa. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 822,
        "window_size": 3,
        "char_count": 65,
        "word_count": 8,
        "page_number": 9,
        "window_text": "Journal of The Korean Academy of Clinical Art Therapy, 9(2),\n\n- 20.  Han, J. H.  (2003).  Effect of cognitive-behavioral group therapy of bulimia nervosa.  Unpublis\n- 21.  Vocks, S., Tuschen Caffier, B., Pietrowsky, R., Rustenbach, S. J., Kersting, A., & Herpertz,\nS.  (2010). ",
        "original_sentence": "Effect of cognitive-behavioral group therapy of bulimia nervosa. "
      }
    },
    {
      "chunk_id": "chunk_824",
      "text": "Unpublis\n- 21. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 823,
        "window_size": 3,
        "char_count": 15,
        "word_count": 3,
        "page_number": 9,
        "window_text": "Han, J. H.  (2003).  Effect of cognitive-behavioral group therapy of bulimia nervosa.  Unpublis\n- 21.  Vocks, S., Tuschen Caffier, B., Pietrowsky, R., Rustenbach, S. J., Kersting, A., & Herpertz,\nS.  (2010).  Meta-analysis of the effectiveness of psychological and pharmacological treatme\n\n- 22. ",
        "original_sentence": "Unpublis\n- 21. "
      }
    },
    {
      "chunk_id": "chunk_825",
      "text": "Vocks, S., Tuschen Caffier, B., Pietrowsky, R., Rustenbach, S. J., Kersting, A., & Herpertz,\nS. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 824,
        "window_size": 3,
        "char_count": 96,
        "word_count": 15,
        "page_number": 62,
        "window_text": "(2003).  Effect of cognitive-behavioral group therapy of bulimia nervosa.  Unpublis\n- 21.  Vocks, S., Tuschen Caffier, B., Pietrowsky, R., Rustenbach, S. J., Kersting, A., & Herpertz,\nS.  (2010).  Meta-analysis of the effectiveness of psychological and pharmacological treatme\n\n- 22.  So Hyeon Yun, & Gaeun Kim (2018). ",
        "original_sentence": "Vocks, S., Tuschen Caffier, B., Pietrowsky, R., Rustenbach, S. J., Kersting, A., & Herpertz,\nS. "
      }
    },
    {
      "chunk_id": "chunk_826",
      "text": "(2010). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 825,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "Effect of cognitive-behavioral group therapy of bulimia nervosa.  Unpublis\n- 21.  Vocks, S., Tuschen Caffier, B., Pietrowsky, R., Rustenbach, S. J., Kersting, A., & Herpertz,\nS.  (2010).  Meta-analysis of the effectiveness of psychological and pharmacological treatme\n\n- 22.  So Hyeon Yun, & Gaeun Kim (2018).  The effects of non-pharmacological interventions for\nadults with eating disorders : A systematic review and meta-analysis. ",
        "original_sentence": "(2010). "
      }
    },
    {
      "chunk_id": "chunk_827",
      "text": "Meta-analysis of the effectiveness of psychological and pharmacological treatme\n\n- 22. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 826,
        "window_size": 3,
        "char_count": 87,
        "word_count": 11,
        "page_number": 62,
        "window_text": "Unpublis\n- 21.  Vocks, S., Tuschen Caffier, B., Pietrowsky, R., Rustenbach, S. J., Kersting, A., & Herpertz,\nS.  (2010).  Meta-analysis of the effectiveness of psychological and pharmacological treatme\n\n- 22.  So Hyeon Yun, & Gaeun Kim (2018).  The effects of non-pharmacological interventions for\nadults with eating disorders : A systematic review and meta-analysis.  Korean Journal of H\n\n- 23. ",
        "original_sentence": "Meta-analysis of the effectiveness of psychological and pharmacological treatme\n\n- 22. "
      }
    },
    {
      "chunk_id": "chunk_828",
      "text": "So Hyeon Yun, & Gaeun Kim (2018). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 827,
        "window_size": 3,
        "char_count": 34,
        "word_count": 7,
        "page_number": 9,
        "window_text": "Vocks, S., Tuschen Caffier, B., Pietrowsky, R., Rustenbach, S. J., Kersting, A., & Herpertz,\nS.  (2010).  Meta-analysis of the effectiveness of psychological and pharmacological treatme\n\n- 22.  So Hyeon Yun, & Gaeun Kim (2018).  The effects of non-pharmacological interventions for\nadults with eating disorders : A systematic review and meta-analysis.  Korean Journal of H\n\n- 23.  National Institute for Health and Care Excellence 홈페이지, https://www.nice.org.uk/guidance\n- 24. ",
        "original_sentence": "So Hyeon Yun, & Gaeun Kim (2018). "
      }
    },
    {
      "chunk_id": "chunk_829",
      "text": "The effects of non-pharmacological interventions for\nadults with eating disorders : A systematic review and meta-analysis. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 828,
        "window_size": 3,
        "char_count": 123,
        "word_count": 16,
        "page_number": 62,
        "window_text": "(2010).  Meta-analysis of the effectiveness of psychological and pharmacological treatme\n\n- 22.  So Hyeon Yun, & Gaeun Kim (2018).  The effects of non-pharmacological interventions for\nadults with eating disorders : A systematic review and meta-analysis.  Korean Journal of H\n\n- 23.  National Institute for Health and Care Excellence 홈페이지, https://www.nice.org.uk/guidance\n- 24.  Eating disorders: recognition and treatment NICE guideline, National Institute for Health an\n- 25. ",
        "original_sentence": "The effects of non-pharmacological interventions for\nadults with eating disorders : A systematic review and meta-analysis. "
      }
    },
    {
      "chunk_id": "chunk_830",
      "text": "Korean Journal of H\n\n- 23. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 829,
        "window_size": 3,
        "char_count": 27,
        "word_count": 6,
        "page_number": 9,
        "window_text": "Meta-analysis of the effectiveness of psychological and pharmacological treatme\n\n- 22.  So Hyeon Yun, & Gaeun Kim (2018).  The effects of non-pharmacological interventions for\nadults with eating disorders : A systematic review and meta-analysis.  Korean Journal of H\n\n- 23.  National Institute for Health and Care Excellence 홈페이지, https://www.nice.org.uk/guidance\n- 24.  Eating disorders: recognition and treatment NICE guideline, National Institute for Health an\n- 25.  The American Psychiatric Association Practice Guideline for the Treatment of Patients With\n- 26. ",
        "original_sentence": "Korean Journal of H\n\n- 23. "
      }
    },
    {
      "chunk_id": "chunk_831",
      "text": "National Institute for Health and Care Excellence 홈페이지, https://www.nice.org.uk/guidance\n- 24. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 830,
        "window_size": 3,
        "char_count": 95,
        "word_count": 11,
        "page_number": 62,
        "window_text": "So Hyeon Yun, & Gaeun Kim (2018).  The effects of non-pharmacological interventions for\nadults with eating disorders : A systematic review and meta-analysis.  Korean Journal of H\n\n- 23.  National Institute for Health and Care Excellence 홈페이지, https://www.nice.org.uk/guidance\n- 24.  Eating disorders: recognition and treatment NICE guideline, National Institute for Health an\n- 25.  The American Psychiatric Association Practice Guideline for the Treatment of Patients With\n- 26.  A Guide to Selecting Evidence-based Psychological Therapies for Eating Disorders Academ\n- 27. ",
        "original_sentence": "National Institute for Health and Care Excellence 홈페이지, https://www.nice.org.uk/guidance\n- 24. "
      }
    },
    {
      "chunk_id": "chunk_832",
      "text": "Eating disorders: recognition and treatment NICE guideline, National Institute for Health an\n- 25. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 831,
        "window_size": 3,
        "char_count": 99,
        "word_count": 14,
        "page_number": 9,
        "window_text": "The effects of non-pharmacological interventions for\nadults with eating disorders : A systematic review and meta-analysis.  Korean Journal of H\n\n- 23.  National Institute for Health and Care Excellence 홈페이지, https://www.nice.org.uk/guidance\n- 24.  Eating disorders: recognition and treatment NICE guideline, National Institute for Health an\n- 25.  The American Psychiatric Association Practice Guideline for the Treatment of Patients With\n- 26.  A Guide to Selecting Evidence-based Psychological Therapies for Eating Disorders Academ\n- 27.  Birgit Wagner., Michaela Nagl., Ruth Dölemeyer., Grit Klinitzke., Jana Steinig., Anja Hilbert.,\nAnette Kersting. ",
        "original_sentence": "Eating disorders: recognition and treatment NICE guideline, National Institute for Health an\n- 25. "
      }
    },
    {
      "chunk_id": "chunk_833",
      "text": "The American Psychiatric Association Practice Guideline for the Treatment of Patients With\n- 26. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 832,
        "window_size": 3,
        "char_count": 97,
        "word_count": 14,
        "page_number": 62,
        "window_text": "Korean Journal of H\n\n- 23.  National Institute for Health and Care Excellence 홈페이지, https://www.nice.org.uk/guidance\n- 24.  Eating disorders: recognition and treatment NICE guideline, National Institute for Health an\n- 25.  The American Psychiatric Association Practice Guideline for the Treatment of Patients With\n- 26.  A Guide to Selecting Evidence-based Psychological Therapies for Eating Disorders Academ\n- 27.  Birgit Wagner., Michaela Nagl., Ruth Dölemeyer., Grit Klinitzke., Jana Steinig., Anja Hilbert.,\nAnette Kersting.  (2016). ",
        "original_sentence": "The American Psychiatric Association Practice Guideline for the Treatment of Patients With\n- 26. "
      }
    },
    {
      "chunk_id": "chunk_834",
      "text": "A Guide to Selecting Evidence-based Psychological Therapies for Eating Disorders Academ\n- 27. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 833,
        "window_size": 3,
        "char_count": 94,
        "word_count": 13,
        "page_number": 9,
        "window_text": "National Institute for Health and Care Excellence 홈페이지, https://www.nice.org.uk/guidance\n- 24.  Eating disorders: recognition and treatment NICE guideline, National Institute for Health an\n- 25.  The American Psychiatric Association Practice Guideline for the Treatment of Patients With\n- 26.  A Guide to Selecting Evidence-based Psychological Therapies for Eating Disorders Academ\n- 27.  Birgit Wagner., Michaela Nagl., Ruth Dölemeyer., Grit Klinitzke., Jana Steinig., Anja Hilbert.,\nAnette Kersting.  (2016).  Randomized Controlled Trial of an Internet-Based Cognitive-Behav\n\n- 28. ",
        "original_sentence": "A Guide to Selecting Evidence-based Psychological Therapies for Eating Disorders Academ\n- 27. "
      }
    },
    {
      "chunk_id": "chunk_835",
      "text": "Birgit Wagner., Michaela Nagl., Ruth Dölemeyer., Grit Klinitzke., Jana Steinig., Anja Hilbert.,\nAnette Kersting. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 834,
        "window_size": 3,
        "char_count": 113,
        "word_count": 14,
        "page_number": 62,
        "window_text": "Eating disorders: recognition and treatment NICE guideline, National Institute for Health an\n- 25.  The American Psychiatric Association Practice Guideline for the Treatment of Patients With\n- 26.  A Guide to Selecting Evidence-based Psychological Therapies for Eating Disorders Academ\n- 27.  Birgit Wagner., Michaela Nagl., Ruth Dölemeyer., Grit Klinitzke., Jana Steinig., Anja Hilbert.,\nAnette Kersting.  (2016).  Randomized Controlled Trial of an Internet-Based Cognitive-Behav\n\n- 28.  Elke D. ter Huurne, Marloes G. Postel, Hein A. de Haan, Job van der Palen, Cor A.J. ",
        "original_sentence": "Birgit Wagner., Michaela Nagl., Ruth Dölemeyer., Grit Klinitzke., Jana Steinig., Anja Hilbert.,\nAnette Kersting. "
      }
    },
    {
      "chunk_id": "chunk_836",
      "text": "(2016). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 835,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "The American Psychiatric Association Practice Guideline for the Treatment of Patients With\n- 26.  A Guide to Selecting Evidence-based Psychological Therapies for Eating Disorders Academ\n- 27.  Birgit Wagner., Michaela Nagl., Ruth Dölemeyer., Grit Klinitzke., Jana Steinig., Anja Hilbert.,\nAnette Kersting.  (2016).  Randomized Controlled Trial of an Internet-Based Cognitive-Behav\n\n- 28.  Elke D. ter Huurne, Marloes G. Postel, Hein A. de Haan, Job van der Palen, Cor A.J.  DeJon\ng. ",
        "original_sentence": "(2016). "
      }
    },
    {
      "chunk_id": "chunk_837",
      "text": "Randomized Controlled Trial of an Internet-Based Cognitive-Behav\n\n- 28. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 836,
        "window_size": 3,
        "char_count": 72,
        "word_count": 9,
        "page_number": 62,
        "window_text": "A Guide to Selecting Evidence-based Psychological Therapies for Eating Disorders Academ\n- 27.  Birgit Wagner., Michaela Nagl., Ruth Dölemeyer., Grit Klinitzke., Jana Steinig., Anja Hilbert.,\nAnette Kersting.  (2016).  Randomized Controlled Trial of an Internet-Based Cognitive-Behav\n\n- 28.  Elke D. ter Huurne, Marloes G. Postel, Hein A. de Haan, Job van der Palen, Cor A.J.  DeJon\ng.  (2017). ",
        "original_sentence": "Randomized Controlled Trial of an Internet-Based Cognitive-Behav\n\n- 28. "
      }
    },
    {
      "chunk_id": "chunk_838",
      "text": "Elke D. ter Huurne, Marloes G. Postel, Hein A. de Haan, Job van der Palen, Cor A.J. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 837,
        "window_size": 3,
        "char_count": 84,
        "word_count": 17,
        "page_number": 62,
        "window_text": "Birgit Wagner., Michaela Nagl., Ruth Dölemeyer., Grit Klinitzke., Jana Steinig., Anja Hilbert.,\nAnette Kersting.  (2016).  Randomized Controlled Trial of an Internet-Based Cognitive-Behav\n\n- 28.  Elke D. ter Huurne, Marloes G. Postel, Hein A. de Haan, Job van der Palen, Cor A.J.  DeJon\ng.  (2017).  Treatment dropout in web-based cognitive behavioral therapy for patients with e\n\n- 29. ",
        "original_sentence": "Elke D. ter Huurne, Marloes G. Postel, Hein A. de Haan, Job van der Palen, Cor A.J. "
      }
    },
    {
      "chunk_id": "chunk_839",
      "text": "DeJon\ng. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 838,
        "window_size": 3,
        "char_count": 9,
        "word_count": 2,
        "page_number": 62,
        "window_text": "(2016).  Randomized Controlled Trial of an Internet-Based Cognitive-Behav\n\n- 28.  Elke D. ter Huurne, Marloes G. Postel, Hein A. de Haan, Job van der Palen, Cor A.J.  DeJon\ng.  (2017).  Treatment dropout in web-based cognitive behavioral therapy for patients with e\n\n- 29.  Selfapy 홈페이지, https://www.selfapy.com/\n- 30. ",
        "original_sentence": "DeJon\ng. "
      }
    },
    {
      "chunk_id": "chunk_840",
      "text": "(2017). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 839,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "Randomized Controlled Trial of an Internet-Based Cognitive-Behav\n\n- 28.  Elke D. ter Huurne, Marloes G. Postel, Hein A. de Haan, Job van der Palen, Cor A.J.  DeJon\ng.  (2017).  Treatment dropout in web-based cognitive behavioral therapy for patients with e\n\n- 29.  Selfapy 홈페이지, https://www.selfapy.com/\n- 30.  디지털치료기기 허가·심사 가이드라인 민원인 안내서, 식품의약품안전처 2020.08\n- 31. ",
        "original_sentence": "(2017). "
      }
    },
    {
      "chunk_id": "chunk_841",
      "text": "Treatment dropout in web-based cognitive behavioral therapy for patients with e\n\n- 29. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 840,
        "window_size": 3,
        "char_count": 87,
        "word_count": 13,
        "page_number": 62,
        "window_text": "Elke D. ter Huurne, Marloes G. Postel, Hein A. de Haan, Job van der Palen, Cor A.J.  DeJon\ng.  (2017).  Treatment dropout in web-based cognitive behavioral therapy for patients with e\n\n- 29.  Selfapy 홈페이지, https://www.selfapy.com/\n- 30.  디지털치료기기 허가·심사 가이드라인 민원인 안내서, 식품의약품안전처 2020.08\n- 31.  의료기기의 사이버보안 허가·심사 가이드라인 민원인안내서, 식품의약품안전처 2023.07.13\n- 32. ",
        "original_sentence": "Treatment dropout in web-based cognitive behavioral therapy for patients with e\n\n- 29. "
      }
    },
    {
      "chunk_id": "chunk_842",
      "text": "Selfapy 홈페이지, https://www.selfapy.com/\n- 30. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 841,
        "window_size": 3,
        "char_count": 45,
        "word_count": 5,
        "page_number": 19,
        "window_text": "DeJon\ng.  (2017).  Treatment dropout in web-based cognitive behavioral therapy for patients with e\n\n- 29.  Selfapy 홈페이지, https://www.selfapy.com/\n- 30.  디지털치료기기 허가·심사 가이드라인 민원인 안내서, 식품의약품안전처 2020.08\n- 31.  의료기기의 사이버보안 허가·심사 가이드라인 민원인안내서, 식품의약품안전처 2023.07.13\n- 32.  의료기기 소프트웨어 허가·심사 가이드라인, 식품의약품안전처, 2023.07.05\n- 33. ",
        "original_sentence": "Selfapy 홈페이지, https://www.selfapy.com/\n- 30. "
      }
    },
    {
      "chunk_id": "chunk_843",
      "text": "디지털치료기기 허가·심사 가이드라인 민원인 안내서, 식품의약품안전처 2020.08\n- 31. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 842,
        "window_size": 3,
        "char_count": 52,
        "word_count": 9,
        "page_number": 9,
        "window_text": "(2017).  Treatment dropout in web-based cognitive behavioral therapy for patients with e\n\n- 29.  Selfapy 홈페이지, https://www.selfapy.com/\n- 30.  디지털치료기기 허가·심사 가이드라인 민원인 안내서, 식품의약품안전처 2020.08\n- 31.  의료기기의 사이버보안 허가·심사 가이드라인 민원인안내서, 식품의약품안전처 2023.07.13\n- 32.  의료기기 소프트웨어 허가·심사 가이드라인, 식품의약품안전처, 2023.07.05\n- 33.  의료기기의 실사용증거(RWE) 적용에 대한 가이드라인 민원인 안내서 2023.07\n- 34. ",
        "original_sentence": "디지털치료기기 허가·심사 가이드라인 민원인 안내서, 식품의약품안전처 2020.08\n- 31. "
      }
    },
    {
      "chunk_id": "chunk_844",
      "text": "의료기기의 사이버보안 허가·심사 가이드라인 민원인안내서, 식품의약품안전처 2023.07.13\n- 32. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 843,
        "window_size": 3,
        "char_count": 58,
        "word_count": 9,
        "page_number": 9,
        "window_text": "Treatment dropout in web-based cognitive behavioral therapy for patients with e\n\n- 29.  Selfapy 홈페이지, https://www.selfapy.com/\n- 30.  디지털치료기기 허가·심사 가이드라인 민원인 안내서, 식품의약품안전처 2020.08\n- 31.  의료기기의 사이버보안 허가·심사 가이드라인 민원인안내서, 식품의약품안전처 2023.07.13\n- 32.  의료기기 소프트웨어 허가·심사 가이드라인, 식품의약품안전처, 2023.07.05\n- 33.  의료기기의 실사용증거(RWE) 적용에 대한 가이드라인 민원인 안내서 2023.07\n- 34.  의료기기 소프트웨어 밸리데이션 가이드라인, 식품의약품안전처, 2007.03\n- 35. ",
        "original_sentence": "의료기기의 사이버보안 허가·심사 가이드라인 민원인안내서, 식품의약품안전처 2023.07.13\n- 32. "
      }
    },
    {
      "chunk_id": "chunk_845",
      "text": "의료기기 소프트웨어 허가·심사 가이드라인, 식품의약품안전처, 2023.07.05\n- 33. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 844,
        "window_size": 3,
        "char_count": 51,
        "word_count": 8,
        "page_number": 9,
        "window_text": "Selfapy 홈페이지, https://www.selfapy.com/\n- 30.  디지털치료기기 허가·심사 가이드라인 민원인 안내서, 식품의약품안전처 2020.08\n- 31.  의료기기의 사이버보안 허가·심사 가이드라인 민원인안내서, 식품의약품안전처 2023.07.13\n- 32.  의료기기 소프트웨어 허가·심사 가이드라인, 식품의약품안전처, 2023.07.05\n- 33.  의료기기의 실사용증거(RWE) 적용에 대한 가이드라인 민원인 안내서 2023.07\n- 34.  의료기기 소프트웨어 밸리데이션 가이드라인, 식품의약품안전처, 2007.03\n- 35.  Grilo, C. M., Lydecker, J. A., Fineberg, S. K., Moreno, J. O., Ivezaj, V., & Gueorguieva, R.\n",
        "original_sentence": "의료기기 소프트웨어 허가·심사 가이드라인, 식품의약품안전처, 2023.07.05\n- 33. "
      }
    },
    {
      "chunk_id": "chunk_846",
      "text": "의료기기의 실사용증거(RWE) 적용에 대한 가이드라인 민원인 안내서 2023.07\n- 34. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 845,
        "window_size": 3,
        "char_count": 52,
        "word_count": 10,
        "page_number": 9,
        "window_text": "디지털치료기기 허가·심사 가이드라인 민원인 안내서, 식품의약품안전처 2020.08\n- 31.  의료기기의 사이버보안 허가·심사 가이드라인 민원인안내서, 식품의약품안전처 2023.07.13\n- 32.  의료기기 소프트웨어 허가·심사 가이드라인, 식품의약품안전처, 2023.07.05\n- 33.  의료기기의 실사용증거(RWE) 적용에 대한 가이드라인 민원인 안내서 2023.07\n- 34.  의료기기 소프트웨어 밸리데이션 가이드라인, 식품의약품안전처, 2007.03\n- 35.  Grilo, C. M., Lydecker, J. A., Fineberg, S. K., Moreno, J. O., Ivezaj, V., & Gueorguieva, R.\n - (2022). ",
        "original_sentence": "의료기기의 실사용증거(RWE) 적용에 대한 가이드라인 민원인 안내서 2023.07\n- 34. "
      }
    },
    {
      "chunk_id": "chunk_847",
      "text": "의료기기 소프트웨어 밸리데이션 가이드라인, 식품의약품안전처, 2007.03\n- 35. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 846,
        "window_size": 3,
        "char_count": 48,
        "word_count": 8,
        "page_number": 9,
        "window_text": "의료기기의 사이버보안 허가·심사 가이드라인 민원인안내서, 식품의약품안전처 2023.07.13\n- 32.  의료기기 소프트웨어 허가·심사 가이드라인, 식품의약품안전처, 2023.07.05\n- 33.  의료기기의 실사용증거(RWE) 적용에 대한 가이드라인 민원인 안내서 2023.07\n- 34.  의료기기 소프트웨어 밸리데이션 가이드라인, 식품의약품안전처, 2007.03\n- 35.  Grilo, C. M., Lydecker, J. A., Fineberg, S. K., Moreno, J. O., Ivezaj, V., & Gueorguieva, R.\n - (2022).  Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eatin\ng Disorder: Randomized Double-Blind Placebo-Controlled Trial. ",
        "original_sentence": "의료기기 소프트웨어 밸리데이션 가이드라인, 식품의약품안전처, 2007.03\n- 35. "
      }
    },
    {
      "chunk_id": "chunk_848",
      "text": "Grilo, C. M., Lydecker, J. A., Fineberg, S. K., Moreno, J. O., Ivezaj, V., & Gueorguieva, R.\n",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 847,
        "window_size": 3,
        "char_count": 93,
        "word_count": 17,
        "page_number": 62,
        "window_text": "의료기기 소프트웨어 허가·심사 가이드라인, 식품의약품안전처, 2023.07.05\n- 33.  의료기기의 실사용증거(RWE) 적용에 대한 가이드라인 민원인 안내서 2023.07\n- 34.  의료기기 소프트웨어 밸리데이션 가이드라인, 식품의약품안전처, 2007.03\n- 35.  Grilo, C. M., Lydecker, J. A., Fineberg, S. K., Moreno, J. O., Ivezaj, V., & Gueorguieva, R.\n - (2022).  Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eatin\ng Disorder: Randomized Double-Blind Placebo-Controlled Trial.  The American journal of ps\n\n- 36. ",
        "original_sentence": "Grilo, C. M., Lydecker, J. A., Fineberg, S. K., Moreno, J. O., Ivezaj, V., & Gueorguieva, R.\n"
      }
    },
    {
      "chunk_id": "chunk_849",
      "text": "- (2022). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 848,
        "window_size": 3,
        "char_count": 10,
        "word_count": 2,
        "page_number": 9,
        "window_text": "의료기기의 실사용증거(RWE) 적용에 대한 가이드라인 민원인 안내서 2023.07\n- 34.  의료기기 소프트웨어 밸리데이션 가이드라인, 식품의약품안전처, 2007.03\n- 35.  Grilo, C. M., Lydecker, J. A., Fineberg, S. K., Moreno, J. O., Ivezaj, V., & Gueorguieva, R.\n - (2022).  Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eatin\ng Disorder: Randomized Double-Blind Placebo-Controlled Trial.  The American journal of ps\n\n- 36.  Mond JM, Hay PJ, Rodgers B, Owen C, Beumont P. Validity of the eating disorder examinat\nion questionnaire (EDE-Q) in screening for eating disorders in community samples. ",
        "original_sentence": "- (2022). "
      }
    },
    {
      "chunk_id": "chunk_850",
      "text": "Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eatin\ng Disorder: Randomized Double-Blind Placebo-Controlled Trial. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 849,
        "window_size": 3,
        "char_count": 141,
        "word_count": 15,
        "page_number": 62,
        "window_text": "의료기기 소프트웨어 밸리데이션 가이드라인, 식품의약품안전처, 2007.03\n- 35.  Grilo, C. M., Lydecker, J. A., Fineberg, S. K., Moreno, J. O., Ivezaj, V., & Gueorguieva, R.\n - (2022).  Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eatin\ng Disorder: Randomized Double-Blind Placebo-Controlled Trial.  The American journal of ps\n\n- 36.  Mond JM, Hay PJ, Rodgers B, Owen C, Beumont P. Validity of the eating disorder examinat\nion questionnaire (EDE-Q) in screening for eating disorders in community samples.  Behav\n\n- 37. ",
        "original_sentence": "Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eatin\ng Disorder: Randomized Double-Blind Placebo-Controlled Trial. "
      }
    },
    {
      "chunk_id": "chunk_851",
      "text": "The American journal of ps\n\n- 36. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 850,
        "window_size": 3,
        "char_count": 34,
        "word_count": 7,
        "page_number": 26,
        "window_text": "Grilo, C. M., Lydecker, J. A., Fineberg, S. K., Moreno, J. O., Ivezaj, V., & Gueorguieva, R.\n - (2022).  Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eatin\ng Disorder: Randomized Double-Blind Placebo-Controlled Trial.  The American journal of ps\n\n- 36.  Mond JM, Hay PJ, Rodgers B, Owen C, Beumont P. Validity of the eating disorder examinat\nion questionnaire (EDE-Q) in screening for eating disorders in community samples.  Behav\n\n- 37.  Mond JM, Myers TC, Crosby RD, Hay PJ, Rodgers B, Morgan JF, Lacey JH, Mitchell JE. ",
        "original_sentence": "The American journal of ps\n\n- 36. "
      }
    },
    {
      "chunk_id": "chunk_852",
      "text": "Mond JM, Hay PJ, Rodgers B, Owen C, Beumont P. Validity of the eating disorder examinat\nion questionnaire (EDE-Q) in screening for eating disorders in community samples. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 851,
        "window_size": 3,
        "char_count": 170,
        "word_count": 27,
        "page_number": 62,
        "window_text": "- (2022).  Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eatin\ng Disorder: Randomized Double-Blind Placebo-Controlled Trial.  The American journal of ps\n\n- 36.  Mond JM, Hay PJ, Rodgers B, Owen C, Beumont P. Validity of the eating disorder examinat\nion questionnaire (EDE-Q) in screening for eating disorders in community samples.  Behav\n\n- 37.  Mond JM, Myers TC, Crosby RD, Hay PJ, Rodgers B, Morgan JF, Lacey JH, Mitchell JE.  Sc\n- - 108 -\nreening for eating disorders in primary care: EDE-Q versus SCOFF. ",
        "original_sentence": "Mond JM, Hay PJ, Rodgers B, Owen C, Beumont P. Validity of the eating disorder examinat\nion questionnaire (EDE-Q) in screening for eating disorders in community samples. "
      }
    },
    {
      "chunk_id": "chunk_853",
      "text": "Behav\n\n- 37. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 852,
        "window_size": 3,
        "char_count": 13,
        "word_count": 3,
        "page_number": 26,
        "window_text": "Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eatin\ng Disorder: Randomized Double-Blind Placebo-Controlled Trial.  The American journal of ps\n\n- 36.  Mond JM, Hay PJ, Rodgers B, Owen C, Beumont P. Validity of the eating disorder examinat\nion questionnaire (EDE-Q) in screening for eating disorders in community samples.  Behav\n\n- 37.  Mond JM, Myers TC, Crosby RD, Hay PJ, Rodgers B, Morgan JF, Lacey JH, Mitchell JE.  Sc\n- - 108 -\nreening for eating disorders in primary care: EDE-Q versus SCOFF.  Behav Res Ther. ",
        "original_sentence": "Behav\n\n- 37. "
      }
    },
    {
      "chunk_id": "chunk_854",
      "text": "Mond JM, Myers TC, Crosby RD, Hay PJ, Rodgers B, Morgan JF, Lacey JH, Mitchell JE. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 853,
        "window_size": 3,
        "char_count": 83,
        "word_count": 16,
        "page_number": 62,
        "window_text": "The American journal of ps\n\n- 36.  Mond JM, Hay PJ, Rodgers B, Owen C, Beumont P. Validity of the eating disorder examinat\nion questionnaire (EDE-Q) in screening for eating disorders in community samples.  Behav\n\n- 37.  Mond JM, Myers TC, Crosby RD, Hay PJ, Rodgers B, Morgan JF, Lacey JH, Mitchell JE.  Sc\n- - 108 -\nreening for eating disorders in primary care: EDE-Q versus SCOFF.  Behav Res Ther.  200\n\n8;46(5):612–22.Return to ref 6 in article\n\n- 38. ",
        "original_sentence": "Mond JM, Myers TC, Crosby RD, Hay PJ, Rodgers B, Morgan JF, Lacey JH, Mitchell JE. "
      }
    },
    {
      "chunk_id": "chunk_855",
      "text": "Sc\n- - 108 -\nreening for eating disorders in primary care: EDE-Q versus SCOFF. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 854,
        "window_size": 3,
        "char_count": 79,
        "word_count": 15,
        "page_number": 9,
        "window_text": "Mond JM, Hay PJ, Rodgers B, Owen C, Beumont P. Validity of the eating disorder examinat\nion questionnaire (EDE-Q) in screening for eating disorders in community samples.  Behav\n\n- 37.  Mond JM, Myers TC, Crosby RD, Hay PJ, Rodgers B, Morgan JF, Lacey JH, Mitchell JE.  Sc\n- - 108 -\nreening for eating disorders in primary care: EDE-Q versus SCOFF.  Behav Res Ther.  200\n\n8;46(5):612–22.Return to ref 6 in article\n\n- 38.  Althunian, T. A., de Boer, A., Groenwold, R. H. H., & Klungel, O. H. ",
        "original_sentence": "Sc\n- - 108 -\nreening for eating disorders in primary care: EDE-Q versus SCOFF. "
      }
    },
    {
      "chunk_id": "chunk_856",
      "text": "Behav Res Ther. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 855,
        "window_size": 3,
        "char_count": 16,
        "word_count": 3,
        "page_number": 115,
        "window_text": "Behav\n\n- 37.  Mond JM, Myers TC, Crosby RD, Hay PJ, Rodgers B, Morgan JF, Lacey JH, Mitchell JE.  Sc\n- - 108 -\nreening for eating disorders in primary care: EDE-Q versus SCOFF.  Behav Res Ther.  200\n\n8;46(5):612–22.Return to ref 6 in article\n\n- 38.  Althunian, T. A., de Boer, A., Groenwold, R. H. H., & Klungel, O. H.  (2017). ",
        "original_sentence": "Behav Res Ther. "
      }
    },
    {
      "chunk_id": "chunk_857",
      "text": "200\n\n8;46(5):612–22.Return to ref 6 in article\n\n- 38. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 856,
        "window_size": 3,
        "char_count": 54,
        "word_count": 9,
        "page_number": 9,
        "window_text": "Mond JM, Myers TC, Crosby RD, Hay PJ, Rodgers B, Morgan JF, Lacey JH, Mitchell JE.  Sc\n- - 108 -\nreening for eating disorders in primary care: EDE-Q versus SCOFF.  Behav Res Ther.  200\n\n8;46(5):612–22.Return to ref 6 in article\n\n- 38.  Althunian, T. A., de Boer, A., Groenwold, R. H. H., & Klungel, O. H.  (2017).  Defining the n\noninferiority margin and analysing noninferiority: An overview. ",
        "original_sentence": "200\n\n8;46(5):612–22.Return to ref 6 in article\n\n- 38. "
      }
    },
    {
      "chunk_id": "chunk_858",
      "text": "Althunian, T. A., de Boer, A., Groenwold, R. H. H., & Klungel, O. H. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 857,
        "window_size": 3,
        "char_count": 69,
        "word_count": 14,
        "page_number": 62,
        "window_text": "Sc\n- - 108 -\nreening for eating disorders in primary care: EDE-Q versus SCOFF.  Behav Res Ther.  200\n\n8;46(5):612–22.Return to ref 6 in article\n\n- 38.  Althunian, T. A., de Boer, A., Groenwold, R. H. H., & Klungel, O. H.  (2017).  Defining the n\noninferiority margin and analysing noninferiority: An overview.  British journal of clinical ph\n\n- 39. ",
        "original_sentence": "Althunian, T. A., de Boer, A., Groenwold, R. H. H., & Klungel, O. H. "
      }
    },
    {
      "chunk_id": "chunk_859",
      "text": "(2017). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 858,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "Behav Res Ther.  200\n\n8;46(5):612–22.Return to ref 6 in article\n\n- 38.  Althunian, T. A., de Boer, A., Groenwold, R. H. H., & Klungel, O. H.  (2017).  Defining the n\noninferiority margin and analysing noninferiority: An overview.  British journal of clinical ph\n\n- 39.  방은별, 한초롱, 전예림, 김율리. ",
        "original_sentence": "(2017). "
      }
    },
    {
      "chunk_id": "chunk_860",
      "text": "Defining the n\noninferiority margin and analysing noninferiority: An overview. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 859,
        "window_size": 3,
        "char_count": 79,
        "word_count": 10,
        "page_number": 62,
        "window_text": "200\n\n8;46(5):612–22.Return to ref 6 in article\n\n- 38.  Althunian, T. A., de Boer, A., Groenwold, R. H. H., & Klungel, O. H.  (2017).  Defining the n\noninferiority margin and analysing noninferiority: An overview.  British journal of clinical ph\n\n- 39.  방은별, 한초롱, 전예림, 김율리.  (2018). ",
        "original_sentence": "Defining the n\noninferiority margin and analysing noninferiority: An overview. "
      }
    },
    {
      "chunk_id": "chunk_861",
      "text": "British journal of clinical ph\n\n- 39. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 860,
        "window_size": 3,
        "char_count": 38,
        "word_count": 7,
        "page_number": 26,
        "window_text": "Althunian, T. A., de Boer, A., Groenwold, R. H. H., & Klungel, O. H.  (2017).  Defining the n\noninferiority margin and analysing noninferiority: An overview.  British journal of clinical ph\n\n- 39.  방은별, 한초롱, 전예림, 김율리.  (2018).  한국판 DSM-5 섭식장애진단척도(Korean version of the\nEating Disorder Diagnostic Scale DSM-5, K-EDDS DSM-5) : 신뢰도와 타당도 연구. ",
        "original_sentence": "British journal of clinical ph\n\n- 39. "
      }
    },
    {
      "chunk_id": "chunk_862",
      "text": "방은별, 한초롱, 전예림, 김율리. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 861,
        "window_size": 3,
        "char_count": 20,
        "word_count": 4,
        "page_number": 115,
        "window_text": "(2017).  Defining the n\noninferiority margin and analysing noninferiority: An overview.  British journal of clinical ph\n\n- 39.  방은별, 한초롱, 전예림, 김율리.  (2018).  한국판 DSM-5 섭식장애진단척도(Korean version of the\nEating Disorder Diagnostic Scale DSM-5, K-EDDS DSM-5) : 신뢰도와 타당도 연구.  대한불안\n\n- 40. ",
        "original_sentence": "방은별, 한초롱, 전예림, 김율리. "
      }
    },
    {
      "chunk_id": "chunk_863",
      "text": "(2018). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 862,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "Defining the n\noninferiority margin and analysing noninferiority: An overview.  British journal of clinical ph\n\n- 39.  방은별, 한초롱, 전예림, 김율리.  (2018).  한국판 DSM-5 섭식장애진단척도(Korean version of the\nEating Disorder Diagnostic Scale DSM-5, K-EDDS DSM-5) : 신뢰도와 타당도 연구.  대한불안\n\n- 40.  K. Bohn,. ",
        "original_sentence": "(2018). "
      }
    },
    {
      "chunk_id": "chunk_864",
      "text": "한국판 DSM-5 섭식장애진단척도(Korean version of the\nEating Disorder Diagnostic Scale DSM-5, K-EDDS DSM-5) : 신뢰도와 타당도 연구. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 863,
        "window_size": 3,
        "char_count": 110,
        "word_count": 17,
        "page_number": 26,
        "window_text": "British journal of clinical ph\n\n- 39.  방은별, 한초롱, 전예림, 김율리.  (2018).  한국판 DSM-5 섭식장애진단척도(Korean version of the\nEating Disorder Diagnostic Scale DSM-5, K-EDDS DSM-5) : 신뢰도와 타당도 연구.  대한불안\n\n- 40.  K. Bohn,.  C. Fairburn. ",
        "original_sentence": "한국판 DSM-5 섭식장애진단척도(Korean version of the\nEating Disorder Diagnostic Scale DSM-5, K-EDDS DSM-5) : 신뢰도와 타당도 연구. "
      }
    },
    {
      "chunk_id": "chunk_865",
      "text": "대한불안\n\n- 40. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 864,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 26,
        "window_text": "방은별, 한초롱, 전예림, 김율리.  (2018).  한국판 DSM-5 섭식장애진단척도(Korean version of the\nEating Disorder Diagnostic Scale DSM-5, K-EDDS DSM-5) : 신뢰도와 타당도 연구.  대한불안\n\n- 40.  K. Bohn,.  C. Fairburn.  (2008). ",
        "original_sentence": "대한불안\n\n- 40. "
      }
    },
    {
      "chunk_id": "chunk_866",
      "text": "K. Bohn,. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 865,
        "window_size": 3,
        "char_count": 10,
        "word_count": 2,
        "page_number": 62,
        "window_text": "(2018).  한국판 DSM-5 섭식장애진단척도(Korean version of the\nEating Disorder Diagnostic Scale DSM-5, K-EDDS DSM-5) : 신뢰도와 타당도 연구.  대한불안\n\n- 40.  K. Bohn,.  C. Fairburn.  (2008).  The Clinical Impairment Assessment questionnaire (CIA), Cog\n- 41. ",
        "original_sentence": "K. Bohn,. "
      }
    },
    {
      "chunk_id": "chunk_867",
      "text": "C. Fairburn. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 866,
        "window_size": 3,
        "char_count": 13,
        "word_count": 2,
        "page_number": 62,
        "window_text": "한국판 DSM-5 섭식장애진단척도(Korean version of the\nEating Disorder Diagnostic Scale DSM-5, K-EDDS DSM-5) : 신뢰도와 타당도 연구.  대한불안\n\n- 40.  K. Bohn,.  C. Fairburn.  (2008).  The Clinical Impairment Assessment questionnaire (CIA), Cog\n- 41.  Kristin Bohn, Helen A. Doll, Zafra Cooper, Marianne O'Connor, Robert L. Palmer, Christoph\ner G. Fairburn. ",
        "original_sentence": "C. Fairburn. "
      }
    },
    {
      "chunk_id": "chunk_868",
      "text": "(2008). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 867,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "대한불안\n\n- 40.  K. Bohn,.  C. Fairburn.  (2008).  The Clinical Impairment Assessment questionnaire (CIA), Cog\n- 41.  Kristin Bohn, Helen A. Doll, Zafra Cooper, Marianne O'Connor, Robert L. Palmer, Christoph\ner G. Fairburn.  (2008). ",
        "original_sentence": "(2008). "
      }
    },
    {
      "chunk_id": "chunk_869",
      "text": "The Clinical Impairment Assessment questionnaire (CIA), Cog\n- 41. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 868,
        "window_size": 3,
        "char_count": 66,
        "word_count": 9,
        "page_number": 62,
        "window_text": "K. Bohn,.  C. Fairburn.  (2008).  The Clinical Impairment Assessment questionnaire (CIA), Cog\n- 41.  Kristin Bohn, Helen A. Doll, Zafra Cooper, Marianne O'Connor, Robert L. Palmer, Christoph\ner G. Fairburn.  (2008).  The measurement of impairment due to eating disorder psychopatho\n\n- 42. ",
        "original_sentence": "The Clinical Impairment Assessment questionnaire (CIA), Cog\n- 41. "
      }
    },
    {
      "chunk_id": "chunk_870",
      "text": "Kristin Bohn, Helen A. Doll, Zafra Cooper, Marianne O'Connor, Robert L. Palmer, Christoph\ner G. Fairburn. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 869,
        "window_size": 3,
        "char_count": 106,
        "word_count": 16,
        "page_number": 62,
        "window_text": "C. Fairburn.  (2008).  The Clinical Impairment Assessment questionnaire (CIA), Cog\n- 41.  Kristin Bohn, Helen A. Doll, Zafra Cooper, Marianne O'Connor, Robert L. Palmer, Christoph\ner G. Fairburn.  (2008).  The measurement of impairment due to eating disorder psychopatho\n\n- 42.  박승진, 최혜라, 최지혜, 김건우, 홍진표. ",
        "original_sentence": "Kristin Bohn, Helen A. Doll, Zafra Cooper, Marianne O'Connor, Robert L. Palmer, Christoph\ner G. Fairburn. "
      }
    },
    {
      "chunk_id": "chunk_871",
      "text": "(2008). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 870,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "(2008).  The Clinical Impairment Assessment questionnaire (CIA), Cog\n- 41.  Kristin Bohn, Helen A. Doll, Zafra Cooper, Marianne O'Connor, Robert L. Palmer, Christoph\ner G. Fairburn.  (2008).  The measurement of impairment due to eating disorder psychopatho\n\n- 42.  박승진, 최혜라, 최지혜, 김건우, 홍진표.  (2010). ",
        "original_sentence": "(2008). "
      }
    },
    {
      "chunk_id": "chunk_872",
      "text": "The measurement of impairment due to eating disorder psychopatho\n\n- 42. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 871,
        "window_size": 3,
        "char_count": 72,
        "word_count": 11,
        "page_number": 62,
        "window_text": "The Clinical Impairment Assessment questionnaire (CIA), Cog\n- 41.  Kristin Bohn, Helen A. Doll, Zafra Cooper, Marianne O'Connor, Robert L. Palmer, Christoph\ner G. Fairburn.  (2008).  The measurement of impairment due to eating disorder psychopatho\n\n- 42.  박승진, 최혜라, 최지혜, 김건우, 홍진표.  (2010).  한글판 우울증 선별도구(Patient Health Question\n- 43. ",
        "original_sentence": "The measurement of impairment due to eating disorder psychopatho\n\n- 42. "
      }
    },
    {
      "chunk_id": "chunk_873",
      "text": "박승진, 최혜라, 최지혜, 김건우, 홍진표. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 872,
        "window_size": 3,
        "char_count": 25,
        "word_count": 5,
        "page_number": 115,
        "window_text": "Kristin Bohn, Helen A. Doll, Zafra Cooper, Marianne O'Connor, Robert L. Palmer, Christoph\ner G. Fairburn.  (2008).  The measurement of impairment due to eating disorder psychopatho\n\n- 42.  박승진, 최혜라, 최지혜, 김건우, 홍진표.  (2010).  한글판 우울증 선별도구(Patient Health Question\n- 43.  김용, 박종일, 박태원, 정상근, 양종철. ",
        "original_sentence": "박승진, 최혜라, 최지혜, 김건우, 홍진표. "
      }
    },
    {
      "chunk_id": "chunk_874",
      "text": "(2010). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 873,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "(2008).  The measurement of impairment due to eating disorder psychopatho\n\n- 42.  박승진, 최혜라, 최지혜, 김건우, 홍진표.  (2010).  한글판 우울증 선별도구(Patient Health Question\n- 43.  김용, 박종일, 박태원, 정상근, 양종철.  (2017). ",
        "original_sentence": "(2010). "
      }
    },
    {
      "chunk_id": "chunk_875",
      "text": "한글판 우울증 선별도구(Patient Health Question\n- 43. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 874,
        "window_size": 3,
        "char_count": 43,
        "word_count": 7,
        "page_number": 26,
        "window_text": "The measurement of impairment due to eating disorder psychopatho\n\n- 42.  박승진, 최혜라, 최지혜, 김건우, 홍진표.  (2010).  한글판 우울증 선별도구(Patient Health Question\n- 43.  김용, 박종일, 박태원, 정상근, 양종철.  (2017).  범불안장애 환자의 스트레스 대처방식과 신체증상\n- 44. ",
        "original_sentence": "한글판 우울증 선별도구(Patient Health Question\n- 43. "
      }
    },
    {
      "chunk_id": "chunk_876",
      "text": "김용, 박종일, 박태원, 정상근, 양종철. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 875,
        "window_size": 3,
        "char_count": 24,
        "word_count": 5,
        "page_number": 115,
        "window_text": "박승진, 최혜라, 최지혜, 김건우, 홍진표.  (2010).  한글판 우울증 선별도구(Patient Health Question\n- 43.  김용, 박종일, 박태원, 정상근, 양종철.  (2017).  범불안장애 환자의 스트레스 대처방식과 신체증상\n- 44.  Kim et al., (2018). ",
        "original_sentence": "김용, 박종일, 박태원, 정상근, 양종철. "
      }
    },
    {
      "chunk_id": "chunk_877",
      "text": "(2017). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 876,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "(2010).  한글판 우울증 선별도구(Patient Health Question\n- 43.  김용, 박종일, 박태원, 정상근, 양종철.  (2017).  범불안장애 환자의 스트레스 대처방식과 신체증상\n- 44.  Kim et al., (2018).  EuroQol Visual Analogue Scale (EQ-VAS) as a Predicting Tool for Frailt\ny in Older Korean Adults: The Korean Frailty an Aging Cohort Study (KFACS). ",
        "original_sentence": "(2017). "
      }
    },
    {
      "chunk_id": "chunk_878",
      "text": "범불안장애 환자의 스트레스 대처방식과 신체증상\n- 44. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 877,
        "window_size": 3,
        "char_count": 32,
        "word_count": 7,
        "page_number": 15,
        "window_text": "한글판 우울증 선별도구(Patient Health Question\n- 43.  김용, 박종일, 박태원, 정상근, 양종철.  (2017).  범불안장애 환자의 스트레스 대처방식과 신체증상\n- 44.  Kim et al., (2018).  EuroQol Visual Analogue Scale (EQ-VAS) as a Predicting Tool for Frailt\ny in Older Korean Adults: The Korean Frailty an Aging Cohort Study (KFACS).  The journal\n\n- 45. ",
        "original_sentence": "범불안장애 환자의 스트레스 대처방식과 신체증상\n- 44. "
      }
    },
    {
      "chunk_id": "chunk_879",
      "text": "Kim et al., (2018). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 878,
        "window_size": 3,
        "char_count": 20,
        "word_count": 4,
        "page_number": 9,
        "window_text": "김용, 박종일, 박태원, 정상근, 양종철.  (2017).  범불안장애 환자의 스트레스 대처방식과 신체증상\n- 44.  Kim et al., (2018).  EuroQol Visual Analogue Scale (EQ-VAS) as a Predicting Tool for Frailt\ny in Older Korean Adults: The Korean Frailty an Aging Cohort Study (KFACS).  The journal\n\n- 45.  Busner, Joan & Targum, Steven. ",
        "original_sentence": "Kim et al., (2018). "
      }
    },
    {
      "chunk_id": "chunk_880",
      "text": "EuroQol Visual Analogue Scale (EQ-VAS) as a Predicting Tool for Frailt\ny in Older Korean Adults: The Korean Frailty an Aging Cohort Study (KFACS). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 879,
        "window_size": 3,
        "char_count": 147,
        "word_count": 24,
        "page_number": 62,
        "window_text": "(2017).  범불안장애 환자의 스트레스 대처방식과 신체증상\n- 44.  Kim et al., (2018).  EuroQol Visual Analogue Scale (EQ-VAS) as a Predicting Tool for Frailt\ny in Older Korean Adults: The Korean Frailty an Aging Cohort Study (KFACS).  The journal\n\n- 45.  Busner, Joan & Targum, Steven.  (2007). ",
        "original_sentence": "EuroQol Visual Analogue Scale (EQ-VAS) as a Predicting Tool for Frailt\ny in Older Korean Adults: The Korean Frailty an Aging Cohort Study (KFACS). "
      }
    },
    {
      "chunk_id": "chunk_881",
      "text": "The journal\n\n- 45. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 880,
        "window_size": 3,
        "char_count": 19,
        "word_count": 4,
        "page_number": 26,
        "window_text": "범불안장애 환자의 스트레스 대처방식과 신체증상\n- 44.  Kim et al., (2018).  EuroQol Visual Analogue Scale (EQ-VAS) as a Predicting Tool for Frailt\ny in Older Korean Adults: The Korean Frailty an Aging Cohort Study (KFACS).  The journal\n\n- 45.  Busner, Joan & Targum, Steven.  (2007).  The Clinical Global Impressions Scale: applying a",
        "original_sentence": "The journal\n\n- 45. "
      }
    },
    {
      "chunk_id": "chunk_882",
      "text": "Busner, Joan & Targum, Steven. ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 881,
        "window_size": 3,
        "char_count": 31,
        "word_count": 5,
        "page_number": 62,
        "window_text": "Kim et al., (2018).  EuroQol Visual Analogue Scale (EQ-VAS) as a Predicting Tool for Frailt\ny in Older Korean Adults: The Korean Frailty an Aging Cohort Study (KFACS).  The journal\n\n- 45.  Busner, Joan & Targum, Steven.  (2007).  The Clinical Global Impressions Scale: applying a",
        "original_sentence": "Busner, Joan & Targum, Steven. "
      }
    },
    {
      "chunk_id": "chunk_883",
      "text": "(2007). ",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 882,
        "window_size": 3,
        "char_count": 8,
        "word_count": 1,
        "page_number": 9,
        "window_text": "EuroQol Visual Analogue Scale (EQ-VAS) as a Predicting Tool for Frailt\ny in Older Korean Adults: The Korean Frailty an Aging Cohort Study (KFACS).  The journal\n\n- 45.  Busner, Joan & Targum, Steven.  (2007).  The Clinical Global Impressions Scale: applying a",
        "original_sentence": "(2007). "
      }
    },
    {
      "chunk_id": "chunk_884",
      "text": "The Clinical Global Impressions Scale: applying a",
      "metadata": {
        "source": "섭식장애+개선+디지털치료기기+안전성·성능+평가+및+임상시험계획서+작성+가이드라인.pdf",
        "chunk_index": 883,
        "window_size": 3,
        "char_count": 49,
        "word_count": 7,
        "page_number": 62,
        "window_text": "The journal\n\n- 45.  Busner, Joan & Targum, Steven.  (2007).  The Clinical Global Impressions Scale: applying a",
        "original_sentence": "The Clinical Global Impressions Scale: applying a"
      }
    }
  ],
  "chunking_analysis": {
    "total_chunks": 884,
    "avg_chunk_length": 92.56900452488688,
    "min_chunk_length": 3,
    "max_chunk_length": 1040,
    "total_characters": 81831,
    "total_words": 18556,
    "window_size": 3
  },
  "statistics": {
    "total_text_blocks": 3203,
    "heading_count": 49,
    "paragraph_count": 1028,
    "list_item_count": 328,
    "table_cell_count": 1798,
    "tables_detected": 16,
    "chunks_generated": 884
  }
}